PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BEALE, SI; CORNEJO, J				BEALE, SI; CORNEJO, J			BIOSYNTHESIS OF PHYCOBILINS - 15,16-DIHYDROBILIVERDIN-IX-ALPHA IS A PARTIALLY REDUCED INTERMEDIATE IN THE FORMATION OF PHYCOBILINS FROM BILIVERDIN-IX-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNICELLULAR RED ALGA; CYANIDIUM-CALDARIUM; BILE-PIGMENTS; HEME OXYGENASE; PHYCOCYANOBILIN; PURIFICATION; EXTRACTS; INVITRO	A partially purified protein fraction from the phycocyanin-containing unicellular rhodophyte, Cyanidium caldarium, reductively transforms biliverdin IX-alpha to a violet colored bilin in the presence of NADPH, ferredoxin, and ferredoxin-NADP+ reductase. This bilin has a violin-like absorption spectrum with maxima at 335 and 560 nm in methanolic HCl and at 337, 567, and 603-604 nm in CHCl3. The bilin has been determined to be 15,16-dihydrobiliverdin IX-alpha by comparative spectrophotometry and H-1 NMR spectroscopy. This product of biliverdin IX-alpha reduction is converted enzymatically to phycobilins by further reduction. A general biosynthetic pathway is proposed which accounts for the formation of the phycobilins from biliverdin IX-alpha by a two-step reduction process followed by isomerization.			BEALE, SI (corresponding author), BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912, USA.							Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BEALE SI, 1984, ARCH BIOCHEM BIOPHYS, V235, P371, DOI 10.1016/0003-9861(84)90210-8; BEALE SI, 1983, PLANT PHYSIOL, V71, P263, DOI 10.1104/pp.71.2.263; BEALE SI, 1991, J BIOL CHEM, V266, P22328; BEALE SI, 1984, PLANT PHYSIOL, V76, P7, DOI 10.1104/pp.76.1.7; BEALE SI, 1991, J BIOL CHEM, V266, P22333; BEALE SI, 1983, ARCH BIOCHEM BIOPHYS, V227, P279, DOI 10.1016/0003-9861(83)90372-7; BEALE SI, 1990, PLANT PHYSIOL, V92, pS62; CORNEJO J, 1988, J BIOL CHEM, V263, P11915; CRESPI HL, 1968, BIOCHEMISTRY-US, V7, P2232, DOI 10.1021/bi00846a028; ELICH TD, 1989, J BIOL CHEM, V264, P12902; GOSSAUER A, 1989, HELV CHIM ACTA, V72, P518, DOI 10.1002/hlca.19890720315; JACKMAN LM, 1969, APPLICATIONS NMR SPE; LAGARIAS JC, 1989, P NATL ACAD SCI USA, V86, P5778, DOI 10.1073/pnas.86.15.5778; Lightner D. A., 1979, PORPHYRINS, VVI, P521; RUDIGER W, 1980, Z NATURFORSCH C, V35, P763; SHIN M, 1978, J BIOCHEM-TOKYO, V83, P357, DOI 10.1093/oxfordjournals.jbchem.a131921; SINGLETON JW, 1965, J BIOL CHEM, V240, P4780; STOLL MS, 1977, BIOCHEM J, V163, P59, DOI 10.1042/bj1630059; TENHUNEN R, 1970, BIOCHEMISTRY-US, V9, P293; WELLER JP, 1980, CHEM BER-RECL, V113, P1603, DOI 10.1002/cber.19801130439	21	52	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22341	22345						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939257				2022-12-25	WOS:A1991GR56400047
J	STEPHENS, JM; PEKALA, PH				STEPHENS, JM; PEKALA, PH			TRANSCRIPTIONAL REPRESSION OF THE GLUT4 AND C/EBP GENES IN 3T3-L1 ADIPOCYTES BY TUMOR-NECROSIS-FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT ACTIVITY; RAT ADIPOSE CELL; INSULIN RESISTANCE; MESSENGER-RNA; HEXOSE-TRANSPORT; SKELETAL-MUSCLE; HORMONAL-REGULATION; POSSIBLE MECHANISM; BINDING-PROTEIN; PLASMA-MEMBRANE	Fully differentiated 3T3-L1 adipocytes were chronically exposed to 5 nM tumor necrosis factor-alpha (TNF). This resulted in the development of an insulin resistance based on the inability of insulin to stimulate hexose uptake. Western blot analysis for glucose transporter protein in isolated membrane fractions indicated a total depletion of GLUT4 protein (insulin-responsive glucose transporter) in cells chronically treated with TNF. Plasma membrane content of GLUT1 protein (growth-related glucose transporter) was similar in both control and TNF-treated cells; however, the GLUT1 content of the intracellular membrane compartment had decreased markedly after TNF treatment. Continuous exposure to TNF resulted in an 85-90% decrease in the mRNA content for both GLUT4 and 422 (aP2, a lipid binding protein) genes relative to age matched controls, whereas insulin receptor mRNA levels declined by at least 50%. This was preceded by a marked decrease in mRNA accumulation for C/EBP, a transcription factor proposed to control expression of both GLUT4 and 422. The specificity of these observations was demonstrated by the lack of an effect of the chronic TNF treatment on either beta-actin or lipoprotein lipase mRNA content. The decreased content of GLUT4 and C/EBP mRNA was judged to be regulated at least in part at the level of transcription, based on the results of transcription run-on assays. Thus, the lack of response to insulin appeared due to a suppression of GLUT4 expression as well as a decreased intracellular content of GLUT1.			STEPHENS, JM (corresponding author), E CAROLINA UNIV,SCH MED,DEPT BIOCHEM,GREENVILLE,NC 27858, USA.		Stephens, Jacqueline M/R-5217-2018		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032892] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32892] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1989, J BIOL CHEM, V264, P3416; BALY DL, 1988, BIOCHIM BIOPHYS ACTA, V947, P571, DOI 10.1016/0304-4157(88)90008-1; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BIRD TA, 1990, J BIOL CHEM, V265, P13578; BLACK PR, 1982, ANN SURG, V196, P420, DOI 10.1097/00000658-198210000-00005; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; CORNELIUS P, 1989, BIOCHEM BIOPH RES CO, V165, P429, DOI 10.1016/0006-291X(89)91088-7; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DOBSON DE, 1987, J BIOL CHEM, V262, P1804; ELBEIN SC, 1986, P NATL ACAD SCI USA, V83, P5223, DOI 10.1073/pnas.83.14.5223; FELVER ME, 1990, ALCOHOL CLIN EXP RES, V14, P255, DOI 10.1111/j.1530-0277.1990.tb00482.x; FONG Y, 1990, CLIN IMMUNOL IMMUNOP, V55, P157, DOI 10.1016/0090-1229(90)90094-7; FROST SC, 1985, J BIOL CHEM, V260, P2646; FUSHIKI T, 1989, AM J PHYSIOL, V256, pE580, DOI 10.1152/ajpendo.1989.256.5.E580; GIMBLE J, 1991, J CELL BIOCH B S, V15, P29; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; GOULD GW, 1989, J BIOL CHEM, V264, P2180; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HISSIN PJ, 1982, J CLIN INVEST, V70, P780, DOI 10.1172/JCI110674; HISSIN PJ, 1982, DIABETES, V31, P589, DOI 10.2337/diabetes.31.7.589; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN BB, 1991, J CLIN INVEST, V87, P561, DOI 10.1172/JCI115031; KAHN BB, 1988, J CLIN INVEST, V82, P691, DOI 10.1172/JCI113649; KARNIELI E, 1981, J CLIN INVEST, V68, P811, DOI 10.1172/JCI110318; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; KLIP A, 1983, ARCH BIOCHEM BIOPHYS, V221, P175, DOI 10.1016/0003-9861(83)90134-0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LANG CH, 1987, CIRC SHOCK, V22, P165; LEE MD, 1987, P NATL ACAD SCI USA, V84, P2590, DOI 10.1073/pnas.84.9.2590; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKALL J, 1979, ANAL BIOCHEM, V95, P270, DOI 10.1016/0003-2697(79)90216-1; Maniatis T., 1982, MOL CLONING; MCKEON C, 1991, BIOCHEM BIOPH RES CO, V174, P721, DOI 10.1016/0006-291X(91)91477-T; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; PILCH PF, 1990, ENDOCRINOLOGY, V126, P3, DOI 10.1210/endo-126-1-3; RAYMOND RM, 1985, J TRAUMA, V25, P845, DOI 10.1097/00005373-198509000-00007; RAYMOND RM, 1981, CIRC SHOCK, V8, P425; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; SHELMET JJ, 1988, J CLIN INVEST, V81, P1137, DOI 10.1172/JCI113428; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; WHEELER TJ, 1985, ANNU REV PHYSIOL, V47, P503, DOI 10.1146/annurev.ph.47.030185.002443; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513; ZECHNER R, 1988, MOL CELL BIOL, V8, P2394, DOI 10.1128/MCB.8.6.2394	62	326	334	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21839	21845						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939208				2022-12-25	WOS:A1991GP80400079
J	PIERCEALL, WE; ANANTHASWAMY, HN				PIERCEALL, WE; ANANTHASWAMY, HN			TRANSFORMATION OF NIH3T3 CELLS BY TRANSFECTION WITH UV-IRRADIATED HUMAN C-HA-RAS-1 PROTOONCOGENE DNA	ONCOGENE			English	Article							EXPOSED BODY SITES; HUMAN-SKIN CANCERS; RAS GENE; N-RAS; XERODERMA PIGMENTOSUM; ACTIVATED ONCOGENES; AMPLIFICATION; MUTATIONS; TUMORS; CARCINOGENESIS	Our previous studies have shown that human skin cancers occurring on sun-exposed body sites frequently contain G --> T mutations at the second position of Ha-ras codon 12. In this study, we investigated whether the c-Ha-ras-1 proto-oncogene could be activated by in vitro UV-irradiation of pEC plasmid DNA, which contains the 6.6 kb BamHI fragment of the human c-Ha-ras-1 proto-onocogene oncogene. Focus formation and nude mouse tumorigenicity assays showed that UV-irradiated pEC DNA induced morphologic and tumorigenic transformation of NIH3T3 cells in multiple cycles of transfection, whereas unirradiated pEC DNA did not. DNAs from secondary cycle foci and tertiary cycle tumors were analyzed for mutations in Ha-ras codons 12 and 61 using the polymerase chain reaction and synthetic oligonucleotide probes. Eleven of 11 secondary cycle foci analyzed possessed a G --> T mutation at the second position of Ha-ras codon 12. However, the nude mouse tumors exhibited a G --> A mutation at position 1 of the Ha-ras codon 12. These results suggest that in vitro UV irradiation of the c-Ha-ras-1 proto-oncogene DNA can induce mutations that are similar to those found in human skin cancers that originated on sun-exposed body sites.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,BOX 178,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [T32-CA-09598, R01-CA-46523] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046523, T32CA009598] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANANTHASWAMY HN, 1988, J CELL BIOCHEM, V36, P137, DOI 10.1002/jcb.240360205; ANANTHASWAMY HN, 1988, CANCER RES, V48, P3341; ANANTHASWAMY HN, 1989, MOL CARCINOGEN, V2, P298, DOI 10.1002/mc.2940020510; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLUM HF, 1959, CARCINOGENESIS ULTRA; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BOS JL, 1989, CANCER RES, V49, P4682; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; Epstein J H, 1978, Natl Cancer Inst Monogr, P13; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FORBES PD, 1981, J INVEST DERMATOL, V77, P139, DOI 10.1111/1523-1747.ep12479351; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUSAIN Z, 1990, ARCH DERMATOL, V126, P324, DOI 10.1001/archderm.126.3.324; KEIJZER W, 1989, CANCER RES, V49, P1229; KRIPKE ML, 1977, CANCER RES, V37, P1395; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; Maniatis T., 1982, MOL CLONING; MARSHALL CJ, 1984, NATURE, V310, P586, DOI 10.1038/310586a0; PADAU RA, 1985, MOL CELL BIOL, V5, P582; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; ROSENSTEIN BS, 1987, PHOTOCHEM PHOTOBIOL, V45, P775, DOI 10.1111/j.1751-1097.1987.tb07881.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Scotto J, 1978, Natl Cancer Inst Monogr, P169; SETLOW JANE K., 1966, CURR TOP RADIAT RES, V2, P195; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SHUKLA VK, 1989, ONCOGENE RES, V5, P121; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRICKLAND P T, 1985, Photochemistry and Photobiology, V41, p110S; SUAREZ HG, 1989, CANCER RES, V49, P1223; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Urbach F, 1969, LONG TERM FIELD MEAS; URBACH F, 1978, NATL CANCER I MONOGR, V50, P5; VANDERLUBBE JLM, 1988, ONCOGENE RES, V3, P9; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOUSDEN KH, 1986, P NATL ACAD SCI USA, V83, P1222, DOI 10.1073/pnas.83.5.1222; WHITE SI, 1988, J INVEST DERMATOL, V91, P407; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0; 1988, NASA1988 OZ TRENDS P	46	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2085	2091						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945413				2022-12-25	WOS:A1991GX11900020
J	CUI, Z; ZUBIAUR, M; BLOCH, DB; MICHEL, T; SEIDMAN, JG; NEER, EJ				CUI, Z; ZUBIAUR, M; BLOCH, DB; MICHEL, T; SEIDMAN, JG; NEER, EJ			EXPRESSION OF A G-PROTEIN SUBUNIT, ALPHA-I-1, IN BALB/C 3T3 CELLS LEADS TO AGONIST-SPECIFIC CHANGES IN GROWTH-REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GUANINE-NUCLEOTIDE-BINDING; ISLET-ACTIVATING PROTEIN; C-MYC EXPRESSION; PERTUSSIS TOXIN; ADENYLATE-CYCLASE; PHOSPHOLIPASE-C; DNA-SYNTHESIS; HAMSTER FIBROBLASTS; SIGNAL TRANSDUCTION	Cellular receptors for many hormones, neurotransmitters, and growth factors are coupled to intracellular effector enzymes or ion channels through a set of heterotrimeric G proteins. In order to determine whether isoforms of G protein alpha-subunits contribute differentially to mitogenic responses, we introduced an alpha-subunit isoform, alpha-i-1, into Balb/c 3T3 cells that normally lack this subtype. Balb/c 3T3 cells transfected with a plasmid containing cDNA encoding alpha-i-1 expressed the alpha-i-1 protein as judged both by the appearance of immunoreactive alpha-i-1 protein on Western blots and by two-dimensional analysis of the proteins [P-32]ADP-ribosylated by pertussis toxin. The amount of alpha-i-1 expressed is less than the amount of alpha-subunits endogenously present in these cells. Expression of alpha-i-1 in the transfected cells slightly blunts stimulation of adenylylcyclase by GTP, guanosine 5'-3-O-(thio)triphosphate, or forskolin, but has no major effect on the ability of thrombin to inhibit the enzyme. In contrast, the expression of alpha-i-1 has significant effects on cell growth and on the mitogenic response to thrombin. The alpha-i-1-transfected cells have a doubling time that is twice as long as control cells transfected with the same plasmid without a cDNA insert. Despite their slower growth, thymidine incorporation in response to thrombin is greater in transfected than in control cells. Thrombin-stimulated DNA synthesis is sensitive to inhibition by pertussis toxin and is 5-fold more sensitive to inhibition by pertussis toxin in transfected cells than in control cells. The changes are receptor-specific since the mitogenic response to platelet-derived growth factor is indistinguishable between control and transfected cells. These studies suggest that the alpha-i subunit composition of the cell may have profound effects on its growth and its response to stimulation through a specific cell surface receptor.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School			Zubiaur, Mercedes/K-9390-2014; Zubiaur, Mercedes/AAC-5792-2021	Zubiaur, Mercedes/0000-0002-4127-3027; Zubiaur, Mercedes/0000-0002-4127-3027; Bloch, Donald/0000-0002-6828-4754	NATIONAL CANCER INSTITUTE [R01CA046361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036295] Funding Source: NIH RePORTER; NCI NIH HHS [CA 46361] Funding Source: Medline; NIGMS NIH HHS [GM 36295] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLOCH DB, 1989, MOL CELL BIOL, V9, P5434, DOI 10.1128/MCB.9.12.5434; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263, P12970; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V152, P285, DOI 10.1016/S0006-291X(88)80712-5; HUFF RM, 1985, J BIOL CHEM, V260, P864; JONES DT, 1987, J BIOL CHEM, V262, P14241; KIM S, 1988, P NATL ACAD SCI USA, V85, P4153, DOI 10.1073/pnas.85.12.4153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1989, FEBS LETT, V249, P139, DOI 10.1016/0014-5793(89)80610-6; LETTERIO JJ, 1986, SCIENCE, V234, P1117, DOI 10.1126/science.3465038; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGNALDO I, 1988, BIOCHEM J, V253, P711, DOI 10.1042/bj2530711; MAGNALDO I, 1987, FEBS LETT, V210, P6, DOI 10.1016/0014-5793(87)81287-5; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; MURAYAMA T, 1985, J BIOL CHEM, V260, P7226; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARIS S, 1988, J BIOL CHEM, V263, P12893; POUYSSEGUR J, 1982, P NATL ACAD SCI-BIOL, V79, P3935, DOI 10.1073/pnas.79.13.3935; POUYSSEGUR J, 1990, G PROTEINS, P555; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; RABEN DM, 1987, BIOCHEMISTRY-US, V26, P2759, DOI 10.1021/bi00384a016; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SPIEGEL AM, 1990, SOC GEN PHY, V45, P185; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAYLOR CW, 1988, BIOCHEM J, V249, P917, DOI 10.1042/bj2490917; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZACHARY I, 1987, BIOCHEM BIOPH RES CO, V146, P456, DOI 10.1016/0006-291X(87)90551-1	43	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20276	20282						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939086				2022-12-25	WOS:A1991GM03900060
J	KESHAVJEE, K; PYNE, C; BOGNAR, AL				KESHAVJEE, K; PYNE, C; BOGNAR, AL			CHARACTERIZATION OF A MUTATION AFFECTING THE FUNCTION OF ESCHERICHIA-COLI FOLYLPOLYGLUTAMATE SYNTHETASE-DIHYDROFOLATE SYNTHETASE AND FURTHER MUTATIONS PRODUCED INVITRO AT THE SAME LOCUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMATE SYNTHETASE; SITE-SPECIFIC MUTAGENESIS; FOLC GENE; PHENOTYPIC SELECTION; PLASMID DNA; PURIFICATION; EXPRESSION; CONSTRUCTION; DELETION; CLONING	The folC gene from mutant strain SF4 was cloned into a pUC19 plasmid. Expression of the mutant gene from the lac promoter of the plasmid complemented the auxotrophy for methionine of the SF4 strain. The only difference in sequence between the mutant and wild-type genes was a G925A base change resulting in an A309T amino acid change. The mutant enzyme had a 30-fold higher K(m) for 10-formyltetrahydrofolate as well as a 60-fold higher K(m) for glutamate and a 200-fold higher K(m) for dihydropteroate of the dihydrofolate synthetase activity. Site-specific mutagenesis was used to substitute other amino acids at codon 309. Mutants with glycine, isoleucine, and valine substitutions at this position, when expressed from multicopy plasmids, complemented the SF4 strain. The glycine mutant had properties similar to the wild-type enzyme, whereas the isoleucine and valine mutants had properties similar to the threonine mutant, SF4. Mutant genes with arginine, glutamate, and leucine substitutions, which did not complement the SF4 strain, could complement a folC deletion strain, but produced smaller colonies on complex plates and did not grow on minimal medium. In the deletion strain, an increasing requirement for folate product supplements was observed as the folylpolyglutamate synthetase-dihydrofolate synthetase activities of the complementing mutants decreased.	UNIV TORONTO,DEPT MICROBIOL,150 COLL ST,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto				Keshavjee, Karim/0000-0003-1317-7035				BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOGNAR A, 1989, J BACTERIOL, V171, P1854, DOI 10.1128/jb.171.4.1854-1861.1989; BOGNAR AL, 1987, J BIOL CHEM, V262, P12337; BOGNAR AL, 1985, J BIOL CHEM, V260, P5625; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIETZLER DN, 1973, ARCH BIOCHEM BIOPHYS, V156, P684, DOI 10.1016/0003-9861(73)90321-4; DRIVER RP, 1985, J BACTERIOL, V162, P598, DOI 10.1128/JB.162.2.598-606.1985; FERONE R, 1986, J BIOL CHEM, V261, P6363; FERONE R, 1986, J BIOL CHEM, V261, P6356; FERONE R, 1983, CHEM BIOL PTERIDINES, P585; FERONE R, 1983, 2ND P WORKSH FOL ANT, P161; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOWELL EE, 1988, J BACTERIOL, V170, P3040, DOI 10.1128/jb.170.7.3040-3045.1988; Ingraham J., 1987, ESCHERICHA COLI SALM, V2, P1543; JASIN M, 1984, J BACTERIOL, V159, P783, DOI 10.1128/JB.159.2.783-786.1984; KIMLOVA LJ, 1991, ARCH BIOCHEM BIOPHYS, V284, P9, DOI 10.1016/0003-9861(91)90254-G; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MASUREKAR M, 1975, BIOCHEMISTRY-US, V14, P2424, DOI 10.1021/bi00682a024; MEACOCK PA, 1979, MOL GEN GENET, V174, P135, DOI 10.1007/BF00268351; Miller J. H., 1972, EXPT MOL GENETICS, P431; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANE B, 1980, J BIOL CHEM, V255, P5655; TOY J, 1990, J BIOL CHEM, V265, P2492; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WHITFIELD CD, 1970, J BIOL CHEM, V245, P390	28	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19925	19929						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939056				2022-12-25	WOS:A1991GM03900012
J	LITCHFIELD, DW; LOZEMAN, FJ; CICIRELLI, MF; HARRYLOCK, M; ERICSSON, LH; PIENING, CJ; KREBS, EG				LITCHFIELD, DW; LOZEMAN, FJ; CICIRELLI, MF; HARRYLOCK, M; ERICSSON, LH; PIENING, CJ; KREBS, EG			PHOSPHORYLATION OF THE BETA SUBUNIT OF CASEIN KINASE-II IN HUMAN-A431 CELLS - IDENTIFICATION OF THE AUTOPHOSPHORYLATION SITE AND A SITE PHOSPHORYLATED BY P34CDC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; MYELIN BASIC-PROTEIN; RAT-LIVER CYTOSOL; LARGE T-ANTIGEN; CDC2 KINASE; MOLECULAR-CLONING; XENOPUS OOCYTES; ALPHA-SUBUNIT; CYCLE CONTROL	To examine the phosphorylation of casein kinase II in cells, the enzyme was isolated by immunoprecipitation from metabolically labeled human epidermal carcinoma A431 cells using polyclonal antipeptide antibodies specific for either the alpha-subunit or the beta-subunit of the enzyme. When isolated from P-32-labeled cells, the beta-subunit was found to be significantly labeled on serine residues whereas only minimal labeling was associated with the a subunit. In vitro, the beta-subunit of purified bovine casein kinase II was autophosphorylated, also on serine residues. Cleavage of the beta-subunit, that had been autophosphorylated in vitro, at tryptophan 9 and tryptophan 12 using N-chlorosuccinimide demonstrated that the autophosphorylation site is located near the amino terminus of the protein, most likely at serine 2 and serine 3. Two-dimensional maps of phosphopeptides generated by digestion of the beta-subunit with endoproteinase Glu-C indicted that the majority of the phosphate that was incorporated into the protein in cells was at sites that were indistinguishable from the sites that were autophosphorylated in vitro. In addition to phosphorylation at the autophosphorylation site, the beta-subunit is also phosphorylated at an additional site, serine 209, in intact cells. This residue, which is near the carboxyl terminus of the protein, can be phosphorylated in vitro by p34cdc2.	UNIV WASHINGTON, DEPT PHARMACOL, MAIL STOP SL-15, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42528] Funding Source: Medline; NIGMS NIH HHS [GM42508, GM-15731] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AGOSTINIS P, 1987, BIOCHEM J, V248, P785, DOI 10.1042/bj2480785; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; COCHET C, 1983, J BIOL CHEM, V258, P1403; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DOOLITTLE RF, 1986, URFS ORFS, P63; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Drapeau G R, 1976, Methods Enzymol, V45, P469; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FIRZLAFF J M, 1989, New Biologist, V1, P44; GRANDE J, 1989, ARCH BIOCHEM BIOPHYS, V275, P478, DOI 10.1016/0003-9861(89)90394-9; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANDROR KV, 1989, EUR J BIOCHEM, V180, P441, DOI 10.1111/j.1432-1033.1989.tb14666.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOPATZ I, 1990, NUCLEIC ACIDS RES, V18, P3639, DOI 10.1093/nar/18.12.3639; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LANGAN TA, 1980, PROTEIN PHOSPHORYLAT, P70; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MEGGIO F, 1988, FEBS LETT, V237, P225, DOI 10.1016/0014-5793(88)80206-0; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MULNERLORILLON O, 1990, EUR J BIOCHEM, V193, P529, DOI 10.1111/j.1432-1033.1990.tb19368.x; MULNERLORILLON O, 1988, EUR J BIOCHEM, V171, P107, DOI 10.1111/j.1432-1033.1988.tb13765.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TUAZON PT, 1991, ADV 2ND MESSENGER PH, V23, P123; VULLIET PR, 1989, J BIOL CHEM, V264, P16292	72	130	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20380	20389						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939094				2022-12-25	WOS:A1991GM03900075
J	PORTER, DJT; CHESTNUT, WG; TAYLOR, LCE; MERRILL, BM; SPECTOR, T				PORTER, DJT; CHESTNUT, WG; TAYLOR, LCE; MERRILL, BM; SPECTOR, T			INACTIVATION OF DIHYDROPYRIMIDINE DEHYDROGENASE BY 5-IODOURACIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA 5-FLUOROURACIL LEVELS; ANTITUMOR-ACTIVITY; RAT-LIVER; DEHALOGENATION; PYRIMIDINE; BROMOVINYLDEOXYURIDINE; ADENOCARCINOMA-755; PURIFICATION; DEGRADATION; MICE	5-Iodouracil was a substrate for bovine liver dihydropyrimidine dehydrogenase (DHPDHase) and was a potent inactivator of the enzyme. NADPH increased the rate of inactivation and thymine protected against inactivation. These findings suggest that 5-iodouracil was a mechanism-based inactivator. However, dithiothreitol and excess 5-iodouracil protected the enzyme against inactivation. Thus, a reactive product, presumably 5-iodo-5,6-dihydrouracil generated through the enzymatic reduction of 5-iodouracil, was released from DHPDHase during processing of 5-iodouracil. Since only 18% of [6-H-3]5-iodouracil reduced by DHPDHase was covalently bound to the enzyme and radiolabel was not lost to the solvent as tritium, the partition coefficient for inactivation was 4.5. However, the enzymatic activity was completely titrated with 1.7 mol of 5-iodouracil per mol of enzyme-bound flavin. These results indicate that there was 0.31 mol of enzyme-bound inactivator per mol of enzyme flavin. This suggests there were 3.2 flavins per active site, which is consistent with the report of multiple flavins per enzymic subunit (Podschun, B., Wahler, G., and Schnackerz, K. D. (1989) Eur. J. Biochem. 185, 219-224). DHPDHase was inactivated by 2.1 mol of racemic 5-iodo-5,6-dihydrouracil per mol of active sites. The stoichiometry for inactivation of the enzyme by the nonenzymatically generated enantiomer of 5-iodo-5,6-dihydrouracil was calculated to be 1. Two radiolabeled fragments were isolated from a tryptic digest of DHPDHase inactivated with radiolabeled 5-iodouracil. The amino acid sequences of these peptides were Asn-Leu-Ser-X-Pro-His and Asn-Leu-Ser-X-Pro-His-Gly-Met-Gly-Glu-Arg where X was the modified amino acid containing radiolabel from [6-H-3]5-iodouracil. Fast atom bombardment mass spectral analysis of the smaller peptide yielded a protonated parent ion mass of 782 daltons that was consistent with X being a S-(hexahydro-2,4-dioxo-5-pyrimidinyl)cysteinyl residue.	WELLCOME RES LABS,DIV ORGAN CHEM,RES TRIANGLE PK,NC 27709	Wellcome Research Laboratories	PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							BARRETT HW, 1956, J AM CHEM SOC, V78, P1612, DOI 10.1021/ja01589a030; BARRETT HW, 1964, BIOCHIM BIOPHYS ACTA, V91, P199, DOI 10.1016/0926-6550(64)90242-7; Bevington P. R., 1969, DATA REDUCTION ERROR; COOPER GM, 1970, CANCER RES, V30, P2937; DESGRANGES C, 1986, CANCER RES, V46, P1094; DEV IK, 1989, J BIOL CHEM, V264, P19132; DIASIO RB, 1988, J CLIN INVEST, V81, P47, DOI 10.1172/JCI113308; DORSETT MT, 1969, CANCER RES, V29, P79; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; HARRIS BE, 1990, CANCER RES, V50, P197; IIGO M, 1989, BIOCHEM PHARMACOL, V38, P1885; IIGO M, 1988, BIOCHEM PHARMACOL, V37, P1609; KLECKER RW, 1985, CLIN PHARMACOL THER, V38, P45, DOI 10.1038/clpt.1985.132; NAGUIB FNM, 1989, BIOCHEM PHARMACOL, V38, P1471, DOI 10.1016/0006-2952(89)90187-1; PODSCHUN B, 1989, EUR J BIOCHEM, V185, P219, DOI 10.1111/j.1432-1033.1989.tb15105.x; PORTER DJT, 1990, J BIOL CHEM, V265, P13540; RORK GS, 1975, J AM CHEM SOC, V97, P5566, DOI 10.1021/ja00852a041; SANDER EG, 1976, BIOORG CHEM, V5, P231, DOI 10.1016/0045-2068(76)90032-8; SHIOTANI T, 1981, J BIOL CHEM, V256, P219; TATSUMI K, 1987, JPN J CANCER RES, V78, P748; WASTERNACK C, 1980, PHARMACOL THERAPEUT, V8, P629, DOI 10.1016/0163-7258(80)90079-0; WATAYA Y, 1975, BIOCHEM BIOPH RES CO, V67, P818, DOI 10.1016/0006-291X(75)90886-4; WOODCOCK TM, 1980, CANCER-AM CANCER SOC, V45, P1135, DOI 10.1002/1097-0142(19800315)45:5+<1135::AID-CNCR2820451318>3.0.CO;2-Q; ZEECHENG K, 1961, J ORG CHEM, V26, P1877, DOI 10.1021/jo01065a046	24	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19988	19994						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939061				2022-12-25	WOS:A1991GM03900022
J	SARASWAT, LD; LOWEY, S				SARASWAT, LD; LOWEY, S			ENGINEERED CYSTEINE MUTANTS OF MYOSIN LIGHT CHAIN-2 - FLUORESCENT ANALOGS FOR STRUCTURAL STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; MUSCLE-CONTRACTION; SKELETAL-MUSCLE; TROPONIN-C; SUBFRAGMENT-1; HEAD; CALMODULIN; POLYMERASE; MICROSCOPY; CLEAVAGE	Site-directed mutagenesis has been used to insert cysteine residues at specific locations in the myosin light chain 2 (LC2) sequence. The aim was to modify these cysteines with one or more spectroscopic probes and to reconstitute myosin with labeled light chains for structural studies. Native LC2 has two endogenous cysteine residues at positions 126 and 155; a third sulfhydryl was added by replacing either Pro2, Ser73, or Pro94 with cysteine. By oxidizing the endogenous cysteines to an intramolecular disulfide bond (Katoh, T., and Lowey, S., (1989) J. Cell Biol. 109, 1549), it was expected that the new cysteine could be selectively labeled with a fluorescent probe. This proved more difficult to accomplish than anticipated due to the formation of secondary disulfide bonds between the newly engineered cysteines and the native ones. Nevertheless, the unpaired cysteines were labeled with 5-(iodoacetamido) fluorescein, and singly labeled species were purified by ion-exchange chromatography. Chymotryptic digestion of the light chains, followed by high performance liquid chromatography separation of the peptides, led to the identification of the fluorescein-labeled cysteines. After light chain exchange into myosin, the position of the thiols was mapped by antifluorescyl antibodies in the electron microscope. Rotary-shadowed images showed the antibody bound at the head/rod junction of myosin for all the mutants. These mapping studies, together with the finding that widely separated cysteines can form multiple disulfide bonds, support a model for LC2 as a flexible, globular molecule that resembles other Ca/Mg-binding proteins in tertiary structure.			SARASWAT, LD (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254, USA.				NIAMS NIH HHS [R37AR17350] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017350] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BECHET JJ, 1989, BIOCHIM BIOPHYS ACTA, V996, P199, DOI 10.1016/0167-4838(89)90248-3; BERTRAND R, 1989, FEBS LETT, V246, P171, DOI 10.1016/0014-5793(89)80277-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; COLLINS JH, 1976, NATURE, V259, P699, DOI 10.1038/259699a0; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; COOKE R, 1984, CONTRACTILE MECHANIS, P413; EARHART CF, 1979, FEMS MICROBIOL LETT, V6, P277; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HAMBLY B, 1991, BIOPHYS J, V59, P127, DOI 10.1016/S0006-3495(91)82205-6; HARRINGTON WF, 1979, P NATL ACAD SCI USA, V76, P5066, DOI 10.1073/pnas.76.10.5066; HARRINGTON WF, 1990, P NATL ACAD SCI USA, V87, P7453, DOI 10.1073/pnas.87.19.7453; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HUBER PAJ, 1989, BIOCHEMISTRY-US, V28, P9116, DOI 10.1021/bi00449a024; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARSH DJ, 1980, BIOCHEMISTRY-US, V19, P774, DOI 10.1021/bi00545a025; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; PASTRALANDIS SC, 1986, J BIOL CHEM, V261, P4811; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; REINACH FC, 1985, J MOL BIOL, V181, P411, DOI 10.1016/0022-2836(85)90229-3; RIMM DL, 1989, J CELL BIOL, V108, P1783, DOI 10.1083/jcb.108.5.1783; SHRIMPTON C, 1990, BIOPHYS J, V57, P545; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOKUNAGA M, 1987, J MOL BIOL, V194, P245, DOI 10.1016/0022-2836(87)90372-X; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; WINKELMANN DA, 1985, J MOL BIOL, V181, P487, DOI 10.1016/0022-2836(85)90422-X; WINKELMANN DA, 1983, CELL, V34, P295, DOI 10.1016/0092-8674(83)90160-5; WINKELMANN DA, 1986, J MOL BIOL, V188, P595, DOI 10.1016/S0022-2836(86)80009-2; WOLFF V, 1991, BIOPHYS J, V59, P410	37	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19777	19785						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918082				2022-12-25	WOS:A1991GK66700093
J	HUDSON, TH; GRILLO, FG				HUDSON, TH; GRILLO, FG			BREFELDIN-A ENHANCEMENT OF RICIN A-CHAIN IMMUNOTOXINS AND BLOCKADE OF INTACT RICIN, MODECCIN, AND ABRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INACTIVATION; TRANS-GOLGI NETWORK; DIPHTHERIA-TOXIN; ENDOPLASMIC-RETICULUM; INTERNALIZED RICIN; SECRETORY PROTEINS; INTRACELLULAR-TRANSPORT; MONOCLONAL-ANTIBODIES; RAT HEPATOCYTES; CELLS	After binding, the protein toxins ricin, abrin, and modeccin are endocytosed and processed through the cell's vesicular system in a poorly understood fashion, prior to translocation to the cytosol. The role of the Golgi apparatus in toxin processing was studied using brefeldin-A (BFA), a fungal metabolite which blocks Golgi function. At concentrations that inhibit secretion of interleukin-2 (IL-2), BFA blocks ricin, modeccin, and abrin intoxication of a lymphocyte derived cell line (Jurkat). Paradoxically, BFA enhances the toxicity of two ricin A-chain immunotoxins targeted against distinct cell surface determinants. BFA concentrations which are optimal for immunotoxin enhancement are below those needed to affect ricin intoxication or IL-2 secretion. BFA blockade of ricin does not involve effects on ricin endocytosis, toxin translocation to the cytosol, or the enzymatic activity of toxin A-chain. In contrast, BFA has no effect on immunotoxin processing but does enhance the immunotoxin translocation step. It is concluded that: 1) intact Golgi function is required for holotoxin processing. 2) Intact Golgi function is not required for holotoxin translocation. 3) Golgi function is tightly linked to immunotoxin translocation. 4) BFA has effects on vesicular routing in addition to the block of Golgi function in secretion which has been reported.	WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,DIV MED,DEPT NEPHROL,WASHINGTON,DC 20307; WALTER REED ARMY MED CTR,WALTER REED ARMY INST RES,DEPT BIOL,DIV EXPTL THERAPEUT,WASHINGTON,DC 20307	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center								BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BJORN MJ, 1985, CANCER RES, V45, P1214; BOQUET P, 1976, P NATL ACAD SCI USA, V73, P4449, DOI 10.1073/pnas.73.12.4449; CASELLAS P, 1984, J BIOL CHEM, V259, P9359; CASELLAS P, 1988, IMMUNOTOXINS, P351; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DRAPER RK, 1984, J BIOL CHEM, V259, P4083; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ESWORTHY RS, 1984, J BIOL CHEM, V259, P1496; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GONATAS J, 1980, J CELL BIOL, V87, P579, DOI 10.1083/jcb.87.3.579; HARRI E, 1963, HELV CHIM ACTA, V46, P1235, DOI 10.1002/hlca.19630460419; HUDSON TH, 1988, J BIOL CHEM, V263, P4773; HUDSON TH, 1985, J BIOL CHEM, V260, P2675; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; HUDSON TH, 1988, IMMUNOTOXINS, P371; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LODISH HF, 1987, J CELL BIOL, V104, P221, DOI 10.1083/jcb.104.2.221; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MORONEY SE, 1987, BIOCHEMISTRY-US, V26, P8390, DOI 10.1021/bi00399a054; NEVILLE DM, 1986, ANNU REV BIOCHEM, V55, P195, DOI 10.1146/annurev.biochem.55.1.195; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; OLSNES S, 1987, MEMBRANE MEDIATED CY, P83; Olsnes S., 1982, MOL ACTION TOXINS VI, P51; PAPPENHEIMER AM, 1973, SCIENCE, V182, P353, DOI 10.1126/science.182.4110.353; PASTAN I, 1986, CELL, V47, P641, DOI 10.1016/0092-8674(86)90506-4; PIRKER R, 1989, CANCER RES, V49, P4791; RAMAKRISHNAN S, 1989, CANCER RES, V49, P613; ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; SANDVIG K, 1986, CANCER RES, V46, P6418; SIMMONS BM, 1986, J BIOL CHEM, V261, P7912; TAKATSUKI A, 1985, AGR BIOL CHEM TOKYO, V49, P899, DOI 10.1080/00021369.1985.10866826; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; THORPE PE, 1984, EUR J BIOCHEM, V140, P63, DOI 10.1111/j.1432-1033.1984.tb08067.x; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; VALERRA DA, 1983, SCIENCE, V222, P512; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1987, EXP CELL RES, V171, P137, DOI 10.1016/0014-4827(87)90257-6; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; VANDEURS B, 1990, TRAFFICKING BACTERIA, P91; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; VITETTA ES, 1984, J EXP MED, V160, P340; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; YOSHIDA T, 1990, EXP CELL RES, V190, P11, DOI 10.1016/0014-4827(90)90137-Y; YOULE RJ, 1982, J BIOL CHEM, V257, P1598; YOULE RJ, 1979, P NATL ACAD SCI USA, V76, P5559, DOI 10.1073/pnas.76.11.5559; YOULE RJ, 1987, J BIOL CHEM, V262, P4676	52	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18586	18592						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917980				2022-12-25	WOS:A1991GJ47200031
J	MOORE, RB; MANKAD, MV; SHRIVER, SK; MANKAD, VN; PLISHKER, GA				MOORE, RB; MANKAD, MV; SHRIVER, SK; MANKAD, VN; PLISHKER, GA			RECONSTITUTION OF CA2+-DEPENDENT K+ TRANSPORT IN ERYTHROCYTE-MEMBRANE VESICLES REQUIRES A CYTOPLASMIC PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; RED BLOOD-CELLS; INTRACELLULAR CALCIUM; SMOOTH-MUSCLE; CA; EFFLUX; APAMIN; PUMP	We have demonstrated that calcium-dependent potassium transport in erythrocytes requires the participation of a cytoplasmic protein. Activation of calcium-dependent potassium transport causes an increase in the membrane-bound levels of this protein which is dependent on the calcium concentration and which is highly correlated (r = 0.791, p < 0.0001) with the loss of potassium. Reconstitution of this transport pathway in sonicated erythrocyte membrane vesicles was achieved only in vesicles containing the cytoplasmic protein indicating a causal relationship in this transport system. The protein is found in high levels within the cytoplasm of erythrocytes (5.6 mg/ml red blood cells) and yet less than 1% of the protein located in the cytoplasm is required to bind to the membrane in order to initiate the potassium efflux. The analysis of rat organ homogenates demonstrated that this protein is located in most tissues with particular enrichment in adrenal glands, brain, lung, and blood. These results demonstrate that there is a cytoplasmic protein, herein named calpromotin, which is a necessary and sufficient cytoplasmic component of calcium-dependent potassium transport in erythrocytes and perhaps other tissues.	BAYLOR COLL MED,DEPT NEUROL,HOUSTON,TX 77030	Baylor College of Medicine	MOORE, RB (corresponding author), UNIV SO ALABAMA,MED CTR,DEPT PEDIAT,COMPREHENS SICKLE CELL CTR,2451 FILLINGIM ST,MOBILE,AL 36617, USA.							BENJAMIN AM, 1984, J CELL PHYSIOL, V121, P508, DOI 10.1002/jcp.1041210309; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BLUM RM, 1971, J MEMBRANE BIOL, V6, P315, DOI 10.1007/BF02116577; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON F, 1988, MUSCLE NERVE, V11, P1029, DOI 10.1002/mus.880111004; CECCHI X, 1986, J MEMBRANE BIOL, V91, P11, DOI 10.1007/BF01870210; COOK NS, 1985, J PHYSIOL-LONDON, V358, P373, DOI 10.1113/jphysiol.1985.sp015556; ENGELMANN B, 1987, J MEMBRANE BIOL, V98, P79, DOI 10.1007/BF01871047; FERREIRA HG, 1976, NATURE, V259, P47, DOI 10.1038/259047a0; FERREIRA HG, 1976, NATURE, V263, P336; Gardos G, 1958, ACTA PHYSL HUNG, V15, P121; GARDOS G, 1957, ACTA PHYSL HUNG, V14, P1; GRYGORCZYK R, 1984, BIOPHYS J, V45, P693, DOI 10.1016/S0006-3495(84)84211-3; HINDS RF, 1988, J CELL BIOL, V107, P75; HUNTER M, 1984, P NATL ACAD SCI-BIOL, V81, P4237, DOI 10.1073/pnas.81.13.4237; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LEW VL, 1970, J PHYSIOL-LONDON, V206, pP35; LEW VL, 1979, MEMBRANE TRANSPORT B, V2, P81; MAUE RA, 1987, J GEN PHYSIOL, V90, P95, DOI 10.1085/jgp.90.1.95; MCCANN JD, 1986, J PHYSIOL-LONDON, V372, P113, DOI 10.1113/jphysiol.1986.sp016000; MOORE RB, 1990, BIOCHEM BIOPH RES CO, V166, P146, DOI 10.1016/0006-291X(90)91923-G; PLISHKER GA, 1986, AM J PHYSIOL, V251, pC535, DOI 10.1152/ajpcell.1986.251.4.C535; PLISHKER GA, 1985, AM J PHYSIOL, V248, pC419, DOI 10.1152/ajpcell.1985.248.5.C419; SCHATZMANN HJ, 1973, J PHYSIOL-LONDON, V235, P551, DOI 10.1113/jphysiol.1973.sp010403; SIMONS TJB, 1976, J PHYSIOL-LONDON, V256, P227, DOI 10.1113/jphysiol.1976.sp011322; TABARES L, 1985, BIOCHIM BIOPHYS ACTA, V814, P96, DOI 10.1016/0005-2736(85)90423-7; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157	29	103	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18964	18968						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918011				2022-12-25	WOS:A1991GJ47200085
J	PHILLIPS, RS; RICHTER, I; GOLLNICK, P; BRZOVIC, P; DUNN, MF				PHILLIPS, RS; RICHTER, I; GOLLNICK, P; BRZOVIC, P; DUNN, MF			REPLACEMENT OF LYSINE-269 BY ARGININE IN ESCHERICHIA-COLI TRYPTOPHAN INDOLE-LYASE AFFECTS THE FORMATION AND BREAKDOWN OF QUINONOID COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; NUCLEOTIDE-SEQUENCE; SALMONELLA-TYPHIMURIUM; PYRIDOXAL-PHOSPHATE; RESIDUES; SUBSTRATE; SYNTHASE; CYSTEINE; GENE; DECARBOXYLASE	Lysine 269 in Escherichia coli tryptophan indolelyase (tryptophanase) has been changed to arginine by site-directed mutagenesis. The resultant K269R mutant enzyme exhibits k(cat) values about 10% those of the wild-type enzyme with S-(o-nitrophenyl)-L-cysteine, L-tryptophan, and S-benzyl-L-cysteine, while k(cat)/K(m) values are reduced to 2% or less. The pH profile of k(cat)/K(m) for S-benzyl-L-cysteine for the mutant enzyme exhibits two pK(a) values which are too close to separate, with an average value of 7.6, while the wild-type enzyme exhibits pK(a) values of 6.0 and 7.8. The pK(a) for the interconversion of the 335 and 412 nm forms of the K269R enzyme is 8.3, while the wild-type enzyme exhibits a pK(a) of 7.4. Steady-state kinetic isotope effects on the reaction of [alpha-H-2]S-benzyl-L-cysteine with the K269R mutant enzyme (Dk(cat) = 2.0; D(k(cat)/K(m)) = 3.9) are larger than those of the wild-type enzyme (D)k(cat) = 1.4; (D)k(cat)/K(m) = 2.9). Rapid scanning stopped-flow kinetic studies demonstrate that the K269R mutant enzyme does not accumulate quinonoid intermediates with L-alanine, L-tryptophan, or S-methyl-L-cysteine, but does form quinonoid absorption peaks in complexes with S-benzyl-L-cysteine and oxindolyl-L-alanine, whereas wild-type enzyme forms prominent quinonoid bands with all these amino acids. Single wavelength stopped-flow kinetic studies demonstrate that the alpha-deprotonation of S-benzyl-L-cysteine is 6-fold slower in the K269R mutant enzyme, while the intrinsic deuterium kinetic isotope effect is less for the K269R enzyme ((D)k = 4.2) than for the wild-type ((D)k = 7.9). The decay of the K269R quinonoid intermediate in the presence of benzimidazole is 7.1-fold slower than that of the wild-type enzyme. These results demonstrate that Lys-269 plays a significant role in the conformational changes or electrostatic effects obligatory to the formation and decomposition of the quinonoid intermediate, although it is not an essential basic residue.	UNIV GEORGIA, SCH CHEM SCI, DEPT BIOCHEM, ATHENS, GA 30602 USA; STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA; UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA	University System of Georgia; University of Georgia; Stanford University; University of California System; University of California Riverside	PHILLIPS, RS (corresponding author), UNIV GEORGIA, SCH CHEM SCI, DEPT CHEM, ATHENS, GA 30602 USA.			Phillips, Robert/0000-0001-8710-562X	NIGMS NIH HHS [GM 42588] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT PA, 1983, BIOCHEMISTRY-US, V22, P4618, DOI 10.1021/bi00289a002; BOSSA F, 1977, BIOCHEM BIOPH RES CO, V78, P177, DOI 10.1016/0006-291X(77)91237-2; Cleland W W, 1979, Methods Enzymol, V63, P103; CRAWFORD IP, 1980, J MOL BIOL, V142, P489, DOI 10.1016/0022-2836(80)90259-4; DEELEY MC, 1981, J BACTERIOL, V147, P787, DOI 10.1128/JB.147.3.787-796.1981; HONDA T, 1985, J BIOCHEM, V97, P851, DOI 10.1093/oxfordjournals.jbchem.a135126; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KAGAMIYAMA H, 1970, J BIOL CHEM, V245, P2819; KAZARINOFF MN, 1977, J BIOL CHEM, V252, P7598; KIICK DM, 1988, BIOCHEMISTRY-US, V27, P7339, DOI 10.1021/bi00419a024; KOERBER SC, 1983, BIOCHEMISTRY-US, V22, P3424, DOI 10.1021/bi00283a019; KUMAGAI H, 1974, BIOCHEM BIOPH RES CO, V59, P789, DOI 10.1016/S0006-291X(74)80049-5; MILES EW, 1989, J BIOL CHEM, V264, P6280; MORINO Y, 1967, J BIOL CHEM, V242, P2800; NIHIRA T, 1985, EUR J BIOCHEM, V149, P129, DOI 10.1111/j.1432-1033.1985.tb08902.x; NIHIRA T, 1979, EUR J BIOCHEM, V101, P341, DOI 10.1111/j.1432-1033.1979.tb19726.x; NIHIRA T, 1981, EUR J BIOCHEM, V119, P273, DOI 10.1111/j.1432-1033.1981.tb05604.x; ODA T, 1988, J BIOCHEM-TOKYO, V104, P178, DOI 10.1093/oxfordjournals.jbchem.a122437; PHILLIPS RS, 1990, FEBS LETT, V268, P213, DOI 10.1016/0014-5793(90)81011-C; PHILLIPS RS, 1990, BIOCHEMISTRY-US, V29, P8608, DOI 10.1021/bi00489a016; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P6228, DOI 10.1021/bi00320a052; PHILLIPS RS, 1989, J BIOL CHEM, V264, P10627; PHILLIPS RS, 1989, J AM CHEM SOC, V111, P727, DOI 10.1021/ja00184a051; PHILLIPS RS, 1991, BIOCHEMISTRY-US, V30, P5927, DOI 10.1021/bi00238a017; PHILLIPS RS, 1989, ENZYME MICROB TECH, V11, P80, DOI 10.1016/0141-0229(89)90064-1; RAIBAUD O, 1977, EUR J BIOCHEM, V73, P591, DOI 10.1111/j.1432-1033.1977.tb11354.x; SANGER F, 1977, P NATL ACAD SCI USA, V80, P3963; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; TOKUSHIGE M, 1979, BIOCHEM BIOPH RES CO, V86, P976, DOI 10.1016/0006-291X(79)90213-4; TOKUSHIGE M, 1989, BIOCHIMIE, V71, P711, DOI 10.1016/0300-9084(89)90087-4; TOKUSHIGE M, 1985, J APPL BIOCHEM, V7, P38; VAALER GL, 1986, J BIOL CHEM, V261, P1010; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; WATANABE T, 1977, J BIOCHEM, V82, P733, DOI 10.1093/oxfordjournals.jbchem.a131750	34	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18642	18648						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917987				2022-12-25	WOS:A1991GJ47200039
J	SUBBARAMAIAH, K; CHARLES, H; SIMMS, SA				SUBBARAMAIAH, K; CHARLES, H; SIMMS, SA			PROBING THE ROLE OF CYSTEINE RESIDUES IN THE CHER METHYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CARBOXYL METHYLTRANSFERASES; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; COVALENT MODIFICATION; SENSORY TRANSDUCTION; S-ADENOSYLMETHIONINE; SIGNAL TRANSDUCTION; ASPARTATE RECEPTOR; GENE-PRODUCT; TRG	The CheR methyltransferase catalyzes the transfer of methyl groups from S-adenosylmethionine to specific glutamyl residues in bacterial chemoreceptor proteins. Studies with sulfhydryl reagents such as p-chloromercuribenzoate, N-ethylmaleimide, and 5,5'-dithiobis(2-nitrobenzoate) suggest that a cysteine residue is required for enzyme activity. The nucleotide sequence of the cheR gene predicts a 288-amino acid protein with cysteine residues at positions 31 and 229. To ascertain the role of these cysteine residues in the structure and function of the enzyme, oligonucleotide-directed mutagenesis was used to change each cysteine to serine. Whereas the Cys229-Ser mutation had essentially no effect on transferase activity, the Cys31-Ser mutation caused an 80% decrease in enzyme activity. The double mutant in which both cysteines were replaced by serines also had markedly reduced transferase activity. Preincubation of the wild type or Cys229-Ser proteins with either S-adenosylmethionine or beta-mercaptoethanol protected it from inhibition by sulfhydryl reagents, whereas prior incubation with the second substrate, the Tar receptor, gave partial protection. From these studies, Cys31 appears to be necessary for enzyme activity, and it seems to be located in the vicinity of the active site.	CUNY CITY COLL, DEPT CHEM, NEW YORK, NY 10031 USA	City University of New York (CUNY) System; City College of New York (CUNY)					NIGMS NIH HHS [NIGMS 08168] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BINSTOCK J, 1984, METHOD ENZYMOL, V106, P310; BOLLINGER J, 1984, P NATL ACAD SCI-BIOL, V81, P3287, DOI 10.1073/pnas.81.11.3287; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; EVERETT EA, 1990, J BIOL CHEM, V265, P17713; FUJIOKA M, 1988, BIOCHEMISTRY-US, V27, P7658, DOI 10.1021/bi00420a013; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; HAZELBAUER GL, 1983, INT REV CYTOL, V81, P33, DOI 10.1016/S0074-7696(08)62334-7; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; KEHRY MR, 1983, J BIOL CHEM, V258, P5050; KEHRY MR, 1983, P NATL ACAD SCI-BIOL, V80, P3599, DOI 10.1073/pnas.80.12.3599; KOSHLAND DE, 1988, BIOCHEMISTRY-US, V27, P5829, DOI 10.1021/bi00416a001; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; LUPAS A, 1989, J BIOL CHEM, V264, P17337; Maniatis T, 1989, MOL CLONING; NARA T, 1991, J BACTERIOL, V173, P1120, DOI 10.1128/jb.173.3.1120-1124.1991; NOWLIN DM, 1987, J BIOL CHEM, V262, P6039; Paik W. K., 1980, PROTEIN METHYLATION; PARK CY, 1990, J BACTERIOL, V172, P7179, DOI 10.1128/jb.172.12.7179-7187.1990; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RAZIN A, 1984, DNA METHYLATION BIOC; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2940, DOI 10.1021/bi00225a030; REICH NO, 1990, J BIOL CHEM, V265, P8929; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMS SA, 1991, J BIOL CHEM, V266, P12741; SIMMS SA, 1985, J BIOL CHEM, V260, P161; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; SOM S, 1991, J BIOL CHEM, V266, P2937; SOM S, 1990, J BIOL CHEM, V265, P4278; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; TOEWS ML, 1979, P NATL ACAD SCI USA, V76, P5544, DOI 10.1073/pnas.76.11.5544; Webb EC, 1984, ENZYME NOMENCLATURE; WU JC, 1987, J BIOL CHEM, V262, P4778; YAMAMOTO K, 1990, J BACTERIOL, V172, P383, DOI 10.1128/JB.172.1.383-388.1990; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	44	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19023	19027						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918019				2022-12-25	WOS:A1991GJ47200094
J	INOUE, J; ITOH, M; AKIZAWA, T; TOYOSHIMA, H; YOSHIDA, M				INOUE, J; ITOH, M; AKIZAWA, T; TOYOSHIMA, H; YOSHIDA, M			HTLV-1 REX PROTEIN ACCUMULATES UNSPLICED RNA IN THE NUCLEUS AS WELL AS IN CYTOPLASM	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; VIRAL MESSENGER-RNA; TRANS-ACTIVATOR GENE; LONG TERMINAL REPEAT; RESPONSIVE ELEMENT; TARGET SEQUENCE; TYPE-1 AFFECTS; EXPRESSION; HIV-1	The Rex protein of human T-cell leukemia viruses (HTLV) is a trans-acting regulator inducing the expression of gag and env mRNA containing the introns. The rex gene can also induce expression of unspliced RNA of human immunodeficiency viruses (HIV). We have analyzed the level of spliced and unspliced RNAs in nucleus and cytoplasm to understand the mechanism by which the Rex protein modulates RNA processing. With the gag gene of HTLV-1, the unspliced RNA was accumulated by Rex protein in both nucleus and cytoplasm. However, the apparent effects on nuclear unspliced RNA depended on the reporter genes: with the env gene of HTLV-1 as well as that of HIV-1, Rex did not accumulate the unspliced RNA in nucleus, but did so only in cytoplasm. These results clearly indicate that Rex protein not only activates the nuclear export of unspliced RNA, but also modulates some steps of RNA processing before the splicing, probably through stabilization of the precursor RNA.	UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research								ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALY TJ, 1989, NATURE, V342, P816, DOI 10.1038/342816a0; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1988, JPN J CANCER RES, V79, P800, DOI 10.1111/j.1349-7006.1988.tb00038.x; HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265, DOI 10.1128/JVI.63.3.1265-1274.1989; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; INOUE J, 1987, P NATL ACAD SCI USA, V84, P3635; INOUE JI, 1986, FEBS LETT, V209, P187, DOI 10.1016/0014-5793(86)81108-5; ITOH M, 1989, ONCOGENE, V4, P1275; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KNIGHT DM, 1987, SCIENCE, V236, P837, DOI 10.1126/science.3033827; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; ROSEN CA, 1988, P NATL ACAD SCI USA, V85, P2071, DOI 10.1073/pnas.85.7.2071; ROSENBLATT JD, 1988, SCIENCE, V240, P916, DOI 10.1126/science.2834826; SADAIE MR, 1988, P NATL ACAD SCI USA, V85, P9224, DOI 10.1073/pnas.85.23.9224; SADAIE RM, 1988, SCIENCE, V239, P2910; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; TERWILLIGER E, 1988, J VIROL, V62, P655, DOI 10.1128/JVI.62.2.655-658.1988; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; TRONO D, 1990, EMBO J, V9, P4155, DOI 10.1002/j.1460-2075.1990.tb07638.x; YOSHIDA M, 1984, HUMAN T CELL LEUKEMI, P141; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0; ZIMM K, 1983, CELL, V34, P865	34	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1753	1757						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923501				2022-12-25	WOS:A1991GX11800005
J	DENIS, CL; KEMP, BE; ZOLLER, MJ				DENIS, CL; KEMP, BE; ZOLLER, MJ			SUBSTRATE SPECIFICITIES FOR YEAST AND MAMMALIAN CAMP-DEPENDENT PROTEIN-KINASES ARE SIMILAR BUT NOT IDENTICAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BASIC RESIDUES; SUBUNIT	The substrate specificity of the cAMP-dependent protein kinase (cAPK) from Saccharomyces cerevisiae has been investigated using synthetic peptides corresponding to the local phosphorylation site sequence around Ser-230 in the yeast transcriptional activator ADR1. ADR1 is required for the expression of the glucose-repressible alcohol dehydrogenase. Yeast cAPK (encoded by the TPK1 gene) phosphorylated Ser-230 in the synthetic peptide ADR1-217-234, VRKRYLKKLTRRASFSAQ-NH2, with a K(m) of 5.3-mu-M compared with 46-mu-M for LRRASLG (Kemptide). Porcine heart cAPK phosphorylated the ADR1 peptide and Kemptide with the considerably lower K(m) values of 0.23 and 1.6-mu-M, respectively. These results indicate that the ADR1 peptide is an excellent substrate for cAPK. Both the yeast and mammalian protein kinases qualitatively shared a number of substrate specificity determinants in common involving residues on the proximal NH2-terminal side and up to the +4 position of the COOH-terminal side of the phosphoacceptor. The mammalian enzyme, however, had a much higher affinity for its substrates than did the yeast enzyme. In addition, the yeast and mammalian enzymes displayed several quantitative differences in their preferences for particular peptide substrates. In particular, the mammalian enzyme strongly preferred substrates with NH2-terminal extensions beyond the -4 position relative to the phosphoacceptor. These results suggest that all eukaryotic cAPKs recognize similar but not identical substrate specificity determinants. They also suggest that the different affinities for substrates that inhere to the individual enzymes could influence their physiological roles.	GENENTECH INC, DEPT PROT ENGN, S SAN FRANCISCO, CA 94080 USA; ST VINCENTS INST MED RES, FITZROY, VIC 3065, AUSTRALIA	Roche Holding; Genentech; St. Vincent's Institute of Medical Research	DENIS, CL (corresponding author), UNIV NEW HAMPSHIRE, DEPT BIOCHEM, DURHAM, NH 03824 USA.		Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082	FOGARTY INTERNATIONAL CENTER [F06TW001583] Funding Source: NIH RePORTER; FIC NIH HHS [F06 TWO1583-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; HILDER RC, 1985, BIOCHEM J, V229, P485; HODGES RS, 1975, ANAL BIOCHEM, V65, P241, DOI 10.1016/0003-2697(75)90509-6; HOUSE C, 1987, J BIOL CHEM, V262, P772; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PROROK M, 1989, BIOCHEM BIOPH RES CO, V165, P368, DOI 10.1016/0006-291X(89)91079-6; RITTENHOUSE J, 1987, J BIOL CHEM, V262, P10114; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; ZOLLER MJ, 1991, GENE, V99, P171, DOI 10.1016/0378-1119(91)90124-T; ZOLLER MJ, 1988, J BIOL CHEM, V263, P9142	15	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17932	17935						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917932				2022-12-25	WOS:A1991GG55300036
J	SCAGNELLI, GP; COOPER, PS; VANDENBROEK, JM; BERMAN, WF; SCHWARTZ, CC				SCAGNELLI, GP; COOPER, PS; VANDENBROEK, JM; BERMAN, WF; SCHWARTZ, CC			PLASMA 1-PALMITOYL-2-LINOLEOYL PHOSPHATIDYLCHOLINE - EVIDENCE FOR EXTENSIVE PHOSPHOLIPASE-A1 HYDROLYSIS AND HEPATIC-METABOLISM OF THE PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; CHOLESTEROL-METABOLISM; SUBSTRATE-SPECIFICITY; LIPASE; RAT; LECITHIN; CELLS; ACYLTRANSFERASE; SEPARATION	1-Palmitoyl-2-linoleoyl phosphatidylcholine (PLPC) labeled in either the choline, glycerol, palmitate, or linoleate component in reconstituted rat high density lipoprotein (rHDL), was administered by vein to rats with bile fistula and taurocholate infusion. PLPC disappeared from plasma in a monoexponential fashion with a half-life of 50 min. A small fraction, about 14%, of PLPC disappearance was due to removal of linoleate from the sn-2 ester bond to form plasma cholesterol esters, presumably by lecithin-cholesterol acyltransferase. Otherwise, nearly all of the PLPC components that disappeared from blood in 1 h were recovered in the liver. The choline, glycerol, and linoleate components appeared predominantly in hepatic phosphatidylcholine (PC). These three components remained together in the liver with similar fractions of each in individual PC molecular species, most notably 1-stearoyl-2-linoleoyl-PC and dilinoleoyl-PC as well as PLPC. However, the palmitate component was spread among hepatic triglyceride, free fatty acid, other phospholipids, and all palmitate-containing molecular species of PC. Less than 2% of any administered PLPC component appeared in 1-stearoyl-2-arachidonyl-PC, the major species by mass in the liver. The palmitate component from plasma PLPC appeared in biliary PC at a more rapid rate than glycerol and linoleate components; the latter components appeared in bile in identical fashion. The results show that about two-thirds of plasma PLPC disappearance is due to phospholipase A1 hydrolysis, probably hepatic lipase. The putative product, 2-linoleoyl-lysoPC, is efficiently reacylated with a saturated fatty acid in the liver, conserving PC.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,POB 711,MCV STN,RICHMOND,VA 23298	Virginia Commonwealth University					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM025920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038030] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-25920] Funding Source: Medline; NIDDK NIH HHS [P01-DK-38030] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAMBERGER M, 1983, J LIPID RES, V24, P869; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; EISENBERG S, 1984, J LIPID RES, V25, P1017; FOLCH J, 1957, J BIOL CHEM, V226, P497; HIRSCH J, 1958, J BIOL CHEM, V233, P311; Holub B J, 1978, Adv Lipid Res, V16, P1; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; KAWAMOTO T, 1980, BIOCHIM BIOPHYS ACTA, V619, P20; Kinnunen P.K.J., 1984, P307; KUKSIS A, 1969, J LIPID RES, V10, P25; LANDIN B, 1984, J LIPID RES, V25, P559; LAPOSATA EA, 1987, J BIOL CHEM, V262, P5333; LEDUC R, 1987, J BIOL CHEM, V262, P7680; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORASH SC, 1989, BIOCHIM BIOPHYS ACTA, V1004, P221, DOI 10.1016/0005-2760(89)90271-3; MORRISON WR, 1964, J LIPID RES, V5, P600; NESTLER JE, 1985, ENDOCRINOLOGY, V117, P502, DOI 10.1210/endo-117-2-502; PATTON GM, 1982, J LIPID RES, V23, P190; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; ROBERTSON A, 1962, BIOCHEMISTRY-US, V1, P804, DOI 10.1021/bi00911a012; ROBINS SJ, 1986, J LIPID RES, V27, P131; ROBINS SJ, 1982, J LIPID RES, V23, P604; RYTTER D, 1968, BIOCHIM BIOPHYS ACTA, V152, P418, DOI 10.1016/0005-2760(68)90054-4; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SCHWARTZ CC, 1982, J CLIN INVEST, V70, P105, DOI 10.1172/JCI110582; SCHWARTZ CC, 1982, J CLIN INVEST, V70, P863, DOI 10.1172/JCI110683; SPARKS JD, 1985, ADV LIPID RES, V21, P1; SUBBAIAH PV, 1985, J BIOL CHEM, V260, P5308; SUBBAIAH PV, 1988, BIOCHIM BIOPHYS ACTA, V963, P445, DOI 10.1016/0005-2760(88)90313-X	31	18	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18002	18011						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917938				2022-12-25	WOS:A1991GG55300048
J	VALENTINRANC, C; COMBEAU, C; CARLIER, MF; PANTALONI, D				VALENTINRANC, C; COMBEAU, C; CARLIER, MF; PANTALONI, D			MYOSIN SUBFRAGMENT-1 INTERACTS WITH 2 G-ACTIN MOLECULES IN THE ABSENCE OF ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; BINDING-SITES; F-ACTIN; COMPLEX; POLYMERIZATION; ADP; STOICHIOMETRY; DISSOCIATION; CONTRACTION; SEPARATION	The interaction between G-actin and myosin subfragment-1 (S1) has been monitored by pyrenylactin fluorescence and light scattering. In low ionic strength buffer and in the absence of ATP the polymerization of G-actin induced by myosin subfragment-1 is preceded by the formation of binary GS and ternary G2S complexes in which S1 interacts tightly in rapid equilibrium (K > 10(7) M-1) with one and two G-actin molecules, respectively. Pyrenyl fluorescence of G-actin is enhanced 4-fold in GS and 3-fold in G2S. At concentrations of G-actin and S1 in the micromolar range and above, G2S is the predominant species at G-actin/S1 ratios equal to or greater than 1. The isomer of myosin subfragment-1 carrying the A1 light chain, S1(A1), forms a tighter ternary complex than the isomer S1(A2). Actin-bound ATP is not hydrolyzed upon formation of GS and G2S. In the presence of one molar equivalent or more of myosin subfragment-1/mol of G-actin, in low ionic strength buffer containing no nucleotides, G-actin polymerizes faster in the presence of S1(A1) than in the presence of S1(A2). The interaction of S1 with G-actin is inhibited by the binding of ATP or ADP to S1, ATP having a higher affinity for S1 than ADP. The possible structural similarity of the G2S complex to the F-acto-S1 complex in the rigor state and the potential significance of a ternary (actin)2-myosin interaction for actomyosin-based motility are discussed.			VALENTINRANC, C (corresponding author), CNRS,ENZYMOL LAB,F-91198 GIF SUR YVETTE,FRANCE.							AMOS LA, 1982, NATURE, V299, P467, DOI 10.1038/299467a0; BRYAN J, 1984, J BIOL CHEM, V259, P7480; BRZESKA H, 1988, J BIOL CHEM, V263, P427; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; CHEN T, 1985, BIOCHEMISTRY-US, V24, P137, DOI 10.1021/bi00322a019; COATES JH, 1985, BIOCHEM J, V232, P351, DOI 10.1042/bj2320351; COOKE R, 1971, J MOL BIOL, V60, P249, DOI 10.1016/0022-2836(71)90291-9; COUE M, 1985, J BIOL CHEM, V260, P5033; DASGUPTA G, 1990, BIOCHEMISTRY-US, V29, P8503, DOI 10.1021/bi00488a043; DETMERS P, 1981, J BIOL CHEM, V256, P99; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; FRANK G, 1974, EUR J BIOCHEM, V44, P317; GEEVES MA, 1989, BIOCHEMISTRY-US, V28, P5864, DOI 10.1021/bi00440a024; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; GEEVES MA, 1986, BIOCHEMISTRY-US, V25, P8454, DOI 10.1021/bi00374a020; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; GREENE LE, 1984, J BIOL CHEM, V259, P7363; GREENE LE, 1980, J BIOL CHEM, V255, P543; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGRI E, 1987, LIFE SCI ADV, V6, P117; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MARQUARDT DW, 1964, IBM1394 SHAR LIBR DI; MCLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18; MILLER L, 1988, J BIOL CHEM, V263, P1996; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOCKRIN S, 1980, BIOCHEMISTRY-US, V9, P5358; MORALES MF, 1987, PERSPECTIVES ENERGY; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; PATE E, 1989, J MUSCLE RES CELL M, V10, P181, DOI 10.1007/BF01739809; PRESS WH, 1989, NUMERICAL RECIPES AR, P157; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; VALENTINRANC C, 1989, J BIOL CHEM, V264, P20871; VIETE F, 1615, CITED INDIRECTLY, pCH6; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WEEDS AG, 1977, J MOL BIOL, V111, P129, DOI 10.1016/S0022-2836(77)80119-8	42	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17872	17879						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917928				2022-12-25	WOS:A1991GG55300028
J	SANDVIG, K; VANDEURS, B				SANDVIG, K; VANDEURS, B			SELECTIVE MODULATION OF THE ENDOCYTIC UPTAKE OF RICIN AND FLUID PHASE MARKERS WITHOUT ALTERATION IN TRANSFERRIN ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV COPENHAGEN, PANUM INST, DEPT ANAT, STRUCT CELL BIOL UNIT, DK-2200 COPENHAGEN, DENMARK	University of Copenhagen	SANDVIG, K (corresponding author), NORWEGIAN RADIUM HOSP, INST CANC RES, N-0310 OSLO 3, NORWAY.							ALLEN RD, 1975, J CELL BIOL, V64, P497, DOI 10.1083/jcb.64.2.497; ANDERSON RGW, 1990, IN PRESS INTRACELLUL; BADER MF, 1983, PROG BRAIN RES, V58, P21, DOI 10.1016/S0079-6123(08)60003-5; BORISY GG, 1967, J CELL BIOL, V34, P525, DOI 10.1083/jcb.34.2.525; BROWN D, 1987, ANAT REC, V218, P237, DOI 10.1002/ar.1092180303; BROWN D, 1986, AM J PHYSIOL, V250, pC605, DOI 10.1152/ajpcell.1986.250.4.C605; BRUNK U, 1976, EXP CELL RES, V103, P295, DOI 10.1016/0014-4827(76)90266-4; BURGOYNE RD, 1987, BIOSCIENCE REP, V7, P281, DOI 10.1007/BF01121449; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COSSON P, 1989, J CELL BIOL, V108, P377, DOI 10.1083/jcb.108.2.377; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DAVIS RJ, 1987, J BIOL CHEM, V262, P13126; DAVOUST J, 1987, EMBO J, V6, P3601, DOI 10.1002/j.1460-2075.1987.tb02691.x; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GIBBS EM, 1986, J BIOL CHEM, V261, P3944; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P213, DOI 10.1002/jcp.1041330203; GOLDMAN R, 1976, EXP CELL RES, V99, P385, DOI 10.1016/0014-4827(76)90596-6; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOSHIMA K, 1984, J CELL BIOL, V98, P801, DOI 10.1083/jcb.98.3.801; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HAIGLER HT, 1979, J CELL BIOL, V83, P82, DOI 10.1083/jcb.83.1.82; HERMAN B, 1984, J CELL BIOL, V98, P565, DOI 10.1083/jcb.98.2.565; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; IZUMI T, 1989, J ELECTRON MICROSC, V38, P47; IZUMI T, 1988, ANAT REC, V220, P225, DOI 10.1002/ar.1092200302; MADSHUS IH, 1987, J CELL PHYSIOL, V131, P14, DOI 10.1002/jcp.1041310104; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MATTER K, 1989, J NEUROCHEM, V52, P370, DOI 10.1111/j.1471-4159.1989.tb09131.x; MIYATA Y, 1989, EXP CELL RES, V181, P454, DOI 10.1016/0014-4827(89)90102-X; MIYATA Y, 1988, EXP CELL RES, V178, P73, DOI 10.1016/0014-4827(88)90379-5; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; OKA JA, 1989, J BIOL CHEM, V264, P12016; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; PAYNE GS, 1988, J CELL BIOL, V106, P1453, DOI 10.1083/jcb.106.5.1453; PETERS KR, 1985, J CELL BIOL, V101, P2233, DOI 10.1083/jcb.101.6.2233; PHAIREWASHINGTON L, 1980, J CELL BIOL, V86, P641, DOI 10.1083/jcb.86.2.641; PHAIREWASHINGTON L, 1980, J CELL BIOL, V86, P634, DOI 10.1083/jcb.86.2.634; PRATTEN MK, 1979, BIOCHEM J, V180, P567, DOI 10.1042/bj1800567; RYSER HJP, 1988, J CELL PHYSIOL, V137, P490, DOI 10.1002/jcp.1041370314; SANDVIG K, 1986, CANCER RES, V46, P6418; SANDVIG K, 1979, EXP CELL RES, V121, P15, DOI 10.1016/0014-4827(79)90439-7; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SANDVIG K, 1988, J CELL BIOCHEM, V36, P73, DOI 10.1002/jcb.240360108; SANDVIG K, 1989, METHOD CELL BIOL, V32, P365; SMITH RM, 1983, J CELL PHYSIOL, V115, P199, DOI 10.1002/jcp.1041150215; TEMPLE A, 1973, IMMUNOLOGY, V24, P655; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VALBERG PA, 1985, J CELL BIOL, V101, P130, DOI 10.1083/jcb.101.1.130; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; VANDEURS B, 1990, TRAFFICKING BACTERIA, P91; VANDEURS B, 1989, INT REV CYTOL, V117, P131; WAGNER R, 1971, J CELL BIOL, V50, P804, DOI 10.1083/jcb.50.3.804; WESSELLS NK, 1971, SCIENCE, V171, P135, DOI 10.1126/science.171.3967.135; WILEMAN T, 1985, BIOCHEM J, V232, P1; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801	64	141	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1990	265	11					6382	6388						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CY587	1969411				2022-12-25	WOS:A1990CY58700074
J	HUANG, SS; KOH, HA; KONISH, Y; BULLOCK, LD; HUANG, JS				HUANG, SS; KOH, HA; KONISH, Y; BULLOCK, LD; HUANG, JS			DIFFERENTIAL PROCESSING AND TURNOVER OF THE ONCOGENICALLY ACTIVATED NEU/ERB B2 GENE-PRODUCT AND ITS NORMAL CELLULAR COUNTERPART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									MONSANTO CO,CHESTERFIELD,MO 63198; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL H4P 2R2,QUEBEC,CANADA	Monsanto; National Research Council Canada	HUANG, SS (corresponding author), ST LOUIS UNIV,SCH MED,EDWARD A DOISY DEPT BIOCHEM,1402 S GRAND BLVD,ST LOUIS,MO 63104, USA.				NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA-38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATHERTON E, 1979, PEPTIDES STRUCTURE F, P361; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEUEL TF, 1984, BLOOD, V64, P951; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; HUANG JS, 1986, J BIOL CHEM, V261, P1600; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OHTSUKA M, 1984, INT J CANCER, V34, P855, DOI 10.1002/ijc.2910340618; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	38	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1990	265	6					3340	3346						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CP236	1968062				2022-12-25	WOS:A1990CP23600054
J	BURBELO, PD; BRUGGEMAN, LA; GABRIEL, GC; KLOTMAN, PE; YAMADA, Y				BURBELO, PD; BRUGGEMAN, LA; GABRIEL, GC; KLOTMAN, PE; YAMADA, Y			CHARACTERIZATION OF A CIS-ACTING ELEMENT REQUIRED FOR EFFICIENT TRANSCRIPTIONAL ACTIVATION OF THE COLLAGEN-IV ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COMPONENTS; DNA-BINDING PROTEINS; HEAD-TO-HEAD; PROMOTER REGION; GENE-EXPRESSION; BIDIRECTIONAL PROMOTER; CHAIN; IDENTIFICATION; ALPHA-1(IV); CELLS	Two regulatory regions in the murine collagen IV enhancer were identified. Transient transfection assays delimited a 210-base pair fragment within the first intron of the alpha-1(IV) collagen gene that had significant transcriptional enhancer activity. DNase I protection and gel mobility shift confirmed that two regions, designated footprints A and B, within this fragment bound nuclear factors. Gel shift studies suggested that the CCTTATCTCTGATGG motif (A-34) in the footprint A region was important for specific nuclear factor binding. Mutations in the A-34 motif abolished factor binding as detected by gel shift and resulted in a significant decrease in enhancer activity in transient transfection assays of F9 teratocarcinoma cells. Two putative transcription factors of M(r) = 37,000 and M(r) = 94,000, which interact with the A-34 motif, were purified from Engelbreth-Holm-Swarm tumor tissue using DEAE-Sephacel, heparin-Sepharose, salmon sperm DNA-Sepharose, and specific A-34 oligonucleotide affinity chromatography. Southwestern analysis revealed that both of these factors were capable of binding the A-34 oligonucleotide directly and did not require additional subunits for binding. These data suggest that positively acting transcription factor(s) interact with the A-34 site in the enhancer and are required for efficient transcription of the alpha-1 and alpha-2(IV) collagen chain genes.			BURBELO, PD (corresponding author), NIDR,DEV BIOL LAB,BETHESDA,MD 20892, USA.		Burbelo, Peter D./B-1027-2009					ALAKOKKO L, 1987, BIOCHEM J, V244, P75, DOI 10.1042/bj2440075; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BURBELO PD, 1990, J BIOL CHEM, V265, P4839; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; CAGLIERO E, 1988, J CLIN INVEST, V82, P735, DOI 10.1172/JCI113655; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; DEAN DC, 1987, P NATL ACAD SCI USA, V84, P1876, DOI 10.1073/pnas.84.7.1876; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBIHARA I, 1988, LAB INVEST, V58, P262; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAYTES P, 1988, J BIOL CHEM, V263, P19274; KILLEN PD, 1988, J BIOL CHEM, V263, P12310; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; ORKIN RW, 1977, J EXP MED, V145, P204, DOI 10.1084/jem.145.1.204; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; PARSLOW TG, 1984, P NATL ACAD SCI USA, V81, P1650; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P13374; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SOININEN R, 1988, J BIOL CHEM, V263, P17217; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723	29	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22297	22302						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939251				2022-12-25	WOS:A1991GR56400039
J	HAWKINS, JR; SUPERTIFURGA, A; STEINMANN, B; DALGLEISH, R				HAWKINS, JR; SUPERTIFURGA, A; STEINMANN, B; DALGLEISH, R			A 9-BASE PAIR DELETION IN COL1A1 IN A LETHAL VARIANT OF OSTEOGENESIS IMPERFECTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN GENE STRUCTURE; TRIPLE-HELICAL DOMAIN; SINGLE BASE MUTATION; SYNDROME TYPE-IV; POINT MUTATIONS; III PROCOLLAGEN; HUMAN DNA; CHAIN; CLEAVAGE; CYSTEINE	A proband with lethal osteogenesis imperfecta has been investigated for the causative defect at the levels of collagen protein, mRNA, and DNA. Analysis of type I collagen synthesized by the proband's fibroblasts showed excessive post-translational modification of alpha-1(I) chains along the entire length of the helix. Overmodification of a chains could be prevented by incubation of the cells at 30 rather than 37-degrees-C, and the thermal stability of the triple helix, as determined by protease digestion, was normal. RNase A cleavage of RNA:RNA hybrids formed between the proband's mRNA and antisense RNA derived from normal pro-alpha-1(I) chain cDNA clones was used to locate an abnormality to exon 43 of the proband's pro-alpha-1(I) collagen gene (COL1A1). The nucleotide sequence of the corresponding gene region showed, in one allele, the deletion of 9 base pairs, not present in either parent, within a repeating sequence of exon 43. The mutation causes the loss of one of three consecutive Gly-Ala-Pro triplets at positions 868-876, but does not otherwise disrupt the Gly-X-Y sequence. Procollagen processing in fibroblast cultures and susceptibility of the mutant collagen I to cleavage with vertebrate collagenase were normal, indicating that the slippage of collagen chains by one Gly-X-Y triplet does not abolish amino-propeptidase and collagenase cleavage sites. How the mutation produces the lethal osteogenesis imperfecta phenotype is not entirely clear; the data suggest that the interaction of alpha-chains immediately prior to helix formation may be affected.	UNIV LEICESTER, DEPT GENET, LEICESTER LE1 7RH, ENGLAND; UNIV ZURICH, DEPT PEDIAT, DIV METAB, CH-8032 ZURICH, SWITZERLAND	University of Leicester; University of Zurich			Dalgleish, Raymond/I-6245-2019; Hawkins, Ross/M-7702-2014; superti-furga, andrea/E-9162-2015	Dalgleish, Raymond/0000-0001-7667-187X; superti-furga, andrea/0000-0002-3543-7531				BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BONADIO J, 1985, NATURE, V316, P363, DOI 10.1038/316363a0; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; BYERS PH, 1988, AM J HUM GENET, V42, P237; BYERS PH, 1989, AM J MED GENET, V34, P72, DOI 10.1002/ajmg.1320340114; CHANDLEY AC, 1989, J MED GENET, V26, P546, DOI 10.1136/jmg.26.9.546; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; COHN DH, 1986, P NATL ACAD SCI USA, V83, P6045, DOI 10.1073/pnas.83.16.6045; CONSTANTINOU CD, 1989, J CLIN INVEST, V83, P574, DOI 10.1172/JCI113920; DAHL HHM, 1990, AM J HUM GENET, V47, P286; DEVRIES WN, 1986, J BIOL CHEM, V261, P9056; GIBBS RA, 1987, SCIENCE, V236, P303, DOI 10.1126/science.3563511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANDE SR, 1989, J BIOL CHEM, V264, P15809; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LOPEZGALINDEZ C, 1988, P NATL ACAD SCI USA, V85, P3522, DOI 10.1073/pnas.85.10.3522; MANIATIS T, 1982, MOL CLONING LABORATO, P280; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; PROCKOP DJ, 1990, ADV HUM GENET, V19, P105; PROCKOP DJ, 1989, AM J MED GENET, V34, P60, DOI 10.1002/ajmg.1320340112; ROYCE PM, 1988, COLLAGEN REL RES, V8, P183; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STEINMANN B, 1984, J BIOL CHEM, V259, P1129; SUPERTIFURGA A, 1988, BIOCHEM BIOPH RES CO, V150, P140, DOI 10.1016/0006-291X(88)90497-4; SUPERTIFURGA A, 1988, J BIOL CHEM, V263, P6226; TABOR S, 1987, P NATL ACAD SCI USA, V74, P5463; TROMP G, 1988, P NATL ACAD SCI USA, V85, P5254, DOI 10.1073/pnas.85.14.5254; VEIS A, 1989, J BIOL CHEM, V264, P3884; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; WALLIS GA, 1989, AM J HUM GENET, V45, P228; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; WILLING MC, 1988, J BIOL CHEM, V263, P8398; WINTER E, 1985, P NATL ACAD SCI USA, V82, P7575, DOI 10.1073/pnas.82.22.7575; WONG Z, 1986, NUCLEIC ACIDS RES, V14, P4605, DOI 10.1093/nar/14.11.4605; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x; Woolley D.E., 1984, EXTRACELLULAR MATRIX, P119	40	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22370	22374						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939261				2022-12-25	WOS:A1991GR56400051
J	SOMAN, J; IISMAA, S; STOUT, CD				SOMAN, J; IISMAA, S; STOUT, CD			CRYSTALLOGRAPHIC ANALYSIS OF 2 SITE-DIRECTED MUTANTS OF AZOTOBACTER-VINELANDII FERREDOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTOCOCCUS-AEROGENES FERREDOXIN; POTENTIAL IRON PROTEIN; REFINEMENT; RESOLUTION; MUTAGENESIS	The crystal structure of the C24A mutant of Azotobacter vinelandii 7Fe ferredoxin (FdI) has been solved and refined at 2.0-angstrom resolution. The structure is isomorphous to native FdI except at the site of mutation where A24 moves toward the [4Fe-4S] cluster. In spite of this inefficient packing results: three of five van der Waals contacts from the S-gamma of C24 in native FdI are lost and the remaining two become longer. Consequently, the [4Fe-4S] cluster is either disordered or has a higher temperature factor (B factor) compared to the rest of the C24A FdI molecule. In addition, the entire C24A FdI structure has a higher overall B factor than native FdI. Therefore, in comparison to native FdI, the C24A mutant is isomorphous but exhibits large differences in B factor, especially at the [4Fe-4S] cluster. In contrast, the C20A FdI structure (Martin, A. G., Burgess, B. K., Stout, C. D., Cash, V. L., Dean, D. R., Jensen, G. M., and Stephens, P. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 598-602), which contains large structural rearrangements in the vicinity of the [4Fe-4S] cluster, exhibits essentially no change in B factor. The conformational change observed at residue 24 is similar in both C24A and C20A Fdl structures. The solvent accessibility of the Fe atoms in the [3Fe-4S] and [4Fe-4S] clusters is similar in C24A, C20A, and native FdI.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine	SOMAN, J (corresponding author), Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.		Iismaa, Siiri/C-9300-2013	Iismaa, Siiri/0000-0003-2409-7356	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036325] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-36325] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN ET, 1976, J BIOL CHEM, V251, P3801; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BENKOVIC SJ, 1988, SCIENCE, V239, P1105, DOI 10.1126/science.3125607; BRIGLE KE, 1987, P NATL ACAD SCI USA, V84, P7066, DOI 10.1073/pnas.84.20.7066; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CARTER CW, 1974, J BIOL CHEM, V249, P6339; CARTER CW, 1977, J BIOL CHEM, V252, P7802; FREER ST, 1975, J BIOL CHEM, V250, P46; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; MAKAROFF CA, 1986, J BIOL CHEM, V261, P1416; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT CD, 1979, J BIOL CHEM, V254, P3598; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; STRAHS G, 1968, J MOL BIOL, V35, P503, DOI 10.1016/S0022-2836(68)80010-5	19	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21558	21562						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939185				2022-12-25	WOS:A1991GP80400039
J	VERNET, T; KHOURI, HE; LAFLAMME, P; TESSIER, DC; MUSIL, R; GOURSALIN, BJ; STORER, AC; THOMAS, DY				VERNET, T; KHOURI, HE; LAFLAMME, P; TESSIER, DC; MUSIL, R; GOURSALIN, BJ; STORER, AC; THOMAS, DY			PROCESSING OF THE PAPAIN PRECURSOR - PURIFICATION OF THE ZYMOGEN AND CHARACTERIZATION OF ITS MECHANISM OF PROCESSING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PEPSINOGEN ACTIVATION; PROTEOLYTIC-ENZYMES; THIOL PROTEASE; DERIVATIVES; MUTAGENESIS; EXPRESSION; INHIBITORS; EFFICIENT; DNA	The precursor of the cysteine protease papain has been expressed and secreted as propapain from insect cells infected with a recombinant baculovirus expressing a synthetic gene coding for prepropapain. This 39-kDa secreted propapain zymogen molecule is glycosylated and can be processed in vitro into an enzymatically active authentic papain molecule of 24.5 kDa (Vernet, T., Tessier, D. C., Richardson, C., Laliberte, F., Khouri, H. E., Bell, A. W., Storer, A. C., and Thomas, D. Y. (1990) J. Biol. Chem. 265, 16661-16666). Recombinant propapain was stabilized with Hg2+ and purified to homogeneity using affinity chromatography, gel filtration, and ion-exchange chromatographic procedures. The maximum rate of processing in vitro was achieved at approximately pH 4.0, at a temperature of 65-degrees-C and under reducing conditions. Precursor processing is inhibited by a variety of reversible and irreversible cysteine protease inhibitors but not by specific inhibitors of serine, metallo or acid proteases. Replacement by site-directed mutagenesis of the active site cysteine with a serine at position 25 also prevents processing. The inhibitor I-125-N-(2S, 3S)-3-trans-hydroxycarbonyloxiran-2-carbonyl-L-tyrosine benzyl ester covalently labeled the wild type papain precursor, but not the C25S mutant, indicating that the active site is accessible to the inhibitor and is in a native conformation within the precursor. Based on biochemical and kinetic analyses of the activation and processing of propapain we have shown that the papain precursor is capable of autoproteolytic cleavage (intramolecular). Once free papain is released processing can then occur in trans (intermolecular).	NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, PROT ENGN SECT, MONTREAL H4P 2R2, QUEBEC, CANADA	National Research Council Canada	VERNET, T (corresponding author), NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, GENET ENGN SECT, 6100 ROYALMOUNT AVE, MONTREAL H4P 2R2, QUEBEC, CANADA.		Vernet, Thierry/G-1118-2012; Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				ALJANABI J, 1972, J BIOL CHEM, V247, P4628; Baker E.N., 1987, BIOL MACROMOL, V3, P314; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BLACKBURN S, 1976, ENZYME STRUCTURE FUN, P267; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKLEHURST K, 1973, NATURE-NEW BIOL, V242, P167, DOI 10.1038/newbio242167a0; Brocklehurst K., 1987, HYDROLYTIC ENZYMES, P39; COHEN LW, 1986, GENE, V48, P219, DOI 10.1016/0378-1119(86)90080-6; COHEN LW, 1990, GENE, V88, P263, DOI 10.1016/0378-1119(90)90041-O; COLL M, 1991, EMBO J, V10, P1; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; Desnuelle P., 1986, MOL CELLULAR BASIS D, P195; FELLEISEN R, 1990, EMBO J, V9, P371, DOI 10.1002/j.1460-2075.1990.tb08120.x; GLICK DM, 1989, BIOCHEMISTRY-US, V28, P2626, DOI 10.1021/bi00432a040; HANADA K, 1978, AGR BIOL CHEM TOKYO, V42, P537, DOI 10.1080/00021369.1978.10863016; HERRIOTT RM, 1938, J GEN PHYSIOL, V21, P65; HOLWERDA BC, 1990, PLANT CELL, V2, P1091, DOI 10.1105/tpc.2.11.1091; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; KASSELL B, 1973, SCIENCE, V180, P1022, DOI 10.1126/science.180.4090.1022; KIERSTAN M P J, 1982, Biochemical Society Transactions, V10, P172; Kunitz M, 1936, J GEN PHYSIOL, V19, P991, DOI 10.1085/jgp.19.6.991; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENARD R, 1990, BIOCHEMISTRY-US, V29, P6706, DOI 10.1021/bi00480a021; MENARD R, 1991, PROTEIN ENG, V4, P307; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH SM, 1989, J BIOL CHEM, V264, P20487; Summers MD, 1987, TEXAS AGR EXP STATIO, V1555; TAMAI M, 1981, AGR BIOL CHEM TOKYO, V45, P675, DOI 10.1080/00021369.1981.10864575; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; VARUGHESE KI, 1989, BIOCHEMISTRY-US, V28, P1330, DOI 10.1021/bi00429a058; VERNET T, 1990, J BIOL CHEM, V265, P16661; VERNET T, 1989, GENE, V77, P229, DOI 10.1016/0378-1119(89)90071-1; WURTZ A, 1879, CR HEBD ACAD SCI, V8, P425; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	36	98	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21451	21457						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939177				2022-12-25	WOS:A1991GP80400025
J	WHITE, BH; HOWARD, S; COHEN, SG; COHEN, JB				WHITE, BH; HOWARD, S; COHEN, SG; COHEN, JB			THE HYDROPHOBIC PHOTOREAGENT 3-(TRIFLUOROMETHYL)-3-M-([I-125]IODOPHENYL)DIAZIRINE IS A NOVEL NONCOMPETITIVE ANTAGONIST OF THE NICOTINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBENE-GENERATING REAGENT; RICH MEMBRANE-FRAGMENTS; AFFINITY BINDING-SITE; TORPEDO-MARMORATA; H-3 CHLORPROMAZINE; ALPHA-SUBUNIT; DELTA-SUBUNIT; CHOLINERGIC RECEPTORS; ELECTRIC ORGAN; LIPID BILAYER	We have shown previously that the lipophilic photoreagent 3-(trifluoromethyl)3-m-([I-125]iodophenyl)-diazirine ([I-125]TID) photolabels all four subunits of the Torpedo nicotinic acetylcholine receptor (AChR) and that > 70% of this photoincorporation is inhibited by cholinergic agonists and some noncompetitive antagonists, including histrionicotoxin (HTX), but not phencyclidine (PCP; White, B. H., and Cohen, J. B. (1988) Biochemistry 27, 8741-8751). We have now examined the effects of nonradioactive TID on (a) AChR photoincorporation of [I-125]TID, (b) AChR-mediated ion transport, and (c) AChR binding of several cholinergic ligands. We find that TID inhibits [I-125]TID photoincorporation into the AChR to the same extent as carbamylcholine. The saturable component of [I-125]TID photolabeling is half-maximal at 4-mu-M [I-125]TID with 0.5 mol specifically incorporated per mol of AChR after 30 min photolysis with 60-mu-M [I-125]TID. Repeated labeling of membranes at a fixed [I-125]TID concentration gave results consistent with a maximal incorporation of one [I-125]TID molecule per AChR. Nonradioactive TID also noncompetitively inhibits agonist-stimulated Na-22+ efflux from Torpedo vesicles with an IC50 of 1-mu-M. Furthermore, TID inhibits allosterically the binding of [H-3]HTX, decreasing its affinity for the AChR 5-fold both in the presence and absence of agonist. In contrast, TID has little effect on [H-3]PCP binding in the absence of agonist but completely inhibits it in the presence of agonist. TID enhances the cooperativity of [H-3]nicotine binding. [I-125]TID is thus a photoaffinity label for a novel noncompetitive antagonist binding site on the AChR that is linked allosterically to the binding sites of both agonists and other noncompetitive antagonists. The [I-125]TID site is presumably located within the central pore of the AChR.	WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA; BRANDEIS UNIV, DEPT CHEM, WALTHAM, MA 02254 USA	Washington University (WUSTL); Brandeis University					NINDS NIH HHS [NS19522] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019522] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS DJ, 1981, J GEN PHYSIOL, V78, P593, DOI 10.1085/jgp.78.6.593; ADAMS PR, 1976, J PHYSIOL-LONDON, V260, P531, DOI 10.1113/jphysiol.1976.sp011530; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; BRISSON A, 1985, NATURE, V315, P474, DOI 10.1038/315474a0; BRUNNER J, 1980, J BIOL CHEM, V255, P3313; BRUNNER J, 1985, BIOCHEMISTRY-US, V24, P5422, DOI 10.1021/bi00341a021; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; BRUNNER J, 1989, METHOD ENZYMOL, V172, P628; BUERKLER J, 1985, FEBS LETT, V182, P167, DOI 10.1016/0014-5793(85)81176-5; CHARNET P, 1990, NEURON, V4, P87, DOI 10.1016/0896-6273(90)90445-L; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Cohen J. B., 1986, MOL CELLULAR MECHANI, P111; COHEN JB, 1985, EFFECTS ANESTHESIA, P53; DIPAOLA M, 1990, J BIOL CHEM, V265, P11017; DREYER EB, 1986, J BIOL CHEM, V261, P3727; ELLIOTT J, 1979, BIOCHEMISTRY-US, V18, P1868, DOI 10.1021/bi00577a004; FORMAN SA, 1989, TRENDS PHARMACOL SCI, V10, P447, DOI 10.1016/S0165-6147(89)80009-4; FORMAN SA, 1987, BIOCHEMISTRY-US, V26, P2807, DOI 10.1021/bi00384a023; FREY AB, 1986, BIOCHEMISTRY-US, V25, P4797, DOI 10.1021/bi00365a012; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GIRAUDAT J, 1985, BIOCHEMISTRY-US, V24, P3121, DOI 10.1021/bi00334a008; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GIRAUDAT J, 1987, BIOCHEMISTRY-US, V26, P2410, DOI 10.1021/bi00383a003; GIRAUDAT J, 1989, FEBS LETT, V253, P190, DOI 10.1016/0014-5793(89)80957-3; HARTER C, 1988, BIOCHEMISTRY-US, V27, P1856, DOI 10.1021/bi00406a010; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P3112, DOI 10.1021/bi00282a014; HORROCKS DL, 1975, CLIN CHEM, V21, P370; HUGANIR RL, 1982, J BIOL CHEM, V257, P9372; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; KARLIN A, 1976, METHODS RECEPTOR RES, P1; KRIEG UC, 1987, BIOCHEMISTRY-US, V26, P103, DOI 10.1021/bi00375a015; KRODEL EK, 1979, MOL PHARMACOL, V15, P294; KUBALEK E, 1987, J CELL BIOL, V105, P9, DOI 10.1083/jcb.105.1.9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LECHLEITER J, 1984, P NATL ACAD SCI-BIOL, V81, P2929, DOI 10.1073/pnas.81.9.2929; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; MCCARTHY MP, 1989, J BIOL CHEM, V264, P10911; MCLARNON JG, 1986, MOL CELLULAR MECHANI, P155; MIDDLEMAS DS, 1983, BIOCHEM BIOPH RES CO, V115, P1075, DOI 10.1016/S0006-291X(83)80045-X; MIDDLEMAS DS, 1987, BIOCHEMISTRY-US, V26, P1219, DOI 10.1021/bi00379a003; NEUBIG RR, 1980, BIOCHEMISTRY-US, V19, P2770, DOI 10.1021/bi00553a036; NICHOLAS RA, 1984, BIOCHEMISTRY-US, V23, P888, DOI 10.1021/bi00300a015; OBERTHUR W, 1986, EMBO J, V5, P1815, DOI 10.1002/j.1460-2075.1986.tb04431.x; OSWALD RE, 1983, BIOCHEMISTRY-US, V22, P3128, DOI 10.1021/bi00282a015; PEDERSEN SE, 1990, BIOPHYS J, V57, pA126; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; ROTH SH, 1989, MOL PHARMACOL, V36, P874; SCHMITZ E, 1973, ORG SYNTH, V5, P897; SOBEL A, 1977, EUR J BIOCHEM, V80, P215, DOI 10.1111/j.1432-1033.1977.tb11874.x; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; TARRABHAZDAI R, 1980, J BIOL CHEM, V255, P1204; TAYLOR P, 1983, CURR TOP MEMBR TRANS, V18, P407; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VANCEUNEBROECK JC, 1986, BIOCHEM BIOPH RES CO, V138, P604, DOI 10.1016/S0006-291X(86)80539-3; VILLARROEL A, 1991, P ROY SOC B-BIOL SCI, V243, P69, DOI 10.1098/rspb.1991.0012; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009	61	77	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21595	21607						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939189				2022-12-25	WOS:A1991GP80400045
J	CHRISTGAU, S; SCHIERBECK, H; AANSTOOT, HJ; AAGAARD, L; BEGLEY, K; KOFOD, H; HEJNAES, K; BAEKKESKOV, S				CHRISTGAU, S; SCHIERBECK, H; AANSTOOT, HJ; AAGAARD, L; BEGLEY, K; KOFOD, H; HEJNAES, K; BAEKKESKOV, S			PANCREATIC BETA-CELLS EXPRESS 2 AUTOANTIGENIC FORMS OF GLUTAMIC-ACID DECARBOXYLASE, A 65-KDA HYDROPHILIC FORM AND A 64-KDA AMPHIPHILIC FORM WHICH CAN BE BOTH MEMBRANE-BOUND AND SOLUBLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; FUSION PROTEIN; RAT; INSULIN; ANTIBODIES; ISLET; GABA; IDENTIFICATION; LOCALIZATION; CDNA	The 64-kDa pancreatic beta-cell autoantigen, which is a target of autoantibodies associated with early as well as progressive stages of beta-cell destruction, resulting in insulin-dependent diabetes (IDDM) in humans, has been identified as the gamma-aminobutyric acid-synthesizing enzyme glutamic acid decarboxylase. We have identified two autoantigenic forms of this protein in rat pancreatic beta-cells, a M(r) 65,000 (GAD65) hydrophilic and soluble form of pI 6.9-7.1 and a M(r) 64,000 (GAD64) component of pI 6.7. GAD64 is more abundant than GAD65 and has three distinct forms with regard to cellular compartment and hydrophobicity. A major portion of GAD64 is hydrophobic and firmly membrane-anchored and can only be released from membrane fractions by detergent. A second portion is hydrophobic but soluble or of a low membrane avidity, and a third minor portion is soluble and hydrophilic. All the GAD64 forms have identical pI and mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Results of pulse-chase labeling with [S-35]methionine are consistent with GAD64 being synthesized as a soluble protein that is processed into a firmly membrane-anchored form in a process which involves increases in hydrophobicity but no detectable changes in size or charge. All the GAD64 forms can be resolved into two isoforms, alpha and beta, which differ by approximately 1 kDa in mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis but are identical with regard to all other parameters analyzed in this study. GAD65 has a shorter half-life than the GAD64 forms, remains hydrophilic and soluble, and does not resolve into isomers. Comparative analysis of the brain and beta-cell forms of GAD show that GAD65 and GAD64 in pancreatic beta-cells correspond to the larger and smaller forms of GAD in brain, respectively. The expression of different forms and the flexibility in subcellular localization of the GAD autoantigen in beta-cells may have implications for both its function and autoantigenicity.	UNIV CALIF SAN FRANCISCO, DEPT MED, DEPT MICROBIOL IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HORMONE RES INST, SAN FRANCISCO, CA 94143 USA; HAGEDORN RES LAB, DK-2820 GENTOFTE, DENMARK	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Novo Nordisk; Hagedorn Research Institute				Aanstoot, Henk-Jan/0000-0002-5534-1633	NIDDK NIH HHS [1PO1DK418] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AANSTOOT HJ, 1991, J CELL BIOCH A S, V15, P306; ATAR D, 1989, J IMMUNOL, V143, P533; BAEKKESKOV S, 1989, DIABETES, V38, P1133, DOI 10.2337/diabetes.38.9.1133; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1987, J CLIN INVEST, V79, P926, DOI 10.1172/JCI112903; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BAEKKESKOV S, 1988, LESSONS ANIMAL DIABE, P40; BJERRUM OJ, 1983, MODERN METHODS PROTE, P79; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CHANG YC, 1988, J NEUROSCI, V8, P2123; CHRISTIE M, 1988, DIABETOLOGIA, V31, P597, DOI 10.1007/BF00264766; CHRISTIE MR, 1990, J BIOL CHEM, V265, P376; ERDO SL, 1989, CELL TISSUE RES, V255, P431; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; FEY S, 1984, THESIS AARHUS U DENM; GARRY DJ, 1986, DIABETES, V35, P1090, DOI 10.2337/diabetes.35.10.1090; JULIEN JF, 1990, J NEUROCHEM, V54, P703, DOI 10.1111/j.1471-4159.1990.tb01928.x; KATAROVA Z, 1990, EUR J NEUROSCI, V2, P190, DOI 10.1111/j.1460-9568.1990.tb00412.x; KAUFMAN DL, 1991, J NEUROCHEM, V56, P720, DOI 10.1111/j.1471-4159.1991.tb08211.x; KAUFMAN DL, 1986, SCIENCE, V232, P1138, DOI 10.1126/science.3518061; KOBAYASHI Y, 1987, J NEUROSCI, V7, P2768; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGAY F, 1987, J NEUROCHEM, V48, P1022, DOI 10.1111/j.1471-4159.1987.tb05620.x; Mugnaini E, 1985, HDB CHEM NEUROANATOM, P436; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; REUSENSBILLEN B, 1984, CELL TISSUE RES, V235, P503, DOI 10.1007/BF00226946; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; SIGURDSSON E, 1990, CURR TOP MICROBIOL, V164, P143; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WOOD JG, 1976, GABA NERVOUS SYSTEM, P133; WYBORSKI RJ, 1990, MOL BRAIN RES, V8, P193, DOI 10.1016/0169-328X(90)90016-7	35	115	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21257	21264						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939164				2022-12-25	WOS:A1991GN00100104
J	PAZIRANDEH, M; CHIRALA, SS; WAKIL, SJ				PAZIRANDEH, M; CHIRALA, SS; WAKIL, SJ			SITE-DIRECTED MUTAGENESIS STUDIES ON THE RECOMBINANT THIOESTERASE DOMAIN OF CHICKEN FATTY-ACID SYNTHASE EXPRESSED IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-BETA-LACTAMASE; ACTIVE-SITE; SERINE; SYNTHETASE; CDNA; SEQUENCE; CYSTEINE; ARCHITECTURE; LIPASE; PAPAIN	The animal fatty acid synthase is a multifunctional protein with a subunit molecular weight of 260,000. We recently reported the expression and characterization of the acyl carrier protein and thioesterase domains of the chicken liver fatty acid synthase in Escherichia coli. In order to gain insight into the mechanism of action of the thioesterase domain, we have replaced the putative active site serine 101 with alanine and cysteine and the conserved histidine 274 with alanine by site-directed mutagenesis. While both the Ser101 --> Ala and His274 --> Ala mutant proteins were inactive, the Ser101 --> Cys mutant enzyme (thiol-thioesterase) retained considerable activity, but the properties of the enzyme were changed from an active serine esterase to an active cysteine esterase, providing strong evidence for the role of Ser101 as the active site nucleophile. In order to further probe into the role of His274, a double mutant was constructed containing both the Ser101 --> Cys and the His274 --> Ala mutations. The double-mutant protein was inactive and exhibited diminished reactivity of the Cys-SH to iodoacetamide as compared to that of the Ser101 --> Cys-thioesterase, suggesting a role of His274 as a general base in withdrawing the proton from the Cys-SH in the thiolthioesterase or Ser101 in the wild-type enzyme. Incubation of the recombinant thioesterases with [1-C-14] palmitoyl-CoA resulted in the incorporation of [1-C-14] palmitoyl into the enzyme only in the double mutant, suggesting that Cys-SH of the double mutant is reactive enough to form the palmitoyl-S-enzyme intermediate. This intermediate is not hydrolyzed because of the lack of His274, which is required for the attack of H2O on the acyl enzyme. These results suggest that the catalytic mechanism of the thioesterases may be similar to that of the serine proteases and lipases, which employ a serine-histidine-aspartic acid catalytic triad as part of their catalytic mechanism.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,1 BAYLOR PLAZA,HOUSTON,TX 77030	Baylor College of Medicine					NIGMS NIH HHS [GM-19091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDALL MR, 1976, EUR J BIOCHEM, V65, P493, DOI 10.1111/j.1432-1033.1976.tb10365.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; Brocklehurst K., 1987, HYDROLYTIC ENZYMES, P39; CHIRALA SS, 1989, J BIOL CHEM, V264, P3750; CRISP DJ, 1982, J PROTEIN CHEM, V3, P241; HARDIE DG, 1985, BIOCHIM BIOPHYS ACTA, V828, P380, DOI 10.1016/0167-4838(85)90320-6; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HIGAKI JN, 1989, BIOCHEMISTRY-US, V28, P9256, DOI 10.1021/bi00450a004; KASTURI R, 1988, BIOCHEMISTRY-US, V27, P7778, DOI 10.1021/bi00420a029; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS SD, 1978, J BIOL CHEM, V253, P5080; LIBERTINI LJ, 1979, ARCH BIOCHEM BIOPHYS, V192, P47, DOI 10.1016/0003-9861(79)90070-5; MATTICK JS, 1983, J BIOL CHEM, V258, P5300; MATTICK JS, 1983, J BIOL CHEM, V258, P5291; Miles E W, 1977, Methods Enzymol, V47, P431; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; NEET KE, 1966, P NATL ACAD SCI USA, V56, P1606, DOI 10.1073/pnas.56.5.1606; NEET KE, 1968, J BIOL CHEM, V243, P6392; PAZIRANDEH M, 1989, J BIOL CHEM, V264, P18195; POLGAR L, 1982, BIOCHEM J, V207, P1; POLGAR L, 1967, BIOCHEMISTRY-US, V6, P610, DOI 10.1021/bi00854a032; POULOSE AJ, 1985, J BIOL CHEM, V260, P5953; POULOSE AJ, 1981, BIOCHEM BIOPH RES CO, V103, P377, DOI 10.1016/0006-291X(81)90463-0; RANDHAWA ZI, 1987, EUR J BIOCHEM, V162, P577, DOI 10.1111/j.1432-1033.1987.tb10678.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONBAUM GR, 1960, J AM CHEM SOC, V82, P1900, DOI 10.1021/ja01493a017; SHIPTON M, 1978, BIOCHEM J, V171, P385, DOI 10.1042/bj1710385; SIGAL IS, 1982, P NATL ACAD SCI-BIOL, V79, P7157, DOI 10.1073/pnas.79.23.7157; SIGAL IS, 1984, J BIOL CHEM, V259, P5327; SINGH N, 1984, J BIOL CHEM, V259, P3605; STOOPS JK, 1975, P NATL ACAD SCI USA, V72, P1940, DOI 10.1073/pnas.72.5.1940; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUKAMOTO Y, 1988, J BIOL CHEM, V263, P16225; TSUKAMOTO Y, 1983, J BIOL CHEM, V258, P5312; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WHITAKER JR, 1968, ARCH BIOCHEM BIOPHYS, V124, P70, DOI 10.1016/0003-9861(68)90304-4; WHITAKER JR, 1962, J AM CHEM SOC, V84, P1900, DOI 10.1021/ja00869a027; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YANG CY, 1988, BIOCHEMISTRY-US, V27, P7773, DOI 10.1021/bi00420a028; YOKOSAMA H, 1977, J BIOCH, V28, P869	44	67	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20946	20952						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939144				2022-12-25	WOS:A1991GN00100057
J	BREITER, DR; MEYER, TE; RAYMENT, I; HOLDEN, HM				BREITER, DR; MEYER, TE; RAYMENT, I; HOLDEN, HM			THE MOLECULAR-STRUCTURE OF THE HIGH-POTENTIAL IRON-SULFUR PROTEIN ISOLATED FROM ECTOTHIORHODOSPIRA-HALOPHILA DETERMINED AT 2.5-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR STRUCTURES; PHOTOTROPHIC BACTERIUM; FERREDOXIN; REFINEMENT; ELECTRON; CRYSTALS; CRYSTALLIZATION; REDUCTION	The molecular structure of a high potential iron-sulfur protein (HiPIP) isolated from the purple photosynthetic bacterium, Ectothiorhodospira halophila strain BN9626, has been solved by x-ray diffraction analysis to a nominal resoltuion of 2.5 angstrom and refined to a crystallographic R value of 18.4% including all measured x-ray data from 30.0- to 2.5-angstrom resolution. Crystals used in the investigation contained two molecules/asymmetric unit and belonged to the space group P2(1) with unit cell dimensions of a = 60.00 angstrom, b = 31.94 angstrom, c = 40.27 angstrom, and beta = 100.5-degrees. An interpretable electron density map, obtained by combining x-ray data from one isomorphous heavy atom derivative with non-crystallographic symmetry averaging and solvent flattening, clearly showed that this high potential iron-sulfur protein contains 71 amino acid residues, rather than 70 as originally reported. As in other bacterial ferredoxins, the [4Fe-4S] cluster adopts a cubane-like conformation and is ligated to the protein via four cysteinyl sulfur ligands. The overall secondary structure of the E. halophila HiPIP is characterized by a series of Type I and Type II turns allowing the polypeptide chain to wrap around the [4Fe-4S] prosthetic group. The hydrogen bonding pattern around the cluster is nearly identical to that originally observed in the 85-amino acid residue Chromatium vinosum HiPIP and consequently, the 240 mV difference in redox potentials between these two proteins cannot be simply attributed to hydrogen bonding patterns alone.	UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53705; UNIV WISCONSIN,INST ENZYME RES,MADISON,WI 53705; UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Arizona; University of Wisconsin System; University of Wisconsin Madison			rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835	NIGMS NIH HHS [GM39082] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039082, R01GM039082] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; Bartsch R G, 1978, Methods Enzymol, V53, P329; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; CARTER CW, 1974, J BIOL CHEM, V249, P4212; CARTER CW, 1977, J BIOL CHEM, V252, P7802; CARTER CW, 1972, P NATL ACAD SCI USA, V69, P3526, DOI 10.1073/pnas.69.12.3526; CHU CTW, 1982, J AM CHEM SOC, V104, P3409; DUS K, 1971, BIOCHEM BIOPH RES CO, V43, P1239, DOI 10.1016/S0006-291X(71)80005-0; FREER ST, 1975, J BIOL CHEM, V250, P46; HOLDEN HM, 1988, J BIOL CHEM, V263, P3960; HOLDEN HM, 1986, J BIOL CHEM, V261, P4746; HOLDEN HM, 1986, J BIOL CHEM, V261, P4219; JONES TA, 1985, METHOD ENZYMOL, V115, P157; MEYER TE, 1983, P NATL ACAD SCI-BIOL, V80, P6740, DOI 10.1073/pnas.80.22.6740; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; ROSSMANN MG, 1960, ACTA CRYSTALLOGR, V13, P221, DOI 10.1107/S0365110X60000510; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; SHERIDAN RP, 1981, J BIOL CHEM, V256, P5052; Spiro T. G., 1982, IRON SULFUR PROTEINS; STROMBAUGH NA, 1976, BIOCHEMISTRY-US, V15, P2633; TEDRO SM, 1985, ARCH BIOCHEM BIOPHYS, V241, P656, DOI 10.1016/0003-9861(85)90592-2; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; THALLER C, 1981, J MOL BIOL, V147, P465, DOI 10.1016/0022-2836(81)90496-4; THALLER C, 1985, METHOD ENZYMOL, V114, P132; Thomson A. J., 1985, METALLOPROTEINS 1, P79; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124	31	103	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18660	18667						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917989				2022-12-25	WOS:A1991GJ47200042
J	HINTON, DM				HINTON, DM			TRANSCRIPTION FROM A BACTERIOPHAGE-T4 MIDDLE PROMOTER USING T4 MOTA PROTEIN AND PHAGE-MODIFIED RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-VIRUS INTERACTIONS; TABC RHO MUTANTS; ESCHERICHIA-COLI; DNA-REPLICATION; INVITRO SYSTEM; T4-PREREPLICATIVE TRANSCRIPTION; ADP-RIBOSYLTRANSFERASE; NUCLEOTIDE-SEQUENCE; REGULATORY PROTEIN; EXPRESSED PROTEIN	The bacteriophage T4 motA protein is required for transcription from T4 middle promoters. These promoters, which contain the Escherichia coli promoter consensus sequence at the -10 region (TATAAT) but a unique sequence centered at -30 ((a/t)(a/t)TGCTT(t/c)A) (Guild, N., Gayle, M., Sweeney, R., Hollingsworth, T., Modeer, T., and Gold, L. (1988) J. Mol. Biol. 199, 241-258), become active about 2 min after infection, a time when the host RNA polymerase has been modified by phage proteins. This paper shows that motA protein binds to a T4 middle promoter in vitro and that the addition of the motA protein allows in vitro transcription from this promoter by T4-modified RNA polymerase. The T4 motA gene was cloned into a multicopy plasmid that complemented T4 motA mutants in vivo. MotA protein, partially purified from cells containing a motA+ plasmid, specifically retarded the electrophoretic mobility of an oligomer containing the T4 middle promoter located 195 bases upstream of uvsX (P(uvsX)). RNA polymerase isolated from infected cells during T4 middle gene expression supported in vitro transcription from P(uvsX) only when fractions containing the motA protein were added. In contrast, unmodified host RNA polymerase catalyzed the synthesis of minor amounts of RNA from P(uvsX), but this synthesis was not motA dependent. Thus, the in vitro transcription system described here provides the basis for a detailed study of the phage and host factors needed to regulate T4 middle gene expression.			HINTON, DM (corresponding author), NIDDKD,BIOCHEM PHARMACOL LAB,NUCLEIC ACID BIOCHEM SECT,BLDG 8,ROOM 2A-13,BETHESDA,MD 20892, USA.		Hinton, Deborah/AAQ-2596-2021					BENNETT GN, 1978, J MOL BIOL, V121, P113, DOI 10.1016/S0022-2836(78)80001-1; BRODY E, 1983, BACTERIOPHAGE T4, P174; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CARUSO M, 1979, J MOL BIOL, V135, P959, DOI 10.1016/0022-2836(79)90522-9; CHACE KV, 1975, J VIROL, V5, P929; CHRISTENSEN AC, 1983, BACTERIOPHAGE T4, P184; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DEFRANCISCIS V, 1982, J BIOL CHEM, V257, P4097; DEFRANCISCIS V, 1982, J BIOL CHEM, V257, P4087; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GEIDUSCHEK EP, 1988, BACTERIOPHAGES, V2, P93; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GOFF CG, 1974, J BIOL CHEM, V249, P6181; GOFF CG, 1980, J VIROL, V33, P547, DOI 10.1128/JVI.33.1.547-549.1980; GRUIDL ME, 1986, GENETICS, V114, P1061; GUILD N, 1988, J MOL BIOL, V199, P241, DOI 10.1016/0022-2836(88)90311-7; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7980; HALL DH, 1981, GENETICS, V97, P1; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERCULES K, 1974, J VIROL, V14, P341, DOI 10.1128/JVI.14.2.341-348.1974; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1989, J BIOL CHEM, V264, P14432; HINTON DM, 1989, J BIOL CHEM, V264, P14440; HINTON DM, 1986, J BIOL CHEM, V261, P5663; HINTON DM, 1985, J BIOL CHEM, V260, P2858; HO YS, 1983, NATURE, V304, P703, DOI 10.1038/304703a0; HORVITZ HR, 1974, J MOL BIOL, V90, P739, DOI 10.1016/0022-2836(74)90537-3; HORVITZ HR, 1974, J MOL BIOL, V980, P727; HSU T, 1987, J VIROL, V61, P366, DOI 10.1128/JVI.61.2.366-374.1987; HSU T, 1990, J BIOL CHEM, V265, P5303; HSU T, 1987, P NATL ACAD SCI USA, V81, P5101; KUTTER E, 1990, GENETIC MAPS, V5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBIG HD, 1989, J MOL BIOL, V208, P517, DOI 10.1016/0022-2836(89)90145-9; LINDER CH, 1980, J VIROL, V33, P724, DOI 10.1128/JVI.33.2.724-732.1980; MALIK S, 1985, J MOL BIOL, V185, P83, DOI 10.1016/0022-2836(85)90184-6; MALIK S, 1984, J BIOL CHEM, V259, P3292; MATTSON T, 1978, J MOL BIOL, V126, P551, DOI 10.1016/0022-2836(78)90058-X; MATTSON T, 1974, NATURE, V250, P48, DOI 10.1038/250048a0; NELSON MA, 1982, MOL GEN GENET, V188, P60, DOI 10.1007/BF00332996; OFARRELL PZ, 1973, J BIOL CHEM, V248, P5502; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; ORSINI G, 1988, VIROLOGY, V162, P397, DOI 10.1016/0042-6822(88)90480-1; PULITZER JF, 1985, J MOL BIOL, V182, P249, DOI 10.1016/0022-2836(85)90343-2; PULITZER JF, 1979, J MOL BIOL, V135, P979, DOI 10.1016/0022-2836(79)90523-0; RABUSSAY D, 1983, BACTERIOPHAGE T4, P167; ROHRER H, 1975, EUR J BIOCHEM, V60, P227, DOI 10.1111/j.1432-1033.1975.tb20995.x; SALSER W, 1970, J MOL BIOL, V49, P271, DOI 10.1016/0022-2836(70)90246-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT DA, 1970, NATURE, V225, P1012, DOI 10.1038/2251012a0; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SKORKO R, 1977, EUR J BIOCHEM, V79, P55, DOI 10.1111/j.1432-1033.1977.tb11783.x; STEVENS A, 1972, P NATL ACAD SCI USA, V69, P603, DOI 10.1073/pnas.69.3.603; STEVENS A, 1975, BIOCHEMISTRY-US, V14, P5074, DOI 10.1021/bi00694a007; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1990, CURRENT PROTOCOLS MO, V11; THERMES C, 1976, P NATL ACAD SCI USA, V73, P2569, DOI 10.1073/pnas.73.8.2569; UZAN M, 1983, EMBO J, V2, P1207, DOI 10.1002/j.1460-2075.1983.tb01568.x; UZAN M, 1990, MOL MICROBIOL, V4, P1487, DOI 10.1111/j.1365-2958.1990.tb02059.x; UZAN M, 1985, J BIOL CHEM, V260, P633; UZAN M, 1988, P NATL ACAD SCI USA, V85, P8895, DOI 10.1073/pnas.85.23.8895; VIDAL S, 1990, EMBO J, V9, P2017, DOI 10.1002/j.1460-2075.1990.tb08330.x; WILLIAMS KP, 1987, J VIROL, V61, P597, DOI 10.1128/JVI.61.2.597-599.1987	67	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18034	18044						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917941				2022-12-25	WOS:A1991GG55300052
J	BEALE, SI; CORNEJO, J				BEALE, SI; CORNEJO, J			BIOSYNTHESIS OF PHYCOBILINS - 3(Z)-PHYCOERYTHROBILIN AND 3(Z)-PHYCOCYANOBILIN ARE INTERMEDIATES IN THE FORMATION OF 3(E)-PHYCOCYANOBILIN FROM BILIVERDIN-IX-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYTOCHROME CHROMOPHORE BIOSYNTHESIS; ALGA CYANIDIUM-CALDARIUM; BILIN LINKAGE DIVERSITY; UNICELLULAR RED ALGA; HEME OXYGENASE; DIMETHYL ESTER; PHYCOCYANOBILIN; PIGMENTS; PHYCOERYTHROBILIN; PURIFICATION	An enzyme extract from the phycocyanin-containing unicellular rhodophyte, Cyanidium caldarium, reductively transforms biliverdin IX-alpha to phycocyanobilin, the chromophore of phycocyanin, in the presence of NADPH. Unpurified cell extract forms both 3(E)-phycocyanobilin, which is identical to the major pigment t hat is released from phycocyanin by methanolysis, and 3(Z)-phycocyanobilin, which is obtained as a minor methanolysis product. After removal of low molecular weight material from the cell extract, only 3(Z)-phycocyanobilin is formed. 3(E)-Phycocyanobilin formation from biliverdin IX-alpha, and the ability to isomerize 3(Z)-phycocyanobilin to 3(E)-phycocyanobilin, are reconstituted by the addition of glutathione to the incubation mixture. Partially purified protein fractions derived from the initial enzyme extract form 3(Z)-phycocyanobilin plus two additional, violet colored bilins, upon incubation with NADPH and biliverdin IX-alpha. Further, purified protein fractions produce only the violet colored bilins from biliverdin IX-alpha. One of these bilins was identified as 3(Z)-phycoerythrobilin by comparative spectrophotometry, reverse-phase high pressure liquid chromatography, and H-1 NMR spectroscopy. A C. caldarium protein fraction catalyzes the conversion of 3(Z)-phycoerythrobilin to 3(Z)-phycocyanobilin. This fraction also catalyzes the conversion of 3(E)-phycoerythrobilin to 3(E)-phycocyanobilin. The conversion of phycoerythrobilins to phycocyanobilins requires neither biliverdin nor NADPH. The synthesis of phycoerythrobilin and its conversion to phycocyanobilin by extracts of C. caldarium, a species that does not contain phycoerythrin, indicates that phycoerythrobilin is a biosynthetic precursor to phycocyanobilin. The enzymatic conversion of the ethylidine group from the Z to the E configuration suggests that the E-isomer is the precursor to the protein-bound chromophore,			BEALE, SI (corresponding author), BROWN UNIV,DIV BIOL & MED,PROVIDENCE,RI 02912, USA.							BEALE SI, 1984, ARCH BIOCHEM BIOPHYS, V235, P371, DOI 10.1016/0003-9861(84)90210-8; BEALE SI, 1991, J BIOL CHEM, V266, P22328; BEALE SI, 1984, PLANT PHYSIOL, V76, P7, DOI 10.1104/pp.76.1.7; BEALE SI, 1991, J BIOL CHEM, V266, P22341; BEALE SI, 1983, ARCH BIOCHEM BIOPHYS, V227, P279, DOI 10.1016/0003-9861(83)90372-7; BEALE SI, 1990, PLANT PHYSIOL, V92, pS62; BISHOP JE, 1986, J BIOL CHEM, V261, P6790; BROWN SB, 1984, BIOCHEM J, V219, P905, DOI 10.1042/bj2190905; CHAPMAN DJ, 1967, J AM CHEM SOC, V89, P5796; COLE WJ, 1967, J AM CHEM SOC, V89, P3643, DOI 10.1021/ja00990a055; CORNEJO J, 1988, J BIOL CHEM, V263, P11915; CRESPI HL, 1967, J AM CHEM SOC, V89, P3642, DOI 10.1021/ja00990a054; CRESPI HL, 1969, PHYTOCHEMISTRY, V8, P759, DOI 10.1016/S0031-9422(00)85848-3; CRESPI HL, 1968, BIOCHEMISTRY-US, V7, P2232, DOI 10.1021/bi00846a028; ELICH TD, 1989, J BIOL CHEM, V264, P12902; ELICH TD, 1989, J BIOL CHEM, V264, P183; ELICH TD, 1987, PLANT PHYSIOL, V84, P304, DOI 10.1104/pp.84.2.304; FELIZ M, 1989, MONATSH CHEM, V120, P445, DOI 10.1007/BF00811556; FU E, 1979, BIOCHEM J, V179, P1; GOSSAUER A, 1989, HELV CHIM ACTA, V72, P518, DOI 10.1002/hlca.19890720315; GOSSAUER A, 1978, J AM CHEM SOC, V100, P5928, DOI 10.1021/ja00486a053; GOSSAUER A, 1974, LIEBIGS ANN CHEM, P1496; JONES RF, 1963, PHYSIOL PLANTARUM, V16, P636, DOI 10.1111/j.1399-3054.1963.tb08342.x; KILLILEA SD, 1980, BIOCHEM J, V187, P311, DOI 10.1042/bj1870311; KLOTZ AV, 1986, J BIOL CHEM, V261, P6797; KNOX WE, 1960, ENZYMES, V2, P253; LAGARIAS JC, 1989, P NATL ACAD SCI USA, V86, P5778, DOI 10.1073/pnas.86.15.5778; McDonagh A. F., 1979, PORPHYRINS, VVI; O CARRA PADRAIG, 1966, PHYTOCHEMBTRY, V5, P993, DOI 10.1016/S0031-9422(00)82796-X; RUDIGER W, 1980, Z NATURFORSCH C, V35, P763; SCHUSTER A, 1983, Plant Cell Reports, V2, P85, DOI 10.1007/BF00270172; SELTZER S, 1972, ENZYMES, V6, P381; STOLL MS, 1977, BIOCHEM J, V163, P59, DOI 10.1042/bj1630059; TROXLER RF, 1967, BIOCHEMISTRY-US, V6, P3840, DOI 10.1021/bi00864a030; TROXLER RF, 1966, PLANT PHYSIOL, V41, P491, DOI 10.1104/pp.41.3.491; WELLER JP, 1980, CHEM BER-RECL, V113, P1603, DOI 10.1002/cber.19801130439	36	53	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22333	22340						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939256				2022-12-25	WOS:A1991GR56400046
J	ROY, S; HASS, PE; BOURELL, JH; HENZEL, WJ; VEHAR, GA				ROY, S; HASS, PE; BOURELL, JH; HENZEL, WJ; VEHAR, GA			LYSINE RESIDUES-165 AND RESIDUES-166 ARE ESSENTIAL FOR THE COFACTOR FUNCTION OF TISSUE FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-VII; MEMBRANES; BINDING	Tissue factor, a 45-kilodalton membrane glycoprotein, is an essential cofactor for the plasma serine protease factor VII which activates factor X in the first step of the extrinsic coagulation cascade. Two adjacent lysine residues (numbers 165 and 166) were identified in the extracytoplasmic domain of tissue factor that are crucial for function. Site-directed mutagenesis of both lysines to alanines results in complete loss of activity. Mutation of either lysine alone results in a molecule which is much more sensitive to the phospholipid composition of the activating surface than the wild-type molecule. It is postulated that interactions between the extracytoplasmic domain of tissue factor and the membrane surface are necessary for bound factor VII or VIIa to assume a conformation capable of efficient catalysis.	GENENTECH INC,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech			Roy, Soumitra/B-9113-2008	Henzel, William/0000-0003-2940-3797				ALMUS FE, 1989, THROMB HAEMOSTASIS, V62, P1067; ANDREWS BS, 1991, GENE, V98, P265, DOI 10.1016/0378-1119(91)90184-D; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; FAIR DS, 1987, J BIOL CHEM, V262, P11692; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; KUCHINKA E, 1989, BIOCHEMISTRY-US, V28, P4216, DOI 10.1021/bi00436a014; MASON AJ, 1989, MOL ENDOCRINOL, V3, P1352, DOI 10.1210/mend-3-9-1352; NEMERSON Y, 1988, BLOOD, V71, P1; OBRIEN DP, 1988, J CLIN INVEST, V82, P206, DOI 10.1172/JCI113571; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; ROY S, 1991, J BIOL CHEM, V266, P4665; SEELIG J, 1987, BIOCHEMISTRY-US, V26, P7535, DOI 10.1021/bi00398a001	14	67	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					22063	22066						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939226				2022-12-25	WOS:A1991GP80400110
J	MIRAULT, ME; TREMBLAY, A; BEAUDOIN, N; TREMBLAY, M				MIRAULT, ME; TREMBLAY, A; BEAUDOIN, N; TREMBLAY, M			OVEREXPRESSION OF SELENO-GLUTATHIONE PEROXIDASE BY GENE-TRANSFER ENHANCES THE RESISTANCE OF T47D HUMAN BREAST CELLS TO CLASTOGENIC OXIDANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; CYTO-TOXICITY; CANCER-CELLS; ENDONUCLEASE ACTIVATION; SUPEROXIDE-DISMUTASE; NUCLEOTIDE-SEQUENCE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; OXYGEN RADICALS; TUMOR PROMOTER	The role of seleno-glutathione peroxidase (GSHPx; EC 1.11.1.9) in the cellular defense against oxidative stress was selectively investigated in novel cell models. Expression vectors designed to overexpress human GSHPx efficiently in a broad range of mammalian cells were used to transfect T47D human breast cells which contain very low levels of endogenous GSHPx. Several stable transfectants expressing GSHPx to various extents, up to 10-100 times more than parental cells, were isolated and characterized. Growth inhibition kinetics following transient exposure to increasing concentrations of H2O2, cumene hydroperoxide or menadione (an intracellular source of free radicals and reactive oxygen intermediates) showed that transfectants overexpressing GSHPx were considerably more resistant than control T47D cell derivatives to each of these oxidants. A sensitive DNA end-labeling procedure was used as a novel approach to compare relative extents of DNA strand breakage in these cells. In contrast to the extensive DNA damage induced in control transfectants by 1-h exposure to cytotoxic concentrations of menadione, the extent of DNA breakage detected in GSHPx-rich transfectants was remarkably reduced (6- to 9-fold, p < 0.005).	UNIV LAVAL,QUEBEC CITY G1V 4G2,QUEBEC,CANADA	Laval University	MIRAULT, ME (corresponding author), CHU LAVAL,RES CTR,DEPT MED ONTOGENESIS & MOLEC GENET,QUEBEC CITY G1V 4G2,QUEBEC,CANADA.							AKMAN SA, 1990, CANCER RES, V50, P1397; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; Anderson ME, 1985, HDB METHODS OXYGEN R, P317; BACHUR NR, 1979, P NATL ACAD SCI USA, V76, P954, DOI 10.1073/pnas.76.2.954; BATIST G, 1986, J BIOL CHEM, V261, P5544; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BIRNBOIM HC, 1982, SCIENCE, V215, P1247, DOI 10.1126/science.6276978; BIRREN BW, 1989, ELECTROPHORESIS, V10, P302, DOI 10.1002/elps.1150100506; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BRAWN K, 1981, ARCH BIOCHEM BIOPHYS, V206, P414, DOI 10.1016/0003-9861(81)90108-9; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CANTONI O, 1989, EUR J BIOCHEM, V182, P209, DOI 10.1111/j.1432-1033.1989.tb14819.x; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHADA S, 1989, BLOOD, V74, P2535; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; CRAWFORD DR, 1988, BIOCHEM BIOPH RES CO, V153, P59, DOI 10.1016/S0006-291X(88)81189-6; DANIELSON KG, 1986, CANCER RES, V46, P4582; DUSRE L, 1989, CANCER RES, V49, P511; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; EMERIT I, 1983, CARCINOGENESIS, V4, P1313, DOI 10.1093/carcin/4.10.1313; FANTONE JC, 1982, AM J PATHOL, V107, P397; Flohe L., 1982, FREE RADICAL BIO MED, V5, P223; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; Gunzler WA, 1985, CRC HDB METHODS OXYG, P285; HALLIWELL B, 1987, ANN INTERN MED, V107, P526; HORWITZ KB, 1978, CANCER RES, V38, P2434; HOUSSET B, 1983, J APPL PHYSIOL, V55, P343, DOI 10.1152/jappl.1983.55.2.343; JONES DP, 1989, J BIOL CHEM, V264, P6398; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; KORNELUK RG, 1984, J BIOL CHEM, V259, P3819; KOZUMBO WJ, 1987, CARCINOGENESIS, V8, P521, DOI 10.1093/carcin/8.4.521; LEE BJ, 1989, J BIOL CHEM, V264, P9724; LEWIS JG, 1985, CANCER RES, V45, P1270; LEWIS JG, 1986, CARCINOGENESIS, V7, P813, DOI 10.1093/carcin/7.5.813; MCCONKEY DJ, 1988, TOXICOL LETT, V42, P123, DOI 10.1016/0378-4274(88)90069-0; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MIRAULT ME, 1982, EMBO J, V1, P1279, DOI 10.1002/j.1460-2075.1982.tb00025.x; MIRAULT ME, 1991, MOL BASIS OXIDATIVE; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; OCHI T, 1987, P NATL ACAD SCI USA, V84, P990, DOI 10.1073/pnas.84.4.990; ODY C, 1985, P SOC EXP BIOL MED, V180, P103; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT EV, 1990, MOL CELL BIOL, V10, P4406, DOI 10.1128/MCB.10.8.4406; SHERMAN L, 1983, P NATL ACAD SCI-BIOL, V80, P5465, DOI 10.1073/pnas.80.18.5465; SINHA BK, 1989, CANCER RES, V49, P3844; STARKE PE, 1985, J BIOL CHEM, V260, P99; SUKENAGA Y, 1987, NUCLEIC ACIDS RES, V15, P7178, DOI 10.1093/nar/15.17.7178; THOR H, 1982, J BIOL CHEM, V257, P2419; WEITBERG AB, 1983, NEW ENGL J MED, V308, P26, DOI 10.1056/NEJM198301063080107; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	58	102	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20752	20760						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939125				2022-12-25	WOS:A1991GN00100027
J	RYBAK, SM; SAXENA, SK; ACKERMAN, EJ; YOULE, RJ				RYBAK, SM; SAXENA, SK; ACKERMAN, EJ; YOULE, RJ			CYTOTOXIC POTENTIAL OF RIBONUCLEASE AND RIBONUCLEASE HYBRID PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL CATIONIC PROTEIN; RICIN-A-CHAIN; MONOCLONAL-ANTIBODY; EUKARYOTIC RIBOSOMES; SEMINAL RIBONUCLEASE; DIPHTHERIA-TOXIN; ALPHA-SARCIN; SELF-INCOMPATIBILITY; NICOTIANA-ALATA; XENOPUS OOCYTES	Pancreatic RNase injected into Xenopus oocytes abolishes protein synthesis at concentrations comparable to the toxin ricin yet has no effect on oocyte protein synthesis when added to the extracellular medium. Therefore RNase behaves like a potent toxin when directed into a cell. To explore the cytotoxic potential of RNase toward mammalian cells, bovine pancreatic ribonuclease A was coupled via a disulfide bond to human transferrin or antibodies to the transferrin receptor. The RNase hybrid proteins were cytotoxic to K562 human erythroleukemia cells in vitro with an IC50 around 10(-7)M whereas greater than 10(-5) M native RNase was required to inhibit protein synthesis. Cytotoxicity requires both components of the conjugate since excess transferrin or ribonuclease inhibitors added to the medium protected the cells from the transferrin-RNase toxicity. Compounds that interfere with transferrin receptor cycling and compartmentalization such as ammonium chloride decreased the cytotoxicity of transferrin-RNase. After a dose-dependent lag period inactivation of protein synthesis by transferrin-RNase followed a first-order decay constant. In a clonogenic assay that measures the extent of cell death 1 x 10(-6) M transferrin-RNase killed at least 4 logs or 99.99% of the cells whereas 70 x 10(-6) M RNase was nontoxic. These results show that RNase coupled to a ligand can be cytotoxic. Human ribonucleases coupled to antibodies also may exhibit receptor-mediated toxicities providing a new approach to selective cell killing possibly with less systemic toxicity and importantly less immunogenicity than the currently employed ligand-toxin conjugates.	NIDDKD,GENET & BIOCHEM BRANCH,BETHESDA,MD 20896	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	RYBAK, SM (corresponding author), NINCDS,SURG NEUROL BRANCH,BIOCHEM SECT,BETHESDA,MD 20896, USA.		Saxena, Shailendra K/ABK-6489-2022; Saxena, Shailendra K/X-4252-2019	Saxena, Shailendra K/0000-0003-2856-4185; Saxena, Shailendra K/0000-0003-2856-4185				ACKERMAN EJ, 1988, J BIOL CHEM, V263, P17076; ARDELT A, 1991, J BIOL CHEM, V266, P245; BEINTEMA J, 1988, PROG BIOPHYS MOL BIO, V1, P165; BOND MD, 1988, ANAL BIOCHEM, V173, P166, DOI 10.1016/0003-2697(88)90174-1; BRAHAM K, 1988, CANCER RES, V48, P806; BREGNI M, 1986, CANCER RES, V46, P1208; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; ENDO Y, 1987, J BIOL CHEM, V262, P8128; ENDO Y, 1982, J BIOL CHEM, V257, P9054; ENDO Y, 1983, J BIOL CHEM, V258, P2662; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FERNANDEZPUENTES C, 1980, CELL, V20, P769, DOI 10.1016/0092-8674(80)90323-2; GILLILAND DG, 1980, P NATL ACAD SCI-BIOL, V77, P4539, DOI 10.1073/pnas.77.8.4539; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GLUKHOV BN, 1976, ARCH NEUROL-CHICAGO, V33, P598, DOI 10.1001/archneur.1976.00500090004002; GULLBERG U, 1986, BIOCHEM BIOPH RES CO, V139, P1239, DOI 10.1016/S0006-291X(86)80310-2; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HARKONEN S, 1987, CANCER RES, V47, P1377; HERTLER AA, 1988, IMMUNOTOXINS, P475; JOHNSON EA, 1961, BIOMETRICS, V17, P79, DOI 10.2307/2527497; JOHNSON VG, 1988, J BIOL CHEM, V263, P1295; JOHNSON VG, 1991, INTRACELLULAR TRAFFI, P183; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KONISKY J, 1982, ANNU REV MICROBIOL, V36, P125, DOI 10.1146/annurev.mi.36.100182.001013; KROLICK KA, 1980, P NATL ACAD SCI-BIOL, V77, P5419, DOI 10.1073/pnas.77.9.5419; Lambert J M, 1988, Cancer Treat Res, V37, P175; LEONE E, 1973, J REPROD FERTIL, V34, P197; LOBUGLIO AF, 1989, P NATL ACAD SCI USA, V86, P4220, DOI 10.1073/pnas.86.11.4220; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATOUSEK J, 1973, EXPERIENTIA, V29, P858, DOI 10.1007/BF01946329; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; OKEEFE DO, 1985, J BIOL CHEM, V260, P932; OLSNES S, 1976, P NATL ACAD SCI USA, V251, P3985; OMARY MB, 1980, NATURE, V286, P888, DOI 10.1038/286888a0; RASO V, 1984, J BIOL CHEM, V259, P1143; RASO V, 1984, J EXP MED, V160, P1234, DOI 10.1084/jem.160.4.1234; ROTH JS, 1963, CANCER RES, V23, P657; RYBAK S, 1991, IMMUNOLOGY ALLERGY C, V2, P359; SAWLER DL, 1985, J IMMUNOL, V135, P1530; SAXENA SK, 1989, J BIOL CHEM, V264, P596; SCHROFF RW, 1985, CANCER RES, V45, P879; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; STCLAIR DK, 1987, P NATL ACAD SCI USA, V84, P8330; STCLAIR DK, 1988, BIOCHEMISTRY-US, V27, P7263, DOI 10.1021/bi00419a013; TARNOWSKI GS, 1976, CANCER RES, V36, P4074; TROWBRIDGE IS, 1981, NATURE, V294, P171, DOI 10.1038/294171a0; UCHIDA T, 1973, J BIOL CHEM, V248, P3845; VESCIA S, 1980, CANCER RES, V40, P3740; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; YOULE RJ, 1980, P NATL ACAD SCI-BIOL, V77, P5483, DOI 10.1073/pnas.77.9.5483; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0	52	112	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21202	21207						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939162				2022-12-25	WOS:A1991GN00100096
J	DUNN, AD; CRUTCHFIELD, HE; DUNN, JT				DUNN, AD; CRUTCHFIELD, HE; DUNN, JT			THYROGLOBULIN PROCESSING BY THYROIDAL PROTEASES - MAJOR SITES OF CLEAVAGE BY CATHEPSIN-B, CATHEPSIN-D, AND CATHEPSIN-L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE THYROGLOBULIN; COMPLEMENTARY-DNA; SEQUENCE; THYROXINE; PROTEINS; ACIDS	The normal provision of thyroid hormones to the body requires their release from the prohormone, thyroglobulin (Tg). Previous work established the importance of cathepsins B, D, and L (formerly designated cysteine proteinase I) to this process but had not defined the points of proteolytic attack for each enzyme. In the present study we labeled rabbit Tg in vivo with sodium I-125 and performed limited digestions with cathepsins B, D, and L, purified from human thyroids. The resultant peptide fragments were analyzed by amino-terminal sequencing and located within the Tg molecule by comparison with the cDNA-derived sequences from human Tg. We identified three cleavage points for cathepsin B, corresponding to P'1 residues 532, 795, and 2487; four cleavage points for cathepsin L, corresponding to P'1 residues 2389, 2452, 2490, and 2657; and four cleavage points for cathepsin D, corresponding to P'1 residues 551, 1835, 2468, and 2643. None of the cleavage points was near Tgs known hormonogenic sites, but these peptide fragments contained three of the four major hormonogenic sites in rabbit Tg, suggesting some preference for their early proteolytic processing. Cathepsin B alone among the three endopeptidases had some exopeptidase activity toward Tg. The cleavage specificities for each of the endopeptidases resembled those described with other protein substrates. Thus, cathepsin D preferentially cleaved bonds between hydrophobic residues, and cathepsin L cleaved bonds with hydrophobic residues at P2 and P3. Although cathepsin Bs specificity was less obvious, it produced a major cleavage between 2 leucine residues. The existence of three endopeptidases cleaving at different sites shows that Tg proteolysis is a complex process, suggests synergism among their enzyme activities, and provides a physiological mechanism for selective hormone release, including its regulation by TSH.			DUNN, AD (corresponding author), UNIV VIRGINIA, SCH MED, DEPT MED, DIV ENDOCRINOL, CHARLOTTESVILLE, VA 22908 USA.				NCI NIH HHS [CA44579] Funding Source: Medline; NIDDK NIH HHS [DK38942, DK11043] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA044579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038942, R01DK011043] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; DILAURO R, 1985, EUR J BIOCHEM, V148, P7; DUNN AD, 1982, ENDOCRINOLOGY, V111, P280, DOI 10.1210/endo-111-1-280; DUNN AD, 1991, ENDOCRINOLOGY, V128, P3073, DOI 10.1210/endo-128-6-3073; DUNN AD, 1988, ENDOCRINOLOGY, V123, P1089, DOI 10.1210/endo-123-2-1089; DUNN AD, 1984, ENDOCRINOLOGY, V114, P375, DOI 10.1210/endo-114-2-375; DUNN AD, 1986, CYSTEINE PROTEINASES, P111; DUNN JT, 1987, J BIOL CHEM, V262, P16948; DUNN JT, 1986, METHODS PROTEIN SEQU, P451; FASSLER CA, 1988, J BIOL CHEM, V263, P17366; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAS L, 1989, J BIOL CHEM, V264, P13541; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MASON RW, 1986, BIOCHEM J, V240, P373, DOI 10.1042/bj2400373; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERCKEN L, 1984, BIOCHEM BIOPH RES CO, V125, P961, DOI 10.1016/0006-291X(84)91377-9; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; NGUYEN Q, 1990, BIOCHEM J, V266, P569; RAWITCH AB, 1983, J BIOL CHEM, V258, P2079; TOKUYAMA T, 1987, ENDOCRINOLOGY, V121, P714, DOI 10.1210/endo-121-2-714; WEBER K, 1969, J BIOL CHEM, V244, P4406; WETZEL BK, 1965, J CELL BIOL, V25, P593, DOI 10.1083/jcb.25.3.593	24	83	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20198	20204						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939080				2022-12-25	WOS:A1991GM03900050
J	OGAWA, H; FUJIOKA, M; SU, Y; KANAMOTO, R; PITOT, HC				OGAWA, H; FUJIOKA, M; SU, Y; KANAMOTO, R; PITOT, HC			NUTRITIONAL REGULATION AND TISSUE-SPECIFIC EXPRESSION OF THE SERINE DEHYDRATASE GENE IN RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; HYPERSENSITIVE SITES; LIVER; CHROMATIN	The mechanism of dietary regulation and tissue-specific expression of the serine dehydratase gene in rat has been studied. The hepatic serine dehydratase activity and its mRNA showed a parallel increase with increasing protein content in the diet. However, when rats that had been maintained on a high protein diet were fed a protein-free diet, the mRNA level rapidly decreased to 0.5 in 3 h, whereas the enzyme activity gradually fell to a low level over a period of 5 days. With animals maintained on a high protein diet or on a protein-free diet, we examined the sites hypersensitive to DNase I in the 5'-flanking region of serine dehydratase gene in the liver chromatins. A series of DNase I-hypersensitive sites were located within 10.5 kilobase pairs upstream of the transcription start site. The DNA regions at -3050 and -3180 (region II) and -3600 to -3850 (region III) were more susceptible to the nuclease in the expressing than in the nonexpressing liver. A reverse situation obtained at -100 (region I). Kidney contained serine dehydratase mRNA at a level of 5% of liver as determined by Northern blotting. The kidney chromatin was found to be susceptible to DNase I only at region I. No conspicuous DNase I-hypersensitive sites were observed in the relevant regions of chromatins from brain and lung, in which serine dehydratase mRNA was scarcely transcribed. These results suggest that nutritional control and tissue-specific expression of the serine dehydratase gene is closely associated with the alteration of DNase I hypersensitivity at specific sites of the 5'-flanking region of the gene.	UNIV WISCONSIN,SCH MED,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	OGAWA, H (corresponding author), TOYAMA MED & PHARMACEUT UNIV,FAC MED,DEPT BIOCHEM,2630 SUGITANI,SUGITANI,TOYAMA 93001,JAPAN.							CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; FALLON HJ, 1968, J NUTR, V96, P220, DOI 10.1093/jn/96.2.220; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; JOST JP, 1968, J BIOL CHEM, V243, P3057; KANAMOTO R, 1991, ARCH BIOCHEM BIOPHYS, V288, P562, DOI 10.1016/0003-9861(91)90236-C; MA XJ, 1990, J BIOL CHEM, V265, P18435; Maniatis T., 1982, MOL CLONING; MORRIS JE, 1976, J BIOL CHEM, V251, P2571; NAKAGAWA H, 1971, SEIKAGAKU, V43, P1; NODA C, 1984, J BIOCHEM-TOKYO, V95, P37, DOI 10.1093/oxfordjournals.jbchem.a134600; OGAWA H, 1990, J BIOL CHEM, V265, P14407; OGAWA H, 1988, NUCLEIC ACIDS RES, V16, P10921, DOI 10.1093/nar/16.22.10921; OGAWA H, 1988, P NATL ACAD SCI USA, V85, P5809, DOI 10.1073/pnas.85.16.5809; OGAWA H, 1982, BIOCHEM BIOPH RES CO, V108, P227, DOI 10.1016/0006-291X(82)91855-1; PERAINO C, 1964, J BIOL CHEM, V239, P4308; PITOT HC, 1965, P NATL ACAD SCI USA, V54, P845, DOI 10.1073/pnas.54.3.845; PITOT HC, 1964, J BIOL CHEM, V239, P1783; PITOT HC, 1963, J BIOL CHEM, V238; SNELL K, 1984, ADV ENZYME REGUL, V22, P325, DOI 10.1016/0065-2571(84)90021-9; SU Y, 1990, BIOCHEM BIOPH RES CO, V170, P892, DOI 10.1016/0006-291X(90)92175-Y; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0	26	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20412	20417						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939096				2022-12-25	WOS:A1991GM03900079
J	CHEN, F; WANG, Y; PUETT, D				CHEN, F; WANG, Y; PUETT, D			ROLE OF THE INVARIANT ASPARTIC ACID-99 OF HUMAN CHORIOGONADOTROPIN-BETA IN RECEPTOR-BINDING AND BIOLOGICAL-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; HUMAN LUTEINIZING-HORMONE; CHORIONIC-GONADOTROPIN; FUNCTIONAL EXPRESSION; TSH RECEPTOR; SUBUNIT; CLONING; LUTROPIN; SEQUENCE; CELLS	The four human glycoprotein hormones are heterodimers that contain a common alpha-subunit and a hormone-specific beta-subunit. Within this hormone family, 23 amino acid sequences from 11 mammalian species are available. There are 19 invariant amino acid residues in the beta-subunits, 12 of which are Cys that form six disulfide bonds. Of the remaining seven conserved amino acid residues, we have investigated the role of an Asp which occurs at position 99 in human choriogonadotropin-beta (hcG-beta). Site-directed mutagenesis was used to replace hCG-beta Asp99 with three residues, Glu, Asn, and Arg, and to prepare an inversion double mutant protein, Arg94 --> Asp and Asp99 --> Arg. The cDNAs were placed in a eukaryotic expression vector, and the plasmids were transiently transfected into Chinese hamster ovary cells containing a stably integrated gene for bovine-alpha. Radioimmunoassays demonstrated that the mutant forms of hCG-beta were capable of subunit assembly to the same extent as hCG-beta wild type. The heterologous heterodimers were assayed in vitro using transformed mouse Leydig cells (MA-10) by competitive inhibition of I-125-hCG binding and stimulation of progesterone production. The gonadotropins containing Glu and Asn were active, although the potency was less than that associated with the hCG-beta wild type-containing gonadotropin. In contrast, the Arg99-containing mutant protein and the inversion mutant protein Asp94/Arg99 were devoid of activity. Thus, in hCG-beta Asp99 can be substituted with certain residues without total loss of function, although replacement with a positively charged residue leads to an inactive heterodimer. The primary role of Asp99 in hCG-beta seems to involve, either directly or indirectly, receptor recognition.	UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,REPROD SCI & ENDOCRINOL LABS DS,MIAMI,FL 33101	University of Miami					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033973] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33973] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; AZUMA C, 1990, J MOL ENDOCRINOL, V5, P97, DOI 10.1677/jme.0.0050097; BIRKEN S, 1987, ENDOCRINOLOGY, V112, P657; BOUSFIELD GR, 1988, J BIOL CHEM, V263, P12602; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHEN F, 1991, J BIOL CHEM, V266, P6904; CHEN F, 1991, IN PRESS BIOCHEMISTR; CHEN WY, 1991, J BIOL CHEM, V266, P6246; COLOMA TAS, 1990, J BIOL CHEM, V265, P5037; ELDEIRY S, 1989, MOL ENDOCRINOL, V3, P1523, DOI 10.1210/mend-3-10-1523; ELDEIRY S, 1991, MOL CELL ENDOCRINOL, V76, P105, DOI 10.1016/0303-7207(91)90265-T; FRAZIER AL, 1990, MOL ENDOCRINOL, V4, P1264, DOI 10.1210/mend-4-8-1264; Gordon WL, 1985, LUTEINIZING HORMONE, P173; HWANG J, 1984, P NATL ACAD SCI-BIOL, V81, P4667, DOI 10.1073/pnas.81.15.4667; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; KAETZEL DM, 1985, P NATL ACAD SCI USA, V82, P7280, DOI 10.1073/pnas.82.21.7280; KEUTMANN HT, 1988, BIOCHEMISTRY-US, V27, P8939, DOI 10.1021/bi00425a010; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; KEUTMANN HT, 1989, MOL ENDOCRINOL, V3, P526, DOI 10.1210/mend-3-3-526; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MANIATIS T, 1982, MOL CLONING LABORATO, P88; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; MOORE WT, 1980, CHORIONIC GONADOTROP, P89; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TALMADGE K, 1983, DNA, V2, P1948; WARD DN, 1990, STRUCTURE FUNCTION R, P1; WARD DN, 1978, STRUCTURE FUNCTION G, P31; XIA H, 1991, 73RD END SOC M WASH, P48	35	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19357	19361						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918051				2022-12-25	WOS:A1991GK66700039
J	ZHANG, PH; GRAMINSKI, GF; ARMSTRONG, RN				ZHANG, PH; GRAMINSKI, GF; ARMSTRONG, RN			ARE THE HISTIDINE-RESIDUES OF GLUTATHIONE-S-TRANSFERASE IMPORTANT IN CATALYSIS - AN ASSESSMENT BY C-13 NMR-SPECTROSCOPY AND SITE-SPECIFIC MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; ACTIVE-SITE; RAT-LIVER; SEQUENCE-ANALYSIS; CDNA CLONE; YB SUBUNIT; STEREOSELECTIVITY; MECHANISM; ANION	To test the proposition that a histidine residue is essential in the catalytic mechanism of glutathione S-transferase, rat liver isoenyzme 3-3 specifically labeled with [ring-2-C-13]histidine was prepared. The C-13 NMR spectrum of the labeled enzyme revealed four resonances corresponding to the 4 histidine residues in the mu gene class type 3 subunit. Titration of the four resonances in the range of pH 4-9 both in the presence and absence of glutathione gave pK(a) values of << 4, 5.2, 7.1, and 7.8 for the four side chains that were identified by site-specific mutagenesis as His14, His83, His84, and His167, respectively. The magnetic resonance properties and titration behavior of His14 suggest that this residue is buried in a hydrophobic environment. Conservative replacement of each histidine with asparagine results in mutant enzymes that have catalytic properties very close to the native protein as assessed with three different substrates, 1-chloro-2,4-dinitrobenzene, 4-phenyl-3-buten-2-one, and phenanthrene 9,10-oxide. The results indicate clearly that none of the histidine residues of isoenzyme 3-3 is essential for stabilization of the bound glutathione thiolate or for any other aspect of catalysis.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park					NCRR NIH HHS [RR02231] Funding Source: Medline; NIGMS NIH HHS [GM30910] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030910] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG RN, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P65; ARMSTRONG RN, 1987, CRC CR REV BIOCH MOL, V22, P39, DOI 10.3109/10409238709082547; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; Asaoka K, 1989, J Enzyme Inhib, V3, P77, DOI 10.3109/14756368909030366; AWASTHI YC, 1987, BIOCHEM BIOPH RES CO, V143, P965, DOI 10.1016/0006-291X(87)90345-7; CHEN WJ, 1988, BIOCHEMISTRY-US, V27, P647, DOI 10.1021/bi00402a023; COBB D, 1983, BIOCHEMISTRY-US, V22, P805, DOI 10.1021/bi00273a015; DING GJF, 1985, J BIOL CHEM, V260, P3268; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P6252, DOI 10.1021/bi00441a017; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; HUNKAPILLER MW, 1973, BIOCHEMISTRY-US, V12, P4732, DOI 10.1021/bi00747a028; JAKOBY WB, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P87; KUBO Y, 1989, CHEM RES TOXICOL, V2, P144, DOI 10.1021/tx00009a003; LAI HCJ, 1986, J BIOL CHEM, V261, P3793; LAI HCJ, 1986, NUCLEIC ACIDS RES, V14, P6101, DOI 10.1093/nar/14.15.6101; MANNERVIK B, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P35; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MARKLEY JL, 1975, ACCOUNTS CHEM RES, V8, P70, DOI 10.1021/ar50086a004; OHAVER TC, 1989, CHEMOMETR INTELL LAB, V6, P95, DOI 10.1016/0169-7439(87)80053-9; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; SACHS DH, 1971, J BIOL CHEM, V246, P6576; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SESAY MA, 1987, J MOL BIOL, V197, P377, DOI 10.1016/0022-2836(87)90133-1; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; TARTOF KD, 1987, FOCUS, V9, P12; WANG RW, 1991, ARCH BIOCHEM BIOPHYS, V286, P574, DOI 10.1016/0003-9861(91)90082-T; ZHANG PH, 1990, BIOPOLYMERS, V29, P159, DOI 10.1002/bip.360290121	27	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19475	19479						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918058				2022-12-25	WOS:A1991GK66700054
J	ETTER, HU; RICHTER, C; OHTA, Y; WINTERHALTER, KH; SASABE, H; KAWATO, S				ETTER, HU; RICHTER, C; OHTA, Y; WINTERHALTER, KH; SASABE, H; KAWATO, S			ROTATION AND INTERACTION WITH EPOXIDE HYDRASE OF CYTOCHROME-P-450 IN PROTEOLIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOCHROME-P-450; PROTEIN-PROTEIN INTERACTIONS; INNER MEMBRANE; PHOSPHOLIPID-VESICLES; MICROSOMAL CYTOCHROME-P-450; ADRENOCORTICAL MITOCHONDRIA; ARACHIDONIC-ACID; CROSS-LINKING; DIFFUSION; OXIDASE	Purified rat liver cytochrome P-450MC or P-450PB was co-reconstituted with epoxide hydrase in liposomal vesicles made of phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine at a lipid to protein weight ratio of 5 by the cholate dialysis procedure. Rotational diffusion of the cytochromes was measured by observing the decay of absorption anisotropy, r(t), after photolysis of the heme.CO complex by a vertically polarized laser flash. Analysis of r(t) was based on a "rotation-about-membrane-normal" model. The measurements were used to investigate interactions of cytochrome P-450MC or P-450PB with epoxide hydrase. Different rotational mobilities of the two cytochromes were observed. The amount of mobile molecules was 78% for cytochrome P-450MC and 91% for P-450PB, and the rest was immobile within the experimental time range of 1 ms. In the presence of epoxide hydrase 85% of cytochrome P-450MC and 96% of P-450PB were mobile. Cross-linking of epoxide hydrase by anti-epoxide hydrase antibodies resulted in a drastic immobilization of the cytochromes, reducing the mobile population to 49% for P-450MC and to 60% for P-450PB. The rotational relaxation times-phi of the mobile populations ranged from 210 to 283-mu-s. These results imply that both cytochromes P-450MC and P-450PB transiently associate with epoxide hydrase in liposomal membranes. Further analysis of the data showed that the angle between the heme plane of P-450MC and the membrane is 48-degrees or 62-degrees, different from the value of 55-degrees reported previously for P-450PB (Gut, J., Richter, C., Cherry, R. J., Winterhalter, K. H., and Kawato, S. (1983) J. Biol. Chem. 258, 8588-8594).	UNIV TOKYO,COLL ARTS & SCI,INST PHYS,MEGURO KU,TOKYO 153,JAPAN; RIKEN,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; SWISS FED INST TECHNOL,DEPT BIOCHEM,CH-8092 ZURICH,SWITZERLAND	University of Tokyo; RIKEN; Swiss Federal Institutes of Technology Domain; ETH Zurich			Ohta, Yoshihiro/C-8741-2013	Ohta, Yoshihiro/0000-0001-7416-0507				BENTLEY P, 1980, MICROSOMES DRUG OXID, P647; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; Cherry R J, 1978, Methods Enzymol, V54, P47; DEPIERRE JW, 1977, ANNU REV BIOCHEM, V46, P201, DOI 10.1146/annurev.bi.46.070177.001221; ESTABROOK RW, 1979, ACS SYM SER, V97, P149; GREINERT R, 1979, J BIOCHEM BIOPH METH, V1, P77, DOI 10.1016/0165-022X(79)90014-9; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, V1; GUENGRICH FP, 1987, MAMMALIAN CYTOCHROME, V2; GUT J, 1982, J BIOL CHEM, V257, P7030; GUT J, 1985, BIOCHIM BIOPHYS ACTA, V817, P217, DOI 10.1016/0005-2736(85)90023-9; GUT J, 1983, J BIOL CHEM, V258, P8588; HARA E, 1983, CANCER RES, V43, P3604; HARADA N, 1981, J BIOCHEM-TOKYO, V89, P237, DOI 10.1093/oxfordjournals.jbchem.a133187; Ingelman-Sundberg M, 1986, CYTOCHROME P450 STRU, P119; KAWATO S, 1982, J BIOL CHEM, V257, P7023; KAWATO S, 1980, J BIOL CHEM, V255, P5508; KAWATO S, 1982, J BIOL CHEM, V257, P6470; KAWATO S, 1981, BIOPHYS J, V36, P277, DOI 10.1016/S0006-3495(81)84728-5; KAWATO S, 1988, J BIOCHEM-TOKYO, V104, P188, DOI 10.1093/oxfordjournals.jbchem.a122439; KAWATO S, 1981, J BIOL CHEM, V256, P7518; KINOSITA K, 1984, BIOCHEMISTRY-US, V23, P5963, DOI 10.1021/bi00320a012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU AYH, 1975, J BIOL CHEM, V250, P8283; MCINTOSH PR, 1980, FEBS LETT, V122, P54, DOI 10.1016/0014-5793(80)80400-5; OESCH F, 1971, BIOCHIM BIOPHYS ACTA, V227, P685, DOI 10.1016/0005-2744(71)90017-9; OESCH F, 1972, BIOCHEM BIOPH RES CO, V46, P1713, DOI 10.1016/0006-291X(72)90807-8; OHTA Y, 1990, J BIOCHEM-TOKYO, V107, P97, DOI 10.1093/oxfordjournals.jbchem.a123020; OMURA T, 1964, J BIOL CHEM, V239, P2370; OMURA T, 1978, CYTOCHROME P450, P1; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; OZOLS J, 1988, FASEB J, V2, pA584; Peterson JA, 1986, CYTOCHROME P 450 STR, P89; RICHTER C, 1979, FEBS LETT, V102, P151, DOI 10.1016/0014-5793(79)80948-5; SCHNEIDER H, 1980, J BIOL CHEM, V255, P3748; SEIDEGARD M, 1978, BIOCHIM BIOPHYS ACTA, V543, P29; THOMAS PE, 1983, J BIOL CHEM, V258, P4590; THOMAS PE, 1976, J BIOL CHEM, V251, P1385; VERGERES G, 1989, BIOCHEMISTRY-US, V28, P3650, DOI 10.1021/bi00435a005; WAXMAN DJ, 1982, J BIOL CHEM, V257, P446; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531	41	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18600	18605						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917981				2022-12-25	WOS:A1991GJ47200033
J	HAYDEN, PJ; ICHIMURA, T; MCCANN, DJ; POHL, LR; STEVENS, JL				HAYDEN, PJ; ICHIMURA, T; MCCANN, DJ; POHL, LR; STEVENS, JL			DETECTION OF CYSTEINE CONJUGATE METABOLITE ADDUCT FORMATION WITH SPECIFIC MITOCHONDRIAL PROTEINS USING ANTIBODIES RAISED AGAINST HALOTHANE METABOLITE ADDUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GLUTAMINE TRANSAMINASE-K; RAT-KIDNEY CYTOSOL; BETA-LYASE; S-CONJUGATE; TOXICITY; NEPHROTOXICITY; MECHANISM; BIOACTIVATION; HEPATITIS; LOCALIZATION	Antibodies raised against halothane metabolite adducts cross-react with S-(1,1,2,2-tetrafluoroethyl)-L-cysteine (TFEC) and S-(2-chloro-1,1,2-trifluoroethyl)-L-cysteine metabolite adducts. Using these antibodies in immunohistochemical experiments, metabolite binding was localized to the damaged areas of the proximal tubule after treatment of male rats with TFEC. Immunoblot analysis of subcellular fractions of rat kidney tissue after in vivo treatment with TFEC revealed a high specificity for binding of metabolites to proteins of the mitochondrial fraction. These proteins may represent target molecules which play a role in cysteine conjugate induced nephrotoxicity.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946; NHLBI,CHEM PHARMACOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Hayden, Patrick/0000-0001-8977-1845	NCI NIH HHS [CA38579] Funding Source: Medline; NIDDK NIH HHS [DK38925] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038925] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARKER VH, 1965, FOOD COSMET TOXICOL, V3, P75; COMMANDEUR JNM, 1989, MOL PHARMACOL, V36, P654; COMMANDEUR JNM, 1990, CHEM RES TOXICOL, V3, P171, DOI 10.1021/tx00015a001; COOPER AJL, 1981, COMP BIOCHEM PHYS B, V69, P137, DOI 10.1016/0305-0491(81)90223-6; COOPER AJL, 1978, ANAL BIOCHEM, V89, P451, DOI 10.1016/0003-2697(78)90374-3; DEKANT W, 1987, P NATL ACAD SCI USA, V84, P7443, DOI 10.1073/pnas.84.21.7443; DEKANT W, 1989, DRUG METAB REV, V20, P43, DOI 10.3109/03602538908994144; HAYDEN PJ, 1990, MOL PHARMACOL, V37, P468; HAYDEN PJ, 1991, BIOCHEMISTRY-US, V30, P5935, DOI 10.1021/bi00238a018; JAFFE DR, 1984, J APPL TOXICOL, V4, P315, DOI 10.1002/jat.2550040607; JONES TW, 1986, ARCH BIOCHEM BIOPHYS, V251, P504, DOI 10.1016/0003-9861(86)90358-9; JONES TW, 1988, MOL PHARMACOL, V34, P621; KENNA JG, 1988, J PHARMACOL EXP THER, V245, P1103; KENNA JG, 1987, J PHARMACOL EXP THER, V242, P733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH LH, 1987, MOL PHARMACOL, V32, P549; LASH LH, 1986, J BIOL CHEM, V261, P5930; LASH LH, 1986, J BIOL CHEM, V261, P3076; LOCK EA, 1990, TOXICOL APPL PHARM, V104, P180, DOI 10.1016/0041-008X(90)90293-4; MACFARLANE M, 1989, TOXICOL APPL PHARM, V98, P185, DOI 10.1016/0041-008X(89)90224-X; NASH JA, 1984, TOXICOL APPL PHARM, V73, P124, DOI 10.1016/0041-008X(84)90061-9; NIBBERING PH, 1987, J HISTOCHEM CYTOCHEM, V35, P1425, DOI 10.1177/35.12.3316377; POHL LR, 1988, ANNU REV PHARMACOL, V28, P367; POHL LR, 1990, SEMIN LIVER DIS, V10, P305, DOI 10.1055/s-2008-1040486; POHL LR, 1989, DRUG METAB REV, V20, P203, DOI 10.3109/03602538909103537; SATOH H, 1985, J PHARMACOL EXP THER, V233, P857; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SCHNELLMANN RG, 1987, TOXICOL APPL PHARM, V90, P513, DOI 10.1016/0041-008X(87)90143-8; SCHNELLMANN RG, 1989, TOXICOL APPL PHARM, V100, P498, DOI 10.1016/0041-008X(89)90297-4; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; STEVENS JL, 1988, J BIOL CHEM, V263, P3395; STEVENS JL, 1985, BIOCHEM BIOPH RES CO, V129, P499, DOI 10.1016/0006-291X(85)90179-2; Stevens JL, 1989, GLUTATHIONE CHEM B B, P45; STONARD MD, 1971, BIOCHEM PHARMACOL, V20, P2429, DOI 10.1016/0006-2952(71)90243-7; STONARD MD, 1971, BIOCHEM PHARMACOL, V20, P2417, DOI 10.1016/0006-2952(71)90242-5; TERRACINI B, 1965, Food Cosmet Toxicol, V3, P67, DOI 10.1016/S0015-6264(65)80010-4; WALLIN A, 1987, ARCH BIOCHEM BIOPHYS, V258, P365, DOI 10.1016/0003-9861(87)90357-2; WELSH CJ, 1991, TOXICOLOGIST, V10, P59; WOLFGANG GHI, 1989, TOXICOLOGY, V58, P33, DOI 10.1016/0300-483X(89)90102-9	39	54	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18415	18418						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917965				2022-12-25	WOS:A1991GJ47200002
J	KAPLAN, S; BARSAGI, D				KAPLAN, S; BARSAGI, D			ASSOCIATION OF P21RAS WITH CELLULAR POLYPEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS PROTEINS; POLYACRYLAMIDE GELS; GENE-PRODUCT; IDENTIFICATION; ONCOGENE; GTPASE; GROWTH; ELECTROPHORESIS; RECEPTORS; RELEASE	p21ras-specific antiserum was used to immunoprecipitate p21ras polypeptides from human A431 cells. In addition to p21ras, this antiserum precipitated a series of polypeptides with relative molecular weights of 150,000, 120,000, 105,000, and 50,000. The precipitation of these polypeptides was prevented by preincubation of the antiserum with an excess of purified Ras protein. These polypeptides do not share an epitope with p21ras, and two of them (120 and 150 kDa) co-purify with a fraction of p21ras. The co-precipitation of p21ras with these polypeptides was detected in a variety of cell types. The pattern of the immunoprecipitates was consistently different in normal and ras-transformed cells. The 120- and 150-kDa polypeptides are phosphorylated on serine and threonine in A431 cells. Serum treatment resulted in a 2-fold increase in the phosphoserine content of the 120-kDa polypeptides.			KAPLAN, S (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Bar-Sagi, Dafna/0000-0003-2597-8948	NATIONAL CANCER INSTITUTE [P01CA046370] Funding Source: NIH RePORTER; NCI NIH HHS [CA46370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LEE G, 1989, P NATL ACAD SCI USA, V86, P8678, DOI 10.1073/pnas.86.22.8678; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; RULEY HE, 1985, CANCER CELL, V3, P257; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	27	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18934	18941						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918009				2022-12-25	WOS:A1991GJ47200081
J	BERANGER, F; TAVITIAN, A; DEGUNZBURG, J				BERANGER, F; TAVITIAN, A; DEGUNZBURG, J			POSTTRANSLATIONAL PROCESSING AND SUBCELLULAR-LOCALIZATION OF THE RAS-RELATED RAP2 PROTEIN	ONCOGENE			English	Article							GTP-BINDING PROTEIN; GAMMA SUBUNITS CONTAIN; NUCLEAR-ENVELOPE; ENDOPLASMIC-RETICULUM; CATALYTIC DOMAIN; PLASMA-MEMBRANE; MEVALONIC ACID; GENE-PRODUCT; LAMIN B; P21	The ras-related rap2 gene encodes a 21 kDa GTP-binding protein that exhibits many structural similarities with Ras proteins. In particular, it contains a C-terminal CAAX sequence (C, cysteine; A, aliphatic residue; X, any amino acid) which has been shown to direct the post-translational modifications responsible for membrane binding of Ras proteins and nuclear lamins. We have generated cell lines overexpressing the Rap2 protein as well as specific anti-Rap2 antibodies and show that the protein is tightly associated with cellular membranes. Similarly to Ras proteins, the Rap2 protein is synthesized as a soluble and hydrophilic precursor that is processed to the mature hydrophobic membrane-bound form. During its maturation, the Rap2 protein is modified by the attachment of both palmitate and polyisoprenoid groups, as is also the case for H- and N-Ras proteins. Subcellular fractionation by sucrose density centrifugation as well as indirect immunofluorescence experiments show that the Rap2 protein is localized in a low-density compartment that morphologically overlaps with the endoplasmic reticulum, whereas Ras proteins are associated with the plasma membrane. In spite of similar post-translational modifications by palmitoylation and polyisoprenylation, Ras and Rap2 proteins are thus located on distinct subcellular structures.			BERANGER, F (corresponding author), FAC MED LARIBOISIERE,INSERM,U248,10 AVE VERDUN,F-75010 PARIS,FRANCE.		Beranger, Florence/R-7581-2019					ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BERGER M, 1984, J BIOL CHEM, V259, P7245; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; HORI Y, 1991, ONCOGENE, V6, P515; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JIMENEZ B, 1991, IN PRESS INT J CANCE; JOHN J, 1988, J BIOL CHEM, V263, P11792; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KHOSRAVIFAR R, 1991, IN PRESS P NATL ACAD; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANDERSLUIJS P, 1991, IN PRESS P NATL ACAD; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VONMOLLARD F, 1990, P NATL ACAD SCI USA, V87, P5692; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	61	31	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1835	1842						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923507				2022-12-25	WOS:A1991GX11800016
J	DELSENNO, L; MAESTRI, I; PIVA, R; BIANCHINI, E; ROSSI, R; UBERTI, ED				DELSENNO, L; MAESTRI, I; PIVA, R; BIANCHINI, E; ROSSI, R; UBERTI, ED			A C-MYC GENE VARIANT WITHOUT EXON 1 AND WITH AN ABNORMAL METHYLATION PATTERN INHERITED IN A WOMAN WITH NO EVIDENCE OF MALIGNANCY	ONCOGENE			English	Note							TRANSLOCATION; ONCOGENES; LYMPHOMAS; CELLS; HYPOMETHYLATION; CHROMOSOME-8; ACTIVATION; CANCER	A c-myc DNA with a deletion which includes 5' flanking, exon 1 and intron I sequences has been found in normal white blood cells of a mother and one daughter in a Northern Italian family. In addition, the degree of methylation of specific CCGG sites in the truncated DNA is lower in both mother and daughter than that found in normal DNA. It is of interest that deletions of the first exon and hypomethylation of the c-myc gene have usually been observed only in some neoplasias. However, our results demonstrate that the c-myc truncated DNA with the abnormal methylation pattern here reported is a genomic variant which by itself is not related to neoplastic transformation.	UNIV FERRARA,CTR STUDI BIOCHIM PATHOL GENOMA UMANO,I-44100 FERRARA,ITALY; UNIV FERRARA,IST MED INTERNA,SEZ ENDOCRINOL,I-44100 FERRARA,ITALY	University of Ferrara; University of Ferrara	DELSENNO, L (corresponding author), UNIV FERRARA,IST CHIM BIOL,VL BORSARI 46,I-44100 FERRARA,ITALY.			degli Uberti, Ettore/0000-0002-9441-7223; Piva, Roberta/0000-0003-2663-6210; maestri, iva/0000-0002-3485-4640				ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; ALT FW, 1986, COLD SPRING HARB SYM, V1, P931; AVVEDIMENTO VE, 1985, HUM GENET, V71, P163, DOI 10.1007/BF00283375; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; CHEAH MSC, 1984, JNCI-J NATL CANCER I, V73, P1057; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DELSENNO L, 1986, FEBS LETT, V196, P296, DOI 10.1016/0014-5793(86)80266-6; DELSENNO L, 1989, J UROLOGY, V142, P146; DELSENNO L, 1984, NEW TRENDS EXPT HEMA, P230; DYSON PJ, 1985, P NATL ACAD SCI USA, V82, P1984, DOI 10.1073/pnas.82.7.1984; HALL JM, 1989, AM J HUM GENET, V44, P577; HALUSKA FG, 1989, NUCLEIC ACIDS RES, V15, P865; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; MIDDLETON PG, 1988, NUCLEIC ACIDS RES, V13, P5723; OCONNELL P, 1987, CYTOGENET CELL GENET, V46, P673; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RANZANI GN, 1989, ATTI ASS GENET ITA Y, V30, P295; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; SILVA AJ, 1988, CELL, V54, P145, DOI 10.1016/0092-8674(88)90546-6	20	4	4	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1895	1898						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923512				2022-12-25	WOS:A1991GX11800024
J	DEPPERT, W; KURTH, M; GRAESSMANN, M; GRAESSMANN, A; KNIPPSCHILD, U				DEPPERT, W; KURTH, M; GRAESSMANN, M; GRAESSMANN, A; KNIPPSCHILD, U			ALTERED PHOSPHORYLATION AT SPECIFIC SITES CONFERS A MUTANT PHENOTYPE TO SV40 WILD-TYPE LARGE T-ANTIGEN IN A FLAT REVERTANT OF SV40-TRANSFORMED CELLS	ONCOGENE			English	Article							SIMIAN VIRUS-40; TUMOR-ANTIGEN; PROTEIN PHOSPHATASE-2A; TRANSFORMED-CELLS; DNA-REPLICATION; BINDING; P53; POLYOMAVIRUS; ASSOCIATION; SUPPRESSOR	The Rev2 cell line is a cellular revertant of the SV40 wild-type transformed rat cell line SV-52 [Bauer, M., Guhl, E., Graessmann, M. & Graessmann, A. (1987). J. Virol., 61, 1821-1827]. To characterize the level of cellular interference with the SV40 large T antigen (large T)-induced transformation pathway in Rev2 cells, we analysed the biological and biochemical properties of large T expressed in Rev2 cells. We found that Rev2 cells encoded an authentic wild-type large T, with regard to its sequence and its transforming functions. No differences were found in the metabolic stability of large T, or in complex formation with the cellular p53 protein, or in p53 metabolic stabilization. In contrast to SV-52 cells, Rev2 cells showed no association of large T with the chromatin fraction of isolated nuclei. This difference correlated with a reduced affinity of the Rev2 large T to SV40 DNA in vitro. The T proteins from both cell lines were phosphorylated at the same multiple sites. However, in Rev2 cells the phosphorylation of large T at specific serine -residues was significantly reduced. Thus the revertant phenotype of Rev2 cells may be due to an altered phosphorylation state of its large T protein, leading to altered nuclear localization and reduced transforming activity. The alterations of Rev2 large T properties and phosphorylation were very similar to the changes observed with mutant large T in FR(tsA58)A cells, an SV40 tsA58 N-type transformant, when the cells had reverted to the normal phenotype at the non-permissive growth temperature. Thus altered phosphorylation might provide a common structural basis for the biological inactivation of the large T proteins in these cells.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,W-1000 BERLIN 33,GERMANY	Free University of Berlin	DEPPERT, W (corresponding author), UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.							BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOURRE F, 1983, NATURE, V305, P68, DOI 10.1038/305068a0; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; DEPPERT W, 1989, CURR TOP MICROBIOL, V144, P77; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1989, ONCOGENE, V4, P1103; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; FANNING E, 1982, EMBO J, V1, P1023, DOI 10.1002/j.1460-2075.1982.tb01290.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; HINZPETER M, 1987, ONCOGENE, V1, P119; HOESS A, 1990, J VIROL, V64, P4799; KNIPPSCHILD U, 1991, J VIROL, V65, P4414, DOI 10.1128/JVI.65.8.4414-4423.1991; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; Martin R G, 1981, Adv Cancer Res, V34, P1, DOI 10.1016/S0065-230X(08)60238-9; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PINTEL D, 1981, J VIROL, V38, P518, DOI 10.1128/JVI.38.2.518-528.1981; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; RICHTER W, 1990, VIROLOGY, V174, P543, DOI 10.1016/0042-6822(90)90108-4; ROBB JA, 1973, EXP CELL RES, V81, P120, DOI 10.1016/0014-4827(73)90118-3; RYAN KW, 1985, MOL CELL BIOL, V5, P3577, DOI 10.1128/MCB.5.12.3577; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1984, J VIROL, V50, P1; SCHEIDTMANN KH, 1984, J VIROL, V50, P636, DOI 10.1128/JVI.50.2.636-640.1984; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHIRMBECK R, 1988, VIROLOGY, V165, P527, DOI 10.1016/0042-6822(88)90597-1; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; STAUFENBIEL M, 1983, EUR J CELL BIOL, V31, P341; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; VANROY F, 1990, ONCOGENE, V5, P207; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	41	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1931	1938						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923516				2022-12-25	WOS:A1991GX11800030
J	GABRIEL, SE; FORSYTH, GW				GABRIEL, SE; FORSYTH, GW			CANDIDATE PROTEINS FOR CONDUCTIVE CHLORIDE TRANSPORT IN PORCINE ILEAL BRUSH-BORDER MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; CYSTIC-FIBROSIS; VESICLES; RECONSTITUTION; CHANNEL	Conductive transport of chloride ion is important in controlling ion and fluid secretion by exocrine tissues. The current study was directed at identifying proteins in the intestinal brush-border membrane that may be involved with conductive chloride transport. Reaction of total brush-border membrane protein with phenylisothiocyanate inhibited conductive chloride transport into brush-border membrane vesicles. The conductive transport process was protected from this inhibition by including the ligands Cl- and alpha-phenylcinnamate in the reaction mixture. Brush-border membrane protein protected by this procedure and labeled with fluorescein had an apparent molecular mass in the region of 130 and 23 kDa on separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Phosphorylation of brush-border membrane protein with [gamma-P-32] ATP and endogenous protein kinase under conditions causing activation of chloride conductance in membrane vesicles caused the transfer of P-32 to several proteins, including ones in the same molecular size range (130 and 23 kDa) as those identified by the fluorescein labeling procedure. Conductive chloride transport in porcine intestinal brush-border vesicles may occur via proteins identified by this differential labeling procedure.	UNIV SASKATCHEWAN,DEPT VET PHYSIOL SCI,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA	University of Saskatchewan								COTTON CU, 1987, J CLIN INVEST, V79, P80, DOI 10.1172/JCI112812; DEJONGE HR, 1984, MECHANISMS INTESTINA, P282; DISTEFANO A, 1985, PFLUG ARCH EUR J PHY, V405, pS95, DOI 10.1007/BF00581787; DUBINSKY WP, 1986, AM J PHYSIOL, V251, pC713, DOI 10.1152/ajpcell.1986.251.5.C713; FIELD M, 1969, J CLIN INVEST, V48, P24; FINN AL, 1989, P NATL ACAD SCI USA, V86, P7649, DOI 10.1073/pnas.86.19.7649; FORSYTH GW, 1989, J MEMBRANE BIOL, V107, P137, DOI 10.1007/BF01871719; FORSYTH GW, 1988, J PHYSIOL-LONDON, V402, P555, DOI 10.1113/jphysiol.1988.sp017221; FORSYTH GW, 1989, BIOCHIM BIOPHYS ACTA, V977, P19, DOI 10.1016/S0005-2728(89)80004-0; FRIZZELL RA, 1986, FASEB J, V45, P2727; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; MAENZ DD, 1982, J MEMBRANE BIOL, V70, P125, DOI 10.1007/BF01870222; PEERCE BE, 1984, J BIOL CHEM, V259, P4105; PEERCE BE, 1984, P NATL ACAD SCI-BIOL, V81, P2223, DOI 10.1073/pnas.81.7.2223; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; SHARP GWG, 1987, FEBS LETT, V221, P309, DOI 10.1016/0014-5793(87)80946-8; SHARP GWG, 1984, MECHANISMS INTESTINA, P241; WANGEMANN P, 1986, PFLUG ARCH EUR J PHY, V407, pS128, DOI 10.1007/BF00584942	20	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17764	17769						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917921				2022-12-25	WOS:A1991GG55300011
J	GERMANN, UA; CHIN, KV; PASTAN, I; GOTTESMAN, MM				GERMANN, UA; CHIN, KV; PASTAN, I; GOTTESMAN, MM			RETROVIRAL TRANSFER OF A CHIMERIC MULTIDRUG RESISTANCE-ADENOSINE DEAMINASE GENE	FASEB JOURNAL			English	Article									NCI, MOLEC BIOL LAB, BLDG 37, 2E18, 9000 ROCKVILLE PIKE, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019; Chin, Khew-Voon/F-2670-2013	pastan, ira/0000-0002-9223-0270; 				BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; DEUCHARS KL, 1987, MOL CELL BIOL, V7, P718, DOI 10.1128/MCB.7.2.718; GALSKI H, 1989, MOL CELL BIOL, V9, P4357, DOI 10.1128/MCB.9.10.4357; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GERMANN UA, 1989, J BIOL CHEM, V264, P7418; GIBLETT ER, 1972, LANCET, V2, P1067; GILBOA E, 1986, BIOTECHNIQUES, V4, P504; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GUILD BC, 1988, J VIROL, V62, P3795, DOI 10.1128/JVI.62.10.3795-3801.1988; GUILD BC, 1988, P NATL ACAD SCI USA, V85, P1595, DOI 10.1073/pnas.85.5.1595; HIRSCHHORN R, 1986, CLIN IMMUNOL IMMUNOP, V40, P157, DOI 10.1016/0090-1229(86)90081-4; KANE SE, 1988, MOL CELL BIOL, V8, P3316, DOI 10.1128/MCB.8.8.3316; KANTOFF PW, 1987, J EXP MED, V166, P219, DOI 10.1084/jem.166.1.219; KREDICH NM, 1982, METABOLIC BASIS INHE, P1157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGLI MC, 1987, P NATL ACAD SCI USA, V84, P789, DOI 10.1073/pnas.84.3.789; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCIVOR RS, 1987, MOL CELL BIOL, V7, P838, DOI 10.1128/MCB.7.2.838; MILLER AD, 1985, MOL CELL BIOL, V5, P431, DOI 10.1128/MCB.5.3.431; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SHIMOTOHNO K, 1981, CELL, V26, P67, DOI 10.1016/0092-8674(81)90034-9; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TANAKA S, 1990, IN PRESS BIOCH BIOPH; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; WILLIAMS DA, 1986, P NATL ACAD SCI USA, V83, P2566, DOI 10.1073/pnas.83.8.2566; YEUNG CY, 1983, J BIOL CHEM, V258, P8330	34	31	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	1990	4	5					1501	1507		10.1096/fasebj.4.5.1968408	http://dx.doi.org/10.1096/fasebj.4.5.1968408			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CT176	1968408				2022-12-25	WOS:A1990CT17600011
J	SAITO, Y; TADA, H; SABE, H; HONJO, T				SAITO, Y; TADA, H; SABE, H; HONJO, T			BIOCHEMICAL-EVIDENCE FOR A 3RD CHAIN OF THE INTERLEUKIN-2 RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CHAIN; IL-2 RECEPTOR; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; LIGAND-BINDING; CROSS-LINKING; SIMIAN CELLS; ALPHA-CHAIN; TAC PEPTIDE	Two receptor proteins that specifically bind interleukin-2 (IL-2) have been identified previously. The L (Tac or alpha) chain can bind IL-2 with a K(d) value of 10 nM (low affinity). Although the H (beta) chain expressed on lymphocytes can bind IL-2 with a K(d) value of 1 nM (intermediate affinity), transfected fibroblasts expressing the H chain cannot bind IL-2, suggesting the involvement of other lymphocyte-specific factors for the function of the H chain. To obtain direct evidence for the presence of a third component of the IL-2 receptor, we examined the IL-2 binding activity of detergent-solubilized cell membrane preparations. We found that lysates of transfected Cos7 cells expressing H chains can bind IL-2 when mixed with lysates from lymphocytes that cannot bind IL-2. Chemical cross-linking of I-125-IL-2-bound lysate mixture and subsequent immunoprecipitation with a noncompetitive anti-H chain antibody gave rise to two I-125-IL-2-bound proteins, a 56-kDa protein (p56) and the H chain, although neither the H chain nor p56 alone is able to bind IL-2. These results indicate that p56 is the IL-2 receptor third chain that is required for IL-2 binding to the H chain. A similar lysate mixing experiment also showed that p56 is involved in IL-2 binding to the high affinity IL-2 receptor by forming the quaternary complex of IL-2, p56, L chain, and H chain.	KYOTO UNIV,CTR MOLEC BIOL & GENET,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	SAITO, Y (corresponding author), KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN.		Sabe, Hisataka/GPF-4385-2022; Honjo, Tasuku/N-4470-2016; Sabe, Hisataka/A-4066-2012					COLAMONICI OR, 1990, J IMMUNOL, V145, P155; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HATAKEYAMA M, 1985, NATURE, V318, P467, DOI 10.1038/318467a0; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1987, J EXP MED, V166, P362, DOI 10.1084/jem.166.2.362; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HERMANN T, 1988, MOL IMMUNOL, V25, P1201; HERMANN T, 1988, EUR J IMMUNOL, V18, P1051; HIRAKI DD, 1986, J IMMUNOL, V136, P4291; KAMIO M, 1990, BLOOD, V75, P415; KONDO S, 1987, NATURE, V327, P64, DOI 10.1038/327064a0; KONDO S, 1986, P NATL ACAD SCI USA, V83, P9026, DOI 10.1073/pnas.83.23.9026; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MINAMOTO S, 1990, J IMMUNOL, V145, P2177; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; OGURA T, 1988, MOL BIOL MED, V5, P123; ROBB RJ, 1987, J EXP MED, V165, P1201, DOI 10.1084/jem.165.4.1201; Sabe H, 1984, Mol Biol Med, V2, P379; SABE H, IN PRESS INT IMMUNOL; SAITO Y, 1990, INT IMMUNOL, V2, P1167, DOI 10.1093/intimm/2.12.1167; SAITO Y, 1988, J EXP MED, V168, P1563, DOI 10.1084/jem.168.5.1563; SARAGOVI H, 1990, P NATL ACAD SCI USA, V87, P11, DOI 10.1073/pnas.87.1.11; SARAGOVI H, 1987, J IMMUNOL, V139, P1918; SHARON M, 1990, P NATL ACAD SCI USA, V87, P4869, DOI 10.1073/pnas.87.12.4869; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SZOLLOSI J, 1987, P NATL ACAD SCI USA, V84, P7246, DOI 10.1073/pnas.84.20.7246; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TANAKA Y, 1985, MICROBIOL IMMUNOL, V29, P959, DOI 10.1111/j.1348-0421.1985.tb02960.x; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; TSUDO M, 1990, J IMMUNOL, V145, P599; TSUI LC, 1982, CELL, V30, P499, DOI 10.1016/0092-8674(82)90247-1; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; VOSS SD, 1990, J EXP MED, V172, P1101, DOI 10.1084/jem.172.4.1101; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; YODOI J, 1985, J IMMUNOL, V134, P1623; ZURAWSKI SM, 1990, EMBO J, V9, P3899, DOI 10.1002/j.1460-2075.1990.tb07610.x	43	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22186	22191						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939240				2022-12-25	WOS:A1991GR56400022
J	STADTMAN, TC; DAVIS, JN				STADTMAN, TC; DAVIS, JN			GLYCINE REDUCTASE PROTEIN-C - PROPERTIES AND CHARACTERIZATION OF ITS ROLE IN THE REDUCTIVE CLEAVAGE OF SE-CARBOXYMETHYL-SELENOPROTEIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL PHOSPHATE; PURIFICATION; SELENOCYSTEINE; COMPLEX; IDENTIFICATION; INTERMEDIATE; COMPONENTS; SYSTEM	The clostridial glycine reductase complex catalyzes the reductive deamination of glycine in an energy-conserving process that results in the esterification of orthophosphate. The complex consists of three protein components: selenoprotein A; protein B, a carbonyl group protein; and protein C, a sulfhydryl protein. The protein C component also catalyzes the arsenate-dependent decomposition of acetyl phosphate. Reaction of protein C with iodoacetate inhibits its ability to decompose acetyl phosphate, but this inactivation of the enzyme by alkylation is prevented in the presence of the substrate indicating the formation of an unreactive enzyme-bound acetylthiol ester. The Se-carboxymethylselenocysteine residue of the selenoprotein A component of glycine reductase was generated by selective alkylation of the ionized selenol group at pH 6 with [C-14]bromoacetate. Using this pure alkylated selenoprotein A as substrate, it was shown that protein C catalyzes the conversion of the [C-14]carboxymethyl group, in selenoether linkage to protein A, to [C-14] acetate in the presence of arsenate, dithiothreitol, and Mg2+. A procedure using hydrophobic chromatographic matrices was developed for the large scale isolation of protein C, and a number of the properties of the enzyme were determined.	NHLBI,BIOCHEM LAB,BLDG 3,ROOM 108,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ARKOWITZ RA, 1990, J AM CHEM SOC, V112, P870, DOI 10.1021/ja00158a059; ARKOWITZ RA, 1991, BIOCHEMISTRY-US, V30, P4090, DOI 10.1021/bi00230a039; ARKOWITZ RA, 1989, BIOCHEMISTRY-US, V28, P4639, DOI 10.1021/bi00437a019; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CONE JE, 1977, J BIOL CHEM, V252, P5337; CONE JE, 1976, P NATL ACAD SCI USA, V73, P2659, DOI 10.1073/pnas.73.8.2659; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DURRE P, 1983, J BACTERIOL, V154, P192; GARCIA GE, 1991, J BACTERIOL, V173, P2093, DOI 10.1128/jb.173.6.2093-2098.1991; Hare P E, 1977, Methods Enzymol, V47, P3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; SLIWKOWSKI M X, 1988, Biofactors, V1, P293; SLIWKOWSKI MX, 1987, J BIOL CHEM, V262, P4899; SLIWKOWSKI MX, 1988, P NATL ACAD SCI USA, V85, P368, DOI 10.1073/pnas.85.2.368; STADTMAN ER, 1950, J BIOL CHEM, V184, P769; STADTMAN ER, 1952, J BIOL CHEM, V196, P527; Stadtman T C, 1978, Methods Enzymol, V53, P373; STADTMAN TC, 1958, J BIOL CHEM, V231, P961; STADTMAN TC, 1966, ARCH BIOCHEM BIOPHYS, V113, P9, DOI 10.1016/0003-9861(66)90151-2; STADTMAN TC, 1989, P NATL ACAD SCI USA, V86, P7853, DOI 10.1073/pnas.86.20.7853; STADTMAN TC, 1956, J AM CHEM SOC, V78, P2020, DOI 10.1021/ja01590a076; STADTMAN TC, 1970, METHODS ENZYMOL A, V17, P959; TANAKA H, 1979, J BIOL CHEM, V254, P447; TURNER DC, 1973, ARCH BIOCHEM BIOPHYS, V154, P366, DOI 10.1016/0003-9861(73)90069-6; WANG JH, 1963, J BIOL CHEM, V238, P2386; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	28	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22147	22153						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939235				2022-12-25	WOS:A1991GR56400016
J	THOMPSON, WR; NADALGINARD, B; MAHDAVI, V				THOMPSON, WR; NADALGINARD, B; MAHDAVI, V			A MYOD1-INDEPENDENT MUSCLE-SPECIFIC ENHANCER CONTROLS THE EXPRESSION OF THE BETA-MYOSIN HEAVY-CHAIN GENE IN SKELETAL AND CARDIAC-MUSCLE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; MYOGENIC DETERMINATION FACTORS; CREATINE-KINASE GENE; TROPONIN-T-GENE; MOUSE MUSCLE; THYROID-HORMONE; MOLECULAR-BASIS; SV40 ENHANCER; MYOD FAMILY; ACETYLCHOLINE-RECEPTOR	The beta-cardiac myosin heavy chain is the major contractile protein expressed in two sarcomeric muscles of distinct embryologic origins. the ventricular myocardium and slow twitch skeletal muscle. Characterization of the cis-acting regulatory sequences of the human and the rat beta-MHC genes established that their expression in these two muscle types is controlled, at least in part, by common mechanisms involving a muscle-specific enhancer. This enhancer consists of distinct but cooperative subelements that interact with muscle-specific nuclear proteins. In contrast to other muscle-specific enhancers, the beta-MHC gene enhancer is unresponsive, directly or indirectly, to the muscle lineage-determining and muscle gene-transactivating helix-loop-helix factors MyoD and myogenin. A MyoD-binding site in the rat beta-MHC promoter is not required for transcriptional activity in skeletal and cardiac cells, but is necessary for activation in 1OT1/2 and CV1 cells transfected with MyoD. In addition, this element is absent from the human beta-MHC promoter. Thus, MyoD and MyoD-related processes are neither required nor sufficient for the expression of the beta-MHC gene either in cardiac or skeletal muscle cells. These observations provide evidence for the existence of myogenic regulatory programs that precede and/or differ from those governed by known myogenic helix-loop-helix transactivators.	CHILDRENS HOSP MED CTR, HOWARD HUGHES MED INST, DEPT CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School								BALDWIN TJ, 1990, NATURE, V345, P364, DOI 10.1038/345364a0; BALDWIN TJ, 1989, NATURE, V341, P716, DOI 10.1038/341716a0; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOUVAGNET P, 1987, CIRC RES, V61, P329, DOI 10.1161/01.RES.61.3.329; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHIEN KR, 1985, J CLIN INVEST, V75, P1770, DOI 10.1172/JCI111889; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; CRIBBS LL, 1989, J BIOL CHEM, V264, P10672; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DEVLIN BH, 1989, J BIOL CHEM, V264, P13896; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KHOURY G, 1983, CELL, V33, P313, DOI 10.1016/0092-8674(83)90410-5; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; LOMPRE AM, 1981, DEV BIOL, V84, P286, DOI 10.1016/0012-1606(81)90396-1; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MAHDAVI V, 1989, UCLA S MOL CELL BIOL, V93, P369; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MICHELSON AM, 1990, GENE DEV, V4, P2086, DOI 10.1101/gad.4.12a.2086; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; MULLE C, 1988, P NATL ACAD SCI USA, V85, P5728, DOI 10.1073/pnas.85.15.5728; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nadal-Ginard B, 1982, MUSCLE DEV MOL CELLU, P143; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; PETROPOULOS CJ, 1989, MOL CELL BIOL, V9, P3785, DOI 10.1128/MCB.9.9.3785; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Rosenthal N, 1989, CURR OPIN CELL BIOL, V1, P1094, DOI 10.1016/S0955-0674(89)80056-0; ROSENTHAL N, 1990, NUCLEIC ACIDS RES, V18, P6239, DOI 10.1093/nar/18.21.6239; RUOQIANSHEN SK, 1991, MOL CELL BIOL, V11, P1676; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SILBERSTEIN L, 1986, CELL, V46, P1075, DOI 10.1016/0092-8674(86)90707-5; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; SUTRAVE P, 1991, J CELL BIOCHEM     S, V15, P4; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; TANIGAWA G, 1990, CELL, V62, P991, DOI 10.1016/0092-8674(90)90273-H; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THOMPSON WR, 1990, DEVELOPMENTAL CARDIOLOGY, P13; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WU JP, 1989, J BIOL CHEM, V264, P6472; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YU YT, 1989, MOL CELL BIOL, V9, P1839, DOI 10.1128/MCB.9.5.1839; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; ZERIVITZ K, 1989, GENE ANAL TECH, V6, P101, DOI 10.1016/0735-0651(89)90016-2; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	83	164	166	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22678	22688						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939278				2022-12-25	WOS:A1991GR56400093
J	WISE, RJ; DORNER, AJ; KRANE, M; PITTMAN, DD; KAUFMAN, RJ				WISE, RJ; DORNER, AJ; KRANE, M; PITTMAN, DD; KAUFMAN, RJ			THE ROLE OF VONWILLEBRAND-FACTOR MULTIMERS AND PROPEPTIDE CLEAVAGE IN BINDING AND STABILIZATION OF FACTOR-VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON WILLEBRAND FACTOR; PLATELET GLYCOPROTEIN-IB; FACTOR VWF CDNA; HEMOPHILIA-A; LIGHT CHAIN; PROCOAGULANT ACTIVITY; MONOCLONAL-ANTIBODY; HETEROLOGOUS CELLS; COFACTOR ACTIVITY; MAMMALIAN-CELLS	von Willebrand factor (vWF) is a multimeric glycoprotein that promotes platelet aggregation and stabilizes coagulation factor VIII in the plasma. vWF is also required for the stable accumulation of recombinant factor VIII secreted from cells in a heterologous expression system. In this report, we show that vWF can promote the in vitro reconstitution of factor VIII activity from dissociated heavy and light chains of factor VIII, suggesting that vWF may act to promote stable assembly of factor VIII subunits at the site of secretion. The structural requirements for vWF propeptide cleavage and for vWF multimerization in its binding and stabilization of factor VIII was examined using specifically altered recombinant vWF. The mutant vWF molecules were also assayed for their function in ristocetin-induced platelet agglutination mediated through the platelet receptor GPIb. Deletion of the vWF propeptide produced a dimeric vWF molecule that failed to mediate platelet agglutination, suggesting that multimerization is required for vWF to attain functional GPIb binding. This mature dimeric form of vWF, however, was fully capable of binding to and supporting stable secretion of factor VIII. A vWF mutant with an altered propeptide cleavage site formed large multimers of uncleaved pro-vWF that functioned in platelet agglutination. However, this noncleavage mutant neither bound to or supported stable accumulation of factor VIII. Analysis of the vWF propeptide, expressed independently, demonstrated that it could not bind factor VIII or stabilize its secretion. These results show that the dimeric mature vWF subunit is sufficient to bind and stabilize factor VIII and that the presence of uncleaved vWF propeptide-inhibits both factor VIII binding and stabilization.	GENET INST, CAMBRIDGE, MA USA									ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; BAHOU WF, 1989, J CLIN INVEST, V84, P56, DOI 10.1172/JCI114169; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BRINKHOUS KM, 1985, P NATL ACAD SCI USA, V82, P8752, DOI 10.1073/pnas.82.24.8752; CACHERIS PM, 1991, J BIOL CHEM, V266, P13499; COLLER BS, 1983, BLOOD, V61, P99; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FAY PJ, 1986, SCIENCE, V232, P995, DOI 10.1126/science.3486471; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FEDERICI AB, 1989, BRIT J HAEMATOL, V73, P93, DOI 10.1111/j.1365-2141.1989.tb00226.x; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; GAUCHER C, 1991, BLOOD, V77, P1937; GRAHAM JB, 1975, BLOOD, V46, P175; HAMER RJ, 1987, EUR J BIOCHEM, V167, P253, DOI 10.1111/j.1432-1033.1987.tb13331.x; HAMER RJ, 1987, EUR J BIOCHEM, V166, P37, DOI 10.1111/j.1432-1033.1987.tb13480.x; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1986, P NATL ACAD SCI USA, V83, P3136, DOI 10.1073/pnas.83.10.3136; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; KOEDAM JA, 1989, THESIS U UTRECHT; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LEYTE A, 1991, BIOCHEM J, V274, P257, DOI 10.1042/bj2740257; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MARTIN SE, 1980, BLOOD, V55, P848; MARTIN SE, 1981, BLOOD, V57, P313; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; MAZURIER C, 1990, BRIT J HAEMATOL, V76, P372, DOI 10.1111/j.1365-2141.1990.tb06371.x; MAZURIER C, 1990, BLOOD, V75, P20; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MONTGOMERY RR, 1986, CIRCULATION, V74, P406; MONTGOMERY RR, 1982, BLOOD, V60, P201; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; NISHINO M, 1989, BLOOD, V74, P1591; OLSON JD, 1977, J LAB CLIN MED, V89, P1278; SADLER JE, 1987, MOL BASIS BLOOD DISE, P575; TAKAHASHI Y, 1987, BLOOD, V70, P1679; TUDDENHAM EGD, 1982, BRIT J HAEMATOL, V52, P259, DOI 10.1111/j.1365-2141.1982.tb03888.x; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x; VERWEIJ CL, 1987, EMBO J, V6, P2885, DOI 10.1002/j.1460-2075.1987.tb02591.x; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; ZUCKER MB, 1983, THROMB HAEMOSTASIS, V49, P37	48	138	145	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21948	21955						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939217				2022-12-25	WOS:A1991GP80400094
J	BROEKEMEIER, KM; SCHMID, PC; DEMPSEY, ME; PFEIFFER, DR				BROEKEMEIER, KM; SCHMID, PC; DEMPSEY, ME; PFEIFFER, DR			GENERATION OF THE MITOCHONDRIAL PERMEABILITY TRANSITION DOES NOT INVOLVE INHIBITION OF LYSOPHOSPHOLIPID ACYLATION - ACYL-COENZYME-A-1-ACYLLYSOPHOSPHOLIPID ACYLTRANSFERASE ACTIVITY IS NOT FOUND IN RAT-LIVER MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-CONFINED PHOSPHOLIPASES; UNSATURATED FATTY-ACIDS; SN-GLYCEROL 3-PHOSPHATE; CA-2+ RELEASE; INORGANIC-PHOSPHATE; REGULATORY ASPECTS; INNER MEMBRANE; CA-2+-DEPENDENT PORE; KIDNEY MITOCHONDRIA; HEART-MITOCHONDRIA	The possible involvement of acyl-coenzyme A:1-acyllysophospholipid acyltransferase activity and phospholipid acylation-deacylation cycles in regulating the mitochondrial permeability transition have been examined by direct methods. 1-Acyllysophospholipid acyltransferase activity found in mitochondrial preparations obtained by differential centrifugation is inhibited by several transition-inducing agents and by glutathione disulfide. However, marker enzyme analysis employing mitochondria prepared by Percoll density gradient centrifugation or fractionated by a shear force-dependent method indicate that this activity is associated with contaminating microsomes and not with mitochondria. The absence of phospholipid acylation-deacylation cycles in isolated mitochondria is demonstrated by the absence of O-18 incorporation from H-2-O-18 into phospholipid acylester carbonyl groups, confirming conclusions arrived at from marker enzyme data by a definitive independent approach. Mitochondria prepared by differential centrifugation and Percoll density gradient centrifugation are shown to be equivalent in requirements for induction of the permeability transition and the apparent rate of this process. It is concluded that 1-acyllysophospholipid acyltransferase activity and phospholipid acylation-deacylation cycles are not factors regulating the transition in isolated mitochondria. However, mitochondrial phospholipase A2 activity remains as a potential regulating factor, whereas the action of transition-inducing agents on microsomal 1-acyllysophospholipid acyltransferase may be important in mechanisms of cell injury.	UNIV MINNESOTA,HORMEL INST,801 16TH AVE NE,AUSTIN,MN 55912; UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL008214, R01HL028176] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28176, HL08214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AARSMAN AJ, 1989, J BIOL CHEM, V264, P10008; ALNASSER I, 1986, BIOCHEM J, V239, P19, DOI 10.1042/bj2390019; ALSHAIKHALY MM, 1977, BIOCHEM SOC T, V5, P1093, DOI 10.1042/bst0051093; ANGIELSKI S, 1980, INT J BIOCHEM, V12, P119, DOI 10.1016/0020-711X(80)90053-1; BARIS RJ, 1976, ANAL BIOCHEM, V73, P1; BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; BEATRICE MC, 1980, J BIOL CHEM, V255, P8663; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V1, P485; BISHOP JE, 1980, ANAL BIOCHEM, V106, P344, DOI 10.1016/0003-2697(80)90531-X; BJERVE KS, 1976, BIOCHEM J, V158, P249, DOI 10.1042/bj1580249; BROCKMAN HL, 1991, GBF MONOGR SER, V16, P95; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; CROMPTON M, 1990, BIOCHEM J, V266, P33, DOI 10.1042/bj2660033; DALTON S, 1984, BIOCHEM J, V224, P423, DOI 10.1042/bj2240423; DAWSON AP, 1979, NATURE, V277, P484, DOI 10.1038/277484a0; DEVILLIERS M, 1986, BIOCHIM BIOPHYS ACTA, V876, P309, DOI 10.1016/0005-2760(86)90289-4; DEWINTER JM, 1982, BIOCHIM BIOPHYS ACTA, V712, P332, DOI 10.1016/0005-2760(82)90351-4; DEWINTER JM, 1984, ARCH BIOCHEM BIOPHYS, V234, P243, DOI 10.1016/0003-9861(84)90346-1; DEWINTER JM, 1987, BIOCHIM BIOPHYS ACTA, V917, P169, DOI 10.1016/0005-2760(87)90297-9; EIBEL H, 1969, EUR J BIOCHEM, V9, P250; ERDAHL WL, 1991, ARCH BIOCHEM BIOPHYS, V285, P252, DOI 10.1016/0003-9861(91)90357-O; Greenawalt J W, 1979, Methods Enzymol, V55, P88; GUNTER TE, 1990, AM J PHYSIOL, V258, pC75; HARRIS EJ, 1982, BIOCHEM BIOPH RES CO, V104, P1264, DOI 10.1016/0006-291X(82)91386-9; HARRIS EJ, 1982, BIOCHEM BIOPH RES CO, V108, P1614, DOI 10.1016/S0006-291X(82)80093-4; HARRIS EJ, 1981, BIOCHEM BIOPH RES CO, V103, P788, DOI 10.1016/0006-291X(81)90518-0; HILLERED L, 1989, J NEUROSCI RES, V24, P247, DOI 10.1002/jnr.490240216; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; IGBAVBOA U, 1988, J BIOL CHEM, V263, P1405; KUWAE T, 1987, BIOCHEM BIOPH RES CO, V142, P86, DOI 10.1016/0006-291X(87)90454-2; KUWAE T, 1990, J BIOL CHEM, V265, P5002; LENTING HBM, 1987, BIOCHIM BIOPHYS ACTA, V917, P178, DOI 10.1016/0005-2760(87)90298-0; LENTING HBM, 1988, BIOCHIM BIOPHYS ACTA, V961, P129, DOI 10.1016/0005-2760(88)90138-5; LENTING HBM, 1988, BIOCHIM BIOPHYS ACTA, V958, P405, DOI 10.1016/0005-2760(88)90226-3; LENZEN S, 1989, BIOCHIM BIOPHYS ACTA, V982, P140, DOI 10.1016/0005-2736(89)90184-3; LOMBARDO D, 1986, J BIOL CHEM, V261, P1663; LYSIAK W, 1988, J BIOL CHEM, V263, P1151; MCMURRAY WC, 1986, BIOCHEM CELL BIOL, V64, P1115, DOI 10.1139/o86-147; MEDVEDEV BI, 1985, GEN PHYSIOL BIOPHYS, V4, P549; MERRILL AH, 1982, J LIPID RES, V23, P1368; MICKELSON JR, 1980, ANAL BIOCHEM, V109, P255, DOI 10.1016/0003-2697(80)90645-4; MONROY G, 1973, J BIOL CHEM, V248, P2845; MONROY G, 1972, J BIOL CHEM, V247, P6884; NACHBAUR J, 1969, FEBS LETT, V3, P121, DOI 10.1016/0014-5793(69)80113-4; NACHBAUR J, 1972, BIOCHIM BIOPHYS ACTA, V274, P426, DOI 10.1016/0005-2736(72)90189-7; NATORI Y, 1983, J BIOCHEM-TOKYO, V93, P631, DOI 10.1093/oxfordjournals.jbchem.a134219; NEUBURGER M, 1982, ARCH BIOCHEM BIOPHYS, V217, P312, DOI 10.1016/0003-9861(82)90507-0; NISHIDA T, 1989, J BIOCHEM-TOKYO, V106, P533, DOI 10.1093/oxfordjournals.jbchem.a122887; PALMER JW, 1981, J BIOL CHEM, V256, P6742; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; REERS M, 1987, BIOCHEMISTRY-US, V26, P8038, DOI 10.1021/bi00399a002; RILEY WW, 1986, J BIOL CHEM, V261, P14018; ROMAN I, 1979, EUR J BIOCHEM, V102, P615, DOI 10.1111/j.1432-1033.1979.tb04279.x; Rubin M S, 1978, Methods Enzymol, V53, P73; RUSTENBECK I, 1989, N-S ARCH PHARMACOL, V339, P37; SARIS NEL, 1988, J BIOENERG BIOMEMBR, V20, P749, DOI 10.1007/BF00762551; SARZALA M G, 1970, Biochimica et Biophysica Acta, V202, P106, DOI 10.1016/0005-2760(70)90222-5; SCHLAME M, 1990, BIOCHIM BIOPHYS ACTA, V1045, P1, DOI 10.1016/0005-2760(90)90196-5; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SCHLENK H, 1960, ANAL CHEM, V32, P1412, DOI 10.1021/ac60167a011; SCHMID PC, 1991, J BIOL CHEM, V266, P13690; SCHMID PC, 1981, J LIPID RES, V22, P882; SCHMID PC, 1988, CHEM PHYS LIPIDS, V46, P165, DOI 10.1016/0009-3084(88)90018-7; SILIPRANDI D, 1979, BIOCHEM BIOPH RES CO, V88, P388, DOI 10.1016/0006-291X(79)92060-6; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STOFFEL W, 1968, H-S Z PHYSIOL CHEM, V349, P1017, DOI 10.1515/bchm2.1968.349.2.1017; TABOR CW, 1954, J BIOL CHEM, V208, P645; WAITE M, 1969, BIOCHEMISTRY-US, V8, P2536, DOI 10.1021/bi00834a041; WAITE M, 1970, BIOCHEMISTRY-US, V9, P746, DOI 10.1021/bi00806a007; WELLS MA, 1971, BIOCHIM BIOPHYS ACTA, V248, P80, DOI 10.1016/0005-2760(71)90077-4; ZURINI M, 1981, EUR J BIOCHEM, V119, P517, DOI 10.1111/j.1432-1033.1981.tb05638.x	75	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20700	20708						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939120				2022-12-25	WOS:A1991GN00100020
J	SCHOWALTER, DB; SULLIVAN, WP; MAIHLE, NJ; DOBSON, ADW; CONNEELY, OM; OMALLEY, BW; TOFT, DO				SCHOWALTER, DB; SULLIVAN, WP; MAIHLE, NJ; DOBSON, ADW; CONNEELY, OM; OMALLEY, BW; TOFT, DO			CHARACTERIZATION OF PROGESTERONE-RECEPTOR BINDING TO THE 90-KDA AND 70-KDA HEAT-SHOCK PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-RECEPTOR; HSP90 BINDING; DNA-BINDING; REGION; CELLS; COMPLEXES; DOMAIN; MUTANT; ACTIVATION; EXPRESSION	In this study a model system for expression of the chicken progesterone receptor in cultured cells was developed using a quail fibroblast cell line, QT6. The chicken progesterone receptor form A expressed in QT6 cells was evaluated and determined to have a number of similarities to receptor isolated from chicken oviduct. These include hormone binding, sedimentation profile, phosphorylation pattern, heat shock protein (hsp) 70 and hsp90 associations and the ability to stimulate a reporter gene construct. Therefore, the receptor expressed in this system functioned adequately for further evaluation of the particular region (or regions) involved in hsp70 and hsp90 binding. Several receptor deletion mutants were tested for hsp70/hsp90 binding; only the d369-659 mutant, which has the entire steroid-binding domain deleted, was unable to bind hsp90 and hsp70. Three separate regions of the steroid-binding domain were found to partially restore hsp90 and hsp70 binding to the d369-659 mutant protein. However, hsp binding was not abolished when these or other regions of the steroid binding domain were deleted individually. These findings indicate that hsp90 and hsp70 both bind to the steroid-binding domain of the receptor through interactions at multiple locations or through some structural quality that is distributed throughout this region of the protein.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Mayo Clinic; Baylor College of Medicine			Dobson, Alan D W/M-7844-2017	Dobson, Alan D W/0000-0002-7713-5574	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140, R01HD018287] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 9140, HD 18287] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMELIN HA, 1974, CONTROL PROLIFERATIO, V1, P97; BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CARSON MA, 1987, MOL ENDOCRINOL, V1, P791, DOI 10.1210/mend-1-11-791; CARSONJURICA MA, 1990, J STEROID BIOCHEM, V34, P1; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DEFRANCO D, 1986, MOL CELL BIOL, V6, P993, DOI 10.1128/MCB.6.4.993; DENIS M, 1988, J BIOL CHEM, V263, P18520; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; EDWARDS DP, 1987, IMMUNOLOGICAL APPROA, P157; Ellis R J, 1990, Semin Cell Biol, V1, P1; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HOOPER C, 1990, J NIH RES, V2, P63; HOUSLEY PR, 1990, J BIOL CHEM, V265, P12778; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P4868, DOI 10.1128/MCB.8.11.4868; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; OTTER T, 1987, ANAL BIOCHEM, V162, P370, DOI 10.1016/0003-2697(87)90406-4; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1988, J BIOL CHEM, V263, P267; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SMITH DF, 1990, J BIOL CHEM, V265, P3996; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; SULLIVAN WP, 1988, J CELL BIOCHEM, V36, P103, DOI 10.1002/jcb.240360202; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1545; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723	43	67	68	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21165	21173						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939158				2022-12-25	WOS:A1991GN00100090
J	CHITNIS, PR; PURVIS, D; NELSON, N				CHITNIS, PR; PURVIS, D; NELSON, N			MOLECULAR-CLONING AND TARGETED MUTAGENESIS OF THE GENE PSAF ENCODING SUBUNIT-III OF PHOTOSYSTEM-I FROM THE CYANOBACTERIUM SYNECHOCYSTIS-SP PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL CROSS-LINKING; SP PCC-6803; NUCLEOTIDE-SEQUENCE; POLYPEPTIDE; PLASTOCYANIN; IDENTIFICATION; PROTEINS; MEMBRANE; CHLAMYDOMONAS; CHLOROPLASTS	Photosystem I is one of the two multisubunit pigment-protein complexes in the thylakoid membranes of cyanobacteria. Subunit III of photosystem I complex was isolated from a mutant of the cyanobacterium Synechocystis sp PCC 6803, which lacks subunit II. The sequence of its NH2-terminal residues was determined and corresponding oligonucleotide probes were used to isolate the gene encoding this subunit. The gene, designated as psaF, codes for a mature protein of 15705 Da that is synthesized with a 23-amino acid extension. The deduced amino acid sequence is homologous to subunit III from spinach and Chlamydomonas reinhardtii. The presequence of subunit III shows characteristics typical of bacterial presequences and exhibits remarkable amino acid identity around the proteolytic processing site when compared to corresponding regions from the precursors of eukaryotic subunit III. There are two conserved hydrophobic regions in the mature subunit III which may cross or interact with thylakoid membrane. The gene psaF exists as a single copy in the genome and is expressed as a monocistronic RNA. A stable mutant strain in which the gene psaF was replaced by a gene conferring resistance to kanamycin was generated by targeted mutagenesis. Photoautotrophic growth of the mutant strain was comparable with that of the wild type suggesting that function of subunit III is dispensable for photosynthesis in Synechocystis sp. PCC 6803. Addition of more MgSO4 to BG11 medium enhanced growth of the mutant strain but not of the wild type cells.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, NUTLEY, NJ 07110 USA	Roche Holding								BENGIS C, 1977, J BIOL CHEM, V252, P4564; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BRIGGS LM, 1990, PLANT MOL BIOL, V15, P633, DOI 10.1007/BF00017837; CANTRELL A, 1987, PLANT MOL BIOL, V9, P453, DOI 10.1007/BF00015877; CAPALDI RA, 1972, P NATL ACAD SCI USA, V69, P930, DOI 10.1073/pnas.69.4.930; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; CHITNIS PR, 1989, J BIOL CHEM, V264, P18381; CHITNIS PR, 1991, PHOTOSYNTHETIC APPAR, P178; FRANZEN LG, 1989, PLANT MOL BIOL, V12, P463, DOI 10.1007/BF00017585; GOLBECK JH, 1988, FEBS LETT, V240, P9, DOI 10.1016/0014-5793(88)80331-4; GOLDEN SS, 1987, METHOD ENZYMOL, V153, P215; HAEHNEL W, 1980, BIOCHIM BIOPHYS ACTA, V593, P384, DOI 10.1016/0005-2728(80)90075-4; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; IKEUCHI M, 1990, FEBS LETT, V263, P274, DOI 10.1016/0014-5793(90)81391-Z; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERCHANT S, 1990, J BIOL CHEM, V265, P12372; NECHUSHTAI R, 1981, J BIOENERG BIOMEMBR, V13, P295, DOI 10.1007/BF00743207; NELSON N, 1987, NEW COMPREHENSIVE BI, V15, P213; NESIN M, 1987, GENE, V51, P149, DOI 10.1016/0378-1119(87)90303-9; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; ORTIZ W, 1985, PLANT PHYSIOL, V77, P389, DOI 10.1104/pp.77.2.389; PHILBRICK JB, 1988, MOL GEN GENET, V212, P418, DOI 10.1007/BF00330845; REILLY P, 1988, J BIOL CHEM, V263, P17658; ROTHER C, 1986, CURR GENET, V11, P171, DOI 10.1007/BF00420603; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELLER HV, 1989, J BIOL CHEM, V264, P18402; STEPPUHN J, 1988, FEBS LETT, V237, P218, DOI 10.1016/0014-5793(88)80205-9; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; WYNN RM, 1988, FEBS LETT, V229, P293, DOI 10.1016/0014-5793(88)81143-8; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZILBER AL, 1988, PLANT PHYSIOL, V88, P810, DOI 10.1104/pp.88.3.810; ZILBER AL, 1990, CURRENT RES PHOTOSYN, V2, P575	40	107	114	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20146	20151						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939076				2022-12-25	WOS:A1991GM03900043
J	LARSSON, T; SOMMARIN, Y; PAULSSON, M; ANTONSSON, P; HEDBOM, E; WENDEL, M; HEINEGARD, D				LARSSON, T; SOMMARIN, Y; PAULSSON, M; ANTONSSON, P; HEDBOM, E; WENDEL, M; HEINEGARD, D			CARTILAGE MATRIX PROTEINS - A BASIC 36-KDA PROTEIN WITH A RESTRICTED DISTRIBUTION TO CARTILAGE AND BONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DODECYL SULFATE COMPLEXES; GEL-ELECTROPHORESIS; PROTEOGLYCANS; COLLAGEN; SYSTEM	A non-collagenous quantitatively prominent protein was purified from guanidine hydrochloride extracts of bovine tracheal cartilage. Purification was achieved by cesium chloride density gradient centrifugation and chromatography on DEAE-cellulose at pH 7.0 followed by CM-cellulose at pH 5.0. The protein has a marked tendency to form aggregates in denaturing solutions of high ionic strength, e.g. 6 M guanidine hydrochloride. The purified protein contains a single, M(r) 36,000 polypeptide chain, with a particularly high content of leucine. It contains about 1% carbohydrate with a remarkable absence of hexosamines and sialic acid, whereas xylose, galactose, mannose, and fucose were identified in the preparation. The protein was identified in extracts of cartilage and bone and could be shown to be primarily extracellular. Tendon may contain trace amounts of the protein, whereas extracts of several other tissues showed no immunoreactivity in enzyme-linked immunosorbent assay.	UNIV BERN, ME MULLER INST BIOMECH, CH-3010 BERN, SWITZERLAND	University of Bern	LARSSON, T (corresponding author), UNIV LUND, DEPT MED & PHYSIOL CHEM, POB 94, S-22100 LUND, SWEDEN.							BANKER GA, 1972, J BIOL CHEM, V247, P5856; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; DEBLAS AL, 1983, ANAL BIOCHEM, V133, P214, DOI 10.1016/0003-2697(83)90245-2; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; FERNANDEZ MP, 1988, J BIOL CHEM, V263, P5921; GILLARD GC, 1977, BIOCHEM J, V163, P145, DOI 10.1042/bj1630145; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; HEINEGARD D, 1987, METHOD ENZYMOL, V144, P319; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMANDER LS, 1986, ANAL BIOCHEM, V154, P75, DOI 10.1016/0003-2697(86)90498-7; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; PAULSSON M, 1983, BIOCHEM J, V212, P659, DOI 10.1042/bj2120659; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; VONBOXBERG Y, 1990, EUR J BIOCHEM, V190, P249	17	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20428	20433						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939097				2022-12-25	WOS:A1991GM03900082
J	LAU, PP; XIONG, WJ; ZHU, HJ; CHEN, SH; CHAN, L				LAU, PP; XIONG, WJ; ZHU, HJ; CHEN, SH; CHAN, L			APOLIPOPROTEIN-B MESSENGER-RNA EDITING IS AN INTRANUCLEAR EVENT THAT OCCURS POSTTRANSCRIPTIONALLY COINCIDENT WITH SPLICING AND POLYADENYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; STOP CODON; INVITRO; TRANSCRIPTION; INTESTINE; SEQUENCE; GENE	The subcellular compartment in which apolipoprotein (apo) B mRNA is edited is unknown. We studied the site of endogenous apoB mRNA editing and correlated the extent of editing with mRNA maturation in the rat liver. RNA editing activity was demonstrated in both nuclear and cytoplasmic extracts. The specific activity of the editing activity was 5.5-fold higher in the nuclear extract, which was not accounted for by activators, inhibitors, or modulators. However, the total editing activity was 3.1 times higher in the cytoplasmic extract. Highly purified rat liver nuclear apoB mRNA contained 17.3 +/- 1.45% edited sequences compared with 56 +/- 2.5% and 62.15 +/- 6.2% edited sequences in hepatic total and polysomal RNAs, respectively. Because of the significant extent of editing of total nuclear RNA, we fractionated it into a poly(A-) and poly(A+) fraction. While the poly(A-) nuclear fraction contained only 10.4 +/- 1.1% edited sequences, which represents a maximum estimate, the poly(A+) nuclear apoB mRNA contained 50 +/- 1.8% edited sequences, a value very similar to that for polysomal RNA. By direct sequencing of cDNA and genomic clones, we found that as in the case of the human apoB gene, the rat apoB gene contains an intron 25 immediately upstream of the edited exon 26. Using this information, we developed a method to examine in a highly selective manner apoB mRNA that is present in the nucleus before splicing of intron 25 and after splicing of this intron. The unspliced nuclear pre-mRNA contained 7.4 +/- 0.2 % edited sequences compared with 51.0 +/- 0.9% edited sequences in the spliced nuclear apoB mRNA. Furthermore, in the poly(A-) pool of apoB pre-mRNA, unspliced nuclear pre-mRNA contained hardly any (1.56%) edited sequences, and the spliced nuclear pre-mRNA contained 7.8 +/- 0.6% edited mRNA. In the poly(A+) fraction, unspliced nuclear pre-mRNA had 25.4 +/- 0.05% and spliced nuclear mRNA 53 +/- 0.6% of its apoB MRNA in an edited form. We conclude that in the rat liver apoB mRNA editing is not a cotranscriptional event. It occurs post-transcriptionally, but the process is essentially complete in the spliced polyadenylated apoB mRNA before it leaves the nucleus. Little, if any, additional editing occurs in the cytoplasmic compartment.	BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine					NHLBI NIH HHS [HL-45516] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045516] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUM CL, 1990, J BIOL CHEM, V265, P19263; BLACKHART BD, 1986, J BIOL CHEM, V261, P5364; BOSTROM K, 1989, J BIOL CHEM, V264, P15701; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHENG SC, 1990, METHOD ENZYMOL, V181, P89; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIDSON NO, 1990, MOL ENDOCRINOL, V4, P779, DOI 10.1210/mend-4-5-779; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; LEIGHTON JK, 1990, J LIPID RES, V31, P1663; LIN RJ, 1985, J BIOL CHEM, V260, P4780; LUDWIG EH, 1987, DNA-J MOLEC CELL BIO, V6, P363, DOI 10.1089/dna.1987.6.363; NOLL H, 1969, TECHNIQUES PROTEIN B, V2, P101; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SEISHIMA M, 1991, J LIPID RES, V32, P941; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1990, BIOCHEM BIOPH RES CO, V173, P74, DOI 10.1016/S0006-291X(05)81023-X; TENNYSON GE, 1989, P NATL ACAD SCI USA, V86, P500, DOI 10.1073/pnas.86.2.500; WU JH, 1990, J BIOL CHEM, V265, P12312	26	114	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20550	20554						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939106				2022-12-25	WOS:A1991GM03900101
J	MORRISON, DF; OBRIEN, PJ; PEPPERBERG, DR				MORRISON, DF; OBRIEN, PJ; PEPPERBERG, DR			DEPALMITYLATION WITH HYDROXYLAMINE ALTERS THE FUNCTIONAL-PROPERTIES OF RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER SEGMENT PHOSPHODIESTERASE; C-TERMINAL PEPTIDES; BOVINE RHODOPSIN; RETINAL TRANSDUCIN; RAT RHODOPSIN; ACYLATION; ACID; PROTEOLYSIS; ACTIVATION; PROTEINS	Rhodopsin, the photosensitive protein found in rod photoreceptors, has two covalently attached palmitates that are thought to anchor a portion of the C terminus to the disc membrane, forming a fourth cytoplasmic loop. Using hydroxylamine (NH2OH) to cleave the thioester linkage, we have characterized the effect of depalmitylation on certain functional properties of rhodopsin. Treatment of rod outer segment membranes (prepared from rat retinas previously labeled in vivo with [H-3]palmitate) with 1 M NH2OH typically removed greater-than-or-equal-to 75% of the [H-3]palmitate initially bound to rhodopsin. Spectrophotometry of rod outer segment membranes that had been treated with 1 M NH2OH indicated preservation of 85% of the native rhodopsin and no effect on the shape of the absorbance spectrum of rhodopsin. In vivo labeled rhodopsin that had been treated with 1 M NH2OH did not reincorporate free endogenous [H-3]palmitate over a 2-h incubation period. Both NH2OH-treated and untreated rhodopsin incorporated [C-14]palmitate from exogenously added [C-14]palmitoyl-CoA. This incorporation was substantially greater in the NH2OH-treated sample. The removal of palmitate by NH2OH inhibited rhodopsin regeneration by 44% and increased the ability of rhodopsin to activate transducin's light-dependent GTPase activity by 61%. However, the removal of palmitate from rhodopsin did not affect the light-dependent binding of transducin (T-alpha and T-beta-gamma).	UNIV ILLINOIS, COLL MED, LIONS ILLINOIS EYE RES INST, DEPT OPHTHALMOL & VISUAL SCI, CHICAGO, IL 60612 USA; NEI, RETINAL CELL & MOLEC BIOL LAB, BETHESDA, MD 20892 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)					NATIONAL EYE INSTITUTE [R01EY005494, P30EY001792] Funding Source: NIH RePORTER; NEI NIH HHS [EY-07038, EY-01792, EY-05494] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; ATON B, 1984, EXP EYE RES, V38, P547, DOI 10.1016/0014-4835(84)90173-8; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P20727; BROWN PK, 1956, J BIOL CHEM, V222, P865; CHAUDHURI TR, 1987, PREP BIOCHEM, V17, P93, DOI 10.1080/00327488708062478; DARTNALL HJ, 1968, VISION RES, V8, P339, DOI 10.1016/0042-6989(68)90104-1; DEVETTEN MP, 1988, J BIOL CHEM, V263, P18193; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1982, BIOCHIM BIOPHYS ACTA, V679, P95, DOI 10.1016/0005-2728(82)90259-6; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; MAGEE AI, 1982, BIOCHIM BIOPHYS ACTA, V694, P279, DOI 10.1016/0304-4157(82)90008-9; MATSUMOTO H, 1975, BIOCHIM BIOPHYS ACTA, V404, P300, DOI 10.1016/0304-4165(75)90337-2; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; OBRIEN PJ, 1984, J BIOL CHEM, V259, P5054; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PELLICONE C, 1985, BIOCHEM BIOPH RES CO, V127, P816, DOI 10.1016/S0006-291X(85)80016-4; SCHMIDT MFG, 1983, CURR TOP MICROBIOL, V102, P101; SCHMIDT MFG, 1985, J GEN VIROL, V66, P2635, DOI 10.1099/0022-1317-66-12-2635; STJULES RS, 1990, EXP EYE RES, V51, P427, DOI 10.1016/0014-4835(90)90155-N; STJULES RS, 1986, EXP EYE RES, V43, P929, DOI 10.1016/0014-4835(86)90071-0; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKEMOTO DJ, 1985, BIOCHEM J, V232, P669, DOI 10.1042/bj2320669; TAKEMOTO DJ, 1986, BIOCHEM J, V235, P309, DOI 10.1042/bj2350309; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; WALD G, 1955, J GEN PHYSIOL, V38, P623, DOI 10.1085/jgp.38.5.623; WEISS ER, 1988, J BIOL CHEM, V263, P6150; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702	35	66	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20118	20123						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939072				2022-12-25	WOS:A1991GM03900039
J	NISSEN, MS; LANGAN, TA; REEVES, R				NISSEN, MS; LANGAN, TA; REEVES, R			PHOSPHORYLATION BY CDC2 KINASE MODULATES DNA-BINDING ACTIVITY OF HIGH MOBILITY GROUP-I NONHISTONE CHROMATIN PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; BOVINE INTERLEUKIN-2 CDNA; POSTTRANSCRIPTIONAL GENE-REGULATION; 3' UNTRANSLATED REGION; LYSINE-RICH HISTONE; HMG-I; CHROMOSOME CONDENSATION; SEQUENCE MOTIF; SEA-URCHIN; M-PHASE	Chromatin high mobility group protein I (HMG-I) is a mammalian nonhistone protein that has been demonstrated both in vitro and in vivo to preferentially bind to A.T-rich sequences of DNA. Recently the DNA-binding domain peptide that specifically mediates the in vitro interaction of high mobility group protein (HMG)-I with the narrow minor groove of A.T-DNA has been experimentally determined. Because of its predicted secondary structure, the binding domain peptide has been called "the A.T hook" motif. Previously we demonstrated that the A.T hook of murine HMG-I protein is specifically phosphorylated by purified mammalian cdc2 kinase in vitro and that the same site(s) are also phosphorylated in vivo in metaphase-arrested cells. We also found that the DNA binding affinity of short synthetic binding domain peptides phosphorylated in vitro by cdc2 kinase was significantly reduced compared with unphosphorylated peptides. Here we extend these findings to intact natural and recombinant HMG-I proteins. We report that the affinity of binding of full-length HMG-I proteins to A.T-rich sequences is highly dependent on ionic conditions and that phosphorylation of intact proteins by cdc2 kinase reduces their affinity of in vitro binding to A.T-DNA by about 20-fold when assayed near normal mammalian physiological salt concentrations. Furthermore, in cell synchronization studies, we demonstrated that murine HMG-I proteins are phosphorylated in vivo in a cell cycle-dependent manner on the same amino acid residues modified by purified cdc2 kinase in vitro. Together these results strongly support the assertion that HMG-I proteins are natural substrates for mammalian cdc2 kinase in vivo and that their cell cycle-dependent phosphorylation by this enzyme (s) significantly modulates their DNA binding affinity, thereby possibly altering their biological function(s).	WASHINGTON STATE UNIV,PROGRAM GENET & CELL BIOL,PULLMAN,WA 99164; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	Washington State University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	NISSEN, MS (corresponding author), WASHINGTON STATE UNIV,DEPT BIOCHEM BIOPHYS,PULLMAN,WA 99164, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026356] Funding Source: NIH RePORTER; NIAID NIH HHS [5-R01-AI26356] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; Ashihara T, 1979, Methods Enzymol, V58, P248; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BRADBURY EM, 1973, EUR J BIOCHEM, V33, P131, DOI 10.1111/j.1432-1033.1973.tb02664.x; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; CHAMBERS TC, 1990, J BIOL CHEM, V265, P16940; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; Dixon G. H., 1975, CIBA F S, V28, P229; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; ELTON TS, 1986, ANAL BIOCHEM, V157, P53, DOI 10.1016/0003-2697(86)90195-8; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GOODWIN G, 1988, ARCHITECTURE EUKARYO, P187; GREEN GR, 1985, DEV BIOL, V108, P235, DOI 10.1016/0012-1606(85)90026-0; GREEN GR, 1988, BIOCHEMISTRY-US, V27, P619, DOI 10.1021/bi00402a019; GRUMMT F, 1988, CANCER CELL, V6, P463; GURLEY LR, 1974, J CELL BIOL, V60, P356, DOI 10.1083/jcb.60.2.356; HAN J, 1991, J IMMUNOL, V146, P1843; HILL CS, 1990, EMBO J, V9, P805, DOI 10.1002/j.1460-2075.1990.tb08177.x; JERZMANOWSKI A, 1990, J BIOL CHEM, V265, P10726; JOHNSON KR, 1990, EXP CELL RES, V187, P69, DOI 10.1016/0014-4827(90)90118-T; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LAKE RS, 1972, BIOCHEMISTRY-US, V11, P4817, DOI 10.1021/bi00775a027; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LANGAN TA, 1982, J BIOL CHEM, V257, P4835; LANGAN TA, 1987, MECHANISMS SIGNAL TR, P215; LANGAN TA, 1980, PROTEIN PHOSPHORYLAT, P70; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHN DA, 1988, BIOCHEM INT, V16, P963; LOONTIENS FG, 1990, BIOCHEMISTRY-US, V29, P9029, DOI 10.1021/bi00490a021; LUND T, 1985, FEBS LETT, V180, P275, DOI 10.1016/0014-5793(85)81085-1; LUND T, 1990, BIOCHEM BIOPH RES CO, V171, P342, DOI 10.1016/0006-291X(90)91399-D; LUND T, 1987, EUR J BIOCHEM, V166, P21, DOI 10.1111/j.1432-1033.1987.tb13477.x; LUND T, 1983, FEBS LETT, V152, P163, DOI 10.1016/0014-5793(83)80370-6; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NURSE P, 1985, TRENDS GENET, V1, P51, DOI 10.1016/0168-9525(85)90023-X; PALVIMO J, 1989, FEBS LETT, V257, P101, DOI 10.1016/0014-5793(89)81796-X; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Record M T Jr, 1985, Adv Biophys, V20, P109; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; REEVES R, 1986, P NATL ACAD SCI USA, V83, P3228, DOI 10.1073/pnas.83.10.3228; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUSSNAK RH, 1988, J BIOL CHEM, V263, P6392; Sambrook J, 1989, MOL CLONING LABORATO; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNG MT, 1978, BIOCHEMISTRY-US, V17, P1884, DOI 10.1021/bi00603a013; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VARTIAINEN E, 1988, FEBS LETT, V228, P45, DOI 10.1016/0014-5793(88)80581-7; WEGNER M, 1989, NUCLEIC ACIDS RES, V17, P9909, DOI 10.1093/nar/17.23.9909; YANYENHF, 1988, MOL CELL BIOL, V8, P3406; ZEILIG CE, 1980, BIOCHEM BIOPH RES CO, V95, P1372, DOI 10.1016/0006-291X(80)91625-3	72	125	125	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19945	19952						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939057				2022-12-25	WOS:A1991GM03900015
J	CASASFINET, JR; KUMAR, A; MORRIS, G; WILSON, SH; KARPEL, RL				CASASFINET, JR; KUMAR, A; MORRIS, G; WILSON, SH; KARPEL, RL			SPECTROSCOPIC STUDIES OF THE STRUCTURAL DOMAINS OF MAMMALIAN DNA BETA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGENIC DETERMINANTS; PROTEIN CONFORMATION; BINDING; IDENTIFICATION; PREDICTION; SEQUENCE; PEPTIDE; LIGANDS	The 8- and 31-kDa fragments of beta-polymerase, prepared by controlled proteolysis as described (Kumar, A., Widen, S. G., Williams, K. R., Kedar, P., Karpel, R. L., and Wilson, S. H. (1990) J. Biol. Chem. 265, 2124-2131), constitute domains that are structurally and functionally dissimilar. There is little disruption of secondary structure upon proteolysis of the intact enzyme, as suggested from CD spectra of the fragments. Beta-Polymerase is capable of binding both single- and double-stranded nucleic acids: the 8-kDa fragment binds specifically to single-stranded lattices, whereas the 31-kDa domain displays affinity exclusively for double-stranded polynucleotides. These domains are connected by a highly flexible protease-hypersensitive segment that may allow the coordinate functioning of the two binding activities in the intact protein. Beta-Polymerase binds to poly(ethenoadenylic acid) with higher affinity, similar cooperativity, but lesser salt dependence than the 8-kDa fragment. Under physiological conditions, the intact enzyme displays greater binding free energy for single-stranded polynucleotides than the 8-kDa fragment, suggesting that the latter may carry a truncated binding site. Binding of double-stranded calf thymus DNA brings about a moderate quenching of the Tyr and Trp fluorescence emission of both the 31-kDa fragment and beta-polymerase and induces a 6-nm blue shift in the Trp emission maximum of the intact enzyme, but not in the fragment. This latter result is likely due to a change in the relative orientation of the 8- and 31-kDa domains in the intact protein upon interaction with double-stranded DNA; alternatively, the binding mode of intact protein may differ from that of the fragment. Simultaneous interaction of both domains with polynucleotides most likely does not occur since double-stranded DNA binding to the 31-kDa domain of intact beta-polymerase induces the displacement of single-stranded polynucleotides from the 8-kDa domain. These results are evaluated in light of the role of beta-polymerase in DNA repair.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,CATONSVILLE,MD 21228; NCI,BIOCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DATE T, 1990, BIOCHEMISTRY-US, V29, P5027, DOI 10.1021/bi00473a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HALFMAN CJ, 1972, BIOCHEMISTRY-US, V11, P3493, DOI 10.1021/bi00768a025; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MASCOTTI DP, 1990, P NATL ACAD SCI USA, V87, P3142, DOI 10.1073/pnas.87.8.3142; MCGHEE JD, 1976, J MOL BIOL, V103, P679; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YANG JT, 1986, METHOD ENZYMOL, V130, P208	22	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19618	19625						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918069				2022-12-25	WOS:A1991GK66700072
J	LOW, P; DALLNER, G; MAYOR, S; COHEN, S; CHAIT, BT; MENON, AK				LOW, P; DALLNER, G; MAYOR, S; COHEN, S; CHAIT, BT; MENON, AK			THE MEVALONATE PATHWAY IN THE BLOOD-STREAM FORM OF TRYPANOSOMA-BRUCEI - IDENTIFICATION OF DOLICHOLS CONTAINING 11 AND 12 ISOPRENE RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; RAT-LIVER; MEMBRANE ANCHOR; STRUCTURAL CHARACTERIZATION; PHOSPHATE BIOSYNTHESIS; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; PROTEINS; LIPOPROTEINS; PURIFICATION	The major surface antigen of the bloodstream form of Trypanosoma brucei, the variant surface glycoprotein, is attached to the plasma membrane via a glycosylphosphatidylinositol anchor. The biosynthesis of the glycosylphosphatidylinositol anchor, as well as the assembly of the asparagine-linked oligosaccharide chains found on the variant surface glycoproteins, involves polyisoprenoid lipids that act as sugar carriers. Preliminary observations (Menon, A. K., Schwarz, R. T., Mayor, and Cross, G. A. M. (1990) J. Biol. Chem. 265, 9033-9042) suggested that the sugar carriers in T. brucei were short-chain polyisoprenoids containing substantially fewer isoprene residues than polyisoprenols in mammalian cells. In this paper we describe metabolic labeling experiments with [H-3]mevalonate, as well as chromatographic and mass spectrometric analyses of products of the mevalonate pathway in T. brucei. We report that cells of the bloodstream form of T. brucei contain a limited spectrum of short chain dolichols and dolichol phosphates (11 and 12 isoprene residues). The total dolichol content was estimated to be 0.28 nmol/10(9) cells; the dolichyl phosphate content was 0.07 nmol/10(9) cells. The same spectrum of dolichol chain lengths was also found in a polar lipid that could be labeled with [H-3]mevalonate, [H-3]glucosamine, and [H-3]mannose, and which was characterized as Man5GlcNAC2-PP-dolichol. The most abundant product of the mevalonate pathway identified in T. brucei was cholesterol (140 nmol/10(9) cells). Ubiquinone (0.09 nmol/10(9) cells) with a solanesol side chain was also identified.	KAROLINSKA INST,HUDDINGE HOSP,CLIN RES CTR,S-10401 STOCKHOLM 60,SWEDEN; ROCKEFELLER UNIV,MOLEC PARASITOL LABS,NEW YORK,NY 10021; ROCKEFELLER UNIV,MASS SPECTROMETRY LABS,NEW YORK,NY 10021	Karolinska Institutet; Rockefeller University; Rockefeller University	LOW, P (corresponding author), UNIV STOCKHOLM,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN.			Menon, Anant Kumar/0000-0001-6924-2698	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021531] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00862] Funding Source: Medline; NIAID NIH HHS [AI 21531] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASTRAND IM, 1986, EUR J BIOCHEM, V155, P447, DOI 10.1111/j.1432-1033.1986.tb09511.x; Behrens N H, 1978, Methods Enzymol, V50, P402; BEYER RE, 1987, CHEM SCRIPTA, V27, P145; BLOCH K, 1985, BIOCH LIPIDS MEMBRAN, P1; CHOJNACKI T, 1988, BIOCHEM J, V251, P1; CHOJNACKI T, 1987, CHEM SCRIPTA, V27, P209; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DANILOV LL, 1981, FEBS LETT, V131, P310, DOI 10.1016/0014-5793(81)80392-4; DEROPP JS, 1985, J BIOL CHEM, V260, P5669; EDLUND C, 1986, CHEM-BIOL INTERACT, V57, P255, DOI 10.1016/0009-2797(86)90001-3; EGGENS I, 1988, CANCER RES, V48, P3418; EKSTROM TJ, 1987, J BIOL CHEM, V262, P4090; ELMBERGER PG, 1989, LIPIDS, V24, P919, DOI 10.1007/BF02544535; ELMBERGER PG, 1988, J LIPID RES, V29, P1651; ERICSSON J, 1991, J BIOL CHEM, V266, P10602; ERNSTER L, 1977, BIOMEDICAL CLIN ASPE, P15; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; Gaylor J. L., 1981, BIOISOPRENOID COMP, V1, P481; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HEMMING FW, 1981, BIOCH ISOPRENOID COM, V2, P305; KALEN A, 1987, BIOCHIM BIOPHYS ACTA, V926, P70, DOI 10.1016/0304-4165(87)90183-8; KELLER RK, 1986, J BIOL CHEM, V261, P2053; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LOW P, 1986, BIOSCIENCE REP, V6, P677, DOI 10.1007/BF01114763; MANKOWSKI T, 1976, BIOCHEMISTRY-US, V15, P2125, DOI 10.1021/bi00655a015; MATSUOKA S, 1991, J BIOL CHEM, V266, P3464; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; PARDOI AJ, 1982, J BIOL CHEM, V257, P7637; QUESADAALLUE LA, 1983, BIOCHEM J, V212, P123, DOI 10.1042/bj2120123; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SAGAMI H, 1989, BIOCHIM BIOPHYS ACTA, V1002, P218, DOI 10.1016/0005-2760(89)90290-7; Spurgeon S.L., 1981, BIOSYNTHESIS ISOPREN, V1, P1; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35; VALTERSSON C, 1985, J BIOL CHEM, V260, P2742; VIJAY IK, 1980, J BIOL CHEM, V255, P1221; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68	45	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19250	19257						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918042				2022-12-25	WOS:A1991GK66700024
J	MUKHOPADHYAY, D; YU, HR; NUCIFORA, G; MISRA, TK				MUKHOPADHYAY, D; YU, HR; NUCIFORA, G; MISRA, TK			PURIFICATION AND FUNCTIONAL-CHARACTERIZATION OF MERD - A COREGULATOR OF THE MERCURY RESISTANCE OPERON IN GRAM-NEGATIVE BACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSPOSON TN501; GEL-ELECTROPHORESIS; PLASMID PDU1358; RNA-POLYMERASE; DNA; BINDING; GENE; PROMOTER; PROTEIN	Mercury resistance operons (mer) from transposons Tn21, Tn501, and plasmid pDU1358 are highly homologous and inducible with Hg2+. The regulatory gene merR is transcribed from one promoter, which is divergently oriented from the promoter for the other mer genes. MerR, the product of the regulatory gene, negatively regulates its own expression as well as the expression of the other genes. MerR activates transcription of the operon in the presence of inducing concentrations of Hg2+. The most promoter distal gene, merD, which is cotranscribed with the structural genes, down regulates the mer operon. A frame-shift mutation in merD, created by deletion of 3 bp and an insertion of a 16 bp sequence upstream of the major inverted repeats present at the 3' end of the merD sequence, resulted in increased synthesis of the structural gene transcript and higher level of resistance to Hg2+ by a factor of about 2. MerD protein was overproduced using a T7 expression system. The overproduced protein was present in the pellet fraction, when cell lysates were centrifuged at a low speed. Approximately 80% pure MerD protein was recovered from the pellet fraction by extracting with a buffer solution containing 5 M urea. The purified protein migrated as a 13,500 molecular weight protein on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the N-terminal amino acid sequence corresponded to that deduced from the DNA sequence of merD. MerD bound specifically with the mer promoter sequence. DNase I footprinting experiments identified a common mer operator sequence for MerR and MerD.	UNIV ILLINOIS, COLL MED, DEPT MICROBIOL & IMMUNOL MC790, 835 S WOLCOTT AVE, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NIGMS NIH HHS [GM-36722] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM036722] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APIRION D, 1980, MOL GEN GENET, V177, P339, DOI 10.1007/BF00267448; BELASCO JG, 1986, CELL, V46, P245, DOI 10.1016/0092-8674(86)90741-5; BHRIAIN NNN, 1983, J BACTERIOL, V155, P690, DOI 10.1128/JB.155.2.690-703.1983; BROWN NL, 1986, MOL GEN GENET, V202, P143, DOI 10.1007/BF00330531; FOSTER TJ, 1979, J BACTERIOL, V140, P167, DOI 10.1128/JB.140.1.167-181.1979; FOSTER TJ, 1987, CRC CR REV MICROBIOL, V15, P117, DOI 10.3109/10408418709104455; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GRIFFIN HG, 1987, P NATL ACAD SCI USA, V84, P3112, DOI 10.1073/pnas.84.10.3112; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; KENNELL D, 1986, MAXIMIZING GENE EXPR, P102; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUSANO T, 1990, J BACTERIOL, V172, P2688, DOI 10.1128/jb.172.5.2688-2692.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE IW, 1989, J BACTERIOL, V171, P2222, DOI 10.1128/jb.171.4.2222-2225.1989; LUND PA, 1989, J MOL BIOL, V205, P343, DOI 10.1016/0022-2836(89)90345-8; LUND PA, 1986, J GEN MICROBIOL, V132, P465; Maxam A M, 1980, Methods Enzymol, V65, P499; MISRA TK, 1987, METHOD ENZYMOL, V155, P119; MULLIGAN ME, 1985, J BIOL CHEM, V260, P3529; NUCIFORA G, 1989, MOL GEN GENET, V220, P69, DOI 10.1007/BF00260858; NUCIFORA G, 1989, J BACTERIOL, V171, P4241, DOI 10.1128/JB.171.8.4241-4247.1989; OHALLORAN T, 1987, SCIENCE, V235, P211, DOI 10.1126/science.3798107; OHALLORAN TV, 1989, MET IONS BIOL SYST, V25, P105; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; Sambrook J, 1989, MOL CLONING LABORATO; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P6140, DOI 10.1021/bi00441a002; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P2340, DOI 10.1021/bi00431a053; SILVER S, 1988, ANNU REV MICROBIOL, V42, P717, DOI 10.1146/annurev.mi.42.100188.003441; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WALSH CT, 1988, FASEB J, V2, P124, DOI 10.1096/fasebj.2.2.3277886	33	64	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18538	18542						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917975				2022-12-25	WOS:A1991GJ47200023
J	SMITH, CL; HAMMOND, GL				SMITH, CL; HAMMOND, GL			AN AMINO-ACID SUBSTITUTION IN BIOBREEDING RAT CORTICOSTEROID BINDING GLOBULIN RESULTS IN REDUCED STEROID BINDING-AFFINITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETES-MELLITUS; CORTISOL; VARIANT; PLASMA; SERUM; GLUCOCORTICOIDS; PURIFICATION; TRANSCORTIN; INHIBITORS; MEMBRANES	BioBreeding (BB) rats are derived from an outbred colony of Wistar rats and are used as a model of autoimmune diabetes mellitus. A corticosteroid binding globulin (CBG) variant with reduced affinity for glucocorticoids has now been found in the blood of these animals. The dissociation rate constants of BB CBG for cortisol (4.42 nM) and corticosterone (1.43 nM) are both about 50% higher than those associated with Wistar CBG, but no obvious difference in the steroid binding specificity of BB and Wistar CBGs was detected. Purified BB and Wistar CBGs exhibit the same size heterogeneity when examined by polyacrylamide gel electrophoresis under denaturing conditions, and the sizes of their respective hepatic mRNAs are identical. The genetic basis for this abnormality was therefore determined by comparing the cDNA sequences for BB and Wistar CBG, and this revealed a point mutation that results in a single amino acid substitution at residue 276 (Ile in BB CBG and Met in Wistar CBG). To confirm that this mutation is responsible for the reduced steroid binding affinity associated with BB CBG, the cDNAs for rat CBG-Ile276 and CBG-Met276 were expressed in Chinese hamster ovary cells. The steroid binding affinities of the CBGs secreted by these cells were essentially identical with those observed in the corresponding serum samples from these two rat strains. The amino acid substitution identified in BB rat CBG therefore clearly accounts for the reduction in its steroid binding affinity, and further analysis of this and other natural CBG variants may reveal important information about the CBG steroid binding site. It is also possible that this mutation may contribute to the etiology of pathological abnormalities that are characteristic of the BB rat.	UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON N6A 4L6, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT ONCOL, LONDON N6A 4L6, ONTARIO, CANADA; UNIV WESTERN ONTARIO, MRC, FETAL & NEONATAL HLTH & DEV GRP, LONDON N6A 4L6, ONTARIO, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	SMITH, CL (corresponding author), UNIV WESTERN ONTARIO, DEPT OBSTET & GYNECOL, LONDON N6A 4L6, ONTARIO, CANADA.			Hammond, Geoffrey/0000-0002-4639-7336				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALLARD PL, 1986, MONOGRAPHS ENDOCRINO, V28; BASSETT JR, 1987, J ENDOCRINOL, V112, P33, DOI 10.1677/joe.0.1120033; CHADER GJ, 1968, J BIOL CHEM, V243, P928; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CLAMAN HN, 1989, ANTIINFLAMMATORY STE, P409; FELDMAN D, 1973, ENDOCRINOLOGY, V92, P1429, DOI 10.1210/endo-92-5-1429; GRADY LJ, 1989, BIOTECHNIQUES, V7, P798; HAMMOND GL, 1990, J CLIN ENDOCR METAB, V71, P34, DOI 10.1210/jcem-71-1-34; HAMMOND GL, 1983, CLIN CHIM ACTA, V132, P101, DOI 10.1016/0009-8981(83)90237-1; HAMMOND GL, 1990, BIOCHEM BIOPH RES CO, V172, P172, DOI 10.1016/S0006-291X(05)80189-5; HAMMOND GL, 1987, P NATL ACAD SCI USA, V84, P5153, DOI 10.1073/pnas.84.15.5153; HAMMOND GL, 1990, ENDOCR REV, V11, P65, DOI 10.1210/edrv-11-1-65; HAMMOND GL, 1991, IN PRESS J STEROID B; HENNING SJ, 1978, AM J PHYSIOL, V235, pE451, DOI 10.1152/ajpendo.1978.235.5.E451; HSU BRS, 1986, C INSERM, V149, P577; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JACOBS RA, 1991, ENDOCRINOLOGY, V128, P1960, DOI 10.1210/endo-128-4-1960; LIKE AA, 1983, DIABETES, V32, P326, DOI 10.2337/diabetes.32.4.326; LIKE AA, 1982, DIABETES, V31, P7, DOI 10.2337/diab.31.1.S7; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOHRENZ FN, 1967, J CLIN ENDOCR METAB, V27, P966, DOI 10.1210/jcem-27-7-966; Maniatis T., 1982, MOL CLONING; MARTIN CE, 1977, ACTA ENDOCRINOL-COP, V84, P167, DOI 10.1530/acta.0.0840167; MOOG F, 1971, HORMONES DEV, P143; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; REFETOFF S, 1989, ENDOCR REV, V10, P275, DOI 10.1210/edrv-10-3-275; ROBINSON PA, 1985, J ENDOCRINOL, V104, P259, DOI 10.1677/joe.0.1040259; ROBINSON PA, 1985, J ENDOCRINOL, V104, P269, DOI 10.1677/joe.0.1040269; ROSNER W, 1973, J CLIN ENDOCR METAB, V37, P983, DOI 10.1210/jcem-37-6-983; ROSNER W, 1990, ENDOCR REV, V11, P80, DOI 10.1210/edrv-11-1-80; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVU L, 1980, FEBS LETT, V113, P102, DOI 10.1016/0014-5793(80)80505-9; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SERALINI GE, 1990, MOL ENDOCRINOL, V4, P1166, DOI 10.1210/mend-4-8-1166; SERALINI GE, 1989, ENDOCRINOLOGY, V125, P1321, DOI 10.1210/endo-125-3-1321; SIITERI PK, 1982, RECENT PROG HORM RES, V38, P457; SINGER CJ, 1988, ENDOCRINOLOGY, V122, P89, DOI 10.1210/endo-122-1-89; SMITH CL, 1989, MOL ENDOCRINOL, V3, P420, DOI 10.1210/mend-3-2-420; SMITH CL, 1991, ENDOCRINOLOGY, V128, P983, DOI 10.1210/endo-128-2-983; STRELCHYONOK OA, 1983, BIOCHIM BIOPHYS ACTA, V755, P514, DOI 10.1016/0304-4165(83)90257-X; TAKEDA K, 1989, J CLIN INVEST, V83, P1344, DOI 10.1172/JCI114021; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANBAELEN H, 1982, J BIOL CHEM, V257, P3397; WESTBY M, 1986, ACTA RADIOL, V27, P55, DOI 10.1177/028418518602700111	46	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18555	18559						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917978				2022-12-25	WOS:A1991GJ47200026
J	TODOROKI, H; KOBAYASHI, R; WATANABE, M; MINAMI, H; HIDAKA, H				TODOROKI, H; KOBAYASHI, R; WATANABE, M; MINAMI, H; HIDAKA, H			PURIFICATION, CHARACTERIZATION, AND PARTIAL SEQUENCE-ANALYSIS OF A NEWLY IDENTIFIED EF-HAND TYPE-13-KDA CA2+-BINDING PROTEIN FROM SMOOTH-MUSCLE AND NONMUSCLE TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; GEL-ELECTROPHORESIS; INTERACTING AGENTS; MOLECULAR-CLONING; CHICKEN GIZZARD; STRONG HOMOLOGY; S-100; GENE; MODULATOR; FAMILY	A novel Ca2+-binding protein, tentatively designated calgizzarin, has been purified to apparent homogeneity from chicken gizzard smooth muscle by W-7 (N-(6-aminohexyl-5-chloro-1-naphthalenesulfonamide))-Sepharose affinity chromatography and ion-exchange chromatography. Application of W-7-Sepharose affinity chromatography to various tissues revealed that calgizzarin-like proteins were abundant in bovine aorta and rabbit lung. Using the same procedure, we could purify a calgizzarin-like protein from rabbit lung. Calgizzarin has a M(r) of 13,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and approximately 30,000 as determined by gel filtration on a TSK G 3000SW high performance liquid chromatography column, suggesting that calgizzarin seems to be a rodlike protein. The isoelectric point of calgizzarin was found to be pH 5.8. Calgizzarin can exist as a dimer by forming a disulfide bridge. The Ca-45 autoradiographic technique showed that the protein binds to Ca2+. On an alkaline/urea gel, calgizzarin migrated faster in the presence of EGTA than in the presence of CaCl2, thereby indicating a Ca2+-dependent conformational change in this protein. The partial amino acid sequence (65 amino acid residues) of calgizzarin was seen to be SLLAVFQRYAGREGDNLKLSKKEFRTFMNTELASFTKNQKDPAVVDRMMKRLDINSDGQLDFQEF, and two putative Ca2+-binding sites (GREGDNLKLSKKE and DINSDGQLDFQE) were detected. So far as the obtained 65-amino acid sequence is concerned, calgizzarin has approximately a 50% sequence homology with S-100-alpha, 47% with S-100-beta, and 39% with pEL-98 protein.	NAGOYA UNIV,SCH MED,DEPT PHARMACOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 1,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University; Nagoya University								ABERSOLD RH, 1986, J BIOL CHEM, V261, P4229; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALABRETTA B, 1986, J BIOL CHEM, V261, P2628; DORIN JR, 1987, NATURE, V326, P614, DOI 10.1038/326614a0; ENDO T, 1981, J BIOL CHEM, V256, P2485; ERIKSON E, 1984, MOL CELL BIOL, V4, P77, DOI 10.1128/MCB.4.1.77; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FERRARI S, 1987, J BIOL CHEM, V262, P8325; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HEXHAM JM, 1986, BIOCHEM BIOPH RES CO, V134, P248, DOI 10.1016/0006-291X(86)90554-1; HIDAKA H, 1978, J PHARMACOL EXP THER, V207, P8; HIDAKA H, 1980, MOL PHARMACOL, V17, P66; HIDAKA H, 1979, MOL PHARMACOL, V15, P49; ISOBE T, 1977, BIOCHIM BIOPHYS ACTA, V494, P222, DOI 10.1016/0005-2795(77)90150-7; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOBAYASHI R, 1990, ARCH BIOCHEM BIOPHYS, V277, P203, DOI 10.1016/0003-9861(90)90570-O; KOBAYASHI R, 1979, BIOCHEM BIOPH RES CO, V88, P1037, DOI 10.1016/0006-291X(79)91513-4; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; MANI RS, 1990, BIOCHEMISTRY-US, V29, P1398, DOI 10.1021/bi00458a009; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MATHEW JK, 1986, J CELL BIOCHEM, V32, P223, DOI 10.1002/jcb.240320309; MOORE PB, 1988, J HISTOCHEM CYTOCHEM, V36, P185, DOI 10.1177/36.2.2961799; MOORE PB, 1982, J BIOL CHEM, V257, P9663; ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TANAKA T, 1980, J BIOL CHEM, V255, P1078	34	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18668	18673						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917990				2022-12-25	WOS:A1991GJ47200043
J	SCHEEL, J; KREIS, TE				SCHEEL, J; KREIS, TE			MOTOR PROTEIN INDEPENDENT BINDING OF ENDOCYTIC CARRIER VESICLES TO MICROTUBULES INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; 2 DISTINCT SUBPOPULATIONS; CYTOPLASMIC DYNEIN; RAT HEPATOCYTES; TRANSFERRIN RECEPTOR; AXONAL-TRANSPORT; GOLGI-APPARATUS; FUSION INVITRO; CELL-SURFACE; MDCK CELLS	We have established an in vitro assay to characterize the binding of endocytic carrier vesicles to microtubules. Magnetic beads coated with microtubules were used as an affinity matrix. A fraction from nocodazole-treated cells enriched in endocytic carrier vesicles, labeled with internalized horseradish peroxidase, was used in the binding experiments. Binding of the endocytic carrier vesicles to microtubules in vitro was cytosol-dependent. This activity of cytosolic factors was saturable, heat-sensitive, and insensitive to N-ethyl-maleimide. Binding was sensitive to GTP and ATP. Addition of neuronal microtubule-associated proteins completely abolished binding of the endocytic organelles to microtubules. This binding was independent of the cytosolic microtubule-based motor proteins kinesin and cytoplasmic dynein, since cytosol depleted of these proteins remained fully active. Microtubule-binding proteins from HeLa cells, however, stimulated the interaction of endocytic carrier vesicles with microtubules. Trypsinized vesicles could no longer bind to microtubules in the presence of cytosol. These results suggest that cytosolic microtubule-binding proteins, other than the known microtubule-based motor proteins, as well as membrane proteins are involved in the nucleotide-dependent interaction of endocytic carrier vesicles with microtubules.	EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)								BAENZIGER JU, 1986, J BIOL CHEM, V261, P7445; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; CARON JM, 1985, J CELL BIOL, V101, P1763, DOI 10.1083/jcb.101.5.1763; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; EUTENEUER U, 1989, EUR J CELL BIOL, V50, P34; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HO WC, 1989, EUR J CELL BIOL, V48, P250; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOPKINS CR, 1986, TRENDS BIOCHEM SCI, V11, P473, DOI 10.1016/0968-0004(86)90250-1; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOWELL KE, 1988, METHODS CELL BIOL A, V31, P263; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; INGOLD AL, 1988, J CELL BIOL, V107, P2659; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KREIS TE, 1990, CELL MOTIL CYTOSKEL, V15, P67, DOI 10.1002/cm.970150202; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; MARSH M, 1986, P NATL ACAD SCI USA, V83, P2899, DOI 10.1073/pnas.83.9.2899; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MCDOWALL A, 1989, EUR J CELL BIOL, V49, P281; MCINTOSH JR, 1989, J BIOL CHEM, V264, P6001; MITHIEUX G, 1988, BIOCHIM BIOPHYS ACTA, V971, P29; MITHIEUX G, 1989, J BIOL CHEM, V264, P4664; OKA JA, 1983, BIOCHIM BIOPHYS ACTA, V763, P368, DOI 10.1016/0167-4889(83)90098-8; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; Pastan I., 1985, ENDOCYTOSIS, V1-44; PRATT MM, 1986, J CELL BIOL, V103, P957, DOI 10.1083/jcb.103.3.957; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; SCHEEL J, 1990, J CELL SCI, V96, P711; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; Vale RD, 1990, CURR OPIN CELL BIOL, V2, P15, DOI 10.1016/S0955-0674(05)80025-0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; WALL DA, 1985, J CELL BIOL, V101, P2104, DOI 10.1083/jcb.101.6.2104; WALL DA, 1980, CELL, V21, P79, DOI 10.1016/0092-8674(80)90116-6; WILEMAN T, 1985, BIOCHEM J, V232, P1; WOODS JW, 1989, EUR J CELL BIOL, V50, P132; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2723, DOI 10.1083/jcb.105.6.2723	56	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18141	18148						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917948				2022-12-25	WOS:A1991GG55300066
J	BOERMAN, MHEM; NAPOLI, JL				BOERMAN, MHEM; NAPOLI, JL			CHOLATE-INDEPENDENT RETINYL ESTER HYDROLYSIS - STIMULATION BY APO-CELLULAR RETINOL-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALMITATE HYDROLASE ACTIVITY; VITAMIN-A METABOLISM; RAT-LIVER MICROSOMES; BETA-LACTOGLOBULIN; ALPHA-TOCOPHEROL; TISSUE; ACID; ESTERIFICATION; ACYLTRANSFERASE; PANCREAS	Apo-cellular retinol-binding protein (apoCRBP) activated the hydrolysis of endogenous retinyl esters in rat liver microsomes by a cholate independent retinyl ester hydrolase. A Michaelis-Menten relationship was observed between the apoCRBP concentration and the rate of retinol formation, with half-maximum stimulation at 2.6 +/- 0.6-mu-M (mean +/- S.D., n = 5). Two other retinol-binding proteins, bovine serum albumin and beta-lactoglobulin, acceptors for the rapid and spontaneous hydration of retinol from membranes, had no effect up to 90-mu-M. These data suggest activation of the hydrolase by apoCRBP directly, rather than by facilitating removal of retinol from membranes. The hydrolase responding was the cholate-independent/cholate-inhibited retinyl ester hydrolase as shown by: 60% inhibition of the apoCRBP effect by 3 mm cholate; apoCRBP enhancement of retinyl ester hydrolysis in liver microsomes that had no detectable cholate-enhanced activity; inhibition of cholate-dependent, but not apoCRBP-stimulated retinyl ester hydrolysis by rabbit anti-rat cholesteryl esterase. Compared to the rate (mean +/-S.D. of [n] different preparations) supported by 5-mu-M apoCRBP in liver microsomes of 6.7 +/- 3.7 pmol/min/mg protein [10], microsomes from rat lung, kidney, and testes had endogenous retinyl ester hydrolysis rates of 1.8 +/- 0.3 [5], 0.5 +/- 0.2 [3], and 0.3 +/- 0.2 [5] pmol/min/mg protein, respectively. N-Ethylmaleimide and N-tosyl-L-phenylalanine chloromethyl ketone were potent inhibitors of apoCRBP-stimulated hydrolysis with IC50 values of 0.25 and 0.15 mM, respectively, but phenylmethylsulfonyl fluoride and diisopropylfluorophosphate were less effective with IC50 values of 1 mM, indicating the importance of imidazole and sulfhydryl groups to the activity. These data provide evidence of a physiological role for the cholate-independent hydrolase in retinoid metabolism and suggest that apoCRBP is a signal for retinyl ester mobilization.	SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT BIOCHEM,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036870] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36870] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASHOR MM, 1973, P NATL ACAD SCI USA, V70, P3483, DOI 10.1073/pnas.70.12.3483; BIESALSKI HK, 1990, METHOD ENZYMOL, V189, P181; BLANER WS, 1984, BIOCHIM BIOPHYS ACTA, V794, P419, DOI 10.1016/0005-2760(84)90008-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; CLEGG JS, 1984, AM J PHYSIOL, V246, pR133, DOI 10.1152/ajpregu.1984.246.2.R133; COOPER DA, 1987, J NUTR, V117, P2066, DOI 10.1093/jn/117.12.2066; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FUGATE RD, 1980, BIOCHIM BIOPHYS ACTA, V625, P28, DOI 10.1016/0005-2795(80)90105-1; GAD MZ, 1991, J LIPID RES, V32, P685; Gallo L L, 1981, Methods Enzymol, V71 Pt C, P664; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; HARRISON EH, 1987, J LIPID RES, V28, P973; HARRISON EH, 1979, J LIPID RES, V20, P760; HARRISON EH, 1990, METHOD ENZYMOL, V189, P459; HARRISON EH, 1989, J BIOL CHEM, V264, P17142; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; Lotan R, 1988, Prog Clin Biol Res, V259, P261; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MAHADEVA.S, 1966, J BIOL CHEM, V241, P57; MATARESE V, 1990, PROG LIPID RES, V28, P245; NAPOLI JL, 1984, ARCH BIOCHEM BIOPHYS, V230, P194, DOI 10.1016/0003-9861(84)90100-0; NAPOLI JL, 1986, METHOD ENZYMOL, V123, P112, DOI 10.1016/S0076-6879(86)23015-3; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NAPOLI JL, 1988, J BIOL CHEM, V263, P17372; NAPOLI JL, 1984, BIOCHEM J, V223, P267, DOI 10.1042/bj2230267; NAPOLI JL, 1990, METHOD ENZYMOL, V189, P470; NAPOLI JL, 1989, ARCH BIOCHEM BIOPHYS, V274, P192, DOI 10.1016/0003-9861(89)90430-X; NAPOLI JL, 1990, CHEM BIOL SYNTHETIC, P229; NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012; NOY N, 1990, BIOCHEMISTRY-US, V29, P3883, DOI 10.1021/bi00468a013; Ong D, 1980, Methods Enzymol, V67, P288; ONG DE, 1975, J BIOL CHEM, V250, P6113; ONG DE, 1988, J BIOL CHEM, V263, P5789; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; PRYSTOWSKY JH, 1981, J BIOL CHEM, V256, P4498; ROSS AC, 1982, J BIOL CHEM, V257, P2453; SONDERGAARD E, 1973, EXPERIENTIA, V28, P773; WILLIAMS JB, 1984, J LIPID RES, V25, P638; WOLF G, 1984, PHYSIOL REV, V64, P874; YOST RW, 1988, J BIOL CHEM, V263, P18693	43	88	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22273	22278						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939249				2022-12-25	WOS:A1991GR56400035
J	COPELAND, WC; WANG, TSF				COPELAND, WC; WANG, TSF			CATALYTIC SUBUNIT OF HUMAN DNA POLYMERASE-ALPHA OVERPRODUCED FROM BACULOVIRUS-INFECTED INSECT CELLS - STRUCTURAL AND ENZYMOLOGICAL CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN KB-CELLS; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; HOMOGENEOUS ENZYME; PRIMASE COMPLEX; GENE-EXPRESSION; HELA-CELLS; REPLICATION; PROLIFERATION; SPECIFICITY	The human DNA polymerase a catalytic polypeptide has been functionally overexpressed by a recombinant baculovirus in insect cells at > 1000-fold higher levels than that found in cultured normal human cells. The recombinant polymerase alpha-protein is translated from its natural translation start codon under the control of the baculovirus polyhedron promoter producing a protein of 180 kDa, identical in size to that isolated from cultured human cells. This recombinant polymerase a is phosphorylated and reactive to a panel of monoclonal antibodies directed against the native polymerase alpha-primase complex and to polyclonal antisera against N- and C-terminal peptides of the polymerase-alpha catalytic polypeptide. The recombinant enzyme was immunopurified from insect cells as a single polypeptide. The single subunit recombinant polymerase-alpha has no detectable 3'-5' exonuclease activity. The K(m) for primer-template and dNTP, reactivity to inhibitors, N2-(p-n-butylphenyl)-dGTP (BuPdGTP) and aphidicolin, thermosensitivity, and DNA synthetic processivity and fidelity of the recombinant polymerase-alpha are identical to that observed with the four-subunit polymerase alpha-primase complex immunopurified from cultured human cells. These results strongly suggest that the presence of the other subunits, (the p70 and the two primase subunits, p48 and p58), does not influence kinetic parameters of polymerase-alpha catalysis, sensitivity to inhibitors, or DNA synthetic fidelity and processivity.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305	Stanford University			Copeland, William/C-4242-2019	Copeland, William/0000-0002-0359-0953	NATIONAL CANCER INSTITUTE [R01CA014835, T32CA009151] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09151, CA 14835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROOKE RG, 1991, J BIOL CHEM, V266, P3005; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COTTERILL S, 1987, J BIOL CHEM, V262, P16100; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5653; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; FILPULA D, 1982, J BIOL CHEM, V257, P2029; FISHER PA, 1977, J BIOL CHEM, V252, P6528; FISHER PA, 1979, J BIOL CHEM, V254, P1033; FISHER PA, 1979, J BIOL CHEM, V254, P6128; FRY M, 1986, ANIMAL CELL DNA POLY, P14; HSI KL, 1990, NUCLEIC ACIDS RES, V18, P6231, DOI 10.1093/nar/18.21.6231; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; KORNBERG A, 1980, DNA REPLICATION, P208; KUNKEL TA, 1989, MOL CELL BIOL, V9, P4447, DOI 10.1128/MCB.9.10.4447; KUNKEL TA, 1988, BIOCHIM BIOPHYS ACTA, V951, P1, DOI 10.1016/0167-4781(88)90020-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; Maniatis T., 1982, MOL CLONING; MILLER MA, 1988, NUCLEIC ACIDS RES, V16, P7961, DOI 10.1093/nar/16.16.7961; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; PIZZAGALLI A, 1988, P NATL ACAD SCI USA, V85, P3772, DOI 10.1073/pnas.85.11.3772; REYLAND ME, 1988, J BIOL CHEM, V263, P6518; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STOOKE T, 1991, MOL CELL BIOL, V11, P3384; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TOMALSKI MD, 1988, VIROLOGY, V167, P591, DOI 10.1016/S0042-6822(88)90122-5; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WANG TSF, 1985, P NATL ACAD SCI USA, V82, P5270, DOI 10.1073/pnas.82.16.5270; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG TSF, 1984, J BIOL CHEM, V259, P1854; WONG SW, 1986, J BIOL CHEM, V261, P7958; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	38	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22739	22748						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939281				2022-12-25	WOS:A1991GR56400100
J	NOHMI, M; KUBA, K; HUA, SY				NOHMI, M; KUBA, K; HUA, SY			ULTRAVIOLET-LIGHT ACTIVATES BLOCKING ACTIONS OF DANTROLENE ON INTRACELLULAR CA2+ RELEASE IN BULLFROG SYMPATHETIC NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; GANGLION CELLS; CALCIUM RELEASE; CA-2+; FLUORESCENCE; CAFFEINE	Effects of dantrolene, a blocker of intracellular Ca2+ release, on the oscillation of the intracellular Ca2+ ([Ca2+]i) induced by caffeine were studied in bullfrog sympathetic ganglion cells, using a Fura-2 fluorescence technique. Dantrolene blocked the Ca2+ oscillation only in the cell illuminated by ultraviolet light (335-385 nm). Likewise, the blocking effects on rhythmic Ca2+-dependent hyperpolarizations, representing Ca2+ oscillations via activation of Ca2+-dependent K+ channel, occurred only under the illumination with ultraviolet light (335-385 nm), but not with visible light (404-417 nm). This wavelength dependence differs from the absorbance spectrum of dantrolene. On the other hand, dantrolene preirradiated with ultraviolet light under dark condition or ultraviolet light itself did not affect the [Ca2+]i oscillation. The blocking action was not prevented by the pretreatment of the cells with reducing agents. These results indicate that illumination of the Ca2+ release channel or dantrolene itself with ultraviolet light (possibly the former) is necessary for the drug to exert its blocking effect. Furthermore, dantrolene was found to decrease Fura-2 fluorescence and to increase cell autofluorescence, leading sometimes to a false decrease in the basal [Ca2+]i.			NOHMI, M (corresponding author), SAGA MED SCH,DEPT PHYSIOL,NABESHIMA,SAGA 849,JAPAN.							BRITT BA, 1984, CAN ANAESTH SOC J, V31, P61, DOI 10.1007/BF03011484; DEHPOUR AR, 1982, BIOCHEM PHARMACOL, V31, P965, DOI 10.1016/0006-2952(82)90328-8; DESMEDT JE, 1979, BIOCHEM PHARMACOL, V28, P957, DOI 10.1016/0006-2952(79)90286-7; ENDO M, 1970, NATURE, V228, P34, DOI 10.1038/228034a0; FORD LE, 1970, SCIENCE, V167, P58, DOI 10.1126/science.167.3914.58; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLIFIELD RD, 1968, ARCH INT PHARMACOD T, V174, P333; KATO K, 1988, J MED CHEM, V31, P793, DOI 10.1021/jm00399a019; KATO K, 1988, MED BIOCH CHEM ASPEC, P477; KATOGI Y, 1982, J CHROMATOGR, V228, P404, DOI 10.1016/S0378-4347(00)80463-6; KOBAYASHI T, 1988, P JPN ACAD B-PHYS, V64, P76, DOI 10.2183/pjab.64.76; KUBA K, 1981, J THEOR BIOL, V93, P1009, DOI 10.1016/0022-5193(81)90352-0; KUBA K, 1980, J PHYSIOL-LONDON, V298, P251, DOI 10.1113/jphysiol.1980.sp013079; KUBA K, 1976, J NEUROPHYSIOL, V39, P547, DOI 10.1152/jn.1976.39.3.547; KUBA K, 1989, PFLUG ARCH EUR J PHY, V414, P105, DOI 10.1007/BF00580950; NOHMI M, 1988, BRAIN RES, V438, P175, DOI 10.1016/0006-8993(88)91336-4; NOHMI M, 1989, NEUROSCIENCE RES S, V9, pS78; OHTA T, 1986, P JPN ACAD B-PHYS, V62, P329, DOI 10.2183/pjab.62.329; OHTA T, 1990, EUR J PHARMACOL, V178, P11	20	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22254	22259						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939247				2022-12-25	WOS:A1991GR56400032
J	SQUIRE, CR; TALEBIAN, M; MENON, JG; DEKRUYFF, S; LEE, TD; SHIVELY, JE; ROTHMAN, BS				SQUIRE, CR; TALEBIAN, M; MENON, JG; DEKRUYFF, S; LEE, TD; SHIVELY, JE; ROTHMAN, BS			LEUCINE AMINOPEPTIDASE-LIKE ACTIVITY IN APLYSIA HEMOLYMPH RAPIDLY DEGRADES BIOLOGICALLY-ACTIVE ALPHA-BAG CELL PEPTIDE-FRAGMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUST SCHISTOCERCA-GREGARIA; EGG-LAYING HORMONE; SINGLE GENE; NEUROPEPTIDES; NEURONS; METABOLISM; MULTIPLE; BESTATIN; NEUROTRANSMITTER; CALIFORNICA	We have investigated the role that proteolytic enzymes in Aplysia hemolymph play in the inactivation of the neurotransmitter a-bag cell peptide (alpha-BCP(19), Ala-Pro-Arg-Leu-Arg-Phe-Tyr-Ser-Leu). Alpha-BCP fragments containing Pro in positions 1 or 2, or Tyr in position 1, were degraded relatively slowly (half-life, t1/2 = 10-64 min), whereas fragments lacking these residues were degraded relatively rapidly (t1/2 = 0.5-2.7 min). Of 12 peptidase inhibitors tested, only bestatin, amastatin, and phenanthroline significantly inhibited alpha-BCP(3-9) degradation. alpha-BCP(3-9) yielded only four observable cleavage products (in order of decreasing abundance at early time points): alpha-BCP (4-9), alpha-BCP(5-9), alpha-BCP(6-9), and alpha-BCP(7-9). Degradation of alpha-BCP(3-9), alpha-BCP(4-9), alpha-BCP(5-9), alpha-BCP(6-9), or alpha-BCP(7-9) was strongly inhibited by bestatin, moderately inhibited by amastatin, and not inhibited by arphramenine B. The rates of degradation of eight alpha-BCP fragments and three other peptides in plasma were well correlated with their rates of degradation in mammalian leucine aminopeptidase (LAP, EC 3.4.11.1). Collectively our data support the following ideas. 1) In hemolymph one or more LAP-like enzymes rapidly and sequentially cleave alpha-BCP(3-9) or other small peptides lacking Pro at positions 1 or 2 or Tyr at position-1. 2) LAP-like peptidases in hemolymph may act in concert with previously described ganglionic peptidases to degrade neurally released alpha-BCP(1-9) and alpha-BCP(1-8) into inactive fragments.	CITY HOPE NATL MED CTR, BECKMAN RES INT, DUARTE, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	SQUIRE, CR (corresponding author), SAN FRANCISCO STATE UNIV, DEPT BIOL, SAN FRANCISCO, CA 94132 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001177, R01NS024046] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-01177, NS-24046] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AOYAGI T, 1978, J ANTIBIOT, V31, P636, DOI 10.7164/antibiotics.31.636; ARCH S, 1972, J GEN PHYSIOL, V60, P102, DOI 10.1085/jgp.60.1.102; COGGESHALL RE, 1967, J NEUROPHYSIOL, V30, P1263, DOI 10.1152/jn.1967.30.6.1263; Delange R. J., 1971, ENZYMES, VIII, P81; ELLIS S, 1964, BIOCHEM BIOPH RES CO, V16, P502; HASKINS JT, 1981, J NEUROCYTOL, V10, P729, DOI 10.1007/BF01262650; HEFTA SA, 1990, J BIOL CHEM, V265, P8618; HIMMELHOCH SR, 1969, ARCH BIOCHEM BIOPHYS, V134, P597, DOI 10.1016/0003-9861(69)90322-1; ISAAC RE, 1987, BIOCHEM J, V245, P365, DOI 10.1042/bj2450365; ISAAC RE, 1988, BIOCHEM J, V255, P843, DOI 10.1042/bj2550843; LOECHNER KJ, 1990, J NEUROPHYSIOL, V63, P738, DOI 10.1152/jn.1990.63.4.738; MAYERI E, 1979, J NEUROPHYSIOL, V42, P1165, DOI 10.1152/jn.1979.42.4.1165; MAYERI E, 1985, J NEUROSCI, V5, P2060; MAYERI E, 1982, STRATEGIES STUDYING, P121; MCDONALD JK, 1987, MAMMALIAN PROTEASES, V2; MCKELVY JF, 1986, ANNU REV NEUROSCI, V9, P415; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; NEWCOMB RW, 1990, BRAIN RES, V521, P229, DOI 10.1016/0006-8993(90)91547-T; OWENS DF, 1991, NEUR ABSTR, V17, P1284; PHARES GA, 1989, NEUR ABSTR, V15, P665; PULST SM, 1987, NEUROPEPTIDES, V10, P249, DOI 10.1016/0143-4179(87)90075-8; ROTHMAN B S, 1987, Society for Neuroscience Abstracts, V13, P39; ROTHMAN B S, 1985, Society for Neuroscience Abstracts, V11, P482; ROTHMAN BS, 1983, P NATL ACAD SCI-BIOL, V80, P5753, DOI 10.1073/pnas.80.18.5753; ROTHMAN BS, 1985, GENE EXPRESSION BRAI, P235; ROTHMAN BS, 1992, IN PRESS T AM SOC NE, V23; SCHELLER RH, 1983, CELL, V32, P7, DOI 10.1016/0092-8674(83)90492-0; Segel IH, 1976, BIOCH CALCULATIONS, P208; SIGVARDT KA, 1986, J NEUROSCI, V6, P803; SQUIRE CR, 1989, NEUR ABSTR, V15, P666; SQUIRE CR, 1990, THESIS SAN FRANCISCO; STEPHENSON SL, 1987, BIOCHEM J, V241, P237, DOI 10.1042/bj2410237; SUDA H, 1976, J ANTIBIOT, V29, P100, DOI 10.7164/antibiotics.29.100; SUDA H, 1976, ARCH BIOCHEM BIOPHYS, V177, P196, DOI 10.1016/0003-9861(76)90429-X; TERENIUS L, 1988, INT REV NEUROBIOL, V30, P101; Turner A., 1987, NEUROPEPTIDES THEIR; TURNER AJ, 1986, ESSAYS BIOCHEM, V22, P69; TURNER AJ, 1989, NEUROPEPTIDES METHOD; UMEZAWA H, 1983, J ANTIBIOT, V36, P1572, DOI 10.7164/antibiotics.36.1572; UMEZAWA H, 1976, J ANTIBIOT, V29, P97, DOI 10.7164/antibiotics.29.97; UMEZAWA H, 1983, PROTEINASE INHIBITOR, P3; WALTER R, 1980, MOL CELL BIOCHEM, V30, P111	42	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22355	22363						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939259				2022-12-25	WOS:A1991GR56400049
J	SUH, YJ; HAGER, LP				SUH, YJ; HAGER, LP			CHEMICAL AND TRANSIENT STATE KINETIC-STUDIES ON THE FORMATION AND DECOMPOSITION OF HORSERADISH-PEROXIDASE COMPOUND-X(I) AND COMPOUND-X(II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORINATION; MECHANISM; RESONANCE; CHLORITE	Previous studies on the chlorination reaction catalyzed by horseradish peroxidase using chlorite as the source of chlorine detected the formation of a chlorinating intermediate that was termed Compound X (Shahangian, S., and Hager, L. P. (1982) J. Biol. Chem. 257, 11529-11533). These studies indicated that at pH 10.7, the optical absorption spectrum of Compound X was similar to the spectrum of horseradish peroxidase Compound II. Compound X was shown to be quite stable at alkaline pH values. This study was undertaken to examine the relationship between the oxidation state of the iron protoporphyrin IX heme prosthetic group in Compound X and the chemistry of the halogenating intermediate. The experimental results show that the optical absorption properties and the oxidation state of the heme prosthetic group in horseradish peroxidase are not directly related to the presence of the activated chlorine atom in the intermediate. The oxyferryl porphyrin heme group in alkaline Compound X can be reduced to a ferric heme species that still retains the activated chlorine atom. Furthermore, the reaction of chlorite with horseradish peroxidase at acidic pH leads to the secondary formation of a green intermediate that has the spectral properties of horseradish peroxidase Compound I (Theorell, H. (1941) Enzymologia 10, 250-252). The green intermediate also retains the activated chlorine atom. By analogy to peroxidase Compound I chemistry, the heme prosthetic group in the green chlorinating intermediate must be an oxyferryl porphyrin pi-cation radical species (Roberts, J. E., Hoffman, B. M., Rutter, R. J., and Hager, L. P. (1981) J. Am. Chem. Soc. 103, 7654-7656). To be consistent with traditional peroxidase nomenclature, the red alkaline form of Compound X has been renamed Compound X(II), and the green acidic form has been named Compound X(I). The transfer of chlorine from the chlorinating intermediate to an acceptor molecule follows an electrophilic (rather than a free radical) path. A mechanism for the reaction is proposed in which the activated chlorine atom is bonded to a heteroatom on an active-site amino acid side chain. Transient state kinetic studies show that the initial intermediate, Compound X(II), is formed in a very fast reaction. The second-order rate constant for the formation of Compound X(II) is approximately 1.1 X 10(7) M-1 s-1. The rate of formation of Compound X(II) is strongly pH-dependent. At pH 9, the second-order rate constant for the formation of Compound X(II) drops to 1.5 M-1 s-1. At acidic pH values, Compound X(II) undergoes a spontaneous first-order decay to yield Compound X(I). The rate of conversion of Compound X(II) to X(I) is maximal at pH 4.1 with a measured rate constant of 1.97 s-1. At alkaline pH values, Compound X(II) is stable and does not decay to form Compound X(I).			SUH, YJ (corresponding author), UNIV ILLINOIS,ROGER ADAMS LAB,DEPT BIOCHEM,URBANA,IL 61801, USA.				NIGMS NIH HHS [GM-00768] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chance B, 1943, J BIOL CHEM, V151, P553; CHIANG R, 1976, J BIOL CHEM, V251, P6340; DOLMAN D, 1975, CAN J BIOCHEM CELL B, V53, P495, DOI 10.1139/o75-069; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; HAGER LP, 1966, J BIOL CHEM, V241, P1769; HEWSON WD, 1979, J BIOL CHEM, V254, P3175; HEWSON WD, 1979, J BIOL CHEM, V254, P3182; HEWSON WD, 1979, PORPHYRINS, V7, P295; HOLLENBERG PF, 1974, J BIOL CHEM, V249, P5816; MONTHEY J, 1985, J BIOL CHEM, V260, P9654; ROBERTS JE, 1981, J AM CHEM SOC, V103, P7654, DOI 10.1021/ja00415a044; ROBERTS JE, 1981, J BIOL CHEM, V256, P2118; SCHONBAUM GR, 1972, J BIOL CHEM, V247, P3353; SCHULZ CE, 1979, FEBS LETT, V103, P102, DOI 10.1016/0014-5793(79)81259-4; SHAHANGIAN S, 1982, J BIOL CHEM, V257, P1529; SHANNON LM, 1966, J BIOL CHEM, V241, P2166; TERNER J, 1984, BIOCHIM BIOPHYS ACTA, V789, P80, DOI 10.1016/0167-4838(84)90064-5	17	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22102	22109						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939231				2022-12-25	WOS:A1991GR56400009
J	YATANI, A; QUILLIAM, LA; BROWN, AM; BOKOCH, GM				YATANI, A; QUILLIAM, LA; BROWN, AM; BOKOCH, GM			RAP1A ANTAGONIZES THE ABILITY OF RAS AND RAS-GAP TO INHIBIT MUSCARINIC K+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PUTATIVE EFFECTOR DOMAIN; SUPPRESSOR ACTIVITY; GENETIC-ANALYSIS; RAS-P21 GTPASE; P21; TRANSFORMATION; PURIFICATION; RESOLUTION; PRODUCT	Rap1A is a Ras-related GTP binding protein which has an amino acid sequence identical to that of Ras in the putative "effector" domain (amino acids 32-40). The binding of Rap1A to Ras-GTPase activating protein (GAP) through this domain is a potential mechanism for explaining the observation that Rap1A can antagonize the ability of oncogenic Ras to transform cells. It was recently shown (Yatani, A., Okabe, K., Polakis, P., Halenbeck, R., McCormick, F., and Brown, A. M. (1990) Cell 61, 769-776) that the activation of M2-muscarinic receptor-coupled K+ channels in heart is inhibited by the addition of exogenous Ras and Ras-GAP. We have made use of this system in the present paper to show that Rap1A is able to effectively block this inhibitory action of Ras-GAP. We observed that both Rap1A-GDP and Rap1A-guanosine 5'-3-O-(thio)triphosphate (GTP-gamma-S) were able to block the inhibitory effect of Ras-GAP upon channel activation. This effect occurred at picomolar concentrations of Rap1A, and the GTP-gamma-S-bound form of the protein was consistently found to be more potent than the GDP form. A Rap1A Thr35 --> Ala mutation which bound GTP-gamma-S did not prevent K+ channel inhibition by Ras-GAP, suggesting that the antagonism by wild type Rap1A involves an interaction with GAP in the effector domain. The effectiveness of Rap1A to inhibit Ras-GAP is dependent upon the amount of Ras-GAP present in the assay and can also be overcome by the addition of GTP-bound N-Ras (GC-43), suggesting a competitive mechanism is operative. Finally, a truncated form of Ras-GAP (GAP32) which is no longer dependent upon Ras for inhibition of the M2-activated K+ channel is also no longer sensitive to blockade by added Rap1A. These data support the concept of GAP as an effector of Ras act ion and indicate that Rap1A can serve as an inhibitor of Ras action in a system distinct from cell transformation by a competitive mechanism involving the GAP binding domain of Rap1A.	Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA	Scripps Research Institute; Baylor College of Medicine			Quilliam, Lawrence/B-6447-2015; Quilliam, Lawrence/Q-4987-2019		NHLBI NIH HHS [HL36930] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036930] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AKAIKE N, 1986, J PHYSIOL-LONDON, V379, P171, DOI 10.1113/jphysiol.1986.sp016246; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; BROWN AM, 1984, NATURE, V311, P570, DOI 10.1038/311570a0; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DER CJ, 1989, ONCOGENES, P73; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HATA Y, 1990, J BIOL CHEM, V265, P7104; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHWEIGHOFFER F, 1990, BIOL MED SIGNAL TRAN, P326; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1990, AM J PHYSIOL, V258, pH1507, DOI 10.1152/ajpheart.1990.258.5.H1507; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	36	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22222	22226						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939245				2022-12-25	WOS:A1991GR56400027
J	TAYLOR, DA; SACK, JS; MAUNE, JF; BECKINGHAM, K; QUIOCHO, FA				TAYLOR, DA; SACK, JS; MAUNE, JF; BECKINGHAM, K; QUIOCHO, FA			STRUCTURE OF A RECOMBINANT CALMODULIN FROM DROSOPHILA-MELANOGASTER REFINED AT 2.2-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; X-RAY-DIFFRACTION; MACROMOLECULAR STRUCTURES; SKELETAL-MUSCLE; TROPONIN-C; CRYSTALS; GENE; EXPRESSION; PROGRAM; HELIX	The crystal structure of calmodulin (M(r) 16,700, 148 residues) from Drosophila melanogaster as expressed in a bacterial system has been determined and refined at 2.2-angstrom resolution. Starting with the structure of mammalian calmodulin, we produced an extensively refitted and refined model with a conventional crystallographic R value of 0. 197 for the 5,239 reflections (F greater-than-or-equal-to 2-sigma(F)) within the 10.0-2.2-angstrom resolution range. The model includes 1,164 protein atoms, 4 calcium ions, and 78 water molecules and has root mean square deviations from standard values of 0.018 angstrom for bond lengths and 0.043 angstrom for angle distances. The overall structure is similar to mammalian calmodulin with a seven-turn central helix connecting the two calcium-binding domains. The "dumb-bell" shaped molecule contains seven alpha-helices and four "EF hand" calcium-binding sites. Although the amino acid sequences of mammalian and Drosophila calmodulins differ by only three conservative amino acid changes, the refined model reveals a number of significant differences between the two structures. Superimposition of the structures yields a root mean square deviation of 1.22 angstrom for the 1,120 equivalent atoms. The calcium-binding domains have a root mean square deviation of 0.85 angstrom for the 353 equivalent atoms. There are also differences in the amino terminus, the bend of the central alpha-helix, and the orientations of some of the side chains.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, POB 4000, PRINCETON, NJ 08543 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; RICE UNIV, DEPT BIOCHEM & CELL BIOL, HOUSTON, TX 77251 USA	Bristol-Myers Squibb; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Rice University								BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARFORD AM, 1986, ANAL BIOCHEM, V158, P361, DOI 10.1016/0003-2697(86)90561-0; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Brunger AT, 1988, CRYSTALLOGRAPHIC COM, V3, P126; COOK WJ, 1983, METHOD ENZYMOL, V102, P143; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; FORSEN S, 1986, CALCIUM CELL FUNCTIO, V6, P113; GORLACH M, 1985, BIOCHIM BIOPHYS ACTA, V832, P228, DOI 10.1016/0167-4838(85)90337-1; HANSON JC, 1979, ACTA CRYSTALLOGR A, V35, P616, DOI 10.1107/S0567739479001443; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HONZATKO RB, 1986, ACTA CRYSTALLOGR A, V42, P172, DOI 10.1107/S0108767386099580; JACK A, 1978, ACTA CRYSTALLOGR A, V34, P931, DOI 10.1107/S0567739478001904; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MARSHAK DR, 1984, BIOCHEMISTRY-US, V23, P2891, DOI 10.1021/bi00308a007; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; MOEWS PC, 1975, J MOL BIOL, V91, P201, DOI 10.1016/0022-2836(75)90160-6; NORTH ACT, 1968, ACTA CRYSTALL A-CRYS, VA 24, P351, DOI 10.1107/S0567739468000707; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SHERIFF S, 1987, ACTA CRYSTALLOGR A, V43, P118, DOI 10.1107/S010876738709977X; SHERIFF S, 1987, J APPL CRYSTALLOGR, V20, P55, DOI 10.1107/S0021889887087132; SMITH VL, 1987, J MOL BIOL, V196, P471, DOI 10.1016/0022-2836(87)90025-8; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SZEBENYI DME, 1986, J BIOL CHEM, V261, P8761; TANAKA T, 1980, J BIOL CHEM, V255, P1078; VYAS NK, 1991, NOVEL CALCIUM BINDIN, P403	37	137	142	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21375	21380						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939171				2022-12-25	WOS:A1991GP80400012
J	ZHAN, Q; WONG, SS; WANG, CLA				ZHAN, Q; WONG, SS; WANG, CLA			A CALMODULIN-BINDING PEPTIDE OF CALDESMON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN GIZZARD CALDESMON; VASCULAR SMOOTH-MUSCLE; HEAVY-MEROMYOSIN; ATPASE ACTIVITY; ACTIN; MYOSIN; FRAGMENT; CALCIUM; PROTEIN; PURIFICATION	Caldesmon is a major actin-binding protein identified in smooth muscle and many non-muscle cells. It also interacts with calmodulin and a number of other acidic proteins. We have shown previously that the polypeptide stretch from Val629 to Ser666 near the C terminus contains a calmodulin binding site (Wang, C.-L. A., Wang, L.-W. C., Xu, S., Lu, R. C., Saavedra-Alanis, V., and Bryan, J. (1991) J. Biol. Chem. 266, 9166-9172). On the other hand, Bartegi et al. (Bartegi, A., Fattoum, A., Derancourt, J., and Kassab, R. (1990) J. Biol. Chem. 265, 15231-15238) reported a cyanogen bromide fragment beginning at Trp659 which is also capable of binding both calmodulin and actin. A comparison of the overlapping sequence between these two peptides suggests that this calmodulin binding site is localized in a 7-residue segment, 659Trp-Glu-Lys-Gly-Asn-Val-Phe665. We have chemically synthesized an 18-residue peptide (GS17C, from Gly651 to Ser667 with an added cysteine at the C terminus) that contains this segment. This peptide was purified by high performance liquid chromatography and labeled with fluorescent probes at the terminal cysteine residue. We found that GS17C indeed binds calmodulin in a Ca2+-dependent manner (K(d) = 8 x 10(-7) M) and appears to compete with caldesmon. Interestingly, this synthetic peptide also co-sediments with F-actin, binding to actin being displaceable by calmodulin, as in the case of the native caldesmon. But GS17C does not have any effect on the actomyosin ATPase activity, indicating that this peptide segment does not contain the inhibitory region.	UNIV LOWELL, DEPT CHEM, LOWELL, MA 01854 USA	University of Massachusetts System; University of Massachusetts Lowell	ZHAN, Q (corresponding author), BOSTON BIOMED RES INST, DEPT MUSCLE RES, BOSTON, MA 02114 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041411] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY JE, 1966, THESIS LONDON U; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1988, CELL BIOPHYS, V12, P73, DOI 10.1007/BF02918351; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; FUJII T, 1987, J BIOL CHEM, V262, P2757; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; IKEBE M, 1978, J BIOCHEM, V83, P1643, DOI 10.1093/oxfordjournals.jbchem.a132077; LASH JA, 1986, J BIOL CHEM, V261, P6155; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P1371, DOI 10.1016/S0006-291X(89)80155-X; LYNCH W, 1986, METHOD ENZYMOL, V134, P37; MARSTON SB, 1984, BIOCHEM SOC T, V12, P945, DOI 10.1042/bst0120945; NGAI PK, 1984, J BIOL CHEM, V259, P3656; PRITCHARD K, 1986, CELL CALCIUM, V7, P309, DOI 10.1016/0143-4160(86)90035-7; ROSENFELD SS, 1985, J BIOL CHEM, V260, P242; SHIRINSKY VP, 1988, BIOCHEM J, V255, P203; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBIESZEK A, 1976, J MOL BIOL, V102, P75, DOI 10.1016/0022-2836(76)90074-7; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1982, BIOMED RES-TOKYO, V3, P188, DOI 10.2220/biomedres.3.188; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TAKAGI T, 1989, J BIOCHEM-TOKYO, V106, P778, DOI 10.1093/oxfordjournals.jbchem.a122930; VELAZ L, 1990, J BIOL CHEM, V265, P2929; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG CLA, 1990, BIOPHYS J, V57, pA162; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144	28	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21810	21814						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939204				2022-12-25	WOS:A1991GP80400074
J	SAITO, K; THIELE, DJ; DAVIO, M; LOCKRIDGE, O; MASSEY, V				SAITO, K; THIELE, DJ; DAVIO, M; LOCKRIDGE, O; MASSEY, V			THE CLONING AND EXPRESSION OF A GENE ENCODING OLD YELLOW ENZYME FROM SACCHAROMYCES-CARLSBERGENSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA	We have identified a gene that encodes Old Yellow Enzyme in brewer's bottom yeast. The open reading frame encodes a polypeptide of 400 amino acids with M(r) = 45,021. Using the T7 RNA polymerase system, recombinant enzyme was expressed in Escherichia coli. 17 mg of Old Yellow Enzyme was obtained from a 3-liter cell culture, and the recombinant enzyme had NADPH oxidase activity. On fast protein liquid chromatography separation, the recombinant enzyme showed a single large peak, while native enzyme from brewer's bottom yeast separated into five fractions on fast protein liquid chromatography. Southern blot analysis showed that there are at least two Old Yellow Enzyme genes in brewer's bottom yeast genomic DNA. These results suggest that the heterogeneity of Old Yellow Enzyme in Saccharomyces carlsbergensis is due to the presence of multiple genes.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIGMS NIH HHS [GM 11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5321; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; CASEY GP, 1988, CARLSBERG RES COMMUN, V53, P209, DOI 10.1007/BF02904408; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HOLMBERG S, 1982, CARLSBERG RES COMMUN, V47, P233, DOI 10.1007/BF02907875; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACHEROUX P, 1990, BIOCHEMISTRY-US, V29, P2670, DOI 10.1021/bi00463a008; Maniatis T., 1982, MOL CLONING; Massey V., 1984, FLAVINS FLAVOPROTEIN, P191; MATTHEWS RG, 1969, J BIOL CHEM, V244, P1779; MATTHEWS RG, 1975, J BIOL CHEM, V250, P9294; MIURA R, 1986, J BIOCHEM-TOKYO, V99, P901, DOI 10.1093/oxfordjournals.jbchem.a135551; MIURA R, 1987, J BIOCHEM-TOKYO, V102, P1311, DOI 10.1093/oxfordjournals.jbchem.a122169; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOPFER LM, 1991, STUDY ENZYMES, V2, P247; SHERMAN F, 1986, LABORATORY COURSE MA; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEORELL H, 1956, ARCH BIOCHEM BIOPHYS, V65, P439, DOI 10.1016/0003-9861(56)90204-1; Warburg O, 1933, BIOCHEM Z, V266, P377	20	89	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20720	20724						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939123				2022-12-25	WOS:A1991GN00100023
J	SHAW, JP; AKIYOSHI, DE; ARRIGO, DA; RHOAD, AE; SULLIVAN, B; THOMAS, J; GENBAUFFE, FS; BACHA, P; NICHOLS, JC				SHAW, JP; AKIYOSHI, DE; ARRIGO, DA; RHOAD, AE; SULLIVAN, B; THOMAS, J; GENBAUFFE, FS; BACHA, P; NICHOLS, JC			CYTOTOXIC PROPERTIES OF DAB486EGF AND DAB389EGF, EPIDERMAL GROWTH-FACTOR (EGF) RECEPTOR-TARGETED FUSION TOXINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST CANCER; HIGH-LEVEL EXPRESSION; DIPHTHERIA-TOXIN; PSEUDOMONAS EXOTOXIN; FACTOR-ALPHA; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CYTO-TOXICITY; FRAGMENT-A; CELLS	Elevated expression of the receptor for epidermal growth factor (EGF) is a characteristic of several malignancies including those of the breast, bladder, prostate, lung, and neuroglia. To therapeutically target the cytotoxic action of diphtheria toxin to EGF receptor-expressing tumor cells, we have constructed a hybrid gene in which the sequences for the binding domain of diphtheria toxin have been replaced by those for human EGF. The resulting fusion toxins, DAB486EGF and DAB389EGF, bind specifically to the EGF receptor and inhibit protein synthesis in a variety of EGF receptor expressing human tumor cell lines with an IC50 as low as 0.1 pM. Comparisons of DAB486EGF and DAB389EGF showed that DAB389EGF was consistently 10- to 100-fold more cytotoxic than DAB486EGF. Like diphtheria toxin, the cytotoxic action of DAB389EGF results from ADP-ribosylation of elongation factor-2 and is sensitive to the action of chloroquine. Studies of the kinetics of cellular intoxication showed that a 15-min exposure of EGF receptor-expressing A431 cells to DAB389EGF results in complete protein synthesis inhibition within 4 h. Furthermore, inhibition of protein synthesis results in elimination of human tumor cell colonies. These findings show that DAB389EGF is a potential therapeutic agent for a wide variety of EGF receptor-expressing solid tumors.			SHAW, JP (corresponding author), SERAGEN INC,97 SOUTH ST,HOPKINTON,MA 01748, USA.							AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BACHA P, 1988, J EXP MED, V167, P612, DOI 10.1084/jem.167.2.612; BATTAGLIA F, 1988, ONCOLOGY, V45, P424, DOI 10.1159/000226658; BATTAGLIA F, 1989, GYNECOL OBSTET INVES, V27, P42, DOI 10.1159/000293614; BAUKNECHT T, 1989, J CANCER RES CLIN, V115, P193, DOI 10.1007/BF00397923; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BISHAI WR, 1987, J BACTERIOL, V169, P5140, DOI 10.1128/jb.169.11.5140-5151.1987; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CAWLEY DB, 1980, CELL, V22, P563, DOI 10.1016/0092-8674(80)90366-9; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; DERYNCK R, 1987, CANCER RES, V47, P707; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EDWARDS GM, 1989, MOL CELL BIOL, V9, P2860, DOI 10.1128/MCB.9.7.2860; FITZPATRICK SL, 1984, CANCER RES, V44, P3442; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HEIMBROOK DC, 1990, P NATL ACAD SCI USA, V87, P4697, DOI 10.1073/pnas.87.12.4697; HERTEL C, 1985, J BIOL CHEM, V260, P2547; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MAKKU VR, 1985, J BIOL CHEM, V260, P9820; MASUDA H, 1988, WORLD J SURG, V12, P616, DOI 10.1007/BF01655864; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; Miller J.H., 1972, EXPT MOL GENETICS; MORRIS GL, 1990, J UROLOGY, V143, P1272, DOI 10.1016/S0022-5347(17)40253-9; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; MOYNIHAN MR, 1981, INFECT IMMUN, V32, P575, DOI 10.1128/IAI.32.2.575-582.1981; NEAL DE, 1990, CANCER, V65, P1619, DOI 10.1002/1097-0142(19900401)65:7<1619::AID-CNCR2820650728>3.0.CO;2-Q; OZAWA S, 1987, INT J CANCER, V39, P333, DOI 10.1002/ijc.2910390311; PAI LH, 1991, CANCER RES, V51, P2808; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PFEIFFER A, 1990, GASTROENTEROLOGY, V98, P961, DOI 10.1016/0016-5085(90)90020-2; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; SMITH K, 1989, CANCER RES, V49, P5810; TOI M, 1989, INT J CANCER, V43, P220, DOI 10.1002/ijc.2910430208; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VEALE D, 1989, CANCER RES, V49, P1313; WATERS CA, 1990, EUR J IMMUNOL, V20, P785, DOI 10.1002/eji.1830200412; WEIDNER U, 1990, CANCER RES, V50, P4504; WILLIAMS DP, 1990, J BIOL CHEM, V265, P11885; WILLIAMS DP, 1987, PROTEIN ENG, V1, P493, DOI 10.1093/protein/1.6.493; YAMADA G, 1987, EMBO J, V6, P2705, DOI 10.1002/j.1460-2075.1987.tb02563.x	46	82	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21118	21124						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939154				2022-12-25	WOS:A1991GN00100083
J	BANNER, DW; HADVARY, P				BANNER, DW; HADVARY, P			CRYSTALLOGRAPHIC ANALYSIS AT 3.0-A RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF 4 ACTIVE SITE-DIRECTED INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRINOGEN-LIKE PEPTIDES; HUMAN ALPHA-THROMBIN; SUBSTITUTED L-ARGININE; CRYSTAL-STRUCTURE; TRYPSIN COMPLEX; SELECTIVE-INHIBITION; AMIDE DERIVATIVES; HIV-1 PROTEASE; CHAIN; GEOMETRY	The mode of binding of four active-site directed inhibitors to human thrombin has been determined by x-ray crystallographic analysis. The inhibitors studied are benzamidine, PPACK, NAPAP, and MD-805, of which the last three are compounds evolved specifically to inhibit thrombin. Crystal structures were determined in the presence of both the inhibitor and the undecapeptide [des-amino Asp55]hirudin(55-65) which binds distant from the active site. Despite having significantly different chemical structures, NAPAP and MD-805 bind to thrombin in a very similar "inhibitor binding mode" which is not that expected by direct analogy with the binding of substrate. Both inhibitors bind to thrombin in a similar way as to trypsin, but thrombin has an extra loop, the "Tyr-Pro-Pro-Trp loop," not present in trypsin, which gives further binding interactions and is seen to move somewhat to accommodate binding of the different inhibitors. The fact that NAPAP and MD-805 require different stereochemistry for potent inhibition is demonstrated, and its structural basis clarified. The wealth of data on analogs and variants of these lead compounds is shown to be compatible with this inhibitor binding mode.			BANNER, DW (corresponding author), F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES DEPT, GRENZACHERSTR 124, CH-4002 BASEL, SWITZERLAND.							BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1990, EUR J BIOCHEM, V193, P175, DOI 10.1111/j.1432-1033.1990.tb19320.x; CARTER CW, 1979, J BIOL CHEM, V254, P2219; DODT J, 1990, J BIOL CHEM, V265, P713; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FENTON JW, 1977, CHEM BIOL THROMBIN, P43; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; GERBER PR, 1988, HELV CHIM ACTA, V71, P1429, DOI 10.1002/hlca.19880710607; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KETTNER C, 1979, THROMB RES, V14, P969, DOI 10.1016/0049-3848(79)90014-8; KIKUMOTO R, 1980, J MED CHEM, V23, P830, DOI 10.1021/jm00182a004; KIKUMOTO R, 1984, BIOCHEMISTRY-US, V23, P85, DOI 10.1021/bi00296a014; KIKUMOTO R, 1980, J MED CHEM, V23, P1293, DOI 10.1021/jm00186a003; MARQUART M, 1983, ACTA CRYSTALLOGR B, V39, P480, DOI 10.1107/S010876818300275X; MATSUZAKI T, 1989, J BIOCHEM-TOKYO, V105, P949, DOI 10.1093/oxfordjournals.jbchem.a122785; MATSUZAKI T, 1988, J BIOCHEM-TOKYO, V103, P537, DOI 10.1093/oxfordjournals.jbchem.a122304; MCKAY DB, 1977, CHEM BIOL THROMBIN, P113; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NAVIA MA, 1989, P NATL ACAD SCI USA, V86, P7, DOI 10.1073/pnas.86.1.7; NI F, 1989, BIOCHEMISTRY-US, V28, P3094, DOI 10.1021/bi00433a053; NI F, 1989, BIOCHEMISTRY-US, V28, P3082, DOI 10.1021/bi00433a052; NI F, 1989, BIOCHEMISTRY-US, V28, P3106, DOI 10.1021/bi00433a054; OKAMOTO S, 1980, J MED CHEM, V23, P827, DOI 10.1021/jm00182a003; OKAMOTO S, 1981, BIOCHEM BIOPH RES CO, V101, P440, DOI 10.1016/0006-291X(81)91279-1; OWEN TJ, 1988, J MED CHEM, V31, P1009, DOI 10.1021/jm00400a020; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; STURZEBECHER J, 1983, THROMB RES, V29, P635, DOI 10.1016/0049-3848(83)90218-9; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VOIGT B, 1988, PHARMAZIE, V43, P412	33	309	317	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20085	20093						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939071				2022-12-25	WOS:A1991GM03900035
J	MOSCH, HU; SCHEIER, B; LAHTI, R; MANTSALA, P; BRAUS, GH				MOSCH, HU; SCHEIER, B; LAHTI, R; MANTSALA, P; BRAUS, GH			TRANSCRIPTIONAL ACTIVATION OF YEAST NUCLEOTIDE BIOSYNTHETIC GENE ADE4 BY GCN4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; SACCHAROMYCES-CEREVISIAE; PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; MOLECULAR MECHANISMS; HIS4 TRANSCRIPTION; PROTEIN GCN4; BASAL LEVEL; TRP4 GENE; MUTAGENESIS; EXPRESSION	The yeast transcriptional regulator protein GCN4 harbors the bZIP DNA binding motif, which is common to a family of DNA-binding proteins in eukaryotic organisms from yeast to man. GCN4 and the mammalian activator protein AP-1 (jun/fos) regulate transcription by binding the same consensus DNA sequence ATGA(C/G)TCAT. GCN4 positively regulates the production of precursors of protein synthesis in yeast cells in response to the environmental signal "amino acid starvation." We find three GCN4 responsive elements (GCREs) in the 5'-flanking region of the purine biosynthetic gene ADE4 and demonstrate that GCN4 efficiently activates transcription of ADE4. Two GCREs are essential to synergistically activate ADE4 transcription by binding GCN4. The distal GCRE1 is also required for basal transcription of ADE4. Therefore, transcription factor GCN4 affects, in addition to protein biosynthesis, also nucleotide biosynthesis and, comparable to its mammalian counterpart AP- 1, has a more general function within the yeast cell than previously assumed.	SWISS FED INST TECHNOL,INST MICROBIOL,SCHMELZBERGSTR 7,CH-8092 ZURICH,SWITZERLAND; UNIV TURKU,DEPT BIOCHEM,SF-20500 TURKU 50,FINLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; Finland National Institute for Health & Welfare; University of Turku			Braus, Gerhard/ABC-6293-2021; Braus, Gerhard H/G-3999-2012	Braus, Gerhard/0000-0002-3117-5626; Braus, Gerhard H/0000-0002-3117-5626				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAUS G, 1989, EMBO J, V8, P939, DOI 10.1002/j.1460-2075.1989.tb03455.x; BRAUS GH, 1988, J BIOL CHEM, V263, P7868; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; CHEN W, 1989, EMBO J, V8, P261, DOI 10.1002/j.1460-2075.1989.tb03372.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FURTER R, 1986, NUCLEIC ACIDS RES, V14, P6357, DOI 10.1093/nar/14.16.6357; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASSAVETIS GA, 1982, EMBO J, V1, P107, DOI 10.1002/j.1460-2075.1982.tb01132.x; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANTSALA P, 1984, J BIOL CHEM, V259, P8478; Maxam A M, 1980, Methods Enzymol, V65, P499; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; MIOZZARI G, 1978, J BACTERIOL, V134, P48, DOI 10.1128/JB.134.1.48-59.1978; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; MOSCH HU, 1990, EMBO J, V9, P2951, DOI 10.1002/j.1460-2075.1990.tb07487.x; NIEDERBERGER P, 1986, CURR GENET, V10, P657, DOI 10.1007/BF00410913; PARAVICINI G, 1989, MOL CELL BIOL, V9, P144, DOI 10.1128/MCB.9.1.144; RUDOLPH H, 1985, GENE, V36, P87, DOI 10.1016/0378-1119(85)90072-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDHEINI T, 1990, MOL GEN GENET, V224, P57, DOI 10.1007/BF00259451; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	36	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20453	20456						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939099				2022-12-25	WOS:A1991GM03900086
J	BLAKE, R; WHITE, KJ; SHUTE, EA				BLAKE, R; WHITE, KJ; SHUTE, EA			MIXED-LIGAND COMPLEXES OF IRON WITH CYANIDE AND PHENANTHROLINE AS NEW PROBES OF METALLOPROTEIN ELECTRON-TRANSFER REACTIVITY - ANALYSIS OF REACTIONS INVOLVING RUSTICYANIN FROM THIOBACILLUS-FERROOXIDANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE COPPER PROTEINS; SULFUR PROTEINS; HORSE-HEART; FERRICYTOCHROME-C; RESPIRATORY-CHAIN; REDUCED PARSLEY; BINDING-SITES; CYTOCHROME-C; OXIDATION; REDUCTION	A family of 12 different mixed ligand complexes of iron with cyanide and substituted 1,10-phenanthroline was prepared. The electron transfer properties of each reagent were systematically manipulated by varying the substituent(s) on the aromatic ring system and the stoichiometry of the two types of ligands in the complex. Values for the standard reduction potentials of each member of this family of electron transfer reagents were determined and spanned from 500 to 900 mV. The one-electron transfer reactions between each of these substitution-inert reagents and the high potential blue copper protein, rusticyanin, from Thiobacillus ferrooxidans were studied by stopped flow spectrophotometry under acidic conditions. For comparison with the protein results, the kinetics of electron transfer between each of these reagents and sulfatoiron were also investigated. The Marcus theory of electron transfer was successfully applied to this set of kinetic data to demonstrate that 10 of the 12 reagents had equal kinetic access to the redox center of the rusticyanin and utilized the same reaction pathway for electron transfer. The utility of these synthetic electron transfer reagents in characterizing the electron transfer properties of very high potential, redox-active metalloproteins is illustrated.			BLAKE, R (corresponding author), MEHARRY MED COLL,DEPT BIOCHEM,NASHVILLE,TN 37208, USA.							Adman E.T., 1985, METALLOPROTEINS ME 1, P1; ADZAMLI IK, 1981, J AM CHEM SOC, V103, P5543, DOI 10.1021/ja00408a044; Albery W. J., 1978, ADV PHYS ORG CHEM, V16, P87; ARMSTRONG FA, 1978, J AM CHEM SOC, V100, P7710, DOI 10.1021/ja00492a045; ARMSTRONG FA, 1979, J AM CHEM SOC, V101, P6912, DOI 10.1021/ja00517a021; BLAKE RC, 1987, J BIOL CHEM, V262, P14983; BLAKE RC, 1990, BIOHYROMETALLURGY 19, P391; COBLEY JG, 1975, FEBS LETT, V60, P29, DOI 10.1016/0014-5793(75)80411-X; COX JC, 1978, BIOCHEM J, V174, P497, DOI 10.1042/bj1740497; COX JC, 1978, FEBS LETT, V93, P157, DOI 10.1016/0014-5793(78)80826-6; HODGES HL, 1974, J AM CHEM SOC, V96, P3132, DOI 10.1021/ja00817a019; HOLWERDA RA, 1976, ANNU REV BIOPHYS BIO, V5, P363, DOI 10.1146/annurev.bb.05.060176.002051; INGLEDEW WJ, 1982, BIOCHIM BIOPHYS ACTA, V683, P89, DOI 10.1016/0304-4173(82)90007-6; INGLEDEW WJ, 1977, FEMS MICROBIOL LETT, V2, P193; INGLEDEW WJ, 1980, BIOCHIM BIOPHYS ACTA, V590, P141, DOI 10.1016/0005-2728(80)90020-1; JOHNSON JM, 1983, ANAL BIOCHEM, V133, P186, DOI 10.1016/0003-2697(83)90241-5; LAPPIN AG, 1979, J AM CHEM SOC, V101, P2297, DOI 10.1021/ja00503a008; LAPPIN AG, 1985, INORG CHEM, V24, P1446, DOI 10.1021/ic00204a008; LEWIS CA, 1983, BIOCHEM SOC T, V12, P503; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MCANDREW RT, 1975, CIM BULL, V68, P101; MCARDLE JV, 1977, J AM CHEM SOC, V99, P2483, DOI 10.1021/ja00450a014; MCARDLE JV, 1974, J AM CHEM SOC, V96, P5737, DOI 10.1021/ja00825a009; MCGINNIS J, 1986, INORG CHEM, V25, P3730, DOI 10.1021/ic00241a004; OHNO N, 1981, BIOPHYS J, V36, P589, DOI 10.1016/S0006-3495(81)84754-6; RAWLINGS J, 1976, J AM CHEM SOC, V98, P2177, DOI 10.1021/ja00424a028; ROSENBERG RC, 1976, J AM CHEM SOC, V98, P6364, DOI 10.1021/ja00436a049; SCHILT AA, 1960, J AM CHEM SOC, V82, P3000, DOI 10.1021/ja01497a007; SISLEY MJ, 1983, J AM CHEM SOC, V105, P225, DOI 10.1021/ja00340a014; SUTIN N, 1961, J AM CHEM SOC, V83, P70, DOI 10.1021/ja01462a014; TUOVINEN OH, 1973, ARCH MIKROBIOL, V88, P285, DOI 10.1007/BF00409941; Wherland S., 1977, BIOL ASPECTS INORGAN, P289; YANDELL JK, 1973, J AM CHEM SOC, V95, P1131, DOI 10.1021/ja00785a022	33	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19203	19211						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918038				2022-12-25	WOS:A1991GK66700017
J	HASTINGS, KEM; KOPPE, RI; MARMOR, E; BADER, D; SHIMADA, Y; TOYOTA, N				HASTINGS, KEM; KOPPE, RI; MARMOR, E; BADER, D; SHIMADA, Y; TOYOTA, N			STRUCTURE AND DEVELOPMENTAL EXPRESSION OF TROPONIN-I ISOFORMS - CDNA CLONE ANALYSIS OF AVIAN CARDIAC TROPONIN-I MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DEPENDENT PROTEIN-KINASE; RABBIT SKELETAL-MUSCLE; BIOLOGICAL-ACTIVITY; TRANSCRIPTIONAL REGULATION; INHIBITORY SUBUNIT; CHICKEN EMBRYOS; SLOW SKELETAL; PHOSPHORYLATION; GENES	We isolated avian (chicken and quail) cardiac troponin I (TnIcardiac) cDNA clones for studies of TnIcardiac protein structure/evolution and developmental gene regulation. Comparison of the cDNA-predicted avian TnIcardiac amino acid sequences with known TnI sequences indicated 1) that the presence of an N-terminal extension sequence carrying a dual protein kinase A phosphorylation target site and an adjacent proline-rich segment is an ancient cardiac-specific feature of TnI which has been conserved since the bird/mammal divergence, 2) that features of the near-N-terminal troponin C (TnC)-binding site sequence suggest isoform-specific adaptation of TnI and TnC, and 3) that the avian TnIcardiac internal actin/TnC-binding, actomyosin-inhibitory, domain shows significant sequence divergence from mammalian TnIcardiac sequences, including the absence of a protein kinase C target site which is a cardiac-specific feature of Tnl in mammals. Use of the cDNA clones to probe TnIcardiac mRNA expression during striated muscle development showed active expression in cardiac muscle from early developmental times (day 4 in ovo), but not in embryonic or adult skeletal muscle or in embryonic skeletal muscle cell cultures. Transcriptional run-on analysis showed that the heart-specific expression of TnIcardiac mRNA in embryonic striated muscle reflects transcriptional control of TnIcardiac gene expression. In many other contractile protein gene families, genes encoding cardiac isoforms are expressed early in skeletal muscle development and are later repressed. Thus, the restriction of active TnIcardiac gene expression to the cardiac muscle cell lineage is an unusual expression pattern for cardiac contractile protein genes and indicates that diverse gene regulatory mechanisms direct the differential expression of cardiac and skeletal muscle isoforms in different muscle gene families.	MCGILL UNIV,MONTREAL NEUROL INST,DEPT BIOL,MONTREAL H3A 2B4,QUEBEC,CANADA; CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; CHIBA UNIV,SCH MED,DEPT ANAT & CELL BIOL,CHIBA,JAPAN	McGill University; Cornell University; Chiba University	HASTINGS, KEM (corresponding author), MCGILL UNIV,MONTREAL NEUROL INST,DEPT NEUROL NEUROSURG,MONTREAL H3A 2B4,QUEBEC,CANADA.							BAHLER M, 1985, DEV BIOL, V112, P345, DOI 10.1016/0012-1606(85)90405-1; BAINS W, 1984, MOL CELL BIOL, V4, P1449, DOI 10.1128/MCB.4.8.1449; BALDWIN AS, 1985, P NATL ACAD SCI USA, V82, P8080, DOI 10.1073/pnas.82.23.8080; BARTON PJR, 1985, J MUSCLE RES CELL M, V6, P461, DOI 10.1007/BF00712583; Battey, 1986, BASIC METHODS MOL BI; BUCHER EA, 1988, MOL CELL BIOL, V8, P4134, DOI 10.1128/MCB.8.10.4134; COLE HA, 1975, BIOCHEM J, V149, P525, DOI 10.1042/bj1490525; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EMERSON CP, 1987, ANNU REV BIOCHEM, V56, P695, DOI 10.1146/annurev.bi.56.070187.003403; ENGLAND PJ, 1976, BIOCHEM J, V160, P295, DOI 10.1042/bj1600295; ENGLAND PJ, 1977, BIOCHEM J, V168, P307, DOI 10.1042/bj1680307; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GELIEBTER J, 1987, FOCUS, V9, P5; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HALLAUER PL, 1984, THESIS U VIRGINIA; HASTINGS KEM, 1982, P NATL ACAD SCI USA, V79, P1552; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KOBAYASHI T, 1989, J BIOL CHEM, V264, P1551; KONIECZNY SF, 1985, MOL CELL BIOL, V5, P2423, DOI 10.1128/MCB.5.9.2423; Konigsberg I R, 1979, Methods Enzymol, V58, P511; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P2821, DOI 10.1021/bi00408a024; LONG CS, 1989, DEV BIOL, V127, P228; MAISONPIERRE PC, 1987, METHOD ENZYMOL, V139, P326; Maniatis T., 1982, MOL CLONING; MCCUBBIN WD, 1980, ACCOUNTS CHEM RES, V13, P185, DOI 10.1021/ar50150a004; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MOIR AJG, 1977, BIOCHEM J, V167, P333, DOI 10.1042/bj1670333; MULVIHILL ER, 1977, J BIOL CHEM, V252, P260; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; NOLAND TA, 1989, J BIOL CHEM, V264, P20778; ORDAHL CP, 1986, DEV BIOL, V117, P488, DOI 10.1016/0012-1606(86)90315-5; PATERSON BM, 1984, SCIENCE, V224, P1436, DOI 10.1126/science.6729461; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; RUBIO R, 1975, J CYCLIC NUCL PROT, V1, P143; SABRY MA, 1989, J MUSCLE RES CELL M, V10, P85, DOI 10.1007/BF01739858; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; SOLARO RJ, 1986, PROTEIN PHOSPHORYLAT, P129; Squire J, 1981, STRUCTURAL BASIS MUS; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; STULL JT, 1977, J BIOL CHEM, V252, P851; SWIDEREK K, 1988, EUR J BIOCHEM, V176, P335, DOI 10.1111/j.1432-1033.1988.tb14286.x; SYSKA H, 1976, BIOCHEM J, V153, P375, DOI 10.1042/bj1530375; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOYOTA N, 1981, J CELL BIOL, V91, P497, DOI 10.1083/jcb.91.2.497; TOYOTA N, 1983, CELL, V33, P297, DOI 10.1016/0092-8674(83)90358-6; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; WADE R, 1990, GENOMICS, V7, P346, DOI 10.1016/0888-7543(90)90168-T; WADE R, 1989, ANNU REV PHYSIOL, V51, P179, DOI 10.1146/annurev.physiol.51.1.179; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; WILKINSON JM, 1976, FEBS LETT, V70, P254, DOI 10.1016/0014-5793(76)80769-7; WILKINSON JM, 1980, EUR J BIOCHEM, V103, P179, DOI 10.1111/j.1432-1033.1980.tb04302.x; WILKINSON JM, 1972, BIOCHEM J, V127, P215, DOI 10.1042/bj1270215; YEAMAN SJ, 1977, BIOCHEM J, V162, P411, DOI 10.1042/bj1620411; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	65	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19659	19665						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918073				2022-12-25	WOS:A1991GK66700077
J	HIPSKIND, RA; NORDHEIM, A				HIPSKIND, RA; NORDHEIM, A			INVITRO TRANSCRIPTIONAL ANALYSIS OF THE HUMAN C-FOS PROTOONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; MAJOR LATE PROMOTER; MULTIPLE SEQUENCE ELEMENTS; SERUM STIMULATION; GROWTH-FACTOR; CYCLIC-AMP; PREINITIATION COMPLEX; MEDIATE INDUCTION; UPSTREAM ELEMENT; FACTOR ATF	The transcription of the human c-fos promoter was characterized in vitro using HeLa nuclear and whole cell extracts. The c-fos gene and c-fos promoter fusions to the SV40 early region and the G-free cassette were active as templates, yielding faithfully initiated transcripts that were sensitive to alpha-amanitin. c-fos-SV40 and -G-free cassette templates were less efficiently transcribed when linearized, suggesting that template topology affected fos activity in vitro. Transcription conditions were optimized for both extracts using a mixture of the fos wild type promoter, a deleted fos promoter retaining just the TATA box, and the adenovirus major late promoter, all driving differently sized G-free cassettes. The fos promoter was inactive at low protein and DNA concentrations, and then showed a sharp rise in efficiency with a subsequent 2-fold increase in the amount of either DNA or protein. In contrast, high protein or DNA concentrations were required for the deleted fos promoter to show only weak activity. Preincubation of templates with extracts shortened the lag time before transcription could be detected, but did not lead to increased activity. By comparing reactions in the presence and absence of Sarkosyl, we estimate that only a subset of fos-driven templates was active, and that these templates were used for several rounds of transcription.	HANOVER MED SCH,INST MOLEC BIOL,POSTFACH 610180,W-3000 HANNOVER 61,GERMANY	Hannover Medical School								BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; Bravo R, 1990, Semin Cancer Biol, V1, P37; BUSCHER M, 1988, ONCOGENE, V3, P301; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HARLAND R, 1983, NATURE, V301, P38; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1271; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; HIPSKIND RA, 1983, CELL, V34, P881, DOI 10.1016/0092-8674(83)90545-7; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUNKEL L, 1991, MOL CELL BIOL, V11, P1270, DOI 10.1128/MCB.11.3.1270; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHAW PE, 1989, NUCLEIC ACIDS MOL BI, V3, P120; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SPENCER CA, 1990, ONCOGENE, V5, P777; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x	55	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19572	19582						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918065				2022-12-25	WOS:A1991GK66700067
J	HOLZMAN, TF; KOHLBRENNER, WE; WEIGL, D; RITTENHOUSE, J; KEMPF, D; ERICKSON, J				HOLZMAN, TF; KOHLBRENNER, WE; WEIGL, D; RITTENHOUSE, J; KEMPF, D; ERICKSON, J			INHIBITOR STABILIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 PROTEINASE DIMER FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC HIV-1 PROTEASE; RETROVIRAL PROTEASES; CRYSTAL-STRUCTURE; DESIGN	We report the first direct observation of the subunit self-association behavior of highly purified recombinant human immunodeficiency virus type-2 (HIV-2) proteinase. Multiple samples of enzyme were subjected to sedimentation equilibrium analytical ultracentrifugation sequentially at 8.8-degrees-C and two PH values in the presence and absence of a C2 symmetric, peptidomimetic inhibitor. At both pH values the enzyme exhibited sedimentation equilibrium behavior which fit a monomer-dimer-tetramer model. In the absence of inhibitor, the apparent K(d) for dimer formation was less than approximately 100-mu-M and the apparent K(d) for the weaker dimer-tetramer association was greater than approximately 100-mu-M. In the presence of inhibitor, at either pH, dimer formation was more strongly favored as indicated by a approximately 5-14-fold decrease in the apparent K(d) for dimer formation and a approximately 1.2-4-fold increase in the apparent K(d) for tetramer formation. The enhanced formation of dimer and decrease in higher order self-associated forms in the presence of an inhibitor is consistent with inhibitor stabilization of an active dimer. The inhibitor-induced stabilization of the dimeric species is consistent with a model for substrate-induced formation of active proteinase dimers in virion assembly.	ABBOTT LABS,ANTIINFECT RES,ABBOTT PK,IL 60064; ABBOTT LABS,DIV PHARMACEUT PROD,PHARMACEUT DISCOVERY RES,NIH,ANTIVIRAL RES,ABBOTT PK,IL 60064	Abbott Laboratories; Abbott Laboratories; National Institutes of Health (NIH) - USA	HOLZMAN, TF (corresponding author), ABBOTT LABS,PROT BIOCHEM,DEPT 47Z DISCOVERY RES,BLDG AP-10-1,ABBOTT PK,IL 60064, USA.							BABE LM, 1991, BIOCHEMISTRY-US, V30, P106, DOI 10.1021/bi00215a016; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; CREPEAU RH, 1974, BIOCHEMISTRY-US, V13, P4860, DOI 10.1021/bi00720a027; EDELSTEI.SJ, 1970, J BIOL CHEM, V245, P4372; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; HOLZMAN TF, 1990, BIOPHYS J, V59, P378; KEMPF D, 1991, J ACQ IMMUN DEF SYND, V4, P354; KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0; RAO M, 1991, BIOCHEMISTRY-US, V30, P4663; RITTENHOUSE J, 1990, BIOCHEM BIOPH RES CO, V171, P60, DOI 10.1016/0006-291X(90)91356-W; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; TOH H, 1985, NATURE, V315, P691, DOI 10.1038/315691a0; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	21	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19217	19220						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918040				2022-12-25	WOS:A1991GK66700019
J	STOCCO, DM; SODEMAN, TC				STOCCO, DM; SODEMAN, TC			THE 30-KDA MITOCHONDRIAL PROTEINS INDUCED BY HORMONE STIMULATION IN MA-10 MOUSE LEYDIG TUMOR-CELLS ARE PROCESSED FROM LARGER PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; STEROIDOGENESIS-ACTIVATOR POLYPEPTIDE; INTRAMITOCHONDRIAL CHOLESTEROL TRANSFER; TRANSLOCATION CONTACT SITES; ADRENAL-CORTEX CELLS; ADRENOCORTICOTROPIC HORMONE; STEROID-SYNTHESIS; CORPUS-LUTEUM; RAPID ACCUMULATION; ACTH REGULATION	Acute regulation of steroidogenesis in steroidogenic tissue is controlled by the transfer of cholesterol from the outer to the inner mitochondrial membrane where cleavage to produce pregnenolone occurs. Hormonal stimulation of MA-10 mouse Leydig tumor cells results in a large increase in steroidogenesis and the concomitant appearance of a series of 30-kDa proteins which have been localized to the mitochondria. In the present study we have shown that the appearance of these proteins occurs in a dose-responsive manner with both human chorionic gonadotropin and cyclic AMP analog. We have also shown that while steroidogenesis is inhibited rapidly in response to a cessation of protein synthesis, the 30-kDa mitochondrial proteins remain in the mitochondria, posing a potential dilemma for arguments favoring their role in the acute regulation of steroidogenesis. We report that the 30-kDa mitochondrial proteins arise from two precursor proteins with molecular masses of 37 and 32 kDa which are also found to be associated with the mitochondria. The use of pulse-chase experiments and the inhibitors orthophenanthroline and carbonyl cyanide m-chlorophenylhydrazone demonstrated the precursor-product relationship between the 37-, 32-, and 30-kDa proteins. We have also demonstrated that, as shown for a number of other mitochondrial proteins, the 30-kDa proteins are transferred to the inner mitochondrial membrane by a process requiring both proteolytic removal of the targeting sequences and an electrical potential across the inner mitochondrial membrane. We propose that during this transfer contact sites form between the two mitochondrial membranes and may offer an ideal situation for the transfer of cholesterol from the outer membrane to the inner membrane by an as yet unknown mechanism. Following transfer, the 30-kDa proteins remain in the inner membrane no longer able to function in the further transfer of cholesterol, and it is the continuing synthesis and processing of more precursor proteins which provides additional substrate for steroidogenesis.			STOCCO, DM (corresponding author), TEXAS TECH UNIV, HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, LUBBOCK, TX 79430 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017481, K04HD000685, R01HD017481] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 03948] Funding Source: Medline; NICHD NIH HHS [HD 00685, HD 17481] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADES IZ, 1980, J BIOL CHEM, V255, P9925; ALBERTA JA, 1989, J BIOL CHEM, V264, P2368; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRDICZKA D, 1990, BIOCHIM BIOPHYS ACTA, V1018, P234, DOI 10.1016/0005-2728(90)90256-4; CHURCHILL PF, 1979, J BIOL CHEM, V254, P443; COOKE BA, 1975, BIOCHEM J, V150, P413, DOI 10.1042/bj1500413; CRIVELLO JF, 1980, J BIOL CHEM, V255, P8144; EPSTEIN LF, 1989, ENDOCR RES, V15, P117, DOI 10.1080/07435808909039092; FRUSTACI J, 1989, MOL CELL ENDOCRINOL, V64, P137, DOI 10.1016/0303-7207(89)90139-1; FUGLER L, 1985, J BIOL CHEM, V260, P4098; Garren L D, 1971, Recent Prog Horm Res, V27, P433; GARREN LD, 1965, P NATL ACAD SCI USA, V53, P1443, DOI 10.1073/pnas.53.6.1443; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; HALL PF, 1979, J BIOL CHEM, V254, P9080; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HAY R, 1984, BIOCHIM BIOPHYS ACTA, V779, P65, DOI 10.1016/0304-4157(84)90004-2; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; IIDA S, 1989, ENDOCRINOLOGY, V124, P2619, DOI 10.1210/endo-124-5-2619; JAUSSI R, 1982, J BIOL CHEM, V257, P13334; JEFCOATE CR, 1986, ENDOCR RES, V12, P315, DOI 10.3109/07435808609035444; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; KARABOYAS GC, 1965, BIOCHEMISTRY-US, V4, P462, DOI 10.1021/bi00879a014; KOWLURU RA, 1984, FED PROC, V43, P1474; KRUEGER RJ, 1983, J BIOL CHEM, V258, P159; KRUEGER RJ, 1988, ENDOCRINOLOGY, V122, P1869, DOI 10.1210/endo-122-5-1869; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENDELSON C, 1975, BIOCHIM BIOPHYS ACTA, V411, P222, DOI 10.1016/0304-4165(75)90302-5; MERTZ LM, 1989, J BIOL CHEM, V264, P15274; MOGER WH, 1991, ENDOCRINOLOGY, V128, P1414, DOI 10.1210/endo-128-3-1414; NAKAGAWA Y, 1979, BIOCHIM BIOPHYS ACTA, V553, P307, DOI 10.1016/0005-2736(79)90234-7; NEHER R, 1982, P NATL ACAD SCI-BIOL, V79, P1727, DOI 10.1073/pnas.79.6.1727; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHASHI A, 1982, J BIOL CHEM, V257, P3042; PAPADOPOULOS V, 1991, J BIOL CHEM, V266, P3682; PEDERSEN RC, 1987, SCIENCE, V236, P188, DOI 10.1126/science.3563495; PEDERSEN RC, 1983, P NATL ACAD SCI-BIOL, V80, P1882, DOI 10.1073/pnas.80.7.1882; PFANNER N, 1990, BIOCHIM BIOPHYS ACTA, V1018, P239, DOI 10.1016/0005-2728(90)90257-5; PON L, 1989, J CELL BIOL, V109, P2603, DOI 10.1083/jcb.109.6.2603; PON LA, 1988, ENDOCRINOLOGY, V123, P1942, DOI 10.1210/endo-123-4-1942; PON LA, 1986, J BIOL CHEM, V261, P3309; PON LA, 1986, ENDOCR RES, V12, P429, DOI 10.3109/07435808609035449; PON LA, 1986, J BIOL CHEM, V261, P6594; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; PRIVALLE CT, 1987, MOL CELL ENDOCRINOL, V53, P87, DOI 10.1016/0303-7207(87)90195-X; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; REID GA, 1982, J BIOL CHEM, V257, P3062; REID GA, 1982, J BIOL CHEM, V257, P3068; RESKO JA, 1974, ENDOCRINOLOGY, V94, P128, DOI 10.1210/endo-94-1-128; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SEYBERT DW, 1979, J BIOL CHEM, V254, P2088; SIMPSON ER, 1979, MOL CELL ENDOCRINOL, V13, P213, DOI 10.1016/0303-7207(79)90082-0; STOCCO DM, 1991, ENDOCRINOLOGY, V128, P1918, DOI 10.1210/endo-128-4-1918; STOCCO DM, 1988, BIOCHEM J, V249, P95, DOI 10.1042/bj2490095; STOCCO DM, 1990, CELL SIGNAL, V2, P161, DOI 10.1016/0898-6568(90)90019-7; STONE D, 1954, ARCH BIOCHEM BIOPHYS, V51, P457, DOI 10.1016/0003-9861(54)90501-9; TEINTZE M, 1982, J BIOL CHEM, V257, P364; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; WARNE PA, 1983, P NATL ACAD SCI-BIOL, V80, P1877, DOI 10.1073/pnas.80.7.1877; YAGO N, 1969, J BIOCHEM-TOKYO, V65, P215; YANAGIBASHI K, 1988, ENDOCRINOLOGY, V123, P2075, DOI 10.1210/endo-123-4-2075	62	230	233	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19731	19738						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918079				2022-12-25	WOS:A1991GK66700087
J	TOOMEY, JR; SMITH, KJ; STAFFORD, DW				TOOMEY, JR; SMITH, KJ; STAFFORD, DW			LOCALIZATION OF THE HUMAN TISSUE FACTOR RECOGNITION DETERMINANT OF HUMAN FACTOR-VIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; HUMAN FACTOR-IX; FACTOR-X; MONOCLONAL-ANTIBODIES; BLOOD-COAGULATION; EXPRESSION; DNA; MUTAGENESIS; ACTIVATION; PROTEINS	Tissue factor is an integral membrane glycoprotein that serves as an essential cofactor for the blood coagulation factor VIIa. Recent studies have attempted to localize the tissue factor recognition determinant of human factor VIIa. While several regions of factor VIIa have been implicated as important for tissue factor binding, the high affinity tissue factor recognition determinant of human factor VIIa is unknown. In order to define the determinant, we constructed a set of six chimeric proteins composed of portions of factor VII and factor IX. We then utilized the chimeras in competition experiments with I-125-labeled factor VIIa for recombinant tissue factor bound to an Immobilon-P membrane. The data indicate that the high affinity tissue factor recognition determinant of human factor VIIa is within the epidermal growth factor domains.	UNIV N CAROLINA,DEPT BIOL,442 WILSON HALL,CHAPEL HILL,NC 27599; UNIV NEW MEXICO,SCH MED,DEPT MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599; UNITED BLOOD SERV,ALBUQUERQUE,NM 87131	University of North Carolina; University of North Carolina Chapel Hill; University of New Mexico; University of New Mexico; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038973] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06350-29, R01 HL38973-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BROZE GJ, 1980, J BIOL CHEM, V255, P1242; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; FAIR DS, 1987, J BIOL CHEM, V262, P11692; FRAZIER D, 1989, BLOOD, V74, P971; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUWADA M, 1981, ANAL BIOCHEM, V117, P259, DOI 10.1016/0003-2697(81)90720-X; LIN SW, 1990, J BIOL CHEM, V265, P144; LIN SW, 1987, BIOCHEMISTRY-US, V26, P5267, DOI 10.1021/bi00391a009; LITTLE JW, 1984, GENE, V32, P67, DOI 10.1016/0378-1119(84)90033-7; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; RUF W, 1991, J BIOL CHEM, V266, P15719; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SMITH KJ, 1984, THROMB RES, V33, P211, DOI 10.1016/0049-3848(84)90182-8; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290	25	92	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19198	19202						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918037				2022-12-25	WOS:A1991GK66700016
J	GAIDO, ML; CIDLOWSKI, JA				GAIDO, ML; CIDLOWSKI, JA			IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF A CALCIUM-DEPENDENT ENDONUCLEASE (NUC18) FROM APOPTOTIC RAT THYMOCYTES - NUC18 IS NOT HISTONE H2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; DEOXYRIBONUCLEIC-ACID; MICROGRAM QUANTITIES; PROTEIN-DEGRADATION; THYMIC LYMPHOCYTES; GLUCOCORTICOIDS; ACTIVATION; NUCLEASE; CLEAVAGE; MICE	Glucocorticoids stimulate apoptosis in rat thymocytes that is characterized by internucleosomal DNA degradation. We have previously identified an 18-kDa calcium-dependent nuclease whose activity is associated with this DNA degradation. The existence of this nuclease has been challenged by Alnemri and Litwack (1989) J. Biol. Chem. 264, 4104-4111, who suggest that the nuclease we observed was histone H2B. We report here a modified nuclease assay which uses [P-32] DNA as a substrate that has enabled the purification and characterization of the 18-kDa nuclease (NUC18). Using Bio-Rex 70 chromatography in conjunction with this assay, we show that NUC18 can be separated from histone H2B. Enzymatically active NUC18, purified to apparent homogeneity, failed to react with two different anti-histone H2B antibodies. NUC18 was inactive in the absence of calcium and known inhibitors of apoptosis, i.e. zinc and aurintricarboxylic acid inhibit its activity. Although NUC18 activity was detected in nuclear extracts of thymocytes of both control and glucocorticoid-treated thymocytes, these activities were distinct. Gel filtration analysis revealed that NUC18 was present as a high molecular weight complex (> 100 kDa) in both groups of cells, whereas it also existed as a low molecular weight form in glucocorticoid-treated cells. Thus, NUC18 remains a candidate for the endonuclease responsible for the DNA degradation component of the apoptotic process.	UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC RES CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill			Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NICHD NIH HHS [5T32-HDO-7315] Funding Source: Medline; NIDDK NIH HHS [DK 32078] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032078] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALNEMRI ES, 1989, J BIOL CHEM, V264, P4104; ALNEMRI ES, 1990, J BIOL CHEM, V265, P17323; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BAXTER GD, 1989, BIOCHEM BIOPH RES CO, V162, P30, DOI 10.1016/0006-291X(89)91957-8; BELL PA, 1975, J STEORID BIOCH, V7, P1147; BOURGEOIS S, 1978, CANCER RES, V28, P4279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CIDLOWSKI JA, 1982, ENDOCRINOLOGY, V111, P184, DOI 10.1210/endo-111-1-184; COHEN JJ, 1984, J IMMUNOL, V132, P38; COMPTON MM, 1986, ENDOCRINOLOGY, V118, P38, DOI 10.1210/endo-118-1-38; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; COMPTON MM, 1987, J STEROID BIOCHEM, V27, P201, DOI 10.1016/0022-4731(87)90311-6; COMPTON MM, 1988, ENDOCRINOLOGY, V122, P2158, DOI 10.1210/endo-122-5-2158; DEPASQUALEJARDIEU P, 1980, J IMMUNOL, V124, P2650; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FRAKER PJ, 1978, P NATL ACAD SCI USA, V75, P5660, DOI 10.1073/pnas.75.11.5660; HALLICK RB, 1977, NUCLEIC ACIDS RES, V4, P3055, DOI 10.1093/nar/4.9.3055; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; Kerr J.F.R., 1987, P93; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD RG, 1980, ENDOCRINOLOGY, V107, P1512, DOI 10.1210/endo-107-5-1512; MACDONALD RG, 1982, BIOCHIM BIOPHYS ACTA, V717, P236, DOI 10.1016/0304-4165(82)90175-1; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MCKONKEY DJ, 1989, FASEB J, V3, P1843; MORITA Y, 1964, BIOCHIM BIOPHYS ACTA, V93, P150, DOI 10.1016/0304-4165(64)90269-7; MUNCK A, 1981, CELL DEATH BIOL PATH, P329; NIKONOVA L V, 1989, Biokhimiya, V54, P1709; NORDEEN SK, 1976, J BIOL CHEM, V251, P7295; RODRIGUEZTARDUCHY G, 1989, BIOCHEM BIOPH RES CO, V164, P1069, DOI 10.1016/0006-291X(89)91778-6; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; ROSENTHAL AL, 1978, J BIOL CHEM, V253, P8674; UMANSKY SR, 1981, BIOCHIM BIOPHYS ACTA, V655, P9, DOI 10.1016/0005-2787(81)90060-5; UMANSKY SR, 1982, J THEOR BIOL, V97, P591, DOI 10.1016/0022-5193(82)90360-5; VANDENBOGERT C, 1989, J STEROID BIOCHEM, V33, P955, DOI 10.1016/0022-4731(89)90246-X; VANDENBROEK HW, 1973, BIOCHEMISTRY-US, V12, P229, DOI 10.1021/bi00726a009; VANDERBILT JN, 1982, J BIOL CHEM, V257, P3009; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Wyllie A.H., 1981, CELL DEATH BIOL PATH, P9; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1987, J PATHOL, V153, P313, DOI 10.1002/path.1711530404; WYLLIE AH, 1986, COORDINATED REGULATI, P33; [No title captured]	47	321	327	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18580	18585						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917979				2022-12-25	WOS:A1991GJ47200030
J	HAMANN, U; WENZEL, A; FRANK, R; SCHWAB, M				HAMANN, U; WENZEL, A; FRANK, R; SCHWAB, M			THE MYCN PROTEIN OF HUMAN NEUROBLASTOMA-CELLS IS PHOSPHORYLATED BY CASEIN KINASE-II IN THE CENTRAL REGION AND AT SERINE 367	ONCOGENE			English	Article							SV40 LARGE-T; RETINOBLASTOMA SUSCEPTIBILITY GENE; EPIDERMAL GROWTH-FACTOR; BALB/C 3T3 FIBROBLASTS; AMINO-ACID-SEQUENCE; HUMAN C-MYC; N-MYC; DNA-BINDING; ADENOVIRUS E1A; NUCLEAR-LOCALIZATION	The MYCN gene has been implicated in certain neuronal tumours, such as neuroblastomas and retinoblastomas. These tumours express high levels of mRNA and protein of MYCN as a result of amplification. MYCN encodes a short-lived nuclear phosphoprotein whose function has not yet been elucidated. This study was undertaken to determine the pattern of MYCN protein (pMYCN) phosphorylation in human neuroblastoma cells. We report that pMYCN is phosphorylated in vitro by purified casein kinase II (CK-II). Two-dimensional phosphopeptide maps showed that most of the phosphopeptides of pMYCN phosphorylated in vitro by CK-II correspond to those phosphorylated in vivo. Fine mapping of the phosphorylation sites was performed using two synthetic MYCN peptides corresponding to pMYCN CK-II consensus sequences. Both peptides were found to be phosphorylated by CK-II and competitively inhibited CK-II phosphorylation of pMYCN in vitro. Thus, we have localized two major CK-II phosphorylation sites in pMYCN, one to the highly acidic central region and the second to serine 367 proximal to the C-terminus. Our data demonstrate that pMYCN is a physiological substrate for CK-II and, since CK-II activity is stimulated in response to mitogens, CK-II phosphorylation of pMYCN may, therefore, represent one signal transduction pathway used by neuroblastoma cells.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	HAMANN, U (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,INST EXPTL PATHOL,W-6900 HEIDELBERG,GERMANY.							ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BISTER K, 1987, ONCOGENE, V1, P97; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CARROLL D, 1988, COLD SPRING HARB SYM, V53, P91, DOI 10.1101/SQB.1988.053.01.014; CAVALIERI F, 1988, ONCOGENE, V2, P289; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; FIGGE J, 1988, NATURE, V334, P109, DOI 10.1038/334109a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FIRZLAFF J M, 1989, New Biologist, V1, P44; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; INGVARSSON S, 1988, MOL CELL BIOL, V8, P3168, DOI 10.1128/MCB.8.8.3168; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KREBS EG, 1987, ANN REV BIOCH, V56, P567; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MA A, 1989, GROWTH REGULATION CA, V2, P17; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINNA LA, 1979, BIOCHEM BIOPH RES CO, V87, P114, DOI 10.1016/0006-291X(79)91654-1; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SPECTOR DL, 1987, ONCOGENE, V1, P5; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; WALTON GM, 1983, J BIOL CHEM, V258, P4440; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	66	23	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1745	1751						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923500				2022-12-25	WOS:A1991GX11800004
J	FORREST, D; MUNOZ, A; RAYNOSCHEK, C; VENNSTROM, B; BEUG, H				FORREST, D; MUNOZ, A; RAYNOSCHEK, C; VENNSTROM, B; BEUG, H			REQUIREMENT FOR THE C-TERMINAL DOMAIN OF THE V-ERBA ONCOGENE PROTEIN FOR BIOLOGICAL FUNCTION AND TRANSCRIPTIONAL REPRESSION	ONCOGENE			English	Article									KAROLINSKA INST,CTR MOLEC BIOL,DEPT MOLEC BIOL,S-10401 STOCKHOLM 60,SWEDEN; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; UNIV AUTONOMA MADRID,FAC MED,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Karolinska Institutet; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Autonomous University of Madrid			Munoz, Alberto/O-6393-2014	Munoz, Alberto/0000-0003-3890-4251				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BENTZEN D, 1987, MOL CELL BIOL, V7, P2416; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1981, VIROLOGY, V111, P201, DOI 10.1016/0042-6822(81)90665-6; BEUG H, 1980, P NATL ACAD SCI-BIOL, V77, P6683, DOI 10.1073/pnas.77.11.6683; BEUG H, 1985, MODERN TRENDS HUMAN, V6, P290; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FREAKE HC, 1988, MOL ENDOCRINOL, V2, P986, DOI 10.1210/mend-2-10-986; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOROWITZ ZD, 1989, MOL ENDOCRINOL, V3, P148, DOI 10.1210/mend-3-1-148; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KAHN P, 1986, 12 S COMP RES LEUK R; KIM HRC, 1988, MOL CELL BIOL, V8, P4416, DOI 10.1128/MCB.8.10.4416; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; Oppenheimer J. H., 1983, MOL BASIS THYROID HO; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VENNSTROM B, 1980, J VIROL, V36, P575; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	49	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					309	316						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1969136				2022-12-25	WOS:A1990CW41500008
J	MORRIS, SA; MANN, A; UNGEWICKELL, E				MORRIS, SA; MANN, A; UNGEWICKELL, E			ANALYSIS OF 100-180-KDA PHOSPHOPROTEINS IN CLATHRIN-COATED VESICLES FROM BOVINE BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY	Max Planck Society				Morris, Stephen/0000-0002-7640-8657				AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BARZVI D, 1988, J BIOL CHEM, V263, P4408; BRETSCHER A, 1978, FEBS LETT, V85, P145, DOI 10.1016/0014-5793(78)81267-8; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; HEUSER J, 1989, J CELL BIOL, V109, P1457, DOI 10.1083/jcb.109.4.1457; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEB JE, 1989, EUR J BIOCHEM, V182, P195, DOI 10.1111/j.1432-1033.1989.tb14817.x; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; PAULOIN A, 1986, J BIOL CHEM, V261, P2568; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; UNGEWICKELL E, 1989, ANAL BIOCHEM, V179, P352, DOI 10.1016/0003-2697(89)90143-7; VIRSHUP DM, 1988, J CELL BIOL, V106, P39, DOI 10.1083/jcb.106.1.39	26	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1990	265	6					3354	3357						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CP236	1968063				2022-12-25	WOS:A1990CP23600056
J	BURNSIDE, J; DARLING, DS; CHIN, WW				BURNSIDE, J; DARLING, DS; CHIN, WW			A NUCLEAR FACTOR THAT ENHANCES BINDING OF THYROID-HORMONE RECEPTORS TO THYROID-HORMONE RESPONSE ELEMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,DEPT MED,DIV GENET,20 SHATTUCK ST,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute			Darling, Douglas S/D-4573-2009	Darling, Douglas/0000-0002-9039-1169				APRILETTI JW, 1984, J BIOL CHEM, V259, P941; BRENT GA, 1989, J BIOL CHEM, V264, P178; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS DP, 1989, MOL ENDOCRINOL, V3, P381, DOI 10.1210/mend-3-2-381; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLUG F, 1987, J BIOL CHEM, V262, P6373; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; ICHIKAWA K, 1986, J BIOL CHEM, V261, P6540; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; LARSEN PR, 1986, J BIOL CHEM, V261, P4373; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P479, DOI 10.1210/mend-2-6-479; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WRIGHT PA, 1987, J BIOL CHEM, V262, P5659	27	188	188	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1990	265	5					2500	2504						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CM848	1968058				2022-12-25	WOS:A1990CM84800019
J	BRUSKIN, A; JACKSON, J; BISHOP, JM; MCCARLEY, DJ; SCHATZMAN, RC				BRUSKIN, A; JACKSON, J; BISHOP, JM; MCCARLEY, DJ; SCHATZMAN, RC			6 AMINO-ACIDS FROM THE RETROVIRAL GENE GAG GREATLY ENHANCE THE TRANSFORMING POTENTIAL OF THE ONCOGENE V-ERB-B	ONCOGENE			English	Article									SYNTEX INC,53-1,3401 HILLVIEW AVE,PALO ALTO,CA 94304; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143	Syntex Corporation; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R35CA044338, R01CA012705] Funding Source: NIH RePORTER; NCI NIH HHS [CA12705, CA44338] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; ANDERSON SM, 1980, J VIROL, V36, P676, DOI 10.1128/JVI.36.3.676-683.1980; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BASSIRI M, 1986, J VIROL, V58, P525; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BISHOP JM, 1985, RNA TUMOR VIRUSES S, V2, P249; BISTER K, 1980, P NATL ACAD SCI-BIOL, V77, P7142, DOI 10.1073/pnas.77.12.7142; BISTER K, 1979, P NATL ACAD SCI USA, V76, P5023, DOI 10.1073/pnas.76.10.5023; BROWN AMC, 1987, DNA CLONING, V3, P189; DAVIS AR, 1981, P NATL ACAD SCI-BIOL, V78, P5376, DOI 10.1073/pnas.78.9.5376; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; EDMONDS M, 1971, P NATL ACAD SCI USA, V68, P1336, DOI 10.1073/pnas.68.6.1336; FREEMAN AE, 1973, P NATL ACAD SCI USA, V70, P2415, DOI 10.1073/pnas.70.8.2415; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GAZIT A, 1986, J VIROL, V60, P19, DOI 10.1128/JVI.60.1.19-28.1986; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; GRAF T, 1976, VIROLOGY, V71, P423, DOI 10.1016/0042-6822(76)90370-6; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HAYMAN MJ, 1979, VIROLOGY, V92, P31, DOI 10.1016/0042-6822(79)90212-5; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HENRY C, 1985, VIROLOGY, V140, P179, DOI 10.1016/0042-6822(85)90457-X; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; HU SSF, 1978, VIROLOGY, V89, P162, DOI 10.1016/0042-6822(78)90049-1; ISHIZAKI R, 1979, CANCER RES, V30, P2827; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; KLINKEN SP, 1988, ONCOGENE RES, V3, P187; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAI MMC, 1980, VIROLOGY, V100, P475, DOI 10.1016/0042-6822(80)90537-1; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MANIATIS T, 1982, MOL CLONING LABORATO, P157; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MAXIM AM, 1977, P NATL ACAD SCI USA, V74, P560; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PAWSON T, 1980, J VIROL, V34, P280, DOI 10.1128/JVI.34.1.280-284.1980; PIERCE JH, 1986, CURR TOP MICROBIOL, V132, P55; PRIVALSKY ML, 1982, P NATL ACAD SCI-BIOL, V79, P3958, DOI 10.1073/pnas.79.13.3958; PRIVALSKY ML, 1984, P NATL ACAD SCI-BIOL, V81, P704, DOI 10.1073/pnas.81.3.704; PRIVALSKY ML, 1983, CELL, V32, P1257, DOI 10.1016/0092-8674(83)90307-0; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; RETTENMIER CW, 1979, J VIROL, V32, P749, DOI 10.1128/JVI.32.3.749-761.1979; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHATZMAN RC, 1986, MOL CELL BIOL, V6, P1329, DOI 10.1128/MCB.6.4.1329; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; SEALY L, 1983, VIROLOGY, V130, P179, DOI 10.1016/0042-6822(83)90126-5; SHEINESS D, 1981, CELL, V23, P291, DOI 10.1016/0092-8674(81)90293-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VENNSTROM B, 1980, J VIROL, V36, P575; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WELLS A, 1988, P NATL ACAD SCI USA, V85, P7597, DOI 10.1073/pnas.85.20.7597; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X	61	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					15	24						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	1969616				2022-12-25	WOS:A1990CM62000003
J	TRIGATTI, BL; MANGROO, D; GERBER, GE				TRIGATTI, BL; MANGROO, D; GERBER, GE			PHOTOAFFINITY-LABELING AND FATTY-ACID PERMEATION IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANES; LIPID-BINDING PROTEIN; ADIPOSE CONVERSION; RAT-LIVER; MESSENGER-RNA; CELL LINE; DIFFERENTIATION; MECHANISM; TRANSPORT; INDUCTION	Long chain fatty acid uptake was investigated in 3T3-L1 cells. Differentiation of these cells from fibroblasts to adipocytes was accompanied by an 8.5-fold increase in the rate of oleate uptake. This was saturable in adipocytes with apparent K(t) and V(max) values of 78 nM and 16 nmol/min/mg cell protein, respectively. A number of proteins in various subcellular fractions of differentiated cells were labeled with the photoreactive fatty acid 11-m-diazirinophenoxy[11-H-3]undecanoate. A 15-kDa cytoplasmic protein was induced upon differentiation to adipocytes. This protein was labeled with the photoreactive fatty acid in cytoplasm isolated from differentiated adipocytes, but not in cytoplasm from undifferentiated, fibroblastic cells. Furthermore. a high affinity fatty acid binding protein of 22 kDa was identified in plasma membranes of undifferentiated cells, and its level of labeling increased 2-fold upon differentiation. These results indicate the usefulness of the photoreactive fatty acid in identifying cellular fatty acid binding proteins, and its potential to elucidate the spatial and temporal distribution of fatty acids in intact cells.	MCMASTER UNIV,DEPT BIOCHEM,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University				Trigatti, Bernardo (Dino) L./0000-0002-4556-119X				ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; ANGUS CW, 1981, BIOCHEM BIOPH RES CO, V103, P1216, DOI 10.1016/0006-291X(81)90252-7; APPELMANS F, 1955, BIOCHEM J, V59, P438, DOI 10.1042/bj0590438; BAILEY H, 1983, PHOTOGENERATED REAGE, P1; BERK PD, 1990, P NATL ACAD SCI USA, V87, P3484, DOI 10.1073/pnas.87.9.3484; CAPONE J, 1983, J BIOL CHEM, V258, P1395; COOPER RB, 1989, J LIPID RES, V30, P1719; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRERMAN FE, 1983, J BIOL CHEM, V258, P7087; GLOTZ JFC, 1983, ANAL BIOCHEM, V132, P89; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; HU CWC, 1983, J BIOL CHEM, V258, P2315; KASTURI R, 1983, J BIOL CHEM, V258, P3559; KAWAMURA M, 1981, P NATL ACAD SCI-BIOL, V78, P732, DOI 10.1073/pnas.78.2.732; KURIHARCUCH W, 1977, J BIOL CHEM, V252, P2158; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE K, 1990, FEBS LETT, V261, P459, DOI 10.1016/0014-5793(90)80615-P; LEBLANC P, 1982, J BIOL CHEM, V257, P4586; LEBLANC P, 1983, CAN J BIOCHEM CELL B, V62, P375; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; MATARESE V, 1988, J BIOL CHEM, V263, P14544; NOY N, 1985, BIOCHEMISTRY-US, V24, P3521, DOI 10.1021/bi00335a020; Paulussen R J, 1990, Subcell Biochem, V16, P175; PEDERSEN AO, 1990, EUR J BIOCHEM, V190, P497, DOI 10.1111/j.1432-1033.1990.tb15601.x; PEETERS RA, 1989, BIOCHIM BIOPHYS ACTA, V1002, P8, DOI 10.1016/0005-2760(89)90057-X; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; POTTER BJ, 1987, BIOCHEM BIOPH RES CO, V148, P1370, DOI 10.1016/S0006-291X(87)80283-8; RECORD M, 1982, BIOCHIM BIOPHYS ACTA, V688, P57, DOI 10.1016/0005-2736(82)90578-8; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SCHWIETERMAN W, 1988, P NATL ACAD SCI USA, V85, P359, DOI 10.1073/pnas.85.2.359; SPECTOR AA, 1969, J LIPID RES, V10, P56; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SPIEGELMAN BM, 1980, J BIOL CHEM, V255, P8811; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STRALFORS P, 1990, FEBS LETT, V263, P153, DOI 10.1016/0014-5793(90)80726-Y; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3086, DOI 10.1073/pnas.83.10.3086; STREMMEL W, 1985, J CLIN INVEST, V75, P1068, DOI 10.1172/JCI111769; STREMMEL W, 1988, J CLIN INVEST, V81, P844, DOI 10.1172/JCI113393; STREMMEL W, 1986, P NATL ACAD SCI USA, V83, P3584, DOI 10.1073/pnas.83.11.3584; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604; WAGGONER DW, 1990, J BIOL CHEM, V265, P11417	48	90	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22621	22625						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939275				2022-12-25	WOS:A1991GR56400086
J	ANAND, NN; MANDAL, S; MACKENZIE, CR; SADOWSKA, J; SIGURSKJOLD, B; YOUNG, NM; BUNDLE, DR; NARANG, SA				ANAND, NN; MANDAL, S; MACKENZIE, CR; SADOWSKA, J; SIGURSKJOLD, B; YOUNG, NM; BUNDLE, DR; NARANG, SA			BACTERIAL EXPRESSION AND SECRETION OF VARIOUS SINGLE-CHAIN FV GENES ENCODING PROTEINS SPECIFIC FOR A SALMONELLA SEROTYPE-B O-ANTIGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE IMMUNOGLOBULIN LIGHT; ESCHERICHIA-COLI; BINDING-PROTEINS; ANTIBODY; CELLS; FRAGMENTS; MUTATIONS	Active single-chain Fv molecules encoded by synthetic genes have been expressed and secreted to the periplasm of Escherichia coli using the ompA secretory signal. Four different constructs were developed to investigate the effects of peptide linker design and V(L)-V(H) orientation on expression, secretion, and binding to a Salmonella O-polysaccharide antigen. Peptide linker sequences derived from the elbow regions of the Fab molecule were used alone or in combination with the flexible (GGGGS), sequence. V(L) and V(H) domain order in the single chain molecules had a profound effect on the level of secretion but hardly influenced total expression levels, which were approximately 50 mg/liter, chiefly in the form of inclusion bodies. With V(L) in the NH2-terminal position, the amount of secreted product obtained was 2.4 mg/liter, but when V(H) occupied this position the yield was less than 5% of this value. Enzyme immunoassays of the four products showed domain order and linker sequence affected antigen binding by less than an order of magnitude. Attempts to express active Fv from dicistronic DNA were unsuccessful, but active Fv was obtained from single-chain Fv by enzymic cleavage at a site in the elbow linker peptide. The thermodynamic binding parameters of intact and cleaved single-chain Fvs determined by titration microcalorimetry were similar to those of bacterially produced Fab and mouse IgG.	NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA K1A 0R6,ONTARIO,CANADA	National Research Council Canada								ANAND NN, 1991, GENE, V100, P39, DOI 10.1016/0378-1119(91)90347-E; ANAND NN, 1990, PROTEIN ENG, V3, P541, DOI 10.1093/protein/3.6.541; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P1066, DOI 10.1073/pnas.87.3.1066; COLCHER D, 1990, JNCI-J NATL CANCER I, V82, P1191, DOI 10.1093/jnci/82.14.1191; CONDRA JH, 1990, J BIOL CHEM, V265, P2292; DAVIS GT, 1991, BIO-TECHNOL, V9, P165, DOI 10.1038/nbt0291-165; DUFFAUD GD, 1987, METHOD ENZYMOL, V153, P492; FIELD H, 1990, PROTEIN ENG, V3, P641, DOI 10.1093/protein/3.7.641; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEMANS R, 1908, GENE AMST, V85, P99; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MEIKLE PJ, 1990, J IMMUNOL METHODS, V132, P255, DOI 10.1016/0022-1759(90)90037-V; MILSTEIN C, 1976, COLD SPRING HARB SYM, V41, P793, DOI 10.1101/SQB.1977.041.01.090; MORENO F, 1980, NATURE, V308, P356; MORRISON SL, 1979, EUR J IMMUNOL, V9, P461, DOI 10.1002/eji.1830090609; MORRISON SL, 1975, J IMMUNOL, V114, P655; MOSMANN TR, 1980, CELL, V20, P283, DOI 10.1016/0092-8674(80)90614-5; NOVOTNY J, 1990, PROTEINS, V7, P93, DOI 10.1002/prot.340070109; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SIDEN EJ, 1979, CELL, V16, P389, DOI 10.1016/0092-8674(79)90014-X; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SONNENSHEIN GE, 1978, J EXP MED, V148, P301; VORBERG E, 1990, J IMMUNOL METHODS, V132, P81, DOI 10.1016/0022-1759(90)90401-G; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	32	68	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21874	21879						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939211				2022-12-25	WOS:A1991GP80400083
J	HISANAGA, S; KUSUBATA, M; OKUMURA, E; KISHIMOTO, T				HISANAGA, S; KUSUBATA, M; OKUMURA, E; KISHIMOTO, T			PHOSPHORYLATION OF NEUROFILAMENT H SUBUNIT AT THE TAIL DOMAIN BY CDC2 KINASE DISSOCIATES THE ASSOCIATION TO MICROTUBULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RABBIT SKELETAL-MUSCLE; NF-H; MAMMALIAN NEUROFILAMENTS; INTERMEDIATE FILAMENTS; AXONAL-TRANSPORT; PROMOTING FACTOR; QUICK-FREEZE; SITES; RAT	We sought the mammalian neurofilament tail domain-specific kinase. Several well known kinases including cAMP-dependent protein kinase, protein kinase C, Ca2+-calmodulin-dependent protein kinase II, casein kinase I, and casein kinase II phosphorylated the high (NF-H) and middle molecular mass subunit (NF-M) of bovine neurofilaments, but they did not reduced the electrophoretic mobility of the dephosphorylated form of NF-M and NF-H by phosphorylation nor was the amount of phosphorylation increased by dephosphorylation of NF proteins, indicating that the phosphorylation sites by these kinases are not major in vivo phosphorylation sites at the tail domain. In contrast, cdc2 kinase phosphorylated specifically the, dephosphorylated form of NF-H. 4 mol of phosphates were incorporated per mol of NF-H and this phosphorylation returned the electrophoretic mobility of the dephosphorylated form of NF-H to the position of the isolated, fully phosphorylated form of NF-H. Furthermore, the phosphorylation by cdc2 kinase dissociated the binding of dephosphorylated NF-H to microtubules. Phosphorylation sites were located at the carboxyl-terminal tail domain. The KSPXK motif, but not KSPXX, in the repetitive sequence was suggested to be the phosphorylation site by using synthetic peptides.	AICHI CANC CTR, RES INST, EXPTL RADIOL LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN	Aichi Cancer Center	HISANAGA, S (corresponding author), TOKYO INST TECHNOL, FAC BIOSCI, CELL & DEV BIOL LAB, MIDORI KU, YOKOHAMA, KANAGAWA 227, JAPAN.							ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; Beavo J A, 1974, Methods Enzymol, V38, P299; BREEN KC, 1988, FEBS LETT, V241, P213, DOI 10.1016/0014-5793(88)81064-0; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; CAPUTO CB, 1989, BIOCHIM BIOPHYS ACTA, V1012, P299, DOI 10.1016/0167-4889(89)90112-2; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CHIN TK, 1983, BIOCHEM J, V215, P239, DOI 10.1042/bj2150239; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; DAUTIGNY A, 1988, BIOCHEM BIOPH RES CO, V154, P1099, DOI 10.1016/0006-291X(88)90254-9; DRAETTA G, 1988, ONCOGENE, V2, P553; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GEISLER N, 1987, FEBS LETT, V221, P403, DOI 10.1016/0014-5793(87)80964-X; HIROKAWA N, 1988, J NEUROSCI, V8, P2769; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HISANAGA S, 1990, CELL REGUL, V1, P237, DOI 10.1091/mbc.1.2.237; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HISANAGA S, 1989, J NEUROSCI, V9, P959; HISANAGA S, 1990, J BIOL CHEM, V265, P21852; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; HUANG KP, 1982, J BIOL CHEM, V257, P3236; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; JONES SM, 1982, J BIOL CHEM, V257, P9902; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; KISHIMOTO T, 1976, NATURE, V260, P321, DOI 10.1038/260321a0; KISHIMOTO T, 1988, DEV GROWTH DIFFER, V30, P105; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LETERRIER JF, 1981, J CELL BIOL, V90, P755, DOI 10.1083/jcb.90.3.755; LOHKA MJ, 1989, J CELL SCI, V92, P131; MEGGIO F, 1979, FEBS LETT, V106, P76, DOI 10.1016/0014-5793(79)80698-5; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1989, MOL BRAIN RES, V5, P93, DOI 10.1016/0169-328X(89)90001-6; NIXON RA, 1982, J CELL BIOL, V94, P150, DOI 10.1083/jcb.94.1.150; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; SIHAG RK, 1988, FEBS LETT, V233, P181, DOI 10.1016/0014-5793(88)81380-2; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TACHIBANA K, 1990, DEV BIOL, V140, P241, DOI 10.1016/0012-1606(90)90074-S; TOKUI T, 1990, BIOCHEM BIOPH RES CO, V169, P896, DOI 10.1016/0006-291X(90)91977-Z; VALLANO ML, 1985, BIOCHEM BIOPH RES CO, V130, P957, DOI 10.1016/0006-291X(85)91708-5; WIBLE BA, 1989, P NATL ACAD SCI USA, V86, P720, DOI 10.1073/pnas.86.2.720; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869	52	149	150	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21798	21803						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939202				2022-12-25	WOS:A1991GP80400072
J	LEWIS, WS; SCHUSTER, SM				LEWIS, WS; SCHUSTER, SM			CARBOXYPEPTIDASE-Y STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOLYSIN-CATALYZED SYNTHESIS; ORGANIC BIPHASIC SYSTEMS; ENZYMATIC-SYNTHESIS; METHYL-ESTER; PEPTIDES; KINETICS	The stability of carboxypeptidase Y under different reaction conditions and in the presence various cosolvents was investigated. Loss of both hydrolysis and transpeptidation activities was monitored. Incubation of the enzyme at high temperatures or high pH resulted in the loss of both activities at the same rate. Addition of ammonium sulfate resulted in loss of transpeptidation activity but not hydrolysis activity. Addition of some organic solvents or Triton X-100 to the incubation mixture resulted in loss of both activities with transpeptidation being lost more rapidly than hydrolysis activity, while other organic solvents were observed to eliminate both activities entirely. Incubation of the enzyme in the presence of sodium dodecyl sulfate resulted in a decrease in both activities but hydrolysis was lost more rapidly than the transpeptidase activity. Implications of the observed preferential loss of activities to the labeling of peptides and proteins is discussed.	UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT BIOCHEM & MOLEC BIOL,BOX J-245,1301 FIFIELD HALL,GAINESVILLE,FL 32610; UNIV NEBRASKA,DEPT CHEM,LINCOLN,NE 68588	State University System of Florida; University of Florida; University of Nebraska System; University of Nebraska Lincoln								BREDDAM K, 1987, CARLSBERG RES COMMUN, V52, P55, DOI 10.1007/BF02910427; BREDDAM K, 1981, CARLSBERG RES COMMUN, V46, P121, DOI 10.1007/BF02910464; CRAMER SM, 1989, BIOTECHNOL BIOENG, V33, P344, DOI 10.1002/bit.260330314; DIXON M, 1961, ADV PROTEIN CHEM, V16, P197; HAYASHI R, 1975, J BIOCHEM-TOKYO, V77, P69; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HELLIO F, 1988, BIOCHIMIE, V70, P791, DOI 10.1016/0300-9084(88)90109-5; HOMANDBERG GA, 1978, BIOCHEMISTRY-US, V17, P5220, DOI 10.1021/bi00617a023; NAKANISHI K, 1986, EUR J BIOCHEM, V161, P541, DOI 10.1111/j.1432-1033.1986.tb10476.x; NAKANISHI K, 1986, EUR J BIOCHEM, V161, P533, DOI 10.1111/j.1432-1033.1986.tb10475.x; SEGAL IH, 1975, ENZYME KINETICS, P928; SEGAL IH, 1975, ENZYME KINETICS, P884; SEGAL IH, 1975, ENZYME KINETICS, P926; WIDMER F, 1981, CARLSBERG RES COMMUN, V46, P97, DOI 10.1007/BF02906202; WONG CH, 1989, SCIENCE, V244, P1145, DOI 10.1126/science.2658059; ZAKS A, 1988, J BIOL CHEM, V263, P8017	16	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20818	20822						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939132				2022-12-25	WOS:A1991GN00100037
J	QURESHI, SA; RIM, M; BRUDER, J; KOLCH, W; RAPP, U; SUKHATME, VP; FOSTER, DA				QURESHI, SA; RIM, M; BRUDER, J; KOLCH, W; RAPP, U; SUKHATME, VP; FOSTER, DA			AN INHIBITORY MUTANT OF C-RAF-1 BLOCKS V-SRC-INDUCED ACTIVATION OF THE EGR-1 PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NIH 3T3 CELLS; SIGNAL TRANSDUCTION; GENE-EXPRESSION; GROWTH-FACTORS; C-FOS; PROTEIN-KINASES; INDUCIBLE GENE; EARLY RESPONSE; TRANSFORMATION; ONCOGENE	The protein-tyrosine kinase activity of v-Src leads to the transcriptional activation of the mitogen-responsive transcription factor Egr-1. c-Raf-1 is a serine/threonine protein kinase that has been implicated in the transduction of signals induced by mitogens. The involvement of c-Raf-1 in v-Src-induced Egr-1 expression was investigated using an inhibitory mutant of c-Raf-1. We report here that expression of a kinase-defective mutant of c-Raf-1 inhibits v-Src-induced activation of the Egr-1 promoter. This inhibition is reversed by overexpression of wild type c-Raf-1. Consistent with an involvement of c-Raf-1 in a signaling pathway leading to Egr-1 expression, we find that v-Raf induces Egr-1 promoter activation. These data suggest that c-Raf-1 is a component in an intracellular signaling pathway initiated by v-Src leading to the induction of the mitogen-responsive transcription factor Egr-1.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, 695 PK AVE, NEW YORK, NY 10021 USA; CUNY HUNTER COLL, DEPT BIOL SCI, NEW YORK, NY 10021 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOLEC GENET, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT CELL BIOL, CHICAGO, IL 60637 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Howard Hughes Medical Institute; University of Chicago; Howard Hughes Medical Institute; University of Chicago; Howard Hughes Medical Institute; University of Chicago			Kolch, Walter/ABF-2102-2021; Sukhatme, Vikas/W-2776-2019	Kolch, Walter/0000-0001-5777-5016	NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KRIEGLER M, 1984, CELL, V38, P483, DOI 10.1016/0092-8674(84)90503-8; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PATWARDHAN S, 1991, ONCOGENE, V6, P917; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, ONCOGENE, V6, P995; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	44	68	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20594	20597						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939108				2022-12-25	WOS:A1991GN00100005
J	BI, X; CHASTEEN, ND				BI, X; CHASTEEN, ND			IRON OXIDATION CHEMISTRY IN FERRITIN - INCREASING FE/O2 STOICHIOMETRY DURING CORE FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSE SPLEEN APOFERRITIN; H-CHAIN FERRITINS; LIPID-PEROXIDATION; MAMMALIAN FERRITIN; DEPOSITION; MECHANISM; CHANNELS; STORAGE; BINDING; IDENTIFICATION	The origin of previously observed variations in stoichiometry of iron oxidation during the oxidative deposition of iron in ferritin has been poorly understood. Knowledge of the stoichiometry of Fe(II) oxidation by O2 is essential to establishing the mechanism of iron core formation. In the present work, the amount of Fe(II) oxidized was measured by Mossbauer spectrometry and the O2 consumed by mass spectrometry. The number of protons produced in the reaction was measured by "pH stat" titration and hydrogen peroxide production by the effect of the enzyme catalase on the measured stoichiometry. For protein samples containing low levels of iron (24 Fe(II)/protein) the stoichiometry was found to be 1.95 +/- 0.18 Fe(II)/O2 with H2O2 being a product, viz. Equation 1. 2Fe2+ + O2 + 4H2O --> 2FeOOH + H2O2 + 4H+ (1) EPR spin trapping experiments showed no evidence of superoxide radical formation. The stoichiometry markedly increased with additional iron (240-960 Fe/protein) protein), to a value of 4 Fe(II)/O2 as in Equation 2. 4Fe2+ + O2 + 6H2O --> 4FeOOH + 8H+ (2) As the iron core is progressively laid down, the mechanism of iron oxidation changes from a protein dominated process with H2O2 being the primary product of O2 reduction to a mineral surface dominated process where H2O is the primary product. These results emphasize the importance of the apoferritin shell in facilitating iron oxidation in the early stage of iron deposition prior to significant development of the polynuclear iron core.	UNIV NEW HAMPSHIRE, DEPT CHEM, DURHAM, NH 03824 USA	University System Of New Hampshire; University of New Hampshire					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020194, R37GM020194] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20194] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKKER GR, 1986, J BIOL CHEM, V261, P3182; BAUMINGER ER, 1989, BIOCHEMISTRY-US, V28, P5486, DOI 10.1021/bi00439a025; BIEMOND P, 1988, FREE RADICAL BIO MED, V4, P185, DOI 10.1016/0891-5849(88)90026-3; Boudart M., 1984, KINETICS HETEROGENEO, P26; CHASTEEN ND, 1985, J BIOL CHEM, V260, P2926; CHASTEEN ND, 1982, J BIOL CHEM, V257, P7672; CHENG YG, 1991, BIOCHEMISTRY-US, V30, P2947, DOI 10.1021/bi00225a031; CLEGG GA, 1980, PROG BIOPHYS MOL BIO, V36, P53; COZZI A, 1990, FEBS LETT, V277, P119, DOI 10.1016/0014-5793(90)80823-2; CRICHTON RR, 1978, J MOL CATAL, V4, P75; CRICHTON RR, 1987, EUR J BIOCHEM, V164, P485, DOI 10.1111/j.1432-1033.1987.tb11155.x; DECKER EA, 1990, J AGR FOOD CHEM, V38, P674, DOI 10.1021/jf00093a019; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; GERFIN GJ, 1991, IN PRESS J AM CHEM S, V113; GRADY JK, 1988, ANAL BIOCHEM, V173, P111, DOI 10.1016/0003-2697(88)90167-4; GRADY JK, 1989, J BIOL CHEM, V264, P20224; GRADY JK, 1990, IRON BIOMINERALS, P315; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HANNA PM, 1991, J BIOL CHEM, V266, P886; HANNA PM, 1991, IN PRESS BIOCHEMISTR, V30; HENLEY R, 1991, ARCH BIOCHEM BIOPHYS, V286, P238, DOI 10.1016/0003-9861(91)90035-H; HEUSTERSPREUTE M, 1981, FEBS LETT, V129, P322, DOI 10.1016/0014-5793(81)80193-7; JACOBS D, 1989, BIOCHEMISTRY-US, V28, P9216, DOI 10.1021/bi00449a038; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; MACARA IG, 1972, BIOCHEM J, V126, P151, DOI 10.1042/bj1260151; MACARA IG, 1973, BIOCHEM J, V135, P343, DOI 10.1042/bj1350343; MAYER DE, 1983, BIOCHEMISTRY-US, V22, P876, DOI 10.1021/bi00273a026; MELINO G, 1978, FEBS LETT, V86, P136, DOI 10.1016/0014-5793(78)80115-X; OCONNELL MJ, 1987, CHEM PHYS LIPIDS, V45, P241, DOI 10.1016/0009-3084(87)90067-3; ROHRER JS, 1987, J BIOL CHEM, V262, P13385; ROHRER JS, 1989, INORG CHEM, V28, P3393, DOI 10.1021/ic00316a031; STEFANINI S, 1989, BIOCHEMISTRY-US, V28, P378, DOI 10.1021/bi00427a052; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THEIL EC, 1989, ADV ENZYMOL RELAT AR, V63, P421; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; TREFFRY A, 1989, FEBS LETT, V247, P268, DOI 10.1016/0014-5793(89)81350-X; TREFFRY A, 1978, FEBS LETT, V95, P221, DOI 10.1016/0014-5793(78)80998-3; WARDESKA JG, 1986, J BIOL CHEM, V261, P6677; WATT GD, 1985, P NATL ACAD SCI USA, V82, P3640, DOI 10.1073/pnas.82.11.3640; WORWOOD M, 1990, BLOOD REV, V4, P259, DOI 10.1016/0268-960X(90)90006-E; YANG CY, 1987, BIOCHEMISTRY-US, V26, P497, DOI 10.1021/bi00376a023; ZANGWILL A, 1988, PHYSICS SURFACES, P375	46	119	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19965	19970						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939058				2022-12-25	WOS:A1991GM03900018
J	SUZUKI, K; OLVERA, J; WOOL, IG				SUZUKI, K; OLVERA, J; WOOL, IG			PRIMARY STRUCTURE OF RAT RIBOSOMAL PROTEIN-S2 - A RIBOSOMAL-PROTEIN WITH ARGININE-GLYCINE TANDEM REPEATS AND RGGF MOTIFS THAT ARE ASSOCIATED WITH NUCLEOLAR LOCALIZATION AND BINDING TO RIBONUCLEIC-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CDNA SEQUENCE; GENE; RNA; ORGANIZATION; CLONING; ANTIGEN; RICH; S5; IDENTIFICATION	The amino acid sequence of the rat 40 S ribosomal subunit protein S2 was deduced from the sequence of nucleotides in two recombinant cDNAs and confirmed from the amino acid sequence of a cyanogen bromide peptide obtained from the protein. Ribosomal protein S2 has 293 amino acids and has a molecular weight of 31,211. Hybridization of the cDNA to digests of nuclear DNA suggests that there are 23-28 copies of the S2 gene. The mRNA for the protein is about 1,000 nucleotides in length. The highly conserved repetitive mammalian gene family designated LLRep3, but not identified before, encodes ribosomal protein S2. Rat S2 is related to Saccharomyces cerevisiae S4, Methanococcus vannielii S5, Escherichia coli S5, and other members of the prokaryotic S5 family. S. cerevisiae S4 and E. coli S5 are involved in the binding of aminoacyl-tRNA to ribosomes and in conditioning the fidelity of translation; it is plausible to assume that rat S2 serves similar functions. The NH2-terminal region of S2 is rich in arginine-glycine repeats including eight that occur in tandem and has two consecutive copies of the motif RGGF; these sequences have been associated with nucleolar localization and binding to RNA.	UNIV CHICAGO,DEPT HISTOPATHOL,920 E 58TH ST,CHICAGO,IL 60637	University of Chicago					NIGMS NIH HHS [GM-21769] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021769] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLROBYN JA, 1990, MOL CELL BIOL, V10, P6544, DOI 10.1128/MCB.10.12.6544; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; AUER J, 1989, J MOL BIOL, V209, P21, DOI 10.1016/0022-2836(89)90167-8; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BOURBON HM, 1990, GENE, V88, P187, DOI 10.1016/0378-1119(90)90031-L; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; CAIZERGUESFERRER M, 1989, GENE DEV, V3, P324, DOI 10.1101/gad.3.3.324; CERRETTI DP, 1983, NUCLEIC ACIDS RES, V11, P2599, DOI 10.1093/nar/11.9.2599; CHAN YL, 1987, J BIOL CHEM, V262, P12879; CHAN YL, 1988, J BIOL CHEM, V263, P2891; CHRISTENSEN ME, 1988, BIOCHEM BIOPH RES CO, V155, P1278, DOI 10.1016/S0006-291X(88)81279-8; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; COBIANCHI F, 1986, J BIOL CHEM, V261, P3536; COLLATZ E, 1976, J BIOL CHEM, V251, P4666; DAYHOFF MO, 1978, ATLAS PROTEIN SEQUEN, V5, P1; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GLUCK A, 1989, EUR J BIOCHEM, V182, P105, DOI 10.1111/j.1432-1033.1989.tb14805.x; HELLER D, 1984, J MOL BIOL, V173, P419, DOI 10.1016/0022-2836(84)90389-9; HELLER DL, 1988, MOL CELL BIOL, V8, P2797, DOI 10.1128/MCB.8.7.2797; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; KIMURA M, 1984, J BIOL CHEM, V259, P1051; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAPEYRE B, 1986, J BIOL CHEM, V261, P9167; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; OHKUBO S, 1987, MOL GEN GENET, V210, P314, DOI 10.1007/BF00325700; PIEPERSBERG W, 1975, MOL GEN GENET, V140, P91, DOI 10.1007/BF00329777; REBOUD AM, 1983, FEBS LETT, V158, P285, DOI 10.1016/0014-5793(83)80596-1; ROKEACH LA, 1988, P NATL ACAD SCI USA, V85, P4832, DOI 10.1073/pnas.85.13.4832; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SLYNN G, 1990, NUCLEIC ACIDS RES, V18, P681, DOI 10.1093/nar/18.3.681; SZYMKOWSKI DE, 1990, NUCLEIC ACIDS RES, V18, P4695, DOI 10.1093/nar/18.16.4695; UCHIUMI T, 1983, EUR J BIOCHEM, V132, P495, DOI 10.1111/j.1432-1033.1983.tb07388.x; WECHSLER SL, 1989, VIROLOGY, V168, P168, DOI 10.1016/0042-6822(89)90416-9; WOOL IG, 1990, RIBOSOME, P203; YOSHIKAWA H, 1990, NUCLEIC ACIDS RES, V18, P1647, DOI 10.1093/nar/18.6.1647	39	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20007	20010						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939063				2022-12-25	WOS:A1991GM03900025
J	HARRISON, SA; BUXTON, JM; CLANCY, BM; CZECH, MP				HARRISON, SA; BUXTON, JM; CLANCY, BM; CZECH, MP			EVIDENCE THAT ERYTHROID-TYPE GLUCOSE TRANSPORTER INTRINSIC ACTIVITY IS MODULATED BY CADMIUM TREATMENT OF MOUSE 3T3-L1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; HEXOSE-TRANSPORT; PLASMA-MEMBRANE; MESSENGER-RNA; DEPENDENT REGULATION; INSULIN REGULATION; PRIMARY CULTURES; SKELETAL-MUSCLE; GENE-EXPRESSION; PHORBOL ESTER	Previous studies suggest that regulation of hexose uptake in Chinese hamster ovary fibroblasts can occur by alterations in glucose transporter intrinsic activity without changes in cell surface transporter number (Harrison, S. A., Buxton, J. M., Helgerson, A. L., MacDonald, R. G., Chlapowski, F. J., Carruthers, A., and Czech, M. P. (1990) J. Biol. Chem. 265, 5793-5801). We tested this hypothesis using 3T3-L1 fibroblasts and adipocytes which exhibit 5-6-fold increases in 2-deoxyglucose or 3-O-methylglucose uptake when exposed to low micromolar concentrations of cadmium for 18 h. Cadmium treatment decreased the apparent K(m) of 3T3-L1 fibroblasts for 3-O-methylglucose influx from approximately 28 to 9 mm and increased the apparent V(max) by 2-3-fold. These fibroblasts lack the skeletal muscle/adipocyte-type (GLUT4) transporter and showed only a small increase in total cellular immunoreactive HepG2 type (GLUT1) transporter in response to cadmium. Furthermore, cell surface GLUT1 levels did not change in 3T3-L1 fibroblasts exposed to cadmium, as assessed by the binding to intact cells of an antibody which recognizes an extracellular GLUT1 epitope. Insulin enhanced 2-deoxyglucose uptake 2-fold in 3T3-L1 fibroblasts, but did not further stimulate cadmium-activated transport rates. In contrast, insulin stimulated hexose transport 15-fold in 3T3-L1 adipocytes, which express both GLUT1 and GLUT4 proteins, and this effect was fully additive with the 5-fold effect of cadmium. Cadmium had little or no effect on immunoreactive GLUT1 or GLUT4 in isolated 3T3-L1 adipocyte plasma membranes. In contrast, insulin action led to marked recruitment (3-fold) of GLUT4 to the plasma membrane fraction in adipocytes treated with or without cadmium. Taken together, these data are consistent with the hypothesis that cadmium-activated sugar uptake is catalyzed by GLUT1, whereas insulin-stimulated sugar uptake is catalyzed predominantly by GLUT4 in 3T3-L1 adipocytes. Furthermore, the data suggest that the GLUT1 transporter can undergo significant increases in intrinsic catalytic activity in response to cadmium treatment of 3T3-L1 fibroblasts and adipocytes.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	HARRISON, SA (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NIDDK NIH HHS [DK 07302, DK 30898] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007302, R01DK030898, R37DK030898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALY DL, 1987, J BIOL CHEM, V262, P21; BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BLOK J, 1988, J CELL BIOL, V106, P69, DOI 10.1083/jcb.106.1.69; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CALDERHEAD DM, 1988, J BIOL CHEM, V263, P12171; CARRUTHERS A, 1986, BIOCHEMISTRY-US, V25, P3592, DOI 10.1021/bi00360a018; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEHERREROS AG, 1989, J BIOL CHEM, V264, P9885; EZAKI O, 1989, J BIOL CHEM, V264, P16118; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FROST SC, 1985, J BIOL CHEM, V260, P2646; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GOULD GW, 1989, J BIOL CHEM, V264, P2180; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; HARRISON SA, 1990, J BIOL CHEM, V265, P20106; HARRISON SA, 1991, IN PRESS P NATL ACAD; HEBERT DN, 1986, J BIOL CHEM, V261, P93; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; HOLMAN GD, 1988, BIOCHIM BIOPHYS ACTA, V946, P75, DOI 10.1016/0005-2736(88)90459-2; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JONES TLZ, 1989, J BIOL CHEM, V264, P7874; JOOST HG, 1986, J BIOL CHEM, V261, P33; JOOST HG, 1987, J BIOL CHEM, V262, P11261; KAESTNER KH, 1991, P NATL ACAD SCI USA, V88, P1933, DOI 10.1073/pnas.88.5.1933; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KASANICKI MA, 1990, DIABETES CARE, V13, P219, DOI 10.2337/diacare.13.3.219; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; KOZKA IJ, 1991, J BIOL CHEM, V266, P11726; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE K, 1990, FEBS LETT, V276, P39, DOI 10.1016/0014-5793(90)80501-9; LANGE K, 1990, FEBS LETT, V61, P459; MATTHAEI S, 1988, BIOCHEM J, V251, P491, DOI 10.1042/bj2510491; MUDD LM, 1990, ENDOCRINOLOGY, V126, P545, DOI 10.1210/endo-126-1-545; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; OKA Y, 1988, J BIOL CHEM, V263, P13432; OKA Y, 1984, J BIOL CHEM, V259, P8125; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; RHOADS DB, 1988, P NATL ACAD SCI USA, V85, P9042, DOI 10.1073/pnas.85.23.9042; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SUZUKI K, 1988, J BIOL CHEM, V263, P12247; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WADZINSKI BE, 1988, BIOCHEM J, V255, P983, DOI 10.1042/bj2550983; WALKER PS, 1989, J BIOL CHEM, V264, P6587; WALKER PS, 1988, J BIOL CHEM, V263, P15594; WHITESELL RR, 1989, BIOCHEMISTRY-US, V28, P6937, DOI 10.1021/bi00443a024; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	57	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19438	19449						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918056				2022-12-25	WOS:A1991GK66700050
J	CARNEY, DF; HAVILAND, DL; NOACK, D; WETSEL, RA; VIK, DP; TACK, BF				CARNEY, DF; HAVILAND, DL; NOACK, D; WETSEL, RA; VIK, DP; TACK, BF			STRUCTURAL ASPECTS OF THE HUMAN C5-GENE - INTRON EXON ORGANIZATION, 5'-FLANKING REGION FEATURES, AND CHARACTERIZATION OF 2 TRUNCATED CDNA CLONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COMPLEMENT COMPONENT-C4; ACUTE-PHASE PROTEIN; DECAY-ACCELERATING FACTOR; FACTOR-B GENE; MURINE COMPLEMENT; 5TH COMPONENT; 3RD COMPONENT; NUCLEOTIDE-SEQUENCE; MOUSE COMPLEMENT; FIFTH COMPONENT	Human C5 cDNA fragments were used to identify five overlapping cosmid clones that spanned the entire C5 gene. Partial sequencing and Southern analysis of the clones were performed to identify intron/exon boundaries and to map intron size. The human C5 gene is 79 kilobases in length and is comprised of 41 exons. Comparison of C5 with the homologous family members C3 and C4 revealed striking similarities in exon size and number. Less, although significant similarities were also observed with the family member alpha-2-macroglobulin. The transcriptional start site for the C5 gene was observed as a doublet at positions 29 and 28 nucleotides upstream of the ATG start codon. The 5'-flanking region of the gene contains sequences homologous with several known responsive elements, including interferon, interleukin-6, glucocorticoid, estrogen, NF-(k)B, and HNF-1. Two previously identified truncated cDNAs, pHC5A and pHC5B, contain 21 and 16 exons, respectively. The last exon in pHC5A, designated exon 21a, is a product of alternative splicing and is not present in the major full-length transcript. Truncation of pHC5A is the result of an alternative polyadenylation signal located in exon 21a. In pHC5B, exon 16 is extended on the 3' end by additional flanking genomic sequence that also contains an alternative polyadenylation signal.	WASHINGTON UNIV,CHILDRENS HOSP,DEPT PEDIAT,ST LOUIS,MO 63110	St. Louis Children's Hospital; Washington University (WUSTL)			Haviland, David/ABH-4952-2020		NIAID NIH HHS [AI25011, AI07163, AI22214] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007163, R55AI025011, R01AI022214, R01AI025011] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA A, 1984, J EXP MED, V160, P411, DOI 10.1084/jem.160.2.411; BANKIER AT, 1983, TECHNIQUES NUCLEIC A, V85, P1; BARNUM SR, 1990, COMPLEMENT INFLAMMAT, V7, P71, DOI 10.1159/000463131; BASTA PV, 1987, J IMMUNOL, V138, P1275; BAUMHUETER S, 1989, ANN NY ACAD SCI, V557, P272; BELT KT, 1985, IMMUNOGENETICS, V21, P173; BELT KT, 1984, CELL, V36, P907; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BILLINGHAM MEJ, 1975, FUTURE TRENDS IMMUNO, V2, P195; BROZNA JP, 1977, J CLIN INVEST, V60, P1280, DOI 10.1172/JCI108887; CAMPBELL RD, 1981, BIOCHEM J, V199, P359, DOI 10.1042/bj1990359; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; CARROLL MC, 1984, NATURE, V307, P237, DOI 10.1038/307237a0; CASTELL JV, 1989, ANN NY ACAD SCI, V557, P87; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE FS, 1983, CLIN IMMUNOL IMMUNOP, V27, P153, DOI 10.1016/0090-1229(83)90065-X; COLE FS, 1982, IMMUNOLOGY, V46, P429; COLTEN HR, 1972, J CLIN INVEST, V51, P725, DOI 10.1172/JCI106866; COLTEN HR, 1989, ACUTE PHASE PROTEINS, P85; COONROD JD, 1977, INFECT IMMUN, V18, P14, DOI 10.1128/IAI.18.1.14-22.1977; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DOMDEY H, 1982, P NATL ACAD SCI-BIOL, V79, P7619, DOI 10.1073/pnas.79.24.7619; FALUS A, 1990, MOL IMMUNOL, V27, P191, DOI 10.1016/0161-5890(90)90114-F; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GROSVELD FG, 1982, NUCLEIC ACIDS RES, V10, P6715, DOI 10.1093/nar/10.21.6715; HARRISON RA, 1981, P NATL ACAD SCI-BIOL, V78, P7388, DOI 10.1073/pnas.78.12.7388; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HATTORI M, 1989, GENE AMST, V77, P330; HAVILAND DL, 1991, J IMMUNOL, V146, P362; HAVILAND DL, 1991, J BIOL CHEM, V266, P11818; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; HUGLI TE, 1984, SPRINGER SEMIN IMMUN, V7, P193; HUGLI TE, 1977, CHEM BIOL THROMBIN, P345; JANATOVA J, 1980, BIOCHEMISTRY-US, V19, P4479, DOI 10.1021/bi00560a015; KAN CC, 1985, P NATL ACAD SCI USA, V82, P2282, DOI 10.1073/pnas.82.8.2282; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; LAPPIN DF, 1990, BIOCHEM J, V268, P387, DOI 10.1042/bj2680387; LUNDWALL A, 1984, J BIOL CHEM, V259, P3851; LUNDWALL AB, 1985, J BIOL CHEM, V260, P2108; Maniatis T, 1989, DECONTAMINATION DILU; MCALEER M A, 1989, Complement and Inflammation, V6, P366; MILLER ME, 1970, NEW ENGL J MED, V282, P354, DOI 10.1056/NEJM197002122820702; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NILSSON UR, 1974, J IMMUNOL, V112, P1164; NILSSON UR, 1975, J IMMUNOL, V114, P815; NONAKA M, 1990, MOL CELL BIOL, V10, P6283, DOI 10.1128/MCB.10.12.6283; NONAKA M, 1985, J BIOL CHEM, V260, P936; OGATA RT, 1989, J BIOL CHEM, V264, P16565; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PERICAKVANCE MA, 1985, CYTOGENET CELL GENET, V40, P721; PERLMUTTER DH, 1986, SCIENCE, V232, P850, DOI 10.1126/science.3010455; POST TW, 1990, J IMMUNOL, V144, P740; REED W, 1990, IMMUNOGENETICS, V31, P145; ROSENFELD SI, 1976, J CLIN INVEST, V57, P1635, DOI 10.1172/JCI108434; ROTHMAN BL, 1990, J IMMUNOL, V145, P592; SAEKI T, 1989, BIOCHEM BIOPH RES CO, V164, P1446, DOI 10.1016/0006-291X(89)91832-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SEPICH DS, 1985, P NATL ACAD SCI USA, V82, P5895, DOI 10.1073/pnas.82.17.5895; SHIN ML, 1988, CYTOTOXIC MEDIATORS, V40, P44; SISSONS JGP, 1977, J CLIN INVEST, V59, P704, DOI 10.1172/JCI108689; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; STRUNK RC, 1988, J CLIN INVEST, V81, P1419, DOI 10.1172/JCI113472; SUNDSTROM SA, 1990, ENDOCRINOLOGY, V126, P1449, DOI 10.1210/endo-126-3-1449; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; TACK BF, 1979, BIOCHEMISTRY-US, V18, P1490, DOI 10.1021/bi00575a016; TAYLOR JL, 1990, VIRUS RES, V15, P1, DOI 10.1016/0168-1702(90)90010-9; VIK DP, 1991, BIOCHEMISTRY-US, V30, P1080, DOI 10.1021/bi00218a029; WALKER P, 1984, NUCLEIC ACIDS RES, V12, P8611, DOI 10.1093/nar/12.22.8611; WETSEL RA, 1982, J IMMUNOL, V128, P2209; WETSEL RA, 1987, BIOCHEMISTRY-US, V26, P737, DOI 10.1021/bi00377a013; WETSEL RA, 1984, J BIOL CHEM, V259, P3857; WETSEL RA, 1983, J EXP MED, V157, P2029, DOI 10.1084/jem.157.6.2029; WETSEL RA, 1988, BIOCHEMISTRY-US, V27, P1474, DOI 10.1021/bi00405a012; WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501; WHITEHEAD AS, 1982, P NATL ACAD SCI-BIOL, V79, P5021, DOI 10.1073/pnas.79.16.5021; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WU LC, 1987, CELL, V48, P331, DOI 10.1016/0092-8674(87)90436-3; ZAHEDI K, 1989, J IMMUNOL, V143, P2880	81	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18786	18791						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917999				2022-12-25	WOS:A1991GJ47200059
J	THORN, JT; TODD, AV; WARRILOW, D; WATT, F; MOLLOY, PL; ILAND, HJ				THORN, JT; TODD, AV; WARRILOW, D; WATT, F; MOLLOY, PL; ILAND, HJ			CHARACTERIZATION OF THE HUMAN N-RAS PROMOTER REGION	ONCOGENE			English	Article							MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR BINDS; DNA-BINDING; PROTO-ONCOGENE; CELL-LINE; C-FOS; PROENKEPHALIN GENE; DELETION ANALYSIS; UPSTREAM ELEMENT; GROWTH-FACTOR	Overexpression of ras proto-oncogenes has been implicated in cancer development. We therefore initiated a study of the human N-ras promoter to determine the regions that control N-ras expression and their potential for interaction with DNA-binding proteins. N-ras CAT constructs were stably integrated into K562 cells by electric field-mediated gene transfer in order to determine functional regions within the human N-ras promoter. A significant proportion of promoter activity was found to lie within a 439 bp fragment comprising an untranslated exon (exon 1) with the adjacent 5' sequence and a small CpG island. A 107 bp fragment at the 5' end of exon 1 was essential for promoter activity, while a 44 bp deletion from within this region decreased promoter activity by two-thirds. Unlike the human H-ras and mouse K-ras promoters, the N-ras promoter did not exhibit bidirectional activity. DNAase footprinting of the 439 bp fragment revealed seven protected regions, many of which contain sequences homologous to known DNA-binding protein sites (MLTF/myc, CREB/ATF, AP-1, AP-2, myb and E4TF1). In contrast, four putative Sp1 sites did not footprint. Using purified MLTF and appropriate competitors in gel shift and DNAase footprinting assays, we demonstrated binding of MLTF to the MLTF consensus sequence within exon 1.	ROYAL PRINCE ALFRED HOSP, KANEMATSU LABS, MISSENDEN RD, CAMPERDOWN, NSW 2050, AUSTRALIA; CSIRO, DIV BIOMOLEC ENGN, N RYDE, NSW 2113, AUSTRALIA	University of Sydney; Commonwealth Scientific & Industrial Research Organisation (CSIRO)			Molloy, Peter L/H-7931-2013	Molloy, Peter L/0000-0002-7788-3417				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; CROAKER GM, 1990, LEUKEMIA, V4, P502; DONIGER J, 1987, ONCOGENE, V1, P331; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HOFLER H, 1988, VIRCHOWS ARCH B, V55, P355; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; JORDANO J, 1988, ONCOGENE, V2, P359; LOWNDES NF, 1989, MOL CELL BIOL, V9, P3758, DOI 10.1128/MCB.9.9.3758; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; PACIUCCI R, 1991, MOL CELL BIOL, V11, P1334, DOI 10.1128/MCB.11.3.1334; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SAWADOGO M, 1986, CANCER CELL, V4, P147; SAWODOGO M, 1985, R G CELL, V43, P165; Sharpiro DJ, 1988, DNA CELL BIOL, V7, P47; SHI XP, 1986, NUCLEIC ACIDS RES, V14, P3729, DOI 10.1093/nar/14.9.3729; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SPANDIDOS DA, 1986, FEBS LETT, V203, P169, DOI 10.1016/0014-5793(86)80736-0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SUAREZ HG, 1989, CANCER RES, V49, P1223; TANAKA T, 1986, CANCER RES, V46, P1465; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; THOR A, 1984, NATURE, V311, P562, DOI 10.1038/311562a0; TRIMBLE WS, 1987, FEBS LETT, V219, P70, DOI 10.1016/0014-5793(87)81192-4; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; YAMAMOTO F, 1988, ONCOGENE RES, V3, P125	60	19	19	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1843	1850						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923508				2022-12-25	WOS:A1991GX11800017
J	HARAGUCHI, T; ALEXANDER, DB; KING, DS; EDWARDS, CP; FIRESTONE, GL				HARAGUCHI, T; ALEXANDER, DB; KING, DS; EDWARDS, CP; FIRESTONE, GL			IDENTIFICATION OF THE GLUCOCORTICOID SUPPRESSIBLE MITOGEN FROM RAT HEPATOMA-CELLS AS AN ANGIOGENIC PLATELET-DERIVED GROWTH FACTOR-A-CHAIN HOMODIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST CANCER; MESSENGER-RNA; FACTOR-ALPHA; AUTOCRINE REGULATION; SIGNAL TRANSDUCTION; FACTOR-BETA; EXPRESSION; RECEPTOR; LINES; GENE	We have previously shown that BDS.1 rat hepatoma cells are hypersensitive to the antiproliferative effects of glucocorticoids, and secrete a glucocorticoid suppressible mitogenic activity (denoted GSM). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that GSM purified to near homogeneity migrated as a 28-kDa protein under nonreducing conditions and as a single 15-kDa polypeptide in the presence of sulfhydryl reducing agents suggesting a homodimeric structure. Anti-platelet-derived growth factor (PDGF) A-chain specific antibodies selectively immunodepleted the mitogenic activity which can be extracted from nonreducing gels in the 26-30-kDa fraction and, in Western blots, recognized the 15-kDa reduced form of GSM. Western blot analysis further showed that dexamethasone suppressed the level of secreted PDGF A-chain protein in BDS.1 cells but not in glucocorticoid receptor-deficient hepatoma cells. Northern blots revealed that dexamethasone reduced expression of the PDGF A-chain 2.3- and 1.7-kilobase transcripts in proportion to the level of detectable PDGF-AA protein. Similarly to PDGF-AA, the hepatoma cell-derived GSM has a potent angiogenic activity. Taken together, our results demonstrate that the predominant glucocorticoid suppressible mitogen secreted from rat hepatoma cells is a PDGF A-chain homodimer and suggest that in vivo glucocorticoids may potentially regulate hepatoma growth by modulating PDGF-stimulated tumor vascularization.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BOX 591 LSA,BERKELEY,CA 94720; UNIV CALIF BERKELEY,CANC RES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NCI NIH HHS [CA-09041] Funding Source: Medline; NICHD NIH HHS [T2HD-07375] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BOWENPOPE DF, 1984, BLOOD, V64, P458; BRONZERT DA, 1990, MOL ENDOCRINOL, V4, P981, DOI 10.1210/mend-4-7-981; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; COOK PW, 1988, J BIOL CHEM, V263, P19296; COOK PW, 1989, J BIOL CHEM, V264, P14151; COOK PW, 1988, MOL CELL BIOL, V8, P1449, DOI 10.1128/MCB.8.4.1449; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DEUEL TF, 1981, J BIOL CHEM, V256, P8896; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HALPER J, 1987, CANCER RES, V47, P4552; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HERINGTON AC, 1983, INT J BIOCHEM, V15, P1201, DOI 10.1016/0020-711X(83)90208-2; Higgins GM, 1931, ARCH PATHOL, V12, P186; HUFF KK, 1988, MOL ENDOCRINOL, V2, P200, DOI 10.1210/mend-2-3-200; JAMES R, 1984, ANNU REV BIOCHEM, V53, P259; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU SC, 1987, MOL ENDOCRINOL, V1, P683, DOI 10.1210/mend-1-10-683; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; NISTER M, 1988, CANCER RES, V48, P3910; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Paulsson Y, 1988, GROWTH FACTORS, V1, P19, DOI 10.3109/08977198809000243; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; ROSS R, 1990, PHILOS T ROY SOC B, V327, P155, DOI 10.1098/rstb.1990.0051; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; Sambrook J, 1989, MOL CLONING LABORATO; SHIPLEY GD, 1984, CANCER RES, V44, P710; SYMS AJ, 1984, BIOCHEM BIOPH RES CO, V122, P68, DOI 10.1016/0006-291X(84)90440-6; TAIRA M, 1978, BIOCHIM BIOPHYS ACTA, V541, P45, DOI 10.1016/0304-4165(78)90266-0; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; TSAI TF, 1988, BIOCHEM BIOPH RES CO, V153, P39, DOI 10.1016/S0006-291X(88)81186-0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	49	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18299	18307						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917957				2022-12-25	WOS:A1991GG55300088
J	MESSINA, JL				MESSINA, JL			INHIBITION AND STIMULATION OF C-MYC GENE-TRANSCRIPTION BY INSULIN IN RAT HEPATOMA-CELLS - INSULIN ALTERS THE INTRAGENIC PAUSING OF C-MYC TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTO-ONCOGENE EXPRESSION; EPIDERMAL GROWTH-FACTOR; MESSENGER-RNA; N-MYC; V-MYC; CULTURED FIBROBLASTS; PROTOONCOGENE MYC; DNA-REPLICATION; HL60 CELLS; KINASE-C	One of insulin's least studied actions is its ability to induce DNA synthesis and cell division. In rat H4IIE hepatoma cells insulin, acting through its own receptor, stimulates cell division. However, little is known about the molecular mechanisms involved in this effect. The proto-oncogene c-myc is a cellular gene which when expressed at abnormal levels is often associated with the process of tumorigenesis. Expression of the normal cellular myc gene may be necessary for growth factor-induced cell cycling. In the present work, insulin was shown to regulate cellular accumulation and transcription of the c-myc gene in rat hepatoma cells. The control of c-myc by insulin was complex, with an initial-induced decrease in c-myc transcription to 50% of control values at 15 and 30 min. This was followed by an increase in transcription of about 3-fold by 60-120 min. Similar to the initial inhibitory effect of insulin, the protein synthesis inhibitors cycloheximide or anisomycin decreased c-myc transcription. However, there was no secondary induction of c-myc transcription by protein synthesis inhibitors. The effects of both insulin and protein synthesis inhibitors were shown to be through alterations in intragenic pausing of transcription of the sense mRNA, not through changes in initiation of transcription.			MESSINA, JL (corresponding author), SUNY HLTH SCI CTR,DEPT PHYSIOL,SYRACUSE,NY 13210, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040456] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40456] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANSKOTA NK, 1989, DIABETES, V38, P123, DOI 10.2337/diabetes.38.1.123; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; CAVALIERI F, 1988, ONCOGENE, V2, P289; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; CHANDAR N, 1989, P NATL ACAD SCI USA, V86, P2703, DOI 10.1073/pnas.86.8.2703; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CRAIG JW, 1985, MOL CELL BIOCHEM, V66, P117; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DEASUA LJ, 1977, NATURE, V265, P450, DOI 10.1038/265450a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; Favaloro J, 1980, Methods Enzymol, V65, P718; FORSTHOEFEL AM, 1987, MOL ENDOCRINOL, V1, P899, DOI 10.1210/mend-1-12-899; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GRIENINGER G, 1975, P NATL ACAD SCI USA, V72, P5007, DOI 10.1073/pnas.72.12.5007; GRIMALDI P, 1983, MOL CELL ENDOCRINOL, V29, P271, DOI 10.1016/0303-7207(83)90017-5; HELDIN NE, 1989, J CELL PHYSIOL, V138, P17, DOI 10.1002/jcp.1041380104; HILL DJ, 1985, PEDIATR RES, V19, P879, DOI 10.1203/00006450-198509000-00001; HOLLENBERG MD, 1975, J BIOL CHEM, V250, P3845; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOONTZ JW, 1984, MOL CELL BIOCHEM, V58, P139, DOI 10.1007/BF00240613; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEFFERT HL, 1974, J CELL BIOL, V62, P792, DOI 10.1083/jcb.62.3.792; LIZARDI PM, 1979, ANAL BIOCHEM, V98, P116, DOI 10.1016/0003-2697(79)90714-0; MALLER JL, 1981, DEV BIOL, V85, P309, DOI 10.1016/0012-1606(81)90262-1; MASSAGUE J, 1982, J BIOL CHEM, V257, P3958; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MESSINA JL, 1989, ENDOCRINOLOGY, V124, P754, DOI 10.1210/endo-124-2-754; MESSINA JL, 1985, J BIOL CHEM, V260, P6418; MESSINA JL, 1990, HDB EXPT PHARM INSUL, P399; MOTOO Y, 1988, TOHOKU J EXP MED, V156, P351, DOI 10.1620/tjem.156.351; MOTTOLA C, 1984, J BIOL CHEM, V259, P2705; MURPHY PR, 1988, ENDOCRINOLOGY, V122, P2476, DOI 10.1210/endo-122-6-2476; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PICHON F, 1988, ONCOGENE, V3, P373; PODSKALNY JM, 1982, J CLIN ENDOCR METAB, V54, P269, DOI 10.1210/jcem-54-2-269; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SCHWEINFEST CW, 1988, MOL CELL BIOL, V8, P3080, DOI 10.1128/MCB.8.8.3080; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SINHA S, 1989, BRIT J CANCER, V59, P674, DOI 10.1038/bjc.1989.139; SPECTOR DL, 1987, ONCOGENE, V1, P5; SQUINTO SP, 1989, MOL ENDOCRINOL, V3, P433, DOI 10.1210/mend-3-3-433; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; TAUB R, 1987, J BIOL CHEM, V262, P10893; TREPEL JB, 1987, MOL CELL BIOL, V7, P2644, DOI 10.1128/MCB.7.7.2644; WEINSTOCK RS, 1988, ENDOCRINOLOGY, V123, P366, DOI 10.1210/endo-123-1-366; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZHOU RP, 1988, P NATL ACAD SCI USA, V85, P2924, DOI 10.1073/pnas.85.9.2924; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	68	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17995	18001						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917937				2022-12-25	WOS:A1991GG55300047
J	KAMIJO, K; TAKETANI, S; YOKOTA, S; OSUMI, T; HASHIMOTO, T				KAMIJO, K; TAKETANI, S; YOKOTA, S; OSUMI, T; HASHIMOTO, T			THE 70-KDA PEROXISOMAL MEMBRANE-PROTEIN IS A MEMBER OF THE MDR (P-GLYCOPROTEIN)-RELATED ATP-BINDING PROTEIN SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									KANSAI MED SCH,DEPT HYG,MORIGUCHI 570,JAPAN; YAMANASKI MED COLL,DEPT ANAT,YAMANASHI 40938,JAPAN	Kansai Medical University; University of Yamanashi	KAMIJO, K (corresponding author), SHINSHU UNIV,SCH MED,DEPT BIOCHEM,MATSUMOTO,NAGANO 390,JAPAN.							ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; DELVALLE R, 1988, BIOCHEM BIOPH RES CO, V156, P1353, DOI 10.1016/S0006-291X(88)80781-2; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; DOUMA AC, 1987, ARCH MICROBIOL, V147, P42, DOI 10.1007/BF00492903; DUNN R, 1981, P NATL ACAD SCI-BIOL, V78, P6744, DOI 10.1073/pnas.78.11.6744; EVANS IJ, 1986, GENE, V43, P95, DOI 10.1016/0378-1119(86)90012-0; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GILL DR, 1986, MOL GEN GENET, V205, P134, DOI 10.1007/BF02428043; GILSON E, 1982, NUCLEIC ACIDS RES, V10, P7449, DOI 10.1093/nar/10.22.7449; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HARTL FU, 1985, ARCH BIOCHEM BIOPHYS, V237, P124, DOI 10.1016/0003-9861(85)90261-9; HARTL FU, 1987, ARCH BIOCHEM BIOPHYS, V255, P109, DOI 10.1016/0003-9861(87)90300-6; HASHIMOTO T, 1986, J BIOCHEM-TOKYO, V100, P301, DOI 10.1093/oxfordjournals.jbchem.a121716; HEIL A, 1974, EUR J BIOCHEM, V43, P131, DOI 10.1111/j.1432-1033.1974.tb03393.x; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HIGGINS CF, 1985, EMBO J, V4, P1033, DOI 10.1002/j.1460-2075.1985.tb03735.x; HIGGINS CF, 1988, BIOESSAYS, V8, P111, DOI 10.1002/bies.950080406; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Maniatis T., 1982, MOL CLONING; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; OHARE K, 1984, J MOL BIOL, V180, P437, DOI 10.1016/0022-2836(84)90021-4; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; RUNSWICK MJ, 1983, J BIOL CHEM, V258, P3081; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SCHUTGENS RBH, 1986, EUR J PEDIATR, V144, P430, DOI 10.1007/BF00441734; SEEBERG E, 1982, P NATL ACAD SCI-BIOL, V79, P988, DOI 10.1073/pnas.79.4.988; STANFIELD SW, 1988, J BACTERIOL, V170, P3523, DOI 10.1128/jb.170.8.3523-3530.1988; SURIN BP, 1985, J BACTERIOL, V161, P189, DOI 10.1128/JB.161.1.189-198.1985; SUZUKI Y, 1987, J BIOCHEM-TOKYO, V101, P491, DOI 10.1093/oxfordjournals.jbchem.a121935; TAKIGUCHI M, 1985, J BIOCHEM, V97, P1447, DOI 10.1093/oxfordjournals.jbchem.a135199; THOMAS J, 1980, BIOCHEM J, V190, P485, DOI 10.1042/bj1900485; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEEKS DP, 1986, ANAL BIOCHEM, V152, P376, DOI 10.1016/0003-2697(86)90423-9; WEINBERGER C, 1985, SCIENCE, V228, P740, DOI 10.1126/science.2581314; YOKOTA S, 1985, HISTOCHEMISTRY, V82, P25, DOI 10.1007/BF00502087	60	363	371	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1990	265	8					4534	4540						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CT101	1968461				2022-12-25	WOS:A1990CT10100057
J	STAATS, J; MARQUARDT, D; CENTER, MS				STAATS, J; MARQUARDT, D; CENTER, MS			CHARACTERIZATION OF A MEMBRANE-ASSOCIATED PROTEIN-KINASE OF MULTIDRUG-RESISTANT HL60 CELLS WHICH PHOSPHORYLATES P-GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									KANSAS STATE UNIV AGR & APPL SCI,DIV BIOL,MANHATTAN,KS 66506	Kansas State University					NATIONAL CANCER INSTITUTE [R01CA037585] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AQUINO A, 1988, CANCER RES, V48, P3324; BECK WT, 1979, CANCER RES, V39, P2070; CARLSEN SA, 1977, BIOCHIM BIOPHYS ACTA, V467, P238, DOI 10.1016/0005-2736(77)90199-7; CENTER MS, 1985, BIOCHEM PHARMACOL, V34, P1471, DOI 10.1016/0006-2952(85)90686-0; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; DALTON WT, 1988, BLOOD, V71, P242; ELIAS L, 1985, J BIOL CHEM, V260, P7023; GARMAN D, 1982, BIOCHEM BIOPH RES CO, V105, P157, DOI 10.1016/S0006-291X(82)80025-9; GARMAN D, 1983, BIOCHEM PHARMACOL, V32, P3633, DOI 10.1016/0006-2952(83)90315-5; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GIRARD PR, 1987, CANCER RES, V47, P2892; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; HAMADA H, 1987, CANCER RES, V47, P2860; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; INABA M, 1978, BIOCHEM PHARMACOL, V27, P2123, DOI 10.1016/0006-2952(78)90284-8; INABA M, 1981, BIOCHEM PHARMACOL, V30, P1863; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KLEMM DJ, 1987, J BIOL CHEM, V262, P7580; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGLIN A, 1970, ANNU REV BIOCHEM, V39, P841, DOI 10.1146/annurev.bi.39.070170.004205; MARSH W, 1987, CANCER RES, V47, P5080; MARSH W, 1986, CANCER RES, V46, P4053; MARSH W, 1985, BIOCHEM PHARMACOL, V34, P4179; MCGRATH T, 1988, CANCER RES, V48, P3959; MELLADO W, 1987, BIOCHEMISTRY-US, V26, P6900, DOI 10.1021/bi00396a005; MELLONI E, 1985, P NATL ACAD SCI USA, V82, P6435, DOI 10.1073/pnas.82.19.6435; PETERSON RHF, 1978, J SUPRAMOL STR CELL, V9, P289, DOI 10.1002/jss.400090302; SAFA AR, 1986, J BIOL CHEM, V261, P6137; SKOVSGAARD T, 1978, CANCER RES, V38, P1785; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2	37	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1990	265	7					4084	4090						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CQ480	1968066				2022-12-25	WOS:A1990CQ48000077
J	FITZPATRICK, PF; CHLUMSKY, LJ; DAUBNER, SC; OMALLEY, KL				FITZPATRICK, PF; CHLUMSKY, LJ; DAUBNER, SC; OMALLEY, KL			EXPRESSION OF RAT TYROSINE-HYDROXYLASE IN INSECT TISSUE-CULTURE CELLS AND PURIFICATION AND CHARACTERIZATION OF THE CLONED ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									TEXAS A&M UNIV SYST, TEXAS AGR EXPT STN, COLLEGE STN, TX 77843 USA; WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M AgriLife Research; Washington University (WUSTL)	FITZPATRICK, PF (corresponding author), TEXAS A&M UNIV SYST, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021318] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21318] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMES MM, 1978, J BIOL CHEM, V253, P27; BAILEY SW, 1989, BIOCHEMISTRY-US, V28, P494, DOI 10.1021/bi00428a013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN ER, 1987, BIOCHEMISTRY-US, V26, P5208, DOI 10.1021/bi00390a046; BULLARD WP, 1983, MOL PHARMACOL, V23, P104; BURAND JP, 1980, VIROLOGY, V101, P286, DOI 10.1016/0042-6822(80)90505-X; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; Cleland W W, 1979, Methods Enzymol, V63, P103; DAUBNER SC, 1985, CANCER RES, V45, P4990; DIX TA, 1987, BIOCHEMISTRY-US, V26, P3354, DOI 10.1021/bi00386a016; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FITZPATRICK PF, 1989, BIOCHEM BIOPH RES CO, V161, P211, DOI 10.1016/0006-291X(89)91582-9; FITZPATRICK PF, 1988, J BIOL CHEM, V263, P16058; FLOCKHART DA, 1984, BRAIN RECEPTOR MET A, P209; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; HAAVIK J, 1988, BIOCHIM BIOPHYS ACTA, V953, P142, DOI 10.1016/0167-4838(88)90019-2; HAAVIK J, 1987, EUR J BIOCHEM, V168, P21, DOI 10.1111/j.1432-1033.1987.tb13381.x; HILL MA, 1988, J BIOL CHEM, V263, P5646; KAUFMAN S, 1985, FOLATES PTERINS, V2, P251; KUCZENSKI R, 1973, J BIOL CHEM, V248, P5074; KUCZENSKI RT, 1972, J BIOL CHEM, V247, P3114; KUHN DM, 1983, BIOCHEM BIOPH RES CO, V117, P894, DOI 10.1016/0006-291X(83)91680-7; KUHN DM, 1987, NEUROCHEM INT, V11, P463, DOI 10.1016/0197-0186(87)90036-2; KUIJPERS GAJ, 1989, J BIOL CHEM, V264, P698; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR MA, 1982, J NEUROCHEM, V39, P409, DOI 10.1111/j.1471-4159.1982.tb03962.x; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LLOYD T, 1974, BIOCHEM BIOPH RES CO, V59, P1262, DOI 10.1016/0006-291X(74)90450-1; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; Maniatis T., 1982, MOL CLONING; MARKEY KA, 1980, MOL PHARMACOL, V17, P79; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; OKA K, 1982, BIOCHIM BIOPHYS ACTA, V706, P188, DOI 10.1016/0167-4838(82)90486-1; OKERBLOM C, 1989, J VIROL, V63, P1256, DOI 10.1128/JVI.63.3.1256-1264.1989; OKUNO S, 1982, EUR J BIOCHEM, V122, P49, DOI 10.1111/j.1432-1033.1982.tb05846.x; OMALLEY KL, 1986, J NEUROSCI RES, V16, P3, DOI 10.1002/jnr.490160103; RICHTAND NM, 1985, J BIOL CHEM, V260, P8465; SHIMAN R, 1971, J BIOL CHEM, V246, P1330; STONE AL, 1980, J NEUROCHEM, V35, P1137, DOI 10.1111/j.1471-4159.1980.tb07869.x; TANK AW, 1987, METHOD ENZYMOL, V142, P71; UDENFRIEND S, 1965, BIOCHEM PHARMACOL, V14, P837, DOI 10.1016/0006-2952(65)90103-6; VULLIET PR, 1980, P NATL ACAD SCI-BIOL, V77, P92, DOI 10.1073/pnas.77.1.92; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	45	45	45	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1990	265	4					2042	2047						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CL028	1967606				2022-12-25	WOS:A1990CL02800038
J	BALEJA, JD; ANDERSON, WF; SYKES, BD				BALEJA, JD; ANDERSON, WF; SYKES, BD			DIFFERENT INTERACTIONS OF CRO REPRESSOR DIMER WITH THE LEFT AND RIGHT HALVES OF OR3 OPERATOR DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SEQUENCE-SPECIFIC INTERACTIONS; CONFORMATIONAL-CHANGES; BACTERIOPHAGE-LAMBDA; PROTEIN RECOGNITION; CRYSTAL-STRUCTURE; PHAGE-LAMBDA; BINDING; COMPLEX; RESOLUTION	Lambda-Cro repressor protein is titrated with two half-operator DNA duplexes comprising the right and left halves of the major binding site on phage lambda-DNA, the O(R)3 operator. The comparison of binding strengths and the conformation of Cro repressor in the two protein-DNA complexes shows that base pair differences between the two halves of the O(R)3 operator affect the binding of Cro repressor protein. Some H-1 NMR resonances are assigned for both protein and DNA in the Cro-operator DNA complexes which are then used to highlight differences between Cro right half and Cro left half protein-operator DNA interactions. These differences are compared to the asymmetry found in the lambda-C(I) repressor-operator DNA complex. Mechanisms for the recognition of the Cro transcriptional regulatory protein have considered only interactions between a single Cro monomer and a consensus half-operator site with the assumption that the interactions in the remaining half-site are related by the 2-fold symmetry of the complex. A revised model is suggested that allows asymmetry in the two halves of the protein-DNA complex. Methods are proposed to avoid problems in the general use of H-1 NMR spectroscopy to study protein-DNA interaction such as intermediate exchange behavior and sample aggregation.	UNIV ALBERTA, DEPT BIOCHEM, MRC CANADA, PROT STRUCT & FUNCT GRP, EDMONTON T6G 2H7, ALBERTA, CANADA	University of Alberta					NIDDK NIH HHS [DK425020] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON WF, 1981, NATURE, V290, P754, DOI 10.1038/290754a0; ARNOTT S, 1972, BIOCHEM BIOPH RES CO, V47, P1504, DOI 10.1016/0006-291X(72)90243-4; BALEJA JD, 1990, BIOCHEMISTRY-US, V29, P4828, DOI 10.1021/bi00472a012; BALEJA JD, 1990, THESIS U ALBERTA EDM; BERG OG, 1988, TRENDS BIOCHEM SCI, V13, P207, DOI 10.1016/0968-0004(88)90085-0; BOSCHELLI F, 1982, J MOL BIOL, V162, P267, DOI 10.1016/0022-2836(82)90526-5; BOSCHELLI F, 1982, J MOL BIOL, V162, P251, DOI 10.1016/0022-2836(82)90525-3; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BRENNAN RG, 1989, TRENDS BIOCHEM SCI, V14, P286, DOI 10.1016/0968-0004(89)90066-2; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P575; DICKERSON RE, 1983, SCI AM, V249, P94, DOI 10.1038/scientificamerican1283-94; FERGUSONMILLER S, 1981, TRENDS BIOCHEM SCI, V6, pR4; HAHN KD, 1985, EUR BIOPHYS J BIOPHY, V12, P87, DOI 10.1007/BF00260431; HULL WE, 1975, THESIS HARVARD U CAM; IWAHASHI H, 1982, J BIOCHEM-TOKYO, V91, P1213, DOI 10.1093/oxfordjournals.jbchem.a133805; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KIM JG, 1987, J MOL BIOL, V196, P149, DOI 10.1016/0022-2836(87)90517-1; KIRPICHNIKOV MP, 1985, J BIOMOL STRUCT DYN, V3, P529, DOI 10.1080/07391102.1985.10508440; KIRPICHNIKOV MP, 1984, FEBS LETT, V175, P317, DOI 10.1016/0014-5793(84)80759-0; LAMERICHS RMJN, 1989, BIOCHEMISTRY-US, V28, P2985, DOI 10.1021/bi00433a037; LEE SJ, 1987, EMBO J, V6, P1129, DOI 10.1002/j.1460-2075.1987.tb04868.x; LEIGHTON P, 1987, BIOCHEMISTRY-US, V26, P7262, DOI 10.1021/bi00397a011; MANIATIS T, 1975, P NATL ACAD SCI USA, V72, P1184, DOI 10.1073/pnas.72.3.1184; MAYER R, 1983, FEBS LETT, V153, P339, DOI 10.1016/0014-5793(83)80638-3; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; METZLER WJ, 1989, J MOL BIOL, V205, P149, DOI 10.1016/0022-2836(89)90372-0; OHLENDORF DH, 1982, NATURE, V298, P718, DOI 10.1038/298718a0; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PTASHNE M, 1980, CELL, V19, P1, DOI 10.1016/0092-8674(80)90383-9; SARAI A, 1989, P NATL ACAD SCI USA, V86, P6513, DOI 10.1073/pnas.86.17.6513; SCHEEK RM, 1983, BIOCHEMISTRY-US, V22, P228, DOI 10.1021/bi00270a033; SCHLIEF R, 1988, SCIENCE, V242, P893; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SYKES BD, 1972, ANNU REV BIOPHYS BIO, V1, P27, DOI 10.1146/annurev.bb.01.060172.000331; TAKEDA Y, 1977, J BIOL CHEM, V252, P6177; TAKEDA Y, 1986, J BIOL CHEM, V261, P8608; TAKEDA Y, 1989, P NATL ACAD SCI USA, V86, P439, DOI 10.1073/pnas.86.2.439; WEBER PL, 1985, BIOCHEMISTRY-US, V24, P4553, DOI 10.1021/bi00338a011; WEISS MA, 1984, P NATL ACAD SCI-BIOL, V81, P130, DOI 10.1073/pnas.81.1.130; WEMMER DE, 1984, J MOL BIOL, V180, P41, DOI 10.1016/0022-2836(84)90429-7; WILLIAMS TC, 1985, NATO ASI SER, V107, P93; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; Wuthrich K., 1986, NMR PROTEINS NUCL AC	46	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22115	22124						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939232				2022-12-25	WOS:A1991GR56400011
J	JACOB, GA; LUSE, SW; LUSE, DS				JACOB, GA; LUSE, SW; LUSE, DS			ABORTIVE INITIATION IS INCREASED ONLY FOR THE WEAKEST MEMBERS OF A SET OF DOWN MUTANTS OF THE ADENOVIRUS-2 MAJOR LATE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; LAC UV5 PROMOTER; TRANSCRIPTION INITIATION; ESCHERICHIA-COLI; TERNARY COMPLEXES; INVITRO; ELONGATION; INTERMEDIATE; NUCLEOTIDES; STRENGTH	We have shown that accurate initiation of productive RNA synthesis in vitro at the adenovirus 2 major late promoter is accompanied by abortive initiation of very short transcripts (Luse, D. S., and Jacob, G. A. (1987) J. Biol. Chem. 262, 14990-14997). We made a set of sequence variants of this promoter, using every possible base at position -28 (in the TATA box) in the context of either the normal base (A) or a T at position +1 on the nontemplate strand. All changes from wild type reduced promoter strength. The two weakest promoters were 10- and 30-fold less active than wild type in productive RNA synthesis. We tested the possibility that the down mutations also caused an increase in the proportion of in vitro initiations which are abortive. This effect was seen only with the two weakest members of the promoter set. For these promoters, which share an A --> C change at the -28 position of the TATA box, the ratio of abortive to productive initiations was 3-4-fold higher than for the other promoters. Interestingly, the sequence change at +1, although a down mutation, did not lead to an increase in abortive initiation.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,231 BETHESDA AVE,CINCINNATI,OH 45267	University of Cincinnati				Jacob, George/0000-0003-4120-7334	NIGMS NIH HHS [GM 29487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNNER M, 1987, EMBO J, V6, P3139, DOI 10.1002/j.1460-2075.1987.tb02624.x; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAI H, 1987, J BIOL CHEM, V262, P298; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CONCINO MF, 1984, NUCLEIC ACIDS RES, V12, P7423, DOI 10.1093/nar/12.19.7423; COPPOLA JA, 1984, J MOL BIOL, V178, P415, DOI 10.1016/0022-2836(84)90151-7; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; HAWLEY DK, 1980, P NATL ACAD SCI-BIOL, V77, P6381, DOI 10.1073/pnas.77.11.6381; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KNAUS R, 1988, EMBO J, V7, P2919, DOI 10.1002/j.1460-2075.1988.tb03150.x; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LUSE DS, 1987, J BIOL CHEM, V262, P14990; LUSE DS, 1987, J BIOL CHEM, V262, P289; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; STRANEY SB, 1987, BIOCHEMISTRY-US, V26, P5063, DOI 10.1021/bi00390a027; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133	26	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22537	22544						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939271				2022-12-25	WOS:A1991GR56400075
J	GERARD, M; FISCHER, L; MONCOLLIN, V; CHIPOULET, JM; CHAMBON, P; EGLY, JM				GERARD, M; FISCHER, L; MONCOLLIN, V; CHIPOULET, JM; CHAMBON, P; EGLY, JM			PURIFICATION AND INTERACTION PROPERTIES OF THE HUMAN RNA POLYMERASE-B(II) GENERAL TRANSCRIPTION FACTOR BTF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA BINDING-PROTEIN; MAJOR LATE PROMOTER; INITIATION-FACTOR; II TRANSCRIPTION; ESSENTIAL COMPONENT; UPSTREAM ELEMENT; COMPLEX; BOX; CLONING; LIVER	A general transcription factor (BTF2) has been purified from HeLa whole cell extract and shown to be absolutely required for the formation of a functional initiation complex. We also demonstrate that this factor binds in solution to RNA polymerase B(II) and to the other general transcription factors BTF1(TFIID), BTF3, and BTF4. These results strongly suggest the existence of multiple interactions between the various components of the multiprotein initiation complex.			GERARD, M (corresponding author), FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE.		MONCOLLIN, Vincent/R-1941-2017; GERARD, Matthieu/D-2235-2014	MONCOLLIN, Vincent/0000-0002-4163-0231; GERARD, Matthieu/0000-0001-8956-0597				ARTAVANISTSAKONAS S, 1979, CELL, V17, P9, DOI 10.1016/0092-8674(79)90290-3; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1990, J BIOL CHEM, V265, P7552; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4117, DOI 10.1128/MCB.6.11.4117; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; GASCH A, 1990, NATURE, V346, P390, DOI 10.1038/346390a0; GISSINGER F, 1974, BIOCHIMIE, V56, P319, DOI 10.1016/S0300-9084(74)80139-2; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KAWAGUCHI T, P NATL ACAD SCI USA, V87, P6619; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MIYAMOTO NG, 1984, NUCLEIC ACIDS RES, V12, P8779, DOI 10.1093/nar/12.23.8779; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; WASYLYK C, 1986, EMBO J, V5, P553, DOI 10.1002/j.1460-2075.1986.tb04246.x; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	42	186	188	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20940	20945						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939143				2022-12-25	WOS:A1991GN00100056
J	HSU, CYJ; PERSONS, PE; SPADA, AP; BEDNAR, RA; LEVITZKI, A; ZILBERSTEIN, A				HSU, CYJ; PERSONS, PE; SPADA, AP; BEDNAR, RA; LEVITZKI, A; ZILBERSTEIN, A			KINETIC-ANALYSIS OF THE INHIBITION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR TYROSINE KINASE BY LAVENDUSTIN-A AND ITS ANALOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN CONVERTING ENZYME; PHOSPHOLIPASE C-II; ATP-BINDING-SITE; SIGNAL TRANSDUCTION; CELL-PROLIFERATION; POINT MUTATION; DNA-SYNTHESIS; PHOSPHORYLATION; MECHANISM; TYRPHOSTINS	Lavendustin-A was reported to be a potent tyrosine kinase inhibitor of the epidermal growth factor (EGF) receptor (Onoda, T., Iinuma, H., Sasaki, Y., Hamada, M., Isshibi, K., Naganawa, H., Takeuchi, T., Tatsuta, K., and Umezawa, K. (1989) J. Nat. Prod. 52, 1252-1257). Its inhibition kinetics was studied in detail using the baculovirus-expressed recombinant intracellular domain of the EGF receptor (EGFR-IC). Lavendustin-A (RG 14355) is a slow and tight binding inhibitor of the receptor tyrosine kinase. The pre-steady state kinetic analysis demonstrates that the inhibition corresponds to a two-step mechanism in which an initial enzyme-inhibitor complex (EI) is rapidly formed followed by a slow isomerization step to form a tight complex (EI*). The dissociation constant for the initial rapid forming complex is 370 nM, whereas the overall dissociation constant is estimated to be less-than-or-equal-to 1 nM. The difference between the two values is due to the tight binding nature of the inhibitor to the enzyme in EI*. The kinetic analysis using a preincubation protocol to pre-equilibrate the enzyme with the inhibitor in the presence of one substrate showed that Lavendustin-A is a hyperbolic mixed-type inhibitor with respect to both ATP and the peptide substrate, with a major effect on the binding affinities for both substrates. An analogue of Lavendustin-A (RG 14467) showed similar inhibition kinetics to that of Lavendustin-A. The results of the pre-steady state analysis are also consistent with the proposed two-step mechanism. The dissociation constant for the initial fast forming complex in this case is 3.4-mu-M, whereas the overall dissociation constant is estimated to be less-than-or-equal-to 30 nM. It is a partial (hyperbolic) competitive inhibitor with respect to ATP. Its inhibition is reduced to different extents by different peptide substrates, when the peptide is added to the enzyme simultaneously with the inhibitor. When studied with the least protective peptide, K1 (a peptide containing the major autophosphorylation site of the EGF receptor), RG 14467 acts as a hyperbolic noncompetitive inhibitor with respect to the peptide.	RHONE POULENC RORER CENT RES,KING OF PRUSSIA,PA 19406; SUNY STONY BROOK,DEPT PHARMACEUT SCI,STONY BROOK,NY 11794; HEBREW UNIV JERUSALEM,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Hebrew University of Jerusalem								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHA S, 1976, BIOCHEM PHARMACOL, V25, P1561; CHA S, 1976, BIOCHEM PHARMACOL, V25, P2695, DOI 10.1016/0006-2952(76)90259-8; ERNEUX C, 1983, J BIOL CHEM, V258, P4137; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HSU CYJ, 1991, J BIOL CHEM, V266, P603; HSU CYJ, 1990, CELL GROWTH DIFFER, V1, P191; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; IMOTO M, 1987, J ANTIBIOT, V40, P1471, DOI 10.7164/antibiotics.40.1471; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; SEGEL IH, 1975, ENZYME KINETICS, P293; SHAPIRO R, 1984, BIOCHEMISTRY-US, V23, P5234, DOI 10.1021/bi00317a022; SHAPIRO R, 1984, BIOCHEMISTRY-US, V23, P5225, DOI 10.1021/bi00317a021; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; Williams J W, 1979, Methods Enzymol, V63, P437; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	30	96	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21105	21112						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939153				2022-12-25	WOS:A1991GN00100081
J	LI, YC; CHIANG, JYL				LI, YC; CHIANG, JYL			THE EXPRESSION OF A CATALYTICALLY ACTIVE CHOLESTEROL 7-ALPHA-HYDROXYLASE CYTOCHROME-P450 IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT LIVER-MICROSOMES; MEMBRANE TOPOLOGY; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; CIRCADIAN-RHYTHM; PURIFICATION; PROTEINS; CLONING; CDNA	We have recently cloned a full-length cDNA encoding the rat hepatic cholesterol 7-alpha-hydroxylase cytochrome P450 (P450c7) (Li, Y. C., Wang, D. P., and Chiang, J. Y. L. (1990) J. Biol. Chem. 265, 12012-12019), which catalyzes the rate-limiting reaction of bile acid synthesis in the liver. By using the polymerase chain reaction, we have designed two P450c7 cDNAs. One has the second Met codon deleted and the third Thr codon replaced with an Ala. The other lacks codons for the NH2-terminal hydrophobic sequence of amino acids 2-24 (P450c7-DELTA-2-24). The cDNAs were separately cloned into the expression vector pKK233-2 and transformed into escherichia coli. After induction with isopropyl-beta-D-thiogalactopyranoside, bacteria harboring recombinant plasmids expressed a polypeptide which reacted with the antibody against cholesterol 7-alpha-hydroxylase in immunoblots. The slightly modified full-length enzyme was expressed to 0.2% of the total bacterial lysate and was located in the membrane fraction, whereas P450c7-DELTA-2-24 was expressed at a 10-fold higher level (2%), of which 85% was in the cytosol and the remaining associated with the membranes. We have purified P450c7-DELTA-2-24 which showed a typical reduced-CO difference spectrum of cytochrome P450 and reconstituted cholesterol 7-alpha-hydroxylase activity in the presence of NADPH-cytochrome P450 reductase. P450c7-DELTA-2-24 has a similar K(m) for cholesterol (24.6-mu-m) but a lower V(max) (0.10 nmol/min) and a lower turnover number (1.93 min-1) as compared with the enzyme isolated from rat liver microsomes. The purified P450c7-DELTA-2-24 has an unique hydrophilic NH2 terminus and contains monomers and dimers in equal amounts. This is the first report demonstrating that a genetically engineered cytochrome P450 enzyme lacking a typical NH2-terminal hydrophobic sequence is mainly cytosolic and catalytically active.	NORTHEASTERN OHIO UNIV,COLL MED,DEPT BIOCHEM & MOLEC PATHOL,ROOTSTOWN,OH 44272	Northeast Ohio Medical University (NEOMED)				Chiang, John/0000-0001-9360-7650	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031584] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK044442] Funding Source: Medline; NIGMS NIH HHS [GM31584] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BOSTROM H, 1982, J BIOL CHEM, V257, P1755; BRIAN WR, 1990, BIOCHEMISTRY-US, V29, P11280, DOI 10.1021/bi00503a018; CHIANG JYL, 1983, BIOCHIM BIOPHYS ACTA, V750, P291, DOI 10.1016/0005-2760(83)90031-0; CHIANG JYL, 1990, J BIOL CHEM, V265, P3889; CLARK BJ, 1991, J BIOL CHEM, V266, P5898; DANIELSSON H, 1975, ANNU REV BIOCHEM, V44, P233, DOI 10.1146/annurev.bi.44.070175.001313; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EDWARDS RJ, 1991, BIOCHEMISTRY-US, V30, P71, DOI 10.1021/bi00215a011; FERRER A, 1990, FEBS LETT, V266, P67, DOI 10.1016/0014-5793(90)81508-L; HUDECEK J, 1988, BIOCHIM BIOPHYS ACTA, V955, P361, DOI 10.1016/0167-4838(88)90216-6; IMAI Y, 1974, J BIOCHEM-TOKYO, V75, P689, DOI 10.1093/oxfordjournals.jbchem.a130441; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KEMPER B, 1989, DRUG METAB REV, V20, P811, DOI 10.3109/03602538909103580; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON JR, 1991, J BIOL CHEM, V266, P7321; LI YC, 1990, J BIOL CHEM, V265, P12012; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; MYANT NB, 1977, J LIPID RES, V18, P135; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NOSHIRO M, 1989, FEBS LETT, V257, P97, DOI 10.1016/0014-5793(89)81795-8; NOSHIRO M, 1990, J BIOL CHEM, V265, P10036; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OGISHIMA T, 1987, J BIOL CHEM, V262, P7646; OMURA T, 1964, J BIOL CHEM, V239, P2370; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; SAKAGUCHI M, 1987, EMBO J, V6, P2425, DOI 10.1002/j.1460-2075.1987.tb02521.x; SAKAKI T, 1986, J BIOCHEM-TOKYO, V99, P741, DOI 10.1093/oxfordjournals.jbchem.a135533; Sambrook J, 1989, MOL CLONING LABORATO, P324; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; TARR GE, 1983, P NATL ACAD SCI-BIOL, V80, P6552, DOI 10.1073/pnas.80.21.6552; TRETIAKOV VE, 1989, ARCH BIOCHEM BIOPHYS, V275, P429, DOI 10.1016/0003-9861(89)90389-5; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701	36	80	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19186	19191						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918035				2022-12-25	WOS:A1991GK66700014
J	MISETA, A; WOODLEY, CL; GREENBERG, JR; SLOBIN, LI				MISETA, A; WOODLEY, CL; GREENBERG, JR; SLOBIN, LI			MAMMALIAN SERYL-TRANSFER-RNA SYNTHETASE ASSOCIATES WITH MESSENGER-RNA INVIVO AND HAS HOMOLOGY TO ELONGATION FACTOR-1-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR-TU; RIBONUCLEOPROTEIN-PARTICLES; ERYTHROLEUKEMIA-CELLS; PROTEIN COMPLEXES; ULTRAVIOLET-LIGHT; THREONYL-TRANSFER; PHOSPHORYLATION; PURIFICATION; TRANSLATION; SEQUENCE	Previous work in our laboratories (Slobin, L. I., and Greenberg, J. R. (1988) Eur. J. Biochem. 173, 305-310) showed that messenger ribonucleoprotein (mRNP) particles possess a polypeptide component of approximately 62 kDa that appears to share a common epitope with eucaryotic elongation factor 1-alpha (EF-1-alpha). We report here that the previously unidentified mRNP constituent corresponds to seryl-tRNA synthetase (SerRS). Furthermore, we show that SerRS contains a sequence motif that is shared by both EF-l-alpha and glutaminyl-tRNA synthetase. We also rind that the association of SerRS with mRNA depends on the functional state of the latter. Our data suggest that SerRS may participate directly in the initiation phase of protein synthesis.	UNIV MISSISSIPPI,MED CTR,SCH MED,DEPT BIOCHEM,2500 N STATE ST,JACKSON,MS 39216; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	University of Mississippi; University of Mississippi Medical Center; University of Rochester				Miseta, Attila/0000-0002-7984-3347	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025434, R01GM038351] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25434, GM 38351] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; BADER M, 1986, EUR J BIOCHEM, V161, P103, DOI 10.1111/j.1432-1033.1986.tb10129.x; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; CHERNIACK AD, 1990, CELL, V62, P745, DOI 10.1016/0092-8674(90)90119-Y; CLEMENS MJ, 1990, TRENDS BIOCHEM SCI, V15, P172, DOI 10.1016/0968-0004(90)90153-3; DANG CV, 1989, J BIOL CHEM, V264, P5861; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; FETT R, 1991, J BIOL CHEM, V266, P1448; GREENBERG JR, 1987, FEBS LETT, V224, P54, DOI 10.1016/0014-5793(87)80421-0; GREENBERG JR, 1985, MOL CELL BIOL, V5, P342, DOI 10.1128/MCB.5.2.342; GREENBERG JR, 1988, NUCLEIC ACIDS RES, V16, P3437, DOI 10.1093/nar/16.8.3437; GREENBERG JR, 1980, NUCLEIC ACIDS RES, V8, P5685, DOI 10.1093/nar/8.23.5685; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; MIZUTANI T, 1984, EUR J BIOCHEM, V143, P9, DOI 10.1111/j.1432-1033.1984.tb08331.x; MOINE H, 1990, BIOCHIM BIOPHYS ACTA, V1050, P343, DOI 10.1016/0167-4781(90)90192-5; RAO TR, 1987, MOL CELL BIOL, V7, P687, DOI 10.1128/MCB.7.2.687; RUZDIJIC S, 1984, EUR J BIOCHEM, V142, P239, DOI 10.1111/j.1432-1033.1984.tb08277.x; SLOBIN LI, 1988, EUR J BIOCHEM, V173, P305, DOI 10.1111/j.1432-1033.1988.tb13999.x; WAGENMAKERS AJM, 1980, EUR J BIOCHEM, V112, P323, DOI 10.1111/j.1432-1033.1980.tb07207.x; WEYGANDDURASEVIC I, 1987, NUCLEIC ACIDS RES, V15, P1887, DOI 10.1093/nar/15.5.1887	23	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19158	19161						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918033				2022-12-25	WOS:A1991GK66700009
J	BRANDSCH, R; BICHLER, V				BRANDSCH, R; BICHLER, V			AUTOFLAVINYLATION OF APO6-HYDROXY-D-NICOTINE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT ATTACHMENT; FLAVIN; 6-HYDROXY-D-NICOTINE; FLAVOPROTEINS; PURIFICATION; POLYPEPTIDE; SEQUENCE; PROTEINS; FAD	6-Hydroxy-D-nicotine oxidase (6-HDNO) was expressed in Escherichia coli JM109 cells from the recombinant plasmid pAX-6-HDNO as a beta-galactosidase-6-HDNO fusion protein. Affinity chromatography of the fusion protein on p-aminobenzyl-1-thio-beta-galactopyranoside-agarose and subsequent digestion with protease Xa yielded highly purified apo6-HDNO. Incubation of the purified protein with [C-14]FAD demonstrated that flavinylation of apo6-HDNO proceeds autocatalytically. Phosphorylated three-carbon compounds such as glycerol-3-P, which are known to stimulate the formation of the histidyl (N3)-(8-alpha) FAD between apo6-HDNO and FAD (Brandsch, R., and Bichler, V. (1989) Eur. J. Biochem. 182, 125-128), could be replaced in their action by high concentrations of glycerol (45%) or sucrose (20%). These substances apparently induced and stabilized a conformational state of the apoenzyme compatible with covalent attachment of FAD. In the absence of glycerol the apoenzyme readily lost the ability to form holoenzyme at temperatures above 30-degrees-C. Holoenzyme formation protected the 6-HDNO polypeptide from this thermal denaturation. Autoflavinylation of 6-HDNO was inhibited by the sulfhydryl reagents dithionitrobenzoate or Nethylmaleimide. Inhibition was prevented by mercaptoethanol or FAD, but not 6-hydroxy-D-nicotine, the substrate of the holoenzyme. A cysteine-thiol group may therefore be involved in reactions leading to the covalent attachment of FAD to apo6-HDNO. When flavinylation of apo6-HDNO proceeded under anaerobic conditions, the amount of incorporation of [C-14] FAD into the polypeptide was indistinguishable from reactions performed in the presence of O2. None of the FAD-derivatives (8-demethyl-FAD, 8-chloro-FAD, and 5-deaza-FAD) could replace FAD in holoenzyme formation. The failure of covalent attachment of 5-deaza-FAD to apo6-HDNO is in agreement with the assumption that the quinone methide form of the isoalloxazine ring is an intermediate in the flavinylation reaction.			BRANDSCH, R (corresponding author), BIOCHEM INST,HERMANN HERDER STR 7,W-7800 FREIBURG,GERMANY.							BRANDSCH R, 1989, EUR J BIOCHEM, V182, P125, DOI 10.1111/j.1432-1033.1989.tb14808.x; COLE ST, 1988, J BACTERIOL, V170, P2448, DOI 10.1128/jb.170.6.2448-2456.1988; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DECKER K, 1982, FLAVINS FLAVOPROTEIN, P465; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GROSS NH, 1984, METHOD ENZYMOL, V107, P261; HINKKANEN A, 1983, H-S Z PHYSIOL CHEM, V364, P801, DOI 10.1515/bchm2.1983.364.2.801; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; MANIATIS T, 1982, MOL CLONING LABORATO, P504; MAUCH L, 1990, J BIOL CHEM, V265, P12761; MOHLER H, 1972, EUR J BIOCHEM, V29, P152, DOI 10.1111/j.1432-1033.1972.tb01969.x; MOORE EG, 1978, J BIOL CHEM, V253, P6413; NAGURSKY M, 1988, EUR J BIOCHEM, V177, P319; RAGAN I, 1977, BIOCHEM J, V163, P605; RUCKER RB, 1988, FASEB J, V2, P2251; SINGER TP, 1984, METHOD ENZYMOL, V106, P369; SINGER TP, 1955, ARCH BIOCHEM BIOPHYS, V60, P255; ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8; VISCO C, 1985, J BIOL CHEM, V260, P6133; WALSH C, 1980, ACCOUNTS CHEM RES, V13, P148, DOI 10.1021/ar50149a004	20	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19056	19062						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918024				2022-12-25	WOS:A1991GJ47200100
J	CLARKE, CL; GRAHAM, J; ROMAN, SD; SUTHERLAND, RL				CLARKE, CL; GRAHAM, J; ROMAN, SD; SUTHERLAND, RL			DIRECT TRANSCRIPTIONAL REGULATION OF THE PROGESTERONE-RECEPTOR BY RETINOIC ACID DIMINISHES PROGESTIN RESPONSIVENESS IN THE BREAST-CANCER CELL-LINE T-47D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; EPIDERMAL GROWTH-FACTOR; THYROID-HORMONE; GENE-TRANSCRIPTION; RESPONSE ELEMENT; CARCINOMA CELLS; BETA-CAROTENE; FACTOR-ALPHA; MCF-7 CELLS; VITAMIN-A	Retinoic acid (RA) treatment of T-47D human breast cancer cells results in a rapid decrease in the concentration of progesterone receptor (PR) mRNA which causes a slow loss of cellular PR protein (Clark, C. L., Roman, S.D., Graham, J., Koga, M., Sutherland, R. L. (1990) J. Biol. Chem. 265, 12694-12700). The mechanisms involved are unknown and this study was undertaken to determine whether the decline in PR mRNA was due to transcriptional inhibition and to evaluate the functional consequences of the RA-mediated decrease in PR. The transcription rate of the PR gene was decreased by RA, and the effect was maximal 2-3 h after treatment. Cycloheximide cotreatment was unable to relieve the inhibitory effect of RA on PR transcription suggesting that the effect was not dependent on ongoing protein synthesis. There was no effect of RA on PR mRNA half-life at the times examined (0-6 h of RA treatment). To determine the functional consequence of PR down-regulation the progestin-responsive plasmid pMSG-CAT was expressed transiently in T-47D cells which were then exposed to RA for 24 h. RA-pretreated cells were then treated with the synthetic progestin ORG 2058 and the extent of progestin stimulation of chloramphenicol acetyltransferase (CAT) activity measured. ORG 2058 treatment resulted in an induction of CAT activity which was maximal at a progestin concentration of 1 nM. Interestingly, the ability of ORG 2058 to induce CAT activity was decreased in RA-pretreated cells. The diminished progestin responsiveness of RA-pretreated cells was confirmed in separate experiments which showed that the progestin inducibility of TGF-alpha mRNA was also decreased in cells treated with ORG 2058 following pretreatment with RA for 24 h. These data demonstrate that RA decreases PR mRNA concentrations by direct transcriptional inhibition, leading to decreased cellular PR concentrations. The decreased levels of PR result in impaired responsiveness to progestins and this suggests that RA derived from dietary vitamin A may have a role in modulating cellular sensitivity to progestins.			CLARKE, CL (corresponding author), ST VINCENTS HOSP,GARVAN INST MED RES,DARLINGHURST,NSW 2010,AUSTRALIA.		ROMAN, SHAUN/G-7047-2013; Roman, Shaun/AFR-5087-2022; Sutherland, Robert L/A-8378-2008	ROMAN, SHAUN/0000-0002-7758-7757; Clarke, Christine/0000-0001-7568-111X				ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; CLARKE CL, 1987, ENDOCRINOLOGY, V121, P1123, DOI 10.1210/endo-121-3-1123; CLARKE CL, 1990, J BIOL CHEM, V265, P12694; CONNEELY OM, 1986, SCIENCE, V233, P767, DOI 10.1126/science.2426779; DANNENBERG AM, 1981, METHODS STUDYING MON, P375; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EWING TM, 1989, INT J CANCER, V44, P744, DOI 10.1002/ijc.2910440432; FEIL PD, 1988, ENDOCRINOLOGY, V123, P2506, DOI 10.1210/endo-123-5-2506; FEIL PD, 1988, CANCER RES, V48, P1143; FONTANA JA, 1988, EXP CELL BIOL, V56, P254; FONTANA JA, 1990, CANCER RES, V50, P1997; FONTANA JA, 1987, EXP CELL BIOL, V55, P136; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GERBER M, 1988, INT J CANCER, V42, P489, DOI 10.1002/ijc.2910420403; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLOVER JF, 1989, J STEROID BIOCHEM, V32, P357, DOI 10.1016/0022-4731(89)90207-0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAHAM S, 1982, AM J EPIDEMIOL, V116, P68, DOI 10.1093/oxfordjournals.aje.a113403; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL RE, 1990, INT J CANCER, V46, P1081, DOI 10.1002/ijc.2910460622; HOLM LE, 1989, J NATL CANCER I, V81, P1218, DOI 10.1093/jnci/81.16.1218; HORWITZ KB, 1985, DNA-J MOLEC CELL BIO, V4, P451, DOI 10.1089/dna.1985.4.451; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; KOGA M, 1991, IN PRESS J STEROID B; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; LOGEAT F, 1985, BIOCHEM BIOPH RES CO, V131, P421, DOI 10.1016/0006-291X(85)91819-4; LOOSFELT H, 1986, P NATL ACAD SCI USA, V83, P9045, DOI 10.1073/pnas.83.23.9045; MARTH C, 1985, J NATL CANCER I, V75, P871, DOI 10.1093/jnci/75.5.871; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Middleton B, 1986, Nutr Cancer, V8, P107; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; MOON RC, 1990, BASIC LIFE SCI, V52, P213; MULLICK A, 1986, J BIOL CHEM, V261, P3236; MURPHY LC, 1989, CANCER RES, V49, P599; MURPHY LC, 1989, MOL ENDOCRINOL, V3, P611, DOI 10.1210/mend-3-4-611; MUSGROVE AE, 1991, IN PRESS MOL CELL BI; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P1532, DOI 10.1210/endo-122-4-1532; NG KW, 1989, MOL ENDOCRINOL, V3, P2079, DOI 10.1210/mend-3-12-2079; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; PAGANINIHILL A, 1987, JNCI-J NATL CANCER I, V79, P443; PEARSON B, 1963, LAB INVEST, V12, P1249; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; RAGSDALE CW, 1989, NATURE, V341, P654, DOI 10.1038/341654a0; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; REDDEL RR, 1985, CANCER RES, V45, P1525; REISS M, 1988, J INVEST DERMATOL, V91, P344, DOI 10.1111/1523-1747.ep12475690; ROHAN TE, 1988, AM J EPIDEMIOL, V128, P478, DOI 10.1093/oxfordjournals.aje.a114996; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; Sambrook J, 1989, MOL CLONING LABORATO; SHERIDAN PL, 1988, MOL ENDOCRINOL, V2, P1329, DOI 10.1210/mend-2-12-1329; SHERIDAN PL, 1989, J BIOL CHEM, V264, P7054; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SPORN MB, 1976, FED PROC, V35, P1332; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; VERMA AK, 1988, CANCER RES, V48, P2168; WEI LL, 1987, BIOCHEMISTRY-US, V26, P6262, DOI 10.1021/bi00393a046; WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62; WETHERALL NT, 1986, EUR J CANCER CLIN ON, V22, P53, DOI 10.1016/0277-5379(86)90342-1; WU KC, 1988, MOL ENDOCRINOL, V2, P1294, DOI 10.1210/mend-2-12-1294; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	77	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18969	18975						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918012				2022-12-25	WOS:A1991GJ47200086
J	REINLIB, L; HOMAIDAN, F; WATSON, A; BREDT, DS; SHARP, GWG; ZAHNISER, D; DONOWITZ, M				REINLIB, L; HOMAIDAN, F; WATSON, A; BREDT, DS; SHARP, GWG; ZAHNISER, D; DONOWITZ, M			UNCOUPLING OF PHOSPHOLIPASE-C FROM RECEPTOR REGULATION OF [CA2+]I IN T84 COLONIC CELLS BY PROLONGED EXPOSURE TO PHORBOL DIBUTYRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; INOSITOL 1,4,5-TRISPHOSPHATE; CHLORIDE SECRETION; 2ND MESSENGER; LINE; CALCIUM; CA-2+; TRISPHOSPHATE; PHOSPHATES; MECHANISMS	The T84 colonic cell line, a cultured Cl- secretory cell, elevates intracellular free Ca2+ ([Ca2+]i) in a concentration-dependent manner when exposed to carbachol or histamine. As determined with a fluorescence microscope imaging system, exposure of T84 cells to 100-mu-M carbachol or histamine resulted in an immediate [Ca2+]i rise of approximately 50-80 nM in all cells. Preincubation of monolayers for 1 h or longer with 0.4-mu-M phorbol 12,13-dibutyrate (PDB) reduced the number of cells which responded to histamine or carbachol and reduced the magnitude of the increase in the responding cells. This effect reached its maximum after 2 h and persisted for at least 24 h of PDB incubation. Binding of quinuclidinyl benzilate, a cholinergic receptor antagonist, indicated that down-regulation of external receptors was not an explanation for this effect. Examination of phospholipase C activity in T84 cell membranes showed increased basal activity in PDB-treated compared with control cells. Measurement of inositol phosphates generated by intact cells using myo-[H-3]inositol incorporation or receptor binding assays showed that 2 h of incubation with PDB elevated basal levels of inositol 1,4,5-trisphosphate and prevented any further carbachol-induced generation of inositol trisphosphate. Probably as a consequence, both total cell calcium and Ca2+ ionophore-releasable calcium were decreased after 2 h of PDB incubation. Membrane-associated protein kinase C activity was elevated after a 2 h exposure to PDB but was below the level of detection after 24 h with PDB. Protein kinase C antagonists neither duplicated nor blocked the uncoupling of carbachol receptors induced by long term treatment with PDB. The results suggest that prolonged PDB incubation caused uncoupling and elevation of phospholipase C activity from cholinergic and histaminergic receptor regulation resulting in increased basal levels of inositol 1,4,5-trisphosphate. Protein kinase C apparently is not involved directly in the mechanism that leads to these effects.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL & NEUROSCI,BALTIMORE,MD 21205; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111; NEW ENGLAND MED CTR HOSP,BOSTON,MA 02111; CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853	Johns Hopkins University; Johns Hopkins University; Tufts University; Tufts University; Tufts Medical Center; Cornell University	REINLIB, L (corresponding author), NIAAA,DIV INTRAMURAL CLIN & BIOL RES,12501 WASHINGTON AVE,ROCKVILLE,MD 20852, USA.		Bredt, David/J-4872-2012		NIDDK NIH HHS [DK31667, P01 DK39428, R01 DK26523] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031667, R01DK026523] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1987, ANN NY ACAD SCI, V494, P39, DOI 10.1111/j.1749-6632.1987.tb29479.x; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BEUERLEIN G, 1987, CLIN RES, V35, P588; Bevington PR, 1969, DATA REDUCTION ERROR; BREDT DS, 1989, BIOCHEM BIOPH RES CO, V159, P976, DOI 10.1016/0006-291X(89)92204-3; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; DHARMSATHAPHORN K, 1989, AM J PHYSIOL, V256, pC1224, DOI 10.1152/ajpcell.1989.256.6.C1224; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; DHARMSATHAPHORN K, 1985, J CLIN INVEST, V75, P462, DOI 10.1172/JCI111721; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; ISSANDOU M, 1989, BIOCHEM BIOPH RES CO, V163, P201, DOI 10.1016/0006-291X(89)92121-9; MADARA JL, 1985, J CELL BIOL, V101, P2124, DOI 10.1083/jcb.101.6.2124; MERRITT JE, 1987, J BIOL CHEM, V262, P4958; MUSCHOLL E, 1970, BAYER S, V2, P168; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RABEN DM, 1987, BIOCHEMISTRY-US, V26, P2759, DOI 10.1021/bi00384a016; REINLIB L, 1989, AM J PHYSIOL, V257, pG950, DOI 10.1152/ajpgi.1989.257.6.G950; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; VONGKOVIT P, 1989, GASTROENTEROLOGY, V96, P532; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314	24	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17904	17911						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917930				2022-12-25	WOS:A1991GG55300032
J	YAMADA, Y; CHANG, YY; DANIELS, GA; WU, LF; TOMICH, JM; YAMADA, M; SAIER, MH				YAMADA, Y; CHANG, YY; DANIELS, GA; WU, LF; TOMICH, JM; YAMADA, M; SAIER, MH			INSERTION OF THE MANNITOL PERMEASE INTO THE MEMBRANE OF ESCHERICHIA-COLI - POSSIBLE INVOLVEMENT OF AN N-TERMINAL AMPHIPHILIC SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; MITOCHONDRIAL OUTER-MEMBRANE; SITE-SPECIFIC MUTAGENESIS; AMINO-ACID SEQUENCE; ENZYME-II; NUCLEOTIDE-SEQUENCE; PROTEIN EXPORT; RHODOBACTER-CAPSULATUS; PHENOTYPIC SELECTION; SUGAR-TRANSPORT	The in vivo membrane assembly of the mannitol permease, the mannitol Enzyme II (II(mtl)) of the Escherichia coli phosphotransferase system, has been studied employing molecular genetic approaches. Removal of the N-terminal amphiphilic leader of the permease and replacement with a short hydrophobic sequence resulted in an inactive protein unable to transport mannitol into the cell or catalyze either phosphoenolpyruvate-dependent or mannitol 1-phosphate-dependent mannitol phosphorylation in vitro. The altered protein (68 kDa) was quantitatively cleaved by an endogenous protease to a membrane-associated 39-kDa fragment and a soluble 28-kDa fragment as revealed by Western blot analyses. Overproduction of the wild-type plasmid-encoded protein also led to cleavage, but repression of the synthesis of the plasmid-encoded enzyme by inclusion of glucose in the growth medium prevented cleavage. Several mtlA-phoA gene fusions encoding fused proteins with N-terminal regions derived from the mannitol permease and C-terminal regions derived from the mature portion of alkaline phosphatase were constructed. In the first fusion protein, F13, the N-terminal 13-aminoacyl residue amphiphilic leader sequence of the mannitol permease replaced the hydrophobic leader sequence of alkaline phosphatase. The resultant fusion protein was inefficiently translocated across the cytoplasmic membrane and became peripherally associated with both the inner and outer membranes, presumably via the noncleavable N-terminal amphiphilic sequence. The second fusion protein, F53, in which the N-terminal 53 residues of the mannitol permease were fused to alkaline phosphatase, was efficiently translocated across the cytoplasmic membrane and was largely found anchored to the inner membrane with the catalytic domain of alkaline phosphatase facing the periplasm. This 53-aminoacyl residue sequence included the amphiphilic leader sequence and a single hydrophobic, potentially transmembrane, segment. Analyses of other MtlA-PhoA fusion proteins led to the suggestion that internal amphiphilic segments may function to facilitate initiation of polypeptide transmembrane translocation. The dependence of II(mtl) insertion on the N-terminal amphiphilic leader sequence was substantiated employing site-specific mutagenesis. The N-terminal sequence of the native permease is Met-Ser-Ser-Asp-Ile-Lys-Ile-Lys-Val-Gln-Ser-Phe-Gly....The following point mutants were isolated, sequenced, and examined regarding the effects of the mutations on insertion of II(mtl) into the membrane: 1) S3P; 2) D4P; 3) D4L; 4) D4R; 5) D4H; 6) I5N; 7) K6P; and 8) K8P. Mutations 1-5 virtually abolished insertion of the permease into the membrane as estimated by (a) mannitol fermentation responses in vivo, (b) mannitol uptake activity in vivo, (c) mannitol phosphorylation activity in vitro, and (d) Western blot analysis of the mutant proteins. By contrast, mutations 6-8 were either without effect or had only a slight inhibitory effect on the insertion process. Mutations 1-5, but not 6-8, also abolished export of the two mannitol permease-alkaline phosphatase fusion proteins, F13 and F53. The results therefore suggest that (a) residues S3 and D4 in II(mtl) are critical for correct insertion of the native mannitol permease into the membrane, (b) residues Ile-5, Lys-6, and Lys-8 are less important to this process, and (c) the recognition process involving the N-terminal targeting sequence for insertion of II(mtl) into the bilayer can also be utilized to initiate secretion of a water-soluble periplasmic protein across the cytoplasmic membrane.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego				TOMICH, JOHN/0000-0001-7848-8307; Yamada, Mamoru/0000-0003-4354-7324	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014176, R01AI021702] Funding Source: NIH RePORTER; NIAID NIH HHS [5RO1AI21702, 2RO1AI14176] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; Boyd D, 1987, PHOSPHATE METABOLISM, P89; CHANG YY, 1986, J BACTERIOL, V167, P312, DOI 10.1128/jb.167.1.312-318.1986; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; DANIELS GA, 1988, J BACTERIOL, V170, P1698, DOI 10.1128/jb.170.4.1698-1703.1988; ERNI B, 1987, J BIOL CHEM, V262, P5238; GASCUEL O, 1986, J MOL EVOL, V24, P130, DOI 10.1007/BF02099961; GRENIER FC, 1985, BIOCHEMISTRY-US, V24, P47, DOI 10.1021/bi00322a008; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HERMES JD, 1989, GENE, V84, P143, DOI 10.1016/0378-1119(89)90148-0; HORABIN JI, 1988, J BIOL CHEM, V263, P11575; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; JACOBSON GR, 1983, J BIOL CHEM, V258, P2955; JACOBSON GR, 1983, J BIOL CHEM, V258, P748; KHANDEKAR SS, 1989, J CELL BIOCHEM, V39, P207, DOI 10.1002/jcb.240390212; King T.E., 1967, METHOD ENZYMOL, V10, P322, DOI DOI 10.1016/0076-6879(67)10061-X; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1986, ANNU REV CELL BIOL, V2, P315, DOI 10.1146/annurev.cellbio.2.1.315; LEE CA, 1981, P NATL ACAD SCI-BIOL, V78, P7336, DOI 10.1073/pnas.78.12.7336; LEE CA, 1983, J BACTERIOL, V153, P685, DOI 10.1128/JB.153.2.685-692.1983; LEE CA, 1983, J BIOL CHEM, V258, P761; LEONARD JE, 1983, J BIOL CHEM, V258, P757; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1987, PHOSPHATE METABOLISM, P94; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Miller J.H., 1972, EXPT MOL GENETICS; NOSSAL NG, 1966, J BIOL CHEM, V241, P3055; OSBORN MJ, 1963, P NATL ACAD SCI USA, V50, P499, DOI 10.1073/pnas.50.3.499; PRIOR TI, 1988, J GEN MICROBIOL, V34, P2757; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; ROISE D, 1988, J BIOL CHEM, V263, P4509; ROOSSIEN FF, 1984, BIOCHEMISTRY-US, V23, P5682, DOI 10.1021/bi00319a003; Ross G W, 1975, Methods Enzymol, V43, P69; SAIER MH, 1988, J BACTERIOL, V170, P2296, DOI 10.1128/jb.170.5.2296-2300.1988; SAIER MH, 1977, J BIOL CHEM, V252, P8899; SAIER MH, 1988, BIOCHIMIE, V70, P1743, DOI 10.1016/0300-9084(88)90033-8; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; SAIER MH, 1988, FASEB J, V2, P199, DOI 10.1096/fasebj.2.3.2832233; SAIER MH, 1989, FEMS MICROBIOL REV, V63, P183; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHWARTZ M, 1987, CELLULAR MOL BIOL, V2, P1482; SHUTTLEWORTH H, 1986, NUCLEIC ACIDS RES, V14, P8689, DOI 10.1093/nar/14.21.8689; SIMONI RD, 1973, J BIOL CHEM, V248, P966; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P8230, DOI 10.1021/bi00373a016; TAMM LK, 1989, J BIOL CHEM, V264, P2587; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGLER AP, 1988, MOL GEN GENET, V213, P175, DOI 10.1007/BF00333417; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WU LF, 1990, J MOL BIOL, V213, P687, DOI 10.1016/S0022-2836(05)80256-6; YAMADA M, 1987, J BACTERIOL, V169, P5416, DOI 10.1128/jb.169.12.5416-5422.1987; YAMADA M, 1987, J BIOL CHEM, V262, P5455; YAMATO I, 1975, J BIOCHEM, V77, P705, DOI 10.1093/oxfordjournals.jbchem.a130774	62	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17863	17871						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917927				2022-12-25	WOS:A1991GG55300027
J	CZAJKOWSKI, C; KARLIN, A				CZAJKOWSKI, C; KARLIN, A			AGONIST BINDING-SITE OF TORPEDO ELECTRIC TISSUE NICOTINIC ACETYLCHOLINE-RECEPTOR - A NEGATIVELY CHARGED REGION OF THE DELTA-SUBUNIT WITHIN 0.9 NM OF THE ALPHA-SUBUNIT BINDING-SITE DISULFIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING REAGENT; MONOCLONAL-ANTIBODIES; MOLECULAR-WEIGHT; CALIFORNICA; PROTEINS; LIGAND; MEMBRANES; IDENTIFICATION; TERMINUS	The positively charged quaternary ammonium group of agonists of the nicotinic acetylcholine (ACh) receptor binds to a negative subsite at most about 1 nm from a readily reducible disulfide. This disulfide is formed by alpha-Cys192 and Cys193 (Kao and Karlin, 1986). In order to identify Asp or Glu residues that may contribute to the negative subsite, we synthesized S-(2-[H-3]glycylamidoethyl)dithio 2-pyridine. Purified ACh receptor from Torpedo californica was mildly reduced and reacted with S-(2-[H-3]glycylamidoethyl)dithio-2-pyridine. The predominant product was a mixed disulfide between the H-3-N-glycylcysteamine moiety and alpha-Cys192 or Cys193. In the extended conformation of [H-3] N-glycylcysteamine, the distance from the glycyl amino group to the cysteamine thio group is 0.9 nm. Thus, the amino group of disulfide-linked [H-3]N-glycylcysteamine could react with carboxyls within 0.9 nm of Cys192/Cys193. To promote amide bond formation between the tethered amino group and receptor carboxyls, we added 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide. The predominant sites of amide coupling were on the delta-subunit, in CNBr fragment 4 (delta-164-257). This reaction was inhibited by ACh. Only the first 61 residues of delta CNBr 4 are predicted to be extracellular, and there are 11 Asp or Glu residues in this region. One or more of these residues is likely to contribute to the binding of ACh.	COLUMBIA UNIV,CTR MOLEC RECOGNIT,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT NEUROL,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT BIOCHEM,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT PHYSIOL,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University				KARLIN, ARTHUR/0000-0002-4813-752X	NINDS NIH HHS [NS-07065, NS-07258] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOULTER J, 1990, J BIOL CHEM, V265, P4472; BROCKLEHURST K, 1973, BIOCHEM J, V133, P67, DOI 10.1042/bj1330067; CHONG PCS, 1981, J BIOL CHEM, V256, P5064; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; CZAJKOWSKI C, 1989, ARCH BIOCHEM BIOPHYS, V272, P412, DOI 10.1016/0003-9861(89)90235-X; DAMLE VN, 1978, BIOCHEMISTRY-US, V17, P2039, DOI 10.1021/bi00604a002; DAMLE VN, 1978, BIOCHEM BIOPH RES CO, V84, P845, DOI 10.1016/0006-291X(78)91661-3; DAMLE VN, 1980, BIOCHEMISTRY-US, V19, P3924, DOI 10.1021/bi00558a006; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DHANASEKARAN N, 1988, J BIOL CHEM, V263, P17942; DIPAOLA M, 1989, J BIOL CHEM, V264, P15457; DIPAOLA M, 1990, J BIOL CHEM, V265, P11017; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; DOWDING AJ, 1987, BIOCHEMISTRY-US, V26, P6372, DOI 10.1021/bi00394a010; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; HAMILTON SL, 1979, BIOCHEMISTRY-US, V18, P155, DOI 10.1021/bi00568a024; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; KARLIN A, 1991, HARVEY LECT, V85, P71; Karlin A, 1977, Methods Enzymol, V46, P582; KARLIN A, 1966, BIOCHIM BIOPHYS ACTA, V126, P525, DOI 10.1016/0926-6585(66)90010-0; KARLIN A, 1983, J BIOL CHEM, V258, P6678; Karlin A., 1969, J GEN PHYSIOL, V54, P245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEANS GE, 1971, CHEM MODIFICATION PR, P144; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; NOMOTO H, 1986, EUR J BIOCHEM, V157, P233, DOI 10.1111/j.1432-1033.1986.tb09661.x; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; PETERS K, 1977, ANNU REV BIOCHEM, V46, P523, DOI 10.1146/annurev.bi.46.070177.002515; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIEBLER W, 1977, FEBS LETT, V81, P39, DOI 10.1016/0014-5793(77)80923-X; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SCHROEDER WA, 1969, ARCH BIOCHEM BIOPHYS, V130, P551, DOI 10.1016/0003-9861(69)90069-1; SILMAN I, 1969, SCIENCE, V164, P1420, DOI 10.1126/science.164.3886.1420; SINE SM, 1981, J BIOL CHEM, V256, P6692; SMITH I, 1969, CHROMATOGR ELECTROPH, V1, P122; SPIVAK CE, 1982, PROGR CHOLINERGIC BI, P323; TARR GE, 1986, METHODS PROTEIN MICR, P164; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TZARTOS S, 1986, J NEUROIMMUNOL, V10, P235, DOI 10.1016/0165-5728(86)90105-0; WEILL CL, 1974, BIOCHEM BIOPH RES CO, V61, P997, DOI 10.1016/0006-291X(74)90254-X	48	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22603	22612						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939274				2022-12-25	WOS:A1991GR56400084
J	KWON, O; KWOK, F; CHURCHICH, JE				KWON, O; KWOK, F; CHURCHICH, JE			CATALYTIC AND REGULATORY PROPERTIES OF NATIVE AND CHYMOTRYPSIN-TREATED PYRIDOXINE-5-PHOSPHATE OXIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PYRIDOXAL KINASE; TRYPTOPHAN-METABOLITES; 5-PHOSPHATE; CLEAVAGE	Brain pyridoxine-5-P oxidase is activated by the trytophan metabolites 3-hydroxyanthranilate and 3-hydroxykynurenine. 3-Hydroxyanthranilate at concentrations of 0.03 mM relieves the inhibition elicited by accumulation of the substrate pyridoxine-5-P (K(i) = 60-mu-M). The results of fluorometric measurements indicate that four molecules of 3-hydroxyanthranilate bind to the dimeric enzyme (56 kDa) with an association constant of 5.5 x 10(4) M-1. Differential spectral measurements failed to detect any direct interaction between the cofactor FMN and the effector 3-hydroxyanthranilate. These results are consistent with the hypothesis that the effector molecules bind to sites of the dimeric protein distinct from the cofactor site. Limited chymotrypsin digestion of pyridoxine-5-P oxidase yields catalytically active species that are no longer susceptible to activation by 3-hydroxykvnurenine. A polypeptide of 16 kDa containing FMN and endowed with full catalytic activity was isolated by ion-exchange chromatography. It is postulated that the structural domain associated with catalytic activity composes approximately one-half of the molecular mass of pyridoxine-5-P oxidase (28 kDa), whereas the remaining portion of the macromolecule contains regulatory binding sites.	HONG KONG POLYTECH,APPL BIOL & CHEM TECHNOL,HONG KONG,HONG KONG	Hong Kong Polytechnic University	KWON, O (corresponding author), UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996, USA.							CHOI JD, 1983, J BIOL CHEM, V258, P810; CHOI SY, 1987, J BIOL CHEM, V262, P12013; CHURCHICH JE, 1984, EUR J BIOCHEM, V138, P327, DOI 10.1111/j.1432-1033.1984.tb07918.x; DONALD EA, 1986, VITAMIN B6 PYRIDOXAL, P477; KARAWYA E, 1981, BIOCHIM BIOPHYS ACTA, V657, P153, DOI 10.1016/0005-2744(81)90138-8; KIM YT, 1989, J BIOL CHEM, V264, P15751; KWOK F, 1980, J BIOL CHEM, V255, P882; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCORMICK DB, 1980, VITAMIN B6 METABOLIS, P1; Snell E. E., 1970, COMPREHENSIVE BIOCH, V21, P47; TAKEUCHI F, 1985, BIOCHEM J, V227, P537, DOI 10.1042/bj2270537; TARELLI GT, 1990, J BIOL CHEM, V265, P21242; TRYFIATES GP, 1986, VITAMIN B6 PYRIDOXAL, P422	13	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22136	22140						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939234				2022-12-25	WOS:A1991GR56400014
J	KUMAR, S; BAGLIONI, C				KUMAR, S; BAGLIONI, C			PROTECTION FROM TUMOR NECROSIS FACTOR-MEDIATED CYTOLYSIS BY OVEREXPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANOUS SUPEROXIDE-DISMUTASE; ARACHIDONIC-ACID METABOLISM; INDUCED CYTO-TOXICITY; PHOSPHOLIPASE-A2 ACTIVATION; VASCULAR ENDOTHELIUM; HUMAN-FIBROBLASTS; CELLS; MECHANISM; RECEPTORS; SERINE	Pretreatment of HT-1080 fibrosarcoma cells with tumor necrosis factor (TNF) induced resistance to the cytolytic activity of this cytokine in combination with cycloheximide. This resistance correlated with the synthesis of plasminogen activator inhibitor type-2 (PAI-2). HT-1080 cells were transfected with a PAI-2 expression vector in both sense and antisense orientation. The resistance to TNF-mediated cytolysis of transfected cell clones was correlated with the level of PAI-2 expression. Cells expressing antisense PAI-2 RNA showed reduced expression of PAI-2 and increased sensitivity to TNF-mediated cytolysis. Cells expressing constitutively PAI-2 were treated with TNF and cycloheximide to select cells with increased resistance to cytolysis and enhanced PAI-2 expression. PAI-2 gradually disappeared during a treatment with TNF and cycloheximide. This finding suggested that PAI-2 formed a complex with a target proteinase, which could be involved in mediating the cytolytic activity of TNF.			KUMAR, S (corresponding author), SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222, USA.				NATIONAL CANCER INSTITUTE [R01CA029895] Funding Source: NIH RePORTER; NCI NIH HHS [CA29895] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; BAGLIONI C, 1985, J BIOL CHEM, V260, P3395; BELIN D, 1989, EMBO J, V8, P3287, DOI 10.1002/j.1460-2075.1989.tb08489.x; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEUTLER B, 1986, IMMUNOL RES, V5, P281, DOI 10.1007/BF02935501; BEVILACQUA MP, 1986, P NATL ACAD SCI USA, V83, P4533, DOI 10.1073/pnas.83.12.4533; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHANG TW, 1980, J IMMUNOL, V124, P1028; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; FRYE LD, 1975, NATURE, V258, P333, DOI 10.1038/258333a0; HOFFMAN T, 1981, P NATL ACAD SCI-BIOL, V78, P3839, DOI 10.1073/pnas.78.6.3839; HUDIG D, 1984, J IMMUNOL, V133, P2647; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; KIRSTEIN M, 1986, J BIOL CHEM, V261, P9565; KRUITHOF EKO, 1986, J BIOL CHEM, V261, P1207; MARAGANORE JM, 1986, TRENDS BIOCHEM SCI, V11, P497, DOI 10.1016/0968-0004(86)90076-9; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MEDCALF RL, 1988, J EXP MED, V168, P751, DOI 10.1084/jem.168.2.751; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NEALE ML, 1988, IMMUNOLOGY, V64, P81; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; PYTEL BA, 1990, J CELL PHYSIOL, V144, P416, DOI 10.1002/jcp.1041440308; RUBIN BY, 1985, J EXP MED, V162, P1099, DOI 10.1084/jem.162.3.1099; RUGGIERO V, 1986, J IMMUNOL, V136, P2445; RUGGIERO V, 1987, CELL IMMUNOL, V107, P317, DOI 10.1016/0008-8749(87)90240-1; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; SUFFYS P, 1988, FEBS LETT, V232, P24, DOI 10.1016/0014-5793(88)80379-X; SUFFYS P, 1987, BIOCHEM BIOPH RES CO, V149, P735, DOI 10.1016/0006-291X(87)90429-3; SUFFYS P, 1988, EUR J BIOCHEM, V178, P257, DOI 10.1111/j.1432-1033.1988.tb14451.x; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WALLACH D, 1984, J IMMUNOL, V132, P2464; WATANABE N, 1988, IMMUNOPHARM IMMUNOT, V10, P109, DOI 10.3109/08923978809014405; WILLIAMSON BD, 1983, P NATL ACAD SCI-BIOL, V80, P5397, DOI 10.1073/pnas.80.17.5397; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6	41	183	189	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20960	20964						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939146				2022-12-25	WOS:A1991GN00100059
J	OKA, T; RAIRKAR, A; CHEN, JH				OKA, T; RAIRKAR, A; CHEN, JH			STRUCTURAL AND FUNCTIONAL-ANALYSIS OF THE REGULATORY SEQUENCES OF THE ETS-1 GENE	ONCOGENE			English	Article							LONG TERMINAL REPEAT; ONCOGENE C-ETS; TRANSCRIPTION FACTOR; EXPRESSION SYSTEM; ENHANCER; LEUKEMIA; PROMOTER; BINDING; LOCALIZATION; CLONING	The ets-1 gene is a human homolog of the oncogene v-ets of avian acute leukemia virus E26. The ets-1 gene is preferentially expressed in lymphoid cells. To understand the regulation of the ets-1 gene expression the regulatory sequences of this gene were identified and isolated. The promoter is found to be functioning in the lymphoid cell line Daudi and the erythromyeloid cell line K562 but not in the promyelocytic cell line HL60. Sequence analysis indicates that the ets-1 promoter does not contain the TATA or CAT box. It contains multiple transcription initiation sites in a tight cluster. The promoter contains one binding site each for AP1 and AP2. It has one definitive and five presumptive sp1-binding sites. In addition, the ets-1 promoter contains one ets-1 protein-binding site. Functional analysis has shown that c-jun enhances the activity of the ets-1 promoter, whereas the combination of c-fos and c-jun expressions has no synergistic effect. The expression of exogenous AP2 and ets-1 also enhances the activity of the ets-1 promoter. These results suggest that the AP1, AP2 and ets-1 proteins have a positive regulatory effect. The presence of the ets-I protein-binding site indicates the existence of an autoregulatory mechanism for the expression of the ets-1 gene. Our results suggested that the presence of a negative regulatory element upstream of the region where most of the positive regulators are located.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIATR,BOX 88,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center								Abate C, 1990, Semin Cancer Biol, V1, P19; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOULUKOS KD, 1989, MOL CELL BIOL, V95, P5718; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1990, ONCOGENE RES, V5, P277; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; FUJIWARA S, 1988, ONCOGENE, V2, P99; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KANEKO Y, 1986, BLOOD, V67, P484; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MAJERUS MA, 1990, 6TH ANN M ON FRED, P193; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WOOD WM, 1989, J BIOL CHEM, V264, P14840	27	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2077	2083						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945412				2022-12-25	WOS:A1991GX11900019
J	DEBIASE, D; BARRA, D; BOSSA, F; PUCCI, P; JOHN, RA				DEBIASE, D; BARRA, D; BOSSA, F; PUCCI, P; JOHN, RA			CHEMISTRY OF THE INACTIVATION OF 4-AMINOBUTYRATE AMINOTRANSFERASE BY THE ANTIEPILEPTIC DRUG VIGABATRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHANOLAMINE-O-SULFATE; GAMMA-VINYL GABA; AMINOBUTYRIC ACID AMINOTRANSFERASE; DOUBLE-BLIND; IRREVERSIBLE INHIBITION; CATALYTIC INHIBITOR; RESISTANT EPILEPSY; AMINO-ACID; METABOLISM; BRAIN	The chemical modification of pig liver 4-aminobutyrate aminotransferase by the antiepileptic drug 4-aminohex-5-enoate (Vigabatrin) has been studied. After inactivation by C-14-labeled Vigabatrin, the enzyme was digested with trypsin, and automated Edman degradation of the purified labeled peptide gave the sequence FWAHEHWGLDDPADVMTFSKK. Chymotryptic digestion of the tryptic peptide and sequencing of a resulting tripeptide identified the penultimate lysine residue of this peptide as the site of covalent modification. This lysine normally binds the coenzyme. Absorption spectroscopy demonstrated the absence of coenzyme from the tryptic peptide, and mass spectrometry showed its mass/charge ratio to be increased by 128. All of the bound coenzyme released after denaturation of the inactivated enzyme was as pyridoxamine phosphate. The structural nature of the modification is deduced, and mechanisms for its occurrence identified. Initially, 1 mol of radiolabeled inhibitor was bound per mol of monomer of the enzyme, although approximately half was released during denaturation and digestion, while the remainder was irreversibly bound. Coenzyme not released as pyridoxamine phosphate retained the absorbance characteristics of the aldimine, although the enzyme was completely inactive. Mass spectrometry of the sample of purified radiolabeled tryptic peptide revealed the presence of an approximately equal amount of a second fragment that contained no modification and from which the second lysine was absent, indicating that at the time of proteolysis the active site lysine was unaltered in 50% of the enzyme molecules.	UNIV WALES COLL CARDIFF, DEPT BIOCHEM, POB 903, CARDIFF CF1 1ST, WALES; UNIV ROME LA SAPIENZA, CNR, DIPARTIMENTO SCI BIOCHIM A ROSSI FANELLI, I-00185 ROME, ITALY; UNIV ROME LA SAPIENZA, CNR, CTR BIOL MOLEC, I-00185 ROME, ITALY; CNR, SERV SPETTROMETRIA MASSA, I-80131 NAPLES, ITALY	Cardiff University; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR)			Barra, Donatella/D-1236-2011; De Biase, Daniela/H-3678-2019	De Biase, Daniela/0000-0003-3536-9927; PUCCI, Pietro/0000-0002-5885-1495				AWAPARA J, 1950, J BIOL CHEM, V187, P35; BAXTER CF, 1961, J BIOL CHEM, V236, P3287; BAZEMORE AW, 1957, J NEUROCHEM, V1, P334, DOI 10.1111/j.1471-4159.1957.tb12090.x; CHURCHICH JE, 1981, J BIOL CHEM, V256, P1101; DEBIASE D, 1989, BIOCHIMIE, V71, P491, DOI 10.1016/0300-9084(89)90179-X; DEBIASE D, 1991, BIOCHEMISTRY-US, V30, P2239, DOI 10.1021/bi00222a029; ELLIOTT KAC, 1956, J NEUROCHEM, V1, P181, DOI 10.1111/j.1471-4159.1956.tb12071.x; FOWLER LJ, 1972, BIOCHEM J, V130, P569, DOI 10.1042/bj1300569; GEHRING H, 1977, BIOCHEMISTRY-US, V16, P4832, DOI 10.1021/bi00641a012; GIBSON JP, 1990, TOXICOL PATHOL, V18, P225, DOI 10.1177/019262339001800201; GRAM L, 1985, ANN NEUROL, V17, P262, DOI 10.1002/ana.410170307; HAYASHI T, 1959, J PHYSIOL-LONDON, V145, P570, DOI 10.1113/jphysiol.1959.sp006163; JOHN RA, 1969, BIOCHEMISTRY-US, V8, P4477, DOI 10.1021/bi00839a038; JOHN RA, 1978, BIOCHEM J, V171, P771, DOI 10.1042/bj1710771; JUNG MJ, 1977, J NEUROCHEM, V28, P717, DOI 10.1111/j.1471-4159.1977.tb10618.x; JUNG MJ, 1978, J BIOL CHEM, V253, P7431; KUFFLER SW, 1958, J NEUROPHYSIOL, V21, P589, DOI 10.1152/jn.1958.21.6.589; KURIYAMA K, 1966, BIOCHEM PHARMACOL, V15, P221, DOI 10.1016/0006-2952(66)90293-0; LEACH MJ, 1977, BIOCHEM PHARMACOL, V26, P1569, DOI 10.1016/0006-2952(77)90070-3; LIKOS JJ, 1982, BIOCHEMISTRY-US, V21, P4377, DOI 10.1021/bi00261a029; LIPPERT B, 1977, EUR J BIOCHEM, V74, P441, DOI 10.1111/j.1432-1033.1977.tb11410.x; LOISEAU P, 1986, EPILEPSIA, V27, P115, DOI 10.1111/j.1528-1157.1986.tb03512.x; METCALF BW, 1979, BIOCHEM PHARMACOL, V28, P1705, DOI 10.1016/0006-2952(79)90529-X; NAYLOR S, 1986, J AM CHEM SOC, V108, P6359, DOI 10.1021/ja00280a037; PALFREYMAN MG, 1987, ESSAYS BIOCHEM, V23, P28; PETERSON EA, 1954, J AM CHEM SOC, V76, P169, DOI 10.1021/ja01630a045; PHILLIPS NI, 1982, BIOCHEM PHARMACOL, V31, P2257, DOI 10.1016/0006-2952(82)90111-3; RANDO RR, 1974, BIOCHEMISTRY-US, V13, P3859, DOI 10.1021/bi00716a006; REYNOLDS EH, 1988, BRIT J CLIN PRACT, V42, P33; REYNOLDS EH, 1990, BRIT MED J, V300, P277, DOI 10.1136/bmj.300.6720.277; RIMMER EM, 1984, LANCET, V1, P189; ROBERTS E, 1950, J BIOL CHEM, V187, P55; SILVERMAN RB, 1988, BIOCHEM BIOPH RES CO, V150, P942, DOI 10.1016/0006-291X(88)90720-6; SILVERMAN RB, 1988, BIOCHEMISTRY-US, V27, P3285, DOI 10.1021/bi00409a024; SILVERMAN RB, 1986, BIOCHEMISTRY-US, V25, P6817, DOI 10.1021/bi00370a013; TARTARA A, 1986, EPILEPSIA, V27, P717, DOI 10.1111/j.1528-1157.1986.tb03600.x; TASSINARI CA, 1987, ARCH NEUROL-CHICAGO, V44, P907, DOI 10.1001/archneur.1987.00520210009010; VANGELDER NM, 1958, J NEUROCHEM, V3, P139; WOOD JD, 1973, J NEUROCHEM, V20, P379, DOI 10.1111/j.1471-4159.1973.tb12137.x	39	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20056	20061						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939068				2022-12-25	WOS:A1991GM03900031
J	MIURA, N; MIYAMOTO, I; ASAHINA, H; SATOKATA, I; TANAKA, K; OKADA, Y				MIURA, N; MIYAMOTO, I; ASAHINA, H; SATOKATA, I; TANAKA, K; OKADA, Y			IDENTIFICATION AND CHARACTERIZATION OF XPAC PROTEIN, THE GENE-PRODUCT OF THE HUMAN XPAC (XERODERMA-PIGMENTOSUM GROUP-A COMPLEMENTING) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA EXCISION REPAIR; DEFECT	We have cloned human xeroderma pigmentosum group A complementing (XPAC) cDNA that encodes a "zinc finger" protein with a predicted size of 31 kDa. To detect the xpac protein in cells, we raised antibody against a recombinant human xpac protein. Using this antibody, we identified the xpac protein in the nucleus of cells. In normal human cells, 40- and 38-kDa proteins were detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. A reduced amount of the smaller protein was detected in XP 39OSSV cells, which show low UV sensitivity, and no xpac proteins were detected in XP 2OSSV cells, which show high UV sensitivity. These levels of xpac proteins in xeroderma pigmentosum cells were determinants of heterogeneity of the DNA repair defect in group A xeroderma pigmentosum. Synthesis of the xpac protein did not increase after UV irradiation.			MIURA, N (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADA OKA,SUITA,OSAKA 565,JAPAN.							CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SELBY CP, 1990, MUTAT RES, V236, P203, DOI 10.1016/0921-8777(90)90005-P; STRUHL K, 1987, CURRENT PROTOCOL MOL; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TANAKA K, 1989, P NATL ACAD SCI USA, V86, P5512, DOI 10.1073/pnas.86.14.5512; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; YAMAIZUMI M, 1986, P NATL ACAD SCI USA, V83, P1476, DOI 10.1073/pnas.83.5.1476	14	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19786	19789						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918083				2022-12-25	WOS:A1991GK66700094
J	STAUDERMAN, KA; MURAWSKY, MM				STAUDERMAN, KA; MURAWSKY, MM			THE INOSITOL 1,4,5-TRISPHOSPHATE-FORMING AGONIST HISTAMINE ACTIVATES A RYANODINE-SENSITIVE CA2+ RELEASE MECHANISM IN BOVINE ADRENAL CHROMAFFIN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SARCOPLASMIC-RETICULUM; CALCIUM CHANNELS; ENDOPLASMIC-RETICULUM; SKELETAL-MUSCLE; CA-2+ STORE; RECEPTOR; CAFFEINE; OSCILLATIONS; MEMBRANES; CONDUCTANCE	The role of a Ca2+-induced Ca2+ release (CICR) mechanism in the generation of agonist-induced increases of intracellular free Ca2+ concentration ([Ca2+]i) was studied in bovine adrenal chromaffin cells. In single cells, repetitive stimulations with caffeine at 200-s intervals evoked reproducible spikes of [Ca2+]i. Ryanodine, an agent that interacts with the CICR channel of muscle, inhibited the caffeine-induced spikes of [Ca2+]i in a "use-dependent" way. High affinity binding sites for [H-3]ryanodine (K(d) 3.3 nm, B(max) 26 fmol/mg protein) were also detected in membranes from chromaffin cells, supporting the presence of a caffeine- and ryanodine-sensitive CICR channel. Pretreatment of single cells with caffeine + ryanodine to reduce the size of the caffeine-sensitive Ca2+ compartment inhibited a subsequent spike of [Ca2+]i evoked by histamine, a D-myo-inositol 1,4,5-trisphosphate-forming agonist. This demonstrates that a significant portion of the Ca2+ released by histamine comes from a caffeine- and ryanodine-sensitive pool. Ryanodine inhibited by 50% the size of [Ca2+]i spikes evoked by repetitive stimulation with histamine and did so in a use-dependent manner. These data suggest that, in addition to D-myo-inositol 1,4,5-trisphosphate, activation of a caffeine and ryanodine-sensitive CICR channel participates in the generation of histamine-induced release of intracellular Ca2+.			STAUDERMAN, KA (corresponding author), MARION MERRELL DOW RES INST,2110 E GALBRAITH RD,POB 156300,CINCINNATI,OH 45215, USA.							ANDERSON K, 1989, J BIOL CHEM, V264, P1329; ASHLEY RH, 1989, J MEMBRANE BIOL, V111, P179, DOI 10.1007/BF01871781; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; CHEEK TR, 1990, FEBS LETT, V266, P91, DOI 10.1016/0014-5793(90)81514-O; CHEEK TR, 1991, BIOCHEM J, V275, P697, DOI 10.1042/bj2750697; DEHLINGERKREMER M, 1991, J MEMBRANE BIOL, V119, P85, DOI 10.1007/BF01868543; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1985, FED PROC, V44, P2970; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; FILL M, 1988, TRENDS NEUROSCI, V11, P453, DOI 10.1016/0166-2236(88)90198-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LIU PS, 1991, J NEUROCHEM, V56, P172, DOI 10.1111/j.1471-4159.1991.tb02577.x; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PRUSS RM, 1985, ENDOCRINOLOGY, V117, P1020, DOI 10.1210/endo-117-3-1020; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; SCHMID A, 1990, NATURE, V346, P374, DOI 10.1038/346374a0; SHOSHANBARMATZ V, 1990, FEBS LETT, V263, P317, DOI 10.1016/0014-5793(90)81403-B; STAUDERMAN KA, 1991, BIOCHEM J, V278, P643, DOI 10.1042/bj2780643; STAUDERMAN KA, 1990, CELL REGUL, V1, P683, DOI 10.1091/mbc.1.9.683; THAYER SA, 1988, MOL PHARMACOL, V34, P664; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435	30	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19150	19153						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918031				2022-12-25	WOS:A1991GK66700007
J	MORI, H; TANIZAWA, K; FUKUI, T				MORI, H; TANIZAWA, K; FUKUI, T			POTATO-TUBER TYPE-H PHOSPHORYLASE ISOZYME - MOLECULAR-CLONING, NUCLEOTIDE-SEQUENCE, AND EXPRESSION OF A FULL-LENGTH CDNA IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MUSCLE GLYCOGEN-PHOSPHORYLASE; ALPHA-GLUCAN PHOSPHORYLASE; LOCALIZATION; PROTEINS; BINDING; SITE; AFFINITY; RESIDUES; ENZYMES	Higher plant tissues contain two alpha-glucan phosphorylase isozymes (EC 2.4.1.1), types L and H, localized in the plastid and the cytoplasm, respectively. We already isolated and sequenced a cDNA clone encoding the type L isozyme. Presently, a cDNA clone encoding the type H counterpart was isolated from a cDNA library of immature potato tuber by plaque hybridization, using two oligonucleotide probes synthesized based on the partial amino acid sequences of the type H isozyme. The message encodes a polypeptide of 838 amino acid residues. Sequence comparison of the two potato tuber phosphorylase isozymes revealed two major distinctions; the type L isozyme contains a 78-residue insertion in the middle of the polypeptide chain as well as a 50-residue amino-terminal extension. Except for these extra portions, the two isozyme sequences show an identity of 63%. The entire structural gene for the type H isozyme was inserted 3'-downstream of the strong T7 RNA polymerase promoter in the expression plasmid pET-3b. Escherichia coli BL21 (DE3) cells carrying this plasmid produced active phosphorylase upon induction with isopropyl-beta-D-thiogalactoside at 22-degrees-C. The expression is entirely dependent on the temperature; the bacteria did not produce a detectable amount of the active enzyme at 37-degrees-C. Addition of pyridoxine to the culture medium was effective for the enzyme production.	OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN	Osaka University				Mori, Hiroyuki/0000-0002-0429-1269				BRISSON N, 1989, PLANT CELL, V1, P559, DOI 10.1105/tpc.1.5.559; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; CONRADS J, 1986, BIOCHIM BIOPHYS ACTA, V882, P452, DOI 10.1016/0304-4165(86)90270-9; FUKUI T, 1982, MOL CELL BIOCHEM, V42, P129, DOI 10.1007/BF00238507; FUKUI T, 1987, BIOCH VITAMIN B6, P267; GERBRANDY SJ, 1972, PHYTOCHEMISTRY, V11, P2403, DOI 10.1016/S0031-9422(00)88506-4; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HEIDECKER G, 1986, ANNU REV PLANT PHYS, V37, P439, DOI 10.1146/annurev.arplant.37.1.439; JOHNSON LN, 1990, J BIOL CHEM, V265, P2409; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P1290; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; MADSEN NB, 1986, ENZYMES, V17, P366; Maniatis T., 1982, MOL CLONING; NAKANO K, 1978, J BIOCHEM, V83, P1085, DOI 10.1093/oxfordjournals.jbchem.a131997; NAKANO K, 1989, J BIOCHEM-TOKYO, V106, P691, DOI 10.1093/oxfordjournals.jbchem.a122918; NAKANO K, 1986, J BIOL CHEM, V261, P8230; NAKANO K, 1986, FEBS LETT, V204, P283, DOI 10.1016/0014-5793(86)80829-8; NAKANO K, 1986, J BIOL CHEM, V261, P8224; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; OKITA TW, 1979, PLANT PHYSIOL, V64, P187, DOI 10.1104/pp.64.2.187; PALM D, 1986, Z NATURFORSCH C, V42, P394; Parikh I, 1974, Methods Enzymol, V34, P77; PREISS J, 1979, PHOTOSYNTHESIS, V2, P282; ROSAHL S, 1986, MOL GEN GENET, V203, P214, DOI 10.1007/BF00333957; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHMIDT GW, 1986, ANNU REV BIOCHEM, V55, P879; SCHNEIDER EM, 1981, PLANTA, V151, P124, DOI 10.1007/BF00387813; SHIMOMURA S, 1982, J BIOCHEM-TOKYO, V91, P703, DOI 10.1093/oxfordjournals.jbchem.a133743; SHIMOMURA S, 1978, BIOCHEM BIOPH RES CO, V82, P462, DOI 10.1016/0006-291X(78)90897-5; SMITH EE, 1971, ARCH BIOCHEM BIOPHYS, V146, P380, DOI 10.1016/0003-9861(71)90140-8; STEUP M, 1979, PLANTA HEIDELB, V167, P444; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDA M, 1987, J BIOCHEM, V102, P471; TAGAYA M, 1982, J BIOCHEM-TOKYO, V91, P599, DOI 10.1093/oxfordjournals.jbchem.a133731; TITANI K, 1977, P NATL ACAD SCI USA, V74, P4762, DOI 10.1073/pnas.74.11.4762; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; VANDENBUNDER B, 1981, BIOCHEMISTRY-US, V20, P2354, DOI 10.1021/bi00511a044	37	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18446	18453						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917968				2022-12-25	WOS:A1991GJ47200010
J	VENABLE, ME; NIETO, ML; SCHMITT, JD; WYKLE, RL				VENABLE, ME; NIETO, ML; SCHMITT, JD; WYKLE, RL			CONVERSION OF 1-O-[H-3]ALKYL-2-ARACHIDONOYL-SN-GLYCERO-3-PHOSPHORYLCHOLINE TO LYSO-PLATELET-ACTIVATING-FACTOR BY THE COA-INDEPENDENT TRANSACYLASE IN MEMBRANE-FRACTIONS OF HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; ARACHIDONIC-ACID; PHOSPHOLIPASE-A2 ACTIVITY; SUBCELLULAR-LOCALIZATION; ALVEOLAR MACROPHAGES; CALCIUM IONOPHORE; PLASMA-MEMBRANE; METABOLISM; RELEASE; BIOSYNTHESIS	The first step in the synthesis of platelet-activating factor (PAF) in stimulated neutrophils is generally accepted to be hydrolysis of 1-O-alkyl-2-acyl-sn-glycero-3-phosphorylcholine (1-O-alkyl-2-acyl-GPC), with 1-O-alkyl-2-arachidonoyl-GPC being the preferred precursor. Characterization of the enzymatic activity responsible for the hydrolysis of 1-O-alkyl-2-arachidonoyl-GPC has been hampered by lack of an active and reliable cell-free system for study. In the present studies, membrane preparations containing 1-O-[H-3]alkyl-2-arachidonoyl-GPC were prepared from intact human neutrophils that had been labeled using 1-O-[H-3]hexadecyl-2-lyso-GPC. When the labeled membrane preparations were incubated in the presence of unlabeled 1-O-alkyl-2-lyso-GPC (5-mu-M), rapid deacylation (up to 25% of the label in 10 min) of the 1-O-[H-3]alkyl-2-arachidonoyl-GPC to 1-O-[H-3]alkyl-2-lyso-GPC (lyso-PAF) was observed. The deacylation activity appeared to be the same in preparations from resting or stimulated cells. No requirement for Ca2+, various nucleotides, or protein kinase activation could be demonstrated. A number of observations indicated that [H-3]lyso-PAF is formed in the system by the action of the CoA-independent transacylase present in the cells rather than by phospholipase A2. Both 1-O-alkyl-2-lyso-GPC and 1-acyl-2-lyso-GPC elicited deacylation of 1-O-[H-3]alkyl-2-arachidonoyl-GPC, whereas neither 3-O-alkyl-2-lyso-GPC nor 1-O-alkyl-2-O-methyl-rac-glycero-3-phosphorylcholine, which should act as detergents but are not transacylase substrates, effected deacylation. The deacylation activity and CoA-independent transacylase activities were blocked in parallel by a number of inhibitors and by heat inactivation. In preparations containing 1-O-alkyl-2-[H-3]arachidonoyl-GPC, no release of free [H-3]arachidonic acid was observed. However, a shift of the [H-3] arachidonate into exogenous 1-O-tetradecyl-2-lyso-GPC was observed in the system. These findings are consistent with the generation of [H-3]lyso-PAF by the CoA-independent transacylase activity.	WAKE FOREST UNIV,MED CTR,DEPT BIOCHEM,300 S HAWTHORNE RD,WINSTON SALEM,NC 27103	Wake Forest University			Nieto, Maria L/G-7492-2015	Nieto, Maria L/0000-0001-6842-799X	NHLBI NIH HHS [HL-26818] Funding Source: Medline; NIAID NIH HHS [AI-17287] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017287] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT DH, 1984, BIOCHIM BIOPHYS ACTA, V796, P92, DOI 10.1016/0005-2760(84)90242-X; ALONSO F, 1986, BIOCHIM BIOPHYS ACTA, V878, P273, DOI 10.1016/0005-2760(86)90156-6; ALONSO F, 1982, J BIOL CHEM, V257, P3376; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BLIGH EG, 1959, CAN J BIOCH PHYSL, V37, P473; BOKOCH GM, 1980, J BIOL CHEM, V255, P223; BORMANN BJ, 1984, P NATL ACAD SCI-BIOL, V81, P767, DOI 10.1073/pnas.81.3.767; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHILTON FH, 1983, J BIOL CHEM, V258, P7268; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DECHATELET LR, 1982, INFECT IMMUN, V35, P206, DOI 10.1128/IAI.35.1.206-212.1982; DIEZ E, 1990, J BIOL CHEM, V265, P14654; FRANSON R, 1978, BIOCHEMISTRY-US, V17, P4029, DOI 10.1021/bi00612a024; GALLIN JI, 1984, J IMMUNOL, V133, P415; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; KRAMER RM, 1984, J BIOL CHEM, V259, P3316; KRAMER RM, 1983, J BIOL CHEM, V258, P3806; LEE TC, 1982, BIOCHEM BIOPH RES CO, V105, P1303, DOI 10.1016/0006-291X(82)90928-7; MCINTYRE TM, 1987, J BIOL CHEM, V262, P15370; MUELLER HW, 1983, J BIOL CHEM, V258, P6213; NIETO M, 1990, J CELL BIOL, V111, P257; NIETO ML, 1991, J BIOL CHEM, V266, P18699; NINIO E, 1982, BIOCHIM BIOPHYS ACTA, V710, P23, DOI 10.1016/0005-2760(82)90185-0; OFLAHERTY JT, 1982, LAB INVEST, V47, P314; OFLAHERTY JT, 1983, BIOCHEM BIOPH RES CO, V111, P1, DOI 10.1016/S0006-291X(83)80108-9; PATTON GM, 1982, J LIPID RES, V23, P190; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RAMESHA CS, 1986, J BIOL CHEM, V261, P7592; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; ROSENTHAL MD, 1989, BIOCHIM BIOPHYS ACTA, V1001, P1, DOI 10.1016/0005-2760(89)90299-3; SISSON JH, 1987, J IMMUNOL, V138, P3918; SNYDER F, 1987, PLATELET ACTIVATING, P89; SUGA K, 1990, J BIOL CHEM, V265, P12363; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; SURLES JR, 1985, J MED CHEM, V28, P73, DOI 10.1021/jm00379a015; SWENDSEN CL, 1983, BIOCHEM BIOPH RES CO, V113, P72, DOI 10.1016/0006-291X(83)90433-3; VICTOR M, 1981, FEBS LETT, V136, P298, DOI 10.1016/0014-5793(81)80639-4; WALSH CE, 1983, BIOCHIM BIOPHYS ACTA, V750, P32, DOI 10.1016/0005-2760(83)90201-1; WALSH CE, 1981, J BIOL CHEM, V256, P7228; WINKLER JD, 1991, BIOCHIM BIOPHYS ACTA, V1081, P339, DOI 10.1016/0005-2760(91)90291-O; WYKLE RL, 1981, BIOCHEM BIOPH RES CO, V100, P1651, DOI 10.1016/0006-291X(81)90708-7; WYKLE RL, 1980, J BIOL CHEM, V255, P256; WYKLE RL, 1987, PLATELET ACTIVATING, P273; WYKLE RL, 1986, ADV INFLAMMAT RES, V11, P71; WYRICK SD, 1985, J LABELLED COMPD RAD, V22, P1169, DOI 10.1002/jlcr.2580221110	49	73	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18691	18698						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917993				2022-12-25	WOS:A1991GJ47200046
J	ASKEW, DS; ASHMUN, RA; SIMMONS, BC; CLEVELAND, JL				ASKEW, DS; ASHMUN, RA; SIMMONS, BC; CLEVELAND, JL			CONSTITUTIVE C-MYC EXPRESSION IN AN IL-3-DEPENDENT MYELOID CELL-LINE SUPPRESSES CELL-CYCLE ARREST AND ACCELERATES APOPTOSIS	ONCOGENE			English	Article							HEMATOPOIETIC-CELLS; B-CELLS; UNREGULATED PROLIFERATION; IMMATURE THYMOCYTES; DNA FRAGMENTATION; PROGENITOR CELLS; MARROW CULTURES; BONE-MARROW; DIFFERENTIATION; GROWTH	In the murine interleukin 3 (IL-3)-dependent myeloid cell line 32D, down-regulation of c-myc and ornithine decarboxylase (ODC) expression is an immediate response to IL-3 deprivation. This is followed by an accumulation of cells in the G1 phase of the cell cycle, and eventual cell death. However, clones of 32D cells harboring an expression vector which constitutively expresses murine c-myc did not down-regulate ODC transcripts in response to IL-3 withdrawal, and they failed to G1 arrest. Moreover, in contrast to control cultures in which the majority of death occurred following G1 arrest, c-myc clones rapidly initiated a program of cell death characteristic of apoptosis following IL-3 deprivation, and their subsequent loss of viability occurred with accelerated kinetics. The premature induction of apoptosis in cells harboring a deregulated c-myc gene suggests that apoptosis may be an important mechanism in the elimination of hematopoietic cells harboring mutations, such as constitutive c-myc expression, which imbalance normal cell cycle regulatory controls.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	CLEVELAND, JL (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA.			Askew, David/0000-0002-6477-2515	NCI NIH HHS [P30 CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1990, CELLULAR MOL BIOL HU, P33; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; CASHMAN JD, 1988, J CLIN INVEST, V81, P87, DOI 10.1172/JCI113315; CASHMAN JD, 1990, BLOOD, V75, P96; Cleveland J L, 1988, Oncogene Res, V3, P357; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CORY S, 1987, ONCOGENE RES, V1, P61; DEAN M, 1987, ONCOGENE RES, V1, P279; DEAN M, 1986, J BIOL CHEM, V261, P9161; DEAN PN, 1980, CELL TISSUE KINET, V13, P672; DEAN PN, 1980, CELL TISSUE KINET, V13, P299, DOI 10.1111/j.1365-2184.1980.tb00468.x; EAVES AC, 1986, P NATL ACAD SCI USA, V83, P5306, DOI 10.1073/pnas.83.14.5306; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Finney D.J., 1971, PROBIT ANAL; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IHLE JN, 1982, J IMMUNOL, V129, P2431; ISFORT RJ, 1990, SOMAT CELL MOLEC GEN, V16, P109, DOI 10.1007/BF01233041; KARN J, 1989, ONCOGENE, V4, P773; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LEARY AG, 1989, P NATL ACAD SCI USA, V86, P4535, DOI 10.1073/pnas.86.12.4535; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MAVILIO F, 1989, ONCOGENE, V4, P301; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCCONKEY DJ, 1990, IMMUNOL TODAY, V11, P120, DOI 10.1016/0167-5699(90)90048-E; MCCONKEY DJ, 1990, J BIOL CHEM, V265, P3009; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OGAWA M, 1989, ENVIRON HEALTH PERSP, V80, P199, DOI 10.2307/3430745; PALLAVICINI MG, 1990, J CELL PHYSIOL, V143, P372, DOI 10.1002/jcp.1041430223; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PRATT RM, 1976, DEV BIOL, V54, P135, DOI 10.1016/0012-1606(76)90292-X; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RODRIGUEZTARDUC.G, 1990, EMBO J, V9, P2977; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLIE AH, 1987, BRIT J CANCER, V56, P251; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	55	918	943	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1915	1922						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923514				2022-12-25	WOS:A1991GX11800028
J	RAMSAY, RG; ISHII, S; GONDA, TJ				RAMSAY, RG; ISHII, S; GONDA, TJ			INCREASE IN SPECIFIC DNA-BINDING BY CARBOXYL TRUNCATION SUGGESTS A MECHANISM FOR ACTIVATION OF MYB	ONCOGENE			English	Article							C-MYB; V-MYB; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATION; HEMATOPOIETIC-CELLS; TRANSFORMING GENE; INVITRO; SEQUENCE; PROTEINS; FOS	Oncogenic forms of the c-myb protein (Myb) often exhibit amino-terminal and/or carboxyl-terminal truncations. When the transcriptional activity of these proteins was examined it was found that carboxyl-truncated Myb is more effective as a transcriptional activator than full-length or amino-truncated Myb. In order to determine the effect of such truncations on sequence-specific DNA binding, we synthesized murine Myb in vitro and assessed DNA binding by using a mobility-shift assay. Compared with the full-length protein no difference in binding was observed following deletion of the amino terminus, despite the removal of much of the first repeat of the DNA-binding domain. However, the specific DNA-binding capacity of carboxyl-truncated Myb was 4-6 times greater than that of the full-length protein; moreover, DNA binding was independent of a 'leucine zipper' motif present in Myb. These observations suggest that the increased transforming and transactivating potential of carboxyl-truncated Myb is due, at least in part, to increased sequence-specific DNA binding.	RIKEN TSUKUBA LIFE SCI CTR,INST PHYS & CHEM RES,TSUKUBA,IBARAKI 305,JAPAN	RIKEN	RAMSAY, RG (corresponding author), PO ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA.		Ramsay, Robert G/C-3291-2015; Ishii, Shunsuke/A-5271-2016	Ramsay, Robert G/0000-0001-5003-0433; Ishii, Shunsuke/0000-0002-6530-2478				BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; COOK WD, 1985, MOL CELL BIOL, V5, P390, DOI 10.1128/MCB.5.2.390; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	33	57	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1875	1879						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923510				2022-12-25	WOS:A1991GX11800021
J	ROYERPOKORA, B; LOOS, U; LUDWIG, WD				ROYERPOKORA, B; LOOS, U; LUDWIG, WD			TTG-2, A NEW GENE ENCODING A CYSTEINE-RICH PROTEIN WITH THE LIM MOTIF, IS OVEREXPRESSED IN ACUTE T-CELL LEUKEMIA WITH THE T(11-14)(P13-Q11)	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; BREAKPOINT CLUSTER REGION; CHROMOSOMAL TRANSLOCATIONS; DEVELOPMENTAL REGULATION; CHAIN LOCUS; ALPHA-CHAIN; RECEPTOR; 11P13; REARRANGEMENTS; HOMEODOMAIN	We have cloned 70 kb of DNA from chromosome 11p13 at the site of a recurrent translocation in T-cell leukaemia (T-ALL): t(11;14)(p13;q11). The translocation involves the TCR-delta-gene on 14q11 and a new site on 11p13. Two new and 10 previously identified translocations all mapped within 25 kb on 11p13, the 11p13 T-cell translocation cluster (11p13 ttc). A search for expressed sequences surrounding the breakpoint cluster region on 11p13 identified a gene telomeric of all breakpoints which is overexpressed in three T-ALL samples with a t(11;14). The gene T-cell translocation gene (TTG-2) encodes a small cysteine-rich protein. Forty-eight per cent of the amino acids are identical with another translocation-deregulated gene, TTG-1 (T-cell translocation gene 1 or rhombotin) in 11p15. There are two copies of a cysteine-rich motif in both proteins. Two tandem copies of the same cysteine-rich motif are also present in the recently described lin-11, isl-1 and mec-3 gene products, and one motif is found in the CRIP protein. Therefore the proteins encoded by these two translocation-deregulated genes belong to this new class of cysteine-rich proteins with the 'LIM' motif, which are important in normal development.	KLINIKUM STEGLITZ,DEPT HEMATOL & ONCOL,W-1000 BERLIN,GERMANY		ROYERPOKORA, B (corresponding author), INST HUMANGENET & ANTHROPOL,NEUENHEIMER FELD 328,W-6900 HEIDELBERG,GERMANY.							BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHENG JT, 1990, J EXP MED, V171, P489, DOI 10.1084/jem.171.2.489; ERIKSON J, 1985, SCIENCE, V229, P784, DOI 10.1126/science.3875152; FORONI L, 1990, GENE CHROMOSOME CANC, V1, P301, DOI 10.1002/gcc.2870010407; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GUEBLER U, 1983, GENE, V25, P263; HARVEY RC, 1989, ONCOGENE, V4, P341; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LAMPERT F, 1988, BLUT, V56, P117, DOI 10.1007/BF00320016; LEWIS WH, 1985, NATURE, V317, P544, DOI 10.1038/317544a0; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; RAIMONDI SC, 1988, BLOOD, V72, P1560; ROYERPOKORA B, 1989, HUM GENET, V82, P264, DOI 10.1007/BF00291167; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SEALEY L, 1987, MOL CELL BIOL, V7, P787, DOI 10.1128/MCB.7.2.787; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; YOFFE G, 1989, BLOOD, V74, P374; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	29	250	263	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1887	1893						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923511				2022-12-25	WOS:A1991GX11800023
J	CUTHBERT, JA; LIPSKY, PE				CUTHBERT, JA; LIPSKY, PE			NEGATIVE REGULATION OF CELL-PROLIFERATION BY MEVALONATE OR ONE OF THE MEVALONATE PHOSPHATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL-BIOSYNTHESIS; INHIBITION; ACID; PROTEINS; PRODUCT; 6-FLUOROMEVALONATE; METABOLISM; PATHWAY	The role of mevalonate and its products in the regulation of cellular proliferation was examined using 6-fluoromevalonate (Fmev), a compound that blocks the conversion of mevalonate pyrophosphate to isopentenyl pyrophosphate. Fmev suppressed DNA synthesis by a variety of transformed and malignant T cell, B cell, and myeloid cell lines. In contrast to results previously reported with mitogen-stimulated human peripheral blood T cell DNA synthesis, low concentrations of low density lipoprotein (LDL) alone could not restore proliferation to these cell lines. The same concentrations of LDL were able to provide sufficient cholesterol and support the growth of all cell lines when mevalonate synthesis was blocked with a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, lovastatin. Fmev-mediated inhibition was totally prevented in some but not all cell lines when the concentration of exogenous LDL was increased 5-10-fold above that required to permit proliferation of lovastatin-blocked cells. Residual HMG-CoA reductase activity of cells cultured with LDL inversely correlated with the restoration of growth to Fmev-blocked cultures. Confirmation of the critical role of HMG-CoA reductase activity and mevalonate synthesis in the inhibition of cellular proliferation by Fmev was obtained by demonstrating that the specific inhibitor of this enzyme, lovastatin, restored proliferation of Fmev-blocked cells. Furthermore, supplementation of cultures with mevalonate, the product of HMG-CoA reductase activity, markedly inhibited proliferation of Fmev-blocked cells. These findings indicate that mevalonate or one of the mevalonate phosphates, which accumulates in Fmev-blocked cells, is a critical negative regulator of cellular proliferation.			CUTHBERT, JA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,LIVER UNIT,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017653] Funding Source: NIH RePORTER; NIAID NIH HHS [AI17653] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; CUTHBERT JA, 1990, J BIOL CHEM, V265, P18568; CUTHBERT JA, 1987, J BIOL CHEM, V262, P7808; DUNNINGTON DJ, 1989, BIOCHEM BIOPH RES CO, V165, P219, DOI 10.1016/0006-291X(89)91057-7; FAUST J, 1987, J BIOL CHEM, V262, P1996; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HABENICHT AJR, 1980, J BIOL CHEM, V255, P5134; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOHL RJ, 1991, BLOOD, V77, P1064; HURLEY JN, 1978, P NATL ACAD SCI USA, V75, P5706, DOI 10.1073/pnas.75.11.5706; KANEKO I, 1978, EUR J BIOCHEM, V87, P313; NAVE JF, 1985, BIOCHEM J, V227, P247, DOI 10.1042/bj2270247; NICKLAS JA, 1984, HUM IMMUNOL, V11, P19, DOI 10.1016/0198-8859(84)90053-3; QUESNEYHUNEEUS V, 1979, P NATL ACAD SCI USA, V76, P5056, DOI 10.1073/pnas.76.10.5056; REARDON JE, 1987, BIOCHEMISTRY-US, V26, P4717, DOI 10.1021/bi00389a018; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; WOLDA SL, 1988, J BIOL CHEM, V263, P5997	18	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17966	17971						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917936				2022-12-25	WOS:A1991GG55300042
J	WILKIN, DJ; KUTSUNAI, SY; EDWARDS, PA				WILKIN, DJ; KUTSUNAI, SY; EDWARDS, PA			ISOLATION AND SEQUENCE OF THE HUMAN FARNESYL PYROPHOSPHATE SYNTHETASE CDNA - COORDINATE REGULATION OF THE MESSENGER-RNAS FOR FARNESYL PYROPHOSPHATE SYNTHETASE, 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE, AND 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A SYNTHASE BY PHORBOL ESTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV CARDIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	WILKIN, DJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ASHBY MN, 1989, J BIOL CHEM, V264, P635; AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BARNARD GF, 1981, BIOCHIM BIOPHYS ACTA, V661, P87, DOI 10.1016/0005-2744(81)90086-3; BREMS DN, 1981, BIOCHEMISTRY-US, V20, P3711, DOI 10.1021/bi00516a007; BROWN MS, 1980, J LIPID RES, V21, P505; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CLARKE CF, 1987, PLASMA LIPOPROTEINS, P261; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DAWSON PA, 1989, J BIOL CHEM, V264, P9046; DOOLITTLE RF, 1979, PROTEINS, P2; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MALTESE WA, 1987, J CELL PHYSIOL, V133, P471, DOI 10.1002/jcp.1041330307; Maniatis T., 1982, MOL CLONING; MEHRABIAN M, 1986, J BIOL CHEM, V261, P6249; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; PAPAYANNOPOULOU T, 1983, BLOOD, V62, P832; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; RILLING HC, 1985, STEROLS BILE ACIDS, P17; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; SKALNIK DG, 1985, J BIOL CHEM, V260, P1991; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1987, CURRENT PROTOCOLS MO; WALLACE DM, 1987, METHOD ENZYMOL, V152, P46; [No title captured]	38	107	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1990	265	8					4607	4614						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CT101	1968462				2022-12-25	WOS:A1990CT10100068
J	MANCHESTER, JK; CHI, MMY; NORRIS, B; FERRIER, B; KRASNOV, I; NEMETH, PM; MCDOUGAL, DB; LOWRY, OH				MANCHESTER, JK; CHI, MMY; NORRIS, B; FERRIER, B; KRASNOV, I; NEMETH, PM; MCDOUGAL, DB; LOWRY, OH			EFFECT OF MICROGRAVITY ON METABOLIC ENZYMES OF INDIVIDUAL MUSCLE-FIBERS	FASEB JOURNAL			English	Article									WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; MINIST PUBL HLTH USSR,INST BIOMED PROBLEMS,MOSCOW,USSR; INSERM,F-69008 LYONS,FRANCE	Washington University (WUSTL); Russian Academy of Sciences; Institute of Biomedical Problems of the Russian Academy of Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm)	MANCHESTER, JK (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS008862] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38375] Funding Source: Medline; NINDS NIH HHS [R01-NS08862] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670; BURCH HB, 1963, J BIOL CHEM, V238, P2267; CHI MMY, 1988, BIOL REPROD, V39, P295, DOI 10.1095/biolreprod39.2.295; CHI MMY, 1986, AM J PHYSIOL, V251, pC633, DOI 10.1152/ajpcell.1986.251.4.C633; ESSEN B, 1975, ACTA PHYSIOL SCAND, V95, P153, DOI 10.1111/j.1748-1716.1975.tb10038.x; GRINDELAND RE, 1990, FASEB J, V4, P10, DOI 10.1096/fasebj.4.1.2403949; HENRIKSSON J, 1986, AM J PHYSIOL, V251, pC614, DOI 10.1152/ajpcell.1986.251.4.C614; HINTZ CS, 1980, AM J PHYSIOL, V239, pC58, DOI 10.1152/ajpcell.1980.239.3.C58; LOWRY CV, 1978, J BIOL CHEM, V253, P8269; MIU B, 1990, FASEB J, V4, P64, DOI 10.1096/fasebj.4.1.2136839; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PETTE D, 1973, PFLUG ARCH EUR J PHY, V338, P257, DOI 10.1007/BF00587391	12	41	41	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1990	4	1					55	63		10.1096/fasebj.4.1.1967237	http://dx.doi.org/10.1096/fasebj.4.1.1967237			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CH311	1967237				2022-12-25	WOS:A1990CH31100011
J	LANGECARTER, CA; MALKINSON, AM				LANGECARTER, CA; MALKINSON, AM			ALTERED REGULATION OF MESSENGER-RNA LEVELS ENCODING THE TYPE-I ISOZYME OF CAMP-DEPENDENT PROTEIN-KINASE IN NEOPLASTIC MOUSE LUNG EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; CATALYTIC SUBUNIT; ADENYLATE-CYCLASE; RIBONUCLEIC-ACID; LYMPHOMA-CELLS; HUMAN TESTIS; GM-CSF; EXPRESSION; TUMORS; BINDING	Neoplastic mouse lung epithelial cells express greatly diminished activity, protein, and mRNA for the type I isozyme of cAMP-dependent protein kinase (PKA I). To address the mechanism of this decrease, the turnover rate of PKA subunit mRNA was examined. Northern blot analysis of PKA mRNAs from transcriptionally inhibited cells indicated that these messages exhibit different stabilities and that they are more stable in neoplastic E9 cells than in normal C10 cells. This suggests that the mechanism of decreased PKA I mRNA in E9 cells resides at the level of transcription. To examine whether this was due to an altered responsiveness to agents which regulate PKA transcription, PKA levels were experimentally manipulated in C10 and E9 cells by long-term treatment with forskolin or 8-chloro-cAMP. PKA activity and the concentration of RI (regulatory subunit of PKA I) and C (catalytic subunit) are coordinately regulated in both cell lines, but this does not reflect the changes in PKA I subunit mRNAs. RI-alpha mRNA is specifically induced by forskolin in normal C10 cells, but not in E9 cells. C-alpha mRNA is forskolin-inducible in E9 cells, but this enhanced level of expression does not approach that found constitutively in C10 cells. Thus, while C10 and E9 undergo similar changes in PKA I protein subunits following these treatments, a differential modulation of their PKA I mRNA occurs. These cell-specific mRNA responses to cAMP-mediated induction suggest that the mechanism of the decreased constitutive concentration of PKA I in E9 cells involves altered regulation of PKA I mRNAs.	UNIV COLORADO, SCH PHARM, COLORADO CANC CTR, MOLEC & ENVIRONM TOXICOL PROGRAM, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder				Lange, Carol/0000-0003-2751-3976	NIEHS NIH HHS [ES02370] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002370] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BEEBE SJ, 1986, ENZYMES, V17, P43; BRETON MF, 1989, MOL CELL ENDOCRINOL, V61, P49, DOI 10.1016/0303-7207(89)90188-3; BUTLEY MS, 1985, CANCER RES, V45, P3677; CHOCHUNG YS, 1990, CANCER RES, V50, P7093; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; Corbin J D, 1975, Adv Cyclic Nucleotide Res, V5, P265; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1977, J BIOL CHEM, V252, P910; DOSKELAND SO, 1975, J REPROD FERTIL, V44, P207; DOWNS RW, 1982, J CYCLIC NUCL PROT, V8, P235; DROMS KA, 1989, EXP CELL RES, V182, P330, DOI 10.1016/0014-4827(89)90238-3; DROMS KA, 1987, BIOCHEM BIOPH RES CO, V144, P591, DOI 10.1016/S0006-291X(87)80007-4; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GILL GN, 1971, P NATL ACAD SCI USA, V68, P786, DOI 10.1073/pnas.68.4.786; GORDON I, 1980, P NATL ACAD SCI-BIOL, V77, P452, DOI 10.1073/pnas.77.1.452; Grady HG, 1940, AM J PATHOL, V16, P417; HANSON LA, 1991, EXP LUNG RES, V17, P371, DOI 10.3109/01902149109064425; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HARPOLD MM, 1981, MOL CELL BIOL, V1, P188, DOI 10.1128/MCB.1.2.188; HELMS SR, 1990, NUCLEIC ACIDS RES, V18, P255, DOI 10.1093/nar/18.2.255; HEMMINGS BA, 1986, FEBS LETT, V196, P126, DOI 10.1016/0014-5793(86)80226-5; HOEFFLER JP, 1991, MOL ENDOCRINOL, V5, P256, DOI 10.1210/mend-5-2-256; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HOUGE G, 1990, MOL ENDOCRINOL, V4, P481, DOI 10.1210/mend-4-3-481; KAPOOR CL, 1979, J BIOL CHEM, V254, P2427; KOSTURA M, 1986, BIOCHEMISTRY-US, V25, P6384, DOI 10.1021/bi00369a007; KWASTWELFELD J, 1991, CANCER RES, V51, P528; LANGECARTER CA, 1990, J BIOL CHEM, V265, P7814; LANGECARTER CA, 1991, EXP LUNG RES, V17, P325; LAUB O, 1980, P NATL ACAD SCI-BIOL, V77, P3297, DOI 10.1073/pnas.77.6.3297; LIU AYC, 1980, CANCER RES, V40, P4100; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; MALKINSON AM, 1978, J EXP ZOOL, V205, P423, DOI 10.1002/jez.1402050311; MALKINSON AM, 1981, CANCER RES, V41, P1334; MERINO A, 1989, J BIOL CHEM, V264, P21266; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NICKS KM, 1989, CANCER RES, V49, P5191; NOWAK I, 1987, EUR J BIOCHEM, V167, P27, DOI 10.1111/j.1432-1033.1987.tb13300.x; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OYEN O, 1988, MOL ENDOCRINOL, V2, P1070, DOI 10.1210/mend-2-11-1070; OYEN O, 1988, ENDOCRINOLOGY, V122, P2658; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; PAN YHL, 1990, MOL CARCINOGEN, V3, P279, DOI 10.1002/mc.2940030508; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; POTTER RL, 1980, J BIOL CHEM, V255, P9706; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; RATOOSH SL, 1987, J BIOL CHEM, V262, P7306; RICHARDSON JM, 1990, J BIOL CHEM, V265, P13635; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHANNON JM, 1990, AM J RESP CELL MOL, V2, P183, DOI 10.1165/ajrcmb/2.2.183; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH GJ, 1984, PATHOLOGY, V16, P401, DOI 10.3109/00313028409084730; STEINBERG RA, 1975, CELL, V5, P29, DOI 10.1016/0092-8674(75)90088-4; STEINBERG RA, 1981, J BIOL CHEM, V256, P731; TASKEN KA, 1991, MOL ENDOCRINOL, V5, P21, DOI 10.1210/mend-5-1-21; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WEBER W, 1979, BIOCHEM BIOPH RES CO, V90, P1073, DOI 10.1016/0006-291X(79)91935-1; WEBER W, 1986, BIOCHEMISTRY-US, V25, P5661, DOI 10.1021/bi00367a047; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070	67	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22529	22536						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939270				2022-12-25	WOS:A1991GR56400074
J	BALZARINI, J; LEE, CK; HERDEWIJN, P; DECLERCQ, E				BALZARINI, J; LEE, CK; HERDEWIJN, P; DECLERCQ, E			MECHANISM OF THE POTENTIATING EFFECT OF RIBAVIRIN ON THE ACTIVITY OF 2',3'-DIDEOXYINOSINE AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECTRUM ANTIVIRAL AGENT; 1-BETA-D-RIBOFURANOSYL-1,2,4-TRIAZOLE-3-CARBOXAMIDE VIRAZOLE; ANTIRETROVIRUS ACTIVITY; VIRAL-INFECTION; INVITRO; NUCLEOSIDE; INVIVO; PHOSPHORYLATION; TRIPHOSPHATE; AEROSOL	Ribavirin enhances the anti-human immunodeficiency virus activity of 2',3'-dideoxyinosine (ddIno) in MT-4, CEM and peripheral blood lymphocyte cells. Ribavirin causes an increase in the levels of IMP, the presumed phosphate donor for the conversion of ddIno to ddIMP by 5'-nucleotidase. Consequently, ribavirin stimulates the conversion of ddIno to its antivirally active metabolite ddATP. Ribavirin also causes a marked depletion of the guanine nucleotide pools. The increase in IMP pool levels may result from (i) a direct inhibitory effect of ribavirin 5'-monophosphate on IMP dehydrogenase (which converts IMP to XMP) and (ii) an indirect inhibition of adenylosuccinate synthetase by the decreased GTP and dGTP pools (since GTP is an obligatory cofactor in the conversion of IMP to succinyl AMP). GTP depletion plays a key role in the accumulation of IMP and the resultant higher rate of ddIno phosphorylation to ddIMP and eventually ddATP. Our findings are in agreement with the observations that guanosine and 2'-deoxyguanosine, but not 2'-deoxyadenosine, reverse (i) the stimulatory effect of ribavirin on the anti-human immunodeficiency virus activity of ddIno and (ii) the accumulation of endogenous IMP pools as well as accumulation of [H-3]IMP from exogenous [H-3]hypoxanthine in ribavirin-treated cells.			BALZARINI, J (corresponding author), CATHOLIC UNIV LEUVEN,REGA INST MED RES,MINDERBROEDERSSTR 10,B-3000 LOUVAIN,BELGIUM.			Herdewijn, Piet/0000-0003-3589-8503; De Clercq, Erik/0000-0002-2985-8890				AHLUWALIA G, 1990, BIOCHEM BIOPH RES CO, V171, P1297, DOI 10.1016/0006-291X(90)90827-A; AHLUWALIA G, 1987, BIOCHEM PHARMACOL, V36, P3797, DOI 10.1016/0006-2952(87)90440-0; ALLEN LB, 1978, J MED CHEM, V21, P742, DOI 10.1021/jm00206a005; BABA M, 1987, ANTIMICROB AGENTS CH, V31, P1613, DOI 10.1128/AAC.31.10.1613; BALZARINI J, 1989, P NATL ACAD SCI USA, V86, P332, DOI 10.1073/pnas.86.1.332; BALZARINI J, 1990, J ACQ IMMUN DEF SYND, V3, P1140; BALZARINI J, 1989, ANTIVIR RES, V11, P161, DOI 10.1016/0166-3542(89)90001-6; BALZARINI J, 1991, BIOCHEM BIOPH RES CO, V178, P563, DOI 10.1016/0006-291X(91)90145-W; BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P2847, DOI 10.1016/0006-2952(88)90049-4; Crumpacker C. S., 1984, CLIN APPLICATIONS RI, P33; FERNANDEZLARSSON R, 1990, MOL PHARMACOL, V38, P766; GILBERT BE, 1986, ANTIMICROB AGENTS CH, V30, P201, DOI 10.1128/AAC.30.2.201; GILBERT BE, 1985, ANTIMICROB AGENTS CH, V27, P309, DOI 10.1128/AAC.27.3.309; HALL CB, 1983, NEW ENGL J MED, V308, P1443, DOI 10.1056/NEJM198306163082403; HARTMAN NR, 1991, MOL PHARMACOL, V40, P118; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; JOHNSON MA, 1989, MOL PHARMACOL, V36, P291; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; MCINTOSH K, 1984, AM J DIS CHILD, V138, P305, DOI 10.1001/archpedi.1984.02140410083024; MUIRHEAD KM, 1974, J BIOL CHEM, V249, P459; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PRUSINER P, 1973, NATURE-NEW BIOL, V244, P116, DOI 10.1038/newbio244116a0; Sidwell R. W., 1984, CLIN APPLICATIONS RI, P19; SMITH RA, 1984, CLIN APPLICATIONS RI, P1; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; STRIDH S, 1983, ARCH VIROL, V77, P223, DOI 10.1007/BF01309269; WILLIS RC, 1978, P NATL ACAD SCI USA, V75, P3042, DOI 10.1073/pnas.75.7.3042; WRAY SK, 1985, ANTIVIR RES, V5, P39, DOI 10.1016/0166-3542(85)90013-0	28	96	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21509	21514						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939181				2022-12-25	WOS:A1991GP80400033
J	DONALD, LJ; CRANE, BR; ANDERSON, DH; DUCKWORTH, HW				DONALD, LJ; CRANE, BR; ANDERSON, DH; DUCKWORTH, HW			THE ROLE OF CYSTEINE 206 IN ALLOSTERIC INHIBITION OF ESCHERICHIA-COLI CITRATE SYNTHASE - STUDIES BY CHEMICAL MODIFICATION, SITE-DIRECTED MUTAGENESIS, AND F-19 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; BINDING; GENE	Escherichia coli citrate synthase is strongly and specifically inhibited by NADH, but this inhibition can be prevented by reacting the enzyme with Ellman's reagent. We have now labeled the single reactive cysteine covalently with monobromobimane and isolated and sequenced the bimane-containing cyanogen bromide peptide and identified the cysteine as Cys-206. Modeling studies suggest.that this residue is on the subunit surface, 25-30 angstrom from the active site. Mutation of Cys-206 to serine (C206S), or of Glu-207 to alanine (E207A), weakened NADH binding and inhibition; when these mutations were present together, NADH binding was weaker by 18-fold and inhibition by 250-fold. The mutations also had small effects on substrate binding at the active site. Cys-206 of wild type enzyme and of the mutant E207A was alkylated with 1,1,1-trifluorobromoacetone and the environment of the fluorine nuclei studied by F-19 NMR. With wild type enzyme, the NMR spectrum consisted of two peaks of about equal intensity but different line widths, at -8.65 ppm (line width 11.2 +/- 0.5 Hz) and -7.6 ppm (line width 57 +/- 4 Hz). As the labeled wild type citrate synthase was titrated with KCl, the narrow peak converted to the broad one. The same range of KCl concentrations was needed for this conversion as for the allosteric activation of E. coli citrate synthase. The E207A mutant gave the broader NMR peak almost exclusively. We propose that the fluorine label in wild type citrate synthase exists in two conformational states with different mobilities, exchanging slowly on the NMR time scale, and that treatment with KCl, or truncation of the Glu-207 side chain by mutagenesis, stabilizes one of these states. Consistent with this explanation is the finding that Cys-206 reacts more quickly with Ellman's reagent in the presence of KCl, and that this rate is faster yet in the E207A mutant.			DONALD, LJ (corresponding author), UNIV MANITOBA,DEPT CHEM,WINNIPEG R3T 2N2,MANITOBA,CANADA.							ANDERSON DH, 1989, BIOCHEM CELL BIOL, V67, P98, DOI 10.1139/o89-015; ANDERSON DH, 1988, J BIOL CHEM, V263, P2163; BHAYANA V, 1984, BIOCHEMISTRY-US, V23, P2900, DOI 10.1021/bi00308a008; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; DANSON MJ, 1973, BIOCHEM J, V135, P513, DOI 10.1042/bj1350513; DETAR DF, 1974, COMPUT PROGRAMS CHEM, V4, P71; Duckworth H W, 1987, Biochem Soc Symp, V54, P83; DUCKWORTH HW, 1982, CAN J BIOCHEM CELL B, V60, P1143, DOI 10.1139/o82-146; DUCKWORTH HW, 1976, BIOCHEMISTRY-US, V15, P108, DOI 10.1021/bi00646a017; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FALOONA GR, 1969, BIOCHEMISTRY-US, V8, P4497, DOI 10.1021/bi00839a041; KOSOWER NS, 1979, P NATL ACAD SCI USA, V76, P3382, DOI 10.1073/pnas.76.7.3382; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Laidler K. J., 1965, CHEM KINETICS; MORSE D, 1980, CAN J BIOCHEM CELL B, V58, P696, DOI 10.1139/o80-098; NER SS, 1983, BIOCHEMISTRY-US, V22, P5243, DOI 10.1021/bi00292a001; SRERE PA, 1963, ACTA CHEM SCAND, V17, pS129; TALGOY MM, 1979, CAN J BIOCHEM CELL B, V57, P385, DOI 10.1139/o79-049; TALGOY MM, 1979, CAN J BIOCHEM CELL B, V57, P822, DOI 10.1139/o79-102; TONG EK, 1975, BIOCHEMISTRY-US, V14, P235, DOI 10.1021/bi00673a007; Weitzman P D, 1976, Curr Top Cell Regul, V10, P161; WIEGAND G, 1986, ANNU REV BIOPHYS BIO, V15, P97	22	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20709	20713						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939121				2022-12-25	WOS:A1991GN00100021
J	GARBER, M; PANCHANATHAN, S; FAN, RS; JOHNSON, DL				GARBER, M; PANCHANATHAN, S; FAN, RS; JOHNSON, DL			THE PHORBOL ESTER, 12-O-TETRADECANOYLPHORBOL-13-ACETATE, INDUCES SPECIFIC TRANSCRIPTION BY RNA POLYMERASE-III IN DROSOPHILA SCHNEIDER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							KINASE-C; GENES; ADENOVIRUS; PROMOTERS; ENHANCER; PROTEINS; EXTRACT	We have examined the ability of the tumor-promoting phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), to regulate RNA polymerase III gene expression in Drosophila. Using nuclear run-on assays, we detected a 3-5-fold increase in tRNA synthesis following treatment of Drosophila Schneider S2 cells with TPA, whereas transcription from the actin 5C, fos-, and jun-related antigen promoters was unaffected. This response is rapid and transient, peaking at about a 45-min exposure of the cells to TPA, and dissipating after 60 min. We have reproduced this stimulation in vitro. Extracts prepared from cells treated with TPA show an approximate 10-fold increase in specific transcription using a 5 S RNA and various tRNA gene templates. The nonspecific transcription by RNA polymerase III in these extracts, however, is essentially unchanged. Mixing the extracts derived from uninduced and induced cells suggests that the TPA stimulation observed may be due to the increase of a positive-acting factor. These results are the first to demonstrate that a phorbol ester can induce RNA polymerase III gene expression. The ability to reproduce this activation in vitro will now allow us to assess the role of the transcription components in this regulatory event, and the biochemical consequence of this signaling pathway.	UNIV SO CALIF,SCH PHARM,DEPT MOLEC PHARMACOL & TOXICOL,1985 ZONAL AVE,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033	University of Southern California; University of Southern California					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040623] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-40623] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AURIERO O, 1990, EMBO J, V9, P497; BERGER SL, 1985, NUCLEIC ACIDS RES, V13, P1413, DOI 10.1093/nar/13.4.1413; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOURNIASVARDIABASIS N, 1986, TOXICOL APPL PHARM, V85, P196, DOI 10.1016/0041-008X(86)90113-4; CAREY MF, 1986, MOL CELL BIOL, V6, P3068, DOI 10.1128/MCB.6.9.3068; DEFRANCO D, 1982, NUCLEIC ACIDS RES, V10, P5799, DOI 10.1093/nar/10.19.5799; DINGERMANN T, 1982, J BIOL CHEM, V257, P4738; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3907, DOI 10.1093/nar/9.16.3907; FALCKPEDERSEN E, 1982, BIOCHEMISTRY-US, V21, P5164, DOI 10.1021/bi00264a009; FRADKIN LG, 1987, MOL CELL BIOL, V7, P3380; FRYBERG EA, 1983, CELL, V33, P115; GAYNOR RB, 1985, SCIENCE, V230, P447, DOI 10.1126/science.2996135; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOEFFLER WK, 1985, CELL, V41, P955, DOI 10.1016/S0092-8674(85)80076-3; JOHNSON DL, 1991, J BIOL CHEM, V266, P16037; JOHNSONBURKE DJ, 1985, J BIOL CHEM, V260, P816; KARIN M, 1989, GENES SIGNAL TRANSDU, P415; LOFQUIST A, 1986, J BIOL CHEM, V261, P16600; MINKE B, 1990, P NATL ACAD SCI USA, V87, P113, DOI 10.1073/pnas.87.1.113; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; ROEDER RG, 1974, J BIOL CHEM, V249, P241; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHARP SJ, 1985, CRC CR REV BIOCH MOL, V19, P107, DOI 10.3109/10409238509082541; STALLCUP MR, 1983, J BIOL CHEM, V258, P2802; TOWER J, 1988, MOL CELL BIOL, V8, P1001, DOI 10.1128/MCB.8.2.1001; TSCHUDI C, 1980, NUCLEIC ACIDS RES, V8, P441, DOI 10.1093/nar/8.3.441; WEBER HW, 1991, MOL CELL BIOCHEM, V104, P201; WHITE RJ, 1990, EMBO J, V9, P3713, DOI 10.1002/j.1460-2075.1990.tb07584.x; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; YAMAMOTO K, 1988, SCIENCE, V239, P916, DOI 10.1126/science.3124270	34	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20598	20601						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939109				2022-12-25	WOS:A1991GN00100006
J	LEWIS, WS; SCHUSTER, SM				LEWIS, WS; SCHUSTER, SM			STRUCTURAL REQUIREMENTS FOR NUCLEOPHILIC SUBSTRATES OF CARBOXYPEPTIDASE-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMIDE	The composition and structural aspects of the amino and carboxylic acid groups required for incorporation into peptides by transpeptidation and inhibition of hydrolysis in carboxypeptidase Y-catalyzed reactions were studied. Separation of these two groups by even one carbon prevents incorporation by transpeptidation and does not inhibit incorporation of other amino acids into model peptides. Substitution of phosphonic or sulfonic acids for the carboxylic acid group also results in loss of incorporation by transpeptidation. Only the sulfonic acid analog of glycine causes inhibition of hydrolysis and this inhibition is lost when serine is included in the reaction. d-Serine is not incorporated by carboxypeptidase Y, and its presence in the reaction mixture does not inhibit the incorporation of the L-isomer.	UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT BIOCHEM & MOLEC BIOL,BOX J-245,1301 FIFIELD HALL,GAINESVILLE,FL 32610; UNIV NEBRASKA,DEPT CHEM,LINCOLN,NE 68588	State University System of Florida; University of Florida; University of Nebraska System; University of Nebraska Lincoln								BAI Y, 1975, J BIOCHEM-TOKYO, V78, P617, DOI 10.1093/oxfordjournals.jbchem.a130948; KULLMANN W, 1987, ENZYMATIC PEPTIDE SY, P9; WIDMER F, 1981, CARLSBERG RES COMMUN, V46, P97, DOI 10.1007/BF02906202	3	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20823	20827						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939133				2022-12-25	WOS:A1991GN00100038
J	WEIS, WI; CRICHLOW, GV; MURTHY, HMK; HENDRICKSON, WA; DRICKAMER, K				WEIS, WI; CRICHLOW, GV; MURTHY, HMK; HENDRICKSON, WA; DRICKAMER, K			PHYSICAL CHARACTERIZATION AND CRYSTALLIZATION OF THE CARBOHYDRATE-RECOGNITION DOMAIN OF A MANNOSE-BINDING PROTEIN FROM RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AREA-DETECTOR DIFFRACTOMETER; HUMAN-SERUM; MACROMOLECULAR CRYSTALLOGRAPHY; CLASSICAL PATHWAY; DIFFRACTION DATA; HIGH-RESOLUTION; LIGAND-BINDING; LECTIN; LIVER; HEPATOCYTES	A portion of rat mannose-binding protein A (MBP-A), a Ca2+-dependent animal lectin, has been overproduced in a bacterial expression system, biochemically characterized, and crystallized. A fragment corresponding to the COOH-terminal 115 residues of native MBP-A, produced by subtilisin digestion of the bacterially expressed protein, contains the carbohydrate-recognition domain (CRD). Gel filtration, chemical cross-linking, and crystallographic self-rotation function analyses indicate that the subtilisin fragment is a dimer, although the complete bacterially expressed fragment, containing the neck and CRD of MBP-A, is a trimer. Crystals of the minimal CRD, obtained only as a complex with a Man6GlcNAc2Asn glycopeptide, diffract to Bragg spacings of at least 1.7 angstrom. Several trivalent lanthanide ions (Ln3+) can substitute for Ca2+, as assessed by their ability to support carbohydrate binding and to protect the CRD from proteolysis in a manner similar to that observed for Ca2+. These assays indicate that Ln3+ binds about 30 times more tightly than Ca2+ to the CRD, and that two Ca2+ or Ln3+ bind to each monomer, a result confirmed by determination of the Ho3+ positions in a Ho3+-containing crystal of the CRD. Crystals grown in the presence of Ln3+ belong to different space groups from those obtained with Ca2+ and are therefore not useable for traditional crystallographic phase determination methods, but are well-suited for high resolution structure determination by multiwavelength anomalous dispersion phasing.	COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Columbia University; Howard Hughes Medical Institute			Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034102, R37GM034102, R01GM042628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34102, GM42628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN TT, 1982, J BIOL CHEM, V257, P8036; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1990, XPLOR MANUAL VERSION; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; COLLEY KJ, 1987, J BIOL CHEM, V262, P10296; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DRICKAMER K, 1987, J BIOL CHEM, V262, P2582; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1989, BIOCHEM SOC T, V17, P13, DOI 10.1042/bst0170013; Evans C.H, 2013, BIOCH LANTHANIDES, V8; EZEKOWITZ RAB, 1988, J EXP MED, V167, P1034, DOI 10.1084/jem.167.3.1034; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; Hendrickson W. A., 1985, T AM CRYSTALLOGR ASS, V21, P11; HUBER R, 1985, MOL REPLACEMENT, P58; IKEDA K, 1987, J BIOL CHEM, V262, P7451; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KAHN R, 1986, NUCL INSTRUM METH A, V246, P596, DOI 10.1016/0168-9002(86)90158-0; KAWASAKI N, 1983, J BIOCHEM, V94, P937, DOI 10.1093/oxfordjournals.jbchem.a134437; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE YC, 1972, METHOD ENZYMOL, V28, P63; LOEB JA, 1988, J BIOL CHEM, V263, P9752; LU J, 1990, J IMMUNOL, V144, P2287; Maniatis T., 1982, MOL CLONING; MAYNARD Y, 1982, J BIOL CHEM, V257, P3788; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MIZUNO Y, 1981, J BIOL CHEM, V256, P4247; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMANN MG, 1961, ACTA CRYSTALLOGR, V14, P33; SUMMERFIELD JA, 1986, BIOCHIM BIOPHYS ACTA, V883, P197, DOI 10.1016/0304-4165(86)90309-0; SUPER M, 1989, LANCET, V2, P1236; TAYLOR ME, 1989, BIOCHEM J, V262, P763, DOI 10.1042/bj2620763; TAYLOR ME, 1987, BIOCHIM BIOPHYS ACTA, V915, P60, DOI 10.1016/0167-4838(87)90125-7; TEMPLETON LK, 1982, ACTA CRYSTALLOGR A, V38, P74, DOI 10.1107/S056773948200014X; TOWNSEND R, 1981, BIOCHEM J, V194, P209, DOI 10.1042/bj1940209; WILD J, 1983, BIOCHEM J, V210, P167, DOI 10.1042/bj2100167; 1979, CCP4 DAR LAB	41	109	112	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20678	20686						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939118				2022-12-25	WOS:A1991GN00100017
J	SACCHI, N; WENDTNER, CM; THIELE, CJ				SACCHI, N; WENDTNER, CM; THIELE, CJ			SINGLE-CELL DETECTION OF ETS-1 TRANSCRIPTS IN HUMAN NEUROECTODERMAL CELLS	ONCOGENE			English	Note							EWINGS-SARCOMA; DNA-BINDING; PROTOONCOGENE EXPRESSION; TRANSFORMING GENE; PROTO-ONCOGENES; SEQUENCE; PROTEINS; ERYTHROBLASTOSIS; LINES; NEUROEPITHELIOMA	The genes of the ets family are thought to code for a novel class of transcriptional factors. These proteins have a specific DNA-binding domain different from the basic domain of both the helix-loop-helix and leucine zipper families of DNA-binding proteins. The ets-1 gene product has been shown to bind to the enhancer region of the human T-cell receptor alpha-gene during thymocyte ontogeny. This finding explains the high expression of ets-1 observed in T cells and the correlation between ets-1 expression and the expression of the T-cell receptor gene during fetal development. The ets-1 gene is also possibly biologically active in neural cells. By using RNA in situ hybridization analysis, we demonstrate the presence of ets-1 transcripts in cells of peripheral embryonal neuroectodermal tumors, specifically neuroepithelioma and neuroblastoma. In addition, the gene is found transcribed in Ewing's sarcoma, postulated to be ontogenetically related to tumors derived from the neural crest.	NCI, PEDIAT ONCOL BRANCH, MOLEC GENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SACCHI, N (corresponding author), NCI, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA.							AMOUYEL P, 1988, BRAIN RES, V447, P149, DOI 10.1016/0006-8993(88)90976-6; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BIEDLER JL, 1989, CANCER RES, V41, P4678; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRESSER J, 1987, GENE ANAL TECH, V4, P89, DOI 10.1016/0735-0651(87)90002-1; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; DONNER L, 1985, ADV NEUROBLASTOMA RE, P347; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; ISRAEL MA, 1989, PRINCIPLES PRACTICE, P623; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOVAR H, 1990, ONCOGENE, V5, P1067; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIPINSKI M, 1987, CANCER RES, V47, P183; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MAVROTHALASSITIS GJ, 1991, CELL GROWTH DIFFER, V2, P215; MCKEON C, 1988, CANCER RES, V48, P4307; MUJOO K, 1987, CANCER RES, V47, P1098; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PAPAS TS, 1990, AM J MED GENET, P251; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SACCHI N, 1988, LEUKEMIA, V2, P12; SETH A, 1990, ONCOGENESIS, P207; SHYAM E, 1990, CANCER RES, V50, P5013; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907	45	16	16	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					2149	2154						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945417				2022-12-25	WOS:A1991GX11900028
J	FAY, PJ; SMUDZIN, TM; WALKER, FJ				FAY, PJ; SMUDZIN, TM; WALKER, FJ			ACTIVATED PROTEIN C-CATALYZED INACTIVATION OF HUMAN FACTOR-VIII AND FACTOR-VIII - IDENTIFICATION OF CLEAVAGE SITES AND CORRELATION OF PROTEOLYSIS WITH COFACTOR ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND FACTOR COMPLEX; ANTI-HEMOPHILIC FACTOR; COAGULATION FACTOR-V; PORCINE FACTOR-VIII; FACTOR-XA; BLOOD-COAGULATION; BINDING-SITE; LIGHT CHAIN; THROMBIN; QUANTITIES	Human factor VIII and factor VIII(a) were proteolytically inactivated by activated protein C. Cleavages occurred within the heavy chain (contiguous A1-A2-B domains) of factor VIII and in the heavy chain-derived Al and A2 subunits of factor VIII(a), whereas no proteolysis was observed in the light chain or light chain-derived A3-C1-C2 subunit. Reactivity to an anti-A2 domain monoclonal antibody and NH2-terminal sequence analysis of three terminal digest fragments from factor VIII allowed ordering of fragments and identification of cleavage sites. Fragment A1 was derived from the NH2 terminus and resulted from cleavage at Arg336-Met337. The A2 domain was bisected following cleavage at Arg562-Gly563 and yielded fragments designated A2N and A2C. A third cleavage site is proposed at the A2-B junction (Arg740-Ser741) since fragment A2C was of equivalent size when derived either from factor VIII or factor VIII(a). The site at Arg562 was preferentially cleaved first in factor VIII(a) compared with the site at Arg336, and it was this initial cleavage that most closely correlated with the loss of cofactor activity. Factor VIII(a) as inactivated 5-fold faster than factor VIII, possibly as a result of increased protease utilization of the site at Arg562 when the A2 subunit is not contiguous with the A1 domain. When initial cleavage occurred at Arg336, it appeared to preclude subsequent cleavage at Arg562, possibly by promoting dissociation of the A2 domain (subunit) from the A1/light chain dimer. This conclusion was supported by the failure of protease treated A1/A3-C1-C2 dimer to bind A2 subunit and gel filtration analysis that showed dissociation of the A2 domain-derived fragments, A2N and A2C, from the A1 fragment/light chain dimer. These results suggest a mechanism for activated protein C-catalyzed inactivation of factor VIII(a) involving both covalent alteration and fragment dissociation.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV CONNECTICUT,AMER RED CROSS BLOOD SERV,FARMINGTON,CT 06032; UNIV CONNECTICUT,DEPT MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,DEPT LAB MED,FARMINGTON,CT 06032	University of Rochester; American Red Cross; University of Connecticut; University of Connecticut; University of Connecticut	FAY, PJ (corresponding author), UNIV ROCHESTER,SCH MED & DENT,MED CTR,DEPT MED,HEMATOL UNIT,POB 610,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.				NHLBI NIH HHS [HL-38199, HL-40328] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040328, R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1990, J BIOL CHEM, V265, P6197; FAY PJ, 1989, BIOCHIM BIOPHYS ACTA, V994, P142, DOI 10.1016/0167-4838(89)90153-2; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FULCHER CA, 1984, BLOOD, V63, P486; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; KANE WH, 1988, BLOOD, V71, P539; KISIEL W, 1977, BIOCHEMISTRY-US, V16, P5824, DOI 10.1021/bi00645a029; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; MANN KG, 1990, BLOOD, V76, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; SUZUKI K, 1983, J BIOL CHEM, V258, P1914; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P322, DOI 10.1016/0003-9861(87)90037-3; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WALKER FJ, 1980, J BIOL CHEM, V255, P5521; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	32	171	174	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20139	20145						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939075				2022-12-25	WOS:A1991GM03900042
J	MATSUMINE, H; HERBST, MA; OU, SHI; WILSON, JD; MCPHAUL, MJ				MATSUMINE, H; HERBST, MA; OU, SHI; WILSON, JD; MCPHAUL, MJ			AROMATASE MESSENGER-RNA IN THE EXTRAGONADAL TISSUES OF CHICKENS WITH THE HENNY-FEATHERING TRAIT IS DERIVED FROM A DISTINCTIVE PROMOTER STRUCTURE THAT CONTAINS A SEGMENT OF A RETROVIRAL LONG TERMINAL REPEAT - FUNCTIONAL-ORGANIZATION OF THE SEBRIGHT, LEGHORN, AND CAMPINE AROMATASE GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; BANTAM CHICKEN; SKIN FIBROBLASTS; DNA; ESTROGEN; CYTOCHROME-P-450; EXPRESSION; CDNA; BACTERIOPHAGE; INHERITANCE	The henny-feathering trait is an autosomal dominant mutation that causes the expression of aromatase activity and accumulation of aromatase mRNA in extra-gonadal tissues of chickens. The current studies establish that the aromatase gene is not amplified and is organized similarly in control (Leghorn) and henny-feathered (Sebright and Campine) birds. Nucleotide sequence analysis of the nine coding exons of the aromatase gene reveals that the predicted amino acid sequence is identical in all three strains. We, therefore, characterized the genomic DNA segments flanking the coding. segment of the Sebright, Leghorn, and Campine aromatase genes. The site of transcription initiation utilized in the ovary of all three strains is located approximately 147 nucleotides upstream of the initiator methionine. In addition to aromatase mRNA derived from this common ovarian promoter, another species of aromatase mRNA is present in Sebright and Campine ovary and is the only type detected in Sebright fibroblasts. cDNA copies of this second species of aromatase mRNA contain a unique 5' terminus, suggesting that a second promoter controls extragonadal aromatase expression in birds that carry the henny-feathering trait. Nucleotide sequence analysis of this 5' terminus indicates that this segment is derived from a retroviral long terminal repeat.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Ou, Sai-Hong/AAA-3389-2020; McPhaul, Michael/AAC-7124-2020		NIDDK NIH HHS [DK03892] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK003892] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BLACK SD, 1986, CYTOCHROME P450 STRU, P161; BURKE JF, 1984, GENE, V30, P63, DOI 10.1016/0378-1119(84)90105-7; CALZONE FJ, 1987, GUIDE MOL CLONING TE, P611; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG BC, 1986, P NATL ACAD SCI USA, V83, P4243, DOI 10.1073/pnas.83.12.4243; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEORGE FW, 1980, J CLIN INVEST, V66, P57, DOI 10.1172/JCI109835; GEORGE FW, 1990, J HERED, V81, P107, DOI 10.1093/oxfordjournals.jhered.a110938; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HICKEY GJ, 1990, MOL ENDOCRINOL, V4, P3, DOI 10.1210/mend-4-1-3; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; HINES RN, 1985, ARCH BIOCHEM BIOPHYS, V237, P465, DOI 10.1016/0003-9861(85)90300-5; HISHINUMA F, 1981, CELL, V23, P155, DOI 10.1016/0092-8674(81)90280-4; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; LESHIN M, 1983, J STEROID BIOCHEM, V18, P33, DOI 10.1016/0022-4731(83)90327-8; LESHIN M, 1985, P NATL ACAD SCI USA, V82, P3005, DOI 10.1073/pnas.82.9.3005; LESHIN M, 1981, J BIOL CHEM, V256, P4341; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MATSUMINE H, 1990, MOL ENDOCRINOL, V4, P905, DOI 10.1210/mend-4-6-905; MCPHAUL MJ, 1988, J BIOL CHEM, V263, P16358; MEANS GD, 1989, J BIOL CHEM, V264, P19385; MIZOKAMI Y, 1983, P NATL ACAD SCI USA, V80, P3958; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V101, P879, DOI 10.1093/oxfordjournals.jbchem.a121955; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SMITH EJ, 1984, VIROLOGY, V134, P493, DOI 10.1016/0042-6822(84)90319-2; SOMES RG, 1984, J HERED, V75, P99, DOI 10.1093/oxfordjournals.jhered.a109902; SUWA Y, 1985, J BIOL CHEM, V260, P7980; TEREBA A, 1991, J HERED, V82, P80, DOI 10.1093/jhered/82.1.80; WILSON JD, 1987, ENDOCR REV, V8, P363, DOI 10.1210/edrv-8-4-363	35	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19900	19907						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939054				2022-12-25	WOS:A1991GM03900009
J	MEKADA, E; SENOH, H; IWAMOTO, R; OKADA, Y; UCHIDA, T				MEKADA, E; SENOH, H; IWAMOTO, R; OKADA, Y; UCHIDA, T			PURIFICATION OF DIPHTHERIA-TOXIN RECEPTOR FROM VERO CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-BILAYER MEMBRANES; FORMS LARGE PORES; MUTANT PROTEINS; RICIN TOXIN; A-FRAGMENT; LOW PH; BINDING; ENTRY; IDENTIFICATION; TOXICITY	Diphtheria toxin receptor has been solubilized from Vero cell membranes with octyl beta-D-glucoside. CRM197, the product of a mutated diphtheria toxin gene, was used for the identification of the receptor. The binding activity of the solubilized receptor was assayed by precipitating the receptor with acetone in the presence of phospholipids and carrier proteins. The solubilized receptor was purified by the combination of several chromatographic steps in the presence of the detergent, resulting in about a 10(6)-fold purification of the receptor. The purified receptor showed essentially a single band of 14.5 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. When partially purified receptor fractions were subjected to ligand blotting analysis using I-125-CRM197 as the probe, the 14.5-kDa protein and a few minor protein bands were identified as diphtheria toxin-binding molecules. These results show clearly that the 14.5-kDa protein is the diphtheria toxin receptor, or at least the major diphtheria toxin-binding molecule. When partially purified receptor was applied to a Sephacryl S-300 column in the presence of detergent, the receptor was eluted in the fractions corresponding to the 60-90-kDa size range. This suggests that the protein forms a complex with itself or with another protein.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Osaka University	MEKADA, E (corresponding author), KURUME UNIV,INST LIFE SCI,KURUME,FUKUOKA 830,JAPAN.			Mekada, Eisuke/0000-0001-8858-4781				BOQUET P, 1976, P NATL ACAD SCI USA, V73, P4449, DOI 10.1073/pnas.73.12.4449; CIEPLAK W, 1987, J BIOL CHEM, V262, P13246; COLLIER RJ, 1964, J EXP MED, V120, P1019, DOI 10.1084/jem.120.6.1019; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; GIANNINI G, 1984, NUCLEIC ACIDS RES, V12, P4063, DOI 10.1093/nar/12.10.4063; GILL DM, 1969, J EXP MED, V129, P1, DOI 10.1084/jem.129.1.1; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HONJO T, 1968, J BIOL CHEM, V243, P3553; ITZHAKI RF, 1964, ANAL BIOCHEM, V9, P401, DOI 10.1016/0003-2697(64)90200-3; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; JIANG GS, 1989, J BIOL CHEM, V264, P17170; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KIM K, 1965, J BACTERIOL, V90, P1552, DOI 10.1128/JB.90.6.1552-1556.1965; KOHNO K, 1985, SOMAT CELL MOLEC GEN, V11, P421, DOI 10.1007/BF01534836; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPLA SH, 1989, J BIOL CHEM, V255, P2247; MEKADA E, 1985, J BIOL CHEM, V260, P2148; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; MEKADA E, 1982, BIOCHEM BIOPH RES CO, V109, P792, DOI 10.1016/0006-291X(82)92009-5; MEKADA E, 1981, J BIOL CHEM, V256, P1225; MERION M, 1983, P NATL ACAD SCI-BIOL, V80, P5315, DOI 10.1073/pnas.80.17.5315; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; ROBBINS AR, 1984, J CELL BIOL, V99, P1296, DOI 10.1083/jcb.99.4.1296; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; STRAUSS N, 1959, J EXP MED, V109, P144; UCHIDA T, 1977, NATURE, V266, P839, DOI 10.1038/266839a0; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; UMATA T, 1990, J BIOL CHEM, V265, P21940	36	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20457	20462						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939100				2022-12-25	WOS:A1991GM03900087
J	ROJO, M; HOVIUS, R; DEMEL, RA; NICOLAY, K; WALLIMANN, T				ROJO, M; HOVIUS, R; DEMEL, RA; NICOLAY, K; WALLIMANN, T			MITOCHONDRIAL CREATINE-KINASE MEDIATES CONTACT FORMATION BETWEEN MITOCHONDRIAL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMS OCTAMERIC STRUCTURES; RAT-HEART MITOCHONDRIA; LIVER MITOCHONDRIA; INNER MEMBRANE; M-LINE; PURIFICATION; PROTEIN; MUSCLE; IMPORT; SITES	Purified mitochondrial creatine kinase (Mi-CK) (EC 2.7.3.2) from chicken heart was shown to interact simultaneously with purified inner and outer mitochondrial membranes, thereby creating an intermembrane contact. Inner and outer mitochondrial membranes were purified from rat liver and thus were fully devoid of Mi-CK. Intermembrane contact formation was demonstrated by measuring the binding of inner membrane vesicles to outer membranes spread at the air-water interface. Mi-CK also mediated intermembrane adhesion when membranes formed with total lipid extracts of both membranes were used, pointing to the role of lipids as potential membrane anchors of Mi-CK in the mitochondrial intermembrane space. Other enzymes of the intermembrane space that (like Mi-CK) are also cationic, as well as cytosolic isoenzymes of creatine kinase, failed to induce contact formation. Thus, of the proteins tested, membrane contact formation was specific for Mi-CK. The two oligomeric forms of Mi-CK (octamer and dimer) differed in their ability to mediate intermembrane adhesion, the octamer being more potent. Highly basic peptides, i.e. poly-L-lysines, were shown to strongly interact with membranes formed with lipid extracts of mitochondrial membranes: they both induced intermembrane binding and fusion. Interestingly, the extent of contact formation mediated by poly-L-lysines was lower than that of octameric Mi-CK. The implications of these findings on the function and localization of Mi-CK and on the structure of the mitochondrial intermembrane compartment are discussed.	SWISS FED INST TECHNOL,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND; STATE UNIV UTRECHT,INST MOLEC BIOL & MED BIOTECHNOL,3584 CH UTRECHT,NETHERLANDS; STATE UNIV UTRECHT,CTR BIOMEMBRANES & LIPID ENZYMOL,3584 CH UTRECHT,NETHERLANDS	Swiss Federal Institutes of Technology Domain; ETH Zurich; Utrecht University; Utrecht University			Wallimann, Theo/C-6047-2008; Nicolay, Klaas/F-4192-2010	Wallimann, Theo/0000-0003-4957-5836; Nicolay, Klaas/0000-0002-4179-616X; Rojo, Manuel/0000-0002-9680-9263; DOMENICUCCI, Maurizio/0000-0002-9745-6439				ADAMS V, 1989, BIOCHIM BIOPHYS ACTA, V981, P213, DOI 10.1016/0005-2736(89)90031-X; BRDICZKA D, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P361; CAPALDI RA, 1982, BIOCHIM BIOPHYS ACTA, V694, P291, DOI 10.1016/0304-4157(82)90009-0; DEKRUIJFF B, 1985, BIOCHIM BIOPHYS ACTA, V820, P295, DOI 10.1016/0005-2736(85)90124-5; Demel R A, 1974, Methods Enzymol, V32, P539; DEMEL RA, 1989, J BIOL CHEM, V264, P3988; EPPENBERGER HM, 1983, ISOZYMES-CURR T BIOL, V7, P19; ERICKSONVIITANEN S, 1982, J BIOL CHEM, V257, P4395; FISCHER WR, 1973, J BIOL CHEM, V248, P3188; Fiske CH, 1925, J BIOL CHEM, V66, P375; FUKUSHIMA K, 1989, BIOPHYS CHEM, V34, P83, DOI 10.1016/0301-4622(89)80045-6; HENNIG B, 1983, METHOD ENZYMOL, V97, P261; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; KOTTKE M, 1991, BIOCHIM BIOPHYS ACTA, V1061, P215, DOI 10.1016/0005-2736(91)90287-I; MALHOTRA SK, 1966, J ULTRA MOL STRUCT R, V15, P14, DOI 10.1016/S0022-5320(66)80091-6; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MULLER M, 1985, J BIOL CHEM, V260, P3839; NICOLAY K, 1990, BIOCHIM BIOPHYS ACTA, V1025, P49, DOI 10.1016/0005-2736(90)90189-U; OHKI S, 1986, BIOCHIM BIOPHYS ACTA, V861, P177, DOI 10.1016/0005-2736(86)90577-8; PATTUS F, 1981, BIOCHIM BIOPHYS ACTA, V647, P29, DOI 10.1016/0005-2736(81)90292-3; QUEMENEUR E, 1988, BIOCHEM BIOPH RES CO, V153, P1310, DOI 10.1016/S0006-291X(88)81371-8; QUEST AFG, 1989, ENZYME, V41, P33, DOI 10.1159/000469048; ROJO M, 1991, FEBS LETT, V281, P123, DOI 10.1016/0014-5793(91)80374-C; SAKS VA, 1985, J BIOL CHEM, V260, P7757; SCHLEGEL J, 1988, J BIOL CHEM, V263, P16942; SCHLEGEL J, 1990, J BIOL CHEM, V265, P9221; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNYDER T, 1991, J CELL BIOL, V112, P95, DOI 10.1083/jcb.112.1.95; SCHNYDER T, 1988, J BIOL CHEM, V263, P16954; SIMBENI R, 1990, J BIOL CHEM, V265, P281; SJOSTRAND FS, 1978, J ULTRA MOL STRUCT R, V64, P217, DOI 10.1016/S0022-5320(78)90033-3; TOMASSELLI AG, 1980, EUR J BIOCHEM, V103, P481, DOI 10.1111/j.1432-1033.1980.tb05972.x; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; VERGER R, 1976, CHEM PHYS LIPIDS, V16, P285, DOI 10.1016/0009-3084(76)90023-2; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; Wallimann T, 1989, Prog Clin Biol Res, V315, P159; WYSS M, 1990, J BIOL CHEM, V265, P15900; 1987, DEV TECHNIQUE FILE, V210	40	103	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20290	20295						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939087				2022-12-25	WOS:A1991GM03900062
J	ELGREN, TE; LYNCH, JB; JUAREZGARCIA, C; MUNCK, E; SJOBERG, BM; QUE, L				ELGREN, TE; LYNCH, JB; JUAREZGARCIA, C; MUNCK, E; SJOBERG, BM; QUE, L			ELECTRON-TRANSFER ASSOCIATED WITH OXYGEN ACTIVATION IN THE B2 PROTEIN OF RIBONUCLEOTIDE REDUCTASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE REDUCTASE; TYROSINE RESIDUE; PARAMAGNETIC-RES; IRON CENTER; SUBUNIT; MOSSBAUER; ENZYME	Each of the two beta-peptides which comprise the B2 protein of Escherichia coli ribonucleotide reductase (RRB2) possesses a nonheme dinuclear iron cluster and a tyrosine residue at position 122. The oxidized form of the protein contains all high spin ferric iron and 1.0-1.4 tyrosyl radicals per RRB2 protein. In order to define the stoichiometry of in vitro dioxygen reduction catalyzed by fully reduced RRB2 we have quantified the reactants and products in the aerobic addition of Fe(II) to metal-free RRB2apo utilizing an oxygraph to quantify oxygen consumption, electron paramagnetic resonance to measure tyrosine radical generation, and Mossbauer spectroscopy to determine the extent of iron oxidation. Our data indicate that 3.1 Fe(II) and 0.8 Tyr122 are oxidized per Mol of O2 reduced. Mossbauer experiments indicate that less than 8% of the iron is bound as mononuclear high spin Fe(III). Further, the aerobic addition of substoichiometric amounts of Fe-57 to RRB2apo consistently produces dinuclear clusters, rather than mononuclear Fe(III) species, providing the first direct spectroscopic evidence for the preferential formation of the dinuclear units at the active site. These stoichiometry studies were extended to include the phenylalanine mutant protein (Y122F)RRB2 and show that 3.9 mol-equivalents of Fe(II) are oxidized per mol of O2 consumed. Our stoichiometry data has led us to propose a model for dioxygen activation catalyzed by RRB2 which invokes electron transfer between iron clusters.	UNIV MINNESOTA, DEPT CHEM, 207 PLEASANT ST SE, MINNEAPOLIS, MN 55455 USA; CARNEGIE MELLON UNIV, DEPT CHEM, PITTSBURGH, PA 15213 USA; UNIV STOCKHOLM, DEPT MOLEC BIOL, S-10691 STOCKHOLM, SWEDEN	University of Minnesota System; University of Minnesota Twin Cities; Carnegie Mellon University; Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022701] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-22701, GM-07323] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTANAITIS BC, 1982, J BIOL CHEM, V257, P5330; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BABCOCK LM, 1980, J AM CHEM SOC, V102, P2849, DOI 10.1021/ja00528a061; BARLOW T, 1983, P NATL ACAD SCI-BIOL, V80, P1492, DOI 10.1073/pnas.80.6.1492; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; BROWN NC, 1969, EUR J BIOCHEM, V9, P512, DOI 10.1111/j.1432-1033.1969.tb00639.x; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; ELIASSON R, 1986, P NATL ACAD SCI USA, V83, P2373, DOI 10.1073/pnas.83.8.2373; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; FOX BG, 1988, J BIOL CHEM, V263, P10553; HENDRICH MP, 1991, BIOCHEM BIOPH RES CO, V176, P705, DOI 10.1016/S0006-291X(05)80241-4; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; PEARCE LL, 1987, J AM CHEM SOC, V109, P7286, DOI 10.1021/ja00258a007; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; SALOWE SP, 1986, J BACTERIOL, V165, P363, DOI 10.1128/jb.165.2.363-366.1986; SALOWE SP, 1987, THESIS U WISCONSIN M; SJOBERG BM, 1983, ADV INORG BIOCHEM, V5, P87; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THELANDER L, 1974, J BIOL CHEM, V249, P4858	24	48	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19265	19268						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918044				2022-12-25	WOS:A1991GK66700026
J	LEE, ME; DHADLY, MS; TEMIZER, DH; CLIFFORD, JA; YOSHIZUMI, M; QUERTERMOUS, T				LEE, ME; DHADLY, MS; TEMIZER, DH; CLIFFORD, JA; YOSHIZUMI, M; QUERTERMOUS, T			REGULATION OF ENDOTHELIN-1 GENE-EXPRESSION BY FOS AND JUN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-1; INDUCIBLE ENHANCER; LEUCINE ZIPPER; C-FOS; PROTEIN COMPLEXES; CELLS; BINDING; PROMOTER; DNA; SEQUENCE	The endothelin peptides constitute a family of potent vasoconstrictor molecules. Endothelin-1 (ET1) is secreted by vascular endothelial cells and may have a role in the regulation of vascular tone. To better understand the function of ET1, we have investigated the transcriptional regulation of the ET1 gene. Utilizing reporter gene transfection experiments, we have previously identified two promoter regions, located at base pairs -148 to -117 (Region A) and -117 to -98 (Region B) of the ET1 gene. Both regions are necessary for high level ET1 transcription in endothelial cells. A nuclear protein binding to the GATA motif in Region A has been identified and proven to be necessary for expression of the ET1 gene. However, the cis-acting sequences and their cognate binding proteins for Region B have not been investigated. To identify protein binding motifs in Region B we performed DNase I footprinting and gel mobility shift assays using a DNA fragment encoding base pairs -204 to -94 of the ET1 gene. Results from these studies indicated that the AP1 consensus sequence (GTGACTAA) in Region B as the only protein-binding motif. Site-directed mutagenesis of the ET1 AP1 site resulted in a 30-fold reduction in promoter activity, establishing the functional significance of this sequence. Additional experiments investigated the role of Jun and Fos in ET1 transcription. By employing antisera to Jun and Fos in gel mobility shift assays, both of these proteins were identified as endothelial cell nuclear proteins binding to the ET1 AP1 sequence. In trans-activation experiments, we showed that cotransfection of c-fos and c-jun expression plasmids markedly increased the transcription rate of chloramphenicol acetyltransferase reporter plasmids containing three synthetic ET1 AP1 sites. Taken together, these data indicate the importance of the AP1 recognition sequence, and the role of Fos and Jun proteins in the regulation of ET1 gene transcription.	MASSACHUSETTS GEN HOSP,GEN MED SERV,CARDIAC UNIT,BOSTON,MA 02114; UNIV TOKYO,MED UNIT,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	Harvard University; Massachusetts General Hospital; University of Tokyo	LEE, ME (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115, USA.			Quertermous, Thomas/0000-0002-7645-9067				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BADR KF, 1989, J CLIN INVEST, V83, P336, DOI 10.1172/JCI113880; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHODOSH L, 1987, CURRENT PROTOCOLS MO; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAGARASAN MO, 1990, P NATL ACAD SCI USA, V87, P7871, DOI 10.1073/pnas.87.20.7871; FINK SJ, 1990, J BIOL CHEM, V266, P3882; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; INOUE A, 1989, J BIOL CHEM, V264, P14954; KAPRINSKI BA, 1989, MOL CELL BIOL, V9, P2588; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; KURIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P1435, DOI 10.1016/0006-291X(89)92270-5; LAMPUGNANI MG, 1990, BLOOD, V76, P1173; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SIMONSON MS, 1983, J CLIN INVEST, V89, P708; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; WILDEMAN AG, 1986, MOL CELL BIOL, V6, P2098, DOI 10.1128/MCB.6.6.2098; WILSON DB, 1990, MOL CELL BIOL, V10, P4854, DOI 10.1128/MCB.10.9.4854; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZUMI M, 1990, BIOCHEM BIOPH RES CO, V166, P324, DOI 10.1016/0006-291X(90)91948-R	44	137	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19034	19039						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918021				2022-12-25	WOS:A1991GJ47200096
J	TOURNIER, S; RAYNAUD, F; GERBAUD, P; LOHMANN, SM; DOREE, M; EVAINBRION, D				TOURNIER, S; RAYNAUD, F; GERBAUD, P; LOHMANN, SM; DOREE, M; EVAINBRION, D			ASSOCIATION OF TYPE-II CAMP-DEPENDENT PROTEIN-KINASE WITH P34CDC2 PROTEIN-KINASE IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN MESSENGER-RNA; XENOPUS CDC2 PROTEIN; REGULATORY SUBUNIT; CELL-CYCLE; FISSION YEAST; MOLECULAR-CLONING; MAMMALIAN-CELLS; GOLGI-COMPLEX; MITOSIS; PHOSPHORYLATION	Previous independent studies suggested that type II cAMP-dependent protein kinase and the p34cdc2 protein kinase cell cycle regulator co-localize at centro-somes. In order to investigate whether there is an association of type II cAMP-dependent protein kinase with p34cdc2 in human fibroblasts, we used three different approaches. First, the regulatory subunits RI and RII were photoaffinity-labeled with 8-N3-[P-32] cAMP, and anti-p34cdc2 immunoprecipitates were screened for the presence of either RI or RII regulatory subunits by one- or two-dimensional gel electrophoresis. Second, anti-RII-alpha immunoprecipitates were screened for the presence of p34cdc2 by Western blot using three different affinity-purified antibodies recognizing different domains of human p34cdc2. Conversely, anti-p34cdc2 immunoprecipitates (three different antibodies), as well as the material retained on p13suc1-Sepharose Bio-Beads, which binds specifically p34cdc2, were screened for the presence of RII-alpha. Finally, we have looked for cAMP-dependent protein kinase activity specifically inhibited by PKI in immunoprecipitates obtained from extracts treated with different anti-p34cdc2 antibodies. All these experiments gave concordant results and demonstrate that at least at G0/G1, human fibroblasts contain a complex of active type II cAMP-dependent protein kinase associated through its RII-alpha subunit with p34cdc2.	UNIV WURZBURG,MED KLIN,KLIN BIOCHEM LAB,W-8700 WURZBURG,GERMANY; CNRS,F-34033 MONTPELLIER,FRANCE; INSERM,F-34100 MONTPELLIER,FRANCE	University of Wurzburg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	TOURNIER, S (corresponding author), ECOLE NORM SUPER,PHYSIOPATHOL DEV LAB,8 ETAGE,46 RUE ULM,F-75230 PARIS 05,FRANCE.			Gerbaud, Pascale/0000-0001-5579-1979				BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHRIVIA JC, 1988, J BIOL CHEM, V263, P5739; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; Evain-Brion D., 1986, P NATL ACAD SCI USA, V83, P5272, DOI [10.1073/pnas.83.14.5272, DOI 10.1073/PNAS.83.14.5272]; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DC, 1983, P NATL ACAD SCI-BIOL, V80, P3608, DOI 10.1073/pnas.80.12.3608; LEE M, 1988, TRENDS GENET, V4, P287, DOI 10.1016/0168-9525(88)90171-0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RABILLOUD T, 1986, J CHROMATOGR, V351, P77, DOI 10.1016/S0021-9673(01)83474-9; RAYNAUD F, 1987, J INVEST DERMATOL, V89, P105, DOI 10.1111/1523-1747.ep12580448; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; RUBIN CS, 1975, ANNU REV BIOCHEM, V44, P831, DOI 10.1146/annurev.bi.44.070175.004151; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TRIPP ML, 1986, P NATL ACAD SCI USA, V83, P5973, DOI 10.1073/pnas.83.16.5973; UHLER MD, 1986, J BIOL CHEM, V261, P5739; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; WALTER U, 1977, J BIOL CHEM, V252, P6494; WALTER U, 1982, HDB EXPT PHARM, P479; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0	44	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19018	19022						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918018				2022-12-25	WOS:A1991GJ47200093
J	CHEN, YM; CHEN, PL; ARNAIZ, N; GOODRICH, D; LEE, WH				CHEN, YM; CHEN, PL; ARNAIZ, N; GOODRICH, D; LEE, WH			EXPRESSION OF WILD-TYPE P53 IN HUMAN A673 CELLS SUPPRESSES TUMORIGENICITY BUT NOT GROWTH-RATE	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; HUMAN PROSTATE CARCINOMA; TUMOR-ANTIGEN; RB GENE; TRANSFORMATION; ONCOGENE; SARCOMAS; CANCER; IMMORTALIZATION; MECHANISMS	The p53 gene has been found to be mutated in many different kinds of human cancers. In a previous study, expression of exogenous wild-type p53 in human osteosarcoma cells by retrovirus-mediated gene transfer resulted in marked enlargement of cell size, reduced growth rate in culture and loss of tumorigenicity in nude mice. Here we examine the effects of expression of wild-type or mutated p53 on human peripheral neuroepithelioma (PNET) A673 cells; these cells contained apparently normal alleles of the p53 gene but did not express a detectable quantity of p53 protein. Various characteristics of the p53-expressing cells were examined including morphology, growth rate, soft-agar colony formation, and tumorigenicity in nude mice. In contrast to osteosarcoma Saos-2 cells, expression of wild-type or mutant p53 protein in A673 cells had no effect on morphology or growth characteristics. However, clones expressing wild-type p53 protein had reduced ability to form colonies in soft agar and tumors in nude mice. To substantiate the genotype of wild-type p53-expressing cells, the proviral p53-encoding DNA of one cell clone was amplified by the polymerase chain reaction and sequenced. We concluded that expression of a single allele of the wild-type p53 gene was sufficient to suppress PNET A673 tumorigenicity but had no detectable effect on growth rate in culture.	UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio	LEE, WH (corresponding author), UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,15355 LAMBDA DR,SAN ANTONIO,TX 78245, USA.				NATIONAL CANCER INSTITUTE [P01CA051495] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY005758] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA51495] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DREYFUS F, 1990, LEUKEMIA, V4, P590; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maniatis T., 1982, MOL CLONING; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	33	76	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1799	1805						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923505				2022-12-25	WOS:A1991GX11800012
J	SONOBE, MH; BRAVO, R; ARMELIN, MS				SONOBE, MH; BRAVO, R; ARMELIN, MS			IMBALANCED EXPRESSION OF CELLULAR NUCLEAR ONCOGENES CAUSED BY V-SIS PDGF-2	ONCOGENE			English	Article							SIMIAN SARCOMA-VIRUS; TRANSFORMING GENE-PRODUCT; FACTOR-LIKE PROTEIN; C-FOS GENE; GROWTH-FACTOR; 3T3 CELLS; LEUCINE ZIPPER; MESSENGER-RNA; DNA-SYNTHESIS; ONC GENE	Two murine cell lines that overexpress v-sis/PDGF-2 were used to study the mechanism of cell transformation by SSV (simian sarcoma virus). In contrast to the parental cells that are phenotypically normal and serum-dependent for growth, v-sis-overexpressing cells grow in PDGF-free plasma medium, are unable to enter the G0 state and are highly tumorigenic. Analysis of the expression of some growth factor-induced early response genes in v-sis-overexpressing cells revealed: (a) high and constitutive c-myc mRNA levels in SSV-NRK cells; (b) unaltered levels of fra-1, fos B, jun B and krox 20 transcripts; (c) high and constitutive FOS staining due to c-FOS and FOS-related protein(s); (d) constitutive c-JUN and higher JUN D expression. These results are compatible with a model in which endogenous production of v-sis/PDGF-2 leads to deregulated expression of key cellular transregulators that, in turn, alter the cells' transcriptional program leading to the transformed state and malignancy.	UNIV SAO PAULO, INST QUIM, DEPT BIOQUIM, CP 20780, BR-01498 SAO PAULO, BRAZIL; SQUIBB INST MED RES, PRINCETON, NJ 08543 USA	Universidade de Sao Paulo			Sonobe, Martha/I-2877-2015					AARONSON SA, 1975, J VIROL, V16, P1117, DOI 10.1128/JVI.16.5.1117-1123.1975; Abate C, 1990, Semin Cancer Biol, V1, P19; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANTONIADES HN, 1987, ONCOGENES GENES GROW, P1; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; CROCE CM, 1985, BLOOD, V65, P1; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; DALLAFAVERA R, 1982, NATURE, V299, P61; DEUEL TF, 1983, SCIENCE, V221, P1348, DOI 10.1126/science.6310754; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OWEN AJ, 1984, SCIENCE, V225, P54, DOI 10.1126/science.6328659; PANTAZIS P, 1986, P NATL ACAD SCI USA, V83, P5526, DOI 10.1073/pnas.83.15.5526; PECH M, 1989, P NATL ACAD SCI USA, V86, P2693, DOI 10.1073/pnas.86.8.2693; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAMEH LE, 1991, IN PRESS ONCOGENE; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; ROBBINS KC, 1982, SCIENCE, V218, P1131, DOI 10.1126/science.6293053; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SCHATZL HM, 1989, ONCOGENE, V4, P1095; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; THEILEN GH, 1971, JNCI-J NATL CANCER I, V47, P881; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VOGT PK, 1988, ONCOGENE, V3, P3; VOGT PK, 1990, CANCER BIOL, V1, P27; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	71	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1991	6	9					1531	1537						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923519				2022-12-25	WOS:A1991GX27400006
J	FREIMUTH, PI; TAYLOR, JW; KAISER, ET				FREIMUTH, PI; TAYLOR, JW; KAISER, ET			INTRODUCTION OF GUEST PEPTIDES INTO ESCHERICHIA-COLI ALKALINE-PHOSPHATASE - EXCISION AND PURIFICATION OF A DYNORPHIN ANALOG FROM AN ACTIVE CHIMERIC PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									ROCKEFELLER UNIV,BIOORGAN CHEM & BIOCHEM LAB,NEW YORK,NY 10021	Rockefeller University					NIDA NIH HHS [R01 DA04197] Funding Source: Medline; NIGMS NIH HHS [GM1950] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004197] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; BARANY F, 1985, GENE, V37, P111, DOI 10.1016/0378-1119(85)90263-X; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOEKE JD, 1981, MOL GEN GENET, V181, P288, DOI 10.1007/BF00425599; BRADSHAW RA, 1981, P NATL ACAD SCI-BIOL, V78, P3473, DOI 10.1073/pnas.78.6.3473; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CHAIT BT, 1981, INT J MASS SPECTROM, V39, P339, DOI 10.1016/0020-7381(81)87007-6; CHARBIT A, 1986, EMBO J, V5, P3029, DOI 10.1002/j.1460-2075.1986.tb04602.x; CHARBIT A, 1987, J IMMUNOL, V139, P1658; COHEN SW, 1970, P NATL ACAD SCI USA, V67, P310; DRAPEAU GR, 1972, J BIOL CHEM, V247, P6720; FREIMUTH PI, 1986, P NATL ACAD SCI USA, V83, P7816, DOI 10.1073/pnas.83.20.7816; GO M, 1980, INT J PEPT PROT RES, V15, P211; GOEDDEL DV, 1979, P NATL ACAD SCI USA, V76, P106, DOI 10.1073/pnas.76.1.106; GOLDSTEIN A, 1979, P NATL ACAD SCI USA, V76, P6666, DOI 10.1073/pnas.76.12.6666; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; HONJO T, 1985, ANNU REV BIOCHEM, V54, P803, DOI 10.1146/annurev.bi.54.070185.004103; INOUYE H, 1981, J BACTERIOL, V146, P668, DOI 10.1128/JB.146.2.668-675.1981; ITAKURA K, 1977, SCIENCE, V198, P1056, DOI 10.1126/science.412251; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LOBEL LI, 1984, P NATL ACAD SCI-BIOL, V81, P4149, DOI 10.1073/pnas.81.13.4149; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; Maxam A M, 1980, Methods Enzymol, V65, P499; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SEGEL IH, 1976, BIOCH CALCULATIONS, P416; SONVEAUX E, 1986, BIOORG CHEM, V14, P274, DOI 10.1016/0045-2068(86)90038-6; SOWADSKI JM, 1981, J MOL BIOL, V150, P245, DOI 10.1016/0022-2836(81)90451-4; STRAUS D, 1985, MOL CELL BIOL, V5, P3497, DOI 10.1128/MCB.5.12.3497; TAYLOR JW, 1982, MOL PHARMACOL, V22, P657; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0	33	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1990	265	2					896	901						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CH533	1967250				2022-12-25	WOS:A1990CH53300043
J	TREICH, I; RIVA, M; SENTENAC, A				TREICH, I; RIVA, M; SENTENAC, A			ZINC-BINDING SUBUNITS OF YEAST RNA-POLYMERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; EUGLENA-GRACILIS; INTRINSIC ZINC; DNA; PROTEIN; GENE; METALLOENZYME; TRANSFORMATION; TRANSCRIPTION	The zinc-binding subunits of yeast RNA polymerase A(I) and B(II) have been identified by a zinc-blotting technique. The two largest subunits of each enzyme (A190, A135, B220, and B150), as well as A12.2, A1O, B44.5, B12.6, and B10, bind Zn-65(II). Predicted zinc-binding motifs have been noted in the NH-2-terminal part of B220 and the COOH-terminal region of B150 subunits. Subdomains encompassing these motifs have been overproduced as MalE-fusion proteins and shown to retain zine binding activity. Site-directed mutagenesis in the predicted metal-binding domain of B150 demonstrated its role in zinc binding. Mutations of cysteine residues C1163, C1166, C1182, and C1185 affected Zn-65(2+) binding in vitro and caused a lethal or thermosensitive phenotype for growth. The ability to bind zinc is not sufficient for function since mutations in vicinal residues not affecting zinc binding were either lethal or thermosensitive. The role of zinc in RNA polymerase structure and function is discussed in the light of the present results.			TREICH, I (corresponding author), CENS,SERV BIOCHIM & GENET MOLEC,F-91191 GIF SUR YVETTE,FRANCE.							ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AULD DS, 1976, BIOCHEM BIOPH RES CO, V69, P548, DOI 10.1016/0006-291X(76)90555-6; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATTERJI D, 1982, BIOCHEMISTRY-US, V21, P4651, DOI 10.1021/bi00262a021; CHATTERJI D, 1984, J BIOL CHEM, V259, P284; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FALCHUK KH, 1976, BIOCHEMISTRY-US, V15, P4468, DOI 10.1021/bi00665a021; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; GIEDROC DP, 1986, BIOCHEMISTRY-US, V25, P4969, DOI 10.1021/bi00365a037; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HIMMELFARB HJ, 1987, MOL CELL BIOL, V7, P2155, DOI 10.1128/MCB.7.6.2155; HUET J, 1985, J BIOL CHEM, V260, P5304; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAMES P, 1991, J BIOL CHEM, V266, P5616; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KONTERMANN R, 1989, MOL GEN GENET, V219, P373, DOI 10.1007/BF00259609; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATTKE H, 1976, FEBS LETT, V65, P288, DOI 10.1016/0014-5793(76)80131-7; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MAZUS B, 1986, BIOCHEMISTRY-US, V25, P2941, DOI 10.1021/bi00358a031; MCCUSKER JH, 1991, MOL CELL BIOL, V11, P746, DOI 10.1128/MCB.11.2.746; MEMET S, 1988, J BIOL CHEM, V263, P2830; MILLER JA, 1979, BIOCHIM BIOPHYS ACTA, V579, P291, DOI 10.1016/0005-2795(79)90056-4; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PETRANYI P, 1977, BIOCHEM BIOPH RES CO, V74, P1031, DOI 10.1016/0006-291X(77)91621-7; RIVA M, 1990, J BIOL CHEM, V265, P16498; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SCAFE C, 1990, MOL CELL BIOL, V10, P1270, DOI 10.1128/MCB.10.3.1270; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; SCRUTTON MC, 1971, P NATL ACAD SCI USA, V68, P2497, DOI 10.1073/pnas.68.10.2497; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SERRANO L, 1988, ANAL BIOCHEM, V172, P210, DOI 10.1016/0003-2697(88)90434-4; SHIRAISHI H, 1988, GENE, V64, P313; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; SWENDSEN PJ, 1980, J BIOCHEM BIOPH METH, V3, P97; SZMELCMAN S, 1990, J ACQ IMMUN DEF SYND, V3, P859; THURIAUX P, 1991, IN PRESS MOL BIOL YE; VALENZUELA P, 1973, BIOCHEM BIOPH RES CO, V53, P1036, DOI 10.1016/0006-291X(73)90196-4; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; VIEIRA J, 1987, METHOD ENZYMOL, V101, P3; WANDZILAK TM, 1977, BIOCHEM BIOPH RES CO, V76, P247, DOI 10.1016/0006-291X(77)90718-5; WITTEKIND M, 1988, MOL CELL BIOL, V8, P3997, DOI 10.1128/MCB.8.10.3997; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17816; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; WU CW, 1977, BIOCHEMISTRY-US, V16, P5449, DOI 10.1021/bi00644a008; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754	54	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21971	21976						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939219				2022-12-25	WOS:A1991GP80400097
J	CALDES, T; ALEMANY, J; ROBCIS, HL; DEPABLO, F				CALDES, T; ALEMANY, J; ROBCIS, HL; DEPABLO, F			EXPRESSION OF INSULIN-LIKE GROWTH FACTOR-I IN DEVELOPING LENS IS COMPARTMENTALIZED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTALLIN GENE-EXPRESSION; IGF-I; DELTA-1-CRYSTALLIN GENE; EARLY ORGANOGENESIS; EPITHELIAL-CELLS; VITREOUS-HUMOR; MESSENGER-RNA; CHICKEN; RECEPTORS; DIFFERENTIATION	We, and others, have recently reported that insulin-like growth factor I (IGF-I) mRNA is expressed in multiple tissues during embryogenesis and in whole embryos during early organogenesis. Therefore, it is likely that, in addition to any effect on embryo growth, IGF-I plays a paracrine/autocrine role in development. The embryonic chicken lens, an avascular organ comp posed by a single type of cell that undergoes differentiation in vivo and in vitro, is an ideal model to characterize the paracrine/autocrine action of IGF-I. The lens cells express IGF-I receptors, and respond to exogenous IGF-I with induction of fiber cells differentiation and stimulation of delta-crystallin gene transcription. Whether embryonic lens cells express IGF-I was uncertain. In the present study, we used a sensitive semiquantitative method (reverse transcription of RNA followed by amplification with the polymerase chain reaction) to analyze IGF-I gene expression. An amplified product of the expected length (209 base pairs) was found in days 8, 12, 15, and 19 lenses. At all embryo ages studied, the product was more readily detected in the lens than in the liver, while in eye tissues (excluding lens), IGF-I expression was relatively high. After microdissection of the epithelial cells from the fully differentiated fiber cells, IGF-I expression was detected exclusively in the epithelial cells. IGF-I immunoactivity was found using high performance liquid chromatography followed by radioimmunoassay in the days 8-19 lens extracts, and in primary cultures of isolated epithelial cells. Our previous and present findings show that the lens has all the elements for IGF-I autocrine/paracrine action in development.	NIDDKD,DIABET BRANCH,BETHESDA,MD 20892; NIH,NATL CTR RES RESOURCES,VET RESOURCES PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA								ALEMANY J, 1990, MOL CELL ENDOCRINOL, V74, P155, DOI 10.1016/0303-7207(90)90117-Q; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; ALEMANY J, 1989, J BIOL CHEM, V264, P17559; BASSAS L, 1987, EXP CELL RES, V168, P561, DOI 10.1016/0014-4827(87)90029-2; BASSNETT S, 1990, INVEST OPHTH VIS SCI, V31, P1637; BEEBE DC, 1980, P NATL ACAD SCI-BIOL, V77, P490, DOI 10.1073/pnas.77.1.490; BEEBE DC, 1987, P NATL ACAD SCI USA, V84, P2327, DOI 10.1073/pnas.84.8.2327; BEEBE DC, 1986, DEV BIOL, V114, P361, DOI 10.1016/0012-1606(86)90200-9; BONDY CA, 1990, MOL ENDOCRINOL, V4, P1386, DOI 10.1210/mend-4-9-1386; BONDY CA, 1990, MOL CELLULAR BIOL IN; BORRAS T, 1988, DEV BIOL, V127, P209, DOI 10.1016/0012-1606(88)90202-3; BREWITT B, 1988, SCIENCE, V242, P777, DOI 10.1126/science.3187521; Chamberlain CG, 1989, GROWTH FACTORS, V1, P125, DOI 10.3109/08977198909029122; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DAWE SR, 1988, J ENDOCRINOL, V117, P173, DOI 10.1677/joe.0.1170173; DEPABLO F, 1990, ENDOCR REV, V11, P558, DOI 10.1210/edrv-11-4-558; DERCOLE AJ, 1980, DEV BIOL, V75, P315, DOI 10.1016/0012-1606(80)90166-9; FURLANETTO RW, 1987, METHOD ENZYMOL, V146, P216; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAN VKM, 1987, SCIENCE, V236, P193, DOI 10.1126/science.3563497; HERNANDEZ ER, 1989, ENDOCRINOLOGY, V125, P572, DOI 10.1210/endo-125-1-572; HEYNER S, 1989, BIOESSAYS, V11, P171, DOI 10.1002/bies.950110604; KAJIMOTO Y, 1989, MOL ENDOCRINOL, V3, P1907, DOI 10.1210/mend-3-12-1907; KIKUCHI K, 1991, ENDOCRINOLOGY, V128, P1323, DOI 10.1210/endo-128-3-1323; KIMMEL AR, 1987, METHOD ENZYMOL, V152, P399; LUND PK, 1986, J BIOL CHEM, V261, P4539; MCAVOY JW, 1989, DEVELOPMENT, V107, P221; MILSTONE LM, 1977, EXP CELL RES, V105, P9, DOI 10.1016/0014-4827(77)90147-1; PATEK CE, 1990, EXP EYE RES, V14, P345; PERSONS BJ, 1970, EXP EYE RES, V9, P144, DOI 10.1016/S0014-4835(70)80069-0; PHILPOTT GW, 1965, EXP CELL RES, V38, P635, DOI 10.1016/0014-4827(65)90387-3; PIATIGOR.J, 1973, DEV BIOL, V30, P214, DOI 10.1016/0012-1606(73)90060-2; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; ROBCIS HL, 1991, ENDOCRINOLOGY, V128, P1895, DOI 10.1210/endo-128-4-1895; SCAVO L, 1989, BIOCHEM BIOPH RES CO, V162, P1167, DOI 10.1016/0006-291X(89)90796-1; SERRANO J, 1990, ENDOCRINOLOGY, V127, P1547, DOI 10.1210/endo-127-3-1547; SMITH EP, 1987, DEVELOPMENT, V101, P73; SOLER AP, 1990, ENDOCRINOLOGY, V127, P595; UNDERWOOD LE, 1984, CLIN ENDOCRINOL META, V13, P69, DOI 10.1016/S0300-595X(84)80009-2	40	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20786	20790						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939129				2022-12-25	WOS:A1991GN00100032
J	WENTE, SR; SCHACHMAN, HK				WENTE, SR; SCHACHMAN, HK			DIFFERENT AMINO-ACID SUBSTITUTIONS AT THE SAME POSITION IN THE NUCLEOTIDE-BINDING SITE OF ASPARTATE TRANSCARBAMOYLASE HAVE DIVERSE EFFECTS ON THE ALLOSTERIC PROPERTIES OF THE ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BISUBSTRATE ANALOG N-(PHOSPHONACETYL)-L-ASPARTATE; ESCHERICHIA-COLI; CATALYTIC CHAIN; RESIDUES 230-245; DOMAIN CLOSURE; DIRECTED MUTAGENESIS; PHENOTYPIC SELECTION; REGULATORY SUBUNIT; BACTERIAL PLASMIDS; CRYSTAL-STRUCTURES	Site-directed mutagenesis was used to determine how the allosteric properties of aspartate transcarbamoylase (ATCase) are affected by amino acid replacements in the nucleotide binding region of the regulatory polypeptide chains. Amino acid substitutions were made for both Lys-60 and Lys-94 in the regulatory chain since those residues have been implicated by x-ray diffraction studies, chemical modification experiments, and site-directed mutagenesis as playing a role in binding CTP and ATP. Lys-60 was replaced by His, Arg, Gln, and Ala, and Lys-94 was changed to His. These mutant forms of ATCase exhibit bewildering changes in the allosteric properties compared to the wild-type enzyme as well as altered affinities for the nucleotide effectors. The enzyme containing His-60 lacks both homotropic and heterotropic effects and exhibits no detectable binding of nucleotides. In contrast, the holoenzymes containing either Gln-60 or Arg-60 retain both homotropic and heterotropic effects. Replacement of Lys-60 by Ala yields a derivative exhibiting altered heterotropic effects involving insensitivity to CTP and activation by ATP. The mutant enzyme containing His-94 in place of Lys exhibits cooperativity with reduced affinity for nucleotides. The multiple substitutions at Lys-60 in the nucleotide binding region of the regulatory chains of ATCase demonstrate that different amino acids in the same location can alter indirectly the delicate balance of interactions responsible for the allosteric properties of ATCase. The studies show that it is hazardous and frequently unwarranted from single amino acid replacements of a specific residue to attribute to that residue the properties observed for the wild-type enzyme.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,WENDELL M STANLEY HALL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,VIRUS LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NIGMS NIH HHS [GM12159] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012159, R37GM012159] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVARADOURBINA G, 1981, SCIENCE, V214, P270, DOI 10.1126/science.6169150; BLACKBURN MN, 1976, BIOCHEMISTRY-US, V15, P1316, DOI 10.1021/bi00651a023; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; CHANGEUX JP, 1968, BIOCHEMISTRY-US, V7, P531, DOI 10.1021/bi00842a007; COHEN SN, 1973, P NATL ACAD SCI USA, V70, P3240, DOI 10.1073/pnas.70.11.3240; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; CORDER TS, 1989, J BIOL CHEM, V264, P7425; DAVIES GE, 1970, J BIOL CHEM, V245, P1175; DEMBOWSKI NJ, 1990, BIOCHEMISTRY-US, V29, P3716, DOI 10.1021/bi00467a018; EISENSTEIN E, 1990, BIOCHEMISTRY-US, V29, P3724, DOI 10.1021/bi00467a019; EISENSTEIN E, 1989, P NATL ACAD SCI USA, V86, P3094, DOI 10.1073/pnas.86.9.3094; GERHART JC, 1968, BIOCHEMISTRY-US, V7, P538, DOI 10.1021/bi00842a600; GERHART JC, 1964, FED PROC, V23, P727; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1965, BIOCHEMISTRY-US, V4, P1054, DOI 10.1021/bi00882a012; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P7702, DOI 10.1021/bi00485a020; GRAY CW, 1973, J BIOL CHEM, V248, P6071; HALTINER M, 1985, NUCLEIC ACIDS RES, V13, P1015, DOI 10.1093/nar/13.3.1015; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; HONZATKO RB, 1982, J MOL BIOL, V160, P265, DOI 10.1016/0022-2836(82)90176-0; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5091, DOI 10.1021/bi00642a023; HOWLETT GJ, 1978, ARCH BIOCHEM BIOPHYS, V190, P809, DOI 10.1016/0003-9861(78)90341-7; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5077, DOI 10.1021/bi00642a021; HU C, 1987, THESIS U CALIFORNIA; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KE HM, 1984, P NATL ACAD SCI-BIOL, V81, P4037, DOI 10.1073/pnas.81.13.4037; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KIM KH, 1987, J MOL BIOL, V196, P853, DOI 10.1016/0022-2836(87)90410-4; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LADJIMI MM, 1987, J BIOL CHEM, V262, P312; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P268, DOI 10.1021/bi00401a041; LONDON RE, 1972, BIOCHEMISTRY-US, V11, P3136, DOI 10.1021/bi00766a029; MATSUMOT.S, 1973, BIOCHEMISTRY-US, V12, P1388, DOI 10.1021/bi00731a019; MIDDLETON SA, 1986, P NATL ACAD SCI USA, V83, P5866, DOI 10.1073/pnas.83.16.5866; MIDDLETON SA, 1988, BIOCHEMISTRY-US, V27, P8653, DOI 10.1021/bi00423a022; MIDDLETON SA, 1989, BIOCHEMISTRY-US, V28, P1617, DOI 10.1021/bi00430a029; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGEL GM, 1975, BIOCHEMISTRY-US, V14, P3195, DOI 10.1021/bi00685a025; NEWELL JO, 1990, BIOPHYS CHEM, V37, P183, DOI 10.1016/0301-4622(90)88018-N; NEWELL JO, 1989, J BIOL CHEM, V264, P2476; NEWTON CJ, 1990, P NATL ACAD SCI USA, V87, P2309, DOI 10.1073/pnas.87.6.2309; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ROBEY EA, 1984, J BIOL CHEM, V259, P1180; ROBEY EA, 1986, P NATL ACAD SCI USA, V83, P5934, DOI 10.1073/pnas.83.16.5934; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583; STEBBINS JW, 1989, BIOCHEMISTRY-US, V28, P2592, DOI 10.1021/bi00432a037; STEBBINS JW, 1989, J BIOL CHEM, V264, P14860; STEBBINS JW, 1990, BIOCHEMISTRY-US, V29, P3821, DOI 10.1021/bi00468a003; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; SUTER P, 1977, J BIOL CHEM, V252, P8136; WALES ME, 1988, J BIOL CHEM, V263, P6109; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; XU W, 1988, BIOCHEMISTRY-US, V27, P5507, DOI 10.1021/bi00415a018; Yang Y R, 1978, Methods Enzymol, V51, P35; ZHANG Y, 1989, BIOCHEMISTRY-US, V28, P7313, DOI 10.1021/bi00444a025; ZHANG Y, 1988, J BIOL CHEM, V263, P1320	61	16	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20833	20839						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939134				2022-12-25	WOS:A1991GN00100040
J	YU, SM; KUO, YH; SHEU, G; SHEU, YJ; LIU, LF				YU, SM; KUO, YH; SHEU, G; SHEU, YJ; LIU, LF			METABOLIC DEREPRESSION OF ALPHA-AMYLASE GENE-EXPRESSION IN SUSPENSION-CULTURED CELLS OF RICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-BINDING-PROTEIN; BARLEY ALEURONE LAYERS; GLUCOSE-REGULATED PROTEIN; GIBBERELLIC-ACID; MESSENGER-RNA; CATABOLITE REPRESSION; BACILLUS-SUBTILIS; STARCH BREAKDOWN; ABSCISIC-ACID; TRANSCRIPTION	We present evidence to show that the alpha-amylase gene family in rice is under two different modes of regulation: 1) hormonal regulation in germinating seeds, and 2) metabolic repression in cultured cells by available carbohydrate nutrients. Expression of alpha-amylase genes in deembryoed rice seeds is known to be induced by exogenous gibberellic acid. On the other hand, expression of alpha-amylase genes in suspension-cultured cells is induced by the deprivation of carbohydrate nutrient. A lag period of 2-4 h is required for the induction of alpha-amylase mRNA in sucrose-depleted medium. The induction of alpha-amylase expression is extraordinarily high and levels of alpha-amylase mRNA can be increased 8-20-folds after 24 h of sucrose starvation. The synthesis and secretion of alpha-amylase is also dependent upon the level of carbon source. The derepression or repression of alpha-amylase synthesis can be readily reversed by the deprivation or replenishment of sucrose in the medium, respectively. Glucose and fructose exert a repression on the alpha-amylase synthesis similar to that of sucrose. A hypothesis that explains the induction of alpha-amylase synthesis by carbohydrate starvation is proposed. Our data have suggested a hitherto undiscovered, potentially important control mechanism of carbohydrate metabolism in higher plants.	NATL TAIWAN UNIV, DEPT AGRON, TAIPEI 10764, TAIWAN; NATL TSING HUA UNIV, INST LIFE SCI, HSINCHU 30043, TAIWAN; NATL TAIWAN UNIV, DEPT BOT, TAIPEI 10764, TAIWAN	National Taiwan University; National Tsing Hua University; National Taiwan University	YU, SM (corresponding author), ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN.		Yu, Su-May/ABB-6950-2021	Yu, Su-May/0000-0001-8744-9246				AKAZAWA T, 1985, ANNU REV PLANT PHYS, V36, P441; AMINO S, 1988, PLANT CELL PHYSIOL, V29, P483; BELANGER FC, 1986, P NATL ACAD SCI USA, V83, P1354, DOI 10.1073/pnas.83.5.1354; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDLER PM, 1984, PLANT MOL BIOL, V3, P407, DOI 10.1007/BF00033389; Chaplin M.F., 1986, MASS SPECTROM, P1; CHRISPEE.MJ, 1967, PLANT PHYSIOL, V42, P398, DOI 10.1104/pp.42.3.398; DEIKMAN J, 1985, PLANT PHYSIOL, V78, P192, DOI 10.1104/pp.78.1.192; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOYER CH, 1988, PLANT PHYSIOL BIOCH, V26, P483; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HENDERSHOT LM, 1988, MOL IMMUNOL, V25, P585, DOI 10.1016/0161-5890(88)90081-8; HIGGINS TJV, 1976, NATURE, V260, P166, DOI 10.1038/260166a0; HO THD, 1987, UCLA S MOL CELL BIOL, V44, P35; Jacobsen J. V., 1987, Plant hormones and their role in plant growth and development, P164; JACOBSEN JV, 1985, NATURE, V316, P275, DOI 10.1038/316275a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAOIDE BM, 1989, J BACTERIOL, V171, P2435, DOI 10.1128/jb.171.5.2435-2442.1989; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Maniatis T., 1982, MOL CLONING; MIYATA S, 1981, PLANT PHYSIOL, V68, P1314, DOI 10.1104/pp.68.6.1314; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MUTHUKRISHNAN S, 1983, J BIOL CHEM, V258, P2370; NICHOLSON WL, 1985, J BACTERIOL, V161, P875, DOI 10.1128/JB.161.3.875-881.1985; OKAMOTO K, 1979, PLANT PHYSIOL, V63, P336, DOI 10.1104/pp.63.2.336; OULEE TM, 1988, P NATL ACAD SCI USA, V85, P6366, DOI 10.1073/pnas.85.17.6366; PRIEST FG, 1977, BACTERIOL REV, V41, P711, DOI 10.1128/MMBR.41.3.711-753.1977; SAEED M, 1990, PLANT PHYSIOL, V94, P1813, DOI 10.1104/pp.94.4.1813; SHEEN J, 1990, PLANT CELL, V2, P1027, DOI 10.1105/tpc.2.10.1027; SIMMONS CR, 1989, ACS SYM SER, V389, P202; Steup M., 1988, BIOCH PLANTS COMPREH, P255; STITT M, 1986, PHLOEM TRANSPORT, P331; THOMAS PS, 1983, METHOD ENZYMOL, V100, P255; Yoshida S., 1976, LAB MANUAL PHYSL STU, P46, DOI DOI 10.1080/01904167.2016.1250907; ZWAR JA, 1986, PLANT PHYSIOL, V80, P459, DOI 10.1104/pp.80.2.459	37	135	139	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21131	21137						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939156				2022-12-25	WOS:A1991GN00100085
J	CHEN, JH; GIBSON, JL; MCCUE, LA; TABITA, FR				CHEN, JH; GIBSON, JL; MCCUE, LA; TABITA, FR			IDENTIFICATION, EXPRESSION, AND DEDUCED PRIMARY STRUCTURE OF TRANSKETOLASE AND OTHER ENZYMES ENCODED WITHIN THE FORM-II CO2 FIXATION OPERON OF RHODOBACTER-SPHAEROIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENE; BISPHOSPHATE CARBOXYLASE-OXYGENASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; RHODOPSEUDOMONAS-SPHAEROIDES; BACILLUS-STEAROTHERMOPHILUS; RHODOSPIRILLUM-RUBRUM; NUCLEOTIDE-SEQUENCE; CANDIDA-BOIDINII	Previous studies had indicated that the form II or B cluster of CO2 fixation structural genes is part of a large operon in Rhodobacter sphaeroides (Gibson, J. L., Chen, J.-H., Tower, P. A., and Tabita, F. R. (1990) Biochemistry 29, 8085-8093). In this investigation, we have sequenced the DNA between the prkB and rbpL genes and provide evidence for three distinct open reading frames which encode additional structural genes of the Calvin reductive pentose phosphate pathway; these genes encode the enzymes transketolase, glyceraldehyde phosphate dehydrogenase, and aldolase. Noteworthy is transketolase, which may be expressed to high levels in Escherichia coli. This study thus represents the initial description of the primary structure of bacterial transketolase, a key enzyme of the reductive and the oxidative pentose phosphate pathways. Each of the genes are separated by short stretches of intergenic sequence, consistent with earlier evidence which suggested that these genes are cotranscribed and part of a large operon controlled by sequences upstream from fbpB.	OHIO STATE UNIV,DEPT MICROBIOL,484 W 12TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210; UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712; UNIV TEXAS,CTR APPL MICROBIOL,AUSTIN,TX 78712	Ohio State University; Ohio State University; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin				Chen, JIann-Hwa/0000-0002-0406-2693; McCue, Lee Ann/0000-0003-4456-517X				ALEFOUNDER PR, 1989, BIOCHEM J, V257, P529, DOI 10.1042/bj2570529; BIESECKER G, 1977, NATURE, V266, P328, DOI 10.1038/266328a0; BRANLANT C, 1989, GENE, V75, P145, DOI 10.1016/0378-1119(89)90391-0; BRINKMANN H, 1989, PLANT MOL BIOL, V13, P81, DOI 10.1007/BF00027337; BYSTRYKH LV, 1981, FEBS LETT, V132, P324, DOI 10.1016/0014-5793(81)81189-1; CONWAY T, 1987, J BACTERIOL, V169, P5653, DOI 10.1128/jb.169.12.5653-5662.1987; Davis R., 1980, ADV BACTERIAL GENETI; GIBSON JL, 1986, GENE, V44, P271, DOI 10.1016/0378-1119(86)90191-5; GIBSON JL, 1987, J BACTERIOL, V169, P3685, DOI 10.1128/jb.169.8.3685-3690.1987; GIBSON JL, 1991, J BIOL CHEM, V266, P14646; GIBSON JL, 1988, J BACTERIOL, V170, P2153, DOI 10.1128/jb.170.5.2153-2158.1988; GIBSON JL, 1990, BIOCHEMISTRY-US, V29, P8085, DOI 10.1021/bi00487a014; GIBSON JL, 1977, J BIOL CHEM, V252, P943; HALLENBECK PL, 1987, J BACTERIOL, V169, P3669, DOI 10.1128/jb.169.8.3669-3678.1987; HARRIS JI, 1976, ENZYMES, V13, P1; HOCKING JD, 1980, EUR J BIOCHEM, V108, P567, DOI 10.1111/j.1432-1033.1980.tb04752.x; HOLLAND JP, 1979, J BIOL CHEM, V254, P9839; JANOWICZ ZA, 1985, NUCLEIC ACIDS RES, V13, P3043, DOI 10.1093/nar/13.9.3043; JORDAN DB, 1981, NATURE, V291, P513, DOI 10.1038/291513a0; JOUANNEAU Y, 1986, J BACTERIOL, V165, P620, DOI 10.1128/jb.165.2.620-624.1986; KATO N, 1982, BIOCHIM BIOPHYS ACTA, V715, P143; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTIN W, 1986, EUR J BIOCHEM, V159, P323, DOI 10.1111/j.1432-1033.1986.tb09871.x; MOUGIN A, 1988, PROTEIN ENG, V2, P45, DOI 10.1093/protein/2.1.45; MULLER ED, 1985, J BACTERIOL, V161, P469, DOI 10.1128/JB.161.1.469-472.1985; NARGANG F, 1984, MOL GEN GENET, V193, P220, DOI 10.1007/BF00330671; NOWAK K, 1981, FEBS LETT, V134, P143, DOI 10.1016/0014-5793(81)80587-X; QUIVEY RG, 1984, GENE, V31, P91, DOI 10.1016/0378-1119(84)90198-7; RAINEY AM, 1989, J GEN MICROBIOL, V135, P1699; SHIH MC, 1986, CELL, V47, P73, DOI 10.1016/0092-8674(86)90367-3; SOUKRI A, 1989, BIOCHEMISTRY-US, V28, P2586, DOI 10.1021/bi00432a036; TABITA FR, 1974, J BIOL CHEM, V249, P3459; TABITA FR, 1988, MICROBIOL REV, V52, P155, DOI 10.1128/MMBR.52.2.155-189.1988; TABITA FR, 1987, CYANOBACTERIA, P95; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAGNER SJ, 1988, FEMS MICROBIOL LETT, V55, P217, DOI 10.1111/j.1574-6968.1988.tb13937.x; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2	37	67	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20447	20452						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939098				2022-12-25	WOS:A1991GM03900085
J	FREIJE, JP; ABRAHAMSON, M; OLAFSSON, I; VELASCO, G; GRUBB, A; LOPEZOTIN, C				FREIJE, JP; ABRAHAMSON, M; OLAFSSON, I; VELASCO, G; GRUBB, A; LOPEZOTIN, C			STRUCTURE AND EXPRESSION OF THE GENE ENCODING CYSTATIN-D, A NOVEL HUMAN CYSTEINE PROTEINASE-INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HEREDITARY CEREBRAL-HEMORRHAGE; RAY CRYSTAL-STRUCTURE; EGG-WHITE CYSTATIN; HUMAN WHOLE SALIVA; HUMAN GAMMA-TRACE; CHICKEN CYSTATIN; CATHEPSIN-B; C GENE; MOLECULAR-CLONING	A new member of the human cystatin multigene family has been cloned from a genomic library using a cystatin C cDNA probe. The complete nucleotide sequence of a 4.3-kilobase DNA segment, containing a complete gene with structure very similar to those of known Family 2 cystatin genes, was determined. The novel gene, called CST4, is composed of three exons and two introns. It contains the coding information for a protein of 142 amino acid residues, which has been tentatively called cystatin D. The deduced amino acid sequence includes a putative signal peptide and presents 51-55% identical residues with the sequences of either cystatin C or the secretory gland cystatins S, SN, or SA. The cystatin D sequence contains all regions of relevance for cysteine proteinase inhibitory activity and also the 4 cysteine residues that form disulfide bridges in the other members of cystatin Family 2. Northern blot analysis revealed that the cystatin D gene is expressed in parotid gland but not in seminal vesicle, prostate, epididymis, testis, ovary, placenta, thyroid, gastric corpus, small intestine, liver, or gallbladder tissue. This tissue-restricted expression is in marked contrast with the wider distribution of all the other Family 2 cystatins, since cystatin C is expressed in all these tissues and the secretory gland cystatins are present in saliva, seminal plasma, and tears. Cystatin D, being the first described member of a third subfamily within the cystatin Family 2, thus appears to have a distinct function in the body in contrast to other cystatins.	UNIV OVIEDO, DEPT BIOL FUNCIONAL, E-33071 OVIEDO, SPAIN; UNIV LUND, DEPT CLIN CHEM, S-22185 LUND, SWEDEN	University of Oviedo; Lund University			Abrahamson, Magnus/CAG-9507-2022; Velasco, Gloria/AAS-5842-2021; Freije, José M.P./A-6535-2008; Lopez-Otin, Carlos/AAB-2106-2020	Velasco, Gloria/0000-0001-8032-5056; Freije, José M.P./0000-0002-4688-8266; Lopez-Otin, Carlos/0000-0001-6964-1904; Grubb, Anders/0000-0002-0125-3662				ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688; ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6; ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ALHASHIMI I, 1988, J BIOL CHEM, V263, P9381; ASSFALGMACHLEIDT I, 1988, BIOL CHEM H-S, V369, P263; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUTTLE DJ, 1990, SCAND J CLIN LAB INV, V50, P509, DOI 10.3109/00365519009089165; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; DYNAN WS, 1986, TRENDS GENET, V2, P209; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; GRUBB A, 1982, P NATL ACAD SCI-BIOL, V79, P3024, DOI 10.1073/pnas.79.9.3024; GRUBB A, 1984, FEBS LETT, V170, P370, DOI 10.1016/0014-5793(84)81346-0; ISEMURA S, 1987, J BIOCHEM-TOKYO, V102, P693, DOI 10.1093/oxfordjournals.jbchem.a122107; ISEMURA S, 1986, FEBS LETT, V198, P145, DOI 10.1016/0014-5793(86)81201-7; ISEMURA S, 1984, J BIOCHEM-TOKYO, V96, P489, DOI 10.1093/oxfordjournals.jbchem.a134861; KOPPEL P, 1984, EXP CELL BIOL, V52, P293; LEVY E, 1989, J EXP MED, V169, P1771, DOI 10.1084/jem.169.5.1771; LOFBERG H, 1987, STROKE, V18, P431, DOI 10.1161/01.STR.18.2.431; MACHLEIDT W, 1989, FEBS LETT, V243, P234, DOI 10.1016/0014-5793(89)80135-8; Maniatis T., 1982, MOL CLONING; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; MOUNT DW, 1986, NUCLEIC ACIDS RES, V14, P443, DOI 10.1093/nar/14.1.443; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MULLERESTERL W, 1986, TRENDS BIOCHEM SCI, V11, P336, DOI 10.1016/0968-0004(86)90293-8; PALSDOTTIR A, 1988, LANCET, V2, P603; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIETRAS RJ, 1978, OBSTET GYNECOL, V52, P321; RAWLINGS ND, 1990, J MOL EVOL, V30, P60, DOI 10.1007/BF02102453; SAITOH E, 1987, GENE, V61, P329, DOI 10.1016/0378-1119(87)90196-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	38	76	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20538	20543						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939105				2022-12-25	WOS:A1991GM03900099
J	MIYAUCHI, A; ALVAREZ, J; GREENFIELD, EM; TETI, A; GRANO, M; COLUCCI, S; ZAMBONINZALLONE, A; ROSS, FP; TEITELBAUM, SL; CHERESH, D; HRUSKA, KA				MIYAUCHI, A; ALVAREZ, J; GREENFIELD, EM; TETI, A; GRANO, M; COLUCCI, S; ZAMBONINZALLONE, A; ROSS, FP; TEITELBAUM, SL; CHERESH, D; HRUSKA, KA			RECOGNITION OF OSTEOPONTIN AND RELATED PEPTIDES BY AN ALPHA-V-BETA-3 INTEGRIN STIMULATES IMMEDIATE CELL SIGNALS IN OSTEOCLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CYTOSOLIC FREE CA-2+; EXTRACELLULAR-MATRIX; HUMAN NEUTROPHILS; RECEPTOR; BONE; RAT; ACTIVATION; ATTACHMENT; EXPRESSION	We have investigated the nature of immediate cell signals produced by occupancy of the chicken osteoclast alpha-v-beta-3 integrin. Synthetic osteopontin and peptides from the osteopontin and bone sialoprotein sequences containing Arg-Gly-Asp stimulated immediate reductions in osteoclast cytosolic Ca2+. The changes in cytosolic Ca2+ required the Arg-Gly-Asp sequence and were blocked by a monoclonal antibody to the alpha-v-beta-3 integrin, LM609. Osteoclast stimulation by the proteins through the integrin did not require immobilization since soluble peptides produced changes in cytosolic Ca2+ and inhibited osteoclast binding to bone particles and bone resorption. The decrease in cytosolic Ca2+ stimulated by osteopontin and related peptides appeared to be due to activation of a plasma membrane Ca2+-ATPase by calmodulin. Thus, the data suggest that ligand binding to the osteoclast alpha-v-beta-3 integrin results in calmodulin-dependent reduction in cytosolic Ca2+ which participates in regulation of osteoclast function.	WASHINGTON UNIV,JEWISH HOSP,MED CTR,DEPT PATHOL,ST LOUIS,MO 63110; UNIV BARI,INST HUMAN ANAT,I-70124 BARI,ITALY; UNIV CHIETI,IST CITOMORFOL NORMALE & PATOL,CHIETI,ITALY; SCRIPPS CLIN & RES FDN,DEPT IMMUNOL,LA JOLLA,CA 92037	Barnes-Jewish Hospital; Washington University (WUSTL); Universita degli Studi di Bari Aldo Moro; G d'Annunzio University of Chieti-Pescara; Scripps Research Institute	MIYAUCHI, A (corresponding author), WASHINGTON UNIV,JEWISH HOSP,MED CTR,DEPT MED,ST LOUIS,MO 63110, USA.			Teti, Anna Maria/0000-0002-5887-4419; Teitelbaum, Steven/0000-0002-4054-6679; Grano, Maria/0000-0002-7121-5899; Colucci, Silvia/0000-0001-9970-3539	NIADDK NIH HHS [AM32788] Funding Source: Medline; NIAMS NIH HHS [AR39561, AR32087] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM032788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039561, P01AR032087] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTIERI DC, 1990, J IMMUNOL, V145, P662; ALVAREZ JI, 1991, ENDOCRINOLOGY, V128, P2324, DOI 10.1210/endo-128-5-2324; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BARSHAVIT Z, 1983, J CLIN INVEST, V72, P516, DOI 10.1172/JCI110999; BLAIR HC, 1986, J CELL BIOL, V102, P1164, DOI 10.1083/jcb.102.4.1164; BREUER D, 1989, EXP CELL RES, V182, P659, DOI 10.1016/0014-4827(89)90268-1; BUTLER WT, 1989, CONNECT TISSUE RES, V23, P123, DOI 10.3109/03008208909002412; CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; GOTHLIN G, 1976, CLIN ORTHOP RELAT R, V120, P201; HEATH JK, 1989, CONNECT TISSUE RES, V20, P15, DOI 10.3109/03008208909023870; HOLTROP ME, 1977, CLIN ORTHOP RELAT R, V123, P177; HORTON MA, 1988, ISI ATLAS-IMMUNOL, V1, P35; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; INGBER DE, 1990, J CELL BIOL, V110, P1803, DOI 10.1083/jcb.110.5.1803; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; MASSAIA M, 1990, J IMMUNOL, V145, P1664; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; NATHAN C, 1990, J CELL BIOL, V111, P2171, DOI 10.1083/jcb.111.5.2171; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; SCHMIDHAUSER C, 1990, P NATL ACAD SCI USA, V87, P9118, DOI 10.1073/pnas.87.23.9118; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TETI A, 1989, J CLIN INVEST, V84, P773, DOI 10.1172/JCI114235; VANOS CH, 1987, BIOCHIM BIOPHYS ACTA, V906, P195, DOI 10.1016/0304-4157(87)90012-8; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YAMAGUCHI A, 1990, BIOCHIM BIOPHYS ACTA, V1054, P8, DOI 10.1016/0167-4889(90)90198-M; YOON K, 1987, BIOCHEM BIOPH RES CO, V148, P1129, DOI 10.1016/S0006-291X(87)80250-4; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8	37	386	405	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20369	20374						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939092				2022-12-25	WOS:A1991GM03900073
J	MUNN, MM; ALBERTS, BM				MUNN, MM; ALBERTS, BM			DNA FOOTPRINTING STUDIES OF THE COMPLEX FORMED BY THE T4 DNA-POLYMERASE HOLOENZYME AT A PRIMER-TEMPLATE JUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEIN COMPLEX; REPLICATION SYSTEM; ESCHERICHIA-COLI; BACTERIOPHAGE-T4 PROTEINS; PHYSICAL CHARACTERIZATION; GENETIC-RECOMBINATION; LATE TRANSCRIPTION; GENE-41 PROTEIN; ATP HYDROLYSIS; NEOCARZINOSTATIN	We have used DNA footprinting techniques to analyze the interactions of five DNA replication proteins at a primer-template junction: the bacteriophage T4 DNA polymerase (the gene 43 protein), its three accessory proteins (the gene 44/62 and 45 proteins), and the gene 32 protein, which is the T4 helix-destabilizing (or single-stranded DNA-binding) protein. The 177-nucleotide-long DNA substrate consisted of a perfect 52-base pair hairpin helix with a protruding single-stranded 5' tail. As expected, the DNA polymerase binds near the 3' end of this molecule (at the primer-template junction) and protects the adjacent double-stranded region from cleavage. When the gene 32 protein binds to the single-stranded tail, it reduces the concentration of the DNA polymerase required to observe the polymerase footprint by 10-30-fold. Periodic ATP hydrolysis. by the 44/62 protein is required to maintain the activity of the DNA polymerase holoenzyme (a complex of the 43, 44/62, and 45 proteins). Footprinting experiments demonstrate the formation of a weak complex between the DNA polymerase and the gene 45 protein, but there is no effect of the 44/62 protein or ATP on this enlarged footprint. We propose a model for holoenzyme function in which the complex of the three accessory proteins uses ATP hydrolysis to keep a moving polymerase tightly bound to the growing 3' end, providing a "clock" to measure polymerase stalling.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024020, R01GM024020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, V3, P241; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ALBERTS BM, 1980, ICN UCLA S MOL CELL, V19, P449; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHA TA, 1986, J BIOL CHEM, V261, P7001; CHA TA, 1989, J BIOL CHEM, V264, P12220; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1985, THESIS U CALIFORNIA; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HOCKENSMITH JW, 1986, J BIOL CHEM, V261, P3512; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HOPFIELD JJ, 1980, P NATL ACAD SCI-BIOL, V77, P5248, DOI 10.1073/pnas.77.9.5248; HUANG CC, 1981, J BIOL CHEM, V256, P4087; HUBERMAN JA, 1971, J MOL BIOL, V62, P39, DOI 10.1016/0022-2836(71)90129-X; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOYCE CM, 1986, UCLA S MOL CELL BIOL, V32, P197; KAPPEN LS, 1978, BIOCHEMISTRY-US, V17, P729, DOI 10.1021/bi00597a027; LIU CC, 1981, J BIOL CHEM, V256, P2813; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MACE DC, 1984, J MOL BIOL, V177, P295, DOI 10.1016/0022-2836(84)90458-3; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; MANIATIS T, 1982, MOL CLONING LABORATO, P122; Maxam A M, 1980, Methods Enzymol, V65, P499; MCHENRY CS, 1985, MOL CELL BIOCHEM, V66, P71; MUNN M, 1986, THESIS U CALIFORNIA; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NEWPORT JW, 1980, THESIS U OREGON; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PIPERNO JR, 1978, J BIOL CHEM, V253, P5180; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; RABUSSAY D, 1983, BACTERIOPHAGE T4, P167; RATNER D, 1974, J MOL BIOL, V88, P373, DOI 10.1016/0022-2836(74)90488-4; SELICK HE, 1987, UCLA S MOL CELLULAR, P183; SILVER LL, 1979, COLD SPRING HARB SYM, V43, P489, DOI 10.1101/SQB.1979.043.01.054; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1923; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WU R, 1975, J MOL BIOL, V96, P539, DOI 10.1016/0022-2836(75)90138-2	50	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20034	20044						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939067				2022-12-25	WOS:A1991GM03900029
J	ARITA, H; HANASAKI, K; NAKANO, T; OKA, S; TERAOKA, H; MATSUMOTO, K				ARITA, H; HANASAKI, K; NAKANO, T; OKA, S; TERAOKA, H; MATSUMOTO, K			NOVEL PROLIFERATIVE EFFECT OF PHOSPHOLIPASE-A2 IN SWISS 3T3 CELLS VIA SPECIFIC BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROUP-II PHOSPHOLIPASE-A2; RAT PANCREATIC PHOSPHOLIPASE-A2; MESSENGER-RNA SYNTHESIS; AMINO-ACID-SEQUENCE; PORCINE PANCREAS; PURIFICATION; EXPRESSION; 3T3-CELLS; GENE; LUNG	Phospholipase A2 (PLA2), EC 3.1.1.4, which catalyzes the release of free fatty acids from the sn-2 position of glycerophospholipids, has been extensively studied from the viewpoint of eicosanoid production (Arita, H., Nakano, T., and Hanasaki, K. (1989) Prog. Lipid Res. 28, 273-301). Several lines of evidence suggest that extracellular PLA2 is pathophysiologically related to some disorders, including inflammation and hypersensitivity. Despite this, little is known of the precise mechanism of the pathological processes as well as their intrinsic correlation with dysfunction. Here, we report a novel PLA2 action on the proliferation of Swiss 3T3 fibroblasts via specific binding sites of approximately M(r) 200,000. Pancreatic type PLA2 in the active form specifically recognized the sites and stimulated thymidine incorporation in DNA. Its inactive zymogen and other PLA2s from platelets, snake, and bee venoms showed much lesser activities. Although the physiological significance remains to be identified, our finding is the first to offer a new viewpoint on the effect of mammalian extracellular PLA2 on cellular function.			ARITA, H (corresponding author), SHIONOGI & CO LTD,SHIONOGI RES LAB,FUKUSHIMA KU,OSAKA 553,JAPAN.							ARITA H, 1989, PROG LIPID RES, V28, P273, DOI 10.1016/0163-7827(89)90002-7; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; GRATAROLI R, 1981, BIOCHIMIE, V63, P677, DOI 10.1016/S0300-9084(81)80216-7; HEINRIKSON RL, 1977, J BIOL CHEM, V252, P4913; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KURIHARA H, 1991, BIOCHIM BIOPHYS ACTA, V1082, P285, DOI 10.1016/0005-2760(91)90204-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1989, J BIOL CHEM, V264, P11503; MIZUSHIMA H, 1989, J BIOCHEM-TOKYO, V105, P520, DOI 10.1093/oxfordjournals.jbchem.a122699; MURAKAMI M, 1990, FEBS LETT, V268, P113, DOI 10.1016/0014-5793(90)80986-S; NAKANO T, 1990, FEBS LETT, V261, P171, DOI 10.1016/0014-5793(90)80663-4; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NAKANO T, 1990, FEBS LETT, V273, P23, DOI 10.1016/0014-5793(90)81042-M; NISHIJIMA J, 1983, J BIOCHEM, V94, P137, DOI 10.1093/oxfordjournals.jbchem.a134322; OKA S, 1991, J BIOL CHEM, V266, P9956; ONO T, 1984, J BIOCHEM-TOKYO, V96, P785, DOI 10.1093/oxfordjournals.jbchem.a134896; PIETERSON WA, 1974, BIOCHEMISTRY-US, V13, P1439, DOI 10.1021/bi00704a019; PUIJK WC, 1979, BIOCHIM BIOPHYS ACTA, V580, P411, DOI 10.1016/0005-2795(79)90153-3; ROZENGURT E, 1983, J CELL PHYSIOL, V116, P379, DOI 10.1002/jcp.1041160316; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; TAKUWA N, 1987, J BIOL CHEM, V262, P182; TAMAKI M, 1989, Patent No. 893086348; TOJO H, 1988, J BIOL CHEM, V263, P5724; VADAS P, 1986, LAB INVEST, V55, P391; YASUDA T, 1990, BIOCHIM BIOPHYS ACTA, V1046, P189, DOI 10.1016/0005-2760(90)90188-4	29	176	178	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19139	19141						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918029				2022-12-25	WOS:A1991GK66700004
J	HOLVOET, P; LAROCHE, Y; LIJNEN, HR; VANCAUWENBERGE, R; DEMARSIN, E; BROUWERS, E; MATTHYSSENS, G; COLLEN, D				HOLVOET, P; LAROCHE, Y; LIJNEN, HR; VANCAUWENBERGE, R; DEMARSIN, E; BROUWERS, E; MATTHYSSENS, G; COLLEN, D			CHARACTERIZATION OF A CHIMERIC PLASMINOGEN-ACTIVATOR CONSISTING OF A SINGLE-CHAIN FV FRAGMENT DERIVED FROM A FIBRIN FRAGMENT D-DIMER-SPECIFIC ANTIBODY AND A TRUNCATED SINGLE-CHAIN UROKINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKED FIBRIN; MOLECULAR WEIGHT FORM; PLASMA MILIEU INVITRO; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; PHARMACOKINETIC PROPERTIES; CROSSLINKED FIBRIN; EXPRESSION VECTORS; COMPRISING LEU144; PRO-UROKINASE	An M(r) 57,000 single-chain chimeric plasminogen activator, K12G0S32, Consisting of a variable region fragment (Fv) derived from the fibrin fragment D-dimer-specific monoclonal antibody MA-15C5 and of a 33-kDa (amino acids Ala132 to Leu411) recombinant single-chain urokinase-type plasminogen activator (rscu-PA-33k) was studied. K12G0S32, Secreted by infected Spodoptera frugiperda insect cells at a rate of 1.5-mu-g/10(6) cells/48 h, was purified to homogeneity by ion-exchange chromatography and gel filtration. It was obtained essentially as a single-chain molecule with a K(a) 5.5 x 10(9) M-1 for immobilized fragment D-dimer, similar to that of MA-15C5. The specific activity of both its single-chain and two-chain forms on fibrin plates was 100,000 IU/mg of urokinase-type plasminogen activator (u-PA) equivalent. Activation of plasminogen by two-chain K12G0S32 obeyed Michaelis-Menten kinetics with K(m) = 2.9 +/- 0.6-mu-M and a k2 = 3.7 +/- 0.6 s-1 (mean +/- S.D.; n = 3), as compared to K(m) = 12-mu-M and k2 = 4.8 s-1 for rtcu-PA-32k (recombinant low M(r) two-chain u-PA consisting of amino acids Leu144 to Leu411). Single-chain K12G0S32 induced a dose- and time-dependent lysis of a I-125-fibrin-labeled human plasma clot immersed in citrated human plasma; 50% lysis in 2 h was obtained with 0.70 +/- 0.07-mu-g/ml (mean +/- S.D.; n = 5), as compared with 8.8 +/- 0.1-mu-g/ml for rscu-PA-32k (recombinant low M(r) single-chain u-PA consisting of amino acids Leul44 to Leu411) (mean +/- S.D.; n = 3). With two-chain K12G0S32, 50% clot lysis in 2 h required 0.25 +/- 0.03-mu-g/ml (mean +/- S.D.; n = 3), as compared with only 0.62 +/- 0.04-mu-g/ml (mean +/- S.D.; n = 2) for rtcu-PA-32k. These results indicate that low M(r) single-chain u-PA can be targeted to a fibrin clot with a single-chain Fv fragment of a fibrin-specific antibody, resulting in a 13-fold increase of the fibrinolytic potency of the single-chain form and a 2.5-fold increase of the potency of the two-chain form.	CORVAS INT NV,GHENT,BELGIUM		HOLVOET, P (corresponding author), CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,CAMPUS GASTHUISBERG,O&N HERESTR 49,B-3000 LOUVAIN,BELGIUM.		Lijnen, Roger/AAA-4085-2020; HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772				ASTRUP T, 1952, ARCH BIOCHEM BIOPHYS, V40, P346, DOI 10.1016/0003-9861(52)90121-5; Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; BATRA JK, 1990, J BIOL CHEM, V265, P15198; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BODE C, 1987, J MOL CELL CARDIOL, V19, P335, DOI 10.1016/S0022-2828(87)80578-3; BODE C, 1985, SCIENCE, V229, P765, DOI 10.1126/science.4023710; BODE C, 1987, J BIOL CHEM, V262, P10819; BODE C, 1988, CLIN RES, V36, pA203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P1066, DOI 10.1073/pnas.87.3.1066; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CLAESSENS M, 1989, PROTEIN ENG, V2, P335, DOI 10.1093/protein/2.5.335; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COLLEN D, 1990, CIRCULATION, V82, P1744, DOI 10.1161/01.CIR.82.5.1744; COLLEN D, 1986, THROMB HAEMOSTASIS, V56, P35; COLLEN D, 1989, FIBRINOLYSIS, V3, P197, DOI 10.1016/0268-9499(89)90046-5; DARRAS V, 1986, THROMB HAEMOSTASIS, V56, P411; DECLERCK PJ, 1987, THROMB HAEMOSTASIS, V58, P1024; DEWERCHIN M, 1990, FIBRINOLYSIS, V4, P19, DOI 10.1016/S0268-9499(05)80036-0; DEWERCHIN M, 1990, FIBRINOLYSIS, V4, P11, DOI 10.1016/S0268-9499(05)80035-9; DEWERCHIN M, 1989, EUR J BIOCHEM, V185, P141, DOI 10.1111/j.1432-1033.1989.tb15095.x; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HABER E, 1986, HOSP PRACT, V21, P147; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; HOCHMAN J, 1973, BIOCHEMISTRY-US, V12, P1130, DOI 10.1021/bi00730a018; HOGG PJ, 1987, MOL IMMUNOL, V24, P797, DOI 10.1016/0161-5890(87)90064-2; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; HOLVOET P, 1989, THROMB HAEMOSTASIS, V61, P307; HONKAPILLER MV, 1983, METHOD ENZYMOL, V91, P399; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHE Y, 1991, J BIOL CHEM, V266, P16343; LIJNEN HR, 1989, BLOOD, V73, P1864; LIJNEN HR, 1986, J BIOL CHEM, V261, P1253; LIJNEN HR, 1986, BIOCHIM BIOPHYS ACTA, V884, P402, DOI 10.1016/0304-4165(86)90190-X; LIJNEN HR, 1987, EUR J BIOCHEM, V169, P359, DOI 10.1111/j.1432-1033.1987.tb13620.x; LIJNEN HR, 1988, J BIOL CHEM, V263, P5594; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MANIATIS T, 1982, MOL CLONING LABORATO, P200; PUTLITZ JZ, 1990, BIO-TECHNOL, V8, P651, DOI 10.1038/nbt0790-651; RODWELL JD, 1989, NATURE, V342, P99, DOI 10.1038/342099a0; RUNGE MS, 1988, BIOCHEMISTRY-US, V27, P1153, DOI 10.1021/bi00404a012; SANGER F, 1977, P NATL ACAD SCI USA, V74, P560; SEN J, 1986, Proteins Structure Function and Genetics, V1, P256, DOI 10.1002/prot.340010308; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDAMME AM, 1990, EUR J BIOCHEM, V192, P767, DOI 10.1111/j.1432-1033.1990.tb19288.x; VERHEIJEN JH, 1982, THROMB HAEMOSTASIS, V48, P266; Wu R., 1984, OLIGONUCLEOTIDE SYNT, P135; ZAMARRON C, 1984, J BIOL CHEM, V259, P2080; 1990, THROMB HAEMOSTASIS, V64, P600	56	42	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19717	19724						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918077				2022-12-25	WOS:A1991GK66700085
J	HEBERT, CA; VITANGCOL, RV; BAKER, JB				HEBERT, CA; VITANGCOL, RV; BAKER, JB			SCANNING MUTAGENESIS OF INTERLEUKIN-8 IDENTIFIES A CLUSTER OF RESIDUES REQUIRED FOR RECEPTOR-BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE; SITE-SPECIFIC MUTAGENESIS; AMINO-ACID; PHENOTYPIC SELECTION; CHEMOTACTIC FACTOR; GLOBULAR-PROTEINS; PURIFICATION; GENERATION; INHIBITOR; CYTOKINES	In order to identify residues required for the binding of interleukin-8 (IL-8) to its receptor, mutants were constructed in which clusters of charged amino acids were systematically replaced with alanine along the entire IL-8 sequence. The mutants were tested for their ability to induce a receptor-mediated rise in cytosolic free Ca2+, a property of wild-type IL-8 which can readily be detected by flow cytometry using neutrophils loaded with the calcium probe Indo-1. Eleven of the 12 mutants caused neutrophil calcium mobilization at 5 nM; the exception being a triple alanine mutant at positions K3, E4, and R6, which was inactive at all concentrations tested (150 nM maximum). A second set of mutants was generated in which residues 1-15 were individually mutated to alanine. Mutants E4A, L5A, or R6A were all inactive in the Ca2+ assay at 5 nM and competed poorly with I-125-IL-8 for neutrophil receptor binding; I10A, E4A, L5A, and R6A had approximately 30-, 100-, 100-, and 1000-fold reduced affinity, as compared with control IL-8, respectively. The nuclear magnetic resonance structure of IL-8 indicates that, in solution, the side chains of E4, L5, R6, and I10 point away from the core of the protein and do not participate in any intramolecular hydrogen bonds or salt bridges (Clore, G. M., and Gronenborn, A. M. (1991) J. Mol. Biol. 217, 611-620).	GENENTECH INC,DEPT MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech	HEBERT, CA (corresponding author), GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080, USA.							BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CLORE GM, 1989, J BIOL CHEM, V264, P18907; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, J MOL BIOL, V217, P611, DOI 10.1016/0022-2836(91)90518-B; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; FINCHAM NJ, 1990, 1ST INT C INFL BARC, P67; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEBERT CA, 1990, J IMMUNOL, V145, P3033; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; JUNE CH, 1988, PATHOL IMMUNOPATH R, V7, P409, DOI 10.1159/000157133; KLAPPER MH, 1977, BIOCHEM BIOPH RES CO, V78, P1018, DOI 10.1016/0006-291X(77)90523-X; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEONARD EJ, 1991, J LEUKOCYTE BIOL, V49, P258, DOI 10.1002/jlb.49.3.258; MATTHAY M A, 1990, American Review of Respiratory Disease, V141, pA97; MILLER E, 1990, FASEB J, V4, pA2117; MILLER E J, 1990, American Review of Respiratory Disease, V141, pA95; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHRAUFSTATTER I U, 1990, Journal of Cell Biology, V111, p48A; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SCHRODER JM, 1990, J IMMUNOL, V144, P2223; SEITZ M, 1991, J CLIN INVEST, V87, P463, DOI 10.1172/JCI115018; SUZUKI K, 1989, BIOCHEM BIOPH RES CO, V163, P1298, DOI 10.1016/0006-291X(89)91119-4; SUZUKI K, 1990, BLOOD S1, V76, pA194; TANAKA S, 1988, FEBS LETT, V236, P467, DOI 10.1016/0014-5793(88)80078-4; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WHEELER ME, 1988, J CLIN INVEST, V82, P1211, DOI 10.1172/JCI113718; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	39	327	350	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18989	18994						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918013				2022-12-25	WOS:A1991GJ47200088
J	KOHL, NE; DIEHL, RE; SCHABER, MD; RANDS, E; SODERMAN, DD; HE, B; MOORES, SL; POMPLIANO, DL; FERRONOVICK, S; POWERS, S; THOMAS, KA; GIBBS, JB				KOHL, NE; DIEHL, RE; SCHABER, MD; RANDS, E; SODERMAN, DD; HE, B; MOORES, SL; POMPLIANO, DL; FERRONOVICK, S; POWERS, S; THOMAS, KA; GIBBS, JB			STRUCTURAL HOMOLOGY AMONG MAMMALIAN AND SACCHAROMYCES-CEREVISIAE ISOPRENYL-PROTEIN TRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL MITOGEN; GROWTH-FACTOR; AMINO-ACID; RAS; FARNESYL; GENE; GAP	Farnesyl-protein transferase (FTase) purified from rat or bovine brain is an alpha/beta-heterodimer, comprised of subunits having relative molecular masses of approximately 47 (alpha) and 45 kDa (beta). In the yeast Saccharomyces cerevisiae, two unlinked genes, RAM1/DPR1 (RAM1) and RAM2, are required for FTase activity. To explore the relationship between the mammalian and yeast enzymes, we initiated cloning and immunological analyses. cDNA clones encoding the 329-amino acid COOH-terminal domain of bovine FTase alpha-subunit were isolated. Comparison of the amino acid sequences deduced from the alpha-subunit cDNA and the RAM2 gene revealed 30% identity and 58% similarity, suggesting that the RAM2 gene product encodes a subunit for the yeast FTase analogous to the bovine FTase alpha-subunit. Antisera raised against the RAM1 gene product reacted specifically with the beta-subunit of bovine FTase, suggesting that the RAM1 gene product is analogous to the bovine FTase beta-subunit. Whereas a ram1 mutation specifically inhibits FTase, mutations in the CDC43 and BET2 genes, both of which are homologous to RAM1, specifically inhibit geranylgeranyl-protein transferase (GGTase) type I and GGTase-II, respectively. In contrast, a ram2 mutation impairs both FTase and GGTase-I, but has little effect on GGTase-II. Antisera that specifically recognized the bovine FTase alpha-subunit precipitated both bovine FTase and GGTase-I activity, but not GGTase-II activity. Together, these results indicate that for both yeast and mammalian cells, FTase, GGTase-I, and GGTase-II are comprised of different but homologous beta-subunits and that the alpha-subunits of FTase and GGTase-I share common features not shared by GGTase-II.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,RAHWAY,NJ 07065; ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; YALE UNIV,DEPT CELL BIOL,NEW HAVEN,CT 06510	Merck & Company; Rutgers State University New Brunswick; Rutgers State University Medical Center; Yale University	KOHL, NE (corresponding author), MERCK SHARP & DOHME LTD,DEPT CANC RES,W POINT,PA 19486, USA.			Powers, Scott/0000-0003-2769-1932				CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; GAN ZR, 1989, GENE, V79, P159; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; JOHNSON DI, 1991, GENE, V98, P149, DOI 10.1016/0378-1119(91)90119-V; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; Maniatis T., 1982, MOL CLONING; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MOORES SL, 1991, J BIOL CHEM, V266, P14603; PETERSENBJORN S, 1990, YEAST, V6, P345, DOI 10.1002/yea.320060407; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M	24	101	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18884	18888						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918005				2022-12-25	WOS:A1991GJ47200074
J	ETO, M; MORITA, F; NISHI, N; TOKURA, S; ITO, T; TAKAHASHI, K				ETO, M; MORITA, F; NISHI, N; TOKURA, S; ITO, T; TAKAHASHI, K			ACTIN POLYMERIZATION PROMOTED BY A HEPTAPEPTIDE, AN ANALOG OF THE ACTIN-BINDING S SITE ON MYOSIN HEAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; SUBFRAGMENT-1 INTERACTION; ATP HYDROLYSIS; PROTEINS; CHAIN; COMPLEX; CLEAVAGE; SEQUENCE; PEPTIDES; RESIDUES	Polymerization of G-actin to F-actin was indicated by an increase in light-scattering intensity after the addition of a heptapeptide (Ile-Arg-Ile-Cys(MT)-Arg-Lys-Gly-OEt), an analog of the actin-binding S-site on S-1 heavy chain. The half-maximal concentration of the heptapeptide which induced an increase in the light-scattering intensity at 25-degrees-C was about 110-mu-M, which was in the range of the dissociation constant of this peptide with F-actin. The polymerization of G-actin to F-actin by binding of the heptapeptide was further demonstrated by ultracentrifugal separation, P(i) liberation, and electron microscopy. The polymerization of G-actin was induced only by the heptapeptide, but not by fragments of the heptapeptide. The well known acceleration of polymerization of G-actin by the myosin head may be due to the binding of G-actin with the S-site on the myosin head.	HOKKAIDO UNIV,FAC SCI,DEPT CHEM,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,FAC SCI,DEPT POLYMER SCI,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,FAC AGR,ELECTRON MICROSCOPE LAB,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,FAC AGR,DEPT ANIM SCI,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido University			Eto, Masumi/ABE-4700-2020	Eto, Masumi/0000-0002-0651-5836				BARDEN JA, 1989, BIOCHEMISTRY-US, V28, P5895, DOI 10.1021/bi00440a028; BURK RR, 1983, METHOD ENZYMOL, V91, P247; CHAUSSEPIED P, 1989, J BIOL CHEM, V264, P20752; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; CHAUSSEPIED P, 1988, P NATL ACAD SCI USA, V85, P7471, DOI 10.1073/pnas.85.20.7471; COOKE R, 1971, J MOL BIOL, V60, P249, DOI 10.1016/0022-2836(71)90291-9; DASGUPTA G, 1990, BIOCHEMISTRY-US, V29, P8503, DOI 10.1021/bi00488a043; DETMERS P, 1981, J BIOL CHEM, V256, P99; ETO M, 1990, J BIOCHEM-TOKYO, V108, P499, DOI 10.1093/oxfordjournals.jbchem.a123228; KATOH T, 1985, J BIOL CHEM, V260, P6723; KATOH T, 1984, J BIOCHEM-TOKYO, V95, P447, DOI 10.1093/oxfordjournals.jbchem.a134626; KATOH T, 1984, J BIOCHEM-TOKYO, V96, P1223, DOI 10.1093/oxfordjournals.jbchem.a134940; KEANE AM, 1990, NATURE, V344, P265, DOI 10.1038/344265a0; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; MILLER L, 1987, BIOCHEMISTRY-US, V26, P6064, DOI 10.1021/bi00393a018; MILLER L, 1988, J BIOL CHEM, V263, P1996; MORITA F, 1988, PEPTIDE CHEM, P743; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; SUZUKI R, 1987, BIOCHIM BIOPHYS ACTA, V912, P147, DOI 10.1016/0167-4838(87)90259-7; SUZUKI R, 1987, J BIOL CHEM, V262, P11410; SUZUKI R, 1990, J BIOL CHEM, V265, P4939; WAGNER PD, 1979, EUR J BIOCHEM, V99, P385, DOI 10.1111/j.1432-1033.1979.tb13267.x; YAGI K, 1965, J BIOL CHEM, V240, P2448; YAGI K, 1965, J BIOCHEM, V57, P55, DOI 10.1093/oxfordjournals.jbchem.a128057; YAMAMOTO K, 1979, J BIOCHEM-TOKYO, V86, P1863, DOI 10.1093/oxfordjournals.jbchem.a132709; YAMAMOTO K, 1983, J BIOCHEM-TOKYO, V94, P2075, DOI 10.1093/oxfordjournals.jbchem.a134565	32	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18233	18236						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917951				2022-12-25	WOS:A1991GG55300078
J	SUGIMOTO, M; MOHRI, H; MCCLINTOCK, RA; RUGGERI, ZM				SUGIMOTO, M; MOHRI, H; MCCLINTOCK, RA; RUGGERI, ZM			IDENTIFICATION OF DISCONTINUOUS VONWILLEBRAND-FACTOR SEQUENCES INVOLVED IN COMPLEX-FORMATION WITH BOTROCETIN - A MODEL FOR THE REGULATION OF VONWILLEBRAND-FACTOR BINDING TO PLATELET GLYCOPROTEIN-IB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND FACTOR; MURINE MONOCLONAL-ANTIBODY; FACTOR-VIII; VENOM COAGGLUTININ; ALPHA-CHAIN; IIB-IIIA; AGGREGATION; DOMAIN; RISTOCETIN; DISEASE	We have used proteolytic fragments and overlapping synthetic peptides to define the domain of von Willebrand factor (vWF) that forms a complex with botrocetin and modulates binding to platelet glycoprotein (GP) Ib. Both functions were inhibited by the dimeric 116-kDa tryptic fragment and by its constituent 52/48-kDa subunit, comprising residues 449-728 of mature vWF, but not by the dimeric fragment III-T2 which lacks amino acid residues 512-673. Three synthetic peptides, representing discrete discontinuous sequences within the region lacking in fragment III-T2, inhibited vWF-botrocetin complex formation; they corresponded to residues 539-553, 569-583, and 629-643. The 116-kDa domain, with intact disulfide bonds, exhibited greater affinity for botrocetin than did the reduced and alkylated 52/48-kDa molecule, and both fragments had significantly greater affinity than any of the inhibitory peptides. Thus, conformational attributes, though not strictly required for the interaction, contribute to the optimal functional assembly of the botrocetin-binding site. Accordingly, I-125-labeled botrocetin bound to vWF and to the 116-kDa fragment immobilized onto nitrocellulose but not to equivalent amounts of the reduced and alkylated 52/48-kDa fragment; it also bound to the peptide 539-553, but only when the peptide was immobilized onto nitrocellulose at a much greater concentration than vWF or the proteolytic fragments. These studies demonstrate that vWF interaction with GP Ib may be modulated by botrocetin binding to a discontinuous site located within residues 539-643. The finding that single point mutations in Type IIB von Willebrand disease are located in the same region of the molecule supports the concept that this domain may contain regulatory elements that modulate vWF affinity for platelets at sites of vascular injury.	Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92037 USA; Scripps Res Inst, RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042846, R01HL015491, R37HL015491, R01HL042846] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0833] Funding Source: Medline; NHLBI NIH HHS [HL-15491, HL-42846] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; AZUMA H, 1991, J BIOL CHEM, V266, P12342; BELLINGER DA, 1987, P NATL ACAD SCI USA, V84, P8100, DOI 10.1073/pnas.84.22.8100; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINKHOUS KM, 1981, P NATL ACAD SCI-BIOL, V78, P3230, DOI 10.1073/pnas.78.5.3230; COLLER BS, 1983, BLOOD, V61, P99; COONEY KA, 1991, J CLIN INVEST, V87, P1227, DOI 10.1172/JCI115123; DEMARCO L, 1987, J CLIN INVEST, V80, P475, DOI 10.1172/JCI113095; DEMARCO L, 1981, J CLIN INVEST, V68, P321, DOI 10.1172/JCI110259; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; DEMARCO L, 1990, J CLIN INVEST, V86, P785, DOI 10.1172/JCI114775; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FOWLER WE, 1985, J CLIN INVEST, V76, P1491, DOI 10.1172/JCI112129; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIMURA Y, 1991, BLOOD, V77, P113; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; FUJIMURA Y, 1987, BLOOD, V70, P985; FUSTER V, 1978, J CLIN INVEST, V61, P722, DOI 10.1172/JCI108985; GIRMA JP, 1990, THROMB HAEMOSTASIS, V64, P326; GIRMA JP, 1986, BIOCHEMISTRY-US, V25, P3156, DOI 10.1021/bi00359a013; HANDA M, 1986, J BIOL CHEM, V261, P2579; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; KAO KJ, 1979, J CLIN INVEST, V63, P656, DOI 10.1172/JCI109348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MILLER JL, 1983, J CLIN INVEST, V72, P1532, DOI 10.1172/JCI111112; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PETERSON DM, 1987, BLOOD, V69, P625; RANDI AM, 1991, J CLIN INVEST, V87, P1220, DOI 10.1172/JCI115122; READ MS, 1978, P NATL ACAD SCI USA, V75, P4514, DOI 10.1073/pnas.75.9.4514; READ MS, 1989, BLOOD, V74, P1031; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; RUGGERI ZM, 1980, NEW ENGL J MED, V302, P1047, DOI 10.1056/NEJM198005083021902; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795; RUGGERI ZM, 1987, BLOOD, V70, P895; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; VICENTE V, 1990, J BIOL CHEM, V265, P274; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WARE J, 1991, P NATL ACAD SCI USA, V88, P2946, DOI 10.1073/pnas.88.7.2946; WEISS HJ, 1974, AM J MED, V57, P920, DOI 10.1016/0002-9343(74)90170-3	46	135	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18172	18178						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917949				2022-12-25	WOS:A1991GG55300070
J	KAHN, NN; SINHA, AK				KAHN, NN; SINHA, AK			STIMULATION OF PROSTAGLANDIN-E1 BINDING TO HUMAN BLOOD-PLATELET MEMBRANE BY INSULIN AND THE ACTIVATION OF ADENYLATE-CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											KAHN, NN (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT MED,DIV CARDIOL,BRONX,NY 10461, USA.				NHLBI NIH HHS [HL-41386] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041386] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHBY B, 1986, J CYCLIC NUCL PROT, V11, P291; BIERMAN ED, 1982, HARRISONS PRINCIPLES, P1156; BUTKUS A, 1982, ARTERY, V11, P238; Colman R., 1987, HEMOSTASIS THROMBOSI, P594; CZECH MP, 1977, ANNU REV BIOCHEM, V46, P359, DOI 10.1146/annurev.bi.46.070177.002043; DAVI G, 1982, THROMB RES, V26, P359, DOI 10.1016/0049-3848(82)90254-7; DUTTAROY AK, 1987, J BIOL CHEM, V262, P12685; DUTTAROY AK, 1985, BIOCHIM BIOPHYS ACTA, V812, P671; ENGFELDT P, 1983, J CLIN ENDOCR METAB, V56, P501, DOI 10.1210/jcem-56-3-501; GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305; HAJEK AS, 1979, J CLIN INVEST, V63, P1060, DOI 10.1172/JCI109375; HALUSHKA PV, 1985, METABOLISM, V34, P32, DOI 10.1016/S0026-0495(85)80007-X; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; Haslam R J, 1975, Ciba Found Symp, V35, P121; HEPP KD, 1972, FEBS LETT, V20, P191, DOI 10.1016/0014-5793(72)80791-9; ILLIANO G, 1972, SCIENCE, V175, P906, DOI 10.1126/science.175.4024.906; KAHN NN, 1988, BIOCHIM BIOPHYS ACTA, V972, P45, DOI 10.1016/S0005-2728(88)80091-4; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; KATADA T, 1984, J BIOL CHEM, V259, P3568; LASSLO A, 1984, BLOOD PLATELET FUNCT; LEVITZKI A, 1982, TRENDS PHARMACOL SCI, V3, P203, DOI 10.1016/0165-6147(82)91093-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARCHMONT RJ, 1980, NATURE, V286, P904, DOI 10.1038/286904a0; MUSTARD JF, 1987, HAEMOSTASIS THROMBOS, P1073; RAY TK, 1986, BIOCHIM BIOPHYS ACTA, V856, P421, DOI 10.1016/0005-2736(86)90132-X; Robison G.A., 1969, PHARMACOL RES COMMUN, V1, P325; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHAFER AI, 1979, J BIOL CHEM, V254, P2914; SINHA AK, 1981, ANAL BIOCHEM, V113, P239, DOI 10.1016/0003-2697(81)90072-5; SINHA AK, 1977, J BIOL CHEM, V252, P3310; SINHA AK, 1983, P NATL ACAD SCI-BIOL, V80, P6086, DOI 10.1073/pnas.80.19.6086; SINHA AK, 1980, P NATL ACAD SCI-BIOL, V77, P2946, DOI 10.1073/pnas.77.5.2946; TATESON JE, 1977, PROSTAGLANDINS, V13, P389, DOI 10.1016/0090-6980(77)90019-3; WEISS HJ, 1979, BLOOD, V53, P244	35	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1990	265	9					4976	4981						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CV587	1969414				2022-12-25	WOS:A1990CV58700036
J	PARGE, HE; BERNSTEIN, SL; DEAL, CD; MCREE, DE; CHRISTENSEN, D; CAPOZZA, MA; KAYS, BW; FIESER, TM; DRAPER, D; SO, M; GETZOFF, ED; TAINER, JA				PARGE, HE; BERNSTEIN, SL; DEAL, CD; MCREE, DE; CHRISTENSEN, D; CAPOZZA, MA; KAYS, BW; FIESER, TM; DRAPER, D; SO, M; GETZOFF, ED; TAINER, JA			BIOCHEMICAL PURIFICATION AND CRYSTALLOGRAPHIC CHARACTERIZATION OF THE FIBER-FORMING PROTEIN PILIN FROM NEISSERIA-GONORRHOEAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											PARGE, HE (corresponding author), SCRIPPS CLIN & RES FDN,RES INST,DEPT MOLEC BIOL,LA JOLLA,CA 92037, USA.		Tainer, John/GWQ-4878-2022; So, Magdalene/ABB-8918-2020	Tainer, John/0000-0003-1659-2429; So, Magdalene/0000-0001-8301-0674	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022160, R01AI020845] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22160, AI-20845] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN JP, 1986, P NATL ACAD SCI USA, V83, P8589, DOI 10.1073/pnas.83.22.8589; BISWAS GD, 1977, J BACTERIOL, V129, P983, DOI 10.1128/JB.129.2.983-992.1977; BLOOMER AC, 1978, NATURE, V276, P362, DOI 10.1038/276362a0; Brinton C., 1978, IMMUNOBIOLOGY NEISER, P155; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DOUGHERTY TJ, 1979, BIOCHEM BIOPH RES CO, V86, P97, DOI 10.1016/0006-291X(79)90386-3; FIESER TM, 1987, P NATL ACAD SCI USA, V84, P8586; FOLKHARD W, 1981, J MOL BIOL, V149, P79, DOI 10.1016/0022-2836(81)90261-8; GARAVITO RM, 1983, J MOL BIOL, V164, P313, DOI 10.1016/0022-2836(83)90079-7; GREENHOUGH TJ, 1982, J APPL CRYSTALLOGR, V15, P493, DOI 10.1107/S0021889882012485; HAGBLOM P, 1985, NATURE, V315, P156, DOI 10.1038/315156a0; KELLOGG DS, 1963, J BACTERIOL, V85, P1274, DOI 10.1128/JB.85.6.1274-1279.1963; KELLOGG DS, 1968, J BACTERIOL, V96, P596, DOI 10.1128/JB.96.3.596-605.1968; KLIMPEL WK, 1988, INFECT IMMUN, V56, P808; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; MARDH PA, 1976, INFECT IMMUN, V13, P661; MARVIN DA, 1986, J MOL BIOL, V191, P299, DOI 10.1016/0022-2836(86)90267-6; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MEYER TF, 1984, P NATL ACAD SCI-BIOL, V81, P6110, DOI 10.1073/pnas.81.19.6110; MICHEL H, 1982, J MOL BIOL, V158, P567, DOI 10.1016/0022-2836(82)90216-9; MUIR LL, 1988, INFECT IMMUN, V56, P1743, DOI 10.1128/IAI.56.7.1743-1747.1988; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEARCE WA, 1978, J CLIN INVEST, V61, P931, DOI 10.1172/JCI109018; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; PUNSALANG AP, 1973, INFECT IMMUN, V8, P255, DOI 10.1128/IAI.8.2.255-263.1973; REID BR, 1973, J MOL BIOL, V80, P199, DOI 10.1016/0022-2836(73)90241-6; REST RF, 1985, INFECT IMMUN, V50, P116, DOI 10.1128/IAI.50.1.116-122.1985; ROSSMANN MG, 1985, METHOD ENZYMOL, V114, P237; ROTH M, 1989, NATURE, V340, P659, DOI 10.1038/340659a0; ROTHBARD JB, 1985, P NATL ACAD SCI USA, V82, P915, DOI 10.1073/pnas.82.3.915; SCHOOLNIK GK, 1984, J EXP MED, V159, P1351, DOI 10.1084/jem.159.5.1351; SEGAL E, 1985, CELL, V40, P293, DOI 10.1016/0092-8674(85)90143-6; SPARLING PF, 1966, J BACTERIOL, V92, P1364, DOI 10.1128/JB.92.5.1364-1371.1966; STEVEN AC, 1980, P NATL ACAD SCI-BIOL, V77, P4721, DOI 10.1073/pnas.77.8.4721; STROMBERG N, 1988, P NATL ACAD SCI USA, V85, P4902, DOI 10.1073/pnas.85.13.4902; SWANSON J, 1971, J EXP MED, V134, P886, DOI 10.1084/jem.134.4.886; SWANSON J, 1987, J EXP MED, V165, P1344, DOI 10.1084/jem.165.5.1344; SWANSON J, 1973, J EXP MED, V137, P571, DOI 10.1084/jem.137.3.571; SWANSON J, 1975, INFECT IMMUN, V11, P1352, DOI 10.1128/IAI.11.6.1352-1361.1975; TAINER JA, 1984, NATURE, V312, P127, DOI 10.1038/312127a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAMONT EC, 1989, CLIN MICROBIOL REV, V2, pS74, DOI 10.1128/CMR.2.Suppl.S74-S77.1989; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VIRJI M, 1986, J GEN MICROBIOL, V132, P503; WATTS TH, 1983, BIOCHEMISTRY-US, V22, P3640, DOI 10.1021/bi00284a016; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; ZULAUF M, 1986, BIOPHYS J, V49, P96, DOI 10.1016/S0006-3495(86)83607-4; 1982, ISOELECTRIC FOCUSING, P77	49	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1990	265	4					2278	2285						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CL028	1967608				2022-12-25	WOS:A1990CL02800073
J	ADACHI, I; PUOPOLO, K; MARQUEZSTERLING, N; ARAI, H; FORGAC, M				ADACHI, I; PUOPOLO, K; MARQUEZSTERLING, N; ARAI, H; FORGAC, M			DISSOCIATION, CROSS-LINKING, AND GLYCOSYLATION OF THE COATED VESICLE PROTON PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111	Tufts University			Puopolo, Karen/AAY-7748-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07542] Funding Source: Medline; NIGMS NIH HHS [GM34478, R01 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1988, P NATL ACAD SCI USA, V85, P1010, DOI 10.1073/pnas.85.4.1010; ADACHI I, 1990, J BIOL CHEM, V265, P960; AMZEL LM, 1983, ANNU REV BIOCHEM, V52, P801, DOI 10.1146/annurev.bi.52.070183.004101; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; ARAI H, 1988, J BIOL CHEM, V263, P8796; BLUCK S, 1987, J BIOL CHEM, V262, P15780; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; KAIFU R, 1979, CARBOHYD RES, V69, P79, DOI 10.1016/S0008-6215(00)85753-5; LAI SP, 1988, J BIOL CHEM, V263, P16731; MANDALA S, 1986, J BIOL CHEM, V261, P2850; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NELSON H, 1989, J BIOL CHEM, V264, P1775; RANDALL SK, 1986, J BIOL CHEM, V261, P1364; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SENIOR AE, 1983, J MEMBRANE BIOL, V73, P105, DOI 10.1007/BF01870434; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; WANG SY, 1988, J BIOL CHEM, V263, P17638; XIE XS, 1988, J BIOL CHEM, V263, P9859; YOUNG GPH, 1988, P NATL ACAD SCI USA, V85, P9590, DOI 10.1073/pnas.85.24.9590; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	31	108	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1990	265	2					967	973						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CH533	1967252				2022-12-25	WOS:A1990CH53300053
J	ALTUS, MS; NAGAMINE, Y				ALTUS, MS; NAGAMINE, Y			PROTEIN-SYNTHESIS INHIBITION STABILIZES UROKINASE-TYPE PLASMINOGEN-ACTIVATOR MESSENGER-RNA - STUDIES INVIVO AND IN CELL-FREE DECAY REACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYADENYLATE-BINDING-PROTEIN; C-MYC; NUCLEOTIDE-SEQUENCE; EUKARYOTIC CELLS; GENE-EXPRESSION; KIDNEY-CELLS; RAT-LIVER; ACID; TRANSCRIPTION; TURNOVER	Inhibition of protein synthesis stabilizes a number of mRNAs, but little is known about the mechanism. To understand the relationship between protein synthesis and mRNA stability, we studied the degradation of calcitonin-induced urokinase-type plasminogen activator (uPA) mRNA in LLC-PK cells. uPA mRNA became highly stable by pretreatment with either cycloheximide or pactamycin, and the stabilizing effect of cycloheximide treatment was time dependent with the full effect exerted by 60 min. Stabilization was also observed with histone H4 mRNA but only partially with c-myc mRNA. To further analyze, we developed a cell-free decay reaction system based on post-mitochondrial supernatant (PMS). In this system, uPA mRNA was completely stable when fractions were obtained from cells pretreated with cycloheximide, but very unstable in control fractions, paralleling uPA mRNA stability in intact cells. However, in contrast to uPA mRNA and the in vivo observation, histone H4 mRNA was unstable whether or not the cells were pretreated with cycloheximide. These results suggest that inhibition of protein synthesis stabilizes mRNAs in at least two different ways in LLC-PK1 cells. When PMS from cycloheximide/calcitonin-treated cells was mixed with PMS from untreated cells, uPA mRNA was not destabilized. This suggests that a putative labile factor responsible for uPA mRNA degradation is not a soluble protein.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ALTUS MS, 1987, BIOCHEM J, V242, P387, DOI 10.1042/bj2420387; ANDRUS L, 1988, J BIOL CHEM, V263, P6183; BAKER EJ, 1986, MOL CELL BIOL, V6, P54, DOI 10.1128/MCB.6.1.54; BANDYOPADHYAY R, 1990, MOL CELL BIOL, V10, P2060, DOI 10.1128/MCB.10.5.2060; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS MJ, 1987, CELL, V49, P157, DOI 10.1016/0092-8674(87)90553-8; Cleveland DW, 1989, CURR OPIN CELL BIOL, V1, P1148, DOI 10.1016/S0955-0674(89)80065-1; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EISENSTEIN RS, 1984, J BIOL CHEM, V259, P9922; ERNEST MJ, 1982, BIOCHEMISTRY-US, V21, P6761, DOI 10.1021/bi00269a022; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOLDBERG IH, 1975, ANTIBIOTICS, V3, P498; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; HUNT T, 1988, NATURE, V334, P567, DOI 10.1038/334567a0; INOUE A, 1989, J BIOL CHEM, V264, P14954; KESAVAN P, 1990, ONCOGENE, V5, P483; LI Y, 1989, ONCOGENE, V4, P795; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LIZARDI PM, 1983, METHOD ENZYMOL, V96, P24; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; NAGAMINE Y, 1983, CELL, V32, P1181, DOI 10.1016/0092-8674(83)90301-X; NAGAMINE Y, 1984, NUCLEIC ACIDS RES, V12, P9525, DOI 10.1093/nar/12.24.9525; PETERSEN RB, 1989, CELL REGUL, V1, P135, DOI 10.1091/mbc.1.1.135; RAGHOW R, 1987, TRENDS BIOCHEM SCI, V12, P358, DOI 10.1016/0968-0004(87)90165-4; RINGOLD GM, 1984, P NATL ACAD SCI-BIOL, V81, P3964, DOI 10.1073/pnas.81.13.3964; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; ROSS J, 1989, SCI AM, V260, P48, DOI 10.1038/scientificamerican0489-48; ROSS J, 1988, MOL BIOL MED, V5, P1; SHAPIRO DJ, 1987, BIOESSAYS, V6, P221, DOI 10.1002/bies.950060507; SONENBERG N, 1981, NUCLEIC ACIDS RES, V9, P1643, DOI 10.1093/nar/9.7.1643; STIMAC E, 1984, MOL CELL BIOL, V4, P2082, DOI 10.1128/MCB.4.10.2082; TAMM I, 1978, ADV VIRUS RES, V22, P188; THEODORAKIS NG, 1987, MOL CELL BIOL, V7, P4357, DOI 10.1128/MCB.7.12.4357; ZIEGLER A, 1990, J BIOL CHEM, V265, P21194	47	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21190	21196						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939161				2022-12-25	WOS:A1991GN00100094
J	GEIERSTANGER, BH; KAGAWA, TF; CHEN, SL; QUIGLEY, GJ; HO, PS				GEIERSTANGER, BH; KAGAWA, TF; CHEN, SL; QUIGLEY, GJ; HO, PS			BASE-SPECIFIC BINDING OF COPPER(II) TO Z-DNA - THE 1.3-A SINGLE-CRYSTAL STRUCTURE OF D(M5CGUAM5CG) IN THE PRESENCE OF CUCL2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; COMPLEXES; DAMAGE	The single crystal structure of d(m5CGUAm5CG) soaked with copper(II) chloride was solved to atomic (1.3 angstrom) resolution to study the base specificity of copper binding to double-stranded DNA. In the present copper (II) chloride-soaked structure, four crystallographically unique copper(II) complexes were observed bound to five of the six purine bases in the hexamer duplex. Covalent copper(II) binding occurred at N-7 of all four guanine bases and at one of the two adenine bases in the DNA duplex. Copper binding was not observed at the position (Ade4) located in an open solvent channel, whereas the second adenine site (Ade10) shared a complex with a guanine residue (Gua12) of a neighboring symmetry-related hexamer. The coordination geometries and distribution of these copper(II) complexes at the guanine bases in the crystal were comparable to the analogous sites in the isomorphous copper(II) chloride-soaked d(CGCGCG) crystal (Kagawa, T., Geierstanger, B. H., Wang, A. H.-J., and Ho, P. S. (1991) J. Biol. Chem. 266, 20175-20184). Thus, the decreased copper(II) binding affinity for Ade4 was not an artifact of crystal packing, but is intrinsic to the chemical properties of this purine base in duplex DNA. This suggests that the adenine bases in dilute solutions of Z-DNA and more generally other duplex DNA conformations are not susceptible to copper(II) modification. Thus, preferential copper(II) binding at guanine bases over adenine bases in double-stranded DNA may explain the observed specificity of copper(II)-induced oxidative DNA damage near guanine residues (Yamamoto, K., and Kawanishi, S. (1989) J. Biol. Chem. 264, 15435-15440; Sagripanti, J.-L., and Kraemer, K. H. (1989) J. Biol. Chem. 264, 1729-1734). The sharing of a single copper(II) complex by Ade10 and Gual2 of an adjacent hexamer suggests that additional and perhaps specific DNA-DNA interactions, as may be found in the densely packed environment of the nuclear matrix in the cell, may render N-7 of adenine bases prone to copper(II) modification.	OREGON STATE UNIV,DEPT PHYSIOL & BIOPHYS,CORVALLIS,OR 97331; CUNY HUNTER COLL,DEPT CHEM,NEW YORK,NY 10021	Oregon State University; City University of New York (CUNY) System; Hunter College (CUNY)			Ho, Pui/AAF-8838-2020; Ho, Pui S/F-6186-2014	Ho, Pui/0000-0002-8082-4311; Ho, Pui S/0000-0002-8082-4311	NCRR NIH HHS [RR03037] Funding Source: Medline; NIGMS NIH HHS [GM41359] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI K, 1976, BIOCHIM BIOPHYS ACTA, V425, P369, DOI 10.1016/0005-2787(76)90264-1; ARUOMA OI, 1991, BIOCHEM J, V273, P601, DOI 10.1042/bj2730601; EICHHORN GL, 1968, J AM CHEM SOC, V90, P7323, DOI 10.1021/ja01028a024; HENDRICKSON WA, 1979, BIOMOLECULAR STRUCTU, P43; HO PS, 1990, BIOPOLYMERS, V30, P151, DOI 10.1002/bip.360300115; KAGAWA TF, 1991, J BIOL CHEM, V266, P20175; MARZILLI LG, 1980, NUCLEIC ACID METAL I, P181; SAGRIPANTI JL, 1989, J BIOL CHEM, V264, P1729; SCHAAPER RM, 1987, MUTAT RES, V177, P179, DOI 10.1016/0027-5107(87)90001-7; Sissoeff I, 1976, Prog Biophys Mol Biol, V31, P165; SLETTEN E, 1974, ACTA CRYSTALLOGR B, V30, P2438, DOI 10.1107/S0567740874007266; SWAMINATHAN V, 1979, CRC CR REV BIOCH MOL, V6, P245, DOI 10.3109/10409237909102565; YAMAMOTO K, 1989, J BIOL CHEM, V264, P15435; ZHOU GW, 1990, BIOCHEMISTRY-US, V29, P7229, DOI 10.1021/bi00483a010; ZIMMER C, 1971, BIOPOLYMERS, V10, P441, DOI 10.1002/bip.360100303	15	97	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20185	20191						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939079				2022-12-25	WOS:A1991GM03900048
J	LIM, WK; SARKAR, SK; HARDMAN, JK				LIM, WK; SARKAR, SK; HARDMAN, JK			ENZYMATIC-PROPERTIES OF MUTANT ESCHERICHIA-COLI TRYPTOPHAN SYNTHASE ALPHA-SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; CATALYTIC RESIDUE; BETA-SUBUNIT; L-SERINE; MECHANISM; COMPLEX; SYNTHETASE; BINDING; SITE; ACCESSIBILITY	Thirty-nine mutant tryptophan synthase alpha-subunits have been purified and analyzed (in the presence of the beta-2-subunit) for their enzymatic (k(cat), K(m)) behavior in the reactions catalyzed by the alpha-2.beta-2 complex, the fully constituted form of this enzyme. The mutant alpha-subunits, obtained by in vitro random, saturation mutagenesis of the encoding trpA gene, contain single amino acid substitutions at sites within the first 121 residues of the alpha-polypeptide. Four categories of altered residues have been tentatively assigned roles in the catalytic functions of this enzyme: 1) catalytic residues (Glu49 and Asp60); 2) residues involved in substrate binding or orientation (Phe22, Thr63, Gln65, Tyr102, and Leu105); 3) residues involved in alpha.beta-subunit interactions (Gly51, Pro53, Asp56, ASP60, Pro62, Ala67, Phe72, Thr77 ,Pro78, Tyr102, Asn104, Leu105, and Asn108); and 4) residues with no apparent catalytic roles. Catalytic residue alterations result in no detectable activity in the alpha-subunit specific reactions. Substrate binding/orientation roles are detected enzymatically primarily as rate defects; alterations only at Tyr102 result in apparent K(m) effects. alpha.beta interaction roles are detected as rate defects in all tryptophan synthase reactions plus K(m) increases for the alpha-subunit substrate, indole-3-glycerol phosphate, only when L-serine is present at the beta-2-subunit active site. A substitution at only one site, Asn104, appears to be unique in its potential effect on intersubunit channeling of indole, the product of the alpha-subunit specific reaction, to the beta-2-subunit active site.	UNIV ALABAMA, DEPT BIOL SCI, CELLULAR & DEV MOLEC BIOL SECT, TUSCALOOSA, AL 35487 USA; UNIV ALABAMA, DEPT PHYS, TUSCALOOSA, AL 35487 USA	University of Alabama System; University of Alabama Tuscaloosa; University of Alabama System; University of Alabama Tuscaloosa								ADACHI O, 1974, J BIOL CHEM, V249, P7756; BEASTY AM, 1986, BIOCHEMISTRY-US, V25, P2965, DOI 10.1021/bi00358a035; CRAWFORD IP, 1987, PROTEINS, V2, P118, DOI 10.1002/prot.340020206; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; FAEDER EJ, 1970, BIOCHEMISTRY-US, V9, P4043, DOI 10.1021/bi00823a003; GSCHWIND HP, 1979, EUR J BIOCHEM, V96, P403, DOI 10.1111/j.1432-1033.1979.tb13052.x; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIRSCHNER K, 1975, EUR J BIOCHEM, V60, P513, DOI 10.1111/j.1432-1033.1975.tb21030.x; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1991, BIOCHEMISTRY-US, V30, P479, DOI 10.1021/bi00216a025; LANE AN, 1983, EUR J BIOCHEM, V133, P531, DOI 10.1111/j.1432-1033.1983.tb07496.x; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIM WK, 1989, APPL ENVIRON MICROB, V55, P1106, DOI 10.1128/AEM.55.5.1106-1111.1989; LIM WK, 1991, J BACTERIOL, V173, P1886, DOI 10.1128/jb.173.6.1886-1893.1991; MILES EW, 1988, J BIOL CHEM, V263, P8611; MILES EW, 1991, ADV ENZYMOL RELAT AR, V64, P93; MILTON DL, 1986, J BIOL CHEM, V261, P6604; NAGATA S, 1989, J BIOL CHEM, V264, P6288; SMITH OH, 1962, METHOD ENZYMOL, V5, P794, DOI 10.1016/S0076-6879(62)05315-X; WALSH CT, 1979, ENZYMATIC REACTION M, P819; WIESINGER H, 1979, BIOCHEMISTRY-US, V18, P1979, DOI 10.1021/bi00577a020; WILHELM P, 1982, EUR J BIOCHEM, V129, P51, DOI 10.1111/j.1432-1033.1982.tb07019.x; YUTANI K, 1987, J BIOL CHEM, V262, P13429	30	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20205	20212						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939081				2022-12-25	WOS:A1991GM03900051
J	PHELPS, A; WOHLRAB, H				PHELPS, A; WOHLRAB, H			MITOCHONDRIAL PHOSPHATE-TRANSPORT - THE SACCHAROMYCES-CEREVISIAE (THREONINE-43 TO CYSTEINE) MUTANT PROTEIN EXPLICITLY IDENTIFIES TRANSPORT WITH GENOMIC SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BEEF-HEART MITOCHONDRIA; N-ETHYLMALEIMIDE; MOLECULAR ASPECTS; BINDING-PROTEIN; IMPORT RECEPTOR; HYDROGEN-BONDS; YEAST; CARRIER; SITE	The yeast mitochondrial phosphate transport protein (PTP) has only 38% sequence similarity to the bovine heart protein, and it has recently been postulated to code for a mitochondrial import receptor. Since the reconstitutively active protein is not completely pure, it is important to demonstrate explicitly that the yeast gene codes for PTP. We have replaced Thr43 with Cys (T43C) and show that its unidirectional and pH gradient-dependent inorganic phosphate transport activity becomes highly sensitive to N-ethylmaleimide. This new PTP/T43C catalyzes less than 10% of the wild type transport activity (1 mM [P(i)]e, pH(e) (6.80); 0 mM [P(i)]i, PH(i) (8.07); 30 s [P(i)] uptake) suggesting that Thr43 occupies an important position in the PTP.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	PHELPS, A (corresponding author), HARVARD UNIV,SCH MED,BOSTON BIOMED RES INST,BOSTON,MA 02115, USA.			Wohlrab, Hartmut/0000-0002-2974-3460	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033357] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33357] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1987, PROTEIN ENG, P289; AQUILA H, 1982, H-S Z PHYSIOL CHEM, V363, P345; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; BEDNAR RA, 1990, BIOCHEMISTRY-US, V29, P3684, DOI 10.1021/bi00467a014; FLUGGE UI, 1989, EMBO J, V8, P39, DOI 10.1002/j.1460-2075.1989.tb03346.x; GAWAZ M, 1990, J BIOL CHEM, V265, P14202; GUERIN B, 1990, J BIOL CHEM, V265, P19736; HE JJ, 1991, SCIENCE, V251, P1479, DOI 10.1126/science.1900953; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOLBE HVJ, 1984, J BIOL CHEM, V259, P9115; KOLBE HVJ, 1985, J BIOL CHEM, V260, P5899; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; LANG B, 1977, ANAL BIOCHEM, V77, P110, DOI 10.1016/0003-2697(77)90295-0; LIN CS, 1982, BIOCHEMISTRY-US, V21, P2950, DOI 10.1021/bi00541a023; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MARTI T, 1991, J BIOL CHEM, V266, P6919; MURAKAMI H, 1990, NATURE, V347, P488, DOI 10.1038/347488a0; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PFLUGRATH JW, 1985, NATURE, V314, P257, DOI 10.1038/314257a0; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; PHELPS A, 1990, FASEB J, V4, pA1762; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; RUNSWICK MJ, 1987, EMBO J, V6, P1361; Sambrook J, 1989, MOL CLONING LABORATO; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SIKORSKI RS, 1989, GENETICS, V122, P19; WOHLRAB H, 1984, BIOCHEMISTRY-US, V23, P1057, DOI 10.1021/bi00301a004; WOHLRAB H, 1986, BIOCHIM BIOPHYS ACTA, V853, P115, DOI 10.1016/0304-4173(86)90007-8; WOHLRAB H, 1982, J BIOL CHEM, V257, P28	30	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19882	19885						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939052				2022-12-25	WOS:A1991GM03900005
J	WANG, LQ; BALAKIR, R; HORTON, WE				WANG, LQ; BALAKIR, R; HORTON, WE			IDENTIFICATION OF A CIS-ACTING SEQUENCE IN THE COLLAGEN-II ENHANCER REQUIRED FOR CHONDROCYTE EXPRESSION AND THE BINDING OF A CHONDROCYTE NUCLEAR FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GENE; CHONDROGENESIS	Collagen II is synthesized at high levels by differentiated chondrocytes. A 620-base pair DNA sequence in the first intron of the rat collagen II gene was previously determined to have chondrocyte-specific enhancer activity. Using mobility shift assays, we have defined a decamer sequence, 5'-CACAATGCAT-3', in the middle of the enhancer that binds a protein or protein complex expressed by chondrocytes but not by NIH3T3 cells or L2 rat fibroblasts. This protein was also induced during the differentiation of limb bud mesenchymal cells into chondroCytes. Mutational analyses, coupled with both in vitro binding studies and direct assays of enhancer activity following transfection into cells, demonstrated that this sequence is involved in the binding of the chondrocyte nuclear protein(s) and is necessary for the enhancer activity. This sequence has homology to the consensus binding sequence for helix-loop-helix transcription factors.	NIA, GERONTOL RES CTR, BIOL CHEM LAB, 4940 EASTERN AVE, BALTIMORE, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON W, 1986, DEV BIOL, V115, P392, DOI 10.1016/0012-1606(86)90258-7; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KIMURA JH, 1979, J BIOL CHEM, V254, P2600; KOSHER RA, 1986, J CELL BIOL, V102, P1151, DOI 10.1083/jcb.102.4.1151; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; SWALLA BJ, 1984, DIFFERENTIATION, V26, P42, DOI 10.1111/j.1432-0436.1984.tb01371.x; von der Mark K, 1980, Curr Top Dev Biol, V14, P199; Von der Mark K., 1986, RHEUMATOLOGY, V10; YAMADA Y, 1989, STRUCTURE MOL BIOL P, V8, P1	13	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19878	19881						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939051				2022-12-25	WOS:A1991GM03900004
J	AIKEN, CR; MCLAUGHLIN, LW; GUMPORT, RI				AIKEN, CR; MCLAUGHLIN, LW; GUMPORT, RI			THE HIGHLY HOMOLOGOUS ISOSCHIZOMERS RSRI ENDONUCLEASE AND ECORI ENDONUCLEASE DO NOT RECOGNIZE THEIR TARGET SEQUENCE IDENTICALLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE ANALOG SUBSTITUTIONS; TRANSFER RNA-SYNTHETASES; FUNCTIONAL-GROUP CHANGES; RESTRICTION ENDONUCLEASE; RI ENDONUCLEASE; MODIFICATION METHYLASE; CLEAVAGE REACTION; ENDODEOXYRIBONUCLEASE ECORI; DNA INTERACTION; PROTEIN	Using a series of decadeoxyribonucleotides containing base analogues as substrates we measured the steady-state kinetic parameters for the reaction catalyzed by RsrI endonuclease and compared the results to those with its isoschizomer EcoRI. The kinetics of RsrI cleavage are affected by each substitution, with the effects being generally more deleterious than with EcoRI, as shown by the greater reduction in the specificity constant k(cat)/K(M). The magnitudes of the effects of several substitutions are consistent with the formation of direct enzyme-nucleobase contacts at the indicated positions. With substrates containing 2-aminopurine or 2,6-diaminopurine at the central adenine or uracil at the outermost thymine in the recognition sequence, cleavage by RsrI was very slow, less than one-tenth the rate of the corresponding EcoRI-catalyzed reaction. The lower tolerance of RsrI endonuclease for functional group changes in its recognition site may reflect differences in the mechanisms of DNA recognition by the two enzymes. Although RsrI and EcoRI endonucleases bind with similar affinities to specific and nonspecific DNA sequences and appear to introduce similar structural distortions in DNA upon binding, the use of substrate analogues reveals significant differences at the level of catalysis in the mechanisms by which these two endonucleases recognize the duplex sequence GAATTC.	UNIV ILLINOIS, COLL MED,DEPT BIOCHEM,415 ROGER ADAMS LAB, 1209 W CALIF ST, URBANA, IL 61801 USA; UNIV ILLINOIS, SCH CHEM SCI, URBANA, IL 61801 USA; BOSTON COLL, DEPT CHEM, CHESTNUT HILL, MA 02167 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Boston College					NIGMS NIH HHS [GM25621] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025621] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; AIKEN C, 1988, NUCLEIC ACIDS RES, V16, P7901, DOI 10.1093/nar/16.16.7901; AIKEN CR, 1991, METHOD ENZYMOL, V208, P433; AIKEN CR, 1991, J BIOL CHEM, V266, P19063; BENNETT SP, 1989, CURR TOP CELL REGUL, V30, P57; BERKNER KL, 1979, J BIOL CHEM, V254, P2551; BERKNER KL, 1977, J BIOL CHEM, V252, P3185; BRENNAN CA, 1986, J BIOL CHEM, V261, P7279; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; BRENNAN CA, 1985, NUCLEIC ACIDS RES, V13, P8665, DOI 10.1093/nar/13.24.8665; CARUTHERS MH, 1980, ACCOUNTS CHEM RES, V13, P155, DOI 10.1021/ar50149a005; Cleland W W, 1979, Methods Enzymol, V63, P103; CLORE GM, 1988, BIOCHEMISTRY-US, V27, P4185, DOI 10.1021/bi00411a042; DELORT AM, 1985, NUCLEIC ACIDS RES, V13, P3343, DOI 10.1093/nar/13.9.3343; DIEKMANN S, 1988, J MOL BIOL, V202, P823, DOI 10.1016/0022-2836(88)90561-X; DOROVSKA VN, 1972, FEBS LETT, V23, P122, DOI 10.1016/0014-5793(72)80299-0; DOUCRASY S, 1989, NUCLEIC ACIDS RES, V17, P5173, DOI 10.1093/nar/17.13.5173; DUGAICZYK A, 1974, BIOCHEMISTRY-US, V13, P503, DOI 10.1021/bi00700a016; DWYERHALLQUIST P, 1982, BIOCHEMISTRY-US, V21, P4693, DOI 10.1021/bi00262a027; Fersht A., 1985, ENZYME STRUCTURE MEC, P350; FERSHT AR, 1980, BIOCHEMISTRY-US, V19, P5520, DOI 10.1021/bi00565a009; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1238, DOI 10.1021/bi00574a019; GREENE PJ, 1988, GENE, V68, P43, DOI 10.1016/0378-1119(88)90597-5; HAGERMAN PJ, 1990, BIOCHEMISTRY-US, V29, P1980, DOI 10.1021/bi00460a003; HALFORD SE, 1980, BIOCHEM J, V191, P593, DOI 10.1042/bj1910593; HEITMAN J, 1990, PROTEINS, V7, P185, DOI 10.1002/prot.340070207; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; Janik B., 1971, PHYSICOCHEMICAL CHAR; JAY E, 1974, NUCLEIC ACIDS RES, V1, P331, DOI 10.1093/nar/1.3.331; KASZUBSKA W, 1989, NUCLEIC ACIDS RES, V17, P10403, DOI 10.1093/nar/17.24.10403; KIM R, 1984, NUCLEIC ACIDS RES, V12, P7285, DOI 10.1093/nar/12.19.7285; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LOFTFIELD RB, 1966, BIOCHIM BIOPHYS ACTA, V130, P426, DOI 10.1016/0304-4165(66)90239-X; Luke P A, 1987, Gene Amplif Anal, V5, P185; MANIATIS T, 1982, MOL CLONING LABORATO, P464; MATTHEWS BW, 1988, NATURE, V335, P294, DOI 10.1038/335294a0; MAZZARELLI J, 1989, BIOCHEMISTRY-US, V28, P4616, DOI 10.1021/bi00437a016; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MCLAUGHLIN LW, 1988, NUCLEIC ACIDS RES, V16, P5631, DOI 10.1093/nar/16.12.5631; MCLAUGHLIN LW, 1987, BIOCHEMISTRY-US, V26, P7238, DOI 10.1021/bi00397a007; MODRICH P, 1989, J BIOL CHEM, V29, P6198; Nardone G, 1987, Gene Amplif Anal, V5, P147; NEEDELS MC, 1989, P NATL ACAD SCI USA, V86, P3579, DOI 10.1073/pnas.86.10.3579; NELSON M, 1989, NUCLEIC ACIDS RES, V17, pR389, DOI 10.1093/nar/17.1.389; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9891, DOI 10.1021/bi00494a020; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9902, DOI 10.1021/bi00494a021; OWENS SL, 1970, J BIOL CHEM, V245, P5515; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; RUBIN RA, 1978, NUCLEIC ACIDS RES, V5, P2991, DOI 10.1093/nar/5.8.2991; SEELA F, 1987, BIOCHEMISTRY-US, V26, P2232, DOI 10.1021/bi00382a024; SEELA F, 1986, NUCLEIC ACIDS RES, V14, P2319, DOI 10.1093/nar/14.5.2319; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STEPHENSON FH, 1989, GENE, V85, P1, DOI 10.1016/0378-1119(89)90458-7; TABOURY JA, 1984, NUCLEIC ACIDS RES, V12, P6291, DOI 10.1093/nar/12.15.6291; TAYLOR JD, 1989, BIOCHEMISTRY-US, V28, P6198, DOI 10.1021/bi00441a011; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; THIELKING V, 1990, BIOCHEMISTRY-US, V29, P4682, DOI 10.1021/bi00471a024; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; WINKLER FK, 1991, J MOL BIOL, V217, P235, DOI 10.1016/0022-2836(91)90536-F; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816	63	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19070	19078						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918026				2022-12-25	WOS:A1991GJ47200102
J	MOUSTAID, N; SUL, HS				MOUSTAID, N; SUL, HS			REGULATION OF EXPRESSION OF THE FATTY-ACID SYNTHASE GENE IN 3T3-L1-CELLS BY DIFFERENTIATION AND TRIIODOTHYRONINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE REGULATION; CHICK-EMBRYO HEPATOCYTES; MESSENGER-RNA PRECURSOR; ADIPOCYTE DIFFERENTIATION; LIPOGENIC ENZYMES; MALIC ENZYME; RAT-LIVER; 3T3 CELLS; TRANSCRIPTION; SYNTHETASE	We have previously reported that fatty acid synthase mRNA levels increase 10-15-fold during the differentiation of 3T3-L1 cells to adipocytes, correlating well with the increase in the relative rate of synthesis for this enzyme. Here we show by transcription run-on assays that fatty acid synthase is highly transcribed in both preadipocytes and adipocytes. Furthermore, the transcription rate of the fatty acid synthase gene increased only 1.5-fold during the adipose conversion, whereas the apparent mRNA half-life increased from 2.5 h in preadipocytes to approximately 20 h in adipocytes. These results indicate that the increase in mRNA level during adipose conversion is not only due to the transcriptional activation of this gene but reflects the post-transcriptional stabilization of the message in adipocytes compared to preadipocytes. As thyroid hormone has been reported to increase lipogenic enzyme activities including fatty acid synthase in adipose tissue and in differentiating adipocytes in vitro, we used fully differentiated 3T3-L1 adipocytes to study T3 regulation of mammalian fatty acid synthase expression. We measured the effect of T3 on the relative rate of protein synthesis, mRNA content, and transcription rate of this gene. When mature adipocytes were treated with 10 nM T3, the relative rate of synthesis of fatty acid synthase increased 1.9-fold at 6 h, and it reached a maximum of 2.9-fold at 12 h. In addition, Northern blot analysis showed that T3 increased the steady-state mRNA level for fatty acid synthase by 2.4-fold at 12 h and 4.5-fold at 24 h. Furthermore, run-on transcription analysis with isolated nuclei from cells treated with T3 showed that the transcription rate of the fatty acid synthase gene increased 4.1-fold after 6 h of T3 treatment and remained at the stimulated level for 24 h. These results demonstrate that the increase in transcription of the fatty acid synthase gene preceded that of the steady-state mRNA level, indicating that T3 regulates expression of fatty acid synthase primarily by modulating the transcription rate of the gene. In conclusion, while the differentiation-dependent increase in fatty acid synthase is mediated by both transcriptional and posttranscriptional processes, T3 regulation is primarily at the transcriptional level.	HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health			Han, Zaiqi/AAI-2233-2019; Moustaid-Moussa, Naima/B-9067-2014	Moustaid-Moussa, Naima/0000-0002-7508-8030	NIDDK NIH HHS [DK 36264] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036264] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACK DW, 1986, J BIOL CHEM, V261, P4190; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; DIAMANT S, 1972, EUR J BIOCHEM, V26, P553, DOI 10.1111/j.1432-1033.1972.tb01798.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLORESDELGADO G, 1987, MOL CELL BIOCHEM, V76, P35; GHARBICHIHI J, 1981, J RECEPTOR RES, V2, P153, DOI 10.3109/10799898109039259; GHARBICHIHI J, 1984, BIOCHIM BIOPHYS ACTA, V783, P26, DOI 10.1016/0167-4781(84)90074-5; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; JUMP DB, 1989, J BIOL CHEM, V264, P4698; LAKSHMAN.MR, 1972, P NATL ACAD SCI USA, V69, P3516, DOI 10.1073/pnas.69.12.3516; MARIASH CN, 1980, ENDOCRINOLOGY, V106, P22, DOI 10.1210/endo-106-1-22; MARIASH CN, 1980, J CLIN INVEST, V65, P1126, DOI 10.1172/JCI109766; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NARAYAN P, 1985, MOL CELL BIOL, V5, P2642, DOI 10.1128/MCB.5.10.2642; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; NTAMBI JM, 1988, J BIOL CHEM, V263, P17291; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PETTY KJ, 1989, J BIOL CHEM, V264, P11483; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; SONG MKH, 1988, J BIOL CHEM, V263, P17970; SPENCE JT, 1982, EUR J BIOCHEM, V128, P15; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; VOLPE JJ, 1972, J NEUROCHEM, V19, P737, DOI 10.1111/j.1471-4159.1972.tb01389.x; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WEISS GH, 1980, J BIOL CHEM, V255, P4751; WILSON SB, 1986, J BIOL CHEM, V261, P5179; WISE LS, 1984, J BIOL CHEM, V259, P4827; YE ZS, 1988, J BIOL CHEM, V263, P7821; ZECHNER R, 1988, MOL CELL BIOL, V8, P2394, DOI 10.1128/MCB.8.6.2394; [No title captured]	36	82	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18550	18554						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917977				2022-12-25	WOS:A1991GJ47200025
J	YADA, Y; HIGUCHI, K; IMOKAWA, G				YADA, Y; HIGUCHI, K; IMOKAWA, G			EFFECTS OF ENDOTHELINS ON SIGNAL TRANSDUCTION AND PROLIFERATION IN HUMAN MELANOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ATRIAL NATRIURETIC PEPTIDE; VASOACTIVE INTESTINAL CONTRACTOR; ALLERGIC CONTACT-DERMATITIS; DEPENDENT PROTEIN-KINASE; PROMOTING PHORBOL ESTERS; FIBROBLAST GROWTH-FACTOR; VASOCONSTRICTOR PEPTIDE; DNA-SYNTHESIS; I-125 ENDOTHELIN-1	We demonstrate here that human melanocytes could be regulated by endothelin (ET) derivatives, potent vasoconstrictive peptides synthesized by endothelial cells, to stimulate their proliferation and melanization via a receptor-mediated signal transduction pathway. Receptor-binding assay using [I-125]ET indicated that unlabeled ET-1 or ET-2 competitively inhibited each binding of labeled ETs to melanocytes with a concentration for half-maximal inhibition (IC50) of 0.7 or 0.9 nM, respectively. The dissociation constant (K(d)) and the number of sites of the specific bindings of ET-1 and those of ET-2 were almost the same (K(d): 1.81 nM, binding sites: 7.0-8.0 x 10(4) per cell). Upon incubation with cultured cells, the mass contents of inositol 1,4,5-trisphosphate and intracellular calcium level were substantially increased by 10 nM ET-1, ET-2, and ET-3, but not by big-ET with maximal response at 80-130-s postincubation. The addition of ET-1 and ET-2 at 1-50 nM concentrations caused human melanocytes to significantly stimulate DNA ([H-3]thymidine incorporation) and melanin synthesis ((H2O)-H-3 release and [C-14] thiouracil incorporation). Furthermore, ETs exhibited an additive stimulatory effect on basic fibroblast growth factor-stimulated DNA synthesis. In a long-term serum-free culture system, the strongest stimulation of growth by 10 nM ET-1 or ET-2 was observed in the presence of 10 nM cholera toxin and 0.2% bovine pituitary extract, resulting in a 4.5-fold increase in cell number for 12 culture days. These findings strongly suggest involvement of ET in the mechanism regulating proliferation and melanization of human melanocytes.	KAO CORP,TOCHIGI RES LABS,ICHIKAIMACHI 2606,TOCHIGI 32134,JAPAN	KAO Corporation								BLUMBERG PM, 1984, BIOCHEM PHARMACOL, V33, P933, DOI 10.1016/0006-2952(84)90448-9; BRENNER BM, 1989, J CLIN INVEST, V84, P1373, DOI 10.1172/JCI114309; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COZZA EN, 1989, J CLIN INVEST, V84, P1032, DOI 10.1172/JCI114226; DAVENPORT AP, 1989, J CARDIOVASC PHARM, V13, pS166, DOI 10.1097/00005344-198900135-00045; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; EISINGER M, 1985, SCIENCE, V229, P984, DOI 10.1126/science.4023718; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; EISINGER M, 1983, CARCINOGENESIS, V4, P779, DOI 10.1093/carcin/4.6.779; ENGLEN RM, 1989, BRIT J PHARMACOL, V97, P1297; FABREGAT I, 1990, BIOCHEM BIOPH RES CO, V167, P161, DOI 10.1016/0006-291X(90)91745-E; FU T, 1990, BIOCHEM J, V272, P71, DOI 10.1042/bj2720071; FUKUDA Y, 1988, BIOCHEM BIOPH RES CO, V155, P167, DOI 10.1016/S0006-291X(88)81064-7; FUKUDA Y, 1989, BIOCHEM BIOPH RES CO, V164, P1431, DOI 10.1016/0006-291X(89)91830-5; GANDHI CR, 1990, J BIOL CHEM, V265, P17432; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263, P12970; HIRATA Y, 1989, BIOCHEM BIOPH RES CO, V160, P228, DOI 10.1016/0006-291X(89)91645-8; HIRATA Y, 1988, BIOCHEM BIOPH RES CO, V154, P868, DOI 10.1016/0006-291X(88)90220-3; HUANG CL, 1989, J BIOL CHEM, V264, P4391; HUANG SS, 1986, J BIOL CHEM, V261, P9568; IMOKAWA G, 1986, ARCH DERMATOL RES, V278, P352, DOI 10.1007/BF00418162; IMOKAWA G, 1982, CANCER RES, V42, P1994; IMOKAWA G, 1987, J INVEST DERMATOL, V89, P540, DOI 10.1111/1523-1747.ep12461181; IMOKAWA G, 1988, J INVEST DERMATOL, V91, P106, DOI 10.1111/1523-1747.ep12464093; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA T, 1988, PFLUG ARCH EUR J PHY, V413, P108, DOI 10.1007/BF00581239; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; ISSEROFF RR, 1983, J INVEST DERMATOL, V80, P217, DOI 10.1111/1523-1747.ep12534464; KLIGMAN LH, 1985, J INVEST DERMATOL, V84, P272, DOI 10.1111/1523-1747.ep12265353; KOSEKI C, 1989, J CARDIOVASC PHARM, V13, pS153, DOI 10.1097/00005344-198900135-00040; KUSUHARA M, 1989, JPN J CANCER RES, V80, P302, DOI 10.1111/j.1349-7006.1989.tb02310.x; KUSUHARA M, 1990, CANCER RES, V50, P3257; MORELLI JG, 1989, J INVEST DERMATOL, V93, P719, DOI 10.1111/1523-1747.ep12284392; MOSCAT J, 1988, MOL ENDOCRINOL, V2, P799, DOI 10.1210/mend-2-9-799; MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778; NAKAKI T, 1989, BIOCHEM BIOPH RES CO, V158, P880, DOI 10.1016/0006-291X(89)92804-0; NEUSER D, 1989, J CARDIOVASC PHARM, V13, pS67, DOI 10.1097/00005344-198900135-00016; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; OHNISHISUZAKI A, 1990, BIOCHEM BIOPH RES CO, V166, P608, DOI 10.1016/0006-291X(90)90852-E; RESINK TJ, 1988, BIOCHEM BIOPH RES CO, V157, P1360, DOI 10.1016/S0006-291X(88)81025-8; RESINK TJ, 1989, BIOCHEM BIOPH RES CO, V158, P279, DOI 10.1016/S0006-291X(89)80209-8; RESINK TJ, 1990, BIOCHEM BIOPH RES CO, V166, P1213, DOI 10.1016/0006-291X(90)90995-Y; REYNOLDS EE, 1989, BIOCHEM BIOPH RES CO, V160, P868, DOI 10.1016/0006-291X(89)92515-1; REYNOLDS EE, 1989, BIOCHEM BIOPH RES CO, V158, P279; SEISHIMA M, 1988, BIOCHEM BIOPH RES CO, V156, P1077, DOI 10.1016/S0006-291X(88)80742-3; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SUGIURA M, 1989, BIOCHEM BIOPH RES CO, V162, P1396, DOI 10.1016/0006-291X(89)90829-2; SUPATTAPONE S, 1989, BIOCHEM BIOPH RES CO, V165, P1115, DOI 10.1016/0006-291X(89)92718-6; UCHIDA Y, 1988, EUR J PHARMACOL, V154, P227, DOI 10.1016/0014-2999(88)90106-9; WATANABE H, 1989, BIOCHEM BIOPH RES CO, V161, P1252, DOI 10.1016/0006-291X(89)91377-6; WHITTAKER JR, 1971, J BIOL CHEM, V246, P6217; WIKLUND NP, 1988, ACTA PHYSIOL SCAND, V134, P311, DOI 10.1111/j.1748-1716.1988.tb08495.x; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; YADA Y, 1989, BIOCHEM BIOPH RES CO, V163, P1517, DOI 10.1016/0006-291X(89)91152-2; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOUNG A, 1982, BRIT J DERMATOL, V107, P77	59	243	251	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18352	18357						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917960				2022-12-25	WOS:A1991GG55300096
J	CARBONE, D; CHIBA, I; MITSUDOMI, T				CARBONE, D; CHIBA, I; MITSUDOMI, T			POLYMORPHISM AT CODON-213 WITHIN THE P53-GENE	ONCOGENE			English	Note							P53 GENE; LUNG-CANCER; MUTATIONS; FREQUENT; PROTEIN; MUTANT	This report describes a rare polymorphism at codon 213 (silent alteration of CGA to CGG) within the coding region of the p53 gene. The rare polymorphic allele was present in six cases out of 189 lung and breast cancer DNAs analyzed (3.2%) and resulted in the loss of a TaqI site. This allele could be mistaken for a mutation when screening methods of mutation analysis are used without comparison with normal tissue DNA.	USN,MED ONCOL BRANCH,BETHESDA,MD 20889	United States Department of Defense; United States Navy	CARBONE, D (corresponding author), UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,2523 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Mitsudomi, Tetsuya/0000-0001-9860-8505				AHUJA HG, 1990, ONCOGENE, V5, P1409; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHIBA I, 1990, ONCOGENE, V5, P1603; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GROMPE M, 1989, P NATL ACAD SCI USA, V86, P5888, DOI 10.1073/pnas.86.15.5888; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	14	159	160	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1691	1692						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923533				2022-12-25	WOS:A1991GX27400027
J	NAGAO, S; MATSUKI, S; KANOH, H; OZAWA, T; YAMADA, K; NOZAWA, Y				NAGAO, S; MATSUKI, S; KANOH, H; OZAWA, T; YAMADA, K; NOZAWA, Y			SITE-DIRECTED MUTAGENESIS OF GLUTAMINE RESIDUE OF CALMODULIN - ACTIVATION OF GUANYLATE-CYCLASE OF TETRAHYMENA PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note									GIFU UNIV,SCH MED,DEPT BIOCHEM,40 TSUKASAMACHI,GIFU 500,JAPAN; KIRIN BREWERY CO LTD,PHARMACEUT LAB,MAEBASHI,GUNMA 371,JAPAN	Gifu University; Kirin Brewery Company Limited								BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CRAIG TA, 1987, J BIOL CHEM, V262, P3278; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HIDAKA H, 1978, BLOOD VESSELS, V15, P55; KAKIUCHI S, 1982, J BIOCHEM-TOKYO, V92, P1041, DOI 10.1093/oxfordjournals.jbchem.a134019; KAKIUCHI S, 1981, J BIOL CHEM, V256, P19; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEVIT RE, 1984, J BIOL CHEM, V259, P5414; KRETSINGER RH, 1975, BIOCHIM BIOPHYS ACTA, V405, P40, DOI 10.1016/0005-2795(75)90312-8; KUDO S, 1982, FEBS LETT, V149, P271, DOI 10.1016/0014-5793(82)81115-0; KUDO S, 1981, BIOCHEM INT, V3, P255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MANN DM, 1989, J BIOL CHEM, V264, P2373; MATSUKI S, 1990, IN PRESS BIOTECHNOL; NAKAZAWA K, 1974, J BIOL CHEM, V249, P4207; NEWTON D, 1985, BIOCHIM BIOPHYS ACTA, V845, P533, DOI 10.1016/0167-4889(85)90222-8; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; NOJIMA H, 1987, J MOL BIOL, V193, P439, DOI 10.1016/0022-2836(87)90258-0; Nozawa Y, 1975, Methods Cell Biol, V10, P105, DOI 10.1016/S0091-679X(08)60732-3; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; PUTKEY JA, 1988, J BIOL CHEM, V263, P11242; PUTKEY JA, 1986, J BIOL CHEM, V261, P9869; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; YAZAWA M, 1981, BIOCHEM BIOPH RES CO, V99, P1051, DOI 10.1016/0006-291X(81)90725-7	32	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1990	265	11					5926	5929						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CY587	1969409				2022-12-25	WOS:A1990CY58700003
J	LIJNEN, HR; VANHOEF, B; NELLES, L; COLLEN, D				LIJNEN, HR; VANHOEF, B; NELLES, L; COLLEN, D			PLASMINOGEN ACTIVATION WITH SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (SCU-PA) - STUDIES WITH ACTIVE-SITE MUTAGENIZED PLASMINOGEN (SER740-]ALA) AND PLASMIN-RESISTANT SCU-PA (LYS158-]GLU)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											LIJNEN, HR (corresponding author), CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,CAMPUS GASTHUISBERG,HERESTR 49,B-3000 LOUVAIN,BELGIUM.		Lijnen, Roger/AAA-4085-2020					ASTRUP T, 1952, ARCH BIOCHEM BIOPHYS, V40, P346, DOI 10.1016/0003-9861(52)90121-5; BUSBY SJ, 1988, FIBRINOLYSIS S1, V2, P64; COLLEN D, 1986, CRC CR REV ONCOL-HEM, V4, P249, DOI 10.1016/S1040-8428(86)80014-2; COLLEN D, 1986, J BIOL CHEM, V261, P1259; COLLEN D, 1980, BIOCHIM BIOPHYS ACTA, V165, P158; COLLEN D, 1989, J VASC MED BIOL, V1, P46; DARRAS V, 1986, THROMB HAEMOSTASIS, V56, P411; DECLERCK PJ, 1989, IN PRESS BLOOD; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ELLIS V, 1987, J BIOL CHEM, V262, P14998; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GERTLER A, 1974, BIOCHEMISTRY-US, V13, P1302, DOI 10.1021/bi00703a038; HOLVOET P, 1985, J BIOL CHEM, V260, P2106; KASAI S, 1985, J BIOL CHEM, V260, P2377; KASSELL B, 1973, SCIENCE, V180, P1022, DOI 10.1126/science.180.4090.1022; LIJNEN HR, 1985, EUR J BIOCHEM, V150, P141, DOI 10.1111/j.1432-1033.1985.tb08999.x; LIJNEN HR, 1989, BLOOD, V73, P1864; LIJNEN HR, 1984, THROMB RES, V34, P431, DOI 10.1016/0049-3848(84)90247-0; LIJNEN HR, 1988, ENZYME, V40, P90, DOI 10.1159/000469150; LIJNEN HR, 1986, BIOCHIM BIOPHYS ACTA, V884, P402, DOI 10.1016/0304-4165(86)90190-X; LIJNEN HR, 1987, SEMIN THROMB HEMOST, V13, P152, DOI 10.1055/s-2007-1003486; MORGAN PH, 1972, P NATL ACAD SCI USA, V69, P3312, DOI 10.1073/pnas.69.11.3312; NELLES L, 1987, J BIOL CHEM, V262, P5682; PANNELL R, 1987, BLOOD, V69, P22; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; SHAPIRO RA, 1988, J BIOL CHEM, V263, P18397; URANO T, 1988, ARCH BIOCHEM BIOPHYS, V264, P222, DOI 10.1016/0003-9861(88)90588-7; WALLEN P, 1970, BIOCHIM BIOPHYS ACTA, V221, P20, DOI 10.1016/0005-2795(70)90194-7; WALLEN P, 1982, BIOCHIM BIOPHYS ACTA, V719, P318, DOI 10.1016/0304-4165(82)90105-2; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229	31	96	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1990	265	9					5232	5236						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CV587	1969415				2022-12-25	WOS:A1990CV58700076
J	GARCIABUSTOS, JF; WAGNER, P; HALL, MN				GARCIABUSTOS, JF; WAGNER, P; HALL, MN			NUCLEAR IMPORT SUBSTRATES COMPETE FOR A LIMITED NUMBER OF BINDING-SITES - EVIDENCE FOR DIFFERENT CLASSES OF YEAST NUCLEAR IMPORT RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE-T-ANTIGEN; ASP-GLU-ASP; SACCHAROMYCES-CEREVISIAE; DEPENDENT TRANSLOCATION; ENDOPLASMIC-RETICULUM; PRECURSOR PROTEINS; TRANSPORT SIGNALS; PORE COMPLEX; LOCALIZATION; INVITRO	A nuclear receptor likely involved in nuclear protein import is described. Purified ATP-depleted yeast nuclei show saturable high-affinity binding of the yeast nuclear protein Mcm1. The dissociation constant for the binding is 0.5-mu-M, and the number of binding sites is approximately 3,500 per nucleus, equivalent to 10-30 binding sites per nuclear pore. Mcm1 competes with other yeast nuclear proteins Ste12 and Swi5, but not with Rap1 or Nop1, indicating that there may be different types of import receptors. Bound Mcm1 is resistant to extraction by nucleases, salt, and non-ionic detergent, but can be released by 5 m urea, suggesting that Mcm1 binds to a yeast equivalent of the nuclear pore complex-lamina fraction of higher eukaryotes.	UNIV BASEL, BIOCTR, DEPT BIOCHEM, CH-4056 BASEL, SWITZERLAND	University of Basel				Hall, Michael N/0000-0002-2998-0757; Garcia-Bustos, Jose/0000-0002-6310-796X				ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKERA T, 1977, BIOCHIM BIOPHYS ACTA, V470, P412, DOI 10.1016/0005-2736(77)90132-8; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; ALLEN JL, 1989, J ULTRA MOL STRUCT R, V102, P95, DOI 10.1016/0889-1605(89)90047-5; AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GARCIABUSTOS JF, 1991, EXP CELL RES, V192, P213, DOI 10.1016/0014-4827(91)90178-W; GEORGATOS SD, 1989, J CELL BIOL, V108, P2069, DOI 10.1083/jcb.108.6.2069; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HURT EC, 1990, J CELL BIOL, V111, P2829, DOI 10.1083/jcb.111.6.2829; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; JACOBS S, 1975, BIOCHEM BIOPH RES CO, V66, P687, DOI 10.1016/0006-291X(75)90564-1; JARVIS EE, 1989, GENE DEV, V3, P936, DOI 10.1101/gad.3.7.936; JORDAN EG, 1977, EXP CELL RES, V104, P446, DOI 10.1016/0014-4827(77)90114-8; KALINICH JF, 1989, J BIOL CHEM, V264, P17979; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KNIPE DM, 1986, MOL CELL BIOL, V6, P2371, DOI 10.1128/MCB.6.7.2371; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; MARKLAND W, 1987, MOL CELL BIOL, V7, P4255, DOI 10.1128/MCB.7.12.4255; MAUL GG, 1977, J CELL BIOL, V73, P748, DOI 10.1083/jcb.73.3.748; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOOR H, 1963, J CELL BIOL, V17, P609, DOI 10.1083/jcb.17.3.609; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PARNAIK VK, 1990, MOL CELL BIOL, V10, P1287, DOI 10.1128/MCB.10.3.1287; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1987, EMBO J, V6, P2635, DOI 10.1002/j.1460-2075.1987.tb02554.x; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SCHNEIDER J, 1988, CELL, V54, P117, DOI 10.1016/0092-8674(88)90185-7; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; TAN S, 1988, EMBO J, V7, P4255, DOI 10.1002/j.1460-2075.1988.tb03323.x; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WHITE EM, 1989, J CELL BIOL, V109, P1983, DOI 10.1083/jcb.109.5.1983; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028; YONEDA Y, 1988, SCIENCE, V242, P275, DOI 10.1126/science.3051382	44	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22303	22306						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939252				2022-12-25	WOS:A1991GR56400040
J	GRAHAME, DA				GRAHAME, DA			CATALYSIS OF ACETYL-COA CLEAVAGE AND TETRAHYDROSARCINAPTERIN METHYLATION BY A CARBON-MONOXIDE DEHYDROGENASE-CORRINOID ENZYME COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWN METHANOSARCINA-THERMOPHILA; AUTOTROPHIC GROWTH; CELL-EXTRACTS; ACETOGENIC BACTERIA; METHANE FORMATION; COENZYME-A; ACETATE; BARKERI; PURIFICATION; PATHWAY	An enzyme complex containing carbon monoxide dehydrogenase and a corrinoid protein has been isolated from Methanosarcina barkeri. Sodium dodecyl sulfate-gel electrophoresis revealed five polypeptides of molecular masses-alpha = 19,700, beta = 84,500, gamma = 63,200, delta = 53,000, and epsilon = 51,400 Da in equimolar amounts. One mol of cobamide cofactor was found per minimal alpha-beta-gamma-delta-epsilon unit. The molecular mass of the native complex was 1,600,000 Da by high pressure liquid chromatography (HPLC) gel filtration, which suggested an alpha-6-beta-6-gamma-6-delta-6-epsilon-6 oligomeric structure. Catalysis of a reaction involving cleavage of acetyl-CoA and methylation of tetrahydrosarcinapterin was indicated by spectrophotometric analyses; a time-dependent absorption decrease in the 300-320 nm region was observed in the complete reaction mixture which contained acetyl-CoA, tetrahydrosarcinapterin, and the enzyme complex. In control samples lacking any one of the these components the absorption spectrum remained virtually unaltered. Reversed-phase HPLC analysis confirmed that tetrahydrosarcinapterin was converted to a product that co-eluted with authentic methyltetrahydrosarcinapterin. The product also exhibited the UV-visible absorption spectrum expected for methyltetrahydrosarcinapterin. Free CoA was identified as an additional product of the reaction. The carbonyl group of acetyl-CoA was oxidized to carbon dioxide. Spectral changes indicated concomitant Fe/S center reduction. Production of CoA was essentially stoichiometric with methyltetrahydrosarcinapterin formation and tetrahydrosarcinapterin consumption. Analyses during purification showed that catalytic activity was restricted exclusively to the fractions that contained the carbon monoxide dehydrogenase-corrinoid enzyme complex.			GRAHAME, DA (corresponding author), NHLBI,BIOCHEM LAB,BLDG 3,RM 114,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ABBANAT DR, 1990, J BACTERIOL, V172, P7145, DOI 10.1128/jb.172.12.7145-7150.1990; ABBANAT DR, 1991, P NATL ACAD SCI USA, V88, P3272, DOI 10.1073/pnas.88.8.3272; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEMOLL E, 1987, J BACTERIOL, V169, P3916, DOI 10.1128/jb.169.9.3916-3920.1987; ESCALANTESEMERENA JC, 1984, J BIOL CHEM, V259, P9447; FAN CL, 1991, BIOCHEMISTRY-US, V30, P431, DOI 10.1021/bi00216a018; FISCHER R, 1988, FEBS LETT, V228, P249, DOI 10.1016/0014-5793(88)80009-7; FISCHER R, 1989, ARCH MICROBIOL, V151, P459, DOI 10.1007/BF00416607; FISCHER R, 1990, ARCH MICROBIOL, V153, P156, DOI 10.1007/BF00247814; FISCHER R, 1990, FEBS LETT, V269, P368, DOI 10.1016/0014-5793(90)81195-T; FUCHS G, 1986, FEMS MICROBIOL LETT, V39, P181, DOI 10.1111/j.1574-6968.1986.tb01859.x; GRAHAME DA, 1987, BIOCHEM BIOPH RES CO, V147, P254, DOI 10.1016/S0006-291X(87)80114-6; GRAHAME DA, 1987, J BIOL CHEM, V262, P3706; GRAHAME DA, 1989, J BIOL CHEM, V264, P12890; HUNGATE RE, 1950, BACTERIOL REV, V14, P1; JETTEN MSM, 1989, EUR J BIOCHEM, V181, P437, DOI 10.1111/j.1432-1033.1989.tb14744.x; KELTJENS JT, 1986, METHOD ENZYMOL, V122, P412; KRZYCKI JA, 1984, J BACTERIOL, V158, P231, DOI 10.1128/JB.158.1.231-237.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGDAHL LG, 1986, ANNU REV MICROBIOL, V40, P415, DOI 10.1146/annurev.mi.40.100186.002215; POSTON JM, 1971, METHOD ENZYMOL, V22, P49; RAGSDALE SW, 1985, P NATL ACAD SCI USA, V82, P6811, DOI 10.1073/pnas.82.20.6811; RAYBUCK SA, 1991, J BACTERIOL, V173, P929, DOI 10.1128/jb.173.2.929-932.1991; TERLESKY KC, 1987, J BIOL CHEM, V262, P15392; TERLESKY KC, 1986, J BACTERIOL, V168, P1053, DOI 10.1128/jb.168.3.1053-1058.1986; WOOD HG, 1986, BIOCHEM INT, V12, P421; WOOD HG, 1991, FASEB J, V5, P156, DOI 10.1096/fasebj.5.2.1900793; WOOD HG, 1986, FEMS MICROBIOL LETT, V39, P345, DOI 10.1016/0378-1097(86)90022-4; WOOD HG, 1986, TRENDS BIOCHEM SCI, V11, P14, DOI 10.1016/0968-0004(86)90223-9	29	86	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22227	22233						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939246				2022-12-25	WOS:A1991GR56400028
J	NAG, B; AKELLA, SS; CANN, PA; TEWARI, DS; GLITZ, DG; TRAUT, RR				NAG, B; AKELLA, SS; CANN, PA; TEWARI, DS; GLITZ, DG; TRAUT, RR			MONOCLONAL-ANTIBODIES TO ESCHERICHIA-COLI RIBOSOMAL-PROTEINS L9 AND L10 - EFFECTS ON RIBOSOME FUNCTION AND LOCALIZATION OF L9 ON THE SURFACE OF THE 50-S RIBOSOMAL-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE ELECTRON-MICROSCOPY; TRANSFER-RNA; EXIT SITE; IDENTIFICATION; EPITOPES; BINDING; L7/L12; 50S; 2-IMINOTHIOLANE; LOCATION	Monoclonal antibodies against Escherichia coli ribosomal proteins L9 and L10 were obtained and their specificity confirmed by Western blot analysis of total ribosomal protein. This was particularly important for the L9 antibody, since the immunizing antigen mixture contained predominantly L11. Each antibody recognized both 70 S ribosomes and 50 S subunits. Affinity-purified antibodies were tested for their effect on in vitro assays of ribosome function. Anti-L10 and anti-L9 inhibited poly(U)-directed polyphenylalanine synthesis almost completely. The antibodies had no effect on subunit association or dissociation and neither antibody inhibited peptidyltransferase activity. Both antibodies inhibited the binding of the ternary complex that consisted of aminoacyl-tRNA, guanylyl beta,gamma-methylenediphosphonate, and elongation factor Tu, and the binding of elongation factor G to the ribosome. The intact antibodies were more potent inhibitors than the Fab fragments. In contrast to the previously established location of L10 at the base of the L7/L12 stalk near the factor-binding site, the site of anti-L9 binding to 50 S subunits was shown by immune electron microscopy to be on the L1 lateral protuberance opposite the L7/L12 stalk as viewed in the quasisymmetric projection. The inhibition of factor binding by both antibodies, although consistent with established properties of L10 in the ribosome, suggests a long range effect on subunit structure that is triggered by the binding of anti-L9.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Davis					NIGMS NIH HHS [GM 17924] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017924, R37GM017924] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTA A, 1990, RIBOSOME, P358; BRANLANT C, 1976, EUR J BIOCHEM, V70, P457, DOI 10.1111/j.1432-1033.1976.tb11037.x; CASIANO C, 1990, J BIOL CHEM, V265, P18757; DABBS ER, 1981, J MOL BIOL, V149, P553, DOI 10.1016/0022-2836(81)90347-8; Dabbs ER, 1986, STRUCTURE FUNCTION G, P733; EGEBJERG J, 1990, RIBOSOME, P168; Engvall E, 1980, Methods Enzymol, V70, P419; EXPERTBEZANCON A, 1975, FEBS LETT, V59, P64, DOI 10.1016/0014-5793(75)80342-5; Galfre G, 1981, Methods Enzymol, V73, P3; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GODING JW, 1982, ANTIBODY TOOL, P273; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE JA, 1981, J MOL BIOL, V153, P979, DOI 10.1016/0022-2836(81)90462-9; LAKE JA, 1978, ADV TECHNIQUES BIOL, V2, P173; LAMBERT JM, 1981, J MOL BIOL, V149, P451, DOI 10.1016/0022-2836(81)90481-2; LILJAS A, 1990, RIBOSOME, P309; Liljas A, 1986, STRUCTURE FUNCTION G, P379; LILL R, 1989, EMBO J, V8, P3933, DOI 10.1002/j.1460-2075.1989.tb08574.x; LILL R, 1988, J MOL BIOL, V203, P699, DOI 10.1016/0022-2836(88)90203-3; MATHESON AT, 1990, RIBOSOME, P617; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; NAG B, 1987, BIOCHEMISTRY-US, V26, P461, DOI 10.1021/bi00376a018; NAG B, 1987, J BIOL CHEM, V262, P9681; NAG B, 1986, J BIOL CHEM, V261, P13892; NAG B, 1991, J BIOL CHEM, V266, P11116; NOWOTNY V, 1986, STRUCTURE FUNCTION G, P101; OLSON HM, 1986, J BIOL CHEM, V261, P6924; OLSON HM, 1991, J BIOL CHEM, V266, P1898; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; ROHL R, 1982, P NATL ACAD SCI-BIOL, V79, P729, DOI 10.1073/pnas.79.3.729; ROMERO DP, 1990, J BIOL CHEM, V265, P18185; SOMMER A, 1985, J BIOL CHEM, V260, P6522; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; STOFFLERMEILICKE M, 1983, P NATL ACAD SCI-BIOL, V80, P6780, DOI 10.1073/pnas.80.22.6780; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; Traut R. R., 1980, RIBOSOMES STRUCTURE, P89; WALLECZEK J, 1989, J BIOL CHEM, V264, P4231; ZIMMERMANN RA, 1976, BIOCHEMISTRY-US, V15, P2007, DOI 10.1021/bi00654a031	39	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22129	22135						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939233				2022-12-25	WOS:A1991GR56400013
J	PLANA, M; ITARTE, E; ERITJA, R; GODAY, A; PAGES, M; MARTINEZ, MC				PLANA, M; ITARTE, E; ERITJA, R; GODAY, A; PAGES, M; MARTINEZ, MC			PHOSPHORYLATION OF MAIZE RAB-17 PROTEIN BY CASEIN KINASE-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID; SPECIFICITY DETERMINANTS; GENE-EXPRESSION; WHEAT-GERM; STRESS; INCREASES; SEQUENCE; CELLS	The maize gene RAB-17, which is responsive to abscisic acid, encodes a basic glycine-rich protein containing, in the middle part of its sequence, a cluster of 8 serine residues followed by a putative casein kinase 2-type substrate consensus sequence. This protein was found to be highly phosphorylated in vivo. Here, we show that RAB-17 protein is a real substrate for casein kinase 2. RAB-17 protein is phosphorylated in vitro by casein kinase 2 isolated from rat liver cytosol and from maize embryos. A maximum of 4 mol of phosphate were incorporated per mol of RAB-17 protein following incubation with casein kinase 2. Phosphopeptide mapping experiments show that the peptide phosphorylated by casein kinase 2 in vitro is identical to that derived from the protein phosphorylated in vivo. Purification by high performance liquid chromatography and partial sequencing of the phosphopeptide indicate that it corresponds to the region of the protein (residues 56-89) containing the cluster of serine residues. Our results indicate that RAB-17 is phosphorylated by casein kinase 2 or a kinase with a similar specificity and that phosphorylation takes place in the serine cluster region of the protein both in vitro and in vivo.	CSIC, CTR INVEST & DESENVOLUPAMENT, DEPT GENET MOLEC, JORGE GIRONA SALGADO 18-26, E-08034 BARCELONA, SPAIN; UNIV AUTONOMA BARCELONA, FAC CIENCIES, DEPT BIOQUIM & BIOL MOLEC, E-08193 BARCELONA, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Barcelona			Torrens, Montserrat Pages/B-6329-2012; Itarte, Emilio/K-5275-2014; Itarte, Emilio/Q-6246-2019; Plana Coll, Maria/L-3414-2014; Pages, Montserrat/ABA-6448-2021; Eritja, Ramon/B-5613-2008	Torrens, Montserrat Pages/0000-0001-8431-5605; Itarte, Emilio/0000-0002-9366-5807; Plana Coll, Maria/0000-0001-5808-9229; Eritja, Ramon/0000-0001-5383-9334; Martinez, M. Carmen/0000-0002-7472-4349; Albert Goday Arno, Albert/0000-0001-7356-1595				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIES JR, 1983, PLANT PHYSIOL, V71, P489, DOI 10.1104/pp.71.3.489; DAVIES WJ, 1983, ABSCISIC ACID, P237; DOBROWOLSKA G, 1989, BIOCHIM BIOPHYS ACTA, V1010, P274, DOI 10.1016/0167-4889(89)90173-0; DOBROWOLSKA G, 1987, BIOCHIM BIOPHYS ACTA, V931, P188, DOI 10.1016/0167-4889(87)90206-0; DURE L, 1989, PLANT MOL BIOL, V12, P475, DOI 10.1007/BF00036962; GODAY A, 1988, PLANT PHYSIOL, V88, P564, DOI 10.1104/pp.88.3.564; GUASCH MD, 1986, BIOCHEM J, V234, P523, DOI 10.1042/bj2340523; GUILFOYLE TJ, 1989, PLANT CELL, V1, P827, DOI 10.1105/tpc.1.8.827; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P317, DOI 10.1016/0076-6879(83)99067-5; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNCH J, 1989, PLANT PHYSIOL, V90, P1271, DOI 10.1104/pp.90.4.1271; MARTOS C, 1985, BIOCHEM J, V225, P321, DOI 10.1042/bj2250321; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; MUNDY J, 1988, EMBO J, V7, P2279, DOI 10.1002/j.1460-2075.1988.tb03070.x; MURRAY MG, 1978, PLANT PHYSIOL, V62, P434, DOI 10.1104/pp.62.3.434; PENA JM, 1983, CANCER RES, V43, P1172; PEREZ M, 1987, EUR J BIOCHEM, V170, P493, DOI 10.1111/j.1432-1033.1987.tb13726.x; PEREZ M, 1988, FEBS LETT, V238, P273, DOI 10.1016/0014-5793(88)80495-2; SANCHEZMARTINEZ D, 1986, PLANT PHYSIOL, V82, P543, DOI 10.1104/pp.82.2.543; SCHROEDER JI, 1989, TRENDS BIOCHEM SCI, V14, P187, DOI 10.1016/0968-0004(89)90272-7; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; TREWAVAS A, 1976, ANNU REV PLANT PHYS, V27, P349, DOI 10.1146/annurev.pp.27.060176.002025; VILARDELL J, 1990, PLANT MOL BIOL, V14, P423, DOI 10.1007/BF00028778; YAN TFJ, 1982, J BIOL CHEM, V257, P7037	28	78	84	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22510	22514						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939268				2022-12-25	WOS:A1991GR56400071
J	WANG, ZG; WU, XH; FRIEDBERG, EC				WANG, ZG; WU, XH; FRIEDBERG, EC			NUCLEOTIDE EXCISION REPAIR OF DNA BY HUMAN CELL-EXTRACTS IS SUPPRESSED IN RECONSTITUTED NUCLEOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS 40; SACCHAROMYCES-CEREVISIAE; PYRIMIDINE DIMERS; INVITRO; TRANSCRIPTION; CHROMATIN; REPLICATION; DISSOLUTION; OOCYTES; INVIVO	Nucleotide excision repair is a complex biochemical process that corrects DNA damage caused by a broad spectrum of physical and chemical agents. We examined the effect of the assembly of ultraviolet-irradiated plasmid DNA into nucleosomes on nucleotide excision repair supported by human cell extracts. Repair synthesis in unassembled UV-irradiated plasmid DNA was readily detected in extracts from repair-proficient human cells. In contrast, repair synthesis was markedly suppressed in UV-irradiated DNA assembled into nucleosomes (minichromosomes). This suppression occurred at a step(s) which precedes repair synthesis during nucleotide excision repair. Human cell extracts were unable to effectively assemble plasmid DNA into nucleosomes under repair synthesis conditions. The addition of purified histones to the extracts restored their capacity for nucleosome assembly and simultaneously led to the suppression of repair synthesis. We propose that the preferential repair of actively transcribed genes relative to transcriptionally silent genes may reflect altered nucleosome conformation during transcription.	UNIV TEXAS, SW MED CTR, DEPT PATHOL, MOLEC PATHOL LAB, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [R37CA012428, R01CA012428] Funding Source: NIH RePORTER; NCI NIH HHS [CA12428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1985, DNA REPAIR; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; EVANS DH, 1984, J BIOL CHEM, V259, P252; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HOEIJMAKERS JHJ, 1990, MUTAT RES, V236, P223, DOI 10.1016/0921-8777(90)90007-R; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; PFAFFLE P, 1990, J BIOL CHEM, V265, P16830; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; TERLETH C, 1991, MUTAGENESIS, V6, P103, DOI 10.1093/mutage/6.2.103; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VANZEELAND AA, 1981, MUTAT RES, V82, P173, DOI 10.1016/0027-5107(81)90148-2; WILKINS RJ, 1974, NATURE, V247, P35, DOI 10.1038/247035a0; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9	30	93	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22472	22478						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939267				2022-12-25	WOS:A1991GR56400066
J	ALLO, SN; MCDERMOTT, PJ; CARL, LL; MORGAN, HE				ALLO, SN; MCDERMOTT, PJ; CARL, LL; MORGAN, HE			PHORBOL ESTER STIMULATION OF PROTEIN-KINASE-C ACTIVITY AND RIBOSOMAL DNA-TRANSCRIPTION - ROLE IN HYPERTROPHIC GROWTH OF CULTURED CARDIOMYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR HYPERTROPHY; MAMMALIAN-CELLS; GENE-EXPRESSION; HEART-CELLS; MYOCARDIAL HYPERTROPHY; CARDIAC-HYPERTROPHY; SIGNAL TRANSDUCTION; RDNA TRANSCRIPTION; RNA SYNTHESIS; RAT	The mechanism by which phorbol esters induce hypertrophic growth of cardiomyocytes was investigated. Control and 4-alpha-phorbol 12,13-didecanoate-treated myocytes demonstrated a slow rate of growth as measured by the protein/DNA ratio and cell area. In contrast, treatment with phorbol 12-myristate 13-acetate (PMA) stimulated protein accumulation by 34%, while cell area was increased by 68% over control myocytes after 72 h. RNA content in PMA-treated myocytes was 33% higher than in control cells and 4-alpha-phorbol 12,13-didecanoate-treated cells after 72 h. Membrane-associated protein kinase C activity was transiently increased after PMA treatment but returned to normal by 48 h. Cytosolic protein kinase C activity was not significantly altered by PMA. Membrane-associated and cytosolic protein kinase C activities were not altered by 4-alpha-phorbol 12,13-didecanoate. Protein kinase C activity, RNA polymerase I activity, and the transcriptional rate of ribosomal DNA (rDNA) were increased in nuclei isolated from PMA-treated cells. However, consistent with a high rate of processing of pre-ribosomal RNA (pre-rRNA), the pool size of pre-rRNA relative to the 28 S rRNA was unaltered by PMA treatment. These data demonstrated that PMA-induced hypertrophic growth of cardiomyocytes was due to an increase in the capacity for protein synthesis (rRNA), and suggest that this results from protein kinase C mediated increase in the rate of transcription of rDNA.	SIGFRIED & JANET WEIS CTR RES, GEISINGER CLIN, DANVILLE, PA 17822 USA									ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; ALLO SN, 1990, BIOCHIM BIOPHYS ACTA, V1023, P206, DOI 10.1016/0005-2736(90)90415-K; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANVERSA P, 1986, CIRC RES, V58, P26, DOI 10.1161/01.RES.58.1.26; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BOWMAN LH, 1987, DEV BIOL, V119, P152, DOI 10.1016/0012-1606(87)90217-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; CAMACHO JA, 1990, AM J PHYSIOL, V258, pC86, DOI 10.1152/ajpcell.1990.258.1.C86; CASSIDY BG, 1987, MOL CELL BIOL, V7, P2388, DOI 10.1128/MCB.7.7.2388; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CESARONE CF, 1979, ANAL BIOCHEM, V100, P188, DOI 10.1016/0003-2697(79)90131-3; CHILIAN WM, 1987, ANNU REV PHYSIOL, V49, P477, DOI 10.1146/annurev.ph.49.030187.002401; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COOPER DR, 1987, J BIOL CHEM, V262, P3633; COOPER G, 1987, ANNU REV PHYSIOL, V49, P501, DOI 10.1146/annurev.ph.49.030187.002441; CUTILLETTA AF, 1978, J MOL CELL CARDIOL, V10, P677, DOI 10.1016/0022-2828(78)90403-0; DELABASTIE D, 1990, CIRC RES, V66, P554, DOI 10.1161/01.RES.66.2.554; FULLER SJ, 1990, BIOCHEM J, V266, P727, DOI 10.1042/bj2660727; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GROVE RI, 1982, BIOCHIM BIOPHYS ACTA, V711, P272, DOI 10.1016/0005-2760(82)90036-4; HANEDA T, 1991, MOL CELL BIOCHEM, V104, P169; HANNUN YA, 1987, J BIOL CHEM, V262, P13620; HII CST, 1990, BIOCHIM BIOPHYS ACTA, V1052, P327, DOI 10.1016/0167-4889(90)90229-7; HOSSENLOPP P, 1975, EUR J BIOCHEM, V58, P237, DOI 10.1111/j.1432-1033.1975.tb02369.x; INOUE M, 1977, J BIOL CHEM, V252, P7610; JETTEN AM, 1985, P NATL ACAD SCI USA, V82, P1941, DOI 10.1073/pnas.82.7.1941; KAKO KJ, 1972, CARDIOVASC RES, V6, P57, DOI 10.1093/cvr/6.1.57; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KOYANAGI S, 1982, CIRC RES, V50, P55, DOI 10.1161/01.RES.50.1.55; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOCKNEY MW, 1984, BIOCHIM BIOPHYS ACTA, V796, P384, DOI 10.1016/0005-2760(84)90141-3; LORELL BH, 1986, CIRC RES, V58, P653, DOI 10.1161/01.RES.58.5.653; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MARINO TA, 1987, AM J PHYSIOL, V253, pH1391, DOI 10.1152/ajpheart.1987.253.6.H1391; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MCDERMOTT PJ, 1991, J BIOL CHEM, V266, P4409; MCDERMOTT PJ, 1989, J BIOL CHEM, V264, P18220; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; NAIR KG, 1968, CIRC RES, V23, P451, DOI 10.1161/01.RES.23.3.451; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PELECH SL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P100, DOI 10.1016/0167-4889(90)90179-H; PETERSON CJ, 1989, CIRC RES, V64, P360, DOI 10.1161/01.RES.64.2.360; RABIN MS, 1986, P NATL ACAD SCI USA, V83, P357, DOI 10.1073/pnas.83.2.357; RESENDEZ E, 1986, J CELL BIOL, V103, P2145, DOI 10.1083/jcb.103.6.2145; RICHTER EA, 1987, FEBS LETT, V217, P232, DOI 10.1016/0014-5793(87)80669-5; ROEDER RG, 1974, J BIOL CHEM, V249, P249; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; WATSON SP, 1988, BIOCHEM J, V249, P345, DOI 10.1042/bj2490345; ZAHRADKA P, 1988, EUR J BIOCHEM, V171, P37, DOI 10.1111/j.1432-1033.1988.tb13755.x; ZIERHUT W, 1989, CIRC RES, V65, P1417, DOI 10.1161/01.RES.65.5.1417	57	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					22003	22009						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939221				2022-12-25	WOS:A1991GP80400102
J	LOUNSBURY, KM; CASEY, PJ; BRASS, LF; MANNING, DR				LOUNSBURY, KM; CASEY, PJ; BRASS, LF; MANNING, DR			PHOSPHORYLATION OF GZ IN HUMAN PLATELETS - SELECTIVITY AND SITE OF MODIFICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; GTP-BINDING-PROTEIN; PERTUSSIS TOXIN; ALPHA-SUBUNIT; ADENYLYL CYCLASE; ADP-RIBOSYLATION; ESCHERICHIA-COLI; IDENTIFICATION; EXPRESSION; GI2	We have demonstrated previously that the G protein alpha-subunit G(z-alpha) (or G(x-alpha) in human platelets is subject to phosphorylation by agents that activate protein kinase C, including phorbol 12-myristate 13-acetate, thrombin, and the thromboxane A2 analog U46619. We examine here the site and selectivity of phosphorylation both in vitro using recombinant G protein alpha-subunits and in situ using permeabilized and intact platelets. Protein kinase C catalyzes the rapid and nearly stoichiometric phosphorylation of recombinant G(z-alpha) with the modification occurring preferentially for the GDP-bound form of the subunit. Under the same conditions, phosphorylation of recombinant G(i-alpha-1), G(i-alpha-2), G(i-alpha-3), G(s-alpha-s), G(s-alpha-L), and G(o-alpha-1) was minimal. Phosphorylation of both rG(z-alpha) and platelet G(z-alpha) occurs at a serine residue near the amino terminus. This conclusion is supported by phosphoamino acid analysis and the incorporation of radiolabel from [gamma-P-32]ATP into the amino-terminal CNBr peptide (residues 2-53 of the encoded protein). One of the antisera used in this study (6354, directed toward residues 24-33) recognizes only the nonphosphorylated form of G(z-alpha), providing strong evidence that Ser25 or Ser" is the site of phosphorylation. Results obtained with 6354 also suggest that phorbol ester-promoted phosphorylation of G(z-alpha) approaches 1 mol of phosphate per mol of subunit in permeabilized platelets.	UNIV PENN,SCH MED,DEPT PHARMACOL,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV TEXAS,SW MED CTR,DALLAS,TX 75230	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Casey, Patrick/0000-0002-7366-9309	NCI NIH HHS [CA39712] Funding Source: Medline; NHLBI NIH HHS [HL45181] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045181] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRASS LF, 1988, J BIOL CHEM, V263, P5348; BRASS LF, 1990, PROGR HEMOSTASIS THR, P127; BUSHFIELD M, 1990, BIOCHEM J, V268, P449, DOI 10.1042/bj2680449; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GAGNON AW, 1991, BLOOD, V78, P1247; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GUNDERSEN RE, 1990, SCIENCE, V248, P591, DOI 10.1126/science.2110382; HINTON DR, 1990, J NEUROSCI, V10, P2763; HOUSE C, 1987, J BIOL CHEM, V262, P772; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MATSUOKA M, 1990, J BIOL CHEM, V265, P13215; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; WILLIAMS AG, 1990, BLOOD, V76, P721	33	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					22051	22056						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939224				2022-12-25	WOS:A1991GP80400108
J	RICCI, G; DELBOCCIO, G; PENNELLI, A; LOBELLO, M; PETRUZZELLI, R; CACCURI, AM; BARRA, D; FEDERICI, G				RICCI, G; DELBOCCIO, G; PENNELLI, A; LOBELLO, M; PETRUZZELLI, R; CACCURI, AM; BARRA, D; FEDERICI, G			REDOX FORMS OF HUMAN PLACENTA GLUTATHIONE TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS PI; ENZYME; IDENTIFICATION; INACTIVATION; DISULFIDES; LIVER	Human placenta glutathione transferase (EC 2.5.1.18) pi-undergoes an oxidative inactivation which leads to the formation of an inactive enzymatic form which is homogeneous in several chromatographic and electrophoretic conditions. This process is pH dependent, and it occurs at appreciable rate in alkaline conditions and in the presence of metal ions. Dithiothreitol treatment completely restores the active form. -SH titration data and electrophoretic studies performed both on the oxidized and reduced forms indicate that one intrachain disulfide is formed, probably between the two faster reacting cysteinyl groups of each subunit. By the use of a specific fluorescent thiol reagent the disulfide forming cysteines have been identified as the 47th and 101st residues. The disulfide formation causes changes in the tertiary structure of this transferase as appears by CD, UV, and fluorometric analyses; evidences are provided that one or both tryptophanyl residues of each subunit together with a number of tyrosyl residues are exposed to a more hydrophilic environment in the oxidized form. Moreover, electrophoretic data indicate that the subunit of the oxidized enzyme has an apparent molecular mass lower than that of the reduced transferase, thereby confirming structural differences between these forms.	UNIV ROME TOR VERGATA,DEPT BIOL,ROME,ITALY; UNIV ROME LA SAPIENZA,DEPT BIOCHEM SCI,I-00185 ROME,ITALY	University of Rome Tor Vergata; Sapienza University Rome	RICCI, G (corresponding author), UNIV CHIETI G DANNUNZIO,INST BIOCHEM SCI,VIA DEI VESTINI 6,CHIETI,ITALY.		Barra, Donatella/D-1236-2011; CACCURI, ANNA MARIA/AFU-2643-2022	CACCURI, ANNA MARIA/0000-0002-3756-4163; Ricci, Giorgio/0000-0002-7108-2846				ADAMS PA, 1990, BIOCHEM PHARMACOL, V39, P1883, DOI 10.1016/0006-2952(90)90605-K; ANANTHANARAYANAN VS, 1969, BIOCHEMISTRY-US, V8, P3723, DOI 10.1021/bi00837a035; BERGSON G, 1958, ARK KEMI, V12, P233; BERGSON G, 1962, ARK KEMI, V18, P409; BEWELY TA, 1977, BIOCHEMISTRY-US, V16, P209; BEYCHOK S, 1966, SCIENCE, V154, P1288, DOI 10.1126/science.154.3754.1288; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CAPPEL RE, 1986, J BIOL CHEM, V261, P5385; CAPPEL RE, 1986, J BIOL CHEM, V261, P5378; CARDIN AD, 1982, BIOCHEMISTRY-US, V21, P4503, DOI 10.1021/bi00261a048; COWELL IJ, 1987, BIOCHEM J, V255, P79; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DANEHY JP, 1960, J AM CHEM SOC, V82, P2511, DOI 10.1021/ja01495a028; DIILIO C, 1986, BIOCHEM INT, V13, P263; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FROST A, 1961, KINETICS MECHANISM, P263; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; Habig W H, 1981, Methods Enzymol, V77, P398; HERSKOVITS TT, 1968, BIOCHEMISTRY-US, V7, P2523, DOI 10.1021/bi00847a012; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2020, P6375; KANO T, 1987, CANCER RES, V47, P5626; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LINDERBERG J, 1970, J AM CHEM SOC, V92, P2619, DOI 10.1021/ja00712a005; LOBELLO M, 1990, FEBS LETT, V263, P389, DOI 10.1016/0014-5793(90)81421-J; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; NAGARAJAN R, 1973, J AM CHEM SOC, V95, P7212, DOI 10.1021/ja00803a005; NISHIHARA T, 1991, BIOCHEM BIOPH RES CO, V174, P580, DOI 10.1016/0006-291X(91)91456-M; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; POLIDORO G, 1981, BIOCHEM MED METAB B, V25, P247, DOI 10.1016/0006-2944(81)90082-X; RICCI G, 1989, J BIOL CHEM, V264, P5462; SHAFFER J, 1988, J BIOL CHEM, V263, P17405; TAMAI K, 1990, BIOCHEM BIOPH RES CO, V167, P331, DOI 10.1016/0006-291X(90)91769-O; WALTERS DW, 1986, J BIOL CHEM, V261, P3135; WARHOLM M, 1983, BIOCHEMISTRY-US, V22, P3610, DOI 10.1021/bi00284a011; WOODY RW, 1973, TETRAHEDRON, V29, P1273, DOI 10.1016/S0040-4020(01)83144-6	40	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21409	21415						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939175				2022-12-25	WOS:A1991GP80400018
J	SANDHU, FA; SALIM, M; ZAIN, SB				SANDHU, FA; SALIM, M; ZAIN, SB			EXPRESSION OF THE HUMAN BETA-AMYLOID PROTEIN OF ALZHEIMERS-DISEASE SPECIFICALLY IN THE BRAINS OF TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR MESSENGER-RNA; INHIBITOR; CORTEX; DAMAGE; VIRUS; FORM	The human beta-amyloid protein is deposited in senile plaques and in the cerebrovasculature of people with Alzheimer's disease and Down's syndrome. The precise role of beta-amyloid in Alzheimer's disease pathology is presently unknown. To study the properties of beta-amyloid in vivo, we generated transgenic mice that harbor the gene for the carboxyl-terminal 100 amino acids of the human amyloid precursor protein, beginning with the beta-amyloid region, under control of the JC viral early region promoter. The mRNA is expressed exclusively in brain tissue. Further, we demonstrate increased levels of beta-amyloid immunoreactivity on fixed brain tissue. These animals will be useful as a model to study beta-amyloid deposition and its consequences.	UNIV ROCHESTER,SCH MED,CTR CANC,ROCHESTER,NY 14642	University of Rochester	SANDHU, FA (corresponding author), UNIV ROCHESTER,SCH MED,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30-CA11198] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIKHAN Z, 1988, ACTA NEUROPATHOL, V77, P82, DOI 10.1007/BF00688246; ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAYAN AD, 1971, BRAIN, V94, P31, DOI 10.1093/brain/94.1.31; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOEDERT M, 1987, EMBO J, V6, P3627, DOI 10.1002/j.1460-2075.1987.tb02694.x; GRILLO M, 1990, BIOTECHNIQUES, V9, P262; HANCOCK MB, 1984, J HISTOCHEM CYTOCHEM, V32, P311, DOI 10.1177/32.3.6198359; HOGAN B, 1986, MANIPULATING MOUSE E; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MAJOCHA RE, 1988, P NATL ACAD SCI USA, V85, P6182, DOI 10.1073/pnas.85.16.6182; Maniatis T., 1982, MOL CLONING; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROTH M, 1966, NATURE, V209, P109, DOI 10.1038/209109a0; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SELKOE DJ, 1987, SCIENCE, V235, P873, DOI 10.1126/science.3544219; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WATSON RE, 1986, PEPTIDES, V7, P155, DOI 10.1016/0196-9781(86)90076-8; WISNIEWSKI HM, 1973, PROGR NEUROPATHOLOGY, V2, P23; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YANKNER BA, 1990, P NATL ACAD SCI USA, V87, P9020, DOI 10.1073/pnas.87.22.9020; ZAIN SB, 1988, P NATL ACAD SCI USA, V85, P929, DOI 10.1073/pnas.85.3.929	33	57	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21331	21334						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939169				2022-12-25	WOS:A1991GP80400002
J	MCGOVERN, K; BECKWITH, J				MCGOVERN, K; BECKWITH, J			MEMBRANE INSERTION OF THE ESCHERICHIA-COLI MALF PROTEIN IN CELLS WITH IMPAIRED SECRETION MACHINERY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; CYTOPLASMIC MEMBRANE; PLASMA-MEMBRANE; EXPORT; SECA; GENE; TOPOLOGY; TRANSLOCATION; MUTANT; OPERON	The MalF protein is an integral membrane protein of Escherichia coli containing eight membrane-spanning stretches and a large periplasmic domain of approximately 180 amino acids. We have asked whether this protein is dependent for its membrane insertion on the bacterial secretion machinery specified by the sec genes. Using azide to inhibit the SecA protein and sec mutants to reduce the functioning of the machinery, we have studied the membrane assembly of MalF and beta-galactosidase and alkaline phosphatase fusions to MalF. In no case did we see an effect of reducing sec gene function on the insertion of MalF or fusion proteins. Selection for mutants that would cause internalization of a MalF-beta-galactosidase hybrid protein yielded no mutations in sec genes. Our results suggest that MalF can assemble in the membrane independently of the bacterial secretion machinery.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, 200 LONGWOOD AVE, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School					NIGMS NIH HHS [GM 38922] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038922, R37GM038922] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA Y, 1989, J BIOL CHEM, V264, P437; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; KUMAMOTO CA, 1988, J BIOL CHEM, V263, P11554; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1989, J BACTERIOL, V171, P4609, DOI 10.1128/jb.171.9.4609-4616.1989; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; Miller J. H., 1972, EXPT MOL GENETICS, P431; OLIVER DB, 1982, J BACTERIOL, V150, P686, DOI 10.1128/JB.150.2.686-691.1982; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SILHAVY TJ, 1979, MOL GEN GENET, V174, P249, DOI 10.1007/BF00267797; VONHEIJNE G, 1988, P NATL ACAD SCI USA, V85, P3363; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	30	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20870	20876						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939136				2022-12-25	WOS:A1991GN00100045
J	NANUS, DM; LYNCH, SA; RAO, PH; ANDERSON, SM; JHANWAR, SC; ALBINO, AP				NANUS, DM; LYNCH, SA; RAO, PH; ANDERSON, SM; JHANWAR, SC; ALBINO, AP			TRANSFORMATION OF HUMAN KIDNEY PROXIMAL TUBULE CELLS BY A SRC-CONTAINING RETROVIRUS	ONCOGENE			English	Article							HUMAN RENAL-CANCER; MOUSE MONOCLONAL-ANTIBODIES; MURINE LEUKEMIA VIRUSES; AVIAN-SARCOMA VIRUSES; SURFACE ANTIGENS; NEOPLASTIC TRANSFORMATION; CARCINOMA; INVITRO; GAP; PROTEINS	Analysis of the cell-surface antigenic phenotypes of normal and malignant renal cells demonstrates that almost-equal-to 90% of cultured normal human kidney cells and virtually all renal cell carcinomas (RCC) derive from the proximal tubule (PT) cell of the nephron. In the present study, the v-src oncogene was introduced into cultured normal human PT cells, and the effects of the v-src-encoded protein (pp60v-src) on the biologic and genetic phenotype of these cells were determined. V-src-containing PT cells underwent a series of phenotypic changes characteristic of renal cells in vivo. These included (i) alterations in morphology, (ii) an increase in proliferative capacity, (iii) loss of contact inhibition, (iv) immortalization and (v) tumorigenicity. Moreover, v-src-infected PT cells developed non-random clonal karyotypic abnormalities which are commonly observed in RCCs, including a deletion of chromosomal region 3p14-21, one of the most frequent deletions observed in human renal tumors. These results indicate that pp60v-src can initiate a complex process leading to the transformation of PT cells. This process includes the induction of genetic instability. Finally, these data provide experimental evidence corroborating cytogenetic and molecular data that a deletion of genes on chromosome 3p is a critical event in the transformation of the human renal cell.	MEM SLOAN KETTERING CANC CTR, MAMMALIAN CELL TRANSFORMAT LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, DIV SOLID TUMOR ONCOL, GENITOURINARY ONCOL SERV, NEW YORK, NY 10021 USA; CORNELL UNIV, MED CTR, COLL MED, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, SOLID TUMOR IMMUNOL LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT PATHOL, CYTOGENET SERV, NEW YORK, NY 10021 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R29CA045241] Funding Source: NIH RePORTER; NCI NIH HHS [CA09149, R29 CA45241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINO AP, 1986, J EXP MED, V164, P1710, DOI 10.1084/jem.164.5.1710; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSON SM, 1983, J VIROL, V46, P594, DOI 10.1128/JVI.46.2.594-605.1983; ANGLARD P, 1991, CANCER RES, V51, P1071; BANDER NH, 1987, J UROLOGY, V137, P603, DOI 10.1016/S0022-5347(17)44154-1; BANDER NH, 1985, J UROLOGY, V133, P502, DOI 10.1016/S0022-5347(17)49041-0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERGERHEIM U, 1989, CANCER RES, V49, P1390; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CARDO CC, 1987, AM J PATHOL, V126, P269; CARROLL PR, 1987, CANCER GENET CYTOGEN, V26, P253, DOI 10.1016/0165-4608(87)90059-8; CHATTOPADHYAY SK, 1981, J VIROL, V39, P777, DOI 10.1128/JVI.39.3.777-791.1981; COLLARD JG, 1987, CANCER RES, V47, P6666; EBERT T, 1990, CANCER RES, V50, P5531; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FINSTAD CL, 1985, P NATL ACAD SCI USA, V82, P2955, DOI 10.1073/pnas.82.9.2955; FRADET Y, 1984, P NATL ACAD SCI-BIOL, V81, P224, DOI 10.1073/pnas.81.1.224; GOLDEN A, 1988, ONCOGENE HDB, P149; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HARRIS CC, 1987, CANCER RES, V47, P1; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAWAI S, 1980, J VIROL, V34, P772, DOI 10.1128/JVI.34.3.772-776.1980; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MILES J, 1988, CANCER GENET CYTOGEN, V34, P135, DOI 10.1016/0165-4608(88)90180-X; NANUS DM, 1990, J UROLOGY, V143, P175, DOI 10.1016/S0022-5347(17)39905-6; NANUS DM, 1989, J EXP MED, V169, P953, DOI 10.1084/jem.169.3.953; OGAWA O, 1991, CANCER RES, V51, P949; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PINCUS T, 1975, VIROLOGY, V65, P333, DOI 10.1016/0042-6822(75)90039-2; PRESTI JC, 1991, CANCER RES, V51, P1544; RABOTTI G, 1987, J NATL CANCER I, V78, P817; RHIM JS, 1988, LEUKEMIA, V2, pS151; RHIM JS, 1989, ANTICANCER RES, V9, P1345; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RHIM JS, 1990, CANCER RES, V50, pS5653; RHIM JS, 1982, P SOC EXP BIOL MED, V170, P350; RITZ J, 1982, LANCET, V2, P60; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Sambrook J, 1989, MOL CLONING LABORATO; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; UEDA R, 1979, J EXP MED, V150, P564, DOI 10.1084/jem.150.3.564; UEDA R, 1981, P NATL ACAD SCI-BIOL, V78, P5122, DOI 10.1073/pnas.78.8.5122; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALTER TA, 1989, CANCER GENET CYTOGEN, V43, P15, DOI 10.1016/0165-4608(89)90123-4; YOSHIDA MA, 1986, CANCER RES, V46, P2139; Zbar B, 1989, Important Adv Oncol, P41; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	54	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					2105	2111						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945415				2022-12-25	WOS:A1991GX11900022
J	MUNN, MM; ALBERTS, BM				MUNN, MM; ALBERTS, BM			THE T4 DNA-POLYMERASE ACCESSORY PROTEINS FORM AN ATP-DEPENDENT COMPLEX ON A PRIMER-TEMPLATE JUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 LATE TRANSCRIPTION; REPLICATION PROTEINS; ESCHERICHIA-COLI; III HOLOENZYME; GENETIC-RECOMBINATION; GENE-45 PROTEIN; RNA-POLYMERASE; NUCLEIC-ACIDS; BINDING; SYSTEM	The DNA polymerase holoenzyme of bacteriophage T4 contains, besides the DNA polymerase itself (the gene 43 protein), a complex of the protein products of T4 genes 44 and 62 (a DNA-dependent ATPase) and of gene 45. Together, the 44/62 and 45 proteins form an ATP-dependent "sliding clamp" that holds a moving DNA polymerase molecule at the 3' terminus of a growing DNA chain. We have used a unique DNA fragment that forms a short hairpin helix with a single-stranded 5' tail (a "primer-template junction") to map the binding sites for these polymerase accessory proteins by DNA footprinting techniques. In the absence of the DNA polymerase, the accessory proteins protect from DNase I cleavage 19-20 nucleotides just behind the 3' end of the primer strand and 27-28 nucleotides on the complementary portion of the template strand. Detection of this DNA-protein complex requires the 44/62 and 45 proteins plus the nonhydrolyzable ATP analogue adenosine 5'-O-(thiotriphosphate). The complex is not detected in the presence of ATP. We suggest that ATP hydrolysis by the 44/62 protein normally activates the accessory proteins at a primer-template junction, permitting the DNA polymerase to bind and thus form the complete holoenzyme. However, when the polymerase is missing, as in these experiments, ATP hydrolysis is instead followed by a release (or loosening) of the accessory protein complex.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024020, R01GM024020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, V3, P241; ALBERTS BM, 1970, NATURE, V227, P1313, DOI 10.1038/2271313a0; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; BITTNER M, 1979, J BIOL CHEM, V254, P9565; BOBST AM, 1982, J BIOL CHEM, V257, P6184; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; COPPO A, 1975, J MOL BIOL, V96, P601, DOI 10.1016/0022-2836(75)90141-2; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FORMOSA T, 1985, THESIS U CALIFORNIA; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GILONI L, 1981, J BIOL CHEM, V256, P8608; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HOCKENSMITH JW, 1986, J BIOL CHEM, V261, P3512; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JONGENEEL CV, 1984, PROTEINS INVOLVED DN, P17; KAPPEN LS, 1978, BIOCHEMISTRY-US, V17, P729, DOI 10.1021/bi00597a027; KAPPEN LS, 1980, P NATL ACAD SCI-BIOL, V77, P1970, DOI 10.1073/pnas.77.4.1970; Kowalczykowski S.C., 1981, ENZYMES, V14, P373; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; Kozinski AW, 1983, BACTERIOPHAGE, V4, P111; KREUZER KN, 1985, P NATL ACAD SCI USA, V82, P3345, DOI 10.1073/pnas.82.10.3345; Laskowski M., 1971, HYDROLYSIS, V4, P289; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MACE DC, 1984, J MOL BIOL, V177, P279, DOI 10.1016/0022-2836(84)90457-1; MANIATIS T, 1982, MOL CLONING LABORATO, P122; Maxam A M, 1980, Methods Enzymol, V65, P499; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRIS CF, 1979, J BIOL CHEM, V254, P6797; MUNN M, 1986, THESIS U CALIFORNIA; MUNN MM, 1991, J BIOL CHEM, V266, P20034; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; PIPERNO JR, 1978, J BIOL CHEM, V253, P5180; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; RABUSSAY D, 1983, BACTERIOPHAGE T4, P167; RATNER D, 1974, J MOL BIOL, V88, P373, DOI 10.1016/0022-2836(74)90488-4; ROSS W, 1982, P NATL ACAD SCI-BIOL, V79, P7724, DOI 10.1073/pnas.79.24.7724; SELICK HE, 1987, UCLA S MOL CELLULAR, P183; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; UMEZAWA H, 1966, J ANTIBIOT, V19, P200; VANDYKE MM, 1984, SCIENCE, V225, P1122, DOI 10.1126/science.6089341; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P1764, DOI 10.1073/pnas.70.6.1764; WU R, 1975, J MOL BIOL, V96, P539, DOI 10.1016/0022-2836(75)90138-2	54	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20024	20033						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939066				2022-12-25	WOS:A1991GM03900028
J	ROBBI, M; BEAUFAY, H				ROBBI, M; BEAUFAY, H			THE COOH TERMINUS OF SEVERAL LIVER CARBOXYLESTERASES TARGETS THESE ENZYMES TO THE LUMEN OF THE ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; SITE-SPECIFIC MUTAGENESIS; RAT-LIVER; RETENTION SIGNAL; PHENOTYPIC SELECTION; DISULFIDE-ISOMERASE; MOLECULAR-CLONING; ESTERASE; IDENTIFICATION; SEQUENCE	To investigate the potential role of the COOH-terminal peptides in retaining a family of soluble carboxylesterases in the lumen of the endoplasmic reticulum, the pI 6.1 esterase cDNA has been cloned into the pKCR3 vector for transient expression in COS cells. The plasmid-encoded product appeared to be identical to the authentic enzyme: it was active on alpha-naphthyl acetate and behaved as a homotrimer of noncovalently bound 60-kDa subunits which contain a single, endo-beta-N-acetylglucosaminidase H-sensitive oligosaccharide chain. This enzyme was retained in the transgenic COS cells. In contrast, a mutated form ending in HVER-COOH was secreted, indicating that the natural terminus HVEL-COOH contains topogenic information, with the ultimate Leu residue as an essential part. Variants of pI 6.1 esterase ending in HIEL-COOH, or HTEL-COOH were retained in cells to the same extent as the wild-type protein. Therefore, the sequences HIEL and HTEL present at the COOH termini of several liver esterases (rabbit forms 1 and 2, human esterase, mouse egasyn, and rat pI 6.4 esterase) most likely have a function in their localization in the endoplasmic reticulum. Finally, an HDEL-COOH variant of pI 6.1 esterase was also normally retained, demonstrating that this signal can be correctly decoded by the sorting machinery of mammalian cells. Cell retention signals of the type HXEL-COOH appear to be common in higher eukaryotes and tolerate considerable variation at the antepenultimate X residue.	INT INST CELLULAR & MOLEC PATHOL,B-1200 BRUSSELS,BELGIUM		ROBBI, M (corresponding author), CATHOLIC UNIV LOUVAIN,CHIM PHYSIOL LAB,B-1200 BRUSSELS,BELGIUM.							ANDRES DA, 1990, J BIOL CHEM, V265, P5952; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; FLIEGEL L, 1990, J BIOL CHEM, V265, P15496; GABATHULER R, 1990, J CELL BIOL, V111, P1803, DOI 10.1083/jcb.111.5.1803; HAUGEJORDEN SM, 1991, J BIOL CHEM, V66, P6015; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORZA G, 1988, J BIOL CHEM, V263, P3486; KUMAR N, 1988, P NATL ACAD SCI USA, V85, P6277, DOI 10.1073/pnas.85.17.6277; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEAVITT R, 1977, J BIOL CHEM, V252, P9018; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LJUNGQUIST A, 1971, EUR J BIOCHEM, V23, P303, DOI 10.1111/j.1432-1033.1971.tb01622.x; LONG RM, 1991, LIFE SCI, V48, P43; Maniatis T., 1982, MOL CLONING; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MENTLEIN R, 1987, BIOCHIM BIOPHYS ACTA, V913, P27, DOI 10.1016/0167-4838(87)90228-7; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOVAK EK, 1991, J BIOL CHEM, V266, P6377; OZOLS J, 1989, J BIOL CHEM, V264, P12533; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; ROBBI M, 1986, EUR J BIOCHEM, V158, P187, DOI 10.1111/j.1432-1033.1986.tb09737.x; ROBBI M, 1987, BIOCHEM J, V248, P545, DOI 10.1042/bj2480545; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROBBI M, 1983, EUR J BIOCHEM, V137, P293, DOI 10.1111/j.1432-1033.1983.tb07828.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; YOSHIMORI T, 1990, J BIOL CHEM, V265, P15984; ZAGOURAS P, 1989, J CELL BIOL, V109, P2633, DOI 10.1083/jcb.109.6.2633	37	86	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20498	20503						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939102				2022-12-25	WOS:A1991GM03900093
J	KALB, E; ENGEL, J				KALB, E; ENGEL, J			BINDING AND CALCIUM-INDUCED AGGREGATION OF LAMININ ONTO LIPID BILAYERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL-REFLECTION FLUORESCENCE; SUPPORTED PHOSPHOLIPID-BILAYERS; BASEMENT-MEMBRANES; SULFATED GLYCOLIPIDS; CELL-ADHESION; PROTEINS; POLYMERIZATION; MICROSCOPY; DOMAIN; ARM	Direct binding of laminin in the form of its complex with nidogen to planar lipid bilayers was demonstrated with total internal reflection fluorescence microscopy. Binding occurred equally well to zwitterionic (phosphatidylcholine) and negatively charged (phosphatidylglycerol) lipids and was enhanced by sulfatides but only at nonphysiological molar ratios higher than 30 mol %. Strong interactions with lipid bilayers were also observed for bovine serum albumin. This explains a strong inhibition of laminin binding by this protein. However, binding of laminin to sulfatide-rich bilayers was not completely inhibited. Observable by the microscopic technique was the formation of laminin clusters on the surface of the bilayer which occurred concomitantly with binding. Both processes were strongly enhanced by the presence of calcium. These results show that calcium-induced laminin self-assembly is enhanced at lipid surfaces.	UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND	University of Basel								ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; AXELROD D, 1984, ANNU REV BIOPHYS BIO, V13, P247, DOI 10.1146/annurev.bb.13.060184.001335; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BRUCH M, 1989, EUR J BIOCHEM, V185, P271, DOI 10.1111/j.1432-1033.1989.tb15112.x; DAVOUST J, 1982, EMBO J, V1, P1233, DOI 10.1002/j.1460-2075.1982.tb00018.x; GINSBURG V, 1988, BIOCHIMIE, V70, P1651, DOI 10.1016/0300-9084(88)90300-8; HOLT GD, 1989, J BIOL CHEM, V264, P12138; KALB E, 1990, BIOCHEMISTRY-US, V29, P1607, DOI 10.1021/bi00458a036; MARTINEZHERNAND.A, 1983, LAB INVEST, V48, P657; MCKEOWNLONGO PJ, 1989, FIBRONECTIN, P163; PAULSSON M, 1988, J BIOL CHEM, V263, P5425; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; ROBERTS DD, 1985, P NATL ACAD SCI USA, V82, P1306, DOI 10.1073/pnas.82.5.1306; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SMITH BA, 1978, P NATL ACAD SCI USA, V75, P2759, DOI 10.1073/pnas.75.6.2759; TAMM LK, 1985, BIOPHYS J, V47, P105, DOI 10.1016/S0006-3495(85)83882-0; TAMM LK, 1988, BIOCHEMISTRY-US, V27, P1450, DOI 10.1021/bi00405a009; TARABOLETTI G, 1990, J BIOL CHEM, V265, P12253; TIMPL R, 1987, METHOD ENZYMOL, V145, P363; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; WEISENHORN AL, 1990, BIOPHYS J, V58, P1251, DOI 10.1016/S0006-3495(90)82465-6; WRIGHT AK, 1975, BIOPHYS J, V15, P137, DOI 10.1016/S0006-3495(75)85797-3; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	27	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19047	19052						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918022				2022-12-25	WOS:A1991GJ47200098
J	MARTI, T; ROSSELET, SJ; OTTO, H; HEYN, MP; KHORANA, HG				MARTI, T; ROSSELET, SJ; OTTO, H; HEYN, MP; KHORANA, HG			THE RETINYLIDENE SCHIFF-BASE COUNTERION IN BACTERIORHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-CHARGE DENSITY; PROTON PUMP MECHANISM; PURPLE MEMBRANE; VIBRATIONAL SPECTROSCOPY; ACID SUBSTITUTIONS; ABSORPTION-SPECTRA; SENSORY RHODOPSIN; ESCHERICHIA-COLI; BACTERIO-OPSIN; LOW PH	Previous studies of bacteriorhodopsin have indicated interactions between Asp-85, Asp-212, Arg-82, and the retinylidene Schiff base. The counterion environment of the Schiff base has now been further investigated by using single and double mutants of the above amino acids. Chromophore regeneration from bacterioopsin proceeds to a normal extent in the presence of a single aspartate or glutamate residue at position 85 or 212, whereas replacement of both charged amino acids in the mutant Asp-85 --> Asn/Asp-212 --> Asn abolishes the binding of retinal. This indicates that a carboxylate group at either residue 85 or 212 is required as counterion for formation and for stabilization of the protonated Schiff base. Measurements of the pK-alpha of the Schiff base reveal reductions of > 3.5 units for neutral single mutants of Asp-85 but only decreases of < 1.2 units for corresponding substitutions of Asp-212, relative to the wild type. Substitutions of Asp-85 show large red shifts in the absorption spectrum that are partially reversible upon addition of anions, whereas mutants of Asp-212 display minor red shifts or blue shifts. We conclude, therefore, that Asp-85 is the retinylidene Schiff base counterion in wild-type bacteriorhodopsin. In the mutant Asp-85 --> Asn/Asp-212 --> Asn formation of a protonated Schiff base chromophore is restored in the presence of salts. The spectral properties of the double mutant are similar to those of the acid-purple form of bacteriorhodopsin. Upon addition of salts the folded structure of wild-type and mutant proteins can be stabilized at low pH in lipid/detergent micelles. The data indicate that exogenous anions serve as surrogate counterions to the protonated Schiff base, when the intrinsic counterions have been neutralized by mutation or by protonation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; FREE UNIV BERLIN, BIOPHYS GRP, W-1000 BERLIN 33, GERMANY	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Free University of Berlin					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM028289, R01GM028289] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11479] Funding Source: Medline; NIGMS NIH HHS [GM 28289] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLATZ PE, 1972, BIOCHEMISTRY-US, V11, P848, DOI 10.1021/bi00755a026; BRAIMAN MS, 1988, BIOCHEMISTRY-US, V27, P8516, DOI 10.1021/bi00423a002; BRAIMAN MS, 1991, P NATL ACAD SCI USA, V88, P2388, DOI 10.1073/pnas.88.6.2388; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; BUTT HJ, 1989, EMBO J, V8, P1657, DOI 10.1002/j.1460-2075.1989.tb03556.x; DEGROOT HJM, 1990, BIOCHEMISTRY-US, V29, P6873, DOI 10.1021/bi00481a017; DEGROOT HJM, 1989, BIOCHEMISTRY-US, V28, P3346, DOI 10.1021/bi00434a033; DRUCKMANN S, 1982, BIOCHEMISTRY-US, V21, P4953, DOI 10.1021/bi00263a019; DUNACH M, 1990, P NATL ACAD SCI USA, V87, P9873, DOI 10.1073/pnas.87.24.9873; EHRENBERG B, 1989, FEBS LETT, V250, P179, DOI 10.1016/0014-5793(89)80715-X; FISCHER U, 1979, BIOPHYS J, V28, P211, DOI 10.1016/S0006-3495(79)85172-3; FODOR SPA, 1989, J BIOL CHEM, V264, P18280; GERWERT K, 1990, P NATL ACAD SCI USA, V87, P9774, DOI 10.1073/pnas.87.24.9774; HACKETT NR, 1987, J BIOL CHEM, V262, P9277; HAUSS T, 1990, BIOCHEMISTRY-US, V29, P4904, DOI 10.1021/bi00472a022; HONIG B, 1979, P NATL ACAD SCI USA, V76, P2503, DOI 10.1073/pnas.76.6.2503; IWASA T, 1980, BIOPHYS STRUCT MECH, V6, P253, DOI 10.1007/BF00538227; JONAS R, 1990, PHOTOCHEM PHOTOBIOL, V52, P1163, DOI 10.1111/j.1751-1097.1990.tb08455.x; KESZTHELYI L, 1990, BIOCHIM BIOPHYS ACTA, V1018, P260, DOI 10.1016/0005-2728(90)90262-3; KOUTALOS Y, 1990, BIOPHYS J, V58, P493, DOI 10.1016/S0006-3495(90)82394-8; KOUYAMA T, 1988, BIOCHEMISTRY-US, V27, P5855, DOI 10.1021/bi00416a006; LIN SW, 1991, PHOTOCHEM PHOTOBIOL, V53, P341, DOI 10.1111/j.1751-1097.1991.tb03638.x; LIN SW, 1989, BIOPHYS J, V56, P653, DOI 10.1016/S0006-3495(89)82712-2; LONDON E, 1982, J BIOL CHEM, V257, P7003; LOZIER RH, 1975, BIOPHYS J, V15, P955, DOI 10.1016/S0006-3495(75)85875-9; LUGTENBURG J, 1986, J AM CHEM SOC, V108, P3104, DOI 10.1021/ja00271a050; MARTI T, 1991, J BIOL CHEM, V266, P6919; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; MOGI T, 1989, J BIOL CHEM, V264, P14197; MOWERY PC, 1979, BIOCHEMISTRY-US, V18, P4100, DOI 10.1021/bi00586a007; NASSAL M, 1987, J BIOL CHEM, V262, P9264; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; OTTO H, 1990, P NATL ACAD SCI USA, V87, P1018, DOI 10.1073/pnas.87.3.1018; RENTHAL R, 1990, BIOCHIM BIOPHYS ACTA, V1016, P378, DOI 10.1016/0005-2728(90)90172-Z; ROTHSCHILD KJ, 1990, J BIOL CHEM, V265, P16985; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERRER P, 1989, BIOCHEMISTRY-US, V28, P829, DOI 10.1021/bi00428a063; SCHOBERT B, 1986, J BIOL CHEM, V261, P2690; SHEVES M, 1986, P NATL ACAD SCI USA, V83, P3262, DOI 10.1073/pnas.83.10.3262; SPUDICH JL, 1986, BIOPHYS J, V49, P479, DOI 10.1016/S0006-3495(86)83657-8; STERN LJ, 1989, J BIOL CHEM, V264, P14202; STOECKENIUS W, 1982, ANNU REV BIOCHEM, V51, P587, DOI 10.1146/annurev.bi.51.070182.003103; SUBRAMANIAM S, 1991, P NATL ACAD SCI USA, V88, P2583, DOI 10.1073/pnas.88.6.2583; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; VARO G, 1989, BIOPHYS J, V56, P1143, DOI 10.1016/S0006-3495(89)82761-4	47	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18674	18683						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917991				2022-12-25	WOS:A1991GJ47200044
J	MULLER, M; ISHIKAWA, T; BERGER, U; KLUNEMANN, C; LUCKA, L; SCHREYER, A; KANNICHT, C; REUTTER, W; KURZ, G; KEPPLER, D				MULLER, M; ISHIKAWA, T; BERGER, U; KLUNEMANN, C; LUCKA, L; SCHREYER, A; KANNICHT, C; REUTTER, W; KURZ, G; KEPPLER, D			ATP-DEPENDENT TRANSPORT OF TAUROCHOLATE ACROSS THE HEPATOCYTE CANALICULAR MEMBRANE MEDIATED BY A 110-KDA GLYCOPROTEIN BINDING ATP AND BILE-SALT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE GENE-PRODUCT; PLASMA-MEMBRANE; RAT-LIVER; MULTIDRUG-RESISTANCE; CONJUGATED HYPERBILIRUBINEMIA; P-GLYCOPROTEIN; MUTANT RATS; ECTO-ATPASE; FUNCTIONAL POLARITY; INSULIN-RECEPTOR	Direct photoaffinity labeling of liver plasma membrane subfractions enriched in sinusoidal and canalicular membranes using [S-35]adenosine 5'-O-(thiotriphosphate) ([S-35]ATP-gamma-S) allows the identification of ATP-binding proteins in these domains. Comparative photoaffinity labeling with [S-35]ATP-gamma-S and with the photolabile bile salt derivative (7,7-azo-3-alpha,12-alpha-dihydroxy-5-beta-[3-beta-H3]-cholan-24-oyl)-2'-aminoethanesulfonate followed by immunoprecipitation with a monoclonal antibody (Be 9.2) revealed the identity of the ATP-binding and the bile salt-binding canalicular membrane glycoprotein with the apparent M(r) of 110,000 (gp110). The isoelectric point of this glycoprotein was 3.7. Transport of bile salt was studied in vesicles enriched in canalicular and sinusoidal liver membranes. Incubation of canalicular membrane vesicles with [H-3] taurocholate in the presence of ATP resulted in an uptake of the bile salt into the vesicles which was sensitive to vanadate. ATP-dependent taurocholate transport was also observed in membrane vesicles from mutant rats deficient in the ATP-dependent transport of cysteinyl leukotrienes and related amphiphilic anions. Substrates of the P-glycoprotein (gp 170), such as verapamil and doxorubicin, did not interfere with the ATP-dependent transport of taurocholate. Reconstitution of purified gp110 into liposomes resulted in an ATP-dependent uptake of [H-3]taurocholate. These results demonstrate that gp110 functions as carrier in the ATP-dependent transport of bile salts from the hepatocyte into bile. This export carrier is distinct from hitherto characterized ATP-dependent transport systems.	FREE UNIV BERLIN,INST MOLEK BIOL,W-1000 BERLIN,GERMANY; UNIV FREIBURG,INST ORGAN CHEM & BIOCHEM,W-7800 FREIBURG,GERMANY	Free University of Berlin; University of Freiburg	MULLER, M (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,DIV TUMOR BIOCHEM,W-6900 HEIDELBERG,GERMANY.		Muller, Michael/B-5795-2008; Keppler, Dietrich/A-5528-2013	Muller, Michael/0000-0002-5930-9905; Keppler, Dietrich/0000-0003-2964-2333				ARIAS IM, 1990, HEPATOLOGY, V12, P159, DOI 10.1002/hep.1840120125; AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BARTLES JR, 1990, CANCER RES, V50, P669; BAYLEY H, 1983, LABORATORY TECHNIQUE, V12; BECKER A, 1985, European Journal of Cell Biology, V39, P417; BECKER A, 1986, BIOL CHEM H-S, V367, P681, DOI 10.1515/bchm3.1986.367.2.681; BECKER A, 1989, HISTOCHEMISTRY, V93, P55, DOI 10.1007/BF00266847; BECKER AJ, 1989, THESIS FREE U BERLIN; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P4; BUCHSEL R, 1980, FEBS LETT, V113, P95, DOI 10.1016/0014-5793(80)80503-5; CHU FF, 1985, J BIOL CHEM, V260, P3097; COLEMAN R, 1987, BIOCHEM J, V244, P249, DOI 10.1042/bj2440249; COOK J, 1983, J CELL BIOL, V97, P1823, DOI 10.1083/jcb.97.6.1823; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ERIKSSON S, 1983, J BIOL CHEM, V258, P5674; EVANS WH, 1980, BIOCHIM BIOPHYS ACTA, V604, P27, DOI 10.1016/0005-2736(80)90584-2; FALK E, 1989, EUR J BIOCHEM, V186, P741, DOI 10.1111/j.1432-1033.1989.tb15268.x; FRICKER G, 1987, BIOL CHEM H-S, V368, P1143, DOI 10.1515/bchm3.1987.368.2.1143; FRIMMER M, 1988, BIOCHIM BIOPHYS ACTA, V947, P75, DOI 10.1016/0304-4157(88)90020-2; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GRIFFITHS JC, 1987, FEBS LETT, V213, P34, DOI 10.1016/0014-5793(87)81460-6; HIXSON DC, 1983, CANCER RES, V43, P3874; HUANG KS, 1981, J BIOL CHEM, V256, P3802; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; HUBER M, 1987, HEPATOLOGY, V7, P224, DOI 10.1002/hep.1840070204; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; INOUE M, 1984, J CLIN INVEST, V73, P659, DOI 10.1172/JCI111257; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; JANSEN PLM, 1988, SEMIN LIVER DIS, V8, P168, DOI 10.1055/s-2008-1040537; JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408; JANSEN PLM, 1985, HEPATOLOGY, V5, P954; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KLAASSEN CD, 1984, PHARMACOL REV, V36, P1; KOBAYASHI K, 1988, FEBS LETT, V240, P55, DOI 10.1016/0014-5793(88)80339-9; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; KRAMER W, 1983, J LIPID RES, V24, P910; KURZ G, 1989, HEPATIC TRANSPORT OR, P267; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SH, 1989, J BIOL CHEM, V264, P14408; LIN SH, 1985, J BIOL CHEM, V260, P976; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P562, DOI 10.1016/0006-291X(90)90845-E; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MEIER PJ, 1984, J BIOL CHEM, V259, P614; MEIER PJ, 1987, BIOCHEM J, V242, P465, DOI 10.1042/bj2420465; MEIER PJ, 1988, SEMIN LIVER DIS, V8, P293, DOI 10.1055/s-2008-1040551; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MEIJER DKF, 1990, J PHARMACOKINET BIOP, V18, P35, DOI 10.1007/BF01063621; MODAK MJ, 1982, J BIOL CHEM, V257, P5105; NATH JP, 1985, BIOCHEMISTRY-US, V24, P1555, DOI 10.1021/bi00327a040; OCKLIND C, 1983, J CELL BIOL, V96, P1168, DOI 10.1083/jcb.96.4.1168; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; RUETZ S, 1987, J BIOL CHEM, V262, P11324; RUETZ S, 1988, P NATL ACAD SCI USA, V85, P6147, DOI 10.1073/pnas.85.16.6147; SCHUSTER DI, 1989, PHOTOCHEM PHOTOBIOL, V49, P785, DOI 10.1111/j.1751-1097.1989.tb05577.x; SIMION FA, 1984, J BIOL CHEM, V259, P814; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; VONDIPPE P, 1990, J BIOL CHEM, V265, P14812; YUE VT, 1977, BIOCHEMISTRY-US, V16, P4678, DOI 10.1021/bi00640a023	63	193	194	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18920	18926						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918007				2022-12-25	WOS:A1991GJ47200079
J	SHAPIRO, RA; FARRELL, L; SRINIVASAN, M; CURTHOYS, NP				SHAPIRO, RA; FARRELL, L; SRINIVASAN, M; CURTHOYS, NP			ISOLATION, CHARACTERIZATION, AND INVITRO EXPRESSION OF A CDNA THAT ENCODES THE KIDNEY ISOENZYME OF THE MITOCHONDRIAL GLUTAMINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-DEPENDENT GLUTAMINASE; 3' UNTRANSLATED REGION; MESSENGER-RNA; MOLECULAR-CLONING; ACUTE ACIDOSIS; RAT-KIDNEY; ARTERIOVENOUS DIFFERENCES; AMINO-ACIDS; PROTEIN; SEQUENCE	A cDNA that encodes the kidney isoenzyme of the mitochondrial glutaminase (pGA) was generated by recombination of two cDNAs that were isolated from a random-primed rat brain lambda-gt11 library. pGA encodes 674 amino acids which includes an N-terminal sequence of 16 residues that should form an amphipathic helix, typical of a mitochondrial targeting sequence. Residues 73-90 correspond to the N-terminal sequence of the more abundant 65-kDa glutaminase peptide. In vitro transcription and translation of pGA yields a 72-kDa peptide that is immunoprecipitated with glutaminase-specific antibodies. Incubation of the glutaminase precursor with isolated mitochondria yields the 68-and 65-kDa peptides that are characteristic of the mature glutaminase. Thus, the two mature glutaminase peptides are synthesized from a single precursor. The complete 3' nontranslated region of the GA mRNA was characterized by sequencing a GA cDNA (pGA12) that was isolated from an oligo(dT)-primed rat kidney lambda-gt10 library. This segment contains numerous AU-rich regions, four potential stem-loop structures, and a 48 base pair repeat of CA dinucleotides. Such domains may contribute to the increased stability of the GA mRNA that occurs in response to metabolic acidosis.	COLORADO STATE UNIV,DEPT BIOCHEM,FT COLLINS,CO 80523	Colorado State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037124] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37124] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANNER C, 1988, MOL BRAIN RES, V3, P247, DOI 10.1016/0169-328X(88)90047-2; Battey, 1986, BASIC METHODS MOL BI; BEALE EG, 1985, J BIOL CHEM, V260, P748; Brosnan JT, 1988, PH HOMEOSTASIS MECHA, P281; BURCH HB, 1978, AM J PHYSIOL, V235, pF246, DOI 10.1152/ajprenal.1978.235.3.F246; BURNHAM CE, 1987, P NATL ACAD SCI USA, V84, P5605, DOI 10.1073/pnas.84.16.5605; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CURTHOYS NP, 1973, J BIOL CHEM, V248, P162; CURTHOYS NP, 1974, J BIOL CHEM, V249, P3261; DIECKMANN CL, 1984, J BIOL CHEM, V259, P4722; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GODFREY S, 1977, J BIOL CHEM, V252, P1927; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HASER WG, 1985, BIOCHEM J, V229, P399, DOI 10.1042/bj2290399; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HUGHEY RP, 1980, AM J PHYSIOL, V238, pF199, DOI 10.1152/ajprenal.1980.238.3.F199; HWANG JJ, 1991, J BIOL CHEM, V266, P9392; HWANG JJ, 1991, IN PRESS BIOCHEMISTR, V30; JAGUS R, 1987, METHOD ENZYMOL, V152, P267; KAISER S, 1991, J BIOL CHEM, V266, P9397; KOVACEVIC Z, 1983, PHYSIOL REV, V63, P547, DOI 10.1152/physrev.1983.63.2.547; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY M, 1980, BIOCHEM J, V190, P771, DOI 10.1042/bj1900771; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; Maniatis T., 1982, MOL CLONING; OHTA S, 1986, J BIOCHEM-TOKYO, V99, P135, DOI 10.1093/oxfordjournals.jbchem.a135452; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PERERA SY, 1990, J BIOL CHEM, V265, P17764; PERERA SY, 1991, BIOCHEM J, V273, P265, DOI 10.1042/bj2730265; REEVES R, 1987, P NATL ACAD SCI USA, V84, P6531, DOI 10.1073/pnas.84.18.6531; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROCK H, 1980, BIOCHEM J, V188, P557, DOI 10.1042/bj1880557; SHAPIRO RA, 1985, ARCH BIOCHEM BIOPHYS, V243, P1, DOI 10.1016/0003-9861(85)90767-2; SHAPIRO RA, 1987, BIOCHEM J, V242, P743, DOI 10.1042/bj2420743; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMMER JP, 1990, J BIOL CHEM, V265, P10395; SMITH EM, 1990, J BIOL CHEM, V265, P10631; SQUIRES EJ, 1976, BIOCHEM J, V160, P125, DOI 10.1042/bj1600125; TANNEN RL, 1979, CLIN SCI, V56, P353, DOI 10.1042/cs0560353; TANNEN RL, 1984, KIDNEY INT, V25, P1, DOI 10.1038/ki.1984.1; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WRIGHT PA, 1990, AM J PHYSIOL, V259, pF961, DOI 10.1152/ajprenal.1990.259.6.F961; WRIGHT PA, 1990, AM J PHYSIOL, V259, pF53, DOI 10.1152/ajprenal.1990.259.1.F53; ZHOU GC, 1990, J BIOL CHEM, V265, P21152	47	100	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18792	18796						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918000				2022-12-25	WOS:A1991GJ47200060
J	WITKOWSKI, A; NAGGERT, J; WESSA, B; SMITH, S				WITKOWSKI, A; NAGGERT, J; WESSA, B; SMITH, S			A CATALYTIC ROLE FOR HISTIDINE-237 IN RAT MAMMARY-GLAND THIOESTERASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHETASE; THIO ESTER HYDROLASE; MOLECULAR-CLONING; ACTIVE-SITE; UROPYGIAL GLAND; SYNTHASE; RESIDUE; LIVER; CDNA; SPECIFICITY	The involvement of a histidyl residue in the catalytic mechanism of thioesterase II, a serine active-site enzyme that catalyzes the chain terminating reaction in de novo fatty acid synthesis, has been inferred from studies with the inhibitor diethyl pyrocarbonate. Its likely location has been predicted by identification of conserved residues in related thioesterases and ultimately confirmed by site-directed mutagenesis. Diethyl pyrocarbonate inactivated the enzyme with a second-order rate constant of 49 M-1 S-1 at pH 6, 10-degrees-C. Data analysis indicated that although several residues reacted with the reagent, modification of a single residue was responsible for the inactivation. Removal of a single ethoxycarbonyl moiety by treatment with neutral hydroxylamine completely restored enzyme activity. Prior ethoxycarbonylation of the histidyl residue blocked the ability of the active-site serine to react with phenylmethanesulfonyl fluoride. Comparison of the amino acid sequences of five structurally related proteins indicated that only 1 histidine has been completely conserved. Replacement of this residue in rat thioesterase II (His-237) with arginine and leucine by mutagenesis reduced the catalytic activity by 2-3 orders of magnitude. The activity of the mutant thioesterases, unlike that of the wild-type enzyme, was relatively insensitive to inhibition by diethyl pyrocarbonate and phenylmethylsulfonyl fluoride. These studies provide strong evidence that His-237 is involved directly in catalysis and suggest that its role is to increase the nucleophilic character of the active-site Ser-101 by acting as a proton acceptor thus facilitating acylation of the seryl residue. The mechanism appears to share certain common features with the charge-relay system characteristic of other esterases.	CHILDRENS HOSP OAKLAND,RES INST,747 52ND ST,OAKLAND,CA 94609	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland				Witkowski, Andrzej/0000-0002-0442-4586	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16073] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BACHOVCHIN WW, 1986, BIOCHEMISTRY-US, V25, P7751, DOI 10.1021/bi00371a070; BLANKE SR, 1990, J BIOL CHEM, V265, P12454; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; CHENG KC, 1989, J BIOL CHEM, V264, P19666; DERENOBALES M, 1980, ARCH BIOCHEM BIOPHYS, V205, P464, DOI 10.1016/0003-9861(80)90129-0; GARRISON CK, 1975, BIOCHEM BIOPH RES CO, V67, P1251, DOI 10.1016/0006-291X(75)90807-4; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; HOLBROOK JJ, 1973, BIOCHEM J, V131, P729, DOI 10.1042/bj1310729; HOLZER KP, 1989, P NATL ACAD SCI USA, V86, P4387, DOI 10.1073/pnas.86.12.4387; HORIIKE K, 1979, J THEOR BIOL, V79, P403, DOI 10.1016/0022-5193(79)90355-2; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KASTURI R, 1988, J BIOL CHEM, V263, P7778; KNUDSEN J, 1976, BIOCHEM J, V160, P683, DOI 10.1042/bj1600683; KORZA G, 1988, J BIOL CHEM, V263, P3486; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LIBERTINI L, 1976, FED PROC, V35, P1069; LIBERTINI LJ, 1979, ARCH BIOCHEM BIOPHYS, V192, P47, DOI 10.1016/0003-9861(79)90070-5; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; LIN CY, 1978, J BIOL CHEM, V253, P1954; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MUHLRAD A., 1967, ACTA BIOCHIM BIOPHYS ACAD SCI HUNG, V2, P19; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; NAGGERT J, 1988, J BIOL CHEM, V263, P1146; NAGGERT J, 1987, BIOCHEM J, V243, P597, DOI 10.1042/bj2430597; OVADI J, 1967, Acta Biochimica et Biophysica Academiae Scientiarum Hungaricae, V2, P455; PAULAUSKIS JD, 1989, BIOCHEM BIOPH RES CO, V158, P690, DOI 10.1016/0006-291X(89)92776-9; POULOSE AJ, 1985, J BIOL CHEM, V260, P5953; RANDHAWA ZI, 1987, BIOCHEMISTRY-US, V26, P1365, DOI 10.1021/bi00379a024; RANDHAWA ZI, 1987, EUR J BIOCHEM, V162, P577, DOI 10.1111/j.1432-1033.1987.tb10678.x; ROGERS L, 1982, J BIOL CHEM, V257, P880; SAFFORD R, 1987, BIOCHEMISTRY-US, V26, P1358, DOI 10.1021/bi00379a023; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; Smith S, 1981, Methods Enzymol, V71 Pt C, P181, DOI 10.1016/0076-6879(81)71026-7; Smith S, 1981, Methods Enzymol, V71 Pt C, P188, DOI 10.1016/0076-6879(81)71027-9; SMITH S, 1979, ARCH BIOCHEM BIOPHYS, V196, P88, DOI 10.1016/0003-9861(79)90554-X; SMITH S, 1985, BIOCHEM SOC T, V14, P583; TSOU C, 1962, SCI SINICA, V11, P1535; WITKOWSKA HE, 1990, J BIOL CHEM, V265, P5662; WITKOWSKI A, 1985, ARCH BIOCHEM BIOPHYS, V243, P420, DOI 10.1016/0003-9861(85)90518-1	42	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18514	18519						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917973				2022-12-25	WOS:A1991GJ47200019
J	BENNETT, WP; HOLLSTEIN, MC; HE, A; ZHU, SM; RESAU, JH; TRUMP, BF; METCALF, RA; WELSH, JA; MIDGLEY, C; LANE, DP; HARRIS, CC				BENNETT, WP; HOLLSTEIN, MC; HE, A; ZHU, SM; RESAU, JH; TRUMP, BF; METCALF, RA; WELSH, JA; MIDGLEY, C; LANE, DP; HARRIS, CC			ARCHIVAL ANALYSIS OF P53 GENETIC AND PROTEIN ALTERATIONS IN CHINESE ESOPHAGEAL CANCER	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; TRANSFORMED-CELLS; BREAST-CANCER; SV40-TRANSFORMED CELLS; MATE DRINKING; LUNG-CANCER; WILD-TYPE; KI-RAS; MUTATIONS; EXPRESSION	A strategy and methods for archival analysis of genetic and protein alterations in the p53 tumor-suppressor gene are presented. The tumor series includes 43 paraffin-embedded esophageal carcinomas from two high-incidence regions in the People's Republic of China. More than half contained elevated p53 protein levels which were detected by a high-titer polyclonal antiserum and a sensitive immunohistochemical method. To estimate the frequency of underlying mutations, DNA was isolated from conventional paraffin sections, amplified by the polymerase chain reaction, and examined by dideoxy termination sequencing. Analysis of exons 5-8 in a subset of 10 tumors revealed mis-sense point mutations in 4 out of 5 immunostain-positive tumors and a mutation encoding a stop codon in 1 of 5 immunostain-negative tumors. In this report of archival material, we conclude that detectable levels of p53 protein correlate closely with the occurrence of mis-sense mutations. Furthermore, these methods render large repositories of paraffin-embedded tumor and non-tumor tissues accesible to analysis. Immunohistochemical screening for elevated protein levels followed by sequence analysis represents an efficient strategy for the evaluation of the p53 mutational spectrum.	NCI, HUMAN CARCINOGENESIS LAB, BLDG 37, ROOM 2C05, BETHESDA, MD 20892 USA; CHINA MED UNIV, CANC RES INST, SHENYANG, PEOPLES R CHINA; SUN YAT-SAN UNIV MED SCI, GUANGZHOU, PEOPLES R CHINA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA; UNIV DUNDEE, INST MED SCI, CANC RES CAMPAIGN LAB, DUNDEE DD1 4HN, SCOTLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); China Medical University; Sun Yat Sen University; University System of Maryland; University of Maryland Baltimore; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARRA S, 1990, INT J CANCER, V46, P1017, DOI 10.1002/ijc.2910460612; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BONHAM K, 1989, MOL CARCINOGEN, V2, P34, DOI 10.1002/mc.2940020106; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHANGCLAUDE JC, 1990, CANCER RES, V50, P2268; CHIBA I, 1990, ONCOGENE, V5, P1603; DESTEFANI E, 1990, CANCER RES, V50, P426; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVI F, 1990, INT J CANCER, V45, P852, DOI 10.1002/ijc.2910450511; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOEB LA, 1989, CANCER RES, V49, P5489; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCMAHON G, 1990, P NATL ACAD SCI USA, V87, P1104, DOI 10.1073/pnas.87.3.1104; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OROURKE RW, 1990, ONCOGENE, V5, P1829; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VICTORA CG, 1990, CANCER RES, V50, P7112; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; [No title captured]	54	210	211	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1779	1784						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923503				2022-12-25	WOS:A1991GX11800009
J	SHAY, JW; BABA, TO; ZHAN, QM; KAMIMURA, N; CUTHBERT, JA				SHAY, JW; BABA, TO; ZHAN, QM; KAMIMURA, N; CUTHBERT, JA			HELATG CELLS HAVE MITOCHONDRIAL-DNA INSERTED INTO THE C-MYC ONCOGENE	ONCOGENE			English	Article							HEPATOMA-CELLS; SEQUENCES; EXPRESSION; MUTATIONS; GENES; CARCINOMA; NUCLEUS; RNAS	To determine whether mitochondrial DNA (mtDNA) fragments found within the nucleus are transcribed, we have differentially screened a HeLaTG cDNA library. A clone that hybridized to mtDNA as well as to c-myc was identified. Analysis of the cDNA disclosed that it contained a mtDNA sequence, encoding cytochrome-c oxidase subunit III (coxIII) that was contiguous with and 5' of a c-myc sequence corresponding to part of exon 2 and exon 3. Hybridization of ScaI-digested DNA with a 1.05 kb c-myc probe revealed a unique band in HeLaTG cells, as well as a band common to HeLaTG and 13 other cell types examined. Solution hybridization of HeLaTG RNA with a radiolabeled, single-stranded cDNA probe containing the coxIII-c-myc junction demonstrated a nuclease-resistant band that matched the full length of the junctional cDNA probe. A smaller band that equaled the size of the c-myc portion alone was also detected. Only the smaller band coinciding with the c-myc sequences was protected from nuclease digestion by RNA from other cells. When a radiolabeled probe synthesized in the opposite orientation was used, nuclease-resistant bands equal in length to the coxIII portion of the probe were detected after hybridization with RNA from all cells. These results indicate that insertion of mtDNA fragments into nuclear genes occurs and that subsequent transcription of a 'chimaeric' or 'fusion' mRNA containing both mitochondrial and nuclear sequences can ensue.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	SHAY, JW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235, USA.		Shay, Jerry W/F-7878-2011		NCI NIH HHS [CA40065, CA50195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050195, R01CA040065] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; ATTARDI G, 1987, BIOESSAYS, V5, P34; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORRAL M, 1989, BIOCHEM BIOPH RES CO, V162, P258, DOI 10.1016/0006-291X(89)91990-6; CORRAL M, 1989, NUCLEIC ACIDS RES, V17, P5191, DOI 10.1093/nar/17.13.5191; CUTHBERT JA, 1989, J BIOL CHEM, V264, P1298; ERISMAN MD, 1988, ONCOGENE HDB, P341; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GELLISSEN G, 1987, ANN NY ACAD SCI, V503, P391, DOI 10.1111/j.1749-6632.1987.tb40625.x; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAYASHI JI, 1986, CANCER RES, V46, P4001; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERRDT BG, 1990, CANCER RES, V50, P1596; KAMIMURA N, 1989, J MOL BIOL, V210, P703, DOI 10.1016/0022-2836(89)90103-4; KOCH I, 1989, VIROLOGY, V170, P591, DOI 10.1016/0042-6822(89)90454-6; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; SHAY JW, 1990, MECHANISMS DIFFERENT, V1, P135; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THORSNESS PE, 1990, NATURE, V346, P376, DOI 10.1038/346376a0; TOURMENTE S, 1990, CELL DIFFER DEV, V31, P137, DOI 10.1016/0922-3371(90)90017-Q; Tzagoloff A, 1982, MITOCHONDRIA	30	37	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1869	1874						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923509				2022-12-25	WOS:A1991GX11800020
J	ZHAO, YH; BAKER, H; WALAAS, SI; SUDOL, M				ZHAO, YH; BAKER, H; WALAAS, SI; SUDOL, M			LOCALIZATION OF P62C-YES PROTEIN IN MAMMALIAN NEURAL TISSUES	ONCOGENE			English	Article							AVIAN-SARCOMA VIRUS; CEREBELLAR MUTANT MOUSE; SRC GENE-PRODUCT; VIRAL YES GENE; C-SRC; RETINAL DEGENERATION; TRANSFORMING GENE; MESSENGER-RNA; CELLULAR-YES; RAT-BRAIN	Expression of the c-yes proto-oncogene in mammalian brain, retina and adrenal gland was studied by immunohistochemistry and immune assays with affinity-purified anti-yes IgG. Immunohistochemical staining with anti-yes IgG showed that in the central nervous system p62c-yes is highly expressed in mitral cells of the olfactory bulb, Purkinje cells of the cerebellum, hippocampal neurons and granule neurons of the dentate gyrus and ependymal cells lining central nervous system ventricles. Less intense labeling by anti-yes IgG was observed in most neuronal cell bodies in the brain. In addition, we observed intense c-yes immunoreactivity in the ganglion cells of the retina, the inner segment layer of rods and cones and medullary cells of the adrenal gland. Mapping p62c-yes expression to specific areas of mammalian neural tissues points to attractive experimental systems which could be used to investigate the function of the proto-oncogene product in neural processes.	ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021; UNIV OSLO,NEUROCHEM LAB,N-0317 OSLO 3,NORWAY; CORNELL UNIV,COLL MED,BURKE MED INST,MOLEC NEUROBIOL LAB,WHITE PLAINS,NY 10605	Rockefeller University; University of Oslo; Cornell University					NCI NIH HHS [CA 45757] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045757] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1987, FUNCTIONAL HISTOLOGY; BAKER H, 1986, J COMP NEUROL, V252, P206, DOI 10.1002/cne.902520206; BLANKS JC, 1982, J COMP NEUROL, V212, P231, DOI 10.1002/cne.902120303; BLOOM W, 1975, TEXT BOOK HISTOLOGY; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; GESSLER M, 1984, BIOSCIENCE REP, V4, P757, DOI 10.1007/BF01128817; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; GREEN MC, 1981, GENETIC VARIANTS STR, P276; Ham A.W., 1979, HISTOLOGY, P866; HANLEY MR, 1988, NEURON, V1, P175, DOI 10.1016/0896-6273(88)90137-7; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KATZ LC, 1984, NATURE, V310, P498, DOI 10.1038/310498a0; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAVAIL MM, 1982, J COMP NEUROL, V212, P217, DOI 10.1002/cne.902120302; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Mitro A., 1981, MORPHOLOGY RAT BRAIN; MULLEN RJ, 1977, NATURE, V270, P245, DOI 10.1038/270245a0; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; ROSS CA, 1988, P NATL ACAD SCI USA, V85, P9831, DOI 10.1073/pnas.85.24.9831; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; Steward O, 1989, PRINCIPLES CELLULAR; SUDOL M, 1989, J NEUROSCI RES, V24, P1, DOI 10.1002/jnr.490240103; SUDOL M, 1988, BRAIN RES REV, V13, P391, DOI 10.1016/0165-0173(88)90014-8; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SUKEGAWA J, 1990, ONCOGENE, V5, P611; YOSHIDA MC, 1985, JPN J CANCER RES, V76, P556; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHENG XF, 1989, ONCOGENE, V4, P99	46	55	55	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1725	1733						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923498				2022-12-25	WOS:A1991GX11800002
J	GILL, S; STRATTON, MR; PATTERSON, H; SPURR, NK; FISHER, C; GUSTERSON, BA; COOPER, CS				GILL, S; STRATTON, MR; PATTERSON, H; SPURR, NK; FISHER, C; GUSTERSON, BA; COOPER, CS			DETECTION OF TRANSFORMING GENES BY TRANSFECTION OF DNA FROM PRIMARY SOFT-TISSUE TUMORS	ONCOGENE			English	Note							SARCOMA CELL-LINES; STRUCTURAL ALTERATIONS; HUMAN-TUMORS; ONCOGENE; IDENTIFICATION; SEQUENCES; RAS	A series of adult soft-tissue tumours were screened for the presence of activated oncogenes by transfecting tumour DNA into NIH3T3 mouse fibroblasts. In these studies an activated K-ras gene that contained a mutation at the second position of codon 12 (GGT --> GAT) was found in a leiomyosarcoma. In addition, following transfection of DNA from a liposarcoma, we identified an activated gene that failed to hybridize to probes prepared from 10 known human oncogenes (K-ras, H-ras, N-ras, ret, met, trk, mas, dbl, raf and hst) that have previously been detected in DNA transfection experiments. BamHI-BamHI fragments of this activated gene of 3.5 and 8.5 kb were cloned from NIH3T3 secondary transfectants using a probe that detects the human alu family of highly repetitive DNA sequences. Repeat-free subclones of these BamHI fragments were used to map this gene to human chromosome 19 (p13.2-q13.3). Our studies also demonstrate that a subclone from one of the BamHI fragments detects a 3.0 kb transcript in primary and secondary transfectants.	IMPERIAL CANC RES FUND,POTTERS BAR EN6 3LD,HERTS,ENGLAND; ROYAL MARSDEN HOSP,DEPT HISTOPATHOL,LONDON SW3 6JJ,ENGLAND; INST CANC RES,CELL BIOL & EXPTL PATHOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	GILL, S (corresponding author), INST CANC RES,MOLEC CARCINOGENESIS SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		gusterson, barry a/D-3752-2009					BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1984, CANCER RES, V44, P1; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COOPER CS, 1991, CARCINOGENESIS, V12, P155, DOI 10.1093/carcin/12.2.155; COOPER CS, 1989, CHEM CARCINOGENESIS, V2, P319; Enzinger RM., 2011, SOFT TISSUE TUMORS, P1178; EVA A, 1987, ONCOGENE, V1, P355; FUKUI M, 1985, P NATL ACAD SCI USA, V82, P5954, DOI 10.1073/pnas.82.17.5954; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HALL A, 1989, CHEM CARCINOGENESIS, V2, P271; MARSHALL CJ, 1982, NATURE, V299, P171, DOI 10.1038/299171a0; MARTINZANCA D, 1986, NATURE, V328, P527; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; RUBIN CM, 1980, NATURE, V284, P372, DOI 10.1038/284372a0; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; STRATTON MR, 1989, CANCER RES, V49, P6324; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	23	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1651	1656						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923531				2022-12-25	WOS:A1991GX27400021
J	HALEVY, O; RODEL, J; PELED, A; OREN, M				HALEVY, O; RODEL, J; PELED, A; OREN, M			FREQUENT P53 MUTATIONS IN CHEMICALLY-INDUCED MURINE FIBROSARCOMA	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; WILD-TYPE P53; TRANSFORMED-CELLS; MUTANT P53; GENE-EXPRESSION; SARCOMA-CELLS; FRIEND-VIRUS; LUNG-CANCER; COS CELLS; ONCOGENE	Patterns of p53 expression were investigated in chemically induced fibrosarcoma tumors and cell lines. Most, if not all, cell lines were found to carry alterations at the protein level, reflected in the overproduction of greatly stabilized p53 proteins. In many cases, this was accompanied by formation of complexes with hsc70. Hence, all of these lines may be expressing one sort or another of mutant p53. The mutant nature of the p53 gene was directly verified, in a number of cases, by PCR-amplified cDNA cloning. In one line, no p53 protein was made at all; this turned out to be because of a mutation in a splice donor site, resulting in the production of an aberrant mRNA. In all other cases, mRNAs carrying mis-sense mutations were present, and were sometimes expressed along with wt p53 mRNA. When tested in an in vitro transformation assay, all cloned mutants possessed a discrete oncogenic activity, while having lost the ability to interfere with oncogene-mediated transformation. The system described here could potentially be very helpful in elucidating the significance of p53 mutations.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,POB 26,IL-76100 REHOVOT,ISRAEL; HEBREW UNIV JERUSALEM,FAC AGR,DEPT ANIM SCI,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Hebrew University of Jerusalem					NCI NIH HHS [R01 CA 40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BENDAVID Y, 1987, J VIROL, V61, P2771; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOW V, 1985, NATURE, V314, P633; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELIYAHU D, 1990, ONCOGENES CANCER RES, P125; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOTI A, 1990, BRIT J HAEMATOL, V76, P143, DOI 10.1111/j.1365-2141.1990.tb07849.x; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; IGGO R, 1990, LANCET, V335, P651; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; MALTZMAN W, 1981, VIROLOGY, V112, P145, DOI 10.1016/0042-6822(81)90620-6; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PHILLIPS DH, 1979, CHEM CARCINOGENS DNA, V2; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIHSAUS E, 1990, ONCOGENE, V5, P137; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROVINSKI B, 1988, ONCOGENE, V2, P445; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUSSI T, 1987, ONCOGENE, V1, P71; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	57	56	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1593	1600						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923526				2022-12-25	WOS:A1991GX27400014
J	OHSAKO, S; DEGUCHI, T				OHSAKO, S; DEGUCHI, T			CLONING AND EXPRESSION OF CDNAS FOR POLYMORPHIC AND MONOMORPHIC ARYLAMINE N-ACETYLTRANSFERASES FROM HUMAN LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									TOKYO METROPOLITAN INST NEUROSCI,DEPT MOLEC NEUROBIOL,2-6 MUSASHIDAI,FUCHU,TOKYO 183,JAPAN	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science								AGARWAL DP, 1986, EXPERIENTIA, V42, P1148, DOI 10.1007/BF01941289; ANDRES HH, 1985, ANAL BIOCHEM, V145, P367, DOI 10.1016/0003-2697(85)90376-8; ANDRES HH, 1987, MOL PHARMACOL, V31, P446; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEGUCHI T, 1988, J BIOL CHEM, V263, P7528; EVANS DAP, 1965, ANN NY ACAD SCI, V123, P178; EVANS DAP, 1960, BRIT MED J, V2, P485, DOI 10.1136/bmj.2.5197.485; GLOWINSKI IB, 1978, MOL PHARMACOL, V14, P940; GRANT DM, 1989, FEBS LETT, V244, P203, DOI 10.1016/0014-5793(89)81193-7; GRANT DM, 1989, NUCLEIC ACIDS RES, V17, P3978, DOI 10.1093/nar/17.10.3978; ISIDA I, 1987, MOL BRAIN RES, V2, P185; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; Marston F. A. O., 1987, DNA CLONING, P59; OHSAKO S, 1988, J BIOL CHEM, V263, P7534; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAFFORD J, 1983, NATURE, V306, P77, DOI 10.1038/306077a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRINIDAD A, 1989, DRUG METAB DISPOS, V17, P238; TUNG AS, 1976, J IMMUNOL, V116, P676; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; WEBER WW, 1984, FED PROC, V43, P2332; WEBER WW, 1985, PHARMACOL REV, V37, P25	26	255	261	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1990	265	8					4630	4634						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CT101	1968463				2022-12-25	WOS:A1990CT10100071
J	RIDER, ED; PINKERTON, KE; JOBE, AH				RIDER, ED; PINKERTON, KE; JOBE, AH			CHARACTERIZATION OF RABBIT LUNG LYSOSOMES AND THEIR ROLE IN SURFACTANT DIPALMITOYLPHOSPHATIDYLCHOLINE CATABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; NATURAL SURFACTANT; LAMELLAR BODIES; II CELLS; PHOSPHATIDYLCHOLINE; CENTRIFUGATION; REUTILIZATION; SPECIFICITY; DEGRADATION; PNEUMOCYTES	Although alveolar surfactant is rapidly catabolized in adult rabbit lungs, the pathways have not been characterized. Pathways of surfactant secretion and recycling involve lamellar bodies and multivesicular bodies, organelles shown to be related to lysosomes by cytochemistry and autoradiography. Since lysosomes are central to intracellular catabolic events, it is possible that lysosomes are involved in intrapulmonary surfactant catabolism. Lysosomes relatively free of contaminating organelles (as determined morphologically and by marker enzymes for mitochondria, endoplasmic reticulum, peroxisomes, and plasma membranes) were obtained from post-lavage lung homogenates of 1-kg rabbits by differential centrifugation in buffered sucrose and gradient separation in percoll (density, 1.075-1.165). The role of lung lysosomes in catabolism of dipalmitoylphosphatidylcholine (DPC) was then studied in rabbits killed 4, 12, and 24 h following intratracheal injection of [H-3]DPC and [C-14] dihexadecyl phosphatidylcholine (DPC-ether). While equal amounts of label were in the lamellar body containing fractions at 4 h, nearly 6-fold more DPC-ether label than DPC label was recovered in the lysosomal fractions. By 24 h, there was 15-fold more DPC-ether in the lysosomes. This is the first report of successful isolation of lysosomes relatively free of other organelles from rabbit lungs. The tracer studies indicate DPC and DPC-ether follow similar intracellular processing after alveolar uptake. The subsequent accumulation of the ether analog in the lysosomal fractions supports a role for these organelles in surfactant DPC catabolism.	UNIV CALIF DAVIS,SCH VET MED,DEPT ANAT,DAVIS,CA 95616	University of California System; University of California Davis	RIDER, ED (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT PEDIAT,TORRANCE,CA 90509, USA.				NICHD NIH HHS [HD-93301, HD-11932] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011932, R37HD011932] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BAUM H, 1959, CLIN CHIM ACTA, V4, P453, DOI 10.1016/0009-8981(59)90119-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDER A, 1987, J CLIN INVEST, V79, P1133, DOI 10.1172/JCI112929; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHEVALIER G, 1972, ANAT RECORD, V174, P289, DOI 10.1002/ar.1091740303; DOBROTA M, 1980, ANAL BIOCHEM, V103, P97; FISHER AB, 1987, AM J PHYSIOL, V253, P792; HINTON RH, 1970, EUR J BIOCHEM, V12, P349, DOI 10.1111/j.1432-1033.1970.tb00857.x; HOOK GER, 1982, J BIOL CHEM, V257, P9211; IKEGAMI M, 1985, BIOCHIM BIOPHYS ACTA, V835, P352, DOI 10.1016/0005-2760(85)90291-7; JACOBS H, 1984, BIOCHIM BIOPHYS ACTA, V793, P300, DOI 10.1016/0005-2760(84)90333-3; JACOBS H, 1982, J BIOL CHEM, V257, P1805; JOBE A, 1981, J CLIN INVEST, V67, P370, DOI 10.1172/JCI110044; JOBE A, 1988, SEMIN PERINATOL, V12, P231; KALINA M, 1990, J HISTOCHEM CYTOCHEM, V38, P483, DOI 10.1177/38.4.2156921; KING RJ, 1972, AM J PHYSIOL, V223, P715, DOI 10.1152/ajplegacy.1972.223.3.715; KUCERA GL, 1988, J BIOL CHEM, V263, P1920; MORRE DJ, 1971, METHOD ENZYMOL, V22, P130; PATEL KM, 1979, LIPIDS, V14, P596, DOI 10.1007/BF02533539; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; PERTOFT H, 1978, BIOCHEM J, V174, P309, DOI 10.1042/bj1740309; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; PETTENAZZO A, 1988, J APPL PHYSIOL, V64, P120, DOI 10.1152/jappl.1988.64.1.120; RIDER ED, 1990, J APPL PHYSIOL, V69, P1856, DOI 10.1152/jappl.1990.69.5.1856; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; SYMONS LJ, 1986, ANAL BIOCHEM, V164, P382; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WILCOX RW, 1987, LIPIDS, V22, P800, DOI 10.1007/BF02535534; WILLIAMS MC, 1984, P NATL ACAD SCI-BIOL, V81, P6383, DOI 10.1073/pnas.81.20.6383; WILLIAMS MC, 1987, AM REV RESPIR DIS, V135, P744; WOLFF DA, 1972, BIOCHIM BIOPHYS ACTA, V286, P197, DOI 10.1016/0304-4165(72)90106-7; WRIGHT JR, 1987, AM REV RESPIR DIS, V135, P426; YOUNG SL, 1981, J APPL PHYSIOL, V51, P248, DOI 10.1152/jappl.1981.51.2.248	36	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22522	22528						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939269				2022-12-25	WOS:A1991GR56400073
J	AHMED, SA; RUVINOV, SB; KAYASTHA, AM; MILES, EW				AHMED, SA; RUVINOV, SB; KAYASTHA, AM; MILES, EW			MECHANISM OF MUTUAL ACTIVATION OF THE TRYPTOPHAN SYNTHASE-ALPHA AND BETA-SUBUNITS - ANALYSIS OF THE REACTION SPECIFICITY AND SUBSTRATE-INDUCED INACTIVATION OF ACTIVE-SITE AND TUNNEL MUTANTS OF THE BETA-SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE O-SULFATE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; TRIOSEPHOSPHATE ISOMERASE; PYRIDOXAL 5'-PHOSPHATE; SUBSTITUTED ALANINES; ABSORPTION-SPECTRA; SCHIFF-BASES; ENZYME; COMPLEX	The origin of reaction and substrate specificity and the control of activity by protein-protein interaction are investigated using the tryptophan synthase alpha-2-beta-2 complex from Salmonella typhimurium. We have compared some spectroscopic and kinetic properties of the wild type beta-subunit and five mutant forms of the beta-subunit that have altered catalytic properties. These mutant enzymes, which were engineered by site-directed mutagenesis, have single amino acid replacements in either the active site or in the wall of a tunnel that extends from the active site of the a subunit to the active site of the beta-subunit in the alpha-2-beta-2 complex. We find that the mutant alpha-2-beta-2 complexes have altered reaction and substrate specificity in beta-elimination and beta-replacement reactions with L-serine and with beta-chloro-L-alanine. Moreover, the mutant enzymes, unlike the wild type alpha-2-beta-2 complex, undergo irreversible substrate-induced inactivation. The mechanism of inactivation appears to be analogous to that first demonstrated by Metzler's group for inhibition of two other pyridoxal phosphate enzymes. Alkaline treatment of the inactivated enzyme yields apoenzyme and a previously described pyridoxal phosphate derivative. We demonstrate for the first time that enzymatic activity can be recovered by addition of pyridoxal phosphate following alkaline treatment. We conclude that the wild type and mutant alpha-2-beta-2 complexes differ in the way they process the amino acrylate intermediate. We suggest that the wild type beta-subunit undergoes a conformational change upon association with the alpha-subunit that alters the reaction specificity and that the mutant beta-subunits do not undergo the same conformational change upon subunit association.	NIDDKD, BIOCHEM PHARMACOL LAB, BLDG 8, RM 2A09, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Kayastha, Arvind M./0000-0002-5090-7159				AHMED SA, 1986, BIOCHEMISTRY-US, V25, P4233, DOI 10.1021/bi00363a010; AHMED SA, 1991, FASEB J, V5, pA1149; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; ATOR MA, 1990, ENZYMES, V19, P213; BADET B, 1984, BIOCHEMISTRY-US, V23, P5188, DOI 10.1021/bi00317a016; BHATTACHARJEE MK, 1990, J BIOL CHEM, V265, P6664; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; BRAUNSTEIN AE, 1984, ADV ENZYMOL RAMB, V56, P1; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; Davis L, 1972, ENZYMES, P33; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; FAEDER EJ, 1970, BIOCHEMISTRY-US, V9, P4043, DOI 10.1021/bi00823a003; FAEDER EJ, 1971, BIOCHEMISTRY-US, V10, P1041; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KALLEN RG, 1985, TRANSAMINASES, P37; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KAYASTHA AM, 1991, J BIOL CHEM, V266, P7618; KAYASTHA AM, 1991, INDIAN J BIOCHEM BIO, V28, P352; KAYASTHA AM, 1991, ANAL BIOCHEM, V193, P200, DOI 10.1016/0003-2697(91)90009-I; KAYASTHA AM, 1991, 8TH P INT S VIT B6 C, P265; KAYASTHA AM, 1990, FASEB J, V4, pA2118; KIRSCHNER K, 1975, EUR J BIOCHEM, V60, P513, DOI 10.1111/j.1432-1033.1975.tb21030.x; KUMAGAI H, 1971, BIOCHEM BIOPH RES CO, V44, P1271, DOI 10.1016/S0006-291X(71)80223-1; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V133, P531, DOI 10.1111/j.1432-1033.1983.tb07496.x; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LIKOS JJ, 1982, BIOCHEMISTRY-US, V21, P4377, DOI 10.1021/bi00261a029; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; METZLER CM, 1988, BIOCHEMISTRY-US, V27, P4923, DOI 10.1021/bi00413a050; METZLER CM, 1980, J AM CHEM SOC, V102, P6075, DOI 10.1021/ja00539a017; METZLER CM, 1987, ANAL BIOCHEM, V166, P313, DOI 10.1016/0003-2697(87)90580-X; METZLER CM, 1991, J BIOL CHEM, V266, P9374; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1975, BIOCHEM BIOPH RES CO, V64, P248, DOI 10.1016/0006-291X(75)90245-4; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1974, J BIOL CHEM, V249, P2852; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1968, BIOCHEMISTRY-US, V7, P2742, DOI 10.1021/bi00848a008; MILES EW, 1975, BIOCHEM BIOPH RES CO, V66, P94, DOI 10.1016/S0006-291X(75)80299-3; MILES EW, 1991, 8TH P INT S VIT B6 C, P249; MORINO Y, 1967, J BIOL CHEM, V242, P2800; MORINO Y, 1967, J BIOL CHEM, V242, P2793; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; NAGATA S, 1989, J BIOL CHEM, V264, P6288; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; ROBITAILLE PM, 1989, J AM CHEM SOC, V111, P3034, DOI 10.1021/ja00190a043; ROISE D, 1984, BIOCHEMISTRY-US, V23, P5195, DOI 10.1021/bi00317a017; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P3557, DOI 10.1021/bi00583a019; SILVERMAN RB, 1988, BIOCHEM BIOPH RES CO, V150, P942, DOI 10.1016/0006-291X(88)90720-6; UENO H, 1982, BIOCHEMISTRY-US, V21, P4387, DOI 10.1021/bi00261a030; WIESINGER H, 1979, BIOCHEMISTRY-US, V18, P1979, DOI 10.1021/bi00577a020; WILHELM P, 1982, EUR J BIOCHEM, V129, P51, DOI 10.1111/j.1432-1033.1982.tb07019.x; Yanofsky C., 1972, ENZYMES, P1, DOI [10.1016/s1874-6047(08)60445-x, DOI 10.1016/S1874-6047(08)60445-X]	59	48	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21548	21557						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939184				2022-12-25	WOS:A1991GP80400038
J	LANGE, Y; ECHEVARRIA, F; STECK, TL				LANGE, Y; ECHEVARRIA, F; STECK, TL			MOVEMENT OF ZYMOSTEROL, A PRECURSOR OF CHOLESTEROL, AMONG 3 MEMBRANES IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-FIBROBLASTS; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; RAT-LIVER; CELL; HETEROGENEITY; BIOSYNTHESIS; LOCALIZATION; TRANSPORT; OXIDASE	Where examined, cholesterol is synthesized in the endoplasmic reticulum; however, its precursor, zymosterol, is found mostly in the plasma membrane. The novel implication of these disparate findings is that zymosterol circulates within the cell. In tracing its movements, we have now established the following: (a) in human fibroblasts, zymosterol is converted to cholesterol solely in the rough ER. (b) Little or no zymosterol or cholesterol accumulates in the rough ER in vivo. (c) Newly synthesized zymosterol moves to the plasma membrane without a detectable lag and with a half-time of 9 min, about twice as fast as cholesterol. (d) The pool of radiolabeled zymosterol in the plasma membrane turns over rapidly, faster than does intracellular cholesterol. Thus, plasma membrane zymosterol is not stagnant. (e) [H-3]Zymosterol pulsed into intact cells is initially found in the plasma membrane. It is rapidly internalized and is then converted to [H-3] cholesterol. Half of the [H-3]cholesterol produced returns to the plasma membrane within 30 min of the initial [H-3]zymosterol pulse. (f) Nascent zymosterol accumulates in a buoyant sterol-rich intracellular membrane before it reaches the plasma membrane. This membrane also acquires nascent cholesterol, exogenous [H-3]zymosterol pulsed into intact cells, and [H-3]cholesterol synthesized from the exogenous [H-3] zymosterol. These results suggest that at least one sterol moves rapidly and in both directions among the rough endoplasmic reticulum, a sterol-rich intracellular membrane bearing nascent cholesterol, and the plasma membrane.	RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT BIOCHEM,CHICAGO,IL 60612; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637	Rush University; University of Chicago	LANGE, Y (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PATHOL,CHICAGO,IL 60612, USA.		Lange, Yvonne/A-7794-2009		NHLBI NIH HHS [HL 32466, HL 28448] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028448, R01HL032466, R55HL028448] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOESZEBATTAGLIA K, 1989, J BIOL CHEM, V264, P8151; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; FREEMAN DA, 1987, J BIOL CHEM, V262, P13061; FUKUSHIMA H, 1981, J BIOL CHEM, V256, P4822; GREEN SA, 1990, J BIOL CHEM, V265, P21269; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; LANGE Y, 1988, J BIOL CHEM, V263, P9366; LANGE Y, 1987, J BIOL CHEM, V262, P4433; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1988, ENDOCRINOLOGY, V123, P81, DOI 10.1210/endo-123-1-81; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LANGEY, 1991, J LIPID RES, V32, P329; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; REINHART MP, 1987, J BIOL CHEM, V262, P9649; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; STECK TL, 1988, J BIOL CHEM, V263, P13023; TABAS I, 1988, J BIOL CHEM, V263, P1266; URBANI L, 1990, J BIOL CHEM, V265, P1919; WIBO M, 1981, J CELL BIOL, V89, P456, DOI 10.1083/jcb.89.3.456; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WIRTZ KWA, 1990, EXPERIENTIA, V46, P592, DOI 10.1007/BF01939698; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5	25	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21439	21443						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939176				2022-12-25	WOS:A1991GP80400023
J	OKAZAKI, T; ZAJAC, JD; IGARASHI, T; OGATA, E; KRONENBERG, HM				OKAZAKI, T; ZAJAC, JD; IGARASHI, T; OGATA, E; KRONENBERG, HM			NEGATIVE REGULATORY ELEMENTS IN THE HUMAN PARATHYROID-HORMONE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; EUKARYOTIC PROMOTERS; 5'-FLANKING REGION; GLOBIN GENE; EXPRESSION; SILENCER; RAT; BINDING; CELLS; SEQUENCE	We have identified and characterized a pair of negative regulatory elements far upstream of the transcription start site of the human parathyroid hormone (hPTH) gene. Transfection of various types of cultured cells with a fusion plasmid containing 4.7 kilobase pairs of the 5'-flanking portion of the hPTH gene linked to the chloramphenicol acetyltransferase (CAT)-coding sequence generated only 10% of the CAT activity of a plasmid containing 684 base pairs of the 5'-flanking region of the hPTH gene. Deletion analyses reveal that there are at least two separate upstream DNA elements in the hPTH gene responsible for the negative regulation. We find that these cultured cells possess nuclear factors which specifically bind to several short DNA sequences within these elements and that these sequences can suppress transcription of the hPTH gene.	MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	OKAZAKI, T (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,3-28-6 MEJIRODAI,BUNKYO KU,TOKYO 112,JAPAN.		Zajac, Jeffrey/ABC-3767-2021	Zajac, Jeffrey/0000-0003-3933-5708	NIDDK NIH HHS [DK11794] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BERG PE, 1989, NUCLEIC ACIDS RES, V17, P8833, DOI 10.1093/nar/17.21.8833; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; IGARASHI T, 1986, MOL CELL BIOL, V6, P1830, DOI 10.1128/MCB.6.5.1830; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LARSEN PR, 1986, P NATL ACAD SCI USA, V83, P8283, DOI 10.1073/pnas.83.21.8283; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maxam A M, 1980, Methods Enzymol, V65, P499; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUGLIA L, 1986, P NATL ACAD SCI USA, V83, P7653, DOI 10.1073/pnas.83.20.7653; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; NEMETH EF, 1986, J BIOL CHEM, V261, P2668; OKAZAKI T, 1988, J BIOL CHEM, V263, P2203; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; PIETTE J, 1986, NUCLEIC ACIDS RES, V14, P9595, DOI 10.1093/nar/14.24.9595; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; SHOBACK DM, 1984, P NATL ACAD SCI-BIOL, V81, P3113, DOI 10.1073/pnas.81.10.3113; STRUHL K, 1989, CURRENT PROTOCOLS MO; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; YAMAMOTO M, 1989, J CLIN INVEST, V83, P1053, DOI 10.1172/JCI113946	31	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21903	21910						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939213				2022-12-25	WOS:A1991GP80400087
J	BELLELLI, A; AGRO, AF; FLORIS, G; BRUNORI, M				BELLELLI, A; AGRO, AF; FLORIS, G; BRUNORI, M			ON THE MECHANISM AND RATE OF SUBSTRATE OXIDATION BY AMINE OXIDASE FROM LENTIL SEEDLINGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA BENZYLAMINE OXIDASE; BINDING; COPPER	The kinetics of reaction between lentil seedlings amine oxidase and two amine substrates, namely putrescine and dimethylaminomethylbenzylamine, have been studied by rapid mixing with diode array detection. In this way several wavelengths can be monitored at once allowing the simultaneous measurement of enzyme bleaching and formation of a yellow radical intermediate. The two substrates are oxidized at rates that differ by one order of magnitude in favor of putrescine. Of the individual five rate constants measured and/or calculated from the experimental ones, k2 alone, the monomolecular transformation of ES to EP accounts for this difference. The reoxidation step is instead not rate limiting and identical for the two substrates.	UNIV ROME TOR VERGATA,DEPT BIOCHEM SCI,I-00185 ROME,ITALY; CNR,CTR MOLEC BIOL,I-00185 ROME,ITALY; UNIV CAGLIARI,INST BIOL CHEM,I-09126 CAGLIARI,ITALY	University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); University of Cagliari	BELLELLI, A (corresponding author), UNIV ROME LA SAPIENZA,DEPT BIOCHEM SCI,P ALDO MORO 5,I-00185 ROME,ITALY.		Bellelli, Andrea/D-2785-2009	Brunori, Maurizio/0000-0002-7795-1635				BARDSLEY WG, 1972, BIOCHEM J, V74, P435; BELLELLI A, 1985, BIOCHEM J, V232, P923, DOI 10.1042/bj2320923; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; FLORIS G, 1983, PHYTOCHEMISTRY, V22, P1871, DOI 10.1016/0031-9422(83)80004-1; FROMM HJ, 1970, BIOCHEM BIOPH RES CO, V40, P692, DOI 10.1016/0006-291X(70)90959-9; GORYACHENKOVA EV, 1956, BIOCHEMISTRY-MOSCOW+, V21, P249; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; LINDSTROM A, 1978, EUR J BIOCHEM, V84, P479, DOI 10.1111/j.1432-1033.1978.tb12189.x; LOBENSTEINVERBE.CL, 1986, FEBS LETT, V206, P111; MONDOVI B, 1967, ARCH BIOCHEM BIOPHYS, V119, P373, DOI 10.1016/0003-9861(67)90468-7; OLSSON B, 1978, EUR J BIOCHEM, V87, P1, DOI 10.1111/j.1432-1033.1978.tb12345.x; PALCIC MM, 1983, BIOCHEMISTRY-US, V22, P5957, DOI 10.1021/bi00294a040	12	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20654	20657						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939114				2022-12-25	WOS:A1991GN00100013
J	PARKIN, DW; HORENSTEIN, BA; ABDULAH, DR; ESTUPINAN, B; SCHRAMM, VL				PARKIN, DW; HORENSTEIN, BA; ABDULAH, DR; ESTUPINAN, B; SCHRAMM, VL			NUCLEOSIDE HYDROLASE FROM CRITHIDIA-FASCICULATA - METABOLIC ROLE, PURIFICATION, SPECIFICITY, AND KINETIC MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP NUCLEOSIDASE; PURINE PHOSPHORIBOSYLTRANSFERASES; LEISHMANIA-DONOVANI; BINDING; ACID; HYDROLYSIS; SECONDARY	Crithidia fasciculata cells grown on complex medium with added [8-C-14,5'-H-3]inosine or [8-C-14,5'-H-3]adenosine metabolize > 50% of the salvaged nucleosides through a pathway involving N-glycoside bond cleavage. Cell extracts contain a substantial nucleoside hydrolase activity but an insignificant purine nucleoside phosphorylase. The nucleoside hydrolase has been purified 1000-fold to > 99% homogeneity from kilogram quantities of C. fasciculata. The enzyme is a tetramer of M(r) 34,000 subunits to give an apparent holoenzyme M(r) of 143,000 by gel filtration. All of the commonly occurring nucleosides are substrates. The K(m) values vary from 0.38 to 4.7 mM with purine nucleosides binding more tightly than the pyrimidines. Values of V(max)/K(m) vary from 3.4 x 10(3) M-1 s-1 to 1.7 x 10(5) M-1 s-1 with the pyrimidine nucleosides giving the larger values. The turnover rate for inosine is 32 s-1 at 30-degrees-C. The kinetic mechanism with inosine as substrate is rapid equilibrium with random product release. The hydrolytic reaction can be reversed to give an experimental K(eq) of 106 M with H2O taken as unity. The product dissociation constants for ribose and hypoxanthine are 0.7 and 6.2 mM, respectively. Deoxynucleosides or 5'-substituted nucleosides are poor substrates or do not react, and are poor inhibitors of the enzyme. The enzyme discriminates against methanol attack from solvent during steady-state catalysis, indicating the participation of an enzyme-directed water nucleophile. The pH profile for inosine hydrolysis gives two apparent pK(a) values of 6.1 with decreasing V(max)/K(m) values below the pK(a) and a plateau at higher pH values. These effects are due to the pH sensitivity of the V(max) values, since K(m) is independent of pH. The pH profile implicates two negatively charged groups which stabilize a transition state with oxycarbonium character.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,1300 MORRIS PK AVE,BRONX,NY 10461; CHESTNUT HILL COLL,DEPT CHEM,PHILADELPHIA,PA 19118	Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041916, R01GM021083, R01GM041916] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41916, GM21083] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cleland W W, 1979, Methods Enzymol, V63, P103; COHN M, 1982, ANNU REV BIOCHEM, V51, P365, DOI 10.1146/annurev.bi.51.070182.002053; DEWEY VC, 1973, ARCH BIOCHEM BIOPHYS, V157, P380, DOI 10.1016/0003-9861(73)90653-X; DEWOLF WE, 1986, BIOCHEMISTRY-US, V25, P4132, DOI 10.1021/bi00362a022; GARRETT ER, 1972, J AM CHEM SOC, V94, P8532, DOI 10.1021/ja00779a040; GIRANDA VL, 1988, BIOCHEMISTRY-US, V27, P5813, DOI 10.1021/bi00415a062; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P91; KIDDER GW, 1979, J PARASITOL, V65, P520, DOI 10.2307/3280314; KIDDER GW, 1978, J CELL PHYSIOL, V96, P165, DOI 10.1002/jcp.1040960205; KIDDER GW, 1958, J GEN MICROBIOL, V18, P621, DOI 10.1099/00221287-18-3-621; KIM BK, 1968, J BIOL CHEM, V243, P1771; MENTCH F, 1987, BIOCHEMISTRY-US, V26, P921, DOI 10.1021/bi00377a037; MILLER RL, 1984, J BIOL CHEM, V259, P5073; NEUBERT TA, 1990, J BIOL CHEM, V265, P7236; PARKIN DW, 1984, J BIOL CHEM, V259, P9411; PARKIN DW, 1987, BIOCHEMISTRY-US, V26, P913, DOI 10.1021/bi00377a036; PIZZI T, 1960, J INFECT DIS, V107, P100, DOI 10.1093/infdis/107.1.100; SCHRAMM VL, 1974, ANAL BIOCHEM, V57, P377, DOI 10.1016/0003-2697(74)90092-X; SCHRAMM VL, 1991, ENZYME MECH ISOTOPE, P367; SCHUBER F, 1976, EUR J BIOCHEM, V69, P593, DOI 10.1111/j.1432-1033.1976.tb10945.x; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STEIGER RF, 1977, J PROTOZOOL, V24, P437, DOI 10.1111/j.1550-7408.1977.tb04771.x; TUTTLE JV, 1980, J BIOL CHEM, V255, P909; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539	27	119	118	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20658	20665						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939115				2022-12-25	WOS:A1991GN00100014
J	KAGAWA, TF; GEIERSTANGER, BH; WANG, AHJ; HO, PS				KAGAWA, TF; GEIERSTANGER, BH; WANG, AHJ; HO, PS			COVALENT MODIFICATION OF GUANINE BASES IN DOUBLE-STRANDED DNA - THE 1.2-A Z-DNA STRUCTURE OF D(CGCGCG) IN THE PRESENCE OF CUCL2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; MOLECULAR-STRUCTURE; COPPER(II) COMPLEX; ATOMIC RESOLUTION; OH ADDUCTS; CRYSTAL; ION; DAMAGE	We have solved the single crystal structure to 1.2-angstrom resolution of the Z-DNA sequence d(CGCGCG) soaked with copper(II) chloride. This structure allows us to elucidate the structural properties of copper in a model that mimics a physiologically relevant environment. A copper(II) cation was observed to form a covalent coordinate bond to N-7 of each guanine base along the hexamer duplex. The occurrence of copper bound at each site was dependent on the exposure of the bases and the packing of the hexamers in the crystal. The copper at the highest occupied site was observed to form a regular octahedral complex, with four water ligands in the equatorial plane and a fifth water along with N-7 of the purine base at the axial positions. All other copper complexes appear to be variations of this structure. By using the octahedral complex as the prototype for copper(II) binding to guanine bases in the Z-DNA crystal, model structures were built showing that duplex B-DNA can accommodate octahedral copper(II) complexes at the guanine bases as well as copper complexes bridged at adjacent guanine residues by a reactive dioxygen species. The increased susceptibility to oxidative DNA cleavage induced by copper(II) ions in solution of the bases located 5' to one or more adjacent guanine residues can thus be explained in terms of the cation and DNA structures described by these models.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,URBANA,IL 61801	Oregon State University; University of Illinois System; University of Illinois Urbana-Champaign			Ho, Pui S/F-6186-2014; Ho, Pui/AAF-8838-2020	Ho, Pui S/0000-0002-8082-4311; Ho, Pui/0000-0002-8082-4311	NIGMS NIH HHS [GM41612] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041612] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI K, 1976, BIOCHIM BIOPHYS ACTA, V425, P369, DOI 10.1016/0005-2787(76)90264-1; ARUOMA OI, 1991, BIOCHEM J, V273, P601, DOI 10.1042/bj2730601; BLACKBURN NJ, 1987, J AM CHEM SOC, V109, P1235, DOI 10.1021/ja00238a037; CHIOU SH, 1985, J BIOCHEM-TOKYO, V98, P1723, DOI 10.1093/oxfordjournals.jbchem.a135445; GEIERSTANGER BH, 1991, J BIOL CHEM, V266, P20185; GESSNER RV, 1989, J BIOL CHEM, V264, P7921; HAZRA DK, 1983, J AM CHEM SOC, V105, P4380, DOI 10.1021/ja00351a042; HENDRICKSON WA, 1979, BIOMOLECULAR STRUCTU, P43; ITO S, 1984, NUCLEIC ACID RES S S, V15, P5; JACOBSON RR, 1988, J AM CHEM SOC, V110, P3690, DOI 10.1021/ja00219a071; JOHNSON GRA, 1988, J CHEM SOC FARAD T 1, V84, P501, DOI 10.1039/f19888400501; JOVANOVIC SV, 1986, J AM CHEM SOC, V108, P5968, DOI 10.1021/ja00279a050; KISTENMACHER TJ, 1976, ACTA CRYSTALLOGR B, V32, P186, DOI 10.1107/S0567740876002562; KITAJIMA N, 1990, J AM CHEM SOC, V112, P8833, DOI 10.1021/ja00180a026; KITAJIMA N, 1989, J AM CHEM SOC, V111, P8975, DOI 10.1021/ja00206a062; MASARWA M, 1988, J AM CHEM SOC, P151; SAGRIPANTI JL, 1989, J BIOL CHEM, V264, P1729; SLETTEN E, 1976, ACTA CRYSTALLOGR B, V32, P3301, DOI 10.1107/S0567740876010157; SLETTEN E, 1976, ACTA CRYSTALLOGR B, V32, P461, DOI 10.1107/S0567740876003245; SLETTEN E, 1974, ACTA CRYSTALLOGR B, V30, P2438, DOI 10.1107/S0567740874007266; STEENKEN S, 1989, CHEM REV, V89, P503, DOI 10.1021/cr00093a003; SWAMINATHAN V, 1979, CRC CR REV BIOCH MOL, V6, P245, DOI 10.3109/10409237909102565; VIERA AJS, 1990, J AM CHEM SOC, V112, P6986; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WEINER PK, 1981, J COMPUT CHEM, V2, P287, DOI 10.1002/jcc.540020311; YAMAMOTO K, 1989, J BIOL CHEM, V264, P15435	26	160	160	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20175	20184						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939078				2022-12-25	WOS:A1991GM03900047
J	MAK, AS; CARPENTER, M; SMILLIE, LB; WANG, JH				MAK, AS; CARPENTER, M; SMILLIE, LB; WANG, JH			PHOSPHORYLATION OF CALDESMON BY P34CDC2 KINASE - IDENTIFICATION OF PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; PROTEIN-KINASE; FISSION YEAST; CELL-CYCLE; M-PHASE; BINDING; CALMODULIN; ACTIN; TROPOMYOSIN; ACTIVATION	It has recently been shown that caldesmon from nonmuscle (Yamashiro, S., Yamakita, Y., Hosoya, H., and Matsumura, F. (1991) Nature 349, 169-172) and smooth muscle cells (Mak, A. S., Watson, M. H., Litwin, C. M. E., and Wang, J. H. (1991) J. Biol. Chem. 266, 6678-6681) can be phosphorylated in vitro by p34cdc2 kinase resulting in the inhibition of caldesmon binding to F-actin and Ca2+-calmodulin. In this study, we have identified five phosphorylation sites in smooth muscle caldesmon at Ser582, Ser667, Thr673, Thr696, and Ser702. All the sites bear some resemblance to the S(T)-P-X-X motif recognized by p34cdc2. The preferred site of phosphorylation at Thr673 accounts for about 40% of the total phosphorylation. Four of the sites occur in two pairs of closely spaced sites, Ser667/Thr673 and Thr696/Ser702; phosphorylation of one site in each pair inhibits strongly the phosphorylation of the second site in the same pair, presumably due to the close proximity of the two sites. Similar negative cooperativity in phosphorylation of Ser667 and Thr673 was observed using a 22-residue synthetic peptide containing the two sites. Phosphorylation of Ser667/Thr673 and Thr696/Ser702 account for about 90% of the total level of phosphorylation and these sites are located within the 10-kDa CNBr fragment at the COOH-terminal end of caldesmon known to bind actin and Ca2+-calmodulin.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,EXPTL PHYS,PROT STRUCT & FUNCT GRP,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV CALGARY,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA	University of Alberta; University of Alberta; University of Calgary	MAK, AS (corresponding author), QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA.							BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHALOVICH JM, 1988, CELL BIOPHYS, V12, P73, DOI 10.1007/BF02918351; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HAYLES J, 1986, EMBO J, V5, P3373, DOI 10.1002/j.1460-2075.1986.tb04653.x; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KEMP BE, 1979, J BIOL CHEM, V254, P2638; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; MAK AS, 1991, J BIOL CHEM, V266, P6678; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NGAI PK, 1984, J BIOL CHEM, V259, P3656; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFFORD RE, 1966, NATURE, V211, P591, DOI 10.1038/211591a0; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1981, P NATL ACAD SCI USA, V78, P5562; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; VELAZ L, 1990, J BIOL CHEM, V265, P2929; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X; WATSON MH, 1990, J BIOL CHEM, V265, P18860; WATSON MH, 1990, BIOCHIM BIOPHYS ACTA, V1054, P103, DOI 10.1016/0167-4889(90)90211-U; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0	34	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19971	19975						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939059				2022-12-25	WOS:A1991GM03900019
J	BOUHOURS, D; ANGSTROM, J; JOVALL, PA; HANSSON, GC; BOUHOURS, JF				BOUHOURS, D; ANGSTROM, J; JOVALL, PA; HANSSON, GC; BOUHOURS, JF			CHARACTERIZATION OF A NOVEL A-ACTIVE OCTAGLYCOSYLCERAMIDE WITH TYPE-1 CHAIN REPEAT INHERITED AS A RECESSIVE TRAIT IN THE EPITHELIAL-CELLS OF THE SMALL-INTESTINE OF INBRED RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP-A; NUCLEAR MAGNETIC-RESONANCE; HUMAN-ERYTHROCYTE MEMBRANES; MOUSE KIDNEY; MASS-SPECTROMETRY; EXTENDED GLOBOGLYCOLIPIDS; AFFINITY-CHROMATOGRAPHY; CONFORMATIONAL-ANALYSIS; EMBRYONIC ANTIGEN-1; SSEA-1 DETERMINANT	Three strains of inbred rats, AVN, DA and LOU/M, were found to express human blood group A-active glycosphingolipids in the small intestine. Two A phenotypes were detected by immunostaining of thin layer chromatograms with monoclonal anti-blood group A antibody. One phenotype (DA and LOU/M) displayed a novel glycolipid which was characterized as an A-active octaglycosylceramide with a type 1 chain repeat by methylation analysis, electron-impact mass spectrometry of the permethylated and permethylated LiAlH4-reduced molecule, and H-1 NMR spectroscopy. It was designated A-8. ]GRAPHICS] It is the first description of a type 1 chain repeat in a linear glycolipid. Calculation of minimum energy conformations showed that the orientations of the oligosaccharide chain and A determinant of A-8 differ from those of the homologous structure with a type 2 chain repeat present in human erythrocytes (Hakomori, S., Stellner, K., and Watanabe, K. (1972) Biochem. Biophys. Res. Commun. 49, 1061-1068). Genetic analysis demonstrated that A-8 is inherited as an autosomal recessive trait.	INSERM,U76,6 RUE ALEXANDRE CABANEL,F-75739 PARIS 15,FRANCE; GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41124 GOTHENBURG,SWEDEN	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Gothenburg			Hansson, Gunnar C/A-1236-2009; Hansson, Gunnar C./AAF-7324-2019	Hansson, Gunnar C/0000-0002-1900-1869; Hansson, Gunnar C./0000-0002-1900-1869				BLASZCZYK M, 1984, ARCH BIOCHEM BIOPHYS, V233, P161, DOI 10.1016/0003-9861(84)90612-X; BOUHOURS D, 1990, ARCH BIOCHEM BIOPHYS, V282, P141, DOI 10.1016/0003-9861(90)90097-I; BOUHOURS D, 1988, J BIOL CHEM, V263, P15540; BOUHOURS D, 1987, GLYCOCONJUGATE J, V4, P59, DOI 10.1007/BF01048445; BOUHOURS JF, 1976, BIOCHIM BIOPHYS ACTA, V441, P123, DOI 10.1016/0005-2760(76)90287-3; BOUHOURS JF, 1989, J BIOL CHEM, V264, P16992; BREIMER ME, 1982, J BIOL CHEM, V257, P906; BREIMER ME, 1980, BIOCHIM BIOPHYS ACTA, V617, P85, DOI 10.1016/0005-2760(80)90226-X; BREIMER ME, 1980, FEBS LETT, V114, P51, DOI 10.1016/0014-5793(80)80859-3; BREIMER ME, 1982, J BIOL CHEM, V257, P50; BUSH CA, 1986, J AM CHEM SOC, V108, P6168, DOI 10.1021/ja00280a010; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLAUSEN H, 1985, P NATL ACAD SCI USA, V82, P1199, DOI 10.1073/pnas.82.4.1199; CLAUSEN H, 1986, BIOCHEMISTRY-US, V25, P7075, DOI 10.1021/bi00370a048; CLAUSEN H, 1985, BIOCHEMISTRY-US, V24, P3578, DOI 10.1021/bi00335a028; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DABROWSKI J, 1981, ARCH BIOCHEM BIOPHYS, V210, P405, DOI 10.1016/0003-9861(81)90203-4; Festing MFW, 1979, LABORATORY RAT, V1, P55; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUKUDA MN, 1982, J BIOL CHEM, V257, P446; HAKOMORI S, 1972, BIOCHEM BIOPH RES CO, V49, P1061, DOI 10.1016/0006-291X(72)90320-8; HAKOMORI S, 1976, GLYCOLIPID METHODOLO, P13; HANSSON GC, 1983, J BIOL CHEM, V258, P9612; HANSSON GC, 1985, J IMMUNOL METHODS, V83, P37, DOI 10.1016/0022-1759(85)90055-9; HASHIMOTO Y, 1983, J BIOCHEM-TOKYO, V94, P2043, DOI 10.1093/oxfordjournals.jbchem.a134559; HASHIMOTO Y, 1983, J BIOCHEM-TOKYO, V93, P895, DOI 10.1093/jb/93.3.895; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V274, P14, DOI 10.1016/0003-9861(89)90410-4; HOLMES EH, 1987, J BIOL CHEM, V262, P11331; KANNAGI R, 1985, J BIOL CHEM, V260, P6410; KARLSSON KA, 1979, J BIOL CHEM, V254, P9311; KARLSSON KA, 1974, BIOCHEMISTRY-US, V13, P3643, DOI 10.1021/bi00715a003; LEMIEUX RU, 1980, CAN J CHEM, V58, P631, DOI 10.1139/v80-098; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; NAKAMURA K, 1990, J BIOCHEM-TOKYO, V107, P3; NAOI M, 1974, ANAL BIOCHEM, V58, P571, DOI 10.1016/0003-2697(74)90226-7; Nyholm P G, 1989, J Mol Recognit, V2, P103, DOI 10.1002/jmr.300020302; PASCHER I, 1977, CHEM PHYS LIPIDS, V20, P175, DOI 10.1016/0009-3084(77)90033-0; PAULSEN H, 1984, LIEBIGS ANN CHEM, P951; SAITO T, 1971, J LIPID RES, V12, P257; SEKINE M, 1989, J BIOCHEM-TOKYO, V105, P680, DOI 10.1093/oxfordjournals.jbchem.a122726; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P563, DOI 10.1093/jb/101.3.563; SEKINE M, 1990, J BIOCHEM-TOKYO, V108, P103, DOI 10.1093/oxfordjournals.jbchem.a123147; SEKINE M, 1987, J BIOCHEM-TOKYO, V101, P553, DOI 10.1093/jb/101.3.553; SEKINE M, 1988, J BIOCHEM-TOKYO, V103, P722, DOI 10.1093/oxfordjournals.jbchem.a122335; SMITH EL, 1975, BIOCHEMISTRY-US, V14, P2120, DOI 10.1021/bi00681a012; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; THOGERSEN H, 1982, CAN J CHEM, V60, P44, DOI 10.1139/v82-009; TORRES BV, 1988, ANAL BIOCHEM, V170, P209, DOI 10.1016/0003-2697(88)90110-8; UENO K, 1978, J LIPID RES, V19, P863; Watkins W M, 1980, Adv Hum Genet, V10, P1; WEISER MM, 1973, J BIOL CHEM, V248, P2536; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; 1977, LIPIDS, V12, P455	54	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18613	18619						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917983				2022-12-25	WOS:A1991GJ47200035
J	GEORGIEVA, EI; LOPEZRODAS, G; SENDRA, R; GROBNER, P; LOIDL, P				GEORGIEVA, EI; LOPEZRODAS, G; SENDRA, R; GROBNER, P; LOIDL, P			HISTONE ACETYLATION IN ZEA-MAYS .2. BIOLOGICAL SIGNIFICANCE OF POSTTRANSLATIONAL HISTONE ACETYLATION DURING EMBRYO GERMINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADENOSINE DIPHOSPHATE RIBOSYLATION); TRANSCRIPTIONALLY ACTIVE CHROMATIN; PHYSARUM-POLYCEPHALUM; DNA-REPAIR; POSTTRANSLATIONAL MODIFICATIONS; SODIUM-BUTYRATE; RAINBOW-TROUT; CELL-CYCLE; RAT-LIVER; HYPERACETYLATION	Multiple forms of histone acetyltransferases and histone deacetylases, which have been separated and characterized in the accompanying manuscript (Lopez-Rodas, G., Georgieva, E. I., Sendra, R., and Loidl, P. (1991) J. Biol. Chem. 266, 18745-18750), together with in vivo acetate incorporation, were studied during the germination of Zea mays embryos. Total histone acetyltransferase activity increases during germination with two maxima at 40 and 72 h after start of germination. This fluctuation is mainly due to the cytoplasmic B-enzyme which predominantly acetylates histone H4 up to the diacetylated form. The nuclear histone acetyltransferase A2, specific for H3, is low throughout germination, except at 24 h, when it transiently becomes the main activity. Both enzymes are also present in the dry embryo, whereas the second nuclear enzyme A1, specific for H3 and H4, is absent in the initial stage of differentiation. The two histone deacetylases, HD1 and HD2, exhibit entirely different patterns. Whereas HD1 activity is low in the dry embryo and increases during germination, HD2 is the predominant enzyme at the start of differentiation, but almost disappears at later stages. Analysis of the in vivo acetate incorporation reveals that H4 is present in up to tetraacetylated subspecies. The pattern of acetate incorporation into core histones closely resembles the fluctuations of histone acetyltransferase B. Based on the analysis of thymidine kinase activity a close correlation was established between histone acetyltransferase B and DNA replication, whereas the A2 enzyme is associated with transcriptional activity. Histone deacetylase HD1 obviously serves a specific function in the dry embryo and could be a prerequisite for DNA repair processes. The study confirms the idea of multiple functions of histone acetylation and assigns distinct enzymes, involved in this modification, to certain nuclear processes.	UNIV INNSBRUCK,SCH MED,FAK MED,INST MIKROBIOL,DEPT MICROBIOL,A-6020 INNSBRUCK,AUSTRIA; UNIV INNSBRUCK,SCH MED,DEPT MED CHEM & BIOCHEM,A-6020 INNSBRUCK,AUSTRIA; UNIV VALENCIA,FAC SCI,DEPT BIOCHEM & MOLEC BIOL,E-46100 BURJASSOT,SPAIN	University of Innsbruck; University of Innsbruck; University of Valencia			Georgieva, Elena/O-1674-2019; Sendra, Ramón/K-3549-2014; LOPEZ-RODAS, GERARDO/I-1349-2015	Sendra, Ramón/0000-0002-5519-4362; LOPEZ-RODAS, GERARDO/0000-0001-8367-653X				ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; BAIZA AM, 1989, J PLANT PHYSIOL, V135, P416, DOI 10.1016/S0176-1617(89)80097-5; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; CHAN S, 1988, J BIOL CHEM, V263, P15643; CHEAH KSE, 1978, NATURE, V272, P593, DOI 10.1038/272593a0; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; CHRISTENSEN ME, 1984, NUCLEIC ACIDS RES, V12, P4575, DOI 10.1093/nar/12.11.4575; CHRISTENSEN ME, 1982, DEV BIOL, V93, P404, DOI 10.1016/0012-1606(82)90127-0; COUPPEZ M, 1987, J BIOL CHEM, V262, P2854; DELTOUR R, 1985, J CELL SCI, V75, P43; DELTOUR R, 1974, ANN BOT, V38, P329; DOENECKE D, 1982, MOL CELL BIOCHEM, V44, P113; GEORGIEVA E, 1989, DOKL BOLG AKAD NAUK, V42, P95; GRIMES SR, 1984, EXP CELL RES, V152, P91, DOI 10.1016/0014-4827(84)90232-5; GROBNER P, 1983, EXP CELL RES, V144, P385, DOI 10.1016/0014-4827(83)90418-4; GROBNER P, 1976, FEBS LETT, V71, P181, DOI 10.1016/0014-5793(76)80926-X; GROBNER P, 1976, J BIOCHEM-TOKYO, V86, P1595; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HENDZEL MJ, 1991, BIOCHEM J, V273, P753, DOI 10.1042/bj2730753; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEHR GW, 1974, METHODEN ENZYMATISCH, V1, P673; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; LOIDL P, 1986, NUCLEIC ACIDS RES, V14, P3745; LOIDL P, 1983, NATURE, V305, P446, DOI 10.1038/305446a0; LOIDL P, 1987, NUCLEIC ACIDS RES, V15, P8351, DOI 10.1093/nar/15.20.8351; LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3; LOPEZRODAS G, 1991, J BIOL CHEM, V266, P18745; MALIK N, 1984, BIOCHEMISTRY-US, V23, P3721, DOI 10.1021/bi00311a023; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PERRY M, 1982, J BIOL CHEM, V257, P7336; RAMANATHAN B, 1989, J BIOL CHEM, V264, P11026; REEVES R, 1984, BIOCHIM BIOPHYS ACTA, V782, P343, DOI 10.1016/0167-4781(84)90044-7; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; SCHAFFHAUSEN BS, 1976, P NATL ACAD SCI USA, V73, P1092, DOI 10.1073/pnas.73.4.1092; SMERDON MJ, 1983, BIOCHEMISTRY-US, V22, P3516, DOI 10.1021/bi00283a033; SMERDON MJ, 1982, J BIOL CHEM, V257, P13441; TALASZ H, 1990, FEBS LETT, V264, P141, DOI 10.1016/0014-5793(90)80785-H; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; WEISS G, 1988, FEBS LETT, V238, P205, DOI 10.1016/0014-5793(88)80257-6; WONG M, 1984, BIOCHEMISTRY-US, V23, P3726, DOI 10.1021/bi00311a024; ZLATANOVA JS, 1987, PLANT MOL BIOL, V10, P139, DOI 10.1007/BF00016151	45	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18751	18760						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917998				2022-12-25	WOS:A1991GJ47200055
J	NIETO, ML; VENABLE, ME; BAULDRY, SA; GREENE, DG; KENNEDY, M; BASS, DA; WYKLE, RL				NIETO, ML; VENABLE, ME; BAULDRY, SA; GREENE, DG; KENNEDY, M; BASS, DA; WYKLE, RL			EVIDENCE THAT HYDROLYSIS OF ETHANOLAMINE PLASMALOGENS TRIGGERS SYNTHESIS OF PLATELET-ACTIVATING-FACTOR VIA A TRANSACYLATION REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; RAT ALVEOLAR MACROPHAGES; ARACHIDONIC-ACID RELEASE; HUMAN-NEUTROPHILS; PHOSPHOLIPASE-A2 ACTIVITY; BROMOPHENACYL BROMIDE; FATTY-ACIDS; FACTOR PAF; RABBIT; BIOSYNTHESIS	Addition of 1-O-alk-1'-enyl-2-lyso-sn-glycero-3-phosphoethanolamine (alkenyl-lyso-GPE) to human neutrophil membrane preparations containing 1-O-[H-3]hexadecyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (1-O-[H-3]alkyl-2-arachidonoyl-GPC) resulted in rapid deacylation of the 1-O-[H-3]alkyl-2-arachidonoyl-GPC to 1-O-[H-3]alkyl-2-lyso-GPC (lyso-platelet-activating factor, lyso-PAF). When acetyl-CoA was included in the incubation mixture, the [H-3] lyso-PAF was converted to [H-3]PAF. Studies of [H-3] arachidonate-labeled neutrophils permeabilized with Staphlococcus aureus alpha-toxin revealed a major shift of labeled [H-3]arachidonate from the choline to the ethanolamine-containing phosphoglycerides upon addition of alkenyl-lyso-GPE. The studies indicated that lyso-PAF is formed in the system by the transfer of arachidonate from 1-O-alkyl-2-arachidonoyl-GPC to the alkenyl-lyso-GPE by a CoA-independent transacylase reaction. Mass measurements revealed a rapid loss of arachidonate from 1-radyl-2-acyl-GPE and a concomitant increase in alkenyl-lyso-GPE upon stimulation of the neutrophils by ionophore A23187. Based on these and other findings, a pathway is proposed that may play a significant, if not obligatory, role in the synthesis of PAF in intact stimulated neutrophils. It has been widely accepted that phospholipase A2 acts directly on 1-O-alkyl-2-arachidonoyl-GPC as the first step in the synthesis of PAF via formation of lyso-PAF. In the proposed scheme, phospholipase A2, upon stimulation, acts rapidly on ethanolamine plasmalogen selectively releasing arachidonic acid and generating alkenyl-lyso-GPE. The CoA-independent transacylase then selectively transfers arachidonate from 1-radyl-2-arachidonoyl-GPC to the alkenyl-lyso-GPE generating lyso-PAF, which is then acetylated to form PAF. The interactions outlined can account for the synthesis of 1-acyl-2-acetyl-GPC, 1-O-alk-1'-enyl-2-acetyl-GPE, and eicosanoids, in parallel with PAF.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT BIOCHEM, WINSTON SALEM, NC 27103 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, WINSTON SALEM, NC 27103 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center			Nieto, Maria L/G-7492-2015	Nieto, Maria L/0000-0001-6842-799X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014929, R01AI017287] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26818] Funding Source: Medline; NIAID NIH HHS [AI-17287, AI-14929] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT DH, 1984, BIOCHIM BIOPHYS ACTA, V796, P92, DOI 10.1016/0005-2760(84)90242-X; ALBERT DH, 1983, J BIOL CHEM, V258, P97; ALONSO F, 1986, BIOCHIM BIOPHYS ACTA, V878, P273, DOI 10.1016/0005-2760(86)90156-6; ANGLE MJ, 1988, BIOCHIM BIOPHYS ACTA, V962, P234, DOI 10.1016/0005-2760(88)90165-8; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BENVENISTE J, 1982, THROMB RES, V25, P375, DOI 10.1016/0049-3848(82)90128-1; BILLAH MM, 1986, J BIOL CHEM, V261, P5824; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAMUSSI G, 1982, ADV EXP MED BIOL, V141, P259; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHILTON FH, 1986, J BIOL CHEM, V261, P7771; CHILTON FH, 1983, J BIOL CHEM, V258, P7268; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CHRISTIANSEN K, 1975, ANAL BIOCHEM, V66, P93, DOI 10.1016/0003-2697(75)90728-9; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DECHATELET LR, 1982, INFECT IMMUN, V35, P206, DOI 10.1128/IAI.35.1.206-212.1982; DIEZ E, 1990, BIOCHIM BIOPHYS ACTA, V1047, P83, DOI 10.1016/0005-2760(90)90264-X; DIEZ E, 1990, J BIOL CHEM, V265, P14654; FRANSON R, 1978, BIOCHEMISTRY-US, V17, P4029, DOI 10.1021/bi00612a024; GOTTFRIED EL, 1967, J LIPID RES, V8, P321; HARSHMAN S, 1988, METHOD ENZYMOL, V165, P3; HOFMANN SL, 1982, ARCH BIOCHEM BIOPHYS, V215, P237, DOI 10.1016/0003-9861(82)90300-9; KRAMER RM, 1984, J BIOL CHEM, V259, P3316; KRAMER RM, 1983, J BIOL CHEM, V258, P3806; KYGER EM, 1984, BIOCHIM BIOPHYS ACTA, V794, P96, DOI 10.1016/0005-2760(84)90302-3; MASUZAWA Y, 1989, BIOCHIM BIOPHYS ACTA, V1005, P1, DOI 10.1016/0005-2760(89)90024-6; MCINTYRE TM, 1987, J BIOL CHEM, V262, P15370; MUELLER HW, 1984, J LIPID RES, V25, P383; MUELLER HW, 1983, J BIOL CHEM, V258, P6213; MUELLER HW, 1984, J BIOL CHEM, V259, P4554; NIETO M, 1990, J CELL BIOL, V111, P257; PATTON GM, 1982, J LIPID RES, V23, P190; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RAMESHA CS, 1986, J BIOL CHEM, V261, P7592; RITTENHOUSESIMMONS S, 1976, BIOCHEM BIOPH RES CO, V70, P295, DOI 10.1016/0006-291X(76)91141-4; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SATOUCHI K, 1985, BIOCHEM BIOPH RES CO, V128, P1409, DOI 10.1016/0006-291X(85)91097-6; SISSON JH, 1987, J IMMUNOL, V138, P3918; SUGA K, 1990, J BIOL CHEM, V265, P12363; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; SUGIURA T, 1990, BIOCHIM BIOPHYS ACTA, V1047, P223, DOI 10.1016/0005-2760(90)90520-8; SWENDSEN CL, 1983, BIOCHEM BIOPH RES CO, V113, P72, DOI 10.1016/0006-291X(83)90433-3; TESSNER TG, 1987, J BIOL CHEM, V262, P12660; TESSNER TG, 1990, J BIOL CHEM, V265, P21032; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; WALSH CE, 1983, BIOCHIM BIOPHYS ACTA, V750, P32, DOI 10.1016/0005-2760(83)90201-1; WRIGHT RS, 1971, J CHROMATOGR, V59, P220, DOI 10.1016/S0021-9673(01)80033-9; WYKLE RL, 1980, BIOCHIM BIOPHYS ACTA, V619, P58, DOI 10.1016/0005-2760(80)90242-8; WYKLE RL, 1987, PLATELET ACTIVATING, P273; WYKLE RL, 1986, ADV INFLAMMAT RES, V11, P71; WYNKOOP EM, 1986, BIOCHEM J, V236, P829, DOI 10.1042/bj2360829; WYRICK SD, 1985, J LABELLED COMPD RAD, V22, P1169, DOI 10.1002/jlcr.2580221110	55	105	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18699	18706						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917994				2022-12-25	WOS:A1991GJ47200047
J	PALCZEWSKI, K; PULVERMULLER, A; BUCZYLKO, J; HOFMANN, KP				PALCZEWSKI, K; PULVERMULLER, A; BUCZYLKO, J; HOFMANN, KP			PHOSPHORYLATED RHODOPSIN AND HEPARIN INDUCE SIMILAR CONFORMATIONAL-CHANGES IN ARRESTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL S-ANTIGEN; HUMAN ANTITHROMBIN-III; 48-KDA PROTEIN; DISK MEMBRANE; PHOSPHODIESTERASE ACTIVATION; PHOTORECEPTOR-MEMBRANES; PHOTOEXCITED RHODOPSIN; CGMP PHOSPHODIESTERASE; ALPHA-TRANSDUCIN; BINDING-SITE	Photoactivated rhodopsin is quenched upon its phosphorylation in the reaction catalyzed by rhodopsin kinase and the subsequent binding of a regulatory protein, arrestin. We have found that heparin and other polyanions compete with photoactivated, phosphorylated rhodopsin to bind arrestin (48-kDa protein, S-antigen). This is shown (a) by the suppression of stabilized metarhodopsin II; (b) by changes in the digestion of arrestin in the presence of heparin; and (c) by the restoration of arrestin-quenched phosphodiesterase activity. When bound to arrestin, heparin also mimics phosphorylated rhodopsin by similarly exposing arrestin to limited proteolysis. We conclude that heparin and rhodopsin have similar means of binding to arrestin, and we propose a cationic region of arrestin (beginning with Lys163 of the bovine sequence) as the interaction site. In agreement with previous kinetic data we interpret the results in terms of a binding conformation of arrestin which is stabilized by rhodopsin or heparin and is open to proteolytic attack.	UNIV FREIBURG,INST BIOPHYS & STRAHLENBIOL,W-7800 FREIBURG,GERMANY	University of Freiburg	PALCZEWSKI, K (corresponding author), GOOD SAMARITAN HOSP,RS DOW NEUROL SCI INST,PORTLAND,OR 97209, USA.				NATIONAL EYE INSTITUTE [R01EY008061, R29EY008061] Funding Source: NIH RePORTER; NEI NIH HHS [EY 08061] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHANG JY, 1989, J BIOL CHEM, V264, P3111; DAWIS SM, 1988, J BIOL CHEM, V263, P8771; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; KAHLERT M, 1991, BIOPHYS J, V59, P375, DOI 10.1016/S0006-3495(91)82231-7; KAHLERT M, 1990, J BIOL CHEM, V265, P18928; KARLSSON K, 1988, BIOCHEM J, V256, P29, DOI 10.1042/bj2560029; KOHNKEGODT B, 1991, BIOCHEMISTRY-US, V30, P55, DOI 10.1021/bi00215a009; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P171; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MANGINI NJ, 1991, INVEST OPHTH VIS SCI, V32, P1150; MOLDAY RS, 1985, BIOCHEMISTRY-US, V24, P776, DOI 10.1021/bi00324a036; PALCZEWSKI JK, 1991, J BIOL CHEM, V266, P4201; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PALCZEWSKI K, 1990, Investigative Ophthalmology and Visual Science, V31, P217; PEPPERBERG DR, 1988, P NATL ACAD SCI USA, V85, P5531, DOI 10.1073/pnas.85.15.5531; POGOZHEVA ID, 1989, BIOL MEMBRANY, V6, P1248; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SECKLER B, 1989, BIOCHEM J, V264, P489, DOI 10.1042/bj2640489; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; SMITH JW, 1990, BIOCHEMISTRY-US, V29, P8950, DOI 10.1021/bi00490a010; SUN XJ, 1990, BIOCHEMISTRY-US, V29, P8957, DOI 10.1021/bi00490a011; WACKER WB, 1977, J IMMUNOL, V119, P1949; WAGNER R, 1988, FEBS LETT, V235, P103, DOI 10.1016/0014-5793(88)81242-0; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WISTOW GJ, 1986, FEBS LETT, V196, P23, DOI 10.1016/0014-5793(86)80207-1; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAKI K, 1988, FEBS LETT, V234, P39, DOI 10.1016/0014-5793(88)81298-5; ZUCKERMAN R, 1986, FEBS LETT, V207, P35, DOI 10.1016/0014-5793(86)80008-4; 1968, EUR J BIOCHEM, V5, P151	46	110	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18649	18654						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917988				2022-12-25	WOS:A1991GJ47200040
J	SCHEK, N; BARTENSCHLAGER, R; KUHN, C; SCHALLER, H				SCHEK, N; BARTENSCHLAGER, R; KUHN, C; SCHALLER, H			PHOSPHORYLATION AND RAPID TURNOVER OF HEPATITIS-B VIRUS X-PROTEIN EXPRESSED IN HEPG2 CELLS FROM A RECOMBINANT VACCINIA VIRUS	ONCOGENE			English	Article							ESCHERICHIA-COLI; GENE-PRODUCT; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; TRANSFORMED-CELLS; MAMMALIAN-CELLS; DNA; BINDING; GENOME; ANTIBODIES	The human hepatitis B viral (HBV) genome contains a conserved open reading frame known as the X-gene which is capable of encoding a polypeptide of 16.565 kDa. The corresponding protein has so far not been identified directly in HBV-infected cells, but in transient transfection assays the X-gene encodes a product that functions as a transcriptional transactivator. To characterize the subcellular distribution, stability and post-translational modifications of X-protein in human hepatoma HepG2 cells, we have established a vaccinia virus expression system. As the major X-gene product, a protein with an apparent molecular weight of 16 kDa, and reacting with an X-protein-specific antiserum, was expressed from recombinant vaccinia virus. In indirect immunofluorescence assay, X-protein appeared to be distributed throughout the cells, with a tendency to localize at the nuclear periphery and to accumulate in granules as its levels increased. By subcellular fractionation, we found about one-third of X-protein associated with the fraction defined as the nuclear framework. In pulse-chase experiments, X-protein decayed with a bimodal half-life of 15 min and 3 h. X-protein having a half-life of about 15 min was found associated with the Triton X-100 detergent-soluble fraction of HepG2 cells, while that associated with the insoluble fraction turned over more slowly. By metabolic labeling with [P-32]orthophosphate, we show that X-protein is capable of being phosphorylated. Modification by phosphorylation could play an important role in the regulation of X-protein function.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL HEIDELBERG,IM NEUENHEIMER FELD 282,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Bartenschlager, Ralf/L-2582-2015	Bartenschlager, Ralf/0000-0001-5601-9307				AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BARTENSCHLAGER R, 1988, EMBO J, V7, P4185, DOI 10.1002/j.1460-2075.1988.tb03315.x; Beasley R.P., 1984, VIRAL HEPATITIS LIVE, P209; BENZEEV A, 1981, VIROLOGY, V111, P475, DOI 10.1016/0042-6822(81)90350-0; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BRANTON PE, 1985, J VIROL, V56, P633, DOI 10.1128/JVI.56.2.633-638.1985; CAPCO DG, 1982, CELL, V29, P847, DOI 10.1016/0092-8674(82)90446-9; CHANG CM, 1987, EMBO J, V6, P675, DOI 10.1002/j.1460-2075.1987.tb04807.x; CHISAKA O, 1987, GENE, V60, P183; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; DEMAGISTRIS L, 1988, NUCLEIC ACIDS RES, V16, P3141, DOI 10.1093/nar/16.8.3141; ELFASSI E, 1986, P NATL ACAD SCI USA, V83, P2219, DOI 10.1073/pnas.83.7.2219; FRANKE CA, 1989, J VIROL, V63, P4285, DOI 10.1128/JVI.63.10.4285-4291.1989; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1988, ANTIBODIES LABORATOR, P460; HESS J, 1988, MED MICROBIOL IMMUN, V177, P195, DOI 10.1007/BF00211219; HILLER G, 1985, J VIROL, V55, P651, DOI 10.1128/JVI.55.3.651-659.1985; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1988, CELL, V55, P123; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KAY A, 1985, EMBO J, V4, P1287, DOI 10.1002/j.1460-2075.1985.tb03774.x; KIENY MP, 1984, NATURE, V312, P163, DOI 10.1038/312163a0; KOSHY R, 1989, CURR TOP MICROBIOL, V144, P265; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LENK R, 1977, CELL, V10, P67, DOI 10.1016/0092-8674(77)90141-6; LEUTZ A, 1988, J BIOL CHEM, V263, P3905; LEVRERO M, 1990, VIROLOGY, V174, P299, DOI 10.1016/0042-6822(90)90079-7; MERRIL CR, 1981, SCIENCE, V211, P1436; MOSS B, 1987, ANNU REV IMMUNOL, V5, P305, DOI 10.1146/annurev.iy.05.040187.001513; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PENMAN S, 1966, J MOL BIOL, V17, P117, DOI 10.1016/S0022-2836(66)80098-0; PFAFF E, 1987, VIROLOGY, V158, P456, DOI 10.1016/0042-6822(87)90221-2; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RICHTER JD, 1988, J VIROL, V62, P1948, DOI 10.1128/JVI.62.6.1948-1955.1988; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHEK N, 1991, HEPADNAVIRAL X PROTE, P181; SCHODEL F, 1989, ADV VIRAL ONCOL, V8, P73; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SEIFER M, 1990, VIROLOGY, V179, P287, DOI 10.1016/0042-6822(90)90297-5; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SLAMON DJ, 1985, SCIENCE, V228, P1427, DOI 10.1126/science.2990027; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; STAMATOS NM, 1987, J VIROL, V61, P516, DOI 10.1128/JVI.61.2.516-525.1987; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STUNNENBERG HG, 1988, NUCLEIC ACIDS RES, V16, P2431, DOI 10.1093/nar/16.6.2431; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENZUELA P, 1980, ANIMAL VIRUS GENETIC, P57; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZAHM P, 1988, ONCOGENE, V3, P169	58	79	84	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1735	1744						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923499				2022-12-25	WOS:A1991GX11800003
J	CHEN, LL; ROSA, JJ; TURNER, S; PEPINSKY, RB				CHEN, LL; ROSA, JJ; TURNER, S; PEPINSKY, RB			PRODUCTION OF MULTIMERIC FORMS OF CD4 THROUGH A SUGAR-BASED CROSS-LINKING STRATEGY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT SOLUBLE CD4; IMMUNODEFICIENCY-VIRUS TYPE-1; EXOTOXIN HYBRID PROTEIN; POLYACRYLAMIDE GELS; GP120 BINDING; HIV; INFECTION; RECEPTOR; CELLS; MOLECULES	We have developed a three-step cross-linking procedure that is specifically targeted at the carbohydrate on a protein and applied it to CD4 as a model system for studying the role of multivalent interactions in function. In the first step CD4 was oxidized with periodate, creating aldehydes that served as targets for the subsequent chemistry. Next the aldehydes were modified with cystamine, converting the reactive group into a thiol. Finally cross-linking through the thiol moiety was generated with the homobifunctional cross-linker bismaleimidohexane. With this procedure, approximately 60% of the CD4 was converted into higher molecular weight complexes that were soluble and retained function as assessed by glycoprotein gp120 binding activity. CD4 dimers and tetramers by mass were 4 and 15 times as active as CD4 monomer in blocking virus infection with HTLV-IIIB in an in vitro cellular assay. The cross-linking chemistry provides an efficient method for producing homomultimers of a glycoprotein.	BIOGEN INC,CAMBRIDGE,MA 02142	Biogen								ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; BERGER EA, 1989, P NATL ACAD SCI USA, V86, P9539, DOI 10.1073/pnas.86.23.9539; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CARR SA, 1989, J BIOL CHEM, V264, P21286; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHAO BH, 1989, J BIOL CHEM, V264, P5812; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; GLAZER AN, 1987, CHEM MODIFICATIONS P, P20; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; JENNINGS HJ, 1981, J IMMUNOL, V127, P1011; LIAO TH, 1973, J BIOL CHEM, V248, P8247; MADDON PJ, 1987, P NATL ACAD SCI USA, V84, P9155, DOI 10.1073/pnas.84.24.9155; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCDOUGAL JS, 1986, SCIENCE, V231, P382, DOI 10.1126/science.3001934; MOORE JP, 1990, AIDS, V4, P297, DOI 10.1097/00002030-199004000-00003; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MORONEY SE, 1987, BIOCHEMISTRY-US, V26, P8390, DOI 10.1021/bi00399a054; PEPINSKY RB, 1983, J BIOL CHEM, V258, P1229; POWELL LD, 1986, ANAL BIOCHEM, V157, P179, DOI 10.1016/0003-2697(86)90211-3; SATTENTAU QJ, 1988, CELL, V52, P631, DOI 10.1016/0092-8674(88)90397-2; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; SKUTELSKY E, 1977, J ULTRA MOL STRUCT R, V61, P325, DOI 10.1016/S0022-5320(77)80057-9; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	31	22	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18237	18243						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917952				2022-12-25	WOS:A1991GG55300079
J	GE, AZ; RIVERS, D; MILNE, R; DEAN, DH				GE, AZ; RIVERS, D; MILNE, R; DEAN, DH			FUNCTIONAL DOMAINS OF BACILLUS-THURINGIENSIS INSECTICIDAL CRYSTAL PROTEINS - REFINEMENT OF HELIOTHIS-VIRESCENS AND TRICHOPLUSIA-NI SPECIFICITY DOMAINS ON CRYIA(C)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; DELTA-ENDOTOXIN; ESCHERICHIA-COLI; BINDING-SITES; GENE; MIDGUT; MUTAGENESIS; EXPRESSION; RECEPTORS; LOCATION	Insecticidal crystal proteins (delta-endotoxins), CryIA(a) and CryIA(c), from Bacillus thuringiensis are 82% homologous. Despite this homology, CryIA(c) was determined to have 10-fold more insecticidal activity toward Heliothis virescens and Trichoplusia ni than CryIA(a). Reciprocal recombinations between these two genes were performed by the homolog-scanning technique. The resultant mutants had different segments of their primary sequences exchanged. Bioassays with toxin proteins from these mutants revealed that amino acids 335-450 on CryIA(c) are associated with the activity against T. ni, whereas amino acids 335-615 on the same toxin are required to exchange full H. virescens specificity. One chimeric protein toxin, involving residues 450-612 from CryIA(c), demonstrated 30 times more activity against H. virescens than the native parental toxin, indicating that this region plays an important role in H. virescens specificity. The structural integrity of mutant toxin proteins was assessed by treatment with bovine trypsin. All actively toxic proteins formed a 65-kDA trypsin-resistant active toxic core, similar to the parental CryIA(c) toxin, indicating that toxin protein structure was not altered significantly. Contrarily, certain inactive mutant proteins were susceptible to complete protease hydrolysis, indicating that their lack of toxicity may have been due to structural alterations.	OHIO STATE UNIV, DEPT BIOCHEM & MOLEC GENET, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT ENTOMOL, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT MICROBIOL, COLUMBUS, OH 43210 USA; FORESTRY PEST MANAGEMENT INST, Sault Ste Marie P6A 5M7, ONTARIO, CANADA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NIAID NIH HHS [R01 AI29092] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029092] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], PATHOGENSIS INVERTEB; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; EDWARDS DL, 1987, Patent No. 228838; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GE AZ, 1989, P NATL ACAD SCI USA, V86, P4037, DOI 10.1073/pnas.86.11.4037; GE AZ, 1990, GENE, V93, P49, DOI 10.1016/0378-1119(90)90134-D; GEISER M, 1986, GENE, V48, P109, DOI 10.1016/0378-1119(86)90357-4; HAIDER MZ, 1989, J MOL BIOL, V208, P183, DOI 10.1016/0022-2836(89)90094-6; HARVEY WR, 1979, J EXP BIOL, V83, P293; HEIMPEL A. M., 1959, JOUR INSECT PATHOL, V1, P152; HOFMANN C, 1988, P NATL ACAD SCI USA, V85, P7844, DOI 10.1073/pnas.85.21.7844; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; HOFTE H, 1988, APPL ENVIRON MICROB, V54, P2010; HOFTE H, 1986, EUR J BIOCHEM, V161, P273, DOI 10.1111/j.1432-1033.1986.tb10443.x; HOFTE H, 1989, MICROBIOL REV, V53, P242; HOLMES KC, 1965, J MOL BIOL, V14, P572, DOI 10.1016/S0022-2836(65)80205-4; HUBER HE, 1981, PATHOGENESIS INVERTE, P207; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MCLINDEN JH, 1985, APPL ENVIRON MICROB, V50, P623, DOI 10.1128/AEM.50.3.623-628.1985; MILNE R, 1990, ACS SYM SER, V432, P22; PACE CN, 1984, BIOCHEM J, V219, P411, DOI 10.1042/bj2190411; Raymond M., 1985, Cahiers O.R.S.T.O.M., Serie Entomologie Medicale et Parasitologie, V23, P117; ROWE GE, 1987, CRIT REV BIOTECHNOL, V6, P87, DOI 10.3109/07388558709086986; SCHNEPF HE, 1990, J BIOL CHEM, V265, P20923; SCHNEPF HE, 1981, P NATL ACAD SCI-BIOL, V78, P2893, DOI 10.1073/pnas.78.5.2893; VANRIE J, 1989, EUR J BIOCHEM, V186, P239, DOI 10.1111/j.1432-1033.1989.tb15201.x; VANRIE J, 1990, APPL ENVIRON MICROB, V56, P1378, DOI 10.1128/AEM.56.5.1378-1385.1990; WIDNER WR, 1990, J BACTERIOL, V172, P2826, DOI 10.1128/jb.172.6.2826-2832.1990; WOLFERSBERGER MG, 1990, EXPERIENTIA, V46, P475, DOI 10.1007/BF01954236	30	88	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17954	17958						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917934				2022-12-25	WOS:A1991GG55300040
J	HINDSGAUL, O; KAUR, KJ; SRIVASTAVA, G; BLASZCZYKTHURIN, M; CRAWLEY, SC; HEERZE, LD; PALCIC, MM				HINDSGAUL, O; KAUR, KJ; SRIVASTAVA, G; BLASZCZYKTHURIN, M; CRAWLEY, SC; HEERZE, LD; PALCIC, MM			EVALUATION OF DEOXYGENATED OLIGOSACCHARIDE ACCEPTOR ANALOGS AS SPECIFIC INHIBITORS OF GLYCOSYLTRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; FUCOSYL-TRANSFERASE; LEWIS-A; GLYCOSYLATION; PURIFICATION; RECOGNITION; DERIVATIVES; DETERMINANT; GLYCOSIDES; ANTIGEN	The glycosyltransferases controlling the biosynthesis of cell-surface complex carbohydrates transfer glycosyl residues from sugar nucleotides to specific hydroxyl groups of acceptor oligosaccharides. These enzymes represent prime targets for the design of glycosylation inhibitors with the potential to specifically alter the structures of cell-surface glycoconjugates. With the aim of producing such inhibitors, synthetic oligosaccharide substrates were prepared for eight different glycosyltransferases. The enzymes investigated were: A, alpha(1 --> 2, porcine submaxillary gland); B, alpha(1 --> 3/4, Lewis); C, alpha(1 --> 4, mung bean); D, alpha(1 --> 3, Le(x))-fucosyltransferases; E, beta(1 --> 4)-galactosyltransferase; F, beta(1 --> 6)-N-acetylglucosaminyltransferase V; G, beta(1 --> 6)-mucin-N-acetylglucosaminyltransferase ("core-2" transferase); and H, alpha(2 --> 3)-sialyltransferase from rat liver. These enzymes all transfer sugar residues from their respective sugar nucleotides (GDP-Fuc, UDP-Gal, UDP-GlcNAc, and CMP-sialic acid) with inversion of configuration at their anomeric centers. The K(m) values for their synthetic oligosaccharide acceptors were in the range of 0.036-1.3 mM. For each of these eight enzymes, acceptor analogs were next prepared where the hydroxyl group undergoing glycosylation was chemically removed and replaced by hydrogen. The resulting deoxygenated acceptor analogs can no longer be substrates for the corresponding glycosyltransferases and, if still bound by the enzymes, should act as competitive inhibitors. In only four of the eight cases examined (enzymes A, C, F, and G) did the deoxygenated acceptor analogs inhibit their target enzymes, and their K(i) values (all competitive) remained in the general range of the corresponding acceptor K(m) values. No inhibition was observed for the remaining four enzymes even at high concentrations of deoxygenated acceptor analog. For these latter enzymes it is suggested that the reactive acceptor hydroxyl groups are involved in a critical hydrogen bond donor interaction with a basic group on the enzyme which removes the developing proton during the glycosyl transfer reaction. Such groups are proposed to represent logical targets for irreversible covalent inactivation of this class of enzyme.	UNIV ALBERTA, DEPT FOOD SCI, EDMONTON T6G 2G2, ALBERTA, CANADA; WISTAR INST, PHILADELPHIA, PA 19104 USA	University of Alberta; The Wistar Institute	HINDSGAUL, O (corresponding author), UNIV ALBERTA, DEPT CHEM, EDMONTON T6G 2G2, ALBERTA, CANADA.		Gagneja, Kanwalinderjit K/K-3204-2017	Gagneja, Kanwalinderjit K/0000-0001-7844-8583	NATIONAL CANCER INSTITUTE [R01CA045363, R01CA050542] Funding Source: NIH RePORTER; NCI NIH HHS [CA45363-01A1, CA50542-2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARITA H, 1972, B CHEM SOC JPN, V45, P3614, DOI 10.1246/bcsj.45.3614; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BEYER TA, 1980, J BIOL CHEM, V255, P5364; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY BK, 1990, CELL, V63, P861; BROCKHAUSEN I, 1983, CARBOHYD RES, V120, P3, DOI 10.1016/0008-6215(83)88002-1; Cleland W W, 1979, Methods Enzymol, V63, P103; CRAWLEY SC, 1989, CARBOHYD RES, V193, P249, DOI 10.1016/0008-6215(89)85123-7; DENNIS JW, 1988, CANCER SURV, V7, P573; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HINDSGAUL O, 1991, IN PRESS AM CHEM SOC, V466; KHARE DP, 1985, CARBOHYD RES, V136, P285, DOI 10.1016/0008-6215(85)85204-6; KIJIMASUDA I, 1986, CANCER RES, V46, P858; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LEMIEUX RU, 1975, J AM CHEM SOC, V97, P4076, DOI 10.1021/ja00847a035; MAZID MA, 1989, Patent No. 7336932; OPPENHEIMER CL, 1981, J BIOL CHEM, V256, P799; PALCIC MM, 1990, J BIOL CHEM, V265, P6759; PALCIC MM, 1989, J BIOL CHEM, V264, P17174; PALCIC MM, 1987, CARBOHYD RES, V159, P315, DOI 10.1016/S0008-6215(00)90224-6; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PALCIC MM, 1989, CARBOHYD RES, V190, P1, DOI 10.1016/0008-6215(89)84141-2; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PRITCHETT TJ, 1987, VIROLOGY, V160, P502, DOI 10.1016/0042-6822(87)90026-2; RATCLIFFE RM, 1981, CARBOHYD RES, V93, P35, DOI 10.1016/S0008-6215(00)80750-8; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SCHWARZ RT, 1982, ADV CARBOHYD CHEM BI, V40, P287, DOI 10.1016/S0065-2318(08)60111-0; Segel I.H., 1975, ENZYME KINETICS; SINHA SK, 1980, CARBOHYD RES, V81, P239, DOI 10.1016/S0008-6215(00)85655-4; SMITH CI, 1991, TRENDS GLYCOSCI GLYC, V3, P116; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SRIVASTAVA OP, 1988, CARBOHYD RES, V179, P137, DOI 10.1016/0008-6215(88)84115-6; TANRISEVEN A, 1989, CARBOHYD RES, V186, P87, DOI 10.1016/0008-6215(89)84007-8; VAGHEFI MM, 1987, J MED CHEM, V30, P1391, DOI 10.1021/jm00391a021; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	39	107	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17858	17862						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917926				2022-12-25	WOS:A1991GG55300026
J	IWAI, Y; BICKEL, M; PLUZNIK, DH; COHEN, RB				IWAI, Y; BICKEL, M; PLUZNIK, DH; COHEN, RB			IDENTIFICATION OF SEQUENCES WITHIN THE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR MESSENGER-RNA 3'-UNTRANSLATED REGION THAT MEDIATE MESSENGER-RNA STABILIZATION INDUCED BY MITOGEN TREATMENT OF EL-4 THYMOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; CYCLOSPORIN-A; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; T-CELLS; DNA; INTERLEUKIN-2; PROTEIN	Phorbol esters (TPA) and concanavalin A (ConA) are known to induce granulocyte-macrophage colony-stimulating factor (GM-CSF) production in murine thymoma EL-4 cells by mRNA stabilization. The role of the 3'-untranslated region (3'-UTR) in GM-CSF mRNA stabilization induced by TPA and ConA in EL-4 cells was examined by transfection studies using chloramphenicol acetyltransferase (CAT) constructions. The GM-CSF 3'-UTR contains a 63-nucleotide region at its 3' end with repeating ATTTA motifs which is responsible for mRNA degradation in a variety of cell types (Shaw, G., and Kamen, R. (1986) Cell 46, 659-666). We produced constructs containing most of the GM-CSF 3'-UTR (303 nucleotides, pRSV-CATgm) or the 3'-terminal AT-rich region (116 nucleotides, pRSV-CATau) and measured CAT enzyme activity and CAT mRNA after transient transfection into EL-4 and NIH 3T3 cells. Low levels of CAT activity were seen in both cells with either plasmid compared with levels of CAT activity obtained with pRSV-CAT. TPA treatment caused an approximately 10-fold increase in CAT activity and mRNA in EL-4 cells transfected with pRSV-CATgm. No increases were seen in EL-4 cells transfected with pRSV-CATau or pRSV-CAT. No response to TPA was detected in transfected NIH 3T3 cells, indicating that the response to TPA is relatively cell-specific. There was no increase in CAT activity after ConA treatment in EL-4 or NIH 3T3 cells transfected with any of the constructs suggesting that the GM-CSF 3'-UTR lacks elements that can respond alone to ConA. Nuclear run-on and actinomycin D chase experiments in EL-4 cells showed that TPA induces CAT activity via mRNA stabilization. By linker-substitution mutagenesis we show that TPA inducibility depends on a 60-nucleotide region of the 3'-UTR whose 5' end is located 160 nucleotides upstream of the 5' end of the AU-rich region.	US FDA,CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BLDG 29A,RM 3B-19,HFB-800,8800 ROCKVILLE PIKE,BETHESDA,MD 20892	US Food & Drug Administration (FDA)								AKAHANE K, 1991, J IMMUNOL, V146, P4190; BAND L, 1990, Experimental Hematology (Charlottesville), V18, P623; BICKEL M, 1988, EXP HEMATOL, V16, P691; BICKEL M, 1990, J IMMUNOL, V145, P840; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; BICKEL M, 1987, J IMMUNOL, V139, P2984; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GRANELLIPIPERNO A, 1984, J EXP MED, V160, P1792, DOI 10.1084/jem.160.6.1792; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUEZ M, 1973, FEBS LETT, V37, P149, DOI 10.1016/0014-5793(73)80446-6; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NIMER SD, 1989, J IMMUNOL, V143, P2374; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; QUESENBERRY PJ, 1980, BLOOD, V56, P1060, DOI 10.1182/blood.V56.6.1060.1060; RYAN GR, 1991, BLOOD, V77, P1195; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P6072; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STIEGLER P, 1981, NUCLEIC ACIDS RES, V9, P2153, DOI 10.1093/nar/9.9.2153; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777	31	89	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17959	17965						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917935				2022-12-25	WOS:A1991GG55300041
J	LEE, CP; SEONG, BL; RAJBHANDARY, UL				LEE, CP; SEONG, BL; RAJBHANDARY, UL			STRUCTURAL AND SEQUENCE ELEMENTS IMPORTANT FOR RECOGNITION OF ESCHERICHIA-COLI FORMYLMETHIONINE TRANSFER-RNA BY METHIONYL-TRANSFER RNA TRANSFORMYLASE ARE CLUSTERED IN THE ACCEPTOR STEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATOR TRANSFER-RNA; TRANSFER RIBONUCLEIC-ACID; PROTEIN-SYNTHESIS; BASE CHANGE; ANTICODON; MUTATION; RESOLUTION; MUTANTS; INVITRO; CODONS	We show that the structure and/or sequence of the first three base pairs at the end of the amino acid acceptor stem of Escherichia coli initiator tRNA and the discriminator base 73 are important for its formylation by E. coli methionyl-tRNA transformylase. This conclusion is based on mutagenesis of the E. coli initiator tRNA gene followed by measurement of kinetic parameters for formylation of the mutant tRNAs in vitro and function in protein synthesis in vivo. The first base pair found at the end of the amino acid acceptor stem in all other tRNAs is replaced by a C.A "mismatch" in E. coli initiator tRNA. Mutation of this C.A to U:A, a weak base pair, or U.G, a mismatch, has little effect on formylation, whereas mutation to C:G, a strong base pair, has a dramatic effect lowering V(max)/K(m)app by 495-fold. Mutation of the second base-pair G2:C71 to U2:A71 lowers V(max)/K(m)app by 236-fold. Replacement of the third base-pair C3:G70 by U3:A70, A3:U70, or G3:C70 lowers V(max)/K(m)app by about 67-, 27-, and 30-fold, respectively. Changes in the rest of the acceptor stem, dihydrouridine stem, anticodon stem, anticodon sequence, and T-psi-C stem have little or no effect on formylation.			LEE, CP (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017151, F32GM017151, R37GM017151] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17151] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DICKERMA.HW, 1967, J BIOL CHEM, V242, P1522; FRANCIS MA, 1990, MOL CELL BIOL, V10, P4486, DOI 10.1128/MCB.10.9.4486; GHOSH K, 1974, J BIOL CHEM, V249, P4720; HUENNEKENS FM, 1963, METHOD ENZYMOL, V6, P806, DOI 10.1016/0076-6879(63)06254-6; KOZAK M, 1983, MICROBIOL REV, V47, P1; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LO KM, 1984, P NATL ACAD SCI-BIOL, V81, P2285, DOI 10.1073/pnas.81.8.2285; MARCKER K, 1964, J MOL BIOL, V8, P835, DOI 10.1016/S0022-2836(64)80164-9; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; RABINOWITZ JC, 1962, J BIOL CHEM, V237, P2898; RAJBHANDARY UL, 1969, J BIOL CHEM, V244, P1104; RAJBHANDARY UL, 1987, FED P, V46; REILLY RM, 1986, J BIOL CHEM, V261, P2928; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHULMAN LH, 1973, J BIOL CHEM, V248, P1341; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SEONG BL, 1988, THESIS MIT CAMBRIDGE; Silberklang M, 1979, Methods Enzymol, V59, P58; SMITH D, 1989, J MOL BIOL, V206, P489, DOI 10.1016/0022-2836(89)90496-8; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; VARSHNEY U, 1990, P NATL ACAD SCI USA, V87, P1586, DOI 10.1073/pnas.87.4.1586	29	99	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18012	18017						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917939				2022-12-25	WOS:A1991GG55300049
J	WRIGHT, PA; LEMOINE, NR; GORETZKI, PE; WYLLIE, FS; BOND, J; HUGHES, C; ROHER, HD; WILLIAMS, ED; WYNFORDTHOMAS, D				WRIGHT, PA; LEMOINE, NR; GORETZKI, PE; WYLLIE, FS; BOND, J; HUGHES, C; ROHER, HD; WILLIAMS, ED; WYNFORDTHOMAS, D			MUTATION OF THE P53-GENE IN A DIFFERENTIATED HUMAN THYROID-CARCINOMA CELL-LINE, BUT NOT IN PRIMARY THYROID-TUMORS	ONCOGENE			English	Note							P53 GENE; ENZYMATIC AMPLIFICATION; RAS ONCOGENE; LUNG-CANCER; CDNA CLONE; TRANSFORMATION; ANTIGEN; DNA; PROTEIN; GROWTH	The p53 gene has been implicated as a tumour suppressor, with mutations occurring in many carcinomas, such as colon, breast and lung. We have sequenced exons 5, 7 and 8 containing conserved gene regions in the only available differentiated thyroid follicular carcinoma cell line and found a mutation at position 273, Arg --> His, with no normal allele present. The same mutation was also present in DNA from the tumour of origin. However immunohistochemical analysis of 129 human thyroid tumours using a panel of p53 antibodies was unequivocally negative. Southern blotting in 20 cases failed to demonstrate any deletion or rearrangement, and direct genomic sequencing of 20 carcinomas showed normal DNA sequence for exons 5, 7 and 8. Thus p53 abnormalities may not be important in human thyroid carcinogenesis, in contrast to colon, breast and lung. However, the FTC 133 cell line was only established after 132 unsuccessful attempts with other differentiated thyroid follicular tumours. Since this line and the corresponding tumour of origin have a p53 mutation, we propose that p53 mutation may confer on thyroid follicular tumour cells the ability to grow in culture. This has potential applications for the future development of thyroid carcinoma cell lines.	HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,MOLEC ONCOL UNIT,LONDON W12 0HS,ENGLAND; UNIV DUSSELDORF,DEPT SURG,W-4000 DUSSELDORF 1,GERMANY	Cancer Research UK; Imperial College London; Heinrich Heine University Dusseldorf	WRIGHT, PA (corresponding author), UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOUR BIOL RES GRP,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.							ALLISON J, 1981, BIOCHEM J, V199, P725, DOI 10.1042/bj1990725; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BENDAVID Y, 1988, ONCOGENE, V3, P179; Boenisch T, 1989, HDB IMMUNOCHEMICAL S, P13; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORETZKI PE, 1989, ANN ENDOCRINOL, V50, P145; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, ONCOGENE, V5, P973; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROSSER J, 1990, ONCOGENE, V5, P1573; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0; WRIGHT PA, 1990, J PATHOL, V162, P99, DOI 10.1002/path.1711620203; WYNFORDTHOMAS D, 1985, EXP CELL RES, V159, P191, DOI 10.1016/S0014-4827(85)80048-3; WYNFORDTHOMAS D, 1990, MOL CELL BIOL, V10, P5365, DOI 10.1128/MCB.10.10.5365	32	111	112	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1693	1697						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923534				2022-12-25	WOS:A1991GX27400028
J	YUASA, Y; KAMIYAMA, T; KATO, M; IWAMA, T; IKEUCHI, T; TONOMURA, A				YUASA, Y; KAMIYAMA, T; KATO, M; IWAMA, T; IKEUCHI, T; TONOMURA, A			TRANSFORMING GENES FROM FAMILIAL ADENOMATOUS POLYPOSIS PATIENT CELLS DETECTED BY A TUMORIGENICITY ASSAY	ONCOGENE			English	Article									TOKYO MED & DENT UNIV, SCH MED, DEPT SURG 2, TOKYO 113, JAPAN; TOKYO MED & DENT UNIV, MED RES INST, TOKYO 113, JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	YUASA, Y (corresponding author), TOKYO MED & DENT UNIV, DEPT HYG & ONCOL, BUNKYO KU, TOKYO 113, JAPAN.							BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KRONTIRIS TG, 1981, P NATL ACAD SCI-BIOL, V78, P1181, DOI 10.1073/pnas.78.2.1181; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; Maniatis T., 1982, MOL CLONING; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; NEEDLEMAN SW, 1983, SCIENCE, V222, P173, DOI 10.1126/science.6623066; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YAMAMOTO A, 1989, BIOCHEM BIOPH RES CO, V159, P1100, DOI 10.1016/0006-291X(89)92222-5; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; YUASA Y, 1986, JPN J CANCER RES, V77, P901; YUASA Y, 1987, JPN J CANCER RES, V78, P1036; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	24	6	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1990	5	4					589	596						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1970154				2022-12-25	WOS:A1990DB85300020
J	LOBIE, PE; BARNARD, R; WATERS, MJ				LOBIE, PE; BARNARD, R; WATERS, MJ			THE NUCLEAR GROWTH-HORMONE RECEPTOR-BINDING PROTEIN - ANTIGENIC AND PHYSICOCHEMICAL CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; KINASE-C; RABBIT LIVER; MONOCLONAL-ANTIBODIES; PROLACTIN RECEPTOR; RAPID ACTIVATION; MESSENGER-RNA; GENE FAMILY; INSULIN; MEMBRANE	The mechanisms involved in transcriptional regulation by growth hormone (GH) remain unknown. We report here that GH receptor immunoreactivity can be demonstrated in the nuclei of GH-responsive rat and rabbit tissues at both the light and electron micrograph level using monoclonal antibodies to the receptor extracellular domain. Nuclear staining is heterogeneous and associated with both chromatin and the nuclear membrane. To confirm these observations, nuclei were isolated from rabbit liver by two methods, one involving extensive nonionic detergent washes. Scatchard analysis of nuclear fractions revealed high affinity, somatogenic receptor in nuclear membranes, nucleoplasm, and chromatin fractions. A panel of GH receptor monoclonal antibodies was used to further define these nuclear binding sites as being antigenically identical to microsomal receptor in all but one case. In addition, affinity cross-linking experiments showed the somatogenic binding subunit to have a reduced M(r) of 67,000, similar to the M(r) of the GH binding protein. We propose that the association of a GH binding protein with the nucleus may provide a means whereby GH can regulate the transcription of specific genes either directly or indirectly through nuclear kinase C activation. This speculation is congruent with the recent demonstration of a GH response element by Yoon et al. (Yoon, J. B., Berry, S. A., Seelig, S., and Towle, H. C. (1990) J. Biol. Chem. 265, 19947-19954).	UNIV QUEENSLAND, CTR MOLEC BIOL, ST LUCIA, QLD 4067, AUSTRALIA	University of Queensland	LOBIE, PE (corresponding author), UNIV QUEENSLAND, DEPT PHYSIOL & PHARMACOL, ST LUCIA, QLD 4067, AUSTRALIA.		Barnard, Ross/AAR-9852-2020; waters, michael j/C-9582-2014	Barnard, Ross/0000-0002-5685-4828; 				BARNARD R, 1990, BIOCHEM J, V267, P471, DOI 10.1042/bj2670471; BARNARD R, 1985, BIOCHEM J, V231, P459, DOI 10.1042/bj2310459; BARNARD R, 1986, BIOCHEM J, V237, P885, DOI 10.1042/bj2370885; BARNARD R, 1984, ENDOCRINOLOGY, V115, P1805, DOI 10.1210/endo-115-5-1805; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BONIFACINO JS, 1983, BIOCHEM J, V214, P121, DOI 10.1042/bj2140121; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; BURWEN SJ, 1987, TRENDS BIOCHEM SCI, V12, P159, DOI 10.1016/0968-0004(87)90074-0; CLEVENGER CV, 1990, ENDOCRINOLOGY, V127, P3151, DOI 10.1210/endo-127-6-3151; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; GISS BJ, 1985, MOL CELL ENDOCRINOL, V42, P259, DOI 10.1016/0303-7207(85)90057-7; GOLDFINE ID, 1978, SCIENCE, V202, P760, DOI 10.1126/science.715440; HOCQUETTE JF, 1989, ENDOCRINOLOGY, V125, P2167, DOI 10.1210/endo-125-4-2167; HUGHES JP, 1983, ENDOCRINOLOGY, V112, P1980, DOI 10.1210/endo-112-6-1980; HYNES MA, 1987, MOL ENDOCRINOL, V1, P233, DOI 10.1210/mend-1-3-233; JIANG LW, 1990, J CELL BIOL, V110, P559, DOI 10.1083/jcb.110.3.559; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD HS, 1986, BIOCHEM BIOPH RES CO, V138, P254, DOI 10.1016/0006-291X(86)90273-1; MACGEOCH C, 1987, BIOCHEM BIOPH RES CO, V143, P782, DOI 10.1016/0006-291X(87)91422-7; MARCHISIO PC, 1980, P NATL ACAD SCI-BIOL, V77, P1656, DOI 10.1073/pnas.77.3.1656; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MASONGARCIA M, 1990, BIOCHEM BIOPH RES CO, V168, P490, DOI 10.1016/0006-291X(90)92348-4; MILLER DS, 1988, SCIENCE, V240, P506, DOI 10.1126/science.2451860; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PODLECKI DA, 1987, J BIOL CHEM, V262, P3362; PURRELLO F, 1983, P NATL ACAD SCI-BIOL, V80, P1189, DOI 10.1073/pnas.80.5.1189; RAJENDRAN KG, 1983, BIOCHEM BIOPH RES CO, V111, P127, DOI 10.1016/S0006-291X(83)80126-0; RAKOWICZSZULCZYNSKA EM, 1986, P NATL ACAD SCI USA, V83, P3728, DOI 10.1073/pnas.83.11.3728; RE RN, 1984, BIOCHEM BIOPH RES CO, V119, P220, DOI 10.1016/0006-291X(84)91641-3; REZVANI I, 1973, BIOCHEM MED METAB B, V7, P432, DOI 10.1016/0006-2944(73)90064-1; ROUPAS P, 1987, ENDOCRINOLOGY, V121, P1521, DOI 10.1210/endo-121-4-1521; RUSSELL DH, 1989, TRENDS PHARMACOL SCI, V10, P40, DOI 10.1016/0165-6147(89)90106-5; SAVION N, 1981, J BIOL CHEM, V256, P1149; SCHRODER HC, 1990, BIOCHEMISTRY-US, V29, P2368, DOI 10.1021/bi00461a022; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SMAL J, 1989, FEBS LETT, V244, P465, DOI 10.1016/0014-5793(89)80584-8; SMAL J, 1987, BIOCHEM BIOPH RES CO, V147, P1232, DOI 10.1016/S0006-291X(87)80202-4; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SPENCER SA, 1988, J BIOL CHEM, V263, P7862; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; VIGNERI R, 1978, J BIOL CHEM, V253, P2098; Wang T.Y., 1967, METHOD ENZYMOL, V12, P417; WATERS MJ, 1979, J BIOL CHEM, V254, P6815; WATERS MJ, 1988, PROG ENDOCRINOL, V1, P601; YANKNER BA, 1979, P NATL ACAD SCI USA, V76, P1269, DOI 10.1073/pnas.76.3.1269; YMER SI, 1987, BIOCHEM J, V242, P713, DOI 10.1042/bj2420713; YOON JB, 1987, J BIOL CHEM, V262, P4284; YOON JB, 1990, J BIOL CHEM, V265, P19947	62	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22645	22652						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939276				2022-12-25	WOS:A1991GR56400089
J	BETZEL, C; LANGE, G; PAL, GP; WILSON, KS; MAELICKE, A; SAENGER, W				BETZEL, C; LANGE, G; PAL, GP; WILSON, KS; MAELICKE, A; SAENGER, W			THE REFINED CRYSTAL-STRUCTURE OF ALPHA-COBRATOXIN FROM NAJA-NAJA-SIAMENSIS AT 2.4-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ACETYLCHOLINE-RECEPTOR; MOLECULAR-CONFORMATION; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; DISULFIDE BRIDGES; SNAKE; BUNGAROTOXIN; NEUROTOXINS; PROTEINS	The crystal structure of the "long" alpha-neurotoxin alpha-cobratoxin was refined to an R-factor of 19.5% using 3271 x-ray data to 2.4-angstrom resolution. The polypeptide chain forms three loops, I, II, III, knotted together by four disulfide bridges, with the most prominent, loop II, containing another disulfide close to its lower tip. Loop I is stabilized by one beta-turn and two beta-sheet hydrogen bonds; loop II by eight beta-sheet hydrogen bonds, with the tip folded into two distorted right-handed helical turns stabilized by two alpha-helical and two-beta-turn hydrogen bonds; and loop III by hydrophobic interactions and one-beta-turn. Loop II and one strand of loop III form an antiparallel triple-pleated beta-sheet, and tight anchoring of the Asn63 side chain fixes the tail segment. In the crystal lattice, the alpha-cobratoxin molecules dimerize by beta-sheet formation between strands 53 and 57 of symmetry-related molecules. Because such interactions are found also in a cardiotoxin and alpha-bungarotoxin, this could be of importance for interaction with acetylcholine receptor.	FREE UNIV BERLIN,INST KRISTALLOG,TAKUSTR 6,W-1000 BERLIN 33,GERMANY; UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,W-6500 MAINZ,GERMANY; DESY,EUROPEAN MOLEC BIOL LAB,W-2000 HAMBURG 52,GERMANY	Free University of Berlin; Johannes Gutenberg University of Mainz; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)			Betzel, Christian/G-8105-2018	Betzel, Christian/0000-0002-3879-5019; Wilson, Keith/0000-0002-3581-2194				BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BYSTROV VF, 1983, TOXINS TOOLS NEUROCH, P193; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P6221, DOI 10.1021/bi00478a016; CONTITRONCONI BM, 1991, BIOCHEMISTRY-US, V30, P2575, DOI 10.1021/bi00224a003; DUFTON HJ, 1988, PHARMACOL THERAPEUT, V36, P1; DUFTON MJ, 1980, TRENDS BIOCHEM SCI, V5, P53, DOI 10.1016/S0968-0004(80)80097-1; DUFTON MJ, 1977, J MOL BIOL, V115, P177, DOI 10.1016/0022-2836(77)90095-X; ENDO T, 1981, EUR J BIOCHEM, V120, P117, DOI 10.1111/j.1432-1033.1981.tb05677.x; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; ENDO T, 1981, PHARMACOL THERAPEUT, V120, P117; HARVEY AL, 1985, J TOXICOL-TOXIN REV, V4, P41, DOI 10.3109/15569548509014413; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HIDER RC, 1982, J MOL BIOL, V158, P275, DOI 10.1016/0022-2836(82)90433-8; INAGAKI F, 1985, J MOL BIOL, V183, P575, DOI 10.1016/0022-2836(85)90173-1; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KANG S, 1980, J BIOL CHEM, V255, P7326; KONDAKOV VI, 1984, BIOORG KHIM+, V10, P1606; KONDAKOV VI, 1984, BIOORG KHIM+, V10, P869; LOVE RA, 1986, PROTEIN ENG, V1, P37, DOI 10.1093/protein/1.1.37; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MACHIN PA, 1984, DARESBURY LAB NEWS, V10, P3; MACHIN PA, 1984, DARESBURY LAB NEWS, V13, P17; MAELICKE A, 1977, J BIOL CHEM, V252, P4811; MARTIN BM, 1983, J BIOL CHEM, V258, P8714; MIYAZAWA T, 1983, BIOPOLYMERS, V22, P139, DOI 10.1002/bip.360220122; REES B, 1990, J MOL BIOL, V214, P281, DOI 10.1016/0022-2836(90)90161-E; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SAENGER W, 1987, RECEPTORS ION CHANNE, P333; SALEMME FR, 1981, J MOL BIOL, V146, P101, DOI 10.1016/0022-2836(81)90368-5; SMITH JL, 1988, ACTA CRYSTALLOGR A, V44, P357, DOI 10.1107/S0108767388000303; SRINIVASAN N, 1990, INT J PEPT PROT RES, V36, P147; TAMIYA N, 1980, BIOCHEM SOC T, V6, P753; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TSERNOGLOU D, 1977, SCIENCE, V197, P1378, DOI 10.1126/science.897675; TSERNOGLOU D, 1977, P NATL ACAD SCI USA, V74, P971, DOI 10.1073/pnas.74.3.971; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; [No title captured]	38	109	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21530	21536						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939183				2022-12-25	WOS:A1991GP80400036
J	GONG, H; OHAD, I				GONG, H; OHAD, I			THE PQ/PQH2 RATIO AND OCCUPANCY OF PHOTOSYSTEM-II-QB SITE BY PLASTOQUINONE CONTROL THE DEGRADATION OF D1 PROTEIN DURING PHOTOINHIBITION INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION CENTER POLYPEPTIDES; ELECTRON-TRANSPORT; CHLAMYDOMONAS-REINHARDTII; LIGHT PHOTOINHIBITION; QUINONE ACCEPTOR; OXIDIZING SIDE; D-1 PROTEIN; REDOX STATE; PHOTOINACTIVATION; PHOTOACTIVATION	Photoinactivation of photosystem II(PSII) and light-dependent degradation of the reaction center II (RCII) protein D1 have been investigated in Chlamydomonas reinhardtii mutants D6, AC208, and B4 deficient in cytochrome b6/f, plastocyanin, and photosystem I (PSI) activity, respectively. These mutants possess active PSII and reduce plastoquinone (PQ) but cannot oxidize plastoquinol (PQH2) via light-dependent reduction of NADP. In light-exposed cells a high ratio PQH2/PQ and a low turnover of PQ/PQH2 at the RCII-QB site are maintained. In all mutants photoinactivation of RCII was slower as compared to the wild-type (wt) cells, and D1 degradation was drastically decreased. The degradation of D1 was also lower in the wt cells under anaerobic conditions and presence of ascorbate, while raising the concentration of dissolved oxygen increased the degradation of the Dl protein in the AC208 mutant. Photoinactivation and light-dependent degradation of the DI protein were drastically increased in the Scenedesmus obliquus LF-1 mutant cells altered in its PSII manganese binding and thus unable to reduce PQ using water as an electron donor. Diuron inhibited the light-dependent degradation of D1 protein in both the LF-1 mutant and wt cells. Based on these results we propose that availability of PQ at the QB site is required for (i) the photoinactivation process of the RCII acceptor side followed by inactivation of the donor side leading to the generation of harmful cation radicals (Z+, P680+, chl(z)+) which damage the D1 protein, and (ii) the accessibility of the cleavage site of the damaged D1 protein to proteolytic degradation.	UNIV OSLO, DEPT BIOL, PHYTOTRON, N-0316 OSLO 3, NORWAY	University of Oslo	GONG, H (corresponding author), HEBREW UNIV JERUSALEM, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL.							ADIR N, 1990, J BIOL CHEM, V265, P12563; Andersson B., 1991, CURRENT TOPICS BIOEN, V16, P1; ARIELI B, 1991, J BIOL CHEM, V266, P104; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ARNTZ B, 1986, FEBS LETT, V194, P43, DOI 10.1016/0014-5793(86)80048-5; BENNETT J, 1988, EUR J BIOCHEM, V171, P95, DOI 10.1111/j.1432-1033.1988.tb13763.x; BENNOUN P, 1982, P NATL ACAD SCI-BIOL, V79, P4352, DOI 10.1073/pnas.79.14.4352; Bishop N.I., 1971, METHODS ENZYMOLOGY A, P53, DOI 10.1016/S0076-6879(71)23079-2; BLUBAUGH DJ, 1990, BIOCHEMISTRY-US, V29, P5109, DOI 10.1021/bi00473a016; CALLAHAN FE, 1986, PLANT PHYSIOL, V82, P261, DOI 10.1104/pp.82.1.261; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEMETER S, 1987, FEBS LETT, V214, P370, DOI 10.1016/0014-5793(87)80090-X; DINER B, 1975, 3RD P INT C PHOT, P589; DINER BA, 1984, BIOCHIM BIOPHYS ACTA, V766, P9, DOI 10.1016/0005-2728(84)90211-1; DINER BA, 1977, BIOCHIM BIOPHYS ACTA, V460, P247, DOI 10.1016/0005-2728(77)90211-0; ECKERT HJ, 1991, PHOTOSYNTH RES, V27, P97, DOI 10.1007/BF00033249; GABA V, 1987, PLANT PHYSIOL, V84, P348, DOI 10.1104/pp.84.2.348; GAL A, 1990, J BIOL CHEM, V265, P19742; GAL A, 1989, FEBS LETT, V221, P210; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; GREENBERG BM, 1989, P NATL ACAD SCI USA, V86, P6617, DOI 10.1073/pnas.86.17.6617; HIRSCHBERG J, 1984, Z NATURFORSCH C, V39, P412; JEGERSCHOLD C, 1990, BIOCHEMISTRY-US, V29, P6179, DOI 10.1021/bi00478a010; KIRILOVSKY D, 1990, BIOCHIM BIOPHYS ACTA, V1020, P87, DOI 10.1016/0005-2728(90)90097-N; KRAUSE GH, 1984, PHOTOSYNTH RES, V5, P139, DOI 10.1007/BF00028527; KRAUSE GH, 1987, TOPICS PHOTOSYNTHESI, V9, P169; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; KYLE DJ, 1987, TOPICS PHOTOSYNTHESI, V9, P197; LAVERGNE J, 1991, TRENDS BIOCHEM SCI, V16, P129, DOI 10.1016/0968-0004(91)90054-Y; LEVINE RP, 1970, ANNU REV GENET, V4, P397, DOI 10.1146/annurev.ge.04.120170.002145; LEVINE RP, 1969, ANN REV PLANT PHYSIO, V20, P523, DOI 10.1146/annurev.pp.20.060169.002515; MAIONE TE, 1986, PLANT PHYSIOL, V80, P364, DOI 10.1104/pp.80.2.364; MATHIS P, 1987, PHOTOSYNTHESIS NEW C, V15, P63; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; METZ JG, 1985, FEBS LETT, V185, P191, DOI 10.1016/0014-5793(85)80768-7; MOENNELOCCOZ P, 1989, BIOCHEMISTRY-US, V28, P3641, DOI 10.1021/bi00435a003; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; OHAD I, 1967, J CELL BIOL, V35, P521, DOI 10.1083/jcb.35.3.521; OHAD I, 1990, J BIOL CHEM, V265, P1972; OHAD I, 1988, BIOCHIM BIOPHYS ACTA, V933, P288, DOI 10.1016/0005-2728(88)90036-9; OHAD N, 1990, Z NATURFORSCH C, V45, P402; OREN A, 1978, J BACTERIOL, V133, P558, DOI 10.1128/JB.133.2.558-563.1978; POWLES SB, 1984, ANNU REV PLANT PHYS, V35, P15, DOI 10.1146/annurev.pp.35.060184.000311; PRASIL O, 1991, TOPICS PHOTOSYNTHESI, V11; RICHTER M, 1990, PHOTOSYNTH RES, V24, P237, DOI 10.1007/BF00032311; ROBINSON HH, 1983, FEBS LETT, V153, P221, DOI 10.1016/0014-5793(83)80152-5; SATOH K, 1971, PLANT CELL PHYSIOL, V12, P13, DOI 10.1093/oxfordjournals.pcp.a074596; SCHMIDT GW, 1977, P NATL ACAD SCI USA, V74, P610, DOI 10.1073/pnas.74.2.610; SCHUSTER G, 1988, EMBO J, V7, P1; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; SCHUSTER G, 1984, BIOCHIM BIOPHYS ACTA, V767, P596, DOI 10.1016/0005-2728(84)90061-6; SETLIK I, 1990, PHOTOSYNTH RES, V23, P39, DOI 10.1007/BF00030061; SHOCHAT S, 1990, Z NATURFORSCH C, V45, P395; STYRING S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P269, DOI 10.1016/0005-2728(90)90031-X; TAYLOR MA, 1988, FEBS LETT, V237, P229, DOI 10.1016/0014-5793(88)80207-2; THEG SM, 1986, BIOCHIM BIOPHYS ACTA, V849, P104, DOI 10.1016/0005-2728(86)90101-5; THOMPSON LK, 1988, BIOCHEMISTRY-US, V27, P6653, DOI 10.1021/bi00418a002; TREBST A, 1988, PHOTOSYNTH RES, V18, P163, DOI 10.1007/BF00042983; TREBST A, 1987, Z NATURFORSCH C, V42, P742; WURTZ EA, 1979, MOL GEN GENET, V170, P235, DOI 10.1007/BF00267056	60	52	54	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21293	21299						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939165				2022-12-25	WOS:A1991GN00100109
J	HII, CST; EDWARDS, YS; MURRAY, AW				HII, CST; EDWARDS, YS; MURRAY, AW			PHORBOL ESTER-STIMULATED HYDROLYSIS OF PHOSPHATIDYLCHOLINE AND PHOSPHATIDYLETHANOLAMINE BY PHOSPHOLIPASE-D IN HELA-CELLS - EVIDENCE THAT THE BASAL TURNOVER OF PHOSPHOGLYCERIDES DOES NOT INVOLVE PHOSPHOLIPASE-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL TRANSDUCTION; PHOSPHATIDATE PHOSPHOHYDROLASE; LINKED PHOSPHOLIPIDS; ENDOTHELIAL-CELLS; ACTIVATION; DIACYLGLYCEROL; BREAKDOWN; BIOSYNTHESIS; DIGLYCERIDE	12-O-Tetradecanoylphorbol-13-acetate (TPA) stimulated the release of [H-3]ethanolamine from HeLa cells prelabeled with [H-3]ethanolamine within 2 min, and of [H-3]choline from cells prelabeled with [H-3]choline after a lag of 10-20 min. This result suggests that TPA activates phospholipase D. Propranolol alone or propranolol plus TPA stimulated phosphatidic acid (PA) labeling in cells prelabeled with [H-3]hexadecanol. In the presence of ethanol, TPA stimulated the accumulation of labeled phosphatidylethanol (PEth); no PEth was formed in the absence of TPA. TPA-dependent PEth accumulation was not observed in cells pretreated with TPA to down-regulate protein kinase C, whereas propranolol-induced accumulation of PA was unaffected by TPA pretreatment. Incubation of prelabeled cells with propranolol alone caused a rapid loss of label and phospholipid mass from both phosphatidylethanolamine and phosphatidylcholine (PC) together with an accumulation of PA and phosphatidylinositol plus phosphatidylserine. When [H-3]hexadecanol-prelabeled cells were pulse labeled with P-32 to label nucleotide pools, propranolol induced the accumulation of both H-3- and P-32-labeled PA. When cells were prelabeled with lyso-PC double labeled with H-3 and P-32, and incubated with propranolol, only H-3-labeled PA accumulated, indicating that the pathways involved in the basal turnover of PC resulted in the loss of P-32 from the lipid. These results suggest that the basal turnover of phosphatidylethanolamine and PC involves the sequential actions of phospholipase C, diglyceride kinase, and PA phosphohydrolase.			HII, CST (corresponding author), FLINDERS UNIV,SCH BIOL SCI,BEDFORD PK,SA 5042,AUSTRALIA.							AGWU DE, 1989, J BIOL CHEM, V264, P1405; ALLAN D, 1975, BIOCHEM J, V148, P471, DOI 10.1042/bj1480471; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BENAV P, 1989, FEBS LETT, V259, P64, DOI 10.1016/0014-5793(89)81495-4; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; CABOT MC, 1989, FEBS LETT, V245, P85, DOI 10.1016/0014-5793(89)80197-8; DIAZMECO MT, 1989, BIOCHEM J, V263, P115, DOI 10.1042/bj2630115; EXTON JH, 1990, J BIOL CHEM, V265, P1; HII CST, 1990, BIOCHIM BIOPHYS ACTA, V1052, P327, DOI 10.1016/0167-4889(90)90229-7; HII CST, 1989, FEBS LETT, V257, P35, DOI 10.1016/0014-5793(89)81779-X; JALINK K, 1990, J BIOL CHEM, V265, P12232; KINSKY SC, 1989, BIOCHEM BIOPH RES CO, V162, P788, DOI 10.1016/0006-291X(89)92379-6; KISS Z, 1990, J BIOL CHEM, V265, P7345; KISS Z, 1989, J BIOL CHEM, V264, P1483; LAVIE Y, 1990, J BIOL CHEM, V265, P3868; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LISCOVITCH M, 1989, J BIOL CHEM, V264, P1450; MARTIN TW, 1990, BIOCHIM BIOPHYS ACTA, V1053, P162, DOI 10.1016/0167-4889(90)90009-3; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MUIR JG, 1987, J CELL PHYSIOL, V130, P382, DOI 10.1002/jcp.1041300311; PAPPU AS, 1983, NEUROCHEM RES, V8, P1565, DOI 10.1007/BF00964158; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PRICE BD, 1989, BIOCHEM J, V264, P509, DOI 10.1042/bj2640509; SCHRAKAMP G, 1988, J LIPID RES, V29, P325; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; WOOD R, 1968, LIPIDS, V3, P129, DOI 10.1007/BF02531729	34	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20238	20243						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939084				2022-12-25	WOS:A1991GM03900056
J	WILLIAMS, GR; HARNEY, JW; FORMAN, BM; SAMUELS, HH; BRENT, GA				WILLIAMS, GR; HARNEY, JW; FORMAN, BM; SAMUELS, HH; BRENT, GA			OLIGOMERIC BINDING OF T3 RECEPTOR IS REQUIRED FOR MAXIMAL T3 RESPONSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE-RECEPTOR; RAT OSTEOCALCIN GENE; CULTURED GH1 CELLS; MALIC ENZYME GENE; GROWTH-HORMONE; RETINOIC-ACID; ESTROGEN-RECEPTOR; NEGATIVE REGULATION; NUCLEAR RECEPTORS; TATA BOX	Receptors in the thyroid-steroid hormone superfamily bind preferentially as dimers to palindromic response elements containing two hexameric half-sites. The 23-base pair rat growth hormone (rGH) T3 response element (T3RE), however, contains three hexameric binding domains, all of which are required for maximal T3 response. We examined the binding of purified T3 receptor-alpha (T3R-alpha), overexpressed in Escherichia coli, to wild-type and up and down mutations of the rGH T3RE to evaluate whether transcriptional potency correlates with changes in T3R binding. T3R binds to the rGH T3RE as a monomer, dimer, or higher order oligomer. Cooperative T3R dimer binding was demonstrated to two hexameric domains of the rGH T3RE arranged as either direct or inverted repeats. Decreased binding was seen with point mutations in each domain as well as with mutations which altered hexamer orientation and spacing within the site. These results demonstrate that all three hexamers of the rGH T3RE are involved in binding T3R. Occupancy of all three hexamers by T3R in the gel shift assay was observed with functional up mutations of the T3RE, increasing receptor concentration or addition of nuclear extract. The transcriptional response potencies of T3RE up or down mutants in a transient transfection assay correlated closely with T3R binding. These results confirm our earlier hypothesis that all three hexamers of the rGH T3RE bind T3R in a novel binding arrangement and provide a model for the interaction of T3R and other nuclear proteins with the DNA sequences of thyroid hormone-regulated genes.	BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU MED CTR,DEPT MED,DIV MOLEC ENDOCRINOL,NEW YORK,NY 10016	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; New York University; New York University	BRENT, GA (corresponding author), BRIGHAM & WOMENS HOSP,DIV THYROID,75 FRANCIS ST,BOSTON,MA 02115, USA.				NIADDK NIH HHS [5-K12-AM01401] Funding Source: Medline; NIDDK NIH HHS [DK-16636, DK-36256] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [K12AM001401] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK016636, R01DK016636, R01DK036256] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BERG JM, 1989, CELL, V57, P1065, DOI 10.1016/0092-8674(89)90042-1; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DEMAY MB, 1989, J BIOL CHEM, V264, P2279; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1991, IN PRESS GENE AMST; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LARSEN PR, 1986, J BIOL CHEM, V261, P4373; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LEES JA, 1990, MOL CELL BIOL, V10, P5529, DOI 10.1128/MCB.10.10.5529; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; PETTY KJ, 1989, J BIOL CHEM, V264, P11483; Ptashne M., 1986, A GENETIC SWITCH; SAMUELS HH, 1973, P NATL ACAD SCI USA, V70, P3488, DOI 10.1073/pnas.70.12.3488; SAMUELS HH, 1974, J CLIN INVEST, V54, P853, DOI 10.1172/JCI107825; SAMUELS HH, 1974, J CLIN INVEST, V53, P656, DOI 10.1172/JCI107601; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SELMI S, 1991, J BIOL CHEM, V266, P11589; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SPINDLER SR, 1982, J BIOL CHEM, V257, P1627; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WONDISFORD FE, 1988, J BIOL CHEM, V263, P12538; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q; YAFFE BM, 1984, J BIOL CHEM, V259, P6284; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	58	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19636	19644						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918070				2022-12-25	WOS:A1991GK66700074
J	FEAVER, WJ; GILEADI, O; KORNBERG, RD				FEAVER, WJ; GILEADI, O; KORNBERG, RD			PURIFICATION AND CHARACTERIZATION OF YEAST RNA POLYMERASE-II TRANSCRIPTION FACTOR-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCURATE INITIATION; SPECIFICITY; PROTEINS; DNA	Heat treatment of yeast nuclear extracts abolished the capacity to initiate transcription at RNA polymerase II promoters. Activity was restored by the addition of both recombinant yeast TFIID and partially purified of both recombinant yeast TFIID and partially purified factor b, a yeast fraction shown previously to be required for polymerase II transcription. On the basis of this assay with heat-treated extract, factor b was purified to virtual homogeneity. The factor appears to comprise polypeptides of approximately 85, 75, and 50 kDa, since these three polypeptides co-purify with activity, and since a native mass of about 200 kDa is estimated from glycerol gradient sedimentation and gel filtration.			FEAVER, WJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,FAIRCHILD CTR,DEPT CELL BIOL,STANFORD,CA 94305, USA.		Gileadi, Opher/F-1105-2013	Gileadi, Opher/0000-0001-6886-898X	NIGMS NIH HHS [GM-36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1991, ANAL BIOCHEM, V194, P545; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1990, J BIOL CHEM, V265, P5629; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KORNBERG RD, 1991, IN PRESS TRANSCRIPTI; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZHENG XM, 1990, NATURE, V344, P556, DOI 10.1038/344556a0	25	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19000	19005						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918015				2022-12-25	WOS:A1991GJ47200090
J	NAKANO, K; MATUDA, S; YAMANAKA, T; TSUBOUCHI, H; NAKAGAWA, S; TITANI, K; OHTA, S; MIYATA, T				NAKANO, K; MATUDA, S; YAMANAKA, T; TSUBOUCHI, H; NAKAGAWA, S; TITANI, K; OHTA, S; MIYATA, T			PURIFICATION AND MOLECULAR-CLONING OF SUCCINYLTRANSFERASE OF THE RAT ALPHA-KETOGLUTARATE DEHYDROGENASE COMPLEX - ABSENCE OF A SEQUENCE MOTIF OF THE PUTATIVE E3 AND OR E1 BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOYL TRANSACETYLASE COMPONENT; MAMMALIAN-PYRUVATE-DEHYDROGENASE; BRANCHED-CHAIN ACYLTRANSFERASE; NUCLEOTIDE-SEQUENCE; 2-OXOGLUTARATE DEHYDROGENASE; AZOTOBACTER-VINELANDII; ESCHERICHIA-COLI; ACETYLTRANSFERASE COMPONENT; SACCHAROMYCES-CEREVISIAE; MULTIENZYME COMPLEXES	Full-length cDNA clones for succinyltransferase of the rat alpha-ketoglutarate dehydrogenase complex were isolated from rat heart cDNA libraries in lambda-gt11. The cDNA clones were identified as those for rat succinyltransferase by the identity of their predicted amino acid sequence with the NH2-terminal amino acid sequence of rat succinyltransferase determined by protein chemical analysis and the known amino acid sequence of bovine succinyltransferase. The clone with the longest cDNA consisted of 2747 base pairs and coded for a leader peptide of 56 amino acid residues and a mature protein of 386 amino acid residues. The primary structure of rat succinyltransferase showed close similarity to Escherichia coli and Azotobacter vinelandii succinyltransferases, in the COOH-terminal part forming the lipoyl-binding domain and the NH2-terminal part forming the inner core-catalytic domain. However, the rat succinyltransferase did not contain a sequence motif that has been found as an E3- and/or E1-binding site in the dihydrolipoamide acyltransferases of three alpha-ketoacid dehydrogenase complexes (Hummel, K. B., Litwer, S., Bradford, A. P., Aitken, A., Danner, D. J., and Yeaman, S. J. (1988) J. Biol. Chem. 263, 6165-6168, Reed, L. J., and Hackert, M. L. (1990) J. Biol. Chem. 265, 8971-8974). The absence of this sequence was confirmed by direct sequencing, of the polymerase chain reaction product of rat heart mRNA and by computer analysis. These results show that the rat succinyltransferase does not have the sequence motif of the putative E3- and/or E1-binding site.	KANOYA NATL INST FITNESS & SPORTS,DEPT HLTH SCI,KAGOSHIMA 89123,JAPAN; KAGOSHIMA WOMENS JR COLL,DEPT BIOCHEM,KAGOSHIMA 890,JAPAN; KAGOSHIMA UNIV,SCH MED,DEPT INTERNAL MED,KAGOSHIMA 890,JAPAN; KAGOSHIMA UNIV,SCH MED,DEPT ANAT,KAGOSHIMA 890,JAPAN; FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DIV BIOMED POLYMER SCI,TOYOAKE,AICHI 47011,JAPAN; JICHI MED SCH,DEPT BIOCHEM,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOL,KYOTO 606,JAPAN	National Institute Fitness & Sports Kanoya; Kagoshima University; Kagoshima University; Fujita Health University; Jichi Medical University; Kyoto University								BORGES A, 1990, EUR J BIOCHEM, V194, P95, DOI 10.1111/j.1432-1033.1990.tb19432.x; BRADFORD AP, 1987, FEBS LETT, V222, P211, DOI 10.1016/0014-5793(87)80221-1; BURNS G, 1988, EUR J BIOCHEM, V176, P311, DOI 10.1111/j.1432-1033.1988.tb14283.x; BURNS G, 1988, EUR J BIOCHEM, V176, P165, DOI 10.1111/j.1432-1033.1988.tb14264.x; COPPEL RL, 1988, P NATL ACAD SCI USA, V85, P7317, DOI 10.1073/pnas.85.19.7317; DANNER DJ, 1989, J BIOL CHEM, V264, P7742; DARLISON MG, 1984, EUR J BIOCHEM, V141, P351, DOI 10.1111/j.1432-1033.1984.tb08199.x; DEMARCUCCI OGL, 1988, BIOCHEM J, V251, P817, DOI 10.1042/bj2510817; DEMARCUCCI OL, 1985, BIOCHEM J, V226, P509, DOI 10.1042/bj2260509; GUEST JR, 1987, FEMS MICROBIOL LETT, V44, P417, DOI 10.1111/j.1574-6968.1987.tb02324.x; HANEMAAIJER R, 1987, EUR J BIOCHEM, V169, P245, DOI 10.1111/j.1432-1033.1987.tb13604.x; HANEMAAIJER R, 1989, EUR J BIOCHEM, V179, P287, DOI 10.1111/j.1432-1033.1989.tb14553.x; HANEMAAIJER R, 1988, EUR J BIOCHEM, V174, P593, DOI 10.1111/j.1432-1033.1988.tb14140.x; Heijne GV, 1986, EMBO J, V5, P1335; HUMMEL KB, 1988, J BIOL CHEM, V263, P6165; HUNTER A, 1986, EUR J BIOCHEM, V155, P103, DOI 10.1111/j.1432-1033.1986.tb09464.x; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATUDA S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P1, DOI 10.1016/0167-4781(91)90076-X; NIU XD, 1990, BIOCHEMISTRY-US, V29, P8614, DOI 10.1021/bi00489a017; NIU XD, 1988, P NATL ACAD SCI USA, V85, P7546, DOI 10.1073/pnas.85.20.7546; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PACKMAN LC, 1987, BIOCHEM J, V242, P531, DOI 10.1042/bj2420531; PACKMAN LC, 1986, FEBS LETT, V206, P193, DOI 10.1016/0014-5793(86)80979-6; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPENCER ME, 1984, EUR J BIOCHEM, V141, P361, DOI 10.1111/j.1432-1033.1984.tb08200.x; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P481, DOI 10.1111/j.1432-1033.1983.tb07490.x; TANAKA N, 1974, J BIOL CHEM, V249, P191; THEKKUMKARA TJ, 1988, FEBS LETT, V240, P45, DOI 10.1016/0014-5793(88)80337-5; THEKKUMKARA TJ, 1989, ANN NY ACAD SCI, V113, P573; TOH H, 1983, NATURE, V305, P827, DOI 10.1038/305827a0; WESTPHAL AH, 1990, EUR J BIOCHEM, V187, P235, DOI 10.1111/j.1432-1033.1990.tb15300.x; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625	38	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19013	19017						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918017				2022-12-25	WOS:A1991GJ47200092
J	BURNS, DJ; BELL, RM				BURNS, DJ; BELL, RM			PROTEIN-KINASE-C CONTAINS 2 PHORBOL ESTER BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY DOMAIN; ACTIVATION; EXPRESSION; PURIFICATION; FAMILY; PHOSPHATIDYLSERINE; MECHANISM; ISOZYMES; ELEMENTS; ENZYME	A series of deletion and truncation mutants of protein kinase C (PKC) were expressed in the baculovirus-insect cell expression system in order to elucidate the ability of various domains of the enzyme to bind phorbol dibutyrate (PDBu). A PKC truncation mutant consisting of only the catalytic domain of the enzyme did not bind [H-3]PDBu, whereas a PKC truncation mutant consisting of the regulatory domain (containing the tandem cysteine-rich putative zinc finger regions) bound [H-3]PDBu. Deletion of the second conserved region (C2) of PKC did not abolish [H-3]PDBu binding, whereas a deletion of the first conserved region (C1) of PKC, containing the two cysteine-rich sequences, completely abolished [H-3]PDBu binding. Additional truncation and deletion mutants helped to localize the region necessary for [H-3]PDBu binding; all PKC mutants that contained either one of the cysteine-rich zinc finger-like regions possessed phorbol ester binding activity. Scatchard analyses of these mutants indicated that each bound [H-3]PDBu with equivalent affinity (21-41 nM); approximately 10-20-fold less than the native enzyme. In addition, a peptide of 146 amino acid residues from the first cysteine-rich region, as well as a peptide of only 86 amino acids residues from the second cysteine-rich region, both bound [H-3]PDBu with high affinity (31 +/- 4 and 59 +/- 13 nM, respectively). These data establish that PKC contains two phorbol ester binding domains which may function in its regulation.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038737] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM12326, GM38737] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P3577, DOI 10.1021/bi00434a064; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLUMBERG PM, 1984, BIOCHEM PHARMACOL, V33, P933, DOI 10.1016/0006-2952(84)90448-9; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; EBELING JG, 1985, P NATL ACAD SCI USA, V82, P815, DOI 10.1073/pnas.82.3.815; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HANNUN YA, 1987, METHOD ENZYMOL, V141, P287; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HARD T, 1990, BIOCHEMISTRY-US, V29, P9015; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; LEE MH, 1986, J BIOL CHEM, V261, P4867; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MARAGANORE JM, 1987, TRENDS BIOCHEM SCI, V12, P176, DOI 10.1016/0968-0004(87)90082-X; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSADA S, 1990, J BIOL CHEM, V265, P22434; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAP D, 1990, J BIOL CHEM, V265, P7301; SUMMERS MD, 1987, TEXAS AGR STATION B, V1555; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELLING GW, 1985, FEBS LETT, V188, P215, DOI 10.1016/0014-5793(85)80374-4	38	230	231	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18330	18338						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917958				2022-12-25	WOS:A1991GG55300093
J	FOUSER, L; IRUELAARISPE, L; BORNSTEIN, P; SAGE, EH				FOUSER, L; IRUELAARISPE, L; BORNSTEIN, P; SAGE, EH			TRANSCRIPTIONAL ACTIVITY OF THE ALPHA-1(I)-COLLAGEN PROMOTER IS CORRELATED WITH THE FORMATION OF CAPILLARY-LIKE STRUCTURES BY ENDOTHELIAL-CELLS INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCE ANGIOGENESIS INVITRO; 1ST INTRON CONTRIBUTE; COLLAGEN GENE; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; REGULATORY ELEMENTS; PHENOTYPIC MODULATION; MAMMALIAN-CELLS; DNA-SEQUENCES; DIFFERENTIATION	Bovine aortic endothelial (BAE) cells spontaneously form structures in vitro that resemble capillary-like cords or tubes. This process is associated with changes in the expression of certain extracellular matrix proteins that include type I collagen. BAE cells exhibiting angiogenesis in vitro were transfected with plasmids containing either chloramphenicol acetyltransferase or human growth hormone genes directed by promoter sequences from the human alpha-1(I)-collagen gene. Immunostaining for chloramphenicol acetyltransferase demonstrated that collagen promoter activity was restricted to cells involved in the formation of endothelial cords. In comparison to transfected monolayers of BAE cells, the transcriptional activity of the alpha-1(I)-collagen promoter increased by 7-fold in cultures undergoing angiogenesis in vitro. The selective ability of angiogenic endothelium to utilize the alpha-1(I)-collagen promoter is consistent with previous studies showing high levels of alpha-1(I)-collagen mRNA in BAE cells actively engaged in the formation of tubes (Iruela-Arispe, L., Hasselaar, P., and Sage, H. (1991) Lab. Invest. 64, 174-186). We conclude that transcriptional activation of the alpha-1(I)-collagen gene is closely linked to the morphologic alterations in cellular phenotype that accompany the transition of quiescent endothelial monolayers to the angiogenic state.	UNIV WASHINGTON,SCH MED,DEPT BIOL STRUCT,SM-20,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Iruela-Arispe, M. Luisa/AAJ-1297-2020	Iruela-Arispe, M. Luisa/0000-0002-3050-4168	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR011248, R37AR011248] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03174, HL 41196] Funding Source: Medline; NIAMS NIH HHS [AR11248] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOAST S, 1990, J BIOL CHEM, V265, P13351; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BORNSTEIN P, 1987, P NATL ACAD SCI USA, V84, P8869, DOI 10.1073/pnas.84.24.8869; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1989, PROG NUCLEIC ACIDS R, V37, P66; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; COTTAPEREIRA G, 1980, J CELL PHYSIOL, V102, P183, DOI 10.1002/jcp.1041020209; DeLuca M., 1978, METHOD ENZYMOL, V57, P3, DOI DOI 10.1016/0076-6879(78)57003-1; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Ekblom P, 1984, ROLE EXTRACELLULAR M, P173; FEDER J, 1983, J CELL PHYSIOL, V116, P1, DOI 10.1002/jcp.1041160102; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1985, PERSPECT BIOL MED, V29, P10; FURCHT LT, 1986, LAB INVEST, V55, P505; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; HASSELAAR P, 1991, J BIOL CHEM, V266, P13178; INGBER D, 1988, LAB INVEST, V59, P44; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; IREULAARISPE ML, 1988, J CELL BIOL, V107, pA579; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; IRUELAARISPE ML, 1991, INPRESS ARTERIOSCLER; JACKSON CJ, 1991, EXP CELL RES, V192, P319, DOI 10.1016/0014-4827(91)90194-Y; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LISKA DJ, 1990, CELL REGUL, V1, P487, DOI 10.1091/mbc.1.6.487; MACIAG T, 1982, J CELL BIOL, V94, P511, DOI 10.1083/jcb.94.3.511; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MADRI JA, 1982, AM J PATHOL, V106, P180; MADRI JA, 1986, J HISTOCHEM CYTOCHEM, V34, P85, DOI 10.1177/34.1.2416801; MADRI JA, 1991, J CELL BIOCHEM, V45, P123, DOI 10.1002/jcb.240450202; MCAUSLAN BR, 1985, CELL BIOL INT REP, V9, P175, DOI 10.1016/0309-1651(85)90092-X; MERWIN JR, 1990, J CELL PHYSIOL, V142, P117, DOI 10.1002/jcp.1041420115; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MONTESANO R, 1987, J CELL PHYSIOL, V130, P284, DOI 10.1002/jcp.1041300215; NICOSIA RF, 1987, AM J PATHOL, V128, P78; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; RAVAZZOLO R, 1991, J BIOL CHEM, V266, P7382; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4; ROSSOUW CMS, 1987, J BIOL CHEM, V262, P15151; SAGE EH, 1991, J BIOL CHEM, V266, P14831; Sage H., 1984, BIOL ENDOTHELIAL CEL, P161, DOI [10.1007/978-1-4613-2825-4_16, DOI 10.1007/978-1-4613-2825-4_16]; SCHOR AM, 1983, J CELL SCI, V62, P267; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; THOMPSON JA, 1988, SCIENCE, V241, P1349, DOI 10.1126/science.2457952; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; [No title captured]	58	55	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18345	18351						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917959				2022-12-25	WOS:A1991GG55300095
J	NESHEIM, M; PITTMAN, DD; GILES, AR; FASS, DN; WANG, JH; SLONOSKY, D; KAUFMAN, RJ				NESHEIM, M; PITTMAN, DD; GILES, AR; FASS, DN; WANG, JH; SLONOSKY, D; KAUFMAN, RJ			THE EFFECT OF PLASMA VONWILLEBRAND-FACTOR ON THE BINDING OF HUMAN FACTOR-VIII TO THROMBIN-ACTIVATED HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON WILLEBRAND FACTOR; PHOSPHOLIPID-VESICLES; FACTOR-XA; PROCOAGULANT PROTEIN; MAMMALIAN-CELLS; LIGHT CHAIN; EXPRESSION; COMPLEX; INACTIVATION; SECRETION	The binding of S-35-labeled recombinant human Factor VIII to activated human platelets was studied in the presence and absence of exogenous plasma von Willebrand factor. In the absence of added von Willebrand Factor, platelets bound 210 molecules of Factor VIII/platelet when the unbound Factor VIII concentration was 2.0 nM (K(d) = 2.9 nM). As the von Willebrand factor concentration was increased, the number of Factor VIII molecules bound/platelet decreased to 10 molecules of Factor VIII bound/platelet at 24-mu-g/ml of added vWF. Addition of an anti-vWF monoclonal antibody that inhibits the vWF-Factor VIII interaction attenuated the ability of vWF to inhibit binding of Factor VIII to platelets. In contrast, addition of a control anti-vWF antibody that does not block the vWF-Factor VIII interaction did not affect the ability of vWF to inhibit Factor VIII binding to platelets. From the vWF concentration dependence of inhibition of Factor VIII-platelet binding, a dissociation constant for the Factor VIII-vWF interaction was calculated (K(d) = 0.44 nM). To further elucidate the role that vWF may play in preventing the interaction of Factor VIII with platelets, the platelet binding properties of a Factor VIII deletion mutant (90-73) which lacks the primary vWF-binding site was studied. The binding of this mutant was unaffected by added exogenous vWF. These observations demonstrate that Factor VIII can interact with platelets in a manner independent of vWF but that excess vWF in plasma can effectively compete with platelets for the binding of Factor VIII. In addition, since cleavage of Factor VIII by thrombin separates a vWF-binding domain from Factor VIIIa, we propose that activation of Factor VIII by thrombin may elicit release of activated Factor VIII from vWF and thereby make it fully available for platelet binding.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON K7L 3N6,ONTARIO,CANADA; QUEENS UNIV,DEPT PATHOL,KINGSTON K7L 3N6,ONTARIO,CANADA; GENET INST,CAMBRIDGE,MA 02140; MAYO CLIN & MAYO FDN,HEMATOL RES SECT,ROCHESTER,MN 55905	Queens University - Canada; Queens University - Canada; Mayo Clinic	NESHEIM, M (corresponding author), QUEENS UNIV,DEPT MED,KINGSTON K7L 3N6,ONTARIO,CANADA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R44HL035946, P01HL017430] Funding Source: NIH RePORTER; NHLBI NIH HHS [2R44-HL35946-02, HL-17430] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PF, 1986, BLOOD COAGULATION, P35; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; FULCHER CA, 1983, BLOOD, V61, P807; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GILBERT GE, 1989, BLOOD, V74, P126; GIRMA JP, 1987, BLOOD, V70, P605; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HOYER LW, 1987, HEMOSTASIS THROMBOSI, P48; KANE WH, 1988, BLOOD, V71, P539; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LEYTE A, 1991, J BIOL CHEM, V266, P740; LEYTE A, 1989, THROMB HAEMOSTASIS, V62, P73; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; PITMANN DD, 1988, P NATL ACAD SCI USA, V85, P2429; PITTMAN DD, 1989, THROMB HAEMOSTASIS, V61, P161; PITTMAN DD, 1987, BLOOD, V70, P392; PRECUP JW, 1991, BLOOD, V77, P1929; ROSING J, 1985, BLOOD, V65, P319; SADLER JE, 1987, MOL BASIS BLOOD DISE, P575; SOBERANO ME, 1986, BRIT J HAEMATOL, V64, P571, DOI 10.1111/j.1365-2141.1986.tb02213.x; THORELL L, 1984, THROMB RES, V35, P431, DOI 10.1016/0049-3848(84)90235-4; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TRACY PB, 1985, J BIOL CHEM, V260, P2119; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; ZIMMERMAN TS, 1985, CLIN HAEMATOL, V14, P343	44	82	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17815	17820						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917924				2022-12-25	WOS:A1991GG55300019
J	MATTER, K; STIEGER, B; KLUMPERMAN, J; GINSEL, L; HAURI, HP				MATTER, K; STIEGER, B; KLUMPERMAN, J; GINSEL, L; HAURI, HP			ENDOCYTOSIS, RECYCLING, AND LYSOSOMAL DELIVERY OF BRUSH-BORDER HYDROLASES IN CULTURED HUMAN INTESTINAL EPITHELIAL-CELLS (CACO-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV BASEL, BIOCTR, DEPT PHARMACOL, CH-4056 BASEL, SWITZERLAND; UNIV LEIDEN, ELECTRON MICROSCOPY LAB, 2333 LEIDEN, NETHERLANDS; UNIV HOSP ZURICH, CH-8091 ZURICH, SWITZERLAND	University of Basel; Leiden University; Leiden University - Excl LUMC; University of Zurich; University Zurich Hospital			Stieger, Bruno/U-6323-2017; Matter, Karl/C-4880-2008	Stieger, Bruno/0000-0002-7190-5785; Matter, Karl/0000-0001-8026-7220				BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BARTLES JR, 1988, TRENDS BIOCHEM SCI, V13, P181, DOI 10.1016/0968-0004(88)90147-8; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BLOK J, 1984, CELL BIOL INT REP, V8, P993, DOI 10.1016/0309-1651(84)90086-9; BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; DOMS RW, 1988, J CELL BIOL, V107, P89, DOI 10.1083/jcb.107.1.89; FRANSEN JAM, 1988, EUR J CELL BIOL, V47, P72; FRANSEN JAM, 1985, EUR J CELL BIOL, V38, P6; FRANSEN JAM, 1989, INT BRUSH BORDER S, P12; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GEUZE HJ, 1984, J CELL BIOL, V98, P2047, DOI 10.1083/jcb.98.6.2047; GORR SU, 1988, J CELL BIOL, V106, P1937, DOI 10.1083/jcb.106.6.1937; GOTTLIEB TA, 1986, J CELL BIOL, V102, P1242, DOI 10.1083/jcb.102.4.1242; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Hauri H P, 1988, Subcell Biochem, V12, P155; HAURI HP, 1985, P NATL ACAD SCI USA, V82, P4423, DOI 10.1073/pnas.82.13.4423; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HILKENS J, 1981, BIOCHIM BIOPHYS ACTA, V678, P7, DOI 10.1016/0304-4165(81)90041-6; HOEFSLOOT LH, 1988, EMBO J, V7, P1697, DOI 10.1002/j.1460-2075.1988.tb02998.x; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; Lorenzsonn V, 1987, GASTROENTEROLOGY, V92, P98, DOI 10.1016/0016-5085(87)90844-4; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; Mage M G, 1980, Methods Enzymol, V70, P142; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; PINTO M, 1983, BIOL CELL, V47, P323; RINDLER MJ, 1985, J CELL BIOL, V100, P136, DOI 10.1083/jcb.100.1.136; SCALERA V, 1980, BIOCHEM J, V186, P177, DOI 10.1042/bj1860177; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SIPS HJ, 1985, J INHERIT METAB DIS, V8, P163, DOI 10.1007/BF01805427; SMITH RE, 1966, J CELL BIOL, V31, P319, DOI 10.1083/jcb.31.2.319; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STIEGER B, 1986, J MEMBRANE BIOL, V91, P19, DOI 10.1007/BF01870211; STIEGER B, 1988, J CELL BIOL, V106, P1853, DOI 10.1083/jcb.106.6.1853; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; VENABLE JH, 1965, J CELL BIOL, V25, P407, DOI 10.1083/jcb.25.2.407; WANDINGERNESS A, 1988, IN PRESS INTRACELLUL; ZWEIBAUM A, 1989, IN PRESS HDB PHYSL; [No title captured]	51	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1990	265	6					3503	3512						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CP236	1968064				2022-12-25	WOS:A1990CP23600079
J	BIANCHI, A; EVANS, JL; IVERSON, AJ; NORDLUND, AC; WATTS, TD; WITTERS, LA				BIANCHI, A; EVANS, JL; IVERSON, AJ; NORDLUND, AC; WATTS, TD; WITTERS, LA			IDENTIFICATION OF AN ISOZYMIC FORM OF ACETYL-COA CARBOXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,DIV ENDOCRINE METAB,HANOVER,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT BIOCHEM,HANOVER,NH 03756	Dartmouth College; Dartmouth College			Evans, Joseph L./N-4501-2013	Evans, Joseph L./0000-0002-9334-1650	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35712] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1978, J BIOL CHEM, V253, P1733; ALLRED JB, 1988, BIOCHEM J, V251, P881, DOI 10.1042/bj2510881; BORTHWICK AC, 1987, BIOCHEM J, V241, P773, DOI 10.1042/bj2410773; COOK GA, 1984, BIOCHEM J, V219, P337, DOI 10.1042/bj2190337; EVANS JL, 1987, ARCH BIOCHEM BIOPHYS, V264, P103; GOODSON J, 1984, BIOCHEM BIOPH RES CO, V122, P694, DOI 10.1016/S0006-291X(84)80089-3; HAYSTEAD TAJ, 1986, BIOCHEM J, V234, P279, DOI 10.1042/bj2340279; HOFSTEE BHJ, 1952, SCIENCE, V116, P329, DOI 10.1126/science.116.3013.329; JAMIL H, 1987, J BIOL CHEM, V262, P638; KORNACKER MS, 1965, BIOCHEM J, V94, P209, DOI 10.1042/bj0940209; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; MAJERUS PW, 1969, J BIOL CHEM, V244, P6254; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MOSS J, 1972, BIOCHEMISTRY-US, V11, P3779, DOI 10.1021/bi00770a017; PAPE ME, 1988, ARCH BIOCHEM BIOPHYS, V267, P104, DOI 10.1016/0003-9861(88)90013-6; SIMON EJ, 1953, J AM CHEM SOC, V75, P2520, DOI 10.1021/ja01106a522; TAKAI T, 1988, J BIOL CHEM, V263, P2651; TAKAI T, 1988, ARCH BIOCHEM BIOPHYS, V266, P313, DOI 10.1016/0003-9861(88)90263-9; THAMPY KG, 1988, J BIOL CHEM, V263, P6454; TIPPER JP, 1982, BIOCHIM BIOPHYS ACTA, V715, P162, DOI 10.1016/0304-4165(82)90354-3; VAGELOS PR, 1963, J BIOL CHEM, V238, P533; WITTERS LA, 1981, J LIPID RES, V22, P364; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; WITTERS LA, 1979, J BIOL CHEM, V254, P6644; WITTERS LA, 1986, ADV PROTEIN PHOSPHAT, V3, P201; WITTERS LA, 1985, MOL BASIS INSULIN AC, P315; ZIERZ S, 1987, BIOCHEM J, V245, P205, DOI 10.1042/bj2450205	29	222	229	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1990	265	3					1502	1509						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CJ676	1967254				2022-12-25	WOS:A1990CJ67600045
J	BILL, CA; GROCHAN, BM; MEYN, RE; BOHR, VA; TOFILON, PJ				BILL, CA; GROCHAN, BM; MEYN, RE; BOHR, VA; TOFILON, PJ			LOSS OF INTRAGENOMIC DNA-REPAIR HETEROGENEITY WITH CELLULAR-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP-C; HAMSTER OVARY CELLS; BETA-ACTIN GENE; ULTRAVIOLET-IRRADIATION; MURINE PROADIPOCYTES; LIPOPROTEIN-LIPASE; PYRIMIDINE DIMERS; GROWTH ARREST; MUSCLE-CELLS; DHFR GENE	The influence of terminal differentiation on UV-induced DNA damage and its repair in transcriptionally active and inactive genomic sequences was investigated using the murine 3T3-T proadipocyte cell culture system. Actively cycling 3T3-T cells terminally differentiate into adipocytes after exposure to media containing platelet-depleted human plasma. Suitable DNA fragments were analyzed from four genes: beta-actin, adenosine deaminase, dihydrofolate reductase, and lipoprotein lipase. As a result of 3T3-T cell differentiation, lipoprotein lipase and beta-actin expression was modified, whereas adenosine deaminase and dihydrofolate reductase expression was not affected. A DNA fragment representing the transcriptionally inactive locus 70-38 was also evaluated. UV-induced cyclobutane pyrimidine dimers, detected as UV-specific endonuclease-sensitive sites, in each fragment increased linearly as a function of UV dose (0-20 J/m2) independently of gene expression or differentiation. Sequence-specific repair of dimers was measured in stem and terminally differentiated 3T3-T cells after UV irradiation (10 J/m2). For undifferentiated stem cells, the rate and extent of dimer repair was higher in the actively transcribed adenosine deaminase and dihydrofolate reductase genes than in the inactive lipoprotein lipase or 70-38 fragments, the greater difference being observed in the first 8 h post-UV irradiation. In contrast, similar dimer repair rates were found for each DNA fragment in terminally differentiated 3T3-T cells. These data suggest that cellular differentiation is accompanied by a loss of heterogeneity in intragenomic DNA repair.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT EXPTL RADIOTHERAPY, HOUSTON, TX 77030 USA; NCI, MOLEC PHARMACOL LAB, BETHESDA, MD 20892 USA	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bohr, Vilhelm/AAP-5931-2020		NATIONAL CANCER INSTITUTE [R01CA050207] Funding Source: NIH RePORTER; NCI NIH HHS [CA50207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALUBAIDI MR, 1990, GENOMICS, V7, P476, DOI 10.1016/0888-7543(90)90189-2; [Anonymous], 1985, DNA REPAIR; BEECHAM EJ, 1991, MOL CELL BIOL, V11, P3095, DOI 10.1128/MCB.11.6.3095; BOHR VA, 1990, J CANCER RES CLIN, V116, P384, DOI 10.1007/BF01612922; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1986, J BIOL CHEM, V261, P6666; BOHR VA, 1986, P NATL ACAD SCI USA, V83, P3830, DOI 10.1073/pnas.83.11.3830; Bohr VA, 1988, DNA REPAIR LABORATOR, V3, P347; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; CROUSE GF, 1982, J BIOL CHEM, V257, P7887; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; DISTECHE CM, 1985, CYTOGENET CELL GENET, V39, P262, DOI 10.1159/000132155; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; HAHN GM, 1971, NATURE-NEW BIOL, V230, P242, DOI 10.1038/newbio230242a0; HANAWALT PC, 1987, MODERN BIOL THEORIES, P183; HO L, 1989, MOL CELL BIOL, V9, P1594, DOI 10.1128/MCB.9.4.1594; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; KAUFMAN SJ, 1980, EXP CELL RES, V130, P41, DOI 10.1016/0014-4827(80)90040-3; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KRAWISZ BR, 1982, J CELL BIOL, V94, P394, DOI 10.1083/jcb.94.2.394; KURTEN RC, 1988, ENDOCRINOLOGY, V123, P2408, DOI 10.1210/endo-123-5-2408; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MITCHELL DL, 1990, BIOESSAYS, V12, P74, DOI 10.1002/bies.950120205; MURRAY D, 1987, RADIAT RES, V109, P153, DOI 10.2307/3576876; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; NIGGLI HJ, 1982, BIOCHEM BIOPH RES CO, V105, P1215, DOI 10.1016/0006-291X(82)91098-1; OKUMOTO DS, 1987, NUCLEIC ACIDS RES, V15, P10021, DOI 10.1093/nar/15.23.10021; ROBBINS JH, 1983, CELLULAR RESPONSES D, P671; SCOTT RE, 1982, P NATL ACAD SCI-BIOL, V79, P845, DOI 10.1073/pnas.79.3.845; SCUDIERO DA, 1986, MUTAT RES, V159, P125, DOI 10.1016/0027-5107(86)90121-1; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SMITH CA, 1987, J CELL SCI, P225; SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092-8674(82)90089-7; STOCKDALE FE, 1972, J CELL BIOL, V52, P589, DOI 10.1083/jcb.52.3.589; TOFILON PJ, 1988, EXP CELL RES, V174, P502, DOI 10.1016/0014-4827(88)90319-9; TOFILON PJ, 1988, RADIAT RES, V116, P217, DOI 10.2307/3577459; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; WHEELER KT, 1983, RADIAT RES, V93, P312, DOI 10.2307/3575986; WILLIAMS JI, 1979, BIOCHEMISTRY-US, V18, P3965, DOI 10.1021/bi00585a019; YEUNG CY, 1985, J BIOL CHEM, V260, P299	43	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21821	21826						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939206				2022-12-25	WOS:A1991GP80400076
J	DOUGLAS, JL; GOPALAKRISHNAN, S; QUINLAN, MP				DOUGLAS, JL; GOPALAKRISHNAN, S; QUINLAN, MP			MODULATION OF TRANSFORMATION OF PRIMARY EPITHELIAL-CELLS BY THE 2ND EXON OF THE AD5 E1A12S GENE	ONCOGENE			English	Article							ADENOVIRUS E1A; GROWTH-FACTOR; FUNCTIONAL DOMAINS; E1A-12S PROTEIN; TERMINAL REGION; DNA FRAGMENTS; TYPE-5; SEQUENCES; INDUCTION; PRODUCTS	Expression of the Ad5 E1A first exon is necessary and sufficient to cooperate with an activated RAS oncogene to transform primary epithelial cells. The second exon, although necessary for immortalization and induction of an epithelial cell growth factor, is not essential for co-transformation with T24 RAS. To determine whether the second exon has a role in the cooperation of ElA with an activated RAS gene, we have performed an extensive mutational analysis of this region. All of the deletion and point mutants that we have generated and analyzed retained the ability to enable the transformants to grow in serum-free media and in soft agar. A region in the C-terminus of the E1A polypeptide encoded by nucleotides 1437-1488 appears to modulate the level of transformation. Co-transfections of T24 RAS and EIA genes with mutations that bring about specific amino acid substitutions or deletions in the C-terminus result in enhanced transformation. There is an increase in the number of transformed foci and they appear earlier. A single amino acid change can bring about this phenotype, which is dominant over wild type. Thus, it seems that expression of the wild-type second exon retards or suppresses transformation. The hypertransforming phenotype does not correlate with any differences in the expression of the mutated E1A or the co-cotransfected RAS gene. The C-terminus encodes a nuclear localization signal for E1A, however the subcellular localization of the mutant polypeptides does not affect their co-transforming ability.	UNIV TENNESSEE CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,858 MADISON AVE,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								ADAMI GR, 1990, J VIROL, V64, P3427, DOI 10.1128/JVI.64.7.3427-3436.1990; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; EGAN C, 1989, ONCOGENE, V4, P383; Flint S. J, 1981, DNA TUMOR VIRUSES; FRISCH SM, 1990, ONCOGENE, V5, P75; GALLIMORE PH, 1974, J MOL BIOL, V8, P49; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORAN E, 1986, J VIROL, V57, P764; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; QUINLAN MP, 1989, ONCOGENE, V4, P1051; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1986, CANCER CELL, V4, P327; REICH R, 1988, CANCER RES, V48, P3307; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPINDLER KR, 1985, J VIROL, V53, P742, DOI 10.1128/JVI.53.3.742-750.1985; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TAUB M, 1979, P NATL ACAD SCI USA, V76, P3338, DOI 10.1073/pnas.76.7.3338; URBANELLI D, 1989, VIROLOGY, V173, P607, DOI 10.1016/0042-6822(89)90572-2; VANORMONDT H, 1980, GENE, V12, P63, DOI 10.1016/0378-1119(80)90016-5; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	46	51	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2093	2103						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945414				2022-12-25	WOS:A1991GX11900021
J	TRATNER, I; VERMA, IM				TRATNER, I; VERMA, IM			IDENTIFICATION OF A NUCLEAR TARGETING SEQUENCE IN THE FOS PROTEIN	ONCOGENE			English	Article							LEUCINE ZIPPER DOMAIN; JUN INTERACTION; V-FOS; C-FOS; LOCALIZATION; LOCATION; SIGNAL; GENE; EXPRESSION; TRANSPORT	The product of the proto-oncogene fos is a nuclear phosphoprotein. We have investigated if nuclear location of Fos protein is mediated by a nuclear targeting sequence. We show that the cytoplasmic chicken pyruvate kinase protein translocates to the nucleus if fused to the 22 amino acid Fos basic region (amino acids 139-161). However, the nuclear localization of the Fos protein is not affected if the basic region is deleted. We propose that Fos protein contains multiple nuclear targeting sequences which may act independently or in concert with one another.			TRATNER, I (corresponding author), SALK INST,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186, USA.		Tratner, Isabelle/ABD-6361-2021					ADDISON C, 1990, ONCOGENE, V5, P423; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1984, CELL, V36, P259; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, J BIOL CHEM, V264, P18019; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KINDY MS, 1990, CELL GROWTH DIFFER, V1, P27; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; MATSUI M, 1990, ONCOGENE, V5, P249; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PAINE PL, 1972, EXP CELL RES, V74, P81, DOI 10.1016/0014-4827(72)90483-1; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STACEY DW, 1984, EXP CELL RES, V154, P283, DOI 10.1016/0014-4827(84)90687-6; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	36	35	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2049	2053						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945410				2022-12-25	WOS:A1991GX11900016
J	GOLENBOCK, DT; HAMPTON, RY; QURESHI, N; TAKAYAMA, K; RAETZ, CRH				GOLENBOCK, DT; HAMPTON, RY; QURESHI, N; TAKAYAMA, K; RAETZ, CRH			LIPID-A-LIKE MOLECULES THAT ANTAGONIZE THE EFFECTS OF ENDOTOXINS ON HUMAN MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING PROTEINS; MACROPHAGE TUMOR-CELLS; MURINE SPLENOCYTES; INDUCTION; PRECURSORS; CACHECTIN; INVITRO; SITES	Lipopolysaccharide (LPS) endotoxin is implicated as the bacterial product responsible for the clinical syndrome of Gram-negative septicemia. Although the lipid A domain of LPS appears to be responsible for the toxicity of endotoxin, lipid A from the photosynthetic bacterium Rhodobacter sphaeroides (RSLA) and a disaccharide precursor of lipid A from enteric bacteria, termed lipid IV(A), have little activity on human cells. Using the human promonomyelocytic cell line THP-1 and human monocytic cells, we now show that both lipid IV(A) and RSLA are antagonists of LPS. Complete, apparently competitive, inhibition of LPS activity is possible at a 10-100-fold excess of antagonist, as judged by measuring the release of cytokines and prostaglandin E2. Both antagonists prevent monocyte stimulation by endotoxin extracted from a variety of Gram-negative bacteria. Cells pretreated with either inhibitor and subsequently washed still show attenuated responses to LPS. Stimulation of monocytes by whole Gram-negative bacteria is also antagonized in a dose-dependent manner. Lipid X has no inhibitory effect in the same dose range as lipid IV(A) and RSLA. These findings rule out LPS sequestration as the explanation for the observed antagonism. Neither inhibitor alters monocyte stimulation by phorbol 12-myristate 13-acetate, Staphylococcus aureus, or purified protein derivative, demonstrating specificity for LPS. Although RSLA appears to inhibit LPS when tested with macrophages from both humans and mice, lipid IV(A) had the unique ability to act as an LPS antagonist with human-derived cells but to exhibit LPS-like effects with murine-derived cells. Like LPS, lipid IV(A) Stimulated the release of both tumor necrosis factor-alpha and arachidonic acid from murine-derived RAW 264.7 macrophage tumor cells. The range of concentrations necessary for lipid IV(A) to induce LPS-like effects in murine cells was similar to that necessary to antagonize the actions of LPS in human monocytes. The agonist activities of lipid IV(A) were completely inhibitable by RSLA. This unique species-dependent pharmacology observed with lipid IV(A) may reflect differences between human and murine LPS receptors. RSLA and lipid IV(A) may be useful in defining the role of LPS in Gram-negative bacterial infections and may prove to be prototypical therapeutic agents for the treatment of Gram-negative septicemia.	WILLIAM S MIDDLETON MEM VET ADM MED CTR,MYCOBACTERIOL RES LAB,MADISON,WI 53705; UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706; MERCK SHARP & DOHME LTD,DEPT BIOCHEM,W POINT,PA 19486; UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BACTERIOL,MADISON,WI 53706	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; Merck & Company; University of Wisconsin System; University of Wisconsin Madison	GOLENBOCK, DT (corresponding author), UNIV WISCONSIN HOSP & CLIN,DEPT MED,MADISON,WI 53729, USA.				NIAID NIH HHS [AI00840] Funding Source: Medline; NIGMS NIH HHS [GM-36054] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036054] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCHAUER H, 1990, J BIOL CHEM, V265, P9159; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; DANNER RL, 1987, J CLIN INVEST, V80, P605, DOI 10.1172/JCI113112; DIJKSTRA J, 1989, INFECT IMMUN, V57, P3357, DOI 10.1128/IAI.57.11.3357-3363.1989; GOLENBOCK DT, 1987, INFECT IMMUN, V55, P2471, DOI 10.1128/IAI.55.10.2471-2476.1987; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; KOVACH NL, 1990, J EXP MED, V172, P77, DOI 10.1084/jem.172.1.77; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; LEI MG, 1988, J IMMUNOL, V141, P996; LEI MG, 1988, J IMMUNOL, V141, P1006; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; POHLMAN TH, 1987, J EXP MED, V165, P1393, DOI 10.1084/jem.165.5.1393; PROCTOR RA, 1986, INFECT IMMUN, V52, P905, DOI 10.1128/IAI.52.3.905-907.1986; PROCTOR RA, 1986, HDB ENDOTOXIN, V4, P161; QURESHI N, 1985, J BIOL CHEM, V260, P5271; QURESHI N, 1988, J BIOL CHEM, V263, P5502; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1988, COLD SPRING HARB SYM, V53, P973, DOI 10.1101/SQB.1988.053.01.112; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; SCHWARTZ BS, 1989, BLOOD, V73, P2188; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SIBLEY CH, 1988, J BIOL CHEM, V263, P5098; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; VANDERMEER JWM, 1988, J LEUKOCYTE BIOL, V43, P216, DOI 10.1002/jlb.43.3.216; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; WALLIS RS, 1986, J IMMUNOL, V136, P193; Wintrobe MM, 1981, CLIN HEMATOLOGY; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P431; ZOELLER RA, 1987, J BIOL CHEM, V262, P17212	33	372	393	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19490	19498						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918061				2022-12-25	WOS:A1991GK66700057
J	HERRICKDAVIS, K; CAMUSSI, G; BUSSOLINO, F; BAGLIONI, C				HERRICKDAVIS, K; CAMUSSI, G; BUSSOLINO, F; BAGLIONI, C			MODULATION OF NEURITE OUTGROWTH IN NEUROBLASTOMA-CELLS BY PROTEIN-KINASE-C AND PLATELET-ACTIVATING-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; BLASTOMA CELLS; MORPHOLOGICAL-DIFFERENTIATION; ENDOTHELIAL-CELLS; TUMOR PROMOTERS; GANGLIOSIDES; GM1; EXPRESSION; MORTALITY; THROMBIN	Previous reports have shown that thrombin and activators of protein kinase C (PKC) inhibit neurite outgrowth (NOG) in neuroblastoma cells cultured in serum-free medium. Therefore, we tested the hypothesis that PKC activation mediates the effect of thrombin on NOG in murine neuroblastoma NB-2a cells. After 2 h in serum-free medium, 70% of the cells displayed neurites; addition of 300 ng/ml thrombin reduced NOG to 24% within 1 h. This inhibition was reduced after NB-2a cells were pretreated for 24 h with 200 nM phorbol dibutyrate down-regulate PKC. Thrombin and phorbol 12-myristate 13-acetate inhibited NOG in an additive way and the protein kinase inhibitors H-7, H-8, and HA1004 reversed the effect of thrombin on NOG with a rank order of activity consistent with PKC inhibition. Furthermore, PKC was translocated from the cytosol to a membrane-bound form 5 to 10 min after addition of thrombin. These findings indicate that thrombin inhibits NOG through a PKC-dependent pathway. Thrombin stimulates the synthesis of the phospholipid platelet-activating factor (PAF) in some cells. However, NOG was markedly stimulated when PAF or its analogue carbamyl-PAF were added to NB-2a cells in medium with serum. Furthermore, the PAF receptor antagonist SRI 63072 inhibited NOG in NB-2a cells in serum-free medium. These cells accumulated PAF with kinetics similar to that of NOG inducPAF was synthesized by the de novo pathway, as shown by the incorporation of [H-3]choline. These findings suggest that PAF is a mediator of NOG in NB-2a cells. Thrombin neither stimulates nor inhibits PAF synthesis in these cells.	NAPLES UNIV,FAC MED 1,DIPARTIMENTO BIOCHIM & BIOFIS,CATTEDRA NEFROL SPERIMENTALE,I-80138 NAPLES,ITALY; UNIV TURIN,DIPARTIMENTO GENET BIOL & CHIM MED,I-10126 TURIN,ITALY	University of Naples Federico II; University of Turin	HERRICKDAVIS, K (corresponding author), SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222, USA.		Camussi, Giovanni/J-7624-2016; Bussolino, Federico/AES-3951-2022; Bussolino, Federico/K-2500-2016	Camussi, Giovanni/0000-0003-2795-232X; Bussolino, Federico/0000-0002-5348-1341	NCI NIH HHS [CA29895] Funding Source: Medline; NIAID NIH HHS [AI16076] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016076] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; AUGUSTIT.G, 1969, P NATL ACAD SCI USA, V64, P311, DOI 10.1073/pnas.64.1.311; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUSSOLINO F, 1988, AM J PHYSIOL, V255, pC559, DOI 10.1152/ajpcell.1988.255.4.C559; BUSSOLINO F, 1989, J BIOL CHEM, V264, P21711; BUSSOLINO F, 1986, J BIOL CHEM, V261, P6502; CALCUTT NA, 1988, J NEUROCHEM, V50, P1478, DOI 10.1111/j.1471-4159.1988.tb03033.x; CAMUSSI G, 1986, KIDNEY INT, V29, P469, DOI 10.1038/ki.1986.23; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; CAMUSSI G, 1982, J IMMUNOL, V128, P86; CAMUSSI G, 1990, CYTOKINES LIPOCORTIN, P71; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; FURMANSKI P, 1971, NATURE, V233, P413, DOI 10.1038/233413a0; GIRARD PR, 1990, J NEUROCHEM, V54, P300, DOI 10.1111/j.1471-4159.1990.tb13315.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HENESY CE, 1989, FEBS LETT, V258, P156; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; ISHII DN, 1978, SCIENCE, V200, P556, DOI 10.1126/science.644318; KARPIAK SE, 1987, STROKE, V18, P184, DOI 10.1161/01.STR.18.1.184; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; MAHADIK SP, 1988, J NEUROSCI RES, V20, P479, DOI 10.1002/jnr.490200411; MARCHISIO PC, 1978, J NEUROCYTOL, V7, P571, DOI 10.1007/BF01260890; MINANA MD, 1990, P NATL ACAD SCI USA, V87, P4335, DOI 10.1073/pnas.87.11.4335; PAHLMAN S, 1983, CELL DIFFER DEV, V12, P165, DOI 10.1016/0045-6039(83)90006-4; PRASAD KN, 1972, NATURE-NEW BIOL, V236, P49, DOI 10.1038/newbio236049a0; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROISEN FJ, 1981, SCIENCE, V214, P557; SABEL BA, 1988, BRAIN RES, V459, P373, DOI 10.1016/0006-8993(88)90655-5; SEEDS NW, 1970, P NATL ACAD SCI USA, V66, P160, DOI 10.1073/pnas.66.1.160; SPINELLI W, 1983, CANCER RES, V43, P4119; SPINELLI W, 1982, CANCER RES, V42, P5067; SPULER M, 1987, ARCH INT PHARMACOD T, V287, P211; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; WADA H, 1989, BIOCHEM BIOPH RES CO, V165, P533, DOI 10.1016/0006-291X(89)91102-9; WILLBERZ S, 1988, DIABETOLOGIA, V31, P855	40	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18620	18625						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917984				2022-12-25	WOS:A1991GJ47200036
J	PARADA, CA; MARIANS, KJ				PARADA, CA; MARIANS, KJ			MECHANISM OF DNA-A PROTEIN-DEPENDENT PBR322 DNA-REPLICATION - DNA-A PROTEIN-MEDIATED TRANS-STRAND LOADING OF THE DNA-B PROTEIN AT THE ORIGIN OF PBR322 DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; ENZYMATIC REPLICATION; RIBONUCLEASE-H; FACTOR-Y; TRANSCRIPTIONAL ACTIVATION; INITIATING REPLICATION; NUCLEOTIDE-SEQUENCE; GEL-ELECTROPHORESIS; PLASMIDS BEARING; TOPOISOMERASE-I	pBR322 DNA can be replicated via a DNA A-dependent pathway mediated by its binding to the two DNA A-binding sites (dnaA boxes) present near the plasmid origin. DNA synthesis requires the transcription of RNA II (the leading-strand primer precursor) to generate a specific unwound structure in the region containing the dnaA boxes. In this structure, the DNA containing the dnaA boxes can take the form of either a RNA II-parental H strand pBR322 DNA hybrid opposed by the displaced parental L strand (in the absence of RNase H and DNA polymerase I), or a nascent leading strand-parental H strand DNA duplex opposed by the displaced parental L strand (in the presence of RNase H and DNA polymerase I). These findings defined three types of potential sites for productive DNA A binding: (i) the displaced parental L single strand, (ii) a hairpin formed by the inverted repeat of the two dnaA boxes, and (iii) either the RNA-DNA duplex or the nascent leading strand-parental DNA duplex. By using a combination of: (i) inhibition of the replication of a plasmid carrying oriC by oligonucleotides of various dnaA box sequences and conformation, (ii) a gel mobility shift assay to measure DNA A binding to the same oligonucleotide substrates, (iii) replication of pBR322 DNA templates with either one or no dnaA box, and (iv) photocross-linking to demonstrate DNA A binding to an RNA-DNA hybrid, evidence is presented here that DNA A-mediated pBR322 DNA replication proceeds by a mechanism in which DNA A binds to the duplex side of the unwound origin structures and loads the DNA B protein in trans to the displaced parental L strand DNA.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1980, J BACTERIOL, V141, P1024, DOI 10.1128/JB.141.3.1024-1030.1980; ARAI K, 1981, J BIOL CHEM, V256, P5273; ARAI K, 1981, J BIOL CHEM, V256, P5281; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BOEKE JD, 1976, P NATL ACAD SCI USA, V76, P2699; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; CHAKRABORTY T, 1986, EMBO J, V1, P1545; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GREENBAUM JH, 1984, J BIOL CHEM, V259, P2594; HANSEN FG, 1982, EMBO J, V1, P1043, DOI 10.1002/j.1460-2075.1982.tb01294.x; HIROTA Y, 1968, COLD SPRING HARB SYM, V33, P677, DOI 10.1101/SQB.1968.033.01.077; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; ITOH T, 1982, NUCLEIC ACIDS RES, V10, P5949, DOI 10.1093/nar/10.19.5949; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KREUZER KN, 1984, J BIOL CHEM, V259, P5339; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; MA D, 1988, J BIOL CHEM, V263, P15008; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MASAI H, 1989, J BACTERIOL, V171, P2975, DOI 10.1128/jb.171.6.2975-2980.1989; MASAI H, 1990, J BIOL CHEM, V265, P15134; MASAI H, 1988, J BIOL CHEM, V263, P15016; MASAMUNE Y, 1971, J BIOL CHEM, V246, P6874; MASUKATA H, 1987, CELL, V51, P1123, DOI 10.1016/0092-8674(87)90598-8; MASUKATA H, 1984, CELL, V36, P513, DOI 10.1016/0092-8674(84)90244-7; MEIJER M, 1979, P NATL ACAD SCI USA, V76, P580, DOI 10.1073/pnas.76.2.580; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MINDEN JS, 1986, J BIOL CHEM, V261, P1906; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; PARADA CA, 1989, J BIOL CHEM, V264, P15120; POLACZEK P, 1984, MOL GEN GENET, V194, P227, DOI 10.1007/BF00383521; ROGERS SG, 1980, GENE, V11, P187, DOI 10.1016/0378-1119(80)90059-1; SAKAKIBARA Y, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1403, DOI 10.1073/pnas.71.4.1403; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SELZER G, 1982, P NATL ACAD SCI-BIOL, V79, P7082, DOI 10.1073/pnas.79.23.7082; SEUFERT W, 1987, CELL, V48, P73, DOI 10.1016/0092-8674(87)90357-6; SEUFERT W, 1988, J BIOL CHEM, V263, P2719; SEUFERT W, 1986, EMBO J, V5, P3401, DOI 10.1002/j.1460-2075.1986.tb04656.x; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STUITJE AR, 1984, NUCLEIC ACIDS RES, V12, P3321, DOI 10.1093/nar/12.7.3321; TOMIZAWA J, 1982, CELL, V31, P575, DOI 10.1016/0092-8674(82)90313-0; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; WEISS B, 1976, J BIOL CHEM, V251, P1896	55	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18895	18906						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918006				2022-12-25	WOS:A1991GJ47200076
J	ROSENBERG, I; CHERAYIL, BJ; ISSELBACHER, KJ; PILLAI, S				ROSENBERG, I; CHERAYIL, BJ; ISSELBACHER, KJ; PILLAI, S			MAC-2-BINDING GLYCOPROTEINS - PUTATIVE LIGANDS FOR A CYTOSOLIC BETA-GALACTOSIDE LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGE-BINDING PROTEIN; MONOCLONAL-ANTIBODIES; SEQUENCE; MAC-2; RECOGNITION; HOMOLOGY; ANTIGEN; SHEETS; CELL	Mac-2, a galactose-binding lectin secretion by activated macrophages, is the major non-integrin laminin-binding protein in these cells. Mac-2 is also expressed by epithelial cells in the intestine and kidney. We wished to identify intestinal glycoproteins other than laminin that have a high affinity for Mac-2 and that could be considered as candidate ligands or partners for this lectin in intestinal epithelium. Certain lines of human colon adenocarcinoma cells produce two Mac-2-binding glycoproteins (M2BP-1 and M2BP-2) that were identified by their avid association with Mac-2 following detergent lysis and immunoprecipitation. These glycoproteins do not share a common epitope with Mac-2, and the interaction between Mac-2 and these proteins is mediated through the carbohydrate-binding domain of Mac-2 and sugar moieties on M2BP-1 and M2BP-2. M2BP-1 (98 kDa) and M2BP-2 (70 kDa) were purified by immunoaffinity chromatography and were specifically eluted with either galactose or lactose. Peptide maps revealed that M2BP-1 and M2BP-2 are structurally related. M2BP-1 is secreted and could conceivably associate with Mac-2 extracellularly. N-terminal sequence analysis of M2BP-2 suggests that these glycoproteins represent a unique subset of candidate ligands for this mammalian beta-galactoside lectin.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET GRP,MOLEC IMMUNOL LAB,BLDG 149,13TH ST,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NIAID NIH HHS [AI-27835] Funding Source: Medline; NIDDK NIH HHS [DK07191] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI027835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007191] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; HO MK, 1982, J IMMUNOL, V128, P1221; JIA SH, 1988, J BIOL CHEM, V263, P6009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOEFFLER H, 1986, J BIOL CHEM, V261, P10119; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOO HJ, 1990, J BIOL CHEM, V265, P7097	19	124	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18731	18736						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917996				2022-12-25	WOS:A1991GJ47200052
J	SHARKEY, DJ; KORNFELD, R				SHARKEY, DJ; KORNFELD, R			DEVELOPMENTAL REGULATION OF ASPARAGINE-LINKED OLIGOSACCHARIDE SYNTHESIS IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH MANNOSE OLIGOSACCHARIDES; ALPHA-D-MANNOSIDASE; N-ACETYLGLUCOSAMINE RESIDUE; ADHESION-BLOCKING FAB; RAT-LIVER; GLYCOPROTEIN-BIOSYNTHESIS; SOLVOLYTIC DESULFATION; ENDOPLASMIC-RETICULUM; STRUCTURAL-ANALYSIS; IDENTIFICATION	In the preceding report we demonstrated that the expression of two developmentally regulated alpha-mannosidase activities is induced in Dictyostelium discoideum during its differentiation from single-cell amoebae to multicellular organism (Sharkey, D.J., and Kornfeld, R. (1991) J. Biol. Chem. 266, 18477-18484). These activities, designated membrane alpha-mannosidase I (MI) and membrane alpha-mannosidase II (MII), were shown to have several properties in common with rat liver Golgi alpha-mannosidases I and II, respectively, suggesting that MI and MII may play a role in the processing of asparagine-linked oligosaccharides in developing D. discoideum. In this study we analyzed the structures of the asparagine-linked oligosaccharides synthesized by D. discoideum at various stages of development to determine the timing and extent of asparagine-linked oligosaccharide processing. Cells were labeled with [2-H-3] mannose, and then total cellular glycoproteins were digested with Pronase to generate glycopeptides that were fractionated on concanavalin A-Sepharose. Glycopeptides from each fraction were digested with endoglycosidase H, both before and after desulfation by solvolysis, and the released, neutral oligosaccharides were sized by high pressure liquid chromatography. At early stages of development, D. discoideum contain predominantly large high mannose-type oligosaccharides (Man9GlcNAc and Man8GlcNAc). Some of these are modified by GlcNAc residues attached beta-1-4 to the mannose-linked alpha-1-6 to the beta-linked core mannose (the "intersecting" position), as well as by fucose, sulfate, and phosphate. In contrast, the oligosaccharides found at late stages of development (18-24 h) have an array of sizes from Man9GlcNAc to Man3GlcNAc. These are still modified by GlcNAc, fucose, sulfate, and phosphate, but the percent of larger high mannose oligosaccharides that are modified with GlcNAc in the intersecting position decreases after 6 h of development, in parallel with the decrease in the intersecting GlcNAc transferase activity. Similarly, the changes in the size of asparagine-linked oligosaccharides synthesized during development correlate well with the appearance of MI and MII activities and suggest that these developmentally regulated alpha-mannosidase activities function in the processing of these oligosaccharides. This is supported further by the observation that oligosaccharide processing was inhibited in late stage cells labeled in the presence of either deoxymannojirimycin, an inhibitor of MI, or swainsonine, an inhibitor of MII.	WASHINGTON UNIV,SCH MED,DEPT BIOL CHEM,ST LOUIS,MO 63110	Washington University (WUSTL)	SHARKEY, DJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110, USA.				NATIONAL CANCER INSTITUTE [R37CA008759, R01CA008759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007067] Funding Source: NIH RePORTER; NCI NIH HHS [CA08759] Funding Source: Medline; NIGMS NIH HHS [5T32GM07067] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BISCHOFF J, 1983, J BIOL CHEM, V258, P7907; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; BISCHOFF J, 1986, J BIOL CHEM, V261, P4758; COUSO R, 1987, J BIOL CHEM, V262, P4521; FREEZE H, 1977, J BIOL CHEM, V252, P820; FREEZE HH, 1983, J BIOL CHEM, V258, P4880; FREEZE HH, 1986, J BIOL CHEM, V261, P127; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; FREEZE HH, 1984, J BIOL CHEM, V259, P641; GABEL CA, 1984, J BIOL CHEM, V259, P3762; GROSS V, 1983, J BIOL CHEM, V258, P4032; Henderson E.J., 1984, P371; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; ICHISHIMA E, 1981, BIOCHIM BIOPHYS ACTA, V658, P45, DOI 10.1016/0005-2744(81)90248-5; INOUE Y, 1973, CARBOHYD RES, V31, P359, DOI 10.1016/S0008-6215(00)86200-X; IVATT RL, 1984, CELL, V38, P561, DOI 10.1016/0092-8674(84)90510-5; JUDELSON HS, 1987, ARCH BIOCHEM BIOPHYS, V253, P305, DOI 10.1016/0003-9861(87)90183-4; KNECHT DA, 1987, DEV BIOL, V121, P277, DOI 10.1016/0012-1606(87)90160-6; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI; Loomis WF., 1975, DICTYOSTELIUM DISCOI; McIlvaine TC, 1921, J BIOL CHEM, V49, P183; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MULLER K, 1978, NATURE, V274, P445, DOI 10.1038/274445a0; MURRAY BA, 1981, J SUPRAMOL STR CELL, V17, P197, DOI 10.1002/jsscb.380170302; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NAGASAWA K, 1974, CARBOHYD RES, V36, P265, DOI 10.1016/S0008-6215(00)83047-5; SAXE CL, 1982, CELL, V29, P755, DOI 10.1016/0092-8674(82)90437-8; SHARKEY DJ, 1991, J BIOL CHEM, V266, P18477; SHARKEY DJ, 1989, J BIOL CHEM, V264, P10411; Sharon N., 1984, BIOL CARBOHYDRATES, V2, P1; SHOUP VA, 1976, J BIOL CHEM, V251, P3845; STEINEMANN C, 1980, NATURE, V286, P621, DOI 10.1038/286621a0; TABAS I, 1978, J BIOL CHEM, V253, P7779; TABAS I, 1979, J BIOL CHEM, V254, P1655; TAI T, 1977, BIOCHEM BIOPH RES CO, V78, P434, DOI 10.1016/0006-291X(77)91273-6; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; VARKI A, 1983, J BIOL CHEM, V258, P2808; WARREN CD, 1988, J BIOL CHEM, V263, P15041; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171	41	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18485	18497						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917971				2022-12-25	WOS:A1991GJ47200015
J	STANLEY, BA; PEGG, AE				STANLEY, BA; PEGG, AE			AMINO-ACID-RESIDUES NECESSARY FOR PUTRESCINE STIMULATION OF HUMAN S-ADENOSYLMETHIONINE DECARBOXYLASE PROENZYME PROCESSING AND CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-DECARBOXYLASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; POLYAMINES; CLONING; SITE	Human S-adenosylmethionine (AdoMet) decarboxylase is synthesized as a 38-kDa proenzyme that is autocatalytically cleaved, forming the covalently attached pyruvate cofactor and the two subunits (67 and 267 amino acid residues) of the mature enzyme. Both the cleavage reaction and the catalytic activity of the mature enzyme are stimulated by putrescine. Using site-specific mutagenesis and in vitro transcription followed by translation of the resultant RNA in a cell-free system, we have examined the importance of several amino acid residues on the processing reaction rate and catalytic activity and on stimulation of each of these by putrescine. Changing Cys82 to Ala decreased the stimulatory effect of putrescine on processing and completely eliminated catalytic activity, indicating a probable role in the active site of the enzyme, whereas changing Cys49 or Cys226 to Ala had minimal effects on processing and activity or the putrescine stimulation of either. Since Cys49 is the only cysteine residue in the smaller subunit, this indicates that disulfide-bond formation between the two subunits cannot be necessary for maintenance of the conformation for proenzyme processing or catalytic activity. Changing Glu8 or Glu11 to Gln produced an AdoMet decarboxylase that processed, but was catalytically inactive. Mutation at Glu11 also completely eliminated the putrescine stimulation of proenzyme processing, as did double mutation at Glu8 and Glu11, whereas the single mutation at Glu8 had no effect on the putrescine stimulation of proenzyme processing. Changing Glu15, Glu61, Glu67, Glu247, or Glu247 and Glu249 to Gln had a minimal effect on processing and activity or putrescine stimulation of either. These results demonstrate a role for the smaller subunit in the catalytic activity of the mature AdoMet decarboxylase enzyme and show that Glu8, Glu11, and Cys82 are essential for catalytic activity, with Glu11 also being essential for the putrescine stimulation of AdoMet decarboxylase proenzyme processing.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT PHARMACOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	STANLEY, BA (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,POB 850,HERSHEY,PA 17033, USA.		Stanley, Bruce/R-9856-2019	Stanley, Bruce/0000-0003-1338-2928	NCI NIH HHS [CA 18138] Funding Source: Medline; NHLBI NIH HHS [HL 07223] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018138, R37CA018138] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007223] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTON DL, 1987, J BIOL CHEM, V262, P2817; DEZEURE F, 1989, INT J BIOCHEM, V21, P889, DOI 10.1016/0020-711X(89)90288-7; DIAZ E, 1991, BIOCHEMISTRY-US, V30, P4078, DOI 10.1021/bi00230a037; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; KAMEJI T, 1987, BIOCHEM J, V243, P285, DOI 10.1042/bj2430285; KANG UJ, 1990, MOL BRAIN RES, V8, P83, DOI 10.1016/0169-328X(90)90013-4; KASHIWAGI K, 1990, J BIOL CHEM, V265, P22321; KOLB M, 1982, J MED CHEM, V25, P550, DOI 10.1021/jm00347a014; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; PAJUNEN A, 1988, J BIOL CHEM, V263, P17040; PEGG AE, 1969, J BIOL CHEM, V244, P682; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PEGG AE, 1983, BIOCHEM J, V213, P495, DOI 10.1042/bj2130495; Sambrook J, 1989, MOL CLONING LABORATO; STANLEY BA, 1989, J BIOL CHEM, V264, P21073; STANLEY BA, 1991, FASEB J, V5, pA504; STANLEY BA, 1990, J CELL BIOCHEM     S, V14, P107; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1987, J BIOL CHEM, V262, P16037; VANDERSLICE P, 1986, J BIOL CHEM, V261, P5186; WAHLFORS J, 1990, DNA CELL BIOL, V9, P103, DOI 10.1089/dna.1990.9.103; WHITE MW, 1989, PHYSL POLYAMINES, P331; Williams-Ashman H G, 1972, Adv Enzyme Regul, V10, P225, DOI 10.1016/0065-2571(72)90016-7; YAMAUCHI K, 1990, NUCLEIC ACIDS RES, V18, P5891, DOI 10.1093/nar/18.19.5891	25	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18502	18506						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917972				2022-12-25	WOS:A1991GJ47200017
J	PEREGO, R; RON, D; KRUH, GD				PEREGO, R; RON, D; KRUH, GD			ARG ENCODES A WIDELY EXPRESSED 145 KDA PROTEIN TYROSINE KINASE	ONCOGENE			English	Note							CHRONIC MYELOGENOUS LEUKEMIA; C-ABL; PHILADELPHIA-CHROMOSOME; GENE-PRODUCT; ONCOGENE; PHOSPHORYLATION; TRANSDUCTION; ACTIVATION; CELLS; K562	Arg encodes a protein highly related to the c-abl gene product with regard to overall structural architecture as well as the amino acid sequences of their tyrosine kinase, and src-homologous 2 and 3 domains. The two genes form a distinct subfamily of non-receptor tyrosine kinases and share a common homolog in Drosophila. In this study we characterized the arg protein product by expression of its coding sequence in bacteria. The recombinant arg protein was detected in bacterial lysates by immunoblotting and exhibited a molecular mass of 145 kDa. Phosphoamino acid analysis of the arg gene product following an immune complex autokinase reaction revealed tyrosine phosphorylation and established that it possesses tyrosine kinase activity. High-titer antibody capable of detecting the cellular arg gene product was generated by expressing a carboxy-terminal segment of arg in bacteria and using the recombinant protein as an immunogen. The arg gene product was identified in cultured human cells as a 145 kDa protein that exhibited autokinase activity. Analysis of arg expression in murine tissues revealed that arg, like c-abl, is widely expressed, further extending the similarities between the two genes, and suggesting that arg probably functions in signaling pathways fundamental to many cell types.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV MILAN,INST GEN PATHOL,I-20122 MILAN,ITALY; CNR,CTR RES CELL PATHOL,I-20133 MILAN,ITALY; TECHNION ISRAEL INST TECHNOL,FAC BIOL,IL-32000 HAIFA,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Milan; Consiglio Nazionale delle Ricerche (CNR); Technion Israel Institute of Technology								BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PAWSON T, 1988, ONCOGENE, V3, P491; PONTICELLI AS, 1982, CELL, V3, P953; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SANDBERG AA, 1986, CANCER GENET CYTOGEN, V21, P129, DOI 10.1016/0165-4608(86)90039-7; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANETTEN ER, 1989, CELL, V4, P669; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG JYJ, 1982, J BIOL CHEM, V257, P13181; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WITTE ON, 1979, NATURE, V281, P396, DOI 10.1038/281396a0	24	44	45	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1899	1902						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923513				2022-12-25	WOS:A1991GX11800025
J	BOFFI, A; BONAVENTURA, C; BONAVENTURA, J; CASHON, R; CHIANCONE, E				BOFFI, A; BONAVENTURA, C; BONAVENTURA, J; CASHON, R; CHIANCONE, E			OXIDIZED DIMERIC SCAPHARCA-INAEQUIVALVIS - CO-DRIVEN PERTURBATION OF THE REDOX EQUILIBRIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION REACTION; ELECTRON-TRANSFER; LIGAND-BINDING; CYTOCHROME-C; HEMOGLOBIN	The dimeric hemoglobin isolated from Scapharca inaequivalvis, HbI, is notable for its highly cooperative oxygen binding and for the unusual proximity of its heme groups. We now report that the oxidized protein, an equilibrium mixture of a dimeric high spin aquomet form and a monomeric low spin hemichrome, binds ferrocyanide tightly which allows for internal electron transfer with the heme iron. Surprisingly, when ferricyanide-oxidized HbI is exposed to CO, its spectrum shifts to that of the ferrous CO derivative. Gasometric removal of CO leads to the oxidized species rather than to ferrous deoxy-HbI. At equilibrium, CO binds with an apparent affinity (p50) of about 10-25 mm of Hg and no cooperativity (20-degrees-C, 10-50 mM buffers at pH 6.1). The kinetics of CO binding under pseudo-first order conditions are biphasic (t1/2 of 15-50 s at pH 6.1). The rates depend on protein, but not on CO concentration. The nitrite-oxidized protein is not reduced readily in the presence of CO unless one equivalent of ferrocyanide, but not of ferricyanide, is added. We infer that ferrocyanide, produced in the oxidation reaction, is tightly bound to the protein forming a redox couple with the heme iron. CO shifts the redox equilibrium by acting as a trap for the reduced heme. The equilibrium and kinetic aspects of the process have been accounted for in a reaction scheme where the internal electron transfer reaction is the rate-limiting step.	DUKE UNIV,MARINE LAB,BEAUFORT,NC 28516	Duke University	BOFFI, A (corresponding author), UNIV ROME LA SAPIENZA,DEPT BIOCHEM SCI,CNR,CTR MOLEC BIOL,I-00185 ROME,ITALY.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001908, P50ES001908] Funding Source: NIH RePORTER; NIEHS NIH HHS [ESO-H287, ESO-1908] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANTONINI E, 1984, J BIOL CHEM, V259, P6730; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P327; BANERJEE R, 1969, J MOL BIOL, V42, P337, DOI 10.1016/0022-2836(69)90047-3; BENESCH R, 1964, SCIENCE, V144, P68, DOI 10.1126/science.144.3614.68; BICKAR D, 1984, J BIOL CHEM, V259, P777; BOELENS R, 1979, BIOCHIM BIOPHYS ACTA, V547, P296, DOI 10.1016/0005-2728(79)90012-4; CHIANCONE E, 1981, J MOL BIOL, V164, P577; CHO KC, 1989, BIOCHIM BIOPHYS ACTA, V973, P53, DOI 10.1016/S0005-2728(89)80402-5; COWAN JA, 1988, ANN NY ACAD SCI, V550, P67; CRUTCHLEY RJ, 1986, FRONTIERS BIOINORGAN, P679; DIXON M, 1971, BIOCHIM BIOPHYS ACTA, V226, P241, DOI 10.1016/0005-2728(71)90092-2; GIBSON QH, 1943, J BIOL CHEM, V37, P615; MAYO SL, 1986, SCIENCE, V233, P948, DOI 10.1126/science.3016897; ROYER WE, 1989, J BIOL CHEM, V264, P21052; ROYER WE, 1990, SCIENCE, V249, P518, DOI 10.1126/science.2382132; SPAGNUOLO C, 1983, J MOL BIOL, V164, P627, DOI 10.1016/0022-2836(83)90054-2; SPAGNUOLO C, 1988, BIOCHIM BIOPHYS ACTA, V956, P119, DOI 10.1016/0167-4838(88)90257-9	17	4	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17898	17903						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917929				2022-12-25	WOS:A1991GG55300031
J	FREISSMUTH, M; SCHUTZ, W; LINDER, ME				FREISSMUTH, M; SCHUTZ, W; LINDER, ME			INTERACTIONS OF THE BOVINE BRAIN ADENOSINE-A1-RECEPTOR WITH RECOMBINANT G-PROTEIN ALPHA-SUBUNITS - SELECTIVITY FOR RGI-ALPHA-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE REGULATORY PROTEINS; GTP-BINDING PROTEIN; BETA-ADRENERGIC RECEPTORS; PHOSPHOLIPID-VESICLES; PERTUSSIS TOXIN; ADENYLATE-CYCLASE; ADP-RIBOSYLATION; RECONSTITUTION; PURIFICATION; SPECIFICITY	The ability of the bovine brain A1-adenosine receptor to discriminate between different G protein subtypes was tested using G protein alpha-subunits synthesized in Escherichia coli (rG-alpha-subunits). When combined with a 3-fold molar excess of beta-gamma-subunit purified from bovine brain and used at high concentrations, all three subtypes of rG(i-alpha) (rG(i-alpha-1), rG(i-alpha-2), and rG(i-alpha-3)) and rG(o-alpha) were capable of reconstituting guanine nucleotide-sensitive high-affinity binding of the agonist radioligand (-)-N6-3-[I-125](iodo-4-hydroxyphenylisopropyl)adenosine ([I-125]HPIA) to the purified A1-adenosine receptor (K(d) approximately 1.2 nM). Titration of the A1-adenosine receptor with increasing amounts of rG-alpha revealed a approximately 10-fold higher affinity for rG(i-alpha-3) compared with rG(i-alpha-1), rG(i-alpha-2), and rG(o-alpha). This selectivity was also observed in the absence of beta-gamma. Other alpha-subunits (rG(s-alpha-s), rG(s-alpha-L), rG(s-alpha)PT, and rG(z-alpha) did not promote [I-125]HPIA binding to the purified receptor. In N-ethylmaleimide-treated bovine brain membranes, rG(i-alpha-3) was the only rG(alpha)-subunit capable of reconstituting high-affinity agonist binding. Similarly, rG(i-alpha-3) competed potently with rG(o-alpha) for activation by the agonist-liganded A1-adenosine receptor, whereas a approximately 50-fold molar excess of rG(o-alpha) was required to quench the receptor-mediated release of [alpha-P-32]GDP from rG(i-alpha-3). Hence, in spite of the extensive homology between alpha-subunits belonging to the G(i)/G(o) group, the A1-adenosine receptor appears to discriminate between the subtypes. This specificity is likely to govern transmembrane signaling pathways in vivo.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	FREISSMUTH, M (corresponding author), UNIV VIENNA,INST PHARMACOL,WAHRINGER STR 13A,A-1090 VIENNA,AUSTRIA.		Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712; Freissmuth, Michael/0000-0001-9398-1765	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1984, J BIOL CHEM, V259, P9351; ASANO T, 1986, MOL PHRM, V29, P2441; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; FREDHOLM BB, 1989, EUR J PHARM-MOLEC PH, V172, P249, DOI 10.1016/0922-4106(89)90055-2; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; FREISSMUTH M, 1991, IN PRESS BIOCH J, V276; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P21907; HEKMAN M, 1984, EMBO J, V3, P3339, DOI 10.1002/j.1460-2075.1984.tb02301.x; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUROSE H, 1986, J BIOL CHEM, V261, P6423; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MUNSHI R, 1989, J BIOL CHEM, V264, P14853; NAKATA H, 1989, J BIOL CHEM, V264, P16545; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHUTZ W, 1991, IN PRESS NAUNYNSCHMI; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; STERNWEIS PC, 1984, J BIOL CHEM, V259, P13086; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; WESS J, 1990, MOL PHARMACOL, V38, P517; WONG SKF, 1990, J BIOL CHEM, V265, P6219	34	109	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17778	17783						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917922				2022-12-25	WOS:A1991GG55300013
J	HAMER, PJ; LAVECCHIO, J; NG, S; DELELLIS, R; WOLFE, H; CARNEY, WP				HAMER, PJ; LAVECCHIO, J; NG, S; DELELLIS, R; WOLFE, H; CARNEY, WP			ACTIVATED VAL-12 RAS P21 IN CELL-CULTURE FLUIDS AND MOUSE PLASMA	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; MONOCLONAL-ANTIBODIES; HUMAN CARCINOMAS; POINT MUTATIONS; GENE-MUTATIONS; PROTO-ONCOGENE; HUMAN-COLON; HUMAN-LUNG; ADENOCARCINOMA; EXPRESSION	Activation of ras oncogenes has been associated with a variety of cancers as well as their precursor lesions. Ras proteins activated by substitutions at amino acid positions 12, 13 or 61 have not been identified in normal tissues and therefore their detection may have clinical value. In this study our objective was to determine whether activated ras proteins could be released into the extracellular environment. To test this hypothesis, we used ras-transformed NIH3T3 cells that express an activated p21 containing valine (Val-12 p21) at position 12 instead of the normal glycine (Gly-12 p21) and a monoclonal antibody (mAb) designated DWP that is specific for the activated Val-12 ras proteins. Culture fluids collected from NIH3T3 cells transformed by the activated Val-12 p21 were shown, using mAb DWP in a sandwich ELISA format, to contain the activated Val-12 p21. In contrast, culture fluids from non-Val-12-containing cells were unreactive with mAb DWP. PSV-LM-EJ cells which overexpress the activated Val-12 p21 were injected subcutaneously (SQ) into nude mice to produce tumors. At the time of gross tumor appearance (14-21 days after tumor cell inoculation), plasma was collected from the PSV-LM-EJ tumor-bearing mice as well as from a series of control mice. Employing mAb DWP as a detection reagent in the sandwich ELISA format, we were able to detect the Val-12 p21 in the plasma of the PSV-LM-EJ tumor-bearing mice. Activated Val-12 p21 was not present in the plasma of non-tumor-bearing mice, or in the plasma of mice bearing SQ tumors composed of non-Val-12 p21 ras-transformed cells. This report is the first description of an activated ras protein (Val-12 p21) in the plasma of tumor-bearing mice and demonstrates that the results of the Val-12 p21-specific ELISA could be validated with Western blot format.	DUPONT CO,DEPT MED PROD,BIOTECHNOL SYST,331 TREBLE COVE RD,N BILLERICA,MA 01862; TUFTS NEW ENGLAND MED CTR,DEPT PATHOL,BOSTON,MA 02115	DuPont; Tufts Medical Center								ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; BRANDTRAUF PW, 1988, BRIT J IND MED, V45, P689; BRANDTRAUF PW, 1991, IN PRESS J SOC OCCUP; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CARNEY WP, 1986, J CELL BIOCHEM, V32, P207, DOI 10.1002/jcb.240320307; CARNEY WP, 1986, P NATL ACAD SCI USA, V83, P7485, DOI 10.1073/pnas.83.19.7485; CARNEY WP, 1989, HUMAN TUMOR ANTIGENS, P53; CARUSO A, 1986, INT J CANCER, V38, P587, DOI 10.1002/ijc.2910380420; CLAIR T, 1987, CANCER RES, V47, P5290; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GREENBERG PL, 1979, AM J MED, V66, P951, DOI 10.1016/0002-9343(79)90450-9; HAMER PJ, 1990, HYBRIDOMA, V9, P573, DOI 10.1089/hyb.1990.9.573; KAKKANAS A, 1990, In Vivo (Attiki), V4, P115; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; LAVECCHIO JA, 1990, ONCOGENE, V5, P1173; LERNER EA, 1980, J EXP MED, V152, P1085, DOI 10.1084/jem.152.4.1085; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; NIMAN HL, 1985, P NATL ACAD SCI USA, V82, P7924, DOI 10.1073/pnas.82.23.7924; PADUA RA, 1988, LEUKEMIA, V2, P503; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TOKSOZ D, 1987, ONCOGENE, V1, P409; UPDYKE TV, 1984, J IMMUNOL METHODS, V73, P83, DOI 10.1016/0022-1759(84)90034-6; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YANEZ L, 1987, ONCOGENE, V1, P315	35	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1609	1615						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923528				2022-12-25	WOS:A1991GX27400016
J	EVANS, DL; MCGROGAN, M; SCOTT, RW; CARRELL, RW				EVANS, DL; MCGROGAN, M; SCOTT, RW; CARRELL, RW			PROTEASE SPECIFICITY AND HEPARIN BINDING AND ACTIVATION OF RECOMBINANT PROTEASE NEXIN-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR WEIGHT HEPARIN; NEURITE-PROMOTING FACTOR; GLIA-DERIVED-NEXIN; ANTI-THROMBIN-III; CONFORMATIONAL CHANGE; ANTITHROMBIN INTERACTIONS; FACTOR-XA; INHIBITOR; ALPHA-1-ANTITRYPSIN; PURIFICATION	Structural and functional properties of alpha-protease nexin I (alpha-PNI) expressed in Chinese hamster ovary cells were studied. All three cysteines were in the reduced form, showing that the potential disulfide bridge between residues Cys117 and Cys131 was not formed. Heparin association rate enhancements were from k(a) = 8.3 x 10(5) to 0.7-1.6 x 10(9) M-1 s-1 for the interaction of PNI with thrombin, from k(a) = 5.1 x 10(3) to 3.5 x 10(5) M-1 s-1 for interaction with Factor Xa, and from k(a). = 2.2 x 10(6) to 1.0 x 10(7) M-1 s-1 for interaction with trypsin; there was no rate enhancement of the plasmin interaction (k(a) = 1.0 x 10(5) M-1 s-1). The minimal heparin pentasaccharide had no effect on these interactions. Cleavage of the reactive center Loop of PNI by three different proteases gave the typical stressed to relaxed change in thermal stability, but unlike with antithrombin III, there was no loss of heparin affinity. A similar difference from antithrombin was that PNI-thrombin complexes retained normal heparin affinity. These results are compatible with a role for protease nexin I as a cell-associated thrombin inhibitor that remains bound to the cell surface even after complexing with the protease, as compared with the role of antithrombin III as a Circulating inhibitor of thrombin that becomes activated on binding to the microvasculature and is released on complex formation.	INVITRON CORP, REDWOOD CITY, CA 94063 USA		EVANS, DL (corresponding author), UNIV CAMBRIDGE, MRC, DEPT HAEMATOL, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER JB, 1982, J CELL PHYSIOL, V112, P291, DOI 10.1002/jcp.1041120220; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BAKER JB, 1986, RECEPTORS, V3, P153; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BOYER C, 1984, THROMB RES, V36, P579, DOI 10.1016/0049-3848(84)90197-X; CARLSTROM AS, 1977, THROMB RES, V11, P785, DOI 10.1016/0049-3848(77)90107-4; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; CHOAY J, 1989, SEMIN THROMB HEMOST, V15, P359, DOI 10.1055/s-2007-1002730; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; EATON DL, 1984, J BIOL CHEM, V259, P6241; ELLIS V, 1986, BIOCHEM J, V238, P329, DOI 10.1042/bj2380329; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; EVANS DL, 1990, NATO ADV SCI I A-LIF, V191, P69; FARRELL DH, 1986, BIOCHEM J, V237, P907, DOI 10.1042/bj2370907; FARRELL DH, 1987, BIOCHEM J, V245, P543, DOI 10.1042/bj2450543; FARRELL DH, 1986, P NATL ACAD SCI USA, V83, P6858, DOI 10.1073/pnas.83.18.6858; GEORGE PM, 1989, BLOOD, V73, P490; GETTINS P, 1989, J BIOL CHEM, V264, P3781; GLOOR S, 1986, CELL, V47, P687; GURWITZ D, 1989, BIOCHEM BIOPH RES CO, V161, P300, DOI 10.1016/0006-291X(89)91596-9; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HOYLAERTS M, 1984, J BIOL CHEM, V259, P5670; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JORDAN R, 1979, J BIOL CHEM, V254, P2902; JORDAN RE, 1987, SCIENCE, V237, P777, DOI 10.1126/science.3649921; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KOREN R, 1976, BIOCHEMISTRY-US, V15, P1165, DOI 10.1021/bi00650a032; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LOW DA, 1982, NATURE, V298, P476, DOI 10.1038/298476a0; MCGROGAN M, 1990, NATO ADV SCI I A-LIF, V191, P147; MCGROGAN M, 1988, BIO-TECHNOL, V6, P172, DOI 10.1038/nbt0288-172; MCKAY EJ, 1981, THROMB RES, V21, P375, DOI 10.1016/0049-3848(81)90138-9; MEIER R, 1989, NATURE, V342, P548, DOI 10.1038/342548a0; MONARD D, 1990, SERINE PROTEASES THE, P257; NESHEIM ME, 1983, J BIOL CHEM, V258, P4708; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; PEMBERTON PA, 1989, BIOCHEM J, V258, P193, DOI 10.1042/bj2580193; POMERANTZ MW, 1978, BIOCHIM BIOPHYS ACTA, V535, P66, DOI 10.1016/0005-2795(78)90033-8; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; STONE SR, 1987, ARCH BIOCHEM BIOPHYS, V252, P237, DOI 10.1016/0003-9861(87)90028-2; TORRI G, 1985, BIOCHEM BIOPH RES CO, V128, P134, DOI 10.1016/0006-291X(85)91655-9; VANNOSTRAND WE, 1988, BIOCHEMISTRY-US, V27, P2176, DOI 10.1021/bi00406a054; VANNOSTRAND WE, 1988, J BIOL CHEM, V263, P3979; WAGNER SL, 1988, BIOCHEMISTRY-US, V27, P2173, DOI 10.1021/bi00406a053; WALLACE A, 1989, BIOCHEM J, V257, P191, DOI 10.1042/bj2570191	49	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22307	22312						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939253				2022-12-25	WOS:A1991GR56400041
J	HOFFMAN, LR; CHANG, EB				HOFFMAN, LR; CHANG, EB			DETERMINANTS OF REGIONAL SUCRASE-ISOMALTASE EXPRESSION IN ADULT-RAT SMALL-INTESTINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION; GLYCOSYLATION; BIOSYNTHESIS; ENZYME; VILLUS; CELLS; GENE; RNA	Sucrase-isomaltase (SI) expression along the longitudinal and vertical axis of the small intestine was studied by sequentially isolating enterocytes from villus to crypt of rat proximal jejunum and distal ileum. Gradients of sucrase activity were observed with greatest activity occurring in jejunal and villus regions. Along the villus-to-crypt axis, gradients of SI mRNA abundance corresponded with activity. However, along the longitudinal axis no differences in SI mRNA levels were observed, thus not accounting for the observed 3-5-fold difference in SI activities between jejunum and ileum. Comparison of SI immunoprecipitates from jejunal and ileal mucosal scrapings showed significant differences in gel mobilities of the more mature forms, which did not appear to affect SI functional activities. When relative rates of de novo SI protein synthesis were compared, [S-35]methionine incorporation into all SI forms was observed to be 3-5-fold greater in jejunum than in ileum at all time points. Because these results suggested differences in regional translational regulation, subcellular distribution of SI mRNA in jejunal and ileal epithelial cells was compared. A greater proportion of jejunal SI mRNA was found to be associated with membrane-bound polyribosomes. We conclude 1) sucrase expression along the villus-to-crypt axis correlates with SI mRNA abundance, 2) post-translational processing of SI differ in ileum and jejunum, but appear not to determine SI expression, and 3) differences in translational processing in distal ileum and proximal jejunum may determine sucrase activity along the longitudinal axis of rat small intestine.	UNIV CHICAGO,DEPT MED,GASTROENTEROL SECT,BOX 400,5841 S MARYLAND AVE,CHICAGO,IL 60637	University of Chicago					NIDDK NIH HHS [DK40922, DK38510, DK26678] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026678, R01DK040922, R01DK038510] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERS DH, 1986, BIOCHEM BIOPH RES CO, V134, P37, DOI 10.1016/0006-291X(86)90523-1; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BONIFACINO JS, 1991, CURRENT PROTOCOLS MO; BRASITUS T, 1985, DIFFERENTIATION, V24, P239; BULLER HA, 1990, GASTROENTEROLOGY, V98, P667; Burton K., 1968, METHODS ENZYMOLOGY B, V12B, P163; CHANDRASENA G, 1990, J CELL BIOL, V111, P1217; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS MJ, 1987, TRANSCRIPTION TRANSL, P221; DAHLQVIST A, 1964, ANAL BIOCHEM, V7, P18, DOI 10.1016/0003-2697(64)90115-0; DANIELSEN EM, 1986, BIOCHEM J, V235, P447, DOI 10.1042/bj2350447; DAVIDSON NO, 1986, J LIPID RES, V27, P30; DEREN JJ, 1967, J CLIN INVEST, V46, P186, DOI 10.1172/JCI105521; FREUND JN, 1989, CELL MOL BIOL, V35, P313; Henning Susan J., 1987, PHYSL GASTROINTESTIN, V1, P285; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; LEEPER LL, 1990, AM J PHYSIOL, V258, pG52, DOI 10.1152/ajpgi.1990.258.1.G52; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NORDSTROM C, 1968, J HISTOCHEM CYTOCHEM, V15, P713; RIBY JE, 1984, AM J PHYSIOL, V246, pG757, DOI 10.1152/ajpgi.1984.246.6.G757; SCHMITZ J, 1973, BIOCHIM BIOPHYS ACTA, V323, P98, DOI 10.1016/0005-2736(73)90434-3; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; TRUGNAN G, 1987, J CELL BIOL, V104, P1199, DOI 10.1083/jcb.104.5.1199; WEISER MM, 1973, J BIOL CHEM, V248, P2536; YAMADA K, 1981, FEBS LETT, V129, P89, DOI 10.1016/0014-5793(81)80762-4; YOUNOSZAI MK, 1972, J LAB CLIN MED, V79, P579	27	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21815	21820						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939205				2022-12-25	WOS:A1991GP80400075
J	MYSZKA, DG; SWENSON, RP				MYSZKA, DG; SWENSON, RP			IDENTIFICATION BY PHOTOAFFINITY-LABELING OF FATTY ACID-BINDING PROTEIN AS A POTENTIAL WARFARIN RECEPTOR IN RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-K 2,3-EPOXIDE; HEPATIC-UPTAKE; RESISTANT RAT; REDUCTASE; BIOSYNTHESIS; PURIFICATION; METABOLISM; SEQUENCE; FRACTION	Two different photoaffinity analogs of 4-hydroxy coumarin, 3-(p-azidobenzyl)-4-hydroxycoumarin (AzBHC) and 3-(4-azido-5-iodosalicylamido)-4-hydroxycoumarin (AzISAHC), are being used in the identification of warfarin-binding proteins present in mammalian tissue (Myszka, D. G., and Swenson, R. P. (1990) Biochem. Biophys. Res. Commun. 172, 415-422; Myszka, D. G., and Swenson, R. P. (1991) J. Biol. Chem. 266, 4789-4797). In this study, [C-14]AzBHC, but not [I-125]AzISAHC, was observed to specifically label a 15,000-dalton protein present in both the microsomal and cytosolic fractions of rat liver. Pretreatment of the crude protein samples with warfarin or dicoumarol completely protected the 15-kDa protein from modification by [C-14]AzBHC, indicating that this photoaffinity reagent is specifically labeling a coumarin-binding protein. 4-Hydroxycoumarin itself and AzISAHC were unable to block the incorporation of this photoaffinity probe. The 15-kDa protein was isolated by two-dimensional electrophoresis and subjected to amino-terminal sequence analysis. The first 20 amino acid residues analyzed were found to be identical with the amino-terminal sequence of rat liver fatty acid-binding protein (L-FABP) (Gordon J. I., Alpers, D. H., Ockner, R. K., and Strauss, A. W. (1983) J. Biol. Chem. 258, 3356-3363). Photoaffinity labeling and protection experiments carried out on purified preparations of L-FABP paralleled the labeling results obtained in the microsomes and cytosol, confirming that L-FABP is capable of specifically binding AzBHC, warfarin, and dicoumarol. Oleic acid, an established ligand for L-FABP, can compete with the binding of the photoaffinity probe; however, it was less effective in protecting the protein than warfarin. The specificity of labeling of crude liver fractions by warfarin photoaffinity analogs reported here as well as the high concentration of FABP in liver tissue together suggest that this protein may represent a major hepatic receptor responsible for the uptake and/or transport of various oral 4-hydroxycoumarin-based anticoagulant drugs.	OHIO STATE UNIV,DEPT BIOCHEM,484 W 12TH AVE,COLUMBUS,OH 43210	Ohio State University								BASS NM, 1985, J BIOL CHEM, V260, P1432; Bayley H., 1984, AZIDES NITRENES REAC, P433; BENYA TJ, 1975, J PHARMACOKINET BIOP, V3, P237, DOI 10.1007/BF01066920; BILLHEIMER JT, 1980, J BIOL CHEM, V255, P8128; CHARESTBOULE L, 1980, CHEM-BIOL INTERACT, V29, P85, DOI 10.1016/0009-2797(80)90088-5; COVELL DG, 1983, J PHARMACOKINET BIOP, V11, P127, DOI 10.1007/BF01061845; DAEMEN MJAP, 1986, J PHARM SCI, V75, P238, DOI 10.1002/jps.2600750305; DELEPELAIRE P, 1979, P NATL ACAD SCI USA, V76, P111, DOI 10.1073/pnas.76.1.111; DEMPSEY ME, 1981, J BIOL CHEM, V256, P1867; DEMPSEY ME, 1974, ANNU REV BIOCHEM, V43, P967, DOI 10.1146/annurev.bi.43.070174.004535; FASCO MJ, 1982, J BIOL CHEM, V257, P4894; GORDON JI, 1983, J BIOL CHEM, V258, P3356; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JJ, 1985, BIOCHEMISTRY-US, V24, P7063, DOI 10.1021/bi00346a007; LEE JJ, 1984, BIOCHEMISTRY-US, V23, P2246, DOI 10.1021/bi00305a024; LEVI AJ, 1969, J CLIN INVEST, V48, P2156, DOI 10.1172/JCI106182; LORUSSO DJ, 1972, MOL PHARMACOL, V8, P197; LOTTSPEICH F, 1990, Journal of Protein Chemistry, V9, P268; MYSZKA DG, 1990, BIOCHEM BIOPH RES CO, V172, P415, DOI 10.1016/0006-291X(90)90689-K; MYSZKA DG, 1991, J BIOL CHEM, V266, P478; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PICCIONI R, 1982, METHODS CHLOROPLAST, P985; RUOHO AE, 1984, MEMBRANES DETERGENTS, P119; SCALLEN TJ, 1985, J BIOL CHEM, V260, P4733; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P14105; STAROS JV, 1978, BIOCHEM BIOPH RES CO, V80, P568, DOI 10.1016/0006-291X(78)91606-6; THIERRY MJ, 1970, AM J PHYSIOL, V219, P854, DOI 10.1152/ajplegacy.1970.219.4.854; THIJSSEN HHW, 1988, DRUG METAB DISPOS, V16, P744; THIJSSEN HHW, 1983, J PHARM PHARMACOL, V35, P793, DOI 10.1111/j.2042-7158.1983.tb02898.x; THIJSSEN HHW, 1987, J PHARMACOL EXP THER, V243, P1082; WARNER M, 1975, CAN J PHYSIOL PHARM, V53, P493, DOI 10.1139/y75-069; WILTON DC, 1989, BIOCHEM J, V261, P273, DOI 10.1042/bj2610273; WOSILAIT WD, 1981, RES COMMUN CHEM PATH, V32, P113; WOSILAIT WD, 1981, DRUG METAB DISPOS, V9, P80; WOSILAIT WD, 1972, RES COMMUN CHEM PATH, V4, P413	36	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20725	20731						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939124				2022-12-25	WOS:A1991GN00100024
J	WARIISHI, H; HUANG, J; DUNFORD, HB; GOLD, MH				WARIISHI, H; HUANG, J; DUNFORD, HB; GOLD, MH			REACTIONS OF LIGNIN PEROXIDASE COMPOUND-I AND COMPOUND-II WITH VERATRYL ALCOHOL - TRANSIENT-STATE KINETIC CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; WHITE ROT BASIDIOMYCETE; HORSERADISH-PEROXIDASE; DIARYLPROPANE OXYGENASE; EXTRACELLULAR PEROXIDASES; SPECTRAL CHARACTERIZATION; MANGANESE PEROXIDASE; HEME ENZYME; OXIDATION; BIODEGRADATION	Stopped-flow techniques were utilized to investigate the kinetics of the reaction of lignin peroxidase compounds I and II (LiPI and LiPII) with veratryl alcohol (VA). All rate data were collected from single turnover experiments under pseudo first-order conditions. The reaction of LiPI with VA strictly obeys second-order kinetics over the pH range 2.72-5.25 as demonstrated by linear plots of the pseudo first-order rate constants versus concentrations of VA. The second-order rate constants are strongly dependent on pH and range from 2.62 x 10(6) M-1 s-1 (pH 2.72) to 1.45 X 10(4) M-1 s-1 (pH 5.25). The reaction of LiPII and VA exhibits saturation behavior when the observed pseudo first-order rate constants are plotted against VA concentrations. The saturation phenomenon is quantitatively explained by the formation of a 1:1 LiPII-substrate complex. Results of kinetic and rapid scan spectral analyses exclude the formation of a LiPII-VA cation radical complex. The first-order dissociation rate constant and the equilibrium dissociation constant for the LiPII reaction are also pH dependent. Binding of VA to LiPII is controlled by a heme-linked ionizable group of pK(a) approximately 4.2. The pH profiles of the second-order rate constants for the LiPI reaction and of the first-order dissociation constants for the LiPII reaction both demonstrate two pK(a) values at approximately 3.0 and approximately 4.2. Protonated oxidized enzyme intermediates are most active, suggesting that only electron transfer, not proton uptake from the reducing substrate, occurs at the enzyme active site. These results are consistent with the one-electron oxidation of VA to an aryl cation radical by LiPI and LiPII.	OREGON GRAD INST SCI & TECHNOL,DEPT CHEM & BIOL SCI,19600 NW VON NEUMANN DR,BEAVERTON,OR 97006; UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,ALBERTA,CANADA	University of Alberta								ANDERSSON LA, 1985, J BIOL CHEM, V260, P6080; ANDERSSON LA, 1987, BIOCHEMISTRY-US, V26, P2258, DOI 10.1021/bi00382a028; ANDRAWIS A, 1988, J BIOL CHEM, V263, P1195; ARAISO T, 1980, BIOCHEM BIOPH RES CO, V94, P1177, DOI 10.1016/0006-291X(80)90543-4; BUSWELL JA, 1987, CRC CR REV BIOTECHN, V6, P1, DOI 10.3109/07388558709086984; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; CRITCHLOW JE, 1972, J BIOL CHEM, V247, P3703; DEBOER HA, 1987, GENE, V60, P93, DOI 10.1016/0378-1119(87)90217-4; DUNFORD HB, 1975, J BIOL CHEM, V250, P2920; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; DUNFORD HB, 1979, BIOCHEM BIOPH RES CO, V89, P764, DOI 10.1016/0006-291X(79)90695-8; GOLD MH, 1984, ARCH BIOCHEM BIOPHYS, V234, P353, DOI 10.1016/0003-9861(84)90280-7; GOLD MH, 1989, ACS SYM SER, V389, P127; HAEMMERLI SD, 1986, J BIOL CHEM, V261, P6900; HAMMEL KE, 1991, ENZYME MICROB TECH, V13, P15, DOI 10.1016/0141-0229(91)90182-A; HARVEY PJ, 1986, FEBS LETT, V195, P242, DOI 10.1016/0014-5793(86)80168-5; HARVEY PJ, 1989, BIOCHIM BIOPHYS ACTA, V994, P59, DOI 10.1016/0167-4838(89)90062-9; HARVEY PJ, 1987, APR P INT S LIGN ENZ, P145; HEWSON WD, 1976, J BIOL CHEM, V251, P6036; HIGUCHI T, 1990, WOOD SCI TECHNOL, V24, P23, DOI 10.1007/BF00225306; KERSTEN PJ, 1985, J BIOL CHEM, V260, P2609; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KUILA D, 1985, BIOCHEMISTRY-US, V24, P3394, DOI 10.1021/bi00335a002; LEISOLA MSA, 1987, J BIOL CHEM, V262, P419; MARQUEZ L, 1988, J BIOL CHEM, V263, P10549; MYLRAJAN M, 1990, BIOCHEMISTRY-US, V29, P9617, DOI 10.1021/bi00493a016; POULOS TL, 1980, J BIOL CHEM, V255, P8199; PRIBNOW D, 1989, J BIOL CHEM, V264, P5036; RENGANATHAN V, 1987, BIOCHEMISTRY-US, V26, P5127, DOI 10.1021/bi00390a035; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; RENGANATHAN V, 1985, ARCH BIOCHEM BIOPHYS, V241, P304, DOI 10.1016/0003-9861(85)90387-X; SCHMIDT HWH, 1989, BIOCHEMISTRY-US, V28, P1776, DOI 10.1021/bi00430a053; SCHOEMAKER HE, 1990, RECL TRAV CHIM PAY B, V109, P255; TIEN M, 1986, J BIOL CHEM, V261, P1687; TIEN M, 1987, CRIT REV MICROBIOL, V15, P141, DOI 10.3109/10408418709104456; Tien M, 1987, NATURE, V326, P520, DOI 10.1038/326520a0; VALLI K, 1990, BIOCHEMISTRY-US, V29, P8535, DOI 10.1021/bi00489a005; WARIISHI H, 1990, J BIOL CHEM, V265, P2070; WARIISHI H, 1990, J BIOL CHEM, V265, P11137; WARIISHI H, 1989, J BIOL CHEM, V264, P3335; WARIISHI H, 1989, FEBS LETT, V243, P165, DOI 10.1016/0014-5793(89)80122-X; WELINDER KG, 1976, FEBS LETT, V72, P19, DOI 10.1016/0014-5793(76)80804-6	43	55	57	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20694	20699						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939119				2022-12-25	WOS:A1991GN00100019
J	PARTANEN, J; ARMSTRONG, E; BERGMAN, M; MAKELA, TP; HIRVONEN, H; HUEBNER, K; ALITALO, K				PARTANEN, J; ARMSTRONG, E; BERGMAN, M; MAKELA, TP; HIRVONEN, H; HUEBNER, K; ALITALO, K			CYL ENCODES A PUTATIVE CYTOPLASMIC TYROSINE KINASE LACKING THE CONSERVED TYROSINE AUTOPHOSPHORYLATION SITE (Y416SRC)	ONCOGENE			English	Article							AMINO-TERMINAL DOMAIN; ROUS-SARCOMA VIRUS; PROTEIN-KINASE; ONC GENES; CELL-LINE; PP60C-SRC; PHOSPHORYLATION; TRANSFORMATION; ACTIVATION; SRC	We have isolated a cDNA encoding a novel tyrosine kinase family member, named cyl (consensus tyrosine-lacking kinase), from the K562 human leukemia cell line. The deduced cyl protein lacks signal and transmembrane sequences but contains features of known cytoplasmic tyrosine kinases, including amino-terminal SH3 and SH2 domains. However, having very short amino and carboxy termini, cyl does not seem to belong to any of the previously characterized subfamilies of cytoplasmic tyrosine kinases. Furthermore, cyl lacks the highly conserved tyrosine autophosphorylation site (Y416src) in the tyrosine kinase catalytic domain. The cyl gene is located on human chromosome 15. It is expressed ubiquitously as two independently regulated mRNA species of 2.6 and 3.4 kb in human leukemia cell lines and fetal tissues.	UNIV HELSINKI,DEPT VIROL,CANC BIOL LAB,SF-00290 HELSINKI 29,FINLAND; UNIV TURKU,DEPT MED BIOCHEM,SF-20520 TURKU 52,FINLAND; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	University of Helsinki; University of Turku; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	PARTANEN, J (corresponding author), UNIV HELSINKI,DEPT PATHOL,CANC BIOL LAB,HAARTMANINK 3,SF-00290 HELSINKI 29,FINLAND.		makela, tomi/B-3734-2009; Alitalo, Kari K/J-5013-2014	makela, tomi/0000-0002-4869-8044; Alitalo, Kari K/0000-0002-7331-0902; Partanen, Juha/0000-0001-8850-4825				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; Bishop JM, 1985, RNA TUMOR VIRUSES, P249; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P4714, DOI 10.1073/pnas.79.15.4714; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GREENBERG SM, 1988, BLOOD, V72, P1968; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HUEBNER K, 1988, ONCOGENE, V3, P449; HUEBNER K, 1985, SCIENCE, V230, P1282, DOI 10.1126/science.2999978; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LETWIN K, 1988, ONCOGENE, V3, P621; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LOZZIO CB, 1975, BLOOD, V45, P335; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8670; MUSTELIN T, 1990, ONCOGENE, V5, P809; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P9103; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PONCZ M, 1987, BLOOD, V69, P219; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SNYDER MA, 1983, CELL, V32, P891, DOI 10.1016/0092-8674(83)90074-0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1990, CELL, V61, P243; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V64, P511; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	58	87	90	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2013	2018						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945408				2022-12-25	WOS:A1991GX11900011
J	BARON, C; BOCK, A				BARON, C; BOCK, A			THE LENGTH OF THE AMINOACYL-ACCEPTOR STEM OF THE SELENOCYSTEINE-SPECIFIC TRANSFER RNASEC OF ESCHERICHIA-COLI IS THE DETERMINANT FOR BINDING TO ELONGATION-FACTORS SELB OR TU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION FACTOR; DISCRIMINATION; PURIFICATION; SEQUENCES; SERINE; GENE	Mutations in selC, which reduce the 8-base pair aminoacyl-acceptor helix to the canonical 7-base pair length (tRNA(Sec)(delAc)) or which replace the extra arm of tRNA(Sec) by that of a serine acceptor tRNA species (tRNA(Sec)(ExS), block the function in selenoprotein synthesis in vivo (Baron, C., Heider, J., and Bock, A. (1990) Nucleic Acids Res. 18, 6761-6766). tRNAs(Sec), tRNA(Sec)(delAc), and tRNA(Sec)(ExS) were purified and analyzed for their interaction with purified seryl-tRNA synthetase, selenocysteine synthase and translation factors SELB and EF-Tu. It was found that seryl-tRNA synthetase displays 10-fold impaired K(m) and K(cat) values for tRNA(Sec) in comparison to tRNA(Ser), decreasing the overall charging efficiency (K(cat)/K(m)) of tRNA(Sec) to 1% of that characteristic for tRNA(Ser). tRNA(Sec)(ExS) was a less efficient substrate for the enzyme (K(cat)/K(m) 0.2% of the tRNA(Ser) value) whereas the tRNA(Ser)(delAc) variant was charged with an approximately 2-3-fold improved rate compared to wild-type tRNA(Sec). Both mutant tRNA variants, when charged with L-serine, were able to interact with selenocysteine synthase to give rise to selenocysteyl-tRNA with tRNA(Sec)(ExS) being as efficient as wild-type tRNA(Sec). Seryl-tRNAs(Sec)(delAc), on the other hand, was selenylated very slowly. Reduction of the length of the aminoacyl-acceptor stem to 7 base pairs prevented the interaction with translation factor SELB but allowed binding to EF-Tu, irrespective of whether tRNA(Sec)(delAc) was charged with serine or selenocysteine. The aminoacyl-acceptor helix of tRNA(Sec), therefore, is a major determinant directing binding to SELB and precluding interaction with EF-Tu.	UNIV MUNICH,LEHRSTUHL MIKROBIOL,MARIA WARD STR 1A,W-8000 MUNICH 19,GERMANY	University of Munich			Baron, Christian/A-5705-2008					BARON C, 1990, NUCLEIC ACIDS RES, V18, P6761, DOI 10.1093/nar/18.23.6761; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; FAULHAMMER HG, 1987, FEBS LETT, V217, P203, DOI 10.1016/0014-5793(87)80664-6; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; FORCHHAMMER K, 1990, J BIOL CHEM, V265, P9346; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6324; FORSTER C, 1990, NUCLEIC ACIDS RES, V18, P487, DOI 10.1093/nar/18.3.487; KNOWLTON RG, 1980, J MOL BIOL, V139, P721, DOI 10.1016/0022-2836(80)90057-1; LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; LEINFELDER W, 1989, J BIOL CHEM, V264, P9720; Miller D L, 1974, Methods Enzymol, V30, P219; PINGOUD A, 1977, EUR J BIOCHEM, V78, P403, DOI 10.1111/j.1432-1033.1977.tb11752.x; ROGERS MJ, 1988, P NATL ACAD SCI USA, V85, P6627, DOI 10.1073/pnas.85.18.6627; ROY KL, 1970, J BIOL CHEM, V245, P1394; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; von Ehrenstein G, 1967, METHOD ENZYMOL, V12, P588; WENZIG P, 1989, ARCH MICROBIOL, V152, P258, DOI 10.1007/BF00409660; WIKMAN FP, 1982, EMBO J, V1, P1095, DOI 10.1002/j.1460-2075.1982.tb01302.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	21	90	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20375	20379						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939093				2022-12-25	WOS:A1991GM03900074
J	KASAHARA, K; CHIDA, K; TSUNENAGA, M; KOHNO, Y; IKUTA, T; KUROKI, T				KASAHARA, K; CHIDA, K; TSUNENAGA, M; KOHNO, Y; IKUTA, T; KUROKI, T			IDENTIFICATION OF LAMIN-B2 AS A SUBSTRATE OF PROTEIN-KINASE-C IN BALB/MK-2 MOUSE KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEINS; CREATINE PHOSPHOKINASE-B; SODIUM DODECYL-SULFATE; RAT-LIVER NUCLEI; PHOSPHORYLATION SITES; GEL-ELECTROPHORESIS; CELLULAR SUBSTRATE; ENVELOPE; MEMBRANE; INVITRO	Protein phosphorylation by activation of protein kinase C was examined using quiescent cultures of the mouse epidermal keratinocyte line BALB/MK-2. Treatment with phorbol ester caused rapid phosphorylation of five proteins with molecular weights of 80,000, 70,000, 40,000, 34,000, 28,000. Of these proteins, the 70,000 molecular weight one (p70) was studied further. Its position on two-dimensional gel suggested that p70 is nuclear envelope lamin B. This possibility was confirmed by the co-migration of p70 with the lamin fraction of mouse liver and its immunoprecipitation with antinuclear lamina antibody. The lamin B fraction consists of lamin B1 and lamin B2. Evidence that p70 is lamin B2 was obtained by peptide mapping and amino acid sequencing. Lamin B2 is the only lamin that shows a substantial increase in phosphorylation on treatment of BALB/MK-2 cells with phorbol ester.	UNIV TOKYO,INST MED SCI,DEPT CANC CELL RES,MINATO KU,TOKYO 108,JAPAN	University of Tokyo			Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351; Kasahara, Kohji/0000-0001-7010-8365				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; APPELBAUM J, 1990, J BIOL CHEM, V265, P4181; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CHELSKY D, 1987, J BIOL CHEM, V262, P4303; CHIDA K, 1986, CANCER RES, V46, P1055; CHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P346, DOI 10.1016/S0006-291X(05)81063-0; CHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P351, DOI 10.1016/S0006-291X(05)81064-2; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DJABALI K, 1991, CELL, V64, P109, DOI 10.1016/0092-8674(91)90213-I; DWYER N, 1976, J CELL BIOL, V70, P5581; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GEORGATOS SD, 1987, P NATL ACAD SCI USA, V84, P6780, DOI 10.1073/pnas.84.19.6780; GERACE L, 1978, J CELL BIOL, V79, P546, DOI 10.1083/jcb.79.2.546; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HASHIMOTO F, 1983, ANAL BIOCHEM, V129, P192, DOI 10.1016/0003-2697(83)90068-4; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOGER TH, 1990, CHROMOSOMA, V99, P379, DOI 10.1007/BF01726689; HORNBECK P, 1988, P NATL ACAD SCI USA, V85, P2279, DOI 10.1073/pnas.85.7.2279; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Kitano T, 1986, Methods Enzymol, V124, P349; KUROKI T, 1988, INT AGENCY RES CANCE, V92, P80; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEHNER CF, 1987, J CELL BIOL, V105, P577, DOI 10.1083/jcb.105.1.577; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MCKEON FD, 1986, NATURE, V319, P463, DOI 10.1038/319463a0; MOSCAT J, 1988, MOL ENDOCRINOL, V2, P799, DOI 10.1210/mend-2-9-799; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OSADA S, 1990, J BIOL CHEM, V265, P22434; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1989, J MOL BIOL, V208, P393, DOI 10.1016/0022-2836(89)90504-4; ROGUE P, 1990, J BIOL CHEM, V265, P4161; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; STICK R, 1988, J CELL BIOL, V107, P397, DOI 10.1083/jcb.107.2.397; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; VORBURGER K, 1989, J MOL BIOL, V208, P405, DOI 10.1016/0022-2836(89)90505-6; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WONG TW, 1983, J BIOL CHEM, V258, P1022; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249	54	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20018	20023						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939065				2022-12-25	WOS:A1991GM03900027
J	SHEN, AL; CHRISTENSEN, MJ; KASPER, CB				SHEN, AL; CHRISTENSEN, MJ; KASPER, CB			NADPH-CYTOCHROME-P-450 OXIDOREDUCTASE - THE ROLE OF CYSTEINE 566 IN CATALYSIS AND COFACTOR BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P-450 REDUCTASE; PORCINE HEPATIC MICROSOMES; DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; STRUCTURAL-ANALYSIS; LIVER; DOMAINS; GENE; FMN; IDENTIFICATION	Site-directed mutagenesis was employed to investigate the role of Cys566 in the catalytic mechanism of rat liver NADPH-cytochrome P-450 oxidoreductase. Rat NADPH-cytochrome P-450 oxidoreductase and mutants containing either alanine or serine at position 566 were expressed in Escherichia coli and purified to homogeneity. Substitution of alanine at position 566 had no effect on enzymatic activity with the acceptors cytochrome c and ferricyanide but did increase transhydrogenase activity with 3-acetylpyridine adenine dinucleotide phosphate by 79%. The K(m) for NADPH was increased 2.5-fold, and the NADP+ K(I) was increased 4.8-fold compared with that found for the wild-type enzyme. The conservative substitution, Ser566, produced a 50% decrease in cytochrome c reductase activity whereas activity with ferricyanide was decreased 57%, and 3-acetylpyridine adenine dinucleotide phosphate activity was unaffected. The NADPH K(m) was increased 4.6-fold, and the NADP+ K(I) increased 7.6-fold. The dependence of cytochrome c reductase activity on the KCl concentration was markedly altered by the Cys566 substitutions. Maximum activity for the wild-type enzyme was observed at approximately 0.18 M KCl whereas maximum activity for the mutant enzymes was observed between 0.04 and 0.09 M KCl. The pH dependence of cytochrome c reductase activity, cytochrome c K(m), and flavin content were unaffected by these substitutions. These results demonstrate that Cys566 is not essential for activity of rat liver NADPH-cytochrome P-450 oxidoreductase although the cysteine side chain does affect the interaction of NADPH with the enzyme.			SHEN, AL (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706, USA.				NATIONAL CANCER INSTITUTE [P01CA022484] Funding Source: NIH RePORTER; NCI NIH HHS [CA22484] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER L, 1981, THESIS U TEXAS HLTH; BLACK SD, 1979, BIOCHEM BIOPH RES CO, V91, P1528, DOI 10.1016/0006-291X(79)91238-5; ERNSTER L, 1982, OXYGENASES OXYGEN ME, P357; HANIU M, 1984, J BIOL CHEM, V259, P3703; HANIU M, 1986, BIOCHEMISTRY-US, V25, P7906, DOI 10.1021/bi00372a018; HANIU M, 1989, BIOCHEMISTRY-US, V28, P8639, DOI 10.1021/bi00447a054; IYANAGI T, 1981, BIOCHEMISTRY-US, V20, P1722, DOI 10.1021/bi00510a004; IYANAGI T, 1973, BIOCHEMISTRY-US, V12, P2297, DOI 10.1021/bi00736a018; KURZBAN GP, 1986, J BIOL CHEM, V261, P7825; LU AYH, 1968, J BIOL CHEM, V243, P1331; MASTERS BSS, 1965, J BIOL CHEM, V240, P921; MASTERS BSS, 1980, ENZYMATIC BASIS DETO, P183; NISIMOTO Y, 1982, J BIOL CHEM, V257, P2532; NISIMOTO Y, 1986, J BIOL CHEM, V261, P14232; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; PORTER TD, 1987, ARCH BIOCHEM BIOPHYS, V254, P353, DOI 10.1016/0003-9861(87)90111-1; SEGAL I, 1975, ENZYME KINETICS, P524; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SUTTER TR, 1990, J BIOL CHEM, V265, P16428; SUTTER TR, 1989, BIOCHEM BIOPH RES CO, V160, P1257, DOI 10.1016/S0006-291X(89)80139-1; VERMILION JL, 1981, J BIOL CHEM, V256, P266; VOGEL F, 1985, BIOL CHEM H-S, V366, P577, DOI 10.1515/bchm3.1985.366.1.577; WALSH C, 1979, ENZYMATIC REACTION M, P335; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587; YABUSAKI Y, 1988, J BIOCHEM-TOKYO, V103, P1004, DOI 10.1093/oxfordjournals.jbchem.a122370; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	28	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19976	19980						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939060				2022-12-25	WOS:A1991GM03900020
J	JOHN, CM; GRIFFISS, JM; APICELLA, MA; MANDRELL, RE; GIBSON, BW				JOHN, CM; GRIFFISS, JM; APICELLA, MA; MANDRELL, RE; GIBSON, BW			THE STRUCTURAL BASIS FOR PYOCIN RESISTANCE IN NEISSERIA-GONORRHOEAE LIPOOLIGOSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN-SERUM; PSEUDOMONAS-AERUGINOSA; MONOCLONAL-ANTIBODIES; ANTIGENIC EXPRESSION; MASS-SPECTROMETRY; MENINGITIDIS; LIPOPOLYSACCHARIDE; OLIGOSACCHARIDES; HETEROGENEITY; SENSITIVITY	Pyocin resistance in a strain of Neisseria gonorrhoeae has been found to be associated with structural differences in the oligosaccharide moieties of the gonococcal outer membrane lipooligosaccharides (LOS). N. gonorrhoeae strain 1291 had been treated with several pyocins, usually lethal bacteriocins produced by Pseudomonas aeruginosa, and a series of surviving mutants were selected. The LOS of these pyocin-resistant mutants had altered electrophoretic mobilities in sodium dodecyl sulfate-polyacrylamide gels (Dudas, K. C., and Apicella, M. A. (1988) Infect. Immun. 56, 499-504). Structural analyses of the oligosaccharide portions of the wild-type (129lwt) and five pyocin-resistant strains (1291a-e) by liquid secondary ion mass spectrometry, tandem mass spectrometry, and methylation analysis revealed that four of the mutant strains make oligosaccharides that differ from the wild-type LOS by successive saccharide deletions (1291a,c-e) and, in the oligosaccharide of 1291b, by the addition of a terminal Gal to the 1291c structure. The composition, sequence, and linkages of the terminal tetrasaccharide of the wild-type LOS are the same as the lacto-N-neotetraose terminus of the human paragloboside (Gal-beta-1 --> 4GlcNAc-beta-1 --> 3Gal-beta-1 --> 4Glc-ceramide), and both glycolipids bound the same monoclonal antibodies O6B4/3F11 that recognize this terminal epitope. None of the pyocin-resistant mutants bound this antibody. The 1291b LOS bound a monoclonal antibody that is specific for Gal-alpha-1 --> 4Gal-beta-1 --> 4Glc-ceramide (P(k) glycosphingolipid) and shared a common composition, sequence, and linkages with this latter glycosphingolipid. Organisms that bound the anti-P(k) monoclone occurred at the rate of almost-equal-to 1/750 among the wild-type parent strain. This structural information supports the conclusion that treatment with pyocin selects for mutants with truncated LOS structures and suggests that the oligosaccharides contained in the LOS of the wild-type strain and 1291b mimic those of human glycosphingolipids.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR IMMUNOCHEM,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,VET AFFAIRS MED CTR,SAN FRANCISCO,CA 94143; SUNY BUFFALO,DEPT MED,BUFFALO,NY 14215	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Mandrell, Robert E/O-9814-2018		NIAID NIH HHS [AI24616, AI8384, AI21620] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024616, R37AI024616, R01AI021620] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APICELLA MA, 1986, J INFECT DIS, V153, P520, DOI 10.1093/infdis/153.3.520; APICELLA MA, 1990, J INFECT DIS, V162, P506, DOI 10.1093/infdis/162.2.506; BLACKWELL CC, 1981, J INFECTION, V3, P370, DOI 10.1016/S0163-4453(81)91996-4; BRODIN NT, 1988, INT J CANCER, V42, P185, DOI 10.1002/ijc.2910420208; CAMPAGNARI AA, 1990, MICROB PATHOGENESIS, V8, P353, DOI 10.1016/0882-4010(90)90094-7; CONNELLY MC, 1981, J BACTERIOL, V148, P796, DOI 10.1128/JB.148.3.796-803.1981; COOPER MD, 1986, INFECT IMMUN, V51, P425, DOI 10.1128/IAI.51.2.425-430.1986; DELL A, 1990, CARBOHYD RES, V200, P59, DOI 10.1016/0008-6215(90)84182-T; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DUDAS KC, 1988, INFECT IMMUN, V56, P499, DOI 10.1128/IAI.56.2.499-504.1988; FALICK AM, 1986, ANAL CHEM, V58, P1308, DOI 10.1021/ac00298a009; GALANOS C, 1977, INT REV BIOCH BIOCH, V14, P239; GIBSON BW, 1989, P NATL ACAD SCI USA, V86, P17, DOI 10.1073/pnas.86.1.17; GOTSCHLICH EC, 1984, BACTERIAL VACCINES, P353; GRIFFISS JM, 1987, INFECT IMMUN, V55, P1792, DOI 10.1128/IAI.55.8.1792-1800.1987; GUYMON LF, 1982, INFECT IMMUN, V36, P541, DOI 10.1128/IAI.36.2.541-547.1982; HELANDER IM, 1988, EUR J BIOCHEM, V177, P483, DOI 10.1111/j.1432-1033.1988.tb14398.x; INGWER I, 1978, J LAB CLIN MED, V92, P211; JENNINGS HJ, 1980, CAN J BIOCHEM CELL B, V58, P128, DOI 10.1139/o80-018; JENNINGS HJ, 1983, CARBOHYD RES, V121, P233, DOI 10.1016/0008-6215(83)84020-8; JOHN CM, 1990, ANAL BIOCHEM, V187, P281, DOI 10.1016/0003-2697(90)90458-L; KASAI K, 1985, J IMMUNOGENET, V12, P213; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; LUDERITZ O, 1966, ANGEW CHEM INT EDIT, V5, P198, DOI 10.1002/anie.196601981; MANDRELL R, 1986, INFECT IMMUN, V54, P63, DOI 10.1128/IAI.54.1.63-69.1986; MANDRELL RE, 1990, J EXP MED, V171, P1649, DOI 10.1084/jem.171.5.1649; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; MICHON F, 1990, J BIOL CHEM, V265, P7243; MORSE SA, 1976, ANTIMICROB AGENTS CH, V10, P354, DOI 10.1128/AAC.10.2.354; MORSE SA, 1982, J INFECT DIS, V145, P206, DOI 10.1093/infdis/145.2.206; PETRICOIN EF, 1989, INFECT IMMUN, V57, P2847, DOI 10.1128/IAI.57.9.2847-2852.1989; PHILLIPS NJ, 1990, BIOMED ENVIRON MASS, V19, P731, DOI 10.1002/bms.1200191112; SCHNEIDER H, 1984, INFECT IMMUN, V45, P544, DOI 10.1128/IAI.45.3.544-549.1984; SCHNEIDER H, 1985, INFECT IMMUN, V50, P672, DOI 10.1128/IAI.50.3.672-677.1985; STEIN DC, 1983, SEX TRANSM DIS, V10, P7, DOI 10.1097/00007435-198301000-00002; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; TAKAYAMA K, 1986, J BIOL CHEM, V261, P624; TRAMONT EC, 1977, J IMMUNOL, V118, P1843; VIRJI M, 1990, MICROB PATHOGENESIS, V9, P441, DOI 10.1016/0882-4010(90)90062-U; WALLS FC, 1990, BIOLOGICAL MASS SPECTROMETRY /, P197; WARD ME, 1978, J GEN MICROBIOL, V108, P205, DOI 10.1099/00221287-108-2-205; WINSTANLEY FP, 1984, J GEN MICROBIOL, V130, P1303; YORK WS, 1985, CARBOHYD RES, V138, P109, DOI 10.1016/0008-6215(85)85228-9; ZOLLINGER WD, 1977, INFECT IMMUN, V18, P424, DOI 10.1128/IAI.18.2.424-433.1977	45	108	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19303	19311						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918047				2022-12-25	WOS:A1991GK66700032
J	MURPHY, ME; PIPER, HM; WATANABE, H; SIES, H				MURPHY, ME; PIPER, HM; WATANABE, H; SIES, H			NITRIC-OXIDE PRODUCTION BY CULTURED AORTIC ENDOTHELIAL-CELLS IN RESPONSE TO THIOL DEPLETION AND REPLENISHMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXING FACTOR; GUANYLATE-CYCLASE; GLUTATHIONE METABOLISM; ORGANIC NITRATES; DEPENDENT RELAXATION; HUMAN-ERYTHROCYTES; SMOOTH-MUSCLE; L-ARGININE; CALCIUM; SUPEROXIDE	The requirements and influence of thiols on the production of nitric oxide (NO) were examined in cultured porcine aortic endothelial cells. NO production was diminished when cells were pretreated with thiol-depleting agents (IC50: N-ethylmaleimide, 30-mu-M; 1-chloro-2,4-dinitrobenzene, 200-mu-M; diamide, 1.5 mM; diethyl maleate, 20 mM). The depletion of glutathione (45-99% loss at the various IC50 values) and protein thiols (3-25% loss at IC50) showed no consistent relationship to decreased NO production. The effects of the agents on NO production were not linked to altered sensitivity to the stimulant (calcium ionophore A23187; maximal effect at 10-mu-M), but roughly paralleled the appearance of cell damage (17-44% lactate dehydrogenase release at IC50). The decrease in NO production due to 1-chloro-2,4-dinitrobenzene was partially reversed by cysteine, dithioerythritol, and dihydrolipoate, whereas cystine partially reversed the decrease due to diamide or diethyl maleate. On the other hand, several thiols diminished NO production in control cells. Overall, alterations of NO production did not parallel the depletion or replenishment of either glutathione, protein thiol, or soluble thiol pools, and so the results argue against hypotheses that cellular thiols are either substrates or necessary cofactors in the pathway of NO synthesis in endothelial cells.	UNIV DUSSELDORF,INST PHYSIOL CHEM 1,MOORENSTR 5,W-4000 DUSSELDORF 1,GERMANY; UNIV DUSSELDORF,INST PHYSIOL 1,W-4000 DUSSELDORF 1,GERMANY	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf			Sies, Helmut/B-7266-2008; Sies, Helmut/ABE-7355-2020	Sies, Helmut/0000-0002-1000-3198; 				AKERBOOM T, 1972, METHOD ENZYMOL, V173, P523; BLOUGH NV, 1985, INORG CHEM, V24, P3502, DOI 10.1021/ic00216a003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDWEIN HJ, 1981, J BIOL CHEM, V256, P2958; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; Cussler E. L., 1984, DIFFUSION MASS TRANS; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; Di Iorio E E, 1981, Methods Enzymol, V76, P57; DOYLE MP, 1983, J INORG BIOCHEM, V19, P329, DOI 10.1016/0162-0134(83)80006-3; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FORSTERMANN U, 1990, BIOCHEM BIOPH RES CO, V168, P727, DOI 10.1016/0006-291X(90)92382-A; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; HARLAN JM, 1984, J CLIN INVEST, V73, P706, DOI 10.1172/JCI111263; HARRIS JW, 1972, BIOCHEM BIOPH RES CO, V46, P1743, DOI 10.1016/0006-291X(72)90045-9; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JONGKIND JF, 1989, FREE RADICAL BIO MED, V7, P507, DOI 10.1016/0891-5849(89)90026-9; KELM M, 1988, BIOCHEM BIOPH RES CO, V154, P236, DOI 10.1016/0006-291X(88)90675-4; KONDO T, 1984, EUR J BIOCHEM, V145, P131, DOI 10.1111/j.1432-1033.1984.tb08531.x; KOSOWER EM, 1972, BIOCHIM BIOPHYS ACTA, V264, P39, DOI 10.1016/0304-4165(72)90114-6; MATSUBARA T, 1986, J CELL PHYSIOL, V127, P207, DOI 10.1002/jcp.1041270203; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MUGGE A, 1991, AM J PHYSIOL, V260, pC219, DOI 10.1152/ajpcell.1991.260.2.C219; MULSCH A, 1990, N-S ARCH PHARMACOL, V341, P143; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NIROOMAND F, 1989, BIOCHEM BIOPH RES CO, V161, P75, DOI 10.1016/0006-291X(89)91562-3; NOACK E., 1989, J CARDIOVASC PHA S11, V14, P1; OHTSUKA Y, 1988, BIOCHEM BIOPH RES CO, V155, P160, DOI 10.1016/S0006-291X(88)81063-5; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PARK JW, 1988, BIOCHEM BIOPH RES CO, V152, P916, DOI 10.1016/S0006-291X(88)80127-X; PEACH MJ, 1987, AM J CARDIOL, V59, pA35, DOI 10.1016/0002-9149(87)90174-3; RUBANYI GM, 1990, ARCH INT PHARMACOD T, V305, P298; SCHMIDT HHHW, 1988, EUR J PHARMACOL, V154, P213, DOI 10.1016/0014-2999(88)90101-X; SCHMIDT K, 1989, EUR J PHARMACOL, V170, P157, DOI 10.1016/0014-2999(89)90536-0; SCHRODER H, 1985, J MOL CELL CARDIOL, V17, P931, DOI 10.1016/S0022-2828(85)80106-1; Spahr R., 1990, CELL CULTURE TECHNIQ, P220; STUEHR DJ, 1990, BIOCHEM BIOPH RES CO, V168, P558, DOI 10.1016/0006-291X(90)92357-6; SUTTORP N, 1986, AM J PHYSIOL, V251, pC671, DOI 10.1152/ajpcell.1986.251.5.C671; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; VANASSENDELFT OW, 1970, SPECTROPHOTOMETRY HA, P55; WEI EP, 1990, HYPERTENSION, V16, P162, DOI 10.1161/01.HYP.16.2.162; WILLIAMS DLH, 1985, CHEM SOC REV, V14, P171, DOI 10.1039/cs9851400171; WINTERBOURN CC, 1976, BIOCHEM J, V155, P493, DOI 10.1042/bj1550493	46	101	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19378	19383						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918052				2022-12-25	WOS:A1991GK66700042
J	WADA, I; RINDRESS, D; CAMERON, PH; OU, WJ; DOHERTY, JJ; LOUVARD, D; BELL, AW; DIGNARD, D; THOMAS, DY; BERGERON, JJM				WADA, I; RINDRESS, D; CAMERON, PH; OU, WJ; DOHERTY, JJ; LOUVARD, D; BELL, AW; DIGNARD, D; THOMAS, DY; BERGERON, JJM			SSR-ALPHA AND ASSOCIATED CALNEXIN ARE MAJOR CALCIUM-BINDING PROTEINS OF THE ENDOPLASMIC-RETICULUM MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL SIGNAL PEPTIDASE; LUMINAL ER PROTEINS; GEL-ELECTROPHORESIS; SECONDARY STRUCTURE; SECRETORY PATHWAY; TRANSLOCATION; SEQUENCE; YEAST; IDENTIFICATION; ANTIBODIES	GTP phosphorylation of rough microsomes in vitro is limited to four integral membrane proteins. Two of these, a phosphoprotein (pp90) and a phosphoglycoprotein (pgp35) were purified as a complex with two nonphosphorylated membrane glycoproteins, gp25H and gp25L. The authenticity of this complex was confirmed using two different purification procedures and by co-immunoprecipitation. By immunofluorescence a reticulated cytoplasmic network was revealed for the proteins which was similar to that for Louvard et al. (Louvard, D., Reggio, H., and Warren, G. (1982) J. Cell Biol. 92, 92-107) marker antisera which also recognized purified pp90 on immunoblots. Amino acid sequencing of peptides derived from pgp35 identified this protein as SSR-alpha, an endoplasmic reticulum constituent as identified by cross-linking of translocating nascent chains (Gorlich, D, Prehn, S., Hartmann, E., Herz, J., Otto, A., Kraft, R., Wiedmann, M., Knespel, S., Dobberstein, B., and Rapoport, T. A. (1990) J. Cell Biol. 111, 2283-2294). The sequence of gp25H was determined from cDNA clones and was identical with SSR-beta identified by Gorlich et al. (1990) as being tightly bound to SSR-alpha. Sequencing of gp25L revealed no similarity of the deduced sequence with other proteins. However, pp90 revealed a high degree of sequence identity with the Ca2+-binding protein, calreticulin. Ca-45(2+) overlay studies indicated that pp90 bound Ca2+ and the name calnexin is proposed. Surprisingly, pgp35 (SSR-alpha) also bound Ca2+ although gp25H (SSR-beta) and gp25L did not. Triton X-114 partitioning of the integral membrane proteins of rough microsomes suggested that pgp35 (SSR-alpha) and calnexin were major Ca2+-binding proteins of the endoplasmic reticulum membrane. We propose that the function of the complex is to regulate Ca2+-dependent retention mechanisms for luminal proteins of the endoplasmic reticulum.	MCGILL UNIV,DEPT ANAT,3640 UNIV ST,MONTREAL H3A 2B2,QUEBEC,CANADA; MCGILL UNIV,DEPT BIOL,MONTREAL H3A 2B2,QUEBEC,CANADA; INST PASTEUR,F-75724 PARIS 15,FRANCE; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL H4P 2R2,QUEBEC,CANADA	McGill University; McGill University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Research Council Canada			Bergeron, John/AAW-1893-2021; Thomas, David/M-7661-2017	Wada, Ikuo/0000-0001-5668-6994; Thomas, David/0000-0002-8854-762X				BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CERIOTTI A, 1988, EMBO J, V7, P633, DOI 10.1002/j.1460-2075.1988.tb02857.x; CHOU PY, 1979, BIOPHYS J, V26, P367, DOI 10.1016/S0006-3495(79)85259-5; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HERMODSON MA, 1982, METHODS PROTEIN SEQU, P313; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MACER DRJ, 1988, J CELL SCI, V91, P61; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MEYER DI, 1988, TRENDS BIOCHEM SCI, V13, P471, DOI 10.1016/0968-0004(88)90233-2; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Neville D M Jr, 1974, Methods Enzymol, V32, P92; NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243; PAIEMENT J, 1987, BIOCHIM BIOPHYS ACTA, V898, P6, DOI 10.1016/0005-2736(87)90105-2; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sambrook J, 1989, MOL CLONING LABORATO; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHELNESS GS, 1988, J BIOL CHEM, V263, P17063; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SMITH RA, 1985, SCIENCE, V229, P1219, DOI 10.1126/science.3939723; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TOUGARD C, 1983, J CELL BIOL, V96, P1197, DOI 10.1083/jcb.96.5.1197; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499	43	492	507	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19599	19610						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918067				2022-12-25	WOS:A1991GK66700070
J	GIESEN, PLA; WILLEMS, GM; HEMKER, HC; HERMENS, WT				GIESEN, PLA; WILLEMS, GM; HEMKER, HC; HERMENS, WT			MEMBRANE-MEDIATED ASSEMBLY OF THE PROTHROMBINASE COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOTTING FACTOR-X; BOVINE FACTOR-V; PHOSPHOLIPID-VESICLES; VARYING COMPOSITION; STUART FACTOR; BINDING; COAGULATION; ACTIVATION; ADSORPTION; PROTEIN	Prothrombinase assembly was studied on macroscopic planar bilayers consisting of 20% dioleoyl-phosphatidylserine (DOPS) and 80% dioleoyl-phosphatidylcholine (DOPC). The dissociation constant for the binding of factor Xa to the bilayer, measured by ellipsometry, was K(d) = 47 +/- 8 nM (mean +/- S.D.) and this value was lowered to K(d) = 2.2 +/- 0.3 pM by preadsorption of factor Va. This latter value was determined from direct measurement of steady-state thrombin production. A comparable value of K(d) = 1.0 +/- 0.1 pM was found by repeating these experiments in suspensions of phospholipid vesicles, and it was verified that prothrombinase assembly was not influenced by the addition of prothrombin. Using a minute amount (0.094 fmol cm-2) of preadsorbed factor Va, it was found that the rate of prothrombinase assembly exceeds the rate of collisions between Xa molecules from the buffer and the sparse Va molecules on the bilayer. Apparently, factor Xa adsorbs first to the membrane and then associates rapidly with factor Va by lateral diffusion. The data indicate almost instantaneous equilibrium of this complex formation on the surface with a lower limit for the bimolecular rate constant of k(on) = 2.8 x 10(13) (mol/cm2)-1 s-1. In suspensions of small phospholipid vesicles, prothrombinase assembly is collisionally limited and the value of k(on) should be proportional to vesicle diameter. This was verified with a method for estimation of k(on) values from thrombin generation curves. Values of 0.36 x 10(9) and 1.6 x 10(9) M-1 s-1 were found for vesicles of 20-30- and 60-80-nm diameter, respectively.	STATE UNIV LIMBURG, CTR BIOMED, CARDIOVASC RES INST, POB 616, 6200 MD MAASTRICHT, NETHERLANDS	Maastricht University				Hemker, Coen/0000-0003-1669-2358				Adam G., 1968, STRUCTURAL CHEM MOL, P198; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; Clegg R. M., 1985, PROGR PROTEIN LIPID, P173; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; CORSEL JW, 1986, J COLLOID INTERF SCI, V111, P544, DOI 10.1016/0021-9797(86)90058-5; CUYPERS PA, 1983, J BIOL CHEM, V258, P2426; DEKRUIJFF B, 1975, BIOCHIM BIOPHYS ACTA, V406, P6, DOI 10.1016/0005-2736(75)90038-3; FORMAN SD, 1986, P NATL ACAD SCI USA, V83, P4675, DOI 10.1073/pnas.83.13.4675; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4892, DOI 10.1021/bi00776a003; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V11, P4882, DOI 10.1021/bi00776a002; GIESEN PLA, 1991, J BIOL CHEM, V266, P1379; HEMKER HC, 1967, NATURE, V215, P248, DOI 10.1038/215248a0; HERMENS WT, 1989, COAGULATION LIPIDS, P73; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JOBIN F, 1967, BIOCHEM J, V102, P666, DOI 10.1042/bj1020666; KOP JMM, 1984, J BIOL CHEM, V259, P3993; KOP JMM, 1989, J COLLOID INTERF SCI, V133, P369, DOI 10.1016/S0021-9797(89)80045-1; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; Levich V.G., 1962, PHYSICOCHEMICAL HYDR; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LINDHOUT T, 1982, BIOCHEMISTRY-US, V21, P5494, DOI 10.1021/bi00265a018; MANN KG, 1981, BIOCHEMISTRY-US, V20, P28, DOI 10.1021/bi00504a005; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OWEN WG, 1974, J BIOL CHEM, V249, P594; PUSEY ML, 1983, BIOCHEM BIOPH RES CO, V114, P526, DOI 10.1016/0006-291X(83)90812-4; PUSEY ML, 1982, BIOCHEMISTRY-US, V21, P5262, DOI 10.1021/bi00264a022; ROSING J, 1980, J BIOL CHEM, V255, P274; SMITH RL, 1973, J BIOL CHEM, V248, P2418; Smoluchowski M., 1917, Z PHYS CHEM, V92, P129, DOI [10.1515/zpch-1918-9209, DOI 10.1515/ZPCH-1918-9209]; TAMM LK, 1988, BIOCHEMISTRY-US, V27, P1450, DOI 10.1021/bi00405a009; TANS G, 1979, EUR J BIOCHEM, V95, P449, DOI 10.1111/j.1432-1033.1979.tb12984.x; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019; VANRIJN JLML, 1984, BIOCHEMISTRY-US, V23, P4557, DOI 10.1021/bi00315a008; WILLEMS G M, 1991, Journal of Biomaterials Science Polymer Edition, V2, P217	43	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18720	18725						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917995				2022-12-25	WOS:A1991GJ47200050
J	PREVIATO, L; PARROTT, CL; SANTAMARINAFOJO, S; BREWER, HB				PREVIATO, L; PARROTT, CL; SANTAMARINAFOJO, S; BREWER, HB			TRANSCRIPTIONAL REGULATION OF THE HUMAN LIPOPROTEIN-LIPASE GENE IN 3T3-L1 ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL REGULATION; INSULIN REGULATION; EXPRESSION; CELLS; DNA; BINDING; HORMONE; PROTEIN; METABOLISM; POLYMERASE	Lipoprotein lipase (LPL), a key enzyme in normal lipoprotein metabolism, has a complex pattern of regulation and tissue-specific expression. Several potential binding sites for transcription factors, including the recognition sequences for CCAAT/enhancer-binding protein and octamer-binding proteins (Oct) have been described in the 5'-flanking region of the human LPL gene. To identify elements which regulate the expression of LPL in adipocytes, plasmids containing deletion mutants of the 5'-LPL promoter region and the luciferase reporter gene were transfected in 3T3-L1 adipocytes. Deletions at -724, -565, -461, -368, -232, -167, -92, -35, and -17 relative to the transcriptional start site modified transcription from 100 to 162, 194, 185, 128, 63, 53, 29, and 0%, respectively, indicating the presence of negative (-724 to -565) and positive (-368 to -35) cis-acting regulatory elements. Transfection of HepG2 cells, which do not synthesize LPL, with the same constructs resulted in a similar pattern of expression for the majority of the deletions. However, deletions between -724 and -368 base pairs resulted in a 75-100% increase in transcription in 3T3 adipocytes but not in HepG2 cells, indicating the presence of tissue-specific regulatory element(s) in this region. An important regulatory element affecting LPL transcription in adipocytes was identified by gel mobility shift assays and DNase I footprint analysis. Using these techniques, a nuclear protein(s) in 3T3-L1 adipocytes was shown to bind specifically to a fragment which included the proximal octamer recognition site (from -46 to -39) present in the LPL promoter. The DNA-protein complex comigrates with an electrophoretic band containing the Oct-1-DNA complex in BJA-B nuclear extracts and the DNA-protein complex was selectively competed only by DNA fragments containing the octamer sequence. Preincubation of 3T3-L1 nuclear extracts with an antibody directed against the POU domain of Oct-1 inhibited the formation of the DNA-protein complex. Deletion of the proximal octanucleotide motif from the plasmid containing the -461 fragment of the LPL promoter, resulted in a 79 and 76% decrease in the level of expression in transfected 3T3-L1 adipocytes and HepG2 hepatocytes, respectively. These combined results have established that the expression of LPL in adipocytes is modulated by multiple positive and negative regulatory elements within the 5'-flanking region of the LPL gene. A proximal octamer binding sequence which specifically interacts with a nuclear protein(s) that exhibits the characteristics of Oct-1 has been identified. Deletional analysis indicates that this transcription factor plays an important role in modulating the expression of LPL in 3T3-L1 adipocytes.	NHLBI, MOLEC DIS BRANCH, 9000 ROCKVILLE PIKE, BLDG 10-7N117, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CHAJEK T, 1977, ATHEROSCLEROSIS, V26, P549, DOI 10.1016/0021-9150(77)90122-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CRYER A, 1981, INT J BIOCHEM, V13, P525, DOI 10.1016/0020-711X(81)90177-4; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOMIN WS, 1991, BIOCHEMISTRY-US, V30, P2570, DOI 10.1021/bi00224a002; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; ECKEL RH, 1987, LIPOPROTEIN LIPASE, P79; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAVEL RJ, 1973, J CLIN INVEST, V52, P32, DOI 10.1172/JCI107171; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1989, J BIOL CHEM, V264, P1473; KO HS, 1988, CELL, V55, P135, DOI 10.1016/0092-8674(88)90016-5; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEFRANC G, 1990, BIOCHIMIE, V72, P7, DOI 10.1016/0300-9084(90)90167-F; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; METZGER S, 1990, J BIOL CHEM, V265, P9978; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PHILLIPS M, 1986, J BIOL CHEM, V261, P821; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRADINESFIGUERES A, 1990, J LIPID RES, V31, P1283; RAYNOLDS MV, 1990, MOL ENDOCRINOL, V4, P1416, DOI 10.1210/mend-4-9-1416; ROBINSON DS, 1989, BIOCHEM SOC T, V17, P40, DOI 10.1042/bst0170040; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUPP E, 1990, NUCLEIC ACIDS RES, V18, P5677, DOI 10.1093/nar/18.19.5677; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SPOONER PM, 1979, J BIOL CHEM, V254, P21; STRUM RA, 1988, GENE DEV, V2, P1582; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644	45	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18958	18963						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918010				2022-12-25	WOS:A1991GJ47200084
J	UENO, T; MUNO, D; KOMINAMI, E				UENO, T; MUNO, D; KOMINAMI, E			MEMBRANE MARKERS OF ENDOPLASMIC-RETICULUM PRESERVED IN AUTOPHAGIC VACUOLAR MEMBRANES ISOLATED FROM LEUPEPTIN-ADMINISTERED RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTO-LYSOSOMES; HEPATOCYTES; PROTEINS; IDENTIFICATION; MECHANISMS; MICROSOMES; CLEAVAGE; ROUGH	We isolated membranes from leupeptin-induced autophagic vacuoles and compared them with lysosomal membranes purified from dextran-administered rats. In protein composition, autophagic vacuole membranes prepared from long term-starved (36 h) rats bear marked resemblance to lysosomal membranes, whereas vacuole membranes prepared from short term-starved (12 h) animals differ significantly from lysosomal membranes. Immunoblotting analyses showed that only autophagic vacuole membranes from short term-starved rats possess endoplasmic reticulum markers such as cytochrome P450 and NADPH-cytochrome c reductase. None of the membranes contain sialyltransferase, a Golgi membrane marker. In experiments in which rats were starved after feeding to induce autophagy, the appearance of the endoplasmic reticulum markers occurred during 6-12 h of starvation, concomitantly with increases in vacuolar proteins and sequestered cytosolic aldolase. The endoplasmic reticulum membrane markers and sequestered aldolase declined gradually after 20-36 h of starvation, suggesting that prolonged starvation causes no further increase in the formation of autophagic vacuoles but an increase in the population of matured autophagic vacuoles. Thus, the prominent markers of endoplasmic reticulum from which autophagosomes originate are well preserved in autophagic vacuole membranes, and retention of these markers is highly dependent on the formation and subsequent maturation process of autophagic vacuoles.	JUNTENDO UNIV,SCH MED,DEPT BIOCHEM,BLDG 9,ROOM 914,2-1-1 HONGO BUNKYO KU,TOKYO 113,JAPAN	Juntendo University			Kominami, Eiki/D-3802-2009					DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FURUNO K, 1982, J BIOCHEM-TOKYO, V91, P1485, DOI 10.1093/oxfordjournals.jbchem.a133840; FURUNO K, 1982, J BIOCHEM-TOKYO, V91, P1943, DOI 10.1093/oxfordjournals.jbchem.a133888; HINO Y, 1978, J BIOCHEM, V83, P909, DOI 10.1093/oxfordjournals.jbchem.a132018; HORTSCH M, 1985, EUR J BIOCHEM, V150, P559, DOI 10.1111/j.1432-1033.1985.tb09057.x; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; ISHIKAWA T, 1983, EXP CELL RES, V144, P15, DOI 10.1016/0014-4827(83)90436-6; KOBAYASHI R, 1989, ANAL BIOCHEM, V183, P9, DOI 10.1016/0003-2697(89)90162-0; KOMINAMI E, 1983, J BIOL CHEM, V258, P6093; KOVACS AL, 1982, EXP CELL RES, V137, P191, DOI 10.1016/0014-4827(82)90020-9; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; Marzella L, 1987, LYSOSOMES THEIR ROLE, P319; MORTIMORE GE, 1983, P NATL ACAD SCI-BIOL, V80, P2179, DOI 10.1073/pnas.80.8.2179; Pfeifer U., 1987, LYSOSOMES THEIR ROLE, P3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UENO T, 1991, BIOMED BIOCHIM ACTA, V50, P365; UENO T, 1990, EUR J BIOCHEM, V190, P63, DOI 10.1111/j.1432-1033.1990.tb15546.x; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; YAMAMOTO A, 1990, J HISTOCHEM CYTOCHEM, V38, P573, DOI 10.1177/38.4.2319125	23	81	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18995	18999						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918014				2022-12-25	WOS:A1991GJ47200089
J	WOO, HJ; LOTZ, MM; JUNG, JU; MERCURIO, AM				WOO, HJ; LOTZ, MM; JUNG, JU; MERCURIO, AM			CARBOHYDRATE-BINDING PROTEIN-35 (MAC-2), A LAMININ-BINDING LECTIN, FORMS FUNCTIONAL DIMERS USING CYSTEINE-186	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-SEQUENCE; S-TYPE LECTIN; MOLECULAR-CLONING; OVERLAP EXTENSION; ESCHERICHIA-COLI; ANIMAL LECTINS; EXPRESSION; CELLS; IGE; GENE	Carbohydrate-binding protein 35 (CBP35), also known as the macrophage surface antigen Mac-2, is a lactosamine-specific lectin whose extracellular properties include the ability to agglutinate cells and to bind avidly to the basement membrane glycoprotein laminin. Although these and other properties would be facilitated by dimerization of this lectin, previous studies have argued against multimeric forms of this protein. We report here that macrophage CBP35, purified by laminin affinity chromatography, exists as several distinct species (M(r) 35,000, 67,000, and 80,000) when analyzed under non-reducing conditions. This unexpected finding prompted us to study the biochemistry of multimerization using recombinant CBP35 (rCBP35). rCBP35 expressed in Escherichia coli forms disulfide-linked homodimers (M(r) 67,000). The dimeric form of CBP35 binds to laminin with higher affinity than does monomer and by a lactosamine-dependent mechanism. Site-directed mutagenesis indicated that cysteine 186, the single cysteine residue in CBP35, is required for dimerization. These results raise the possibility that homo- and heterodimeric forms of CBP35 contribute to its postulated functions in cell-matrix interactions and growth regulation.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,CANC BIOL LAB,50 BINNEY ST,BOSTON,MA 02215; HARVARD UNIV,SCH MED,NEW ENGLAND REG PRIMATE CTR,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA042276] Funding Source: NIH RePORTER; NCI NIH HHS [CA42276] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT WM, 1991, J BIOL CHEM, V266, P5552; AGRWAL N, 1989, J BIOL CHEM, V264, P17236; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BEGOVAC PC, 1990, J CELL BIOL, V110, P461, DOI 10.1083/jcb.110.2.461; BOUZON M, 1990, EXP CELL RES, V190, P47, DOI 10.1016/0014-4827(90)90142-W; CERRA RF, 1985, J BIOL CHEM, V260, P10474; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; COWLES EA, 1990, J BIOL CHEM, V265, P17706; DEAN JW, 1990, J BIOL CHEM, V265, P12553; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DUFFAUD GD, 1987, METHOD ENZYMOL, V153, P492; FODDY L, 1990, J CELL SCI, V97, P139; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; HO MK, 1982, J IMMUNOL, V128, P1221; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HYNES MA, 1990, J NEUROSCI, V10, P1004; JESSELL TM, 1990, ANNU REV NEUROSCI, V13, P227, DOI 10.1146/annurev.ne.13.030190.001303; JIA SH, 1988, J BIOL CHEM, V263, P6009; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; LAING JG, 1989, J BIOL CHEM, V264, P1907; LEE RT, 1990, J BIOL CHEM, V265, P7864; Mercurio AM, 1990, CURR OPIN CELL BIOL, V2, P845, DOI 10.1016/0955-0674(90)90082-P; MERKLE RK, 1989, ARCH BIOCHEM BIOPHYS, V274, P404, DOI 10.1016/0003-9861(89)90453-0; PAROUTAUD P, 1987, P NATL ACAD SCI USA, V84, P6345, DOI 10.1073/pnas.84.18.6345; RAZ A, 1991, CANCER RES, V51, P2173; RAZ A, 1989, CANCER RES, V49, P3489; ROFF CF, 1983, J BIOL CHEM, V258, P657; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; WILSON TJG, 1989, BIOCHEM J, V261, P847, DOI 10.1042/bj2610847; WOO HJ, 1990, J BIOL CHEM, V265, P7097; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	35	63	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18419	18422						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917966				2022-12-25	WOS:A1991GJ47200003
J	CASEY, G; LOHSUEH, M; LOPEZ, ME; VOGELSTEIN, B; STANBRIDGE, EJ				CASEY, G; LOHSUEH, M; LOPEZ, ME; VOGELSTEIN, B; STANBRIDGE, EJ			GROWTH SUPPRESSION OF HUMAN BREAST-CANCER CELLS BY THE INTRODUCTION OF A WILD-TYPE P53 GENE	ONCOGENE			English	Article							PHENOL-CHLOROFORM EXTRACTION; CELLULAR TUMOR-ANTIGEN; SINGLE-STEP METHOD; SHORT ARM; RNA ISOLATION; LUNG-CANCER; ALLELE LOSS; MUTANT P53; TRANSFORMATION; MUTATIONS	Mutations in the p53 gene are associated with a wide variety of human tumors, including those of the breast. To assess functionally the role of the p53 gene in the development of human breast cancer, we introduced either wild-type or mutant p53 cDNA into three human breast cancer cell lines by DNA transfection. The cell lines MDA-MB 468 and T47 D contain only single mutated copies of the p53 gene, whereas the status of p53 in the breast cancer cell line MCF 7 remains equivocal. Following transfection, MCF 7 cells continued to grow unaffected both in vitro and in vivo in the presence of high levels of expression of the exogenous wild-type p53 gene. In contrast, however, the continued expression of an exogenous wild-type p53 gene was incompatible with cellular growth in both the MDA-MB 468 and T47 D cell lines. Elevated levels of expression of the exogenous mutant p53 gene did not alter the growth of the cell lines in vitro. These data strongly suggest that the wild-type p53 gene can function as a suppressor of cellular growth in breast cancer cells. That the wild-type p53 gene does not suppress the growth of MCF 7 cells indicates that at least some human breast tumors can arise without functional inactivation of the p53 gene by mutation. These tumors may represent a separate prognostic group.	JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; UNIV CALIF IRVINE,DEPT MICROBIOL,IRVINE,CA 92717	Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California Irvine	CASEY, G (corresponding author), UNIV CALIF IRVINE,DEPT PHARM,IRVINE,CA 92717, USA.				NATIONAL CANCER INSTITUTE [R01CA043460, R37CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA 43460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLARD MW, 1991, BIOTECHNIQUES, V10, P24; ALTHERR MR, 1989, GENOMICS, V5, P581, DOI 10.1016/0888-7543(89)90026-8; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BAKER SJ, 1990, SCIENCE, V249, P217; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; Crawford L V, 1984, Mol Biol Med, V2, P261; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HIGUCHI R, 1989, AMPLIFICATIONS, V2, P1; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROSSER J, 1990, ONCOGENE, V5, P1573; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sambrook J, 1989, MOL CLONING LABORATO; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; VARLEY JM, 1991, ONCOGENE, V6, P413; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	47	258	273	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1791	1797						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923504				2022-12-25	WOS:A1991GX11800011
J	SCHUUR, ER; BALUDA, MA				SCHUUR, ER; BALUDA, MA			EXPRESSION OF MYB PROTEINS IN AVIAN HEMATOPOIETIC TISSUES	ONCOGENE			English	Article							HUMAN C-MYB; MYELOBLASTOSIS VIRUS; V-MYB; TRANSFORMING GENE; NUCLEOTIDE-SEQUENCE; PROTO-ONCOGENE; CHICKEN DNA; DIFFERENTIAL EXPRESSION; STRUCTURAL ORGANIZATION; MYELOID-LEUKEMIA	MYB gene products are thought to be regulators of cellular replication and of differentiation. The major product of the avian MYB gene is a 75 kDa nuclear phosphoprotein which can activate transcription. A minor 89 kDa MYB protein of unknown function has also been described in murine and human cells. Additional heterogeneity at the level of MYB RNA which could affect the structure of MYB proteins has been described in several species. Such heterogeneity could explain the diverse effects of the MYB gene. To investigate the possible existence of heterogeneous and/or cell lineage-specific MYB proteins, five different avian hematopoietic tissues (bone marrow, bursa of Fabricius, embryonic spleen, thymus and yolk sac) were examined by immunoprecipitation with several MYB-specific antisera and SDS-PAGE analysis. In all five tissues there was a 75 kDa protein of uniform size which varied in abundance in a tissue-specific manner paralleling that observed for the 4.0 kb MYB RNA. A less abundant 89 kDa protein was also detected by several antisera in bone marrow, spleen, thymus and yolk sac but not in bursa. This 89 kDa MYB protein appears to be analogous to the 89 kDa MYB protein encoded by a minor but larger (360 nucleotides) MYB mRNA in murine and human cells. Immunoprecipitation of MYB proteins with an antiserum specific for exons 8 and 9 revealed a 74 kDa protein which coprecipitated and appeared to be complexed with p75 in normal hematopoietic cells and with the 48 kDa product of v-myb in leukemic cells.	UNIV CALIF LOS ANGELES,SCH MED,MED LAB,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,JONNSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BALUDA MA, 1990, ONCOGENESIS ONCOGENE, P131; BENDER TP, 1987, J IMMUNOL, V139, P3822; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DAVIS JN, 1990, ONCOGENE, V5, P1109; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GARCIA A, 1991, IN PRESS ONCOGENE; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Moscovici C., 1973, Methods Cell Biol, V7, P313; NUNN MF, 1985, VIROLOGY, V139, P330; PERBAL B, 1983, J VIROL, V45, P925, DOI 10.1128/JVI.45.3.925-940.1983; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SORET J, 1988, FEBS LETT, V232, P227, DOI 10.1016/0014-5793(88)80422-8; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; VELLARD M, 1991, ONCOGENE, V6, P505; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	57	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1923	1929						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923515				2022-12-25	WOS:A1991GX11800029
J	MIRESLUIS, AR; THORPE, R				MIRESLUIS, AR; THORPE, R			INTERLEUKIN-4 PROLIFERATIVE SIGNAL TRANSDUCTION INVOLVES THE ACTIVATION OF A TYROSINE-SPECIFIC PHOSPHATASE AND THE DEPHOSPHORYLATION OF AN 80-KDA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATORY FACTOR-I; HEMATOPOIETIC PROGENITOR CELLS; T-CELL; GM-CSF; RECOMBINANT INTERLEUKIN-4; B-LYMPHOCYTES; PHOSPHORYLATION; GROWTH; MURINE; LINES	Interleukin-4 (IL-4) is a cytokine that expresses its biological effects by binding to specific membrane receptors. Although the diverse biological properties of this molecule have been characterized extensively the biochemical mechanisms by which extracellular binding events lead to biological responses remain unclear. IL-4 can stimulate the proliferation of several hemopoietic cell types, and we have taken advantage of its ability to induce the growth of leukemic cell lines to investigate the role that protein phosphorylation events might play in IL-4 mitogenic signal transduction. We show that the addition of IL-4 to several leukemic cell lines of different origin causes the rapid dephosphorylation of an 80-kDa phosphoprotein (p80) from tyrosine residues. This event occurs in a dose-responsive manner closely correlating to that of biological activity, and both are blocked by an anti-IL-4-specific antiserum. The ability of sodium orthovanadate to prevent IL-4-induced dephosphorylation of p80 suggests that this event is mediated by a protein-tyrosine-phosphatase (EC 3.1.3.48). The importance of the role that tyrosine-specific dephosphorylation plays in mediating IL-4 mitogenic signal transduction is substantiated by the ability of sodium orthovanadate in cell culture to block effectively IL-4-induced proliferation at doses that enhance the proliferation stimulated by either granulocyte-macrophage colony-stimulating factor or interleukin-3.			MIRESLUIS, AR (corresponding author), NATL INST BIOL STAND & CONTROLS,DIV IMMUNOBIOL,BLANCHE LANE,POTTERS BAR EN6 3QG,HERTS,ENGLAND.		Thorpe, Robin/E-6853-2013					AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALDERSON MR, 1987, P NATL ACAD SCI USA, V84, P1389, DOI 10.1073/pnas.84.5.1389; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; EVANS JPM, 1990, BLOOD, V75, P88; FERNANDEZBOTRAN R, 1986, P NATL ACAD SCI USA, V83, P9689, DOI 10.1073/pnas.83.24.9689; FERRIS DK, 1988, BIOCHEM BIOPH RES CO, V154, P991, DOI 10.1016/0006-291X(88)90237-9; FINNEY M, 1990, EUR J IMMUNOL, V20, P151, DOI 10.1002/eji.1830200122; GARLAND JM, 1989, BIOCHEM BIOPH RES CO, V164, P520, DOI 10.1016/0006-291X(89)91750-6; HOFMAN FM, 1988, J IMMUNOL, V141, P1185; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; JUSTEMENT L, 1986, J IMMUNOL, V137, P3664; KANAKURA Y, 1990, BLOOD, V76, P706; KAPLAN J, 1976, AM J HEMATOL, V1, P219, DOI 10.1002/ajh.2830010206; KARRAY S, 1988, J IMMUNOL, V142, P3452; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KLEIN E, 1968, CANCER RES, V28, P1300; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MCGARVIE GM, 1989, CELL SIGNAL, V1, P447, DOI 10.1016/0898-6568(89)90030-2; MCGARVIE GM, 1989, IMMUNOL LETT, V22, P221, DOI 10.1016/0165-2478(89)90195-8; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLER MR, 1978, BIOCHEMISTRY-US, V17, P1073, DOI 10.1021/bi00599a021; MIRE AR, 1985, BIOCHIM BIOPHYS ACTA, V847, P159, DOI 10.1016/0167-4889(85)90169-7; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MOSMANN TR, 1986, P NATL ACAD SCI USA, V83, P5654, DOI 10.1073/pnas.83.15.5654; NISHI M, 1990, FEBS LETT, V271, P178, DOI 10.1016/0014-5793(90)80400-D; Ohara J, 1989, Year Immunol, V5, P126; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; RABIN H, 1981, J IMMUNOL, V127, P1852; REDDY GPV, 1980, P NATL ACAD SCI-BIOL, V77, P3312; RENNICK D, 1987, P NATL ACAD SCI USA, V84, P6889, DOI 10.1073/pnas.84.19.6889; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; SONODA Y, 1990, BLOOD, V75, P1615; SORENSEN PHB, 1989, BLOOD, V73, P406; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Weber K., 1975, PROTEINS, VI, P179; YANG YC, 1989, TRANSPLANT P, V21, P50; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; YOKOTA T, 1988, IMMUNOL REV, V102, P137, DOI 10.1111/j.1600-065X.1988.tb00744.x; ZUBER CE, 1990, EUR J IMMUNOL, V20, P551, DOI 10.1002/eji.1830200314	49	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18113	18118						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917945				2022-12-25	WOS:A1991GG55300062
J	SORCITHOMAS, M; KEARNS, MW				SORCITHOMAS, M; KEARNS, MW			TRANSCRIPTIONAL REGULATION OF THE APOLIPOPROTEIN A-I GENE - SPECIES-SPECIFIC EXPRESSION CORRELATES WITH RATES OF GENE-TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEIN; TISSUE-SPECIFIC EXPRESSION; HUMAN APOA-I; MESSENGER-RNA; DIETARY-FAT; PLASMA-LIPOPROTEINS; NONHUMAN-PRIMATES; SEQUENCE-ANALYSIS; DNA-POLYMERASE; METABOLISM	Previous studies have shown that the abundance of apoA-I mRNA in liver and intestine correlates with a 2-3-fold species-specific difference in the plasma concentration of high density lipoprotein and apoA-I. In order to determine the role of gene transcription in regulating the tissue, steady state apoA-I mRNA abundance nuclear run-on assays were conducted using nuclei from two species of nonhuman primates. The transcriptional activity expressed as the ratio of apo-I signal intensity to that for the constitutively expressed glyceraldehyde-3-phosphate dehydrogenase was calculated for seven individual animals in each of the two nonhuman primate species. The African green monkey showed a ratio of 4.18 +/- 0.35, and the cynomolgus monkey showed 2.03 +/- 0.13 (n = 7, p < 0.004). To identify possible cis-acting elements that may be involved in transcriptional regulation of the apoA-I gene, a portion of the apoA-I regulatory region, corresponding to nucleotides -231 to +263 (where +1 is the start site of transcription), was isolated from both species using the polymerase chain reaction. The nucleotide sequence of this region was compared between monkey species, as well as with the same region from the apoA-I gene isolated from human genomic DNA. In this region, the African green monkey apoA-I gene showed 95% similarity, whereas the cynomolgus monkey showed 94% similarity to the human sequence. Although a high degree of sequence similarity was observed among all species, numerous sequence specific differences were noted in the first intron between the two primate species and between nonhuman and human primate sequences. Results from studies measuring relative promoter strength indicated that the African green monkey 5'-regulatory region had a consistently higher level of activity (1.4-3.0-fold) than the same region from the cynomolgus monkey. Interestingly, the African green monkey promoter also showed a significantly higher transcriptional activity than the human or rabbit promoter, suggesting the presence of a nonhuman primate specific cis-acting element(s) regulating apoA-I gene expression. These results demonstrate that a portion of the species-specific difference in apoA-I gene expression may be explained by sequence divergence in the 5'-regulatory region including exon/intron 1 of the apoA-I gene.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,ATHEROSCLEROSIS RES CTR,WINSTON SALEM,NC 27103	Wake Forest University; Wake Forest Baptist Medical Center	SORCITHOMAS, M (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT COMPARAT MED,300 S HAWTHORNE RD,WINSTON SALEM,NC 27103, USA.			Sorci-Thomas, Mary/0000-0002-6464-5006	NHLBI NIH HHS [HL41916] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041916] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; AUSBEL FM, 1987, CURRENT PROTOCOLS MO, V1; BORNSTEIN P, 1988, J BIOL CHEM, V263, P1603; BRESLOW JL, 1989, METABOLIC BASIS INHE, P1251; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BRINTON EA, 1990, J CLIN INVEST, V85, P144, DOI 10.1172/JCI114405; BRINTON EA, 1989, J CLIN INVEST, V84, P262, DOI 10.1172/JCI114149; CHAO Y, 1984, J BIOL CHEM, V259, P5306; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHONG KS, 1987, J CLIN INVEST, V79, P675, DOI 10.1172/JCI112870; Cox RA., 1968, METHODS ENZYMOL, V12, P120, DOI 10.1016/0076-6879(67)12123-X; DAVIDSON NO, 1988, J LIPID RES, V29, P1511; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EISENBERG S, 1984, J LIPID RES, V25, P1017; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; FIELDING PE, 1983, J CLIN INVEST, V71, P449, DOI 10.1172/JCI110789; FORGEZ P, 1990, CIRCULATION S3, V82, P11; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HIGUCHI K, 1988, J BIOL CHEM, V263, P18530; HUANG LS, 1985, P NATL ACAD SCI USA, V82, P6825, DOI 10.1073/pnas.82.20.6825; JEFFREYS AJ, 1988, NUCLEIC ACIDS RES, V16, P10953, DOI 10.1093/nar/16.23.10953; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEBOEUF RC, 1990, J LIPID RES, V31, P91; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADORE SJ, 1988, CIRCULATION S2, V78, P95; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORAM JF, 1981, J BIOL CHEM, V256, P8348; PAGANI F, 1990, J LIPID RES, V31, P1371; PAIK YK, 1988, J BIOL CHEM, V263, P13340; PAN TC, 1987, EUR J BIOCHEM, V170, P99, DOI 10.1111/j.1432-1033.1987.tb13672.x; PANDURO A, 1990, BIOCHEMISTRY-US, V29, P8430, DOI 10.1021/bi00488a033; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PARKS JS, 1982, J LIPID RES, V23, P410; PARKS JS, 1990, J LIPID RES, V31, P455; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; POERNAMA F, 1990, J LIPID RES, V30, P955; POLITES HG, 1986, GENE, V49, P103, DOI 10.1016/0378-1119(86)90389-6; PROTTER AA, 1982, NUCLEIC ACIDS RES, V10, P4935, DOI 10.1093/nar/10.16.4935; QUIG DW, 1989, ATHEROSCLEROSIS, V76, P9, DOI 10.1016/0021-9150(89)90189-5; REUE K, 1988, J BIOL CHEM, V263, P6857; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SCHAEFER EJ, 1982, J LIPID RES, V23, P850; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHEPHERD J, 1978, J CLIN INVEST, V61, P1582, DOI 10.1172/JCI109078; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; SORCITHOMAS M, 1988, J BIOL CHEM, V263, P5183; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; STROBL W, 1990, J CLIN INVEST, V85, P659, DOI 10.1172/JCI114489; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TARUGI P, 1986, BIOCHIM BIOPHYS ACTA, V868, P51, DOI 10.1016/0167-4781(86)90086-2; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WILCOX HG, 1982, J LIPID RES, V23, P1159; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	60	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18045	18050						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917942				2022-12-25	WOS:A1991GG55300053
J	BARTEK, J; BARTKOVA, J; VOJTESEK, B; STASKOVA, Z; LUKAS, J; REJTHAR, A; KOVARIK, J; MIDGLEY, CA; GANNON, JV; LANE, DP				BARTEK, J; BARTKOVA, J; VOJTESEK, B; STASKOVA, Z; LUKAS, J; REJTHAR, A; KOVARIK, J; MIDGLEY, CA; GANNON, JV; LANE, DP			ABERRANT EXPRESSION OF THE P53-ONCOPROTEIN IS A COMMON FEATURE OF A WIDE SPECTRUM OF HUMAN MALIGNANCIES	ONCOGENE			English	Note							P53 GENE-MUTATIONS; BREAST-CANCER; LUNG-CANCER; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; ONCOGENE; TRANSFORMATION; DELETIONS; SUPPRESSOR; FREQUENT	Accumulation of the p53 protein was analysed in 212 human malignant lesions. Immunohistochemical staining with new polyclonal (CM-1) and monoclonal antibodies (BP 53-12 and BP53-24) to p53 on methacarn-fixed paraffin sections showed positive staining in 161 (76%). The positive tumours were found across a wide range of human malignancies including breast, colon, stomach, bladder and testis carcinomas, soft-tissue sarcomas and melanomas. The staining was always confined to the malignant lesion. Immunoprecipitation and quantitative ELISA assays established that the positive staining was associated with accumulation of the protein and that the protein was frequently in a mutant conformation. Accumulation of mutant p53 protein is therefore a common feature of human malignant disease.	UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; MASARYK INST ONCOL, DEPT IMMUNOL & MOLEC BIOL, CS-65653 BRNO, CZECHOSLOVAKIA; CLARE HALL LABS, IMPERIAL CANC RES FUND, MOLEC IMMUNOCHEM LAB, S MIMMS EN6 3LD, HERTS, ENGLAND; UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND	University of Dundee; Masaryk Memorial Cancer Institute; University of Dundee			Lane, David P/C-4920-2008; Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Lane, David/0000-0003-0551-3545				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHIBA I, 1990, ONCOGENE, V5, P1603; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HANSEN MF, 1987, CANCER RES, V47, P5518; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KNUDSON AG, 1985, CANCER RES, V45, P1437; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	31	581	594	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1991	6	9					1699	1703						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923535				2022-12-25	WOS:A1991GX27400029
J	MURAL, RJ; SOPER, TS; LARIMER, FW; HARTMAN, FC				MURAL, RJ; SOPER, TS; LARIMER, FW; HARTMAN, FC			EXAMINATION OF THE INTERSUBUNIT INTERACTION BETWEEN GLUTAMATE-48 AND LYSINE-168 OF RIBULOSE-BISPHOSPHATE CARBOXYLASE OXYGENASE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											MURAL, RJ (corresponding author), OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN & MOLEC MUTAGENESIS PROGRAM,OAK RIDGE,TN 37831, USA.							ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; Childs J., 1985, SEQUENCE SPECIFICITY, P341; HARTMAN FC, 1987, BIOCHEM BIOPH RES CO, V145, P1158, DOI 10.1016/0006-291X(87)91558-0; HARTMAN FC, 1985, J BIOL CHEM, V260, P3968; HARTMAN FC, 1987, J BIOL CHEM, V262, P3496; HARTMAN FC, 1989, J BIOL CHEM, V264, P11784; Horecker B. L., 1958, BIOCHEM PREP, V6, P83; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LARIMER FW, 1990, PROTEIN ENG, V3, P227, DOI 10.1093/protein/3.3.227; LEE EH, 1987, BIOCHEMISTRY-US, V26, P4599, DOI 10.1021/bi00389a001; LORIMER GH, 1977, ANAL BIOCHEM, V78, P66, DOI 10.1016/0003-2697(77)90009-4; LORIMER GH, 1988, J BIOL CHEM, V263, P6468; LUNDQVIST T, 1989, J BIOL CHEM, V264, P7078; MIZIORKO HM, 1979, J BIOL CHEM, V254, P270; MURAL RJ, 1986, DNA-J MOLEC CELL BIO, V5, P84; NIYOGI SK, 1986, J BIOL CHEM, V261, P87; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PIERCE J, 1980, BIOCHEMISTRY-US, V19, P934, DOI 10.1021/bi00546a018; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLOSS JV, 1982, METHOD ENZYMOL, V90, P522; SCHNEIDER G, 1990, IN PRESS J MOL BIOL; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SMITH H B, 1988, Journal of Cell Biology, V107, p830A; SMITH HB, 1988, J BIOL CHEM, V263, P4921; SOPER TS, 1989, J PROTEIN CHEM, V8, P239, DOI 10.1007/BF01024947; SOPER TS, 1988, PROTEIN ENG, V2, P39, DOI 10.1093/protein/2.1.39; SUE JM, 1982, BIOCHEMISTRY-US, V21, P5404, DOI 10.1021/bi00265a004; UHLMANN E, 1986, TETRAHEDRON LETT, V27, P1023, DOI 10.1016/S0040-4039(86)80038-7; VANDYK DE, 1986, BIOCHEMISTRY-US, V25, P5145, DOI 10.1021/bi00366a024; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	36	24	24	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1990	265	11					6501	6505						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CY587	1969412				2022-12-25	WOS:A1990CY58700092
J	CHAKERIAN, AE; MATTHEWS, KS				CHAKERIAN, AE; MATTHEWS, KS			CHARACTERIZATION OF MUTATIONS IN OLIGOMERIZATION DOMAIN OF LAC REPRESSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ASPARTATE-TRANSCARBAMYLASE; SITE-SPECIFIC MUTATION; AMINO-ACID SEQUENCE; SUGAR-BINDING SITE; ESCHERICHIA-COLI; LACTOSE REPRESSOR; OPERATOR DNA; CATALYTIC CHAIN; INDUCER; GENE	A series of mutant lac repressor proteins at positions 281 or 282 was isolated for detailed characterization. Although Cys281 modification by sulfhydryl reagents abrogates pH effects on inducer binding and diminishes operator binding (Daly, T. J., Olson, J. S., and Matthews, K. S. (1986) Biochemistry 25, 5468-5474), substitution at this site by alanine, serine, phenylalanine, isoleucine, or methionine did not abolish completely the pH shift nor affect operator affinity. Thus, ionization of the sulfhydryl residue does not account fully for the alterations in inducer affinity and cooperativity of binding observed with elevated pH. Substitution for Cys281 did, however, alter the kinetic parameters for inducer association with the protein. The polarity of the side chain at 281 influenced the rates of sugar binding, presumably by altering the rate of opening/closing of the binding site. Furthermore, the presence of the branched side chain of isoleucine at position 281 disrupted oligomerization of the repressor. In contrast to the tolerance for substitution at 281, the only amino acid side chain exchanges for Tyr282 which yielded tetrameric protein with near normal operator binding characteristics were phenylalanine and leucine; this result is consistent with studies of suppressed nonsense mutations at position 282 which indicated repression occurred only for the corresponding substitutions (Kleina, L. G., and Miller, J. H. (1990) J. Mol. Biol. 221, 295-318). Despite the tetrameric character of the Y282F mutant protein, the pH dependence and cooperativity of inducer binding for this mutant protein were altered. All amino acid substitutions other than phenylalanine and leucine at this position resulted in either monomeric protein or no detectable repressor in the cell. Thus, the hydrophobic character of the side chain at position 282 is essential for tetramer formation, and the phenyl ring alone alters inducer binding parameters. The monomeric mutant proteins with substitutions for Tyr282 exhibited lower stability than their tetrameric counterparts, and the absence of dimer formation suggests alterations at this site affect both dimer and tetramer interfaces. Based on previous genetic studies and our detailed mutant characterization, the region encompassing 281 and 282, indicated by secondary structure prediction to be a turn or coil, is essential for oligomer formation and additionally exerts a strong influence on the dynamic properties of the protein, presumably mediated by interactions at the subunit interface which regulate the rate of opening and closing of the inducer binding cleft.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022441, R01GM035133] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22441, GM 35133] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTI S, 1991, NEW BIOL, V3, P57; BARKLEY MD, 1975, BIOCHEMISTRY-US, V14, P1700, DOI 10.1021/bi00679a024; BETZ JL, 1986, GENE, V42, P283, DOI 10.1016/0378-1119(86)90232-5; BEYREUTHER K, 1978, NATURE, V274, P767, DOI 10.1038/274767a0; BEYREUTHER K, 1975, EUR J BIOCHEM, V59, P491, DOI 10.1111/j.1432-1033.1975.tb02477.x; BEYREUTHER K, 1973, P NATL ACAD SCI USA, V70, P3576, DOI 10.1073/pnas.70.12.3576; BOURGEOIS S, 1979, BIOPOLYMERS, V18, P2625, DOI 10.1002/bip.1979.360181017; BOURGEOIS S, 1971, METHODS ENZYMOLOGY D, V21, P491; BRENOWITZ M, 1991, J BIOL CHEM, V266, P1281; CHAKERIAN AE, 1991, J BIOL CHEM, V266, P1371; CLEWELL DB, 1970, BIOCHEMISTRY-US, V9, P4428; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5479, DOI 10.1021/bi00367a020; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5468, DOI 10.1021/bi00367a018; DALY TJ, 1986, BIOCHEMISTRY-US, V25, P5474, DOI 10.1021/bi00367a019; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FRIEDMAN BE, 1977, J MOL BIOL, V111, P27; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; GORDON AJE, 1988, J MOL BIOL, V200, P239, DOI 10.1016/0022-2836(88)90237-9; HAMADA F, 1973, J BIOCHEM, V73, P1299, DOI 10.1093/oxfordjournals.jbchem.a130204; HARE DL, 1978, GENE, V3, P269, DOI 10.1016/0378-1119(78)90037-9; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HSUANYU YC, 1989, J BIOL CHEM, V264, P17259; ISHIMORI K, 1989, J BIOL CHEM, V264, P14624; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KANIA J, 1977, EUR J BIOCHEM, V79, P381, DOI 10.1111/j.1432-1033.1977.tb11819.x; KANIA J, 1976, P NATL ACAD SCI USA, V73, P3529, DOI 10.1073/pnas.73.10.3529; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LECLERC JE, 1988, J MOL BIOL, V203, P619, DOI 10.1016/0022-2836(88)90197-0; LEHMING N, 1987, EMBO J, V6, P3145, DOI 10.1002/j.1460-2075.1987.tb02625.x; LEHMING N, 1988, P NATL ACAD SCI USA, V85, P7947, DOI 10.1073/pnas.85.21.7947; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LUNDEBERG J, 1990, GENET ANAL-BIOMOL E, V7, P47, DOI 10.1016/0735-0651(90)90040-M; MANDAL N, 1990, GENE DEV, V4, P410, DOI 10.1101/gad.4.3.410; MATTHEWS KS, 1979, J BIOL CHEM, V254, P3348; MATTHEWS KS, 1987, DNA PROTEIN INTERACT, P13; Miller J. H., 1980, OPERON; MILLER JH, 1979, J MOL BIOL, V131, P249, DOI 10.1016/0022-2836(79)90075-5; MILLER JH, 1979, J MOL BIOL, V131, P191, DOI 10.1016/0022-2836(79)90073-1; Muller-Hill B, 1975, Prog Biophys Mol Biol, V30, P227; MULLERHILL B, 1983, NATURE, V302, P163, DOI 10.1038/302163a0; MULLERHILL B, 1971, METHODS ENZYMOLOGY D, V21, P483; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; OGORMAN RB, 1980, J BIOL CHEM, V255, P107; OGORMAN RB, 1980, J BIOL CHEM, V255, P100; PACE HC, 1990, P NATL ACAD SCI USA, V87, P1870, DOI 10.1073/pnas.87.5.1870; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PLATT T, 1973, J BIOL CHEM, V248, P110; QUIOCHO FA, 1977, J BIOL CHEM, V252, P5142; RIGGS AD, 1968, J MOL BIOL, V34, P361, DOI 10.1016/0022-2836(68)90260-X; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROSENBERG JM, 1977, NUCLEIC ACIDS RES, V4, P567, DOI 10.1093/nar/4.3.567; ROYER CA, 1986, BIOCHEMISTRY-US, V25, P8308, DOI 10.1021/bi00373a027; ROYER CA, 1990, BIOCHEMISTRY-US, V29, P4959, DOI 10.1021/bi00472a028; SAMS CF, 1985, J BIOL CHEM, V260, P1185; SAMS CF, 1984, NATURE, V310, P429, DOI 10.1038/310429a0; SANDBERG WS, 1989, SCIENCE, V245, P54, DOI 10.1126/science.2787053; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHMITZ A, 1976, J BIOL CHEM, V251, P3359; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; WANG S S, 1987, Journal of Biological Chemistry, V262, P6357; WEDLER FC, 1989, J BIOL CHEM, V264, P17266; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	65	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22206	22214						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939243				2022-12-25	WOS:A1991GR56400025
J	KATO, K; KANEDA, Y; SAKURAI, M; NAKANISHI, M; OKADA, Y				KATO, K; KANEDA, Y; SAKURAI, M; NAKANISHI, M; OKADA, Y			DIRECT INJECTION OF HEPATITIS-B VIRUS-DNA INTO LIVER INDUCED HEPATITIS IN ADULT-RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSGENIC MICE; EXPRESSION; REPLICATION; BIOLOGY; GENOME; GENE	Hepatitis B virus (HBV) surface antigen (HBsAg) genes were injected directly into the liver of adult rats with non-histone chromosomal protein high mobility group 1 by the hemagglutinating B virus of Japan (Sendai virus)-liposome method (Kato, K., Nakanishi, M., Kaneda, Y., Uchida, T., and Okada, Y. (1991) J. Biol. Chem. 266, 3361-3364). Immunohistochemical analysis showed that HBV surface antigen was expressed by the hepatocytes in vivo. On successive injections of the HBsAg genes, the antibody to HBV surface polypeptides was produced in the rats, and characteristic pathological changes of lymphocytic focal necrosis and denaturation of hepatic cells were observed in the liver of all the rats. We conclude that hepatitis is caused by the direct injection of HBsAg genes.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADA OKA,SUITA,OSAKA 565,JAPAN; OSAKA CITY UNIV,SCH MED,DEPT PATHOL,ABENO KU,OSAKA 545,JAPAN	Osaka University; Osaka Metropolitan University								ARAKI K, 1989, P NATL ACAD SCI USA, V86, P207, DOI 10.1073/pnas.86.1.207; BARNABA V, 1990, NATURE, V345, P258, DOI 10.1038/345258a0; BRUSS V, 1991, P NATL ACAD SCI USA, V88, P1059, DOI 10.1073/pnas.88.3.1059; CHISARI FV, 1989, MICROB PATHOGENESIS, V6, P311, DOI 10.1016/0882-4010(89)90073-9; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; KANEDA Y, 1989, J BIOL CHEM, V264, P12126; KATO K, 1991, J BIOL CHEM, V266, P3361; KOST TA, 1983, NUCLEIC ACIDS RES, V11, P8287, DOI 10.1093/nar/11.23.8287; MORIYAMA T, 1990, SCIENCE, V248, P361, DOI 10.1126/science.1691527; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TSURIMOTO T, 1987, P NATL ACAD SCI USA, V84, P444, DOI 10.1073/pnas.84.2.444; UEDA K, 1991, J VIROL, V65, P3521, DOI 10.1128/JVI.65.7.3521-3529.1991; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678	16	56	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22071	22074						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939228				2022-12-25	WOS:A1991GR56400002
J	HALE, JE; WILLIAMSON, MK; PRICE, PA				HALE, JE; WILLIAMSON, MK; PRICE, PA			CARBOXYL-TERMINAL PROTEOLYTIC PROCESSING OF MATRIX GLA PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYLASE; ACID; BONE; PEPTIDE; GELS; RAT	The present study was undertaken to determine the extent of COOH-terminal proteolytic processing in matrix Gla protein (MGP), a 10-kDa protein which contains 5 residues of the vitamin K-dependent Ca2+ binding amino acid, gamma-carboxyglutamic acid (Gla). Two forms of MGP were isolated from demineralization and urea extracts of bovine cortical bone, one 79 residues in length with the COOH terminus Phe-Arg-Gln and the other 83 residues in length with the COOH terminus Phe-Arg-Gln-Arg-Arg-Gly-Ala. The 84-residue form of bovine MGP predicted from the message structure could not be detected in the bone extracellular matrix extracts, and it therefore seems probable that the lysine at position 84 was removed by the action of a carboxypeptidase B-like enzyme prior to secretion. A plausible sequence of proteolytic cleavages that could generate the 79-residue form of MGP would be a trypsin-like cleavage at Arg80-Arg81 or Arg81-Gly82 followed by carboxypeptidase B-like cleavage to remove COOH-terminal arginine(s). Since essentially equal amounts of the 79- and 83-residue forms of MGP were also detected in bovine articular cartilage and plasma, it seems likely that the COOH-terminal processing events identified in bone apply to many of the other tissues which synthesize this protein. Only one form of MGP was detected in human bone extracts, a 77-residue protein that lacks the COOH-terminal residues Arg-Lys-Arg-Arg-Gly-Thr-Lys. This shortened version of human MGP is consistent with the proposed model for COOH-terminal processing, since the amino acid substitution in the COOH terminus of the human protein, Lys79 for Gln79, would allow removal of the additional basic residues from the human MGP COOH terminus by the action of the carboxypeptidase B-like enzymic activity. Recent studies have shown that MGP is strongly induced by retinoic acid in fibroblasts, chondrocytes, and osteoblasts, a response which suggests that MGP mediates an action of retinoic acid on an aspect of cell growth or differentiation. If this hypothesis is true, the present evidence for complex COOH-terminal processing events could provide a means to regulate the as yet unknown activity of MGP in the extracellular environment in a mechanism similar to the activation of hormones such as anaphlotoxins and kinins.	UNIV CALIF SAN DIEGO,DEPT BIOL,0322,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR025921] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR25921] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CANCELA L, 1990, J BIOL CHEM, V265, P15040; CANCELA ML, 1991, IN PRESS ENDOCRINOLO; CUNICO R, 1986, BIOCHROMATOGRAPHY, V1, P6; EINARSSON S, 1983, J CHROMATOGR, V282, P609, DOI 10.1016/S0021-9673(00)91638-8; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FRASER JD, 1988, J BIOL CHEM, V263, P11033; FRICKER LD, 1985, TRENDS NEUROSCI, V8, P210, DOI 10.1016/0166-2236(85)90081-5; GIULIAN GG, 1983, ANAL BIOCHEM, V129, P277, DOI 10.1016/0003-2697(83)90551-1; GLUSCHANKOF P, 1987, J BIOL CHEM, V262, P9615; HALE JE, 1988, J BIOL CHEM, V263, P5820; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; JAHNEN W, 1990, BIOCHEM BIOPH RES CO, V166, P139, DOI 10.1016/0006-291X(90)91922-F; KIEFER MC, 1988, NUCLEIC ACIDS RES, V16, P5213, DOI 10.1093/nar/16.11.5213; OTAWARA Y, 1986, J BIOL CHEM, V261, P828; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRICE PA, 1985, J BIOL CHEM, V260, P4971; PRICE PA, 1983, BIOCHEM BIOPH RES CO, V117, P765, DOI 10.1016/0006-291X(83)91663-7; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6	18	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21145	21149						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939157				2022-12-25	WOS:A1991GN00100087
J	INAKA, K; KUROKI, R; KIKUCHI, M; MATSUSHIMA, M				INAKA, K; KUROKI, R; KIKUCHI, M; MATSUSHIMA, M			CRYSTAL-STRUCTURES OF THE APOMUTANT AND HOLOMUTANT HUMAN LYSOZYMES WITH AN INTRODUCED CA2+ BINDING-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LACTALBUMIN; REFINED STRUCTURE; CALCIUM; RESOLUTION; PROTEINS; LOOP	The three-dimensional structures of apo- and holomutant human lysozymes (D86/92 lysozyme), in which a calcium binding site was designed and created for enhancing molecular stability by replacing both Gln86 and Ala92 with aspartic acids, were refined at 1.8-angstrom resolution by x-ray crystallography. The overall structures and crystallographic thermal factors of all three proteins, the apo-, holo-D86/92, and the wild-type human lysozymes, were essentially identical; these results showed that the introduction of the calcium binding site did not affect either the overall structure or molecular rigidity of the proteins. However, structure analyses of the apo-D86/92 lysozyme revealed that the mutations affected the side chain conformation of residue 86 and hydrogen networks between the protein and the internal solvent molecules. In the structure of the holo-D86/92 lysozyme, seven oxygen ligands formed a slightly distorted pentagonal bipyramid around the calcium ion, indicating that the coordination around the calcium ion was quite similar to that in baboon alpha-lactalbumin. The pentagonal bipyramid coordination could be one of the most widely found and appropriate calcium binding schemes in proteins.	PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN									ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; AMEMIYA Y, 1988, NUCL INSTRUM METH A, V266, P645, DOI 10.1016/0168-9002(88)90458-5; ARTYMIUK PJ, 1981, J MOL BIOL, V152, P737, DOI 10.1016/0022-2836(81)90125-X; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BRITTON D, 1963, CAN J CHEM, V41, P1632, DOI 10.1139/v63-227; FUJII I, 1991, ACTA CRYSTALLOGR B, V47, P137, DOI 10.1107/S0108768190009430; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HERZBERG O, 1985, NATURE, V313, P635; HIRAOKA Y, 1980, BIOCHEM BIOPH RES CO, V95, P1098, DOI 10.1016/0006-291X(80)91585-5; HUBER R, 1985, J APPL CRYSTALLOGR, V18, P165, DOI 10.1107/S0021889885010044; INAKA K, 1991, J BIOL CHEM, V266, P12599; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MIYAHARA J, 1986, NUCL INSTRUM METH A, V246, P572, DOI 10.1016/0168-9002(86)90156-7; NITTA K, 1987, FEBS LETT, V223, P405, DOI 10.1016/0014-5793(87)80328-9; NITTA K, 1988, HOPPESEYLERS BIOL CH, V369, P671; OSSERMAN EF, 1967, SCIENCE, V155, P1536, DOI 10.1126/science.155.3769.1536; STEIGEMAN W, 1974, THESIS TU MUNCHEN; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; STUART DI, 1986, NATURE, V324, P84, DOI 10.1038/324084a0; SWAIN AL, 1989, J BIOL CHEM, V264, P16620; SZEBENYI DME, 1986, J BIOL CHEM, V261, P8761; TAGA T, 1967, B CHEM SOC JPN, V51, P1697; TANAKA I, 1990, J APPL CRYSTALLOGR, V23, P334, DOI 10.1107/S0021889890004009; THANKI N, 1988, J MOL BIOL, V202, P637, DOI 10.1016/0022-2836(88)90292-6; VAYS NK, 1987, NATURE, V327, P635; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0; ZENG J, 1990, J BIOL CHEM, V265, P14886	30	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20666	20671						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939116				2022-12-25	WOS:A1991GN00100015
J	SAXENA, SK; RYBAK, SM; WINKLER, G; MEADE, HM; MCGRAY, P; YOULE, RJ; ACKERMAN, EJ				SAXENA, SK; RYBAK, SM; WINKLER, G; MEADE, HM; MCGRAY, P; YOULE, RJ; ACKERMAN, EJ			COMPARISON OF RNASES AND TOXINS UPON INJECTION INTO XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL CATIONIC PROTEIN; HUMAN CARCINOMA-CELLS; RIBONUCLEASE-ACTIVITY; ESCHERICHIA-COLI; ALPHA-SARCIN; HOMOLOGOUS RECOMBINATION; EUKARYOTIC RIBOSOMES; HUMAN-PLASMA; ANGIOGENIN; SITE	Several toxins abolish cellular protein synthesis by attacking specific sites in 28 S RNA. One of these toxins, alpha-sarcin, is an RNase that also cleaves nonspecifically on the 3' side of purines in deproteinized RNA. Several other RNases were injected into Xenopus oocytes, examined for their ability to abolish protein synthesis, and compared with alpha-sarcin and ricin. Surprisingly, pancreatic RNase A or B abolished oocyte protein synthesis at concentrations (approximately 0.03 nM) comparable to, or lower than, the amount of alpha-sarcin (approximately 2 nM) or ricin (approximately 0.07 nm) required to abolish protein synthesis. RNases S and T1 only inhibited oocyte protein synthesis when used at concentrations approximately 10 x higher than RNase A whereas RNases C, T2, U2, and nuclease P1 required concentrations approximately 100 times higher than RNase A to abolish protein synthesis. There was a direct correlation between the degradation of oocyte RNA and the inhibition of protein synthesis. The RNase inhibitors RNasin and Inhibit-Ace injected into the oocyte both prevented RNase A from hydrolyzing oocyte rRNA and abolishing protein synthesis. Enzymatically inactive oxidized RNase A did not inhibit protein synthesis when injected into the oocyte. None of the RNases or alpha-sarcin abolished protein synthesis when added to oocyte extracellular medium. Angiogenin is a human plasma protein that induces blood vessel formation in chick embryos, has 35% amino acid identity with RNase A, and cleaves 18 S and 28 S RNA in rabbit reticulocyte lysates (St. Clair, D. K., Rybak, S. M., Riordan, J. F. & Vallee, B. L. (1988) Biochemistry 27, 7263-7268, and references therein). Recombinant angiogenin injected into oocytes abolished protein synthesis, and this toxic effect was inhibited by RNasin but was not inhibited by Inhibit-Ace. Unlike RNase A and the other nucleases that hydrolyzed cellular rRNA, no cleavage of 18 or 28 S RNA by recombinant angiogenin was seen at concentrations 100 x greater than necessary to abolish protein synthesis. Recombinant angiogenin must selectively attack specific RNA(s) or another target in the cell.	NIDDKD,GENET & BIOCHEM BRANCH,BLDG 10,RM 9D-15,BETHESDA,MD 20892; NINCDS,SURG NEUROL BRANCH,BIOCHEM SECT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)			Saxena, Shailendra K/X-4252-2019; Saxena, Shailendra K/ABK-6489-2022	Saxena, Shailendra K/0000-0003-2856-4185; Saxena, Shailendra K/0000-0003-2856-4185				ACKERMAN EJ, 1988, J BIOL CHEM, V263, P17076; ARDELT W, 1991, J BIOL CHEM, V266, P245; ARIMA T, 1968, BIOCHEM J, V106, P609, DOI 10.1042/bj1060609; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; Blackburn P, 1982, ENZYMES, VXV, P317; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CONDE FP, 1989, EUR J BIOCHEM, V178, P795, DOI 10.1111/j.1432-1033.1989.tb14511.x; DENEFLE P, 1987, GENE, V56, P61, DOI 10.1016/0378-1119(87)90158-2; ENDO Y, 1982, J BIOL CHEM, V257, P9054; ENDO Y, 1983, J BIOL CHEM, V258, P2662; ENDO Y, 1987, J BIOL CHEM, V262, P5908; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; FREDENS K, 1982, J ALLERGY CLIN IMMUN, V70, P361, DOI 10.1016/0091-6749(82)90025-2; FUJIMOTO M, 1974, AGR BIOL CHEM TOKYO, V38, P777, DOI 10.1080/00021369.1974.10861230; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GOFF S, 1986, MAXIMIZING GENE EXPR; GULLBERG U, 1986, BIOCHEM BIOPH RES CO, V139, P1239, DOI 10.1016/S0006-291X(86)80310-2; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HIRS CHW, 1953, J BIOL CHEM, V200, P493; HIRS CHW, 1956, J BIOL CHEM, V219, P611; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; HONJO T, 1968, J BIOL CHEM, V243, P3553; KURACHI K, 1985, BIOCHEMISTRY-US, V24, P5494, DOI 10.1021/bi00341a032; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCLAREN DJ, 1981, PARASITE IMMUNOL, V3, P359, DOI 10.1111/j.1365-3024.1981.tb00414.x; MORINAGA Y, 1984, BIO-TECHNOL, V2, P636, DOI 10.1038/nbt0784-636; NEFF NT, 1981, J CELL BIOL, V91, P184, DOI 10.1083/jcb.91.1.184; PLUMMER TH, 1963, J BIOL CHEM, V238, P1396; PRIOR TI, 1991, CELL, V64, P1017, DOI 10.1016/0092-8674(91)90325-S; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; ROTH JS, 1963, CANCER RES, V23, P657; ROTH JS, 1967, METHOD CANCER RES, V3, P153; RYBAK SM, 1991, J BIOL CHEM, V266, P21202; RYBAK SM, 1988, BIOCHEMISTRY-US, V27, P2288, DOI 10.1021/bi00407a007; SAXENA SK, 1990, J BIOL CHEM, V265, P17106; SAXENA SK, 1989, J BIOL CHEM, V264, P596; SCHMUKLER M, 1975, J BIOL CHEM, V250, P2206; SHAPIRO R, 1987, BIOCHEMISTRY-US, V26, P5141, DOI 10.1021/bi00390a037; SHAPIRO R, 1988, ANAL BIOCHEM, V175, P450, DOI 10.1016/0003-2697(88)90569-6; SIERAKOWSKA H, 1977, PROG NUCLEIC ACIDS R, V20, P50; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; STCLAIR DK, 1987, P NATL ACAD SCI USA, V84, P8330; STCLAIR DK, 1988, BIOCHEMISTRY-US, V27, P7263, DOI 10.1021/bi00419a013; STRYDOM DJ, 1985, BIOCHEMISTRY-US, V24, P5486, DOI 10.1021/bi00341a031; TAKAHASHI K, 1962, J BIOCHEM-TOKYO, V51, P95, DOI 10.1093/oxfordjournals.jbchem.a127515; UCHIDA T, 1966, J BIOCHEM-TOKYO, V60, P115, DOI 10.1093/oxfordjournals.jbchem.a128410; VESCIA S, 1980, CANCER RES, V40, P3740; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; 1990, PRIME REPORT, V2, P1; 1989, PROMEGA NOTES, V19, P1	50	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21208	21214						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939163				2022-12-25	WOS:A1991GN00100097
J	VOLK, R; BACHER, A				VOLK, R; BACHER, A			BIOSYNTHESIS OF RIBOFLAVIN - STUDIES ON THE MECHANISM OF L-3,4-DIHYDROXY-2-BUTANONE 4-PHOSPHATE SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; C-13-LABELED PRECURSORS; ENZYMATIC FORMATION; 4-CARBON PRECURSOR; XYLENE RING; 6,7-DIMETHYL-8-RIBITYLLUMAZINE; PENTOSE; RIBULOSE-1,5-BISPHOSPHATE; MUTANTS; MOIETY	The riboflavin precursor, L-3,4-dihydroxy-2-butanone 4-phosphate, is formed from D-ribulose 5-phosphate by a single 24-kDa enzyme. Studies with various specifically C-13-labeled D-ribulose 5-phosphates as substrate showed that the carbon atoms 1-3 of the enzyme product correspond to carbon atoms 1-3 of the substrate, whereas C-4 of the product stems from C-5 of the substrate. Carbon atom 4 of the substrate is released as formate together with the hydrogen atom attached to it. The skeletal rearrangement which leads to the loss of C-4 and the direct linkage between C-3 and C-5 of the substrate is an intramolecular reaction. The hydrogen atom at C-3 of the enzyme product is introduced from solvent water. A reaction mechanism which is in agreement with all experimental data is proposed.			VOLK, R (corresponding author), TECH UNIV MUNICH,LEHRSTUHL ORGAN CHEM & BIOCHEM,LICHTENBERGSTR 4,W-8046 GARCHING,GERMANY.							ALI SN, 1966, BIOCHEM J, V98, P182, DOI 10.1042/bj0980182; ALWORTH WL, 1977, BIOCHEMISTRY-US, V16, P526, DOI 10.1021/bi00622a029; BACHER A, 1983, J BIOL CHEM, V258, P3431; BACHER A, 1985, J AM CHEM SOC, V107, P6380, DOI 10.1021/ja00308a037; Bacher A., 1991, CHEM BIOCH FLAVOPROT, P215; BRESLER SE, 1976, GENETIKA+, V12, P83; Brown G. M., 1987, ESCHERICHIA COLI SAL, V1, P521; BRYN K, 1976, BIOCHIM BIOPHYS ACTA, V428, P257, DOI 10.1016/0304-4165(76)90127-6; CROUT DHG, 1987, J CHEM SOC CHEM COMM, P742, DOI 10.1039/c39870000742; GOODWIN TW, 1958, BIOCHEM J, V70, pP14; HOLLANDER IJ, 1980, BIOCHEM BIOPH RES CO, V94, P515, DOI 10.1016/0006-291X(80)91261-9; LEVAN Q, 1985, J BACTERIOL, V162, P1280, DOI 10.1128/JB.162.3.1280-1284.1985; LOGVINENKO E M, 1984, Biokhimiya, V49, P45; LOGVINENKO E M, 1982, Biokhimiya, V47, P931; NAKAJIMA K, 1984, Acta Vitaminologica et Enzymologica, V6, P271; NEUBERGER G, 1985, BIOCHEM BIOPH RES CO, V127, P175, DOI 10.1016/S0006-291X(85)80141-8; NEUBERGER G, 1986, BIOCHEM BIOPH RES CO, V139, P1111, DOI 10.1016/S0006-291X(86)80292-3; NIELSEN P, 1986, J BIOL CHEM, V261, P3661; PAECH C, 1978, BIOCHEM BIOPH RES CO, V83, P1084, DOI 10.1016/0006-291X(78)91506-1; PLAUT GWE, 1954, J BIOL CHEM, V211, P111; VOLK R, 1990, J BIOL CHEM, V265, P19479; VOLK R, 1988, J AM CHEM SOC, V110, P3651, DOI 10.1021/ja00219a047; VOLK R, 1989, CHEM BIOL PTERIDINES, P344; YOUNG DW, 1986, NAT PROD REP, V3, P395, DOI 10.1039/np9860300395	24	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20610	20618						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939111				2022-12-25	WOS:A1991GN00100008
J	POLACK, A; STROBL, L; FEEDERLE, R; SCHWEIZER, M; KOCH, E; EICK, D; WIEGAND, H; BORNKAMM, GW				POLACK, A; STROBL, L; FEEDERLE, R; SCHWEIZER, M; KOCH, E; EICK, D; WIEGAND, H; BORNKAMM, GW			THE INTRON ENHANCER OF THE IMMUNOGLOBULIN KAPPA GENE ACTIVATES C-MYC BUT DOES NOT INDUCE THE BURKITT-SPECIFIC PROMOTER SHIFT	ONCOGENE			English	Article							PHOSPHORYLATION-DEPENDENT BINDING; LYMPHOMA CELLS; 1ST EXON; TRANS-ACTIVATION; NEGATIVE AUTOREGULATION; TRANSCRIPTION FACTOR; REGULATORY ELEMENT; V-MYC; EXPRESSION; PROTEIN	In Burkitt's lymphoma cells the c-myc gene locus is consistently fused to the constant region of one of the immunoglobulin genes by chromosomal translocation. The translocated c-myc gene is transcriptionally activated and preferentially transcribed from the P1 promoter whenever the exon-intron structure of c-myc remains intact. In order to define elements involved in this promoter shift we have cloned the translocated c-myc allele from Burkitt's lymphoma cell line BL60, which is characterized by several point mutations. The mutated c-myc allele of BL60 was stably introduced into baby hamster kidney and Burkitt's lymphoma cells. S1 nuclease and RNAase protection mapping experiments demonstrated that the mutated c-myc allele was expressed at a low level and with a normal promoter usage (P2 > P1) in Burkitt's lymphoma and baby hamster kidney cells. Furthermore, we have studied the expression of a construct consisting of the mutated c-myc allele, part of the bvr1 (Burkitt's variant rearranging region 1) locus, the human immunoglobulin kappa constant region, and the kappa intron enhancer after stable transfection into Burkitt's lymphoma cells. Although c-myc expression was about fivefold increased, the transcripts still initiated predominantly at promoter P2. This indicates that 5 kb of the constant kappa light-chain locus including the kappa intron enhancer is not sufficient to induce the Burkitt's lymphoma-specific promoter shift.	INST KLIN MIKROBIOL & HYG,VIROL ABT,W-7800 FREIBURG,GERMANY		POLACK, A (corresponding author), GESELL SCHWERIONENFORSCH GMBH,INST KLIN MOLEK BIOL & TUMORGENET,MARCHIONINISTR 25,W-8000 MUNICH 70,GERMANY.		Strobl, Lothar J/M-7357-2014	Strobl, Lothar J/0000-0001-8389-1862				ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EICK D, 1988, ONCOGENE, V3, P397; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GOTSCHL M, 1988, BIOCHEM BIOPH RES CO, V157, P379, DOI 10.1016/S0006-291X(88)80058-5; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HAGMAN J, 1990, GENE DEV, V4, P978, DOI 10.1101/gad.4.6.978; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KLOBECK HG, 1986, NUCLEIC ACIDS RES, V14, P4591, DOI 10.1093/nar/14.11.4591; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYER KB, 1990, NUCLEIC ACIDS RES, V18, P5609, DOI 10.1093/nar/18.19.5609; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; RICHMAN A, 1989, SCIENCE, V246, P494, DOI 10.1126/science.2683072; SACCA R, 1990, ONCOGENE, V5, P1499; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SEN R, 1989, IMMUNOGLOBULIN GENES, P327; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; SPENCER CA, 1991, ADV CANCER RES; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; SZAJNERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553, DOI 10.1093/nar/15.11.4553; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TAUB R, 1984, CELL, V37, P511, DOI 10.1016/0092-8674(84)90381-7; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TONEGUZZO F, 1986, MOL CELL BIOL, V6, P703, DOI 10.1128/MCB.6.2.703; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	65	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2033	2040						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945409				2022-12-25	WOS:A1991GX11900014
J	DANIEL, H; MORSE, EL; ADIBI, SA				DANIEL, H; MORSE, EL; ADIBI, SA			THE HIGH AND LOW AFFINITY TRANSPORT-SYSTEMS FOR DIPEPTIDES IN KIDNEY BRUSH-BORDER MEMBRANE RESPOND DIFFERENTLY TO ALTERATIONS IN PH GRADIENT AND MEMBRANE-POTENTIAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCYL-L-PROLINE; PEPTIDE-TRANSPORT; SMALL-INTESTINE; RABBIT; VESICLES; MECHANISM; GLYCYLSARCOSINE; COTRANSPORT; HYDROLYSIS; METABOLISM	The principal aim of the present study was to investigate the effects of variation in proton gradient and membrane potential on the transport of glycyl-L-glutamine (Gly-Gln) by renal brush border membrane vesicles. Under our conditions of transport assay, Gly-Gln was taken up by brush border membrane vesicles almost entirely as intact dipeptide. This uptake was mediated by two transporters shared by other dipeptides and characterized as the high affinity (K(t) = 44.1 +/- 11.2-mu-M)/low capacity (V(max) = 0.41 +/- 0.03 nmol/mg protein/5 s) and low affinity (K(t) = 2.62 +/- 0.50 mM)/high capacity (V(max) 4.04 +/- 0.80 nmol/mg protein/5 s) transporters. In the absence of a pH gradient, only the low affinity system was operational, but with a reduced transport capacity. Imposing a pH gradient of 1.6 pH units increased the V(max) of both transporters. Kinetic analysis of the rates of Gly-Gln uptake as a function of external pH revealed Hill coefficients of close or equal to 1, indicating that transporters contain only one binding site for the interaction with external H+. The effects of membrane potential on Gly-Gln uptake were investigated with valinomycin-induced K+ diffusion potentials. The velocity of the high affinity system but not of the low affinity system increased linearly with increasing inside-negative K+ diffusion potentials (p < 0.01). The K(t) of neither system was affected by alterations in either pH gradient or membrane potential. We conclude that (a) the high affinity transporter is far more sensitive to changes in proton gradient and membrane potential than the low affinity transporter and (b) in the presence of a pH gradient, transport of each dipeptide molecule requires cotransport of one hydrogen ion to serve as the driving force.	UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	DANIEL, H (corresponding author), UNIV PITTSBURGH,MONTEFIORE HOSP,CLIN NUTR UNIT,3459 5TH AVE,PITTSBURGH,PA 15213, USA.		Daniel, Hannelore/B-8982-2009		NIDDK NIH HHS [DK 15861] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015861] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE M, 1987, J PHYSIOL-LONDON, V394, P481, DOI 10.1113/jphysiol.1987.sp016882; ABUMRAD NN, 1989, AM J PHYSIOL, V257, pE228, DOI 10.1152/ajpendo.1989.257.2.E228; ADIBI SA, 1989, METABOLISM, V38, P89, DOI 10.1016/0026-0495(89)90149-2; GANAPATHY V, 1985, AM J PHYSIOL, V249, pG153, DOI 10.1152/ajpgi.1985.249.2.G153; GANAPATHY V, 1983, J BIOL CHEM, V258, P4189; GANAPATHY V, 1984, J BIOL CHEM, V259, P8954; GANAPATHY V, 1985, BIOCHIM BIOPHYS ACTA, V816, P234, DOI 10.1016/0005-2736(85)90490-0; GANAPATHY V, 1981, J BIOL CHEM, V256, P118; GANAPATHY V, 1987, CONTRIB INFUSION THE, V17, P54; GUSTIN MC, 1981, J BIOL CHEM, V256, P651; HOSHI T, 1986, ION GRADIENT COUPLED, P183; KRAMER W, 1990, BIOCHIM BIOPHYS ACTA, V1028, P174, DOI 10.1016/0005-2736(90)90152-E; LOCHS H, 1986, J BIOL CHEM, V261, P4976; LOCHS H, 1990, BIOCHEM J, V271, P133, DOI 10.1042/bj2710133; LOMBARDO YB, 1988, J BIOL CHEM, V263, P12920; MATTHEWS DM, 1976, GASTROENTEROLOGY, V71, P151; MILLER RT, 1987, J BIOL CHEM, V262, P9115; MIYAMOTO Y, 1989, BIOCHIM BIOPHYS ACTA, V978, P25, DOI 10.1016/0005-2736(89)90493-8; RAGHUNATH M, 1990, AM J PHYSIOL, V259, pE463, DOI 10.1152/ajpendo.1990.259.4.E463; SEGAL IH, 1975, ENZYME KINETICS, P371; SILBERNAGL S, 1987, AM J PHYSIOL, V253, pF448, DOI 10.1152/ajprenal.1987.253.3.F448; TAKUWA N, 1985, BIOCHIM BIOPHYS ACTA, V814, P186, DOI 10.1016/0005-2736(85)90435-3; THIERFELDER H, 1919, Z PHYSL CHEM, V105, P58; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P14870; TIRUPPATHI C, 1990, BIOCHEM J, V268, P27, DOI 10.1042/bj2680027	25	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19917	19924						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939055				2022-12-25	WOS:A1991GM03900011
J	GROOM, CR; THILLET, J; NORTH, ACT; PICTET, R; GEDDES, AJ				GROOM, CR; THILLET, J; NORTH, ACT; PICTET, R; GEDDES, AJ			TRIMETHOPRIM BINDS IN A BACTERIAL MODE TO THE WILD-TYPE AND E30D MUTANT OF MOUSE DIHYDROFOLATE-REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; MECHANISM; SEQUENCE; FOLATE; L1210	Previous crystallographic studies of the antibacterial trimethoprim in complexes with bacterial and avian dihydrofolate reductases have shown substantial differences in the mode of binding, providing plausible explanations for the origin of the remarkable species selectivity of this inhibitor (Matthews, D. A., Bolin, J. T., Burridge, J. M., Filman, D. J., Volz, K. W., Kaufman, B. T., Beddell, C. R., Champness, J. N., Stammers, D. K., and Kraut, J. (1985) J. Biol. Chem. 260, 381-391; Matthews, D. A., Bolin, J. T., Burridge, J. M., Filman, D. J., Volz, K. W., and Kraut, J. (1985) J. Biol. Chem. 260, 392-399). A major species difference between the active sites is that the only carboxylate present is always Glu in vertebrates and Asp in bacteria. Crystallographic studies of the wild-type and E30D mutant of the enzyme from mouse now reveal that in both cases trimethoprim is bound in an identical fashion to that observed with the bacterial enzyme, and there is no obvious single explanation for the origin of the 10(5)-fold selectivity of trimethoprim binding. In an earlier study of a mouse wild-type enzyme using more limited data it was proposed that trimethoprim bound in the avian mode (Stammers, D. K., Champness, J. N., Beddell, C. R., Dann, J. G., Eliopoulos, E. E., Geddes, A. J., Ogg, D., and North, A. C. T. (1987) FEBS Lett. 218, 178-184), but a re-examination indicates that the occupancy of the active site by trimethoprim is less than had been thought, and we are currently unable to make an unambiguous interpretation of the electron density maps and cannot confirm the avian mode of binding in those crystals.	UNIV PARIS 07,INST JACQUES MONOD,INSERM,U257,F-75251 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	GROOM, CR (corresponding author), UNIV LEEDS,DEPT BIOCHEM & MOLEC BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.			Groom, Colin/0000-0001-8921-9575				ANDERSON GM, 1979, J AM CHEM SOC, V101, P2344, DOI 10.1021/ja00503a018; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BYSTROFF C, 1991, BIOCHEMISTRY-US, V30, P2227, DOI 10.1021/bi00222a028; CHAMPNESS JN, 1986, FEBS LETT, V199, P61, DOI 10.1016/0014-5793(86)81224-8; CHANG ACY, 1978, NATURE, V275, P617, DOI 10.1038/275617a0; CROUSE GF, 1982, J BIOL CHEM, V257, P7887; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; MATTHEWS DA, 1985, J BIOL CHEM, V260, P392; MATTHEWS DA, 1985, J BIOL CHEM, V260, P381; MCDONALD JJ, 1991, J AM CHEM SOC, V113, P2295, DOI 10.1021/ja00006a058; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; NUNBERG JH, 1980, CELL, V19, P355, DOI 10.1016/0092-8674(80)90510-3; OEFNER C, 1988, EUR J BIOCHEM, V174, P377, DOI 10.1111/j.1432-1033.1988.tb14108.x; STAMMERS DK, 1987, FEBS LETT, V218, P178, DOI 10.1016/0014-5793(87)81042-6; STONE D, 1979, J BIOL CHEM, V254, P480; STONE SR, 1984, BIOCHEMISTRY-US, V23, P2753, DOI 10.1021/bi00307a034; STONE SR, 1986, BIOCHIM BIOPHYS ACTA, V869, P275, DOI 10.1016/0167-4838(86)90067-1; THILLET J, 1988, J BIOL CHEM, V263, P12500; THILLET J, 1990, BIOCHEMISTRY-US, V29, P5195, DOI 10.1021/bi00473a028	20	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19890	19893						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939053				2022-12-25	WOS:A1991GM03900007
J	WALSH, MT; SEN, AC; CHAKRABARTI, B				WALSH, MT; SEN, AC; CHAKRABARTI, B			MICELLAR SUBUNIT ASSEMBLY IN A 3-LAYER MODEL OF OLIGOMERIC ALPHA-CRYSTALLIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LENS CRYSTALLINS; STATISTICAL MECHANICAL DECONVOLUTION; HEAT-SHOCK PROTEINS; CIRCULAR-DICHROISM; MOLECULAR-WEIGHT; THERMAL TRANSITIONS; SPECTROSCOPIC INVESTIGATIONS; EXCIMER FLUORESCENCE; QUATERNARY STRUCTURE; SULFHYDRYL-GROUP	Differential scanning calorimetry was performed to monitor the heat-induced changes that occur in the structural domain of lens alpha-crystallin. Circular dichroism and fluorescence also were used to resolve the controversial issue of the quaternary structure of alpha-crystallin. Based on the thermal behavior as monitored by these techniques, a model is proposed that can account for all previous data as well as the currently reported thermal data. The proposed model of native alpha-crystallin has a three-layer structure in which the inner layer (core) is a micelle containing 12 subunits arranged in cuboctahedral symmetry. The apolar region is directed inward constituting a hydrophobic core similar to a micelle and adding structural stability. A second layer of six subunits has a similar but not identical structure to the first layer, directing its apolar face toward the hydrophobic core. Thus, these two layers constitute a micelle-like structure with octahedral symmetry. The third layer adds more subunits for a total of not more than 24. Differential scanning calorimetry, circular dichroism, and fluorescence studies indicated that the inner two-layer structure of molecular mass 360 kDa is highly stable and is most likely of the alpha-m form. The three-layer structure of the native protein, however, is rather unstable. At 35-45-degrees-C the outer layer dissociates from the inner two layers, and at higher temperatures rapidly reassociates to a slightly modified two-layer structure with a stability similar to that of alpha-m. The proposed model does not require any specific assembly of the alpha-A and alpha-B subunits in each layer, but the fluorescence results suggest that the native inner two layers probably contain mostly alpha-A.	HARVARD UNIV,SCH MED,EYE RES INST,20 STANIFORD ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02114; BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Boston University					NEI NIH HHS [EY04161] Funding Source: Medline; NHLBI NIH HHS [HL26335] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004161] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDLEY UP, 1982, BIOCHEMISTRY-US, V21, P1853, DOI 10.1021/bi00537a023; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; BETTELHEIM F A, 1982, Current Eye Research, V2, P803, DOI 10.3109/02713688209020015; BETTELHEIM FA, 1990, EXP EYE RES, V50, P715, DOI 10.1016/0014-4835(90)90119-F; BHAT S P, 1990, Investigative Ophthalmology and Visual Science, V31, P52; BINDELS JG, 1979, OPHTHALMIC RES, V11, P441, DOI 10.1159/000265048; COOPMAN S, 1984, EXP EYE RES, V38, P463, DOI 10.1016/0014-4835(84)90124-6; De Jong W.W., 1981, MOL CELLULAR BIOL EY, P221, DOI DOI 10.1146/ANNUREV.ECOLSYS.33.020602.095451; DEJONG WW, 1984, EUR J BIOCHEM, V141, P131; FREIRE E, 1978, BIOPOLYMERS, V17, P481, DOI 10.1002/bip.1978.360170213; FREIRE E, 1978, BIOPOLYMERS, V17, P497, DOI 10.1002/bip.1978.360170214; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; FUKUDA H, 1983, J BIOL CHEM, V258, P13193; GRACEFFA P, 1980, J BIOL CHEM, V255, P1296; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HOENDERS HJ, 1981, MOL CELLULAR BIOL EY, P279; HORWITZ J, 1976, EXP EYE RES, V23, P471, DOI 10.1016/0014-4835(76)90156-1; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; KONO M, 1988, PHOTOCHEM PHOTOBIOL, V47, P593, DOI 10.1111/j.1751-1097.1988.tb08849.x; KONO M, 1990, BIOCHEMISTRY-US, V29, P464, DOI 10.1021/bi00454a022; KRESHECK GC, 1988, BIOCHEMISTRY-US, V27, P2490, DOI 10.1021/bi00407a035; Krishinan K S, 1978, Methods Enzymol, V49, P3; LAWSON EQ, 1981, J BIOL CHEM, V256, P6523; LERMAN S, 1976, DOC OPHTHALMOL, V8, P241; LI LK, 1974, EXP EYE RES, V18, P383, DOI 10.1016/0014-4835(74)90116-X; LI LK, 1974, EXP EYE RES, V19, P49, DOI 10.1016/0014-4835(74)90071-2; LIANG JN, 1982, BIOCHEMISTRY-US, V21, P1847, DOI 10.1021/bi00537a022; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MESSMER M, 1988, EXP EYE RES, V47, P173, DOI 10.1016/0014-4835(88)90001-2; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; RIGELL CW, 1985, BIOCHEMISTRY-US, V24, P5638, DOI 10.1021/bi00341a053; RUSSNAK RH, 1983, NUCLEIC ACIDS RES, V11, P3187, DOI 10.1093/nar/11.10.3187; SEN AC, 1990, EXP EYE RES, V51, P701, DOI 10.1016/0014-4835(90)90055-Y; SEN AC, 1990, J BIOL CHEM, V265, P14277; SIEZEN RJ, 1982, EXP EYE RES, V34, P969, DOI 10.1016/0014-4835(82)90077-X; SIEZEN RJ, 1978, BIOCHIM BIOPHYS ACTA, V537, P456, DOI 10.1016/0005-2795(78)90530-5; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P56, DOI 10.1016/0167-4838(83)90027-4; SPECTOR A, 1967, J BIOL CHEM, V242, P3594; STEADMAN BL, 1989, BIOCHEMISTRY-US, V28, P9653, DOI 10.1021/bi00451a017; STURTEVANT JM, 1974, ANNU REV BIOPHYS BIO, V3, P35, DOI 10.1146/annurev.bb.03.060174.000343; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; THOMSON JA, 1989, BIOCHIM BIOPHYS ACTA, V994, P246, DOI 10.1016/0167-4838(89)90300-2; THOMSON JA, 1984, J BIOL CHEM, V259, P4339; THOMSON JA, 1983, EXP EYE RES, V37, P367, DOI 10.1016/0014-4835(83)90173-2; VANDENOETELAAR PJM, 1985, J BIOL CHEM, V260, P4030; WALSH M T, 1990, Investigative Ophthalmology and Visual Science, V31, P51; WALSH MT, 1990, J LIPID RES, V31, P1051; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9	51	127	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20079	20084						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939070				2022-12-25	WOS:A1991GM03900034
J	HAMPTON, RY; RAETZ, CRH				HAMPTON, RY; RAETZ, CRH			MACROPHAGE CATABOLISM OF LIPID-A IS REGULATED BY ENDOTOXIN STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PERITONEAL-MACROPHAGES; ESCHERICHIA-COLI LIPOPOLYSACCHARIDE; NECROSIS FACTOR-ALPHA; BACTERIAL LIPOPOLYSACCHARIDES; INTRALYSOSOMAL ACCUMULATION; SALMONELLA-TYPHIMURIUM; CHOLESTEROL DEPOSITION; ACYLOXYACYL HYDROLASE; BASIC SUBSTANCES; BINDING-SITES	Lipopolysaccharide (LPS) is a Gram-negative bacterial glycolipid that is believed to cause, by virtue of its stimulatory actions on macrophages and other eukaryotic cells, the life-threatening symptoms associated with Gram-negative infections. Macrophages both respond to and catabolically deactivate LPS. The lipid A moiety of LPS is responsible for the stimulatory actions of LPS on macrophages. We have previously developed methods employing a radiolabeled bioactive lipid A precursor, 4'-P-32-lipid IV(A), to study the interaction of this class of lipids with animal cells (Hampton, R. Y., Golenbock, D. T., and Raetz, C. R. H. (1988). J. Biol. Chem. 263, 14802-14807). In the current work, we have examined the uptake and catabolism of 4'-P-32-lipid IV(A) by the RAW 264.7 cell line in serum-containing medium at physiological temperatures and have studied the effect of LPS stimulation on the ability of these cells to catabolize lipid IV(A). RAW 264.7 macrophage-like cells avidly take up 4'-P-32-lipid IV(A) under cell culture conditions at nanomolar concentrations. Uptake of lipid IV(A) was accompanied by lysosomal dephosphorylation of a fraction of the lipid to yield 4'-monophosphoryl lipid IV(A). Chemically generated 4'-monophosphoryl lipid IV(A) was found to be substantially less bioactive than lipid IV(A) in the RAW cell, indicating that this catabolic dephosphorylation results in detoxification. In uptake experiments of 3-4 h duration, all metabolism of lipid IV(A) is blocked by ligands of the macrophage scavenger receptor. In longer experiments (24 h), both scavenger receptor-dependent and -independent uptake are responsible for the lysosomal catabolism of lipid IV(A). Preincubation of RAW 264.7 cells with LPS caused dose-dependent inhibition of lipid IV(A) dephosphorylation. Sufficient LPS stimulation resulted in essentially complete inhibition of lipid IV(A) catabolism in both short- and long-term uptake experiments. This effect occurred at physiologically relevant concentrations of LPS (IC50 < 1 ng/ml), and our data indicate that LPS-induced blockade of lipid IV(A) catabolism was due to the resultant physiological stimulation of the cells, and not inhibition of dephosphorylation by competition for uptake or enzymatic sites or by simple sequestration of labeled lipid IV(A) by LPS aggregates. We suggest that in the macrophage, LPS can modulate its own catabolism by virtue of its pharmacological properties. This effect of LPS could play a role in LPS pathophysiology as well as in macrophage biology.	MERCK SHARP & DOHME LTD,DEPT BIOCHEM,POB 2000 RY80K,RAHWAY,NJ 07065; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	Merck & Company; University of Wisconsin System; University of Wisconsin Madison								BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; COHN ZA, 1983, HARVEY LECT, V77, P63; DEWHALLEY CV, 1991, EXP CELL RES, V192, P460, DOI 10.1016/0014-4827(91)90065-3; DUNCAN RL, 1984, J IMMUNOL, V132, P1416; ERWIN AL, 1990, J BIOL CHEM, V265, P16444; FILKINS JP, 1971, P SOC EXP BIOL MED, V137, P1396, DOI 10.3181/00379727-137-35797; FLESCH IEA, 1988, INFECT IMMUN, V56, P1464, DOI 10.1128/IAI.56.6.1464-1469.1988; FREUDENBERG MA, 1984, REV INFECT DIS, V6, P483; GALANOS C, 1984, EUR J BIOCHEM, V140, P221, DOI 10.1111/j.1432-1033.1984.tb08090.x; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLENBOCK DT, 1990, INFECT IMMUN, V58, P4069, DOI 10.1128/IAI.58.12.4069-4075.1990; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; GOREN MB, 1977, ANNU REV MICROBIOL, V31, P507, DOI 10.1146/annurev.mi.31.100177.002451; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HAMPTON RY, 1991, THESIS U WISCONSIN; KIELIAN MC, 1982, J CELL BIOL, V93, P875, DOI 10.1083/jcb.93.3.875; KIELIAN MC, 1982, J CELL BIOL, V93, P866, DOI 10.1083/jcb.93.3.866; KIRKLAND TN, 1991, INFECT IMMUN, V59, P131, DOI 10.1128/IAI.59.1.131-136.1991; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOTANI S, 1984, INFECT IMMUN, V45, P293, DOI 10.1128/IAI.45.1.293-296.1984; KOVACH NL, 1990, J EXP MED, V172, P77, DOI 10.1084/jem.172.1.77; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; MUNFORD RS, 1985, INFECT IMMUN, V48, P464, DOI 10.1128/IAI.48.2.464-473.1985; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; MUNFORD RS, 1989, J BIOL CHEM, V264, P15613; OBRIEN AD, 1980, CELL IMMUNOL, V67, P325; OHKUMA S, 1986, J CELL BIOL, V102, P959, DOI 10.1083/jcb.102.3.959; OHKUMA S, 1981, J CELL BIOL, V90, P656, DOI 10.1083/jcb.90.3.656; PETERSON AA, 1987, INFECT IMMUN, V55, P974, DOI 10.1128/IAI.55.4.974-978.1987; POHLMAN TH, 1987, J EXP MED, V165, P1393, DOI 10.1084/jem.165.5.1393; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; QURESHI N, 1988, J BIOL CHEM, V263, P5502; QURESHI N, 1991, INFECT IMMUN, V59, P441, DOI 10.1128/IAI.59.1.441-444.1991; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1988, COLD SPRING HARB SYM, V53, P973, DOI 10.1101/SQB.1988.053.01.112; RICHES DWH, 1986, J CELL BIOL, V102, P1606, DOI 10.1083/jcb.102.5.1606; RICK PD, 1977, J BIOL CHEM, V252, P4904; RIEDO FX, 1990, J IMMUNOL, V144, P3506; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; ROUTENBURG SH, 1960, J EXP MED, V112, P801; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SIBLEY CH, 1988, J BIOL CHEM, V263, P5098; SKARNES RC, 1985, HDB ENDOTOXIN, V3, P56; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; TAKADA H, 1989, CRIT REV MICROBIOL, V16, P477, DOI 10.3109/10408418909104475; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; TAKAYAMA K, 1984, INFECT IMMUN, V45, P350, DOI 10.1128/IAI.45.2.350-355.1984; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANLENTEN BJ, 1985, J IMMUNOL, V134, P3718; VIA DP, 1985, BIOCHIM BIOPHYS ACTA, V833, P417, DOI 10.1016/0005-2760(85)90099-2; VIRCA GD, 1989, J BIOL CHEM, V264, P21951; ZOELLER RA, 1987, J BIOL CHEM, V262, P17212	59	33	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19499	19509						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918062				2022-12-25	WOS:A1991GK66700058
J	KARDAMI, E; STOSKI, RM; DOBLE, BW; YAMAMOTO, T; HERTZBERG, EL; NAGY, JI				KARDAMI, E; STOSKI, RM; DOBLE, BW; YAMAMOTO, T; HERTZBERG, EL; NAGY, JI			BIOCHEMICAL AND ULTRASTRUCTURAL EVIDENCE FOR THE ASSOCIATION OF BASIC FIBROBLAST GROWTH-FACTOR WITH CARDIAC GAP-JUNCTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; FACTOR FGF; PROTEIN; HEART; IMMUNOLOCALIZATION; COMMUNICATION; CONNEXIN-43; MYOCYTES; CULTURE; BRAIN	Basic fibroblast growth factor (bFGF) is a ubiquitous and multifunctional polypeptide that is believed to have a role in tissue repair and to act as a morphogen in embryonic development. Here, we have used immunohistochemical and biochemical methods with antibodies directed against the amino-terminal domain of bFGF, designated IS2, which recognize native and denatured bFGF, to demonstrate that in addition to its known intracellular and extracellular localization in heart, bFGF is also associated with cardiomyocyte gap junctions. In tissue sections, IS2 labeled regions of intercalated discs, producing an immunofluorescence pattern virtually indistinguishable from that obtained with antibodies against the heart gap junction protein connexin-43. By electron microscopy, gap junctions but not other regions of plasma membrane were heavily immunolabeled with this antibody. By solid phase immunoassay, bFGF was found to be more concentrated in a fraction enriched in cardiac gap junctions than in whole sarcolemmal preparations. Finally, an 18-kDa protein was recognized by several different antibodies specific for bFGF on Western blots of heart subcellular fractions enriched in gap junctions. We suggest that bFGF-like peptides are either an integral part of, or exist in close association with, cardiac gap junctions and thus may play a role in modulating gap junctional intercellular communication.	UNIV MANITOBA,DEPT PHYSIOL,WINNIPEG R3T 2N2,MANITOBA,CANADA; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ANAT,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT STRUCT BIOL,BRONX,NY 10461	University of Manitoba; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	KARDAMI, E (corresponding author), ST BONIFACE GEN HOSP,RES CTR,WINNIPEG R2H 2A6,MANITOBA,CANADA.		Doble, Brad/L-7551-2016; Doble, Bradley/V-7848-2019	Doble, Brad/0000-0002-0260-2983; Doble, Bradley/0000-0002-0260-2983; Kardami, Elissavet/0000-0002-3198-8432; Nagy, James Imre/0000-0003-2753-091X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030667] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30667] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARELLANO RO, 1988, J MEMBRANE BIOL, V101, P119, DOI 10.1007/BF01872827; Bennett MVL, 1978, NEUROSCI RES PROG B, V16, P373; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; CASSCELLS W, 1990, J CLIN INVEST, V85, P433, DOI 10.1172/JCI114456; CAVENEY S, 1985, ANNU REV PHYSIOL, V47, P319; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; CUEVAS P, 1988, BIOCHEM BIOPH RES CO, V156, P611, DOI 10.1016/S0006-291X(88)80887-8; DOBLE BW, 1990, BIOCHEM BIOPH RES CO, V173, P1116, DOI 10.1016/S0006-291X(05)80901-5; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FEIGE JJ, 1989, P NATL ACAD SCI USA, V86, P3174, DOI 10.1073/pnas.86.9.3174; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FORBES MS, 1985, TISSUE CELL, V17, P605, DOI 10.1016/0040-8166(85)90001-1; GROTHE C, 1990, FEBS LETT, V260, P35, DOI 10.1016/0014-5793(90)80059-R; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; HERZBERG EL, 1982, COLD SPRING HARB SYM, V46, P639; JOSEPHSILVERSTEIN J, 1989, J CELL BIOL, V108, P2459, DOI 10.1083/jcb.108.6.2459; KARDAMI E, 1989, J CELL BIOL, V109, P1865, DOI 10.1083/jcb.109.4.1865; KARDAMI E, 1989, UCLA S MOL CELL BIOL, V93, P315; KARDAMI E, 1991, IN PRESS ANN NY ACAD; Kardami E, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011012; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; MADHUKAR BV, 1989, CARCINOGENESIS, V10, P13, DOI 10.1093/carcin/10.1.13; MALDONADO PE, 1988, J MEMBRANE BIOL, V106, P203, DOI 10.1007/BF01872158; MANJUNATH CK, 1987, BIOCHEM BIOPH RES CO, V142, P228, DOI 10.1016/0006-291X(87)90475-X; MANJUNATH CK, 1985, J MEMBRANE BIOL, V85, P159, DOI 10.1007/BF01871268; MANJUNATH CK, 1988, GAP JUNCTIONS, P69; Morissey J. H., 1981, ANAL BIOCHEM, V117, P307; NICHOLSON B, 1987, NATURE, V329, P732, DOI 10.1038/329732a0; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PERACCHIA C, 1983, PFLUG ARCH EUR J PHY, V399, P152, DOI 10.1007/BF00663912; Peracchia C, 1989, Lens Eye Toxic Res, V6, P613; PIERCE GN, 1989, J APPL PHYSIOL, V66, P1715, DOI 10.1152/jappl.1989.66.4.1715; REVEL JP, 1967, J CELL BIOL, V33, pC7, DOI 10.1083/jcb.33.3.C7; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RISS TL, 1989, J CELL PHYSIOL, V138, P405, DOI 10.1002/jcp.1041380224; SATO Y, 1989, MOL ENDOCRINOL, V3, P744, DOI 10.1210/mend-3-4-744; SCHNEIDER MD, 1990, CIRCULATION, V81, P1443, DOI 10.1161/01.CIR.81.5.1443; SCHUBERT D, 1987, J CELL BIOL, V104, P635, DOI 10.1083/jcb.104.3.635; SENO M, 1988, BIOCHEM BIOPH RES CO, V151, P701, DOI 10.1016/S0006-291X(88)80337-1; SHERIDAN JD, 1985, ANNU REV PHYSIOL, V47, P337; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; TSUBOI R, 1990, J EXP MED, V172, P245, DOI 10.1084/jem.172.1.245; YAMAMOTO T, 1991, BRAIN RES, V554, P336, DOI 10.1016/0006-8993(91)90213-F; YAMAMOTO T, 1990, J COMP NEUROL, V302, P853, DOI 10.1002/cne.903020414; YAMAMOTO T, 1990, BRAIN RES, V508, P313, DOI 10.1016/0006-8993(90)90415-8; YANCEY SB, 1989, J CELL BIOL, V108, P2241, DOI 10.1083/jcb.108.6.2241	48	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19551	19557						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918064				2022-12-25	WOS:A1991GK66700064
J	POT, DA; WOODFORD, TA; REMBOUTSIKA, E; HAUN, RS; DIXON, JE				POT, DA; WOODFORD, TA; REMBOUTSIKA, E; HAUN, RS; DIXON, JE			CLONING, BACTERIAL EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF THE CYTOPLASMIC DOMAIN OF RAT LAR, A RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; SRC HOMOLOGY REGION-2; SIGNAL TRANSDUCTION; FAMILY; BINDING; MEMBER; CDNA; POLYMERASE; KINASE; CELLS	This report describes the cloning and characterization of rat leukocyte common antigen-related protein (rLAR), a receptor-like protein tyrosine phosphatase (PTPase). The recombinant cytoplasmic PTPase domain was expressed at high levels in bacteria and purified to homogeneity. Kinetic properties of the PTPase were examined along with potential modulators of PTPase activity. Several sulfhydryl-directed reagents were effective inhibitors, and a surprising distinction between iodoacetate and iodoacetamide was observed. The latter compound was an extremely poor inhibitor when compared to iodoacetate, suggesting that iodoacetate may interact selectively with a positive charge at or near the active site of the enzyme. Site-directed mutants were made at 4 highly conserved cysteine residues found at positions 1434, 1522, 1723, and 1813 within the protein. The Cys-1522/Ser mutation resulted in a 99% loss of enzymatic activity of the pure protein. This observation is consistent with greater than 99% of the PTPase activity being found in the first domain of the PTPase and demonstrates the critical importance of this cysteine residue in catalysis. The recombinant C1522S mutant phosphatase could also be phosphorylated in vitro by protein kinase C and p43v-abl tyrosine kinase. When pure recombinant PTPase was mixed with P-32-labeled tyrosine substrate and then rapidly denatured, a P-32-labeled enzyme intermediate could be trapped and visualized by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The catalytically inactive C1522S mutant did not form the phosphoenzyme intermediate.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA; PURDUE UNIV, WALTHER CANC INST, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Walther Cancer Institute				Pot, David/0000-0002-1480-9826	PHS HHS [18024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEXANDER D R, 1990, New Biologist, V2, P1049; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANLANT G, 1985, EUR J BIOCHEM, V150, P61, DOI 10.1111/j.1432-1033.1985.tb08988.x; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COHENP, 1989, ANNU REV BIOCHEM, V58, P453; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GHOSH SS, 1986, SCIENCE, V231, P145, DOI 10.1126/science.3510454; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LAB MANUA, P632; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; JONES SW, 1989, J BIOL CHEM, V264, P7747; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KENNEDY RM, 1990, METHOD ENZYMOL, V182, P339; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NISHI M, 1990, FEBS LETT, V271, P178, DOI 10.1016/0014-5793(90)80400-D; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHWARTZ JH, 1961, P NATL ACAD SCI USA, V47, P1996, DOI 10.1073/pnas.47.12.1996; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SWARUP G, 1989, J BIOL CHEM, V264, P7801; TABOR S, 1990, CURRENT PROTOCOLS MO, V2; THOMAS ML, 1985, CELL, V41, P83, DOI 10.1016/0092-8674(85)90063-7; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27	45	150	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19688	19696						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918076				2022-12-25	WOS:A1991GK66700081
J	COGHLAN, VM; VICKERY, LE				COGHLAN, VM; VICKERY, LE			SITE-SPECIFIC MUTATIONS IN HUMAN FERREDOXIN THAT AFFECT BINDING TO FERREDOXIN REDUCTASE AND CYTOCHROME-P450SCC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; STEROIDOGENIC ELECTRON-TRANSPORT; HUMAN PLACENTAL FERREDOXIN; SIDE-CHAIN CLEAVAGE; ADRENODOXIN REDUCTASE; TERNARY COMPLEXES; ACTH FUNCTION; CHEMICAL MODIFICATION; BOVINE ADRENODOXIN; MOLECULAR-CLONING	Ferredoxins found in animal mitochondria function in electron transfer from NADPH-dependent ferredoxin reductase (Fd-reductase) to cytochrome P450 enzymes. To identify residues involved in binding of human ferredoxin to its electron transfer partners, neutral amino acids were introduced in a highly conserved acidic region (positions 68-86) by site-directed mutagenesis of the cDNA. Mutant ferredoxins were produced in Escherichia coli, and separate assays were used to determine the effect of substitutions on the capacity of each mutant to bind to Fd-reductase and cytochrome P450scc and to participate in the cholesterol side chain cleavage reaction. Replacements at several positions (mutants D68A, E74Q, and D86A) did not significantly affect activity, suggesting that acidic residues at these positions are not required for binding or electron transfer interactions. In contrast, substitutions at positions 76 and 79 (D76N and D79A) caused dramatic decreases in activity and in the affinity of ferredoxin for both Fd-reductase and P450scc; this suggests that the binding sites on ferredoxin for its redox partners overlap. Other substitutions (mutants D72A, D72N, E73A, E73Q, and D79N), however, caused differential effects on binding to Fd-reductase and P450scc, suggesting that the interaction sites are not identical. We propose a model in which Fd-reductase and P450scc share a requirement for ferredoxin residues Asp-76 and Asp-79 but have other determinants that differ and play an important role in binding. This model is consistent with the hypothesis that ferredoxin functions as a mobile shuttle in steroidogenic electron transfer, and it is considered unlikely that a functional ternary complex is formed.	UNIV CALIF IRVINE,DEPT BIOL CHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717	University of California System; University of California Irvine; University of California System; University of California Irvine					NIGMS NIH HHS [GM43548] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043548] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM GE, 1973, J CLIN ENDOCR METAB, V37, P40, DOI 10.1210/jcem-37-1-40; ADAMOVICH TB, 1989, BIOCHIM BIOPHYS ACTA, V996, P247, DOI 10.1016/0167-4838(89)90254-9; AKHREM AA, 1978, BIOORG KHIM+, V4, P462; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; COGHLAN VM, 1989, P NATL ACAD SCI USA, V86, P835, DOI 10.1073/pnas.86.3.835; COGHLAN VM, 1988, ARCH BIOCHEM BIOPHYS, V264, P376, DOI 10.1016/0003-9861(88)90302-5; CUPP JR, 1988, J BIOL CHEM, V263, P17418; CUPP JR, 1989, J BIOL CHEM, V264, P1602; DUVAL JF, 1980, STEROIDS, V36, P473, DOI 10.1016/0039-128X(80)90034-3; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; FERSHT AR, 1972, J MOL BIOL, V64, P497, DOI 10.1016/0022-2836(72)90513-X; GEREN LM, 1984, J BIOL CHEM, V259, P2155; HAMAMOTO I, 1988, BIOCHIM BIOPHYS ACTA, V953, P207, DOI 10.1016/0167-4838(88)90026-X; HANUKOGLU I, 1981, J BIOL CHEM, V256, P4321, DOI 10.1016/S0021-9258(19)69436-6; HARA T, 1989, J BIOCHEM-TOKYO, V105, P601, DOI 10.1093/oxfordjournals.jbchem.a122711; HIWATASHI A, 1976, BIOCHEMISTRY-US, V15, P3082, DOI 10.1021/bi00659a023; HUANG JJ, 1973, BIOCHEMISTRY-US, V12, P406, DOI 10.1021/bi00727a007; KAGIMOTO K, 1988, BIOCHEM BIOPH RES CO, V155, P379, DOI 10.1016/S0006-291X(88)81096-9; KIDO T, 1979, J BIOL CHEM, V254, P1806; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; LIGHT DR, 1981, J BIOL CHEM, V256, P343; MITTAL S, 1988, ARCH BIOCHEM BIOPHYS, V264, P383, DOI 10.1016/0003-9861(88)90303-7; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; OMURA T, 1964, J BIOL CHEM, V239, P2379; Sambrook J, 1989, MOL CLONING LABORATO; SEYBERT DW, 1979, J BIOL CHEM, V254, P2088; SHEETS JJ, 1983, J BIOL CHEM, V258, P1720; TANAKA M, 1973, J BIOL CHEM, V248, P1141; TSUBAKI M, 1989, BIOCHEMISTRY-US, V28, P6899, DOI 10.1021/bi00443a019; TULS J, 1989, J BIOL CHEM, V264, P16421; TULS J, 1987, J BIOL CHEM, V262, P10020; USANOV SA, 1985, BIOCHIM BIOPHYS ACTA, V832, P288, DOI 10.1016/0167-4838(85)90262-6; VARADARAJAN R, 1985, P NATL ACAD SCI USA, V82, P5681, DOI 10.1073/pnas.82.17.5681; ZASSENHAUS HP, 1982, ANAL BIOCHEM, V125, P125, DOI 10.1016/0003-2697(82)90392-X	36	157	159	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18606	18612						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917982				2022-12-25	WOS:A1991GJ47200034
J	DUIGOU, GJ; SU, ZZ; BABISS, LE; DRISCOLL, B; FUNG, YKT; FISHER, PB				DUIGOU, GJ; SU, ZZ; BABISS, LE; DRISCOLL, B; FUNG, YKT; FISHER, PB			ANALYSIS OF VIRAL AND CELLULAR GENE-EXPRESSION DURING PROGRESSION AND SUPPRESSION OF THE TRANSFORMED PHENOTYPE IN TYPE 5 ADENOVIRUS-TRANSFORMED RAT EMBRYO CELLS	ONCOGENE			English	Article							PROTEIN-KINASE-C; ANCHORAGE-INDEPENDENT GROWTH; RETINOBLASTOMA GENE; TUMOR PROMOTERS; MOLECULAR-CLONING; NEOPLASTIC TRANSFORMATION; CHEMICAL CARCINOGENS; FIBROBLAST CELLS; THYROID-HORMONE; VIRUS GENOME	Transformation of secondary Sprague-Dawley rat embryo (RE) cells with type 5 adenovirus (Ad5) results in morphologically transformed cells which can undergo a series of sequential changes resulting in enhanced expression of the transformed phenotype, a process termed progression. Selection for a progressed phenotype often occurs after growth in agar or tumor formation in nude mice, and this process is reversible following treatment of cells with 5-azacytidine. In the present study we have analyzed a series of clonal populations of Ad5-transformed RE cells representing different stages in a defined progression lineage. Progression was not associated with alterations in the steady-state levels of mRNA produced by the viral transforming genes, E1A and E1B, or the cellular gene, c-myc. In addition, the tumor-promoting agent 12-O-tetradecanoyl-phorbol-13-acetate (TPA), which induces expression of a progressed phenotype in Ad5-transformed RE cells, did not significantly alter the RNA transcription rates of the Ad5 E1A or E1B genes, the TPA-inducible gene TPA-S1 or the TPA-responsive genes Pro1 or protein kinase C. TPA did, however, increase by 1 h the steady-state level of c-fos mRNA, but this effect was similar in both progressed and unprogressed cells. Progression also did not involve a change in the RNA transcription rate of a number of cellular and viral genes, including actin, c-Ha-ras, c-myc, v-fos, erbB, TGF-alpha, TGF-beta, Pro-2, transin, TPA-R1, v-myb and c-mos, or other adenovirus genes in addition to E1A and E1B, including E2A and E4. Immunoblotting analysis using E1B polyclonal antiserum further indicated that progression was not associated with changes in the levels of an M(r) 21 000 polypeptide encoded by E1B. Similarly, immunoprecipitation analysis with an Ad2 E1A monoclonal antibody indicated similar levels of the M(r) 55 000 and 48 000 E1A polypeptides, as well as co-precipitated proteins of M(r) 300 000, 107 000 and 105 000 [which is the retinoblastoma (Rb) protein], in E11 and E11-NMT cells. Immunoprecipitation of cell lysates with a monoclonal antibody specific for the M(r) 105 000 Rb protein further demonstrated that progression also was not associated with a change in the level or state of phosphorylation of the Rb protein. However, transfection of a human Rb gene (also containing a neomycin resistance gene) into Ad5-transformed RE cells was more inhibitory, with respect to formation of G418-resistant colonies, in unprogressed than in progressed Ad5-transformed RE cells. These findings suggest that progression of the transformed phenotype in Ad5-transformed RE cells does not involve the altered expression of virus-encoded transforming genes. Moreover, progression of these cells is not associated with an alteration of genes previously shown to be associated with enhanced expression of the transformed cell phenotype in other progression model cell culture systems. It appears that regulation of the progression phenotype in Ad5-transformed RE cells is controlled by a cellular-encoded gene(s) which remains to be identified. This gene(s) modulates the stage of progression in these cells without directly altering expression of viral genes or the Rb tumor-suppressor gene, which is associated with expression of the transformed phenotype.	COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES,DEPT PATHOL,CTR CANC,650 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES, DEPT UROL, CTR CANC, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES, DEPT NEUROL SURG, CTR CANC, NEW YORK, NY 10032 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; CHILDRENS HOSP, DEPT OPHTHALMOL, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, LOS ANGELES, CA 90054 USA	Columbia University; Columbia University; Columbia University; Rockefeller University; Children's Hospital Los Angeles; University of Southern California					NCI NIH HHS [CA35675, CA43208, CA44754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044754, R29CA044754, R01CA035675, R01CA043208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BABISS LE, 1983, J VIROL, V46, P454, DOI 10.1128/JVI.46.2.454-465.1983; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1983, P NATL ACAD SCI-BIOL, V80, P1352, DOI 10.1073/pnas.80.5.1352; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P2167, DOI 10.1073/pnas.83.7.2167; BABISS LE, 1985, CANCER RES, V45, P6017; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3297, DOI 10.1073/pnas.75.7.3297; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BOYLAN JF, 1990, ANTICANCER RES, V10, P717; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; COLBURN NH, 1987, J CELL BIOCHEM, V34, P129, DOI 10.1002/jcb.240340207; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DORSCHHASLER K, 1980, J VIROL, V34, P305; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; DUIGOU GJ, 1989, ANN NY ACAD SCI, V567, P302, DOI 10.1111/j.1749-6632.1989.tb16487.x; DYSON N, 1989, CELL, V30, P491; FISHER PB, 1983, P NATL ACAD SCI-BIOL, V80, P196, DOI 10.1073/pnas.80.1.196; FISHER PB, 1979, CELL, V18, P695, DOI 10.1016/0092-8674(79)90124-7; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FISHER PB, 1979, NATURE, V281, P591, DOI 10.1038/281591a0; FISHER PB, 1979, CANCER RES, V39, P3051; Fisher PB, 1984, TUMOR PROMOTION COCA, P57; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; FUNG YKT, 1991, IN PRESS SCIENCE; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HEPPNER GH, 1984, CANCER RES, V44, P2259; HERBST RS, 1988, J VIROL, V62, P4634, DOI 10.1128/JVI.62.12.4634-4643.1988; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; JOHNSON MD, 1987, MOL CELL BIOL, V7, P2821, DOI 10.1128/MCB.7.8.2821; JOHNSON MD, 1987, ENVIRON HEALTH PERSP, V76, P89, DOI 10.2307/3430469; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LERMAN MI, 1986, INT J CANCER, V37, P293, DOI 10.1002/ijc.2910370219; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; NICOLSON GL, 1987, CANCER RES, V47, P1473; NOWELL PC, 1986, CANCER RES, V46, P2203; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SU ZZ, 1990, MOL CARCINOGEN, V3, P309, DOI 10.1002/mc.2940030512; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TIMMERS HTM, 1988, ONCOGENE RES, V3, P67; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VANDEREB AJ, 1989, CURR TOP MICROBIOL, V144, P197; VARLEY JM, 1989, ONCOGENE, V4, P725; VENNSTROM B, 1980, J VIROL, V36, P575; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	69	12	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1813	1824						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923506				2022-12-25	WOS:A1991GX11800014
J	GROSSI, M; CALCONI, A; TATO, F				GROSSI, M; CALCONI, A; TATO, F			V-JUN ONCOGENE PREVENTS TERMINAL DIFFERENTIATION AND SUPPRESSES MUSCLE-SPECIFIC GENE-EXPRESSION IN ASV-17-INFECTED MUSCLE-CELLS	ONCOGENE			English	Article							MYOGENIC CELLS; DNA-BINDING; ENHANCER BINDING; PROTO-ONCOGENE; C-JUN; MYOBLASTS; MYC; PROTEINS; AP-1; FOS	Infection of replicating quail myoblasts with avian sarcoma virus 17 (ASV-17) results in the inhibition of terminal differentiation into multinucleated myotubes and in the acquisition of anchorage-independent proliferation. Expression of v-jun, the ASV-17 oncogene, concomitantly leads to the accumulation of the gag-jun polyprotein P65 in the nucleus and to the lack of expression of typical differentiation-specific genes such as myosin heavy chain (MHC) and alpha-actinin. Surprisingly, expression of desmin, the muscle-specific subunit of intermediate filaments, is conserved in ASV-17-transformed myoblasts. Analysis of clonal strains of transformed myoblasts suggests that (i) suppression of morphological and biochemical differentiation depends on the absence of muscle-specific gene transcripts; (ii) inhibition of muscle differentiation by v-jun does not depend on the transcriptional silencing of MyoD, a muscle-specific regulatory gene; (iii) expression of desmin is compatible with proliferation of ASV-17-transformed cells and is independent of v-jun and MyoD levels of expression. The present data suggest that nuclear localization of v-jun prevents terminal differentiation in myoblasts and selectively down-regulates muscle-specific genes in terminally differentiated myotubes. In this respect, the behaviour of v-jun is quite different from that of v-myc, thus suggesting that these two oncogenes, although both encoding nuclear proteins, may have different mechanisms of action.	UNIV ROME LA SAPIENZA,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,SEZ SCI MICROBIOL,I-00185 ROME,ITALY	Sapienza University Rome			Grossi, Milena/D-2955-2009					ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; CAPETANAKI YG, 1984, COLD SPRING HARB SYM, P415; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; GROSSI M, 1989, PATHOLOGY GENE EXPRE, P313; HASTINGS KEM, 1982, MUSCLE DEV MOL CELLU, P215; HILL CS, 1986, J CELL BIOL, V103, P2185, DOI 10.1083/jcb.103.6.2185; HOLTZER H, 1975, Q REV BIOPHYS, V8, P523, DOI 10.1017/S0033583500001980; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; SU HY, 1991, ONCOGENE, V6, P1759; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TATO F, 1983, DIFFERENTIATION, V24, P131, DOI 10.1111/j.1432-0436.1983.tb01312.x; VOGEL Z, 1972, P NATL ACAD SCI USA, V69, P3180, DOI 10.1073/pnas.69.11.3180; VOGT PK, 1988, ONCOGENE, V3, P3; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	30	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1767	1773						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923502				2022-12-25	WOS:A1991GX11800007
J	BUTLER, AJ; EAGLETON, MJ; WANG, D; HOWELL, RL; STRAUCH, AR; KHASGIWALA, V; SMITH, HC				BUTLER, AJ; EAGLETON, MJ; WANG, D; HOWELL, RL; STRAUCH, AR; KHASGIWALA, V; SMITH, HC			INDUCTION OF THE PROLIFERATIVE PHENOTYPE IN DIFFERENTIATED MYOGENIC CELLS BY HYPOXIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GLUCOSE-REGULATED PROTEINS; SKELETAL MYOBLASTS; RADIATION RESPONSE; EXTREME HYPOXIA; MAMMALIAN-CELLS; GROWTH-FACTOR; HEAT-SHOCK; OXYGEN; EXPRESSION	The effect of cellular differentiation on the response of cells to hypoxic stress has been evaluated using the myogenic cell line BC3H1. Aerobic myocytes were predominantly in G0/G1 of the cell cycle and could be induced into S and G2/M of the cell cycle only by replating in high serum-containing medium at subconfluent cell density. In contrast, hypoxic myocytes demonstrated marked progression into S and G2/M upon reoxygenation without replating in the presence of serum. This modulation of myocytes by hypoxia was suggested further by the induction of 100-kDa and 9-kDa proteins (PSP 100 and PSP 9) which were otherwise only detectable in myoblasts. Two-dimensional gel analysis of newly synthesized proteins demonstrated that the five major glucose/oxygen-regulated proteins (GRP/ORP 260, 150, 100, 80, and 33) were induced in hypoxic myogenic cells independent of their state of differentiation. In addition to the GRP/ORPs, synthesis of 20 and 23 other major proteins was influenced in myocytes and myoblasts, respectively. The bulk of these alterations in myoblasts (70%) were inhibitions. In contrast, 75% of the alterations in myocyte protein synthesis were either enhancements or inductions. The data show that hypoxia can modulate the myocyte phenotype and invoke proliferative characteristics. Moreover, the data suggest that ischemia will have a different effect on and prognosis for tissues with a high mitotic index compared with differentiated tissues.	UNIV ROCHESTER,DEPT PATHOL,CTR CANC,DIV TUMOR BIOL,601 ELMWOOD AVE,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; OHIO STATE UNIV,DEPT CELL BIOL NEUROBIOL & ANAT,COLUMBUS,OH 43210	University of Rochester; University of Rochester; University of Rochester; University of Oxford; University System of Ohio; Ohio State University				Smith, Harold/0000-0001-6257-6791	NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NCI NIH HHS [5P30 CA 11198-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOXEN I, 1989, MED HYPOTHESES, V30, P157, DOI 10.1016/0306-9877(89)90056-X; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; CLOWES AW, 1988, J CELL BIOL, V107, P1939, DOI 10.1083/jcb.107.5.1939; COCHRAN DL, 1985, J CELL PHYSIOL, V124, P29, DOI 10.1002/jcp.1041240106; COLEMAN CN, 1988, J NATL CANCER I, V80, P310, DOI 10.1093/jnci/80.5.310; DEGROOT H, 1987, BIOCHEM SOC T, V15, P363, DOI 10.1042/bst0150363; FRITZE LMS, 1985, J CELL BIOL, V100, P1041, DOI 10.1083/jcb.100.4.1041; GUTTMAN SD, 1980, CELL, V22, P299, DOI 10.1016/0092-8674(80)90177-4; HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264; HEACOCK CS, 1986, INT J RADIAT ONCOL, V12, P1287, DOI 10.1016/0360-3016(86)90155-0; KOCH CJ, 1982, ADV EXP MED BIOL, V157, P123; KOCH CJ, 1981, RADIAT RES, V87, P265, DOI 10.2307/3575583; KOCH CJ, 1975, RADIAT RES, V64, P256, DOI 10.2307/3574263; KOCH CJ, 1971, RADIAT RES, V48, P74, DOI 10.2307/3573396; KONDZIOLKA D, 1988, J NEUROSURG, V69, P494, DOI 10.3171/jns.1988.69.4.0494; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KWOK TT, 1989, RADIAT RES, V119, P261, DOI 10.2307/3577618; KWOK TT, 1989, INT J RADIAT ONCOL, V16, P1301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1983, J BIOL CHEM, V258, P597; MAJACK RA, 1984, J CELL BIOL, V99, P1688, DOI 10.1083/jcb.99.5.1688; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MICHAEL BD, 1973, RADIAT RES, V54, P239, DOI 10.2307/3573702; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PELMAN HRB, 1986, CELL, V46, P959; PREEDY VR, 1985, BIOCHEM J, V228, P179, DOI 10.1042/bj2280179; RICE GC, 1985, INT J RADIAT ONCOL, V11, P1817, DOI 10.1016/0360-3016(85)90038-0; ROLL DE, 1991, MOL CELL BIOCHEM, V103, P141; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SCHWARTZ SM, 1987, HUM PATHOL, V18, P240, DOI 10.1016/S0046-8177(87)80006-0; SCIANDRA JJ, 1984, P NATL ACAD SCI-BIOL, V81, P4843, DOI 10.1073/pnas.81.15.4843; SEJERSEN T, 1986, P NATL ACAD SCI USA, V83, P6844, DOI 10.1073/pnas.83.18.6844; SHEN JW, 1989, MOL CELL BIOL, V9, P3284, DOI 10.1128/MCB.9.8.3284; STAVENOW L, 1987, ARTERY, V14, P198; STENMARK KR, 1988, CHEST, V93, P127; STRAUCH AR, 1984, J BIOL CHEM, V259, P3152; STRAUCH AR, 1989, J BIOL CHEM, V264, P8345; STRAUCH AR, 1986, J BIOL CHEM, V261, P849; SUTHERLAND RM, 1982, INT J RADIAT ONCOL, V8, P745, DOI 10.1016/0360-3016(82)90726-X; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; VAUPEL P, 1987, RADIAT RES, V2, P707; VEKI N, 1987, P NATL ACAD SCI USA, V84, P9049; WEBSTER KA, 1988, CAN J ZOOL, V66, P1046, DOI 10.1139/z88-155; WIGHT TN, 1983, J CELL BIOL, V96, P167, DOI 10.1083/jcb.96.1.167; WILSON RE, 1989, J NATL CANCER I, V81, P1235, DOI 10.1093/jnci/81.16.1235; WOOLF N, 1981, SMOKING ARTERIAL DIS, P46; YAMAMOTO H, 1983, BRIT J EXP PATHOL, V64, P156; YOUNG SD, 1988, P NATL ACAD SCI USA, V85, P9533, DOI 10.1073/pnas.85.24.9533; 1986, ENV TOBACCO SMOKE CO, P257; 1988, PHS DHHS CDC888406 U, P591	52	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18250	18258						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917953				2022-12-25	WOS:A1991GG55300081
J	KAWAICHI, M; OKA, C; REEVES, R; KINOSHITA, M; HONJO, T				KAWAICHI, M; OKA, C; REEVES, R; KINOSHITA, M; HONJO, T			RECOMBINATION OF EXOGENOUS INTERLEUKIN-2 RECEPTOR GENE FLANKED BY IMMUNOGLOBULIN RECOMBINATION SIGNAL SEQUENCES IN A PRE-B CELL-LINE AND TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIABLE REGION GENE; HEAVY-CHAIN GENES; V(D)J RECOMBINATION; SEGMENTS; REARRANGEMENT; VECTOR; DNA; IDENTIFICATION; TRANSCRIPTION; DIVERSITY	We have constructed a plasmid, pLTR100, which contains human interleukin 2 receptor light (IL-2R L) chain cDNA in the inverted orientation relative to the upstream SV40 promoter. The cDNA segment is flanked by the immunoglobulin gene recombination signal sequences so that the cDNA segment can invert and the human IL-2R L chain is subsequently expressed under the control of the SV40 promoter. A murine pre-B cell line, 38B9, transfected with pLTR100 began to express the human IL-2R L chain on the cell surface. The frequency of human IL-2R L chain positive cells increased almost linearly up to 50% for 60 days of culture after transfection. Southern blot analysis and sequencing of the DNA fragments at the recombination junction confirmed that the cDNA segment was inverted in a signal sequence-dependent manner by the variable-diversity-joining recombination process. Transgenic mice bearing the recombination substrate DNA similar to pLTR100 expressed the human IL-2 L chain in the spleen, thymus, and bone marrow, but no tin the other tissues examined at the detectable level. Both IgM- and CD3-positive cells expressed the human IL-2R L chain, indicating that this artificial DNA can serve as a substrate for recombination both in B- and T-cells and that another DNA segment may be necessary to confer the cell-type specificity on the substrate DNA.	KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN	Kyoto University			Honjo, Tasuku/N-4470-2016					AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BLACKWELL TK, 1984, CELL, V37, P105; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHUN JJM, 1991, CELL, V64, P189, DOI 10.1016/0092-8674(91)90220-S; CORY S, 1980, P NATL ACAD SCI-BIOL, V77, P4943, DOI 10.1073/pnas.77.8.4943; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; FARRAR WL, 1987, IMMUNOL REV, V100, P361, DOI 10.1111/j.1600-065X.1987.tb00539.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; Ferrier P, 1989, INT IMMUNOL, V1, P66, DOI 10.1093/intimm/1.1.66; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; HAMAGUCHI Y, 1989, NUCLEIC ACIDS RES, V17, P9015, DOI 10.1093/nar/17.22.9015; HARLOW E, 1988, ANTIBODIES LAB MANUA, P319; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HOGAN B, 1986, MANIPULATING MOUSE E; HONJO T, 1985, ANNU REV BIOCHEM, V54, P803, DOI 10.1146/annurev.bi.54.070185.004103; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KUROSAWA Y, 1981, NATURE, V290, P565, DOI 10.1038/290565a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEWIS S, 1984, NATURE, V308, P425, DOI 10.1038/308425a0; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MIYAZAKI J, 1989, GENE, V79, P269; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OHARE K, 1981, P NATL ACAD SCI-BIOL, V78, P1527, DOI 10.1073/pnas.78.3.1527; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; REIF AE, 1964, J EXP MED, V120, P413, DOI 10.1084/jem.120.3.413; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	40	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18387	18394						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917962				2022-12-25	WOS:A1991GG55300101
J	THOMPSON, SL; KRISANS, SK				THOMPSON, SL; KRISANS, SK			RAT-LIVER PEROXISOMES CATALYZE THE INITIAL STEP IN CHOLESTEROL-SYNTHESIS - THE CONDENSATION OF ACETYL-COA UNITS INTO ACETOACETYL-COA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182; SAN DIEGO STATE UNIV,INST MOLEC BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University; California State University System; San Diego State University					NIDDK NIH HHS [DK32852] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032852] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXSON SEH, 1985, J CELL BIOL, V101, P294, DOI 10.1083/jcb.101.1.294; ARAGON JJ, 1983, J BIOL CHEM, V258, P4725; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; Bergmeyer HU, 1974, METHODS ENZYME ANAL, P495; BODNAR AG, 1989, J CELL BIOL, V109, P57; CHAPMAN MJ, 1973, J CELL BIOL, V58, P284, DOI 10.1083/jcb.58.2.284; CLINKENBEARD KD, 1975, J BIOL CHEM, V250, P3108; CLINKENBEARD KD, 1973, J BIOL CHEM, V248, P2275; FUJIKI Y, 1985, BIOCHEM J, V226, P697, DOI 10.1042/bj2260697; FUKUDA K, 1978, ACTA HISTOCHEM CYTOC, V11, P432, DOI 10.1267/ahc.11.432; GORGAS K, 1989, J LIPID RES, V30, P1859; GRAY RH, 1984, HEPATOLOGY, V4, P520, DOI 10.1002/hep.1840040328; HAYASHI H, 1981, EUR J BIOCHEM, V120, P47, DOI 10.1111/j.1432-1033.1981.tb05668.x; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; HORIE S, 1989, ARCH BIOCHEM BIOPHYS, V274, P64, DOI 10.1016/0003-9861(89)90415-3; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KURIHARA T, 1988, FEBS LETT, V229, P215, DOI 10.1016/0014-5793(88)80830-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAROW PB, 1978, J BIOL CHEM, V253, P1522; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; MAXWELL RE, 1983, ATHEROSCLEROSIS, V48, P195, DOI 10.1016/0021-9150(83)90038-2; MAXWELL RE, 1982, RES CLIN FORUMS, V4, P43; MIDDLETON B, 1973, BIOCHEM J, V132, P717, DOI 10.1042/bj1320717; MIDDLETON B, 1973, BIOCHEM J, V132, P731, DOI 10.1042/bj1320731; MIYAZAWA S, 1980, EUR J BIOCHEM, V103, P589, DOI 10.1111/j.1432-1033.1980.tb05984.x; MIYAZAWA S, 1981, J BIOCHEM, V90, P511, DOI 10.1093/oxfordjournals.jbchem.a133499; NEWTON RS, 1985, TODAYS THERAPEUT T S, V1, P13; NOLTMANN EA, 1966, METHOD ENZYMOL, V9, P557; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1980, DRUGS AFFECTING LIPI, P301; REED WD, 1977, BIOCHEM J, V164, P27, DOI 10.1042/bj1640027; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SEUBERT W, 1968, BIOCHIM BIOPHYS ACTA, V164, P498, DOI 10.1016/0005-2760(68)90180-X; STAACK H, 1978, J BIOL CHEM, V253, P1827; THOMPSON SL, 1987, J BIOL CHEM, V262, P17420; TSUNEOKA M, 1988, J BIOCHEM-TOKYO, V104, P560, DOI 10.1093/oxfordjournals.jbchem.a122510	40	99	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1990	265	10					5731	5735						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CW480	1969406				2022-12-25	WOS:A1990CW48000068
J	SHIMIZU, M; YOKOTA, J; MORI, N; SHUIN, T; SHINODA, M; TERADA, M; OSHIMURA, M				SHIMIZU, M; YOKOTA, J; MORI, N; SHUIN, T; SHINODA, M; TERADA, M; OSHIMURA, M			INTRODUCTION OF NORMAL CHROMOSOME-3P MODULATES THE TUMORIGENICITY OF A HUMAN RENAL-CELL CARCINOMA CELL-LINE YCR	ONCOGENE			English	Article									KANAGAWA CANC CTR,RES INST,CYTOGENET LAB,54-2 NAKAO CHO,ASAHI KU,YOKOHAMA 241,JAPAN; NATL CANC CTR,RES INST,CHUO KU,TOKYO 151,JAPAN; YOKOHAMA CITY UNIV,SCH MED,DEPT UROL,MINAMI KU,YOKOHAMA,KANAGAWA 232,JAPAN; HOSHI COLL PHARM,DEPT BIOCHEM,SHINAGAWA KU,TOKYO 142,JAPAN	Kanagawa Prefectural Cancer Center; National Cancer Center - Japan; Yokohama City University; Hoshi University								BENEDICT WF, 1984, CANCER RES, V44, P3471; BERGERHEIM U, 1989, CANCER RES, V49, P1390; CARROLL PR, 1987, CANCER GENET CYTOGEN, V26, P253, DOI 10.1016/0165-4608(87)90059-8; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GREEN AR, 1988, BRIT J CANCER, V58, P115, DOI 10.1038/bjc.1988.176; HARPER ME, 1981, P NATL ACAD SCI-BIOL, V78, P4458, DOI 10.1073/pnas.78.7.4458; HARRIS H, 1988, CANCER RES, V48, P3302; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KOI M, 1989, JPN J CANCER RES, V80, P122, DOI 10.1111/j.1349-7006.1989.tb02278.x; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KOVACS G, 1987, INT J CANCER, V40, P171, DOI 10.1002/ijc.2910400208; KUBOTA Y, 1987, FEBS LETT, V212, P159, DOI 10.1016/0014-5793(87)81577-6; OSHIMURA M, 1988, CANCER RES, V48, P1623; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; OSHIMURA M, IN PRESS J CELL BIOC; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SANDBERG AA, 1988, CANCER RES, V48, P1049; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; Stanbridge E.J., 1987, ADV VIRAL ONCOL, V6, P83; STANBRIDGE EJ, 1981, CANCER RES, V41, P573; STANBRIDGE EJ, 1986, CANCER RES, V46, P4759; SZUCS S, 1987, CANCER GENET CYTOGEN, V26, P369, DOI 10.1016/0165-4608(87)90072-0; VANDERHOUT AH, 1988, CANCER GENET CYTOGEN, V32, P281, DOI 10.1016/0165-4608(88)90292-0; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1989, CANCER RES, V49, P3598; YOSHIDA MA, 1986, CANCER RES, V46, P2139; YOSHIDA MA, 1988, JPN J CANCER RES, V79, P600, DOI 10.1111/j.1349-7006.1988.tb00029.x; YOSHIDA MC, 1975, P JPN ACAD, V51, P181; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	36	109	109	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1990	5	2					185	194						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU029	1969617				2022-12-25	WOS:A1990CU02900004
J	GUM, JR; HICKS, JW; LAGACE, RE; BYRD, JC; TORIBARA, NW; SIDDIKI, B; FEARNEY, FJ; LAMPORT, DTA; KIM, YS				GUM, JR; HICKS, JW; LAGACE, RE; BYRD, JC; TORIBARA, NW; SIDDIKI, B; FEARNEY, FJ; LAMPORT, DTA; KIM, YS			MOLECULAR-CLONING OF RAT INTESTINAL MUCIN - LACK OF CONSERVATION BETWEEN MAMMALIAN-SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; GOBLET-CELL MUCIN; CDNA; GENE; GLYCOPROTEINS; PROTEIN; DIFFERENTIATION; POLYPEPTIDE; COMPLEXITY; EXPRESSION	We have prepared antisera to deglycosylated rat intestinal mucin and used it to obtain immunoreactive clones from a rat jejunum cDNA library. Four of these clones were sequenced, and all were found to be partial cDNAs that contained 18-base pair tandem repeats characteristic of a mucin. These cDNAs encoded a repetitive peptide with a consensus sequence of TTTPDV. Thus, they bear little resemblance to either of the two human intestinal mucin cDNAs isolated previously (Gum, J. R., Byrd, J. C., Hicks, J. W., Toribara, N. W., Lamport, D. T. A., and Kim, Y. S. (1989) J. Biol. Chem. 264, 6480-6487 and Gum, J. R., Hicks, J. W., Swallow, D. M., Lagace, R. E., Byrd, J. C., Lamport, D. T. A., Siddiki, B., and Kim, Y. S. (1990) Biochem. Biophys. Res. Commun. 171, 407-415). One of these rat mucin clones, designated RMUC 176, was chosen for further analysis. This clone recognized a band of approximately 9 kilobases when used to probe RNA blots. A strong hybridization band was present using rat small intestine and colon RNA but was not detectable when RNA isolated from heart, liver, or kidney was tested. The RMUC 176 clone and the two previously isolated human intestinal mucin cDNA clones were used to probe blots prepared from BamHI-digested DNA of various species. Here, the human probes detected fragments present only in human and chimpanzee DNA, whereas the RMUC 176 clone recognized fragments only in rat and mouse DNA. Thus, the-repetitive portions of intestinal mucin genes are apparently not well conserved between phylogenetically distant species.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT ENERGY PLANT RES, E LANSING, MI 48824 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	Michigan State University; Michigan State University; University of California System; University of California San Francisco	GUM, JR (corresponding author), VET AFFAIRS MED CTR, GASTROINTESTINAL RES LAB, SAN FRANCISCO, CA 94121 USA.							BELLA A, 1972, ARCH BIOCHEM BIOPHYS, V150, P679, DOI 10.1016/0003-9861(72)90086-0; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BOLAND CR, 1982, P NATL ACAD SCI-BIOL, V79, P2051, DOI 10.1073/pnas.79.6.2051; BRIAND JP, 1981, J BIOL CHEM, V256, P2205; BURCHELL J, 1983, J IMMUNOL, V131, P508; BYRD JC, 1989, BIOCHEM J, V261, P617, DOI 10.1042/bj2610617; BYRD JC, 1988, CANCER RES, V48, P6678; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FAHIM REF, 1987, BIOCHEM J, V243, P631, DOI 10.1042/bj2430631; FAHIM REF, 1983, BIOCHEM J, V209, P117, DOI 10.1042/bj2090117; FORSTNER JF, 1973, CAN J BIOCHEM CELL B, V51, P1154, DOI 10.1139/o73-152; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GRIFFITHS B, 1990, ANN HUM GENET, V54, P277, DOI 10.1111/j.1469-1809.1990.tb00383.x; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1987, J BIOL CHEM, V262, P1092; HANOVER JA, 1980, J BIOL CHEM, V255, P6713; HARDING SE, 1989, ADV CARBOHYD CHEM BI, V47, P345; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOFFMANN W, 1988, J BIOL CHEM, V263, P7686; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; LAN MS, 1990, J BIOL CHEM, V265, P15294; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MIURA S, 1983, BIOCHIM BIOPHYS ACTA, V761, P66, DOI 10.1016/0304-4165(83)90363-X; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; PASCALE E, 1990, P NATL ACAD SCI USA, V87, P9481, DOI 10.1073/pnas.87.23.9481; PODOLSKY DK, 1984, GASTROENTEROLOGY, V87, P991; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; ROUSSEL P, 1988, BIOCHIMIE, V70, P1471, DOI 10.1016/0300-9084(88)90284-2; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; SPICER AP, 1991, J BIOL CHEM, V266, P15099; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; WESLEY A, 1985, J BIOL CHEM, V260, P7955; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x	42	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22733	22738						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939280				2022-12-25	WOS:A1991GR56400099
J	HART, MJ; SHINJO, K; HALL, A; EVANS, T; CERIONE, RA				HART, MJ; SHINJO, K; HALL, A; EVANS, T; CERIONE, RA			IDENTIFICATION OF THE HUMAN PLATELET GTPASE ACTIVATING PROTEIN FOR THE CDC42HS PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE EFFECTOR DOMAIN; BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; BOVINE BRAIN; ENCODE PROTEINS; HUMAN HOMOLOG; RAS PROTEINS; GENE; GAP	The CDC42Hs protein appears to be an isoform of the ras-related GTP-binding protein G25K and is an apparent human homolog of the Saccharomyces cerevisiae cell-division-cycle protein, CDC42Sc. In this study, we report the identification of a GTPase-activating protein (GAP) for CDC42Hs from human platelets (designated from here on as CDC42Hs-GAP). The CDC42Hs-GAP activity was solubilized from platelet membranes, recovered through successive chromatography steps (the final step being Mono-Q chromatography), and purified approximately 3500-fold. The CDC42Hs-GAP activity appeared to correspond to a polypeptide with an apparent M(r) of approximately 25,000. The GTPase activities of the purified human platelet CDC42Hs, the Escherichia coli-recombinant CDC42Hs, and the Spodoptera frugiperda-recombinant GTP-binding proteins are all stimulated by the CDC42Hs-GAP to identical extents, which indicates that the recombinant CDC42Hs proteins are as effective as the native human platelet protein in coupling to the GAP. However, a mutant form of the E. coli-recombinant CDC42Hs which contains a valine residue at position 12 (CDC42Hs(Val-12)) has a significantly reduced intrinsic GTPase activity (relative to the wild type CDC42Hs(Gly-12)) which is not stimulated by the CDC42Hs-GAP. The CDC42Hs-GAP also does not stimulate the GTPase activities of the ras or rap GTP-binding proteins; however, it is capable of a weak stimulation of the GTPase activity of mammalian rho. Based on the apparent similarities in the molecular size of the CDC42Hs- and rho-GAPs (i.e. 25-30 kDa), and the cross-reactivity of rho with the CDC42Hs-GAP, it seems likely that the CDC42Hs- and rho-GAPs will constitute a specific subclass of the ras-related GAP superfamily.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; GENENTECH INC,DEPT CELL BIOL,SAN FRANCISCO,CA 94080; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Cornell University; Roche Holding; Genentech; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	HART, MJ (corresponding author), CORNELL UNIV,DEPT BIOCHEM CELLULAR & MOLEC BIOL,SCHURMAN HALL,ITHACA,NY 14853, USA.			Hart, Matthew/0000-0002-2683-480X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EVANS T, 1986, J BIOL CHEM, V261, P7052; EVANS T, 1991, IN PRESS CURR OPINIO; FUNG MC, 1988, J VIROL METHODS, V19, P33, DOI 10.1016/0166-0934(88)90005-5; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GARRETT MD, 1989, J BIOL CHEM, V624, P10; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HART MJ, 1990, J BIOL CHEM, V265, P5990; HATA Y, 1990, J BIOL CHEM, V265, P7104; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MORII N, 1991, J BIOL CHEM, V266, P7646; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RUBINFELD B, 1991, CELL, V65, P1; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	44	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20840	20848						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939135				2022-12-25	WOS:A1991GN00100041
J	BIDART, JM; TROALEN, F; GHILLANI, P; PUISIEUX, A; BOHUON, C; BELLET, D				BIDART, JM; TROALEN, F; GHILLANI, P; PUISIEUX, A; BOHUON, C; BELLET, D			IMMUNOCHEMICAL MAPPING OF ANTIGENIC REGIONS ON THE HUMAN THYROTROPIN BETA-SUBUNIT BY ANTIPEPTIDE ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; THYROID-STIMULATING HORMONE; BOVINE THYROTROPIN; MONOCLONAL-ANTIBODIES; PEPTIDE; LUTROPIN; PROTEIN; ALPHA; DETERMINANTS; IODINATION	To study antigenic sites present in the beta-subunit of human thyrotropin (hTSH), we produced site-specific antibodies directed against synthetic peptides analogous to the 1-18, 44-59, and 85-112 regions of the thyrotropin beta-subunit. The hTSH-beta(1-18) peptide-carrier conjugate elicited antisera capable of binding to both radiolabeled hTSH and its beta-subunit whereas antibodies elicited against the hTSH-beta(44-59) peptide-carrier conjugate bound only to the peptide. Thus, the NH2-terminal region of hTSH-beta appears to be accessible at the surface of the hormone whereas the hTSH-beta(44-59) region may be poorly accessible. Two monoclonal antipeptide antibodies that bound to I-125-hTSH-beta, designated as TS01 and TS02, were selected after immunization with the hTSH-beta(85-112) peptide-carrier conjugate. The antigenic site recognized by TS01 was located on the eight COOH-terminal(105-112) amino acid residues. TS02 antibody bound to an antigenic region included within Cys95 and Cys105. Both antigenic sites appeared to be more accessible on the free hTSH-beta than on the hormone. Immunoblots performed on various preparations containing TSH revealed that TS02 antibody detected the beta-subunit from both the human and bovine species but not the rat TSH-beta. Under reducing conditions, a low molecular weight material was identified in hTSH-beta, likely caused by intrachain nicking.	INST GUSTAVE ROUSSY, DEPT BIOL CLIN, F-94805 VILLEJUIF, FRANCE	UNICANCER; Gustave Roussy				PUISIEUX, Alain/0000-0002-9938-3798				BELLET DH, 1986, J CLIN ENDOCR METAB, V63, P1319, DOI 10.1210/jcem-63-6-1319; BENKIRANE MM, 1987, ENDOCRINOLOGY, V121, P1171, DOI 10.1210/endo-121-3-1171; BEYER CF, 1984, J IMMUNOL METHODS, V67, P79, DOI 10.1016/0022-1759(84)90087-5; BIDART JM, 1988, INT CONGR SER, V798, P63; BIDART JM, 1985, J IMMUNOL, V134, P457; BIDART JM, 1987, J BIOL CHEM, V262, P8551; BIDART JM, 1990, SCIENCE, V248, P736, DOI 10.1126/science.1692160; BIOZZI G, 1970, J EXP MED, V132, P752, DOI 10.1084/jem.132.4.752; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHENG KW, 1973, J BIOL CHEM, V248, P7930; COSTAGLIOLA S, 1988, MOL ENDOCRINOL, V2, P613, DOI 10.1210/mend-2-7-613; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GARNIERJ, 1989, PREDICTION PROTEIN S, P417; HAYASHIZAKI Y, 1985, FEBS LETT, V188, P394, DOI 10.1016/0014-5793(85)80409-9; HAYASHIZAKI Y, 1989, EMBO J, V8, P2291, DOI 10.1002/j.1460-2075.1989.tb08355.x; HILL BL, 1987, ENDOCRINOLOGY, V120, P574, DOI 10.1210/endo-120-2-574; LASH RW, 1989, 71ST AN M END SOC SE, P266; LIAO TH, 1971, J BIOL CHEM, V246, P850; MAGNER JA, 1990, ENDOCR REV, V11, P354, DOI 10.1210/edrv-11-2-354; MAURER RA, 1984, J BIOL CHEM, V259, P5024; MORRIS JC, 1990, J BIOL CHEM, V265, P1881; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; Pierce J G, 1971, Recent Prog Horm Res, V27, P165; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PUISIEUX A, 1990, ENDOCRINOLOGY, V126, P687, DOI 10.1210/endo-126-2-687; RIDGWAY EC, 1982, J CLIN ENDOCR METAB, V55, P44, DOI 10.1210/jcem-55-1-44; ROUAS N, 1990, 72ND ANN M END SOC A, P187; RYAN RJ, 1987, RECENT PROG HORM RES, V43, P383; SAIRAM MR, 1977, CAN J BIOCHEM CELL B, V55, P755, DOI 10.1139/o77-108; SAKAKIBARA R, 1990, J BIOCHEM-TOKYO, V107, P858, DOI 10.1093/oxfordjournals.jbchem.a123138; SALESSE R, 1990, MOL CELL ENDOCRINOL, V68, P113, DOI 10.1016/0303-7207(90)90183-9; SANTACOLOMA TA, 1991, J BIOL CHEM, V266, P2759; SHOME B, 1988, J PROTEIN CHEM, V7, P325, DOI 10.1007/BF01024882; STANTON PG, 1987, J BIOL CHEM, V262, P1623; STRICKLAND TW, 1984, INT J PEPT PROT RES, V24, P328; TAKATA KI, 1989, BIOCHEM BIOPH RES CO, V165, P1035, DOI 10.1016/0006-291X(89)92706-X; TROALEN F, 1990, MOL IMMUNOL, V27, P363, DOI 10.1016/0161-5890(90)90049-6; TROALEN F, 1988, J BIOL CHEM, V263, P10370; WARD DN, 1989, SERONO SYM, V65, P1; WARD DN, 1986, INT J PEPT PROT RES, V27, P70; WARD DN, 1990, GLYCOPROTEIN HORMONE, P81; WEARE JA, 1979, J BIOL CHEM, V254, P6972; WONDISFORD FE, 1988, J BIOL CHEM, V263, P12538	43	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19238	19244						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918041				2022-12-25	WOS:A1991GK66700022
J	MIFFLIN, RC; KELLEMS, RE				MIFFLIN, RC; KELLEMS, RE			COUPLED TRANSCRIPTION-POLYADENYLATION IN A CELL-FREE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA PRECURSORS; POLYMERASE-II; 3' END; SNRNA PROMOTER; GLOBIN GENE; INVITRO; CLEAVAGE; SITE; POLY(A); TERMINATION	To investigate the relationship between transcription and polyadenylation, an in vitro system has been developed in which endogenously transcribed pre-mRNAs containing functional polyadenylation sites are rapidly and accurately cleaved in a HeLa nuclear extract. Cleavage of endogenously transcribed substrates differed from that of exogenous substrates in that a proximal 3' terminus was not required, the reaction was more tolerant of increased Mg2+ levels, and endogenous substrates were cleaved more efficiently. A promoter dependence for this reaction was suggested by the observation that substrates transcribed by bacteriophage T7 RNA polymerase in the presence of nuclear extract were not cleaved. In addition, analysis of the bovine growth hormone poly(A) site indicated that it is highly efficient in vitro which agrees with previous in vivo data. The availability of an in vitro system in which transcription and polyadenylation are coupled should facilitate analysis of the relation between 3' end processing and RNA polymerase II transcription termination as well as the promoter requirements for polyadenylation.	BAYLOR COLL MED,INST MOLEC GENET,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030	Baylor College of Medicine					NIGMS NIH HHS [GM30204, 5 F32 GM 12253-03] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012253, R01GM030204] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED YF, 1991, CELL, V64, P727, DOI 10.1016/0092-8674(91)90502-P; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARSWELL S, 1989, MOL CELL BIOL, V9, P4248, DOI 10.1128/MCB.9.10.4248; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; DAHLBERG JE, 1988, NUCLEIC ACIDS RES, V16, P5827, DOI 10.1093/nar/16.13.5827; DEVEGVAR HEN, 1986, CELL, V47, P259; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECONOMIDIS IV, 1983, P NATL ACAD SCI-BIOL, V80, P4296, DOI 10.1073/pnas.80.14.4296; GILMAN M, 1987, CURRENT PROTOCOLS MO, V1; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GIMMI ER, 1989, NUCLEIC ACIDS RES, V17, P6983, DOI 10.1093/nar/17.17.6983; HERNANDEZ N, 1986, CELL, V47, P249, DOI 10.1016/0092-8674(86)90447-2; HUMPHREY T, 1987, EMBO J, V6, P4159, DOI 10.1002/j.1460-2075.1987.tb02762.x; INNIS JW, 1991, IN PRESS J BIOL CHEM, V266; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LANOIX J, 1988, EMBO J, V7, P2515, DOI 10.1002/j.1460-2075.1988.tb03099.x; LEWIS ED, 1988, P NATL ACAD SCI USA, V83, P8555; LOBO SM, 1989, CELL, V58, P155; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; PFARR DS, 1986, DNA-J MOLEC CELL BIO, V5, P115, DOI 10.1089/dna.1986.5.115; RYNER LC, 1989, MOL CELL BIOL, V9, P1759, DOI 10.1128/MCB.9.4.1759; SHEETS MD, 1987, MOL CELL BIOL, V7, P1518, DOI 10.1128/MCB.7.4.1518; SKOLNIKDAVID H, 1987, GENE DEV, V1, P672, DOI 10.1101/gad.1.7.672; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; SPERRY AO, 1986, MOL CELL BIOL, V6, P4734, DOI 10.1128/MCB.6.12.4734; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WOYCHIK RP, 1984, P NATL ACAD SCI-BIOL, V81, P3944, DOI 10.1073/pnas.81.13.3944	38	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19593	19598						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918066				2022-12-25	WOS:A1991GK66700069
J	DOWD, DR; MACDONALD, PN; KOMM, BS; HAUSSLER, MR; MIESFELD, R				DOWD, DR; MACDONALD, PN; KOMM, BS; HAUSSLER, MR; MIESFELD, R			EVIDENCE FOR EARLY INDUCTION OF CALMODULIN GENE-EXPRESSION IN LYMPHOCYTES UNDERGOING GLUCOCORTICOID-MEDIATED APOPTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CHICKEN-EMBRYO FIBROBLASTS; CELL-CYCLE; DEATH; RECEPTOR; MECHANISMS; PROTEIN; LINE	Glucocorticoid treatment of certain lymphoma cell lines and thymocytes activates a self-destructive pathway of programmed cell death referred to as apoptosis. Calcium and calmodulin (CaM) may be important signals in the apoptotic cascade because an early event is a sustained elevation in cytosolic Ca2+ and CaM inhibitors interfere with the death pathway. In the present study, expression of the CaM gene was examined during glucocorticoid-induced apoptosis in WEHI7.2 lymphocytes. Steady state levels of CaM mRNA were increased up to 10-fold following a 4-6-h exposure of WEHI7.2 cells to 10(-6) M dexamethasone. This increase was mediated through the glucocorticoid receptor since the response was not observed in WEHI7.418, a variant line which does not express active glucocorticoid receptor. Induction of CaM mRNA was dose-dependent and highly specific for glucocorticoids, as other steroids were unable to elicit the response. A stringent cell specificity was also observed. Pretreatment of WEHI7.2 lymphocytes with cycloheximide did not interfere with dexamethasone-dependent increases in CaM mRNA levels, and studies with actinomycin D demonstrated that the stability of the transcript was not altered by hormone. Finally, a calmodulin inhibitor elicited a protective effect on WEHI7.2 cells following glucocorticoid exposure. These results indicate that CaM mRNA levels were hormonally controlled in WEHI7.2 lymphocytes and support the putative involvement of CaM in glucocorticoid-induced apoptosis.	UNIV ARIZONA, ARIZONA CANC CTR, TUCSON, AZ 85724 USA; UNIV ARIZONA, DEPT PHYSIOL, TUCSON, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona	DOWD, DR (corresponding author), UNIV ARIZONA, DEPT BIOCHEM, TUCSON, AZ 85724 USA.			Haussler, Mark/0000-0002-7097-1801	NIAMS NIH HHS [AR 15781] Funding Source: Medline; NIGMS NIH HHS [1 F32 GM13846] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR015781, R37AR015781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013846] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; BOURGEOIS S, 1977, CELL, V11, P423, DOI 10.1016/0092-8674(77)90060-5; CAHFOULEAS JG, 1980, CALCIUM BINDING PROT, P189; CHAFOULEAS JG, 1981, P NATL ACAD SCI-BIOL, V78, P996, DOI 10.1073/pnas.78.2.996; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHAFOULEAS JG, 1984, CELL, V36, P73, DOI 10.1016/0092-8674(84)90075-8; COHEN JJ, 1984, J IMMUNOL, V132, P38; CONNOR CG, 1983, BIOCHEM BIOPH RES CO, V112, P647, DOI 10.1016/0006-291X(83)91512-7; DANIELSEN M, 1983, MOL CELL BIOL, V3, P1310, DOI 10.1128/MCB.3.7.1310; DANIELSEN M, 1984, MOL CELL BIOL, V4, P449, DOI 10.1128/MCB.4.3.449; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; FERAMISCO JR, 1982, J BIOL CHEM, V257, P1024; GROVE JR, 1980, CELL, V21, P47, DOI 10.1016/0092-8674(80)90113-0; GRUOL DJ, 1986, J BIOL CHEM, V261, P4909; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; HARRIS AW, 1973, J IMMUNOL, V110, P431; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; LAPORTE DC, 1979, BIOCHEM BIOPH RES CO, V86, P1169, DOI 10.1016/0006-291X(79)90240-7; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; SASAKI Y, 1982, BIOCHEM BIOPH RES CO, V104, P451, DOI 10.1016/0006-291X(82)90658-1; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; VEDECKIS WV, 1983, MOL CELL ENDOCRINOL, V30, P215, DOI 10.1016/0303-7207(83)90049-7; VEIGL ML, 1983, BIOCHIM BIOPHYS ACTA, V738, P21, DOI 10.1016/0304-419X(84)90018-0; WATTERSON DM, 1976, P NATL ACAD SCI USA, V73, P2711, DOI 10.1073/pnas.73.8.2711; ZENDEGUI JG, 1984, MOL CELL BIOL, V4, P883, DOI 10.1128/MCB.4.5.883	30	140	142	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18423	18426						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917967				2022-12-25	WOS:A1991GJ47200004
J	MARKUSSEN, J; HALSTROM, J; WIBERG, FC; SCHAFFER, L				MARKUSSEN, J; HALSTROM, J; WIBERG, FC; SCHAFFER, L			IMMOBILIZED INSULIN FOR HIGH-CAPACITY AFFINITY-CHROMATOGRAPHY OF INSULIN-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MEMBRANES; PURIFICATION; LIVER	Insulin receptors can be purified by affinity chromatography on immobilized insulin, but published methods all suffer from a rather low capacity of the affinity columns. By using insulin that has been protected in positions A1 and B29, we have been able to couple the insulin selectively through the B1 amino group to divinyl sulfone-activated agarose. The N terminus of the B-chain is the most innocuous site as far as receptor-insulin interaction is concerned, and this strategy allowed us to make affinity columns with capacities of several milligrams of receptor/ml of resin. The receptor used was the soluble ectodomain of the human insulin receptor, produced in transfected baby hamster kidney cells. The column preparation and the elution conditions are described in detail, as the efficacy of the purification depends strongly on both. The purity of the eluted receptors was so high that quantitative amino acid analysis fitted with theory. The molar absorption coefficient at 278.5 nm was 296,000 M-1 cm-1. Finally, it could be unequivocally established that the soluble receptor binds two molecules of insulin with equal affinity.			MARKUSSEN, J (corresponding author), NOVO RES INST,NOVO ALLE,DK-2880 BAGSVAERD,DENMARK.							ANDERSEN AS, 1990, BIOCHEMISTRY-US, V29, P7363, DOI 10.1021/bi00484a002; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P1277, DOI 10.1073/pnas.69.5.1277; CUATRECASAS P, 1972, P NATL ACAD SCI USA, V69, P318, DOI 10.1073/pnas.69.2.318; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Ellis L, 1988, J Mol Recognit, V1, P25, DOI 10.1002/jmr.300010106; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; GLIEMANN J, 1973, DIABETOLOGIA, V10, P105; HOFMANN K, 1987, BIOCHEMISTRY-US, V26, P7384, DOI 10.1021/bi00397a028; JACOBS S, 1977, BIOCHEM BIOPH RES CO, V77, P981, DOI 10.1016/S0006-291X(77)80074-0; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; JORGENSEN KH, 1980, DIABETOLOGIA, V19, P546; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEWMAN JD, 1985, BIOCHEM BIOPH RES CO, V132, P1059, DOI 10.1016/0006-291X(85)91914-X; PULLEN RA, 1976, NATURE, V259, P369, DOI 10.1038/259369a0; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; STELZEL P, 1974, METHODEN ORGANISCHEN, V15, P188; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHITTAKER J, 1988, J BIOL CHEM, V263, P3063	18	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18814	18818						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918001				2022-12-25	WOS:A1991GJ47200064
J	SHOHET, JM; BERGAMASCHINI, L; DAVIS, AE; CARROLL, MC				SHOHET, JM; BERGAMASCHINI, L; DAVIS, AE; CARROLL, MC			LOCALIZATION OF THE HUMAN-COMPLEMENT COMPONENT-C3 BINDING-SITE ON THE IGG HEAVY-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE PATHWAY; COVALENT BINDING; RABBIT IGG; ACTIVATION; ANTIBODY; PROTEINS; SYSTEM; C-3; COMPLEXES; PROPERDIN	The location of the covalent binding site of the third component of complement (C3) on the IgG heavy chain was determined by sequence analysis of peptides generated by cyanogen bromide digestion of C3-IgG adducts. Activation of the alternative pathway by incubation of heat-aggregated human IgG1 with fresh normal human plasma formed covalent adducts of C3b-IgG. CNBr peptides of these adducts were transferred to a polyvinylidene difluoride membrane, and amino-terminal sequences were determined. A 40-kDa dipeptide containing the covalent bond was identified by labeling the free thiol group (generated during activation of the internal thioester of C3b) with iodo[1-C-14]acetamide and analyzed by amino acid sequencing. The resulting double sequence suggested an adduct with NH2 termini at residue 938 (pro-C3 numbering) of C3 (75 residues NH2-terminal to the thioester) and residue 84 in the variable region of the IgG heavy chain. These results combined with results from hydroxylamine treatment (splits ester linkage between C3b and IgG) imply that this adduct peptide consists of a 22-kDa C3 fragment and an 18-kDa IgG fragment. Therefore, C3 binds covalently within the region extending from the last 20 residues of the variable region through the first 20 residues of CH2.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118; UNIV MILAN,I-20122 MILAN,ITALY; HOSP SAN PAOLO,MILAN,ITALY; CHILDRENS HOSP RES FDN,DIV NEPHROL,CINCINNATI,OH 45229	Harvard University; Harvard Medical School; Boston University; University of Milan; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation			BERGAMASCHINI, LUIGI CESARE/T-6367-2017	BERGAMASCHINI, LUIGI CESARE/0000-0002-5103-0942	NICHD NIH HHS [HD17461, HD22082] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017461, R01HD022082, R37HD022082] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBAR JP, 1981, MOL IMMUNOL, V18, P925, DOI 10.1016/0161-5890(81)90015-8; ANTON LC, 1989, BIOCHEM J, V257, P832; AUGENER W, 1971, IMMUNOCHEMISTRY, V8, P1011, DOI 10.1016/0019-2791(71)90489-7; Campbell R D, 1986, Adv Immunol, V38, P203, DOI 10.1016/S0065-2776(08)60007-3; CAMPBELL RD, 1980, BIOCHEM J, V189, P67, DOI 10.1042/bj1890067; CARROLL MC, 1990, P NATL ACAD SCI USA, V87, P6868, DOI 10.1073/pnas.87.17.6868; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DIAMOND RD, 1974, J IMMUNOL, V112, P2260; DODDS AW, 1978, BIOCHEM J, V175, P383, DOI 10.1042/bj1750383; DODDS AW, 1985, EMBO J, V4, P2339; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; GADD KJ, 1981, IMMUNOLOGY, V42, P75; GADD KJ, 1981, BIOCHEM J, V195, P471, DOI 10.1042/bj1950471; HOSEA SW, 1980, J INFECT DIS, V142, P903, DOI 10.1093/infdis/142.6.903; ISENMAN DE, 1984, J IMMUNOL, V132, P3019; ISHIZAKA T, 1961, J IMMUNOL, V87, P443; KABAT EA, 1987, SEQUENCES PROTEINS I, P293; KINOSHITA T, 1991, FASEB J, V5; KONOZO H, 1990, J BIOL CHEM, V265, P14444; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SK, 1980, P NATL ACAD SCI-BIOL, V77, P7194, DOI 10.1073/pnas.77.12.7194; LAW SKA, 1983, ANN NY ACAD SCI, V421, P246, DOI 10.1111/j.1749-6632.1983.tb18113.x; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; MULLEREBERHARD HJ, 1967, J EXP MED, V125, P359, DOI 10.1084/jem.125.2.359; NICHOL PAE, 1973, IMMUNOLOGY, V24, P259; OKADA N, 1982, NATURE, V299, P261, DOI 10.1038/299261a0; PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279; Porter R R, 1979, Adv Protein Chem, V33, P1, DOI 10.1016/S0065-3233(08)60458-1; REID KBM, 1981, MOL IMMUNOL, V18, P949, DOI 10.1016/0161-5890(81)90112-7; REID KBM, 1981, ANNU REV BIOCHEM, V50, P433, DOI 10.1146/annurev.bi.50.070181.002245; Sandberg A L, 1970, J Immunol, V104, P329; SISSONS JGP, 1980, P NATL ACAD SCI-BIOL, V77, P559, DOI 10.1073/pnas.77.1.559; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TAKATA Y, 1984, J IMMUNOL, V132, P2531; TSUNASAWA S, 1985, J BIOCHEM-TOKYO, V97, P701, DOI 10.1093/oxfordjournals.jbchem.a135108; ZINGDE SM, 1986, ANAL BIOCHEM, V155, P10, DOI 10.1016/0003-2697(86)90216-2	39	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18520	18524						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917974				2022-12-25	WOS:A1991GJ47200020
J	ABRAHAM, LJ; BRADSHAW, AD; NORTHEMANN, W; FEY, GH				ABRAHAM, LJ; BRADSHAW, AD; NORTHEMANN, W; FEY, GH			IDENTIFICATION OF A GLUCOCORTICOID RESPONSE ELEMENT CONTRIBUTING TO THE CONSTITUTIVE EXPRESSION OF THE RAT-LIVER ALPHA-1-INHIBITOR-III GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; ENRICHED TRANSCRIPTIONAL ACTIVATOR; ALPHA-1-ACID GLYCOPROTEIN GENE; MESSENGER-RNA; GEL-ELECTROPHORESIS; PROTEIN-SYNTHESIS; EUKARYOTIC CELLS; NUCLEAR-PROTEIN; C-JUN; RECEPTOR	Alpha-1-inhibitor III (alpha-1I3), a broad range plasma proteinase inhibitor, is synthesized with striking tissue specificity in rat livers. The gene is expressed strongly in periportal hepatocytes of healthy adults and less abundantly in regions near the centrilobular vein. This expression pattern is suggestive of a concentration gradient of a blood-borne hormone that enters through the portal vein and diffuses across the lobe toward the centrilobular vein. The alpha-1I3 gene was known to be regulated both by glucocorticoids and interleukin 6, and therefore the hypothesis was tested that the normal constitutive expression of this gene depended on glucocorticoids. Alpha-1I3 mRNA levels in the livers of hypophysectomized rats with low endogenous glucocorticoid levels were only about 20% of those in control rat livers. Injection of exogenous glucocorticoids reconstituted hepatic alpha-1I3 mRNA levels up to 64% of their original values in a dose-dependent manner. Similarly, treatment of FAZA rat hepatoma cells with the synthetic glucocorticoid dexamethasone induced alpha-1I3 mRNA levels in a dose-dependent manner. Taken together these data suggested that glucocorticoids are required for the constitutive high level expression of this gene in normal adult rat livers. A series of 5' deletion constructs and linker scanning mutants of the promoter upstream region were produced and transfected into FAZA cells. A functional glucocorticoid response element was mapped between -168 and -151 base pairs 5' of the transcription start site. This element conforms with an inverted consensus glucocorticoid response element (GRE) but differs in two positions essential for protein DNA interaction between the GRE and the glucocorticoid receptor (GR). The induction of alpha-1I3 gene promoter region constructs by dexamethasone was abolished by the receptor antagonist RU486, indicating that the GR participated in the activation of the alpha-1I3 gene. In DNase I footprinting experiments with nuclear protein extracts from untreated and dexamethasone-treated FAZA cells, similar extents of alpha-1I3 promoter upstream sequences were protected, indicating that proteins capable of binding in the glucocorticoid response-mediating element (GME) region were present before and after arrival of the hormonal signal. However, a purified recombinant fragment of the GR which contained essentially only its DNA binding domain was unable to bind at the GME although it interacted strongly with a consensus GRE sequence.	Scripps Res Inst, RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA	Scripps Research Institute					FOGARTY INTERNATIONAL CENTER [F05TW004073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022166, R01AI023351] Funding Source: NIH RePORTER; FIC NIH HHS [1F05 TW04073-01] Funding Source: Medline; NIAID NIH HHS [AI22166, AI23351] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM LJ, 1990, MOL CELL BIOL, V10, P3483, DOI 10.1128/MCB.10.7.3483; ABRAHAM LJ, 1990, MOL BIOL MED, V7, P261; ADDISON WR, 1986, MOL CELL BIOL, V6, P2334, DOI 10.1128/MCB.6.7.2334; ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; AIELLO LP, 1988, J BIOL CHEM, V263, P4013; BAUMANN H, 1986, MOL CELL BIOL, V6, P2551, DOI 10.1128/MCB.6.7.2551; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERNUAU D, 1989, J EXP MED, V170, P349, DOI 10.1084/jem.170.1.349; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GEHRING MR, 1987, J BIOL CHEM, V262, P446; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KLEIN ES, 1987, J BIOL CHEM, V262, P520; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KUSHNER I, 1978, J EXP MED, V148, P466, DOI 10.1084/jem.148.2.466; LONBERGHOLM K, 1987, J BIOL CHEM, V262, P438; MALAWISTA SE, 1974, P NATL ACAD SCI USA, V71, P927, DOI 10.1073/pnas.71.3.927; Maxam A M, 1980, Methods Enzymol, V65, P499; MBAULIEU EE, 1985, ANTIPROGESTERONE RU4; MROCZKA DL, 1984, J MOL BIOL, V174, P141, DOI 10.1016/0022-2836(84)90369-3; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; NORTHEMANN W, 1989, BIOCHEMISTRY-US, V28, P84, DOI 10.1021/bi00427a013; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; REINKE R, 1985, J BIOL CHEM, V260, P4397; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWEIZER G, 1985, BIOCHEMISTRY-US, V24, P1742, DOI 10.1021/bi00328a026; SCHWEIZER M, 1987, EUR J BIOCHEM, V164, P375, DOI 10.1111/j.1432-1033.1987.tb11068.x; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1985, P NATL ACAD SCI USA, V82, P9, DOI 10.1073/pnas.82.1.9; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TURPIN TH, 1987, BIOTECHNIQUES, V4, P11; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	59	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18268	18275						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917955				2022-12-25	WOS:A1991GG55300083
J	STEGMANN, T; DELFINO, JM; RICHARDS, FM; HELENIUS, A				STEGMANN, T; DELFINO, JM; RICHARDS, FM; HELENIUS, A			THE HA2 SUBUNIT OF INFLUENZA HEMAGGLUTININ INSERTS INTO THE TARGET MEMBRANE PRIOR TO FUSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS HEMAGGLUTININ; PH; LIPOSOMES; PROTEINS; VESICLES; PEPTIDE	The interaction between influenza virus and target membrane lipids during membrane fusion was studied with hydrophobic photoactivatable probes. Two probes, the newly synthesized bisphospholipid diphosphatidylethanolamine trifluoromethyl [H-3]phenyl diazirine and the phospholipid analogue 1-palmitoyl-2(11-{4-[3-(trifluoromethyl)diazirinyl]phenyl}-[2-H-3]-undecanoyl)-sn-glycero-3-phosphocholine (Harter, C., Bachi, T., Semenza, G., and Brunner, J. (1988) Biochemistry 27, 1856-1864), were used. Both labeled the HA2 subunit of the virus at low pH. By measuring virus-liposome interactions at 0-degrees-C, it could be demonstrated that HA2 was inserted into the target membrane prior to fusion. As we have recently demonstrated, at this temperature, exposure of the fusion peptide of HA2 takes place within 15 s after acidification, but fusion does not start for 4 min (Stegmann, T., White, J. M., and Helenius, A. (1990) EMBO J. 9, 4231-4241). HA2 was labeled at least 2 min before fusion. No labeling of the HA1 subunit was seen. These data indicate that fusion is triggered by a direct interaction of the HA2 subunit of a kinetic intermediate form of HA with the lipids of the target membrane. Most likely, it is the fusion peptide of HA2 that is inserted into the target membrane. Just before fusion, HA is thus an integral membrane protein in both membranes. In contrast, the bromelain-derived ectodomain of HA was labeled by 1-palmitoyl-2(11-{4-[3-(trifluoromethyl)diazirinyl]phenyl} - [2-H-3]undecanoyl) - sn - glycero-3-phosphocholine at low pH but not by diphosphatidylethanolamine trifluoromethyl [H-3]phenyl diazirine. This indicates that insertion of the fusion peptide of the bromelain-derived ectodomain of HA into a membrane differs from that of viral HA during fusion.	YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018599, R37AI018599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM039546] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18599] Funding Source: Medline; NIGMS NIH HHS [GM-39546] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; BRUNNER J, 1989, FEBS LETT, V257, P369, DOI 10.1016/0014-5793(89)81574-1; BRUNNER J, 1991, BIOCHEMISTRY-US, V30, P2432, DOI 10.1021/bi00223a019; DELFINO JM, 1987, TETRAHEDRON LETT, V28, P2323, DOI 10.1016/S0040-4039(00)96114-8; DOMS RW, 1986, J VIROL, V57, P603, DOI 10.1128/JVI.57.2.603-613.1986; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; FOLCH J, 1957, J BIOL CHEM, V226, P497; HARTER C, 1989, J BIOL CHEM, V264, P6459; HARTER C, 1988, BIOCHEMISTRY-US, V27, P1856, DOI 10.1021/bi00406a010; HJERTEN S, 1962, ARCH BIOCHEM BIOPHYS, V99, P466, DOI 10.1016/0003-9861(62)90295-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1985, BIOCHEMISTRY-US, V24, P3107, DOI 10.1021/bi00334a006; STEGMANN T, 1989, BIOCHEMISTRY-US, V28, P1698, DOI 10.1021/bi00430a041; STEGMANN T, 1987, EMBO J, V6, P2651, DOI 10.1002/j.1460-2075.1987.tb02556.x; STEGMANN T, 1986, J BIOL CHEM, V261, P966; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; WHITE J, 1982, EMBO J, V1, P217, DOI 10.1002/j.1460-2075.1982.tb01150.x; WHITE JM, 1990, ANNU REV PHYSIOL, V52, P675, DOI 10.1146/annurev.ph.52.030190.003331; Wilschut J., 1990, MEMBRANE FUSION; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	27	180	184	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18404	18410						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917964				2022-12-25	WOS:A1991GG55300103
J	SZEWCZAK, AA; WEBSTER, KR; SPICER, EK; MOORE, PB				SZEWCZAK, AA; WEBSTER, KR; SPICER, EK; MOORE, PB			AN NMR CHARACTERIZATION OF THE REGA PROTEIN-BINDING SITE OF BACTERIOPHAGE-T4 GENE-44 MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; 2-DIMENSIONAL SPECTROSCOPY; COUPLING-CONSTANTS; DNA-REPLICATION; 2D NMR; SEQUENCE; TRANSCRIPTION; ORGANIZATION; EXCHANGE; CLONING	The conformations of two RNA dodecamers that differ markedly in affinity for the regA protein from bacteriophage T4 have been examined by NMR to see if the ability of that protein to discriminate between mRNAs is based on pre-existing differences in their three-dimensional structures. One of the RNAs examined has the same sequence as the site where regA protein binds when it inhibits the expression of gene 44's mRNA. The second RNA differs from the first in having a U instead of a G at position -9; it binds regA protein 100 times less tightly. The NMR data indicate that both RNAs have similar single-stranded conformations and that they each resemble an isolated strand of a double helix. They also show that most, if not all of the ribose rings in both molecules have appreciable 2'-endo puckering. It is unlikely that regA protein distinguishes between these two molecules on the basis of differences in their global conformations in solution.	YALE UNIV,DEPT CHEM,225 PROSPECT ST,NEW HAVEN,CT 06511; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University; Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012607, R01GM041651, R01GM030191] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-30191, GM-12607, GM-41651] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADARI HY, 1985, P NATL ACAD SCI USA, V82, P1901, DOI 10.1073/pnas.82.7.1901; ALTONA C, 1982, RECL TRAV CHIM PAY B, V101, P413; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAX A, 1988, J MAGN RESON, V79, P429, DOI 10.1016/0022-2364(88)90080-7; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BROIDA J, 1985, J MOL BIOL, V185, P545, DOI 10.1016/0022-2836(85)90071-3; DAEGELEN P, 1990, GENETICS, V125, P237; DELEEUW FAAM, 1982, J CHEM SOC PERK T 2, P375, DOI 10.1039/p29820000375; GAUSS P, 1987, MOL GEN GENET, V206, P24, DOI 10.1007/BF00326532; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; Gorenstein D. G., 1984, PHOSPHORUS 31 NMR PR; GRAM H, 1985, EMBO J, V4, P257, DOI 10.1002/j.1460-2075.1985.tb02344.x; HSU T, 1987, J VIROL, V61, P366, DOI 10.1128/JVI.61.2.366-374.1987; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KIME MJ, 1983, FEBS LETT, V153, P199, DOI 10.1016/0014-5793(83)80147-1; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; OTTING G, 1986, J MAGN RESON, V66, P187, DOI 10.1016/0022-2364(86)90122-8; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PRIBNOW D, 1981, J MOL BIOL, V149, P337, DOI 10.1016/0022-2836(81)90477-0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAENGER W, 1984, PRINCIPLES NUCLEIC A, pCH4; SHAKA AJ, 1983, J MAGN RESON, V51, P169, DOI 10.1016/0022-2364(83)90117-8; SPICER EK, 1984, J BIOL CHEM, V259, P5425; SPICER EK, 1982, J BIOL CHEM, V257, P8972; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; TOMASCHEWSKI J, 1985, NUCLEIC ACIDS RES, V13, P7551, DOI 10.1093/nar/13.21.7551; TROJANOWSKA M, 1984, NUCLEIC ACIDS RES, V12, P5979, DOI 10.1093/nar/12.15.5979; VANDENHOOGEN F, 1988, THESIS U LEIDEN NETH; WEBSTER KR, 1990, J BIOL CHEM, V265, P19007; WEBSTER KR, 1989, NUCLEIC ACIDS RES, V17, P10044; Wiberg J. S., 1983, BACTERIOPHAGE T4, P193; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822; WOKAUN A, 1977, CHEM PHYS LETT, V52, P407, DOI 10.1016/0009-2614(77)80476-4; Wuthrich K., 1986, NMR PROTEINS NUCLEIC; ZHANG P, 1989, BIOCHEMISTRY-US, V28, P4607, DOI 10.1021/bi00437a015	37	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17832	17837						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917925				2022-12-25	WOS:A1991GG55300022
J	MABROUK, GM; HELMY, IM; THAMPY, KG; WAKIL, SJ				MABROUK, GM; HELMY, IM; THAMPY, KG; WAKIL, SJ			ACUTE HORMONAL-CONTROL OF ACETYL-COA CARBOXYLASE - THE ROLES OF INSULIN, GLUCAGON, AND EPINEPHRINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									BAYLOR UNIV,VERNA & MARRS MCLEAN DEPT BIOCHEM,1 BAYLOR PLAZA,HOUSTON,TX 77030	Baylor College of Medicine; Baylor University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035419] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35419] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad F, 1981, Methods Enzymol, V71 Pt C, P16, DOI 10.1016/0076-6879(81)71004-8; BAI DH, 1986, J BIOL CHEM, V261, P2395; BEATY NB, 1983, J BIOL CHEM, V258, P3043; BORTHWICK AC, 1987, BIOCHEM J, V241, P773, DOI 10.1042/bj2410773; BROWNSEY RW, 1982, BIOCHEM J, V202, P77, DOI 10.1042/bj2020077; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; HARDIE DG, 1978, FEBS LETT, V91, P1, DOI 10.1016/0014-5793(78)80005-2; HARDIE DG, 1979, FEBS LETT, V103, P333, DOI 10.1016/0014-5793(79)81356-3; HARDIE DG, 1980, EUR J BIOCHEM, V110, P167, DOI 10.1111/j.1432-1033.1980.tb04852.x; HARDIE DG, 1980, MOL ASPECTS CELLULAR, V1, P33; HAYSTEAD TAJ, 1986, BIOCHEM J, V240, P99, DOI 10.1042/bj2400099; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P339, DOI 10.1111/j.1432-1033.1988.tb14202.x; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HOLLAND R, 1985, FEBS LETT, V181, P308, DOI 10.1016/0014-5793(85)80282-9; HOLLAND R, 1984, EUR J BIOCHEM, V140, P325, DOI 10.1111/j.1432-1033.1984.tb08105.x; KIM KH, 1979, MOL CELL BIOCHEM, V28, P27; KIM KH, 1983, CURR TOP CELL REGUL, V22, P143; KIM KH, 1989, FASEB J, V3, P2250, DOI 10.1096/fasebj.3.11.2570725; KRAKOWER GR, 1981, J BIOL CHEM, V256, P2408; Lane M D, 1974, Curr Top Cell Regul, V8, P139; LANE MD, 1979, CRC CR REV BIOCH MOL, V7, P121, DOI 10.3109/10409237909105429; LENT B, 1982, J BIOL CHEM, V257, P1897; LENT BA, 1983, ARCH BIOCHEM BIOPHYS, V225, P972, DOI 10.1016/0003-9861(83)90113-3; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; LOWENSTEIN JOHN M., 1968, P61; MAJERUS PW, 1969, J BIOL CHEM, V244, P6254; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; NAKANISHI S, 1970, EUR J BIOCHEM, V16, P161, DOI 10.1111/j.1432-1033.1970.tb01068.x; Numa S, 1984, FATTY ACID METABOLIS, P1; PEKALA PH, 1978, J BIOL CHEM, V253, P5267; SIESS EA, 1978, H-S Z PHYSIOL CHEM, V359, P785, DOI 10.1515/bchm2.1978.359.2.785; SIM ATR, 1988, FEBS LETT, V233, P294, DOI 10.1016/0014-5793(88)80445-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWENSON TL, 1985, J BIOL CHEM, V260, P3791; THAMPY KG, 1985, J BIOL CHEM, V260, P6318; THAMPY KG, 1988, J BIOL CHEM, V263, P6447; THAMPY KG, 1988, J BIOL CHEM, V263, P6454; THAMPY KG, 1986, ADV PROTEIN PHOSPHAT, V3, P257; TIPPER JP, 1982, BIOCHIM BIOPHYS ACTA, V715, P162, DOI 10.1016/0304-4165(82)90354-3; VAARTJES WJ, 1987, BIOCHEM BIOPH RES CO, V142, P135, DOI 10.1016/0006-291X(87)90461-X; WADA K, 1983, EUR J BIOCHEM, V135, P17, DOI 10.1111/j.1432-1033.1983.tb07612.x; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WAKIL SJ, 1958, J AM CHEM SOC, V80, P6465, DOI 10.1021/ja01556a086; WAKIL SJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P225, DOI 10.1016/0006-3002(58)90177-X; WAKIL SJ, 1971, COMPREHENSIVE BIOCH, V185, P57; WITTERS LA, 1981, J LIPID RES, V22, P364; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; WITTERS LA, 1979, J BIOL CHEM, V254, P6644; WITTERS LA, 1981, BIOCHEM BIOPH RES CO, V100, P872, DOI 10.1016/S0006-291X(81)80254-9; WITTERS LA, 1983, J BIOL CHEM, V258, P5463; ZAMMIT VA, 1982, BIOCHEM J, V208, P783, DOI 10.1042/bj2080783	55	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1990	265	11					6330	6338						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CY587	1969410				2022-12-25	WOS:A1990CY58700067
J	BEREBBI, M; MARTIN, PM; BERTHOIS, Y; BERNARD, AM; BLANGY, D				BEREBBI, M; MARTIN, PM; BERTHOIS, Y; BERNARD, AM; BLANGY, D			ESTRADIOL DEPENDENCE OF THE SPECIFIC MAMMARY TISSUE TARGETING OF POLYOMA-VIRUS ONCOGENICITY IN NUDE-MICE	ONCOGENE			English	Article									CNRS,UPR 272,BP 8,F-94801 VILLEJUIF,FRANCE; JE CNRS,F-13009 MARSEILLE,FRANCE; CNRS,URA 1175,F-13326 MARSEILLE 15,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			Berthois, Yolande/O-1168-2017	BERTHOIS, Yolande/0000-0001-9603-1626				ANDERSON TJ, 1982, BRIT J CANCER, V46, P376, DOI 10.1038/bjc.1982.213; BARTON MC, 1988, P NATL ACAD SCI USA, V85, P7119, DOI 10.1073/pnas.85.19.7119; BEREBBI M, 1988, ONCOGENE, V2, P149; BRESCIANI F, 1971, BASIC ACTIONS SEX ST, P130; FREUND R, 1987, J VIROL, V61, P2232, DOI 10.1128/JVI.61.7.2232-2239.1987; Fried M, 1975, Cold Spring Harb Symp Quant Biol, V39 Pt 1, P45; HAWKINS RA, 1988, ENDOCRINE MANAGEMENT, P45; HENDERSON BE, 1988, CANCER RES, V48, P246; IQBAL MJ, 1987, BREAST NEWS INT 2, V2, P7; IQBAL MJ, 1986, BREAST NEWS INT 1, V2, P8; ISON EJ, 1981, AM J MED TECHNOL, V47, P38; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LEGOFF JM, 1988, J STEROID BIOCHEM, V31, P167, DOI 10.1016/0022-4731(88)90050-7; MARTIN PM, 1982, J STEROID BIOCHEM, V16, P215, DOI 10.1016/0022-4731(82)90170-4; MERKEL DE, 1988, ENDOCRIN MANAGEMENT, P84; RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0	18	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					505	509						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1970153				2022-12-25	WOS:A1990DB85300008
J	RAVIV, Y; POLLARD, HB; BRUGGEMANN, EP; PASTAN, I; GOTTESMAN, MM				RAVIV, Y; POLLARD, HB; BRUGGEMANN, EP; PASTAN, I; GOTTESMAN, MM			PHOTOSENSITIZED LABELING OF A FUNCTIONAL MULTIDRUG TRANSPORTER IN LIVING DRUG-RESISTANT TUMOR-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									NCI,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	RAVIV, Y (corresponding author), NIDDKD,CELL BIOL & GENET LAB,BLDG 8,RM 404,BETHESDA,MD 20892, USA.		pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				BERCOVICI T, 1978, BIOCHEMISTRY-US, V17, P1484, DOI 10.1021/bi00601a020; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CONRAD RA, 1979, J MED CHEM, V22, P391, DOI 10.1021/jm00190a008; CORNWELL MM, 1986, J BIOL CHEM, V261, P7921; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CORNWELL MM, 1986, P NATL ACAD SCI USA, V83, P3847, DOI 10.1073/pnas.83.11.3847; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; DANA K, 1973, BIOCHIM BIOPHYS ACTA, V323, P446; FOJO A, 1985, CANCER RES, V45, P3002; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; Gitler C, 1980, Ann N Y Acad Sci, V346, P199, DOI 10.1111/j.1749-6632.1980.tb22100.x; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1986, P NATL ACAD SCI USA, V83, P337, DOI 10.1073/pnas.83.2.337; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITCHELL JB, 1988, P AM ASSOC CANC RES, V29, P315; NAITO M, 1988, J BIOL CHEM, V263, P11887; NEYFAKH AA, 1988, EXP CELL RES, V128, P513; RAMU A, 1989, INT J CANCER, V44, P539, DOI 10.1002/ijc.2910440328; RAMU N, 1988, ISRAEL J MED SCI, V24, P477; RAVIV Y, 1984, BIOCHEMISTRY-US, V23, P503, DOI 10.1021/bi00298a016; RAVIV Y, 1989, BIOCHEMISTRY-US, V28, P1313, DOI 10.1021/bi00429a055; RAVIV Y, 1987, P NATL ACAD SCI USA, V84, P6103, DOI 10.1073/pnas.84.17.6103; RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SAFA AR, 1987, J BIOL CHEM, V262, P7884; SCOTTO KW, 1986, SCIENCE, V232, P751, DOI 10.1126/science.2421411; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SHEN DW, 1986, J BIOL CHEM, V261, P7762; TSURUO T, 1981, CANCER RES, V41, P1967; WILLINGHAM MC, 1986, CANCER RES, V46, P5941	35	363	368	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1990	265	7					3975	3980						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CQ480	1968065				2022-12-25	WOS:A1990CQ48000062
J	FRERIKSEN, A; SEYKENS, D; SCHARLOO, W; HEINSTRA, PWH				FRERIKSEN, A; SEYKENS, D; SCHARLOO, W; HEINSTRA, PWH			ALCOHOL-DEHYDROGENASE CONTROLS THE FLUX FROM ETHANOL INTO LIPIDS IN DROSOPHILA LARVAE - A C-13 NMR-STUDY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; TRICARBOXYLIC-ACID CYCLE; METABOLIC FLUX; MELANOGASTER LARVAE; DIETARY ETHANOL; CARBON FLUX; SPECTROSCOPY; PATHWAYS; LIVER; HEART	The dependence of the flux in the alcohol-degrading pathway on the activity of alcohol dehydrogenase was investigated in Drosophila larvae. Third-instar larvae were supplied with [2-C-13]ethanol as a dietary carbon source. Specific carbon enrichments in de novo synthesized fatty acids were determined in vitro by means of C-13 nuclear magnetic resonance spectroscopy. Carbon fluxes deduced from these enrichment patterns were correlated with the in vitro alcohol dehydrogenase activities in three different Adh genotypes in seven different strains. The flux control coefficient for alcohol dehydrogenase was shown to be approximately 1.0. This indicates that the alcohol dehydrogenase gene-enzyme system in Drosophila larvae can be a major target of natural selection.	UNIV UTRECHT, DEPT ORGAN CHEM, 3584 CH UTRECHT, NETHERLANDS	Utrecht University	FRERIKSEN, A (corresponding author), UNIV UTRECHT, DEPT PLANT ECOL & EVOLUT BIOL, EVOLUT GENET SECT, PADUALAAN 8, 3584 CH UTRECHT, NETHERLANDS.							ALGER JR, 1986, NMR LIVING SYSTEMS, P231; BEENAKKERS AMT, 1985, PROG LIPID RES, V24, P19; CANET D, 1976, J MAGN RESON, V23, P361, DOI 10.1016/0022-2364(76)90220-1; CANIONI P, 1983, BIOCHEMISTRY-US, V22, P4974, DOI 10.1021/bi00290a015; CAVENER DR, 1981, EVOLUTION, V35, P1, DOI 10.1111/j.1558-5646.1981.tb04853.x; CAVENER DR, 1981, P NATL ACAD SCI-BIOL, V78, P4444, DOI 10.1073/pnas.78.7.4444; CHAMBERS GK, 1988, ADV GENET, V25, P40; CLARK AG, 1988, GENETICS, V119, P595; COHEN SM, 1989, METHOD ENZYMOL, V177, P417; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P581, DOI 10.1021/bi00376a033; COHEN SM, 1981, J BIOL CHEM, V256, P3428; COHEN SM, 1979, P NATL ACAD SCI USA, V76, P4808, DOI 10.1073/pnas.76.10.4808; Downer R.G.H., 1985, P77; DYKHUIZEN DE, 1987, GENETICS, V115, P25; EISSES KT, 1985, MOL GEN GENET, V199, P76, DOI 10.1007/BF00327513; GEER BW, 1985, BIOCHEM GENET, V23, P607, DOI 10.1007/BF00504295; GEER BW, 1989, J EXP ZOOL, V250, P22, DOI 10.1002/jez.1402500105; GEER BW, 1986, BIOCHEM GENET, V24, P51, DOI 10.1007/BF00502978; GEER BW, 1977, INSECT BIOCHEM, V7, P371, DOI 10.1016/0020-1790(77)90040-3; GEER BW, 1991, DRUG ALCOHOL ABUSE R, P325; GREEN PR, 1979, ARCH INT PHYSIOL BIO, V87, P485, DOI 10.3109/13813457909070512; HARTL DL, 1985, GENETICS, V111, P655; HEINSTRA PWH, 1990, INSECT BIOCHEM, V20, P343, DOI 10.1016/0020-1790(90)90053-W; HEINSTRA PWH, 1991, MOL BIOL EVOL, V8, P703; HEINSTRA PWH, 1987, GENETICS, V117, P75; HEINSTRA PWH, 1988, BIOCHIM BIOPHYS ACTA, V967, P224, DOI 10.1016/0304-4165(88)90013-X; JANS AWH, 1989, BIOCHEM J, V263, P231, DOI 10.1042/bj2630231; JANS AWH, 1989, MAGNET RESON MED, V9, P419, DOI 10.1002/mrm.1910090315; KACSER H, 1987, TRENDS BIOCHEM SCI, V12, P5, DOI 10.1016/0968-0004(87)90005-3; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MALLOY CR, 1987, FEBS LETT, V212, P58, DOI 10.1016/0014-5793(87)81556-9; MALLOY CR, 1988, J BIOL CHEM, V263, P6964; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MCKECHNIE SW, 1988, GENET RES, V52, P179, DOI 10.1017/S0016672300027634; MCKECHNIE SW, 1984, INSECT BIOCHEM, V14, P231, DOI 10.1016/0020-1790(84)90034-9; MIDDLETON RJ, 1983, GENETICS, V105, P633; NICOLAY K, 1987, PHYSL GENETIC MODULA, V104, P97; STANLEYSAMUELSON DW, 1988, ARCH INSECT BIOCHEM, V9, P1, DOI 10.1002/arch.940090102; THOMPSON SN, 1990, INSECT BIOCHEM, V20, P223, DOI 10.1016/0020-1790(90)90039-W; ZERA AJ, 1985, COMPREHENSIVE INSECT, V10, P633	40	38	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21399	21403						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939174				2022-12-25	WOS:A1991GP80400016
J	KASHIWAGI, K; SUZUKI, T; SUZUKI, F; FURUCHI, T; KOBAYASHI, H; IGARASHI, K				KASHIWAGI, K; SUZUKI, T; SUZUKI, F; FURUCHI, T; KOBAYASHI, H; IGARASHI, K			COEXISTENCE OF THE GENES FOR PUTRESCINE TRANSPORT PROTEIN AND ORNITHINE DECARBOXYLASE AT 16-MIN ON ESCHERICHIA-COLI CHROMOSOME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIODEGRADATIVE ORNITHINE; POLYAMINE TRANSPORT; POLYACRYLAMIDE GELS; FILM DETECTION; PHYSICAL MAP; IDENTIFICATION; SPERMIDINE; POLYMERASE; MUTANTS; CLONING	The nucleotide sequence of one of the putrescine transport operons (pPT71), located at 16 min of the Escherichia coli chromosome, was determined. It contained the genes for an induced ornithine decarboxylase and a putrescine transport protein. The gene for the ornithine decarboxylase contained a 2,196-nucleotide open reading frame encoding a 732-amino acid protein whose calculated M(r) was 82,414, and the predicted amino acid sequence from the open reading frame had 65% homology with that of a constitutive ornithine decarboxylase encoded by the gene at 64 min. The ornithine decarboxylase activity was observed in the cells carrying pPT71 cultured at pH 5.2, but not in the cells cultured at pH 7.0. The gene for the putrescine transport protein contained a 1,317-nucleotide open reading frame encoding a 439-amino acid protein whose calculated M(r) was 46,494. The hydropathy profile of the putrescine transport protein revealed that it consisted of 12 putative transmembrane spanning segments linked by hydrophilic segments of variable length. The transport protein was in fact found in the membrane fraction. When the gene for the putrescine transport protein was linked to the tet promoter of the vector instead of its own promoter, the putrescine transport activity increased greatly. The results suggest that the gene expression of the operon is repressed strongly under standard conditions.	CHIBA UNIV, FAC PHARMACEUT SCI, 1-33 YAYOI CHO, CHIBA 260, JAPAN	Chiba University				Igarashi, Kazuei/0000-0003-3751-3187				APPLEBAUM D, 1975, BIOCHEMISTRY-US, V14, P3675, DOI 10.1021/bi00687a025; APPLEBAUM DM, 1977, BIOCHEMISTRY-US, V16, P1580, DOI 10.1021/bi00627a008; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOYLE SM, 1984, GENE, V30, P129, DOI 10.1016/0378-1119(84)90113-6; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CUNNINGHAMRUNDLES S, 1975, J BACTERIOL, V124, P791, DOI 10.1128/JB.124.2.791-799.1975; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; ITO K, 1990, ARCH BIOCHEM BIOPHYS, V278, P277, DOI 10.1016/0003-9861(90)90260-6; KARPEL R, 1988, J BIOL CHEM, V263, P10408; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1990, J BIOL CHEM, V265, P20893; KASHIWAGI K, 1986, J BACTERIOL, V165, P972, DOI 10.1128/jb.165.3.972-977.1986; KASHIWAGI K, 1988, J BACTERIOL, V170, P3131, DOI 10.1128/jb.170.7.3131-3135.1988; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LINDEROTH N, 1983, BIOCHEM BIOPH RES CO, V117, P616, DOI 10.1016/0006-291X(83)91245-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAAS WK, 1972, MOL GEN GENET, V119, P1, DOI 10.1007/BF00270439; MORRIS DR, 1983, METHOD ENZYMOL, V94, P125; MUNRO GF, 1974, J BACTERIOL, V118, P952, DOI 10.1128/JB.118.3.952-963.1974; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PLATT T, 1981, CELL, V24, P10, DOI 10.1016/0092-8674(81)90496-7; SANCAR A, 1979, J BACTERIOL, V137, P692, DOI 10.1128/JB.137.1.692-693.1979; SANCAR A, 1981, J MOL BIOL, V148, P45, DOI 10.1016/0022-2836(81)90234-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATISHCHANDRAN C, 1990, J BACTERIOL, V172, P4748, DOI 10.1128/jb.172.9.4748.1990; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; TABOR CW, 1966, J BIOL CHEM, V241, P3714; TABOR CW, 1986, P NATL ACAD SCI USA, V83, P6040, DOI 10.1073/pnas.83.16.6040; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WATANABE Y, 1981, BIOCHIM BIOPHYS ACTA, V656, P134, DOI 10.1016/0005-2787(81)90078-2; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	40	98	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20922	20927						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939141				2022-12-25	WOS:A1991GN00100053
J	LUO, XN; ARCASOY, MO; BRICKNER, HE; MISTRY, S; SCHECHTER, AD; ATWEH, GF				LUO, XN; ARCASOY, MO; BRICKNER, HE; MISTRY, S; SCHECHTER, AD; ATWEH, GF			REGULATED EXPRESSION OF P18, A MAJOR PHOSPHOPROTEIN OF LEUKEMIC-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-ENRICHED PHOSPHOPROTEIN; HYPERSENSITIVE SITES; GEL-ELECTROPHORESIS; PHORBOL ESTER; GLOBIN GENES; DNA; PROTEIN; PHOSPHORYLATION; DIFFERENTIATION; TRANSCRIPTION	p18 is a phosphoprotein that is present in great abundance in acute leukemia blasts and in less abundance in proliferating lymphocytes. This protein undergoes major changes in its state of phosphorylation upon induction of differentiation of leukemic cells in culture. The same protein appears to be involved in a variety of other cellular processes that include regulation of hormone secretion, T cell activation, muscle differentiation, and brain development. In this report, we describe our studies of the regulation of expression of this gene in leukemic cells. We show that the expression of this gene is markedly reduced upon induction of differentiation of a variety of leukemic cells in culture. We use a cDNA clone that we constructed earlier which encodes this protein as a probe to isolate the human chromosomal p18 gene. We characterize the 5' end of this gene in detail and identify its promoter element. We also identify a regulatory element in the first intervening sequence (IVS-1) of this gene which loses its DNase I hypersensitivity upon induction of differentiation of leukemic cells in culture. Our DNase I footprinting experiments demonstrate nuclear protein binding to multiple sequence motifs within its promoter element and its IVS-1 regulatory element. Functional studies using a transient expression system show that deletion of these sequence motifs has profound effects on the expression of this gene. These studies begin to shed some light on the mechanism of regulation of a gene that may be involved in control of cell growth and differentiation and in a variety of other vital cellular processes.	VET ADM MED CTR,800 POLY PL,BROOKLYN,NY 11209; SUNY HLTH SCI CTR,DEPT MED,BROOKLYN,NY 11209; SUNY HLTH SCI CTR,DEPT ANAT & CELL BIOL,BROOKLYN,NY 11209	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL016008, R01HL042919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42919, HL-16008] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRETA L, 1989, J BIOL CHEM, V264, P9932; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COLLINS SJ, 1987, BLOOD, V70, P1233; COOPER HL, 1989, J IMMUNOL, V143, P956; COOPER HL, 1990, J IMMUNOL, V145, P1205; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOYE V, 1989, J BIOL CHEM, V264, P12134; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Favaloro J, 1980, Methods Enzymol, V65, P718; FERRARI AC, 1990, GENE CHROMOSOME CANC, V2, P125, DOI 10.1002/gcc.2870020208; FEUERSTEIN N, 1985, CANCER RES, V45, P3243; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HABERMAN E, 1979, P NATL ACAD SCI USA, V76, P1293; HANASH SM, 1988, J BIOL CHEM, V263, P12813; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Maniatis T, 1989, DECONTAMINATION DILU; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCARTHY DM, 1983, LEUKEMIA RES, V7, P51, DOI 10.1016/0145-2126(83)90057-7; PASMANTIER R, 1986, ENDOCRINOLOGY, V119, P1229, DOI 10.1210/endo-119-3-1229; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TUAN D, 1984, P NATL ACAD SCI-BIOL, V81, P2718, DOI 10.1073/pnas.81.9.2718; ULRICH MJ, 1990, BLOOD, V75, P990; WELGUS HG, 1986, J CLIN INVEST, V77, P1675, DOI 10.1172/JCI112485; WILSON JT, 1978, NUCLEIC ACIDS RES, V5, P563, DOI 10.1093/nar/5.2.563; WU R, 1971, J MOL BIOL, V57, P491, DOI 10.1016/0022-2836(71)90105-7; ZHU XX, 1989, J BIOL CHEM, V264, P14556	41	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21004	21010						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939149				2022-12-25	WOS:A1991GN00100066
J	MEDEMA, RH; BURGERING, BMT; BOS, JL				MEDEMA, RH; BURGERING, BMT; BOS, JL			INSULIN-INDUCED P21RAS ACTIVATION DOES NOT REQUIRE PROTEIN-KINASE-C, BUT A PROTEIN SENSITIVE TO PHENYLARSINE OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 ADIPOCYTES; RAS P21; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; DIACYLGLYCEROL PRODUCTION; BIOCHEMICAL-PROPERTIES; CELLS; GAP; MICROINJECTION; EXPRESSION	Insulin treatment of fibroblasts overexpressing the insulin receptor causes a rapid accumulation of the GTP-bound form of p21ras. We have studied the involvement of protein kinase C (PKC) in, and the effect of phenylarsine oxide (PAO), a putative inhibitor of tyrosine phosphatase activity on, this process. Activation of p21ras was not observed when the cells were stimulated with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) and pretreatment with TPA for 16 h, sufficient to down-regulate PKC activity, did not abolish p21ras activation by insulin. These results show that PKC is not involved in the insulin-induced activation of p21ras. Pretreatment of the cells with PAO for 5 min completely blocked insulin-induced p21ras activation. Addition of 2,3-dimercaptopropanol prevented this inhibition by PAO. Also, addition of PAO after insulin stimulation could reverse the activation of p21ras. Since PAO did not affect overall phosphorylation of the insulin receptor beta-chain, we conclude that a PAO-sensitive protein is involved in the induction of p21ras activation by insulin.	STATE UNIV UTRECHT,PHYSIOL CHEM LAB,VONDELLAAN 24A,3521 GG UTRECHT,NETHERLANDS	Utrecht University				Medema, Rene/0000-0002-6754-0381				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHU DTW, 1986, J BIOL CHEM, V261, P6848; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER DR, 1989, BIOCHEM BIOPH RES CO, V161, P327, DOI 10.1016/0006-291X(89)91600-8; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FARAGO A, 1990, FEBS LETT, V268, P350, DOI 10.1016/0014-5793(90)81284-U; FARESE RV, 1987, SCIENCE, V236, P586, DOI 10.1126/science.3107122; FARESE RV, 1984, J BIOL CHEM, V259, P7094; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FROST SC, 1985, J BIOL CHEM, V260, P2646; FROST SC, 1987, J BIOL CHEM, V262, P9872; FROST SC, 1990, BIOCHEM J, V269, P589, DOI 10.1042/bj2690589; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HOSHINO M, 1988, MOL CELL BIOL, V8, P4169, DOI 10.1128/MCB.8.10.4169; HRESKO RC, 1990, J BIOL CHEM, V265, P21075; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; LIAO K, 1991, J BIOL CHEM, V266, P6544; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCAFFREY PG, 1987, BIOCHEM BIOPH RES CO, V146, P140, DOI 10.1016/0006-291X(87)90702-9; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1988, FEBS LETT, V236, P185, DOI 10.1016/0014-5793(88)80311-9; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; STRULOVICI B, 1991, J BIOL CHEM, V266, P168; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; WU VS, 1981, LIFE SCI, V29, P1855, DOI 10.1016/0024-3205(81)90516-6; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	55	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21186	21189						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939160				2022-12-25	WOS:A1991GN00100093
J	SINHA, S; KNOPS, J; ESCH, F; MOYER, ED; OLTERSDORF, T				SINHA, S; KNOPS, J; ESCH, F; MOYER, ED; OLTERSDORF, T			CONVERSION OF THE ALZHEIMERS BETA-AMYLOID PRECURSOR PROTEIN (APP) KUNITZ DOMAIN INTO A POTENT HUMAN NEUTROPHIL ELASTASE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LEUKOCYTE ELASTASE; CATHEPSIN-G; VARIANTS; DISEASE; ALPHA-1-ANTITRYPSIN	Site-specific mutagenesis techniques have been used to construct active site variants of the Kunitz-type protease inhibitor domain present in the Alzheimer's beta-amyloid precursor protein (APP-KD). Striking alteration of its protease inhibitory properties were obtained when the putative P1 residue, arginine, was replaced with the small hydrophobic residue valine. The altered protein was no longer inhibitory toward bovine pancreatic trypsin, human Factor XI(a), mouse epidermal growth factor-binding protein, or bovine chymotrypsin, all of which are strongly inhibited by the unaltered APP-KD (Sinha, S., Dovey, H. F., Seubert, P., Ward, P. J., Blacher, R. W., Blaber, M., Bradshaw, R. A., Arici, M., Mobley, W. C., and Lieberburg, I. (1990) J. Biol. Chem. 265, 8983-8985). Instead, the P1-Val-APP-KD was a potent inhibitor of human neutrophil elastase, with a K(i) = 0.8 nM, as estimated by the inhibition of the activity of human neutrophil elastase measured using a chromogenic substrate. It also inhibited the degradation of insoluble elastin by the enzyme virtually stoichiometrically. Replacement of the P1' (Ala) and P2' (Met) residues of P1-Val-MKD with the corresponding residues (Ser, Ile) from alpha-1 proteinase inhibitor resulted in an inactive protein, underscoring the mechanistic differences between the serpins from the Kunitz-type protease inhibitor family. These results confirm the importance of the P1 arginine residue of APP-KD in determining inhibitory specificity, and are also the first time that a single amino acid replacement has been shown to generate a specific potent human neutrophil elastase inhibitor from a human KD sequence.			SINHA, S (corresponding author), ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080, USA.							AUERSWALD EA, 1988, BIOL CHEM H-S, V369, P27; BANDA MJ, 1981, METHODS STUDYING MON, P603; CARRELL RW, 1982, NATURE, V298, P329, DOI 10.1038/298329a0; COLLINS J, 1990, BIOL CHEM H-S, V371, P29; HYNES TR, 1990, BIOCHEMISTRY-US, V29, P10018, DOI 10.1021/bi00495a002; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; MCWHERTER CA, 1989, BIOCHEMISTRY-US, V28, P5708, DOI 10.1021/bi00440a002; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; PATSTON PA, 1990, J BIOL CHEM, V265, P10786; REILLY CF, 1980, BIOCHIM BIOPHYS ACTA, V621, P147, DOI 10.1016/0005-2795(80)90070-7; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SINHA S, 1990, J BIOL CHEM, V265, P8983; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; TRAVIS J, 1985, J BIOL CHEM, V260, P4384; WENZEL HR, 1986, CHEM PEPTIDES PROTEI, V3, P105	18	12	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21011	21013						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939150				2022-12-25	WOS:A1991GN00100067
J	WOLKERS, WF; GREGORY, JD; CHURCHICH, JE; SERPERSU, EH				WOLKERS, WF; GREGORY, JD; CHURCHICH, JE; SERPERSU, EH			ARRANGEMENT OF THE SUBSTRATES AT THE ACTIVE-SITE OF BRAIN PYRIDOXAL KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMIUM(III) ADENOSINE 5'-TRIPHOSPHATE; MAGNETIC-RESONANCE; STAPHYLOCOCCAL NUCLEASE; PYRUVATE-KINASE; BINDING-SITES; ENZYME; 5'-DIPHOSPHATE; PURIFICATION; MECHANISM; AFFINITY	The distances between enzyme-bound paramagnetic CrATP (a stable, beta,gamma-bidentate complex of Cr3+ and ATP) at the active site of sheep brain pyridoxal kinase and the protons of bound inhibitor 4-dPyr (4-deoxypyridoxine) were determined in the ternary enzyme-CrATP.4-dPyr complex by measuring the paramagnetic effects of Cr3+ on the longitudinal relaxation rates (1/T1p) of the protons of 4-dPyr. The correlation time for the Cr3+-4-dPyr dipolar interaction on the enzyme was estimated as 1.59 ns by the frequency dependence of 1/T1p of water protons. Temperature dependence of 1/T1p values indicated the fast exchange of 4-dPyr from the paramagnetic enzyme-CrATP.4-dPyr complex; hence the measured 1/T1p values can be used for metal-nucleus distance determinations. The distances from the Cr3+ of the enzyme-bound CrATP to the 2-methyl (7.19 angstrom), 4-methyl (7.18 angstrom), and H6 proton (6.18 angstrom) of the 4-dPyr are too great to permit a direct coordination of any group from 4-dPyr. However, these distances can be built into a model in which phosphorus of the gamma-phosphoryl group of ATP is 4 angstrom away from the oxygen atom of the 5-CH2OH group of the 4-dpyr. This suggests that phosphorylation of pyridoxal can occur via direct transfer of the phosphoryl group between the bound substrates at the active site of pyridoxal kinase.	UNIV TENNESSEE,DEPT BIOCHEM,KNOXVILLE,TN 37996	University of Tennessee System; University of Tennessee Knoxville			Wolkers, Wim/AAT-1110-2021	Wolkers, Willem/0000-0002-7406-4651	NIGMS NIH HHS [R29 GM422661] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNONE A, 1989, J BIOL CHEM, V264, P4322; CARR HY, 1954, PHYS REV, V94, P630, DOI 10.1103/PhysRev.94.630; CHURCHICH JE, 1982, J BIOL CHEM, V257, P2136; CLELAND WW, 1979, ADV INORG BIOCHEM, V1, P163; DOMINICI P, 1988, J BIOL CHEM, V263, P14712; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1496, DOI 10.1021/bi00548a037; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1506, DOI 10.1021/bi00548a038; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; GUPTA RK, 1976, J BIOL CHEM, V251, P2421; KERRY JA, 1986, EUR J BIOCHEM, V158, P581, DOI 10.1111/j.1432-1033.1986.tb09794.x; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; MACGILLOVRY CH, 1962, INT TABLES XRAY CRYS, P266; MCCORMICK D, 1961, J BIOL CHEM, V236, P2076; Mildvan A S, 1978, Methods Enzymol, V49, P322; Mildvan A S, 1972, Methods Enzymol, V26, P654; MILDVAN AS, 1970, ADV ENZYMOL REL S BI, V33, P1; NEARY JT, 1970, J BIOL CHEM, V245, P5585; REUBEN J, 1970, J BIOL CHEM, V245, P6539; ROSEVEAR PR, 1981, BIOCHEMISTRY-US, V21, P6156; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; SERPERSU EH, 1986, BIOCHEMISTRY-US, V25, P68, DOI 10.1021/bi00349a011; SERPERSU EH, 1990, EUR J BIOCHEM, V191, P397, DOI 10.1111/j.1432-1033.1990.tb19135.x; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; TAKEUCHI F, 1985, BIOCHEM J, V227, P537, DOI 10.1042/bj2270537	24	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20761	20766						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939126				2022-12-25	WOS:A1991GN00100028
J	SHAW, P; TARDY, S; BENITO, E; OBRADOR, A; COSTA, J				SHAW, P; TARDY, S; BENITO, E; OBRADOR, A; COSTA, J			OCCURRENCE OF KI-RAS AND P53 MUTATIONS IN PRIMARY COLORECTAL TUMORS	ONCOGENE			English	Article							CHROMOSOME-5 ALLELE LOSS; FAMILIAL POLYPOSIS COLI; SHORT ARM; GENE-MUTATIONS; LONG ARM; CARCINOMAS; ANTIGEN; ONCOGENE; DNA; TRANSFORMATION	Twenty-four colorectal tumors and their paired mucosa were examined for allele loss on chromosomes 5 and 17, using polymerase chain reaction-amplified DNA, and for mutations in the Ki-ras and p53 genes. In addition, 19 benign polyps were analysed for mutations in the p53 gene. RFLP analysis of the long arm of chromosome 5 indicated an allele loss frequency of 47% for malignant tumors, a value somewhat higher than previously observed. Examination of the short arm of chromosome 17 indicated an allele loss of 60%. Sequence analysis of the p53 gene in colorectal tumors indicated that 64% contained a mutation. All tumors showing allele loss on chromosome 17 were mutant for p53, suggesting that mutation of one p53 allele precedes the hemizygotic loss of the wild-type allele. Sequence analysis of the p53 gene in 19 benign polyps, devoid of severe dysplasia, did not reveal any mutants, suggesting that the mutation of one p53 allele is an event that takes place after polyp formation. Ki-ras mutations were observed in 48% of the tumors examined. All tumors which were mutant for Ki-ras, except for one, were also mutant for p53.	EPIDEMIOL UNIT,E-07012 MALLORCA,SPAIN; TUMOR REGISTRY MALLORCA,E-07012 MALLORCA,SPAIN; HOSP SON DURETA ANDREA DORIA,GASTROENTEROL UNIT,E-07014 MALLORCA,SPAIN	Hospital Universitari Son Espases; Hospital Universitari Son Dureta	SHAW, P (corresponding author), UNIV LAUSANNE,INST PATHOL,DIV ONCOL EXPTL,RUE BUGNON 25,CH-1011 LAUSANNE,SWITZERLAND.			Benito Oliver, Enrique/0000-0002-0489-4668				ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BENITO E, 1990, INT J CANCER, V45, P69, DOI 10.1002/ijc.2910450114; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINDLAY CA, 1989, CELL, V57, P1083; FORESTER K, 1987, NATURE, V327, P298; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; KHAN PM, 1988, HUMAN GENETICS; KLINGER H, 1987, CYTOGENET CELL GENET, V46, P1; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Maniatis T., 1982, MOL CLONING; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MITCHELL LG, 1989, ANAL BIOCHEM, V178, P239, DOI 10.1016/0003-2697(89)90631-3; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; MULERIS M, 1985, CR ACAD SCI III-VIE, P315; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; SAHLI R, 1985, NUCLEIC ACIDS RES, V13, P3617, DOI 10.1093/nar/13.10.3617; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; STEWART GD, 1987, NUCLEIC ACIDS RES, V15, P3939, DOI 10.1093/nar/15.9.3939; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WILDRICK DM, 1988, BIOCHEM BIOPH RES CO, V150, P591, DOI 10.1016/0006-291X(88)90434-2	37	85	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2121	2128						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945416				2022-12-25	WOS:A1991GX11900024
J	HU, E; RUBIN, CS				HU, E; RUBIN, CS			CASEIN KINASE-II FROM CAENORHABDITIS-ELEGANS - CLONING, CHARACTERIZATION, AND DEVELOPMENTAL REGULATION OF THE GENE ENCODING THE BETA SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MESSENGER-RNA; CATALYTIC SUBUNIT; LEADER SEQUENCE; GROWTH-FACTOR; CDNA; EXPRESSION; CELLS; PHOSPHORYLATION; IDENTIFICATION	Complementary DNAs encoding the beta-subunit of casein kinase II (CKII-beta) from the nematode Caenorhabditis elegans were cloned and sequenced. The predicted beta-subunit polypeptide comprises 234 amino acid residues and has a M(r) of 26,452. CKII-beta is not homologous with other types of proteins. In synchronously developing C. elegans the abundance of the 1.3-kilobase mRNA for CKII-beta varies in parallel with the level of mRNA encoding the catalytic subunit (alpha) of CKII. Thus, the developmental expression of CKII subunits is controlled coordinately and pretranslationally. CKII-beta and CKII-alpha mRNAs are enriched 5-10-fold in C. elegans embryos relative to their concentrations at several other stages of nematode development. A 3.8-kilobase pair segment of C. elegans DNA that contains the CKII-beta gene and an extensive 5'-flanking region was cloned and sequenced. The CKII-beta gene is divided into 6 exons by introns ranging from 49 to 533 base pairs in length. The first exon encodes 88 nucleotides of 5'-untranslated mRNA. Exon 2 (72 base pairs) contains the initiator Met codon and only 5 additional codons. Exons 3-6 encode 52, 63, 64, and 49 amino acid residues, respectively. The 5' terminus of CKII-beta mRNA is modified post-transcriptionally by trans-splicing with a leader sequence of 22 nucleotides. The CKII-beta gene was mapped to a position on C. elegans chromosome 2 that is in close proximity to the lin-11 gene.			HU, E (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,ATRAN LABS,DEPT MOLEC PHARMACOL,BRONX,NY 10461, USA.				NIGMS NIH HHS [GM22792] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; CARROLL D, 1989, J BIOL CHEM, V264, P7345; COCHET C, 1983, J BIOL CHEM, V258, P1403; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; EMMONS SW, 1988, NEMATODE CAENORHABDI, P56; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GROSS RE, 1990, J BIOL CHEM, V265, P6896; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HU E, 1990, J BIOL CHEM, V265, P20609; HU ED, 1990, J BIOL CHEM, V265, P5072; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; JACOBI R, 1989, EUR J BIOCHEM, V183, P227; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; LAND H, 1981, NUCLEIC ACIDS RES, V9, P2251, DOI 10.1093/nar/9.10.2251; LU XY, 1990, J BIOL CHEM, V265, P3293; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARIDOR G, 1991, J BIOL CHEM, V266, P2362; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEREZ M, 1987, EUR J BIOCHEM, V170, P493, DOI 10.1111/j.1432-1033.1987.tb13726.x; PINNA LA, 1990, PEPT PROT PHOSPH, P145; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SLUSTON J, 1988, NEMATODE CAENORHABDI, P603; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8832; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; SUL HS, 1984, J BIOL CHEM, V259, P1201; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; Wood W. B., 1988, NEMATODE CAENORHABDI, P10	40	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19796	19802						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918084				2022-12-25	WOS:A1991GK66700096
J	LETO, TL; GARRETT, MC; FUJII, H; NUNOI, H				LETO, TL; GARRETT, MC; FUJII, H; NUNOI, H			CHARACTERIZATION OF NEUTROPHIL NADPH OXIDASE FACTOR-P47-PHOX AND FACTOR-P67-PHOX FROM RECOMBINANT BACULOVIRUSES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; RESPIRATORY BURST OXIDASE; 2 CYTOSOLIC COMPONENTS; BOVINE POLYMORPHONUCLEAR NEUTROPHILS; CYTOCHROME-B; CHROMOSOMAL LOCATION; DIPHENYLENE IODONIUM; GUANINE-NUCLEOTIDES; LIGHT CHAIN	Superoxide production by phagocytic blood cells involves assembly of an active NADPH oxidase complex from components found both in membrane and cytosolic locations in resting cells. We recently cloned cDNAs encoding two cytosolic components (p47-phox and p67-phox) of the oxidase that are deficient in distinct forms of autosomal recessive chronic granulomatous disease. The precise roles of p47-phox and p67-phox were explored further using purified factors produced in large quantities using recombinant baculoviruses to infect cultured Sf9 insect cells. Neither p47-phox nor p67-phox are thought to represent the flavoprotein components of the oxidase, since neither of the purified recombinant factors contained or bound FAD. Recombinant p47-phox and p67-phox are capable of restoring the deficient cytosol from chronic granulomatous disease patient neutrophils to nearly normal levels in a cell-free reconstitution system. Both p47-phox and p67-phox, used together in the absence of neutrophil cytosol, are incapable of supporting cell free production of superoxide, confirming the involvement of other soluble factor(s) in the assembly of an active oxidase in vitro.	NHLBI,CLIN HEMATOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	LETO, TL (corresponding author), NIAID,HOST DEF LAB,BLDG 10,RM 11N106,BETHESDA,MD 20892, USA.							BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1987, J BIOL CHEM, V262, P5563; CURNUTTE JT, 1987, J BIOL CHEM, V262, P6450; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DOUSSIERE J, 1986, BIOCHEM BIOPH RES CO, V139, P85, DOI 10.1016/S0006-291X(86)80083-3; DOUSSIERE J, 1985, BIOCHEMISTRY-US, V24, P7231, DOI 10.1021/bi00346a032; DOUSSIERE J, 1988, BIOCHEM BIOPH RES CO, V152, P993, DOI 10.1016/S0006-291X(88)80382-6; ELLIS JA, 1989, BIOCHEM J, V262, P575, DOI 10.1042/bj2620575; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FRANCKE U, 1990, AM J HUM GENET, V47, P483; FRANCKE U, 1985, AM J HUM GENET, V37, P250; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GABIG TG, 1990, J IMMUNOL, V145, P945; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; ISHIDA K, 1989, FEBS LETT, V243, P169, DOI 10.1016/0014-5793(89)80123-1; KAKINUMA K, 1987, J BIOL CHEM, V262, P12316; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KWONG CH, 1991, CLIN RES, V39, pA273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LOMAX KJ, 1989, SCIENCE, V246, P987, DOI 10.1126/science.2587992; LU DJ, 1990, J BIOL CHEM, V265, P13721; MARKERT M, 1985, P NATL ACAD SCI USA, V82, P3144, DOI 10.1073/pnas.82.10.3144; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; PARKINSON JF, 1988, J BIOENERG BIOMEMBR, V20, P653, DOI 10.1007/BF00762547; PARKOS CA, 1989, BLOOD, V73, P1416; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; PICK E, 1989, J IMMUNOL, V143, P4180; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1978, LANCET, V2, P446; SEGAL AW, 1983, NEW ENGL J MED, V308, P245, DOI 10.1056/NEJM198302033080503; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SEIFERT R, 1987, EUR J BIOCHEM, V162, P563, DOI 10.1111/j.1432-1033.1987.tb10676.x; SMITH RM, 1991, BLOOD, V77, P673; SMITH RM, 1989, J BIOL CHEM, V264, P1958; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAKASUGI S, 1989, J BIOCHEM-TOKYO, V105, P155, DOI 10.1093/oxfordjournals.jbchem.a122630; TEAHAN CG, 1990, BIOCHEM J, V267, P485, DOI 10.1042/bj2670485; TEHAN C, 1987, NATURE, V327, P720; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEI T, 1986, J BIOL CHEM, V261, P5229; UMEKI S, 1990, J BIOL CHEM, V265, P5049; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P9563; WEBB N R, 1990, Technique (Philadelphia), V2, P173; YEA CM, 1990, BIOCHEM J, V265, P95, DOI 10.1042/bj2650095	61	122	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19812	19818						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918085				2022-12-25	WOS:A1991GK66700098
J	RANISH, JA; HAHN, S				RANISH, JA; HAHN, S			THE YEAST GENERAL TRANSCRIPTION FACTOR TFIIA IS COMPOSED OF 2 POLYPEPTIDE SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TATA-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; INITIATION; ACTIVATION; PROMOTER; INVITRO; IDENTIFICATION; PURIFICATION; SEQUENCES	The general transcription factor TFIIA was purified from yeast. A key step in the purification was affinity chromatography using a column containing the adenovirus major late promoter with bound recombinant TFIID to which TFIIA binds with high affinity. TFIIA activity copurifies with two polypeptides of molecular mass 32 and 13.5 kDa. Elution and renaturation of these two polypeptides from sodium dodecyl sulfate-polyacrylamide gels showed that both polypeptides were required for TFIIA activity. TFIIA activity was measured by both a native gel shift assay and by in vitro complementation of transcription using yeast nuclear extracts depleted of TFIIA. The purified renatured yeast TFIIA also complements basal level transcription using a mammalian transcription system depleted of TFIIA. Native TFIIA has an apparent molecular mass of approximately 90 kDa measured by gel filtration chromatography. TFIIA binds to a TFIID. TATA element.DNA complex with an apparent equilibrium dissociation constant (K(D)) of 20 pm. This affinity is about 100-fold greater than the affinity of TFIID for TATA elements and much greater than the affinity of TFIIA for TFIID not bound to DNA.			RANISH, JA (corresponding author), FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA.			Hahn, Steven/0000-0001-7240-2533				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DUNN MJ, 1989, PROTEIN PURIFICATION, P34; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HENDRICKSON W, 1984, J MOL BIOL, V178, P611, DOI 10.1016/0022-2836(84)90241-9; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Kadonaga JT, 1990, CURR OPIN CELL BIOL, V2, P496, DOI 10.1016/0955-0674(90)90133-Y; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KAMBADUR R, 1990, P NATL ACAD SCI USA, V87, P9168, DOI 10.1073/pnas.87.23.9168; KIM W, 1988, J BIOL CHEM, V263, P1880; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MATSUI T, 1980, J BIOL CHEM, V255, P1992; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L	43	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19320	19327						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918049				2022-12-25	WOS:A1991GK66700034
J	GIRONES, N; ALVAREZ, E; SETH, A; LIN, IM; LATOUR, DA; DAVIS, RJ				GIRONES, N; ALVAREZ, E; SETH, A; LIN, IM; LATOUR, DA; DAVIS, RJ			MUTATIONAL ANALYSIS OF THE CYTOPLASMIC TAIL OF THE HUMAN TRANSFERRIN RECEPTOR - IDENTIFICATION OF A SUBDOMAIN THAT IS REQUIRED FOR RAPID ENDOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LOW-DENSITY-LIPOPROTEIN; PROTEIN KINASE-C; CELL-SURFACE; MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; RATE-CONSTANT; COATED PITS; AMINO-ACID; INTERNALIZATION	It has been reported that the sequence Tyr20-X-Arg-Phe23 present within the cytoplasmic tail of the transferrin receptor may represent a tyrosine internalization signal (Collawn, J. F., Stangel, M., Kuhn, L. A., Esekogwu, V., Jing, S., Trowbridge, I. S., and Tainer, J. A. (1990) Cell 63, 1061-1072). However, as Tyr20 is not conserved between species (Alvarez, E., Girones, N., and Davis, R. J. (1990) Biochem. J. 267, 31-35), the functional role of the putative tyrosine internalization signal is not clear. To address this question, we constructed a series of 32 deletions and point mutations within the cytoplasmic tail of the human transferrin receptor. The effect of these mutations on the apparent first order rate constant for receptor endocytosis was examined. It was found that the region of the cytoplasmic tail that is proximal to the transmembrane domain (residues 28-58) is dispensible for rapid endocytosis. In contrast, the distal region of the cytoplasmic tail (residues 1-27) was found to be both necessary and sufficient for the rapid internalization of the transferrin receptor. The region identified includes Tyr20-X-Arg-Phe23, but is significantly larger than this tetrapeptide. It is therefore likely that structural information in addition to the proposed tyrosine internalization signal is required for endocytosis. To test this hypothesis, we investigated whether a heterologous tyrosine internalization signal (from the low density lipoprotein receptor) could function to cause the rapid endocytosis of the transferrin receptor. It was observed that this heterologous tyrosine internalization signal did not allow rapid endocytosis. We conclude that the putative tyrosine internalization signal (Tyr20-Thr-Arg-Phe23) is not sufficient to determine rapid endocytosis of the transferrin receptor. The data reported here indicate that the transferrin receptor internalization signal is formed by a larger cytoplasmic tail structure located at the amino terminus of the receptor.	UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	GIRONES, N (corresponding author), UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605, USA.		Gironès, Núria/AAR-7436-2020; ALVAREZ, ELVIRA/S-8977-2019; Girones, Nuria/L-7865-2017; ALVAREZ, ELVIRA/F-2994-2017	Gironès, Núria/0000-0002-8130-2750; Girones, Nuria/0000-0002-8130-2750; ALVAREZ, ELVIRA/0000-0002-9074-3857; Girones Pujol, Nuria/0000-0002-0932-5018	NIGMS NIH HHS [GM37845] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1990, BIOCHEM J, V267, P31, DOI 10.1042/bj2670031; ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; ALVAREZ E, 1989, EMBO J, V8, P2231, DOI 10.1002/j.1460-2075.1989.tb08347.x; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DAVIS RJ, 1986, EMBO J, V5, P653, DOI 10.1002/j.1460-2075.1986.tb04263.x; DAVIS RJ, 1987, J BIOL CHEM, V262, P13126; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; DAVIS RJ, 1986, J BIOL CHEM, V261, P9034; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAMB JE, 1983, J BIOL CHEM, V258, P8751; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; Maniatis T., 1982, MOL CLONING; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MCGRAW TE, 1988, J CELL BIOL, V106, P1061, DOI 10.1083/jcb.106.4.1061; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SPIESS M, 1985, J BIOL CHEM, V260, P1979; STEARNE PA, 1985, J IMMUNOL, V134, P3474; TANNER LI, 1987, J BIOL CHEM, V262, P8975; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P16309; WARD DM, 1986, BIOCHEM J, V238, P721, DOI 10.1042/bj2380721; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1984, P NATL ACAD SCI USA, V81, P175; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479; [No title captured]	45	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19006	19012						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918016				2022-12-25	WOS:A1991GJ47200091
J	SEHAYEK, E; EISENBERG, S				SEHAYEK, E; EISENBERG, S			MECHANISMS OF INHIBITION BY APOLIPOPROTEIN C OF APOLIPOPROTEIN-E-DEPENDENT CELLULAR-METABOLISM OF HUMAN TRIGLYCERIDE-RICH LIPOPROTEINS THROUGH THE LOW-DENSITY-LIPOPROTEIN RECEPTOR PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN-FIBROBLASTS; SMOOTH-MUSCLE CELLS; HUMAN-PLASMA; MEDIATED UPTAKE; CULTURED-CELLS; LDL RECEPTOR; BINDING; CHOLESTEROL; PROTEIN; APOPROTEINS	The mechanism of inhibition by apolipoprotein C of the uptake and degradation of triglyceride-rich lipoproteins from human plasma via the low density lipoprotein (LDL) receptor pathway was investigated in cultured human skin fibroblasts. Very low density lipoprotein (VLDL) density subfractions and intermediate density lipoprotein (IDL) with or without added exogenous recombinant apolipoprotein E-3 were used. Total and individual (C-I, C-II, C-III-1, and C-III-2) apoC molecules effectively inhibited apoE-3-mediated cell metabolism of the lipoproteins through the LDL receptor, with apoC-I being most effective. When the incubation was carried out with different amounts of exogenous apoE-3 and exogenous apoC, it was shown that the ratio of apoE-3 to apoC determined the uptake and degradation of VLDL. Excess apoE-3 overcame, at least in part, the inhibition by apoC. ApoC, in contrast, did not affect LDL metabolism. Neither apoA-I nor apoA-II, two apoproteins that do not readily associate with VLDL, had any effect on VLDL cell metabolism. The inhibition of VLDL and IDL metabolism cannot be fully explained by interference of association of exogenous apoE-3 with or displacement of endogenous apoE from the lipoproteins. IDL is a lipoprotein that contains both apoB-100 and apoE. By using monoclonal antibodies 4G3 and 1D7, which specifically block cell interaction by apoB-100 and apoE, respectively, it was possible to assess the effects of apoC on either apoprotein. ApoC dramatically depressed the interaction of IDL with the fibroblast receptor through apoE, but had only a moderate effect on apoB-100. The study thus demonstrates that apoC inhibits predominantly the apoE-3-dependent interaction of triglyceride-rich lipoproteins with the LDL receptor in cultured fibroblasts and that the mechanism of inhibition reflects association of apoC with the lipoproteins and specific concentration-dependent effects on apoE-3 at the lipoprotein surface.			SEHAYEK, E (corresponding author), HADASSAH UNIV HOSP, DEPT MED B, LIPID RES LAB, IL-91120 JERUSALEM, ISRAEL.							ALBERS JJ, 1976, ARTERY, V2, P337; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BATES SR, 1987, J LIPID RES, V28, P787; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BIERMAN EL, 1974, CIRC RES, V35, P136, DOI 10.1161/01.RES.35.1.136; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BORENSZTAJN J, 1984, P NATL ACAD SCI-BIOL, V81, P5863, DOI 10.1073/pnas.81.18.5863; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1975, CELL, V6, P307, DOI 10.1016/0092-8674(75)90182-8; BROWN WV, 1970, BIOCHIM BIOPHYS ACTA, V200, P573, DOI 10.1016/0005-2795(70)90115-7; EISENBER.S, 1972, BIOCHIM BIOPHYS ACTA, V280, P94, DOI 10.1016/0005-2760(72)90216-0; EISENBERG S, 1988, ARTERIOSCLEROSIS, V8, P480, DOI 10.1161/01.ATV.8.5.480; EISENBERG S, 1976, LOW DENSITY LIPOPROT, P73; FAINARU M, 1988, ARTERIOSCLEROSIS, V8, P130, DOI 10.1161/01.ATV.8.2.130; FRIEDMAN G, 1990, BIOCHIM BIOPHYS ACTA, V1044, P118, DOI 10.1016/0005-2760(90)90226-N; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; GIANTURCO SH, 1982, J LIPID RES, V23, P984; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAVEL RJ, 1985, ARTERIOSCLEROSIS, V5, P569, DOI 10.1161/01.ATV.5.6.569; HERTZ J, 1988, EMBO J, V7, P4119; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; KLEINMAN Y, 1985, J CLIN INVEST, V75, P1796, DOI 10.1172/JCI111892; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRUL ES, 1985, J CLIN INVEST, V75, P361, DOI 10.1172/JCI111708; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUX SE, 1972, BIOCHIM BIOPHYS ACTA, V278, P266, DOI 10.1016/0005-2795(72)90231-0; MAHLEY RW, 1989, J CLIN INVEST, V83, P2125, DOI 10.1172/JCI114126; MAHLEY RW, 1984, ADV INTERNAL MED, V29, P385; MILNE RW, 1981, J CLIN INVEST, V68, P111, DOI 10.1172/JCI110225; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; PATSCH W, 1976, J LIPID RES, V17, P182; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; SEHAYEK E, 1990, ARTERIOSCLEROSIS, V10, P1088, DOI 10.1161/01.ATV.10.6.1088; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WANGIVERSON P, 1985, BIOCHEM BIOPH RES CO, V126, P578, DOI 10.1016/0006-291X(85)90645-X; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WINDLER E, 1980, J BIOL CHEM, V255, P8303; WINDLER E, 1985, J LIPID RES, V26, P556; YAMADA N, 1989, P NATL ACAD SCI USA, V86, P665, DOI 10.1073/pnas.86.2.665; 1976, DHEW NIH76628 PUBL	43	243	245	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18259	18267						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917954				2022-12-25	WOS:A1991GG55300082
J	HU, YL; RAMSAY, RG; KANEIISHII, C; ISHII, S; GONDA, TJ				HU, YL; RAMSAY, RG; KANEIISHII, C; ISHII, S; GONDA, TJ			TRANSFORMATION BY CARBOXYL-DELETED MYB REFLECTS INCREASED TRANSACTIVATING CAPACITY AND DISRUPTION OF A NEGATIVE REGULATORY DOMAIN	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; GENE V-MYB; C-MYB; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL DOMAINS; PROTO-ONCOGENE; CELLULAR PROGENITOR; FOS PROTEIN; EXPRESSION; SEQUENCE	Carboxyl-truncated forms of the product of the c-myb proto-oncogene (Myb) are encoded by the v-myb oncogene, the rearranged c-myb genes of certain murine cell lines and a transforming recombinant c-myb retrovirus. We report here an examination of the abilities of a series of carboxyl deletions of Myb to transform hemopoietic cells. Increasing degrees of truncation resulted in increasing transforming capacity until the deletions removed the region responsible for transactivation by Myb. Because the effects of these deletions on transformation paralleled their previously described effects on the transactivating capacity of Myb but did not correlate with their ability to repress transcription, our results imply that removal of a domain which negatively regulates transactivation is responsible for oncogenic activation of carboxyl-truncated forms of Myb. Moreover, these data support the view that activated forms of myb transform by increasing and/or deregulating the expression of other genes.	ROYAL MELBOURNE HOSP,MELBOURNE TUMOUR BIOL BRANCH,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; RIKEN			Hu, Yinling/G-5682-2015; Ramsay, Robert G/C-3291-2015; Ishii, Shunsuke/A-5271-2016; Gonda, Thomas J/A-3620-2012	Hu, Yinling/0000-0002-4795-8537; Ramsay, Robert G/0000-0001-5003-0433; Ishii, Shunsuke/0000-0002-6530-2478; 				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; DUDEK H, 1989, ONCOGENE, V4, P1489; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Frykberg L, 1988, Oncogene Res, V3, P313; GELINAS C, 1988, ONCOGENE, V3, P349; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MILLER AD, 1984, CELL, V36, P51; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1991, IN PRESS ONCOGENE; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	37	114	115	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1549	1553						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923521				2022-12-25	WOS:A1991GX27400008
J	MAZARS, R; PUJOL, P; MAUDELONDE, T; JEANTEUR, P; THEILLET, C				MAZARS, R; PUJOL, P; MAUDELONDE, T; JEANTEUR, P; THEILLET, C			P53 MUTATIONS IN OVARIAN-CANCER - A LATE EVENT	ONCOGENE			English	Article							PROTO-ONCOGENE; HUMAN-BREAST; TUMOR-ANTIGEN; LUNG-CANCER; ALLELE LOSS; MUTANT P53; GENE; TRANSFORMATION; CHROMOSOME-17; CELLS	Using a combination of polymerase chain reaction and single-strand conformation polymorphism techniques we analyzed 34 ovarian cancer samples (30 primary tumors and four matched metastases) for the presence of mutations in exons 5, 6, 7, 8 and 9 of the p53 gene. Mutations in this portion of the gene are known to lead to the loss of the oncosuppressive potential of p53. Thirty-six percent (11/30) of the ovarian carcinomas tested presented a mutated p53 allele. Mutations were clustered in exons 5 and 7 to the exclusion of the other exons screened. Most mutations (10/11) were point mutations, but no preferential pattern of nucleotide substitution could be observed. In three tumors the mutation of one allele was concomitant with the loss of the wild-type counterpart. Another sample presented both alleles independently mutated. These observations are in agreement with the recessive nature of the p53 mutation. However, analysis of tissue sections from two tumors showed that the portion composed of 100% cancer cells could hold both the mutated and the wild-type form. Moreover analysis of serial sections gave evidence of a heterogeneous cellular content in one of these tumors, suggesting that p53 mutations may, in some cases, occur late during ovarian cancer evolution. It is, moreover, noticeable that, in matched sets of primary tumors and metastases, the same mutation was observed in both tumor samples. Therefore, even as a late event, p53 mutation occurs before metastatic spread.	CTR PAUL LAMARQUE,BIOCHIM LAB,CNRS,UA 1191,VAL AURELLE,F-34094 MONTPELLIER 5,FRANCE; CHR MONTPELLIER,BIOL CELLULAIRE LAB,F-34090 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; CHU de Montpellier			Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				ADNANE J, 1991, ONCOGENE, V6, P659; ADNANE J, 1989, ONCOGENE, V4, P1389; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BIRD A, 1987, TRENDS GENED, V3, P32; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIBA I, 1990, ONCOGENE, V5, P1603; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FILMUS JE, 1985, CANCER RES, V45, P4468; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE JH, 1989, CANCER RES, V49, P1220; LOEB LA, 1990, MUTAT RES, V238, P297, DOI 10.1016/0165-1110(90)90021-3; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, ONCOGENE, V5, P973; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NANDA RR, 1990, P NATL ACAD SCI USA, V87, P7555; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROSSER J, 1990, ONCOGENE, V5, P1573; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SOUSSI T, 1990, ONCOGENE, V5, P945; STATTON MR, 1990, ONCOGENE, V5, P1297; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	36	201	204	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1685	1690						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923532				2022-12-25	WOS:A1991GX27400026
J	NERLOV, C; RORTH, P; BLASI, F; JOHNSEN, M				NERLOV, C; RORTH, P; BLASI, F; JOHNSEN, M			ESSENTIAL AP-1 AND PEA3 BINDING-ELEMENTS IN THE HUMAN UROKINASE ENHANCER DISPLAY CELL TYPE-SPECIFIC ACTIVITY	ONCOGENE			English	Article							PLASMINOGEN-ACTIVATOR GENE; MIDDLE-T-ONCOGENE; HUMAN-TUMOR-CELLS; TRANSCRIPTION FACTOR; C-JUN; GLUCOCORTICOID RECEPTOR; POLYOMAVIRUS ENHANCER; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; PHORBOL-ESTER	We have characterized a transcriptional enhancer of the human urokinase-type plasminogen activator (uPA) gene in three transformed human cell lines: HeLa, HepG2 and HT1080. The enhancer is located approximately 2 kbp upstream of the mRNA cap site and is active in all three cell lines. By footprinting and gel retardation analysis we found that it contained two binding sites for transcription factor AP-1, encoded by the fos and jun proto-oncogene families. The most upstream of these sites was juxtaposed to a binding site for PEA3, a product of the ets/Spi proto-oncogene family. By transient transfection analysis of deletions, point mutations and subcloned fragments, we found these sites to be crucial for enhancer activity. However, the sites displayed differences in activity in the three different cell lines. The downstream AP-1 site was almost exclusively responsible for enhancer activity in HeLa cells, whereas the AP-1/PEA3 site played a major role in HT1080 and HepG2 cells. The implications of our findings for the known regulation of uPA expression by transforming oncogenes, adenovirus E1A protein and glucocorticoids are discussed.	UNIV COPENHAGEN,INST MICROBIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK	University of Copenhagen			Johnsen, Morten/L-8016-2014; Rørth, Pernille/H-3020-2011	Johnsen, Morten/0000-0003-3763-2362; Blasi, Francesco/0000-0001-9406-1784				ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Blasi F, 1990, Semin Cancer Biol, V1, P117; CANNIO R, 1991, NUCLEIC ACIDS RES, V19, P2303, DOI 10.1093/nar/19.9.2303; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; ELLIS V, 1989, J BIOL CHEM, V264, P1180; FRISCH SM, 1990, ONCOGENE, V5, P75; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIMALDI G, 1986, EMBO J, V5, P855, DOI 10.1002/j.1460-2075.1986.tb04295.x; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1990, CELL, V61, P1165; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; QUAX P, 1991, UNPUB; REICH R, 1988, CANCER RES, V48, P3307; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHIRM S, 1987, GENE DEV, V1, P65, DOI 10.1101/gad.1.1.65; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SKRIVER L, 1984, Journal of Cell Biology, V99, P752; STOPPELLI MP, 1986, J CELL BIOL, V102, P1235, DOI 10.1083/jcb.102.4.1235; TANG WJ, 1987, MOL CELL BIOL, V7, P1681, DOI 10.1128/MCB.7.5.1681; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WILLIAMS RL, 1988, CELL, V52, P121; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	48	186	189	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1583	1592						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923525				2022-12-25	WOS:A1991GX27400013
J	GREENE, LE; EISENBERG, E				GREENE, LE; EISENBERG, E			DISSOCIATION OF CLATHRIN FROM COATED VESICLES BY THE UNCOATING ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											GREENE, LE (corresponding author), NHLBI,CELL BIOL LAB,BLDG 3,RM B1-22,BETHESDA,MD 20892, USA.		Gimenez, Luis E Diaz/D-9291-2011					BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CRAIG EA, 1987, P NATL ACAD SCI USA, V84, P4156, DOI 10.1073/pnas.84.12.4156; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; GREENE L E, 1988, Journal of Cell Biology, V107, p130A; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; NANDI PK, 1982, P NATL ACAD SCI USA, V107, P5885; PATZER EJ, 1982, J CELL BIOL, V93, P230, DOI 10.1083/jcb.93.1.230; PEARSE BMF, 1987, EMBO J, V6, P2507, DOI 10.1002/j.1460-2075.1987.tb02536.x; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRASAD K, 1985, BIOCHEMISTRY-US, V24, P6421, DOI 10.1021/bi00344a017; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHMID SL, 1985, J BIOL CHEM, V260, P10050; SCHMID SL, 1985, J BIOL CHEM, V260, P57; SCHMID SL, 1985, J BIOL CHEM, V260, P44; UNANUE ER, 1981, CELL, V26, P439, DOI 10.1016/0092-8674(81)90213-0; WILEMAN T, 1985, BIOCHEM J, V232, P1	24	104	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1990	265	12					6682	6687						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CZ677	1969864				2022-12-25	WOS:A1990CZ67700033
J	WADA, T; MYERS, JN; KOKAI, Y; BROWN, VI; HAMURO, J; LEVEA, CM; GREENE, MI				WADA, T; MYERS, JN; KOKAI, Y; BROWN, VI; HAMURO, J; LEVEA, CM; GREENE, MI			ANTIRECEPTOR ANTIBODIES REVERSE THE PHENOTYPE OF CELLS TRANSFORMED BY 2 INTERACTING PROTOONCOGENE ENCODED RECEPTOR PROTEINS	ONCOGENE			English	Article											WADA, T (corresponding author), UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,JOHN MORGAN BLDG,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.							AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8489; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEBERMANN TA, 1985, NATURE, V313, P144; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RODECK U, 1987, CANCER RES, V47, P3692; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; VOLLMERS HP, 1983, P NATL ACAD SCI-BIOL, V80, P6863, DOI 10.1073/pnas.80.22.6863; YAMAMOTO T, 1986, CANCER RES, V46, P414; YOKOTA J, 1986, LANCET, V1, P765	30	37	54	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					489	495						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1970151				2022-12-25	WOS:A1990DB85300006
J	FRIEDMAN, DL; PERRYMAN, MB				FRIEDMAN, DL; PERRYMAN, MB			COMPARTMENTATION OF MULTIPLE FORMS OF CREATINE-KINASE IN THE DISTAL NEPHRON OF THE RAT-KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE PEPTIDE; SEQUENCE-ANALYSIS; SKELETAL-MUSCLE; LOCALIZATION; ISOENZYMES; CELLS; HEART; PHOSPHOKINASE; SEGMENTS; ENERGY	Creatine kinase enzymes are present in tissues such as muscle and brain to interconvert creatine phosphate and ADP, thus providing a system to interconnect energy production and utilization (Bessman, S. P., and Carpenter, C. L. (1985) Annu. Rev. Biochem. 54, 831-862). Creatine kinase isoenzymes in kidney have received little attention since kidney contains relatively low creatine kinase activity compared with muscle and brain and because there is disagreement regarding the identity of the specific isoforms expressed in kidney. Using a combination of chromatographic and immunological techniques, we have identified two isoforms of creatine kinase in rat kidney supernatants, B creatine kinase, and the non-sarcomeric form of the mitochondrial creatine kinase, which represent 82 and 15%, respectively, of the total creatine kinase activity in this tissue. The identity of the non-muscle form of the mitochondrial creatine kinase was confirmed by N-terminal sequence analysis and compared with recently published cDNA sequences (Haas, R. C., and Strauss, A. W. (1990) J. Biol. Chem. 265, 6921-6927). We prepared multiple antisera specific for each isoform using synthetic peptide immunogens based upon nonhomologous regions from the primary sequence of each creatine kinase isoform. Immunocytochemical results demonstrate that both creatine kinase isoforms are colocalized in the inner stripe of the outer medulla in tubules of the distal nephron. A similar distribution of creatine kinase isoforms was obtained when different layers of the renal cortex and medulla were examined for creatine kinase activity and isozyme content using nondenaturing electrophoresis. In general, the distribution of creatine kinase enzymes in kidney corresponds to the regions of greatest ATP utilization, oxygen consumption, and sodium transport. These results suggest a role for creatine kinase enzymes in the coupling of ion transport and oxidative phosphorylation in the distal nephron of the mammalian kidney.	BAYLOR COLL MED,DEPT MED,MOLEC CARDIOL UNIT,HOUSTON,TX 77030	Baylor College of Medicine								BASTIN J, 1987, KIDNEY INT, V31, P1239, DOI 10.1038/ki.1987.137; BESSMAN SP, 1972, ISRAEL J MED SCI, V8, P344; BESSMAN SP, 1966, BIOCHEM BIOPH RES CO, V22, P597, DOI 10.1016/0006-291X(66)90317-2; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; DOUCET A, 1982, AM J PHYSIOL, V242, pF346, DOI 10.1152/ajprenal.1982.242.4.F346; FRIEDMAN DL, 1989, EXP EYE RES, V49, P445, DOI 10.1016/0014-4835(89)90053-5; GARG LC, 1981, AM J PHYSIOL, V240, pF536, DOI 10.1152/ajprenal.1981.240.6.F536; GREGER R, 1990, RENAL PHYSIOL BIOCH, V13, P37; GUDER WG, 1976, KIDNEY INT, V10, P532; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HAAS RC, 1989, J BIOL CHEM, V264, P2890; HAMBURG RJ, 1990, J BIOL CHEM, V265, P6403; HANDLER JS, 1972, AM J PHYSIOL, V222, P1071, DOI 10.1152/ajplegacy.1972.222.5.1071; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIGGINS ES, 1978, P SOC EXP BIOL MED, V158, P595; JACOBUS WE, 1973, J BIOL CHEM, V248, P4803; KLEIN KL, 1981, KIDNEY INT, V20, P29, DOI 10.1038/ki.1981.100; LEVITSKY DO, 1978, MEMBRANE BIOCHEM, V2, P81, DOI 10.3109/09687687809063859; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANI RS, 1976, BIOCHIM BIOPHYS ACTA, V453, P391, DOI 10.1016/0005-2795(76)90134-3; MAUDE DL, 1970, BIOCHIM BIOPHYS ACTA, V215, P216; PERRYMAN MB, 1983, BIOCHIM BIOPHYS ACTA, V747, P284, DOI 10.1016/0167-4838(83)90107-3; PERRYMAN MB, 1986, BIOCHEM BIOPH RES CO, V140, P981, DOI 10.1016/0006-291X(86)90732-1; PERRYMAN MB, 1985, J BIOL CHEM, V260, P9399; REA C, 1972, AM J PHYSIOL, V140, P276; SAKS VA, 1977, BIOCHIM BIOPHYS ACTA, V465, P550, DOI 10.1016/0005-2736(77)90272-3; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCHLEGEL J, 1990, J BIOL CHEM, V265, P9221; SCHOLTE HR, 1973, BIOCHIM BIOPHYS ACTA, V305, P413, DOI 10.1016/0005-2728(73)90187-4; SHAROV VG, 1977, BIOCHIM BIOPHYS ACTA, V468, P495, DOI 10.1016/0005-2736(77)90299-1; URBAITIS BK, 1971, AM J PHYSIOL, V220, P1116, DOI 10.1152/ajplegacy.1971.220.4.1116; VILLARREALLEVY G, 1987, BIOCHEM BIOPH RES CO, V144, P1116, DOI 10.1016/0006-291X(87)91427-6; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WALLIMANN T, 1986, P NATL ACAD SCI USA, V83, P3816, DOI 10.1073/pnas.83.11.3816; WATTS DC, 1973, ENZYMES, V8, P383	35	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22404	22410						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939264				2022-12-25	WOS:A1991GR56400057
J	LIU, YH; TENG, CT				LIU, YH; TENG, CT			CHARACTERIZATION OF ESTROGEN-RESPONSIVE MOUSE LACTOFERRIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOTRANSFERRIN GENE; NUCLEOTIDE-SEQUENCE; CHROMOSOMAL LOCALIZATION; HUMAN TRANSFERRIN; MAMMARY-GLAND; EXPRESSION; TRANSCRIPTION; CDNA; ELEMENTS; CELLS	Mouse lactoferrin is expressed in a variety of tissues under different types of control. To understand how molecular mechanisms govern the mode of lactoferrin expression, we isolated and characterized the 5'-flanking region of the lactoferrin gene. Several clones containing lactoferrin gene fragments were isolated from a mouse (129/J) genomic library including clone lambda-J14, which contains a 7.5-kilobase pair 5'-flanking sequence. Sequence analysis of the region flanking the transcription initiation site revealed the following: a TATA-like sequence, two CAAT boxes, three GC boxes including one within the first intron, an AP2 site, seven PU boxes, an AC-rich region, a B1 sequence, and an estrogen-responsive element consensus sequence overlapping with a chicken ovalbumin upstream promoter-binding element. Footprinting analysis demonstrated that several regions, including the putative estrogen-responsive element region, in the 5'-flanking sequence were protected from DNase I digestion. Promoter fragments were cloned into a chloramphenicol acetyltransferase reporter plasmid to study functional activity. The mouse lactoferrin gene promoter was active in human endometrium carcinoma RL 95-2 cells and in rat glioma C6 cells. Multiple upstream elements modulated the basal transcriptional promoter activity. The transcription level directed by this minimal promoter was controlled by both positive (between -1739 and -922) and negative (between -2644 and -1739, and between -589 and -291) regulatory sequences. A tissue-specific regulatory sequence was critical for the establishment of lactoferrin expression in human endometrium carcinoma cells, but not in rat glioma cells located between -1739 and -922. Reporter plasmid 0.6 mL14-CAT, containing the estrogen-responsive element sequence, was estrogen-responsive in the presence of estrogen receptor in human endometrium carcinoma RL 95-2 cells.	NIEHS, REPROD & DEV TOXICOL, DEV ENDOCRINOL & PHARMACOL SECT, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)				Liu, Youhua/0000-0002-4740-805X				ANDERSON BF, 1987, P NATL ACAD SCI USA, V84, P1769, DOI 10.1073/pnas.84.7.1769; ARNOLD RR, 1977, SCIENCE, V197, P263, DOI 10.1126/science.327545; BARNES D, 1980, ANAL BIOCHEM, V102, P255, DOI 10.1016/0003-2697(80)90151-7; BOWMAN BH, 1988, ADV GENET, V25, P1; BROXMEYER HE, 1987, BLOOD CELLS, V13, P31; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GREEN MR, 1978, ENDOCRINOLOGY, V103, P1510, DOI 10.1210/endo-103-4-1510; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GUERIN SL, 1990, J BIOL CHEM, V265, P22035; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KRAYEV AS, 1980, NUCLEIC ACIDS RES, V8, P1201, DOI 10.1093/nar/8.6.1201; LI L, 1987, CANCER RES, V47, P4184; MANIATIS T, 1982, MOL CLONING LABORATO, P75; MASSON PL, 1971, COMP BIOCHEM PHYSIOL, V39, P119, DOI 10.1016/0305-0491(71)90258-6; MASSON PL, 1966, CLIN CHIM ACTA, V14, P735, DOI 10.1016/0009-8981(66)90004-0; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; MCCOMBS JL, 1988, CYTOGENET CELL GENET, V47, P16, DOI 10.1159/000132496; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; PANELLA TJ, 1991, CANCER RES, V51, P3037; PARK I, 1985, P NATL ACAD SCI USA, V82, P3149, DOI 10.1073/pnas.82.10.3149; PENTECOST BT, 1987, J BIOL CHEM, V262, P10134; PETIT C, 1986, P NATL ACAD SCI USA, V83, P2561, DOI 10.1073/pnas.83.8.2561; PETTERSSON M, 1987, GENE DEV, V1, P962, DOI 10.1101/gad.1.9.962; POWELL MJ, 1990, NUCLEIC ACIDS RES, V18, P4013, DOI 10.1093/nar/18.13.4013; RADO TA, 1987, BLOOD, V70, P989; REY MW, 1990, NUCLEIC ACIDS RES, V18, P5288, DOI 10.1093/nar/18.17.5288; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TENG CT, 1989, ENDOCRINOLOGY, V124, P992, DOI 10.1210/endo-124-2-992; TENG CT, 1987, SOMAT CELL MOLEC GEN, V13, P689, DOI 10.1007/BF01534490; WAY DL, 1983, IN VITRO CELL DEV B, V19, P147; WONG G, 1989, J BIOL CHEM, V264, P2920; YANG FM, 1984, P NATL ACAD SCI-BIOL, V81, P2752, DOI 10.1073/pnas.81.9.2752	39	78	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21880	21885						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939212				2022-12-25	WOS:A1991GP80400084
J	MARTEL, RR; LAW, JH				MARTEL, RR; LAW, JH			PURIFICATION AND PROPERTIES OF AN OMMOCHROME-BINDING PROTEIN FROM THE HEMOLYMPH OF THE TOBACCO HORNWORM, MANDUCA-SEXTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; LARVAL; ACID; LIPOPROTEIN; LIPOPHORIN; ARYLPHORIN; HOMOLOGY	A Yellow-colored protein (YCP) was isolated from the hemolymph (i.e. blood) of fifth instar wandering stage larvae of Manduca sexta. The molecular mass of YCP was 31 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Gel filtration chromatography suggested that native YCP was a monomer. The absorbance spectrum of YCP revealed maxima at 278 and 405 nm. Chromophore was released from YCP through denaturation of the protein with methanol and chloroform. In neutral solution and in acid, the released chromophore showed the absorbance characteristics of an ommochrome: ommatin D. In addition, the chromophore was sensitive to treatment with arylsulfatase as would be expected for ommatin D. The amino acid composition and the N-terminal sequence of YCP were determined. The YCP polypeptide chain was found to be glycosylated. Carbohydrate analysis suggested that Man and GlcNAc were present in a 3:1 ratio. Circular dichroism indicated that YCP consisted of 68% beta-pleated sheet with no alpha-helices being detected. An in vitro incubation of larval fat body in the presence of [S-35]methionine indicated that this organ was the site of synthesis. Ommochromes arise in insects as end products of the metabolism of tryptophan. It is well-documented that ommochromes occur in both the tissues and the excreta of insects. We propose that in M. sexta, one such tryptophan metabolite is found in the hemolymph associated with a specific protein.	UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721; UNIV ARIZONA,CTR INSECT SCI,TUCSON,AZ 85721	University of Arizona; University of Arizona					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029238] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29238] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJAMI AM, 1971, BIOCHEMISTRY-US, V10, P1455; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BUTENANDT A, 1960, H-S Z PHYSIOL CHEM, V321, P258, DOI 10.1515/bchm2.1960.321.1.258; BUTENANDT A, 1963, H-S Z PHYSIOL CHEM, V334, P71, DOI 10.1515/bchm2.1963.334.1.71; Butenandt A, 1962, RECENT PROGR CHEM NA, P13; GRIMES WJ, 1976, CANCER RES, V36, P3905; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HORI H, 1982, J COMP PHYSL, V147, P1; ISHIGURO I, 1971, MED BIOL, V82, P123; Kanost M.R., 1990, Advances in Insect Physiology, V22, P299, DOI 10.1016/S0065-2806(08)60008-9; KAWOOYA JK, 1986, J BIOL CHEM, V261, P844; KAWOOYA JK, 1985, ACS SYM SER, V276, P511; Kayser H., 1985, P367; KAYSER H, 1979, J INSECT PHYSIOL, V25, P641, DOI 10.1016/0022-1910(79)90113-6; KRAMER SJ, 1980, INSECT BIOCHEM, V10, P279, DOI 10.1016/0020-1790(80)90023-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; Linzen B., 1974, ADV INSECT PHYSL, P117, DOI DOI 10.1016/S0065-2806(08)60130-7; NAGAO E, 1987, J LIPID RES, V28, P450; NAGAO E, 1987, INSECT BIOCHEM, V17, P531, DOI 10.1016/0020-1790(87)90051-5; OSIR EO, 1986, INSECT BIOCHEM, V16, P471, DOI 10.1016/0020-1790(86)90023-5; PERVAIZ S, 1987, FASEB J, V1, P209, DOI 10.1096/fasebj.1.3.3622999; PRASAD SV, 1986, J BIOL CHEM, V261, P7174; REINECKE JP, 1980, BIOL BULL-US, V158, P129, DOI 10.2307/1540764; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P341; RIDDIFORD LM, 1982, DEV BIOL, V92, P330, DOI 10.1016/0012-1606(82)90179-8; RYAN RO, 1985, J BIOL CHEM, V260, P782; RYAN RO, 1985, ARCH BIOCHEM BIOPHYS, V243, P115, DOI 10.1016/0003-9861(85)90779-9; SAWADA H, 1990, INSECT BIOCHEM, V20, P785, DOI 10.1016/0020-1790(90)90096-D; SHAPIRO JP, 1983, BIOCHEM BIOPH RES CO, V115, P924, DOI 10.1016/S0006-291X(83)80023-0; SHAPIRO JP, 1984, J BIOL CHEM, V259, P3680; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLOTT E, 1989, J BIOL CHEM, V264, P19052	35	15	17	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21392	21398						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939173				2022-12-25	WOS:A1991GP80400015
J	MARET, W; MAKINEN, MW				MARET, W; MAKINEN, MW			THE PH VARIATION OF STEADY-STATE KINETIC-PARAMETERS OF SITE-SPECIFIC CO2+-RECONSTITUTED LIVER ALCOHOL-DEHYDROGENASE - A MECHANISTIC PROBE FOR THE ASSIGNMENT OF METAL-LINKED IONIZATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; ENZYME-CATALYZED REACTIONS; ZINC-BOUND WATER; TERNARY-COMPLEX; PROTON-TRANSFER; ACTIVE-SITE; COENZYME BINDING; ISOTOPE; ION; TRANSITION	To identify ionizations of the active site metal-bound water in horse liver alcohol dehydrogenase (alcohol:NAD+ oxidoreductase; EC 1.1.1.1), the pH, solvent isotope, temperature, and anion dependences of the steady-state kinetic parameters k(cat) and k(cat)/K(M) have been evaluated under initial velocity conditions for the native and the active site-specific Co2+-reconstituted enzyme. In the oxidation of benzyl alcohol, a bell-shaped pattern of four prototropic equilibria was observed under conditions of saturating concentrations of NAD+. It is shown that the ionizations governing k(cat) (pK1 congruent-to 6.7, pK2 congruent-to 10.6) belong to the ternary enzyme-NAD+-alcohol complex, whereas the ionizations governing k(cat)/K(M) (pK1' congruent-to 7.5, pK2' congruent-to 8.9) belong to the binary enzyme-NAD+ complex. The ionizations pK1 and pK1' are not influenced by metal substitution and are ascribed to His-51 on the basis of experimental estimates of their associated enthalpies of ionization. On the other hand, pK2 and pK2' are significantly decreased (DELTA-pK(a) congruent-to 1.0) in the Co2+-enzyme and are attributed to the active site metal-bound water molecule. The shape of the pH profiles requires that the metal ion coordinates a neutral water molecule in the ternary enzyme-NAD+-alcohol complex under physiological conditions. The possible catalytic role of the water molecule within a pentacoordinate metal ion complex in the active site is discussed.	UNIV CHICAGO,CUMMINGS LIFE SCI CTR,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637	University of Chicago					NIAAA NIH HHS [AA 06374] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006374] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSON DC, 1982, BIOCHEMISTRY-US, V21, P3569, DOI 10.1021/bi00258a007; ANDERSSON P, 1981, EUR J BIOCHEM, V113, P425, DOI 10.1111/j.1432-1033.1981.tb05082.x; BEAUCAMP K, 1974, METHODEN ENZYMATISCH, P580; BERTINI I, 1984, J AM CHEM SOC, V106, P1826, DOI 10.1021/ja00318a047; BOYD RH, 1969, SOLUTE SOLVENT INTER, P97; Branden C.-I., 1975, ENZYMES, V11, P103; BROCKLEHURST K, 1976, BIOCHEM J, V155, P61, DOI 10.1042/bj1550061; BROOKS RL, 1971, BIOCHEMISTRY-US, V10, P3855, DOI 10.1021/bi00797a009; BROOKS RL, 1972, J BIOL CHEM, V247, P2382; CEDERGRENZEPPEZAUER E, 1982, BIOCHEMISTRY-US, V21, P4895, DOI 10.1021/bi00263a011; Cleland W W, 1979, Methods Enzymol, V63, P103; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; COATES JH, 1977, FEBS LETT, V84, P25, DOI 10.1016/0014-5793(77)81049-1; COLEMAN PL, 1973, BIOCHEMISTRY-US, V12, P1705, DOI 10.1021/bi00733a007; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1805, DOI 10.1021/bi00510a015; Cornish-Bowden A., 1979, FUNDAMENTALS ENZYME, P99; DALZIEL K, 1966, BIOCHEM J, V100, P34, DOI 10.1042/bj1000034; DALZIEL K, 1966, BIOCHEM J, V100, P491, DOI 10.1042/bj1000491; DALZIEL K, 1963, J BIOL CHEM, V238, P2850; DIETRICH H, 1983, BIOCHEMISTRY-US, V22, P3432, DOI 10.1021/bi00283a020; DIXON M, 1953, BIOCHEM J, V55, P161, DOI 10.1042/bj0550161; DWORSCHACK RT, 1977, BIOCHEMISTRY-US, V16, P2716, DOI 10.1021/bi00631a020; EFTINK MR, 1986, BIOCHEMISTRY-US, V25, P6620, DOI 10.1021/bi00369a043; EHRIG T, 1991, BIOCHEMISTRY-US, V30, P1062, DOI 10.1021/bi00218a026; EKLUND H, 1982, J BIOL CHEM, V257, P4349; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; EVANS SA, 1980, J BIOL CHEM, V255, P1509; KLINMAN JP, 1981, CRC CR REV BIOCH MOL, V10, P39, DOI 10.3109/10409238109114635; KLUGER R, 1984, J AM CHEM SOC, V106, P1113, DOI 10.1021/ja00316a051; KVASSMAN J, 1978, EUR J BIOCHEM, V87, P417, DOI 10.1111/j.1432-1033.1978.tb12391.x; KVASSMAN J, 1980, EUR J BIOCHEM, V103, P565, DOI 10.1111/j.1432-1033.1980.tb05981.x; KVASSMAN J, 1979, EUR J BIOCHEM, V100, P115, DOI 10.1111/j.1432-1033.1979.tb02039.x; KVASSMAN J, 1981, EUR J BIOCHEM, V114, P555, DOI 10.1111/j.1432-1033.1981.tb05180.x; LOWRY OH, 1961, J BIOL CHEM, V236, P2756; MAKINEN MW, 1979, J BIOL CHEM, V254, P356; MAKINEN MW, 1983, P NATL ACAD SCI-BIOL, V80, P2584, DOI 10.1073/pnas.80.9.2584; MAKINEN MW, 1981, P NATL ACAD SCI-BIOL, V78, P6221, DOI 10.1073/pnas.78.10.6221; MAKINEN MW, 1986, ZINC ENZYMES, P465; MARET W, 1979, EUR J BIOCHEM, V98, P501, DOI 10.1111/j.1432-1033.1979.tb13211.x; MORRIS RG, 1980, BIOCHEMISTRY-US, V19, P725, DOI 10.1021/bi00545a018; PETTERSSON G, 1987, CRIT REV BIOCHEM MOL, V21, P349, DOI 10.3109/10409238609113616; Plapp B V, 1987, Prog Clin Biol Res, V232, P227; POCKER Y, 1990, J BIOL CHEM, V265, P22101; SARTORIUS C, 1987, THESIS U SAARLANDES; SCHMIDT J, 1979, J AM CHEM SOC, V101, P3634, DOI 10.1021/ja00507a033; SCHNEIDER G, 1983, P NATL ACAD SCI-BIOL, V80, P5289, DOI 10.1073/pnas.80.17.5289; SEKHAR VC, 1988, BIOCHEMISTRY-US, V27, P5082, DOI 10.1021/bi00414a020; SHORE JD, 1974, BIOCHEMISTRY-US, V13, P4185, DOI 10.1021/bi00717a019; SHORE JD, 1966, ARCH BIOCHEM BIOPHYS, V117, P375, DOI 10.1016/0003-9861(66)90425-5; SHORE JD, 1970, BIOCHEMISTRY-US, V9, P4655, DOI 10.1021/bi00826a006; SHORE JD, 1975, J BIOL CHEM, V250, P2008; SUBRAMANIAN S, 1979, J BIOL CHEM, V254, P7827; TANIGUCHI S, 1967, ACTA CHEM SCAND, V21, P1903, DOI 10.3891/acta.chem.scand.21-1903; TAYLOR KB, 1983, BIOCHEMISTRY-US, V22, P1040, DOI 10.1021/bi00274a007; THEORELL H, 1955, ACTA CHEM SCAND, V9, P1148, DOI 10.3891/acta.chem.scand.09-1148; Tipton K F, 1979, Methods Enzymol, V63, P183; WEIDIG CF, 1977, BIOCHEMISTRY-US, V16, P2916, DOI 10.1021/bi00632a018; WELSH KM, 1980, BIOCHEMISTRY-US, V19, P2005, DOI 10.1021/bi00551a001; WOLFE JK, 1977, J BIOL CHEM, V252, P433; WRATTEN CC, 1965, BIOCHEMISTRY-US, V4, P2442, DOI 10.1021/bi00887a025; YIM MB, 1986, FRONTIERS BIOINORGAN, P562; Zeppezauer M., 1983, COORDINATION CHEM ME, P99; ZUNDEL G, 1969, HYDRATION INTERMOLEC, P76	63	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20636	20644						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939113				2022-12-25	WOS:A1991GN00100011
J	ZWEIER, JL; JACOBUS, WE; KORECKY, B; BRANDEJSBARRY, Y				ZWEIER, JL; JACOBUS, WE; KORECKY, B; BRANDEJSBARRY, Y			BIOENERGETIC CONSEQUENCES OF CARDIAC PHOSPHOCREATINE DEPLETION INDUCED BY CREATINE ANALOG FEEDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GUANIDINOPROPIONIC ACID; HIGH-ENERGY PHOSPHATE; NUCLEAR MAGNETIC-RESONANCE; HEART-CELLS; RAT HEARTS; METABOLISM; KINASE; CONTRACTILE; TRANSPORT; SHUTTLE	To further evaluate the bioenergetic role of phosphocreatine, we assessed several parameters in normal and depleted rat hearts. Rats were fed (8 weeks) a diet containing either 1% beta-guanidinoproprionic acid or 2% beta-guanidinobutyric acid (beta-GBA), resulting in an 80% phosphocreatine depletion compared to controls. Left ventricular pressure-volume curves were obtained to determine contractile function. At any volume, the developed pressure in depleted hearts was lower than in controls. At the plateau, the rate-pressure product was between 37-45% lower: 34,000 (beta-GBA), 30,174 (beta-guanidinoproprionic acid) versus 54,400 (control). P-31 NMR spectroscopy on beta-GBA-treated hearts obtained the [ATP] and [phosphocreatine], which with saturation transfer estimated the rates of creatine kinase and ATP production. In depleted hearts, the rate constant for ATP synthesis from phosphocreatine was increased 33%. However, the flux was 72% lower. ATP production from ADP and P(i) were similar under normal conditions, in spite of higher rates of oxygen consumption in the depleted hearts. The addition of 50 mM creatine to control perfusate had no effect on function or high energy phosphates. In contrast, a 28% increase in function and a 52% increase in [phosphocreatine] was seen in beta-GBA hearts. There was a marked increase in free [ADP] in beta-GBA hearts, resulting in a lower estimated ATP phosphorylation potential. Overall, the results suggest that phosphocreatine may play an important function by optimizing the thermodynamics of cardiac high energy phosphate utilization.	JOHNS HOPKINS UNIV, SCH MED, PETER BELFER LAB MYOCARDIAL RES, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM & ANESTHESIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CRIT CARE MED, BALTIMORE, MD 21205 USA; UNIV OTTAWA, DEPT PHYSIOL, OTTAWA K1H 8M5, ONTARIO, CANADA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Ottawa					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017655, R01HL033592] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL-17655, HL-20658, HL-33592] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BONAS JE, 1963, MICROCHEM J, V7, P63, DOI 10.1016/0026-265X(63)90012-2; BRAUTBAR N, 1986, ADV EXP BIOL MED, V194, P1; DAWSON MJ, 1978, NATURE, V274, P861, DOI 10.1038/274861a0; DUBNOFF JW, 1957, METHOD ENZYMOL, V3, P635, DOI 10.1016/S0076-6879(57)03433-3; Engelhardt WA, 1939, NATURE, V144, P668, DOI 10.1038/144668b0; EPPENBERGER HM, 1967, J BIOL CHEM, V242, P204; FOSSEL ET, 1986, CIRCULATION, V74, P326; FOSSEL ET, 1985, SOC MAG RESON MED, V4, P655; GUDBJARNASON S, 1970, Journal of Molecular and Cellular Cardiology, V1, P325; HAMMAN BL, 1986, SOC MAG RESON MED, V5, P133; Hill AV, 1932, PHYSIOL REV, V12, P0056, DOI 10.1152/physrev.1932.12.1.56; HOERTER JA, 1986, CIRC RES, V58, P539, DOI 10.1161/01.RES.58.4.539; JACOBS EE, 1956, J BIOL CHEM, V223, P147; JACOBUS WE, 1985, BIOCHEM BIOPH RES CO, V133, P1035, DOI 10.1016/0006-291X(85)91240-9; JACOBUS WE, 1985, ANNU REV PHYSIOL, V47, P707; JACOBUS WE, 1986, J BIOL CHEM, V261, P6579; JACOBUS WE, 1982, INTRACELLULAR PH ITS, P537; KAMMERMEIER H, 1987, BASIC RES CARDIOL, V82, P31; KAMMERMEIER H, 1982, J MOL CELL CARDIOL, V14, P267, DOI 10.1016/0022-2828(82)90205-X; KAPELKO VI, 1988, J MOL CELL CARDIOL, V20, P465, DOI 10.1016/S0022-2828(88)80074-9; KORECKY B, 1987, BASIC RES CARDIOL, V82, P103; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P398; Lipmann F, 1941, ADV ENZYMOL REL S BI, V1, P99, DOI 10.1002/9780470122464.ch4; MEKHFI H, 1990, AM J PHYSIOL, V258, pH1151, DOI 10.1152/ajpheart.1990.258.4.H1151; MEYER RA, 1984, BIOPHYS J, V45, pA91; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; MURPHY E, 1989, P NATL ACAD SCI USA, V86, P2981, DOI 10.1073/pnas.86.8.2981; OCHOA S, 1955, METHOD ENZYMOL, V1, P735, DOI 10.1016/0076-6879(55)01128-2; ROWLEY GL, 1971, J AM CHEM SOC, V93, P5542, DOI 10.1021/ja00750a038; SAKS VA, 1975, EUR J BIOCHEM, V57, P273, DOI 10.1111/j.1432-1033.1975.tb02299.x; SAKS VA, 1978, CAN J PHYSIOL PHARM, V56, P691, DOI 10.1139/y78-113; SAKS VA, 1980, J BIOL CHEM, V255, P755; SCARPA A, 1973, J GEN PHYSIOL, V62, P756, DOI 10.1085/jgp.62.6.756; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHOUBRIDGE EA, 1985, BIOCHIM BIOPHYS ACTA, V847, P25, DOI 10.1016/0167-4889(85)90148-X; SHOUBRIDGE EA, 1984, BIOCHIM BIOPHYS ACTA, V805, P79, DOI 10.1016/0167-4889(84)90039-9; UGURBIL K, 1985, J MAGN RESON, V64, P207, DOI 10.1016/0022-2364(85)90345-2; VEECH RL, 1979, J BIOL CHEM, V254, P6538; ZWEIER JL, 1987, J BIOL CHEM, V262, P8015; ZWEIER JL, 1986, CIRCULATION, V74, P326; ZWEIER JL, 1986, J MOL CELL CARDIOL, V18, P79	44	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20296	20304						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939088				2022-12-25	WOS:A1991GM03900063
J	MIURA, S; TOMITA, S; ICHIKAWA, Y				MIURA, S; TOMITA, S; ICHIKAWA, Y			MODIFICATION OF HISTIDINE-56 IN ADRENODOXIN WITH DIETHYL PYROCARBONATE INHIBITED THE INTERACTION WITH CYTOCHROME-P-450SCC AND ADRENODOXIN REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROIDOGENIC ELECTRON-TRANSPORT; NUCLEAR MAGNETIC-RESONANCE; AMINO-ACID SEQUENCE; 2FE-2S FERREDOXIN; MITOCHONDRIAL CYTOCHROME-P-450SCC; CROSS-LINKING; IDENTIFICATION; CHOLESTEROL; COMPLEX; BINDING	Three histidine residues of bovine adrenodoxin, His-10, His-56, and His-62, were modified with diethyl pyrocarbonate. The order of the modification among the three histidines were monitored by measuring the proton NMR spectra. The modified adrenodoxin exhibited reduced affinity for adrenodoxin reductase as determined in cytochrome c reductase activity. In the presence of cholesterol, the modified adrenodoxin induced a high spin form of cytochrome P-450scc on complex formation in the same manner as native adrenodoxin. The spectral titration showed that adrenodoxin modified with diethyl pyrocarbonate exhibited a 5-fold higher K(d) value than that of native adrenodoxin. These effects of the modification of adrenodoxin on the affinities for the redox partners were not proportional to the number of modified histidines determined by the optical absorbance change at 240 nm. Modification of adrenodoxin up to 2 histidine residues did not affect the affinity for the redox partners, but further modification on the third one resulted in an increase of apparent K(m) in cytochrome c reductase activity by 2-fold and of K(d) for cytochrome P-450scc by 5-fold. The H-1 NMR spectra of the modified adrenodoxin unequivocally demonstrated that histidine residues at His-10 and His-62 reacted more readily with diethyl pyrocarbonate than His-56 did, indicating that modification of His-56 was responsible for the reduction of binding affinities of adrenodoxin for redox partners. These results are consistent with the proposal that the residue of His-56 in adrenodoxin has an essential role in the electron transfer mechanism where adrenodoxin functions as a mobile shuttle.			MIURA, S (corresponding author), KAGAWA UNIV,SCH MED,DEPT BIOCHEM,MIKI,KAGAWA 76107,JAPAN.							ALTMAN J, 1989, BIOCHEMISTRY-US, V28, P7516, DOI 10.1021/bi00445a004; CUPP JR, 1989, J BIOL CHEM, V264, P1602; FUKUYAMA K, 1980, NATURE, V286, P522, DOI 10.1038/286522a0; GEREN L, 1986, J BIOL CHEM, V261, P5491; GEREN LM, 1984, J BIOL CHEM, V259, P2155; HANUKOGLU I, 1981, J BIOL CHEM, V256, P4321, DOI 10.1016/S0021-9258(19)69436-6; HANUKOGLU I, 1980, J BIOL CHEM, V255, P3057, DOI 10.1016/S0021-9258(19)85851-9; HINTZ MJ, 1982, J BIOL CHEM, V257, P4324; HIWATASHI A, 1976, BIOCHEMISTRY-US, V15, P3082, DOI 10.1021/bi00659a023; HIWATASHI A, 1986, FEBS LETT, V209, P311, DOI 10.1016/0014-5793(86)81133-4; KIDO T, 1979, J BIOL CHEM, V254, P1806; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LAMBETH JD, 1980, J BIOL CHEM, V255, P138; LAMBETH JD, 1982, MOL CELL BIOCHEM, V45, P13, DOI 10.1007/BF01283159; LAMBETH JD, 1984, J BIOL CHEM, V259, P25; LIGHT DR, 1981, J BIOL CHEM, V256, P343; Miles E W, 1977, Methods Enzymol, V47, P431; MIURA S, 1991, EUR J BIOCHEM, V197, P747, DOI 10.1111/j.1432-1033.1991.tb15967.x; MIURA S, 1991, J BIOL CHEM, V266, P6252; OKAMURA T, 1985, P NATL ACAD SCI USA, V82, P5705, DOI 10.1073/pnas.82.17.5705; OMURA T, 1964, J BIOL CHEM, V239, P2370; SMITH GM, 1981, BIOCHEMISTRY-US, V20, P4340, DOI 10.1021/bi00518a017; TANAKA M, 1974, J BIOL CHEM, V249, P3689; TANAKA M, 1973, J BIOL CHEM, V248, P111; TSUBAKI M, 1986, BIOCHIM BIOPHYS ACTA, V870, P564, DOI 10.1016/0167-4838(86)90266-9; TSUBAKI M, 1989, BIOCHEMISTRY-US, V28, P9777, DOI 10.1021/bi00451a035; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; TSUKIHARA T, 1981, J BIOCHEM-TOKYO, V90, P1763, DOI 10.1093/oxfordjournals.jbchem.a133654; TULS J, 1987, J BIOL CHEM, V262, P10020; USANOV SA, 1985, BIOCHIM BIOPHYS ACTA, V832, P288, DOI 10.1016/0167-4838(85)90262-6	30	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19212	19216						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918039				2022-12-25	WOS:A1991GK66700018
J	NAKAMURA, T; SUGINO, K; TITANI, K; SUGINO, H				NAKAMURA, T; SUGINO, K; TITANI, K; SUGINO, H			FOLLISTATIN, AN ACTIVIN-BINDING PROTEIN, ASSOCIATES WITH HEPARAN-SULFATE CHAINS OF PROTEOGLYCANS ON FOLLICULAR GRANULOSA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; FIBROBLAST GROWTH-FACTOR; MESODERM-INDUCING FACTOR; FSH-RELEASING PROTEIN; STIMULATING-HORMONE; FLUID INHIBIN; FACTOR EDF; TGF-BETA; PURIFICATION; LEUKEMIA	Follistatin, an activin-binding protein secreted by cultured rat granulosa cells, was shown to associate with the cell surface by affinity labeling with I-125-activin. Addition of follistatin to the cultured cells demonstrated a typical ligand-binding saturation curve, suggesting that granulosa cells have a specific binding site for follistatin. This binding was markedly inhibited by heparin and heparan sulfate, but not by chondroitin sulfates A and C, keratan sulfate, and dermatan sulfate. When granulosa cells were treated with glycosaminoglycan-degrading enzymes before or after addition of follistatin to the cultures, heparinase and heparitinase treatments resulted in significant suppression of the binding, whereas treatment with chondroitinase ABC had no effect. A competition study of the binding using heparin derivatives demonstrated that follistatin seemed to recognize O-sulfate groups in the heparin molecule. Heparitinase-treated granulosa cells exhibited almost full responsiveness to activin, indicating that the enzyme treatment had no effect on activin and receptor interaction. These results suggest that follistatin/activin-binding protein binds to heparan sulfate side chains of proteoglycans on the granulosa cell surface to regulate the various actions of activin.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; FUJITA HLTH UNIV,SCH MED,TOYOAKE,AICHI 47011,JAPAN	RIKEN; Fujita Health University								ALBANO RM, 1990, DEVELOPMENT, V110, P435; ASASHIMA M, 1991, ROUX ARCH DEV BIOL, V200, P4, DOI 10.1007/BF02457635; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAMPEN CA, 1988, BIOCHEM BIOPH RES CO, V157, P844, DOI 10.1016/S0006-291X(88)80326-7; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FUKUDA M, 1986, MOL CELL ENDOCRINOL, V44, P55, DOI 10.1016/0303-7207(86)90105-X; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HASEGAWA Y, 1988, BIOCHEM BIOPH RES CO, V156, P668, DOI 10.1016/S0006-291X(88)80894-5; HASEGAWA Y, 1986, ENDOCRINOL JAPON, V33, P645; HINO M, 1989, J BIOL CHEM, V264, P10309; HUTCHINSON LA, 1987, BIOCHEM BIOPH RES CO, V146, P1405, DOI 10.1016/0006-291X(87)90806-0; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; KONDO S, 1989, BIOCHEM BIOPH RES CO, V161, P1267, DOI 10.1016/0006-291X(89)91379-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVERSHA LJ, 1987, J ENDOCRINOL, V113, P213, DOI 10.1677/joe.0.1130213; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; LING N, 1985, P NATL ACAD SCI USA, V82, P7217, DOI 10.1073/pnas.82.21.7217; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; MIYAMOTO K, 1985, BIOCHEM BIOPH RES CO, V129, P396, DOI 10.1016/0006-291X(85)90164-0; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; NAKAMURA T, 1990, J CELL BIOL, V111, P351; RIVIER J, 1985, BIOCHEM BIOPH RES CO, V133, P120, DOI 10.1016/0006-291X(85)91849-2; ROBERTSON DM, 1986, MOL CELL ENDOCRINOL, V44, P271, DOI 10.1016/0303-7207(86)90133-4; ROBERTSON DM, 1987, BIOCHEM BIOPH RES CO, V149, P744, DOI 10.1016/0006-291X(87)90430-X; ROBERTSON DM, 1985, BIOCHEM BIOPH RES CO, V126, P220, DOI 10.1016/0006-291X(85)90594-7; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAITO S, 1991, BIOCHEM BIOPH RES CO, V176, P413, DOI 10.1016/0006-291X(91)90940-9; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAWCHENKO PE, 1988, NATURE, V334, P615, DOI 10.1038/334615a0; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SUGINO H, 1988, BIOCHEM BIOPH RES CO, V153, P281, DOI 10.1016/S0006-291X(88)81219-1; SUGINO H, 1988, J BIOL CHEM, V263, P15249; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TSUJI T, 1988, BIOTECHNOL BIOENG, V31, P675, DOI 10.1002/bit.260310708; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	49	177	190	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19432	19437						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918055				2022-12-25	WOS:A1991GK66700049
J	NOUR, JM; RABINOWITZ, JC				NOUR, JM; RABINOWITZ, JC			ISOLATION, CHARACTERIZATION, AND STRUCTURAL ORGANIZATION OF 10-FORMYLTETRAHYDROFOLATE SYNTHETASE FROM SPINACH LEAVES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE-METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE; METHENYL-METHYLENETETRAHYDROFOLATE SYNTHETASE; NUCLEAR MAGNETIC-RESONANCE; PHASEOLUS-MUNGO SEEDLINGS; CLOSTRIDIUM-ACIDI-URICI; ASCITES TUMOR-CELLS; C1-TETRAHYDROFOLATE SYNTHASE; FORMYLTETRAHYDROFOLATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; TRIFUNCTIONAL ENZYME	One-carbon metabolism mediated by folate coenzymes plays an essential role in several major cellular processes. In the prokaryotes studied, three folate-dependent enzymes, 10-formyltetrahydrofolate synthetase (EC 6.3.4.3), 5,10-methenyltetrahydrofolate cyclohydrolase (EC 3.5.4.9), and 5,10-methylenetetrahydrofolate dehydrogenase (EC 1.5.1.5) generally exist as monofunctional or bifunctional proteins, whereas in eukaryotes the three activities are present on one polypeptide. The structural organization of these enzymes in plants had not previously been examined. We have purified the 10-formyltetrahydrofolate synthetase activity from spinach leaves to homogeneity and raised antibodies to it. The protein was a dimer with a subunit molecular weight of M(r) = 67,000. The K(m) values for the three substrates, (6R)-tetrahydrofolate, ATP, and formate were 0.94, 0.043, and 21.9 mM, respectively. The enzyme required both monovalent and divalent cations for maximum activity. The 5,10-methylenetetrahydrofolate dehydrogenase and 5,10-methenyltetrahydrofolate cyclohydrolase activities of spinach coeluted separately from the 10-formyltetrahydrofolate synthetase activity on a Matrex Green-A column. On the same column, the activities of the yeast trifunctional C1-tetrahydrofolate synthase coeluted. In addition, antibodies raised to the purified spinach protein immunoinactivated and immunoprecipitated only the 10-formyltetrahydrofolate synthetase activity in a crude extract of spinach leaves. These results suggest that unlike the trifunctional form of C1-tetrahydrofolate synthase in the other eukaryotes examined, 10-formyltetrahydrofolate synthetase in spinach leaves is monofunctional and 5,10-methylenetetrahydrofolate dehydrogenase and 5,10-methenyltetrahydrofolate cyclohydrolase appear to be bifunctional. Although structurally dissimilar to the other eukaryotic trifunctional enzymes, the 35 amino-terminal residues of spinach 10-formyltetrahydrofolate synthetase showed 35% identity with six other tetrahydrofolate synthetases.	UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NIADDK NIH HHS [AM2109] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM002109] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED SI, 1969, J BACTERIOL, V99, P231, DOI 10.1128/JB.99.1.231-237.1969; APPLING DR, 1985, BIOCHEMISTRY-US, V24, P3540, DOI 10.1021/bi00335a023; APPLING DR, 1985, J BIOL CHEM, V260, P1248; BARLOWE CK, 1990, BIOCHEMISTRY-US, V29, P7089, DOI 10.1021/bi00482a020; BERLYN MB, 1969, J BACTERIOL, V99, P222, DOI 10.1128/JB.99.1.222-230.1969; BLAKLEY RL, 1957, BIOCHEM J, V65, P331, DOI 10.1042/bj0650331; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COGGINS JR, 1987, METHOD ENZYMOL, V142, P325; Cossins E. A., 1980, The biochemistry of plants. A comprehensive treatise. Volume 2. Metabolism and respiration., P365; COSSINS EA, 1987, BIOCH PLANTS, V11, P317, DOI DOI 10.1016/B978-0-12-675411-7.50015-X; CROSTI P, 1974, ITAL J BIOCHEM, V23, P72; CURTHOYS NP, 1971, J BIOL CHEM, V246, P6942; CURTHOYS NP, 1972, BIOCHEMISTRY-US, V11, P345, DOI 10.1021/bi00753a006; DAVISON BL, 1979, J BIOL CHEM, V254, P9220; DELK AS, 1976, J BIOL CHEM, V251, P7649; DEV IK, 1978, J BIOL CHEM, V253, P4245; DIJESO F, 1968, J BIOL CHEM, V243, P2022; DUNCAN K, 1987, BIOCHEM J, V246, P375, DOI 10.1042/bj2460375; FIEDLER E, 1985, PLANT PHYSIOL, V79, P212, DOI 10.1104/pp.79.1.212; HIATT AJ, 1965, PLANT PHYSIOL, V40, P189, DOI 10.1104/pp.40.1.189; HIATT AJ, 1965, PLANT PHYSIOL, V40, P184, DOI 10.1104/pp.40.1.184; HIMES RH, 1962, J BIOL CHEM, V237, P2903; HUM DW, 1988, J BIOL CHEM, V263, P15946; Hurn B A, 1980, Methods Enzymol, V70, P104; IWAI K, 1967, PLANT CELL PHYSIOL, V8, P307, DOI 10.1093/oxfordjournals.pcp.a079264; IWAI K, 1967, AGR BIOL CHEM TOKYO, V31, P267, DOI 10.1080/00021369.1967.10858807; KOSHIBA T, 1979, PLANT CELL PHYSIOL, V20, P667; KOSHIBA T, 1978, BIOCHIM BIOPHYS ACTA, V522, P10, DOI 10.1016/0005-2744(78)90317-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ljungdahl L G, 1980, Methods Enzymol, V66, P599; LOVELL CR, 1990, BIOCHEMISTRY-US, V29, P5687, DOI 10.1021/bi00476a007; MacKenzie R E, 1984, FOLATES PTERINS CHEM, V1, P255; MACKENZIE RE, 1971, J BIOL CHEM, V246, P3731; MEJIA NR, 1988, BIOCHEM BIOPH RES CO, V155, P1, DOI 10.1016/S0006-291X(88)81040-4; MEJIA NR, 1986, J BIOL CHEM, V261, P9509; MOUSDALE DM, 1987, PHYTOCHEMISTRY, V26, P2665, DOI 10.1016/S0031-9422(00)83568-2; OBRIEN WE, 1973, J BIOL CHEM, V248, P403; PAUKERT JL, 1976, J BIOL CHEM, V251, P5104; PAUKERT JL, 1977, BIOCHEM BIOPH RES CO, V77, P147, DOI 10.1016/S0006-291X(77)80176-9; POLLEY LD, 1978, BIOCHIM BIOPHYS ACTA, V526, P259, DOI 10.1016/0005-2744(78)90310-8; RIOSORLANDI EM, 1988, J BIOL CHEM, V263, P4662; SCHIRCH L, 1978, ARCH BIOCHEM BIOPHYS, V189, P283, DOI 10.1016/0003-9861(78)90214-X; SCOTT JM, 1967, BIOCHEM BIOPH RES CO, V29, P418, DOI 10.1016/0006-291X(67)90473-1; SHANNON K W, 1986, P865; SHANNON KW, 1986, J BIOL CHEM, V261, P2266; SHANNON KW, 1988, J BIOL CHEM, V263, P7717; SOMACK R, 1980, ANAL BIOCHEM, V104, P464, DOI 10.1016/0003-2697(80)90100-1; STABEN C, 1986, J BIOL CHEM, V261, P4629; STABEN C, 1983, P NATL ACAD SCI-BIOL, V80, P6799, DOI 10.1073/pnas.80.22.6799; STABEN C, 1987, ANAL BIOCHEM, V162, P257, DOI 10.1016/0003-2697(87)90035-2; Staben C., 1984, FOLATES PTERINS, VI, P457; SUAREZDEMATA Z, 1980, J BIOL CHEM, V255, P2569; SUZUKI N, 1974, J NUTR SCI VITAMINOL, V20, P89; THIGPEN AE, 1990, J BIOL CHEM, V265, P7907; WELCH WH, 1968, BIOCHEM BIOPH RES CO, V30, P255, DOI 10.1016/0006-291X(68)90443-9; WENDLAND MF, 1983, BIOCHEMISTRY-US, V22, P819, DOI 10.1021/bi00273a017; WHITEHEAD TR, 1988, J BACTERIOL, V170, P3255, DOI 10.1128/jb.170.7.3255-3261.1988; WHITEHEAD TR, 1988, J BACTERIOL, V170, P995, DOI 10.1128/jb.170.2.995-997.1988; YEH CH, 1988, BIOCHEM J, V251, P89, DOI 10.1042/bj2510089	59	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18363	18369						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917961				2022-12-25	WOS:A1991GG55300098
J	ADACHI, I; ARAI, H; PIMENTAL, R; FORGAC, M				ADACHI, I; ARAI, H; PIMENTAL, R; FORGAC, M			PROTEOLYSIS AND ORIENTATION ON RECONSTITUTION OF THE COATED VESICLE PROTON PUMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111	Tufts University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK 34928] Funding Source: Medline; NIGMS NIH HHS [R01 GM034478, GM 34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P67; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; ARAI H, 1988, J BIOL CHEM, V263, P8796; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN EJ, 1983, J BIOL CHEM, V258, P5238; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; CIDON S, 1986, J BIOL CHEM, V261, P9222; DEAN GE, 1984, J BIOL CHEM, V259, P9569; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; FORGAC M, 1984, J BIOL CHEM, V259, P8101; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GALLOWAY CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3334, DOI 10.1073/pnas.80.11.3334; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GOLDIN SM, 1988, METHOD ENZYMOL, V156, P127; GOLDIN SM, 1977, J BIOL CHEM, V252, P5630; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND C, 1981, J BIOL CHEM, V256, P8298; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDALA S, 1986, J BIOL CHEM, V261, P2850; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MORIYAMA Y, 1986, BIOCHIM BIOPHYS ACTA, V854, P102, DOI 10.1016/0005-2736(86)90069-6; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; NELSON H, 1989, J BIOL CHEM, V264, P1775; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PERCY JM, 1986, BIOCHEM J, V239, P77, DOI 10.1042/bj2390077; PERCY JM, 1985, BIOCHEM J, V231, P557, DOI 10.1042/bj2310557; RANDALL SK, 1986, J BIOL CHEM, V261, P1364; RANDALL SK, 1987, J BIOL CHEM, V262, P7135; RAO R, 1988, J BIOL CHEM, V263, P5640; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHNEIDER DL, 1981, J BIOL CHEM, V256, P3858; STONE DK, 1983, J BIOL CHEM, V258, P4059; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929; ZHANG F, 1983, BIOCHEM BIOPH RES CO, V114, P620, DOI 10.1016/0006-291X(83)90825-2; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	44	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1990	265	2					960	966						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CH533	1967251				2022-12-25	WOS:A1990CH53300052
J	CHAKRABORTI, PK; GARABEDIAN, MJ; YAMAMOTO, KR; SIMONS, SS				CHAKRABORTI, PK; GARABEDIAN, MJ; YAMAMOTO, KR; SIMONS, SS			CREATION OF SUPER GLUCOCORTICOID RECEPTORS BY POINT MUTATIONS IN THE STEROID BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TISSUE-CULTURE CELLS; DEXAMETHASONE 21-MESYLATE; FUNCTIONAL DOMAINS; AMINO-ACID; HORMONE; IDENTIFICATION; EXPRESSION; COVALENT; ARSENITE; FRAGMENT	Almost all modifications of the steroid binding domain of glucocorticoid receptors are known to cause a reduction or loss of steroid binding activity. Nonetheless, we now report that mutations of cysteine 656 of the rat receptor, which was previously suspected to be a crucial amino acid for the binding process, have produced "super" receptors. These receptors displayed an increased affinity for glucocorticoid steroids and a decreased relative affinity for cross-reacting steroids such as progesterone and aldosterone. The increased in vitro affinity of the super receptors was maintained in a whole cell bioassay. These results indicate that additional modifications of the glucocorticoid receptor, and probably the other steroid receptors, may further increase the binding affinity and/or specificity.	NIDDKD,STEROID HORMONES SECT,BLDG 8,RM B2A-07,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Francisco								BAXTER JD, 1971, P NATL ACAD SCI USA, V68, P932, DOI 10.1073/pnas.68.5.932; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1338, DOI 10.1016/0006-291X(91)90433-8; CHAKRABORTI PK, 1990, ENDOCRINOLOGY, V265, P2530; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DISORBO DM, 1980, ENDOCRINOLOGY, V106, P922, DOI 10.1210/endo-106-3-922; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOLLENBERG SM, 1989, CANCER RES, V49, pS2292; HURLEY DM, 1991, J CLIN INVEST, V87, P680, DOI 10.1172/JCI115046; King R.J.B., 1974, STEROID CELL INTERAC; LAMONTAGNE N, 1984, ENDOCRINOLOGY, V114, P2252, DOI 10.1210/endo-114-6-2252; LOPEZ S, 1990, J BIOL CHEM, V265, P16039; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MILLER NR, 1988, J BIOL CHEM, V263, P15217; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Raynaud J.-P., 1983, STEROID HORMONE RECE, P141; Rodbard D, 1973, RECEPTORS REPRODUCTI, V36, P289; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SIMONS SS, 1987, J BIOL CHEM, V262, P9676; SIMONS SS, 1990, J BIOL CHEM, V265, P1938; SIMONS SS, 1979, BIOCHEM BIOPH RES CO, V86, P793, DOI 10.1016/0006-291X(79)91782-0; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; SIMONS SS, 1987, J BIOL CHEM, V262, P9669; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SIMONS SS, 1981, P NATL ACAD SCI-BIOL, V78, P3541, DOI 10.1073/pnas.78.6.3541; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMITH LI, 1988, BIOCHEMISTRY-US, V27, P3747, DOI 10.1021/bi00410a034; STROMSTEDT PE, 1990, J BIOL CHEM, V265, P12973; TEUTSCH G, 1988, J STEROID BIOCHEM, V31, P549, DOI 10.1016/0022-4731(88)90006-4; WILLIAMS GH, 1987, HARRISONS PRINCIPLES, P1772	33	89	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22075	22078						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939229				2022-12-25	WOS:A1991GR56400003
J	MACDONALD, MJ; KAYSEN, JH; MORAN, SM; POMIJE, CE				MACDONALD, MJ; KAYSEN, JH; MORAN, SM; POMIJE, CE			PYRUVATE-DEHYDROGENASE AND PYRUVATE-CARBOXYLASE - SITES OF PRETRANSLATIONAL REGULATION BY GLUCOSE OF GLUCOSE-INDUCED INSULIN RELEASE IN PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; MESSENGER-RNA; PHOSPHOENOLPYRUVATE CARBOXYKINASE; PRIMARY CULTURES; BETA-CELLS; METABOLISM; LEUCINE; GLUCOKINASE; HEPATOCYTES; ACTIVATION	It has been shown previously that glucose-induced insulin release is completely absent in rat pancreatic islets that had been cultured for 1 day at low glucose (1 mM) and that it is restored by culturing islets for a 2nd day at high (20 mm) glucose (MacDonald, M. J., Fahien, L. A., McKenzie, D. I., and Moran, S. M. (1991) Am. J. Physiol. 259, E548-E554). It has been suggested that the incapacitation of glucose's insulinotropism is due to down-regulation of the synthesis of enzymes that process glucose's metabolic signal for insulin release. In the current study, results of metabolic, enzymic, and molecular biologic experiments were each consistent with (an) intramitochondrial site(s) of down-regulation in islets cultured at low glucose. Glucose metabolism was inhibited 80% in islets cultured at 1 mM glucose. The suppression of release of (CO2)-C-14 from [6-C-14]glucose > from [U-C-14]glucose > [3,4-C-14] glucose > from [1-C-14]glucose in islets cultured at low glucose indicated a mitochondrial site of down-regulation because C-6 of glucose can only be converted to CO2 in the citric acid cycle, whereas C-1 can be released as CO2 in the glucose-6-phosphate dehydrogenase reaction, and C-6 of glucose dwells in the citric acid cycle longer than carbons 2-5 of glucose. Since carbons 3 and 4 of glucose can be decarboxylated in the pyruvate dehydrogenase reaction, incomplete suppression of CO2 formation from these carbons is consistent with suppression of pyruvate carboxylation as well as decarboxylation. Formation of (HOH)-H-3 from [5-H-3]glucose was equal in the two groups of islets, indicating that glycolysis as far as phosphoenolpyruvate was intact. This idea was supported by assays which showed that activities of enzymes of the glycolytic pathway between glucokinase/hexokinase and pyruvate kinase were equal in both types of islets. Additional studies indicated that regulation by glucose was at transcription of genes coding for some mitochondrial enzymes. Glucokinase, malic enzyme, and fumarase mRNAs were not affected by glucose, whereas the pyruvate dehydrogenase E1-alpha subunit and pyruvate carboxylase mRNAs were decreased 85-90% in islets cultured at 1 mM glucose. Pyruvate dehydrogenase enzyme activity was decreased to a similar extent in these islets. About 24 h was required for maximal (de)induction of pyruvate dehydrogenase E1-alpha and pyruvate carboxylase mRNAs, and the amounts of transcripts were proportional to the concentrations of glucose between 1 and 20 mm. These results suggest that glucose regulates its own signal for insulin release via glucose response elements in the genes coding for pyruvate carboxylase and the E1-alpha subunit of pyruvate dehydrogenase. Both pyruvate decarboxylation via pyruvate dehydrogenase and pyruvate carboxylation via pyruvate carboxylase are influenced by glucose, whereas pyruvate carboxylation in the cytosol catalyzed by malic enzyme appears not to be affected by glucose at the level of enzyme synthesis.	UNIV WISCONSIN, SCH MED, DEPT PEDIAT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK028348, R01DK028348] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEYASSINE H, 1970, ENDOCRINOLOGY, V87, P84, DOI 10.1210/endo-87-1-84; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; BLOCK KP, 1988, METHOD ENZYMOL, V166, P201; BUCHER T, 1955, METHOD ENZYMOL, V1, P415, DOI 10.1016/0076-6879(55)01068-9; BURCH PT, 1981, DIABETES, V30, P923, DOI 10.2337/diabetes.30.11.923; COOPER RH, 1974, BIOCHEM J, V143, P625, DOI 10.1042/bj1430625; DEMEIRLEIR L, 1988, J BIOL CHEM, V263, P1991; DEUTSCH J, 1987, METHOD ENZYMAT AN, P90; FREYTAG SO, 1984, J BIOL CHEM, V259, P2831; HELLMAN B, 1971, BIOCHIM BIOPHYS ACTA, V241, P147, DOI 10.1016/0005-2736(71)90312-9; HOXWORTH B, 1985, DIABETES, V34, P295, DOI 10.2337/diabetes.34.3.295; Hsu R.Y., 1969, METHODS ENZYMOL, V13, P230, DOI DOI 10.1016/0076-6879(69)13042-6; IYNEDJIAN PB, 1989, P NATL ACAD SCI USA, V86, P7838, DOI 10.1073/pnas.86.20.7838; JENSEN MD, 1988, AM J PHYSIOL, V254, pE700, DOI 10.1152/ajpendo.1988.254.6.E700; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; JOOST HG, 1980, METABOLISM, V29, P23, DOI 10.1016/0026-0495(80)90093-1; KATZ J, 1963, J BIOL CHEM, V238, P517; KELLEY DS, 1984, BIOCHEM J, V217, P543, DOI 10.1042/bj2170543; LAYCHOCK SG, 1983, MOL CELL ENDOCRINOL, V32, P157, DOI 10.1016/0303-7207(83)90079-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD M, 1976, AM J PHYSIOL, V231, P619, DOI 10.1152/ajplegacy.1976.231.2.619; MACDONALD MJ, 1991, J BIOL CHEM, V266, P1335; MACDONALD MJ, 1990, AM J PHYSIOL, V259, pE548, DOI 10.1152/ajpendo.1990.259.4.E548; MACDONALD MJ, 1985, DIABETES, V34, P246, DOI 10.2337/diabetes.34.3.246; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V270, P15, DOI 10.1016/0003-9861(89)90002-7; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MACDONALD MJ, 1985, MOL CELL BIOCHEM, V68, P115; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1974, DIABETOLOGIA, V10, P761, DOI 10.1007/BF01219538; MACDONALD MJ, 1975, BIOCHIM BIOPHYS ACTA, V385, P188, DOI 10.1016/0304-4165(75)90347-5; MACDONALD MJ, 1980, BIOCHIM BIOPHYS ACTA, V615, P223, DOI 10.1016/0005-2744(80)90025-X; MAGNUSON MA, 1986, J BIOL CHEM, V261, P1183; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MCCLURE WR, 1971, J BIOL CHEM, V246, P3569; MCCORMACK JG, 1990, BIOCHEM J, V267, P527, DOI 10.1042/bj2670527; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; PORTENHAUSER R, 1972, EUR J BIOCHEM, V31, P308, DOI 10.1111/j.1432-1033.1972.tb02534.x; REINHART GD, 1980, BIOCHEMISTRY-US, V19, P1477, DOI 10.1021/bi00548a034; Rutter W.J., 1966, METHODS ENZYMOL, V9, P479; SNYDER PJ, 1970, AM J PHYSIOL, V219, P876, DOI 10.1152/ajplegacy.1970.219.4.876; SONG BJ, 1989, ANN NY ACAD SCI, V573, P455, DOI 10.1111/j.1749-6632.1989.tb15038.x; STUMPO DJ, 1984, EUR J BIOCHEM, V144, P497, DOI 10.1111/j.1432-1033.1984.tb08493.x; SUGDEN MC, 1989, ANN NY ACAD SCI, V573, P314, DOI 10.1111/j.1749-6632.1989.tb15008.x; VAZQUEZ JA, 1986, AM J PHYSIOL, V250, pE615, DOI 10.1152/ajpendo.1986.250.6.E615; WOLTERS GHJ, 1977, DIABETES, V26, P530, DOI 10.2337/diab.26.6.530	47	69	69	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22392	22397						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939263				2022-12-25	WOS:A1991GR56400055
J	TAVARE, JM; ZHANG, B; ELLIS, L; ROTH, RA				TAVARE, JM; ZHANG, B; ELLIS, L; ROTH, RA			INSULIN-STIMULATED SERINE AND THREONINE PHOSPHORYLATION OF THE HUMAN INSULIN-RECEPTOR - AN ASSESSMENT OF THE ROLE OF SERINES 1305-1306 AND THREONINE-1348 BY THEIR REPLACEMENT WITH NEUTRAL OR NEGATIVELY CHARGED AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; TYROSINE KINASE; BETA-SUBUNIT; HEPATOMA-CELLS; INTACT-CELLS; AUTOPHOSPHORYLATION; IDENTIFICATION; RESIDUES; SITES; CDNA	Insulin promotes insulin receptor beta-subunit phosphorylation on tyrosine, serine, and threonine residues in a variety of cells, including simian COS cells which transiently express human insulin receptors following transfection with a cDNA encoding the wild-type receptor protein. To examine the potential roles of serines 1305 and 1306 and threonine 1348 as sites of insulin-stimulated phosphorylation in these cells, these residues (i.e. either serines 1305 and 1306, or threonine 1348) were replaced with neutral (alanine) or negatively charged (aspartate) amino acids. Following transient expression of each of these mutant receptors in COS cells, two-dimensional phosphopeptide mapping reveals that threonine 1348 is the major, if not the only, insulin-stimulated threonine phosphorylation site. In contrast, while serines 1305 and/or 1306 are phosphorylated in an insulin-dependent manner, these sites comprise only a minor proportion of insulin receptor serine phosphorylation in these cells. Substitution of either serines 1305 and 1306 or threonine 1348 with neutral or negatively charged amino acids has no effect on insulin-stimulated tyrosine autophosphorylation of these mutant receptors in intact cells. Furthermore, insulin-stimulated exogenous protein-tyrosine kinase activity of the mutant receptors is unaffected, as assessed following either phosphorylation of receptors in intact cells or following immunopurification of receptors and their autophosphorylation in vitro.	UNIV TEXAS,HLTH SCI CTR,SW MED SCH,HOWARD HUGHES MED INST,5323 HARRY HINES BLVD,DALLAS,TX 75235; STANFORD UNIV,MED CTR,SCH MED,DEPT PHARMACOL,STANFORD,CA 94305	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University					PHS HHS [34962, 41765, 40511] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALLOTTI R, 1987, BIOCHEM J, V241, P99, DOI 10.1042/bj2410099; BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; DURONIO V, 1990, ENDOCRINOLOGY, V127, P481, DOI 10.1210/endo-127-1-481; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; FONG YL, 1989, J BIOL CHEM, V264, P16759; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; ISSAD T, 1991, BIOCHEM J, V275, P15, DOI 10.1042/bj2750015; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KLEIN HH, 1986, J BIOL CHEM, V261, P4691; KOSHIO O, 1989, FEBS LETT, V254, P22, DOI 10.1016/0014-5793(89)81001-4; LEVINE BA, 1991, J BIOL CHEM, V266, P3565; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; LEWIS RE, 1990, J BIOL CHEM, V265, P947; PANG DT, 1985, J BIOL CHEM, V260, P7131; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SMITH DM, 1988, BIOCHEM J, V256, P903, DOI 10.1042/bj2560903; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TAVARE JM, 1991, J BIOL CHEM, V266, P1390; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; TAVARE JM, 1991, BIOCHEM J, V274, P173, DOI 10.1042/bj2740173; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; YU KT, 1984, J BIOL CHEM, V259, P5277; YU KT, 1986, J BIOL CHEM, V261, P4715; ZHANG B, 1991, J BIOL CHEM, V266, P990	35	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21804	21809						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939203				2022-12-25	WOS:A1991GP80400073
J	DARSILLO, P; HUBER, PW				DARSILLO, P; HUBER, PW			THE USE OF CHEMICAL NUCLEASES TO ANALYZE RNA-PROTEIN INTERACTIONS - THE TFIIIA-5-S RIBOSOMAL-RNA COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; XENOPUS-LAEVIS OOCYTES; 5S RIBOSOMAL-RNA; ALPHA-SARCIN; BINDING-SITE; FACTOR-A; RIBONUCLEASE PROBE; 5S-RNA STRUCTURE; DNA; GENE	The complex of Xenopus transcription factor IIIA (TFIIIA) with 5 S rRNA was analyzed in nuclease protection experiments using hydroxyl radical. The protection pattern reveals that TFIIIA interacts with a substantial amount of the RNA molecule, with close association between the factor and the arm of the RNA composed of helix IV-loop E-helix V. Additional sites of protection punctuate the other arm of the molecule. Important contact sites within the complex were identified in "missing nucleoside" experiments. Random single-nucleoside gaps were introduced into 5 S rRNA using either Fe[EDTA]2-/H2O2 or bis(1,10-phenanthroline)copper(I). This modified RNA was allowed to bind to TFIIIA in an exchange reaction, and, afterward, bound and unbound fractions were separated on nondenaturing polyacrylamide gels. Missing nucleoside positions specifically enriched in the unbound fraction of RNA are located in the two strands that comprise loop E. These are not necessarily sites of sequence-specific contacts, but rather may constitute a region of secondary structure essential to recognition and binding of TFIIIA to 5 S rRNA.	UNIV NOTRE DAME, DEPT CHEM & BIOCHEM, NOTRE DAME, IN 46556 USA	University of Notre Dame					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038200] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN J, 1986, J BIOL CHEM, V261, P2912; ANDERSEN J, 1984, BIOCHEMISTRY-US, V23, P5759, DOI 10.1021/bi00319a014; ANDERSEN J, 1984, BIOCHEMISTRY-US, V23, P5752, DOI 10.1021/bi00319a013; BAUDIN F, 1989, NUCLEIC ACIDS RES, V17, P2043, DOI 10.1093/nar/17.5.2043; BRENOWITZ M, 1986, P NATL ACAD SCI USA, V83, P8462, DOI 10.1073/pnas.83.22.8462; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CALLACI TP, 1990, BIOCHEMISTRY-US, V29, P4653, DOI 10.1021/bi00471a021; CHRISTIANSEN J, 1987, EMBO J, V6, P453, DOI 10.1002/j.1460-2075.1987.tb04775.x; DALY TJ, 1989, J BIOL CHEM, V264, P20394; ENDO Y, 1983, J BIOL CHEM, V258, P2662; England T E, 1980, Methods Enzymol, V65, P65; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HANAS JS, 1983, P NATL ACAD SCI-BIOL, V80, P2142, DOI 10.1073/pnas.80.8.2142; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HUBER PW, 1986, J BIOL CHEM, V261, P3002; HUBER PW, 1988, METHOD ENZYMOL, V164, P468; HUBER PW, 1984, P NATL ACAD SCI-BIOL, V81, P322, DOI 10.1073/pnas.81.2.322; HUBER PW, 1986, P NATL ACAD SCI USA, V83, P1593, DOI 10.1073/pnas.83.6.1593; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; MURAKAWA GJ, 1989, NUCLEIC ACIDS RES, V17, P5361, DOI 10.1093/nar/17.13.5361; PELKA H, 1986, BIOCHEMISTRY-US, V25, P4450, DOI 10.1021/bi00363a042; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; PIELER T, 1983, FEBS LETT, V157, P283, DOI 10.1016/0014-5793(83)80562-6; PIELER T, 1984, NUCLEIC ACIDS RES, V12, P8393, DOI 10.1093/nar/12.22.8393; RANA TM, 1990, J AM CHEM SOC, V112, P2457, DOI 10.1021/ja00162a077; ROMANIUK PJ, 1987, NUCLEIC ACIDS RES, V15, P2737, DOI 10.1093/nar/15.6.2737; ROMANIUK PJ, 1985, NUCLEIC ACIDS RES, V13, P5369, DOI 10.1093/nar/13.14.5369; ROMANIUK PJ, 1989, BIOCHEMISTRY-US, V28, P1388, DOI 10.1021/bi00429a067; ROMANIUK PJ, 1988, NUCLEIC ACIDS RES, V16, P2295, DOI 10.1093/nar/16.5.2295; ROMBY P, 1990, BIOCHIMIE, V72, P437, DOI 10.1016/0300-9084(90)90068-R; SANDS MS, 1987, MOL CELL BIOL, V7, P3985, DOI 10.1128/MCB.7.11.3985; SHANG ZG, 1988, ANAL BIOCHEM, V168, P156, DOI 10.1016/0003-2697(88)90023-1; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; Silberklang M, 1979, Methods Enzymol, V59, P58; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P8050, DOI 10.1021/bi00348a032; TIMMINS PA, 1988, NUCLEIC ACIDS RES, V16, P8633, DOI 10.1093/nar/16.17.8633; TULLIUS TD, 1989, ANNU REV BIOPHYS BIO, V18, P213, DOI 10.1146/annurev.bb.18.060189.001241; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; VANDYKE MW, 1983, NUCLEIC ACIDS RES, V11, P5555; VARANI G, 1989, BIOCHEMISTRY-US, V28, P7760, DOI 10.1021/bi00445a036; WANG XD, 1989, P NATL ACAD SCI USA, V86, P7795, DOI 10.1073/pnas.86.20.7795; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028	45	27	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21075	21082						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939152				2022-12-25	WOS:A1991GN00100077
J	TIGYI, G; HENSCHEN, A; MILEDI, R				TIGYI, G; HENSCHEN, A; MILEDI, R			A FACTOR THAT ACTIVATES OSCILLATORY CHLORIDE CURRENTS IN XENOPUS OOCYTES COPURIFIES WITH A SUBFRACTION OF SERUM-ALBUMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEINS; MESSENGER-RNA; HUMAN-PLASMA; FRAGMENTS; SEQUENCE; CADMIUM; SYSTEM; CELLS; ACID	Vertebrate blood sera contain a factor that elicits oscillatory chloride currents in Xenopus oocytes through activation of the phosphatidylinositol second messenger system. This factor was purified from rabbit and human sera by a sequence of Blue-Agarose chromatography, concanavalin A affinity chromatography, and hydroxyapatite fractionation, yielding a single active protein band (67 kDa). This protein is a subfraction of serum albumin, as revealed by its molecular mass, isoelectric properties, peptide maps, amino acid composition, and NH2-terminal sequence. Moreover, the factor could be purified with a monoclonal antibody to serum albumin and its ability to elicit oscillatory currents was inhibited by several polyclonal-monospecific antibodies to serum albumin. Various commercial high purity albumin preparations elicited oscillatory currents in oocytes. The activity of albumin was partially reduced by charcoal absorption and was greatly diminished when crystalline albumin was extracted with dry methanol. However, the activity was resistant to extraction with chloroform/ether, disulfide cleavage, and denaturation with 8 M urea, 6 M guanidinium chloride, and 1% sodium dodecyl sulfate. Trypsin or lipase treatment substantially reduced the potency of the active albumin, but neither treatment alone abolished the factor even after prolonged digestion. In contrast to serum or serum albumin, freshly collected blood plasma or purified plasma albumin did not evoke oscillatory currents. This indicates that some of the plasma albumin changes during blood coagulation and acquires a "factor" that makes it capable of activating the phosphatidylinositol-Ca2+ system in Xenopus oocytes. The serum factor also activates the phosphatidylinositol system in a variety of mammalian cells, suggesting that the modified albumin may play a role in cellular events related to tissue repair following injury.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	University of California System; University of California Irvine	TIGYI, G (corresponding author), UNIV CALIF IRVINE,DEPT PSYCHOBIOL,CELLULAR & MOLEC NEUROBIOL LAB,IRVINE,CA 92717, USA.				NINDS NIH HHS [NS23284] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023284] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALMON RR, 1978, J NEUROCHEM, V30, P1559, DOI 10.1111/j.1471-4159.1978.tb10493.x; BRADSHAW RA, 1968, J BIOL CHEM, V243, P3817; BRODERSEN R, 1978, ALBUMIN STRUCTURE BI, P61; CHEN RF, 1967, J BIOL CHEM, V242, P173; CLARK P, 1962, J BIOL CHEM, V237, P2509; COHN EJ, 1947, J AM CHEM SOC, V69, P1753, DOI 10.1021/ja01199a051; COHN EJ, 1946, J AM CHEM SOC, V68, P459, DOI 10.1021/ja01207a034; DUGAICZYK A, 1982, P NATL ACAD SCI-BIOL, V79, P71, DOI 10.1073/pnas.79.1.71; DYER D, 1989, 3RD INT S NEUR REG, P8; DYER DL, 1989, WIN P MIAM BIOT S, P322; Edman P, 1975, PROTEIN SEQUENCE DET, P232; ENGLAND P, 1988, J PHYSIOL-LONDON, V410, P68; Foster J. F., 1977, ALBUMIN STRUCTURE FU, P53; GHINEA N, 1989, J BIOL CHEM, V264, P4755; GHINEA N, 1988, J CELL BIOL, V107, P231, DOI 10.1083/jcb.107.1.231; GUTHANS SL, 1982, ARCH BIOCHEM BIOPHYS, V218, P320, DOI 10.1016/0003-9861(82)90350-2; HAWKINS D, 1969, J CLIN INVEST, V48, P536, DOI 10.1172/JCI106011; HEANEY-KIERAS J, 1977, Journal of Biological Chemistry, V252, P4326; HILAK MC, 1974, INT J PEPT PROT RES, V6, P95; HJERTEN S, 1962, ARCH BIOCHEM BIOPHYS, P147; HJERTEN S, 1959, BIOCHIM BIOPHYS ACTA, V31, P216, DOI 10.1016/0006-3002(59)90459-7; IKEHARA Y, 1977, J BIOCHEM-TOKYO, V81, P1293; ITO Y, 1974, PROC R SOC SER B-BIO, V187, P235, DOI 10.1098/rspb.1974.0072; KALMAN SM, 1980, P NATL ACAD SCI-BIOL, V77, P6820, DOI 10.1073/pnas.77.11.6820; KING TP, 1970, J BIOL CHEM, V245, P6134; KUMBARACI NM, 1982, J PHYSIOL-LONDON, V325, P195, DOI 10.1113/jphysiol.1982.sp014145; MARSHALL JJ, 1970, J CHROMATOGR, V53, P370; MCMENAMY RH, 1971, J BIOL CHEM, V246, P4744; MELOUN B, 1975, FEBS LETT, V58, P134, DOI 10.1016/0014-5793(75)80242-0; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MILEDI R, 1989, J PHYSIOL-LONDON, V417, P173, DOI 10.1113/jphysiol.1989.sp017796; MOOLENAAR WH, 1981, CELL, V23, P789, DOI 10.1016/0092-8674(81)90443-8; MOOLENAR WH, 1979, NATURE, V279, P712; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PALLOTTA T, 1989, J PHYSIOL-LONDON, V416, P589, DOI 10.1113/jphysiol.1989.sp017779; PETERS T, 1978, ALBUMIN STRUCTURE BI, P11; PETERS T, 1975, PLASMA PROTEINS, P133; Peters T Jr, 1970, Adv Clin Chem, V13, P37, DOI 10.1016/S0065-2423(08)60385-6; ROBERTS CA, 1988, LIFE SCI, V42, P1369, DOI 10.1016/0024-3205(88)90166-X; SPECTOR AA, 1978, ALBUMIN STRUCTURE BI, P51; SPENCER EM, 1971, J BIOL CHEM, V246, P201; TIGYI G, 1990, P NATL ACAD SCI USA, V87, P1521, DOI 10.1073/pnas.87.4.1521; TIGYI G, 1990, P NATL ACAD SCI USA, V87, P528, DOI 10.1073/pnas.87.2.528; TIGYI G, 1989, ORD INT REG S, P7; TRAVIS J, 1976, BIOCHEM J, V157, P301, DOI 10.1042/bj1570301; TUNON P, 1984, J BIOCHEM BIOPH METH, V9, P171, DOI 10.1016/0165-022X(84)90008-3; WALKER JE, 1976, FEBS LETT, V66, P173, DOI 10.1016/0014-5793(76)80496-6; Watt J G, 1970, Vox Sang, V18, P42	48	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20602	20609						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939110				2022-12-25	WOS:A1991GN00100007
J	WATANABE, T; WADA, N; KIM, EE; WYCKOFF, HW; CHOU, JY				WATANABE, T; WADA, N; KIM, EE; WYCKOFF, HW; CHOU, JY			MUTATION OF A SINGLE AMINO-ACID CONVERTS GERM-CELL ALKALINE-PHOSPHATASE TO PLACENTAL ALKALINE-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIOCARCINOMA CELLS; EXPRESSION; GENE; SEMINOMA; SEQUENCE; ISOZYME; CLONING	Human placental and germ cell alkaline phosphatases (PLAP and GCAP, respectively), are characterized by their differential sensitivities to inhibition by L-leucine, EDTA, and heat. Yet, they differ by only 7 amino acids at positions 15, 67, 68, 84, 241, 254, and 429 within their respective 484 residues. To determine the structural basis and the amino acid(s) involved in these physicochemical differences, we constructed three GCAP mutants by site-directed mutagenesis and six GCAP/PLAP chimeras and then expressed these alkaline phosphatase mutants in COS-1 cells. We report that the differential reactivity of PLAP and GCAP depends critically on a single amino acid at position 429. GCAP with Gly-429 is strongly inhibited by L-leucine, EDTA, and heat, whereas PLAP with Glu-429 is resistant. By substituting Gly-429 of GCAP with a series of amino acids, we demonstrate that the relative sensitivities of these mutants to L-leucine, EDTA, and heat inhibition are, in general, parallel. Mutants in the order of resistance to these treatments are: Glu (most resistant), Asp/Ile/Leu, Gln/Val/Lys, Ser/His, and Arg/Thr/Met/Cys/Phe/Trp/Tyr/Pro/Asn/Ala/Gly (least resistant). However, the Ser-429 and His-429 mutants were more resistant to EDTA and heat inhibition than the wild-type GCAP, but were equally sensitive to L-leucine inhibition. Structural analysis of mammalian alkaline phosphatase modeled on the refined crystal structure of Escherichia coli alkaline phosphatase indicates that the negative charge of Glu-429 of PLAP, which simultaneously stabilizes the protein as a whole and the metal binding specifically, probably acts through interactions with the metal ligand His-320 (His-331 in E. coli alkaline phosphatase). Replacement of codon 429 with Gly in GCAP leads to destabilization and loosening of the metal binding. The data suggest that the natural binding site for L-leucine may be near position 429, with the amino and carboxyl groups of L-leucine interacting with bound phosphate and His-432 (His-412 in E. coli alkaline phosphatase), respectively.	NICHHD,HUMAN GENET BRANCH,BLDG 10,RM 9S242,BETHESDA,MD 20892; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Yale University								CHANG CH, 1980, CANCER RES, V40, P1506; CHLEBOWSKI JF, 1977, J BIOL CHEM, V252, P7042; FISHMAN L, 1976, CANCER RES, V36, P2268; FISHMAN WH, 1968, CANCER RES, V28, P150; FISHMAN WH, 1979, IMMUNODIAGNOSIS CANC, P442; GOLDSTEIN DJ, 1982, CLIN CHIM ACTA, V125, P63, DOI 10.1016/0009-8981(82)90046-8; HULETT FM, 1991, J BIOL CHEM, V266, P1077; ITO F, 1984, J BIOL CHEM, V259, P2526; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KIM EE, 1989, CLIN CHIM ACTA, V186, P175; KNOLL BJ, 1988, J BIOL CHEM, V263, P12020; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANGE PH, 1982, CANCER RES, V42, P3244; MARTIN D, 1987, ANN HUM GENET, V51, P145, DOI 10.1111/j.1469-1809.1987.tb01056.x; MICANOVIC R, 1988, P NATL ACAD SCI USA, V85, P1398, DOI 10.1073/pnas.85.5.1398; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MILLAN JL, 1988, ANTICANCER RES, V8, P995; MILLAN JL, 1988, P NATL ACAD SCI USA, V85, P3024, DOI 10.1073/pnas.85.9.3024; NAKAYAMA T, 1970, CLIN CHIM ACTA, V30, P546; NOVAK ER, 1979, GYNECOLOGIC OBSTETRI, P476; OGATA S, 1988, J BIOL CHEM, V263, P10489; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; SAKIYAMA T, 1978, ARCH BIOCHEM BIOPHYS, V191, P782, DOI 10.1016/0003-9861(78)90420-4; SAKIYAMA T, 1979, J BIOL CHEM, V254, P935; STIGBRAND T, 1982, ISOZYMES-CURR T BIOL, V6, P93; SUSSMAN HH, 1984, HUMAN ALKALINE PHOSP, P87; WAHREN B, 1979, INT J CANCER, V24, P749, DOI 10.1002/ijc.2910240608; WATANABE S, 1989, J BIOL CHEM, V264, P12611; WYCKOFF HW, 1983, ADV ENZYMOL RAMB, V55, P453; Wyckoff HW, 1987, PHOSPHATE METABOLISM, P118	30	24	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21174	21178						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939159				2022-12-25	WOS:A1991GN00100091
J	BIENROTH, S; WAHLE, E; SUTERCRAZZOLARA, C; KELLER, W				BIENROTH, S; WAHLE, E; SUTERCRAZZOLARA, C; KELLER, W			PURIFICATION OF THE CLEAVAGE AND POLYADENYLATION FACTOR INVOLVED IN THE 3'-PROCESSING OF MESSENGER-RNA PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEINS; POLY(A) POLYMERASE; MULTIPLE FACTORS; 3' TERMINI; INVITRO; COMPLEXES; SITE; SEPARATION; PARTICLES; REQUIRES	Polyadenylation of messenger RNA precursors requires the nucleotide sequence AAUAAA and two factors: poly(A) polymerase and a specificity factor termed cleavage and polyadenylation factor (CPF). We have purified CPF from calf thymus and from HeLa cells to near homogeneity. Four polypeptides with molecular masses of 160, 100, 73, and 30 kDa cofractionate with CPF activity. Glycerol gradient centrifugation and gel filtration indicate that these four proteins form one large complex with a sedimentation constant of 12 S, a Stokes radius near 100 angstrom and a native molecular mass near 500 kDa. Purified CPF binds specifically to an RNA that contains the AAUAAA sequence. Mutation of the AAUAAA sequence inhibits CPF binding as well as polyadenylation. Purified CPF contains only trace amounts of RNA and does not react with antibodies against common epitopes of small nuclear ribonucleoprotein particles. Thus, contrary to previous indications, CPF does not appear to be a small nuclear ribonucleoprotein particle.			BIENROTH, S (corresponding author), UNIV BASEL,BIOCTR,DEPT CELL BIOL,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Wahle, Elmar/0000-0003-2504-0677				BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BERGET SM, 1986, CELL, V46, P691, DOI 10.1016/0092-8674(86)90344-2; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BIRNSTIEL ML, 1988, STRUCTURE FUNCTION M, P155; BOCHNIG P, 1987, EUR J BIOCHEM, V168, P461, DOI 10.1111/j.1432-1033.1987.tb13439.x; BOHME HJ, 1972, J CHROMATOGR, V69, P209, DOI 10.1016/S0021-9673(00)83103-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FRENDEWEY D, 1987, COLD SPRING HARB SYM, V52, P287, DOI 10.1101/SQB.1987.052.01.034; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GILMARTIN GM, 1988, GENE DEV, V2, P578, DOI 10.1101/gad.2.5.578; HASHIMOTO C, 1986, CELL, V45, P581, DOI 10.1016/0092-8674(86)90290-4; HUMPHREY T, 1987, EMBO J, V6, P4159, DOI 10.1002/j.1460-2075.1987.tb02762.x; KRAMER A, 1985, EMBO J, V4, P3571, DOI 10.1002/j.1460-2075.1985.tb04119.x; KRAMER A, 1987, P NATL ACAD SCI USA, V84, P8408, DOI 10.1073/pnas.84.23.8408; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMOND AI, 1990, NUCLEIC ACIDS MOL BI, V4, P243; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LUHRMANN R, 1988, STRUCTURE FUNCTION M, P71; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MCDEVITT MA, 1988, GENE DEV, V2, P588, DOI 10.1101/gad.2.5.588; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; MOORE CL, 1988, MOL CELL BIOL, V8, P226, DOI 10.1128/MCB.8.1.226; MOORE CL, 1985, CELL, V41, P845, DOI 10.1016/S0092-8674(85)80065-9; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; Sambrook J, 1989, MOL CLONING LABORATO; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SKOLNIKDAVID H, 1987, GENE DEV, V1, P672, DOI 10.1101/gad.1.7.672; STEFANO JE, 1988, MOL CELL BIOL, V8, P2052, DOI 10.1128/MCB.8.5.2052; SUTERCRAZZOLARA C, 1991, GENE EXPRESSION, V1, P91; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; ZARKOWER D, 1987, EMBO J, V6, P177, DOI 10.1002/j.1460-2075.1987.tb04736.x; ZARKOWER D, 1987, EMBO J, V6, P4185, DOI 10.1002/j.1460-2075.1987.tb02765.x; ZHANG F, 1987, MOL CELL BIOL, V7, P3277, DOI 10.1128/MCB.7.9.3277	43	147	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19768	19776						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918081				2022-12-25	WOS:A1991GK66700092
J	NEMOTO, Y; NAMBA, T; KOZAKI, S; NARUMIYA, S				NEMOTO, Y; NAMBA, T; KOZAKI, S; NARUMIYA, S			CLOSTRIDIUM-BOTULINUM-C3 ADP-RIBOSYLTRANSFERASE GENE - CLONING, SEQUENCING, AND EXPRESSION OF A FUNCTIONAL PROTEIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; BOTULINUM C1 NEUROTOXIN; BOVINE BRAIN MEMBRANES; LABILE ENTERO-TOXIN; NUCLEOTIDE-SEQUENCE; CLOSTRIDIUM-BOTULINUM; ENZYMATIC AMPLIFICATION; DIPHTHERIA-TOXIN; STRUCTURAL GENE; PRODUCT	C3 ADP-ribosyltransferase is an exoenzyme produced by certain strains of Clostridium botulinum types C and D, which specifically ADP-ribosylates rho and rac proteins in eukaryotic cells. The enzyme was purified from a culture filtrate of C. botulinum type C strain 003-9, and the amino acid sequence from the amino-terminal Ser to Asn192 was determined by Edman degradation. Using a set of degenerate primers based on the sequence, we amplified a part of the gene for this enzyme by polymerase chain reaction. A 2.1-kilobase pair HincII fragment of C. botulinum DNA containing the whole structural gene was then identified by Southern analysis with the polymerase chain reaction product as a probe, and the complete nucleotide structure of the gene together with flanking regions was determined by cloning and DNA sequencing the HincII fragment. The gene encodes a protein of 244 amino acids with a M(r) of 27,362 which begins with a putative signal peptide of 40 amino acids. Escherichia coli carrying this gene produced the active enzyme, and about 60% of it was found in the culture medium. Immunoblot analysis with antiserum against the enzyme revealed the presence of two immunoreactive proteins of 27 and 23 kDa in the cytoplasmic/membrane fraction and only the 23-kDa protein in the periplasm and the medium, suggesting that the enzyme expressed is processed in the E. coli, exported into the periplasm and released into the culture medium.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 606,JAPAN; UNIV OSAKA PREFECTURE,COLL AGR,DEPT VET SCI,SAKAI,OSAKA 591,JAPAN	Kyoto University; Osaka Metropolitan University								ABRAHMSEN L, 1985, EMBO J, V4, P3901, DOI 10.1002/j.1460-2075.1985.tb04164.x; ADAMVIZI V, 1988, FEBS LETT, V238, P277, DOI 10.1016/0014-5793(88)80496-4; AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BINZ T, 1990, NUCLEIC ACIDS RES, V18, P5556, DOI 10.1093/nar/18.18.5556; BINZ T, 1990, J BIOL CHEM, V265, P9153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; Cato E., 1986, BERGEYS MANUAL SYSTE, P1141; CHANG S, 1987, METHOD ENZYMOL, V153, P507; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; FAIRWEATHER NF, 1986, J BACTERIOL, V165, P21, DOI 10.1128/jb.165.1.21-27.1986; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FITZMAURICE WP, 1989, MOL GEN GENET, V218, P340, DOI 10.1007/BF00331287; GOLD L, 1981, ANNU REV MICROBIOL, V35, P365, DOI 10.1146/annurev.mi.35.100181.002053; GRAVES MC, 1986, J BIOL CHEM, V261, P1409; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HAUSER D, 1990, NUCLEIC ACIDS RES, V18, P4924, DOI 10.1093/nar/18.16.4924; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; IKLUND MW, 1972, NATURE-NEW BIOL, V235, P16; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; KURAZONO H, 1985, FEMS MICROBIOL LETT, V30, P47; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCHT C, 1986, SCIENCE, V232, P1258, DOI 10.1126/science.3704651; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; Maniatis T., 1982, MOL CLONING; MCLAUGHLIN JR, 1981, J BIOL CHEM, V256, P1283; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; MORII N, 1990, J BIOCHEM-TOKYO, V107, P769, DOI 10.1093/oxfordjournals.jbchem.a123123; MORII N, 1988, J BIOL CHEM, V263, P12420; MORIISHI K, 1990, J BIOL CHEM, V265, P16614; Moss J, 1990, ADP RIBOSYLATING TOX; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OGOROCHI T, 1989, BIOCHEM BIOPH RES CO, V163, P1175, DOI 10.1016/0006-291X(89)92344-9; OHASHI Y, 1987, BIOCHEM BIOPH RES CO, V142, P1032, DOI 10.1016/0006-291X(87)91518-X; OHASHI Y, 1987, J BIOL CHEM, V262, P1430; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; POPOFF M, 1990, NUCLEIC ACIDS RES, V18, P1291, DOI 10.1093/nar/18.5.1291; Pugsley A. P., 1988, PROTEIN TRANSFER ORG, P607; RATTI G, 1983, NUCLEIC ACIDS RES, V11, P6589, DOI 10.1093/nar/11.19.6589; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; ROSENER S, 1987, FEBS LETT, V224, P38, DOI 10.1016/0014-5793(87)80418-0; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPICER EK, 1982, J BIOL CHEM, V257, P5716; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; UHLEN M, 1984, J BIOL CHEM, V259, P1695; VLASUK GP, 1983, J BIOL CHEM, V258, P7141; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YAMAMOTO T, 1984, J BIOL CHEM, V259, P5037; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG M, 1989, FEMS MICROBIOL LETT, V63, P301, DOI 10.1111/j.1574-6968.1989.tb03402.x	70	82	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19312	19319						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918048				2022-12-25	WOS:A1991GK66700033
J	STUDWELLVAUGHAN, PS; ODONNELL, M				STUDWELLVAUGHAN, PS; ODONNELL, M			CONSTITUTION OF THE TWIN POLYMERASE OF DNA POLYMERASE-III HOLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GAMMA-SUBUNIT; TAU-SUBUNIT; PRIMED TEMPLATE; READING FRAME; GENE-PRODUCT; PROTEIN; PURIFICATION; REPLICATION; BACTERIOPHAGE-T4	It is speculated that DNA polymerases which duplicate chromosomes are dimeric to provide concurrent replication of both leading and lagging strands. DNA polymerase III holoenzyme (holoenzyme), is the 10-subunit replicase of the Escherichia coli chromosome. A complex of the alpha (DNA polymerase) and epsilon (3'-5' exonuclease) subunits of the holoenzyme contains only one of each protein. Presumably, one of the eight other subunit(s) functions to dimerize the alpha-epsilon-polymerase within the holoenzyme. Based on dimeric subassemblies of the holoenzyme, two subunits have been elected as possible agents of polymerase dimerization, one of which is the tau-subunit (McHenry, C. S. (1982) J. Biol. Chem. 257, 2657-2663). Here, we have used pure alpha, epsilon, and tau-subunits in binding studies to determine whether tau can dimerize the polymerase. We find tau binds directly to alpha. Whereas alpha is monomeric, tau is a dimer in its native state and thereby serves as an efficient scaffold to dimerize the polymerase. The epsilon-subunit does not associate directly with tau but becomes dimerized in the alpha-epsilon-tau-complex by virtue of its interaction with alpha. We have analyzed the dimeric alpha-epsilon-tau-complex by different physical methods to increase the confidence that this complex truly contains a dimeric polymerase. The tau-subunit is comprised of the NH2-terminal two-thirds of tau but does not bind to alpha-epsilon, identifying the COOH-terminal region of tau as essential to its polymerase dimerization function. The significance of these results with respect to the organization of subunits within the holoenzyme is discussed.			STUDWELLVAUGHAN, PS (corresponding author), CORNELL UNIV,MED CTR,COLL MED,HOWARD HUGHES MED INST,DEPT MICROBIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FAY PJ, 1981, J BIOL CHEM, V257, P76; FLOWER AM, 1986, NUCLEIC ACIDS RES, V14, P8091, DOI 10.1093/nar/14.20.8091; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P713; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; KORNBERG A, 1982, 1982 SUPPLEMENT DNA, P5122; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; LUND RI, 1987, GEL FILTRATION THEOR, P27; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1983, P NATL ACAD SCI-BIOL, V80, P7137, DOI 10.1073/pnas.80.23.7137; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6547; MAKI S, 1988, J BIOL CHEM, V263, P6561; MCHENRY C, 1981, ENZYMES, V14, P39; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; RAY DS, 1969, J MOL BIOL, V43, P631, DOI 10.1016/0022-2836(69)90364-7; RICE RH, 1971, J BIOL CHEM, V246, P831; ROWEN L, 1978, J BIOL CHEM, V253, P758; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SMITH MH, 1970, HDB BIOCHEMISTRY, pC1; STUDWELL PS, 1990, UCLA SYM BI, V127, P153; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TOMASIEWICZ HG, 1987, J BACTERIOL, V169, P5735, DOI 10.1128/jb.169.12.5735-5744.1987; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511	44	106	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19833	19841						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918087				2022-12-25	WOS:A1991GK66700101
J	WISE, CA; MARTIN, NC				WISE, CA; MARTIN, NC			DRAMATIC SIZE VARIATION OF YEAST MITOCHONDRIAL RNAS SUGGESTS THAT RNASE P-RNAS CAN BE QUITE SMALL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RIBONUCLEASE-P; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; RIBOSOMAL-RNA; GENE; DNA; COMPONENT; SUBUNIT; ENZYME	The gene coding for the AU-rich RNA required for mitochondrial RNase P activity in Saccharomyces cerevisiae codes for a 490-base RNA while that in Candida glabrata codes for a 227-base RNA. We have detected a 140-nucleotide RNA coded by the mitochondrial DNA from Saccharomycopsis fibuligera by hybridization with an oligonucleotide complementary to a conserved sequence found in mitochondrial and prokaryotic RNase P RNAs. DNA sequence analysis of the mitochondrial DNA from the region coding for this RNA revealed a second conserved sequence block characteristic of RNase P RNA genes and the presence of a downstream tRNA(Pro) gene. Like previously characterized mitochondrial RNase P RNAs, this small RNA is extremely AU-rich. The discovery of this 140-base RNA suggests that naturally occurring RNase P RNAs may be quite small.	UNIV LOUISVILLE,SCH MED,DEPT BIOCHEM,LOUISVILLE,KY 40292; UNIV TEXAS,SW GRAD SCH,DEPT BIOCHEM,DALLAS,TX 75235	University of Louisville; University of Texas System; University of Texas Dallas				Wise, Carol/0000-0002-6790-2194	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027597] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27597] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABOSHI E, 1980, BIOCHEM BIOPH RES CO, V96, P831, DOI 10.1016/0006-291X(80)91430-8; ALTMAN S, 1990, J BIOL CHEM, V265, P20053; BAER M, 1985, SCIENCE, V228, P999, DOI 10.1126/science.2408335; BARTKIEWICZ M, 1989, GENE DEV, V3, P488, DOI 10.1101/gad.3.4.488; CLARKWALKER GD, 1985, EMBO J, V4, P465, DOI 10.1002/j.1460-2075.1985.tb03652.x; DUJON B, 1980, CELL, V20, P185, DOI 10.1016/0092-8674(80)90246-9; FORSTER AC, 1990, CELL, V62, P402; GARDINER K, 1980, J BIOL CHEM, V255, P7507; GARRIGA G, 1986, CELL, V56, P323; GRAY MW, 1990, RIBOSOME, P589; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAAS ES, 1991, IN PRESS SCIENCE; HOLLINGSWORTH MJ, 1986, MOL CELL BIOL, V6, P1058, DOI 10.1128/MCB.6.4.1058; HUDSPETH MES, 1982, CELL, V30, P617, DOI 10.1016/0092-8674(82)90258-6; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KRUPP G, 1986, EMBO J, V5, P1697, DOI 10.1002/j.1460-2075.1986.tb04413.x; LEE JY, 1989, MOL CELL BIOL, V9, P2536, DOI 10.1128/MCB.9.6.2536; MARTIN NC, 1985, ACHIEVEMENTS PERSPEC, V2, P193; MILLER DL, 1983, CELL, V34, P911, DOI 10.1016/0092-8674(83)90548-2; MILLER DL, 1985, NUCLEIC ACIDS RES, V13, P859, DOI 10.1093/nar/13.3.859; MORALES MJ, 1989, NUCLEIC ACIDS RES, V17, P6865, DOI 10.1093/nar/17.17.6865; MUELLER DM, 1986, J BIOL CHEM, V261, P1756; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; RAGNINI A, 1991, CURR GENET, V19, P169, DOI 10.1007/BF00336483; REED RE, 1982, CELL, V30, P627, DOI 10.1016/0092-8674(82)90259-8; ROIHA H, 1989, GENE, V82, P137, DOI 10.1016/0378-1119(89)90038-3; SHU HH, 1991, MOL CELL BIOL, V11, P1662, DOI 10.1128/MCB.11.3.1662; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; SOR F, 1982, NUCLEIC ACIDS RES, V10, P1625, DOI 10.1093/nar/10.5.1625; STARK BC, 1978, P NATL ACAD SCI USA, V75, P3717, DOI 10.1073/pnas.75.8.3717; UNDERBRINKLYON K, 1983, MOL GEN GENET, V191, P512, DOI 10.1007/BF00425771; VINCENT RD, 1980, CURR GENET, V2, P27, DOI 10.1007/BF00445691; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; WILSON C, 1989, NUCLEIC ACIDS RES, V17, P4485, DOI 10.1093/nar/17.12.4485; WISE CA, 1991, THESIS U TEXAS SW ME	35	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19154	19157						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918032				2022-12-25	WOS:A1991GK66700008
J	GOLDSMITH, JO; LEE, SJ; ZAMBIDIS, I; KUO, LC				GOLDSMITH, JO; LEE, SJ; ZAMBIDIS, I; KUO, LC			CONTROL OF L-ORNITHINE SPECIFICITY IN ESCHERICHIA-COLI ORNITHINE TRANSCARBAMOYLASE - SITE-DIRECTED MUTAGENIC AND PH STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; SUBSTRATE-SPECIFICITY; PROTONATION STATE; ZN-2+ REGULATION; BINDING; CARBAMOYLTRANSFERASE; SEQUENCE; TRANSCARBAMYLASES	Escherichia coli ornithine transcarbamoylase displays a strict specificity toward its second substrate L-ornithine. After forming a binary complex with carbamoyl phosphate and undergoing an induced-fit isomerization (Miller, A. W., and Kuo, L. C. (1990) J. Biol. Chem. 265, 15023-15027), the enzyme selects only the minor, zwitterionic ornithine with an uncharged delta-amino group for transcarbamoylation. Formation of the productive ternary complex is linked to two enzymic ionizations (pK(a) 6.2 approximately 6.3 and 9.1 approximately 9.3) and two ornithine ionizations (pK(a) 8.5 and 10.6) (Kuo, L. C., Herzberg, W., and Lipscomb, W. N. (1985) Biochemistry 24, 4754-4761). To elucidate the mechanism through which substrate specificity is achieved, the binding of L-ornithine to two site-specific point mutants (Arg-57 --> Gly and Cys-273 --> Ala) of the enzyme has been examined. For the Gly-57 mutant enzyme, which does not undergo the induced-fit isomerization, affinity for ornithine drops by a factor of 500. The pH profile of the apparent equilibrium constant governing the association of L-ornithine to the binary complex of this mutant reveals that only two enzymic ionizations affect ornithine binding. The ionizations linked to L-ornithine are not detected. Hence, the preisomerized binary complex binds not only poorly but also indiscriminately all ionic species of L-ornithine. For the Ala-273 mutant enzyme, which exhibits the induced-fit isomerization, affinity of the amino acid is decreased by an order of magnitude. Ionizations of L-ornithine to yield a zwitterion for binding are detected in pH analyses for this mutant, but the pK(a) of 6.2 associated with the enzymic deprotonation in the wild type is absent. Therefore, Cys-273 is a binding site of L-ornithine. The D-isomer of ornithine is a very weak, deadend ligand to all three forms of the enzyme with affinities in the millimolar range. Employing the estimated affinities of D- and L-ornithine, the binding stereospecificity of the wild-type and mutant binary complexes toward the amino acid substrate may be evaluated. L-Ornithine binds preferentially over D-ornithine by two and four orders of magnitude in the absence and presence of protein isomerization, respectively. The combined results suggest that: 1) the same enzymic ionizations are associated with L-ornithine binding both in the preisomerized and postisomerized binary complexes; 2) the interaction between ornithine and the thiol of Cys-273 assists in anchoring the amino acid in the ternary complex, but Cys-273 is not the sole anionic ligand to L-ornithine; and 3) the conformational changes of ornithine transcarbamoylase, elicited by carbamoyl phosphate, provides the predominant influence to sequester one ionic form of L-ornithine for reaction.	BOSTON UNIV,METCALF CTR SCI & ENGN,DEPT CHEM,BOSTON,MA 02215	Boston University					NIDDK NIH HHS [DK38089, DK01721] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK001721, R01DK038089] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Batchelder AC, 1940, J PHYS CHEM-US, V44, P893, DOI 10.1021/j150403a008; BENCINI DA, 1983, NUCLEIC ACIDS RES, V11, P8509, DOI 10.1093/nar/11.23.8509; CLELAND WW, 1982, METHOD ENZYMOL, V87, P390; DIXON M, 1953, BIOCHEM J, V55, P161, DOI 10.1042/bj0550161; Edsall J.T., 1943, PROTEINS AMINO ACIDS, P75; EISENSTEIN E, 1986, J BIOL CHEM, V261, P6192; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; ITOH Y, 1988, J BACTERIOL, V170, P2725, DOI 10.1128/jb.170.6.2725-2734.1988; KUO LC, 1989, BIOCHEMISTRY-US, V28, P4522, DOI 10.1021/bi00436a060; KUO LC, 1985, BIOCHEMISTRY-US, V24, P4754, DOI 10.1021/bi00339a007; KUO LC, 1989, J BIOL CHEM, V264, P16246; KUO LC, 1982, P NATL ACAD SCI-BIOL, V79, P2250, DOI 10.1073/pnas.79.7.2250; KUO LC, 1990, J MOL BIOL, V211, P271, DOI 10.1016/0022-2836(90)90026-I; KUO LC, 1988, BIOCHEMISTRY-US, V27, P8823, DOI 10.1021/bi00424a021; LEE SJ, 1990, J MOL BIOL, V211, P255, DOI 10.1016/0022-2836(90)90025-H; LEGRAIN C, 1976, EUR J BIOCHEM, V63, P289, DOI 10.1111/j.1432-1033.1976.tb10230.x; MARSHALL M, 1972, J BIOL CHEM, V247, P1654; MARSHALL M, 1980, J BIOL CHEM, V255, P7287; MARSHALL M, 1972, J BIOL CHEM, V255, P7291; MARSHALL M, 1972, J BIOL CHEM, V255, P7296; MILLER AW, 1990, J BIOL CHEM, V265, P15023; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; SCHLEIF RF, 1984, PRACTICAL METHODS MO, P196; Segel I., 1975, ENZYME KINETICS, P170; WARGNIES B, 1978, EUR J BIOCHEM, V89, P203, DOI 10.1111/j.1432-1033.1978.tb20914.x; ZAMBIDIS I, 1990, J BIOL CHEM, V265, P2620	26	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18626	18634						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917985				2022-12-25	WOS:A1991GJ47200037
J	SACEDA, M; KNABBE, C; DICKSON, RB; LIPPMAN, ME; BRONZERT, D; LINDSEY, RK; GOTTARDIS, MM; MARTIN, MB				SACEDA, M; KNABBE, C; DICKSON, RB; LIPPMAN, ME; BRONZERT, D; LINDSEY, RK; GOTTARDIS, MM; MARTIN, MB			POSTTRANSCRIPTIONAL DESTABILIZATION OF ESTROGEN-RECEPTOR MESSENGER-RNA IN MCF-7 CELLS BY 12-O-TETRADECANOYLPHORBOL-13-ACETATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MAMMARY-CARCINOMA CELLS; GROWTH-FACTOR RECEPTOR; BREAST-CANCER-CELLS; GENE-TRANSCRIPTION; TUMOR PROMOTERS; PHORBOL ESTERS; SIGNAL-TRANSDUCTION; SEQUENCE; LINE	The effect of 12-O-tetradecanoylphorbol-13-acetate (TPA) on the regulation of the estrogen receptor (ER) was investigated in this study. After treatment with 100 nM TPA the concentration of receptor protein was measured using an enzyme immunoassay. By 24 h the receptor protein declined by about 80% from a level of approximately 236 fmol of ER/mg of protein in control cells to 50 fmol of ER/mg of protein in cells treated with TPA. Similar results were obtained with an estrogen receptor ligand binding assay. After removal of TPA, the level of ER returned to control values. 4-alpha-Phorbol, a compound related to TPA, had no effect on ER. The effects of TPA on ER expression appear to be mediated by activation of protein kinase C as H-7, an inhibitor of protein kinase C, blocks these effects. In addition to the effect on ER protein, TPA treatment also resulted in a decrease in the steady-state level of ER mRNA as determined by a RNase protection assay. The metabolic inhibitor cycloheximide was unable to prevent the TPA-induced decrease in ER mRNA. Transcription run-off experiments demonstrated that TPA had no effect on ER gene transcription. A half-life study demonstrated that TPA decreased ER mRNA half-life by a factor of 6 from approximately 4 h in control cells to 40 min in TPA-treated cells. These data suggest that the decline in ER expression is mediated by post-transcriptional destabilization of ER mRNA.	GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,S-LEVEL,3800 RESERVOIR RD NW,WASHINGTON,DC 20007; UNIV HAMBURG,CLIN EPPENDORF,W-2000 HAMBURG 13,GERMANY; NCI,CLIN TRIALS EVALUAT PROGRAM,BETHESDA,MD 20892	Georgetown University; University of Hamburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Saceda, Miguel/A-1581-2008	Saceda, Miguel/0000-0002-1564-3602	NATIONAL CANCER INSTITUTE [R01CA050445, U01CA051908] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA51908-01, R01 CA50445-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BLUMBERG PM, 1980, CRC CR REV TOXICOL, V8, P153, DOI 10.3109/10408448009037493; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; COLBURN NH, 1987, MECHANISMS ENV CARCI, P81; DARBON JM, 1986, BIOCHEM PHARMACOL, V35, P2683, DOI 10.1016/0006-2952(86)90175-9; DESOMBRE ER, 1980, CANCER, V46, P2783, DOI 10.1002/1097-0142(19801215)46:12+<2783::AID-CNCR2820461408>3.0.CO;2-4; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUILBAUD N, 1988, MOL CELL ENDOCRINOL, V56, P157, DOI 10.1016/0303-7207(88)90020-2; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LEE CSL, 1989, BIOCHEM BIOPH RES CO, V162, P415, DOI 10.1016/0006-291X(89)92013-5; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; MARTIN MB, 1986, J BIOL CHEM, V261, P2355; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ROOS W, 1986, P NATL ACAD SCI USA, V83, P991, DOI 10.1073/pnas.83.4.991; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; SACEDA M, 1989, MOL ENDOCRINOL, V3, P1782, DOI 10.1210/mend-3-11-1782; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH KB, 1983, J CELL PHYSIOL, V117, P91, DOI 10.1002/jcp.1041170113; STROBL JS, 1984, ENDOCRINOLOGY, V115, P1116, DOI 10.1210/endo-115-3-1116; VALETTE A, 1987, CANCER RES, V47, P1615; WANG JL, 1975, P NATL ACAD SCI USA, V72, P1917, DOI 10.1073/pnas.72.5.1917; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YUSPA SH, 1978, CANCER RES, V36, P4062; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	38	95	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17809	17814						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917923				2022-12-25	WOS:A1991GG55300018
J	HUDSON, LG; ERTL, AP; GILL, GN				HUDSON, LG; ERTL, AP; GILL, GN			STRUCTURE AND INDUCIBLE REGULATION OF THE HUMAN C-ERB B2/NEU PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	HUDSON, LG (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093, USA.				NATIONAL CANCER INSTITUTE [F32CA008629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER; NCI NIH HHS [CA08629] Funding Source: Medline; NIDDK NIH HHS [NIDDK13149] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	36	57	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1990	265	8					4389	4393						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CT101	1968458				2022-12-25	WOS:A1990CT10100039
J	JENNINGS, I; COTTON, R				JENNINGS, I; COTTON, R			STRUCTURAL SIMILARITIES AMONG ENZYME PTERIN BINDING-SITES AS DEMONSTRATED BY A MONOCLONAL ANTI-IDIOTYPIC ANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									ROYAL CHILDRENS HOSP,MURDOCH INST,OLIVE MILLER PROT LAB,PARKVILLE,VIC 3052,AUSTRALIA	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne				Jennings, Ian/0000-0002-4781-9465				BJERCKE RJ, 1987, BIOCHEM BIOPH RES CO, V145, P847, DOI 10.1016/0006-291X(87)91042-4; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; CAYANIS E, 1986, J BIOL CHEM, V261, P5094; CHOO KH, 1981, BIOCHEM J, V199, P527, DOI 10.1042/bj1990527; CHUNG HK, 1984, J BIOL CHEM, V259, P1756; CLEVELAND WL, 1983, NATURE, V305, P56, DOI 10.1038/305056a0; COTTON RGH, 1978, EUR J BIOCHEM, V85, P357, DOI 10.1111/j.1432-1033.1978.tb12247.x; DAHL HHM, 1987, NUCLEIC ACIDS RES, V15, P1921, DOI 10.1093/nar/15.5.1921; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; DAVIES DR, 1983, ANNU REV IMMUNOL, V1, P87, DOI 10.1146/annurev.iy.01.040183.000511; FIRGAIRA FA, 1981, BIOCHEM J, V197, P31, DOI 10.1042/bj1970031; FISHER DB, 1973, J BIOL CHEM, V248, P4345; GRENETT HE, 1987, P NATL ACAD SCI USA, V84, P5530, DOI 10.1073/pnas.84.16.5530; HAAN EA, 1987, BRAIN RES, V426, P19, DOI 10.1016/0006-8993(87)90420-3; HSINGHSU K, 1987, J IMMUNOL, V139, P2376; JENNINGS IG, 1986, BIOCHEM J, V235, P133, DOI 10.1042/bj2350133; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KAUFMAN S, 1964, J BIOL CHEM, V239, P332; LOVENBERG W, 1967, SCIENCE, V155, P217, DOI 10.1126/science.155.3759.217; MATTHEWS DA, 1986, BIOCHEMISTRY-US, V25, P4194, DOI 10.1021/bi00363a005; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NAGATSU T, 1972, BIOCHEM PHARMACOL, V21, P1945; PARHAM P, 1982, J IMMUNOL METHODS, V53, P133, DOI 10.1016/0022-1759(82)90137-5; RATNAM S, 1989, IN PRESS ARCH BIOCH; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SMITH SC, 1984, J BIOL CHEM, V259, P1284; SPRANG S, 1982, BIOCHEMISTRY-US, V21, P2036, DOI 10.1021/bi00538a010; STONE D, 1979, J BIOL CHEM, V254, P857; SUEOKA T, 1982, BIOCHIM BIOPHYS ACTA, V717, P265, DOI 10.1016/0304-4165(82)90178-7; VISCONTINI M, 1958, HELV CHIM ACTA, V41, P2170, DOI 10.1002/hlca.19580410725; WALLICK DE, 1984, BIOCHEMISTRY-US, V23, P1295, DOI 10.1021/bi00301a043; YENDELL JW, 1983, J VIROL, V48, P239	33	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1990	265	4					1885	1889						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CL028	1967605				2022-12-25	WOS:A1990CL02800014
J	BLUM, JS; FIANI, ML; STAHL, PD				BLUM, JS; FIANI, ML; STAHL, PD			PROTEOLYTIC CLEAVAGE OF RICIN A CHAIN IN ENDOSOMAL VESICLES - EVIDENCE FOR THE ACTION OF ENDOSOMAL PROTEASES AT BOTH NEUTRAL AND ACIDIC PH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE ENDOSOMES; CATHEPSIN-B; A-CHAIN; CELLS; RECEPTOR; ENDOCYTOSIS; MEMBRANE; PROTEINS; ENTRY; IDENTIFICATION	Macrophages actively internalize macromolecules into endosomal vesicles containing proteases. The plant toxin, ricin A chain delivered into this pathway by receptor-mediated endocytosis, was found to be exquisitely sensitive to cleavage by these proteases. Proteolytic fragments of ricin A chain were generated within cells as early as 2-3 min after internalization. Toxin proteolysis was initiated in early endosomal vesicles, and transport to lysosomes was not required. As endosomes transit the cell, their lumenal pH drops from neutral to acidic. Previous studies in macrophages had suggested that endosomal proteolysis is dependent on vesicle acidification. Isolated endosomal vesicles containing ricin A chain catalyzed the cleavage of this protein in vitro; however, proteolysis was observed at both neutral and acidic pH. Experiments using isolated endosomes demonstrated that both cysteine and aspartyl proteases were responsible for the cleavage of ricin A chain. The cysteine protease, cathepsin B, catalyzed toxin proteolysis in endosomes between pH 4.5 and 7.0 while aspartyl protease activity was maximal below pH 5.5. Radiolabeling the lumenal contents of macrophage endosomes confirmed that both the cysteine protease, cathepsin B, and the aspartyl protease, cathepsin D, were present in these vesicles. These proteases were not present on the plasma membrane but were found in early endosomes indicating they are derived from an intracellular source. The presence of proteases with different pH optima in early endosomes suggests that processing in these vesicles may be regulated by changes in endosomal pH. This result represents an important difference in protein processing in endosomes versus lysosomes and provides new insights into the function of endosomal proteases.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, 660 S EUCLID, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Stahl, Philip/D-6315-2012; Fiani, Maria Luisa/G-9369-2016	Fiani, Maria Luisa/0000-0003-2997-0767	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020015, R01AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20015] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONSON NN, 1978, BIOCHEM J, V171, P759, DOI 10.1042/bj1710759; BARRETT AJ, 1977, RES MONOGRAPHS CELL, V2, P209; BLUM JS, 1989, COLD SH Q B, V54, P287; DAVIDSON HW, 1990, J IMMUNOL, V144, P4101; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, METHOD CELL BIOL, V31, P25; DIMENT S, 1989, J BIOL CHEM, V264, P13403; DIMENT S, 1990, J IMMUNOL, V145, P417; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DIMENT S, 1987, J LEUKOCYTE BIOL, V42, P485, DOI 10.1002/jlb.42.5.485; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; Kassell B., 1970, METHODS ENZYMOLOGY, VVolume 19, P844, DOI [10.1016/0076-6879(70)19074-4, DOI 10.1016/0076-6879(70)19074-4]; KIRSCHKE H, 1988, FEBS LETT, V228, P128, DOI 10.1016/0014-5793(88)80600-8; LEE YC, 1976, BIOCHEMISTRY-US, V15, P3956, DOI 10.1021/bi00663a008; MARSH M, 1984, BIOCHEM J, V218, P1; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; MCKAY TJ, 1978, BIOCHEMISTRY-US, V17, P401, DOI 10.1021/bi00596a003; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MUNDY DI, 1985, CELL, V40, P645, DOI 10.1016/0092-8674(85)90213-2; OLSNES S, 1989, IMMUNOL TODAY, V10, P291; POLGAR L, 1987, J BIOL CHEM, V262, P14448; PRESS OW, 1988, J IMMUNOL, V141, P4410; RICH DH, 1986, BIOCHEM J, V235, P731, DOI 10.1042/bj2350731; RODMAN JS, 1990, J LEUKOCYTE BIOL, V48, P116, DOI 10.1002/jlb.48.2.116; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAUDIES RP, 1987, BIOCHEM BIOPH RES CO, V143, P710, DOI 10.1016/0006-291X(87)91412-4; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SIMMONS BM, 1986, J BIOL CHEM, V261, P7912; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; TAKAHASHI H, 1989, J IMMUNOL, V142, P2221; THOMAS DJ, 1989, FEBS LETT, V243, P145, DOI 10.1016/0014-5793(89)80117-6; TYCKO B, 1982, CELL, V28, P643, DOI 10.1016/0092-8674(82)90219-7; UMEZAWA H, 1977, PROTEINASES MAMMALIA, V2, P637	42	88	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22091	22095						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939230				2022-12-25	WOS:A1991GR56400007
J	FERRARI, S; BANDI, HR; HOFSTEENGE, J; BUSSIAN, BM; THOMAS, G				FERRARI, S; BANDI, HR; HOFSTEENGE, J; BUSSIAN, BM; THOMAS, G			MITOGEN-ACTIVATED 70K S6 KINASE - IDENTIFICATION OF INVITRO 40-S RIBOSOMAL S6 PHOSPHORYLATION SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; DEPENDENT PROTEIN-KINASE; POLYACRYLAMIDE-GEL ELECTROPHORESIS; CHICKEN-EMBRYO FIBROBLASTS; ACTIN GENE-TRANSCRIPTION; SWISS MOUSE 3T3-CELLS; 3T3 CELLS; RAT-LIVER; LATE PHASE; C-MYC	Recently we purified and cloned the mitogen/oncogene-activated M(r) 70,000 (70K) S6 kinase from the livers of rats treated with cycloheximide (Kozma, S. C., Lane, H. A., Ferrari, S., Luther, H., Siegmann, M., and Thomas, G. (1989) EMBO J. 8, 4125-4132; Kozma, S. C., Ferrari, S., Bassand, P., Siegmann, M., Totty, N., and Thomas, G. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7365-7369). Prior to determining the ability of this kinase to phosphorylate the same sites observed in S6 in vivo, we established the effects of different cations and autophosphorylation on kinase activity. The results show that the 70K S6 kinase is dependent on Mg2+ for activity and that this requirement cannot be substituted for by Mn2+. Furthermore, 50-fold lower concentrations of Mn2+ block the effect of Mg2+ on the kinase. This effect is not limited to Mn2+ but can be substituted for by a number of cations. with Zn2+ being the most potent inhibitor, IC50 almost-equal-to 2-mu-M. In the presence of optimum Mg2+ concentrations the enzyme incorporates an average of 1.2 mol of phosphate/mol of kinase and an average of 3.7 mol of phosphate/mol mol of S6. The autophosphorylation reaction appears to be intramolecular and leads to a 25% reduction in kinase activity toward S6. In the case of S6 all of the sites of phosphorylation are found to reside in a 19-amino acid peptide at the carboxyl end of the protein. Four of these sites have been identified as Ser Ser236, Ser240, and Ser244, equivalent to four of the five sites previously observed in vivo (Krieg, J., Hofsteenge, J., and Thomas, G. (1988) J. Biol. Chem. 263, 11473-11477). A fifth mole of phosphate is incorporated at low stoichiometry into the peptide, but the amino acid which is phosphorylated cannot be unequivocally assigned. The low level of phosphorylation of the fifth site in vitro is discussed with regard to known results ind to a potential three-dimensional model for the carboxyl terminus of S6.	FRIEDRICH MIESCHER INST,POSTFACH 2543,CH-4002 BASEL,SWITZERLAND; CIBA GEIGY AG,ZENTRUM FACHINFORMAT,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; Novartis			Ferrari, Stefano/I-7357-2016	Ferrari, Stefano/0000-0002-6607-215X				AHN NG, 1990, J BIOL CHEM, V265, P11487; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANDI HR, 1991, NATO ASI SERIES H, V56, P245; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BRANDON SD, 1991, J BIOL CHEM, V266, P380; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; DUNCAN R, 1982, EUR J BIOCHEM, V123, P535; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ERIKSON E, 1986, J BIOL CHEM, V261, P350; FALVEY AK, 1970, J MOL BIOL, V53, P1, DOI 10.1016/0022-2836(70)90042-2; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUANG KP, 1986, J BIOL CHEM, V261, P2134; JENO P, 1989, J BIOL CHEM, V264, P1293; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KOZMA SC, 1989, EMBO J, V8, P4125, DOI 10.1002/j.1460-2075.1989.tb08597.x; KOZMA SC, 1989, CELL SIGNAL, V1, P219, DOI 10.1016/0898-6568(89)90039-9; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KWIATKOWSKI AP, 1988, J BIOL CHEM, V263, P6484; LANE HA, 1990, METHOD ENZYMOL, V200, P268; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MARTINPEREZ J, 1984, CELL, V36, P287, DOI 10.1016/0092-8674(84)90222-8; MARTINPEREZ J, 1983, P NATL ACAD SCI-BIOL, V80, P926, DOI 10.1073/pnas.80.4.926; MEYER HE, 1987, J CHROMATOGR, V397, P113, DOI 10.1016/S0021-9673(01)84994-3; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; NILSSON L, 1990, EUR J BIOCHEM, V191, P1; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; PALEN E, 1987, J BIOL CHEM, V262, P3518; PETSKO GA, 1976, J MOL BIOL, V106, P453, DOI 10.1016/0022-2836(76)90096-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; SWEET LJ, 1990, MOL CELL BIOL, V10, P2787, DOI 10.1128/MCB.10.6.2787; SWEET LJ, 1990, MOL CELL BIOL, V10, P2413, DOI 10.1128/MCB.10.5.2413; THOMAS G, 1982, CELL, V30, P235, DOI 10.1016/0092-8674(82)90029-0; TODHUNTER JA, 1977, BIOCHIM BIOPHYS ACTA, V485, P87, DOI 10.1016/0005-2744(77)90195-4; VANTHOFF JH, 1884, ETUDES DYNAMIQUE CHI, P87; WETTENHALL REH, 1983, FEBS LETT, V162, P171, DOI 10.1016/0014-5793(83)81072-2; WETTENHALL REH, 1984, J BIOL CHEM, V259, P2084; WETTENHALL REH, 1970, METHOD ENZYMOL, V60, P186	49	121	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22770	22775						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939282				2022-12-25	WOS:A1991GR56400104
J	JHUN, BH; HAH, JS; JUNG, CY				JHUN, BH; HAH, JS; JUNG, CY			PHENYLARSINE OXIDE CAUSES AN INSULIN-DEPENDENT, GLUT4-SPECIFIC DEGRADATION IN RAT ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; 3T3-L1 ADIPOCYTES; TYROSINE PHOSPHORYLATION; ADIPOSE-CELLS; DIABETES-MELLITUS; HEXOSE-TRANSPORT; PLASMA-MEMBRANE; SKELETAL-MUSCLE; RESISTANCE; MECHANISM	An incubation of rat adipocytes with phenylarsine oxide (PAO) and then with insulin caused an inhibition of 3-O-methylglucose equilibrium exchange flux and a parallel reduction in cellular GLUT4 content detected by Western blots. Both the transport inhibition and the GLUT4 reduction were saturable with an increasing concentration of PAO showing essentially an identical K(i) value of 35-mu-M. Both effects were not observed in the absence of insulin or if cells were incubated with insulin first. The reduction was specific to GLUT4; the immunoreactivities of GLUT1, insulin receptor, and clathrin were not affected in these experiments. The GLUT4 reduction occurred only in intact cells and was not observed in homogenized cells or fractionated membranes. GLUT4 in both the microsomal storage pool and the plasma membrane pool were affected with no indication of insulin-induced recruitment impairment. GLUT4 reduction was not observed in the presence of chloroquine or at 18-degrees-C suggesting involvement of the lysosomal pathway. Based on these results, we propose that there is a PAO-sensitive protein mechanism that controls an insulin-dependent GLUT4 degradation pathway in adipocytes. This protein mechanism and the GLUT4 degradation pathway may play an important role in determining the steady-state GLUT4 level in the insulin-sensitive peripheral tissues in normal and diseased states.	VET ADM MED CTR,BIOPHYS LAB,3495 BAILEY AVE,BUFFALO,NY 14215; SUNY BUFFALO,DEPT BIOPHYS SCI,BUFFALO,NY 14260	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013376] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK13376] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BERNIER M, 1988, J BIOL CHEM, V263, P13626; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x; DOUEN AG, 1988, BIOCHIM BIOPHYS ACTA, V968, P109, DOI 10.1016/0167-4889(88)90050-X; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; DUNN WA, 1980, J BIOL CHEM, V255, P5971; EZAKI O, 1986, J BIOL CHEM, V261, P3295; FROST SC, 1985, J BIOL CHEM, V260, P2646; FROST SC, 1987, J BIOL CHEM, V262, P9872; FUSHIKI T, 1989, AM J PHYSIOL, V256, pE580, DOI 10.1152/ajpendo.1989.256.5.E580; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GIBSON AE, 1989, AM J PHYSIOL, V257, pC182, DOI 10.1152/ajpcell.1989.257.2.C182; GOULD GW, 1989, ARCH BIOCHEM BIOPHYS, V268, P264, DOI 10.1016/0003-9861(89)90588-2; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; JACOBS DB, 1984, J CLIN INVEST, V74, P1679, DOI 10.1172/JCI111584; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JUNG CY, 1971, BIOCHIM BIOPHYS ACTA, V241, P613, DOI 10.1016/0005-2736(71)90059-9; KAHN BB, 1988, J CLIN INVEST, V82, P691, DOI 10.1172/JCI113649; KAHN BB, 1989, J CLIN INVEST, V83, P199, DOI 10.1172/JCI113859; KARNIELI E, 1986, J CLIN INVEST, V78, P1051, DOI 10.1172/JCI112660; KASANICKI MA, 1990, DIABETES CARE, V13, P219, DOI 10.2337/diacare.13.3.219; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; MARTZ A, 1986, J BIOL CHEM, V261, P3606; RAMLAL T, 1989, ENDOCRINOLOGY, V125, P890, DOI 10.1210/endo-125-2-890; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RODBELL M, 1964, J BIOL CHEM, V239, P375; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1095; SINHA MK, 1991, DIABETES, V40, P472, DOI 10.2337/diabetes.40.4.472; STANLEY PE, 1986, METHOD ENZYMOL, V133, P14; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; WEBB JL, 1966, ENZYMES METABOL INH, V3, P595; WHEELER TJ, 1989, BIOCHIM BIOPHYS ACTA, V979, P331, DOI 10.1016/0005-2736(89)90253-8; WHITESELL RR, 1985, J BIOL CHEM, V260, P2894; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	42	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22260	22265						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939248				2022-12-25	WOS:A1991GR56400033
J	COLEMAN, DL; KUZAVA, JE				COLEMAN, DL; KUZAVA, JE			GENETIC-REGULATION OF MALIC ENZYME-ACTIVITY IN THE MOUSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A PROTEINS MAP; THYROID-HORMONE; MESSENGER-RNA; CHROMOSOME-7; LIVER; DEHYDROEPIANDROSTERONE; TRIIODOTHYRONINE; PURIFICATION; EXPRESSION; INDUCTION	Cytosolic malic enzyme catalyzes the NADP+-dependent oxidative decarboxylation of malate to pyruvate and CO2. Additionally, this enzyme produces large amounts of reducing equivalents (NADPH) required for de novo fatty acid synthesis and provides a precursor for oxaloacetate replacement in the mitochondria. Malic enzyme is considered a key lipogenic enzyme and changes in enzyme activity parallel changes in the lipogenic rate. As would be expected, the activity of malic enzyme responds to a variety of dietary and hormonal factors acting mainly on the rate of enzyme synthesis. In the mouse, the structural locus for malic enzyme (Mod-1) is located on chromosome 9. Two alleles reflecting differences in electrophoretic mobility have been identified. This report demonstrates that the amount of hepatic malic enzyme activity is strain-dependent and is regulated by a malic enzyme regulator locus (Mod1r) located on the proximal end of chromosome 12. Two alleles have been identified: Mod1r(a), conferring high enzyme activity (C57BL/6J), and Mod1r(b), conferring low enzyme activity (C57BL/KsJ). Biochemical studies have demonstrated differences in the apparent K(m) and V(max) and in specific activity on purification and immunoprecipitation, features that suggest changes in enzyme structure even though no differences were observed by electrophoresis and isoelectric focusing. These combined data suggest that differences in both enzyme quantity and structure may be involved in the genetic regulation of malic enzyme activity in mice.			COLEMAN, DL (corresponding author), JACKSON LAB, BAR HARBOR, ME 04609 USA.			Coleman, David/0000-0003-4803-5387	NIDDK NIH HHS [DK14461] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK014461] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI S, 1987, J BIOL CHEM, V262, P1558; BRILLIANT MH, 1987, J NEUROGENET, V4, P259, DOI 10.3109/01677068709102346; CASAZZA JP, 1986, J NUTR, V116, P304, DOI 10.1093/jn/116.2.304; CHOMCZYNSKI P, 1989, CINNA BIOTECX B, V3; COLEMAN DL, 1984, DIABETES, V33, P26, DOI 10.2337/diabetes.33.1.26; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DEUSTACHIO P, 1984, J EXP MED, V160, P827, DOI 10.1084/jem.160.3.827; DOZIN B, 1985, BIOCHEMISTRY-US, V24, P5581, DOI 10.1021/bi00341a044; DOZIN B, 1986, J BIOL CHEM, V261, P290; Frenkel R, 1975, Curr Top Cell Regul, V9, P157; Gibson D M, 1972, Adv Enzyme Regul, V10, P187, DOI 10.1016/0065-2571(72)90014-3; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; HENDERSON NS, 1966, ARCH BIOCHEM BIOPHYS, V117, P28, DOI 10.1016/0003-9861(66)90121-4; Hsu R.Y., 1969, METHODS ENZYMOL, V13, P230, DOI DOI 10.1016/0076-6879(69)13042-6; HUMMEL KP, 1972, BIOCHEM GENET, V7, P1, DOI 10.1007/BF00487005; JOHNSON FM, 1981, J HERED, V72, P134, DOI 10.1093/oxfordjournals.jhered.a109448; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1980, BIOCHEMISTRY-US, V19, P5098, DOI 10.1021/bi00563a025; LEGRAVEREND C, 1984, GENETICS, V107, P447; LI JJ, 1975, J BIOL CHEM, V250, P141; MANIATIS T., 1982, MOL CLONING LABORATO, P382; RIGHETTI PG, 1983, ISOELECTRIC FOCUSING, P146; SELDEN RF, 1989, CURRENT PROTOCOLS MO, V1; SONG MKH, 1988, J BIOL CHEM, V263, P17970; TAYLOR BA, 1984, MOL GEN GENET, V195, P491, DOI 10.1007/BF00341452; TEPPERMA.HM, 1968, AM J PHYSIOL, V214, P1126, DOI 10.1152/ajplegacy.1968.214.5.1126; TOWLE HC, 1980, BIOCHEMISTRY-US, V19, P579, DOI 10.1021/bi00544a029; USA American Institute of Nutrition, 1977, Journal of Nutrition, V107, P1340; WISE LS, 1984, ANAL BIOCHEM, V140, P256, DOI 10.1016/0003-2697(84)90162-3	29	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21997	22002						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939220				2022-12-25	WOS:A1991GP80400101
J	RUTLEDGE, EA; MIKORYAK, CA; DRAPER, RK				RUTLEDGE, EA; MIKORYAK, CA; DRAPER, RK			TURNOVER OF THE TRANSFERRIN RECEPTOR IS NOT INFLUENCED BY REMOVING MOST OF THE EXTRACELLULAR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; POLYACRYLAMIDE GELS; CYTOPLASMIC DOMAIN; BINDING-PROPERTIES; HEPATOMA-CELLS; K562 CELLS; ENDOCYTOSIS; SEQUENCE; MEMBRANE; ELECTROPHORESIS	We treated intact cells with trypsin to remove most of the external domain of the transferrin receptor and investigated what effect the absence of the external domain had on the turnover of the fragment that remained associated with the cells. To detect the cell-associated tryptic fragment, which contains a small amount of the external domain, the transmembrane domain, and the cytoplasmic domain, we prepared an anti-peptide antibody against a segment of the cytoplasmic domain. This antibody specifically immunoprecipitated the intact transferrin receptor as well as a 21-kDa peptide from trypsin-treated HeLa cells. Several lines of evidence indicated that the 21-kDa peptide was the cell-associated tryptic fragment of the transferrin receptor. The fragment was only present in trypsin-treated cells; the fragment migrated as a dimer in nonreducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis, as it should if it were derived from the transferrin receptor; a goat antibody prepared to the purified human transferrin receptor also precipitated the 21-kDa peptide from trypsinized cells. In addition, treating the tryptic fragment with neuraminidase increased the electrophoretic mobility in sodium dodecyl sulfate-polyacrylamide gels, suggesting the fragment contained O-linked carbohydrate. When cells were trypsinized and then incubated at 37-degrees-C, the half-life of the tryptic fragment (15 +/- 4 h) was not significantly different than the half-life of the intact receptor (19 +/- 6 h). This indicates that removing 95% of the external domain of the transferrin receptor has little effect on processes operating in the turnover of the receptor.	UNIV TEXAS,MOLEC & CELL BIOL PROGRAM,F031,POB 830688,RICHARDSON,TX 75083	University of Texas System; University of Texas Dallas					NIGMS NIH HHS [GM-32042] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032042] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DO SI, 1990, J BIOL CHEM, V265, P114; ENNS CA, 1988, EXP CELL RES, V174, P89, DOI 10.1016/0014-4827(88)90144-9; GIRONES N, 1989, BIOCHEM J, V264, P35, DOI 10.1042/bj2640035; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; HARE JF, 1985, EXP CELL RES, V161, P331, DOI 10.1016/0014-4827(85)90090-4; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KING TP, 1970, J BIOL CHEM, V245, P6134; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LESLEY JF, 1985, MOL CELL BIOL, V5, P1814, DOI 10.1128/MCB.5.8.1814; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MICHAEL NL, 1984, EMBO J, V3, P3165, DOI 10.1002/j.1460-2075.1984.tb02275.x; NEEFJES JJ, 1988, J CELL BIOL, V107, P79, DOI 10.1083/jcb.107.1.79; OMARY MB, 1981, J BIOL CHEM, V256, P2888; OMARY MB, 1980, NATURE, V286, P888, DOI 10.1038/286888a0; PELTZ GA, 1987, ANAL BIOCHEM, V167, P239, DOI 10.1016/0003-2697(87)90159-X; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; TALBOT DN, 1971, ANAL BIOCHEM, V44, P246, DOI 10.1016/0003-2697(71)90367-8; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; WARD JH, 1982, J BIOL CHEM, V257, P317; WEISSMAN AM, 1986, J CELL BIOL, V102, P951, DOI 10.1083/jcb.102.3.951; YOSHIMORI T, 1988, CELL STRUCT FUNCT, V13, P311, DOI 10.1247/csf1975.13.311; YOSHITAKE S, 1982, J BIOCHEM-TOKYO, V92, P1413, DOI 10.1093/oxfordjournals.jbchem.a134065	34	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21125	21130						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939155				2022-12-25	WOS:A1991GN00100084
J	SCHEIBE, RJ; MOELLERRUNGE, I; MUELLER, WH				SCHEIBE, RJ; MOELLERRUNGE, I; MUELLER, WH			RETINOIC ACID INDUCES THE EXPRESSION OF ALKALINE-PHOSPHATASE IN P19 TERATOCARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; DEPENDENT PROTEIN-KINASE; CHICK LIMB BUD; MOLECULAR-CLONING; BINDING-PROTEIN; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SPATIAL-DISTRIBUTION; CELLULAR-REGULATION; STEROID-HORMONES	Retinoic acid (RA), the natural acid derivative of vitamin A, can induce the differentiation of some cell lines, such as the murine P19 teratocarcinoma cell line. RA can alter the expression of specific genes and the level of the corresponding protein. This report describes the effect of RA on the level of the alkaline phosphatase (ALP) mRNA and protein in P19 teratocarcinoma cells. RA caused a rapid, dose-dependent, and protein synthesis-dependent induction of ALP activity. The increased enzyme activity was detected 4 h after initiation of treatment and maximum induction of ALP activity required 48 h of RA exposure. Increased enzymatic activity was coincidental with increased levels of both a 67-kDa ALP protein and ALP mRNA. By Northern (RNA) blot analysis the increase of a 2.7-kilobase ALP mRNA was observed within 3 h of RA treatment. The RA-induced enhanced ALP mRNA level did not appear to be mainly due to the stabilization of preexisting mRNA, but rather to an increase in transcription of the ALP gene.	MED HSCH HANNOVER,ZENTRUM BIOCHEM,W-3000 HANNOVER 61,GERMANY	Hannover Medical School								BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGER J, 1987, P NATL ACAD SCI USA, V84, P695, DOI 10.1073/pnas.84.3.695; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BROWN NA, 1990, J BIOL CHEM, V265, P13181; BURCH WM, 1985, METABOLISM, V34, P169, DOI 10.1016/0026-0495(85)90128-3; BURSTONE MS, 1961, J HISTOCHEM CYTOCHEM, V9, P146, DOI 10.1177/9.2.146; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN JRA, 1986, J BIOL CHEM, V261, P7635; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHYTIL F, 1984, PHARMACOL REV, V36, P93; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; EK B, 1982, NATURE, V295, P419, DOI 10.1038/295419a0; EMMELOT P, 1964, BIOCHIM BIOPHYS ACTA, V90, P126, DOI 10.1016/0304-4165(64)90125-4; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fernley H.N., 1971, ENZYMES, V4, P417; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1989, NATURE, V337, P566, DOI 10.1038/337566a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HARRIS H, 1981, HARVEY LECT, V76, P95; HENTHORN PS, 1987, P NATL ACAD SCI USA, V84, P1234, DOI 10.1073/pnas.84.5.1234; HOSEY MM, 1982, BIOCHIM BIOPHYS ACTA, V690, P106; HSU HHT, 1985, J BIOL CHEM, V260, P1826; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; IIZUMI Y, 1983, CHEM PHARM BULL, V31, P772; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; IWASA Y, 1984, J BIOL CHEM, V259, P534; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KAM W, 1985, P NATL ACAD SCI USA, V82, P8715, DOI 10.1073/pnas.82.24.8715; KURKINEN M, 1983, NUCLEIC ACIDS RES, V11, P6199, DOI 10.1093/nar/11.18.6199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LOW MG, 1986, TRENDS BIOCHEM SCI, V11, P212, DOI 10.1016/0968-0004(86)90009-5; MADEN M, 1988, NATURE, V335, P733, DOI 10.1038/335733a0; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; McComb Jr RB, 1979, ALKALINE PHOSPHATASE, DOI 10.1007/978-1-4613-2970-1_4; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MOEREMANS M, 1984, J IMMUNOL METHODS, V74, P353, DOI 10.1016/0022-1759(84)90303-X; OMALLEY BW, 1974, SCIENCE, V183, P610, DOI 10.1126/science.183.4125.610; ONG DE, 1975, J BIOL CHEM, V250, P6113; OYAMA VJ, 1978, P SOC EXP BIOL MED, V91, P305; PAULIN D, 1980, J MOL BIOL, V144, P95, DOI 10.1016/0022-2836(80)90216-8; PETKOVICH M, 1987, NATURE, V330, P440; PIZAURO JM, 1987, COMP BIOCHEM PHYS B, V87, P921, DOI 10.1016/0305-0491(87)90413-5; REYNOLDS FH, 1981, NATURE, V292, P259, DOI 10.1038/292259a0; Seargeant L E, 1979, Can J Biochem, V57, P2000; SEHGAL PB, 1976, CELL, V9, P473, DOI 10.1016/0092-8674(76)90092-1; STONER CM, 1989, CANCER RES, V49, P1497; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TERAO M, 1990, BIOCHEM J, V268, P641, DOI 10.1042/bj2680641; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; WALTER K, 1974, METHODEN ENZYMATISCH, V3, P818; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	64	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21300	21305						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939166				2022-12-25	WOS:A1991GN00100110
J	KAWANISHI, T; NIEMINEN, AL; HERMAN, B; LEMASTERS, JJ				KAWANISHI, T; NIEMINEN, AL; HERMAN, B; LEMASTERS, JJ			SUPPRESSION OF CA2+ OSCILLATIONS IN CULTURED RAT HEPATOCYTES BY CHEMICAL HYPOXIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; CYTOSOLIC FREE CA-2+; CELL-DEATH; FURA-2-LOADED HEPATOCYTES; HUMAN-NEUTROPHILS; 2ND MESSENGER; PH; INJURY; FURA-2; LIVER	The model of "chemical hypoxia" with KCN plus iodoacetic acid mimics the ATP depletion and reductive stress of hypoxia. Here, we examined the effects of chemical hypoxia on cytosolic free Na+ and Ca2+ in single cultured rat hepatocytes by multiparameter digitized video microscopy and ratio imaging of sodium-binding furan indicator (SBFI) and Fura-2. Intracellular Na+ increased from about 10 mM to more than 100 mM after 20 min of chemical hypoxia, whereas cytosolic free Ca2+ remained virtually unchanged. In normoxic hepatocytes, phenylephrine (50-mu-M) and Arg-vasopressin (20-40 nm) induced Ca2+ oscillations in 70 and 40% of cells, respectively. These Ca2+ oscillations were suppressed after one spike following the onset of chemical hypoxia. Phenylephrine and vasopressin also increased inositol phosphate formation by 22 and 147%, respectively. This effect was suppressed by KCN plus iodoacetate. Intracellular acidosis is characteristic of chemical hypoxia. Intracellular acidosis induced by 40 mM Na-acetate suppressed Ca2+ oscillations but did not inhibit hormone-induced inositol phosphate formation. Cytosolic alkalinization also suppressed Ca2+ oscillations. However, prevention of intracellular acidosis with monensin (10-mu-M) did not prevent suppression of Ca2+ oscillations during chemical hypoxia. Mitochondrial depolarization with uncoupler did not change free Ca2+ levels during chemical hypoxia, indicating that mitochondria do not regulate free Ca2+ during chemical hypoxia. From these results, we conclude: 1) chemical hypoxia does not block Na+ influx across the plasma membrane; 2) Chemical hypoxia inhibits hormone-stimulated Ca2+ flux pathways across cellular membranes by two different mechanisms: (a) by ATP depletion, which disrupts hormone-myo-inositol 1,4,5-triphosphate coupling, and (b) by intracellular acidosis, which inhibits myo-inositol 1,4,5-triphosphate-stimulated Ca2+ release from intracellular stores; 3) during ATP depletion by chemical hypoxia, mitochondria do not take up Ca2+ to maintain cytosolic free Ca2+ at low concentrations.	UNIV N CAROLINA,SCH MED,DEPT CELL BIOL & ANAT,CELL BIOL LABS,CAMPUS BOX 7090,236 TAYLOR HALL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL INSTITUTE ON AGING [R37AG007218, R01AG007218] Funding Source: NIH RePORTER; NIA NIH HHS [AG-07218] Funding Source: Medline; NIDDK NIH HHS [DK-30874] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON BS, 1987, AM J PHYSIOL, V252, pC349, DOI 10.1152/ajpcell.1987.252.4.C349; AW TY, 1987, AM J PHYSIOL, V252, pC356, DOI 10.1152/ajpcell.1987.252.4.C356; BELLOMO G, 1987, J BIOL CHEM, V262, P1530; BERGER ML, 1989, HEPATOLOGY, V9, P219, DOI 10.1002/hep.1840090210; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BUJA LM, 1988, CELL CALCIUM, V9, P205, DOI 10.1016/0143-4160(88)90002-4; BURGESS G M, 1986, P311; BURGESS GM, 1984, NATURE, V309, P63, DOI 10.1038/309063a0; Campbell A.K, 1983, INTRACELLULAR CALCIU; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHAREST R, 1985, BIOCHEM J, V227, P79, DOI 10.1042/bj2270079; EXTON JH, 1985, AM J PHYSIOL, V248, pE633, DOI 10.1152/ajpendo.1985.248.6.E633; GORES GJ, 1989, J CLIN INVEST, V83, P386, DOI 10.1172/JCI113896; GORES GJ, 1988, AM J PHYSIOL, V255, pC315, DOI 10.1152/ajpcell.1988.255.3.C315; GORES GJ, 1989, AM J PHYSIOL, V257, pG347; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; HARMAN AW, 1990, BIOCHEM BIOPH RES CO, V170, P477, DOI 10.1016/0006-291X(90)92116-H; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; IRVINE RF, 1985, BIOCHEM J, V229, P505, DOI 10.1042/bj2290505; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; KRAUSE KH, 1989, CELL CALCIUM, V10, P351, DOI 10.1016/0143-4160(89)90061-4; LATTANZIO FA, 1990, BIOCHEM BIOPH RES CO, V171, P102, DOI 10.1016/0006-291X(90)91362-V; LEMASTERS JJ, 1987, NATURE, V325, P78, DOI 10.1038/325078a0; LOUD AV, 1968, J CELL BIOL, V37, P27, DOI 10.1083/jcb.37.1.27; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MINTA A, 1989, J BIOL CHEM, V264, P19449; MORENOSANCHEZ R, 1988, BIOCHEM J, V256, P403, DOI 10.1042/bj2560403; NIEMINEN AL, 1988, CELL CALCIUM, V9, P237, DOI 10.1016/0143-4160(88)90004-8; NIEMINEN AL, 1990, J BIOL CHEM, V265, P2399; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; RINK TJ, 1989, TRENDS NEUROSCI, V12, P43, DOI 10.1016/0166-2236(89)90133-1; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SAAREDRAMOLINA A, 1990, BIOCHEM BIOPH RES CO, V167, P148; SHUTTLEWORTH TJ, 1991, J BIOL CHEM, V266, P1410; UHING RJ, 1986, J BIOL CHEM, V261, P2140; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1092; VONTSCHARNER V, 1986, J BIOL CHEM, V261, P163; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	47	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20062	20069						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939069				2022-12-25	WOS:A1991GM03900032
J	PESSINO, A; HEBERT, DN; WOON, CW; HARRISON, SA; CLANCY, BM; BUXTON, JM; CARRUTHERS, A; CZECH, MP				PESSINO, A; HEBERT, DN; WOON, CW; HARRISON, SA; CLANCY, BM; BUXTON, JM; CARRUTHERS, A; CZECH, MP			EVIDENCE THAT FUNCTIONAL ERYTHROCYTE-TYPE GLUCOSE TRANSPORTERS ARE OLIGOMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE LOCALIZATION; 3T3-L1 ADIPOCYTES; LIGAND-BINDING; MESSENGER-RNA; PROTEIN; INSULIN; SEQUENCE; TISSUE; INTESTINE; ISOFORMS	In this study we tested the hypothesis that functional erythrocyte-type glucose transporters (GLUT1) exist as oligomeric complexes by expressing chimeric transporter proteins in Chinese hamster ovary cells harboring endogenous GLUT1 transporters. The chimeric transporters were GLUT1-4c, in which the 29 C-terminal residues of human GLUT1 were replaced by the 30 C-terminal residues of rat skeletal muscle glucose transporter (GLUT4), and GLUT1n-4, containing the N-terminal 199 residues of GLUT1 and the 294 C-terminal residues of GLUT4. Endogenous GLUT1 was quantitatively co-immunoprecipitated by using an anti-GLUT4 C-terminal peptide antibody from detergent extracts of Chinese hamster ovary cells expressing either of the chimeric proteins, as detected by immunoblotting the precipitates with an anti-GLUT1 C-terminal peptide antiserum. No co-immunoprecipitation of native GLUT1 with native GLUT4 from extracts of 3T3-L1 adipocytes, which contain both these transporters, was observed with the same antibody. These data are consistent with the hypothesis that GLUT1 transporters exist as homodimers or higher order oligomers and that a major determinant of oligomerization is located within the first 199 residues of GLUT1.	UNIV MASSACHUSETTS,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	PESSINO, A (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NIDDK NIH HHS [DK 30898, DK 07302, DK 36081] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007302, R56DK036081, R01DK030898, R01DK036081, R37DK030898] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; BIMBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3898, DOI 10.1021/bi00230a014; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3907, DOI 10.1021/bi00230a015; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CUPPOLETTI J, 1980, J BIOL CHEM, V256, P1303; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HELGERSON AL, 1987, J BIOL CHEM, V262, P5464; HINKLE PC, 1979, FUNCTION MOL ASPECTS, P487; IMAI K, 1983, J MOL BIOL, V167, P741, DOI 10.1016/S0022-2836(83)80107-7; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JARVIS SM, 1986, BIOCHIM BIOPHYS ACTA, V855, P312, DOI 10.1016/0005-2736(86)90179-3; JUNG CY, 1980, J BIOL CHEM, V255, P361; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KAYANO T, 1990, J BIOL CHEM, V265, P13276; LACHAAL M, 1990, J BIOL CHEM, V265, P15449; LAHUE RS, 1986, J BIOL CHEM, V261, P3079; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEMAIRE M, 1976, BIOCHEMISTRY-US, V15, P2336, DOI 10.1021/bi00656a014; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NAFTALIN RJ, 1989, BIOCHEM J, V260, P143, DOI 10.1042/bj2600143; SARDET C, 1976, J MOL BIOL, V105, P383, DOI 10.1016/0022-2836(76)90100-5; SCHUBERT D, 1983, FEBS LETT, V163, P81, DOI 10.1016/0014-5793(83)81168-5; TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; WARDZINSKI BE, 1988, BIOCHEM J, V255, P987; WHITE MK, 1989, NATURE, V340, P103, DOI 10.1038/340103b0; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	33	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20213	20217						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939082				2022-12-25	WOS:A1991GM03900052
J	SEGAL, R; BERK, AJ				SEGAL, R; BERK, AJ			PROMOTER ACTIVITY AND DISTANCE CONSTRAINTS OF ONE VERSUS 2 SP1 BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTIONAL CONTROL SIGNALS; DIRECTED MUTAGENESIS; ADENOVIRUS TYPE-5; DNA; ACTIVATION; GENE; PROTEIN; ORGANIZATION; PURIFICATION	In the simple adenovirus 2 early 1B (E1B) promoter, moving the single Sp1 transcription factor binding site (GC box) from its wild-type position eight base pairs (bp) from the TATA box to 30 bp upstream is equivalent to its deletion (Wu, L., and Berk, A. (1988) Genes & Dev. 2, 403-41 1). In more complex promoters, multiple upstream elements regulate transcription over greater distances. To understand these spacing constraints, we placed two GC boxes in phase at various distances from the E1B TATA box. Whereas one GC box at eight bp from TATA increases transcription in vivo 5-fold compared with TATA alone (Wu, L., Rosser, D. S. E., Schmidt, M. C., and Berk, A. (1987) Nature 326, 512-515), two GC boxes increased in vivo transcription 25-30-fold. Transcriptional stimulation by two GC boxes fell off rapidly in vivo at 30 bp from TATA, remained approximately constant through 50 bp, then decreased again at 70 bp. Consequently, two GC boxes have a multiplicative effect at eight bp from TATA and continue to stimulate transcription at a greater distance from TATA than a single Sp1 site. Quantitatively different results were observed for in vitro transcription using a nuclear extract; a more linear fall off with increasing distance from TATA was observed. Separating the two GC boxes progressively decreased transcription. E1A stimulation of these promoters in vivo indicates that Sp1 transcription control is independent of E1A transactivation.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, INST MOLEC BIOL, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			BERK, ARNOLD/AAF-7052-2020		NATIONAL CANCER INSTITUTE [R37CA025235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001878] Funding Source: NIH RePORTER; NCI NIH HHS [R37CA25235] Funding Source: Medline; NIDDK NIH HHS [DK01878] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; COHEN RS, 1988, NATURE, V332, P856, DOI 10.1038/332856a0; DIGMAN JD, 1983, METHOD ENZYMOL, V101, P582; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LILY W, 1987, NATURE, V326, P512, DOI 10.1038/326512a0; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PARKS CL, 1988, VIROLOGY, V62, P54; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; STOW ND, 1981, J VIROL, V37, P171, DOI 10.1128/JVI.37.1.171-180.1981; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WU L, 1988, VIROLOGY, V167, P318, DOI 10.1016/0042-6822(88)90089-X; WU L, 1988, GENE DEV, V2, P403, DOI 10.1101/gad.2.4.403; YOUNGSUN L, 1990, NATURE, V345, P359; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	42	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20406	20411						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939095				2022-12-25	WOS:A1991GM03900078
J	ARMENGOD, ME; GARCIASOGO, M; PEREZROGER, I; MACIAN, F; NAVARROAVINO, JP				ARMENGOD, ME; GARCIASOGO, M; PEREZROGER, I; MACIAN, F; NAVARROAVINO, JP			TANDEM TRANSCRIPTION TERMINATION SITES IN THE DNAN GENE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; RECF GENE; PROTEIN; REPLICATION; K-12; RHO; PURIFICATION; TRANSLATION; EXPRESSION	The dnaN gene of Escherichia coli encodes the beta-subunit of DNA polymerase III and maps between the dnaA and recF genes. We demonstrated previously that dnaN and recF constitute a transcriptional unit under control of the dnaN promoters. However, the recF gene has its own promoter region located in the middle of the dnaN structural gene. In this report, we use S1 mapping of mRNAs, transcriptional and translational fusions to the galK and lacZ genes, and in vitro mutagenesis to identify and characterize three tandem transcription termination sites responsible for transcriptional polarity in the dnaN-recF operon. These sites are located in the dnaN gene, downstream from the recF promoter region. Cumulatively, they terminate about 80% of the untranslated transcripts started at the recF promoters. As expected, they do not reduce transcription coming from the dnaN promoters unless dnaN translation was prematurely disrupted by the presence of a nonsense codon. The particular arrangement of regulatory elements (promoters and terminators) in the dnaN-recF region provides an exceptional in vivo system to confirm the latent termination site model of transcriptional polarity. In addition, our results contribute to the understanding of the complex regulation of the dnaA, dnaN, and recF genes. We propose that these three genes constitute an operon and that the terminators described in this work could be used to reduce expression of the distal genes of the operon under circumstances in which the dnaN translation happens to be slowed down.			ARMENGOD, ME (corresponding author), INST INVEST CITOLOGICAL CAJA AHORROS VALENCIA,AMADEO DE SABOYA 4,E-46010 VALENCIA,SPAIN.		Pérez Roger, Ignacio/K-1346-2014; Armengod, M. Eugenia/A-9609-2014; Armengod, Maria Eugenia/K-6030-2014	Pérez Roger, Ignacio/0000-0002-5564-6912; Armengod, Maria Eugenia/0000-0003-1512-2687; Macian, Fernando/0000-0003-2666-035X				AIBA H, 1985, J BIOL CHEM, V260, P3063; ALIFANO P, 1991, CELL, V64, P553; ANDRUP L, 1988, J BACTERIOL, V170, P1333, DOI 10.1128/jb.170.3.1333-1338.1988; ARMENGOD ME, 1986, GENE, V43, P183, DOI 10.1016/0378-1119(86)90206-4; ARMENGOD ME, 1981, MOL GEN GENET, V181, P497, DOI 10.1007/BF00428742; ARMENGOD ME, 1988, J BIOL CHEM, V263, P12109; BLANAR MA, 1984, P NATL ACAD SCI-BIOL, V81, P4622, DOI 10.1073/pnas.81.15.4622; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GRIFFIN TJ, 1990, J BACTERIOL, V172, P6291, DOI 10.1128/jb.172.11.6291-6299.1990; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KORNBERG A, 1988, J BIOL CHEM, V263, P1; MAKI S, 1988, J BIOL CHEM, V263, P6561; Maniatis T., 1982, MOL CLONING; MATSUMOTO Y, 1986, J BACTERIOL, V166, P945, DOI 10.1128/jb.166.3.945-958.1986; Maxam A M, 1980, Methods Enzymol, V65, P499; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; McKenney K, 1981, Gene Amplif Anal, V2, P383; Miller JH., 1972, EXPT MOL GENETICS; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; PEREZROGER I, 1991, BIOCHIMIE, V73, P329, DOI 10.1016/0300-9084(91)90220-U; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RICHARDSON JP, 1991, CELL, V64, P1047, DOI 10.1016/0092-8674(91)90257-Y; RUTHESHOUSER EC, 1989, J MOL BIOL, V208, P23; SANDLER SJ, 1990, GENE, V86, P35, DOI 10.1016/0378-1119(90)90111-4; Silhavy T.J., 1984, EXPT GENE FUSIONS; STANSSENS P, 1986, CELL, V44, P711, DOI 10.1016/0092-8674(86)90837-8; TORREY TA, 1987, MOL GEN GENET, V208, P420, DOI 10.1007/BF00328133; WEK RC, 1987, J BIOL CHEM, V262, P15256; WRIGHT JJ, 1987, EMBO J, V6, P1115, DOI 10.1002/j.1460-2075.1987.tb04866.x; WUINONES A, 1988, MOL GEN GENET, V213, P118; XIANMING Y, 1984, J MOL BIOL, V172, P355; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241; YANOFSKY C, 1988, J BIOL CHEM, V263, P609; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	35	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19725	19730						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918078				2022-12-25	WOS:A1991GK66700086
J	KINOSHITA, A; URATA, H; BUMPUS, FM; HUSAIN, A				KINOSHITA, A; URATA, H; BUMPUS, FM; HUSAIN, A			MULTIPLE DETERMINANTS FOR THE HIGH SUBSTRATE-SPECIFICITY OF AN ANGIOTENSIN-II-FORMING CHYMASE FROM THE HUMAN HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC LYMPHOCYTES-T; MAST-CELL PROTEASE; SERINE PROTEINASES; MOLECULAR-CLONING; CATHEPSIN-G; LOCALIZATION; INHIBITORS; CONVERSION; GRANULES	Human heart chymase, a chymotrypsin-like serine proteinase that hydrolyzes the Phe8-His9 bond in angiotensin I (Ang I) to yield the octapeptide hormone angiotensin II (Ang II) and His-Leu, is the most specific, efficient Ang II-forming enzyme described. Other mammalian chymases display a much broader substrate specificity. To better define its substrate specificity, we have mapped the extended substrate-binding site of human heart chymase using Ang I analogs. The enzyme has a preference for aromatic amino acids phenylalanine, tyrosine, and tryptophan at the P1 site. At the S2 subsite there is a significant preference for proline over hydrophobic or hydrophilic amino acids. There is no clear preference for hydrophobic or hydrophilic amino acids at the S'1 and S'2 subsites, but an Ang I analog containing a P'1 proline is not hydrolyzed and one with a P'2 proline is hydrolyzed poorly. An increasing reduction in reactivity occurs when the P position amino acids in Ang I are deleted sequentially from the N terminus. An increase or decrease in the length of the His-Leu leaving group also produces a marked decrease in reactivity. No single determinant in Ang I is preeminently required for efficient catalysis, but several factors acting synergistically appear to be important. Thus, we propose that ideal substrates for human heart chymase should contain the structure nXaa-Pro-[Phe, Tyr, or Trp]-Yaa-Yaa, where n greater-than-or-equal-to 6; Xaa = any amino acid; Yaa = any amino acid except proline. This structure exists in Ang I and neurotensin, both of which are good substrates for human heart chymase. These findings indicate that the selection of the scissile bond by the extended substrate-binding site of human heart chymase is more restricted than that in other chymases.	CLEVELAND CLIN FDN, RES INST, DEPT HEART & HYPERTENS RES, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation			Husain, Ahsan/J-6861-2012	Husain, Ahsan/0000-0003-3426-3469	NHLBI NIH HHS [HL 33713] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033713] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENFEY PN, 1987, J BIOL CHEM, V262, P5377; CAUGHEY GH, 1990, BIOCHEMISTRY-US, V29, P5166, DOI 10.1021/bi00473a024; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; HARTLEY BS, 1970, PHILOS T ROY SOC B, V257, P77, DOI 10.1098/rstb.1970.0010; KOBAYASHI K, 1978, J BIOCHEM-TOKYO, V84, P477, DOI 10.1093/oxfordjournals.jbchem.a132149; KOBAYASHI K, 1978, J BIOCHEM-TOKYO, V84, P65, DOI 10.1093/oxfordjournals.jbchem.a132120; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; LOBE CG, 1986, P NATL ACAD SCI USA, V83, P1448, DOI 10.1073/pnas.83.5.1448; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; POLGAR L, 1989, MECHANISMS PROTEASE, P87; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; REILLY CF, 1982, J BIOL CHEM, V257, P8619; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; SAYAMA S, 1987, J BIOL CHEM, V262, P6808; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; URATA H, 1991, J BIOL CHEM, V266, P17173; URATA H, 1990, J BIOL CHEM, V265, P22348; WINTROUB BU, 1984, J INVEST DERMATOL, V83, P336, DOI 10.1111/1523-1747.ep12264144; WOODBURY RG, 1980, FEBS LETT, V114, P189, DOI 10.1016/0014-5793(80)81112-4; YOSHIDA N, 1980, BIOCHEMISTRY-US, V19, P5799, DOI 10.1021/bi00566a021	26	112	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19192	19197						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918036				2022-12-25	WOS:A1991GK66700015
J	KRONER, PA; FRIEDMAN, KD; FAHS, SA; SCOTT, JP; MONTGOMERY, RR				KRONER, PA; FRIEDMAN, KD; FAHS, SA; SCOTT, JP; MONTGOMERY, RR			ABNORMAL BINDING OF FACTOR-VIII IS LINKED WITH THE SUBSTITUTION OF GLUTAMINE FOR ARGININE-91 IN VONWILLEBRAND-FACTOR IN A VARIANT FORM OF VONWILLEBRAND DISEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MONOCLONAL-ANTIBODY; PLASMA; VWF	von Willebrand factor (vWf) is a multimeric plasma glycoprotein that functions in hemostasis as the initiator of platelet adhesion to damaged blood vessels and as the carrier of Factor VIII (FVIII). Montgomery et al. (Montgomery, R. R., Hathaway, W. E., Johnson, J., Jacobsen, L., and Muntean, W. (1982) Blood 60, 201-207) reported a variant of von Willebrand disease characterized by the abnormal interaction between FVIII and a defective vWf. To identify the molecular basis of this abnormal interaction, we isolated platelet RNA from members of one of the affected families and determined the nucleotide sequence of the FVIII-binding domain encoded by the vWf mRNA. A single G to A transition at nucleotide 2561 was linked with disease expression and results in the substitution of Gln for Arg91 in mature vWf. A restriction fragment containing this mutation was introduced into a full-length vWf expression vector, and both wild type and mutant vWf were expressed in COS-7 cells. In a solid-phase binding assay, expressed vWf was captured with anti-vWf monoclonal antibody AVW1 and then incubated with 6.25-400 milliunits of recombinant FVIII. After washing, vWf-bound FVIII activity was determined with a chromogenic assay. Mutant vWf showed reduced binding of FVIII compared with wild type, suggesting that the substitution of Gln for Arg91 is the likely basis for the abnormal vWf/FVIII interaction in this von Willebrand disease variant.	MED COLL WISCONSIN,DEPT PEDIAT,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT PATHOL,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin	KRONER, PA (corresponding author), BLOOD CTR SE WISCONSIN INC,BLOOD RES INST,MILWAUKEE,WI 53233, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028444, R01HL033721, P01HL044612] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44612, HL33721, HL28444] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1989, J CLIN INVEST, V84, P56, DOI 10.1172/JCI114169; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FOSTER PA, 1987, J BIOL CHEM, V262, P8443; FOSTER PA, 1989, BLOOD REV, V3, P180, DOI 10.1016/0268-960X(89)90015-5; GAUCHER C, 1991, BLOOD, V77, P1937; GRALNICK HR, 1991, DISORDERS HAEMOSTASI, P203; LAEMMLI UK, 1970, NATURE, V227, P29; LEYTE A, 1991, BIOCHEM J, V274, P257, DOI 10.1042/bj2740257; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MAZURIER C, 1990, BLOOD, V75, P20; MONTGOMERY RR, 1986, METHOD ENZYMOL, V121, P702; MONTGOMERY RR, 1982, BLOOD, V60, P201; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; NISHINO M, 1989, BLOOD, V74, P1591; OWEN WG, 1972, THROMB DIATH HAEMOST, V27, P502, DOI 10.1055/s-0038-1649389; RUGGERI ZM, 1987, BLOOD, V70, P895; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788	18	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19146	19149						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918030				2022-12-25	WOS:A1991GK66700006
J	BENVENISTE, EN; VIDOVIC, M; PANEK, RB; NORRIS, JG; REDDY, AT; BENOS, DJ				BENVENISTE, EN; VIDOVIC, M; PANEK, RB; NORRIS, JG; REDDY, AT; BENOS, DJ			INTERFERON-GAMMA-INDUCED ASTROCYTE CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX GENE-EXPRESSION IS ASSOCIATED WITH BOTH PROTEIN-KINASE-C ACTIVATION AND NA+ ENTRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IA-ANTIGEN EXPRESSION; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MURINE PERITONEAL-MACROPHAGES; NECROSIS-FACTOR-ALPHA; MYELIN BASIC-PROTEIN; MULTIPLE-SCLEROSIS; ENDOTHELIAL-CELLS; IMMUNE INTERFERON; PRESENTING CELLS; T-CELL	Astrocytes can be induced by interferon-gamma (IFN-gamma) to express class II major histocompatibility complex (MHC) antigens. This study was undertaken to elucidate the intracellular signaling pathways involved in IFN-gamma induction of class II MHC. We examined the effects of Na+/H+ antiporter and protein kinase C (PKC) inhibitors on class II expression and Na+ influx in astrocytes. We found that amiloride and ethyl isopropylamiloride, inhibitors of Na+/H+ exchange, blocked IFN-gamma-induced class II gene expression. IFN-gamma stimulated Na+ influx, and this increased influx was inhibited by amiloride. Treatment of astrocytes with the PKC inhibitor H7 also blocked the increase in Na+ uptake induced by IFN-gamma, indicating that IFN-gamma-induced PKC activation is required for subsequent Na+ influx. IFN-gamma treatment produced an increase of total PKC activity, which was associated with a rapid translocation of PKC activity from cytosolic to particulate fraction. H7 and another PKC inhibitor, staurosporine, inhibited IFN-gamma-induced class II gene expression. However, 4-beta-phorbol 12-beta-myristate 13-alpha-acetate, a potent PKC activator, did not affect class II expression. Taken together, our data indicate that both IFN-gamma-induced PKC activation and Na+ influx are required for class II MHC expression in astrocytes but that activation of PKC alone is not sufficient for ultimate expression of this gene.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	BENVENISTE, EN (corresponding author), UNIV ALABAMA,DEPT NEUROL,UAB STN,BIRMINGHAM,AL 35294, USA.				NIAID NIH HHS [AI-27290] Funding Source: Medline; NIDDK NIH HHS [DK-37206] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI027290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1984, J PHARMACOL EXP THER, V231, P141; BENACERRAF B, 1981, SCIENCE, V212, P1229, DOI 10.1126/science.6165083; Benos D.J, 1982, AM J PHYSIOL, V242, P131; BENOS DJ, 1991, IN PRESS MEMBRANE TR; BENVENISTE EN, 1989, J NEUROIMMUNOL, V25, P209, DOI 10.1016/0165-5728(89)90139-2; BENVENISTE EN, 1986, NATURE, V321, P610, DOI 10.1038/321610a0; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; CELADA A, 1991, J IMMUNOL, V146, P114; CELADA A, 1986, J IMMUNOL, V137, P2373; CHUNG IY, 1991, J EXP MED, V173, P801, DOI 10.1084/jem.173.4.801; CIVITELLI R, 1989, J IMMUNOL, V143, P4000; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; FALTYNEK CR, 1989, J BIOL CHEM, V264, P14304; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FIERZ W, 1985, J IMMUNOL, V134, P3785; FONTANA A, 1987, IMMUNOL REV, V100, P185, DOI 10.1111/j.1600-065X.1987.tb00532.x; FONTANA A, 1984, NATURE, V307, P273, DOI 10.1038/307273a0; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; GASPARI AA, 1988, J IMMUNOL, V141, P2216; GASSER DL, 1973, SCIENCE, V181, P872, DOI 10.1126/science.181.4102.872; GHIGO D, 1990, J CELL PHYSIOL, V145, P147, DOI 10.1002/jcp.1041450120; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; HAMILTON TA, 1985, J BIOL CHEM, V260, P1378; HAMMERLING GJ, 1975, IMMUNOGENETICS, V1, P428; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KINSELLA JL, 1981, AM J PHYSIOL, V241, P374; KOIDE Y, 1988, P NATL ACAD SCI USA, V85, P3120, DOI 10.1073/pnas.85.9.3120; LIEBERMAN AP, 1990, J EXP MED, V172, P989, DOI 10.1084/jem.172.3.989; MAO C, 1990, J IMMUNOL, V145, P4257; MARKMANN J, 1988, NATURE, V336, P476, DOI 10.1038/336476a0; MASSA PT, 1986, NATURE, V320, P543, DOI 10.1038/320543a0; MASSA PT, 1987, P NATL ACAD SCI USA, V84, P4219, DOI 10.1073/pnas.84.12.4219; MATHIS DJ, 1983, CELL, V32, P745, DOI 10.1016/0092-8674(83)90060-0; MATTILA P, 1989, FEBS LETT, V250, P362, DOI 10.1016/0014-5793(89)80756-2; MCCARRON RM, 1985, J IMMUNOL, V134, P3100; MOOLENAAR WH, 1984, NATURE, V312, P371, DOI 10.1038/312371a0; MOORE MJ, 1980, J IMMUNOL, V124, P1815; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; POLITIS AD, 1990, J IMMUNOL, V145, P3788; PRPIC V, 1989, SCIENCE, V244, P469, DOI 10.1126/science.2541500; SAPIRSTEIN VS, 1984, J NEUROCHEM, V43, P1098, DOI 10.1111/j.1471-4159.1984.tb12849.x; SASAKI A, 1990, J NEUROIMMUNOL, V29, P213, DOI 10.1016/0165-5728(90)90164-I; SMITH LL, 1988, J BIOL CHEM, V263, P7359; SOMERS SD, 1986, J IMMUNOL, V136, P4199; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TRAUGOTT U, 1988, J NEUROL SCI, V84, P257, DOI 10.1016/0022-510X(88)90130-X; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VIDOVIC M, 1990, J NEUROIMMUNOL, V30, P189, DOI 10.1016/0165-5728(90)90103-T; VIGNE P, 1984, MOL PHARMACOL, V25, P131; WONG GHW, 1984, NATURE, V310, P688, DOI 10.1038/310688a0; YAP WH, 1986, SCIENCE, V234, P355, DOI 10.1126/science.2429366; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	55	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18119	18126						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917946				2022-12-25	WOS:A1991GG55300063
J	FUJIYAMA, A; TSUNASAWA, S; TAMANOI, F; SAKIYAMA, F				FUJIYAMA, A; TSUNASAWA, S; TAMANOI, F; SAKIYAMA, F			S-FARNESYLATION AND METHYL ESTERIFICATION OF C-TERMINAL DOMAIN OF YEAST RAS2 PROTEIN PRIOR TO FATTY-ACID ACYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; POSTTRANSLATIONAL MODIFICATION; MATING PHEROMONE; A-FACTOR; RHODOSPORIDIUM-TORULOIDES; CARBOXYL TERMINUS; CYSTEINE RESIDUE; RHODOTORUCINE-A; TUBE FORMATION; SARCOMA-VIRUS	Posttranslational processing/modification is required for membrane localization and activation of ras proteins. In the case of yeast RAS2 protein, we have reported that the process starts with the removal of the initiator methionine followed by polyisoprenylation, removal of 3 amino acid residues from the C terminus, methyl esterification, and fatty acid acylation (Fujiyama, A., and Tamanoi, F. (1990) J. Biol. Chem. 265, 3362-3368). In this study, we demonstrate that polyisoprenylation and methyl esterification of the cysteine residue in the C-terminal domain of the RAS2 protein are involved in the conversion process from precursor form to intermediate form. The polyisoprenoid moiety attached to the RAS2 protein was identified as a 15-carbon farnesyl group through two independent experiments: the release of S-farnesylcysteine with carboxypeptidase Y from the RAS2 protein, and the recovery of radioactive farnesol through methyliodide treatment of the RAS2 protein purified from yeast cells labeled with [H-3]mevalonic acid. The farnesyl group attached to the RAS2 protein was detected predominantly in the C-terminal peptide, SGSGGCC, both in the intermediate and in the fatty acid acylated RAS2 protein. The C-terminal cysteine of the intermediate protein is also modified by methyl esterification in a nearly stoichiometric manner.	OSAKA UNIV, INST PROT, SUITA, OSAKA 565, JAPAN; UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA	Osaka University; University of Chicago	FUJIYAMA, A (corresponding author), NATL INST GENET, MISHIMA, SHIZUOKA 411, JAPAN.				NATIONAL CANCER INSTITUTE [R01CA041996] Funding Source: NIH RePORTER; NCI NIH HHS [CA41996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKADA R, 1987, AGR BIOL CHEM TOKYO, V51, P1211, DOI 10.1080/00021369.1987.10868162; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BETZ R, 1987, J BIOL CHEM, V262, P546; BINSTOCK J, 1984, METHOD ENZYMOL, V106, P310; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHELSKY D, 1987, J BIOL CHEM, V262, P4303; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; Cooper T., 1982, MOL BIOL YEAST SACCH, P399; COREY EJ, 1972, TETRAHEDRON LETT, P4339; DEFEOJONES D, 1983, NATURE, V306, P707, DOI 10.1038/306707a0; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAYASHI R, 1975, J BIOCHEM-TOKYO, V77, P69; ISHIBASHI Y, 1984, BIOCHEMISTRY-US, V23, P1399, DOI 10.1021/bi00302a010; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P363, DOI 10.1080/00021369.1979.10863433; Koshland Jr D.E, 1980, BACTERIAL CHEMOTAXIS; LEONARD S, 1990, J BIOL CHEM, V265, P5157; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MAGEE T, 1988, NATURE, V335, P114, DOI 10.1038/335114a0; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MASAKI T, 1978, AGR BIOL CHEM TOKYO, V42, P1443, DOI 10.1080/00021369.1978.10863183; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; SAKAGAMI Y, 1981, SCIENCE, V212, P1525, DOI 10.1126/science.212.4502.1525; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; TAMANOI F, 1988, BIOCHIM BIOPHYS ACTA, V948, P1, DOI 10.1016/0304-419X(88)90002-9; TAMANOI F, 1988, J CELL BIOCHEM, V36, P261, DOI 10.1002/jcb.240360307; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WEEKS MO, 1985, J VIROL, V54, P586, DOI 10.1128/JVI.54.2.586-597.1985; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WILSON KL, 1987, GENETICS, V115, P441	48	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17926	17931						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917931				2022-12-25	WOS:A1991GG55300035
J	PHAM, TA; HWUNG, YP; MCDONNELL, DP; OMALLEY, BW				PHAM, TA; HWUNG, YP; MCDONNELL, DP; OMALLEY, BW			TRANSACTIVATION FUNCTIONS FACILITATE THE DISRUPTION OF CHROMATIN STRUCTURE BY ESTROGEN-RECEPTOR DERIVATIVES INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; HYPERSENSITIVE SITES; TRANSCRIPTIONAL REGULATION; DNA-BINDING; MAJOR LATE; YEAST; NUCLEOSOME; GENE; ACTIVATION	The activation of gene transcription by nuclear receptors is invariably associated with alterations in chromatin structure at hormone-responsive elements of target genes. To identify the molecular functions underlying receptor-mediated chromatin structure alterations we have evaluated the effects of DNA binding and transactivation of estrogen receptor derivatives on the promoter chromatin structure of estrogen-responsive reporter minichromosomes in Saccharomyces cerevisiae. We report here that the DNase I-hypersensitive chromatin structure at the promoter region is not simply a consequence of estrogen receptor binding to estrogen-responsive elements but is greatly enhanced by transactivation functions. These chromatin structure alterations are dependent on the presence of more than one estrogen-responsive element as well as downstream promoter sequences and appear to be correlated with transcriptional competence of the promoter. Our results imply that a disruption of chromatin structure at promoters is associated with the establishment of active transcription complexes. Since RNA polymerase cannot initiate transcription on nucleosomal DNA in vitro (Lorch, Y., Lapointe, J. W., and Kornberg, R. D. (1987) Cell 49, 203-210) this local disruption of chromatin structure may represent a nucleosome-free window, allowing initiation to occur in vivo.			PHAM, TA (corresponding author), BAYLOR COLL MED, DEPT CELL BIOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA.							BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; ELLISTON JF, 1990, J BIOL CHEM, V265, P11517; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HECHT A, 1988, EMBO J, V7, P2063, DOI 10.1002/j.1460-2075.1988.tb03046.x; HOYLAERTS M, 1986, FEBS LETT, V204, P83, DOI 10.1016/0014-5793(86)81391-6; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLEINHITPASS L, 1988, J MOL BIOL, V201, P537; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; LOWARY PT, 1989, P NATL ACAD SCI USA, V86, P8266, DOI 10.1073/pnas.86.21.8266; MAK P, 1989, J BIOL CHEM, V264, P21613; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MCDONNELL DP, 1989, MOL CELL BIOL, V9, P3517, DOI 10.1128/MCB.9.8.3517; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; NELSON RG, 1979, P NATL ACAD SCI USA, V76, P6515, DOI 10.1073/pnas.76.12.6515; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PEDERSON DS, 1990, EMBO J, V9, P1873, DOI 10.1002/j.1460-2075.1990.tb08313.x; PELLMAN D, 1990, NATURE, V348, P82, DOI 10.1038/348082a0; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PHAM TA, 1991, P NATL ACAD SCI USA, V88, P3125, DOI 10.1073/pnas.88.8.3125; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PTASHNE M, 1988, NATURE, V341, P657; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; van Holde KE., 1989, SPRINGER SERIES MOL; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WU C, 1989, METHOD ENZYMOL, V170, P269; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	50	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18179	18187						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917950				2022-12-25	WOS:A1991GG55300071
J	TARAKHOVSKY, AM; RESNIKOV, M; ZAICHUK, T; TUGUSHEVA, MV; BUTENKO, ZA; PRASSOLOV, VS				TARAKHOVSKY, AM; RESNIKOV, M; ZAICHUK, T; TUGUSHEVA, MV; BUTENKO, ZA; PRASSOLOV, VS			POLYMORPHIC CHANGES OF CELL PHENOTYPE CAUSED BY ELEVATED EXPRESSION OF AN EXOGENOUS NEU PROTOONCOGENE	ONCOGENE			English	Article									ACAD SCI USSR,INST MOLEC BIOL,MOSCOW V-71,USSR		TARAKHOVSKY, AM (corresponding author), ACAD SCI UKSSR,INST ONCOL PROBLEMS,DEPT LEUKEMIAGENESIS,VASILKOVSKAYA 45,KIEV 252022,UKRAINE,USSR.							ADAMSON ED, 1981, MOL CELL BIOCHEM, V34, P129, DOI 10.1007/BF02359619; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Cowley GO, 1984, CANCER CELL, V1, P5; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GURROFF G, 1988, GROWTH MATURATION FA; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTIN GS, 1971, P NATL ACAD SCI USA, V68, P2739, DOI 10.1073/pnas.68.11.2739; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; PRASOLOV VS, 1988, DOKL AKAD NAUK SSSR+, V300, P1498; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SEMBA K, 1985, SCIENCE, V85, P6479; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH JJ, 1987, P NATL ACAD SCI USA, V84, P7567, DOI 10.1073/pnas.84.21.7567; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816	38	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					405	410						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1969137				2022-12-25	WOS:A1990CW41500019
J	GUO, ZK; WALS, PA; KATZ, J				GUO, ZK; WALS, PA; KATZ, J			STIMULATION OF GLYCOGEN-SYNTHESIS BY PROGLYCOSYN (LY177507) BY ISOLATED HEPATOCYTES OF NORMAL AND STREPTOZOTOCIN DIABETIC RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The phenacylimidazolium compound LY177507 was shown by Harris et al. (Harris, R. A., Yamanuchi, K., Roach, P. J., Yen, T. T., Dominiani, S. J., and Stephens, T. W. (1989) J. Biol. Chem. 264, 14674-14680) to stimulate glycogen synthesis greatly in isolated rat hepatocytes. We extended studies with this compound, designated proglycosyn (Yamaguchi, K., Stephens, T. W., Chikadar, K., Depaoli-Roach, A., and Harris, R. A. (1991) Diabetes 40, (Suppl. 1) 102 (abstr.)) employing hepatocytes from normal and streptozotocin diabetic rats. Proglycosyn is more effective than amino acids in stimulating glycogen synthesis. In cells incubated with glucose, lactate, or dihydroxyacetone the effect of glutamine and proglycosyn was synergistic. In cells incubated with glucose plus lactate, or glucose plus dihydroxyacetone, the stimulation by the two agonists was additive. Proglycosyn diverted the gluconeogenic flux from glucose to glycogen. The maximal rates of glycogen deposition attained in the presence of glutamine and proglycosyn from cells incubated with glucose plus lactate, or glucose plus dihydroxyacetone, where about 80 and 110-mu-mol/h/g of liver, respectively. Proglycosyn depressed glycogenolysis in hepatocytes of fed rats and stimulated glycogen synthesis from lactate and dihydroxyacetone. The incorporation of [U-C-14]glucose and [U-C-14]lactate in these cells occurred in the presence of glycogen breakdown or exceeded net production, indicating the occurrence of recycling of glycogen in hepatocytes of fed rats. Hepatocytes from fasted streptozotocin diabetic rats contained high levels of glycogen. Glycogenolysis was markedly depressed by proglycosyn. Glycogen-synthesis from lactate and dihydroxyacetone in these cells was stimulated by glutamine and proglycosyn in a fashion similar to that in cells from fasted control rats, and the rates of glycogen synthesis were similar in cells of control and diabetic rats. With glucose as sole substrate, glutamine did not stimulate glycogen synthesis. When both agonists were present, there was a marked synergism and substantial glycogen formation. Streptozotocin diabetic rats prior to the onset of cachexia have a normal capacity for glycogen synthesis.			GUO, ZK (corresponding author), CEDARS SINAI MED CTR,LOS ANGELES,CA 90048, USA.				NIDDK NIH HHS [5 RO1 DK 36449] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036449] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAQUET A, 1990, J BIOL CHEM, V265, P955; BARRET EJ, 1986, A BENZON S, V30, P415; CHEN KS, 1985, J BIOL CHEM, V260, P4683; FREIDMAN B, 1967, ENDOCRINOLOGY, V81, P486; FRIEDMAN.B, 1965, J BIOL CHEM, V240, P3729; GOLDEN S, 1979, BIOCHEM J, V182, P727, DOI 10.1042/bj1820727; HARRIS RA, 1989, J BIOL CHEM, V264, P14674; HAUSSINGER D, 1991, BIOCHEM CELL BIOL, V69, P1; HUE L, 1991, A BENZON S, V30, P447; KATZ J, 1976, P NATL ACAD SCI USA, V73, P3433, DOI 10.1073/pnas.73.10.3433; KATZ J, 1991, P NATL ACAD SCI USA, V88, P2103, DOI 10.1073/pnas.88.6.2103; KATZ J, 1979, BIOCHEM J, V180, P389, DOI 10.1042/bj1800389; LANGLEY RW, 1957, P SOC EXP BIOL MED, V94, P108; LAVOINNE A, 1987, BIOCHEM J, V248, P429, DOI 10.1042/bj2480429; OKAJIMA F, 1979, BIOCHEM BIOPH RES CO, V87, P155, DOI 10.1016/0006-291X(79)91660-7; ROGNSTAD R, 1985, BIOCHEM BIOPH RES CO, V130, P229, DOI 10.1016/0006-291X(85)90406-1; YAMANOUCHI K, 1991, DIABETES S1, V40, P102	17	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22323	22327						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939254				2022-12-25	WOS:A1991GR56400044
J	MUNSHI, R; PANG, IH; STERNWEIS, PC; LINDEN, J				MUNSHI, R; PANG, IH; STERNWEIS, PC; LINDEN, J			A1 ADENOSINE RECEPTORS OF BOVINE BRAIN COUPLE TO GUANINE NUCLEOTIDE-BINDING PROTEINS GI1, GI2, AND GO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A1-ADENOSINE RECEPTORS; REGULATORY PROTEINS; HIGH-AFFINITY; MEMBRANES; CHANNELS; SUBUNITS; AGONIST; RECONSTITUTION; RADIOLIGAND; ACTIVATION	A1 adenosine receptors and associated guanine nucleotide-binding proteins (G proteins) were purified from bovine cerebral cortex by affinity chromatography (Munshi, R., and Linden, J. (1989) J. Biol. Chem. 264, 14853-14859). In this study we have identified the pertussis toxin-sensitive G protein subunits that co-purify with A1 adenosine receptors by immunoblotting with specific antipeptide antisera. G(i-alpha-1), G(i-alpha-2), G(o-alpha), G(beta-35), and G(beta-36) were detected. Of the total [S-35]guanosine 5'-O-(3-thio)triphosphate ([S-35]GTP-gamma-S) binding sites, G(i-alpha-1) and G(o-alpha) each accounted for > 37% whereas G(i-alpha-2) comprised < 13%. G(beta-35) was found in excess over G(beta-36). Low molecular mass (21-25 kDa) GTP-binding proteins were not detected. We also examined the characteristics of purified receptors and various purified bovine brain G proteins reconstituted into phospholipid vesicles. All three alpha-subunits restored GTP-gamma-S-sensitive high affinity binding of the agonist I-125-aminobenzyladenosine to a fraction (25%) of reconstituted receptors with a selectivity order of G(i2) > G(o) greater-than-or-equal-to G(i1) (ED50 values of G proteins measured as fold excess over the receptor concentration were 4.7 +/- 1.2, 24 +/- 5, and 34 +/- 7, respectively). Furthermore, receptors occupied with the agonist R-phenylisopropyladenosine catalytically increased the rate of binding of [S-35]GTP-gamma-S to reconstituted G proteins by 6.5-8.5-fold. These results suggest that A1 adenosine receptors couple indiscriminately to pertussis toxin-sensitive G proteins.	UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED CARDIOL,BOX 158,CHARLOTTESVILLE,VA 22908; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV VIRGINIA,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Virginia					NHLBI NIH HHS [R01-HL-37942] Funding Source: Medline; NIGMS NIH HHS [GM31954] Funding Source: Medline; PHS HHS [P30-DIK-38942] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1990, J BIOCHEM-TOKYO, V108, P988, DOI 10.1093/oxfordjournals.jbchem.a123326; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; EARL CQ, 1988, J MED CHEM, V31, P752, DOI 10.1021/jm00399a011; EWALD DA, 1988, P NATL ACAD SCI USA, V85, P3633, DOI 10.1073/pnas.85.10.3633; EWALD DA, 1989, NEURON, V2, P1185, DOI 10.1016/0896-6273(89)90185-2; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GREEN A, 1990, J BIOL CHEM, V265, P5206; GUSTAFSSON LE, 1990, PURINES IN CELLULAR SIGNALLING, P200; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; KLOTZ KN, 1986, J NEUROCHEM, V46, P1528, DOI 10.1111/j.1471-4159.1986.tb01772.x; KURACHI Y, 1986, PFLUG ARCH EUR J PHY, V407, P264, DOI 10.1007/BF00585301; LEID M, 1988, MOL PHARMACOL, V34, P334; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; LINDEN J, 1990, PURINE NUCLEOSIDES N, P56; LINDEN J, 1991, ADENOSINE NERVOUS SY, P103; LINDEN J, 1987, TOPICS PERSPECTIVES, P3; LONGABAUGH JP, 1989, MOL PHARMACOL, V36, P681; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUNSHI R, 1990, MOL PHARMACOL, V38, P170; MUNSHI R, 1989, J BIOL CHEM, V264, P14853; OKAJIMA F, 1989, FEBS LETT, V248, P145, DOI 10.1016/0014-5793(89)80450-8; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; PATEL A, 1988, MOL PHARMACOL, V33, P585; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SCHOLFIELD CN, 1988, NEUROSCIENCE, V24, P81, DOI 10.1016/0306-4522(88)90313-2; SCOTT RH, 1987, TOPICS PERSPECTIVES, P549; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; UEDA H, 1990, J NEUROCHEM, V54, P841, DOI 10.1111/j.1471-4159.1990.tb02328.x; UKENA D, 1986, FEBS LETT, V209, P122, DOI 10.1016/0014-5793(86)81096-1; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040	34	131	133	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22285	22289						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939250				2022-12-25	WOS:A1991GR56400037
J	LUO, GX; NISHIMURA, JS				LUO, GX; NISHIMURA, JS			SITE-DIRECTED MUTAGENESIS OF ESCHERICHIA-COLI SUCCINYL-COA SYNTHETASE - HISTIDINE-142-ALPHA IS A FACILITATIVE CATALYTIC RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; ACTIVE-SITE; SUBSTRATE SYNERGISM; COOPERATIVITY; PARAMETERS; MECHANISM; SUBUNIT; ENZYME	There are 11 histidine residues in Escherichia coli succinyl-CoA synthetase. His-246-alpha is well established as the phosphorylation site of the enzyme. Replacement of this histidine by asparagine (Mann, C. J., Mitchell, T., and Nishimura, J. S. (1991) Biochemistry 30, 1497-1503) or by aspartic acid (Majumdar, R., Guest, J. R., and Bridger, W. A. (1991) Biochim. Biophys. Acta 1076, 86-90) through site-directed mutagenesis resulted in complete loss of enzyme activity. Chemical modification experiments suggested a second histidine at the active site (Collier, G. E., and Nishimura, J. S. (1979) J. Biol. Chem. 254,10925-10930). In the present study, we have changed His-142-alpha to an asparagine residue using the technique of site-directed mutagenesis and have purified the mutant enzyme to homogeneity. The resulting mutant enzyme is practically devoid of enzyme activity but can be thiophosphorylated with adenosine 5'-O-(thiotriphosphate) and dethiophosphorylated with ADP at rates that are significantly faster than those with wild type enzyme. The observation that phosphorylated mutant enzyme can be dephosphorylated with succinate and with succinate plus desulfo-CoA at rates comparable with those with wild type enzyme suggests that mutant enzyme can bind succinate and COA. Dethiophosphorylation of the enzyme in the presence of CoA plus succinate proceeds much faster with wild type than with mutant. While there was no significant change in K(CoA) or K(succinate), the turnover number for dethiophosphorylation of the mutant was 10-fold lower. These data are consistent with location of His-142-alpha at the active site and a facilitative role for this residue in catalysis.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017534] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-17534] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; BANKIER AT, 1983, TECHNIQUES NUCLEIC B, V5, P1; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Bridger W. A., 1974, ENZYMES, P581; BRIDGER WA, 1968, BIOCHEMISTRY-US, V7, P3608, DOI 10.1021/bi00850a038; BUCK D, 1985, BIOCHEMISTRY-US, V24, P6245, DOI 10.1021/bi00343a031; Cha S, 1969, METHOD ENZYMOL, V13, P62, DOI 10.1016/0076-6879(69)13017-7; COLLIER GE, 1978, J BIOL CHEM, V253, P4938; COLLIER GE, 1979, J BIOL CHEM, V254, P925; GRINNELL FL, 1969, BIOCHEMISTRY-US, V8, P568, DOI 10.1021/bi00830a016; Hayashi R, 1977, Methods Enzymol, V47, P84; HAYASHI R, 1975, J BIOCHEM-TOKYO, V77, P69; HILDEBRAND JG, 1969, J BIOL CHEM, V244, P2606; KAUFMAN S, 1955, J BIOL CHEM, V216, P153; KREBS A, 1974, CAN J BIOCHEM CELL B, V52, P594, DOI 10.1139/o74-086; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJUMDAR R, 1991, BIOCHIM BIOPHYS ACTA, V1076, P86, DOI 10.1016/0167-4838(91)90223-M; MANN CJ, 1989, J BIOL CHEM, V264, P1457; MANN CJ, 1991, BIOCHEMISTRY-US, V30, P1497, DOI 10.1021/bi00220a008; MOFFET FJ, 1970, J BIOL CHEM, V245, P2758; NISHIMURA JS, 1965, BIOCHEMISTRY-US, V4, P1457, DOI 10.1021/bi00883a034; NISHIMURA JS, 1984, J BIOL CHEM, V259, P9642; NISHIMURA JS, 1972, ADV ENZYMOL RAMB, V36, P183; NISHIMURA JS, 1986, ADV ENZYMOL, V58, P142; PEARSON PH, 1975, J BIOL CHEM, V250, P8524; VOGEL HJ, 1982, J BIOL CHEM, V257, P4834; WANG T, 1972, BIOCHEMISTRY-US, V11, P2067, DOI 10.1021/bi00761a011; WOLODKO WT, 1983, J BIOL CHEM, V258, P4116; WOLODKO WT, 1984, J BIOL CHEM, V259, P5316	31	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20781	20785						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939128				2022-12-25	WOS:A1991GN00100031
J	CHAPPELL, DA; FRY, GL; WAKNITZ, MA; BERNS, JJ				CHAPPELL, DA; FRY, GL; WAKNITZ, MA; BERNS, JJ			LIGAND SIZE AS A DETERMINANT FOR CATABOLISM BY THE LOW-DENSITY-LIPOPROTEIN (LDL) RECEPTOR PATHWAY - A LATTICE MODEL FOR LDL BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-FIBROBLASTS; MONOCLONAL-ANTIBODIES; APOPROTEIN-E; STOICHIOMETRIC BINDING; QUANTITATIVE-ANALYSIS; APOLIPOPROTEIN-B; PROTEINS; AFFINITY; SURFACE; HYPERCHOLESTEROLEMIA	Low density lipoproteins (LDL) are large (M(r) = 2.5 x 1O(6)) in comparison to LDL receptors (M(r) = 1 15,000). Since most LDL receptors are clustered in coated pits, we tested the hypothesis that crowding of receptor-bound LDL particles would cause steric effects. The apparent affinity of LDL for receptors on cultured fibroblasts decreased near saturation causing concave-upward Scatchard plots. Both the higher and lower affinity components of binding were up-regulated by the cholesterol synthesis inhibitor, lovastatin, indicating that the entire binding curve was sterol-responsive. In contrast, neither component of LDL binding was present on lovastatin-treated or untreated null fibroblasts which are incapable of expressing LDL receptors. Therefore, the concave-upward Scatchard plots were entirely due to binding to LDL receptors. These results are consistent with a lattice model in which receptor-bound LDL are large enough to decrease binding to adjacent receptors. A lattice model implies that large LDL should produce steric effects at a lower receptor occupancy than should small LDL. This was tested using seven LDL fractions that differed in diameter from 20 to 27 nm. Fewer large than small LDL were bound to the cell surface at 4-degrees-C and 37-degrees-C, and fewer were internalized and degraded at 37-degrees-C. Since large LDL bound via both apolipoprotein (apo) E and apoBl00, receptor cross-linking could have caused fewer large LDL to be bound at saturation. However, when the potential for cross-linking was prevented by an apo-E-specific monoclonal antibody (1D7), the difference in binding by large versus small LDL was not eliminated; instead, it was exaggerated. Taken together, these results support a lattice model for LDL binding and indicate that steric hindrance associated with crowding of LDL particles on receptor lattices is a major determinant for catabolism by the LDL receptor pathway in vitro.			CHAPPELL, DA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242, USA.				NHLBI NIH HHS [HL14230, HL02024] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014230, K08HL002024] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOEYNAEMS JM, 1975, J CYCLIC NUCL PROT, V1, P123; BROWN MS, 1978, J BIOL CHEM, V253, P1121; CHAPPELL DA, 1989, J CLIN INVEST, V84, P1906, DOI 10.1172/JCI114378; CHAPPELL DA, 1989, ARTERIOSCLEROSIS, V9, pA728; CHECOVICH WJ, 1991, ARTERIOSCLER THROMB, V11, P351, DOI 10.1161/01.ATV.11.2.351; COWAN R, 1988, J THEOR BIOL, V132, P319, DOI 10.1016/S0022-5193(88)80218-2; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DELISI C, 1979, BIOPHYSICS-USSR, V1, P117; DOWER SK, 1981, BIOCHEMISTRY-US, V20, P6326, DOI 10.1021/bi00525a007; EDELSTEIN C, 1986, METHOD ENZYMOL, V128, P151; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HARDY MR, 1985, BIOCHEMISTRY-US, V24, P22, DOI 10.1021/bi00322a004; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HEUSER J, 1980, J CELL BIOL, V84, P560, DOI 10.1083/jcb.84.3.560; HILL TL, 1975, P NATL ACAD SCI USA, V72, P4918, DOI 10.1073/pnas.72.12.4918; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; HOLLEMAN JG, 1975, CLIN CHEM, V21, P1769; INNERARITY TL, 1980, BIOCHEMISTRY-US, V19, P4359, DOI 10.1021/bi00559a032; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; INNERARITY TL, 1990, J LIPID RES, V31, P1337; INNERARITY TL, 1981, P NATL ACAD SCI-BIOL, V78, P4378, DOI 10.1073/pnas.78.7.4378; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE SW, 1988, J BIOL CHEM, V263, P15467; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MENDEL CM, 1985, J BIOL CHEM, V260, P3451; MILNE RW, 1982, FEBS LETT, V146, P97, DOI 10.1016/0014-5793(82)80712-6; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; ORCI L, 1978, EXP CELL RES, V113, P1, DOI 10.1016/0014-4827(78)90081-2; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; ROBENEK H, 1991, ARTERIOSCLER THROMB, V11, P261, DOI 10.1161/01.ATV.11.2.261; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; STANKOWSKI S, 1983, BIOCHIM BIOPHYS ACTA, V735, P352, DOI 10.1016/0005-2736(83)90149-9; STANKOWSKI S, 1983, BIOCHIM BIOPHYS ACTA, V735, P341, DOI 10.1016/0005-2736(83)90148-7; STURM J, 1981, BIOPOLYMERS, V20, P765, DOI 10.1002/bip.1981.360200410; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; VANDRIEL IR, 1989, J BIOL CHEM, V264, P9533; VEGA GL, 1986, ARTERIOSCLEROSIS, V6, P395, DOI 10.1161/01.ATV.6.4.395; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WEISGRABER KH, 1978, J BIOL CHEM, V253, P6281; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178	51	53	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19296	19302						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918046				2022-12-25	WOS:A1991GK66700031
J	GARDLIK, S; GASSER, R; PHILPOT, RM; SERABJITSINGH, CJ				GARDLIK, S; GASSER, R; PHILPOT, RM; SERABJITSINGH, CJ			THE MAJOR ALPHA-CLASS GLUTATHIONE S-TRANSFERASES OF RABBIT LUNG AND LIVER - PRIMARY SEQUENCES, EXPRESSION, AND REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT CDNA CLONE; NUCLEOTIDE-SEQUENCE; GEL-ELECTROPHORESIS; RIBONUCLEIC-ACID; SEPARATE GENES; MESSENGER-RNA; YB SUBUNIT; RAT; DNA; YC	The complete primary structures of two distinct rabbit alpha-class glutathione S-transferase (GST) subunits, rbGST-alpha-I and rbGST-alpha-II, have been derived from cDNA sequences. Clones encoding rbGST-alpha-I were isolated from both hepatic and pulmonary cDNA libraries, whereas clones encoding rbGST-alpha-II were isolated only from the hepatic library. Immunochemical and peptide sequence data confirmed that rbGST-alpha-I corresponds to the 27-kDa alpha-class subunit purified from rabbit lung (Serabjit-Singh, C. J., and Bend, J. R. (1988) Arch. Bioch. Biophys. 267, 184-194). Expression of rbGST-alpha-II in liver but not in lung and expression of rbGST-alpha-I in both liver and lung was substantiated by Northern and immunochemical analyses. rbGST-alpha-I and rbGST-alpha-II are composed of 223 and 221 amino acids, respectively, and are 78% identical in amino acid sequence. Compared to published GST sequences, both proteins are most closely related to the human Ha subunit (> 80% identity). On the basis of sequence comparison and Northern and Southern analyses, we conclude that rbGST-alpha-I and rbGST-alpha-II are products of different genes that are independently regulated. Further, the regulatory elements of the alpha-class GST genes may be significantly different in the rabbit as compared to the rat, as evidenced by the lack of induction by phenobarbital of rabbit hepatic or pulmonary alpha-class GST subunits, enzymatic activity, or mRNA. This tissue- and species-dependent expression of the predominant class of cytosolic GST implies unique functions for each isozyme and may contribute to the differential susceptibility of tissues and animals to toxicants.	GLAXO INC,RES INST,DEPT DRUG METAB,5 MOORE DR,RES TRIANGLE PK,NC 27709; NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709	GlaxoSmithKline; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BEND JR, 1986, DRUG RELATED DAMAGE, P61; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOW NWI, 1988, J BIOL CHEM, V263, P12797; DANIEL V, 1987, DNA-J MOLEC CELL BIO, V6, P317, DOI 10.1089/dna.1987.6.317; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DING VDH, 1985, ARCH BIOCHEM BIOPHYS, V240, P553, DOI 10.1016/0003-9861(85)90062-1; DOMIN BA, 1984, ANAL BIOCHEM, V136, P390, DOI 10.1016/0003-2697(84)90234-3; ENRIETTO PJ, 1983, CELL, V35, P369, DOI 10.1016/0092-8674(83)90170-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GASSER R, 1988, MOL PHARMACOL, V32, P22; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GREGUS Z, 1985, COMP BIOCHEM PHYS C, V80, P85, DOI 10.1016/0742-8413(85)90135-5; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAYES JD, 1986, BIOCHEM J, V233, P779, DOI 10.1042/bj2330779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI HCJ, 1986, J BIOL CHEM, V261, P3793; LAI HCJ, 1984, J BIOL CHEM, V259, P5536; LAI HCJ, 1986, NUCLEIC ACIDS RES, V14, P6101, DOI 10.1093/nar/14.15.6101; MANIATIS T, 1975, P NATL ACAD SCI USA, V72, P1184, DOI 10.1073/pnas.72.3.1184; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MESSING J, 1983, METHOD ENZYMOL, V101, P20; OMURA T, 1964, J BIOL CHEM, V239, P2379; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PICKETT CB, 1984, J BIOL CHEM, V259, P5182; RHOADS DM, 1987, BIOCHEM BIOPH RES CO, V145, P474, DOI 10.1016/0006-291X(87)91345-3; ROTHKOPF GS, 1986, BIOCHEMISTRY-US, V25, P993, DOI 10.1021/bi00353a007; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERABJITSINGH CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P184, DOI 10.1016/0003-9861(88)90022-7; SIEBERT PD, 1989, CLONTECH CRUISER, V1, P6; Smith GJ, 1980, REV BIOCHEM TOXICOL, V2, P1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TELAKOWSKIHOPKINS CA, 1985, J BIOL CHEM, V260, P5820; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSEND AJ, 1989, J BIOL CHEM, V264, P21582; TU CPD, 1986, BIOCHEM BIOPH RES CO, V141, P229, DOI 10.1016/S0006-291X(86)80358-8; TU CPD, 1984, J BIOL CHEM, V259, P9434; VOS RME, 1990, CHEM-BIOL INTERACT, V75, P241, DOI 10.1016/0009-2797(90)90069-Y; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	45	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19681	19687						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918075				2022-12-25	WOS:A1991GK66700080
J	BRENNAN, MJ; HANNAH, JH; LEININGER, E				BRENNAN, MJ; HANNAH, JH; LEININGER, E			ADHESION OF BORDETELLA-PERTUSSIS TO SULFATIDES AND TO THE GALNAC BETA 4GAL SEQUENCE FOUND IN GLYCOSPHINGOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-EPITHELIAL-CELLS; ACTINOMYCES-NAESLUNDII; FILAMENTOUS HEMAGGLUTININ; MONOCLONAL-ANTIBODIES; BINDING; ADHERENCE; GLYCOLIPIDS; NEUROPATHY; BACTERIA; LECTINS	The adherence of the human respiratory pathogen, Bordetella pertussis, to purified glycosphingolipids was investigated using thin layer chromatography overlay assays. Both virulent and avirulent strains of B. pertussis bound to asialo G(M1). The bacterium did not bind to the gangliosides G(M1), G(D1a), G(D1b), and G(T1b), nor to lactosylceramide, trihexosylceramide, globoside, or Forssman antigen. However, after treatment of the chromatography plates with sialidase, B. pertussis bound to the gangliosides G(M1), G(M2), G(D1a), G(D1b), and G(T1b) but not to G(M3). Comparison of the oligosaccharide structures of these gangliosides suggests that the minimum sugar structure needed for avid bacterial binding is GalNAc-beta-4Gal. This structure has been previously implicated as a receptor for other human respiratory pathogens (Krivan, H. C., Roberts, D. D., Ginsburg, V. (1988) Proc. Natl. Acad. Sci. U. S. A 85, 6157-6161). Virulent strains of B. pertussis also bound specifically to sulfatide. This response was dose-dependent and inhibited by the anionic polysaccharide dextran sulfate. The sulfated-sugars dextran sulfate, fucoidan, and heparin inhibited the attachment of virulent strains of B. pertussis to human WiDr cells and to hamster trachea cells indicating that sulfatides on the surface of mammalian cells may function as a receptor for B. pertussis. The occurrence of both sulfatides and asialo G(M1) in human lung and trachea suggests that these glycolipids may serve as specific receptors for B. pertussis.			BRENNAN, MJ (corresponding author), US FDA, CTR BIOL EVALUAT & RES, DIV BACTERIAL PROD, 8800 ROCKVILLE PIKE, BETHESDA, MD 20892 USA.							ARMSTRONG SK, 1986, J BACTERIOL, V166, P212, DOI 10.1128/jb.166.1.212-216.1986; BABA H, 1989, J NEUROIMMUNOL, V25, P143, DOI 10.1016/0165-5728(89)90131-8; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BOCK K, 1985, J BIOL CHEM, V260, P8545; BRENNAN MJ, 1987, INFECT IMMUN, V55, P487, DOI 10.1128/IAI.55.2.487-489.1987; BRENNAN MJ, 1988, J BIOL CHEM, V263, P4895; BRENNAN MJ, 1986, INFECT IMMUN, V52, P840, DOI 10.1128/IAI.52.3.840-845.1986; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CISAR JO, 1988, MOL MECHANISMS MICRO, P164; DAVIS LE, 1984, PEDIATR INFECT DIS J, V3, P448, DOI 10.1097/00006454-198409000-00015; HANNAH JH, 1990, DHHS FDA901163 DEP H, P141; HANSSON GC, 1984, FEBS LETT, V170, P15, DOI 10.1016/0014-5793(84)81359-9; ISHIKAWA H, 1987, INFECT IMMUN, V55, P1607, DOI 10.1128/IAI.55.7.1607-1609.1987; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; KRIVAN HC, 1989, J BIOL CHEM, V264, P9283; LEDUR A, 1980, J BACTERIOL, V143, P78, DOI 10.1128/JB.143.1.78-88.1980; LEININGER E, 1991, P NATL ACAD SCI USA, V88, P345, DOI 10.1073/pnas.88.2.345; LI ZM, 1988, INFECT IMMUN, V56, P3184; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MENOZZI FD, 1991, FEMS MICROBIOL LETT, V78, P59; OFEK I, 1988, INFECT IMMUN, V56, P539, DOI 10.1128/IAI.56.3.539-547.1988; PLOTKIN BJ, 1984, INFECT IMMUN, V46, P697, DOI 10.1128/IAI.46.3.697-702.1984; QUARLES RH, 1989, METHOD ENZYMOL, V179, P291; RELMAN DA, 1989, P NATL ACAD SCI USA, V86, P2637, DOI 10.1073/pnas.86.8.2637; ROBERTS DD, 1987, METHOD ENZYMOL, V138, P473; ROBERTS DD, 1986, J BIOL CHEM, V261, P6872; SANDBERG AL, 1986, INFECT IMMUN, V54, P472, DOI 10.1128/IAI.54.2.472-476.1986; SHARON N, 1987, FEBS LETT, V217, P145, DOI 10.1016/0014-5793(87)80654-3; STROMBERG N, 1990, J BIOL CHEM, V265, P11251; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; TUOMANEN E, 1985, J INFECT DIS, V152, P118, DOI 10.1093/infdis/152.1.118; TUOMANEN E, 1988, J EXP MED, V168, P267, DOI 10.1084/jem.168.1.267; URISU A, 1986, INFECT IMMUN, V52, P695, DOI 10.1128/IAI.52.3.695-701.1986	33	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18827	18831						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918002				2022-12-25	WOS:A1991GJ47200066
J	OKUNO, H; SUZUKI, T; YOSHIDA, T; HASHIMOTO, Y; CURRAN, T; IBA, H				OKUNO, H; SUZUKI, T; YOSHIDA, T; HASHIMOTO, Y; CURRAN, T; IBA, H			INHIBITION OF JUN TRANSFORMATION BY A MUTATED FOS GENE - DESIGN OF AN ANTIONCOGENE	ONCOGENE			English	Article							CHICKEN-EMBRYO FIBROBLASTS; GROWTH-STIMULATING ACTIVITY; TRANSCRIPTION FACTOR AP-1; LEUCINE ZIPPER PROTEINS; OSTEO-SARCOMA VIRUS; DNA-BINDING DOMAIN; PROTO-ONCOGENE; C-JUN; V-FOS; ANTISENSE RNA	The protein products of the fos and jun oncogenes (Fos and Jun) function as transcriptional regulators in the form of homo- or heterodimeric complexes that bind to DNA. Dimerization is mediated by a leucine zipper structure that serves to juxtapose-alpha-helical regions of each protein, rich in basic amino acids, that form a bipartite DNA-binding domain. Although Fos participates exclusively in heterodimeric complexes, Jun can function either as a homodimer that has a low apparent affinity for DNA or as a more stable heterodimer with Fos that has a higher apparent affinity for DNA. We have used these properties of Fos and Jun to design a mutated fos gene, lacking a functional DNA-binding domain (supfos1), that suppresses the transforming activity of jun in trans. Here we show that chicken embryo fibroblasts transformed by jun revert to a normal phenotype after infection by a retroviral vector encoding supFos1. Furthermore, infection of normal cells with the supfos1 vector renders them resistant to subsequent transformation by jun. Inhibition of jun transformation was associated with the appearance of supFos1-Jun heterodimers and a reduction in the AP-1 DNA-binding activity contributed by Jun homodimers. These findings demonstrate that the function of leucine zipper-containing transcription factors can be investigated by the procedure of intracellular immunization.	UNIV TOKYO,INST MED SCI,DEPT TUMOR VIRUS RES,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; ROCHE INST MOLEC BIOL,ROCHE RES CTR,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	University of Tokyo; Roche Holding			Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Curran, Tom/C-1164-2008	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; OKUNO, HIROYUKI/0000-0001-6237-6503				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; IBA H, 1988, ONCOGENE RES, V2, P121; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KORNBLUTH S, 1986, MOL CELL BIOL, V6, P1545, DOI 10.1128/MCB.6.5.1545; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MILLER AD, 1984, CELL, V36, P259; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; YOSHIDA T, 1989, ONCOGENE RES, V5, P79; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	51	60	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1491	1497						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923517				2022-12-25	WOS:A1991GX27400001
J	TIRUPPATHI, C; GANAPATHY, V; LEIBACH, FH				TIRUPPATHI, C; GANAPATHY, V; LEIBACH, FH			EVIDENCE FOR TRIPEPTIDE-PROTON SYMPORT IN RENAL BRUSH-BORDER MEMBRANE-VESICLES - STUDIES IN A NOVEL RAT STRAIN WITH A GENETIC ABSENCE OF DIPEPTIDYL PEPTIDASE .4.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											TIRUPPATHI, C (corresponding author), MED COLL GEORGIA,DEPT CELL & MOLEC BIOL,AUGUSTA,GA 30912, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028389] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 28389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADDISON JM, 1975, CLIN SCI MOL MED, V49, P305, DOI 10.1042/cs0490305; Adibi S. A., 1981, PHYSL GASTROINTESTIN, V2, P1073; ADIBI SA, 1976, AM J CLIN NUTR, V29, P205, DOI 10.1093/ajcn/29.2.205; ADIBI SA, 1989, J LAB CLIN MED, V113, P665; ADIBI SA, 1987, METABOLISM, V36, P1001, DOI 10.1016/0026-0495(87)90140-5; BERTELOOT A, 1982, BIOCHIM BIOPHYS ACTA, V686, P47, DOI 10.1016/0005-2736(82)90150-X; BERTELOOT A, 1981, BIOCHIM BIOPHYS ACTA, V649, P179, DOI 10.1016/0005-2736(81)90405-3; GANAPATHY V, 1985, AM J PHYSIOL, V249, pG153, DOI 10.1152/ajpgi.1985.249.2.G153; GANAPATHY V, 1983, J BIOL CHEM, V258, P4189; GANAPATHY V, 1986, AM J PHYSIOL, V251, pF945, DOI 10.1152/ajprenal.1986.251.6.F945; GANAPATHY V, 1984, J BIOL CHEM, V259, P8954; GANAPATHY V, 1982, BIOCHIM BIOPHYS ACTA, V691, P362, DOI 10.1016/0005-2736(82)90427-8; GANAPATHY V, 1985, BIOCHIM BIOPHYS ACTA, V816, P234, DOI 10.1016/0005-2736(85)90490-0; GANAPATHY V, 1981, J BIOL CHEM, V256, P118; GANAPATHY V, 1987, ADV BIOSCI, V65, P91; GANAPATHY V, 1987, CONTRIB INFUSION THE, V17, P54; HAMA T, 1982, MOL CELL BIOCHEM, V43, P35; LUCAS M, 1983, GUT, V24, P734, DOI 10.1136/gut.24.8.734; MATTHEWS DM, 1976, GASTROENTEROLOGY, V71, P151; MATTHEWS DM, 1975, PHYSIOL REV, V55, P537, DOI 10.1152/physrev.1975.55.4.537; MIYAMOTO Y, 1985, BIOCHEM BIOPH RES CO, V132, P946, DOI 10.1016/0006-291X(85)91899-6; MIYAMOTO Y, 1987, AM J PHYSIOL, V252, pF670, DOI 10.1152/ajprenal.1987.252.4.F670; RAJENDRAN VM, 1985, AM J PHYSIOL, V248, pG682, DOI 10.1152/ajpgi.1985.248.6.G682; RAJENDRAN VM, 1984, BIOCHIM BIOPHYS ACTA, V778, P443, DOI 10.1016/0005-2736(84)90392-4; SAID HM, 1988, BIOCHIM BIOPHYS ACTA, V941, P232, DOI 10.1016/0005-2736(88)90184-8; SILBERNAGL S, 1987, AM J PHYSIOL, V253, pF448, DOI 10.1152/ajprenal.1987.253.3.F448; SKOPICKI HA, 1988, AM J PHYSIOL, V255, pC822, DOI 10.1152/ajpcell.1988.255.6.C822; STEINHARDT HJ, 1987, CONTRIB INFUSION THE, V17, P91; TAKUWA N, 1985, BIOCHIM BIOPHYS ACTA, V814, P186, DOI 10.1016/0005-2736(85)90435-3; TAKUWA N, 1985, JPN J PHYSIOL, V35, P629, DOI 10.2170/jjphysiol.35.629; TIRUPPATHI C, 1987, PEDIATR RES, V22, P641; TURRINI F, 1989, J MEMBRANE BIOL, V107, P1, DOI 10.1007/BF01871078; WATANABE Y, 1987, EXPERIENTIA, V43, P400, DOI 10.1007/BF01940426	33	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1990	265	4					2048	2053						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CL028	1967607				2022-12-25	WOS:A1990CL02800039
J	CHIN, KV; TANAKA, S; DARLINGTON, G; PASTAN, I; GOTTESMAN, MM				CHIN, KV; TANAKA, S; DARLINGTON, G; PASTAN, I; GOTTESMAN, MM			HEAT-SHOCK AND ARSENITE INCREASE EXPRESSION OF THE MULTIDRUG RESISTANCE (MDR1) GENE IN HUMAN RENAL-CARCINOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									BAYLOR UNIV, DEPT PATHOL, HOUSTON, TX 77030 USA	Baylor University	CHIN, KV (corresponding author), NCI, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.		Chin, Khew-Voon/F-2670-2013; pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437; BANERJI SS, 1987, GENE DEV, V1, P946, DOI 10.1101/gad.1.9.946; BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; BOND U, 1987, ADV GENET, V24, P1, DOI 10.1016/S0065-2660(08)60005-X; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BURDON RH, 1986, BIOCHEM J, V240, P313, DOI 10.1042/bj2400313; BURDON RH, 1982, BRIT J CANCER, V45, P953, DOI 10.1038/bjc.1982.148; FAIRCHILD CR, 1987, P NATL ACAD SCI USA, V84, P7701, DOI 10.1073/pnas.84.21.7701; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FOJO AT, 1987, J CLIN ONCOL, V5, P1922, DOI 10.1200/JCO.1987.5.12.1922; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI GC, 1983, J CELL PHYSIOL, V115, P116, DOI 10.1002/jcp.1041150203; LI GC, 1985, J CELL PHYSIOL, V122, P91, DOI 10.1002/jcp.1041220114; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RICHERT ND, 1988, BIOCHEMISTRY-US, V27, P7607, DOI 10.1021/bi00420a006; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, J BIOL CHEM, V262, P17432; UEDA K, 1987, J BIOL CHEM, V262, P505; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WEBBER MM, 1988, CANCER RES, V48, P4503; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994	30	367	374	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1990	265	1					221	226						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CF662	1967174				2022-12-25	WOS:A1990CF66200036
J	TERRY, MJ; LAGARIAS, JC				TERRY, MJ; LAGARIAS, JC			HOLOPHYTOCHROME ASSEMBLY - COUPLED ASSAY FOR PHYTOCHROMOBILIN SYNTHASE INORGANELLO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED DEVELOPING CHLOROPLASTS; ALGA CYANIDIUM-CALDARIUM; PISUM-SATIVUM-L; CHROMOPHORE BIOSYNTHESIS; 5-AMINOLEVULINIC ACID; BILIVERDIN; PHYCOCYANOBILIN; INVITRO; ARABIDOPSIS; GABACULINE	Utilizing an in vitro coupled assay system, we show that isolated plastids from cucumber cotyledons convert the linear tetrapyrrole biliverdin IX-alpha to the free phytochrome chromophore, phytochromobilin, which assembles with oat apophytochrome to yield photoactive holoprotein. The spectral properties of this synthetic phytochrome are indistinguishable from those of the natural photoreceptor. The plastid-dependent biliverdin conversion activity is strongly stimulated by both NADPH and ATP. Substitution of the nonnatural XIII-alpha isomer of biliverdin for the IX-alpha isomer affords a synthetic holophytochrome adduct with blue-shifted difference spectra. These results, together with experiments using boiled plastids, indicate that phytochromobilin synthesis from biliverdin is enzyme-mediated. Experiments where NADPH (and ATP) levels in intact developing chloroplasts are manipulated by feeding the metabolites 3-phosphoglycerate, dihydroxyacetone phosphate, and glucose 6-phosphate or by illumination with white light, support the hypothesis that the enzyme that accomplishes this conversion, phytochromobilin synthase, is plastid-localized. It is therefore likely that all of the enzymes of the phytochrome chromophore biosynthetic pathway reside in the plastid.	UNIV CALIF DAVIS,DEPT BIOCHEM & BIOPHYS,DAVIS,CA 95616	University of California System; University of California Davis			Terry, Matthew/ABE-6419-2020; Terry, Matthew/B-3000-2012; Lagarias, John Clark/L-3139-2013	Terry, Matthew/0000-0001-5002-2708; Terry, Matthew/0000-0001-5002-2708; Lagarias, John Clark/0000-0002-2093-0403				ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BEALE SI, 1984, PLANT PHYSIOL, V76, P7, DOI 10.1104/pp.76.1.7; BEALE SI, 1983, ARCH BIOCHEM BIOPHYS, V227, P279, DOI 10.1016/0003-9861(83)90372-7; BOWSHER CG, 1989, PLANTA, V177, P359, DOI 10.1007/BF00403594; BROWN SB, 1984, BIOCHEM J, V219, P905, DOI 10.1042/bj2190905; CHORY J, 1989, PLANT CELL, V1, P867, DOI 10.1105/tpc.1.9.867; COLBERT JT, 1983, P NATL ACAD SCI-BIOL, V80, P2248, DOI 10.1073/pnas.80.8.2248; CORNEJO J, 1988, J BIOL CHEM, V263, P11915; ELICH TD, 1988, PLANT PHYSIOL, V88, P747, DOI 10.1104/pp.88.3.747; ELICH TD, 1989, J BIOL CHEM, V264, P12902; ELICH TD, 1989, J BIOL CHEM, V264, P183; ELICH TD, 1987, PLANT PHYSIOL, V84, P304, DOI 10.1104/pp.84.2.304; FUESLER T P, 1984, Plant Physiology (Rockville), V74, P928; FURUYA M, 1987, PHYTOCHROME PHOTOREG; HELDT HW, 1991, PLANT PHYSIOL, V95, P341, DOI 10.1104/pp.95.2.341; HUANG L, 1990, PLANT PHYSIOL, V94, P375, DOI 10.1104/pp.94.1.375; JONES AM, 1986, PLANT PHYSIOL, V81, P1014, DOI 10.1104/pp.81.4.1014; KELLER JM, 1989, CELL CULTURE SOMATIC, V6, P175; KONOMI K, 1986, PLANT CELL PHYSIOL, V27, P1507; LAGARIAS JC, 1989, P NATL ACAD SCI USA, V86, P5778, DOI 10.1073/pnas.86.15.5778; LAGARIAS JC, 1987, PHOTOCHEM PHOTOBIOL, V46, P5, DOI 10.1111/j.1751-1097.1987.tb04729.x; PARKS BM, 1989, PLANT MOL BIOL, V12, P425, DOI 10.1007/BF00017582; QUAIL PH, 1986, PHILOS T ROY SOC B, V314, P469, DOI 10.1098/rstb.1986.0066; RUDIGER W, 1980, Z NATURFORSCH C, V35, P763; THOMAS J, 1990, PLANT PHYSIOL, V94, P1414, DOI 10.1104/pp.94.3.1414; VIESTRA RD, 1986, PHOTOMORPHOGENESIS P, P35; WAHLEITHNER JA, 1991, IN PRESS P NATL ACAD; WONG YS, 1984, PLANT PHYSIOL, V75, P658, DOI 10.1104/pp.75.3.658	29	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22215	22221						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939244				2022-12-25	WOS:A1991GR56400026
J	BAKSH, S; MICHALAK, M				BAKSH, S; MICHALAK, M			EXPRESSION OF CALRETICULIN IN ESCHERICHIA-COLI AND IDENTIFICATION OF ITS CA2+ BINDING DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; AMINO-ACID SEQUENCE; MOLECULAR-CLONING; HIGH-AFFINITY; ENDOPLASMIC-RETICULUM; RYANODINE RECEPTOR; CDNA CLONING; PROTEIN; CALCIUM; CALSEQUESTRIN	Recombinant calreticulin and discrete domains of calreticulin were expressed in Escherichia coli, using the glutathione S-transferase fusion protein system, and their Ca" binding properties were determined. Native calreticulin bound 1 mol of Ca2+/mol of protein with high affinity, and also bound approximately 20 mol of Ca2+/mol of protein with low affinity. Both Ca2+ binding sites were present in the recombinant calreticulin indicating that proper folding of the protein was achieved using this system. Calreticulin is structurally divided into three distinct domains: the N-domain encompassing the first 200 residues; the P-domain which is enriched in proline residues (residue 187-317); and the C-domain which covers the carboxyl-terminal quarter of the protein (residues 310-401), and contains a high concentration of acidic residues. These domains were expressed in E. coli, isolated, and purified, and their Ca2+ binding properties were analyzed. The C-domain bound approximately 18 mol of Ca2+/mol of protein with a dissociation constant of approximately 2 mM. The P-domain bound approximately 0.6-1 mol of Ca2+/ mol of protein with a dissociation constant of approximately 10-mu-M. The P-domain and the C-domain, when expressed together as the P+C-domain, bound Ca2+ with both high affinity and low affinity, reminiscent of both full length recombinant calreticulin and native calreticulin. In contrast the N-domain, did not bind any detectable amount of Ca-45(2+). We conclude that calreticulin has two quite distinct types of Ca2+ binding sites, and that these sites are in different structural regions of the molecule. The P-domain binds Ca2+ with high affinity and low capacity, whereas the C-domain binds Ca2+ with low affinity and high capacity.	UNIV ALBERTA, CARDIOVASC DIS RES GRP, EDMONTON T6G 2S2, ALBERTA, CANADA; UNIV ALBERTA, DEPT PEDIAT, EDMONTON T6G 2S2, ALBERTA, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2S2, ALBERTA, CANADA	University of Alberta; University of Alberta; University of Alberta			Baksh, Shairaz/GRX-2106-2022					Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BAUMANN O, 1991, P NATL ACAD SCI USA, V88, P741, DOI 10.1073/pnas.88.3.741; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FLIEGEL L, 1989, BIOCHEM CELL BIOL, V67, P696, DOI 10.1139/o89-104; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FLIEGEL L, 1989, BIOCHIM BIOPHYS ACTA, V982, P1, DOI 10.1016/0005-2736(89)90166-1; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; JONES LR, 1981, J BIOL CHEM, V256, P1809; KELLY RB, 1990, NATURE, V345, P480, DOI 10.1038/345480a0; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KRAUSE KH, 1990, BIOCHEM J, V270, P545, DOI 10.1042/bj2700545; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACER DRJ, 1988, J CELL SCI, V91, P61; MacLennan D., 1983, CALCIUM CELL FUNCT, V4, P151; MACLENNAN DH, 1973, COLD SPRING HARB SYM, V37, P469, DOI 10.1101/SQB.1973.037.01.058; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P244, DOI 10.1021/bi00349a034; MICHALAK M, 1980, J BIOL CHEM, V255, P1317; MICHALAK M, 1990, J BIOL CHEM, V265, P5869; MILNER RE, 1991, J BIOL CHEM, V266, P7155; Moncrief N.D., 1988, CALCIUM CHANNEL STRU, P16; MURTHY KK, 1990, NUCLEIC ACIDS RES, V18, P4933, DOI 10.1093/nar/18.16.4933; OHNISHI M, 1987, BIOCHEMISTRY-US, V26, P7458, DOI 10.1021/bi00397a039; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SIMON JP, 1989, BIOCHEM J, V262, P1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVES S, 1990, BIOCHEM J, V271, P473, DOI 10.1042/bj2710473; VAN PN, 1989, J BIOL CHEM, V264, P17494; WAISMAN DM, 1985, J BIOL CHEM, V260, P1652; WALKER JM, 1978, NATURE, V271, P281, DOI 10.1038/271281a0; YOO SH, 1991, J BIOL CHEM, V266, P7740; ZAGOURAS P, 1989, J CELL BIOL, V109, P2633, DOI 10.1083/jcb.109.6.2633; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	50	295	306	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21458	21465						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939178				2022-12-25	WOS:A1991GP80400026
J	BARPELED, M; LEWINSOHN, E; FLUHR, R; GRESSEL, J				BARPELED, M; LEWINSOHN, E; FLUHR, R; GRESSEL, J			UDP-RHAMNOSE-FLAVANONE-7-O-GLUCOSIDE-2''-O-RHAMNOSYLTRANSFERASE - PURIFICATION AND CHARACTERIZATION OF AN ENZYME CATALYZING THE PRODUCTION OF BITTER COMPOUNDS IN CITRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCOSE; EXOGENOUS FLAVANONES; CELL-CULTURES; GLUCOSYLTRANSFERASE; GLUCOSYLATION; BIOSYNTHESIS; SEEDLINGS; NARINGIN; EXTRACTS; PROTEINS	The rhamnosyltransferase catalyzing the production of the bitter flavanone-glucosides, naringin and neohesperidin, was purified to homogeneity. The enzyme catalyzes the transfer of rhamnose from UDP-rhamnose to the C-2 hydroxyl group of glucose attached via C-7-O- of naringenin or hesperetin. To our knowledge this is the first complete purification of a rhamnosyltransferase. The enzyme from young pummelo leaves was purified > 2,700-fold to a specific activity of over 600 pmol/min/mg of protein by sequential column chromatographies on Sephacryl S-200, reactive green 19-agarose, and Mono-Q. The enzyme was selectively eluted from the green dye column with only three other proteins by a pulse of the substrate hesperetin-7-O-glucoside followed by UDP. The rhamnosyltransferase is monomeric (approximately 52 kDa) by gel filtration and electrophoresis. The enzyme rhamnosylates only with UDP-rhamnose. Flavonoid-7-O-glucosides are usable acceptors but 5-O-glucosides or aglycones are not. It is inhibited by 10-mu-M UDP, its end product, but not by naringin or neohesperidin. Several flavonoid-aglycones at 100-mu-m inhibited the rhamnosyltransferase; UDP-sugars did not. The K(m) for UDP-rhamnose was similar with prunin (1.3-mu-M) and hesperetin-7-O-glucoside (1.1-mu-M) as substrate. The affinity for the natural acceptor prunin (K(m) = 2.4-mu-M) was much higher than for hesperetin-7-O-glucoside (K(m) = 41.5-mu-M). The isolation of the gene may enable its use in genetic engineering directed to modifying grapefruit bitterness.	WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								BAJAJ KL, 1983, PLANT PHYSIOL, V72, P891, DOI 10.1104/pp.72.3.891; BARBER GA, 1962, BIOCHEMISTRY-US, V1, P463, DOI 10.1021/bi00909a015; BERHOW MA, 1989, PHYTOCHEMISTRY, V26, P1627; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DOONER HK, 1977, P NATL ACAD SCI USA, V74, P5623, DOI 10.1073/pnas.74.12.5623; Ebel J., 1982, FLAVONOIDS ADV RES, P641; FLORINI JR, 1957, BIOCHIM BIOPHYS ACTA, V25, P575, DOI 10.1016/0006-3002(57)90529-2; GAVISH H, 1989, PLANT CELL REP, V8, P391, DOI 10.1007/BF00270076; HOROWITZ RM, 1969, J AGR FOOD CHEM, V17, P696, DOI 10.1021/jf60164a049; HOROWITZ ROBERT M., 1964, P545; JOURDAN PS, 1985, PLANT PHYSIOL, V77, P903, DOI 10.1104/pp.77.4.903; KAMSTEEG J, 1980, Z NATURFORSCH C, V35, P249; KAMSTEEG J, 1979, FEBS LETT, V91, P281; KESTERSON JW, 1953, FLORIDA STATE HORTIC, V65, P223; KLEINEHOLLENHORST G, 1982, Z NATURFORSCH C, V37, P587; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWINSOHN E, 1989, PLANT PHYSIOL, V91, P1323, DOI 10.1104/pp.91.4.1323; LEWINSOHN E, 1989, PLANT SCI, V61, P23, DOI 10.1016/0168-9452(89)90114-3; LEWINSOHN E, 1986, PHYTOCHEMISTRY, V25, P2531, DOI 10.1016/S0031-9422(00)84502-1; MCINTOSH CA, 1990, ARCH BIOCHEM BIOPHYS, V282, P50, DOI 10.1016/0003-9861(90)90085-D; ORTMANN R, 1972, BIOCHIM BIOPHYS ACTA, V289, P293, DOI 10.1016/0005-2744(72)90080-0; PARTRIDGE SM, 1949, NATURE, V164, P443, DOI 10.1038/164443a0; ROUSEFF RL, 1987, J AGR FOOD CHEM, V35, P1027, DOI 10.1021/jf00078a040; SALEH NAM, 1976, PHYTOCHEMISTRY, V15, P1865, DOI 10.1016/S0031-9422(00)88832-9; SCHMID G, 1982, EUR J BIOCHEM, V123, P363, DOI 10.1111/j.1432-1033.1982.tb19776.x; SUTTER A, 1972, BIOCHIM BIOPHYS ACTA, V258, P71, DOI 10.1016/0005-2744(72)90967-9; VANBREDERODE J, 1975, HEREDITY, V35, P429	28	67	78	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20953	20959						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939145				2022-12-25	WOS:A1991GN00100058
J	LIAO, HX; SPREMULLI, LL				LIAO, HX; SPREMULLI, LL			INITIATION OF PROTEIN-SYNTHESIS IN ANIMAL MITOCHONDRIA - PURIFICATION AND CHARACTERIZATION OF TRANSLATIONAL INITIATION FACTOR-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II; EUGLENA-GRACILIS; MESSENGER-RNA; RIBOSOMES; IDENTIFICATION; COMPLEX; LIVER; ASSAY; DNA	Bovine liver mitochondrial translational initiation factor 2 (IF-2mt) has been purified to near homogeneity. The scheme developed results in a 24,000-fold purification of the factor with about 26% recovery of activity. SDS-polyacrylamide gel electrophoresis indicates that IF-2mt has a subunit molecular mass of 85 kDa. IF-2mt promotes the binding of formyl(f)Met-tRNA to mitochondrial ribosomes but is inactive with the nonformylated derivative. IF-2mt is active on chloroplast 30 S ribosomal subunits, but IF-2chl has no activity in promoting fMet-tRNA binding to animal mitochondrial ribosomes. IF-2mt is sensitive to elevated temperatures and is inactivated by treatment with N-ethylmaleimide. It is partially protected from heat and N-ethylmaleimide inactivation by the presence of either GTP or GDP suggesting that guanine nucleotides may bind to this factor directly. The binding of fMet-tRNA to mitochondrial ribosomes requires the presence of GTP and is inhibited by GDP. DeoxyGTP is very effective in replacing GTP in promoting fMet-tRNA binding to ribosomes and some activity is also observed with ITP. No activity is observed with ATP, CTP, or UTP. Nonhydrolyzable analogs of GTP can promote formation of both 28 S and 55 S initiation complexes indicating that GTP hydrolysis is not required for subunit joining in the animal mitochondrial system.	UNIV N CAROLINA,DEPT CHEM CB 3290,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM32734] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; BOMMER UA, 1989, FEBS LETT, V244, P223; CARVALLO P, 1987, FEBS LETT, V215, P109, DOI 10.1016/0014-5793(87)80123-0; CHUNG HKJ, 1990, J BIOL CHEM, V265, P21000; EBERLY SL, 1985, J BIOL CHEM, V260, P8721; GOLD JC, 1985, J BIOL CHEM, V260, P4897; GRAVES MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P192, DOI 10.1016/0003-9861(83)90516-7; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HARBITZ I, 1976, ARCH BIOCHEM BIOPHYS, V176, P766, DOI 10.1016/0003-9861(76)90221-6; Hershey JW., 1987, ESCHERICHIA COLI SAL, P613; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; JURNAK F, 1988, TRENDS BIOCHEM SCI, V13, P195, DOI 10.1016/0968-0004(88)90080-1; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPADAT MA, 1990, PROTEINS, V8, P237, DOI 10.1002/prot.340080306; LIAO HX, 1990, J BIOL CHEM, V265, P11761; LIAO HX, 1990, J BIOL CHEM, V265, P13618; LIAO HX, 1989, J BIOL CHEM, V264, P7518; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA L, 1990, J BIOL CHEM, V265, P13560; MAHLER H R, 1973, Critical Reviews in Biochemistry, V1, P381, DOI 10.3109/10409237309105439; MARECHALDROUARD L, 1988, NUCLEIC ACIDS RES, V16, P4777, DOI 10.1093/nar/16.11.4777; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; MAZUMDER R, 1969, P NATL ACAD SCI USA, V63, P98, DOI 10.1073/pnas.63.1.98; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; OBRIEN TW, 1976, HDB GENETICS, V5, P535; OJALA DK, 1980, NATURE, V287, P79, DOI 10.1038/287079a0; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PLUMBRIDGE JA, 1982, P NATL ACAD SCI-BIOL, V79, P5033, DOI 10.1073/pnas.79.16.5033; PON CL, 1985, J BIOL CHEM, V260, P8918; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2140; REVEL M, 1970, MOL MECHANISMS PROTE, P245; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SUTTLE DP, 1973, BIOCHEM BIOPH RES CO, V51, P376, DOI 10.1016/0006-291X(73)91268-0; WALKER RT, 1972, J BIOL CHEM, V247, P4879; WONG TW, 1986, CELL, V45, P817, DOI 10.1016/0092-8674(86)90556-8; ZALE SE, 1986, BIOCHEMISTRY-US, V25, P5432, DOI 10.1021/bi00367a014	41	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20714	20719						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939122				2022-12-25	WOS:A1991GN00100022
J	KOHARA, A; YAMAMOTO, Y; KIKUCHI, M				KOHARA, A; YAMAMOTO, Y; KIKUCHI, M			ALTERATION OF N-TERMINAL RESIDUES OF MATURE HUMAN LYSOZYME AFFECTS ITS SECRETION IN YEAST AND TRANSLOCATION INTO CANINE MICROSOMAL VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SIGNAL SEQUENCE; PROTEIN TRANSLOCATION; MEMBRANE-VESICLES; DISULFIDE BONDS; ATP; MECHANISM; INVITRO; GLYCOSYLATION	Signal sequences play a central role in the initial membrane translocation of secretory proteins. Their functions depend on factors such as hydrophobicity and conformation of the signal sequences themselves. However, some characteristics of mature proteins, especially those of the N-terminal region, might also affect the function of the signal sequences. To examine this possibility, several mutants of human lysozyme modified in the N-terminal region of the mature protein were constructed, and their secretion in yeast as well as in vitro translocation into canine pancreatic microsomes were analyzed using an idealized signal sequence L8 (MR(L)8PLAALG). Our results show the following. (1) Change in the charge at the N-terminal residue of the mature protein does not affect secretion drastically. (2) Substitution of a proline residue at the N terminus prevents cleavage of the signal sequence, although translocation itself is not impaired. (3) Excessive positive charges in the N-terminal region delay translocation of the precursor protein across the membrane. (4) Polar and negatively charged residues introduced into the N-terminal region affect the secretion of the mature protein by preventing its correct folding.	PROT ENGN RES INST,6-2-3 FURUEDAI,SUITA,OSAKA 565,JAPAN									ALBERTS B, 1989, MOL BIOL CELL, P446; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; EMR SD, 1984, MOL CELL BIOL, V4, P2347, DOI 10.1128/MCB.4.11.2347; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; JIGAMI Y, 1986, GENE, V43, P273, DOI 10.1016/0378-1119(86)90216-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWS JK, 1989, EMBO J, V8, P2095, DOI 10.1002/j.1460-2075.1989.tb03618.x; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; MIYANOHARA A, 1983, P NATL ACAD SCI-BIOL, V80, P1, DOI 10.1073/pnas.80.1.1; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; ROTHBLATT JA, 1986, EMBO J, V5, P1031; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TANIYAMA Y, 1990, J BIOL CHEM, V265, P7570; TANIYAMA Y, 1988, BIOCHEM BIOPH RES CO, V152, P962, DOI 10.1016/S0006-291X(88)80377-2; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; YAMAMOTO Y, 1989, EUR J BIOCHEM, V184, P233, DOI 10.1111/j.1432-1033.1989.tb15011.x; YAMAMOTO Y, 1989, BIOCHEMISTRY-US, V28, P2728, DOI 10.1021/bi00432a054; YAMAMOTO Y, 1987, BIOCHEM BIOPH RES CO, V149, P431, DOI 10.1016/0006-291X(87)90385-8; YAMANE K, 1988, J BIOL CHEM, V263, P19690; YAMANE K, 1987, J BIOL CHEM, V262, P2358; YOSHIMURA K, 1987, BIOCHEM BIOPH RES CO, V145, P712, DOI 10.1016/0006-291X(87)91023-0	32	16	18	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20363	20368						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939091				2022-12-25	WOS:A1991GM03900072
J	QUINN, CP; SINGH, Y; KLIMPEL, KR; LEPPLA, SH				QUINN, CP; SINGH, Y; KLIMPEL, KR; LEPPLA, SH			FUNCTIONAL MAPPING OF ANTHRAX TOXIN LETHAL FACTOR BY IN-FRAME INSERTION MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENYLATE-CYCLASE; PROTECTIVE ANTIGEN GENE; BACILLUS-ANTHRACIS; ESCHERICHIA-COLI; EDEMA FACTOR; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; EUKARYOTIC CELLS; EXPRESSION; TRANSFORMATION	Linker insertion mutagenesis was employed to create structural disruptions of the lethal factor (LF) protein of anthrax toxin to map functional domains. A dodecameric linker was inserted at 17 blunt end restriction enzyme sites throughout the gene. Paired MluI restriction sites within the linker allowed the inserts to be reduced from four to two amino acids. Shuttle vectors containing the mutated genes were transformed into the avirulent Bacillus anthracis UM23C1-1 for expression and secretion of the gene products. Mutations at five sites in the central one-third of the sequence made the protein unstable, and purified protein could not be obtained. Mutated LF proteins with insertions at the other sites were purified and assessed for toxic activity in a macrophage lysis assay and for their ability to bind to the protective antigen (PA) component of anthrax toxin, the receptor binding moiety. Most insertions located in the NH2-terminal one-third of the LF protein eliminated both toxicity and binding to PA, while all four insertions in the COOH-terminal one-third of the protein eliminated toxicity without affecting binding to PA. These data support the hypothesis that the NH2-terminal domain contains the structures required for binding to PA and the COOH-terminal domain contains the putative catalytic domain of LF.	NIDR, MICROBIAL ECOL LAB, BLDG 30, RM 309, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BARANY F, 1985, P NATL ACAD SCI USA, V82, P4202, DOI 10.1073/pnas.82.12.4202; BEALL FA, 1962, J BACTERIOL, V83, P1274, DOI 10.1128/JB.83.6.1274-1280.1962; BHATNAGAR R, 1989, INFECT IMMUN, V57, P2107, DOI 10.1128/IAI.57.7.2107-2114.1989; BOLIVAR F, 1977, GENE, V2, P75, DOI 10.1016/0378-1119(77)90074-9; BRAGG TS, 1989, GENE, V81, P45, DOI 10.1016/0378-1119(89)90335-1; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; ESCUYER V, 1988, GENE, V71, P293, DOI 10.1016/0378-1119(88)90045-5; EZZELL JW, 1984, INFECT IMMUN, V45, P761, DOI 10.1128/IAI.45.3.761-767.1984; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Gill D., 1978, BACTERIAL TOXINS CEL, P291; HAMBLETON P, 1984, Vaccine, V2, P125, DOI 10.1016/0264-410X(84)90003-3; Hambleton P, 1990, Adv Biotechnol Processes, V13, P105; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARRISSMITH PW, 1958, J GEN MICROBIOL, V19, P91, DOI 10.1099/00221287-19-1-91; IVINS BE, 1986, INFECT IMMUN, V54, P537, DOI 10.1128/IAI.54.2.537-542.1986; LABRUYERE E, 1990, BIOCHEMISTRY-US, V29, P4922, DOI 10.1021/bi00472a024; LEPPLA SH, 1988, METHOD ENZYMOL, V165, P103; LEPPLA SH, 1991, METHOD ENZYMOL, V195, P153; LEPPLA SH, 1984, ADV CYCLIC NUCL PROT, V17, P189; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; LEPPLA SH, 1985, MICROBIOLOGY 1985, P63; LEPPLA SH, 1990, SALISBURY MED B S, V68, P41; Leppla SH, 1988, BACTERIAL PROTEIN TO, P111; LITTLE SF, 1990, INFECT IMMUN, V58, P1606, DOI 10.1128/IAI.58.6.1606-1613.1990; LOWE JR, 1990, ABSTRACTS AM SOC MIC; MACALUSO A, 1989, ABSTRACTS AM SOC MIC; MACNEIL DJ, 1988, J BACTERIOL, V170, P5607, DOI 10.1128/jb.170.12.5607-5612.1988; MOCK M, 1988, GENE, V64, P277, DOI 10.1016/0378-1119(88)90342-3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; QUINN CP, 1988, BIOCHEM J, V252, P753, DOI 10.1042/bj2520753; QUINN CP, 1990, J GEN MICROBIOL, V136, P1211, DOI 10.1099/00221287-136-7-1211; REDDY A, 1987, J BACTERIOL, V169, P5263, DOI 10.1128/jb.169.11.5263-5270.1987; ROBERTSON DL, 1988, GENE, V73, P363, DOI 10.1016/0378-1119(88)90501-X; ROBERTSON DL, 1986, GENE, V44, P71, DOI 10.1016/0378-1119(86)90044-2; ROBERTSON DL, 1988, BIOCHEM BIOPH RES CO, V157, P1027, DOI 10.1016/S0006-291X(88)80977-X; ROSS JM, 1957, J PATHOL BACTERIOL, V73, P485, DOI 10.1002/path.1700730219; Sambrook J, 1989, MOL CLONING LABORATO; SINGH Y, 1989, J BIOL CHEM, V264, P11099; SINGH Y, 1989, J BIOL CHEM, V264, P19103; Singh Y, 1990, SALISBURY MED B, V68, P46; SMITH H, 1962, J GEN MICROBIOL, V29, P517, DOI 10.1099/00221287-29-3-517; SMITH H, 1954, NATURE, V173, P869, DOI 10.1038/173869a0; Stephen J., 1986, Pharmacology of bacterial toxins, P381; STONE JC, 1984, CELL, V37, P549, DOI 10.1016/0092-8674(84)90385-4; TIPPETTS MT, 1988, J BACTERIOL, V170, P2263, DOI 10.1128/jb.170.5.2263-2266.1988; Turnbull P. C. B., 1986, Abstracts on Hygiene and Communicable Diseases, V61, pR1; TURNBULL PCB, 1990, SALISBURY MED B S, V68; VODKIN MH, 1983, CELL, V34, P693, DOI 10.1016/0092-8674(83)90402-6; WELKOS SL, 1988, GENE, V69, P287, DOI 10.1016/0378-1119(88)90439-8; XIA ZG, 1990, J BIOL CHEM, V265, P6517	52	69	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20124	20130						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939073				2022-12-25	WOS:A1991GM03900040
J	VANDEERLIN, VMD; TOLLEFSEN, DM				VANDEERLIN, VMD; TOLLEFSEN, DM			THE N-TERMINAL ACIDIC DOMAIN OF HEPARIN COFACTOR-II MEDIATES THE INHIBITION OF ALPHA-THROMBIN IN THE PRESENCE OF GLYCOSAMINOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE; ESCHERICHIA-COLI; BINDING-SITE; REACTIVE SITE; HIGH-AFFINITY; IDENTIFICATION; ANTITHROMBIN; ACTIVATION; EXPRESSION; RESIDUES	Heparin cofactor II (HCII) is a glycoprotein in human plasma that inhibits thrombin and chymotrypsin. Inhibition occurs when the protease attacks the reactive site peptide bond in HCII (Leu444-Ser445) and becomes trapped as a covalent 1:1 complex. Dermatan sulfate and heparin increase the rate of inhibition of thrombin, but not of chymotrypsin, > 1000-fold. The N-terminal portion of HCII contains two acidic repeats (Glu56-Asp-Asp-Asp-Tyr-Leu-Asp and Glu69-Asp-Asp-Asp-Tyr-Ile-Asp) that may bind to anion-binding exosite I of thrombin to facilitate covalent complex formation. To examine the importance of the acidic domain, we have constructed a series of 5' deletions in the HCII cDNA and expressed the recombinant HCII (rHCII) in Escherichia coli. Apparent second-order rate constants (k2) for inhibition of alpha-thrombin and chymotrypsin by each variant were determined. Deletion of amino acid residues 1-74 had no effect on the rate of inhibition of alpha-thrombin or chymotrypsin in the absence of a glycosaminoglycan. Similarly, the rate of inhibition of alpha-thrombin in the presence of a glycosaminoglycan was unaffected by deletion of residues 1-52. However, deletion of residues 1-67 (first acidic repeat) or 1-74 (first and second acidic repeats) greatly decreased the rate of inhibition of alpha-thrombin in the presence of heparin, dermatan sulfate, or a dermatan sulfate hexasaccharide that comprises the minimum high-affinity binding site for HCII. Deletion of one or both of the acidic repeats increased the apparent affinity of rHCII for heparin-Sepharose, suggesting that the acidic domain may interact with the glycosaminoglycan-binding site of native rHCII. The stimulatory effect of glycosaminoglycans on native rHCII was decreased by a C-terminal hirudin peptide which binds to anion-binding exosite I of alpha-thrombin. Furthermore, the ability of native rHCII to inhibit gamma-thrombin, which lacks the binding site for hirudin, was stimulated weakly by glycosaminoglycans. These results support a model in which the stimulatory effect of glycosaminoglycans on the inhibition of alpha-thrombin is mediated, in part, by the N-terminal acidic domain of HCII.	WASHINGTON UNIV,SCH MED,DIV HEMATOL ONCOL,BOX 8125,660 S EUCLID AVE,ST LOUIS,MO 63110	Washington University (WUSTL)					NHLBI NIH HHS [HL-14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER LJ, 1984, MOL CELL BIOCHEM, V61, P159; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; BLINDER MA, 1990, J BIOL CHEM, V265, P286; BRAY B, 1989, BIOCHEM J, V262, P225, DOI 10.1042/bj2620225; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CHURCH FC, 1985, P NATL ACAD SCI USA, V82, P6431, DOI 10.1073/pnas.82.19.6431; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; FENTON JW, 1991, BLOOD COAGUL FIBRIN, V2, P69, DOI 10.1097/00001721-199102000-00011; GRIFFITH MJ, 1983, P NATL ACAD SCI-BIOL, V80, P5460, DOI 10.1073/pnas.80.18.5460; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HORTIN G, 1986, J BIOL CHEM, V261, P5827; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; KAUFMAN DL, 1990, BIOTECHNIQUES, V9, P304; LI E, 1987, J BIOL CHEM, V262, P13773; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; PARKER KA, 1985, J BIOL CHEM, V260, P3501; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1990, J BIOL CHEM, V265, P22386; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEMULLER U, 1986, PROTEINASE INHIBITOR, P337; STONE SR, 1991, BIOCHEMISTRY-US, V30, P3950, DOI 10.1021/bi00230a021; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; WHINNA HC, 1991, J BIOL CHEM, V266, P8129	33	117	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20223	20231						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939083				2022-12-25	WOS:A1991GM03900054
J	INOUE, H; KIMURA, T; MAKABE, O; TAKAHASHI, K				INOUE, H; KIMURA, T; MAKABE, O; TAKAHASHI, K			THE GENE AND DEDUCED PROTEIN SEQUENCES OF THE ZYMOGEN OF ASPERGILLUS-NIGER ACID PROTEINASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSENSITIVE CARBOXYL PROTEINASE; VAR MACROSPORUS; CLEAVAGE SITES; PURIFICATION; PEPSINOGEN; PROTEASES; CLONING; CDNA; POLYADENYLATION; PREDICTIONS	Proteinase A obtained from the culture medium of Aspergillus niger var. macrosporus is a unique acid endopeptidase that is insensitive (or less sensitive) to specific inhibitors of ordinary acid or aspartic proteinases, such as pepstatin, diazoacetyl-DL-norleucine methyl ester, and 1,2-epoxy-3-(p-nitrophenoxy)propane. In the preceding paper (Takahashi, K., Inoue, H., Sakai, K., Kohama, T., Kitahara, S., Takishima, K., Tanji, M., Athauda, S. B. P., Takahashi, T., Akanuma, H., Mamiya, G., Yamasaki, M. J. Biol. Chem. 266, 19480-19483), we reported the complete primary structure of the mature enzyme determined at the protein level. The enzyme has a unique two-chain structure with a 39-residue light (L) chain and a 173-residue heavy (H) chain linked noncovalently. As an extension of this study, we isolated genomic and cDNA clones encoding this proteinase and determined their nucleotide sequences. To isolate a genomic clone, the genomic DNA was selectively amplified by polymerase chain reaction using mixed oligonucleotide primers designed from the amino acid sequence of the H chain, and a specific probe thus generated was used for screening a lambda-gtl0 genomic library. A cDNA for the enzyme was also selectively amplified by polymerase chain reaction using primers synthesized based on the sequence of the genomic DNA. Sequencing of the cloned genomic DNA and cDNA revealed the nucleotide sequence of the structural gene for the enzyme of 846 base pairs without introns. It encodes the precursor form of proteinase A, including an NH2-terminal preprosequence of 59 residues, the L chain of 39 residues, an intervening sequence of 11 residues, and the H chain of 173 residues linked in that order. Thus, proteinase A is thought to be synthesized as a single peptide chain preproenzyme of 282 residues, which is processed to generate the mature two-chain form.	MEIJI SEIKA KAISHA LTD,KOHOKU KU,YOKOHAMA 222,JAPAN	Meiji Holdings Co., Ltd.	INOUE, H (corresponding author), UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN.							BAUDYS M, 1983, EUR J BIOCHEM, V136, P89, DOI 10.1111/j.1432-1033.1983.tb07709.x; BOEL E, 1984, EMBO J, V3, P1097, DOI 10.1002/j.1460-2075.1984.tb01935.x; CHANG WJ, 1976, J BIOCHEM-TOKYO, V80, P975, DOI 10.1093/oxfordjournals.jbchem.a131385; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOLTMANN B, 1977, P NATL ACAD SCI USA, V74, P2321, DOI 10.1073/pnas.74.6.2321; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; HAYANO T, 1988, J BIOL CHEM, V263, P1382; HIGGS DR, 1983, NATURE, V306, P398, DOI 10.1038/306398a0; HORIUCHI S, 1969, SCI PAP COLL GEN ED, V19, P127; HORIUCHI S, 1969, SCI PAP COLL GEN ED, V19, P141; HYNES MJ, 1983, MOL CELL BIOL, V3, P1430, DOI 10.1128/MCB.3.8.1430; ICHIHARA Y, 1985, J BIOCHEM-TOKYO, V98, P683; IDO E, 1987, AGR BIOL CHEM TOKYO, V51, P2855; IIO K, 1976, BIOCHIM BIOPHYS ACTA, V429, P912, DOI 10.1016/0005-2744(76)90336-3; KOAZE Y, 1964, AGR BIOL CHEM TOKYO, V28, P216, DOI 10.1080/00021369.1964.10858233; KOBAYASHI H, 1985, AGR BIOL CHEM TOKYO, V49, P2393, DOI 10.1080/00021369.1985.10867083; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LIN XL, 1990, J BIOL CHEM, V265, P1490; MAITA T, 1984, J BIOCHEM-TOKYO, V95, P465, DOI 10.1093/oxfordjournals.jbchem.a134628; Maniatis T., 1982, MOL CLONING; MONTELL C, 1983, NATURE, V305, P600, DOI 10.1038/305600a0; MURAO S, 1988, AGR BIOL CHEM TOKYO, V52, P1629; MURAO S, 1972, AGR BIOL CHEM TOKYO, V36, P1647, DOI 10.1080/00021369.1972.10860454; ODA K, 1986, AGR BIOL CHEM TOKYO, V50, P651, DOI 10.1080/00021369.1986.10867441; ODA K, 1987, AGR BIOL CHEM TOKYO, V51, P3073; ODA K, 1987, BIOCHIM BIOPHYS ACTA, V923, P463, DOI 10.1016/0304-4165(87)90055-9; PEDERSEN VB, 1973, FEBS LETT, V35, P255, DOI 10.1016/0014-5793(73)80298-4; PERLMANN GE, 1963, J MOL BIOL, V6, P452, DOI 10.1016/S0022-2836(63)80057-1; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTORIS S, 1987, GENE, V56, P301, DOI 10.1016/0378-1119(87)90148-X; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEPANOV VM, 1973, BIOCHEM BIOPH RES CO, V54, P1164, DOI 10.1016/0006-291X(73)90814-0; TAKAHASHI K, 1991, J BIOL CHEM, V266, P19480; TERASHITA T, 1981, AGR BIOL CHEM TOKYO, V45, P1937, DOI 10.1080/00021369.1981.10864821; TERASHITA T, 1984, AGR BIOL CHEM TOKYO, V48, P1029, DOI 10.1080/00021369.1984.10866245; TSURU D, 1986, J BIOCHEM-TOKYO, V99, P1537, DOI 10.1093/oxfordjournals.jbchem.a135624; TSURU D, 1989, AGR BIOL CHEM TOKYO, V53, P1305, DOI 10.1080/00021369.1989.10869464; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611	44	53	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19484	19489						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918060				2022-12-25	WOS:A1991GK66700056
J	JALAL, F; LEMAY, G; ZOLLINGER, M; BERTELOOT, A; BOILEAU, G; CRINE, P				JALAL, F; LEMAY, G; ZOLLINGER, M; BERTELOOT, A; BOILEAU, G; CRINE, P			NEUTRAL ENDOPEPTIDASE, A MAJOR BRUSH-BORDER PROTEIN OF THE KIDNEY PROXIMAL NEPHRON, IS DIRECTLY TARGETED TO THE APICAL DOMAIN WHEN EXPRESSED IN MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE GLYCOPROTEIN; EPITHELIAL-CELLS; SURFACE POLARITY; MONOCLONAL-ANTIBODIES; COS-1 CELLS; MDCK CELLS; BIOGENESIS; DELIVERY; ENZYME; EXOCYTOSIS	We have used a retroviral vector containing both the cDNA for rabbit neutral endopeptidase (EC 3.4.24. 11; NEP) and the neomycin resistance gene to promote the expression of NEP in a polarized Madin-Darby canine kidney (MDCK) cell line. Cells resistant to G418 (a neomycin synthetic analog) were analyzed with a fluorescence-activated cell sorter to isolate a homogeneous population of cells which stably expressed NEP at their surface. When cells grown in Petri dishes were labeled with an antibody to NEP coupled to colloidal gold and examined under the electron microscope, a strong labeling of microvilli was observed, whereas very few particles were present on the basolateral domain, suggesting that the polarized distribution of this enzyme typical of proximal tubule cells is maintained in this MDCK cell population. To study more accurately the mechanism by which MDCK cells target NEP to the apical surface, cultures were grown to confluence on Costar Transwell chambers and used for pulse-chase experiments with [S-35]methionine. Immunoprecipitation of recombinant NEP was then performed by adding an anti-NEP polyclonal antibody to the apical or basolateral surface of intact monolayers and by analyzing immunoprecipitates by gel electrophoresis and fluorography. Our results suggest that NEP is delivered directly to the apical domain and does not transit through the basolateral domain of the plasma membrane. This NEP-expressing MDCK cell line therefore constitutes a new model for investigating the molecular basis of apical membrane targeting in polarized epithelial cells.	UNIV MONTREAL,FAC MED,DEPT BIOCHIM,CP 6128,SUCC A,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV MONTREAL,FAC MED,DEPT PHYSIOL,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV MONTREAL,FAC MED,DEPT MICROBIOL & IMMUNOL,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV MONTREAL,RECH & TRANSPORT MEMBRANAIRE GRP,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal			Lemay, Guy/B-2165-2008	Lemay, Guy/0000-0002-0402-1285				AUBRY M, 1988, BIOCHIM BIOPHYS ACTA, V967, P56, DOI 10.1016/0304-4165(88)90188-2; BALCAROVASTANDER J, 1984, EMBO J, V3, P2687, DOI 10.1002/j.1460-2075.1984.tb02194.x; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; CEREIJIDO M, 1980, J MEMBRANE BIOL, V52, P147, DOI 10.1007/BF01869120; DANIELS PU, 1989, FEBS LETT, V244, P57, DOI 10.1016/0014-5793(89)81161-5; DEDDISH PA, 1990, J BIOL CHEM, V265, P15083; DEMEY J, 1981, CELL BIOL INT REP, V5, P889, DOI 10.1016/0309-1651(81)90204-6; ERDOS EG, 1985, LAB INVEST, V52, P437; FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0; GEE NS, 1983, BIOCHEM J, V214, P377, DOI 10.1042/bj2140377; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HAURI HP, 1979, P NATL ACAD SCI USA, V76, P5183, DOI 10.1073/pnas.76.10.5183; HERZ RE, 1989, J BIOL CHEM, V264, P4605; HERZLINGER DA, 1984, J CELL BIOL, V98, P1777, DOI 10.1083/jcb.98.5.1777; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEMAY G, 1990, BIOCHEM J, V267, P447, DOI 10.1042/bj2670447; LEMAY G, 1989, J BIOL CHEM, V264, P15620; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LOUVARD D, 1980, P NATL ACAD SCI-BIOL, V77, P4132, DOI 10.1073/pnas.77.7.4132; MASSEY D, 1987, J MEMBRANE BIOL, V96, P19, DOI 10.1007/BF01869331; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATTER K, 1990, J BIOL CHEM, V265, P3503; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MISEK DE, 1984, CELL, V39, P537, DOI 10.1016/0092-8674(84)90460-4; PFEIFFER S, 1985, J CELL BIOL, V101, P470, DOI 10.1083/jcb.101.2.470; RINDLER MJ, 1985, J CELL BIOL, V100, P136, DOI 10.1083/jcb.100.1.136; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTH J, 1982, J HISTOCHEM CYTOCHEM, V30, P691, DOI 10.1177/30.7.7050239; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; TRANPATERSON R, 1990, BLOOD, V76, P775; VEGASALAS DE, 1988, J CELL BIOL, V107, P1717, DOI 10.1083/jcb.107.5.1717; WESSELS HP, 1990, J CELL BIOL, V111, P2923, DOI 10.1083/jcb.111.6.2923	39	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19826	19832						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918086				2022-12-25	WOS:A1991GK66700100
J	KIM, WS; NAKAYAMA, K; NAKAGAWA, T; KAWAMURA, Y; HARAGUCHI, K; MURAKAMI, K				KIM, WS; NAKAYAMA, K; NAKAGAWA, T; KAWAMURA, Y; HARAGUCHI, K; MURAKAMI, K			MOUSE SUBMANDIBULAR-GLAND PRORENIN-CONVERTING ENZYME IS A MEMBER OF GLANDULAR KALLIKREIN FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-BINDING-PROTEIN; SUB-MANDIBULAR GLAND; HAMSTER OVARY CELLS; IMMUNOCYTOCHEMICAL LOCALIZATION; PROCESSING ENDOPROTEASE; CDNA SEQUENCE; GENE-PRODUCT; YEAST KEX2; RENIN	Mouse submandibular gland prorenin-converting enzyme (PRECE) consists of the two polypeptide chains of 17 and 10 kDa and cleaves mouse Ren-2 prorenin at a dibasic site to yield mature renin. Western blot analysis using an antiserum against this enzyme gave rise to multiple bands in mouse submandibular glands, suggesting that PRECE is a member of a protease family. Partial amino acid sequence analysis of purified PRECE and cloning and sequence analyses of its cDNA indicated that it is identical to the mGK-13 gene product, epidermal growth factor-binding protein type B, which is a member of the glandular kallikrein family and is involved in maturation of epidermal growth factor. Conditioned medium from Chinese hamster ovary cells transfected with an expression plasmid for PRECE had prorenin converting activity. These results indicate that PRECE is involved in the maturation of two bioactive polypeptides expressed in mouse submandibular glands, Ren-2 renin and epidermal growth factor.	UNIV TSUKUBA, INST BIOL SCI, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, CTR GENE EXPRESS, TSUKUBA, IBARAKI 305, JAPAN; NATL FOOD RES INST, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba; University of Tsukuba; University of Tsukuba; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan			Nakayama, Kazuhisa/ABF-2924-2020	Nakayama, Kazuhisa/0000-0001-7701-7183				BARKA T, 1980, J HISTOCHEM CYTOCHEM, V28, P836, DOI 10.1177/28.8.7003006; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLABER M, 1989, BIOCHEMISTRY-US, V28, P7813, DOI 10.1021/bi00445a043; BLABER M, 1987, BIOCHEMISTRY-US, V26, P6742, DOI 10.1021/bi00395a025; BRADSHAW RA, 1978, ANNU REV BIOCHEM, V47, P191, DOI 10.1146/annurev.bi.47.070178.001203; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHIANG TS, 1968, CIRC RES, V23, P507, DOI 10.1161/01.RES.23.4.507; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; Cohen S, 1974, Recent Prog Horm Res, V30, P551; COHEN S, 1972, BIOCHEMISTRY-US, V11, P4286, DOI 10.1021/bi00773a015; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DRINKWATER CC, 1988, J BIOL CHEM, V263, P8565; DRINKWATER CC, 1987, BIOCHEMISTRY-US, V26, P6750, DOI 10.1021/bi00395a026; EIPPER BA, 1987, PSYCHOPHARMACOLOGY 3, P385; EVANS BA, 1985, EMBO J, V4, P133, DOI 10.1002/j.1460-2075.1985.tb02327.x; EVANS BA, 1987, J BIOL CHEM, V262, P8027; FREY P, 1979, P NATL ACAD SCI USA, V76, P6294, DOI 10.1073/pnas.76.12.6294; FUKUSHIMA D, 1985, BIOCHEMISTRY-US, V24, P8037, DOI 10.1021/bi00348a030; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GRESIK E, 1977, J HISTOCHEM CYTOCHEM, V25, P1027, DOI 10.1177/25.9.333017; GRESIK E, 1978, J HISTOCHEM CYTOCHEM, V26, P855, DOI 10.1177/26.10.363930; HATSUZAWA K, 1990, J BIOCHEM-TOKYO, V107, P854, DOI 10.1093/oxfordjournals.jbchem.a123137; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOLM I, 1984, EMBO J, V3, P557, DOI 10.1002/j.1460-2075.1984.tb01846.x; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Inagami T., 1981, BIOCH REGULATION BLO, P39; IRIE A, 1985, JPN J CLIN CHEM, V14, P27; ISHIZUKA Y, 1988, BIOCHEM BIOPH RES CO, V152, P849, DOI 10.1016/S0006-291X(88)80116-5; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KIKUNO Y, 1983, J BIOCHEM, V93, P235, DOI 10.1093/oxfordjournals.jbchem.a134158; KIM WS, 1990, J BIOL CHEM, V265, P5930; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; LUNDGREN S, 1984, J BIOL CHEM, V259, P7780; MASUDA T, 1982, BIOMED RES-TOKYO, V3, P541, DOI 10.2220/biomedres.3.541; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P6719, DOI 10.1093/nar/18.22.6719; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; NAGAHAMA M, 1991, EUR J BIOCHEM, V197, P135, DOI 10.1111/j.1432-1033.1991.tb15891.x; NAKAYAMA K, 1989, BIOCHEM BIOPH RES CO, V158, P369, DOI 10.1016/S0006-291X(89)80057-9; NAKAYAMA K, 1990, J BIOL CHEM, V265, P21027; NAKAYAMA K, 1989, FEBS LETT, V257, P89, DOI 10.1016/0014-5793(89)81793-4; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NEXO E, 1981, ACTA PHYSIOL SCAND, V111, P367, DOI 10.1111/j.1748-1716.1981.tb06749.x; PEDERSEN EB, 1983, ACTA ENDOCRINOL-COP, V104, P510, DOI 10.1530/acta.0.1040510; RE R, 1982, LIFE SCI, V30, P99, DOI 10.1016/0024-3205(82)90641-5; REID IA, 1978, ANNU REV PHYSIOL, V40, P377, DOI 10.1146/annurev.ph.40.030178.002113; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHINAGAWA T, 1990, P NATL ACAD SCI USA, V87, P1927, DOI 10.1073/pnas.87.5.1927; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SUZUKI F, 1990, AGR BIOL CHEM TOKYO, V54, P2407, DOI 10.1080/00021369.1990.10870306; TAKADA Y, 1985, BIOCHEM J, V232, P851, DOI 10.1042/bj2320851; TAYLOR JM, 1974, J BIOL CHEM, V249, P2188; TAYLOR JM, 1974, J BIOL CHEM, V249, P3198; TAYLOR JM, 1970, P NATL ACAD SCI USA, V67, P164, DOI 10.1073/pnas.67.1.164; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANLEEUWEN BH, 1986, J BIOL CHEM, V261, P5529; WILSON CM, 1981, BIOCHEM GENET, V19, P509, DOI 10.1007/BF00484623	63	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19283	19287						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918045				2022-12-25	WOS:A1991GK66700029
J	MOYLE, M; NAPIER, MA; MCLEAN, JW				MOYLE, M; NAPIER, MA; MCLEAN, JW			CLONING AND EXPRESSION OF A DIVERGENT INTEGRIN SUBUNIT BETA-8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PLATELET GLYCOPROTEIN-IIIA; ALPHA-V SUBUNIT; FIBRONECTIN RECEPTOR; EPITHELIAL-CELLS; VITRONECTIN RECEPTOR; CYTOPLASMIC DOMAIN; MESSENGER-RNA; PROTEIN; CDNA	Rabbit and human cDNA clones have been identified that encode a novel integrin beta-subunit. The sequences that encode this subunit, which has been designated as beta-8, were isolated initially from rabbit placental cDNA libraries using an oligonucleotide probe derived from a highly conserved region of integrin beta-subunit sequences. The rabbit clone was used to isolate human beta-8-cDNA clones from human placental and MG-63 osteosarcoma cell libraries. The putative beta-8-polypeptides, which comprise 769 and 768 residues in human and rabbit, respectively, show a high degree of inter-species conservation (approximately 90% identity). In contrast, beta-8 is distinct from the other integrin beta-subunits. At the amino acid level human beta-8 ranges from 31 to 37% identity with human beta-1-7. The domain structure of beta-8 is typical of the integrin beta-subunits. Human beta-8 has a 42-residue N-terminal signal peptide, a large extracellular domain (approximately 639 residues) that contains four cysteine-rich repeats, a transmembrane domain (approximately 30 residues), and a C-terminal cytoplasmic domain (approximately 58 residues). There are several structural features that are unique to the beta-8 polypeptide, as compared with the other integrin beta-subunits. Six of the 56 cysteine residues that are conserved within the extracellular domains of beta-1, beta-2, beta-3, beta-5, beta-6, and the beta-subunit from Drosophila are absent in the beta-8-polypeptide. Also, the cytoplasmic domain of the beta-8 subunit shares no homology with the cytoplasmic regions of any of the other integrin beta-subunits. Northern analysis demonstrated an approximately 8-kilobase beta-8 mRNA in rabbit placenta, kidney, brain, ovary, and uterus. PCR analysis revealed that beta-8 mRNA is also present in several transformed human cell lines. The beta-8-polypeptide has been transiently expressed in 293 human embryonic kidney cells. A polyclonal antipeptide antibody specific for beta-8 and a polyclonal antibody that recognizes a, epitopes were used to show that beta-8 can complex with the endogenous alpha-v-subunit in 293 cells and that the resulting integrin is expressed as a cell surface complex.	GENENTECH INC, DEPT CELL BIOL, 460 PT SAN BRUNO BLVD, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT CARDIOVASC RES, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech								ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARGRAVES WS, 1989, CELL, V58, P623, DOI 10.1016/0092-8674(89)90097-4; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; ERLE DJ, 1991, J BIOL CHEM, V266, P11009; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; HEMLER ME, 1989, J BIOL CHEM, V264, P6529; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKRELL AJ, 1988, P NATL ACAD SCI USA, V85, P2633, DOI 10.1073/pnas.85.8.2633; MCDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; PHILLIPS DR, 1977, J BIOL CHEM, V252, P2121; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RICCA GA, 1981, J BIOL CHEM, V256, P362; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; SUZUKI S, 1986, P NATL ACAD SCI USA, V83, P8614, DOI 10.1073/pnas.83.22.8614; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; SUZUKI S, 1990, P NATL ACAD SCI USA, V87, P5354, DOI 10.1073/pnas.87.14.5354; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TANFORD C, 1978, SCIENCE, V200, P1012, DOI 10.1126/science.653353; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YUAN Q, 1990, INT IMMUNOL, V2, P1097, DOI 10.1093/intimm/2.11.1097; ZIMRIN AB, 1990, J BIOL CHEM, V265, P8590	46	165	171	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19650	19658						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918072				2022-12-25	WOS:A1991GK66700076
J	NAKAMURA, H; YOSHIMURA, K; JAFFE, HA; CRYSTAL, RG				NAKAMURA, H; YOSHIMURA, K; JAFFE, HA; CRYSTAL, RG			INTERLEUKIN-8 GENE-EXPRESSION IN HUMAN BRONCHIAL EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE; CHEMOTACTIC FACTOR; POLYMORPHONUCLEAR LEUKOCYTES; ALPHA-1-PROTEINASE INHIBITOR; MAMMALIAN-CELLS; LYMPHOCYTES-T; MESSENGER-RNA; PROTEIN; RELEASE; LUNG	The capacity of cells of the human bronchial epithelium to express the gene for interleukin-8 (IL-8) was evaluated in bronchial epithelium derived cell lines, HS-24 and BET-1A, using tumor necrosis factor-alpha (TNF) as a model inflammatory stimulus. As in other epithelium, TNF markedly increased the level of the 1.8-kilobase IL-8 mRNA transcripts in both bronchial epithelial cell lines. In HS-24 cells, nuclear run-on analyses showed the IL-8 gene transcription rate was dramatically increased, more than 30-fold, after TNF stimulation. The half-life of IL-8 mRNA transcripts in these cells was approximately 40 min and did not change after TNF stimulation, suggesting that TNF up-regulated IL-8 gene expression mainly at the transcriptional level. DNase I hypersensitivity site mapping of chromatin DNA in resting HS-24 cells demonstrated two hypersensitivity sites within 400 base pairs (bp) 5' to exon I and one site within exon I. However, after TNF stimulation, the exon I hypersensitivity site disappeared and a new site approximately 120 bp 5' to exon I emerged. Consistent with these observations, transfection studies with HS-24 cells using fusion genes composed of the 5'-flanking sequences of the IL-8 gene and a luciferase reporter gene demonstrated potent promoter activity in a 174-bp segment (-130 to +44 relative to the transcription start site), which also exhibited a response to TNF, while a segment from -112 to +44 showed very low promoter activity and no response to TNF. Thus, human bronchial epithelial cells can express the IL-8 gene, with expression in response to the inflammatory mediator TNF regulated mainly at the transcriptional level, and with elements within the 5'-flanking region of the gene that are directly or indirectly modulated by the TNF signal.	NHLBI,PULM BRANCH,BLDG 10,RM 6D03,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								APPELHANS B, 1987, FEBS LETT, V224, P14, DOI 10.1016/0014-5793(87)80413-1; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEZE RG, 1977, AM REV RESPIR DIS, V116, P705, DOI 10.1164/arrd.1977.116.4.705; BURROWS LJ, 1989, CYTOKINE, V1, P100; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE SW, 1991, LUNG, P1845; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; CRYSTAL RG, 1991, LUNG SCI FDN, P527; DAHINDEN CA, 1989, J EXP MED, V170, P1787, DOI 10.1084/jem.170.5.1787; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELNER VM, 1990, AM J PATHOL, V136, P745; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRANTE A, 1982, J IMMUNOL METHODS, V48, P81, DOI 10.1016/0022-1759(82)90212-5; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREGORY H, 1988, BIOCHEM BIOPH RES CO, V151, P883, DOI 10.1016/S0006-291X(88)80364-4; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARVATH L, 1980, J IMMUNOL METHODS, V37, P39, DOI 10.1016/0022-1759(80)90179-9; HUNNINGHAKE GW, 1981, SCIENCE, V212, P925, DOI 10.1126/science.7233186; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; KOYAMA S, 1989, AM J PHYSIOL, V257, pL130, DOI 10.1152/ajplung.1989.257.2.L130; LARSEN CG, 1989, IMMUNOLOGY, V68, P31; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEONARD EJ, 1990, AM J RESP CELL MOL, V2, P479, DOI 10.1165/ajrcmb/2.6.479; LIU JM, 1991, VIROLOGY, V182, P361, DOI 10.1016/0042-6822(91)90682-2; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RANKIN JA, 1990, J CLIN INVEST, V86, P1556, DOI 10.1172/JCI114875; REDDEL RR, 1988, CANCER RES, V48, P190; RENNARD SI, 1981, P NATL ACAD SCI-BIOL, V78, P7147, DOI 10.1073/pnas.78.11.7147; RENNARD SI, 1991, LUNG, P157; REYNOLDS HY, 1991, LUNG SCI FDN, P1899; ROBBINS RA, 1989, AM J PHYSIOL, V257, pL109, DOI 10.1152/ajplung.1989.257.2.L109; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID J, 1987, J IMMUNOL, V139, P250; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHEFFERY M, 1984, J MOL BIOL, V172, P417, DOI 10.1016/S0022-2836(84)80015-7; SHOJI S, 1987, CLIN RES, V35, pA539; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; STRIETER RM, 1990, AM J RESP CELL MOL, V2, P321, DOI 10.1165/ajrcmb/2.4.321; STRIETER RM, 1989, J BIOL CHEM, V264, P10621; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; SUZUKI K, 1989, J EXP MED, V169, P1895, DOI 10.1084/jem.169.6.1895; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527, DOI 10.1164/ajrccm/140.6.1527; WANNER A, 1988, AM REV RESPIR DIS, V138, pS1, DOI 10.1164/ajrccm/138.6_Pt_2.S1; WARREN JS, 1991, LUNG SCI F, P1939; WATSON ML, 1988, IMMUNOLOGY, V65, P567; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	63	252	257	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19611	19617						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918068				2022-12-25	WOS:A1991GK66700071
J	RANGAN, VS; WITKOWSKI, A; SMITH, S				RANGAN, VS; WITKOWSKI, A; SMITH, S			ISOLATION OF A FUNCTIONAL TRANSFERASE COMPONENT FROM THE RAT FATTY-ACID SYNTHASE BY LIMITED TRYPSINIZATION OF THE SUBUNIT MONOMER - FORMATION OF A STABLE FUNCTIONAL COMPLEX BETWEEN TRANSFERASE AND ACYL CARRIER PROTEIN DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLASS-FIBER SHEETS; MALONYL-COENZYME-A; ESCHERICHIA-COLI; THIOESTERASE COMPONENT; MICROSEQUENCE ANALYSIS; STRUCTURAL PROTEINS; MAMMARY-GLAND; SYNTHETASE; PURIFICATION; ENZYME	Limited trypsinization of rat fatty acid synthase monomers results in cleavage at sites protected in the native dimer. A 47,000-Da polypeptide containing the transferase component was isolated from the digest and its location in the multifunctional polypeptide established. Both acetyl and malonyl moieties are transferred stoichiometrically from CoA ester to this polypeptide and each can replace the other, confirming that a single common site is utilized in the loading of these substrates onto the fatty acid synthase. Transferase activity of the 47,000-Da polypeptide decreases with increasing acyl donor chain length (malonyl = acetyl > butyryl > hexanoyl > octanoyl). Activity is inhibited by certain thiol-directed reagents, and protection is afforded by substrate suggesting the presence of a sensitive cysteine residue near the substrate binding site. The transferase was also able to utilize as acyl acceptor the Escherichia coli acyl carrier protein and the acyl carrier protein domain of the multifunctional fatty acid synthase. When the fatty acid synthase monomer was trypsinized under milder conditions, the 47,000-Da transferase domain could be isolated in association with the 8,000-Da acyl carrier protein domain. The transferase was capable of translocating substrate moieties from CoA ester donors to the associated acyl carrier protein. The results provide the first direct evidence that, in the head-to-tail oriented fatty acid synthase homodimer, functional communication between the transferase domain located near the end of one polypeptide and the acyl carrier protein domain located at the opposite end of the other polypeptide is facilitated by a stable physical interaction between these domains.	CHILDRENS HOSP,OAKLAND RES INST,747 52ND ST,OAKLAND,CA 94609	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute				Witkowski, Andrzej/0000-0002-0442-4586	NIDDK NIH HHS [DK 16073] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; ANDERSON VE, 1985, BIOCHEMISTRY-US, V24, P2147, DOI 10.1021/bi00330a007; FIESER LF, 1941, EXPT ORGANIC CHEM, P419; JOSHI VC, 1971, ARCH BIOCHEM BIOPHYS, V143, P493, DOI 10.1016/0003-9861(71)90234-7; JOSHI VC, 1970, J BIOL CHEM, V245, P2857; KUMAR S, 1975, J BIOL CHEM, V250, P5150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CY, 1978, J BIOL CHEM, V253, P1954; LINN TC, 1981, ARCH BIOCHEM BIOPHYS, V209, P613, DOI 10.1016/0003-9861(81)90320-9; LINN TC, 1979, J BIOL CHEM, V254, P1691; MATTICK JS, 1983, J BIOL CHEM, V258, P5300; MCCARTHY AD, 1983, FEBS LETT, V162, P300, DOI 10.1016/0014-5793(83)80776-5; MCCARTHY AD, 1983, EUR J BIOCHEM, V136, P501, DOI 10.1111/j.1432-1033.1983.tb07769.x; MCCARTHY AD, 1983, FEBS LETT, V160, P296, DOI 10.1016/0014-5793(83)80986-7; MIKKELSEN J, 1985, BIOCHEM J, V227, P981, DOI 10.1042/bj2270981; NIXON JE, 1970, ARCH BIOCHEM BIOPHYS, V138, P372, DOI 10.1016/0003-9861(70)90359-0; PLATE CA, 1970, J BIOL CHEM, V245, P2868; PLOWMAN KM, 1967, J BIOL CHEM, V242, P4239; RUCH FE, 1973, J BIOL CHEM, V248, P8095; SHIMAKATA T, 1983, J BIOL CHEM, V258, P3592; Smith S, 1981, Methods Enzymol, V71 Pt C, P188, DOI 10.1016/0076-6879(81)71027-9; SMITH S, 1976, P NATL ACAD SCI USA, V73, P1184, DOI 10.1073/pnas.73.4.1184; SMITH S, 1985, EUR J BIOCHEM, V152, P547, DOI 10.1111/j.1432-1033.1985.tb09230.x; SMITH S, 1979, ARCH BIOCHEM BIOPHYS, V197, P379, DOI 10.1016/0003-9861(79)90259-5; SMITH S, 1983, ARCH BIOCHEM BIOPHYS, V222, P259, DOI 10.1016/0003-9861(83)90523-4; SMITH S, 1971, J BIOL CHEM, V246, P6428; STAPLETON SR, 1984, BIOCHIM BIOPHYS ACTA, V794, P240, DOI 10.1016/0005-2760(84)90151-6; STERN A, 1982, J BIOL CHEM, V257, P799; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WITKOWSKI A, 1991, EUR J BIOCHEM, V198, P571, DOI 10.1111/j.1432-1033.1991.tb16052.x; WITKOWSKI A, 1990, FASEB J, V4, pA2128; XU QY, 1988, ANAL BIOCHEM, V170, P19, DOI 10.1016/0003-2697(88)90084-X	32	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19180	19185						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918034				2022-12-25	WOS:A1991GK66700013
J	SHAPIRA, R; NUSS, DL				SHAPIRA, R; NUSS, DL			GENE-EXPRESSION BY A HYPOVIRULENCE-ASSOCIATED VIRUS OF THE CHESTNUT BLIGHT FUNGUS INVOLVES 2 PAPAIN-LIKE PROTEASE ACTIVITIES - ESSENTIAL RESIDUES AND CLEAVAGE SITE REQUIREMENTS FOR P48 AUTOPROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT POTYVIRUS GENOME; CYSTEINE PROTEINASES; NUCLEOTIDE-SEQUENCE; DNA; POLYPROTEINS; TRANSLATION; RNA	Proteolytic processing plays a fundamental role in gene expression of a recently characterized viral-like double-stranded RNA associated with biological control of the chestnut blight fungus. Polypeptide p29, a papain-like protease, was shown to autocatalytically release itself from the NH2 terminus of the polyprotein specified by the first of two encoded open reading frames, ORF A (Choi, G. H., Shapira, R., and Nuss, D. L. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1167-1171; Choi, G. H., Pawlyk, D. M.. and Nuss, D. L. (1991) Virology 183, 747-752). The characterization of a second autocatalytic protease, p48, which is encoded by ORF B, is the subject of this report. Deletion analysis revealed that the catalytic domain resides within the carboxyl-terminal region, while site-specific mutational analysis identified Cys-341 and His-388 as residues essential for autoproteolysis. Autoproteolytic processing by p48 was also demonstrated when expressed in Escherichia coli and microsequence analysis of the recovered COOH-terminal cleavage product indicated that cleavage occurred between Gly-418 and Ala-419. The requirements for a functional cleavage site, including confirmation of the cleavage dipeptide, were defined by amino acid substitution analysis. Similarities between p29 and p48 suggest that the respective coding domains could have arisen as a result of a gene duplication event.			SHAPIRA, R (corresponding author), ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT MOLEC ONCOL & VIROL, NUTLEY, NJ 07110 USA.							ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ALLISON R, 1986, VIROLOGY, V154, P9, DOI 10.1016/0042-6822(86)90425-3; ANAGNOSTAKIS SL, 1982, SCIENCE, V215, P466, DOI 10.1126/science.215.4532.466; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; CARRINGTON JC, 1987, VIROLOGY, V160, P355, DOI 10.1016/0042-6822(87)90006-7; CARRINGTON JC, 1987, J VIROL, V61, P2540, DOI 10.1128/JVI.61.8.2540-2548.1987; CARRINGTON JC, 1989, EMBO J, V8, P365, DOI 10.1002/j.1460-2075.1989.tb03386.x; CHOI GH, 1991, VIROLOGY, V183, P747, DOI 10.1016/0042-6822(91)91004-Z; CHOI GH, 1991, P NATL ACAD SCI USA, V88, P1167, DOI 10.1073/pnas.88.4.1167; DAVIDSON AD, 1991, J GEN VIROL, V72, P989, DOI 10.1099/0022-1317-72-4-989; DOMIER L, 1986, NUCLEIC ACIDS RES, V14, P5417; FULBRIGHT DW, 1990, UCLA S MOL CELL BIOL, V2, P121; Griffin G. J., 1986, Horticultural Reviews, V8, P291, DOI 10.1002/9781118060810.ch8; HARDY WR, 1989, J VIROL, V63, P4653, DOI 10.1128/JVI.63.11.4653-4664.1989; KASHIWAZAKI S, 1991, J GEN VIROL, V72, P995, DOI 10.1099/0022-1317-72-4-995; KASHIWAZAKI S, 1990, J GEN VIROL, V71, P2781, DOI 10.1099/0022-1317-71-12-2781; KOONIN EV, 1991, IN PRESS P NATL ACAD; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I; LOWE G, 1976, TETRAHEDRON, V32, P291, DOI 10.1016/0040-4020(76)80040-3; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NUSS DL, 1990, ANNU REV PHYTOPATHOL, V28, P37, DOI 10.1146/annurev.py.28.090190.000345; OH CS, 1989, VIROLOGY, V173, P692, DOI 10.1016/0042-6822(89)90582-5; POLGAR L, 1982, BIOCHEM J, V207, P1; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; RICH DH, 1986, PROTEINASE INHIBITOR, P153; Roane MK, 1986, CHESTNUT BLIGHT OTHE, P53; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHAPIRA R, 1991, EMBO J, V10, P731, DOI 10.1002/j.1460-2075.1991.tb08004.x; VANALFEN NK, 1987, EXTRACHROMOSOMAL ELE, P227; WELLINK J, 1988, ARCH VIROL, V98, P1, DOI 10.1007/BF01321002	35	63	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19419	19425						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918054				2022-12-25	WOS:A1991GK66700047
J	SHORE, EM; NELSON, WJ				SHORE, EM; NELSON, WJ			BIOSYNTHESIS OF THE CELL-ADHESION MOLECULE UVOMORULIN (E-CADHERIN) IN MADIN-DARBY CANINE KIDNEY EPITHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; L-CAM; EMBRYONIC HISTOGENESIS; ANIMAL MORPHOGENESIS; CYTOPLASMIC DOMAIN; SURFACE POLARITY; MEMBRANE; IDENTIFICATION; EXPRESSION; PROTEINS	The Ca2+-dependent cell adhesion molecule uvomorulin is a transmembrane glycoprotein that functions at the cell surface to regulate epithelial cell recognition and adhesion. We have investigated the temporal and spatial regulation of uvomorulin biosynthesis and cell surface expression in Madin-Darby canine kidney epithelial cells. We show that uvomorulin is synthesized as a precursor polypeptide (M(r) 135,000) that is core glycosylated in the endoplasmic reticulum. The precursor is processed to the mature polypeptide (M(r) 120,000) shortly after addition of complex carbohydrate groups in the late Golgi complex, but prior to delivery of the polypeptide to the cell surface. However, glycosylation is not required for either efficient processing of the precursor or transport of uvomorulin to the cell surface. At the cell surface, uvomorulin is turned over rapidly (t1/2 approximately 5 h). Induction of Ca2+-dependent cell-cell contact results in rapid localization of cell surface uvomorulin to regions of contact and an increase in the proportion of uvomorulin that is insoluble in buffers containing Triton X-100. These results indicate several regulatory steps in the biosynthesis and cell surface expression of uvomorulin in epithelial cells.	FOX CHASE CANC INST,INST CANC RES,PHILADELPHIA,PA 19111	Fox Chase Cancer Center			Shore, Eileen/D-2593-2009		NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035527, R01GM035527] Funding Source: NIH RePORTER; NCI NIH HHS [CA 06927] Funding Source: Medline; NCRR NIH HHS [RR 05539] Funding Source: Medline; NIGMS NIH HHS [GM 35527] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONICEK H, 1987, J CELL BIOL, V104, P1587, DOI 10.1083/jcb.104.6.1587; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; BOYER B, 1989, J MEMBRANE BIOL, V112, P97, DOI 10.1007/BF01871271; BUSKIRK DR, 1980, NATURE, V285, P488, DOI 10.1038/285488a0; CROSSIN KL, 1985, P NATL ACAD SCI USA, V82, P6942, DOI 10.1073/pnas.82.20.6942; CUNNINGHAM BA, 1984, P NATL ACAD SCI-BIOL, V81, P5787, DOI 10.1073/pnas.81.18.5787; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; EDELMAN GM, 1984, P NATL ACAD SCI-BIOL, V81, P1460, DOI 10.1073/pnas.81.5.1460; GALLIN WJ, 1987, P NATL ACAD SCI USA, V84, P2808, DOI 10.1073/pnas.84.9.2808; GALLIN WJ, 1983, P NATL ACAD SCI-BIOL, V80, P1038, DOI 10.1073/pnas.80.4.1038; GALLIN WJ, 1986, P NATL ACAD SCI USA, V83, P8234; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; HIRAI Y, 1989, DEVELOPMENT, V105, P271; HIRAI Y, 1989, DEVELOPMENT, V105, P263; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; HOFFMAN S, 1986, J CELL BIOL, V103, P145, DOI 10.1083/jcb.103.1.145; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HYAFIL F, 1981, CELL, V26, P447, DOI 10.1016/0092-8674(81)90214-2; HYAFIL F, 1980, CELL, V21, P927, DOI 10.1016/0092-8674(80)90456-0; KEMLER R, 1977, P NATL ACAD SCI USA, V74, P4449, DOI 10.1073/pnas.74.10.4449; KLEIN G, 1988, DEVELOPMENT, V102, P749; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MISFELDT DS, 1976, P NATL ACAD SCI USA, V73, P1212, DOI 10.1073/pnas.73.4.1212; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NELSON WJ, 1987, J CELL BIOL, V104, P1527, DOI 10.1083/jcb.104.6.1527; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; OJAKIAN GK, 1990, AM J PHYSIOL, V258, pC390, DOI 10.1152/ajpcell.1990.258.3.C390; OVERTON J, 1982, DEV BIOL, V92, P66, DOI 10.1016/0012-1606(82)90151-8; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; PASDAR M, 1989, J CELL BIOL, V109, P163, DOI 10.1083/jcb.109.1.163; PASDAR M, 1988, J CELL BIOL, V106, P687, DOI 10.1083/jcb.106.3.687; PEYRIERAS N, 1985, P NATL ACAD SCI USA, V82, P8067, DOI 10.1073/pnas.82.23.8067; PEYRIERAS N, 1983, P NATL ACAD SCI-BIOL, V80, P6274, DOI 10.1073/pnas.80.20.6274; PLUMMER TH, 1981, J BIOL CHEM, V256, P243; RINDLER MJ, 1979, J CELL BIOL, V81, P635, DOI 10.1083/jcb.81.3.635; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAKEICHI M, 1987, TRENDS GENET, V3, P213, DOI 10.1016/0168-9525(87)90238-1; Tarentino A L, 1978, Methods Enzymol, V50, P574; THIERY JP, 1984, DEV BIOL, V102, P61, DOI 10.1016/0012-1606(84)90175-1; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VESTWEBER D, 1985, DEV BIOL, V112, P213, DOI 10.1016/0012-1606(85)90135-6; VESTWEBER D, 1987, DEV BIOL, V124, P451, DOI 10.1016/0012-1606(87)90498-2	56	199	200	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19672	19680						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918074				2022-12-25	WOS:A1991GK66700079
J	MUNGER, JS; SHI, GP; MARK, EA; CHIN, DT; GERARD, C; CHAPMAN, HA				MUNGER, JS; SHI, GP; MARK, EA; CHIN, DT; GERARD, C; CHAPMAN, HA			A SERINE ESTERASE RELEASED BY HUMAN ALVEOLAR MACROPHAGES IS CLOSELY RELATED TO LIVER MICROSOMAL CARBOXYLESTERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; GLYCOPROTEIN ESTERASE; ENDOPLASMIC-RETICULUM; PLASMINOGEN-ACTIVATOR; NUCLEOTIDE-SEQUENCE; HUMAN-LUNG; PURIFICATION; PROTEINS; ACID; BIOSYNTHESIS	We identified a 60-kDa diisopropylfluorophosphate-(DFP) reactive protein in human bronchoalveolar lavage fluid, at a yield of 50-100 pmol/lavage. The protein is associated with the cell-free lavage fluid sediment, which consists mainly of surfactant. [H-3]DFP labeling is inhibited by heating to 56-degrees-C, 2 mM phenylmethylsulfonylfluoride and 1 mM bis(4-nitrophenyl)-phosphate. An identical 60-kDa [H-3]DFP-reactive protein is present in the insoluble fraction of alveolar macrophage-conditioned culture medium and in total membrane preparations of alveolar macrophages. The [H-3]DFP-labeled protein was purified approximately 30-fold from lavage fluid sediment by size-exclusion (Sephacryl S-200) and ion-exchange (Mono-Q) chromatography. Cyanogen bromide treatment of the partially purified protein produced a major labeled peptide of 14 kDa with an NH2-terminal sequence 90% identical to a region of form 1 rabbit liver microsomal carboxylesterase. Esterase activity in unlabeled starting material, detected using p-nitrophenyl valerate as substrate, copurified with the [H-3]DFP-labeled enzyme. Degenerate oligonucleotide primers were designed based on the partial amino acid sequence and on a highly conserved region of known liver carboxylesterase sequences. Polymerase chain reaction using these primers and reverse-transcribed human alveolar macrophage mRNA yielded a 354-base pair product which was then used to screen a human alveolar macrophage cDNA library. A complete esterase sequence was obtained from two incomplete, overlapping clones, and is virtually identical to human liver carboxylesterase partial sequences. Northern blot analysis demonstrated a single approximately 1.7-kilobase transcript in human monocytes and alveolar macrophages, with much higher levels in the latter. These data indicate that human alveolar macrophages both contain and release a serine esterase that is apparently identical to liver microsomal carboxylesterase. Its enzymatic profile suggests it is a major component of alveolar macrophage-nonspecific esterase activity. We hypothesize that it acts as a detoxication enzyme in the lung.	BRIGHAM & WOMENS HOSP,DIV RESP,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Munger, John/0000-0002-9679-2983	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041277, T32HL007633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41277, HL07633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAO T, 1972, J BIOCHEM, V72, P1245, DOI 10.1093/oxfordjournals.jbchem.a130012; ANDRES DA, 1990, J BIOL CHEM, V265, P5952; BOWEN RM, 1985, J LAB CLIN MED, V106, P667; BOZDECH MJ, 1981, J EXP MED, V153, P182, DOI 10.1084/jem.153.1.182; BRAUNSTEIN H, 1959, J HISTOCHEM CYTOCHEM, V7, P202, DOI 10.1177/7.3.202; CHAPMAN HA, 1988, AM REV RESPIR DIS, V137, P1417, DOI 10.1164/ajrccm/137.6.1417; CHAPMAN HA, 1984, J CLIN INVEST, V73, P806, DOI 10.1172/JCI111275; CHAPMAN HA, 1985, J CLIN INVEST, V75, P2030, DOI 10.1172/JCI111922; CHAPMAN HA, 1984, J CLIN INVEST, V74, P1693, DOI 10.1172/JCI111586; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DREXLER HG, 1987, CANCER, V59, P77, DOI 10.1002/1097-0142(19870101)59:1<77::AID-CNCR2820590118>3.0.CO;2-A; GOMORI G, 1953, J HISTOCHEM CYTOCHEM, V1, P469, DOI 10.1177/1.6.469; HARANO T, 1988, J BIOCHEM-TOKYO, V103, P149, DOI 10.1093/oxfordjournals.jbchem.a122221; HAUGEJORDEN SM, 1991, J BIOL CHEM, V266, P6015; HAWGOOD S, 1989, AM J PHYSIOL, V257, pL13, DOI 10.1152/ajplung.1989.257.2.L13; HEYMANN E, 1980, ENZYMATIC BASIS DETO, V2, P291; HOSOKAWA M, 1990, ARCH BIOCHEM BIOPHYS, V277, P219, DOI 10.1016/0003-9861(90)90572-G; JAKOBY WB, 1990, J BIOL CHEM, V265, P20715; JUNGE W, 1974, ARCH BIOCHEM BIOPHYS, V165, P749, DOI 10.1016/0003-9861(74)90304-X; KENNEDY TE, 1988, P NATL ACAD SCI USA, V85, P7008, DOI 10.1073/pnas.85.18.7008; KETTERMAN AJ, 1989, INT J BIOCHEM, V21, P1303, DOI 10.1016/0020-711X(89)90149-3; KORZA G, 1988, J BIOL CHEM, V263, P3486; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG RM, 1988, BIOCHEM BIOPH RES CO, V156, P866, DOI 10.1016/S0006-291X(88)80924-0; LONG RM, 1991, LIFE SCI, V84, pPL43; MARKEY GM, 1989, J CLIN PATHOL, V43, P282; MCCORMICK JA, 1991, BRIT J HAEMATOL, V77, P287, DOI 10.1111/j.1365-2141.1991.tb08572.x; MCGEE MP, 1985, AM REV RESPIR DIS, V131, P331; MENTLEIN R, 1980, ARCH BIOCHEM BIOPHYS, V200, P547, DOI 10.1016/0003-9861(80)90386-0; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKSTAD B, 1989, ULTRASTRUCT PATHOL, V13, P1; ORNSTEIN L, 1976, BLOOD CELLS, V2, P557; ORTEL J, 1985, BRIT J HAEMATOL, V61, P717; OZOLS J, 1987, J BIOL CHEM, V262, P15316; OZOLS J, 1989, J BIOL CHEM, V264, P12533; ROBBI M, 1987, BIOCHEM J, V248, P545, DOI 10.1042/bj2480545; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; ROBBI M, 1988, BIOCHEM J, V254, P51, DOI 10.1042/bj2540051; ROBBI M, 1983, EUR J BIOCHEM, V137, P293, DOI 10.1111/j.1432-1033.1983.tb07828.x; SABOORI AM, 1990, J BIOL CHEM, V265, P19792; SCOTT RE, 1977, LAB INVEST, V37, P430; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKAGI Y, 1988, J BIOCHEM-TOKYO, V104, P801, DOI 10.1093/oxfordjournals.jbchem.a122553; The BAL Cooperative Group Steering Committee, 1990, AM REV RESPIR DIS, V141, pS169; WAHL GM, 1987, METHOD ENZYMOL, V152, P415; WEINER RS, 1982, ADV EXP MED BIOL, V155, P209; YOURNO J, 1986, BLOOD, V68, P479	47	139	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18832	18838						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918003				2022-12-25	WOS:A1991GJ47200067
J	KITAGAWA, T; MASUMI, A; AKAMATSU, Y				KITAGAWA, T; MASUMI, A; AKAMATSU, Y			TRANSFORMING GROWTH FACTOR-BETA-1 STIMULATES GLUCOSE-UPTAKE AND THE EXPRESSION OF GLUCOSE TRANSPORTER MESSENGER-RNA IN QUIESCENT SWISS MOUSE 3T3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; GENE-TRANSCRIPTION; FACTOR RECEPTOR; FIBRONECTIN; FIBROBLASTS; COLLAGEN; BINDING; DIFFERENTIATION; INDUCTION; FAMILY	Transforming growth factor-beta-1 (TGF-beta-1) is a multifunctional polypeptide that regulates the proliferation and differentiation of various types of animal cells. TGF-beta-1 stimulated glucose uptake and the expression of a brain-type glucose transporter (GLUT1) mRNA in quiescent mouse 3T3 cells. TGF-beta-1 also synergistically stimulated these activities when given together with calf serum, phorbol ester, fibroblast growth factor, or epidermal growth factor. The increases in glucose uptake and the GLUT1 mRNA level were induced by picomolar concentrations of TGF-beta-1 within 3 h of stimulation, reached a peak between 6 and 9 h, and then decreased gradually to basal levels before an increase in DNA synthesis. The stimulation of GLUT1 mRNA expression was completely abolished by actinomycin D, but was not affected by cycloheximide, suggesting that new protein synthesis was not required for the expression of GLUT1 mRNA. TGF-beta-1 had little mitogenic activity and did not affect serum-induced DNA synthesis in quiescent 3T3 cells. However, it stimulated DNA synthesis synergistically when given with fibroblast growth factor, epidermal growth factor, phorbol ester, or insulin. These results suggest that TGF-beta-1 mediates the stimulation of glucose uptake, GLUT1 mRNA expression, and DNA synthesis via a pathway(s) and cellular components distinct from those for other growth factors. The possible role of the TGF-beta-1-induced stimulation of glucose transport activity in the control of mouse fibroblast proliferation is also discussed.			KITAGAWA, T (corresponding author), NATL INST HLTH,DEPT CHEM,10-35 KAMIOSAKI-2,SHINAGAWA KU,TOKYO 141,JAPAN.							BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BLATTI SP, 1988, P NATL ACAD SCI USA, V85, P1119, DOI 10.1073/pnas.85.4.1119; BOENER P, 1985, P NATL ACAD SCI USA, V82, P1350; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FUKUMOTO H, 1988, DIABETES, V37, P657, DOI 10.2337/diabetes.37.5.657; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; GRONWALD RGK, 1989, J BIOL CHEM, V264, P8120; HATANAKA M, 1974, BIOCHIM BIOPHYS ACTA, V355, P77, DOI 10.1016/0304-419X(74)90008-0; HIRAKI Y, 1988, J BIOL CHEM, V263, P13655; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; INMAN WH, 1985, P NATL ACAD SCI USA, V82, P1346, DOI 10.1073/pnas.82.5.1346; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KITAGAWA T, 1989, BIOCHIM BIOPHYS ACTA, V980, P100, DOI 10.1016/0005-2736(89)90205-8; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LI L, 1990, J BIOL CHEM, V265, P1556; LIKE B, 1986, J BIOL CHEM, V261, P3426; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1982, MOL CLONING LABORATO; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MASSAGUE J, 1985, J BIOL CHEM, V260, P4551; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; RANGANATHAN G, 1990, J BIOL CHEM, V265, P3001; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1984, CANCER RES, V44, P1635; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROLLINS BJ, 1988, J BIOL CHEM, V263, P16523; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SOGIN DC, 1980, P NATL ACAD SCI-BIOL, V77, P5725, DOI 10.1073/pnas.77.10.5725; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; THOMPSON KL, 1988, J BIOL CHEM, V263, P19519; WILLIAMS SA, 1988, J BIOL CHEM, V263, P19513	40	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18066	18071						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917944				2022-12-25	WOS:A1991GG55300056
J	VARSHNEY, U; LEE, CP; SEONG, BL; RAJBHANDARY, UL				VARSHNEY, U; LEE, CP; SEONG, BL; RAJBHANDARY, UL			MUTANTS OF INITIATOR TRANSFER-RNA THAT FUNCTION BOTH AS INITIATORS AND ELONGATORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLMETHIONINE TRANSFER-RNA; ESCHERICHIA-COLI INITIATOR; PROTEIN-SYNTHESIS; CHLORAMPHENICOL ACETYLTRANSFERASE; SPECIFICITY; HYDROLASE; CLEAVAGE; INVITRO; ACT; ARM	We describe the effect of mutations in the acceptor stem of Escherichia coli initiator tRNA on its function in vivo. The acceptor stem mutations were coupled to mutations in the anticodon sequence from CAU --> CUA to allow functional studies on the mutant tRNAs in initiation and in elongation in vivo. We show that, with one exception, there is a good correlation between the kinetic parameters for formylation of the mutant tRNAs in vitro (preceding paper, Lee, C. P., Seong, B. L., and RajBhandary, U. L. (1991) J. Biol. Chem. 266, 18012-18017) and their activity in initiation in vivo. These results suggest an important role for formylation of initiator tRNA in its function in initiation, at least when it is aminoacylated with glutamine as is the case with the mutant tRNAs used here. Mutant tRNAs that have a base pair between nucleotides 1 and 72 at the top of the acceptor stem function as elongators, as analyzed by their ability to suppress an amber mutation in the E. coli beta-galactosidase gene. One of these mutants is also quite active in initiation. Thus, activities of a tRNA in initiation and elongation steps of protein synthesis are not mutually exclusive. Using a mRNA with two in frame UAG codons, we show that this mutant tRNA can both initiate protein synthesis from the upstream UAG and suppress the down-stream UAG. We discuss the potential use of tRNAs with such "dual" functions in tightly regulated expression of genes for proteins in E. coli.			VARSHNEY, U (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		Varshney, Umesh/Q-6914-2019; Varshney, Umesh/A-8062-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017151, R37GM017151, R01GM017151] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17151] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHERLY AG, 1972, NATURE-NEW BIOL, V240, P245, DOI 10.1038/newbio240245a0; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GOLDMAN E, 1983, ARCH BIOCHEM BIOPHYS, V224, P134, DOI 10.1016/0003-9861(83)90197-2; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KOSSEL H, 1968, J MOL BIOL, V35, P539, DOI 10.1016/S0022-2836(68)80013-0; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CP, 1991, J BIOL CHEM, V266, P18012; Miller J.H., 1972, EXPT MOL GENETICS; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; OKIMOTO R, 1990, EMBO J, V9, P3405, DOI 10.1002/j.1460-2075.1990.tb07542.x; PERONA JJ, 1988, J MOL BIOL, V202, P121, DOI 10.1016/0022-2836(88)90524-4; RAJBHANDARY UL, 1969, J BIOL CHEM, V244, P1104; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SCHULMAN LH, 1974, J BIOL CHEM, V249, P7102; SCHULMAN LH, 1975, J BIOL CHEM, V250, P542; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SHAW WV, 1983, CRC CR REV BIOCH MOL, V14, P1, DOI 10.3109/10409238309102789; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; TOMIZAWA J, 1985, CELL, V40, P527, DOI 10.1016/0092-8674(85)90201-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARSHNEY U, 1990, P NATL ACAD SCI USA, V87, P1586, DOI 10.1073/pnas.87.4.1586; YARUS M, 1980, P NATL ACAD SCI-BIOL, V77, P5092, DOI 10.1073/pnas.77.9.5092; YARUS M, 1986, J MOL BIOL, V192, P235, DOI 10.1016/0022-2836(86)90362-1	28	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18018	18024						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917940				2022-12-25	WOS:A1991GG55300050
J	AGUILARCORDOVA, E; STRANGE, R; YOUNG, LJT; BILLY, HT; GUMERLOCK, PH; CARDIFF, RD				AGUILARCORDOVA, E; STRANGE, R; YOUNG, LJT; BILLY, HT; GUMERLOCK, PH; CARDIFF, RD			VIRAL HA-RAS MEDIATED MAMMARY-TUMOR PROGRESSION	ONCOGENE			English	Article							MOUSE SKIN CARCINOGENESIS; TRANSGENIC MICE; EPITHELIAL-CELLS; ENZYMATIC AMPLIFICATION; MOLECULAR-BIOLOGY; HARVEY; TISSUE; VIRUS; GENE; DNA	An immortal mammary epithelial cell line, Comma 1D, and primary cultures of mammary epithelial cells were used to examine the effects of vHa-ras on mammary tumor development. In culture, Comma 1D and primary cells were morphologically indistinguishable. Infection with a replication defective vHa-ras retroviral vector (psi-ras) did not alter their in vitro phenotype. Uninfected Comma 1D cells implanted into gland-cleared mammary fat pads gave rise to dysplastic outgrowths, while implants of primary cells gave rise to normal gland structures. After psi-ras infection, implants of Comma 1D cells progressed to adenocarcinomas and those of primary cells resulted in initiated dysplastic outgrowths. High level infection of either cell type with replication competent HaMSV (psi-ras plus helper virus) resulted in in vitro transformation and undifferentiated in vivo tumors. Thus, in vivo analysis was necessary to detect the observed correlation between tumorigenic stage and level of infection. In this system, expression of vHa-ras was vital but not sufficient for mammary tumor initiation and progression, which resulted from an accumulation of events that did not need to occur in a specific order.	UNIV CALIF DAVIS,SCH MED,DEPT PATHOL,DAVIS,CA 95616; UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT INTERNAL MED,DIV HEMATOL ONCOL,SACRAMENTO,CA 95817	University of California System; University of California Davis; University of California System; University of California Davis								ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ASCH BB, 1986, CANCER RES, V46, P1255; ASHLEY RL, 1980, CANCER RES, V40, P4232; BALL RK, 1988, MOL ENDOCRINOL, V2, P133, DOI 10.1210/mend-2-2-133; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CARDIFF RD, 1988, ANTICANCER RES, V8, P925; COHEN JC, 1979, J VIROL, V32, P483, DOI 10.1128/JVI.32.2.483-496.1979; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; EDWARDS PAW, 1988, ONCOGENE, V2, P402; EHMANN UK, 1987, JNCI-J NATL CANCER I, V78, P751; EHMANN UK, 1984, J CELL BIOL, V98, P1026, DOI 10.1083/jcb.98.3.1026; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HENNINGS H, 1985, J NATL CANCER I, V74, P735; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KAWABE TT, 1986, LAB MED, V17, P143, DOI 10.1093/labmed/17.3.143; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SATO Y, 1986, AM J PATHOL, V125, P431; SINN E, 1987, CELL, V49, P466; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRANGE R, 1989, ONCOGENE, V4, P309; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	32	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1601	1607						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923527				2022-12-25	WOS:A1991GX27400015
J	VANLEEUWEN, F; VANDEVIJVER, MJ; LOMANS, J; VANDEEMTER, L; JENSTER, G; AKIYAMA, T; YAMAMOTO, T; NUSSE, R				VANLEEUWEN, F; VANDEVIJVER, MJ; LOMANS, J; VANDEEMTER, L; JENSTER, G; AKIYAMA, T; YAMAMOTO, T; NUSSE, R			MUTATION OF THE HUMAN NEU PROTEIN FACILITATES DOWN-MODULATION BY MONOCLONAL-ANTIBODIES	ONCOGENE			English	Article									NETHERLANDS CANC INST,DIV MOLEC BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	Netherlands Cancer Institute; University of Tokyo			van Leeuwen, Frank/AAQ-6799-2020	van Leeuwen, Frank/0000-0003-1107-6513				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ALI IU, 1988, ONCOGENE RES, V3, P139; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERGER MS, 1988, CANCER RES, V48, P1238; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1988, ONCOGENE, V2, P387; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAL M, 1988, CANCER RES, V48, P1517; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VANDEVIJVER MJ, 1988, ONCOGENE, V2, P175; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YOKOTA J, 1988, ONCOGENE, V2, P283; YOKOTA J, 1986, LANCET, V1, P765; ZHOU DJ, 1987, CANCER RES, V47, P6123	47	26	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					497	503						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1970152				2022-12-25	WOS:A1990DB85300007
J	STACHOWIAK, MK; JIANG, HK; POISNER, AM; TUOMINEN, RK; HONG, JS				STACHOWIAK, MK; JIANG, HK; POISNER, AM; TUOMINEN, RK; HONG, JS			SHORT AND LONG-TERM REGULATION OF CATECHOLAMINE BIOSYNTHETIC-ENZYMES BY ANGIOTENSIN IN CULTURED ADRENAL-MEDULLARY CELLS - MOLECULAR MECHANISMS AND NATURE OF 2ND-MESSENGER SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									NIEHS,MOLEC & INTEGRAT NEUROSCI,NEUROPHARMACOL SECT,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Poisner, Alan/AAC-8152-2022; Poisner, Alan/Q-8226-2019; Hong, Jau-Shyong/F-1920-2019	Poisner, Alan/0000-0002-0161-8238; Hong, Jau-Shyong/0000-0002-3056-8401				AXELROD J, 1962, J BIOL CHEM, V237, P1657; BOADLEBIBER MC, 1972, BRIT J PHARMACOL, V46, P289, DOI 10.1111/j.1476-5381.1972.tb06874.x; BOARDER MR, 1988, J BIOL CHEM, V263, P15319; D'MELLO SR, 1989, J NEUROSCI RES, V23, P31, DOI 10.1002/jnr.490230105; EIDEN LE, 1984, NATURE, V312, P661, DOI 10.1038/312661a0; EIKENBURG DC, 1981, CENTRAL NERVOUS SYST, P215; ELLIOTT ME, 1982, HYPERTENSION, V4, P52, DOI 10.1161/01.HYP.4.3_Pt_2.52; FELDBERG W, 1963, J PHYSIOL-LONDON, V167, P288; FOSTER R, 1983, AM J PHYSIOL, V245, pE281, DOI 10.1152/ajpendo.1983.245.3.E281; GIETZEN K, 1981, BIOCHEM BIOPH RES CO, V101, P418, DOI 10.1016/0006-291X(81)91276-6; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HAYCOCK GRN, 1982, ABSTR SOC NEUROSCI, V8, P817; HEALY DP, 1984, J HYPERTENSION S3, V2, P56; ISRAEL A, 1985, CELL MOL NEUROBIOL, V5, P211, DOI 10.1007/BF00711007; ITO S, 1979, BRIT J PHARMACOL, V65, P319, DOI 10.1111/j.1476-5381.1979.tb07833.x; JIANG HK, 1989, J CELL BIOL, P506; KANAMATSU T, 1986, P NATL ACAD SCI USA, V83, P9242; KAPLAN BB, 1979, BIOCHEM J, V183, P181, DOI 10.1042/bj1830181; KAPLAN BB, 1985, GENE EXPRESSION BRAI, P1; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52, DOI 10.1016/0006-291X(88)90485-8; KAWASAKI H, 1982, J PHARMACOL EXP THER, V221, P112; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KOJIMA I, 1985, AM J PHYSIOL, V248, pE36, DOI 10.1152/ajpendo.1985.248.1.E36; KOJIMA I, 1985, J BIOL CHEM, V260, P9177; KRAMER RE, 1988, AM J PHYSIOL, V255, pE338, DOI 10.1152/ajpendo.1988.255.3.E338; KRAMER RE, 1988, MOL CELL ENDOCRINOL, V60, P199, DOI 10.1016/0303-7207(88)90179-7; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LIHRMANN I, 1987, CELL CALCIUM, V8, P269, DOI 10.1016/0143-4160(87)90003-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLEAN ML, 1984, PHYSL SOC, P73; MALIGENI JA, 1982, J BIOL CHEM, V257, P12632; MARLEY PD, 1989, NEUROSCIENCE, V28, P777, DOI 10.1016/0306-4522(89)90022-5; MAZZEI GJ, 1984, BIOCHEM PHARMACOL, V33, P125, DOI 10.1016/0006-2952(84)90379-4; MILLER GR, 1966, SIMULTANEOUS STATIST, P26; NARANJO JR, 1986, P NATL ACAD SCI USA, V83, P1513, DOI 10.1073/pnas.83.5.1513; OSULLIVAN AJ, 1989, BIOSCIENCE REP, V9, P243, DOI 10.1007/BF01116001; OSULLIVAN AJ, 1989, EMBO J, V8, P401, DOI 10.1002/j.1460-2075.1989.tb03391.x; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PLEVIN R, 1988, J NEUROCHEM, V51, P634, DOI 10.1111/j.1471-4159.1988.tb01085.x; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; POISNER AM, 1965, FED PROC, V24, P488; REINHARD JF, 1986, LIFE SCI, V39, P2185, DOI 10.1016/0024-3205(86)90395-4; ROBINSON RL, 1967, J PHARMACOL EXP THER, V156, P252; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; RUBIN RP, 1980, CELL CALCIUM, V1, P391, DOI 10.1016/0143-4160(80)90041-X; STACHOWIAK M, 1985, BRAIN RES, V359, P356, DOI 10.1016/0006-8993(85)91450-7; STACHOWIAK M, 1988, MOL BRAIN RES, V3, P193, DOI 10.1016/0169-328X(88)90066-6; STACHOWIAK MK, 1988, MOL BRAIN RES, V3, P263, DOI 10.1016/0169-328X(88)90049-6; STACHOWIAK MK, 1990, ONCOGENE, V5, P69; STACHOWIAK MK, 1988, MOL BRAIN RES, V3, P275, DOI 10.1016/0169-328X(88)90050-2; STACHOWIAK MK, 1988, J CELL BIOL, P506; TANK AW, 1985, J NEUROCHEM, V45, P1030, DOI 10.1111/j.1471-4159.1985.tb05519.x; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; UNGAR A, 1983, PHYSIOL REV, V63, P878; VULLIET PR, 1985, FEBS LETT, V182, P335, DOI 10.1016/0014-5793(85)80328-8; WADA A, 1985, N-S ARCH PHARMACOL, V328, P273, DOI 10.1007/BF00515553; WAYMIRE JC, 1988, J BIOL CHEM, V263, P12439; WILSON SP, 1981, EXP CELL RES, V133, P159, DOI 10.1016/0014-4827(81)90366-9; ZIMLICHMAN R, 1987, CELL CALCIUM, V8, P315, DOI 10.1016/0143-4160(87)90006-6; ZIMMERMAN BG, 1978, FED PROC, V37, P199	61	85	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1990	265	8					4694	4702						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CT101	1968464				2022-12-25	WOS:A1990CT10100080
J	GUNTER, KK; ZUSCIK, MJ; GUNTER, TE				GUNTER, KK; ZUSCIK, MJ; GUNTER, TE			THE NA+-INDEPENDENT CA2+ EFFLUX MECHANISM OF LIVER-MITOCHONDRIA IS NOT A PASSIVE CA2+ 2H+ EXCHANGER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; RUTHENIUM RED; ELECTROCHEMICAL GRADIENT; HEART-MITOCHONDRIA; CALCIUM-TRANSPORT; INNER MEMBRANE; CA-2+; PH; RELEASE; RESPIRATION	Whether the Na2+-independent Ca2+ efflux mechanism of liver mitochondria is a Ca2+/2H+ exchanger and whether this exchanger is a passive mechanism have been controversial since shortly after the discovery of this mechanism. Here, a new approach to determining if the mechanism is passive is developed based on the energy available to a passive Ca2+/2H+ exchanger. Conditions are identified in which the Na+-independent Ca2+ efflux mechanism transports Ca2+ out of mitochondria against a Ca2+ gradient many times greater than that possible for a passive Ca2+/2H+ exchanger, thus ruling this out as a possible mechanism.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOPHYS, ROCHESTER, NY 14642 USA	University of Rochester				Zuscik, Michael/0000-0003-0461-8708	NCRR NIH HHS [RR05403] Funding Source: Medline; NIGMS NIH HHS [GM35550] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035550] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDANKI S, 1968, J BIOL CHEM, V243, P2337; AKERMAN KEO, 1978, ARCH BIOCHEM BIOPHYS, V189, P256, DOI 10.1016/0003-9861(78)90211-4; ANTONIO RV, 1991, BIOCHIM BIOPHYS ACTA, V1056, P250, DOI 10.1016/S0005-2728(05)80056-8; BERNARDI P, 1979, EUR J BIOCHEM, V102, P555, DOI 10.1111/j.1432-1033.1979.tb04272.x; BRAND MD, 1985, BIOCHEM J, V225, P413, DOI 10.1042/bj2250413; BROEKEMEIER KM, 1985, J BIOL CHEM, V260, P105; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BUSTAMANTE E, 1977, ANAL BIOCHEM, V80, P401, DOI 10.1016/0003-2697(77)90661-3; COCKRELL RS, 1985, ARCH BIOCHEM BIOPHYS, V243, P70, DOI 10.1016/0003-9861(85)90774-X; CROMPTON M, 1976, EUR J BIOCHEM, V69, P453, DOI 10.1111/j.1432-1033.1976.tb10930.x; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1979, FEBS LETT, V104, P352, DOI 10.1016/0014-5793(79)80850-9; CROMPTON M, 1986, INTRACELLULAR CALCIU, P67; DAVIS MH, 1987, BIOCHEM BIOPH RES CO, V149, P40, DOI 10.1016/0006-291X(87)91602-0; FISKUM G, 1979, J BIOL CHEM, V254, P6236; FISKUM G, 1978, FEBS LETT, V92, P125, DOI 10.1016/0014-5793(78)80736-4; FISKUM G, 1979, J BIOL CHEM, V254, P6288; GARLID KD, 1986, J BIOL CHEM, V261, P1529; GAVIN CE, 1991, ANAL BIOCHEM, V192, P44, DOI 10.1016/0003-2697(91)90180-2; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER TE, 1978, BIOCHEMISTRY-US, V17, P339, DOI 10.1021/bi00595a023; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; GUNTER TE, 1983, BIOCHEMISTRY-US, V22, P6341, DOI 10.1021/bi00295a046; GUNTER TE, 1990, CELL CALCIUM, V11, P445, DOI 10.1016/0143-4160(90)90077-8; HOLIAN A, 1980, BIOCHEMISTRY-US, V19, P4213, DOI 10.1021/bi00559a012; HUDSPETH AJ, 1988, J PHYSIOL-LONDON, V400, P237, DOI 10.1113/jphysiol.1988.sp017119; JENSEN BD, 1986, ARCH BIOCHEM BIOPHYS, V248, P305, DOI 10.1016/0003-9861(86)90427-3; JURKOWITZ MS, 1983, ARCH BIOCHEM BIOPHYS, V223, P120, DOI 10.1016/0003-9861(83)90577-5; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; NEDERGAARD J, 1984, EUR J BIOCHEM, V144, P159, DOI 10.1111/j.1432-1033.1984.tb08444.x; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; Palmieri F, 1979, Methods Enzymol, V56, P279; PFEIFFER DR, 1983, BIOCH METABOLIC PROC, P67; PUSKIN JS, 1973, BIOCHEM BIOPH RES CO, V51, P797, DOI 10.1016/0006-291X(73)91385-5; PUSKIN JS, 1976, BIOCHEMISTRY-US, V15, P3834, DOI 10.1021/bi00662a029; ROBINSON RA, 1970, ELECTROLYTE SOLUTION, P232; ROSIER RN, 1981, ARCH BIOCHEM BIOPHYS, V210, P549, DOI 10.1016/0003-9861(81)90221-6; Rottenberg H, 1979, Methods Enzymol, V55, P547; ROTTENBERG H, 1990, FEBS LETT, V274, P65, DOI 10.1016/0014-5793(90)81330-Q; ROTTENBERG H, 1989, METHOD ENZYMOL, V172, P63; SARIS NEL, 1987, ACTA CHEM SCAND B, V41, P79, DOI 10.3891/acta.chem.scand.41b-0079; SIMON W, 1986, MATH TECHNIQUE BIOL, P227; SORDAHL LA, 1974, ARCH BIOCHEM BIOPHYS, V167, P104; TSOKOS J, 1980, FEBS LETT, V119, P297, DOI 10.1016/0014-5793(80)80276-6; WAN B, 1989, J BIOL CHEM, V264, P13430; WINGROVE DE, 1986, J BIOL CHEM, V261, P5159; WINGROVE DE, 1984, J BIOL CHEM, V259, P9390; WINGROVE DE, 1986, J BIOL CHEM, V261, P5166; WOLKOWICZ PE, 1981, ARCH BIOCHEM BIOPHYS, V209, P408, DOI 10.1016/0003-9861(81)90298-8; [No title captured]	51	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21640	21648						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939193				2022-12-25	WOS:A1991GP80400050
J	KARINO, K; KADOR, PF; BERKOWITZ, B; BALABAN, RS				KARINO, K; KADOR, PF; BERKOWITZ, B; BALABAN, RS			F-19 NMR QUANTITATION OF LENS ALDOSE REDUCTASE-ACTIVITY USING 3-DEOXY-3-FLUORO-D-GLUCOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; DIABETIC COMPLICATIONS; METABOLISM; SPECTROSCOPY; INHIBITORS; EYE	In the present study we have determined the kinetics of 3-deoxy-3-fluoro-D-glucose (3-FG) as a substrate for the aldose reductase reaction in vitro. In addition, we compared the 3-deoxy-3-fluoro-sorbitol (3-FS) production rates from 3-FG in the intact lens using F-19 NMR with conventional aldose reductase determinations in extracts from the same lenses. The affinity of in vitro aldose reductase for 3-FG was approximately 20 times greater (9.3 mM) than that for glucose (188 mM). An excellent correlation between the rate of 3-FS production in the intact canine lens, determined with F-19 NMR, and extracted aldose reductase activity was observed. The relatively high affinity of aldose reductase for 3-FG and the correlation of 3-FS production with enzyme activity in the intact lens suggests that 3-FS production from 3-FG detected by F-19 NMR could provide an accurate noninvasive determination of aldose reductase activity in the eye lens.	NHLBI,CARDIAC ENERGET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	KARINO, K (corresponding author), NEI,MECHANISM OCULAR DIS LAB,BETHESDA,MD 20892, USA.		Balaban, Robert S/A-7459-2009	Balaban, Robert S/0000-0003-4086-0948				ACKERMAN JJH, 1980, NATURE, V283, P167, DOI 10.1038/283167a0; Araie M, 1989, Nihon Rinsho, V47, P1357; BECKER ED, 1979, ANAL CHEM, V51, P1413, DOI 10.1021/ac50045a016; BENFIELD P, 1986, DRUGS, V32, P43, DOI 10.2165/00003495-198600322-00010; BERKOWITZ BA, 1987, BIOPHYS J, V51, P681, DOI 10.1016/S0006-3495(87)83393-3; BERKOWITZ BA, 1990, J BIOL CHEM, V265, P12417; CECKLER TL, 1991, IN PRESS INVEST OPHT; DUFFEY RJ, 1986, ARCH OPHTHALMOL-CHIC, V104, P1135; ELBRINK J, 1972, BIOCHIM BIOPHYS ACTA, V282, P337, DOI 10.1016/0005-2736(72)90339-2; GREENE DA, 1985, DIABETES CARE, V8, P290, DOI 10.2337/diacare.8.3.290; JEDZINIAK JA, 1981, INVEST OPHTH VIS SCI, V20, P314; KADOR PF, 1990, ARCH OPHTHALMOL-CHIC, V108, P1301, DOI 10.1001/archopht.1990.01070110117035; KADOR PF, 1984, CIBA F SYMP, V106, P110; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; KINOSHITA JH, 1979, METABOLISM, V28, P462, DOI 10.1016/0026-0495(79)90057-X; Kwee I L, 1989, NMR Biomed, V2, P44, DOI 10.1002/nbm.1940020109; KWEE IL, 1987, J NEUROCHEM, V49, P428, DOI 10.1111/j.1471-4159.1987.tb02883.x; LOU MF, 1967, BIOCHIM BIOPHYS ACTA, V141, P547, DOI 10.1016/0304-4165(67)90184-5; NAKADA T, 1988, MAGNET RESON MED, V6, P307, DOI 10.1002/mrm.1910060309; OBAZAWA H, 1974, INVEST OPHTH VISUAL, V13, P204; SATO S, 1990, EXP EYE RES, V50, P629, DOI 10.1016/0014-4835(90)90105-4; SCHWARTZ B, 1962, INVEST OPHTH VISUAL, V1, P513; SHEAFF CM, 1976, J BIOL CHEM, V251, P2696; VANHEYNINGEN R, 1964, BIOCHEM J, V92, pC14, DOI 10.1042/bj0920014C; VONKIENLIN M, 1991, J MAGN RESON, V94, P268, DOI 10.1016/0022-2364(91)90106-4	26	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20970	20975						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939148				2022-12-25	WOS:A1991GN00100061
J	ABERGEL, C; MOULARD, M; MOREAU, H; LORET, E; CAMBILLAU, C; FONTECILLACAMPS, JC				ABERGEL, C; MOULARD, M; MOREAU, H; LORET, E; CAMBILLAU, C; FONTECILLACAMPS, JC			SYSTEMATIC USE OF THE INCOMPLETE FACTORIAL APPROACH IN THE DESIGN OF PROTEIN CRYSTALLIZATION EXPERIMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRELIMINARY-X-RAY; BOVINE 6S PROCARBOXYPEPTIDASE; ANDROCTONUS-AUSTRALIS HECTOR; HUMAN PANCREATIC-JUICE; RABBIT GASTRIC LIPASE; AMINO-ACID SEQUENCE; SUBUNIT-III; PURIFICATION; VENOM; COMPLEX	We have used the Incomplete Factorial Approach (Carter, C. W., and Carter, C. W., Jr. (1979) J. Biol. Chem. 254, 12219-12223) in conjunction with the program Cristal (Roussel, A., Serre, L., Frey M., and Fontecilla-Camps, J. (1990) J. Crystal Growth 106, 405-409) to crystallize six different proteins. We were able to obtain crystals and to identify the critical factors for crystallization for each of these six proteins. In some of the cases, we succeeded on the first try while using only minute amounts of protein. This study proves that the Incomplete Factorial Approach is a powerful tool in identifying the factors that need to be varied to achieve crystallization. Single crystals of adequate size were obtained for all the proteins reported here, although some did not diffract well enough to be studied by x-ray diffraction methods; the asymmetric units of these latter crystals contain a large number of molecules, which is most likely due to the presence of significant amounts of carbohydrate in the proteins.	FAC MED SECTEUR NORD MARSEILLE, CRISTALLOG & CRISTALLISAT MACROMOLEC BIOL LAB, CNRS, URA 1296, F-13326 MARSEILLE 15, FRANCE; CNRS, CTR BIOCHIM & BIOL MOLEC, F-13402 MARSEILLE, FRANCE; FAC MED SECTEUR NORD MARSEILLE, MEMBRANES BIOL & TOXINES ANIM LAB,CNRS,URA 1179, INSERM,U172, F-13326 MARSEILLE 15, FRANCE; CEN, DIRECT STUDIES VIVANT, CRISTALLOGENESE & CRISTALLOG PROT LAB, F-38041 GRENOBLE, FRANCE; CEN, INGN PROT LAB, F-38041 GRENOBLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite				Abergel, Chantal/0000-0003-1875-4049				ABERGEL C, 1990, J MOL BIOL, V214, P637, DOI 10.1016/0022-2836(90)90280-Y; BELL JB, 1991, PROTEINS, V9, P143, DOI 10.1002/prot.340090208; BETTS L, 1989, J BIOL CHEM, V264, P6737; CAMBILLAU C, 1986, J MOL BIOL, V189, P709, DOI 10.1016/0022-2836(86)90500-0; CARTER C W JR, 1990, Methods (Orlando), V1, P12, DOI 10.1016/S1046-2023(05)80142-2; CARTER CW, 1979, J BIOL CHEM, V254, P2219; COX MJ, 1987, J APPL CRYSTALLOGR, V20, P366, DOI 10.1107/S0021889887086461; DARBON H, 1982, INT J PEPT PROT RES, V20, P320; DIJKSTRA BW, 1978, J MOL BIOL, V124, P53, DOI 10.1016/0022-2836(78)90146-8; DIJKSTRA BW, 1982, ACTA CRYSTALLOGR B, V38, P793, DOI 10.1107/S0567740882004099; DRENTH J, 1976, NATURE, V264, P373, DOI 10.1038/264373a0; FISHER RA, 1942, DESIGN EXPT; GARGOURI Y, 1989, BIOCHIM BIOPHYS ACTA, V1006, P255, DOI 10.1016/0005-2760(89)90012-X; GARGOURI Y, 1988, J BIOL CHEM, V263, P2159; GILLILAND GL, 1988, J CRYST GROWTH, V90, P51, DOI 10.1016/0022-0248(88)90298-9; GUYCROTTE O, 1988, BIOCHEM BIOPH RES CO, V156, P318, DOI 10.1016/S0006-291X(88)80842-8; HOUGH E, 1978, J MOL BIOL, V121, P567, DOI 10.1016/0022-2836(78)90401-1; JANCARIK J, 1991, IN PRESS J APPL CRYS; KAM Z, 1978, J MOL BIOL, V123, P539, DOI 10.1016/0022-2836(78)90206-1; KELLER PJ, 1956, J BIOL CHEM, V223, P457; KERFELEC B, 1986, EUR J BIOCHEM, V157, P531, DOI 10.1111/j.1432-1033.1986.tb09699.x; KERFELEC B, 1984, BIOCHEM BIOPH RES CO, V121, P162, DOI 10.1016/0006-291X(84)90701-0; LESTER D, 1982, BIOCHIM BIOPHYS ACTA, V701, P370, DOI 10.1016/0167-4838(82)90240-0; LEWITBENTLEY A, 1989, J MOL BIOL, V210, P875, DOI 10.1016/0022-2836(89)90115-0; LORET EP, 1991, BIOCHEMISTRY-US, V30, P633, DOI 10.1021/bi00217a007; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MICHEL H, 1980, P NATL ACAD SCI-BIOL, V77, P1283, DOI 10.1073/pnas.77.3.1283; MOREAU H, 1988, FEBS LETT, V236, P383, DOI 10.1016/0014-5793(88)80061-9; MOREAU H, 1988, BIOCHIM BIOPHYS ACTA, V960, P286, DOI 10.1016/0005-2760(88)90036-7; MOULARD M, 1989, FEBS LETT, V250, P166, DOI 10.1016/0014-5793(89)80712-4; PASCUAL R, 1989, EUR J BIOCHEM, V179, P609, DOI 10.1111/j.1432-1033.1989.tb14590.x; PASEK M, 1975, J MOL BIOL, V97, P395, DOI 10.1016/S0022-2836(75)80048-9; PUIGSERVER A, 1975, P NATL ACAD SCI USA, V72, P2442, DOI 10.1073/pnas.72.6.2442; Rochat H, 1979, Adv Cytopharmacol, V3, P325; ROUSSEL A, 1990, J CRYST GROWTH, V106, P405, DOI 10.1016/0022-0248(90)90086-Z; TIRUPPATHI C, 1982, BIOCHIM BIOPHYS ACTA, V712, P692, DOI 10.1016/0005-2760(82)90299-5; TOMOO K, 1989, J BIOL CHEM, V264, P3636; VENOT N, 1986, EUR J BIOCHEM, V157, P91, DOI 10.1111/j.1432-1033.1986.tb09642.x; WANG AHJ, 1981, J BIOL CHEM, V256, P9279; WICKER C, 1981, FEBS LETT, V128, P13, DOI 10.1016/0014-5793(81)81067-8; WLODAWER A, 1975, P NATL ACAD SCI USA, V72, P398, DOI 10.1073/pnas.72.1.398; YAMASAKI M, 1963, BIOCHEMISTRY-US, V2, P859, DOI 10.1021/bi00904a039; ZLOTKIN E, 1971, TOXICON, V9, P9, DOI 10.1016/0041-0101(71)90038-9; ZLOTKIN E, 1975, INSECT BIOCHEM, V5, P243, DOI 10.1016/0020-1790(75)90062-1; [No title captured]; [No title captured]	46	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20131	20138						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939074				2022-12-25	WOS:A1991GM03900041
J	CROSBIE, R; ADAMS, S; CHALOVICH, JM; REISLER, E				CROSBIE, R; ADAMS, S; CHALOVICH, JM; REISLER, E			THE INTERACTION OF CALDESMON WITH THE COOH TERMINUS OF ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; ACTOMYOSIN ATPASE ACTIVITY; CHICKEN GIZZARD CALDESMON; SMOOTH-MUSCLE CALDESMON; TROPONIN-TROPOMYOSIN; MYOSIN SUBFRAGMENT-1; HEAVY-MEROMYOSIN; THIN-FILAMENTS; F-ACTIN; SKELETAL	Caldesmon interacts with the NH2-terminal region of actin. It is now shown in airfuge centrifugation experiments that modification of the penultimate cysteine residue of actin significantly weakens its binding to caldesmon both in the presence and absence of tropomyosin. Furthermore, as revealed by fluorescence measurements, caldesmon increases the exposure of the COOH-terminal region of actin to the solvent. This effect of caldesmon, like its inhibitory effect on actomyosin ATPase activity, is enhanced in the presence of tropomyosin. Proteolytic removal of the last three COOH-terminal residues of actin, containing the modified cysteine residue, restores the normal binding between caldesmon and actin. These results establish a correlation between the binding of caldesmon to actin and the conformation of the COOH-terminal region of actin and suggest an indirect rather than direct interaction between caldesmon and this part of actin.	E CAROLINA UNIV,SCH MED,DEPT BIOCHEM,GREENVILLE,NC 27858; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of North Carolina; East Carolina University; University of California System; University of California Los Angeles	CROSBIE, R (corresponding author), UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024, USA.			Chalovich, Joseph/0000-0002-1243-4055	NIAMS NIH HHS [R01 AR022031, R01 AR035216, AR 22031, AR 35216] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035216, R01AR022031] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS S, 1990, J BIOL CHEM, V265, P19652; BALL EH, 1988, BIOCHEMISTRY-US, V27, P6093, DOI 10.1021/bi00416a039; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BERTRAND R, 1989, EUR J BIOCHEM, V181, P747, DOI 10.1111/j.1432-1033.1989.tb14787.x; BOYER M, 1987, BIOCHEM J, V248, P359, DOI 10.1042/bj2480359; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BRYAN J, 1991, J MUSCLE RES CELL M, V12, P372, DOI 10.1007/BF01738592; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHALOVICH JM, 1981, J BIOL CHEM, V256, P575; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; CRIDDLE AH, 1985, BIOCHEM J, V232, P343, DOI 10.1042/bj2320343; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; DASGUPTA G, 1989, J MOL BIOL, V207, P833, DOI 10.1016/0022-2836(89)90249-0; DOI YK, 1991, BIOCHEMISTRY-US, V30, P5769, DOI 10.1021/bi00237a020; FUJII T, 1987, J BIOL CHEM, V262, P2757; GRABAREK Z, 1987, BIOPHYS J, V51, pA331; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH JA, 1986, J BIOL CHEM, V261, P6155; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; LEVINE BA, 1990, EUR J BIOCHEM, V193, P687, DOI 10.1111/j.1432-1033.1990.tb19388.x; LEVINE BA, 1988, EUR J BIOCHEM, V172, P389, DOI 10.1111/j.1432-1033.1988.tb13899.x; LIN TI, 1983, J BIOL CHEM, V258, P5142; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALM B, 1980, FEBS LETT, V113, P241, DOI 10.1016/0014-5793(80)80601-6; MARSTON SB, 1985, BIOCHEM J, V231, P517, DOI 10.1042/bj2310517; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEJEAN C, 1987, BIOCHEM J, V244, P571, DOI 10.1042/bj2440571; MILLER L, 1987, BIOCHEMISTRY-US, V26, P6064, DOI 10.1021/bi00393a018; MILLER L, 1988, J BIOL CHEM, V263, P1996; MOODY CJ, 1985, FEBS LETT, V191, P107, DOI 10.1016/0014-5793(85)81003-6; MORNET D, 1984, P NATL ACAD SCI-BIOL, V81, P3680, DOI 10.1073/pnas.81.12.3680; NGAI PK, 1985, BIOCHEM J, V230, P695, DOI 10.1042/bj2300695; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; PATCHELL VB, 1989, BIOCHEM SOC T, V17, P901, DOI 10.1042/bst0170901; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; SMITH CWJ, 1985, FEBS LETT, V184, P115, DOI 10.1016/0014-5793(85)80665-7; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STRZELECKAGOLASZEWSKA H, 1980, EUR J BIOCHEM, V104, P41, DOI 10.1111/j.1432-1033.1980.tb04397.x; SUTOH K, 1984, BIOCHEMISTRY-US, V23, P6757, DOI 10.1021/bi00321a073; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1989, BIOCHEMISTRY-US, V28, P5269, DOI 10.1021/bi00438a052; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144	58	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20001	20006						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939062				2022-12-25	WOS:A1991GM03900024
J	MCNEIL, HP; AUSTEN, KF; SOMERVILLE, LL; GURISH, MF; STEVENS, RL				MCNEIL, HP; AUSTEN, KF; SOMERVILLE, LL; GURISH, MF; STEVENS, RL			MOLECULAR-CLONING OF THE MOUSE MAST-CELL PROTEASE-5 GENE - A NOVEL SECRETORY GRANULE PROTEASE EXPRESSED EARLY IN THE DIFFERENTIATION OF SEROSAL MAST-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIVE-TISSUE-TYPE; SERINE PROTEASES; CARBOXYPEPTIDASE-A; DNA; ORGANIZATION; FAMILY; RNA; IDENTIFICATION; PURIFICATION; PROTEINS	cDNAs were isolated that encode mouse mast cell protease-5 (MMCP-5), an approximately 30,000 M(r) serine protease stored in the secretory granules of serosal mast cells (SMC) and Kirsten sarcoma virus-immortalized mast cells. Based on the deduced amino acid sequences of these cDNAs, MMCP-5 is synthesized as a 247-amino acid preproenzyme composed of a novel 19-residue hydrophobic signal peptide, a Gly-Glu activation peptide not present in other mast cell chymases, and a 226-amino acid protein that represents the mature enzyme. MMCP-5 possesses a unique Asn residue in the substrate binding cleft at residue 176 and is highly basically charged. The MMCP-5 gene was isolated, sequenced, and found to belong to a distinct subset of chymase genes. Allelic variations of the MMCP-5 gene were also detected. MMCP-5 is expressed in bone marrow-derived mast cells (BMMC), Kirsten sarcoma virus-immortalized mast cells, and SMC, but not in gastrointestinal mucosal mast cells of helminth-infected mice. The abundant levels of MMCP-5 mRNA in immature BMMC indicate that this chymase is expressed relatively early during the differentiation of mast cells. MMCP-5 is the first chymase to be molecularly cloned from progenitor mast cells and is also the first chymase shown to be expressed preferentially in the SMC subclass.	BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital	MCNEIL, HP (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA.			McNeil, Hugh Patrick/0000-0003-4336-2960	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007306, R37AI022531, P50AI023401, R01AI022531] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07306, AI-22531, AI-23401] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAUGHEY GH, 1990, BIOCHEMISTRY-US, V29, P5166, DOI 10.1021/bi00473a024; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE KR, 1991, BIOCHEMISTRY-US, V30, P648, DOI 10.1021/bi00217a009; DUBUSKE L, 1984, J IMMUNOL, V133, P1535; EVERITT MT, 1980, FEBS LETT, V110, P292, DOI 10.1016/0014-5793(80)80095-0; GURISH MF, 1991, J IMMUNOL, V146, P1527; HARTLEY BS, 1970, PHILOS T ROY SOC B, V257, P77, DOI 10.1098/rstb.1970.0010; HOHN PA, 1989, J BIOL CHEM, V264, P13412; JENNE DE, 1989, BIOCHEMISTRY-US, V28, P7953, DOI 10.1021/bi00445a060; KOKKONEN JO, 1986, J BIOL CHEM, V261, P6067; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; LOBE CG, 1988, BIOCHEMISTRY-US, V27, P6941, DOI 10.1021/bi00418a040; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; RAZIN E, 1984, J IMMUNOL, V132, P1479; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1988, J BIOL CHEM, V263, P12783; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; TRONG HL, 1989, BIOCHEMISTRY-US, V28, P391; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YURT R, 1977, J EXP MED, V146, P1405, DOI 10.1084/jem.146.5.1405; YURT RW, 1977, J BIOL CHEM, V252, P518; ZON L, 1991, IN PRESS J BIOL CHEM, V266	39	115	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20316	20322						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939089				2022-12-25	WOS:A1991GM03900066
J	USUKI, K; MIYAZONO, K; HELDIN, CH				USUKI, K; MIYAZONO, K; HELDIN, CH			COVALENT LINKAGE BETWEEN NUCLEOTIDES AND PLATELET-DERIVED ENDOTHELIAL-CELL GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-ANTIGEN; GENOME-LINKED PROTEIN; OUTER SEGMENTS; KINASE-C; PHOSPHORYLATION; BINDING; RNA; IDENTIFICATION; PURIFICATION; PHOSPHOTYROSINE	Platelet-derived endothelial cell growth factor (PD-ECGF) is a 45-kDa peptide mitogen which is present in platelets and placenta and produced by certain cultured cell lines. Immunoprecipitation of A431 cells metabolically labeled with [P-32]orthophosphate revealed the incorporation of P-32 radioactivity into PD-ECGF. Phosphoamino acid analysis showed that serine residues of PD-ECGF were phosphorylated in vivo. Forskolin, 12-O-tetradecanoylphorbol-13-acetate, and epidermal growth factor had no effect on the in vivo phosphorylation of PD-ECGF. Moreover, incubation of pure PD-ECGF with [gamma-P-32]ATP led to labeling of PD-ECGF. Optimal labeling was achieved by incubation at 95-degrees-C for 5 min in the presence of sodium dodecyl sulfate, dithiothreitol, and Mg2+ or Mn2+. PD-ECGF was also labeled with [2,8-H-3]ATP, [2,5'-8-H-3] ATP, or [alpha-P-32]ATP. ATP and GTP were the preferred nucleotide substrates by comparison with other nucleotides and related components. Partial amino acid hydrolysis liberated a significant amount of O-[P-32]phosphoserine from PD-ECGF labeled in vitro with [gamma-P-32] ATP. Furthermore, P-32-radiolabeled nucleotides were released after snake venom phosphodiesterase or piperidine treatment from PD-ECGF labeled in vitro with [alpha-P-32]ATP or [gamma-P-32]ATP, as well as from PD-ECGF labeled in vivo with [P-32]orthophosphate. These data indicate that serine residues of PD-ECGF can be covalently linked to phosphate groups of nucleotides, resulting in a nucleotidylated protein. The functional significance of this post-translational modification remains to be determined.			USUKI, K (corresponding author), BIOMED CTR, LUDWIG INST CANC RES, S-75124 UPPSALA, SWEDEN.							BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRADLEY MK, 1984, P NATL ACAD SCI-BIOL, V81, P6574, DOI 10.1073/pnas.81.21.6574; BREDEHORST R, 1978, EUR J BIOCHEM, V92, P129, DOI 10.1111/j.1432-1033.1978.tb12730.x; BRODY YB, 1988, PROGR LEUCOCYTE BIOL, V8, P101; BROWN MS, 1971, P NATL ACAD SCI USA, V68, P2949, DOI 10.1073/pnas.68.12.2949; BRUNNER AM, 1988, MOL CELL BIOL, V8, P2229, DOI 10.1128/MCB.8.5.2229; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DARLIX JL, 1984, P NATL ACAD SCI-BIOL, V81, P5425, DOI 10.1073/pnas.81.17.5425; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EK B, 1984, J BIOL CHEM, V259, P1145; FEIGE JJ, 1989, J CELL BIOL, V109, P3105, DOI 10.1083/jcb.109.6.3105; FEIGE JJ, 1991, BIOCHEM BIOPH RES CO, V175, P31, DOI 10.1016/S0006-291X(05)81195-7; FEIGE JJ, 1989, P NATL ACAD SCI USA, V86, P3174, DOI 10.1073/pnas.86.9.3174; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; HERMOSO JM, 1980, P NATL ACAD SCI-BIOL, V77, P6425, DOI 10.1073/pnas.77.11.6425; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KHANDJIAN EW, 1982, P NATL ACAD SCI-BIOL, V79, P1139, DOI 10.1073/pnas.79.4.1139; KOBAYASHI Y, 1988, J IMMUNOL, V140, P2279; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LEE YF, 1977, P NATL ACAD SCI USA, V74, P59, DOI 10.1073/pnas.74.1.59; MASCARELLI F, 1989, EMBO J, V8, P2265, DOI 10.1002/j.1460-2075.1989.tb08351.x; MIYAZONO K, 1989, BIOCHEMISTRY-US, V28, P1704, DOI 10.1021/bi00430a042; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; PLOUET J, 1988, EMBO J, V7, P373, DOI 10.1002/j.1460-2075.1988.tb02823.x; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROTHBERG PG, 1978, P NATL ACAD SCI USA, V75, P4868, DOI 10.1073/pnas.75.10.4868; SAMAD A, 1991, MOL CELL BIOL, V11, P1598, DOI 10.1128/MCB.11.3.1598; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHIEVEN G, 1988, J BIOL CHEM, V263, P15590; SHAPIRO BM, 1967, P NATL ACAD SCI USA, V58, P642, DOI 10.1073/pnas.58.2.642; SKUBITZ KM, 1991, BIOCHEM BIOPH RES CO, V174, P49, DOI 10.1016/0006-291X(91)90483-N; USUKI K, 1990, CELL REGUL, V1, P577, DOI 10.1091/mbc.1.8.577; USUKI K, 1989, P NATL ACAD SCI USA, V86, P7427, DOI 10.1073/pnas.86.19.7427; WIERENGA RK, 1983, NATURE, V302, P842, DOI 10.1038/302842a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	38	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20525	20531						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939103				2022-12-25	WOS:A1991GM03900097
J	SWANSON, BA; DUTTON, DR; LUNETTA, JM; YANG, CS; DEMONTELLANO, PRO				SWANSON, BA; DUTTON, DR; LUNETTA, JM; YANG, CS; DEMONTELLANO, PRO			THE ACTIVE-SITES OF CYTOCHROME-P450 IA1, IIB1, IIB2, AND IIE1 - TOPOLOGICAL ANALYSIS BY INSITU REARRANGEMENT OF PHENYL-IRON COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MICROSOMES; POLYCHLORINATED-BIPHENYLS; SECONDARY STRUCTURE; MEMBRANE TOPOLOGY; CRYSTAL-STRUCTURE; AMINO-ACID; ARYL-IRON; PHENYLHYDRAZINE; PURIFICATION; STEREOSELECTIVITY	The reactions of cytochromes P450 IA1, IIB1, IIB2, and IIE1 with phenyldiazene yield complexes with absorption maxima at either 474 or 480 nm. Anaerobic extraction of the prosthetic group from the phenyldiazene-treated proteins followed by its exposure to oxygen and strong acid produces an equal mixture of the four possible N-phenylprotoporphyrin IX regioisomers. Exposure of the anaerobically extracted heme complexes to oxygen in the absence of strong acid results in their decomposition to heme and products other than N-phenylprotoporphyrin IX. These results show that the 474/480 nm absorption maxima are due to sigma-phenyl-iron complexes. Treatment of the intact hepatic cytochrome P450 complexes with K3Fe(CN)6 results in disappearance of the 474/480 nm band. Extraction of the prosthetic group then yields only the two N-phenylprotoporphyrin IX regioisomers with the N-phenyl group on pyrrole rings A and D. The same regioisomer pattern is obtained if the cytochrome P450IA1 phenyl-iron complex is simply warmed to 37-degrees-c, but this thermal rearrangement occurs much less readily, if at all, with the complexes of the other isozymes. The regioisomers with the N-phenyl on pyrrole rings A and D are obtained in a 2:1 ratio with isozyme IA1, 1:1 with IIB2, 1:1.7 with IIBI, and 1:2 with IIE1. These results establish that the active sites of these cytochrome P450 isozymes have a common architecture despite their gross differences in substrate specificity. In this architecture, the region directly above pyrrole rings A and D is relatively open whereas that above pyrrole rings B and C is occluded by protein residues.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143; RUTGERS STATE UNIV,COLL PHARM,DEPT CHEM BIOL & PHARMACOGNOSY,PISCATAWAY,NJ 08855	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rutgers State University New Brunswick			Lunetta, Jennine/A-9819-2008	Lunetta, Jennine/0000-0002-7821-0257	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025515, R01GM025515] Funding Source: NIH RePORTER; NIDDK NIH HHS [5 P30 DK26743] Funding Source: Medline; NIGMS NIH HHS [GM 25515] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anders M.W., 1985, BIOACTIVATION FOREIG, P121; ATOR MA, 1987, J BIOL CHEM, V262, P1542; AUGUSTO O, 1982, J BIOL CHEM, V257, P6231; BLACK SD, 1986, CYTOCHROME P450 STRU, P161; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DELAFORGE M, 1986, CHEM-BIOL INTERACT, V60, P101, DOI 10.1016/0009-2797(86)90020-7; DEMONTELLANO PRO, 1983, J BIOL CHEM, V258, P558; DEMONTELLANO PRO, 1985, BIOCHEMISTRY-US, V24, P1147, DOI 10.1021/bi00326a013; EDWARDS RJ, 1989, BIOCHEMISTRY-US, V28, P3762, DOI 10.1021/bi00435a021; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; GROVES JT, 1983, J AM CHEM SOC, V105, P6243, DOI 10.1021/ja00358a009; GROVES JT, 1983, J AM CHEM SOC, V105, P5786, DOI 10.1021/ja00356a015; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, V1, P1; HANIU M, 1982, J BIOL CHEM, V257, P2664; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; Jefcoate C.R., 1986, CYTOCHROME P 450 STR, P387; JERINA DM, 1982, MICROSOMES DRUG OXID, P195; JONEN HG, 1982, J BIOL CHEM, V257, P4404; KADLUBAR FF, 1987, MAMMALIAN CYTOCHROME, V2, P81; KOMIVES EA, 1987, J BIOL CHEM, V262, P9793; KOSOWER EM, 1965, J AM CHEM SOC, V87, P4645, DOI 10.1021/ja00948a046; KUNZE KL, 1983, J BIOL CHEM, V258, P4202; KUNZE KL, 1983, J AM CHEM SOC, V105, P1380, DOI 10.1021/ja00343a057; LEWIS DFV, 1986, BIOCHEM PHARMACOL, V35, P2179, DOI 10.1016/0006-2952(86)90589-7; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; NEBERT DW, 1987, DNA-J MOLEC CELL BIO, V6, P1, DOI 10.1089/dna.1987.6.1; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; NELSON SD, 1987, MAMMALIAN CYTOCHROME, V2, P19; OMURA T, 1964, J BIOL CHEM, V239, P2370; PATTEN CJ, 1986, ARCH BIOCHEM BIOPHYS, V251, P629, DOI 10.1016/0003-9861(86)90373-5; POULOS TL, 1988, PHARMACEUT RES, V5, P67, DOI 10.1023/A:1015920931701; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; REICH NO, 1986, CYTOCHROME P450 STRU, P273; RINGE D, 1984, BIOCHEMISTRY-US, V23, P2, DOI 10.1021/bi00296a001; RYAN DE, 1979, J BIOL CHEM, V254, P1365; RYAN DE, 1982, ARCH BIOCHEM BIOPHYS, V216, P272, DOI 10.1016/0003-9861(82)90212-0; SHEPHARD EA, 1983, ANAL BIOCHEM, V129, P430, DOI 10.1016/0003-2697(83)90573-0; SLIGAR SG, 1986, CYTOCHROME P450 STRU, P429; SWANSON BA, 1991, IN PRESS J AM CHEM S; THAKKER DR, 1986, J BIOL CHEM, V261, P5404; TRETIAKOV VE, 1989, ARCH BIOCHEM BIOPHYS, V275, P429, DOI 10.1016/0003-9861(89)90389-5; UNGER BP, 1986, J BIOL CHEM, V261, P1158; VANBLADEREN PJ, 1987, BIOCHEM BIOPH RES CO, V145, P160, DOI 10.1016/0006-291X(87)91301-5; VANBLADEREN PJ, 1984, J BIOL CHEM, V259, P8966; VYAS KP, 1983, MOL PHARMACOL, V24, P115; WAXMAN DJ, 1982, J BIOL CHEM, V257, P446	48	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19258	19264						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918043				2022-12-25	WOS:A1991GK66700025
J	AIKEN, CR; FISHER, EW; GUMPORT, RI				AIKEN, CR; FISHER, EW; GUMPORT, RI			THE SPECIFIC BINDING, BENDING, AND UNWINDING OF DNA BY RSRI ENDONUCLEASE, AN ISOSCHIZOMER OF ECORI ENDONUCLEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTION ENDONUCLEASE; RI ENDONUCLEASE; ENDODEOXYRIBONUCLEASE ECORI; MODIFICATION ENZYMES; NUCLEOTIDE-SEQUENCE; CLEAVAGE REACTION; RECOGNITION; PROTEIN; SITE; PURIFICATION	To determine whether RsrI endonuclease recognizes and cleaves the sequence GAATTC in duplex DNA similarly to its isoschizomer EcoRI we initiated a functional comparison of the two enzymes. Equilibrium binding experiments showed that at 20-degrees-C RsrI endonuclease binds to specific and nonspecific sequences in DNA with affinities similar to those of EcoRI. At 0-degrees-C the affinity of RsrI for its specific recognition sequence is reduced 7-fold whereas the affinity for noncanonical sequences remains relatively unchanged. Unlike EcoRI, incubation of RsrI endonuclease with N-ethylmaleimide inactivates the enzyme; however, preincubation with DNA prevents the inactivation. The N-ethylmaleimide-treated enzyme fails to bind DNA as assayed by gel mobility shift assays. Comparison of the deduced amino acid sequences of RsrI and EcoRI endonucleases suggests that modification of Cys245 is responsible for the inactivation. Fe(II).EDTA and methidiumpropyl-EDTA.Fe(II) footprinting results indicate that RsrI, like EcoRI, protects 12 base pairs from cleavage when bound to its specific recognition sequence in the absence of Mg2+. RsrI bends DNA by approximately 50-degrees, as determined by measuring the realtive electrophoretic mobilities of specific RsrI-DNA complexes with the binding site in the center or near the end of the DNA fragment. This value is similar to that reported for EcoRI. RsrI also unwinds the DNA helix by 25-degrees +/- 5-degrees, a value close to that reported for EcoRI endonuclease. Collectively, these results indicate that the overall structural changes induced in the DNA by the binding of RsrI and EcoRI endonucleases to DNA in the absence of Mg2+ are similar. In the accompanying paper (Aiken, C. R., McLaughlin, L. W., and Gumport, R. I. (1991) J. Biol. Chem. 266, 19070-19078) we present results of studies of RsrI endonuclease using oligonucleotide substrates containing base analogues which suggest differences in the ways the two enzymes cleave DNA.	UNIV ILLINOIS, COLL MED,DEPT BIOCHEM,415 ROGER ADAMS LAB, 1209 W CALIF ST, URBANA, IL 61801 USA; UNIV ILLINOIS, SCH CHEM SCI, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025621] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25621] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKEN C, 1986, FASEB J, V45, P1914; AIKEN C, 1988, NUCLEIC ACIDS RES, V16, P7901, DOI 10.1093/nar/16.16.7901; AIKEN CR, 1991, J BIOL CHEM, V266, P19070; BENNETT SP, 1989, CURR TOP CELL REGUL, V30, P57; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; CHENG SC, 1984, J BIOL CHEM, V259, P1571; Cleland W W, 1979, Methods Enzymol, V63, P103; CONNOLLY BA, 1984, J BIOL CHEM, V259, P760; DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0; DIEKMANN S, 1988, J MOL BIOL, V202, P823, DOI 10.1016/0022-2836(88)90561-X; DOUCRASY S, 1989, NUCLEIC ACIDS RES, V17, P5173, DOI 10.1093/nar/17.13.5173; GREENE PJ, 1988, GENE, V68, P43, DOI 10.1016/0378-1119(88)90597-5; GREENE PJ, 1981, J BIOL CHEM, V256, P2143; GREENE PJ, 1974, DNA REPLICATION, V7, P87; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HAGERMAN PJ, 1988, UNUSUAL DNA STRUCTUR, P225; HEDGPETH J, 1972, P NATL ACAD SCI USA, V69, P3448, DOI 10.1073/pnas.69.11.3448; HEITMAN J, 1990, PROTEINS, V7, P185, DOI 10.1002/prot.340070207; Jack W E, 1981, Gene Amplif Anal, V1, P165; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; JENJACOBSON L, 1986, CELL, V45, P619, DOI 10.1016/0092-8674(86)90294-1; KIM R, 1984, NUCLEIC ACIDS RES, V12, P7285, DOI 10.1093/nar/12.19.7285; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KING K, 1989, J BIOL CHEM, V264, P11807; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LUKE PA, 1985, GENE, V37, P241, DOI 10.1016/0378-1119(85)90278-1; MANIATIS T, 1982, MOL CLONING LABORATO, P93; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MCLAUGHLIN LW, 1987, BIOCHEMISTRY-US, V26, P7238, DOI 10.1021/bi00397a007; MODRICH P, 1976, J BIOL CHEM, V251, P5866; NEEDELS MC, 1989, P NATL ACAD SCI USA, V86, P3579, DOI 10.1073/pnas.86.10.3579; NERDAL W, 1989, BIOCHEMISTRY-US, V28, P10008, DOI 10.1021/bi00452a020; NEWMAN AK, 1981, J BIOL CHEM, V256, P2131; OELGESCHLAGER T, 1990, GENE, V89, P19, DOI 10.1016/0378-1119(90)90201-2; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SEELA F, 1987, BIOCHEMISTRY-US, V26, P2232, DOI 10.1021/bi00382a024; SEELA F, 1986, NUCLEIC ACIDS RES, V14, P2319, DOI 10.1093/nar/14.5.2319; STEPHENSON FH, 1989, GENE, V85, P1, DOI 10.1016/0378-1119(89)90458-7; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; THOMAS GA, 1989, BIOCHEMISTRY-US, V28, P2001, DOI 10.1021/bi00431a007; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; UPOROVA TM, 1985, VOP MED KHIM, V31, P131; WOLFES H, 1986, NUCLEIC ACIDS RES, V14, P9063, DOI 10.1093/nar/14.22.9063; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; YANOFSKY SD, 1987, PROTEINS, V2, P273, DOI 10.1002/prot.340020403	49	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19063	19069						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918025				2022-12-25	WOS:A1991GJ47200101
J	DENTINO, AR; RAJ, PA; BHANDARY, KK; WILSON, ME; LEVINE, MJ				DENTINO, AR; RAJ, PA; BHANDARY, KK; WILSON, ME; LEVINE, MJ			ROLE OF PEPTIDE BACKBONE CONFORMATION ON BIOLOGICAL-ACTIVITY OF CHEMOTACTIC PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; BETA-SHEET CONFORMATION; LEUCYL-L-PHENYLALANINE; CIRCULAR-DICHROISM; EXTENDED STRUCTURES; RABBIT NEUTROPHILS; CRYSTAL-STRUCTURES; CYSTINE PEPTIDES; CYCLIC-PEPTIDES; RECEPTOR	To investigate the role of peptide backbone conformation on the biological activity of chemotactic peptides, we synthesized a unique analog of N-formyl-Met-Leu-Phe-OH incorporating the C-alpha,alpha disubstituted residue, dipropylglycine (Dpg) in place of Leu. The conformation of the stereochemically constrained Dpg analog was examined in the crystalline state by x-ray diffraction and in solution using NMR, IR, and CD methods. The secretagogue activity of the peptide on human neutrophils was determined and compared with that of a stereochemically constrained, folded type II beta-turn analog incorporating 1-aminocyclohexanecarboxylic acid (Ac6c) at position 2 (f-Met-Ac6c-Phe-OMe), the parent peptide (f-Met-Leu-Phe-OH) and its methyl ester derivative (f-Met-Leu-Phe-OMe). In the solid state, the Dpg analog adopts an extended beta-sheet-like structure with an intramolecular hydrogen bond between the NH and CO groups of the Dpg residue, thereby forming a fully extended (C5) conformation at position 2. The phi and psi values for Met and Phe residues are significantly lower than the values expected for an ideal antiparallel beta-conformation causing a twist in the extended backbone both at the N and C termini. Nuclear magnetic resonance studies suggest the presence of a significant population of the peptide molecules in an extended antiparallel beta-conformation and the involvement of Dpg NH in a C5 intramolecular hydrogen bond in solutions of deuterated chloroform and deuterated dimethyl sulfoxide. IR studies provide evidence for the presence of an intramolecular hydrogen bond in the molecule and the antiparallel extended conformation in chloroform solution. CD spectra in methanol, trifluoroethanol, and trimethyl phosphate indicate that the Dpg peptide shows slight conformational flexibility, whereas the folded Ac6c analog is quite rigid. The extended Dpg peptide consistently shows the highest activity in human peripheral blood neutrophils, being approximately 8 and 16 times more active than the parent peptide and the folded Ac6c analog, respectively. However, the finding that all four peptides have ED50 (the molar concentration of peptide to induce half-maximal enzyme release) values in the 10(-8)-10(-9) M range suggests that an induced fit mechanism may indeed be important in this ligand-receptor interaction. Moreover, it is also possible that alterations in the backbone conformation at the tripeptide level may not significantly alter the side chain topography and/or the accessibility of key functional groups important for interaction with the receptor.	SUNY BUFFALO,DENT RES INST,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	DENTINO, AR (corresponding author), SUNY BUFFALO,DEPT ORAL BIOL,109 FOSTER HALL,BUFFALO,NY 14214, USA.		RAJ, PROFESSORDES/AAA-1007-2020	RAJ, PROFESSORDES/0000-0002-4050-4778	NIDCR NIH HHS [DE00158, DE08240] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K16DE000158, P50DE008240] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		[Anonymous], 1967, CUTEZATORII, V1, P2; ASWANIKUMAR S, 1977, BIOCHEM BIOPH RES CO, V74, P810, DOI 10.1016/0006-291X(77)90375-8; BAKIR M, 1982, INT J PEPT PROT RES, V19, P133; BARDI R, 1985, INT J PEPT PROT RES, V25, P628; BECKER EL, 1987, AM J PATHOL, V129, P16; BECKER EL, 1979, BIOCHEMISTRY-US, V18, P4656, DOI 10.1021/bi00588a029; BELLEAU B, 1989, INT J IMMUNOPHARMACO, V11, P467, DOI 10.1016/0192-0561(89)90175-6; BENEDETTI E, 1984, J AM CHEM SOC, V106, P8146, DOI 10.1021/ja00338a024; BEYCHOK S, 1967, POLY ALPHA AMINO ACI, V1, P293; BILLETER M, 1982, J MOL BIOL, V155, P321, DOI 10.1016/0022-2836(82)90008-0; BISMARA C, 1985, INT J PEPT PROT RES, V26, P482; BONORA GM, 1984, J AM CHEM SOC, V106, P8152, DOI 10.1021/ja00338a025; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOVEY FA, 1988, NUCLEAR MAGNETIC RES; CHOTHIA C, 1973, J MOL BIOL, V75, P295, DOI 10.1016/0022-2836(73)90022-3; CRISMA M, 1984, INT J PEPT PROT RES, V23, P411; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; EDMUNDSON AB, 1985, MOL IMMUNOL, V22, P463, DOI 10.1016/0161-5890(85)90131-2; EGGLESTON DS, 1990, ACTA CRYSTALLOGR C, V46, P1314, DOI 10.1107/S0108270189013934; EGGLESTON DS, 1988, INT J PEPT PROT RES, V31, P164; FELLER DC, 1989, INT J PEPT PROT RES, V34, P229; FREER RJ, 1982, BIOCHEMISTRY-US, V21, P257, DOI 10.1021/bi00531a009; FREER RJ, 1980, BIOCHEMISTRY-US, V19, P2404, DOI 10.1021/bi00552a019; FRENZ BA, 1985, STRUCTURE DETERMINAT; GAVUZZO E, 1989, INT J PEPT PROT RES, V34, P409; HARDY PM, 1983, INT J PEPT PROT RES, V21, P392; HRUBY VJ, 1990, BIOCHEM J, V268, P249, DOI 10.1042/bj2680249; IQBAL M, 1984, FEBS LETT, V165, P171, DOI 10.1016/0014-5793(84)80163-5; JOHNSON CK, 1965, ORNL3794 REP; KARLE IL, 1989, INT J PEPT PROT RES, V34, P37; KARLE IL, 1988, J AM CHEM SOC, V110, P1958, DOI 10.1021/ja00214a049; KARLE IL, 1983, ACTA CRYSTALLOGR B, V39, P625, DOI 10.1107/S0108768183003080; KARPLUS M, 1963, J AM CHEM SOC, V85, P2870, DOI 10.1021/ja00901a059; KESSLER H, 1982, ANGEW CHEM INT EDIT, V21, P512, DOI 10.1002/anie.198205121; KONIG W, 1970, CHEM BER-RECL, V103, P788, DOI 10.1002/cber.19701030319; KOPPLE KD, 1972, J AM CHEM SOC, V94, P3644, DOI 10.1021/ja00765a074; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; KUO MC, 1980, BIOPHYS J, V32, P807, DOI 10.1016/S0006-3495(80)85018-1; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; METCALFE JA, 1986, LABORATORY MANUAL NE; MORFFEW AJ, 1981, CRYST STRUCT COMMUN, V10, P781; OHNISHI M, 1969, BIOCHEM BIOPH RES CO, V36, P194, DOI 10.1016/0006-291X(69)90314-3; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PITNER TP, 1972, J AM CHEM SOC, V94, P1399, DOI 10.1021/ja00759a083; Pope M. T., 1983, HETEROPOLY ISOPOLY O; RAJ PA, 1988, BIOPOLYMERS, V27, P683, DOI 10.1002/bip.360270411; RAJ PA, 1990, BIOPOLYMERS, V30, P73, DOI 10.1002/bip.360300109; RAJ PA, 1985, BIOPOLYMERS, V24, P1131, DOI 10.1002/bip.360240703; RAJ PA, 1986, J INDIAN I SCI, V66, P342; RAO BNN, 1983, J AM CHEM SOC, V105, P7423, DOI 10.1021/ja00363a036; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SALEMME FR, 1981, J MOL BIOL, V146, P101, DOI 10.1016/0022-2836(81)90368-5; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SEMUS SF, 1988, BIOCHEM BIOPH RES CO, V157, P569, DOI 10.1016/S0006-291X(88)80287-0; SHOWELL HJ, 1976, J EXP MED, V143, P1154, DOI 10.1084/jem.143.5.1154; SUKUMAR M, 1985, BIOCHEM BIOPH RES CO, V128, P339, DOI 10.1016/0006-291X(85)91684-5; TONIOLO C, 1989, Peptide Research, V2, P275; TONIOLO C, 1976, CAN J CHEM, V54, P70, DOI 10.1139/v76-013; TONIOLO C, 1989, BIOPOLYMERS, V28, P247, DOI 10.1002/bip.360280125; TONIOLO C, 1988, ISI ATLAS-BIOCHEM, V1, P225; TONIOLO C, 1980, CRC CR REV BIOCH MOL, V9, P1, DOI 10.3109/10409238009105471; TONIOLO C, 1989, PEPTIDES, V9, P1195; VALENSIN G, 1986, INT J PEPT PROT RES, V28, P334; WILLIAMS LT, 1977, P NATL ACAD SCI USA, V74, P1204, DOI 10.1073/pnas.74.3.1204; Wuthrich K, 1976, NMR BIOL RES PEPTIDE; 1970, BIOCHEMISTRY-US, V9, P3471	66	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18460	18468						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917969				2022-12-25	WOS:A1991GJ47200012
J	LOPEZRODAS, G; GEORGIEVA, EI; SENDRA, R; LOIDL, P				LOPEZRODAS, G; GEORGIEVA, EI; SENDRA, R; LOIDL, P			HISTONE ACETYLATION IN ZEA-MAYS .1. ACTIVITIES OF HISTONE ACETYLTRANSFERASES AND HISTONE DEACETYLASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-BUTYRATE; CALF THYMUS; SACCHAROMYCES-CEREVISIAE; EXTENSIVE PURIFICATION; CELL-NUCLEI; RAT-LIVER; CHROMATIN; NUCLEOSOMES; INVITRO; YEAST	DEAE-Sepharose chromatography of extracts from Zea mays meristematic cells revealed multiple histone acetyltransferase and histone deacetylase enzyme forms. An improved method for nuclear isolation allowed us to discriminate nuclear and cytoplasmic enzymes. Two nuclear histone acetyltransferases, A1 and A2, a cytoplasmic B-enzyme and two nuclear histone deacetylases, HD1 and HD2, have been identified. The histone specificity of the different enzyme forms has been studied in an in vitro system, using chicken erythrocyte histones as substrate. The cytoplasmic histone acetyltransferase B is the predominant enzyme, which acetylates mainly histone H4 and to a lesser extent H2A. The nuclear histone acetyltransferase A1 preferentially acetylates H3 and also H4, whereas enzyme A2 is specific for H3. This substrate specificity was confirmed with homologous Z. mays histones. The two histone deacetylases differ from each other with respect to ionic strength dependence, inhibition by acetate and butyrate, and substrate specificity. The strong inhibitory effect of acetate on histone deacetylases was exploited to distinguish different histone acetyltransferase forms.	UNIV INNSBRUCK, SCH MED, FAK MED, INST MIKROBIOL, FRITZ PREGLSTR 3, A-6020 INNSBRUCK, AUSTRIA; UNIV VALENCIA, FAC SCI, DEPT BIOCHEM & MOLEC BIOL, E-46100 BURJASSOT, SPAIN	University of Innsbruck; University of Valencia			Sendra, Ramón/K-3549-2014; Georgieva, Elena/O-1674-2019; LOPEZ-RODAS, GERARDO/I-1349-2015	Sendra, Ramón/0000-0002-5519-4362; LOPEZ-RODAS, GERARDO/0000-0001-8367-653X				ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; ALLFREY VG, 1970, HISTONES NUCLEOHISTO, P241; ALONSO WR, 1986, BIOCHIM BIOPHYS ACTA, V866, P161, DOI 10.1016/0167-4781(86)90113-2; ARFMANN HA, 1981, PLANT SCI LETT, V21, P317, DOI 10.1016/0304-4211(81)90104-8; BELIKOFF E, 1980, J BIOL CHEM, V255, P1448; BOHM J, 1980, EUR J BIOCHEM, V112, P353, DOI 10.1111/j.1432-1033.1980.tb07212.x; CANDIDO EPM, 1975, CAN J BIOCHEM CELL B, V53, P796, DOI 10.1139/o75-107; CANO A, 1979, EUR J BIOCHEM, V97, P65, DOI 10.1111/j.1432-1033.1979.tb13086.x; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; COTTEN M, 1986, NUCLEIC ACIDS RES, V14, P3671, DOI 10.1093/nar/14.9.3671; COUPPEZ M, 1987, J BIOL CHEM, V262, P2854; COUSENS LS, 1979, J BIOL CHEM, V254, P1716; DELPECH M, 1983, BIOCHIMIE, V65, P291, DOI 10.1016/S0300-9084(83)80281-8; DOENECKE D, 1982, MOL CELL BIOCHEM, V44, P113; ESTEPA I, 1983, EUR J BIOCHEM, V132, P249, DOI 10.1111/j.1432-1033.1983.tb07356.x; FERENZ CR, 1985, NUCLEIC ACIDS RES, V13, P1977, DOI 10.1093/nar/13.6.1977; FUJIMOTO D, 1972, J BIOCHEM-TOKYO, V72, P1269, DOI 10.1093/oxfordjournals.jbchem.a130016; GARCEA RL, 1980, J BIOL CHEM, V255, P1454; GEORGIEVA EI, 1991, J BIOL CHEM, V266, P18751; HAY CW, 1983, J BIOL CHEM, V258, P3726; INOUE A, 1970, BIOCHIM BIOPHYS ACTA, V220, P307, DOI 10.1016/0005-2744(70)90015-X; INOUE A, 1969, BIOCHEM BIOPH RES CO, V36, P146, DOI 10.1016/0006-291X(69)90661-5; KIKUCHI H, 1973, FEBS LETT, V29, P280, DOI 10.1016/0014-5793(73)80038-9; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIBBY PR, 1970, BIOCHIM BIOPHYS ACTA, V213, P234, DOI 10.1016/0005-2787(70)90027-4; LIBBY PR, 1978, J BIOL CHEM, V253, P233; LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3; LOPEZRODAS G, 1989, J BIOL CHEM, V264, P19028; LOPEZRODAS G, 1991, BIOCHEMISTRY-US, V30, P3728, DOI 10.1021/bi00229a020; LOPEZRODAS G, 1985, ARCH BIOCHEM BIOPHYS, V239, P184, DOI 10.1016/0003-9861(85)90825-2; MOLD DE, 1987, BIOCHEMISTRY-US, V26, P8257, DOI 10.1021/bi00399a036; NOHARA H, 1966, BIOCHIM BIOPHYS ACTA, V127, P282, DOI 10.1016/0304-4165(66)90511-3; NOHARA H, 1968, BIOCHIM BIOPHYS ACTA, V154, P529, DOI 10.1016/0005-2795(68)90013-5; PAIK WK, 1970, BIOCHIM BIOPHYS ACTA, V213, P513, DOI 10.1016/0005-2787(70)90058-4; PEDERSEN TJ, 1988, J PLANT PHYSIOL, V132, P623, DOI 10.1016/S0176-1617(88)80266-9; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; SALVADOR ML, 1985, FEBS LETT, V191, P55, DOI 10.1016/0014-5793(85)80992-3; SAXHOLM HJK, 1982, MOL CELL BIOCHEM, V46, P129; SEALY L, 1978, CELL, V14, P115, DOI 10.1016/0092-8674(78)90306-9; SENDRA R, 1986, PLANT SCI, V46, P189, DOI 10.1016/0168-9452(86)90191-3; SENDRA R, 1988, PLANT MOL BIOL, V11, P857, DOI 10.1007/BF00019525; TRAVIS GH, 1984, J BIOL CHEM, V259, P4406; VIDALI G, 1972, J BIOL CHEM, V247, P7365; WATERBORG JH, 1982, ANAL BIOCHEM, V122, P313, DOI 10.1016/0003-2697(82)90288-3; WATERBORG JH, 1987, ARCH BIOCHEM BIOPHYS, V256, P167, DOI 10.1016/0003-9861(87)90435-8; WATERBORG JH, 1990, BIOCHIM BIOPHYS ACTA, V1049, P324, DOI 10.1016/0167-4781(90)90105-B; WATERBORG JH, 1982, EXP CELL RES, V138, P462, DOI 10.1016/0014-4827(82)90200-2; WEINTRAUB H, 1975, CELL, V6, P85, DOI 10.1016/0092-8674(75)90077-X; WIEGAND RC, 1981, J BIOL CHEM, V256, P4578; WIKTOROWICZ JE, 1982, J BIOL CHEM, V257, P2893; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YUKIOKA M, 1984, J BIOL CHEM, V259, P8372	54	35	39	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18745	18750						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917997				2022-12-25	WOS:A1991GJ47200054
J	WOYCHIK, NA; LANE, WS; YOUNG, RA				WOYCHIK, NA; LANE, WS; YOUNG, RA			YEAST RNA POLYMERASE-II SUBUNIT RPB9 IS ESSENTIAL FOR GROWTH AT TEMPERATURE EXTREMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MOLECULAR-CLONING; GENE; DROSOPHILA; PROTEIN; MUTAGENESIS	The Saccharomyces cerevisiae RNA polymerase II subunit gene RPB9 was isolated and sequenced. RPB9 is a single copy gene on chromosome VII. The RPB9 sequence predicts a protein of 122 amino acids with a molecular mass of 14,200 Da. The yeast RPB9 subunit is similar in size and sequence to a protein encoded by DNA adjacent to the suppressor of the Hairy Wing gene in Drosophila melanogaster. Deletion of the RPB9 gene produced cells that were heat- and cold-sensitive. The RPB9 subunit, like the previously described RNA polymerase II subunit RPB4, is not essential for synthesis of mRNA, but is required for normal cell growth over a wide temperature range.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; HARVARD UNIV,MICROCHEM FACIL,CAMBRIDGE,MA 02138	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NIGMS NIH HHS [GM-34365, GM-11605] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034365, F32GM011605] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AHEARN JM, 1987, J BIOL CHEM, V262, P10695; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BIRD DM, 1989, MOL CELL BIOL, V9, P4119, DOI 10.1128/MCB.9.10.4119; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; INGLES CJ, 1984, P NATL ACAD SCI-BIOL, V81, P2157, DOI 10.1073/pnas.81.7.2157; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LATTKE H, 1976, FEBS LETT, V65, P288, DOI 10.1016/0014-5793(76)80131-7; PARKHURST SM, 1988, GENE DEV, V2, P1205, DOI 10.1101/gad.2.10.1205; PATI UK, 1990, J BIOL CHEM, V265, P8400; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; VENEZUELA P, 1978, METHOD CELL BIOL, V19, P1; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17816; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	24	84	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19053	19055						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918023				2022-12-25	WOS:A1991GJ47200099
J	KLEIN, SC; HAAS, RC; PERRYMAN, MB; BILLADELLO, JJ; STRAUSS, AW				KLEIN, SC; HAAS, RC; PERRYMAN, MB; BILLADELLO, JJ; STRAUSS, AW			REGULATORY ELEMENT ANALYSIS AND STRUCTURAL CHARACTERIZATION OF THE HUMAN SARCOMERIC MITOCHONDRIAL CREATINE-KINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; SYNTHASE BETA-SUBUNIT; TROPONIN-C GENE; SKELETAL-MUSCLE; MESSENGER-RNA; TRANSCRIPTIONAL ENHANCER; BINDING PROTEIN; CARDIAC-MUSCLE; CHAIN GENE; I GENE	Creatine kinase (EC 2.7.3.2) (CK) isoenzymes are crucial to energy metabolism, particularly in tissues with high energy requirements. Nuclear genes encode four known CK subunits: cytoplasmic muscle, cytoplasmic brain, ubiquitous mitochondrial (uMtCK), and sarcomeric mitochondrial (sMtCK). Herein, we report the isolation and complete structural characterization of the human sMtCK gene. It contains 11 exons and encompasses more than 37 kilobase pairs (kb). The sites of exon localization in the sMtCK-coding region and their precise sizes are identical with the human uMtCK gene. The translation start codon is in the third exon and lies 17 kb from the transcription start site. The human sMtCK gene is located on chromosome 5. Sequence analysis of the sMtCK genomic upstream sequences reveals a typical TATAA box within the 80 base pairs (bp) that, by transfection experiments, are sufficient to promote expression of chimeric plasmids with the chloramphenicol acetyltransferase reporter. Cis-acting sequences in a fragment containing 3360 bp of upstream sequence, the first exon, and 750 bp of the first intron are sufficient to mediate tissue-specific expression. However, these sequences only partially regulate induction of sMtCK expression in differentiating mouse myoblasts. MEF1/MYOD and MEF2 sequence motifs present in the sMtCK gene are not sufficient to regulate differentiation-specific expression. The sMtCK gene contains sequences homologous to several motifs that are shared among some nuclear genes encoding mitochondrial proteins and that may be essential for the coordinated activation of these genes during mitochondrial biogenesis.	BAYLOR UNIV,SCH MED,DEPT MED,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Baylor University; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL38898] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BILLETER R, 1988, MOL CELL BIOL, V8, P1361, DOI 10.1128/MCB.8.3.1361; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BROOKS SPJ, 1987, ARCH BIOCHEM BIOPHYS, V257, P144, DOI 10.1016/0003-9861(87)90553-4; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAUBAS P, 1988, NUCLEIC ACIDS RES, V16, P1251, DOI 10.1093/nar/16.4.1251; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DORSMAN JC, 1988, NUCLEIC ACIDS RES, V16, P7287, DOI 10.1093/nar/16.15.7287; EDMUNDSON DG, 1989, GENE DEV, V3, P628; EPPENBERGER HM, 1964, DEV BIOL, V10, P1, DOI 10.1016/0012-1606(64)90002-8; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAHLMANN R, 1990, J BIOL CHEM, V265, P12520; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRENS A, 1990, J BIOL CHEM, V265, P11810; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HAAS RC, 1989, J BIOL CHEM, V264, P2890; HOSSLE JP, 1988, BIOCHEM BIOPH RES CO, V151, P408, DOI 10.1016/0006-291X(88)90608-0; KARPINSKI BA, 1989, MOL CELL BIOL, V9, P2588, DOI 10.1128/MCB.9.6.2588; KONIECZNY SF, 1987, MOL CELL BIOL, V7, P3065, DOI 10.1128/MCB.7.9.3065; KU DH, 1990, J BIOL CHEM, V265, P16060; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LI K, 1989, J BIOL CHEM, V264, P13988; LIGHTOWLERS R, 1990, J BIOL CHEM, V265, P2677; Maniatis T., 1982, MOL CLONING; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1988, J CELL BIOL, V107, P573, DOI 10.1083/jcb.107.2.573; MARIMAN E C M, 1987, Genomics, V1, P126, DOI 10.1016/0888-7543(87)90004-8; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NIGRO JM, 1987, AM J HUM GENET, V40, P115; OHTA S, 1988, J BIOL CHEM, V263, P11257; PARMACEK MS, 1990, J BIOL CHEM, V265, P15970; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SAKS VA, 1985, J BIOL CHEM, V260, P7757; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEGEL J, 1988, J BIOL CHEM, V263, P16963; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STALLINGS RL, 1988, AM J HUM GENET, V43, P144; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; SUZUKI H, 1989, J BIOL CHEM, V264, P1368; SUZUKI H, 1990, J BIOL CHEM, V265, P8159; TOMURA H, 1990, J BIOL CHEM, V265, P6525; TRASK R, 1989, J BIOL CHEM, V263, P17142; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZAHLER R, 1987, BIOPHYS J, V51, P883, DOI 10.1016/S0006-3495(87)83416-1	56	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18058	18065						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917943				2022-12-25	WOS:A1991GG55300055
J	MATSUZAWA, Y; SEMBA, K; KAWAMURATSUZUKU, J; SUDO, T; ISHII, S; TOYOSHIMA, K; YAMAMOTO, T				MATSUZAWA, Y; SEMBA, K; KAWAMURATSUZUKU, J; SUDO, T; ISHII, S; TOYOSHIMA, K; YAMAMOTO, T			CHARACTERIZATION OF THE PROMOTER REGION OF THE C-YES PROTOONCOGENE - THE IMPORTANCE OF THE GC BOXES ON ITS PROMOTER ACTIVITY	ONCOGENE			English	Article							TYROSINE KINASE; TRANSCRIPTION FACTOR; START SITES; GENE; EXPRESSION; SEQUENCE; RECEPTOR; CELLS; PURIFICATION; BINDING	In this study we cloned the 5' flanking sequence of the human c-yes gene and identified its promoter region. A 0.53 kilobase pair (kbp) fragment containing the 5' terminus of the c-yes gene showed strong promoter activity when placed upstream of the bacterial chloramphenicol acetyltransferase (CAT) gene and transfected into monkey CV-1 cells. By nuclease S1 mapping multiple transcriptional start sites were detected within the promoter region. Nucleotide sequence analysis revealed that the c-yes promoter region had high G + C contents (64%) and contained six GC box-like sequences (one at the 5' distal region and five in a cluster at the 5' proximal region), but not a TATA box. These features of the c-yes promoter region are similar to those of other protooncogenes, ras-family genes and c-raf-1, and some housekeeping genes. Deletion analysis suggested that the most downstream 0.21 kbp region is primarily important for the promoter activity. This 0.21 kbp region contains one major and another minor transcriptional start site. Five GC box-like sequences were located within this region, and four of them were shown to bind with purified Sp1 transcription factor. Furthermore, using the base-substituted mutants of the Sp1-binding sites, each GC box in the cluster (GC1 to GC4) was shown to affect the c-yes gene expression.	UNIV TOKYO, INST MED SCI,DEPT ONCOL,4-6-1 SHIROKANEDAI, MINATO KU, TOKYO 108, JAPAN; INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC GENET LAB, TSUKUBA, IBARAKI 305, JAPAN; OSAKA UNIV, MICROBIAL DIS RES INST, DEPT ONCOGENE RES, SUITA, OSAKA 565, JAPAN	University of Tokyo; RIKEN; Osaka University			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1990, SRC FAMILY PROTEIN T, P85; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE JM, 1987, CURRENT PROTOCOLS MO, V1; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MANIATIS T, 1982, NUCLEASE SI MAPPING, P207; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; PATEL M, 1990, ONCOGENE, V5, P201; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEMBA K, 1985, SCIENCE, V227, P1038, DOI 10.1126/science.2983418; SEMBA K, 1990, STRUCTURE FUNCTION S, P74; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SUKEGAWA J, 1990, ONCOGENE, V5, P611; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TSUKITA S, 1991, IN PRESS J CELL BIOL; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	47	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1991	6	9					1561	1567						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923523				2022-12-25	WOS:A1991GX27400010
J	WAGNER, P; SIMANIS, V; MAIMETS, T; KEENAN, E; ADDISON, C; BRAIN, R; GRIMALDI, M; STURZBECHER, HW; JENKINS, J				WAGNER, P; SIMANIS, V; MAIMETS, T; KEENAN, E; ADDISON, C; BRAIN, R; GRIMALDI, M; STURZBECHER, HW; JENKINS, J			A HUMAN TUMOR-DERIVED MUTANT P53-PROTEIN INDUCES A P34CDC2 REVERSIBLE GROWTH ARREST IN FISSION YEAST	ONCOGENE			English	Article							SMALL-CELL CARCINOMA; P53 GENE; T-ANTIGEN; SCHIZOSACCHAROMYCES-POMBE; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; DNA-REPLICATION; CYCLE CONTROL; SHORT ARM; PROTEIN	We have expressed wild-type and human tumour-derived mutant p53 cDNA genes in the fission yeast Schizosaccharomyces pombe. In the case of one mutant this resulted in a growth arrest of recipient yeast cells. In contrast, wild-type p53 and three other mutant proteins tested did not block outgrowth of colonies. Human and yeast cdc2 acted as functionally equivalent extragenic suppressors of the mutant-induced growth arrest allowing the establishment of viable p53 expressor strains. In cotransformation assays the mutant allele was found to be dominant over wt p53. Our results provide the first evidence of a functional relationship between p53 and p34cdc2 in an in-vivo system and suggest that the wide variety of mutant proteins present in human tumours may fall into functionally distinct subclasses.	ESTONIAN BIOCENTER,TARTU 202400,ESTONIA,USSR; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research	WAGNER, P (corresponding author), MARIE CURIE CANC RES INST,CELL PROLIFERAT LAB,THE CHART,OXTED RH8 0TL,SURREY,ENGLAND.		Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365				BENCHIMOL S, 1985, SOMAT CELL MOLEC GEN, V11, P505, DOI 10.1007/BF01534845; BENDAVID Y, 1988, ONCOGENE, V3, P179; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BROEKER M, 1987, Biotechniques, V5, P518; CARR AM, 1989, MOL GEN GENET, V218, P41, DOI 10.1007/BF00330563; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FANTES PA, 1989, MOL BIOL FISSION YEA; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; GOULD K, 1990, NATURE, V342, P39; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; Gutz H, 1974, HDB GENETICS, P395, DOI 10.1007/978-1-4899-1710-2_25; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LATHE RA, 1988, CYTOGENET CELL GENET, V41, P404; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maniatis T., 1982, MOL CLONING; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; Mitchison J. M., 1988, YEAST PRACTICAL APPR, P51; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MULERIS M, 1985, Annales de Genetique, V28, P206; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STREIBLOVA E, 1988, YEAST PRACTICAL APPR, P9; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1988, ONCOGENE, V3, P405; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAGNER P, 1987, EMBO J, V6, P2373, DOI 10.1002/j.1460-2075.1987.tb02514.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471	53	33	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1539	1547						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923520				2022-12-25	WOS:A1991GX27400007
J	BRAULKE, T; TIPPMER, S; CHAO, HJ; VONFIGURA, K				BRAULKE, T; TIPPMER, S; CHAO, HJ; VONFIGURA, K			INSULIN-LIKE GROWTH FACTOR-I AND FACTOR-II STIMULATE ENDOCYTOSIS BUT DO NOT AFFECT SORTING OF LYSOSOMAL-ENZYMES IN HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											BRAULKE, T (corresponding author), UNIV GOTTINGEN,BIOCHEM ABT 2,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY.		Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532				BALLARD FJ, 1988, BIOCHEM J, V249, P721, DOI 10.1042/bj2490721; BAUMBACH GA, 1984, P NATL ACAD SCI-BIOL, V81, P2985, DOI 10.1073/pnas.81.10.2985; BLOK J, 1988, J CELL BIOL, V106, P69, DOI 10.1083/jcb.106.1.69; BRAULKE T, 1988, BIOCHEM BIOPH RES CO, V150, P1287, DOI 10.1016/0006-291X(88)90769-3; BRAULKE T, 1987, J CELL BIOL, V104, P1735, DOI 10.1083/jcb.104.6.1735; BRAULKE T, 1989, EMBO J, V8, P681, DOI 10.1002/j.1460-2075.1989.tb03426.x; BRAULKE T, 1990, IN PRESS EUR J BIOCH; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEVROEDE MA, 1986, J CLIN INVEST, V77, P602, DOI 10.1172/JCI112343; GARTUNG C, 1985, EMBO J, V4, P1725, DOI 10.1002/j.1460-2075.1985.tb03842.x; HARI J, 1987, EMBO J, V6, P3367, DOI 10.1002/j.1460-2075.1987.tb02658.x; KIESS W, 1988, J BIOL CHEM, V263, P9339; KIESS W, 1989, J BIOL CHEM, V264, P4710; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LEMANSKY P, 1984, J BIOL CHEM, V259, P129; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; OKA Y, 1984, P NATL ACAD SCI-BIOL, V81, P4028, DOI 10.1073/pnas.81.13.4028; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PARKER KC, 1983, BIOCHEMISTRY-US, V22, P1145, DOI 10.1021/bi00274a024; POLYCHRONAKOS C, 1988, ENDOCRINOLOGY, V123, P2943, DOI 10.1210/endo-123-6-2943; POLYCHRONAKOS C, 1988, BIOCHEM BIOPH RES CO, V157, P632, DOI 10.1016/S0006-291X(88)80297-3; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; ROGERS SA, 1989, J BIOL CHEM, V264, P4273; ROGERS SA, 1988, P NATL ACAD SCI USA, V85, P4037, DOI 10.1073/pnas.85.11.4037; ROTH RA, 1987, BIOCHEM BIOPH RES CO, V149, P600, DOI 10.1016/0006-291X(87)90410-4; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; STEIN C, 1989, J BIOL CHEM, V264, P1252; TONG PY, 1988, J BIOL CHEM, V263, P2585; VONFIGURA K, 1984, EMBO J, V3, P1281, DOI 10.1002/j.1460-2075.1984.tb01963.x; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WAHEED A, 1982, H-S Z PHYSIOL CHEM, V363, P425, DOI 10.1515/bchm2.1982.363.1.425; WAHEED A, 1982, EUR J BIOCHEM, V123, P317, DOI 10.1111/j.1432-1033.1982.tb19770.x; WAHEED A, 1988, BIOCHEM BIOPH RES CO, V152, P1248, DOI 10.1016/S0006-291X(88)80419-4; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; ZAPF J, 1981, J CLIN INVEST, V68, P1321, DOI 10.1172/JCI110379; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	40	33	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1990	265	12					6650	6655						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CZ677	1969863				2022-12-25	WOS:A1990CZ67700028
J	KNUHTSEN, S; ESTEVE, JP; CAMBILLAU, C; COLAS, B; SUSINI, C; VAYSSE, N				KNUHTSEN, S; ESTEVE, JP; CAMBILLAU, C; COLAS, B; SUSINI, C; VAYSSE, N			SOLUBILIZATION AND CHARACTERIZATION OF ACTIVE SOMATOSTATIN RECEPTORS FROM RAT PANCREAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									CHU RANGUEIL,INSERM,U151,F-31054 TOULOUSE,FRANCE; UNIV ALCALA DE HENARES,FAC MED,DEPT BIOCHEM & MOLEC BIOL,ALCALA DE HENARES,SPAIN	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universidad de Alcala								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTRONEO P, 1988, EUR J BIOCHEM, V174, P219, DOI 10.1111/j.1432-1033.1988.tb14085.x; ELREFAI MF, 1984, MEMBRANES DETERGENTS, P99; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; HAGA T, 1988, TRENDS PHARM SCI S, V3, P12; HELMESTE DM, 1986, P NATL ACAD SCI USA, V83, P67, DOI 10.1073/pnas.83.1.67; HIEROWSKI MT, 1985, FEBS LETT, V179, P252, DOI 10.1016/0014-5793(85)80529-9; KNUHTSEN S, 1988, BIOCHEM J, V254, P641, DOI 10.1042/bj2540641; KOCH BD, 1985, J BIOL CHEM, V260, P3138; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMASNEY JW, 1986, J BIOL CHEM, V261, P7710; PATTHI S, 1988, J BIOL CHEM, V263, P19363; REDDING TW, 1984, P NATL ACAD SCI-BIOL, V81, P248, DOI 10.1073/pnas.81.1.248; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REISINE T, 1985, J PHARMACOL EXP THER, V235, P551; REUBI JC, 1982, ENDOCRINOLOGY, V110, P1049, DOI 10.1210/endo-110-3-1049; REYLDESMARS F, 1987, REGUL PAPT, V16, P207; ROSENBERGER LB, 1980, J BIOL CHEM, V255, P820; SAKAMOTO C, 1988, J BIOL CHEM, V263, P14441; SAKAMOTO C, 1987, AM J PHYSIOL, V253, pG308, DOI 10.1152/ajpgi.1987.253.3.G308; SCHONBRUNN A, 1983, ENDOCRINOLOGY, V113, P1559, DOI 10.1210/endo-113-5-1559; STRIKANT CB, 1986, J BIOL CHEM, V261, P7690; STRIKANT CB, 1981, ENDOCRINOLOGY, V116, P1717; STRIKANT CB, 1986, BIOCHEM BIOPH RES CO, V139, P757; SUSINI C, 1986, J BIOL CHEM, V261, P6738; SUSINI C, 1980, GASTROENTEROLOGY, V79, P720; TAPAREL D, 1983, BIOCHEM BIOPH RES CO, V115, P827, DOI 10.1016/S0006-291X(83)80009-6; THERMOS K, 1988, MOL PHARMACOL, V33, P1370; VIGUERIE N, 1988, AM J PHYSIOL, V255, pG113, DOI 10.1152/ajpgi.1988.255.1.G113; VIGUERIE N, 1989, ENDOCRINOLOGY, V124, P1017, DOI 10.1210/endo-124-2-1017	31	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1990	265	2					1129	1133						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CH533	1967249				2022-12-25	WOS:A1990CH53300076
J	EXPOSITO, JY; LEGUELLEC, D; LU, Q; GARRONE, R				EXPOSITO, JY; LEGUELLEC, D; LU, Q; GARRONE, R			SHORT CHAIN COLLAGENS IN SPONGES ARE ENCODED BY A FAMILY OF CLOSELY RELATED GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; MOLECULAR-BIOLOGY; MESENCHYMAL CELLS; ALPHA-1 CHAIN; MESSENGER-RNA; EXPRESSION; DROSOPHILA; IV; TRANSCRIPTS; SEQUENCES	Two previously described sponge cDNAs, EmC4 and C23, respectively encoding a short chain collagen and a fibrillar collagen, were used to characterize collagen gene families in a freshwater sponge. EmC4 detected several clones when used to screen a cDNA library. Two overlapping clones, EmC13 1 and 2, were sequenced and appeared highly homologous to EmC4. Contrarily to C23, EmC4 hybridized with 10-12 fragments of genomic DNA digested with restriction endonucleases and detected 10 times more positive clones than C23 when used to screen a genomic library. The genomic clone G41 contained two closely related genes, COLNF13, corresponding to EmC13 and COLNF6. Partial characterization of COLNF13 revealed two partial exons and four complete exons of 153, 219, 207, and 144 base pairs, with split glycine codons at their boundaries. The deduced encoded protein is a short chain collagen containing two uninterrupted collagenous domains of 66 and 171 amino acids and noncollagenous domains. A characterized 207-base pair exon of COLNF6 is 77% identical with the comparable COLNF13 exon. In situ hybridization using EmC4 cDNA and electron microscopy suggested that the cells expressing these genes were secreting spongin, a nonfibrillar, surface collagen of these sponges.			EXPOSITO, JY (corresponding author), UNIV LYON 1, INST BIOL & CHIM PROT, CNRS, UNITE PROPRE RECH 412, BATIMENT 403, F-69622 VILLEURBANNE, FRANCE.			Exposito, Jean-Yves/0000-0002-4926-4942				AEGERTER E, 1987, NUCLEIC ACIDS RES, V15, P372, DOI 10.1093/nar/15.1.372; Bairati A., 1985, BIOL INVERTEBRATE LO; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; BUTTICE G, 1990, J MOL EVOL, V30, P479, DOI 10.1007/BF02101102; COX GN, 1984, MOL CELL BIOL, V4, P2389, DOI 10.1128/MCB.4.11.2389; COX GN, 1990, ACTA TROP, V47, P269, DOI 10.1016/0001-706X(90)90028-X; DALESSIO M, 1989, P NATL ACAD SCI USA, V86, P9303, DOI 10.1073/pnas.86.23.9303; DALESSIO M, 1990, J BIOL CHEM, V265, P7050; DARDEL F, 1988, COMPUT APPL BIOSCI, V4, P483; EXPOSITO JY, 1990, EUR J BIOCHEM, V190, P401, DOI 10.1111/j.1432-1033.1990.tb15589.x; EXPOSITO JY, 1990, P NATL ACAD SCI USA, V87, P6669, DOI 10.1073/pnas.87.17.6669; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARRONE R, 1973, J SUBMICR CYTOL PATH, V5, P199; GARRONE R, 1985, ROLE EXTRACELLULAR M, P461; Garrone R., 1978, PHYLOGENESIS CONNECT; Gordon MK, 1990, CURR OPIN CELL BIOL, V2, P833, DOI 10.1016/0955-0674(90)90080-X; GROSS J, 1956, J HISTOCHEM CYTOCHEM, V4, P227, DOI 10.1177/4.3.227; GUO XD, 1989, J BIOL CHEM, V264, P17574; KNIBIEHLER B, 1990, CELL DIFFER DEV, V30, P147, DOI 10.1016/0922-3371(90)90082-8; KRAMER JM, 1982, CELL, V30, P599, DOI 10.1016/0092-8674(82)90256-2; LEPARCO Y, 1989, INSECT BIOCHEM, V19, P789; Maniatis T., 1982, MOL CLONING; Mayne R., 1987, STRUCTURE FUNCTION C; MIRRE C, 1988, DEVELOPMENT, V102, P369; MONSON JM, 1982, P NATL ACAD SCI-BIOL, V79, P1761, DOI 10.1073/pnas.79.6.1761; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; OLSEN BR, 1989, CONNECT TISSUE RES, V23, P115, DOI 10.3109/03008208909002411; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAITTA B, 1989, BIOCHEM BIOPH RES CO, V158, P633, DOI 10.1016/0006-291X(89)92768-X; SAITTA B, 1990, J BIOL CHEM, V265, P6473; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491; VANDERREST M, 1990, BIOCHIMIE, V72, P473, DOI 10.1016/0300-9084(90)90071-N; VENKATESAN M, 1986, P NATL ACAD SCI USA, V83, P3351, DOI 10.1073/pnas.83.10.3351; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201	38	54	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21923	21928						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939214				2022-12-25	WOS:A1991GP80400090
J	GARDNER, LC; SMITH, SJ; COX, TM				GARDNER, LC; SMITH, SJ; COX, TM			BIOSYNTHESIS OF DELTA-AMINOLEVULINIC-ACID AND THE REGULATION OF HEME FORMATION BY IMMATURE ERYTHROID-CELLS IN MAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL ERYTHROPOIETIC PORPHYRIA; BONE-MARROW CELLS; 5-AMINOLEVULINATE SYNTHASE; IRON; PURIFICATION; SYNTHETASE; RETICULOCYTES; MITOCHONDRIA; PROTEASE; CLONING	Heme formation in the erythron is subject to end product regulation by negative feedback, but the exact point of metabolic control in human erythroid cells is unknown. To investigate the mode of action of heme on its own formation, the effects of micromolar concentrations of hemin on de novo synthesis of protoporphyrin IX and delta-aminolevulinate (delta-ALA) by intact human reticulocytes were examined in the presence of 1 mM alpha, alpha'-bipyridyl and 200-mu-M 4,6-dioxoheptanoate to block their further conversion by ferrochelatase or delta-ALA dehydrase, respectively. At final concentrations (25-40-mu-M), hemin, which is known to reduce incorporation of [2-C-14]glycine into cellular heme, significantly inhibited formation of protoporphyrin IX and total delta-aminolevulinate in situ by these cells. Since synthesis of the first committed precursor, delta-aminolevulinate, as well as protoporphyrin (which is derived from it) were diminished, the effects of hemin on delta-aminolevulinate synthase (EC 2.3.1.37) were studied. Hemin, at concentrations up to 40-mu-M, had no direct effect on enzymatic activity, as measured with [5-C-14] alpha-ketoglutarate (in hypotonically lysed cells) or [1,4-C-14] succinyl coenzyme A (in deoxycholate lysates), even after preincubation. However, when intact human reticulocytes were incubated with hemin before assay for delta-ALA synthase, there was a rapid, concentration-dependent reduction in enzymatic activity (mean 42 and 23% inhibition after 60 min for these two substrates, respectively). Hemin had no effect on steady-state levels of delta-ALA synthase mRNA, as determined by Northern blot hybridization using an erythroid-specific human cDNA probe. Thus, a mechanism for inducing feedback inhibition of the tetrapyrrole pathway exists in human erythroid cells. It controls formation of the first committed precursor of protoporphyrin IX, delta-aminolevulinate, and hence regulates heme biosynthesis by limiting the availability of the porphyrin, rather than the metal substrate for the ferrochelatase reaction. Hemin interacts with constituents of the intact reticulocyte significantly to reduce delta-aminolevulinic acid synthase activity by an indirect cellular process that does not influence the abundance of erythroid-specific synthase mRNA but may either inhibit its ribosomal translation in an unknown manner or promote degradation of the enzyme itself by specific proteolysis.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,DEPT MED,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge				Smith, Stuart/0000-0001-7266-6790	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; ANDERSON PM, 1980, J BIOL CHEM, V255, P1993; ANDREW TL, 1990, BIOSYNTHESIS HEME CH, P163; AOKI Y, 1974, J CLIN INVEST, V53, P1326, DOI 10.1172/JCI107680; AOKI Y, 1971, BIOCHEM BIOPH RES CO, V42, P568, DOI 10.1016/0006-291X(71)90409-8; AOKI Y, 1978, J BIOL CHEM, V253, P2026; AOKI Y, 1975, BIOCHEM BIOPH RES CO, V65, P567, DOI 10.1016/S0006-291X(75)80184-7; BANNERMAN RM, 1959, BRIT J HAEMATOL, V5, P102, DOI 10.1111/j.1365-2141.1959.tb04016.x; BISHOP DF, 1990, NUCLEIC ACIDS RES, V18, P7187, DOI 10.1093/nar/18.23.7187; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BISHOP DF, 1982, ENZYME, V28, P94, DOI 10.1159/000459094; BURNHAM BF, 1963, BIOCHEM J, V87, P462, DOI 10.1042/bj0870462; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; COX TM, 1990, IRON TRANSPORT STORA, P200; DANDEKAR T, 1991, EMBO J, V10, P1902; Dierks P, 1990, BIOSYNTHESIS HEME CH, P201; EBERT PS, 1979, BIOCHEM BIOPH RES CO, V88, P1382, DOI 10.1016/0006-291X(79)91133-1; EBERT PS, 1970, BIOCHIM BIOPHYS ACTA, V208, P236, DOI 10.1016/0304-4165(70)90242-4; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARDNER LC, 1988, J BIOL CHEM, V263, P6676; HEGESH E, 1968, J LAB CLIN MED, V72, P339; Jordan PM, 1990, BIOSYNTHESIS HEME CH, P55; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; LAGHAI A, 1977, BIOCHEM SOC T, V5, P299, DOI 10.1042/bst0050299; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LONDON IM, 1987, ENZYMES, V18, P359; MAY BK, 1990, MOL BIOL MED, V7, P405; MORGAN EH, 1983, BIOCHIM BIOPHYS ACTA, V733, P39, DOI 10.1016/0005-2736(83)90089-5; NEUWIRT J, 1969, EUR J BIOCHEM, V9, P36, DOI 10.1111/j.1432-1033.1969.tb00572.x; PIPPARD MJ, 1979, LANCET, V2, P819; PONKA P, 1985, BLOOD, V65, P850; PONKA P, 1985, J BIOL CHEM, V260, P4717; RANK JM, 1990, MOL ASPECTS MED, V11, P86; Ranu R S, 1979, Methods Enzymol, V60, P459; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LABORATO, P743; SHEMIN D, 1953, J AM CHEM SOC, V75, P4873, DOI 10.1021/ja01115a546; SIMON EJ, 1953, J AM CHEM SOC, V75, P2520, DOI 10.1021/ja01106a522; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TSHUDY DP, 1965, BIOCHEM BIOPH RES CO, V21, P480; WATANABE N, 1983, BIOCHEM BIOPH RES CO, V113, P377, DOI 10.1016/0006-291X(83)91737-0; WATSON CJ, 1974, P NATL ACAD SCI USA, V71, P278, DOI 10.1073/pnas.71.2.278; WHITCOMBE D, 1991, IN PRESS GENOMICS BA; WILSON JT, 1978, NUCLEIC ACIDS RES, V5, P563, DOI 10.1093/nar/5.2.563	48	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					22010	22018						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939222				2022-12-25	WOS:A1991GP80400103
J	GREEN, SM; GINSBURG, A; LEWIS, MS; HENSLEY, P				GREEN, SM; GINSBURG, A; LEWIS, MS; HENSLEY, P			ROLES OF METAL-IONS IN THE MAINTENANCE OF THE TERTIARY AND QUATERNARY STRUCTURE OF ARGINASE FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIVER ARGINASE; DNA-BINDING DOMAIN; COLI ASPARTATE TRANSCARBAMOYLASE; L-ORNITHINE CARBAMOYLTRANSFERASE; SINGLE ZINC FINGER; ESCHERICHIA-COLI; COMPLEX-FORMATION; LIGAND-BINDING; YEAST ADR1; PURIFICATION	Arginase from Saccharomyces cerevisiae has long been known to be a metal ion-requiring enzyme as it requires heating at 45-degrees-C in the presence of 10 mM Mn2+ for catalytic activation. Metals are also thought to play a structural role in the enzyme, but the identity of the structural metal and its precise structural role have not been defined. Analysis of the metal ions that bind to yeast arginase by atomic absorption spectroscopy reveals that there is a weakly associated Mn2+ that binds to the trimeric enzyme with a stoichiometry of 1.04 +/- 0.05 mol of Mn2+ bound per subunit and an apparent K(D)' value of 26-mu-M at pH 7.0 and 4-degrees-C. A more tightly associated Zn2+ ion can only be removed by dialysis against chelating agents. In occasional preparations, this site contained some Mn2+; however, Zn2+ and Mn2+ together bind to high affinity sites with a stoichiometry of 1.14 +/- 0.25/mol of subunit. Both the loosely associated catalytic Mn2+ ion and the more tightly associated structural Zn2+ ion confer stability to the enzyme. Removal of the weakly bound Mn2+ ion results in a 3-degrees-C decrease in the midpoint of the thermal transition (T1/2) (from 57 by 54-degrees-C) as monitored by UV difference absorption spectroscopy. Removal of the tightly bound Zn2+ ion produces a 19-degrees-C decrease in T1/2 (to 38-degrees-C). Similar results are obtained by circular dichroism measurements. When the Zn2+ ion is removed, the steady-state fluorescence intensity increases 100% as compared to the holoenzyme, with a shift in the emission maximum from 337 to 352 nm. This suggests that in the folded trimeric metalloenzyme, the tryptophan fluorescence is quenched and that upon removal of the structural metal, the quenching is relieved as tryptophan residues become exposed to more polar environments. Equilibrium sedimentation experiments performed after dialysis of the enzyme against EDTA demonstrate that arginase exists in a reversible monomer-trimer equilibrium, in the absence of metal ions, with a K(D) value of 5.05 x 10(-11) M2. In contrast, the native enzyme exists as a trimer with no evidence of dissociation when Mn2+ and Zn2+ are present (Eisenstein, E., Duong, L. T., Ornberg, R. L., Osborne, J. C., Jr., and Hensley, P. (1986) J. Biol. Chem. 261, 12814-12819). In summary, the study presented here demonstrates that binding of a weakly bound Mn2+ ion confers catalytic activity. In contrast, binding of a more tightly associated Zn2+ ion confers substantial stability to the tertiary and quaternary structure of the enzyme.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WASHINGTON,DC 20007; NCI,INST HEART LUNG & BLOOD,BIOCHEM LAB,PROT CHEM SECT,BETHESDA,MD 20892; NCI,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BECHET J, 1965, BIOCHEM BIOPH RES CO, V21, P226, DOI 10.1016/0006-291X(65)90276-7; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; CARVAJAL N, 1978, BIOCHIM BIOPHYS ACTA, V527, P1, DOI 10.1016/0005-2744(78)90250-4; CARVAJAL N, 1977, BIOCHIM BIOPHYS ACTA, V481, P177, DOI 10.1016/0005-2744(77)90149-8; CARVAJAL N, 1971, BIOCHIM BIOPHYS ACTA, V250, P437, DOI 10.1016/0005-2744(71)90200-2; COHLBERG JA, 1972, BIOCHEMISTRY-US, V11, P3396, DOI 10.1021/bi00768a013; DUONG LT, 1986, J BIOL CHEM, V261, P2807; EISENSTEIN E, 1986, J BIOL CHEM, V261, P2814; EISENSTEIN E, 1986, J BIOL CHEM, V261, P6192; EISENSTEIN E, 1984, J BIOL CHEM, V259, P5139; EISENSTEIN E, 1985, THESIS GEORGETOWN U; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; GERHART JC, 1965, BIOCHEMISTRY-US, V4, P1054, DOI 10.1021/bi00882a012; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; GREEN S M, 1988, Journal of Cell Biology, V107, p200A; GREEN S M, 1989, Biophysical Journal, V55, p532A; GREEN SM, 1990, BIOCHEMISTRY-US, V29, P9159, DOI 10.1021/bi00491a009; GREEN SM, 1986, FASEB J, V45, P1920; GREEN SM, 1990, J BIOL CHEM, V265, P1601; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; Hellerman L, 1935, J BIOL CHEM, V112, P175; HENSLEY P, 1988, CURR TOP CELL REGUL, V29, P35; HIRSCHKO.H, 1971, J BIOL CHEM, V246, P395; HIRSCHKOLB H, 1970, COMP BIOCHEM PHYSIOL, V37, P345, DOI 10.1016/0010-406X(70)90563-3; HIRSCHKOLB H, 1968, J BIOL CHEM, V243, P6123; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; HUNT JB, 1984, J BIOL CHEM, V259, P4793; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MESSENGUY F, 1969, FEBS LETT, V3, P47, DOI 10.1016/0014-5793(69)80093-1; MIDDELHOVEN WJ, 1969, BIOCHIM BIOPHYS ACTA, V191, P122, DOI 10.1016/0005-2744(69)90321-0; MIDDELHOVEN WJ, 1969, BIOCHIM BIOPHYS ACTA, V191, P110, DOI 10.1016/0005-2744(69)90320-9; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MONACO HL, 1978, P NATL ACAD SCI USA, V75, P5276, DOI 10.1073/pnas.75.11.5276; NELBACH ME, 1972, BIOCHEMISTRY-US, V11, P315, DOI 10.1021/bi00753a002; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PENNINCKX M, 1976, J MOL BIOL, V104, P819, DOI 10.1016/0022-2836(76)90184-4; PENNINCKX M, 1975, EUR J BIOCHEM, V58, P533, DOI 10.1111/j.1432-1033.1975.tb02402.x; PENNINCKX M, 1974, EUR J BIOCHEM, V49, P429, DOI 10.1111/j.1432-1033.1974.tb03848.x; POLLAK M, 1979, COLLECT CZECH CHEM C, V44, P725, DOI 10.1135/cccc19790725; ROARK DE, 1976, BIOPHYS CHEM, V5, P185, DOI 10.1016/0301-4622(76)80034-8; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SPANGLER CS, 1991, THESIS J HOPKINS U; STEWART JA, 1977, J NEUROCHEM, V29, P657, DOI 10.1111/j.1471-4159.1977.tb07783.x; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; SUMRADA RA, 1984, J BACTERIOL, V160, P1078, DOI 10.1128/JB.160.3.1078-1087.1984; TANAKA M, 1968, INORG CHEM, V7, P573, DOI 10.1021/ic50061a038; VIELLEBREITBURD F, 1972, J BIOL CHEM, V247, P1227; WIAME JM, 1971, CURRENT TOPICS CELLU, V4, P1	58	51	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21474	21481						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939179				2022-12-25	WOS:A1991GP80400028
J	HENDZEL, MJ; DELCUVE, GP; DAVIE, JR				HENDZEL, MJ; DELCUVE, GP; DAVIE, JR			HISTONE DEACETYLASE IS A COMPONENT OF THE INTERNAL NUCLEAR MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE COMPETENT CHROMATIN; NUCLEOSOME CORE PARTICLE; LINKING NUMBER CHANGE; CHICKEN ERYTHROCYTES; ACETYLATION SITES; GENES; TRANSCRIPTION; ORGANIZATION; CELLS; LOOP	In chicken immature erythrocytes, approximately 4% of the modifiable histone lysine sites participate in active acetylation. There are two categories of actively acetylated histone H-4. Although both are acetylated at the same rate (t1/2 = 12 min), one is acetylated to the tetraacetylated form and is rapidly deacetylated (class 1), and the other is acetylated to mono- and diacetylated forms and is slowly deacetylated (class 2). We show that the chromatin distribution of the class 1 labeled tetraacetylated H-4 species paralleled that of the transcriptionally active DNA sequences. For example, the chromatin fragments of the insoluble nuclear material contained 76% of the active DNA and 74% of the labeled tetraacetylated H-4. Class 2 labeled acetylated H-4 species were found in repressed chromatin and were enriched in active/competent gene-enriched chromatin fragments. The majority of the histone deacetylase activity (75-80%) was located with the insoluble residual nuclear material. Further, approximately 40-50% of the enzyme activity was associated with nuclear matrices prepared by two methods using high salt and intermediate/high salt extraction. Histone deacetylase was solubilized by extracting the nuclear matrices with high salt and 2-mereaptoethanol, a procedure that generates nuclear pore-lamina complexes. These results demonstrate that histone deacetylase is a component of the internal nuclear matrix.	UNIV MANITOBA,FAC MED,DEPT BIOCHEM & MOLEC BIOL,WINNIPEG R3E 0W3,MANITOBA,CANADA	University of Manitoba			Hendzel, Michael/C-3391-2009	Hendzel, Michael/0000-0002-9603-7945; Davie, James/0000-0002-0420-6888				ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; BOFFA LC, 1990, EUR J BIOCHEM, V194, P811, DOI 10.1111/j.1432-1033.1990.tb19474.x; CHAN S, 1988, J BIOL CHEM, V263, P15643; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COHEN RB, 1985, J MOL BIOL, V182, P109, DOI 10.1016/0022-2836(85)90031-2; COOK PR, 1988, J CELL SCI, V90, P1; DELCUVE GP, 1989, BIOCHEM J, V263, P179, DOI 10.1042/bj2630179; EINCK L, 1986, BIOCHEMISTRY-US, V25, P7063; HAY CW, 1983, BIOCHEMISTRY-US, V22, P6175, DOI 10.1021/bi00295a021; HAY CW, 1983, J BIOL CHEM, V258, P3726; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; HENDZEL MJ, 1990, BIOCHEM J, V271, P67, DOI 10.1042/bj2710067; HENDZEL MJ, 1989, J BIOL CHEM, V264, P19208; HENDZEL MJ, 1991, BIOCHEM J, V273, P753, DOI 10.1042/bj2730753; IP YT, 1988, J BIOL CHEM, V263, P14044; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MOLD DE, 1987, BIOCHEMISTRY-US, V26, P8257, DOI 10.1021/bi00399a036; NICKEL BE, 1987, BIOCHEMISTRY-US, V26, P4417, DOI 10.1021/bi00388a034; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; NORTON VG, 1990, J BIOL CHEM, V265, P19848; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PESIS KH, 1986, ARCH BIOCHEM BIOPHYS, V251, P665, DOI 10.1016/0003-9861(86)90376-0; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; ROBERGE M, 1988, J MOL BIOL, V201, P545, DOI 10.1016/0022-2836(88)90636-5; ROSE SM, 1984, J BIOL CHEM, V259, P8534; STRATLING WH, 1986, BIOCHEMISTRY-US, V25, P495, DOI 10.1021/bi00350a033; STRATLING WH, 1987, BIOCHEMISTRY-US, V26, P7893, DOI 10.1021/bi00398a053; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; TURNER BM, 1989, EXP CELL RES, V182, P206, DOI 10.1016/0014-4827(89)90292-9; VERHEIJEN R, 1988, J CELL SCI, V90, P11; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WALKER J, 1990, J BIOL CHEM, V265, P5736; WATERBORG JH, 1990, J BIOL CHEM, V265, P17157; ZHANG DE, 1988, BIOCHEM J, V250, P241, DOI 10.1042/bj2500241; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233; ZHANG DE, 1986, BIOCHEM J, V240, P857, DOI 10.1042/bj2400857	40	103	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21936	21942						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939216				2022-12-25	WOS:A1991GP80400092
J	MCANDREW, SJ; CHEN, NY; WIEHL, P; DICAPRIO, L; YUN, J; WAGNER, TE; OKADA, S; KOPCHICK, JJ				MCANDREW, SJ; CHEN, NY; WIEHL, P; DICAPRIO, L; YUN, J; WAGNER, TE; OKADA, S; KOPCHICK, JJ			EXPRESSION OF TRUNCATED FORMS OF THE BOVINE GROWTH-HORMONE GENE IN CULTURED MOUSE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SECONDARY STRUCTURE; MESSENGER-RNA; ENDOPLASMIC-RETICULUM; PROTEINS; TRANSFECTION; MEMBRANES; PROLACTIN; VARIANT; CLONING; VIRUS	A synthetic oligonucleotide, 5'-d(CTAGTCTAGACTAG)-3' which encodes translational termination codons in three reading frames, was inserted into either exon IV (pbGH-4A) or V (pbGH-5A) of the bovine growth hormone gene. The resultant plasmids, under the transcriptional regulation of the mouse metallothionein 1 promoter, were introduced into cultured mouse L-cells or rat GH3 cells. Compared to wild type bGH RNA, bGH-specific RNA transiently expressed from pBGH-5A or pBGH-4A DNA in mouse L-cells was similar or slightly smaller in size, respectively. Unexpectedly, bGH-4A RNA lacked exon IV sequences. Immunofluorescence and immunoprecipitation analyses revealed that wild type bGH was localized to the Golgi apparatus, while truncated hormones were confined to the cytoplasmic compartment of transfected cells. In addition, truncated hormones were shown to be secretion-defective albeit the bGH signal peptide was efficiently and precisely processed. Thus, structural alterations in the bGH gene can dramatically affect bGH precursor mRNA processing and hormone localization within cultured mouse fibroblast or rat pituitary cells.	OHIO UNIV,EDISON ANIM BIOTECHNOL CTR,201 WILSON HALL W GREEN,ATHENS,OH 45701; OHIO UNIV,DEPT ZOOL & BIOMED SCI,MOLEC & CELLULAR BIOL PROGRAM,ATHENS,OH 45701	University System of Ohio; Ohio University; University System of Ohio; Ohio University								BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRINSTER RL, 1982, NATURE, V296, P39, DOI 10.1038/296039a0; CHEN WY, 1991, J BIOL CHEM, V266, P2252; CHEN WY, 1990, P NATL ACAD SCI USA, V87, P5061, DOI 10.1073/pnas.87.13.5061; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAMPSON RK, 1987, P NATL ACAD SCI USA, V84, P2673, DOI 10.1073/pnas.84.9.2673; HAMPSON RK, 1989, MOL CELL BIOL, V9, P1604, DOI 10.1128/MCB.9.4.1604; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KOPCHICK JJ, 1985, DNA-J MOLEC CELL BIO, V4, P23, DOI 10.1089/dna.1985.4.23; KOSTYO JL, 1985, P NATL ACAD SCI USA, V82, P4250, DOI 10.1073/pnas.82.12.4250; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEUNG FC, 1986, ENDOCRINOLOGY, V119, P1490; LEWIS UJ, 1978, J BIOL CHEM, V253, P2679; LEWIS UJ, 1984, ANNU REV PHYSIOL, V46, P33; LEWIS UJ, 1987, BELTSVILLE S AGR RES, V12; LINGAPPA VR, 1977, P NATL ACAD SCI USA, V74, P2432, DOI 10.1073/pnas.74.6.2432; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MILLER WL, 1980, J BIOL CHEM, V255, P7521; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; SOLNICK D, 1985, CELL, V43, P667, DOI 10.1016/0092-8674(85)90239-9; SOLNICK D, 1987, MOL CELL BIOL, V7, P3194, DOI 10.1128/MCB.7.9.3194; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; WILLS JW, 1984, J CELL BIOL, V99, P2011, DOI 10.1083/jcb.99.6.2011; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; WOYCHIK RP, 1982, NUCLEIC ACIDS RES, V10, P7197, DOI 10.1093/nar/10.22.7197	32	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20965	20969						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939147				2022-12-25	WOS:A1991GN00100060
J	SHIRATAKI, H; KAIBUCHI, K; HIROYOSHI, M; ISOMURA, M; ARAKI, S; SASAKI, T; TAKAI, Y				SHIRATAKI, H; KAIBUCHI, K; HIROYOSHI, M; ISOMURA, M; ARAKI, S; SASAKI, T; TAKAI, Y			INHIBITION OF THE ACTION OF THE STIMULATORY GDP GTP EXCHANGE PROTEIN FOR SMG P21 BY THE GERANYLGERANYLATED SYNTHETIC PEPTIDES DESIGNED FROM ITS C-TERMINAL REGION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE EFFECTOR DOMAIN; BOVINE BRAIN CYTOSOL; RAS-RELATED PROTEIN; BINDING PROTEIN; HUMAN-PLATELETS; CARBOXYL-METHYLATION; ACTIVATING PROTEINS; MOLECULAR-WEIGHT; PURIFICATION; CYSTEINE	smg p21B, a member of the ras p21-like small GTP-binding protein superfamily, undergoes post-translational modifications, which are geranylgeranylation of the cysteine residue in the C-terminal region followed by removal of the three C-terminal amino acids (QLL) and the subsequent carboxyl methylation of the exposed prenylated cysteine residue. smg p21B has a polybasic region upstream of the prenylated cysteine residue. We have previously proposed that these C-terminal structures of smg p21B are essential for the action of its stimulatory GDP/GTP exchange protein, named GDP dissociation stimulator (GDS). We studied here which structure of the C-terminal region of smg p21B is important for its interaction with smg p21 GDS. For this purpose, we synthesized a peptide according to the C-terminal structure of smg p21B, which was PGKARKKSSC-geranylgeranyl-carboxyl methyl, and its variously modified peptides and examined their ability to interact with smg p21 GDS and to interfere with the smg p21 GDS action to stimulate the GDP/GTP exchange reaction of smg p2lB. The results indicate that the phosphorylated form of PGKARKKSSC-geranylgeranyl stoichiometrically interacts with smg p21 GDS, that the presence of the geranylgeranyl moiety is essential for, but not sufficient for, the smg p21 GDS action, and that the presence of the methyl moiety, removal of the three C-terminal amino acids, and the presence of the polybasic amino acids also affect the smg p21 GDS action. It is likely that all the steps of the post-translational processing and presence of the polybasic region in the C-terminal region of smg p21B are related to its interaction with smg p21 GDS.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HATA Y, 1991, J BIOL CHEM, V266, P6571; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P363, DOI 10.1080/00021369.1979.10863433; KAWAMURA S, 1991, BIOCHEM BIOPH RES CO, V174, P1095, DOI 10.1016/0006-291X(91)91533-I; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KAWATA M, 1991, ONCOGENE, V6, P841; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; OHMORI T, 1989, J BIOL CHEM, V264, P1877; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; TACHIBANA S, 1988, PEPTIDE CHEM, P481; TAKAI Y, 1991, IN PRESS INT REV CYT; UEDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1411, DOI 10.1016/0006-291X(89)92267-5; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	38	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20672	20677						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939117				2022-12-25	WOS:A1991GN00100016
J	BURNS, PA; JACK, A; NEILSON, F; HADDOW, S; BALMAIN, A				BURNS, PA; JACK, A; NEILSON, F; HADDOW, S; BALMAIN, A			TRANSFORMATION OF MOUSE SKIN ENDOTHELIAL-CELLS INVIVO BY DIRECT APPLICATION OF PLASMID DNA ENCODING THE HUMAN T24 H-RAS ONCOGENE	ONCOGENE			English	Article							BLADDER-CARCINOMA ONCOGENE; MURINE SARCOMA-VIRUS; EMBRYO FIBROBLASTS; TRANSGENIC MICE; TUMOR PROMOTERS; POINT MUTATION; HARVEY; GENE; CARCINOGENESIS; ACTIVATION	Plasmid DNA containing the human T24 H-ras oncogene, with or without viral transcriptional enhancer sequences, was applied to scarified mouse skin, followed by multiple treatments with the tumour promoter 12-O-tetradecanoyl-phorbol-13-acetate. This resulted in the formation of vasoformative tumours histologically characterized as lymphangiosarcomas. All of the animals treated developed cystic fluid-filled swellings. Polymerase chain reaction analysis revealed the presence of human H-ras sequences within the cystic fluid from 3 out of 4 swellings. An endothelial cell line established from the cystic fluid removed from one of these swellings was found to contain human H-ras sequences and to express the mutant human p21ras. Injection of the cell line into nude mice, or adult syngeneic mice, resulted in the formation of aggressive angiosarcomas. Further experiments showed that 12-O-tetradecanol-phorbol-13-acetate promotion is not required for tumour formation and would appear to reduce the yield of tumours. These results indicate that a single application of the human H-ras oncogene is sufficient to induce endothelial cell transformation in vivo, even in the absence of any further promotional stimulus.	UNIV LEEDS, DEPT PATHOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds	BURNS, PA (corresponding author), BEATSON INST CANC RES, CRC BEATSON LABS, GARSCUBE ESTATE, GLASGOW G61 1BD, SCOTLAND.							ARMES J, 1989, ADV CANCER RES, V53, P73; ASSELIN C, 1984, MOL CELL BIOL, V4, P755, DOI 10.1128/MCB.4.4.755; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DONOGHUE DJ, 1984, NATURE, V308, P748, DOI 10.1038/308748a0; DOTTO GP, 1985, NATURE, V318, P472; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FUNG YKT, 1983, P NATL ACAD SCI-BIOL, V80, P353, DOI 10.1073/pnas.80.2.353; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0; HSIAO WLW, 1984, SCIENCE, V226, P552, DOI 10.1126/science.6436974; KATZ L, 1973, J BACTERIOL, V114, P577, DOI 10.1128/JB.114.2.577-591.1973; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAITOH A, 1990, ONCOGENE, V5, P1195; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WILLIAMS RL, 1988, CELL, V52, P121; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614	29	22	23	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					1973	1978						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945407				2022-12-25	WOS:A1991GX11900005
J	GUAN, E; BURGESS, WH; ROBINSON, SL; GOODMAN, EB; MCTIGUE, KJ; TENNER, AJ				GUAN, E; BURGESS, WH; ROBINSON, SL; GOODMAN, EB; MCTIGUE, KJ; TENNER, AJ			PHAGOCYTIC CELL MOLECULES THAT BIND THE COLLAGEN-LIKE REGION OF C1Q - INVOLVEMENT IN THE C1Q-MEDIATED ENHANCEMENT OF PHAGOCYTOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; 1ST COMPLEMENT COMPONENT; WISKOTT-ALDRICH SYNDROME; HUMAN PERIPHERAL-BLOOD; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; HUMAN MONONUCLEAR PHAGOCYTES; DIPEPTIDYL PEPTIDASE-IV; HUMAN-MONOCYTES; MONOCLONAL-ANTIBODY; SURFACE SIALOGLYCOPROTEIN	C1q binds to and elicits cellular responses by several cell types, including monocytes, macrophages, neutrophils, B cells, and fibroblasts. The cell-binding domain is located within the collagen-like pepsin-resistant region of the C1q molecule (C1q tails). An affinity matrix of C1q tails coupled to Sepharose was used to select C1q-binding proteins from detergent extracts of surface-iodinated human monocytes, polymorphonuclear leukocytes, and the U937 cells. The major radiolabeled polypeptide eluted specifically from the ligand affinity column had an apparent molecular mass (M(r)) of 126,000. Minor iodinated components eluted from Sepharose-tails migrated with M(r) of 216,000 and 55,000. When subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions no change in the migration of any of these polypeptide bands was detected. None of these polypeptides reacted with antibodies directed against the integrins alpha-5-beta-1 (fibronectin receptor) or alpha-upsilon-beta-3 (vitronectin receptor), LFA-1, or to several other cell adhesion molecules. The M(r) 126,000 band was found to contain more than one polypeptide. Lectin binding properties, susceptibility to glycosidases and proteases, and immunoreactivity with the monoclonal antibody L-10, indicated that CD43 (sialophorin/leukosialin) is a component of this band. However, further data show that a monoclonal antibody, generated by immunization with the isolated C1q-binding fractions, recognizes a cell surface sialoglycoprotein distinct from CD43 and inhibits the C1q-mediated enhancement of phagocytosis in monocytes. These latter observations provide the first definitive connection between a specific phagocytic cell surface protein and a known C1q-mediated function. While these proteins contain sialic acid, binding assays and functional assays using neuraminidase-treated cells demonstrate that the functional interaction between C1q and the cell surface is not via sialic acid. The data taken together indicate either that the functional C1q receptor on phagocytic cells is a multisubunit complex or that multiple proteins can interact with the fragment of C1q containing the cell-binding domain, at least one of which is involved in the C1q-mediated enhancement of phagocytosis.	AMER RED CROSS, BIOCHEM LAB, BIOMED RES & DEV, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA; AMER RED CROSS, MOLEC BIOL LAB, BIOMED RES & DEV, BETHESDA, MD 20855 USA	American Red Cross; American Red Cross					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027168] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-27168] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON CL, 1982, J EXP MED, V156, P1794, DOI 10.1084/jem.156.6.1794; ANTES U, 1988, ARTHRITIS RHEUM, V31, P457, DOI 10.1002/art.1780310401; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; AUDETTE M, 1987, MOL IMMUNOL, V24, P1177, DOI 10.1016/0161-5890(87)90164-7; BAUVOIS B, 1988, BIOCHEM J, V252, P723, DOI 10.1042/bj2520723; BOBAK DA, 1988, EUR J IMMUNOL, V18, P2001, DOI 10.1002/eji.1830181220; BOBAK DA, 1986, J IMMUNOL, V136, P4604; BOBAK DA, 1987, J IMMUNOL, V138, P1150; BOBAK DA, 1988, J IMMUNOL, V141, P592; BOHNSACK JF, 1985, J EXP MED, V161, P912, DOI 10.1084/jem.161.5.912; BOYUM A, 1976, SCAND J IMMUNOL, P9, DOI 10.1111/j.1365-3083.1976.tb03851.x; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; DAHA MR, 1990, J IMMUNOL, V144, P1227; DANG NH, 1990, J EXP MED, V172, P649, DOI 10.1084/jem.172.2.649; DANG NH, 1990, J IMMUNOL, V144, P4092; DEBETS JMH, 1990, J IMMUNOL, V144, P1304; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; ERDEI A, 1988, MOL IMMUNOL, V25, P1067, DOI 10.1016/0161-5890(88)90139-3; ERDEI A, 1988, BIOCHEM J, V255, P493; FRANZBLAU C, 1976, BIOCHIM BIOPHYS ACTA, V427, P302, DOI 10.1016/0005-2795(76)90306-8; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GHEBREHIWET B, 1986, J IMMUNOL, V137, P618; GHEBREHIWET B, 1990, CLIN IMMUNOL IMMUNOP, V54, P148, DOI 10.1016/0090-1229(90)90014-H; GHEBREHIWET B, 1984, J EXP MED, V160, P1375, DOI 10.1084/jem.160.5.1375; Ghebrehiwet B, 1989, Behring Inst Mitt, P204; GOYERT SM, 1986, J IMMUNOL, V137, P3909; HAMADA A, 1988, J CLIN INVEST, V82, P945, DOI 10.1172/JCI113702; HAMADA A, 1987, J IMMUNOL, V138, P1240; HEGEN M, 1990, J IMMUNOL, V144, P2908; HOEKZEMA R, 1985, J IMMUNOL, V135, P265; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; KOLB WP, 1979, J IMMUNOL, V122, P2103; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURELL AB, 1978, ACTA PATH MICRO IM C, V86, P299; LEU RW, 1989, CELL IMMUNOL, V122, P48, DOI 10.1016/0008-8749(89)90147-0; LEU RW, 1989, J IMMUNOL, V143, P3250; Lionetti F. J., 1980, METHODS CELL SEPARAT, P141; MALHOTRA R, 1988, BIOCHEM SOC T, V16, P735, DOI 10.1042/bst0160735; MALHOTRA R, 1989, BIOCHEM J, V262, P625, DOI 10.1042/bj2620625; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; MORIMOTO C, 1989, J IMMUNOL, V143, P3430; Narahashi Y., 1970, METHOD ENZYMOL, V19, P651, DOI DOI 10.1016/0076-6879(70)19052-5; NONG YH, 1989, J EXP MED, V170, P259, DOI 10.1084/jem.170.1.259; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OIKI S, 1988, J IMMUNOL, V141, P3177; PEERSCHKE EIB, 1990, J IMMUNOL, V144, P221; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; PEZZUTTO A, 1987, J IMMUNOL, V138, P2793; REID KBM, 1976, BIOCHEM J, V155, P5, DOI 10.1042/bj1550005; REID KBM, 1972, BIOCHEM J, V130, P749, DOI 10.1042/bj1300749; REID KBM, 1983, BIOCHEM SOC T, V11, P1; REMOLDODONNELL E, 1990, J IMMUNOL, V145, P3372; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; REMOLDODONNELL E, 1987, BLOOD, V70, P104; RIMOLDI MT, 1989, J CLIN INVEST, V84, P1982, DOI 10.1172/JCI114388; ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SCHON E, 1987, EUR J IMMUNOL, V17, P1821, DOI 10.1002/eji.1830171222; SEGREST JP, 1971, BIOCHEM BIOPH RES CO, V44, P390, DOI 10.1016/0006-291X(71)90612-7; SIEGEL RC, 1983, MOL IMMUNOL, V20, P53, DOI 10.1016/0161-5890(83)90105-0; SIEGERT CEH, 1990, ARTHRITIS RHEUM, V33, P1646, DOI 10.1002/art.1780331107; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; SORVILLO JM, 1986, J IMMUNOL, V136, P1023; TENNER A, 1989, BEHRING I MITT, V84, P220; TENNER AJ, 1987, FED PROC, V46, P1195; TENNER AJ, 1980, J IMMUNOL, V125, P1658; TENNER AJ, 1981, J IMMUNOL, V126, P1174; TENNER AJ, 1981, J IMMUNOL, V127, P648; TENNER AJ, 1982, J IMMUNOL, V128, P2547; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UWATOKO S, 1989, ARTHRITIS RHEUM, V32, P1601, DOI 10.1002/anr.1780321216; WISNIESKI JJ, 1989, ARTHRITIS RHEUM-US, V32, P1119, DOI 10.1002/anr.1780320910; WONG RCK, 1990, J IMMUNOL, V144, P1455; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YOUNG KR, 1991, J IMMUNOL, V146, P3356; ZICCARDI RJ, 1979, J IMMUNOL, V123, P788	82	100	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20345	20355						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939090				2022-12-25	WOS:A1991GM03900070
J	MINOTTI, G; IKEDASAITO, M				MINOTTI, G; IKEDASAITO, M			BOVINE HEART MICROSOMES CONTAIN AN MR = 66,000 NONHEME IRON PROTEIN WHICH STIMULATES NADPH OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; NADPH-CYTOCHROME-P-450 REDUCTASE; MITOCHONDRIAL IRON; RADICAL PRODUCTION; SULFUR CENTERS; IRON(III); FERRITIN; RELEASE; BINDING; ANIMALS	Bovine heart microsomes have been found to contain a non-heme iron protein which serves as an electron acceptor for NADPH-cytochrome P-450 reductase and therefore stimulates NADPH oxidation. This protein, tentatively referred to as Microsomal Iron Protein (MIP), has been extracted with Triton N-101 and purified by ion exchange chromatography on CM- and DEAE-celluloses and gel filtration on Sepharose 6B. MIP is an M(r) = 66,000 monomer with 17 atoms of Fe(III)/molecule. Incubation with dithionite removes iron from MIP and abolishes the stimulation of NADPH oxidation, but subsequent incubation with nitrilotriacetic-Fe(III) reincorporates iron and restores the stimulation of NADPH oxidation. Oxygen is the ultimate electron acceptor. In the presence of oxygen, the enzymatic reduction of MIP Fe(III) is followed by the reoxidation of Fe(II) at the expense of oxygen, generating superoxide anion and regenerating MIP Fe(III) for the continuous oxidation of NADPH. In the absence of oxygen, electron transfer from the reductase to MIP Fe(III) causes the release of Fe(II), which limits the ability of MIP to serve as an electron acceptor and stimulate NADPH oxidation. The -NH2-terminal of MIP has been sequenced, and no homology has been found with the sequence of other iron storage or transport proteins such as ferritin or transferrin.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Case Western Reserve University			Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015	Minotti, Giorgio/0000-0002-5678-6175	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR005659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039359, R01GM039492] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05659] Funding Source: Medline; NIGMS NIH HHS [GM39492, GM39359] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ALBANO E, 1988, CHEM-BIOL INTERACT, V65, P223, DOI 10.1016/0009-2797(88)90108-1; BATES GW, 1971, J BIOL CHEM, V246, P3679; BEERS RF, 1952, J BIOL CHEM, V195, P133; Cammack R, 1990, IRON TRANSPORT STORA, P17; CHASTEEN ND, 1982, J BIOL CHEM, V257, P7672; CLEJAN LA, 1991, ARCH BIOCHEM BIOPHYS, V285, P83, DOI 10.1016/0003-9861(91)90331-C; DOUSSIERE J, 1985, BIOCHEMISTRY-US, V24, P7231, DOI 10.1021/bi00346a032; FLOREANI M, 1989, ARCH BIOCHEM BIOPHYS, V270, P33, DOI 10.1016/0003-9861(89)90004-0; HARRISON PM, 1977, CIBA F S, V51, P19; HARRSON DM, 1990, IRON TRANSPORT STORA, P81; KENNEDY CH, 1990, J BIOL CHEM, V265, P11425; KRIKUN G, 1986, FEBS LETT, V208, P292, DOI 10.1016/0014-5793(86)81035-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH DO, 1982, BIOCHIM BIOPHYS ACTA, V719, P501, DOI 10.1016/0304-4165(82)90239-2; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LINDER MC, 1989, ARCH BIOCHEM BIOPHYS, V273, P34, DOI 10.1016/0003-9861(89)90159-8; MALKIN R, 1973, IRON SULPHUR PROTEIN, V2, P1; MASON H. S., 1965, FEDERATION PROC, V24, P1172; MAY EM, 1977, PROTEINS IRON METABO, P31; MCCORD JM, 1969, J BIOL CHEM, V243, P5763; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; MINOTTI G, 1990, ARCH BIOCHEM BIOPHYS, V277, P268, DOI 10.1016/0003-9861(90)90578-M; MINOTTI G, 1989, ARCH BIOCHEM BIOPHYS, V273, P137, DOI 10.1016/0003-9861(89)90171-9; MINOTTI G, 1987, J BIOL CHEM, V262, P1098; MINOTTI G, 1989, ARCH BIOCHEM BIOPHYS, V268, P398, DOI 10.1016/0003-9861(89)90601-2; MINOTTI G, 1990, ARCH BIOCHEM BIOPHYS, V282, P270, DOI 10.1016/0003-9861(90)90116-G; MIYAKE Y, 1968, J BIOL CHEM, V243, P5788; MONTGOMERY MR, 1974, ARCH BIOCHEM BIOPHYS, V160, P113, DOI 10.1016/S0003-9861(74)80015-9; MOREHOUSE LA, 1984, ARCH BIOCHEM BIOPHYS, V232, P366, DOI 10.1016/0003-9861(84)90552-6; MOREHOUSE LA, 1988, FREE RADICAL BIO MED, V4, P269, DOI 10.1016/0891-5849(88)90047-0; NEBERT DW, 1973, J BIOL CHEM, V248, P169; OHNISHI T, 1976, BIOCHEM J, V153, P39, DOI 10.1042/bj1530039; OMURA T, 1964, J BIOL CHEM, V239, P2370; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEDERSON TC, 1970, BIOCHEM PHARMACOL, V19, P2221, DOI 10.1016/0006-2952(70)90121-8; PUNTARULO S, 1989, FREE RADICAL BIO MED, V7, P269, DOI 10.1016/0891-5849(89)90134-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Strobel H W, 1978, Methods Enzymol, V52, P89; TANGERAS A, 1980, BIOCHIM BIOPHYS ACTA, V589, P162, DOI 10.1016/0005-2728(80)90035-3; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THOMAS C E, 1985, Journal of Free Radicals in Biology and Medicine, V1, P293; VILE GF, 1987, FEBS LETT, V215, P151, DOI 10.1016/0014-5793(87)80131-X; WEIR MP, 1984, BIOCHEM J, V223, P31, DOI 10.1042/bj2230031; WINSTON GW, 1984, ARCH BIOCHEM BIOPHYS, V232, P378, DOI 10.1016/0003-9861(84)90553-8; 1988, WORTHINGTON ENZYME M, P155	47	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20011	20017						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939064				2022-12-25	WOS:A1991GM03900026
J	MILLER, H; CLAIBORNE, A				MILLER, H; CLAIBORNE, A			PEROXIDE MODIFICATION OF MONOALKYLATED GLUTATHIONE-REDUCTASE - STABILIZATION OF AN ACTIVE-SITE CYSTEINE-SULFENIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCAL NADH PEROXIDASE; 2-ELECTRON REDUCED ENZYME; FLAVIN REDOX CENTER; CRYSTALLOGRAPHIC ANALYSIS; 3-DIMENSIONAL STRUCTURE; HUMAN-ERYTHROCYTES; ESCHERICHIA-COLI; RESOLUTION; REACTIVITY; BINDING	Hydrogen peroxide reacts with two-electron reduced glutathione reductase (GR EH2 species) to give the native oxidized enzyme (E) without detectable intermediates. Prior alkylation of the EH2 interchange thiol with iodoacetamide, however, dramatically changes both the course and overall rate of the peroxide reaction. This oxidation, monitored spectrally, is characterized by an intermediate (EHR(int)) with enhanced long wavelength absorbance extending to 800 nm. This species decays in a second peroxide-dependent phase to an enzyme form (EHR(ox)) easily distinguished from E. Quenching experiments with catalase allow the isolation of a stable mixture consisting of 36% monoalkylated GR (EHR), 60% EHR(int) and 4% EHR(ox); NADPH titration and anaerobic dithiothreitol addition lead to quantitative reduction of EHR(int) to EHR, and there is an increase in thiol titer of 0.8 -SH/FAD on NADPH reduction. Of the four titratable thiols present in EHR, 2.7 are lost on oxidation to EHR(ox) and 0.7-0.8 mol of cysteic acid/FAD is formed. On the basis of these and other observations, we conclude that alkylation of the EH2 interchange thiol, which blocks disulfide formation, allows peroxide reaction at the remaining charge-transfer thiol to proceed via a stabilized cysteine-sulfenic acid intermediate (EHR(int)), which undergoes further oxidation to the corresponding cysteic acid (EHR(ox)).	WAKE FOREST UNIV,MED CTR,DEPT BIOCHEM,MED CTR BLVD,WINSTON SALEM,NC 27157	Wake Forest University			Miller, Holly/I-6942-2015	Miller, Holly/0000-0002-9076-5335	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035394] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35394] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; ALLISON WS, 1970, ARCH BIOCHEM BIOPHYS, V136, P383, DOI 10.1016/0003-9861(70)90209-2; ARSCOTT LD, 1981, BIOCHEMISTRY-US, V20, P1513, DOI 10.1021/bi00509a016; BOTT R, 1988, J BIOL CHEM, V263, P7895; BULGER JE, 1971, J BIOL CHEM, V246, P5578; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DAVIS FA, 1986, J ORG CHEM, V51, P1033, DOI 10.1021/jo00357a017; DEONARAIN MP, 1990, P ROY SOC B-BIOL SCI, V241, P179, DOI 10.1098/rspb.1990.0083; Frost AA, 1961, KINETICS MECHANISM, P166; HECKEL A, 1983, TETRAHEDRON LETT, V24, P5047, DOI 10.1016/S0040-4039(00)94037-1; JANES W, 1990, BIOCHEMISTRY-US, V29, P4022, DOI 10.1021/bi00468a033; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; KARPLUS PA, 1988, EUR J BIOCHEM, V171, P193, DOI 10.1111/j.1432-1033.1988.tb13775.x; KARPLUS PA, 1989, EUR J BIOCHEM, V178, P693, DOI 10.1111/j.1432-1033.1989.tb14500.x; KICE JL, 1980, ADV PHYS ORG CHEM, V17, P65; KRAUTHSIEGEL RL, 1982, EUR J BIOCHEM, V121, P259, DOI 10.1111/j.1432-1033.1982.tb05780.x; LIN WS, 1975, CAN J BIOCHEM CELL B, V53, P298, DOI 10.1139/o75-042; LIU TY, 1977, PROTEINS, V3, P239; MASSEY V, 1965, J BIOL CHEM, V240, P4470; MILLER H, 1990, J BIOL CHEM, V265, P9857; MOORE S, 1963, J BIOL CHEM, V238, P235; PAI EF, 1983, J BIOL CHEM, V258, P1752; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; PAL BC, 1969, J AM CHEM SOC, V91, P3634, DOI 10.1021/ja01041a036; PERHAM RN, 1986, BIOCHEMISTRY-US, V25, P2736; POLGAR L, 1973, EUR J BIOCHEM, V33, P104, DOI 10.1111/j.1432-1033.1973.tb02660.x; POOLE LB, 1989, J BIOL CHEM, V264, P12322; POOLE LB, 1989, J BIOL CHEM, V264, P12330; POOLE LB, 1986, J BIOL CHEM, V261, P4525; POOLE LB, 1988, BIOCHEM BIOPH RES CO, V153, P261; ROSS RP, 1991, IN PRESS J MOL BIOL, V221; SAHLMAN L, 1989, J BIOL CHEM, V264, P8033; SCRUTTON NS, 1987, BIOCHEM J, V245, P875, DOI 10.1042/bj2450875; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STEHLE T, 1991, IN PRESS J MOL BIOL, V221; STIPANUK MH, 1987, METHOD ENZYMOL, V143, P155; STOLL VS, 1988, ARCH BIOCHEM BIOPHYS, V260, P752, DOI 10.1016/0003-9861(88)90505-X; THIEME R, 1981, J MOL BIOL, V152, P763, DOI 10.1016/0022-2836(81)90126-1; UNTUCHTGRAU R, 1981, EUR J BIOCHEM, V120, P407, DOI 10.1111/j.1432-1033.1981.tb05718.x; WILLIAMS CH, 1976, FLAVINS FLAVOPROTEIN, P455; Williams CH., 1976, ENZYMES, P89; WONG KK, 1988, BIOCHEMISTRY-US, V27, P7091, DOI 10.1021/bi00418a063; ZANETTI G, 1986, ARCH BIOCHEM BIOPHYS, V244, P831, DOI 10.1016/0003-9861(86)90652-1	45	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19342	19350						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918050				2022-12-25	WOS:A1991GK66700037
J	NOIVA, R; KIMURA, H; ROOS, J; LENNARZ, WJ				NOIVA, R; KIMURA, H; ROOS, J; LENNARZ, WJ			PEPTIDE BINDING BY PROTEIN DISULFIDE ISOMERASE, A RESIDENT PROTEIN OF THE ENDOPLASMIC-RETICULUM LUMEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCES; OLIGOSACCHARYL TRANSFERASE; PROLYL 4-HYDROXYLASE; N-GLYCOSYLATION; BETA-SUBUNIT; OVALBUMIN; GLYCOPROTEIN; PURIFICATION; TRANSLATION; RECOGNITION	Previously we had demonstrated by photoaffinity labeling that a 57-kDa protein of the endoplasmic reticulum can bind and become covalently linked to glycosylatable photoreactive peptides containing the sequence-Asn-Xaa-Ser/Thr-. Subsequently, it was found that this protein, called glycosylation site-binding protein, was a multifunctional protein, i.e. it was identical to protein disulfide isomerase (PDI), the beta-subunit of prolyl hydroxylase and thyroid hormone-binding protein. In this study, the peptide specificity for binding to this 57-kDa protein, hereafter called PDI, has been investigated in more detail using photoaffinity probes. The results reveal that although N-glycosylation by oligosaccharyl transferase in the endoplasmic reticulum has an absolute requirement for an hydroxyamino acid in the third amino acid residue of the glycosylation site sequence, no such specificity is observed in the binding of such peptides to PDI. In addition to the lack of specificity for an hydroxyamino acid in the third residue position, no specificity was observed for the asparagine residue in the first position. Thus, binding is not restricted to peptides containing N-glycosylation sites. We have investigated the discrepancy between this apparent lack of sequence specificity and earlier results indicating that binding of peptides to PDI was specific for N-glycosylation site sequences. We now demonstrate that PDI in the lumen of microsomes is more efficiently labeled by peptides containing photoreactive-Asn-Xaa-Ser/Thr-sequences than by nonacceptor site sequences because the former become glycosylated. This increased labeling does not occur because the glycosylated form of the probes are preferentially recognized by PDI. Rather, it appears that increased polarity of the affinity probe after attachment of the oligosaccharide chain prevents its exit from the sealed microsomes, in effect concentrating it within the lumen of the microsome. These results, coupled with other studies on the multifunctional nature of PDI, suggest that the observed peptide binding may be a manifestation of the ability of PDI to recognize the backbone of polypeptides in the lumen of the endoplasmic reticulum.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	University of Texas System; UTMD Anderson Cancer Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GM33185, GM12628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033185, F32GM012628, R37GM033185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU L, 1986, P NATL ACAD SCI USA, V80, P7466; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; BULLEID NJ, 1990, EMBO J, V9, P3527, DOI 10.1002/j.1460-2075.1990.tb07561.x; CHENG SY, 1987, J BIOL CHEM, V262, P11221; Dallner G, 1978, Methods Enzymol, V52, P71; DAS RC, 1980, P NATL ACAD SCI-BIOL, V77, P3811, DOI 10.1073/pnas.77.7.3811; DEWAAL A, 1985, BIOCHEMISTRY-US, V24, P6493, DOI 10.1021/bi00344a028; FERNLUND P, 1982, J BIOL CHEM, V257, P2170; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GLABE CG, 1980, J BIOL CHEM, V255, P9236; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HUANG CC, 1970, CARBOHYD RES, V13, P127, DOI 10.1016/S0008-6215(00)84902-2; KAPLAN HA, 1988, J BIOL CHEM, V263, P7814; KAPLAN HA, 1987, BIOCHIM BIOPHYS ACTA, V906, P161, DOI 10.1016/0304-4157(87)90010-4; KIMURA H, 1990, BIOCHEM BIOPH RES CO, V170, P1319, DOI 10.1016/0006-291X(90)90538-X; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; Marshall R D, 1974, Biochem Soc Symp, P17; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; NOIVA R, 1991, P NATL ACAD SCI USA, V88, P1986, DOI 10.1073/pnas.88.5.1986; Palmiter R D, 1980, Ann N Y Acad Sci, V343, P192, DOI 10.1111/j.1749-6632.1980.tb47252.x; PARKKONEN T, 1988, BIOCHEM J, V256, P1005, DOI 10.1042/bj2561005; SHARMA C, 1981, EUR J BIOCHEM, V116, P101, DOI 10.1111/j.1432-1033.1981.tb05306.x; SHEARES BT, 1986, P NATL ACAD SCI USA, V83, P1993, DOI 10.1073/pnas.83.7.1993; STENFLO J, 1982, J BIOL CHEM, V257, P2180; TAI T, 1975, J BIOL CHEM, V250, P8569; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WELPLY JK, 1986, ARCH BIOCHEM BIOPHYS, V246, P808, DOI 10.1016/0003-9861(86)90337-1; WELPLY JK, 1985, J BIOL CHEM, V260, P6459	36	78	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19645	19649						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918071				2022-12-25	WOS:A1991GK66700075
J	POPHAM, D; KEENER, J; KUSTU, S				POPHAM, D; KEENER, J; KUSTU, S			PURIFICATION OF THE ALTERNATIVE SIGMA-FACTOR, SIGMA-54, FROM SALMONELLA-TYPHIMURIUM AND CHARACTERIZATION OF SIGMA-54-HOLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; LAC UV5 PROMOTER; ESCHERICHIA-COLI; KLEBSIELLA-PNEUMONIAE; NITROGEN-FIXATION; TRANSCRIPTION INITIATION; NUCLEOTIDE-SEQUENCE; TERNARY COMPLEXES; NTRA GENE; RHODOBACTER-CAPSULATUS	The alternative sigma factor sigma-54 of enteric bacteria, or its homologue in other purple bacteria, is required for transcription of genes whose products have diverse physiological roles. Previous studies have indicated that sigma-54 confers on core RNA polymerase the ability to recognize a specific class of promoters but not the ability to isomerize from closed to open complexes. Isomerization requires ATP and one member of a family of activator proteins, it being different activator proteins that allow this form of polymerase to respond to different physiological signals. We have developed a strategy for overproducing and purifying sigma-54 from Salmonella typhimurium and have studied several biochemical properties of reconstituted sigma-54-holoenzyme. The initial binding constant K(B) for the formation of closed complexes between this holoenzyme and the glnA promoter in our transcription buffer is approximately 3 x 10(8) M-1, which was determined from DNaseI protection assays at 37-degrees-C. After the formation of open complexes, several properties of sigma-54-holoenzyme appear to be similar to those of sigma-70-holoenzyme. We have determined the complete nucleotide sequence of the gene encoding sigma-54 (ntrA) in Salmonella.	UNIV CALIF BERKELEY,DEPT PLANT PATHOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley			Popham, David L/F-8066-2015	Popham, David L/0000-0002-2614-143X				ALIAS A, 1989, NUCLEIC ACIDS RES, V17, P5377, DOI 10.1093/nar/17.13.5377; ARTZ SW, 1975, P NATL ACAD SCI USA, V72, P3453, DOI 10.1073/pnas.72.9.3453; AUERBACH JI, 1981, J BACTERIOL, V146, P713, DOI 10.1128/JB.146.2.713-717.1981; BERGER DK, 1990, J BACTERIOL, V172, P4399, DOI 10.1128/jb.172.8.4399-4406.1990; BERNHARD SL, 1986, BIOCHEMISTRY-US, V25, P5914, DOI 10.1021/bi00368a012; BIRKMANN A, 1987, MOL GEN GENET, V210, P535, DOI 10.1007/BF00327209; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; DAYTON CJ, 1984, J BIOL CHEM, V259, P1616; DEBRUIJN FJ, 1983, MOL GEN GENET, V192, P342, DOI 10.1007/BF00392173; DRUMMOND M, 1983, NATURE, V301, P302, DOI 10.1038/301302a0; DUVALVALENTIN G, 1986, NUCLEIC ACIDS RES, V14, P1967, DOI 10.1093/nar/14.5.1967; GOLD L, 1981, ANNU REV MICROBIOL, V35, P365, DOI 10.1146/annurev.mi.35.100181.002053; GUSSIN GN, 1986, ANNU REV GENET, V20, P567, DOI 10.1146/annurev.ge.20.120186.003031; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HIRSCHMAN J, 1985, P NATL ACAD SCI USA, V82, P7525, DOI 10.1073/pnas.82.22.7525; HOFER B, 1985, NUCLEIC ACIDS RES, V13, P5995, DOI 10.1093/nar/13.16.5995; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; INOUYE S, 1989, GENE AMST, V85, P142; ISHIMOTO KS, 1989, P NATL ACAD SCI USA, V86, P1954, DOI 10.1073/pnas.86.6.1954; JOHNSON K, 1986, J BIOL CHEM, V261, P5703; Johnston D. E., 1976, RNA POLYMERASE, P413; JONES R, 1989, MOL GEN GENET, V215, P507, DOI 10.1007/BF00427050; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KEENER J, 1987, RNA POLYM REGULATION, P159; KOHLER T, 1989, NUCLEIC ACIDS RES, V17, P10125, DOI 10.1093/nar/17.23.10125; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KULLIK I, 1991, J BACTERIOL, V173, P1125, DOI 10.1128/jb.173.3.1125-1138.1991; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1986, S SOC GENERAL MICROB, P139; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LI X, 1988, DNA PROTEIN INTERACT, P63; LUSE DS, 1987, J BIOL CHEM, V262, P14990; LUSE DS, 1987, J BIOL CHEM, V262, P289; MAGASANIK B, 1988, TRENDS BIOCHEM SCI, V13, P475, DOI 10.1016/0968-0004(88)90234-4; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MAURER R, 1981, ICN UCLA S MOL CELL, V22, P375; Maxam A M, 1980, Methods Enzymol, V65, P499; MERRICK M, 1987, MOL GEN GENET, V210, P323, DOI 10.1007/BF00325701; MERRICK MJ, 1985, NUCLEIC ACIDS RES, V13, P7607, DOI 10.1093/nar/13.21.7607; MEYER TF, 1984, P NATL ACAD SCI-BIOL, V81, P6110, DOI 10.1073/pnas.81.19.6110; Miller JH., 1972, EXPT MOL GENETICS; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; MOSIG H, 1985, EUR J BIOCHEM, V149, P337, DOI 10.1111/j.1432-1033.1985.tb08931.x; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; OGATA RT, 1979, J MOL BIOL, V132, P709, DOI 10.1016/0022-2836(79)90384-X; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; RONSON CW, 1987, J BACTERIOL, V169, P2424, DOI 10.1128/jb.169.6.2424-2431.1987; SANTERO E, 1989, P NATL ACAD SCI USA, V86, P7346, DOI 10.1073/pnas.86.19.7346; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SCOTT K F, 1981, Journal of Molecular and Applied Genetics, V1, P71; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; STACKEBRANDT E, 1988, INT J SYST BACTERIOL, V38, P321, DOI 10.1099/00207713-38-3-321; STACKHOUSE TM, 1988, BIOCHEMISTRY-US, V27, P3038, DOI 10.1021/bi00408a056; STACKHOUSE TM, 1989, BIOCHEMISTRY-US, V28, P7781, DOI 10.1021/bi00445a038; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; SUNDARESAN V, 1983, NATURE, V301, P728, DOI 10.1038/301728a0; THONY B, 1989, FEMS MICROBIOL LETT, V63, P341; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WONG PK, 1987, J BACTERIOL, V169, P2876, DOI 10.1128/jb.169.6.2876-2880.1987	76	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19510	19518						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918063				2022-12-25	WOS:A1991GK66700059
J	JEYAPAUL, J; SESHAMMA, T; KHAN, SA				JEYAPAUL, J; SESHAMMA, T; KHAN, SA			SYNTHETIC HIV-1 TAT CAN DISSOCIATE HELA NUCLEAR-PROTEIN TAR RNA COMPLEXES INVITRO - A NOVEL TAT-NUCLEAR PROTEIN-INTERACTION	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATOR GENE; MUTATIONAL ANALYSIS; TRANSCRIPTIONAL ACTIVATION; RESPONSIVE SEQUENCE; FUNCTIONAL DOMAINS; LOOP SEQUENCE; NASCENT RNA; TYPE-1	Multiple binding of Tat and nuclear protein(s) to HIV-1 TAR RNA appears to be essential for the Tat-mediated trans-activation. As synthetic Tat-(1-47), which lacks the basic domain and does not bind TAR RNA in vitro, efficiently transactivated HIV-1 LTR in HeLa nuclear extracts, we hypothesized that Tat might trans-activate by interaction with TAR RNA via a host nuclear protein. The role of nuclear proteins in Tat-TAR interaction was examined through evaluation of several synthetic Tat peptides for ability to bind TAR RNA in vitro both in the presence and in the absence of HeLa nuclear proteins. Our data show that both Tat-(1-47) and Tat-(1-86) interact with TAR RNA-bound nuclear proteins, leading to dissociation of the nuclear protein-TAR RNA complexes; the N-terminal sequence of Tat appears to be involved in this interaction. Thus, after binding to TAR RNA, Tat can interact with a proximal TAR-bound nuclear protein and the resulting Tat-nuclear protein complex, now displaced from TAR, may initiate a facile and rapid assembly of the RNA polymerase II transcription complex. This study thus recognizes a novel interaction between Tat and a nuclear protein(s). Here we propose that the interaction of Tat with a nuclear protein(s) occurring on TAR RNA may be one of several steps in the mechanism of Tat-mediated trans-activation of the HIV-1 LTR.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NIAID NIH HHS [AI27422, AI25380] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027422, P01AI025380] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; DINGWALL C, 1989, CELL, V57, P1155; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; JEYAPAUL J, 1990, P NATL ACAD SCI USA, V87, P7030, DOI 10.1073/pnas.87.18.7030; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAPPAPORT J, 1989, New Biologist, V1, P101; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; RUBEN S, 1989, J VIROL, V63, P1; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SENGUPTA DN, 1990, P NATL ACAD SCI USA, V87, P7492, DOI 10.1073/pnas.87.19.7492; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002	48	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1507	1513						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923518				2022-12-25	WOS:A1991GX27400003
J	WIMAN, KG; MAGNUSSON, KP; RAMQVIST, T; KLEIN, G				WIMAN, KG; MAGNUSSON, KP; RAMQVIST, T; KLEIN, G			MUTANT P53 DETECTED IN A MAJORITY OF BURKITT-LYMPHOMA CELL-LINES BY MONOCLONAL-ANTIBODY PAB240	ONCOGENE			English	Article							TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; INCREASED EXPRESSION; TRANSFORMED-CELLS; FRIEND-VIRUS; LUNG-CANCER; NUDE-MICE; GENE; ONCOGENE	The status of the p53 gene in lymphoblastoid cell lines (LCLs) and Burkitt lymphoma cell lines (BLs) was investigated. Southern blot analysis demonstrated that no major deletions or rearrangements had occurred in the p53 gene in any of the cell lines. The p53 protein was examined by immunoprecipitation using two monoclonal anti-p53 antibodies. PAb1801 recognizes both wild-type and mutant p53. PAb240 reacts exclusively with mutant p53. Fourteen LCLs reacted with PAb1801, but not with PAb240, suggesting that none of them expressed mutant p53. However, one LCL had mutant p53. This LCL differs from other LCLs in that it grows to higher cell densities and has a higher agarose clonability. All BLs expressed p53. Out of 15 BLs, nine (60%) carried mutant p53, as indicated by their reactivity with PAb240. Among the nine BLs with mutant p53, eight were Epstein-Barr virus (EBV)-positive. Three out of the six BLs with wild-type p53 were EBV-positive. Multiple EBV-converted sublines all exhibited the same p53 status as the parental line. Our results indicate that the p53 gene is mutated in a majority of Burkitt lymphoma cell lines (BLs), and suggest that p53 mutation contributes to the malignant phenotype of these cell lines.			WIMAN, KG (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.		Magnusson, Kristinn P Pétur/X-4907-2019; Magnusson, Kristinn/A-6479-2011; Wiman, Klas/AAB-8399-2021	Magnusson, Kristinn P Pétur/0000-0003-4528-6826; Magnusson, Kristinn/0000-0003-4528-6826; Wiman, Klas/0000-0002-7113-524X	NATIONAL CANCER INSTITUTE [R01CA030264] Funding Source: NIH RePORTER; NCI NIH HHS [2 R01 CA 30264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DILLNER J, 1988, ADV CANCER RES, V50, P95, DOI 10.1016/S0065-230X(08)60436-4; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EPSTEIN MA, 1966, J NATL CANCER I, V37, P547; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRESEN KO, 1976, INT J CANCER, V17, P161, DOI 10.1002/ijc.2910170203; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GIOVANELLA B, 1979, INT J CANCER, V24, P103, DOI 10.1002/ijc.2910240118; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINUMA Y, 1967, P SOC EXP BIOL MED, V124, P107; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KLEIN E, 1968, CANCER RES, V28, P1300; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KLEIN G, 1972, INT J CANCER, V10, P44, DOI 10.1002/ijc.2910100108; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LENOIR GM, 1985, BURKITTS LYMPHOMA HU, P309; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASUCCI MG, 1987, P NATL ACAD SCI USA, V84, P4567, DOI 10.1073/pnas.84.13.4567; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MENEZES J, 1975, BIOMEDICINE, V22, P276; MILLER CW, 1990, CANCER RES, V50, P7950; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NILSSON K, 1977, INT J CANCER, V19, P337, DOI 10.1002/ijc.2910190309; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROONEY CM, 1984, INT J CANCER, V34, P339, DOI 10.1002/ijc.2910340310; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; Sambrook J, 1989, MOL CLONING LABORATO; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1988, ONCOGENE, V3, P501; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VENTURELLI D, 1988, HAEMATOLOGICA, V73, P259; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790	65	90	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1633	1639						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923530				2022-12-25	WOS:A1991GX27400019
J	KUHN, DM; ARTHUR, R; YOON, H; SANKARAN, K				KUHN, DM; ARTHUR, R; YOON, H; SANKARAN, K			TYROSINE-HYDROXYLASE IN SECRETORY GRANULES FROM BOVINE ADRENAL-MEDULLA - EVIDENCE FOR AN INTEGRAL MEMBRANE FORM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											KUHN, DM (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT PSYCHIAT,LAFAYETTE CLIN,DETROIT,MI 48207, USA.							BILLINGSLEY ML, 1986, NEUROCHEM INT, V8, P255, DOI 10.1016/0197-0186(86)90172-5; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURDELLES LB, 1988, J NEUROCHEM, V50, P988; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL DG, 1986, J BIOL CHEM, V261, P489; CREUTZ CE, 1985, J BIOL CHEM, V260, P7171; CREUTZ CE, 1987, J BIOL CHEM, V262, P1860; DUONG LT, 1984, ARCH BIOCHEM BIOPHYS, V228, P332, DOI 10.1016/0003-9861(84)90074-2; Goldstein M, 1987, PSYCHOPHARMACOLOGY 3, P75; GRIMA B, 1987, NATURE, V326, P707, DOI 10.1038/326707a0; HAYCOCK JW, 1985, NEUROCHEM INT, V7, P301, DOI 10.1016/0197-0186(85)90119-6; HOELDTKE R, 1977, J BIOL CHEM, V252, P3160; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; KANEDA N, 1987, BIOCHEM BIOPH RES CO, V146, P971, DOI 10.1016/0006-291X(87)90742-X; KELNER KL, 1985, NEUROCHEM INT, V7, P373, DOI 10.1016/0197-0186(85)90128-7; KUCZENSKI R, 1983, J NEUROCHEM, V40, P821, DOI 10.1111/j.1471-4159.1983.tb08053.x; KUCZENSKI R, 1973, J BIOL CHEM, V248, P5074; KUCZENSKI RT, 1972, J BIOL CHEM, V247, P3114; KUHN DM, 1987, NEUROCHEM INT, V11, P463, DOI 10.1016/0197-0186(87)90036-2; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LERNER P, 1978, NEUROCHEM RES, V3, P641, DOI 10.1007/BF00963765; LEVITT M, 1965, J PHARMACOL EXP THER, V148, P1; LOW MG, 1987, BIOCHEM J, V244, P1; MENNITI FS, 1987, J BIOL CHEM, V262, P7651; MILNER JD, 1985, NEUROSCI LETT, V59, P215, DOI 10.1016/0304-3940(85)90202-2; MOGI M, 1988, NEUROCHEM INT, V12, P187, DOI 10.1016/0197-0186(88)90126-X; MORITA K, 1987, J BIOL CHEM, V262, P5654; MUSACCHIO JM, 1973, NEW CONCEPTS NEUROTR, P69; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NOLAN J, 1985, ARCH BIOCHEM BIOPHYS, V240, P257, DOI 10.1016/0003-9861(85)90031-1; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OMALLEY KL, 1986, J NEUROSCI RES, V16, P3, DOI 10.1002/jnr.490160103; PETRACK B, 1968, J BIOL CHEM, V243, P743; PRYDE JG, 1986, BIOCHEM J, V233, P525, DOI 10.1042/bj2330525; SHIMAN R, 1971, J BIOL CHEM, V246, P1330; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; STEWART LC, 1988, J BIOL CHEM, V263, P12183; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREIMAN M, 1983, J NEUROCHEM, V40, P661, DOI 10.1111/j.1471-4159.1983.tb08031.x; WAKADE AR, 1988, J NEUROCHEM, V51, P820, DOI 10.1111/j.1471-4159.1988.tb01817.x; WAYMIRE JC, 1988, J BIOL CHEM, V263, P12439; WILSON SP, 1977, MOL PHARMACOL, V13, P382; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; WURZBURG.RJ, 1971, J PHARMACOL EXP THER, V177, P155; ZAREMBA S, 1981, J BIOL CHEM, V256, P2310	46	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1990	265	10					5780	5786						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CW480	1969407				2022-12-25	WOS:A1990CW48000075
J	KARNIK, PS; WOLFE, MM				KARNIK, PS; WOLFE, MM			SOMATOSTATIN STIMULATES GASTRIN MESSENGER-RNA TURNOVER IN DOG ANTRAL MUCOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									BETH ISRAEL HOSP,CHARLES A DANA RES INST,DIV GASTROENTEROL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; HARVARD UNIV,CTR DIGEST DIS,HARVARD THORNDIKE LAB,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University					NCRR NIH HHS [RR01032] Funding Source: Medline; NIDDK NIH HHS [DK35636] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035636] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEALE EG, 1982, J BIOL CHEM, V257, P2022; BERGER FG, 1986, BIOCHEMISTRY-US, V25, P1170, DOI 10.1021/bi00353a034; BERLIN CM, 1965, MOL PHARMACOL, V1, P149; BLOOM SR, 1974, LANCET, V2, P1106; BOEL E, 1983, P NATL ACAD SCI-BIOL, V80, P2866, DOI 10.1073/pnas.80.10.2866; CAMPBELL G, 1982, NEUROSCIENCE, V7, P2013, DOI 10.1016/0306-4522(82)90116-6; CARR D, 1975, BMJ-BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5975.67; CHAYVIALLE JAP, 1978, GASTROENTEROLOGY, V75, P13; CHIBA T, 1981, GASTROENTEROLOGY, V81, P321; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANCYGIER H, 1984, GASTROENTEROLOGY, V86, P892; GERICH JE, 1976, ANNU REV PHYSIOL, V38, P353, DOI 10.1146/annurev.ph.38.030176.002033; GODLEY JM, 1989, P NATL ACAD SCI USA, V86, P3036, DOI 10.1073/pnas.86.9.3036; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUYETTE WA, 1979, CELL, V17, P1013, DOI 10.1016/0092-8674(79)90340-4; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HARTY RF, 1981, GASTROENTEROLOGY, V81, P707; HARTY RF, 1986, GUT, V27, P652, DOI 10.1136/gut.27.6.652; JACOBS KH, 1983, NATURE, V303, P177; KARNIK PS, 1989, J CLIN INVEST, V83, P367, DOI 10.1172/JCI113893; KUROKAWA K, 1983, KIDNEY INT, V24, P754, DOI 10.1038/ki.1983.223; LAVERRIERE JN, 1983, EMBO J, V2, P1493, DOI 10.1002/j.1460-2075.1983.tb01613.x; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MANIATIS T, 1982, MOL CLONING LABORATO, P390; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULVIHILL ER, 1977, J BIOL CHEM, V252, P2060; PARK J, 1987, J BIOL CHEM, V262, P14190; POLAK JM, 1975, LANCET, V1, P1220; REICHLIN S, 1987, J LAB CLIN MED, V109, P320; SAFFOURI B, 1979, LIFE SCI, V25, P1749, DOI 10.1016/0024-3205(79)90478-8; SARIBAN E, 1988, J CLIN INVEST, V81, P1506, DOI 10.1172/JCI113482; SHAW J, 1987, MOL IMMUNOL, V24, P409, DOI 10.1016/0161-5890(87)90014-9; SHORT GM, 1985, GASTROENTEROLOGY, V88, P984, DOI 10.1016/S0016-5085(85)80018-4; SLATTERY E, 1979, P NATL ACAD SCI USA, V76, P4778, DOI 10.1073/pnas.76.10.4778; STRAUS DS, 1987, J BIOL CHEM, V262, P1955; TOVO MJ, 1988, HORM RES, V29, P59; WOLFE MM, 1988, NEW ENGL J MED, V319, P1707; WOLFE MM, 1983, J CLIN INVEST, V72, P1586, DOI 10.1172/JCI111117; WOLFE MM, 1984, GASTROENTEROLOGY, V87, P86; YAMADA T, 1980, P NATL ACAD SCI-BIOL, V77, P1691, DOI 10.1073/pnas.77.3.1691	43	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1990	265	5					2550	2555						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CM848	1968059				2022-12-25	WOS:A1990CM84800027
J	HOSOYA, H; YAMASHIRO, S; MATSUMURA, F				HOSOYA, H; YAMASHIRO, S; MATSUMURA, F			MITOSIS-SPECIFIC PHOSPHORYLATION OF MYOSIN LIGHT CHAIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; SMOOTH; CALMODULIN; CELL	Cell cytosol preparations from mitotic HeLa cells exhibit a kinase activity that phosphorylates myosin light chain kinase (MLCK). This MLCK kinase activity is apparently distinct from the known MLCK kinases, including cAMP-dependent protein kinase, cGMP-dependent protein kinase, Ca2+-activated phospholipid-dependent protein kinase, or Ca2+-calmodulin-dependent protein kinase II, based on the following criteria. First, the MLCK kinase activity of mitotic cells does not respond to a variety of characteristic activators or inhibitors of these known kinases. Second, one- and two-dimensional peptide maps have revealed that the site of phosphorylation by the MLCK kinase of mitotic cells differs from those by these known kinases. The mitotic MLCK kinase phosphorylates MLCK at a threonine residue at a ratio of up to 1 mol of phosphate/mol of chicken gizzard MLCK. The MLCK kinase is mitosis-specific because mitotic cell extracts show much higher phosphorylation activity than nonmitotic cell extracts.	RUTGERS STATE UNIV,DEPT MOLEC BIOL & BIOCHEM,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick				Matsumura, Fumio/0000-0002-8204-153X; Yamashiro, Shigeko/0000-0001-7207-9406	NATIONAL CANCER INSTITUTE [R37CA042742, K04CA001304] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA42742, K04 CA01304] Funding Source: Medline; PHPPO CDC HHS [PHSRR 07058-24] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHPPO CDC HHS		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; CONTI MA, 1981, J BIOL CHEM, V256, P3178; FOSTER C, 1986, ARCH BIOCHEM BIOPHYS, V251, P616, DOI 10.1016/0003-9861(86)90371-1; FOYT HL, 1985, J CYCLIC NUCLEOTIDE, V260, P8978; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; HUNT T, 1991, NATURE, V350, P462, DOI 10.1038/350462a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IKEBE M, 1989, J BIOL CHEM, V264, P6967; IKEBE M, 1985, J BIOL CHEM, V260, P4547; IKEBE M, 1990, J BIOL CHEM, V265, P8975; IKEBE M, 1987, J BIOL CHEM, V262, P13828; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; OLOSN NJ, 1990, P NATL ACAD SCI USA, V89, P2284; PAYNE ME, 1986, J BIOL CHEM, V261, P6346; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; SCHROEDER TE, 1976, CELL MOTILITY, P265; YAMASHIRO S, 1990, NATURE, V344, P675, DOI 10.1038/344675a0; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0	26	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22173	22178						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939238				2022-12-25	WOS:A1991GR56400020
J	DEDHAR, S; ROBERTSON, K; GRAY, V				DEDHAR, S; ROBERTSON, K; GRAY, V			INDUCTION OF EXPRESSION OF THE ALPHA-V-BETA-1 AND ALPHA-V-BETA-3 INTEGRIN HETERODIMERS DURING RETINOIC ACID-INDUCED NEURONAL DIFFERENTIATION OF MURINE EMBRYONAL CARCINOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEO-SARCOMA CELLS; ALKALINE-PHOSPHATASE ACTIVITY; MOUSE TERATOCARCINOMA CELLS; RECEPTOR ALPHA-SUBUNIT; GROWTH FACTOR-BETA; FIBRONECTIN RECEPTOR; VITRONECTIN RECEPTOR; PROCESS OUTGROWTH; COLLAGEN-IV; ADHESION RECEPTORS	All-trans-retinoic acid, an endogenous morphogen, induced neuronal differentiation of P19 murine embryonal carcinoma cells. Peak differentiation, as judged by the elaboration of neuronal processes, occurred 8 days after exposure of the cells to 0.5 mM retinoic acid, a concentration known to induce neuronal differentiation. An examination of the expression of the extracellular matrix receptors, integrins, during this retinoic acid-induced differentiation period, demonstrated a specific and strong induction of expression of two polypeptides (130 and 115 kDa) immunoprecipitated with an anti-human vitronectin receptor antiserum. The expression of a 90-kDa polypeptide, also immunoprecipitating with this antiserum was induced as well, but to a much smaller extent. The expression of a 96-kDa polypeptide immunoprecipitated by this antiserum and present in the untreated cells was not induced by retinoic acid. The increase in the expression of these polypeptides paralleled the neuronal differentiation of the P19 embryonal carcinoma cells. The expression of these integrins was not induced in a variant of the P19 cells, P19RAC65, which are resistant to differentiation induction by retinoic acid. Utilizing integrin subunit-specific anti-cytoplasmic peptide antibodies together with immunoprecipitation and Western blot analysis, the 130- and 115-kDa polypeptides were identified as the integrin alpha-v and beta-1 subunits, respectively. The 90-kDa polypeptide, also induced by retinoic acid, was identified as beta-3 whereas the identity of the uninduced 96-kDa polypeptide remains unclear as yet. Peptide map analysis of deglycosylated polypeptides demonstrated that the 90- and 96-kDa polypeptides are distinct proteins and that the 115-kDa polypeptides immunoprecipitated with either anti-alpha-v or anti-beta-1 antibodies are identical, further establishing that the 115-kDa polypeptide associating with alpha-v is beta-1. The retinoic acid-induced expression of beta-1 occurred at the level of mRNA expression which also paralleled neuronal differentiation, but peaked slightly ahead of the cell surface expression of beta-1. The expression of other beta-1-associated alpha-subunits was not induced by retinoic acid in these cells. These data demonstrate that retinoic acid strongly induces the expression of the integrin heterodimer alpha-v-beta-1 and also, to a smaller extent, the expression of alpha-v-beta-3. The retinoic acid-induced, high level surface expression of the alpha-v-beta-1 heterodimer is tightly correlated with the induction of neuronal differentiation by retinoic acid. This finding suggests an important role for the alpha-v-beta-1 heterodimer in the neuronal differentiation process.	UNIV BRITISH COLUMBIA, FAC MED, DEPT PATHOL, VANCOUVER V6T 1Z7, BC, CANADA; SUNNYBROOK MED CTR, REICHMANN RES BLDG, 2075 BAYVIEW AVE, TORONTO M4N 3M5, ONTARIO, CANADA	University of British Columbia; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	DEDHAR, S (corresponding author), CANC CONTROL AGCY, DEPT ADV THERAPEUT, VANCOUVER V5Z 4E6, BC, CANADA.			Dedhar, Shoukat/0000-0003-4355-1657				ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; DAVIS GE, 1985, J NEUROSCI, V5, P2662; DAVIS GE, 1987, SCIENCE, V236, P1106, DOI 10.1126/science.3576223; DEDHAR S, 1989, J CELL PHYSIOL, V138, P291, DOI 10.1002/jcp.1041380210; DEDHAR S, 1989, EXP CELL RES, V183, P207, DOI 10.1016/0014-4827(89)90430-8; DEDHAR S, 1987, J CELL BIOL, V105, P1175, DOI 10.1083/jcb.105.3.1175; DEDHAR S, 1989, J BIOL CHEM, V264, P4832; DEDHAR S, 1990, J CELL BIOL, V110, P2185, DOI 10.1083/jcb.110.6.2185; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; HEINO J, 1989, J BIOL CHEM, V264, P380; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIEN TW, 1982, J IMMUNOL, V129, P2287; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; SMITH SC, 1987, J CELL PHYSIOL, V131, P74, DOI 10.1002/jcp.1041310112; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; TOMASELLI KJ, 1986, J CELL BIOL, V103, P2659, DOI 10.1083/jcb.103.6.2659; TOMASELLI KJ, 1987, J CELL BIOL, V105, P2347, DOI 10.1083/jcb.105.5.2347; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; WANG SY, 1990, J BIOL CHEM, V265, P15818; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880	43	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21846	21852						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939209				2022-12-25	WOS:A1991GP80400080
J	LANGERT, W; MEUTHEN, M; MUELLER, K				LANGERT, W; MEUTHEN, M; MUELLER, K			FUNCTIONAL-CHARACTERISTICS OF THE RRND PROMOTERS OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; RNA-POLYMERASE HOLOENZYME; OPEN COMPLEX-FORMATION; RIBOSOMAL-RNA; TRANSCRIPTION INITIATION; INVITRO TRANSCRIPTION; BACTERIOPHAGE-T7 DNA; TERNARY COMPLEXES; STRINGENT CONTROL; CHAIN INITIATION	The function of the tandem rrnD promoters (P1, P2) of Escherichia coli, which are highly efficient in directing rRNA synthesis, was studied in vitro using the strong hybrid promoter P(tacI) as a reference. One of the characteristics of the rrnD promoters is a pronounced instability of binary and initiating complexes formed with RNA polymerase. The rate of productive complex formation and of chain initiation at these promoters was found to be limited by a step in binary complex transitions with an apparent first-order rate constant equal to 3.9 x 10(-2) s-1. A comparison of this rate with that determined previously by filter binding assays (Gourse, R. (1988) Nucleic Acids Res. 16, 9789-9809) suggests that the rate-limiting step is a conversion of an intermediate species of open complex to one that is efficient in productive initiation. The slow rate of this reaction and the instability of open complexes account for the relatively low competitive strengths of the rrnD promoters. However, this limitation of rrn promoter function changes with promoter occupancy because the rate of chain initiation increased after completion of the first round of initiation. Despite their poor competitive strength, the rrnD promoters are more productive than P(tacI) at nonlimiting RNA polymerase concentrations. This can be ascribed to the different rates with which RNA polymerases leave P(tacI) and the rrnD promoters. These functional differences of the promoters are consistent with a "stressed intermediate" model of chain initiation (Straney, D. C., and Crothers, D. M. (1987) J. Mol. Biol. 193, 267-278) which predicts that rapid clearance of the rrn promoters is mechanistically related to the instability of the binary complexes.			LANGERT, W (corresponding author), UNIV MUNSTER,INST ZOOL,SCHLOSSPLATZ 5,W-4400 MUNSTER,GERMANY.							BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527; BROSIUS J, 1984, GENE, V27, P161, DOI 10.1016/0378-1119(84)90137-9; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BRUNNER M, 1987, EMBO J, V6, P3139, DOI 10.1002/j.1460-2075.1987.tb02624.x; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CARPOUSIS AJ, 1982, J MOL BIOL, V157, P619, DOI 10.1016/0022-2836(82)90502-2; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1310; CECH CL, 1980, BIOCHEMISTRY-US, V19, P2440, DOI 10.1021/bi00552a023; Chamberlin M., 1976, RNA POLYMERASE, V6, P193; Chamberlin M., 1976, RNA POLYMERASE BOOK, P17; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; GIACOMONI PU, 1977, EUR J BIOCHEM, V78, P215, DOI 10.1111/j.1432-1033.1977.tb11732.x; GILBERT SF, 1979, CELL, V17, P211, DOI 10.1016/0092-8674(79)90309-X; GLASER G, 1983, NATURE, V302, P74, DOI 10.1038/302074a0; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GRALLA JD, 1990, METHOD ENZYMOL, V185, P37; HAMMING J, 1980, NUCLEIC ACIDS RES, V8, P3947, DOI 10.1093/nar/8.17.3947; Hawley D. K., 1982, PROMOTERS STRUCTURE, P54; IGARASHI K, 1989, NUCLEIC ACIDS RES, V17, P8755, DOI 10.1093/nar/17.21.8755; ISHIHAMA A, 1987, RNA POLYMERASE REGUL, P397; JORGENSEN P, 1976, MOL GEN GENET, V146, P303, DOI 10.1007/BF00701255; KADESCH TR, 1982, J MOL BIOL, V155, P1, DOI 10.1016/0022-2836(82)90489-2; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P3873, DOI 10.1093/nar/11.12.3873; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; KISS I, 1978, BIOCHIM BIOPHYS ACTA, V518, P257, DOI 10.1016/0005-2787(78)90182-X; KLIEMANN J, 1985, THESIS WESTFALISCHE; KNAUS R, 1988, EMBO J, V7, P2929; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KUPPER H, 1975, P NATL ACAD SCI USA, V72, P4754, DOI 10.1073/pnas.72.12.4754; LAMOND AI, 1985, CELL, V41, P6, DOI 10.1016/0092-8674(85)90050-9; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LINDAHL L, 1986, ANNU REV GENET, V20, P297; Maniatis T., 1982, MOL CLONING; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MELANCON P, 1983, BIOCHEMISTRY-US, V22, P5169, DOI 10.1021/bi00291a017; MIZUSHIMASUGANO J, 1983, MOL GEN GENET, V189, P185, DOI 10.1007/BF00337802; MUELLER K, 1971, MOL GEN GENET, V111, P273, DOI 10.1007/BF00433112; MUELLER K, 1977, CELL, V10, P121, DOI 10.1016/0092-8674(77)90146-5; MULLIGAN ME, 1985, J BIOL CHEM, V260, P3529; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; MUNSON LM, 1981, BIOCHEMISTRY-US, V20, P2081, DOI 10.1021/bi00511a003; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; PETHO A, 1986, BIOCHIM BIOPHYS ACTA, V866, P37, DOI 10.1016/0167-4781(86)90098-9; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; ROSENBERG S, 1982, J MOL BIOL, V155, P31, DOI 10.1016/0022-2836(82)90490-9; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; SCHALLER H, 1972, EUR J BIOCHEM, V26, P474, DOI 10.1111/j.1432-1033.1972.tb01789.x; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; STAHL SJ, 1977, J MOL BIOL, V112, P577, DOI 10.1016/S0022-2836(77)80165-4; STEFANO JE, 1979, BIOCHEMISTRY-US, V18, P1063, DOI 10.1021/bi00573a020; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; STUBER D, 1982, EMBO J, V1, P1399; SUMEGI J, 1977, MOL GEN GENET, V151, P305, DOI 10.1007/BF00268794; TRAVERS A, 1976, MOL GEN GENET, V147, P225, DOI 10.1007/BF00267575; TRAVERS AA, 1987, CRIT REV BIOCHEM MOL, V22, P181, DOI 10.3109/10409238709101483; TRAVERS AA, 1984, NUCLEIC ACIDS RES, V12, P2605, DOI 10.1093/nar/12.6.2605; VANOOYEN AJJ, 1976, CELL, V8, P123, DOI 10.1016/0092-8674(76)90193-8; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WAHLE E, 1985, J BACTERIOL, V162, P458, DOI 10.1128/JB.162.1.458-460.1985; WAHLE E, 1980, MOL GEN GENET, V179, P661, DOI 10.1007/BF00271755; YOUNG RA, 1979, CELL, V17, P225, DOI 10.1016/0092-8674(79)90310-6	70	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21608	21615						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939190				2022-12-25	WOS:A1991GP80400046
J	LIU, WK; KSIEZAKREDING, H; YEN, SH				LIU, WK; KSIEZAKREDING, H; YEN, SH			ABNORMAL TAU PROTEINS FROM ALZHEIMERS-DISEASE BRAINS - PURIFICATION AND AMINO-ACID-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; MICROTUBULE-ASSOCIATED PROTEIN; NEUROFIBRILLARY TANGLES; EPITOPES; PHOSPHORYLATION; POLYMERIZATION; LOCALIZATION; INVITRO; TUBULIN; ALZ-50	Abnormal tau proteins (PHF-tau) were isolated from Alzheimer's disease brains by treatment of paired helical filament enriched-fractions with perchloric acid and boiling of the acid precipitable fraction with beta-mercaptoethanol. These proteins were purified further by a second perchloric acid treatment. The purified PHF-tau proteins were soluble in buffers devoid of sodium dodecyl sulfate. However, they were similar to the abnormal tau extracted from paired helical filaments with sodium dodecyl sulfate, also named A68, in molecular mass (68, 64, and 60 kDa), isoelectric point (pI 5.5-6.5), reactivity with anti-tau antibodies, and in requirement for alkaline phosphatase treatment to bind the Tau-1 antibody. Compared to normal tau, the soluble PHF-tau contained 100% more glycine and 35% less lysine residue. The results suggest that besides phosphorylation other types of modification may be involved in differentiating PHF-tau from normal tau.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,F-538,1300 MORRIS PK AVE,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE ON AGING [R37AG001136, R01AG001136, R01AG004145] Funding Source: NIH RePORTER; NIA NIH HHS [AG1136, AG4145] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BRAAK H, 1986, NEUROSCI LETT, V65, P351, DOI 10.1016/0304-3940(86)90288-0; DEGARCINI EM, 1987, J BIOCHEM-TOKYO, V102, P1415, DOI 10.1093/oxfordjournals.jbchem.a122187; DELACOURTE A, 1986, J NEUROL SCI, V76, P173, DOI 10.1016/0022-510X(86)90167-X; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; FLAMENT S, 1989, CR ACAD SCI III-VIE, V308, P77; GACHE Y, 1990, FEBS LETT, V272, P65, DOI 10.1016/0014-5793(90)80450-W; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1990, ACTA NEUROPATHOL, V81, P105, DOI 10.1007/BF00334497; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HIRANO A, 1962, ARCH NEUROL-CHICAGO, V7, P227, DOI 10.1001/archneur.1962.04210030065009; IHARA Y, 1983, NATURE, V304, P727, DOI 10.1038/304727a0; IQBAL K, 1989, P NATL ACAD SCI USA, V86, P5646, DOI 10.1073/pnas.86.14.5646; IQBAL K, 1984, ACTA NEUROPATHOL, V62, P167, DOI 10.1007/BF00691849; KIDD M, 1964, BRAIN, V87, P307, DOI 10.1093/brain/87.2.307; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4094; KSIEZAKREDING H, 1987, P NATL ACAD SCI USA, V84, P3410, DOI 10.1073/pnas.84.10.3410; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; KSIEZAKREDING H, 1988, J BIOL CHEM, V263, P7948; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P412, DOI 10.1002/jnr.490250319; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; RUBINSTEIN R, 1986, BRAIN RES, V372, P80; VOGELSANG GD, 1990, J NEUROCHEM, V54, P148, DOI 10.1111/j.1471-4159.1990.tb13295.x; VOGELSANG GD, 1988, MOL BIOL ALZHEIMERS, P150; WISCHIK C, 1988, P NATL ACAD SCI USA, V85, P4885; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040; YEN SH, 1987, AM J PATHOL, V126, P81	38	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21723	21727						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939196				2022-12-25	WOS:A1991GP80400061
J	PORTER, DJT; BOYD, FL				PORTER, DJT; BOYD, FL			MECHANISM OF BOVINE LIVER S-ADENOSYLHOMOCYSTEINE HYDROLASE STEADY-STATE AND PRE-STEADY-STATE KINETIC-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPLANOCIN-A; PURIFICATION; ENZYME; 3-DEAZANEPLANOCIN-A; METHYLATION; METABOLISM; INHIBITORS; CELLS	The kinetic mechanism of S-adenosylhomocysteine hydrolase was investigated by stopped-flow spectrofluorometry at pH 7.0 and 25-degrees-C. Pre-steady-state kinetic steps were identified with chemical steps proposed for the mechanism of this enzyme (Palmer, J. L., and Abeles, R. H. (1979) J. Biol. Chem. 254, 1217-1226). The steady-state kinetic constants for the hydrolysis or synthesis of S-adenosylhomocysteine were in good agreement with those values calculated from the pre-steady-state rate constants. The equilibrium constant for dehydration of 3'-ketoadenosine to 3'-keto-4',5'-dehydroadenosine on the enzyme was 3. The analogous equilibrium constant for addition Of L-homocysteine to S-3'-keto-4',5'-dehydroadenosylhomocysteine on the enzyme was 0.3. The elimination of H2O from adenosine in solution had an equilibrium constant of 1.4 (alpha-H2O = 1). Thus, the equilibrium constants for these elimination reactions on the enzyme were probably not perturbed significantly from those in solution. The equilibrium constant for the reduction of enzyme-bound NAD+ by adenosine was 8, and the analogous constant for the reduction of the enzyme by S-adenosylhomocysteine was 4. The equilibrium constant for the reduction of NAD+ by a secondary alcohol in solution was 5 x 10(-5) at pH 7.0. Consequently, the reduction of enzyme-bound NAD+ by adenosine was 10(5)-fold more favorable than the reduction of free NAD+. The magnitude of the first-order rate constants for the interconversion of enzyme-bound intermediates varied over a relatively small range (3-80 s-1). Similarly, the magnitude of the equilibrium constants among enzyme-bound intermediates varied over a narrow range (0.3-10). These results were consistent with the overall reversibility of the reaction.			PORTER, DJT (corresponding author), WELLCOME RES LABS, DIV EXPTL THERAPY, 3030 CORNWALLIS RD, RES TRIANGLE PK, NC 27709 USA.							ABELES RH, 1982, BIOCHEMISTRY-US, V21, P5557, DOI 10.1021/bi00265a027; BACKLUND PS, 1986, EUR J BIOCHEM, V160, P245, DOI 10.1111/j.1432-1033.1986.tb09963.x; Bevington P. R., 1969, DATA REDUCTION ERROR; BURBAUM JJ, 1989, BIOCHEMISTRY-US, V28, P9306, DOI 10.1021/bi00450a010; BURTON RM, 1955, METHOD ENZYMOL, V1, P397, DOI 10.1016/0076-6879(55)01064-1; Chance B, 1943, J BIOL CHEM, V151, P553; COOLS M, 1989, BIOCHEM PHARMACOL, V38, P1061, DOI 10.1016/0006-2952(89)90249-9; DECLERCQ E, 1987, BIOCHEM PHARMACOL, V36, P2567, DOI 10.1016/0006-2952(87)90533-8; DECLERCQ E, 1989, ANTIMICROB AGENTS CH, V33, P1291, DOI 10.1128/AAC.33.8.1291; DELAHABA G, 1959, J BIOL CHEM, V234, P603; DUGGLEBY RG, 1990, ANAL BIOCHEM, V189, P84, DOI 10.1016/0003-2697(90)90048-E; EIGEN M, 1964, PROG REACT KINET MEC, V2, P285; FROST AA, 1961, KINETICS MECHANISM, P162; FUJIOKA M, 1981, J BIOL CHEM, V256, P1631; GLAZER RI, 1986, BIOCHEM PHARMACOL, V35, P4523, DOI 10.1016/0006-2952(86)90774-4; HASOBE M, 1989, ANTIMICROB AGENTS CH, V33, P828, DOI 10.1128/AAC.33.6.828; HERSHFIELD MS, 1985, BIOCHEM J, V230, P43, DOI 10.1042/bj2300043; LIAU MC, 1986, DRUG EXP CLIN RES, V12, P77; MATUSZEWSKA B, 1987, J BIOL CHEM, V262, P265; NARAYANAN SR, 1988, BIOCHIM BIOPHYS ACTA, V965, P22, DOI 10.1016/0304-4165(88)90146-8; PAISLEY SD, 1989, J MED CHEM, V32, P1415, DOI 10.1021/jm00127a001; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PALMER JL, 1976, J BIOL CHEM, V251, P5817; PARRY RJ, 1985, J AM CHEM SOC, V107, P1417, DOI 10.1021/ja00291a055; RICHARDS HH, 1978, J BIOL CHEM, V253, P4476; SEGAL IH, 1975, ENZYME KINETICS, P544; SINHABABU AK, 1985, J AM CHEM SOC, V107, P7628, DOI 10.1021/ja00311a066; STIPANUK MH, 1986, ANNU REV NUTR, V6, P179, DOI 10.1146/annurev.nu.06.070186.001143; WHAUN JM, 1986, J PHARMACOL EXP THER, V236, P277; 1961, OR18 PABST LAB CIRC, P2	30	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21616	21625						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939191				2022-12-25	WOS:A1991GP80400047
J	DENT, CL; LILLYCROP, KA; BYBEE, A; LATCHMAN, DS; THOMAS, NSB				DENT, CL; LILLYCROP, KA; BYBEE, A; LATCHMAN, DS; THOMAS, NSB			INTERFERON-ALPHA TREATMENT OF DAUDI CELLS DOWN-REGULATES THE OCTAMER BINDING TRANSCRIPTION DNA-REPLICATION FACTORS OCT-1 AND OCT-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; FACTOR STIMULATES TRANSCRIPTION; LYMPHOID-SPECIFIC PROMOTERS; IMMEDIATE-EARLY GENES; NON-B CELLS; RESPONSE ELEMENT; MESSENGER-RNA; PHORBOL ESTER; WILD-TYPE; PROTEIN	Treatment of Daudi cells with a-interferon (alpha-IFN) results in a considerable decrease in the levels of the octamer-binding DNA replication/transcription factors Oct-1 and Oct-2 and specifically inhibits gene expression by octamer-containing promoters. The inhibitory effect on octamer-binding proteins also occurs after culturing cells with phorbol 12-myristate 13-acetate but it does not occur following alpha-IFN treatment of an alpha-IFN-resistant variant of the Daudi cell line or of HeLa cells. We discuss the potential role of the decreased levels of octamer-binding proteins in the inhibition of cell proliferation.	UNIV COLL & MIDDLESEX SCH MED, DEPT HAEMATOL, LONDON WC1E 6HX, ENGLAND; UNIV COLL & MIDDLESEX SCH MED, DEPT BIOCHEM, MED MOLEC BIOL UNIT, LONDON WC1E 6HX, ENGLAND	University of London; University College London; University of London; University College London								ADAMS A, 1975, J GEN VIROL, V28, P207, DOI 10.1099/0022-1317-28-2-207; AFFOLTER M, 1900, CURR OPIN CELL BIOL, V2, P4859; BALKWILL F, 1978, INT J CANCER, V22, P258, DOI 10.1002/ijc.2910220307; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; DENT CL, 1990, MOL CELL BIOL, V10, P3258, DOI 10.1128/MCB.10.6.3258; DESTASIO PR, 1990, J VIROL, V64, P2588, DOI 10.1128/JVI.64.6.2588-2593.1990; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EPSTEIN MA, 1979, EPSTEINBARR VIRUS; EXLEY R, 1987, P NATL ACAD SCI USA, V84, P6467, DOI 10.1073/pnas.84.18.6467; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; KEMP LM, 1990, NEURON, V4, P215, DOI 10.1016/0896-6273(90)90096-X; KEMP LM, 1988, EMBO J, V7, P4239, DOI 10.1002/j.1460-2075.1988.tb03321.x; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MCMAHON M, 1986, J VIROL, V57, P362, DOI 10.1128/JVI.57.1.362-366.1986; MEURS E, 1988, EMBO J, V7, P1689, DOI 10.1002/j.1460-2075.1988.tb02997.x; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; OBERMAN F, 1988, J GEN VIROL, V69, P1167, DOI 10.1099/0022-1317-69-6-1167; OHARE P, 1988, CELL, V52, P435, DOI 10.1016/S0092-8674(88)80036-9; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PRUIJN GJM, 1986, NATURE, V322, P656, DOI 10.1038/322656a0; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; ROSENFELD PJ, 1987, MOL CELL BIOL, V7, P875, DOI 10.1128/MCB.7.2.875; ROSNER MH, 1991, CELL, V64, P1103, DOI 10.1016/0092-8674(91)90265-Z; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SHARP NA, 1989, ONCOGENE, V4, P1043; SILVERMAN RH, 1982, EUR J BIOCHEM, V126, P333; Stewart W, 1979, INTERFERON SYSTEM; THOMAS NSB, 1991, ONCOGENE, V6, P317; THOMAS NSB, 1989, J BIOL CHEM, V264, P13697; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; WHITTON JL, 1984, NUCLEIC ACIDS RES, V12, P2061, DOI 10.1093/nar/12.4.2061; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	45	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20888	20892						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939139				2022-12-25	WOS:A1991GN00100048
J	LANG, JC; WILKIE, NM; CLARK, AM; CHUDLEIGH, A; TALBOT, S; WHITELAW, B; FRAME, MC				LANG, JC; WILKIE, NM; CLARK, AM; CHUDLEIGH, A; TALBOT, S; WHITELAW, B; FRAME, MC			REGULATORY DOMAINS WITHIN THE P0 PROMOTER OF HUMAN C-MYC	ONCOGENE			English	Article							IMMEDIATE EARLY GENE; TRANSCRIPTIONAL REGULATION; MODULATE EXPRESSION; BURKITT-LYMPHOMA; TRANS-ACTIVATION; THYMIDINE KINASE; PROTEIN-BINDING; MAMMALIAN-CELLS; DNA-BINDING; CCAAT BOX	Expression of P0 RNA in some Burkitt lymphoma cell lines varies independently of levels of RNA derived from P1 and P2. These data suggest the possibility that expression of P0 RNA may be capable of independent regulation. In order to investigate this possibility we have isolated putative regulatory domains flanking P0 RNA starts within the human c-myc gene and analysed both their ability to direct expression of control reporter genes and their ability to interact with specific transcription factors. Regulatory regions necessary for expression of P0 RNA have been located within 131 bp 5' of the first major P0 RNA start. DNAase 1 footprint analysis and gel retardation assays demonstrate binding of transcription factors Sp1, NF1 and CBP to this region. NF1 binds specifically to two consensus sequences. The more distal site overlaps with the binding site for CBP, and it is likely that concomitant binding of NF1 and CBP within the distal region of the P0 promoter is not possible. Previous work from our laboratory has described a negative regulatory domain within the 5' flanking region of c-myc. The P0 promoter resides within this domain and therefore may contain a negative regulator of c-myc gene expression.	BEATSON INST CANC RES, GLASGOW G61 1BD, SCOTLAND; AFRC, INST ANIM PHYSIOL & GENET RES, EDINBURGH EH9 3JQ, MIDLOTHIAN, SCOTLAND	Beatson Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute								ASSELIN C, 1989, ONCOGENE, V4, P549; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BATLEY J, 1983, CELL, V34, P779; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COHEN RB, 1986, MOL CELL BIOL, V6, P821, DOI 10.1128/MCB.6.3.821; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1990, ONCOGENE, V5, P1397; FRAME MC, 1991, ONCOGENE, V6, P205; GAFFNEY DF, 1985, NUCLEIC ACIDS RES, V13, P7847, DOI 10.1093/nar/13.21.7847; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HALL DJ, 1990, ONCOGENE, V5, P47; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KIT S, 1963, BIOCHEM BIOPH RES CO, V11, P55, DOI 10.1016/0006-291X(63)90027-5; LANG JC, 1983, J GEN VIROL, V64, P2679, DOI 10.1099/0022-1317-64-12-2679; LANG JC, 1988, BRIT J CANCER, V58, P62; LANG JC, 1984, EMBO J, V3, P389, DOI 10.1002/j.1460-2075.1984.tb01817.x; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; NEPVEU A, 1987, ONCOGENE, V1, P243; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PEI DQ, 1990, J VIROL, V64, P1517, DOI 10.1128/JVI.64.4.1517-1522.1990; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; RAY D, 1987, MOL CELL BIOL, V7, P940, DOI 10.1128/MCB.7.2.940; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; ROMAN D, 1990, New Biologist, V2, P642; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPANDIDOS DA, 1983, EMBO J, V2, P1193, DOI 10.1002/j.1460-2075.1983.tb01566.x; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; TOURKINE N, 1989, ONCOGENE, V4, P973; WEISINGER G, 1988, ONCOGENE, V3, P635; WHITELAW B, 1988, UCLA S MOL CELL BIOL, V58, P337; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505	62	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					2067	2075						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945411				2022-12-25	WOS:A1991GX11900018
J	LOWERY, DE; PASTERNACK, JM; GONZALEZDEWHITT, PA; ZURCHERNEELY, H; TOMICH, CSC; ALTMAN, RA; FAIRBANKS, MB; HEINRIKSON, RL; YOUNKIN, SG; GREENBERG, BD				LOWERY, DE; PASTERNACK, JM; GONZALEZDEWHITT, PA; ZURCHERNEELY, H; TOMICH, CSC; ALTMAN, RA; FAIRBANKS, MB; HEINRIKSON, RL; YOUNKIN, SG; GREENBERG, BD			ALZHEIMERS AMYLOID PRECURSOR PROTEIN PRODUCED BY RECOMBINANT BACULOVIRUS EXPRESSION - PROTEOLYTIC PROCESSING AND PROTEASE INHIBITORY PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEXIN-II; KUNITZ DOMAIN; DISEASE; IDENTIFICATION; FORM; PURIFICATION; QUANTITATION; CHYMOTRYPSIN; SPECIFICITY; BIOGENESIS	The baculovirus expression system was used to generate recombinant Alzheimer's amyloid precursor (AAP) 1 proteins. Recombinant baculoviruses were constructed, designed to express full-length 695-, 751-, and 770-amino acid forms. Recombinant baculoviruses designed for constitutive secretion were engineered by placing a termination codon between the beta-protein domain and cytoplasmic anchor of the full-length forms. Insect cells infected with each of these baculoviruses produced both secreted and cell-associated AAPs. Full-length constructs produced secreted derivatives which were COOH-terminally cleaved within the beta-protein domain at Gln15 or Lys16, essentially identical to previous reports utilizing mammalian cell systems (1). Rare secreted forms (< 5%) appeared to extend to Lys28. Secretion constructs produced these same forms, but in different ratios. Most (approximately 60%) terminated at Gln15 or Lys16, while the remainder apparently extended to LyS28. AAPs containing the Kunitz-type serine protease inhibitory domain (AAP-751 and -770) were shown to be active inhibitors. No differences were observed in the inhibitory activities of these two forms. The similarities in AAP processing by insect and mammalian systems, together with the large amounts of recombinant protein produced by baculovirus expression, make this an attractive system for studies of AAP processing and biochemical properties.	UPJOHN CO,LABS,7242-267,301 HENRIETTA ST,KALAMAZOO,MI 49001; CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106	Pfizer; Case Western Reserve University				Lowery, David/0000-0001-5111-4719				ABRAHAM CR, 1989, BIO-TECHNOL, V7, P147, DOI 10.1038/nbt0289-147; ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; ARAI H, 1991, IN PRESS ANN NEUROL; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTRO M, 1990, FEBS LETT, V267, P207, DOI 10.1016/0014-5793(90)80926-A; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CRAS P, 1990, AM J PATHOL, V137, P241; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; Hunkapiller M.W., 1986, METHODS PROTEIN MICR, P89, DOI DOI 10.1007/978-1-59259-436-8_3; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDO H, 1990, BIOCHEM BIOPH RES CO, V167, P716, DOI 10.1016/0006-291X(90)92084-D; KITAGUCHI N, 1990, BIOCHIM BIOPHYS ACTA, V1038, P105, DOI 10.1016/0167-4838(90)90017-A; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KNOPS J, 1991, J BIOL CHEM, V266, P7285; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LUO LQ, 1990, J NEUROSCI, V10, P3849, DOI 10.1523/JNEUROSCI.10-12-03849.1990; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; NELSON RB, 1990, J BIOL CHEM, V265, P3836; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RAMAKRISHNA N, 1991, BIOCHEM BIOPH RES CO, V174, P983, DOI 10.1016/0006-291X(91)91515-E; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; SINHA S, 1990, J BIOL CHEM, V265, P8983; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SUMMERS MD, 1987, MANUAL METHODS BACUL, P10; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TAPE C, 1988, SCAND J IMMUNOL, V28, P317, DOI 10.1111/j.1365-3083.1988.tb01455.x; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P9764; TOMICH CSC, 1989, NUCLEIC ACIDS RES, V17, P3179, DOI 10.1093/nar/17.8.3179; VANNOSTRAND WE, 1987, J BIOL CHEM, V262, P8508; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; VANNOSTRAND WE, 1989, NATURE, V341, P546; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	43	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19842	19850						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918088				2022-12-25	WOS:A1991GK66700102
J	CHOW, BKC; TING, V; TUFARO, F; MACGILLIVRAY, RTA				CHOW, BKC; TING, V; TUFARO, F; MACGILLIVRAY, RTA			CHARACTERIZATION OF A NOVEL LIVER-SPECIFIC ENHANCER IN THE HUMAN PROTHROMBIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; DNA-BINDING PROTEINS; HEPATITIS-B VIRUS; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; BLOOD-COAGULATION; MESSENGER-RNA; HEMOPHILIA-B; FACTOR-VIII; RAT-LIVER	The 5'-flanking sequence of the human prothrombin gene was isolated by screening a human liver phage library with a human prothrombin cDNA as a hybridization probe. A phage was identified that contained 3 kilobase pairs of DNA upstream of the initiator methionine codon. Primer extension studies showed that the major transcription initiation sites were located 23 and 36 base pairs upstream of the initiator codon. DNA sequences in the 5'-flanking region of the human prothrombin gene were then analyzed for cis-activating transcriptional activity by a transient expression system using the human growth hormone gene as the reporter gene. The chimeric expression vector was introduced into HepG2 cells, and secreted human growth hormone was monitored by using a radio-immunoassay. These studies showed that the 3-kilobase pair fragment contained sequences that were sufficient for the initiation of transcription in HepG2 cells. Subsequent deletion studies showed that the 3-kilobase pair fragment contained two elements: a weak promoter in the region immediately upstream of the mRNA coding sequence and an enhancer located between nucleotides -860 and -940. The enhancer element was active at a distance and in either orientation. In addition, the enhancer was liver cell-specific and acted on heterologous promoters including the herpes simplex virus thymidine kinase promoter and the mouse metallothionein I promoter. Comparison of the nucleotide sequence of the enhancer with a DNA sequence data base showed the enhancer sequence to be unique. The enhancer sequence is flanked by an inverted repeat 5' CCTCCC 3' and contains a putative binding site for hepatic nuclear factor 1. Deoxyribonuclease I footprint analysis and linker scanning mutagenesis showed that the enhancer contains multiple protein binding motifs. Mutagenesis of the 3' boundary CCTCCC sequence eliminated the enhancer activity. Comparison with other liver genes showed the presence of the CCTCCC sequence in the hepatitis B virus enhancer, the alpha-1-antitrypsin promoter, and the fibrinogen beta-chain promoter, suggesting a functional role for this motif.	UNIV BRITISH COLUMBIA,DEPT MICROBIOL,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia	CHOW, BKC (corresponding author), UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1W5,BC,CANADA.		Chow, Billy/D-3064-2009	Chow, Billy/0000-0003-3390-0307				Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; ATTREE O, 1989, THROMB HAEMOSTASIS, V62, P8; BUTKOWSKI RJ, 1977, J BIOL CHEM, V252, P4942; COOL DE, 1987, J BIOL CHEM, V262, P13662; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7933; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DEGEN SJF, 1987, BIOCHEMISTRY-US, V26, P6165, DOI 10.1021/bi00393a033; DEGEN SJF, 1989, THROMB HAEMOSTASIS, V62, P153; DENOTO FM, 1981, NUCLEIC ACIDS RES, V9, P3719, DOI 10.1093/nar/9.15.3719; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; FAIR DS, 1984, BLOOD, V64, P194; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAVES CB, 1982, J BIOL CHEM, V257, P3108; GRAVES CB, 1981, P NATL ACAD SCI-BIOL, V78, P4772, DOI 10.1073/pnas.78.8.4772; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KUGLER W, 1988, NUCLEIC ACIDS RES, V16, P3165, DOI 10.1093/nar/16.8.3165; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LILLIE JW, 1989, NATURE, V341, P279, DOI 10.1038/341279a0; MACGILLIVRAY RTA, 1984, BIOCHEMISTRY-US, V23, P1626, DOI 10.1021/bi00303a007; MAGNUSSON S, 1975, PROTEASES BIOL CONTR, P123; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maniatis T, 1989, DECONTAMINATION DILU; MCKNIGHT SL, 1984, CELL, V37, P253, DOI 10.1016/0092-8674(84)90321-0; MORGAN JG, 1988, MOL CELL BIOL, V8, P2628, DOI 10.1128/MCB.8.6.2628; NARDACCI NJ, 1975, BIOCHEM BIOPH RES CO, V64, P51, DOI 10.1016/0006-291X(75)90218-1; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NUSSINOV R, 1990, CRIT REV BIOCH MOL B, V25, P188; PLUTZKY J, 1986, P NATL ACAD SCI USA, V83, P546, DOI 10.1073/pnas.83.3.546; REITSMA PH, 1988, BLOOD, V72, P1074; SAILER JP, 1990, J BIOL CHEM, V265, P7062; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SEALE PF, 1985, MOL CELL BIOL, V5, P1480; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHAW E, 1979, BRIT J HAEMATOL, V41, P585, DOI 10.1111/j.1365-2141.1979.tb05895.x; TOLLERSRUD OK, 1989, BIOCHIM BIOPHYS ACTA, V1010, P35, DOI 10.1016/0167-4889(89)90181-X; WALZ DA, 1977, P NATL ACAD SCI USA, V74, P1969, DOI 10.1073/pnas.74.5.1969; WASYLYK B, 1988, CRC CR REV BIOCH MOL, V23, P77, DOI 10.3109/10409238809088317; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	49	48	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18927	18933						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918008				2022-12-25	WOS:A1991GJ47200080
J	CHAUCHEREAU, A; LOOSFELT, H; MILGROM, E				CHAUCHEREAU, A; LOOSFELT, H; MILGROM, E			PHOSPHORYLATION OF TRANSFECTED WILD-TYPE AND MUTATED PROGESTERONE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-DEPENDENT PHOSPHORYLATION; CASEIN KINASE-II; LIVER GLUCOCORTICOID RECEPTOR; STEROID-BINDING SUBUNIT; PROTEIN-KINASE; DNA-BINDING; RAT-LIVER; POLYACRYLAMIDE GELS; FUNCTIONAL DOMAINS; SITES	An expression vector encoding wild type or mutated forms of the rabbit progesterone receptor was transfected into COS-7 cells and phosphorylation was studied by incubation with P-32i followed by specific immunoprecipitation. The features of phosphorylation of the wild type receptor were identical to those previously observed in uterine cells: there was a basal level of phosphorylation which was increased approximately 7-fold by incubation with the hormone. The hyperphosphorylated receptor had decreased electrophoretic mobility ("upshift"). These experiments thus showed that the presence of the receptor specific kinase is not restricted to the target cells. Cleavage of the receptor by hydroxylamine and cyanogen bromide, and use of receptor mutants deleted in the N-terminal region, showed the absence of any detectable phosphorylation downstream from amino acid 520 (thus in the DNA and steroid binding domains). The majority of the phosphorylation sites were localized between amino acids 166 and 520. This localization was similar for basal and hormone-induced phosphorylation. DNA binding and hormone-induced hyperphosphorylation were not directly related, since deletion of the first zinc finger provided a hyperphosphorylated receptor. We showed that the constitutive receptor (totally deleted in the steroid binding region) exhibited only a low basal level of phosphorylation, and antagonist RU 486-receptor complexes were found to be hyperphosphorylated, leading us to conclude that the active form of the receptor was not the hyperphosphorylated one. Moreover receptor down regulation and hormone-induced receptor hyperphosphorylation were two independent phenomena. Basal phosphorylation was observed for both cytoplasmic and nuclear mutants, whereas nuclear localization was necessary but not sufficient for hyperphosphorylation. Finally, the second finger region and the hormone binding domain, which are necessary for receptor hyperphosphorylation, may be involved in the hormonally induced increased affinity of the receptor toward its kinase.	UNIV PARIS SUD, FAC MED,INSERM,U135,UNITE RECH HORMONES & REPROD, F-94275 LE KREMLIN BICETRE, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay			Chauchereau, Anne/N-8880-2016; CHAUCHEREAU, Anne/B-1074-2009	Chauchereau, Anne/0000-0001-9447-3797; 				ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; BAILLY A, 1986, EMBO J, V5, P3235, DOI 10.1002/j.1460-2075.1986.tb04634.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENJAMIN WSV, 1990, BIOCHEM BIOPH RES CO, V166, P931, DOI 10.1016/0006-291X(90)90900-8; Bornstein P, 1977, Methods Enzymol, V47, P132; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHAN PK, 1990, BIOCHEM J, V270, P549, DOI 10.1042/bj2700549; DALMAN FC, 1988, J BIOL CHEM, V263, P12259; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1989, ENDOCRINOLOGY, V125, P3051, DOI 10.1210/endo-125-6-3051; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GARCIA T, 1986, BIOCHEMISTRY-US, V25, P7937, DOI 10.1021/bi00372a023; GARCIA T, 1983, BIOCHEM BIOPH RES CO, V113, P960, DOI 10.1016/0006-291X(83)91092-6; GLINEUR C, 1989, ONCOGENE, V4, P1247; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOUELI SA, 1984, BIOCHEM BIOPH RES CO, V123, P778, DOI 10.1016/0006-291X(84)90297-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HAI MTV, 1977, ANN NY ACAD SCI, V286, P199, DOI 10.1111/j.1749-6632.1977.tb29417.x; HERRMANN W, 1982, CR ACAD SCI III-VIE, V294, P933; HOECK W, 1990, J BIOL CHEM, V265, P5403; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JAHNEN W, 1990, BIOCHEM BIOPH RES CO, V166, P139, DOI 10.1016/0006-291X(90)91922-F; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KURL RN, 1984, BIOCHEM BIOPH RES CO, V119, P700, DOI 10.1016/S0006-291X(84)80307-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGEAT F, 1987, EUR J BIOCHEM, V170, P51, DOI 10.1111/j.1432-1033.1987.tb13666.x; LOGEAT F, 1985, BIOCHEM BIOPH RES CO, V131, P421, DOI 10.1016/0006-291X(85)91819-4; LOOSFELT H, 1986, P NATL ACAD SCI USA, V83, P9045, DOI 10.1073/pnas.83.23.9045; LOOSFELT H, 1984, J BIOL CHEM, V259, P4196; LORENZO F, 1988, EUR J BIOCHEM, V176, P53, DOI 10.1111/j.1432-1033.1988.tb14250.x; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIGLIACCIO A, 1982, BIOCHEM BIOPH RES CO, V109, P1002, DOI 10.1016/0006-291X(82)92039-3; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; MILGROM E, 1987, BIOCHEM ACTION HORM, V14, P349; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; SARIS CJM, 1983, ANAL BIOCHEM, V132, P54, DOI 10.1016/0003-2697(83)90425-6; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHERIDAN PL, 1988, MOL ENDOCRINOL, V2, P1329, DOI 10.1210/mend-2-12-1329; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SINGH VB, 1986, BIOCHIM BIOPHYS ACTA, V888, P237, DOI 10.1016/0167-4889(86)90026-1; SINGH VB, 1984, BIOCHEM BIOPH RES CO, V125, P1067, DOI 10.1016/0006-291X(84)91392-5; SINGH VB, 1985, J BIOL CHEM, V260, P3684; SMITH CL, 1989, J VIROL, V63, P1569, DOI 10.1128/JVI.63.4.1569-1577.1989; SMITH LI, 1989, BIOCHEMISTRY-US, V28, P4490, DOI 10.1021/bi00436a055; STORMSHAK F, 1976, ENDOCRINOLOGY, V99, P1501, DOI 10.1210/endo-99-6-1501; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; WEI LL, 1987, BIOCHEMISTRY-US, V26, P6262, DOI 10.1021/bi00393a046; WEIGEL NL, 1981, BIOCHEM BIOPH RES CO, V102, P513, DOI 10.1016/0006-291X(81)91549-7; WILLMANN T, 1986, NATURE, V324, P688, DOI 10.1038/324688a0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	64	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18280	18286						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917956				2022-12-25	WOS:A1991GG55300085
J	HINCHMAN, CA; MATSUMOTO, H; SIMMONS, TW; BALLATORI, N				HINCHMAN, CA; MATSUMOTO, H; SIMMONS, TW; BALLATORI, N			INTRAHEPATIC CONVERSION OF A GLUTATHIONE CONJUGATE TO ITS MERCAPTURIC ACID - METABOLISM OF 1-CHLORO-2,4-DINITROBENZENE IN ISOLATED PERFUSED RAT AND GUINEA-PIG LIVERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACIDS; S-CONJUGATE; KIDNEY; BILIARY; EXCRETION; NEPHROTOXICITY; TRANSPORT; INVIVO; CELLS; BIOSYNTHESIS	Because of the low hepatic activity of gamma-glutamyl-transferase in the rat, the liver is generally considered to play only a minor role in the degradation of glutathione conjugates, a limiting step in mercapturic acid formation. Recent findings indicate, however, that the liver has a prominent role in glutathione catabolism, particularly in species other than rat. To examine the contributions of liver to mercapturic acid biosynthesis, mercapturate formation was compared in isolated perfused livers from rats and guinea pigs dosed with either 0.3 or 3.0-mu-mol of 1-chloro-2,4-dinitrobenzene (CDNB). Chemically synthesized glutathione conjugate, mercapturic acid, and intermediary metabolites of CDNB were used as standards in the high performance liquid chromatography analysis of bile and perfusate samples. Biliary excretion accounted for almost all of the recovered metabolites. A marked species difference was observed in the pattern of CDNB metabolism. Rat livers dosed with 0.3-mu-mol of CDNB excreted 55% of total biliary metabolites as the glutathione conjugate and 8.2% as the mercapturic acid, whereas guinea pig livers excreted only 4.8% as the glutathione conjugate and 47% as the mercapturate. Mercapturic formation was also dose-dependent, with a larger fraction formed at the 0.3- versus the 3.0-mu-mol dose (8.2 versus 3.7% in the rat; 47 versus 19% in the guinea pig). Hepatic conversion of the glutathione conjugate to the mercapturic acid was markedly inhibited in both species after retrograde intrabiliary infusion of acivicin, an inhibitor of gamma-glutamyltransferase activity. These findings provide direct evidence for intrahepatic biosynthesis of mercapturic acids. Thus, glutathione conjugates synthesized within hepatocytes are secreted into bile and broken down to cysteine conjugates; the latter are then presumably reabsorbed by the liver, N-acetylated to form the mercapturic acid and re-excreted into bile.	UNIV ROCHESTER,SCH MED,CTR ENVIRONM HLTH SCI,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Rochester					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK039165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004400] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-39165] Funding Source: Medline; NIEHS NIH HHS [ES-07026, ES-04400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERT Z, 1961, NATURE, V191, P767, DOI 10.1038/191767a0; ANDERS MW, 1987, ARCH TOXICOL, V60, P103, DOI 10.1007/BF00296959; BAKKE JE, 1981, DRUG METAB DISPOS, V9, P525; BAKKE JE, 1982, SCIENCE, V217, P645, DOI 10.1126/science.6806905; BAKKE JE, 1986, XENOBIOTIC CONJUGATI, P301; BALLATORI N, 1988, AM J PHYSIOL, V254, pG1, DOI 10.1152/ajpgi.1988.254.1.G1; BALLATORI N, 1989, AM J PHYSIOL, V256, pG482, DOI 10.1152/ajpgi.1989.256.3.G482; BALLATORI N, 1986, J BIOL CHEM, V261, P7860; BARTELS MJ, 1986, DRUG METAB DISPOS, V14, P97; BOOGAARD PJ, 1989, BIOCHEM PHARMACOL, V38, P3731, DOI 10.1016/0006-2952(89)90579-0; BOYLAND E, 1969, ADV ENZYMOL RELAT AR, V32, P172; BOYLAND E, 1959, ADV ENZYMOL, V73, P465; COHEN AJ, 1964, BIOCHEM J, V90, P449; CORNER EDS, 1954, BIOCHEM J, V58, P647, DOI 10.1042/bj0580647; DAVISON KL, 1990, XENOBIOTICA, V20, P375, DOI 10.3109/00498259009046854; ELFARRA AA, 1984, BIOCHEM PHARMACOL, V33, P3729, DOI 10.1016/0006-2952(84)90032-7; ELFERINK RPJ, 1989, J CLIN INVEST, V84, P476, DOI 10.1172/JCI114189; GRAFSTROM R, 1979, BIOCHEM PHARMACOL, V28, P3573, DOI 10.1016/0006-2952(79)90402-7; GREEN RM, 1975, BIOCHEM J, V147, P283, DOI 10.1042/bj1470283; GREGUS Z, 1988, J PHARMACOL EXP THER, V244, P91; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HAN DH, 1990, CHEM RES TOXICOL, V3, P118, DOI 10.1021/tx00014a006; HINCHMAN CA, 1990, BIOCHEM PHARMACOL, V40, P1131, DOI 10.1016/0006-2952(90)90503-D; HORNING MG, 1987, J CHROMATOGR, V399, P303; HUGHEY RP, 1978, ARCH BIOCHEM BIOPHYS, V186, P211, DOI 10.1016/0003-9861(78)90430-7; INOUE M, 1987, BIOCHEM PHARMACOL, V36, P2145, DOI 10.1016/0006-2952(87)90143-2; INOUE M, 1982, HEPATOLOGY, V2, P311; INOUE M, 1984, J BIOCHEM, V95, P247, DOI 10.1093/oxfordjournals.jbchem.a134591; KANHAI W, 1989, CHEM RES TOXICOL, V2, P51, DOI 10.1021/tx00007a009; LINDWALL G, 1987, J BIOL CHEM, V262, P5151; LOCK EA, 1988, CRIT REV TOXICOL, V19, P23, DOI 10.3109/10408448809040816; MCINTYRE TM, 1980, INT J BIOCHEM, V12, P543; MEISTER A, 1976, ANNU REV BIOCHEM, V45, P559, DOI 10.1146/annurev.bi.45.070176.003015; MOLDEUS P, 1978, BIOCHEM BIOPH RES CO, V83, P195, DOI 10.1016/0006-291X(78)90416-3; MULDER GJ, 1984, MOL PHARMACOL, V26, P342; ORLOWSKI M, 1976, EUR J BIOCHEM, V71, P549, DOI 10.1111/j.1432-1033.1976.tb11144.x; ORLOWSKI M, 1963, BIOCHIM BIOPHYS ACTA, V73, P676; ORRENIUS S, 1983, FED PROC, V42, P3177; RUTENBURG AM, 1969, J HISTOCHEM CYTOCHEM, V17, P517, DOI 10.1177/17.8.517; Saunders BC, 1934, BIOCHEM J, V28, P1977, DOI 10.1042/bj0281977; SCHON MR, 1988, TOXICOL LETT, V42, P265, DOI 10.1016/0378-4274(88)90111-7; SOKOLOVSKY M, 1964, J AM CHEM SOC, V86, P1212; STEELE JW, 1981, J PHARMACOL EXP THER, V219, P35; TATE SS, 1974, J BIOL CHEM, V249, P7593; TATEISHI M, 1978, J BIOL CHEM, V253, P8854; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WAHLLANDER A, 1979, EUR J BIOCHEM, V96, P441, DOI 10.1111/j.1432-1033.1979.tb13056.x; WETTSTEIN M, 1989, EUR J BIOCHEM, V181, P115, DOI 10.1111/j.1432-1033.1989.tb14701.x; WIT JG, 1969, BIOCHIM BIOPHYS ACTA, V177, P329, DOI 10.1016/0304-4165(69)90143-3; ZAHN H, 1954, Z NATURFORSCH B, V9, P518	51	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22179	22185						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939239				2022-12-25	WOS:A1991GR56400021
J	POON, M; MEGYESI, J; GREEN, RS; ZHANG, H; ROLLINS, BJ; SAFIRSTEIN, R; TAUBMAN, MB				POON, M; MEGYESI, J; GREEN, RS; ZHANG, H; ROLLINS, BJ; SAFIRSTEIN, R; TAUBMAN, MB			INVIVO AND INVITRO INHIBITION OF JE GENE-EXPRESSION BY GLUCOCORTICOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; GROWTH-FACTOR; RIBONUCLEIC-ACID; MESSENGER-RNA; CELL-LINE; C-JUN; PROTEIN; DEXAMETHASONE; PURIFICATION; RECEPTOR	Glucocorticoids are potent anti-inflammatory agents which affect cell growth and migration in a wide variety of systems and have profound effects on monocytes, decreasing their circulating number as well as inhibiting their accumulation at sites of inflammation and injury. Although the mechanisms by which glucocorticoids regulate gene induction have been established, the mechanisms by which they inhibit inflammation or cell growth and migration have yet to been determined. JE is one of the most abundant genes induced by platelet-derived growth factor (PDGF) in vitro and is also induced in vivo in response to ischemia or injury. JE encodes a low molecular weight glycoprotein that functions in part as a monocyte chemotactic factor and thus may be important in recruiting monocytes to sites of tissue injury and/or inflammation. We report that glucocorticoids block the induction of JE mRNA by serum or PDGF in cultured vascular smooth muscle cells. The effect of glucocorticoids appears largely due to destabilization of JE mRNA and has specificity for JE, in that other "early" PDGF-inducible genes are not inhibited by glucocorticoids. The effect of glucocorticoids also occurs in vivo: methyl prednisolone blocks the constitutive expression and inhibits the ischemia-induced elevation of JE mRNA levels in rat kidneys. The inhibition of JE mRNA accumulation by glucocorticoids may be related to the anti-inflammatory effects of these agents and defines JE as a member of what may be a group of PDGF-inducible genes that are responsive to corticosteroids.	CUNY MT SINAI SCH MED, DEPT MED, BROOKDALE CTR MOLEC BIOL, DIV MOLEC MED, NEW YORK, NY 10029 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; CUNY MT SINAI SCH MED, DEPT MED, DIV CARDIOL, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, DEPT MED, DIV RENAL, NEW YORK, NY 10029 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CHEM, BOSTON, MA 02115 USA; CUNY MT SINAI SCH MED, DEPT PEDIAT, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard Medical School; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA53901] Funding Source: Medline; NHLBI NIH HHS [HL43302] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053901] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043302] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERK BC, 1988, J CELL PHYSIOL, V137, P391, DOI 10.1002/jcp.1041370302; BROCK TA, 1985, HYPERTENSION, V7, pI105, DOI 10.1161/01.HYP.7.3_Pt_2.I105; CHARRON J, 1986, P NATL ACAD SCI USA, V83, P8903, DOI 10.1073/pnas.83.23.8903; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLOWES AW, 1989, J CARDIOVASC PHARM, V14, pS12, DOI 10.1097/00005344-198906146-00005; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAWAHARA RS, 1991, J BIOL CHEM, V266, P13261; KURTJONES EA, 1987, J IMMUNOL, V139, P2317; LONGENECKER JP, 1982, J CELL PHYSIOL, V113, P197, DOI 10.1002/jcp.1041130203; MADCONALD RG, 1987, AM J CARDIOL, V60, pB56; MARMUR JD, 1990, CIRCULATION, V82, P698; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MUKAIDA N, 1991, J IMMUNOL, V146, P1212; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PARRILLO JE, 1979, ANNU REV PHARMACOL, V19, P179, DOI 10.1146/annurev.pa.19.040179.001143; PHILIPPE J, 1990, ENDOCRINOLOGY, V127, P1640, DOI 10.1210/endo-127-4-1640; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SAFIRSTEIN R, 1991, IN PRESS AM J PHYSL; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TIMMERS HT, 1990, NUCLEIC ACIDS RES, V18, P23, DOI 10.1093/nar/18.1.23; WATANABE K, 1989, J BIOL CHEM, V264, P19559; WEINER FR, 1987, J BIOL CHEM, V262, P6955; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449	37	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22375	22379						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939262				2022-12-25	WOS:A1991GR56400052
J	SHAI, Y; HADARI, YR; FINKELS, A				SHAI, Y; HADARI, YR; FINKELS, A			PH-DEPENDENT PORE FORMATION PROPERTIES OF PARDAXIN ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERABLE MEMBRANE PORES; FORMING PEPTIDE ALAMETHICIN; SEA MOSES SOLE; LIPID BILAYERS; CIRCULAR-DICHROISM; SYNTHETIC MELITTIN; MODEL MEMBRANES; IONIC CHANNELS; DESTABILIZATION; VESICLES	The interaction of pardaxin, a shark-repellent neurotoxin, and its charge-modified analogues with vesicles and human erythrocytes is described. The following six analogues and derivatives were synthesized by a solid phase method: [Glu8,Glu16]pardaxin, [N1-succinamido, Glu8,Glu16]pardaxin, [N1,Lys8,Lys16-trisuccinamido] pardaxin, [N1,Lys8,Lys16-triacetyl]pardaxin, des-[l --> 9]pardaxin (Shai, Y., Bach, D., and Yanovsky, A. (1990) J. Biol. Chem. 265, 2020220209), and des-[l --> 9][Glu16]pardaxin. The relative hydrophobic characteristics of the analogues were examined using reverse-phase high performance liquid chromatography. The pH-dependent spectroscopic and functional characteristics of the analogues were also investigated at either neutral or acidic pH. Spectroscopic characterization was achieved by measuring circular dichroism both before and after binding to vesicles, at either neutral or acidic pH. The ability of the peptides to dissipate a diffusion potential, to cause calcein release or the pH-dependent release of 8-aminonaphthalene, 1,3,6-trisulfonic acid disodium salt/p-xylene-bis [pyridinium bromide] from sonicated unilamellar liposomes, as well as measurements of cytolytic activity on human erythrocytes, served to functionally characterize the peptides. We show a direct correlation between alpha-helical content, the analogues' hydrophobicity, and their pore-forming properties at the different pH values tested. We also demonstrate that the charge of the N terminus and of the peptide backbone, but not of the C terminus, affects the secondary structure as well as the activities of the analogues. Finally, we show that the cytolytic activity of pardaxin at neutral pH is not retained by any of the analogues.			SHAI, Y (corresponding author), WEIZMANN INST SCI, DEPT MEMBRANES RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL.							ALLEN TM, 1980, BIOCHIM BIOPHYS ACTA, V597, P418, DOI 10.1016/0005-2736(80)90118-2; [Anonymous], [No title captured]; Barlett G.R., 1959, J BIOL CHEM, V234, P466; BATENBURG AM, 1985, BIOCHEMISTRY-US, V24, P7101, DOI 10.1021/bi00346a013; BESCHIASCHVILI G, 1990, BIOCHEMISTRY-US, V29, P52, DOI 10.1021/bi00453a007; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; DEFRISEQUERTAIN F, 1989, BIOCHEMISTRY-US, V28, P3406, DOI 10.1021/bi00434a040; DEGRADO WF, 1982, BIOPHYS J, V37, P329, DOI 10.1016/S0006-3495(82)84681-X; EHRENSTEIN G, 1977, Q REV BIOPHYS, V10, P1, DOI 10.1017/S0033583500000123; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELLENS H, 1984, BIOCHEMISTRY-US, V23, P1532, DOI 10.1021/bi00302a029; FAUCON JF, 1983, BIOCHEMISTRY-US, V22, P2179, DOI 10.1021/bi00278a019; HARSHMAN S, 1989, J BIOL CHEM, V264, P14978; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KINI RM, 1989, INT J PEPT PROT RES, V34, P277; KINI RM, 1989, BIOCHEMISTRY-US, V28, P9209, DOI 10.1021/bi00449a037; KONO K, 1990, BIOCHEMISTRY-US, V29, P3631, DOI 10.1021/bi00467a007; LAZAROVICI P, 1990, ACS SYM SER, V418, P347; LAZAROVICI P, 1986, J BIOL CHEM, V261, P6704; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LOEW LM, 1985, BIOCHEMISTRY-US, V24, P2101, DOI 10.1021/bi00330a001; LOEW LM, 1983, BIOCHEMISTRY-US, V22, P837, DOI 10.1021/bi00273a020; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MOLLE G, 1988, BIOPHYS J, V53, P193, DOI 10.1016/S0006-3495(88)83081-9; Moran A., 1984, P13; MORGAN CG, 1983, BIOCHIM BIOPHYS ACTA, V732, P668, DOI 10.1016/0005-2736(83)90245-6; MURATA M, 1987, BIOCHEMISTRY-US, V26, P4056, DOI 10.1021/bi00387a047; OIKI S, 1988, P NATL ACAD SCI USA, V85, P8703, DOI 10.1073/pnas.85.22.8703; OIKI S, 1988, P NATL ACAD SCI USA, V85, P2393, DOI 10.1073/pnas.85.7.2393; PARNESS J, 1976, TOXICON, V14, P85, DOI 10.1016/0041-0101(76)90097-0; PRIMOR N, 1984, BRIT J PHARMACOL, V82, P43, DOI 10.1111/j.1476-5381.1984.tb16440.x; REGNIER FE, 1987, SCIENCE, V238, P319, DOI 10.1126/science.3310233; RIZZO V, 1987, BIOCHEMISTRY-US, V26, P2751, DOI 10.1021/bi00384a015; SABERWAL G, 1989, BIOCHIM BIOPHYS ACTA, V984, P360, DOI 10.1016/0005-2736(89)90303-9; SCHWARZ G, 1989, BIOCHIM BIOPHYS ACTA, V979, P82, DOI 10.1016/0005-2736(89)90526-9; SCHWARZ G, 1986, BIOCHIM BIOPHYS ACTA, V861, P141, DOI 10.1016/0005-2736(86)90412-8; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; SHAI Y, 1990, J BIOL CHEM, V265, P20202; SHAI Y, 1987, BIOCHEMISTRY-US, V26, P669, DOI 10.1021/bi00377a002; SHAI Y, 1988, FEBS LETT, V242, P161, DOI 10.1016/0014-5793(88)81007-X; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SMOLARSKY M, 1977, J IMMUNOL METHODS, V15, P255, DOI 10.1016/0022-1759(77)90063-1; SUBBARAO NK, 1987, BIOCHEMISTRY-US, V26, P2964, DOI 10.1021/bi00385a002; SUENAGA M, 1989, BIOCHIM BIOPHYS ACTA, V981, P143, DOI 10.1016/0005-2736(89)90092-8; THOMPSON SA, 1986, SCIENCE, V233, P341, DOI 10.1126/science.233.4761.341; TOSTESON MT, 1989, P NATL ACAD SCI USA, V86, P707, DOI 10.1073/pnas.86.2.707; TOSTESON MT, 1987, BIOCHEMISTRY-US, V26, P6627, DOI 10.1021/bi00395a010; TOSTESON MT, 1985, REGUL PEPTIDES, P39; VOGEL H, 1981, FEBS LETT, V134, P37, DOI 10.1016/0014-5793(81)80545-5; VOGEL H, 1986, BIOPHYS J, V50, P573, DOI 10.1016/S0006-3495(86)83497-X; WEAVER AJ, 1989, BIOCHEMISTRY-US, V28, P8614, DOI 10.1021/bi00447a052; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019	54	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22346	22354						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1939258				2022-12-25	WOS:A1991GR56400048
J	HAJJAR, RJ; BONVENTRE, JV				HAJJAR, RJ; BONVENTRE, JV			OSCILLATIONS OF INTRACELLULAR CALCIUM INDUCED BY VASOPRESSIN IN INDIVIDUAL FURA-2-LOADED MESANGIAL CELLS - FREQUENCY-DEPENDENCE ON BASAL CALCIUM-CONCENTRATION, AGONIST CONCENTRATION, AND TEMPERATURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; RENAL EPITHELIAL-CELLS; CA-2+ OSCILLATIONS; FURA-2; HEPATOCYTES; MUSCLE; FLUORESCENCE; CHANNELS; MODEL	Intracellular free calcium concentration ([Ca2+]i) was measured in fura-2-loaded single rat mesangial cells by dual wavelength spectrofluorometry. Stimulation with arginine vasopressin (AVP) caused an initial sharp rise of [Ca2+]i followed by repetitive spikes. The frequency of the oscillations was dependent on the concentration of AVP. At 0.1, 1.0, 10.0, and 100.0 nM AVP, the frequencies of oscillations were 0.17 +/- 0.05 (n = 6), 0.32 +/- 0.05 (n = 6), 0.49 +/- 0.05 (n = 6), and 0.48 +/- 0.05 min-1 (n = 5), respectively. Reduction in extracellular [Ca2+] reduced the frequency of AVP-induced oscillations but did not abolish the oscillations. The frequency of calcium oscillations, upon stimulation with 1.0 nM AVP, was directly correlated with the basal [Ca2+]i prior to stimulation. Oscillation frequency increased with increasing temperature. An Arrhenius plot between 24 and 37-degrees-C indicated a strong temperature dependency of the oscillations with a Q(10) of 3.0. Protein kinase C stimulation by active phorbol esters inhibited AVP-induced calcium oscillations but not the initial [Ca2+] response to AVP. These observations are consistent with a model incorporating a feedback loop linking [Ca2+]i to the mechanism of [Ca2+]i increase. Ca2+-induced Ca2+ release may be involved, whereby inositol 1,4,5-trisphosphate (inositol 1,4,5-P3) formation releases Ca2+ from an inositol 1,4,5-P3-sensitive pool, with subsequent Ca2+ uptake and release from an inositol 1,4,5-P3-insensitive pool.	MASSACHUSETTS GEN HOSP,MED SERV,RENAL UNIT,JACKSON 8,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039773, P01DK038452, R37DK039773, P50DK039249] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39249, DK38452, DK39773] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN DG, 1984, J PHYSIOL-LONDON, V352, P113, DOI 10.1113/jphysiol.1984.sp015281; AMBLER SK, 1988, J BIOL CHEM, V263, P1952; BERRIDGE MJ, 1988, J PHYSIOL-LONDON, V403, P589, DOI 10.1113/jphysiol.1988.sp017266; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BONVENTRE JV, 1986, AM J PHYSIOL, V250, pF329, DOI 10.1152/ajprenal.1986.250.2.F329; BONVENTRE JV, 1990, ENVIRON HEALTH PERSP, V84, P155, DOI 10.2307/3430717; BONVENTRE JV, 1988, AM J PHYSIOL, V254, pF87, DOI 10.1152/ajprenal.1988.254.1.F87; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHEUNG JY, 1986, AM J PHYSIOL, V251, pF690, DOI 10.1152/ajprenal.1986.251.4.F690; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FRIESEN WO, 1984, AM J PHYSIOL, V246, pR847, DOI 10.1152/ajpregu.1984.246.6.R847; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOBER R, 1948, PHYSICAL CHEM CELLS, P23; HYMAN GA, 1990, J AM SOC NEPHROL, V1, P721; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; KORT AA, 1985, CIRC RES, V57, P844, DOI 10.1161/01.RES.57.6.844; KRUSKAL BA, 1987, J CELL BIOL, V105, P2685, DOI 10.1083/jcb.105.6.2685; LIPSCOMBE D, 1988, P NATL ACAD SCI USA, V85, P2398, DOI 10.1073/pnas.85.7.2398; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MOORE EDW, 1990, CELL CALCIUM, V11, P157, DOI 10.1016/0143-4160(90)90068-6; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; RASMUSSEN H, 1984, PHYSIOL REV, V64, P938, DOI 10.1152/physrev.1984.64.3.938; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SCANLON M, 1987, J BIOL CHEM, V262, P6308; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	34	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21589	21594						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939188				2022-12-25	WOS:A1991GP80400044
J	INNIS, JW; MOORE, DJ; KASH, SF; RAMAMURTHY, V; SAWADOGO, M; KELLEMS, RE				INNIS, JW; MOORE, DJ; KASH, SF; RAMAMURTHY, V; SAWADOGO, M; KELLEMS, RE			THE MURINE ADENOSINE-DEAMINASE PROMOTER REQUIRES AN ATYPICAL TATA BOX WHICH BINDS TRANSCRIPTION FACTOR-IID AND TRANSCRIPTIONAL ACTIVITY IS STIMULATED BY MULTIPLE UPSTREAM SP1 BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; DIHYDROFOLATE-REDUCTASE GENE; DEVELOPMENTAL EXPRESSION; SEQUENCE REQUIREMENTS; INVITRO TRANSCRIPTION; MOLECULAR-CLONING; RECEPTOR GENE; IDENTIFICATION; INITIATION; ACTIVATION	We have explored the template and factor requirements for in vitro transcription of the GC-rich promoter of the murine adenosine deaminase gene. The core promoter consists of an A-rich sequence (TAAAAAA) 27 base pairs upstream of the initiation site which binds transcription factor IID (TFIID) and a high affinity Spl binding site located 27 base pairs further upstream. Multiple upstream elements increased core promoter activity 20-fold and correspond to protected regions in DNase I footprinting assays with purified Sp1 protein. Internal deletion of the TA6 element alone eliminated transcription in spite of the presence of all other promoter elements including,four Sp1 binding sites. Recombinant human TFIID supported weak basal transcription in heat-treated nuclear extracts whereas a partially purified TFIID fraction from HeLa cells reconstituted a maximal level of transcription. Inclusion of 12 base pairs immediately adjacent to the proximal Sp1 site resulted in a 5-fold boost in transcriptional activity and corresponds to a second Sp1 binding site. These results serve as a basis for further exploration of the factors involved in the developmental and selective high level tissue expression of the murine adenosine deaminase gene.	BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	INNIS, JW (corresponding author), BAYLOR COLL MED,DEPT BIOCHEM,T-321,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030204, R01GM038212] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25255] Funding Source: Medline; NIGMS NIH HHS [GM30204, GM38212] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; CHEN Z, 1990, MOL CELL BIOL, V10, P4555, DOI 10.1128/MCB.10.9.4555; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P2392, DOI 10.1128/MCB.6.7.2392; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; HONG L, 1991, BIOL REPROD, V44, P83, DOI 10.1095/biolreprod44.1.83; INGOLIA DE, 1986, MOL CELL BIOL, V6, P4458, DOI 10.1128/MCB.6.12.4458; INNIS JW, 1991, IN PRESS MOL CELL BI; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KIM CH, 1987, P NATL ACAD SCI USA, V84, P6025, DOI 10.1073/pnas.84.17.6025; KNUDSEN TB, 1988, BIOL REPROD, V39, P937, DOI 10.1095/biolreprod39.4.937; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MIZUTANI M, 1991, P NATL ACAD SCI USA, V88, P718, DOI 10.1073/pnas.88.3.718; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; SAMUELS M, 1986, J BIOL CHEM, V261, P2003; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859	37	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21765	21772						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939199				2022-12-25	WOS:A1991GP80400067
J	SONG, Y; KITAJIMA, K; INOUE, S; INOUE, Y				SONG, Y; KITAJIMA, K; INOUE, S; INOUE, Y			ISOLATION AND STRUCTURAL ELUCIDATION OF A NOVEL TYPE OF GANGLIOSIDE, DEAMINATED NEURAMINIC ACID (KDN)-CONTAINING GLYCOSPHINGOLIPID, FROM RAINBOW-TROUT SPERM - THE 1ST EXAMPLE OF THE NATURAL OCCURRENCE OF KDN-GANGLIOSIDE, (KDN)GM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; RICH GLYCOPROTEIN; VITELLINE ENVELOPE; CELL-GROWTH; GLYCOLIPIDS; GM3; POLYSIALOGLYCOPROTEIN; OLIGOSACCHARIDE; DIFFERENTIATION; CHROMATOGRAPHY	Rainbow trout sperm contained almost exclusively monoanionic ganglioside fraction as a major acidic glycosphingolipid. Two monoacidic gangliosides were isolated and purified in this study and designated as sperm ganglioside 1 and 2 (sg-1 and sg-2). The two gangliosides, sg-1 and sg-2, contained the same neutral sugars, galactose and glucose in molar ratio of 1:1 and no GaINAc except for the presence of N-acetyl-neuraminic acid (NeuAc) in sg-1 and deaminated neuraminic acid (KDN; 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid) in sg-2. The complete structures of these gangliosides were determined by a combination of methylation analysis, fast atom bombardment mass spectrometry, 400-MHz one- and two-dimensional H-1 nuclear magnetic resonance spectroscopy, fatty acid analysis, and endoglycoceramidase digestion NeuAc-alpha-2 --> 3Gal-beta-1 --> Cer sg-1 [(NeuAc)G(M3)] KDN-alpha-2 --> 3Gal-beta-1 --> Cer sg-1 [(KDN)G(M3)] where, for both sg-1 and sg-2, the ceramide moieties (Cer) were found to be made up of 4-sphingenine and mainly C16:0 fatty acid (palmitate; 95%) with a minor amount of C24:1 fatty acyl chain (nervonate, 5%). The structure of sg-2 is novel and represents the first example of a new class of gangliosides, i.e. KDN-ganglio-sides.	UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, HONGO 7, TOKYO 113, JAPAN; SHOWA UNIV, SCH PHARMACEUT SCI, TOKYO 142, JAPAN	University of Tokyo; Showa University								ANDO S, 1971, J BIOCHEM-TOKYO, V70, P335, DOI 10.1093/oxfordjournals.jbchem.a129645; ANDO S, 1976, BIOCHIM BIOPHYS ACTA, V424, P98; ANDO S, 1979, J BIOL CHEM, V254, P2224; BOOTH DA, 1962, J NEUROCHEM, V9, P265, DOI 10.1111/j.1471-4159.1962.tb09448.x; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CORNFIELD AP, 1982, SIALIC ACIDS CHEM ME, P5; DYATLOVITSKAYA EV, 1987, BIOCHIM BIOPHYS ACTA, V907, P125, DOI 10.1016/0304-419X(87)90002-3; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FISHMAN PH, 1982, J MEMBRANE BIOL, V54, P61; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAMMACK DB, 1963, BIOCHEM J, V88, P373, DOI 10.1042/bj0880373; HAKOMORI S, 1985, CANCER RES, V45, P2405; HAKOMORI S, 1991, PURE APPL CHEM, V63, P473, DOI 10.1351/pac199163040473; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HANAI N, 1988, J BIOL CHEM, V263, P6296; INOUE S, 1988, BIOCHEM BIOPH RES CO, V153, P172, DOI 10.1016/S0006-291X(88)81204-X; ITO F, 1991, 11TH P S GLYC, P153; ITO M, 1986, J BIOL CHEM, V261, P14278; IWAMORI M, 1978, BIOCHIM BIOPHYS ACTA, V528, P257; IWASAKI M, 1987, BIOCHEMISTRY-US, V26, P1452, DOI 10.1021/bi00379a036; KANAMORI A, 1989, BIOCHEM BIOPH RES CO, V164, P744, DOI 10.1016/0006-291X(89)91522-2; KANAMORI A, 1990, J BIOL CHEM, V265, P21811; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KIELCZYNSKI W, 1991, P NATL ACAD SCI USA, V88, P1991, DOI 10.1073/pnas.88.5.1991; KNIREL YA, 1989, CARBOHYD RES, V188, P145, DOI 10.1016/0008-6215(89)84067-4; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; LEDEEN RW, 1989, NEUROBIOLOGY GLYCOCO, P43; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; MOMOI T, 1976, BIOCHIM BIOPHYS ACTA, V441, P488; NADANO D, 1986, J BIOL CHEM, V261, P1550; Ng S.-S., 1976, BIOL ROLES SIALIC AC, P59; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; SAITO M, 1989, DEV GROWTH DIFFER, V31, P509; SHIMAMURA M, 1988, J BIOL CHEM, V263, P12124; SPIEGEL S, 1985, SCIENCE, V230, P1285, DOI 10.1126/science.2999979; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; SUGANO K, 1978, FEBS LETT, V89, P321, DOI 10.1016/0014-5793(78)80246-4; SUZUKI K, 1965, J NEUROCHEM, V12, P629, DOI 10.1111/j.1471-4159.1965.tb04256.x; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; USUKI S, 1988, J BIOL CHEM, V263, P6847; WIEGANDT H, 1982, ADV NEUROCHEM, V4, P149; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; YU RK, 1970, J LIPID RES, V11, P506	47	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21929	21935						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939215				2022-12-25	WOS:A1991GP80400091
J	TANS, G; JANSSENCLAESSEN, T; HEMKER, HC; ZWAAL, RFA; ROSING, J				TANS, G; JANSSENCLAESSEN, T; HEMKER, HC; ZWAAL, RFA; ROSING, J			MEIZOTHROMBIN FORMATION DURING FACTOR XA-CATALYZED PROTHROMBIN ACTIVATION - FORMATION IN A PURIFIED SYSTEM AND IN PLASMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECHIS-CARINATUS VENOM; COAGULATION FACTOR-V; BLOOD-COAGULATION; THROMBIN; INTERMEDIATE; CONVERSION; HEPARIN; PHOSPHATIDYLSERINE; CHROMATOGRAPHY; PURIFICATION	Meizothrombin and thrombin formation were quantitated during factor Xa-catalyzed activation of human prothrombin in reaction systems containing purified proteins and in plasma. In the purified system considerable amounts of meizothrombin accumulated when prothrombin was activated by factor Xa (with or without accessory components) under initial steady state conditions. The ratio of the rates of meizothrombin and thrombin formation was not influenced by variation of the pH, temperature, or ionic strength of the reaction medium. When 2-mu-M prothrombin was activated by the complete prothrombinase complex (factor Xa, factor Va, Ca2+, and phospholipid) 80-90% of the initially formed reaction product was meizothrombin. Lowering the prothrombin concentration from 2 to 0.03-mu-M caused a gradual decrease in the ratio of meizothrombin/thrombin formation from 5 to 0.6. When the phosphatidylserine content of the phospholipid vesicles was varied between 20 and 1 mol% and prothrombin activation was analyzed at 2-mu-M prothrombin the relative amount of meizothrombin formed decreased from 85 to 55%. With platelets, cephalin, or thromboplastin as procoagulant lipid, thrombin was the major reaction product and only 30-40% of the activation product was meizothrombin. We also analyzed complete time courses of prothrombin activation both with purified proteins and in plasma. In reaction systems with purified proteins substantial amounts of meizothrombin accumulated under a wide variety of experimental conditions. However, little or no meizothrombin was detected in plasma in which coagulation was initiated via the extrinsic pathway with thromboplastin or via the intrinsic pathway with kaolin plus phospholipid (cephalin, platelets, or phosphatidylserine-containing vesicles). Thus, thrombin was the only active prothrombin activation product that accumulated during ex vivo coagulation experiments in plasma.			TANS, G (corresponding author), UNIV LIMBURG,CARDIOVASC RES INST,DEPT BIOCHEM,POB 616,6200 MD MAASTRICHT,NETHERLANDS.			Hemker, Coen/0000-0003-1669-2358				BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; CARLISLE TL, 1990, J BIOL CHEM, V265, P22044; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1974, J BIOL CHEM, V249, P7782; FISCHER AM, 1981, THROMB HAEMOSTASIS, V45, P51; FRANZA BR, 1975, J BIOL CHEM, V250, P7057; HEMKER HC, 1986, THROMB HAEMOSTASIS, V56, P9; KORNALIK F, 1975, THROMB RES, V6, P53, DOI 10.1016/0049-3848(75)90150-4; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDHOUT T, 1982, BIOCHEMISTRY-US, V21, P5494, DOI 10.1021/bi00265a018; LIU DTH, 1975, THROMB RES, V7, P213, DOI 10.1016/0049-3848(75)90137-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANN KG, 1990, BLOOD, V76, P1; MORITA T, 1976, J BIOCHEM, V79, P1089, DOI 10.1093/oxfordjournals.jbchem.a131150; OWREN PA, 1951, SCAND J CLIN INVEST, V3, P210; PLETCHER CH, 1982, J BIOL CHEM, V257, P5342; RHEE MJ, 1982, BIOCHEMISTRY-US, V21, P3437, DOI 10.1021/bi00257a029; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; SCHIFFMAN S, 1969, BIOCHEMISTRY-US, V8, P1397, DOI 10.1021/bi00832a014; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; SMITH RL, 1973, J BIOL CHEM, V248, P2418; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TANS G, 1989, THROMB HAEMOSTASIS, V61, P386; THALER E, 1975, BRIT J HAEMATOL, V31, P233, DOI 10.1111/j.1365-2141.1975.tb00853.x; TIJBURG PNM, 1991, J BIOL CHEM, V266, P4017; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDAMMIERAS MCE, 1984, METHOD ENZYMAT AN, V5, P352; VANRIJN J, 1983, EUR J BIOCHEM, V133, P1; VANRIJN JLM, 1984, BIOCHEMISTRY-US, V23, P4457; ZWAAL RFA, 1978, BIOCHIM BIOPHYS ACTA, V515, P163, DOI 10.1016/0304-4157(78)90003-5	39	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21864	21873						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939210				2022-12-25	WOS:A1991GP80400082
J	ISSANDOU, M; DARBON, JM				ISSANDOU, M; DARBON, JM			DES-ARG9 BRADYKININ MODULATES DNA-SYNTHESIS, PHOSPHOLIPASE-C, AND PROTEIN-KINASE-C IN CULTURED MESANGIAL CELLS - DISTINCTION FROM EFFECTS OF BRADYKININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; SWISS 3T3 FIBROBLASTS; PHORBOL ESTERS; GROWTH-FACTOR; RECEPTOR ANTAGONISTS; INOSITOL PHOSPHATES; RAPIDLY STIMULATE; 80,000 PROTEIN; 2ND MESSENGER; PHOSPHORYLATION	The effects of the neuropeptide bradykinin (BK) and its natural proteolytic fragment Des-Arg9 bradykinin (DBK) on DNA synthesis and phospholipase C activation were investigated in cultured mesangial cells. DBK, acting through a distinct bradykinin receptor, induced DNA synthesis in serum-starved cultured mesangial cells. The effect of DBK was dose dependent (ED50 = 0.6-mu-M) and was strongly potentiated by insulin. Under the same conditions, BK had no effect. Down-regulation of protein kinase C by long term pretreatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) markedly reduced DBK-induced DNA synthesis. In the same way, co-incubation with the protein kinase C inhibitor staurosporine potently attenuated the response to DBK, suggesting a role of protein kinase C in DBK-induced mitogenesis. Analysis of phosphoproteins from P-32-labeled mesangial cells by two-dimensional gel electrophoresis revealed that DBK, like TPA but not BK, induced a net increase in the phosphorylation of an acidic cellular protein migrating with an apparent M(r) = 80,000 (termed 80K), identified as a major and specific substrate of protein kinase C. Phosphorylation of the 80K protein by DBK or TPA was completely abolished in cells depleted of protein kinase C. DBK and TPA also induced an increase in phosphorylation of an M(r) = 28,000 protein. Moreover, DBK but not TPA stimulated the phosphorylation of an M(r) = 18,000 protein in normal as well as in protein kinase C-depleted cells. Analysis of phospholipase C activation revealed that DBK induced a large and sustained increase in diacylglycerol production and inositol phosphate accumulation over a 10-min incubation. BK had only a minor effect on both parameters. These results demonstrate that DBK, but not BK, modulates DNA synthesis through protein kinase C activation in cultured mesangial cells.	FAC MED TOULOUSE,INSERM,U133,133 ROUTE NARBONNE,F-31062 TOULOUSE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)								BARABE J, 1982, CAN J PHYSIOL PHARM, V60, P1551, DOI 10.1139/y82-229; BASCANDS JL, 1989, BIOCHEM BIOPH RES CO, V158, P99, DOI 10.1016/S0006-291X(89)80182-2; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BURCH RM, 1990, MED RES REV, V10, P237, DOI 10.1002/med.2610100204; DARBON JM, 1990, BIOCHEM BIOPH RES CO, V168, P527, DOI 10.1016/0006-291X(90)92353-2; DARBON JM, 1986, J BIOL CHEM, V261, P8002; DARBON JM, 1987, BIOCHEM BIOPH RES CO, V137, P1159; DEMOLLE D, 1988, J BIOL CHEM, V263, P18459; EMOND C, 1990, EUR J PHARMACOL, V190, P3381; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1989, FEBS LETT, V255, P149, DOI 10.1016/0014-5793(89)81079-8; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FARMER SG, 1991, AM J RESP CELL MOL, V4, P273, DOI 10.1165/ajrcmb/4.3.273; FARMER SG, 1989, MOL PHARMACOL, V36, P1; FASOLATO C, 1988, J BIOL CHEM, V263, P17350; GANZ MB, 1988, AM J PHYSIOL, V255, pF898, DOI 10.1152/ajprenal.1988.255.5.F898; GOLDSTEIN RH, 1984, J BIOL CHEM, V259, P9263; HIGASHIDA H, 1986, P NATL ACAD SCI USA, V83, P942, DOI 10.1073/pnas.83.4.942; HUANG CF, 1990, J BIOL CHEM, V265, P14858; ISSANDOU M, 1989, BIOCHEM BIOPH RES CO, V163, P201, DOI 10.1016/0006-291X(89)92121-9; ISSANDOU M, 1988, CANCER RES, V48, P6943; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; ISSANDOU M, 1991, FEBS LETT, V281, P196, DOI 10.1016/0014-5793(91)80392-G; JAFFER F, 1989, AM J PATHOL, V135, P261; KAYA H, 1989, J BIOL CHEM, V264, P4972; MARCEAU F, 1986, LIFE SCI, V39, P2351, DOI 10.1016/0024-3205(86)90666-1; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MENE P, 1990, KIDNEY INT, V37, P1256, DOI 10.1038/ki.1990.109; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLSEN R, 1988, J BIOL CHEM, V263, P18030; OWEN NE, 1983, CELL, V32, P979, DOI 10.1016/0092-8674(83)90082-X; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PFEILSCHIFTER JM, 1989, RENAL PHYSIOL BIOCH, V12, P1; REGOLI D, 1986, EUR J PHARMACOL, V123, P61, DOI 10.1016/0014-2999(86)90687-4; REGOLI D, 1980, PHARMACOL REV, V32, P1; REGOLI D, 1990, TRENDS PHARMACOL SCI, V11, P156, DOI 10.1016/0165-6147(90)90067-I; ROBAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301, DOI 10.1016/0006-291X(89)92135-9; Roberts R A, 1989, Prog Growth Factor Res, V1, P237, DOI 10.1016/0955-2235(89)90013-6; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAHA JK, 1990, J PHARMACOL EXP THER, V252, P1012; SAKO T, 1988, CANCER RES, V48, P4646; SCHACHTER M, 1987, BRIT J PHARMACOL, V92, P851, DOI 10.1111/j.1476-5381.1987.tb11390.x; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SCHINI VB, 1990, J PHARMACOL EXP THER, V252, P581; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; STERANKA LR, 1989, FASEB J, V3, P2019, DOI 10.1096/fasebj.3.9.2545496; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TAKUWA N, 1989, AM J PHYSIOL, V257, pF431, DOI 10.1152/ajprenal.1989.257.3.F431; TILLY BC, 1987, BIOCHEM J, V244, P129, DOI 10.1042/bj2440129; UNWIN RJ, 1990, KIDNEY INT, V37, P1031, DOI 10.1038/ki.1990.83; Woll PJ, 1988, GROWTH FACTORS, V1, P75, DOI 10.3109/08977198809000249; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0	60	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21037	21043						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939151				2022-12-25	WOS:A1991GN00100072
J	FASOLATO, C; ZOTTINI, M; CLEMENTI, E; ZACCHETTI, D; MELDOLESI, J; POZZAN, T				FASOLATO, C; ZOTTINI, M; CLEMENTI, E; ZACCHETTI, D; MELDOLESI, J; POZZAN, T			INTRACELLULAR CA2+ POOLS IN PC12 CELLS - 3 INTRACELLULAR POOLS ARE DISTINGUISHED BY THEIR TURNOVER AND MECHANISMS OF CA2+ ACCUMULATION, STORAGE, AND RELEASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C ACTIVATION; ACINAR-CELLS; CALCIUM HOMEOSTASIS; INOSITOL PHOSPHATES; CYTOSOLIC CA-2+; BRADYKININ; GENERATION; TRANSPORT; ENTRY; ATP	Three, non-cytosolic Ca2+ pools were characterized in intact PC12 cells. The first pool, sensitive to both inositol 1,4,5-trisphosphate and caffeine (Zacchetti, D., Clementi, E., Fasolato, C., Zottini, M., Grohovaz, F., Fumagalli, G., Pozzan, T., and Meldolesi, J. (1991) J. Biol Chem. 266, 20152-20158) accounts for approximately equals 200-mu-M of Ca2+/liter of cell water (< 30% of total exchangeable Ca2+ and takes up Ca2+ from the cytosol via a Ca2+-ATPase, blocked by thapsigargin. A second pool, approximately equals 400-mu-M/liter, is insensitive to both inositol 1,4,5-trisphosphate, caffeine, and thapsigargin and is released by the Ca2+ ionophore ionomycin. This pool is probably heterogeneous and its intracellular localization and physiological roles remain undefined. The third pool, approximately equals 170-mu-moles of Ca2+/liter, was discharged by the combination of ionomycin together with a substance that collapsed intracellular pH gradients, such as monensin or NH4Cl. This indicates that the pool is acidic, at variance with the first two. When exocytosis was stimulated, the size of this pool declined, indicating its primary residence within secretory granules. In the conditions of our experiments no major transfer of Ca2+ among the pools seemed to occur. This is the first comprehensive description of non-cytosolic Ca2+ pools investigated in intact neurosecretory cells by non-invasive procedures.	UNIV MILANO,SCI INST SAN RAFFAELE,CTR CYTOPHARMACOL,CNR,DEPT PHARMACOL,VIA OLGETTINA 6071,I-20132 MILAN,ITALY; UNIV MILANO,SCI INST SAN RAFFAELE,CTR BRUNO CECCARELLI,I-20132 MILAN,ITALY; UNIV PADUA,CTR BIOMEMBRANE,CNR,INST GEN PATHOL,I-35100 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); University of Padua			Zacchetti, Daniele/AAC-2724-2022; Zottini, Michela/Y-3763-2019; Fasolato, Cristina/AAE-6024-2019	Zacchetti, Daniele/0000-0003-2724-7559; Fasolato, Cristina/0000-0002-9816-7751; zottini, michela/0000-0001-8930-2969				ANDREWS SB, 1988, P NATL ACAD SCI USA, V85, P1682, DOI 10.1073/pnas.85.5.1682; BOND M, 1987, J BIOL CHEM, V262, P15630; BURGOYNE RD, 1989, NATURE, V342, P72, DOI 10.1038/342072a0; CAPPONI A, 1987, METHOD ENZYMOL, V124, P116; DANTHULURI NR, 1990, J BIOL CHEM, V265, P19071; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DIVIRGILIO F, 1984, NATURE, V310, P691, DOI 10.1038/310691a0; DIVIRGILIO F, 1987, J BIOL CHEM, V262, P9189; FASOLATO C, 1988, J BIOL CHEM, V263, P17350; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; GRATZL M, 1987, STIMULUS SECRETION C, P111; GREENE L, 1976, P NATL ACAD SCI USA, V73, P2422; GROHOVAZ F, 1991, J CELL BIOL, V113, P1341, DOI 10.1083/jcb.113.6.1341; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KWAN CY, 1990, J BIOL CHEM, V265, P678; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MELDOLESI J, 1984, P NATL ACAD SCI-BIOL, V81, P620, DOI 10.1073/pnas.81.2.620; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; PIETROBON D, 1990, EUR J BIOCHEM, V193, P599, DOI 10.1111/j.1432-1033.1990.tb19378.x; POZZAN T, 1980, BIOCHIM BIOPHYS ACTA, V602, P558, DOI 10.1016/0005-2736(80)90334-X; POZZAN T, 1984, J CELL BIOL, V99, P628, DOI 10.1083/jcb.99.2.628; PRESSMAN BC, 1982, ANNU REV PHARMACOL, V22, P465, DOI 10.1146/annurev.pa.22.040182.002341; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RINK TJ, 1983, CELL CALCIUM, V6, P113; ROBINSON IM, 1991, J NEUROCHEM, V56, P1587, DOI 10.1111/j.1471-4159.1991.tb02055.x; THAYER SA, 1988, J NEUROSCI, V8, P4089; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; WATANABE O, 1983, NEUROSCIENCE, V10, P1011, DOI 10.1016/0306-4522(83)90239-7; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; ZECCHETTI D, 1991, J BIOL CHEM, V266, P20152	33	169	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20159	20167						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939077				2022-12-25	WOS:A1991GM03900045
J	IWAMOTO, R; SENOH, H; OKADA, Y; UCHIDA, T; MEKADA, E				IWAMOTO, R; SENOH, H; OKADA, Y; UCHIDA, T; MEKADA, E			AN ANTIBODY THAT INHIBITS THE BINDING OF DIPHTHERIA-TOXIN TO CELLS REVEALED THE ASSOCIATION OF A 27-KDA MEMBRANE-PROTEIN WITH THE DIPHTHERIA-TOXIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN TOXIN; VERO CELLS; ENTRY; MOLECULE; IDENTIFICATION; DEGRADATION; FRAGMENT; MUTANTS	A monoclonal antibody that blocks the binding of diphtheria toxin to Vero cells was isolated by immunizing mice with Vero cell membrane. The antibody inhibits the binding of diphtheria toxin and also CRM197, a mutant form of diphtheria toxin, to Vero cells, and consequently inhibits the cytotoxicity of diphtheria toxin. This antibody does not directly react with the receptor molecule of diphtheria toxin (DTR14.5). Immunoprecipitation and immunoblotting studies revealed that this antibody binds to a novel membrane protein of 27 kDa (DRAP27). When diphtheria toxin receptor was passed through an affinity column made with this antibody, the receptor was trapped only in the presence of DRAP27. These results indicate that DRAP27 and DTR14.5 closely associate in Vero cell membrane and that the inhibition of the binding of diphtheria toxin to the receptor is due to the binding of the antibody to the DRAP27 molecule. Binding studies using I-125-labeled antibody showed that there are many more molecules of DRAP27 on the cell surface than diphtheria toxin-binding sites. However, there is a correlation between the sensitivity of a cell line to diphtheria toxin and the number of DRAP27 molecules on the cell surface, suggesting that DRAP27 is involved in the entry of diphtheria toxin into the target cell.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Osaka University	IWAMOTO, R (corresponding author), KURUME UNIV,INST LIFE SCI,KURUME,FUKUOKA 830,JAPAN.			Mekada, Eisuke/0000-0001-8858-4781				CIEPLAK W, 1987, J BIOL CHEM, V262, P13246; COLLIER RJ, 1964, J EXP MED, V120, P1019, DOI 10.1084/jem.120.6.1019; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; GILL DM, 1969, J EXP MED, V129, P1, DOI 10.1084/jem.129.1.1; HONJO T, 1968, J BIOL CHEM, V243, P3553; KANEDA Y, 1984, J CELL BIOL, V98, P466, DOI 10.1083/jcb.98.2.466; KIM K, 1965, J BACTERIOL, V90, P1552, DOI 10.1128/JB.90.6.1552-1556.1965; KOELER G, 1975, NATURE, V256, P495; KOELLER G, 1976, EUR J IMMUNOL, V6, P511; KOHNO K, 1987, EXP CELL RES, V172, P54, DOI 10.1016/0014-4827(87)90092-9; KOHNO K, 1985, SOMAT CELL MOLEC GEN, V11, P421, DOI 10.1007/BF01534836; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPLA SH, 1980, J BIOL CHEM, V255, P2247; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MEKADA E, 1985, J BIOL CHEM, V260, P2148; MEKADA E, 1988, J CELL BIOL, V107, P511, DOI 10.1083/jcb.107.2.511; MEKADA E, 1982, BIOCHEM BIOPH RES CO, V109, P792, DOI 10.1016/0006-291X(82)92009-5; MEKADA E, 1981, J BIOL CHEM, V256, P1225; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; STRAUSS N, 1959, J EXP MED, V109, P144; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; UMATA T, 1990, J BIOL CHEM, V265, P21940; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5	27	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20463	20469						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939101				2022-12-25	WOS:A1991GM03900088
J	ZAMZE, SE; ASHFORD, DA; WOOTEN, EW; RADEMACHER, TW; DWEK, RA				ZAMZE, SE; ASHFORD, DA; WOOTEN, EW; RADEMACHER, TW; DWEK, RA			STRUCTURAL CHARACTERIZATION OF THE ASPARAGINE-LINKED OLIGOSACCHARIDES FROM TRYPANOSOMA-BRUCEI TYPE-II AND TYPE-III VARIANT SURFACE GLYCOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDO-BETA-GALACTOSIDASE; MANNOSE-TYPE OLIGOSACCHARIDES; SUGAR CHAINS; H-1-NMR SPECTROSCOPY; BACTEROIDES-FRAGILIS; LEISHMANIA-MEXICANA; MASS-SPECTROMETRY; N-GLYCOSYLATION; MEMBRANE ANCHOR; CARCINOMA-CELLS	The complete primary structures of the major Asn-linked oligosaccharides from the type II variant surface glycoproteins (VSGs), MITat 1.2 and MITat 1.7, and the type III VSG, MITat 1.5, were determined using a combination of exo- and endoglycosidase digestions, methylation analysis, acetolysis, and 500 MHz H-1 NMR spectroscopy. Each variant contained classical branched oligomannose-type and biantennary complex oligosaccharides, a proportion of the latter substituted with terminal alpha(1-3)-linked galactose residues, the first report of the presence of this epitope in Trypanosoma brucei. In addition both the type II variants contained relatively large amounts of the unusual small oligomannose-type oligosaccharides, Man4GlcNAC2 and Man3GlcNAC2, and a diverse array of novel branched poly-N-acetyllactosamine oligosaccharides, similar but not identical to those from mammalian glycoproteins. These latter structures were also partially substituted with terminal alpha(1-3)-linked galactose residues. Glycosylation in the type II variants showed site specificity in that the poly-N-acetyllactosamine and Man(9-5)GlcNAC2 oligosaccharides were located exclusively at Asn-glycosylation site 1 very close to the C terminus, whereas the Man(4-3)GlcNAC2 and biantennary complex oligosaccharides were located exclusively at site 2. This is the first report of the presence of poly-N-acetyllactosamine oligosaccharides in protozoa.			ZAMZE, SE (corresponding author), UNIV OXFORD, DEPT BIOCHEM, GLYCOBIOL UNIT, S PK RD, OXFORD OX1 3QU, ENGLAND.							ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; AUFFRET CA, 1981, BIOCHEM J, V193, P647, DOI 10.1042/bj1930647; AVILA JL, 1989, J IMMUNOL, V142, P2828; AVILA JL, 1988, J CLIN MICROBIOL, V26, P126, DOI 10.1128/JCM.26.1.126-132.1988; BANGS JD, 1988, J BIOL CHEM, V263, P17697; BEAN MF, 1989, ANAL CHEM, V61, P2686, DOI 10.1021/ac00198a019; BOOTHROYD JC, 1985, ANNU REV MICROBIOL, V39, P475, DOI 10.1146/annurev.mi.39.100185.002355; BOUTIGNON F, 1988, BIOL CELL, V64, P131, DOI 10.1016/0248-4900(88)90072-X; BULOW R, 1989, MOL BIOCHEM PARASIT, V32, P85, DOI 10.1016/0166-6851(89)90132-1; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CLARKE MW, 1987, MOL IMMUNOL, V24, P707, DOI 10.1016/0161-5890(87)90052-6; COUTO AS, 1990, MOL BIOCHEM PARASIT, V39, P101, DOI 10.1016/0166-6851(90)90012-B; CROSS GAM, 1984, PHILOS T R SOC B, V307, P3, DOI 10.1098/rstb.1984.0104; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; DORLAND L, 1984, BIOCHEM BIOPH RES CO, V122, P859, DOI 10.1016/S0006-291X(84)80113-8; ELICES MJ, 1989, J BIOL CHEM, V264, P1375; ENGEL JC, 1985, J BIOL CHEM, V260, P105; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FREYMANN DM, 1984, NATURE, V311, P167, DOI 10.1038/311167a0; FUJII S, 1990, J BIOL CHEM, V265, P6009; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; FUKUDA MN, 1978, J BIOL CHEM, V253, P6814; GALILI U, 1988, J BIOL CHEM, V263, P17755; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HARDY MR, 1988, P NATL ACAD SCI USA, V85, P3289, DOI 10.1073/pnas.85.10.3289; HOLDER AA, 1985, CURR TOP MICROBIOL, V117, P57; HOLDER AA, 1981, MOL BIOCHEM PARASIT, V2, P135, DOI 10.1016/0166-6851(81)90095-5; HOMANS SW, 1989, BIOCHEMISTRY-US, V28, P2881, DOI 10.1021/bi00433a020; HUBBARD SC, 1988, J BIOL CHEM, V263, P19303; ICHISHIMA E, 1981, BIOCHIM BIOPHYS ACTA, V658, P45, DOI 10.1016/0005-2744(81)90248-5; JAHNIG F, 1987, EUR J BIOCHEM, V311, P37; KAMADA Y, 1988, J BIOCHEM-TOKYO, V104, P738, DOI 10.1093/oxfordjournals.jbchem.a122543; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; LEVERY SB, 1989, BIOCHEMISTRY-US, V28, P7772, DOI 10.1021/bi00445a037; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MENDELZON DH, 1986, J BIOL CHEM, V261, P2129; METCALF P, 1987, NATURE, V325, P84, DOI 10.1038/325084a0; MORAES CT, 1988, BIOCHEMISTRY-US, V27, P1543, DOI 10.1021/bi00405a022; NATSUKA S, 1987, ANAL BIOCHEM, V167, P154, DOI 10.1016/0003-2697(87)90146-1; OLAFSON RW, 1990, J BIOL CHEM, V265, P12240; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; PARODI AJ, 1984, BIOCHEM BIOPH RES CO, V118, P1, DOI 10.1016/0006-291X(84)91058-1; REHABER P, 1990, BIOCHEMISTRY-US, V29, P8217, DOI 10.1021/bi00488a004; RENKONEN O, 1989, GLYCOCONJUGATE J, V6, P129, DOI 10.1007/BF01047895; ROSEN G, 1990, J BIOL CHEM, V265, P7708; ROSEN G, 1989, J BIOL CHEM, V264, P10457; SCUDDER P, 1987, EUR J BIOCHEM, V168, P585, DOI 10.1111/j.1432-1033.1987.tb13457.x; SCUDDER P, 1984, J BIOL CHEM, V259, P6586; SCUDDER P, 1983, 7TH P INT S GLYC, P484; SPIRO RG, 1984, J BIOL CHEM, V259, P9858; SPOONCER E, 1984, J BIOL CHEM, V259, P4792; Turner M.J., 1988, MBL (Marine Biology Laboratory) Lectures in Biology, V9, P349; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMASHITA K, 1980, J BIOL CHEM, V255, P5635; ZAMZE SE, 1990, EUR J BIOCHEM, V187, P657, DOI 10.1111/j.1432-1033.1990.tb15350.x	60	98	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20244	20261						18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939085				2022-12-25	WOS:A1991GM03900057
J	TAKAHASHI, K; INOUE, H; SAKAI, K; KOHAMA, T; KITAHARA, S; TAKISHIMA, K; TANJI, M; ATHAUDA, SBP; TAKAHASHI, T; AKANUMA, H; MAMIYA, G; YAMASAKI, M				TAKAHASHI, K; INOUE, H; SAKAI, K; KOHAMA, T; KITAHARA, S; TAKISHIMA, K; TANJI, M; ATHAUDA, SBP; TAKAHASHI, T; AKANUMA, H; MAMIYA, G; YAMASAKI, M			THE PRIMARY STRUCTURE OF ASPERGILLUS-NIGER ACID PROTEINASE-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-B; VAR MACROSPORUS; SEQUENCE; INACTIVATION; THERMOPSIN	The complete amino acid sequence of the acid proteinase A, a non-pepsin type acid proteinase from the fungus Aspergillus niger var. macrosporus, was determined by protein sequencing. The enzyme was first dissociated at pH 8.5 into a light (L) chain and a heavy (H) chain, and the L chain was sequenced completely. Further sequencing was performed with the reduced and pyridylethylated or aminoethylated derivative of the whole protein, using peptides obtained by digestions with Staphylococcus aureus V8 protease, trypsin, chymotrypsin, and lysylendopeptidase. The location of the two disulfide bonds was determined by analysis of cystine-containing peptides obtained from a chymotryptic digest of the unmodified protein. These results established that the protein consists of a 39-residue L chain and a 173-residue H chain that associate noncovalently to form the native enzyme of 212 residues (M(r) 22,265). This is, to our knowledge, the first time that such a protein with a rather short peptide chain associated noncovalently has been found. No sequence homology is found with other acid or aspartic proteinases, except for Scytalidium lignicolum acid proteinase B, an enzyme unrelated to pepsin by sequence, which has about 50% identity with the present enzyme. These two enzymes, however, are remarkably different from each other in some structural features.	UNIV TOKYO,COLL ARTS & SCI,DEPT CHEM,MEGURO KU,TOKYO 153,JAPAN; NATL DEF MED COLL,DEPT BIOCHEM 1,TOKOROZAWA,SAITAMA 359,JAPAN	University of Tokyo; National Defense Medical College - Japan	TAKAHASHI, K (corresponding author), UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN.			Kohama, Takafumi/0000-0002-6822-8170				AOYAGI T, 1971, J ANTIBIOT, V24, P687, DOI 10.7164/antibiotics.24.687; Barrett A, 1977, PROTEINASES MAMMALIA, P209; BARRETT AJ, 1980, MAMMALIAN PROTEASES, P301; CHANG WJ, 1976, J BIOCHEM-TOKYO, V80, P975, DOI 10.1093/oxfordjournals.jbchem.a131385; Edman P, 1975, PROTEIN SEQUENCE DET, P232; Foltmann B, 1977, Adv Exp Med Biol, V95, P3; FOLTMANN B, 1981, ESSAYS BIOCHEM, V17, P52; FOLTMANN B, 1985, ASPARTIC PROTEINASES, P19; FUSEK M, 1990, J BIOL CHEM, V265, P1496; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3146, DOI 10.1021/bi00741a002; HOFMANN T, 1964, BIOCHEMISTRY-US, V3, P356, DOI 10.1021/bi00891a010; HORIUCHI S, 1969, SCI PAP COLL GEN ED, V19, P127; IDO E, 1987, AGR BIOL CHEM TOKYO, V51, P2855; IIO K, 1976, BIOCHIM BIOPHYS ACTA, V429, P912, DOI 10.1016/0005-2744(76)90336-3; INOUE H, 1991, J BIOL CHEM, V266, P19484; KOAZE Y, 1964, AGR BIOL CHEM TOKYO, V28, P216, DOI 10.1080/00021369.1964.10858233; LIN XL, 1990, J BIOL CHEM, V265, P1490; MAITA T, 1984, J BIOCHEM-TOKYO, V95, P465, DOI 10.1093/oxfordjournals.jbchem.a134628; Murao S., 1985, ASPARTIC PROTEINASES, P379; RAJAGOPALAN TG, 1966, J BIOL CHEM, V241, P4295; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TANG J, 1971, J BIOL CHEM, V246, P4510; TSURU D, 1986, J BIOCHEM-TOKYO, V99, P1537, DOI 10.1093/oxfordjournals.jbchem.a135624; TSURU D, 1989, AGR BIOL CHEM TOKYO, V53, P1305, DOI 10.1080/00021369.1989.10869464; TSURU D, 1989, AGR BIOL CHEM TOKYO, V53, P2751, DOI 10.1080/00021369.1989.10869723	26	39	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19480	19483						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918059				2022-12-25	WOS:A1991GK66700055
J	CAROFF, M; DEPRUN, C; KARIBIAN, D; SZABO, L				CAROFF, M; DEPRUN, C; KARIBIAN, D; SZABO, L			ANALYSIS OF UNMODIFIED ENDOTOXIN PREPARATIONS BY 252CF PLASMA DESORPTION MASS-SPECTROMETRY - DETERMINATION OF MOLECULAR MASSES OF THE CONSTITUENT NATIVE LIPOPOLYSACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; COMPLETE STRUCTURAL DETERMINATION; GRAM-NEGATIVE BACTERIA; HEPTOSE-LESS MUTANT; LIPID-A BACKBONE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; BORDETELLA-PERTUSSIS; LASER DESORPTION; PURIFICATION	Nine unmodified endotoxin preparations constituted of Re-, Rd-, and Rc-type lipopolysaccharides (2 to 5 glycoses), representing four species of enterobacteria were analyzed by Cf-252 plasma desorption mass spectrometry. The constituent lipopolysaccharides were characterized by the ion pair: (M - H)- and its corresponding lipid fragment ion. The lipid fragment ion is produced by cleavage of the glycosidic bond of the 3-deoxy-D-manno-oct-2-ulosonic acid unit that substitutes O-6' of the glucosamin-beta-1'-6glucosamine ("lipid A backbone") disaccharide of the lipid A moiety. These lipid fragment ions were identical to the (M - H)- ions seen in the spectra of homologous isolated lipid A preparations that were obtained by hydrolysis (pH 4.5, 100-degrees-C) promoted by sodium dodecyl sulfate. Since the molecular components present in the endotoxin preparations analyzed are known, the ion pair (M - H)(-)-lipid fragment ion defines the molecular compositions of each individual lipopolysaccharide. Heterogeneity of the R-type endotoxin preparations analyzed was due almost exclusively to differing lipid A moieties. In three Salmonella minnesota 595 Re endotoxin preparations 10 different lipopolysaccharides were identified, only two of which were common to all three preparations. Of the nine lipopolysaccharides identified in two S. minnesota R7 endotoxin preparations, only two were present in both.	INST PHYS NUCL,EQUIPE INTERACT ION SURFACE & MAT,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; Universite Paris Saclay	CAROFF, M (corresponding author), UNIV PARIS 11,INST BIOCHIM,CNRS,EQUIPE ENDOTOXINES,F-91405 ORSAY,FRANCE.		Caroff, Martine/N-4293-2019	CAROFF, Martine/0000-0002-7329-5247				AUZANNEAU FI, 1991, IN PRESS CARBOHYDR R; BOWMAN HG, 1975, J BACTERIOL, V121, P455; BUTTKE TM, 1975, J BACTERIOL, V124, P1566, DOI 10.1128/JB.124.3.1566-1573.1975; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CHENG CH, 1973, J INFECT DIS, V128, P343; COTTER RJ, 1987, BIOMED ENVIRON MASS, V14, P591, DOI 10.1002/bms.1200141103; DELLANEGRA S, 1986, REV PHYS APPL, V21, P401, DOI 10.1051/rphysap:01986002106040100; Deprun C, 1989, Rapid Commun Mass Spectrom, V3, P171, DOI 10.1002/rcm.1290030602; FIELD AM, 1989, BIOCHEM J, V263, P695, DOI 10.1042/bj2630695; HASE S, 1976, EUR J BIOCHEM, V63, P101, DOI 10.1111/j.1432-1033.1976.tb10212.x; IKAWA M, 1953, J AM CHEM SOC, V75, P3439, DOI 10.1021/ja01110a041; JANN B, 1975, EUR J BIOCHEM, V60, P239, DOI 10.1111/j.1432-1033.1975.tb20996.x; JANSSON PE, 1981, EUR J BIOCHEM, V115, P571; JONSSON GP, 1986, ANAL CHEM, V58, P1084, DOI 10.1021/ac00297a023; KARIBIAN D, 1991, IN PRESS INT J MASS; LEDUR A, 1978, EUR J BIOCHEM, V84, P579, DOI 10.1111/j.1432-1033.1978.tb12201.x; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; MCNEAL CJ, 1979, ANAL CHEM, V51, P2036, DOI 10.1021/ac50048a032; Morgan WTJ, 1937, BIOCHEM J, V31, P2003, DOI 10.1042/bj0312003; OSBORN MJ, 1964, SCIENCE, V115, P783; PALVA ET, 1980, EUR J BIOCHEM, V107, P137, DOI 10.1111/j.1432-1033.1980.tb04634.x; QURESHI N, 1983, J BIOL CHEM, V258, P2947; QURESHI N, 1985, J BIOL CHEM, V260, P5271; QURESHI N, 1988, J BIOL CHEM, V263, P11971; QURESHI N, 1988, J BIOL CHEM, V263, P5502; QURESHI N, 1982, J BIOL CHEM, V257, P1808; RICK PD, 1977, J BIOL CHEM, V252, P4895; RICK PD, 1972, P NATL ACAD SCI USA, V69, P3756, DOI 10.1073/pnas.69.12.3756; ROSNER MR, 1979, J BIOL CHEM, V254, P5918; ROSNER MR, 1979, J BIOL CHEM, V254, P5906; SCHMIDT G, 1969, ZENTBL BAKTERIOLOG P, V210, P381; SHANDS JW, 1980, J BIOL CHEM, V255, P1221; TAKADA H, 1989, CRIT REV MICROBIOL, V16, P477, DOI 10.3109/10408418909104475; TAKAYAMA K, 1986, J BIOL CHEM, V261, P624; VOLK WA, 1970, FEBS LETT, V8, P161, DOI 10.1016/0014-5793(70)80252-6; WEISS J, 1986, INFECT IMMUN, V51, P594, DOI 10.1128/IAI.51.2.594-599.1986; WESTPHAL O, 1952, Z NATURFORSCH B, V7, P148, DOI 10.1515/znb-1952-0303; WESTPHAL O, 1983, PROG ALLERGY, V35, P9; WILKINSON RG, 1972, J GEN MICROBIOL, V70, P527, DOI 10.1099/00221287-70-3-527; WRIGHT A, 1965, P NATL ACAD SCI USA, V54, P235, DOI 10.1073/pnas.54.1.235	40	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18543	18549						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917976				2022-12-25	WOS:A1991GJ47200024
J	MULLER, B; BOEHMER, PE; EMMERSON, PT; WEST, SC				MULLER, B; BOEHMER, PE; EMMERSON, PT; WEST, SC			ACTION OF RECBCD ENZYME ON HOLLIDAY STRUCTURES MADE BY RECA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECA; DOUBLE-STRANDED DNA; ENDONUCLEASE-VII; GENETIC-RECOMBINATION; CRUCIFORM DNA; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; K-12 REVEALS; RUV REGION; JUNCTIONS	In vitro, Escherichia coli RecA protein acts upon gapped and partially homologous linear duplex DNA to generate recombination products linked by Holliday junctions. When strand exchange reactions are supplemented with purified RecBCD enzyme, we observe the formation of products that resemble "patch" recombinants. The formation of "splice" recombinant products was not observed. The individual subunits, RecB, RecC, or RecD, had no effect on RecA protein-mediated strand exchange nor on the Holliday junctions formed in the reaction. Analysis of the way in which patch products arise indicates exonucleolytic digestion of the linear arms of the recombination intermediates (alpha-structures) by RecBCD enzyme. We find no evidence for specific resolution events at the site of the Holliday junction by RecBCD enzyme using these DNA substrates.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK				Muller, Berndt/0000-0003-1279-5421; Boehmer, Paul/0000-0003-4479-0529; West, Stephen/0000-0001-8848-9418				AMUNDSEN SK, 1990, GENETICS, V126, P25; BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; BIRGE EA, 1974, J MOL BIOL, V83, P447, DOI 10.1016/0022-2836(74)90506-3; BOEHMER PE, 1991, GENE, V102, P1, DOI 10.1016/0378-1119(91)90529-K; BRAEDT G, 1989, P NATL ACAD SCI USA, V86, P871, DOI 10.1073/pnas.86.3.871; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; COX MM, 1981, J BIOL CHEM, V256, P4676; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DICKIE P, 1987, J MOL BIOL, V196, P541, DOI 10.1016/0022-2836(87)90031-3; EICHLER DC, 1977, J BIOL CHEM, V252, P499; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; FAULDS D, 1979, J MOL BIOL, V131, P681, DOI 10.1016/0022-2836(79)90197-9; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; JENSCH F, 1986, EMBO J, V5, P181, DOI 10.1002/j.1460-2075.1986.tb04194.x; KALLENBACH NR, 1983, NATURE, V305, P829, DOI 10.1038/305829a0; KEMPER B, 1984, COLD SPRING HARB SYM, V49, P815, DOI 10.1101/SQB.1984.049.01.092; KLEFF S, 1988, EMBO J, V7, P1527, DOI 10.1002/j.1460-2075.1988.tb02972.x; KOSAK HG, 1990, EUR J BIOCHEM, V194, P779, DOI 10.1111/j.1432-1033.1990.tb19469.x; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LUISIDELUCA C, 1989, GENETICS, V122, P269; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MIZUUCHI K, 1982, CELL, V29, P357, DOI 10.1016/0092-8674(82)90152-0; MULLER B, 1990, NUCLEIC ACIDS RES, V18, P5633, DOI 10.1093/nar/18.19.5633; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; ROMAN LJ, 1989, J BIOL CHEM, V264, P18340; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; ROSENBERG SM, 1987, CELL, V48, P855, DOI 10.1016/0092-8674(87)90082-1; ROSENBERG SM, 1988, GENETICS, V120, P7; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHURVINTON CE, 1982, MOL GEN GENET, V185, P352, DOI 10.1007/BF00330811; SMITH GR, 1988, MICROBIOL REV, V52, P1; SMITH GR, 1987, ANNU REV GENET, V21, P179, DOI 10.1146/annurev.genet.21.1.179; STAHL FW, 1982, GENETICS, V6102, P599; SYMINGTON LS, 1985, P NATL ACAD SCI USA, V82, P7247, DOI 10.1073/pnas.82.21.7247; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1990, J MOL BIOL, V211, P117, DOI 10.1016/0022-2836(90)90015-E; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; THOMPSON BJ, 1976, P NATL ACAD SCI USA, V73, P2299, DOI 10.1073/pnas.73.7.2299; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; WIEGAND RC, 1977, J MOL BIOL, V116, P805, DOI 10.1016/0022-2836(77)90272-8	52	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19028	19033						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918020				2022-12-25	WOS:A1991GJ47200095
J	CHOU, DKH; FLORES, S; JUNGALWALA, FB				CHOU, DKH; FLORES, S; JUNGALWALA, FB			EXPRESSION AND REGULATION OF UDP-GLUCURONATE - NEOLACTOTETRAOSYLCERAMIDE GLUCURONYLTRANSFERASE IN THE NERVOUS-SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURKINJE-CELL ABNORMALITY; HNK-1 ANTIBODY; HNK-1-REACTIVE ANTIGENS; CEREBELLAR HYPOPLASIA; ADHESION MOLECULES; MURINE MUTANTS; GLYCOLIPIDS; SULFOGLUCURONYL; ACID; LOCALIZATION	Sulfoglucuronyl glycolipids (SGGLs) are temporally and spatially regulated molecules present in the nervous system during its development. The characteristics of the rat brain enzyme glucuronyltransferase involved in the biosynthesis of SGGLs have been described. The enzyme catalyzes the transfer of glucuronic acid (GlcA) from UDP-GlcA to terminal galactose of the neolacto (type 2) series of glycolipids to form beta-1-3-linked glucuronyl neolacto glycolipids. The enzyme was highly specific for the neolacto series of acceptor glycolipids, neolactotetraosylceramide (nLcOse4Cer), neolactohexaosylceramide (nLcOse6Cer), and neolactooctaosylceramide (nLcOse8Cer) and was different from the drug-inducible phenol:GlcA transferase. Considerable activity of GlcA transferase was present in the adult rat cerebral cortex, even though SGGLs almost completely disappeared from the cortex by postnatal day 15. In the cerebellum, although levels of SGGLs increased with development, the specific activity of GlcA transferase declined. The results indicated that GlcA transferase was not a regulatory enzyme controlling the expression of SGGLs. Measurements of the levels of nLcOse4Cer and nLcOse6Cer in these neural tissues indicated that the availability of these precursors may regulate the differential expression of SGGLs seen previously. GlcA transferase was significantly reduced in the cerebellar Purkinje cell degenerating murine mutant (pcd/pcd), which is consistent with the loss of SGGLs in the cerebellum of this mutant and specific association of these glycolipids with Purkinje cells.	EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC,DEPT BIOCHEM,200 TRAPELO RD,WALTHAM,MA 02254; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02114	Harvard University; Harvard Medical School					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD005515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024405] Funding Source: NIH RePORTER; NICHD NIH HHS [P01-HD05515] Funding Source: Medline; NINDS NIH HHS [R01-NS24405] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABO T, 1982, J IMMUNOL, V129, P1752; AOKI E, 1982, J NEUROCHEM, V39, P1072, DOI 10.1111/j.1471-4159.1982.tb11499.x; ARIGA T, 1987, J BIOL CHEM, V262, P848; CHAWDHURY JR, 1985, P NATL ACAD SCI USA, V82, P2990; CHOU DKH, 1990, J NEUROCHEM, V54, P1598, DOI 10.1111/j.1471-4159.1990.tb01210.x; CHOU DKH, 1987, J NEUROCHEM, V49, P865, DOI 10.1111/j.1471-4159.1987.tb00974.x; CHOU DKH, 1988, J NEUROCHEM, V50, P1655, DOI 10.1111/j.1471-4159.1988.tb03056.x; CHOU DKH, 1990, J NEUROCHEM, V54, P1589, DOI 10.1111/j.1471-4159.1990.tb01209.x; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; CHOU DKH, 1989, J NEUROCHEM S, V52; CHOU DKH, 1990, T AM SOC NEUROCHEM, V21, P120; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; DAS KK, 1991, J BIOL CHEM, V266, P5238; EGEA JFG, 1987, NEUROPHARMACOLOGY, V26, P367; FIGLEWICZ DA, 1985, J LIPID RES, V26, P140; HAKAMORI S, 1990, J BIOL CHEM, V265, P18713; ILYAS AA, 1990, J NEUROCHEM, V55, P594, DOI 10.1111/j.1471-4159.1990.tb04175.x; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JUNGALWALA FB, 1990, INT C BIOL FUNCTION, P58; KOHRIYAMA T, 1988, J NEUROCHEM, V51, P869, DOI 10.1111/j.1471-4159.1988.tb01823.x; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; KUNDU SK, 1983, J BIOL CHEM, V258, P3857; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; MACKENZIE PI, 1984, J BIOL CHEM, V259, P2153; MIKOSHIBA K, 1980, J NEUROCHEM, V35, P1309, DOI 10.1111/j.1471-4159.1980.tb09003.x; PESHEVA P, 1988, J NEUROSCI RES, V20, P420, DOI 10.1002/jnr.490200404; PRASADARAO N, 1990, J HISTOCHEM CYTOCHEM, V38, P1193, DOI 10.1177/38.8.1694876; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; SCHWARTING GA, 1988, BIOESSAYS, V9, P19, DOI 10.1002/bies.950090106; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; SHASHOUA VE, 1986, BIOCHEM BIOPH RES CO, V138, P902, DOI 10.1016/S0006-291X(86)80581-2; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; WATANABE K, 1979, J BIOL CHEM, V254, P8223; WENGER DA, 1973, J NEUROCHEM, V20, P607, DOI 10.1111/j.1471-4159.1973.tb12159.x; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3045, DOI 10.1073/pnas.82.9.3045; YOUNG WW, 1981, J BIOL CHEM, V256, P967	37	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17941	17947						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917933				2022-12-25	WOS:A1991GG55300038
J	OLTERSDORF, T; WARD, PJ; HENRIKSSON, T; BEATTIE, EC; NEVE, R; LIEBERBURG, I; FRITZ, LC				OLTERSDORF, T; WARD, PJ; HENRIKSSON, T; BEATTIE, EC; NEVE, R; LIEBERBURG, I; FRITZ, LC			THE ALZHEIMER AMYLOID PRECURSOR PROTEIN - IDENTIFICATION OF A STABLE INTERMEDIATE IN THE BIOSYNTHETIC DEGRADATIVE PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	OLTERSDORF, T (corresponding author), ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080, USA.							BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CUNNINGHAM BA, 1983, P NATL ACAD SCI USA, V80, P5762; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PAULSON JC, 1987, BIOCHEM SOC T, V15, P618, DOI 10.1042/bst0150618; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1989, NATURE, V341, P546; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	28	278	290	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1990	265	8					4492	4497						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CT101	1968460				2022-12-25	WOS:A1990CT10100052
J	TIRUPPATHI, C; MIYAMOTO, Y; GANAPATHY, V; ROESEL, RA; WHITFORD, GM; LEIBACH, FH				TIRUPPATHI, C; MIYAMOTO, Y; GANAPATHY, V; ROESEL, RA; WHITFORD, GM; LEIBACH, FH			HYDROLYSIS AND TRANSPORT OF PROLINE-CONTAINING PEPTIDES IN RENAL BRUSH-BORDER MEMBRANE-VESICLES FROM DIPEPTIDYL PEPTIDASE-IV-POSITIVE AND DIPEPTIDYL PEPTIDASE-IV-NEGATIVE RAT STRAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									MED COLL GEORGIA, DEPT CELL & MOLEC BIOL, AUGUSTA, GA 30912 USA	University System of Georgia; Augusta University					NIDDK NIH HHS [DK 42069] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042069] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANSORGE S, 1987, ACTA HISTOCHEM, V82, P41, DOI 10.1016/S0065-1281(87)80049-1; BARTH A, 1974, ACTA BIOL MED GER, V32, P157; BOND JS, 1986, CURR TOP CELL REGUL, V28, P263; BONSNES RW, 1945, J BIOL CHEM, V158, P581; CARONE FA, 1980, AM J PHYSIOL, V238, pF151, DOI 10.1152/ajprenal.1980.238.3.F151; CARONE FA, 1982, J LAB CLIN MED, V100, P1; CHILOSI M, 1982, AM J CLIN PATHOL, V77, P714; GANAPATHY ME, 1986, BIOCHEM J, V238, P201, DOI 10.1042/bj2380201; GANAPATHY V, 1980, BIOCHEM BIOPH RES CO, V97, P1133, DOI 10.1016/0006-291X(80)91493-X; GANAPATHY V, 1985, BIOCHEM PHARMACOL, V34, P1287, DOI 10.1016/0006-2952(85)90507-6; GANAPATHY V, 1986, AM J PHYSIOL, V251, pF945, DOI 10.1152/ajprenal.1986.251.6.F945; Ganapathy V, 1984, Contrib Nephrol, V42, P10; GANAPATHY V, 1984, J BIOL CHEM, V259, P8954; GANAPATHY V, 1982, LIFE SCI, V30, P2137, DOI 10.1016/0024-3205(82)90287-9; GANAPATHY V, 1982, BIOCHIM BIOPHYS ACTA, V691, P362, DOI 10.1016/0005-2736(82)90427-8; GANAPATHY V, 1987, ADV BIOSCI, V65, P91; GANAPATHY V, 1987, CONTRIB INFUSION THE, V17, P54; GOODMAN SI, 1971, LANCET, V1, P234; HAMA T, 1982, MOL CELL BIOCHEM, V43, P35; HARTRODT B, 1982, PHARMAZIE, V37, P72; HENSCHEN A, 1979, H-S Z PHYSIOL CHEM, V360, P1217; HEYMANN E, 1982, NATURWISSENSCHAFTEN, V69, P189, DOI 10.1007/BF00364899; HEYMANN E, 1978, FEBS LETT, V91, P360, DOI 10.1016/0014-5793(78)81210-1; HOPSUHAV.VK, 1969, HISTOCHEMISTRY, V17, P30, DOI 10.1007/BF00306327; Kenny A J, 1978, Essays Biochem, V14, P1; Kenny AJ, 1978, BIOCHEM SOC T, V6, P825, DOI 10.1042/bst0060825; KENNY AJ, 1988, FEBS LETT, V232, P1, DOI 10.1016/0014-5793(88)80375-2; KENNY AJ, 1976, BIOCHEM J, V157, P169, DOI 10.1042/bj1570169; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOJDA Z, 1977, HISTOCHEMISTRY, V54, P299, DOI 10.1007/BF00508273; MATTHEWS DM, 1976, GASTROENTEROLOGY, V71, P151; McDonalds JK, 1971, TISSUE PROTEINASES, P69; MIYAMOTO Y, 1986, J BIOL CHEM, V261, P6133; MIYAMOTO Y, 1985, BIOCHEM BIOPH RES CO, V132, P946, DOI 10.1016/0006-291X(85)91899-6; MIYAMOTO Y, 1987, AM J PHYSIOL, V252, pF670, DOI 10.1152/ajprenal.1987.252.4.F670; MORITA A, 1983, J CLIN INVEST, V72, P610, DOI 10.1172/JCI111009; OCONNOR B, 1986, EUR J BIOCHEM, V154, P329, DOI 10.1111/j.1432-1033.1986.tb09401.x; SCHON E, 1984, ACTA HISTOCHEM, V75, P175, DOI 10.1016/S0065-1281(84)80056-2; SCHULMAN JD, 1975, BIOCHEM BIOPH RES CO, V65, P68, DOI 10.1016/S0006-291X(75)80062-3; SCRIVER CR, 1977, METABOLIC BASIS INHE, P336; SEETHARAM B, 1987, ARCH BIOCHEM BIOPHYS, V253, P189, DOI 10.1016/0003-9861(87)90651-5; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; SILBERNAGL S, 1982, BIOCH KIDNEY FUNCTIO, P429; SILBERNAGL S, 1978, CURRENT PROBLEMS CLI, V8, P59; SMITHSON KW, 1977, J CLIN INVEST, V60, P665, DOI 10.1172/JCI108818; WALTER R, 1980, MOL CELL BIOCHEM, V30, P111; WATANABE Y, 1987, EXPERIENTIA, V43, P400, DOI 10.1007/BF01940426; WENDEL A, 1978, CURRENT PROBLEMS CLI, V8, P73; YOSHIOKA M, 1988, J CLIN INVEST, V81, P1090, DOI 10.1172/JCI113421; YOSHIOKA M, 1987, AM J PHYSIOL, V253, pG781, DOI 10.1152/ajpgi.1987.253.6.G781	51	102	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1990	265	3					1476	1483						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CJ676	1967253				2022-12-25	WOS:A1990CJ67600041
J	HSU, SC; MOLDAY, RS				HSU, SC; MOLDAY, RS			GLYCOLYTIC-ENZYMES AND A GLUT-1 GLUCOSE TRANSPORTER IN THE OUTER SEGMENTS OF ROD AND CONE PHOTORECEPTOR CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTES; MONOCLONAL-ANTIBODIES; PLASMA-MEMBRANE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; SKELETAL-MUSCLE; SUGAR-TRANSPORT; CYTOCHALASIN-B; PROTEIN; RHODOPSIN; BOVINE	The presence of glycolytic enzymes and a GLUT-1-type glucose transporter in rod and cone outer segments was determined by enzyme activity assays, glucose uptake measurements, Western blotting, and immunofluorescence microscopy. Enzyme activities of six glycolytic enzymes including hexokinase, phosphofructokinase, aldolase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, pyruvate kinase, and lactate dehydrogenase, were found to be present in purified rod outer segment (ROS) preparations. Immunofluorescence microscopy of bovine and chicken retina sections labeled with monoclonal antibodies against glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, and lactate dehydrogenase have confirmed that these enzymes are present in rod and cone outer segments and not simply contaminants from the inner segments or other cells. Rod outer segments were also found to contain glucose transport activity as detected by 3-O-[C-14]methylglucose uptake and exchange. The glucose transporter had a K(m) of 6.3 mM and a V(max) of 0.15 nmol of 3-0-methylglucose/s/mg of ROS membrane protein for net uptake and a K(m) of 29 mM and a V(max) of 1.06 nmol of 3-0-methylglucose/s/mg of ROS membrane protein for equilibrium exchange. These K(m) values for net uptake and equilibrium exchange are similar to values obtained for human red blood cells and are characteristic of GLUT-1-type glucose transporter. The transport was inhibited by both cytochalasin B and phloretin. Western blot analysis and immunofluorescence microscopy using type-specific glucose transporter antibodies indicated that both rod and cone outer segment plasma membranes have a GLUT-1 glucose transporter of M(r) 45K as found in red blood cells and brain microsomal membranes. Solid-phase radioimmune competitive inhibition studies indicated that rod outer segment plasma membranes contained 15% the number of glucose transporters found in human red blood cell membranes and had an estimated density of 400 glucose transporter per mu-m2 of plasma membrane. These studies support the view that outer segments can generate energy in the form of ATP and GTP by anaerobic glycolysis to supply at least some of the energy requirements for phototransduction and other metabolic processes.			HSU, SC (corresponding author), UNIV BRITISH COLUMBIA,FAC MED,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA.				NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY-02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLARD WJ, 1985, J BIOL CHEM, V260, P8668; BERGER SJ, 1980, J BIOL CHEM, V255, P3128; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BLOCH R, 1973, BIOCHEMISTRY-US, V12, P4799, DOI 10.1021/bi00747a036; BOWNDS D, 1972, NATURE-NEW BIOL, V237, P125, DOI 10.1038/newbio237125a0; BRAHM J, 1983, J PHYSIOL-LONDON, V339, P339, DOI 10.1113/jphysiol.1983.sp014720; COOK NJ, 1989, J BIOL CHEM, V264, P6996; COPES RK, 1982, METHOD ENZYMOL, V90, P479; CRAIK JD, 1979, BIOCHEM J, V182, P503, DOI 10.1042/bj1820503; DONTSOV AE, 1978, BIOCHEMISTRY-MOSCOW+, V43, P471; EASTERBY JS, 1982, METHOD ENZYMOL, V90, P11; EDWARDS PAW, 1974, BIOCHIM BIOPHYS ACTA, V345, P373, DOI 10.1016/0005-2736(74)90199-0; EILAM Y, 1975, BIOCHIM BIOPHYS ACTA, V401, P364, DOI 10.1016/0005-2736(75)90236-9; EVANS E, 1972, MICROVASC RES, V4, P335, DOI 10.1016/0026-2862(72)90069-6; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; FUTTERMAN S, 1970, J NEUROCHEM, V17, P149, DOI 10.1111/j.1471-4159.1970.tb02195.x; GERHART DZ, 1989, J NEUROSCI RES, V22, P464, DOI 10.1002/jnr.490220413; GORGA FR, 1979, BIOCHEM BIOPH RES CO, V91, P955, DOI 10.1016/0006-291X(79)91972-7; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; HARRIS BG, 1982, METHOD ENZYMOL, V90, P45; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; HODGES RS, 1988, J BIOL CHEM, V263, P11768; HOOS RT, 1972, BIOCHIM BIOPHYS ACTA, V266, P174, DOI 10.1016/0005-2736(72)90133-2; HSU SC, 1990, J BIOL CHEM, V265, P13308; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JOHNSON LV, 1984, CURR EYE RES, V3, P969, DOI 10.3109/02713688409167215; KAHN A, 1982, METHOD ENZYMOL, V90, P131; KANT JA, 1973, J BIOL CHEM, V248, P8457; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KULBE KD, 1982, METHOD ENZYMOL, V90, P115; KUWATA O, 1990, FEBS LETT, V272, P128, DOI 10.1016/0014-5793(90)80465-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1982, METHOD ENZYMOL, V89, P351; LEFEVRE PG, 1959, J BIOL CHEM, V234, P3022; LIN S, 1977, J BIOL CHEM, V252, P5464; LOWE AG, 1985, ANAL BIOCHEM, V144, P385, DOI 10.1016/0003-2697(85)90131-9; LOWRY OH, 1961, J BIOL CHEM, V236, P2813; LOWRY OH, 1956, J BIOL CHEM, V220, P879; MACKENZIE D, 1982, J BIOL CHEM, V257, P7100; MARETZKI D, 1989, TRENDS BIOCHEM SCI, V14, P93, DOI 10.1016/0968-0004(89)90128-X; MILLER DM, 1968, BIOPHYS J, V8, P1329, DOI 10.1016/S0006-3495(68)86559-2; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PAN LX, 1989, HISTOCHEM J, V21, P638, DOI 10.1007/BF01002483; REID DM, 1990, BIOCHEMISTRY-US, V29, P1601, DOI 10.1021/bi00458a035; SCHNETKAMP PPM, 1981, BIOCHIM BIOPHYS ACTA, V672, P307, DOI 10.1016/0304-4165(81)90298-1; Steck T. L., 1974, METHODS MEMBRANE BIO, V2, P245; Stein WD., 1986, FACILITATED DIFFUSIO, P231; SZEL A, 1986, EXP EYE RES, V43, P871, DOI 10.1016/0014-4835(86)90066-7; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TOYODA N, 1986, J BIOL CHEM, V261, P2117; WALLIMANN T, 1986, P NATL ACAD SCI USA, V83, P3816, DOI 10.1073/pnas.83.11.3816; WANG C, 1987, J BIOL CHEM, V262, P15689; WHEELER TJ, 1981, J BIOL CHEM, V256, P8907; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276; YELTMAN DR, 1982, METHOD ENZYMOL, V90, P251; ZOCCOLI MA, 1977, J BIOL CHEM, V252, P3131	63	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21745	21752						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939198				2022-12-25	WOS:A1991GP80400064
J	VOYNOW, JA; KAISER, RS; SCANLIN, TF; GLICK, MC				VOYNOW, JA; KAISER, RS; SCANLIN, TF; GLICK, MC			PURIFICATION AND CHARACTERIZATION OF GDP-L-FUCOSE-N-ACETYL-BETA-D-GLUCOSAMINIDE-ALPHA-1-]6FUCOSYLTRANSFERASE FROM CULTURED HUMAN SKIN FIBROBLASTS - REQUIREMENT OF A SPECIFIC BIANTENNARY OLIGOSACCHARIDE AS SUBSTRATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS FIBROBLASTS; N-LINKED OLIGOSACCHARIDES; GDP-L-FUCOSE; GLYCOPROTEIN-SYNTHESIS; 3-DIMENSIONAL STRUCTURE; MEMBRANE-GLYCOPROTEINS; BOVINE COLOSTRUM; RAT-LIVER; BLOOD; CELLS	GDP-L-fucose-N-acetyl-beta-D-glucosaminide alpha-1 --> 6-fucosyltransferase which catalyzes the transfer of fucose from GDP-L-fucose to the asparagine-linked N-acetyl-beta-D-glucosamine of N-linked glycoproteins has been purified 37,000-fold from cultured human skin fibroblasts. The K(m) values for the substrate asialoagalactotransferrin glycopeptide, and GDP-L-fucose were 66 and 4.2-mu-M, respectively. The V(max) was 1.4-mu-mol/mg/min. The key step in enzyme purification was affinity chromatography using the immobilized substrate asialoagalactotransferrin glycopeptide-CH-Sepharose. The affinity-purified enzyme had a minimum substrate requirement for a biantennary oligosaccharide with GlcNAc in terminal position, having a K(m) value of 55-mu-M. It was heretofore unexpected that the oligosaccharide would serve as substrate, since the site of enzyme activity is GlcNAc-1-linked to Asn. Although the presence of amino acids on this oligosaccharide enhanced the activity 3-fold, it is proposed that this may be the result of an alpha/beta anomeric mixture (2:1) of oligosaccharide used in these studies with only the beta-anomer active as substrate. The implication is that the amino acid is required only to retain the beta-anomeric position of the substrate. Removal of GlcNAc or addition of Gal to either the oligosaccharide or glycopeptide destroyed the ability to serve as substrates. In addition, di-N-acetylchitobiose, tri-N-acetylchitotriose and GlcNAc-beta-1 --> Asn were nonpermissible substrates. This rigid substrate requirement is unique among fucosyl-transferases thus far reported, since the natural substrates for the other enzymes may be substituted by one of several disaccharides.	CHILDRENS HOSP PHILADELPHIA,JOSEPH STOKES JR RES INST,34TH ST & CIVIC CTR BLVD,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL001573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016859] Funding Source: NIH RePORTER; NHLBI NIH HHS [K11 HL 01573] Funding Source: Medline; NIDDK NIH HHS [R01 DK 16859] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENDIAK B, 1987, J BIOL CHEM, V262, P5775; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BOSMANN HB, 1968, ARCH BIOCHEM BIOPHYS, V128, P470, DOI 10.1016/0003-9861(68)90053-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BRISSON JR, 1983, CAN J BIOCHEM CELL B, V61, P1067, DOI 10.1139/o83-135; CARVER JP, 1987, PURE APPL CHEM, V59, P1465, DOI 10.1351/pac198759111465; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHESTER MA, 1976, EUR J BIOCHEM, V69, P583, DOI 10.1111/j.1432-1033.1976.tb10944.x; DALLOLIO F, 1991, INT J CANCER, V47, P291, DOI 10.1002/ijc.2910470220; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; FINCH PR, 1969, ANAL BIOCHEM, V31, P296, DOI 10.1016/0003-2697(69)90269-3; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; GLEESON PA, 1983, J BIOL CHEM, V258, P6162; GUINTOLI RL, 1990, GLYCOCONJUGATE J, V7, P445; HOLMES EH, 1985, J BIOL CHEM, V260, P7619; JELINEKKELLY S, 1988, J BIOL CHEM, V263, P14757; JOZIASSE DH, 1987, J BIOL CHEM, V262, P2025; KOSCIELAK J, 1987, GLYCOCONJUGATE J, V4, P43, DOI 10.1007/BF01048443; KUWOWSKALATALLO JF, 1990, GENE DEV, V4, P1288; KYPRIANOU P, 1990, GLYCOCONJUGATE J, V7, P573, DOI 10.1007/BF01189078; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBLIN G, 1984, J BIOL CHEM, V259, P9051; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEIBOLD DM, 1988, J CELL PHYSIOL, V137, P411, DOI 10.1002/jcp.1041370304; LONGMORE GD, 1982, CARBOHYD RES, V100, P365, DOI 10.1016/S0008-6215(00)81049-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONTREUIL J, 1983, BIOCHEM SOC T, V11, P134, DOI 10.1042/bst0110134; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SANTER UV, 1983, CARBOHYD RES, V120, P197, DOI 10.1016/0008-6215(83)88017-3; SANTER UV, 1979, BIOCHEMISTRY-US, V18, P2533, DOI 10.1021/bi00579a016; SANTER UV, 1989, EUR J BIOCHEM, V181, P249, DOI 10.1111/j.1432-1033.1989.tb14719.x; SCANLIN TF, 1985, PEDIATR RES, V19, P368, DOI 10.1203/00006450-198519040-00011; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SHAO MC, 1988, J BIOL CHEM, V263, P5771; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; VLIEGENTHART JFG, 1981, PURE APPL CHEM, V53, P45, DOI 10.1351/pac198153010045; VOYNOW JA, 1988, ANAL BIOCHEM, V168, P367, DOI 10.1016/0003-2697(88)90331-4; WANG YM, 1990, CLIN CHIM ACTA, V188, P193, DOI 10.1016/0009-8981(90)90201-3; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WESLEY A, 1983, PEDIATR RES, V17, P65, DOI 10.1203/00006450-198301000-00013; [No title captured]	45	76	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21572	21577						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1939186				2022-12-25	WOS:A1991GP80400041
J	ALMAHMOOD, S; COLIN, S; BONALY, R				ALMAHMOOD, S; COLIN, S; BONALY, R			KLUYVEROMYCES-BULGARICUS YEAST LECTINS - ISOLATION OF 2 GALACTOSE-SPECIFIC LECTIN FORMS FROM THE YEAST-CELL WALL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; AGGLUTINATION FACTOR; FLOCCULATION; RECOGNITION; MECHANISM; MANNANS; UVARUM	Incubation of galactose treated Kluyveromyces bulgaricus yeast cells in EDTA/phosphate-buffered saline led to an extract possessing hemagglutinating and yeast flocculating properties. Purification of this extract by affinity chromatography and gel filtration gave two lectin forms, Kb-CWL I and Kb-CWL II, with an apparent molecular mass of 38,000 and 150,000 Da, respectively. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that Kb-CWL I and Kb-CWL II were dimeric and octameric of a subunit of 18,900 Da. At high concentration, purified Kb-CWL I associated to give Kb-CWL II. This association seemed to be independent on pH. The two lectin forms were glycoproteins, the peptide counterpart was very rich in Lys, Glu, and Gly, and the carbohydrate part represented 1% of the whole molecule and was composed of Glc, Man, and Ara. The two lectin forms (KB-CWL I and Kb-CWL II) agglutinated human red blood cells and flocculated EDTA-treated K. bulgaricus yeast cells. The activity of both lectin forms required Ca2+ ions, while Sr2+ showed some competitive inhibition. Optimal activity was obtained within a pH range of 4-6.5 for both forms. Temperatures of 80-90-degrees-C for 20 min, or proteolytic treatment reduced irreversibly the activity of Kb-CWL I and Kb-CWL II. The role of the cell wall phosphopeptidomannan as a ligand and a potential physiological receptor of these lectin forms was demonstrated.	FAC SCI PHARMACEUT & BIOL NANCY,BIOCHIM MICROBIENNE LAB,5 RUE ALBERT LEBRUN,BP 403,F-54001 NANCY,FRANCE	Universite de Lorraine								ALMAHMOOD S, 1987, APPL MICROBIOL BIOT, V26, P462, DOI 10.1007/BF00253533; ALMAHMOOD S, 1988, J BIOL CHEM, V263, P3930; ALMAHMOOD S, 1986, 8 P C SECT MICR IND, P247; AMRI MA, 1982, J GEN MICROBIOL, V128, P2001; AMRI MA, 1979, EUR J APPL MICROBIOL, V7, P227, DOI 10.1007/BF00498016; AMRI MA, 1981, BIOCHIMIE, V63, P575, DOI 10.1016/S0300-9084(81)80055-7; BALDO BA, 1978, BIOCHEM J, V175, P467, DOI 10.1042/bj1750467; BRUKE D, 1980, P NATL ACAD SCI USA, V77, P318; CONCHIE J, 1954, BIOCHEM J, V58, P552, DOI 10.1042/bj0580552; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Ghuysen J-M., 1966, METHOD ENZYMOL, P685, DOI DOI 10.1016/0076-6879(66)08124-2; HISMODA C, 1975, ANTON LEEUW INT J G, V41, P513; HUSSAIN T, 1986, APPL MICROBIOL BIOT, V23, P269, DOI 10.1007/BF00261927; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liener I.E., 1986, LECTINS; LIPKE PN, 1980, J BACTERIOL, V141, P1170, DOI 10.1128/JB.141.3.1170-1177.1980; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARQUARDT MD, 1975, EXP CELL RES, V91, P310, DOI 10.1016/0014-4827(75)90109-3; MBAWALA A, 1990, J GEN MICROBIOL, V136, P1279, DOI 10.1099/00221287-136-7-1279; MIKI BLA, 1982, J BACTERIOL, V150, P878, DOI 10.1128/JB.150.2.878-889.1982; OKUBO Y, 1981, ARCH BIOCHEM BIOPHYS, V212, P204, DOI 10.1016/0003-9861(81)90360-X; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PEAT S, 1961, J CHEM SOC, P29, DOI 10.1039/jr9610000029; PIERCE M, 1983, J BIOL CHEM, V258, P3576; STRATHERN JN, 1982, MOL BIOL YEAST METAB; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; WEINSTOCK K, 1986, J BIOL CHEM, V261, P6174; YEN PH, 1974, BIOCHEMISTRY-US, V13, P2428, DOI 10.1021/bi00708a030; YEN PH, 1973, J BIOL CHEM, V248, P8316	29	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20882	20887						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1939138				2022-12-25	WOS:A1991GN00100047
J	LENNY, N; GREEN, M				LENNY, N; GREEN, M			REGULATION OF ENDOPLASMIC-RETICULUM STRESS PROTEINS IN COS CELLS TRANSFECTED WITH IMMUNOGLOBULIN-MU HEAVY-CHAIN CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; BINDING-PROTEIN; DISULFIDE ISOMERASE; B-CELLS; GLUCOSE; EXPRESSION; GENES; SECRETION; SHOCK; HEMAGGLUTININ	The mechanism by which endoplasmic reticulum (ER) stress proteins are induced by the accumulation of incompletely assembled or malfolded proteins in the ER is poorly understood. The 78-kDa glucose-regulated protein (BiP), one of the ER stress proteins, has often been detected in stable complexes with these accumulated proteins. We have transfected COS cells with an immunoglobulin (Ig)-mu-heavy chain expression plasmid. Expressed mu-chain accumulated in the cells and formed stable complexes with BiP. As a result, the synthesis of three ER stress proteins, BiP, the 94-kDa glucose-regulated protein (GRP94/ERp99), and ERp72, was increased as were their mRNA levels. In addition, the degradation rate of BiP was increased, possibly because of its interaction with mu-chain. Cotransfection of the mu-chain plasmid with an Ig lambda-light chain expression plasmid resulted in the appearance of mu-chain in the media in a covalent complex with lambda-chain. An intracellular consequence of this was a reduction in the levels of BiP.mu-chain complex, and a diminished stimulation in the synthesis of the ER stress proteins. These results suggest that the BiP.mu-chain complex in the ER may be involved in the signaling pathway for the induction of ER stress proteins and may represent one regulatory mechanism operating in differentiating B-lymphocytes.	ST LOUIS UNIV,DEPT MICROBIOL,1402 S GRAND BLVD,ST LOUIS,MO 63104	Saint Louis University					NIGMS NIH HHS [GM 41602] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041602] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOTHWELL ALM, 1982, NATURE, V298, P380, DOI 10.1038/298380a0; BOTHWELL ALM, 1981, CELL, V24, P625, DOI 10.1016/0092-8674(81)90089-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KIM YK, 1987, J CELL PHYSIOL, V133, P553, DOI 10.1002/jcp.1041330317; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; LEWIS MJ, 1986, ARCH BIOCHEM BIOPHYS, V245, P389, DOI 10.1016/0003-9861(86)90230-4; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Sambrook J, 1989, MOL CLONING LABORATO; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SHANDS JW, 1973, AM J PATHOL, V70, P1; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; SHOHAT M, 1973, EUR J IMMUNOL, V3, P680, DOI 10.1002/eji.1830031106; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393	38	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20532	20537						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1939104				2022-12-25	WOS:A1991GM03900098
J	BURKE, C; MAYO, KH; SKUBITZ, APN; FURCHT, LT				BURKE, C; MAYO, KH; SKUBITZ, APN; FURCHT, LT			H-1-NMR AND CD SECONDARY STRUCTURE-ANALYSIS OF CELL-ADHESION PROMOTING PEPTIDE F9 FROM LAMININ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRO-SARCOMA CELLS; BASEMENT-MEMBRANE COMPONENTS; HUMAN-FIBRINOGEN; HEPARIN-BINDING; WATER SOLUTION; SEQUENCE; SURFACE; PROTEINS; SPECTROSCOPY; H-1-NMR	A heparin binding, cell adhesion promoting domain, termed peptide F-9, from the B1 chain of human laminin, residues 641 to 660, i.e. RYVVLPRPVCFEKGMNYTVR, has been investigated by H-1 NMR (500 MHz) spectroscopy and CD spectropolarimetry. While small linear peptides in water solution normally exist in a number of fluctuating conformational states, CD data analysis of peptide F9 indicates the existence of some preferred average structural populations consisting of about 30% beta-sheet, 22% beta-turn, and 6% alpha-helix. NMR structural analysis supports this observation and indicates specific sequences of preferred structural populations. Evidence for these is indicated by the presence of d(NN) nuclear Overhauser effect (NOE) populations and attenuated or absent d-alpha-N NOEs at short mixing times (0.1 S), 3J-alpha-N coupling constants of 5 and 10 Hz, and chemical shifts significantly removed from random coil positions. The NH2-terminal VVL sequence primarily exists in an extended chain conformation by virtue of large d-alpha-NOEs and 9-10 Hz 3J-alpha-N coupling constants. Residues Cl0-Nl6 have turn-like or helix character with a run of d(NN) and d-beta-N NOEs and attenuated d-alpha-N NOEs. These midchain reversals include the lysine and asparagine residues proposed to be involved in heparin binding and N-glycosylation, respectively, to laminin peptide F-9.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,STRUCT BIOL GRP,PHILADELPHIA,PA 19107; UNIV MINNESOTA,DEPT LAB MED,MINNEAPOLIS,MN 55455	Jefferson University; University of Minnesota System; University of Minnesota Twin Cities				Skubitz, Amy/0000-0003-4672-3450	NCI NIH HHS [CA 21463, CA 29995] Funding Source: Medline; NIDDK NIH HHS [DK 32660] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA021463, R37CA021463, R01CA029995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032660] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CITRON BA, 1984, J BACTERIOL, V158, P269, DOI 10.1128/JB.158.1.269-278.1984; DYSON HJ, 1985, NATURE, V318, P480; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1988, J MOL BIOL, V201, P201, DOI 10.1016/0022-2836(88)90447-0; DYSON HJ, 1986, CIBA F SYMP, V119, P58; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; FROHLICH KU, 1985, GENE, V36, P105, DOI 10.1016/0378-1119(85)90074-5; GALIBERT F, 1979, GENE, V6, P1, DOI 10.1016/0378-1119(79)90081-7; HERISSE J, 1980, NUCLEIC ACIDS RES, V8, P2173, DOI 10.1093/nar/8.10.2173; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAGEYAMA R, 1984, BIOCHEMISTRY-US, V23, P3603, DOI 10.1021/bi00311a006; KESSLER H, 1986, METHODS STEREOCHEMIC, V6; KIM PS, 1984, NATURE, V307, P329, DOI 10.1038/307329a0; KLEINMAN HK, 1983, BIOCHEMISTRY-US, V22, P4969, DOI 10.1021/bi00290a014; LAUDANO AP, 1983, ANN NY ACAD SCI, V408, P315, DOI 10.1111/j.1749-6632.1983.tb23254.x; MALINOFF HL, 1983, J CELL BIOL, V96, P1475, DOI 10.1083/jcb.96.5.1475; MALINOFF HL, 1984, INT J CANCER, V33, P651, DOI 10.1002/ijc.2910330516; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MAYO KH, 1991, BIOCHEMISTRY-US, V30, P8251, DOI 10.1021/bi00247a022; MAYO KH, 1990, BIOCHEMISTRY-US, V29, P3277, DOI 10.1021/bi00465a019; MCCOY JP, 1984, J CELL SCI, V65, P139; NI F, 1989, BIOCHEMISTRY-US, V28, P3082, DOI 10.1021/bi00433a052; REED J, 1988, EUR J BIOCHEM, V178, P141, DOI 10.1111/j.1432-1033.1988.tb14439.x; SAKASHITA S, 1980, FEBS LETT, V116, P243, DOI 10.1016/0014-5793(80)80654-5; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SITU R, 1984, J CELL SCI, V70, P167; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; SKUBITZ APN, 1990, CANCER RES, V50, P7612; STACHELEK C, 1986, NUCLEIC ACIDS RES, V14, P945, DOI 10.1093/nar/14.2.945; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; SUGRUE SP, 1981, J CELL BIOL, V91, P45, DOI 10.1083/jcb.91.1.45; TERRANOVA VP, 1980, CELL, V22, P719, DOI 10.1016/0092-8674(80)90548-6; TEWKSBURY DA, 1981, BIOCHEM BIOPH RES CO, V99, P1311, DOI 10.1016/0006-291X(81)90762-2; TIMPL R, 1983, TRENDS BIOCHEM SCI, V8, P207, DOI 10.1016/0968-0004(83)90213-X; VONDERMARK K, 1985, BIOCHIM BIOPHYS ACTA, V823, P147; WIDER G, 1984, J MAGN RESON, V56, P207, DOI 10.1016/0022-2364(84)90099-4; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	44	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19407	19412						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918053				2022-12-25	WOS:A1991GK66700045
J	KURANDA, MJ; ROBBINS, PW				KURANDA, MJ; ROBBINS, PW			CHITINASE IS REQUIRED FOR CELL-SEPARATION DURING GROWTH OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; YEAST INVERTASE; MESSENGER-RNAS; GENES; EXPRESSION; CLONING; ENZYME; GLYCOSYLATION; ACCUMULATION	The Saccharomyces cerevisiae chitinase described by Correa et al. (Correa, J. U., Elango, N., Polacheck, I., and Cabib, E. (1982) J. Biol. Chem. 257, 1392-1397) has been cloned and sequenced. Analysis of the derived amino acid sequence suggests that the protein contains four domains: a signal sequence, a catalytic domain, a serine/threonine-rich region, and a carboxyl-terminal domain with high binding affinity for chitin. Most of the enzyme produced by cells is secreted into the growth medium and is extensively glycosylated with a series of short O-linked mannose oligosaccharides ranging in size from Man2 to Man5. Chitinase O-mannosylation was further examined in the temperature-sensitive secretion mutants sec18, sec7, and sec6. Oligosaccharides isolated from chitinase accumulating in cells at the nonpermissive temperature revealed Man1 and Man2 associated with the sec18 mutant. sec6 and sec7 accumulated Man2-Man5 with a higher proportion of Man5 relative to the secreted protein. A significant amount of chitinase is also found associated with the cell wall through binding of COOH-terminal domain to chitin. Disruption of the gene for the enzyme leads to a defect in cell separation but does not substantially alter the level of cellular chitin.	MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)				Robbins, Phillips/0000-0002-5121-1524	NATIONAL CANCER INSTITUTE [P30CA014051, F32CA007901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031318, R01GM031318] Funding Source: NIH RePORTER; NCI NIH HHS [CA07901, CA14051] Funding Source: Medline; NIGMS NIH HHS [GM31318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADSHAW HD, 1990, NATURE, V345, P299, DOI 10.1038/345299b0; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; BULAWA CE, 1986, CELL, V46, P213, DOI 10.1016/0092-8674(86)90738-5; CABIB E, 1989, J CELL BIOL, V108, P1665, DOI 10.1083/jcb.108.5.1665; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CROUSE GF, 1983, METHOD ENZYMOL, V101, P202; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHANSSON G, 1989, FEBS LETT, V243, P389, DOI 10.1016/0014-5793(89)80168-1; JONES JDG, 1986, EMBO J, V5, P467, DOI 10.1002/j.1460-2075.1986.tb04235.x; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KNOWLES J, 1987, TRENDS BIOTECHNOL, V5, P255, DOI 10.1016/0167-7799(87)90102-8; KURANDA MJ, 1987, P NATL ACAD SCI USA, V84, P2585, DOI 10.1073/pnas.84.9.2585; Maniatis T., 1982, MOL CLONING; METRAUX JP, 1989, P NATL ACAD SCI USA, V86, P896, DOI 10.1073/pnas.86.3.896; MOLANO J, 1977, ANAL BIOCHEM, V83, P648, DOI 10.1016/0003-2697(77)90069-0; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; PARSONS TJ, 1989, P NATL ACAD SCI USA, V86, P7895, DOI 10.1073/pnas.86.20.7895; ROBBINS PW, 1988, J BIOL CHEM, V263, P443; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAKUDA S, 1990, AGR BIOL CHEM TOKYO, V54, P1333, DOI 10.1080/00021369.1990.10870108; Schekman R, 1982, MOL BIOL YEAST SACCH, VII, P361; Sherman F., 1986, METHODS YEAST GENETI; SHINSHI H, 1987, P NATL ACAD SCI USA, V84, P89, DOI 10.1073/pnas.84.1.89; STARK MJR, 1984, NUCLEIC ACIDS RES, V12, P6011, DOI 10.1093/nar/12.15.6011; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; TAUSSIG R, 1983, NUCLEIC ACIDS RES, V11, P1943, DOI 10.1093/nar/11.6.1943; 1982, J BIOL CHEM, V257, P1392	31	520	537	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19758	19767						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918080				2022-12-25	WOS:A1991GK66700091
J	TAPIO, S; YEH, F; SHUMAN, HA; BOOS, W				TAPIO, S; YEH, F; SHUMAN, HA; BOOS, W			THE MALZ GENE OF ESCHERICHIA-COLI, A MEMBER OF THE MALTOSE REGULON, ENCODES A MALTODEXTRIN GLUCOSIDASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPOSON-GAMMA-DELTA; BINDING-PROTEIN; ALPHA-AMYLASE; CYTOPLASMIC MEMBRANE; PERIPLASMIC PROTEIN; OUTER-MEMBRANE; PLASMID DNA; CLONING; SYSTEM; IDENTIFICATION	We have characterized a maltodextrin glucosidase, previously described as a maltose-inducible, cytoplasmic enzyme that cleaves p-nitrophenyl-alpha-maltoside in Escherichia coli. The gene encoding the enzyme activity, referred to as malZ, is located at 9.3 min on the chromosomal map. We cloned the gene in a high copy number vector and purified the enzyme. It is a monomer, with an apparent molecular weight of 65,000. The enzyme degrades maltodextrins, ranging from maltotriose to maltoheptaose, to shorter oligosaccharides, the final hydrolysis products being maltose and glucose. We measured the kinetic parameters, K(m) and V(max), for the hydrolysis to glucose of the five different substrates. The binding of the substrate is enhanced by increasing the number of glucosyl residues in the maltodextrin. In contrast, the maximum rate of hydrolysis (V(max)) is fastest for maltotriose. To study the mode of action of the enzyme, we quantitatively measured the amount of free glucose liberated from the different maltodextrin substrates after a long incubation. More glucose is liberated from the long dextrins, as compared to the shorter ones, showing that the primary hydrolysis product was glucose, not maltose. Furthermore, [C-14]maltotriose, specifically labeled at the reducing end, was hydrolyzed to [C-14]glucose and unlabeled maltose. These data demonstrate that the malZ gene product is a maltodextrin glucosidase, liberating glucose from the reducing end of malto-oligosaccharides. The nucleotide sequence of malZ and the deduced amino acid sequence showed that malZ encodes a protein with a molecular weight of 68,960. Homology to glucosidases, alpha-amylases, and pullulanases were observed. Conserved regions thought to represent active sites in dextrin hydrolases were found in the MalZ protein.	UNIV CONSTANCE,DEPT BIOL,W-7750 CONSTANCE,GERMANY; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032	University of Konstanz; Columbia University			Tapio, Soile/M-7358-2014; Tapio, Soile/CAJ-5871-2022	Tapio, Soile/0000-0001-9860-3683; 	NIAID NIH HHS [AI-19276] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019276] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BACHMANN B, 1990, MICROBIOL REV, V54, P405; BELFORT M, 1985, CELL, V41, P375, DOI 10.1016/S0092-8674(85)80010-6; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BREMER E, 1990, GENE, V96, P59, DOI 10.1016/0378-1119(90)90341-N; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; CHAPON C, 1982, J BACTERIOL, V150, P722, DOI 10.1128/JB.150.2.722-729.1982; FREUNDLIEB S, 1988, J BIOL CHEM, V263, P314; FREUNDLIEB S, 1986, J BIOL CHEM, V261, P2946; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GILSON E, 1986, J MOL BIOL, V191, P303, DOI 10.1016/0022-2836(86)90127-0; GROISMAN EA, 1986, J BACTERIOL, V168, P357, DOI 10.1128/jb.168.1.357-364.1986; GUYER MS, 1983, METHOD ENZYMOL, V101, P362; HATFIELD D, 1969, J BACTERIOL, V98, P559, DOI 10.1128/JB.98.2.559-567.1969; HENGGE R, 1983, BIOCHIM BIOPHYS ACTA, V737, P443, DOI 10.1016/0304-4157(83)90009-6; HORINOUCHI S, 1988, EUR J BIOCHEM, V176, P243, DOI 10.1111/j.1432-1033.1988.tb14275.x; JAMES AA, 1989, GENE, V75, P73, DOI 10.1016/0378-1119(89)90384-3; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LIU L, 1990, J BACTERIOL, V172, P2814, DOI 10.1128/jb.172.5.2814-2816.1990; MACGREGOR EA, 1989, BIOCHEM J, V259, P145, DOI 10.1042/bj2590145; Maniatis T., 1982, MOL CLONING; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MELASNIEMI H, 1990, J GEN MICROBIOL, V136, P447, DOI 10.1099/00221287-136-3-447; Miller J.H., 1972, EXPT MOL GENETICS; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NAKAJIMA R, 1986, APPL MICROBIOL BIOT, V23, P355; PALMER TN, 1976, EUR J BIOCHEM, V69, P105, DOI 10.1111/j.1432-1033.1976.tb10863.x; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RAIBAUD O, 1980, J BACTERIOL, V143, P761, DOI 10.1128/JB.143.2.761-771.1980; RAIBAUD O, 1987, J BACTERIOL, V169, P3059, DOI 10.1128/jb.169.7.3059-3061.1987; REYES M, 1986, J BACTERIOL, V165, P918, DOI 10.1128/jb.165.3.918-922.1986; RICHTERICH P, 1989, BIOTECHNIQUES, V7, P52; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWACHA A, 1990, J BACTERIOL, V172, P5991, DOI 10.1128/jb.172.10.5991-5998.1990; SCHWARTZ M, 1987, MALTOSE REGULON ESCH, V2, P1482; SETO D, 1990, NUCLEIC ACIDS RES, V18, P5905, DOI 10.1093/nar/18.19.5905; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; SILHAVY TJ, 1979, MOL GEN GENET, V174, P249, DOI 10.1007/BF00267797; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2971, DOI 10.1093/nar/10.9.2971; SVENSSON B, 1988, FEBS LETT, V230, P72, DOI 10.1016/0014-5793(88)80644-6; SZMELCMAN S, 1975, J BACTERIOL, V124, P112, DOI 10.1128/JB.124.1.112-118.1975; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; TOUSSAINT A, 1983, MOBILE GENETIC ELEME, P105; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; VIDALINGIGLIARDI D, 1991, J MOL BIOL, V218, P323, DOI 10.1016/0022-2836(91)90715-I; VIHINEN M, 1989, CRIT REV BIOCHEM MOL, V24, P329, DOI 10.3109/10409238909082556; WALSH C, 1979, ENZYMATIC REACTION M, P68; WU TT, 1966, GENETICS, V54, P405; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	55	54	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19450	19458						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1918057				2022-12-25	WOS:A1991GK66700051
J	BESNARD, F; BRENNER, M; NAKATANI, Y; CHAO, R; PUROHIT, HJ; FREESE, E				BESNARD, F; BRENNER, M; NAKATANI, Y; CHAO, R; PUROHIT, HJ; FREESE, E			MULTIPLE INTERACTING SITES REGULATE ASTROCYTE-SPECIFIC TRANSCRIPTION OF THE HUMAN GENE FOR GLIAL FIBRILLARY ACIDIC PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYOMAVIRUS JC-VIRUS; DIBUTYRYL-CYCLIC-AMP; NUCLEAR FACTOR-I; CHLORAMPHENICOL ACETYLTRANSFERASE; MAMMALIAN-CELLS; PHORBOL ESTER; BOX BINDING; EXPRESSION; PROMOTER; SEQUENCES	The gfa gene encodes glial fibrillary acidic protein, an intermediate filament protein found almost exclusively in astrocytes. Transient transfection studies with a chloramphenicol acetyltransferase reporter gene were used to identify regions of the gfa gene responsible for its expression. Three regions, A, B, and D, were found to be important. The D region is located near the basal promoter, while A and B are next to each other about 1500 bp further upstream. The regions contain several sequences homologous to binding sites of known transcription factors, and in addition, each contains an identical novel 10-bp motif. The A, B, and D regions act in a cell-specific manner; when joined to the SV40 early promoter, they enhance transcription in the glial cell line U251, but not in the nonglial cell line HepG2. Consistent with this observation, the DNase I footprint produced in these regions by nuclear extract from U251 cells differs from that produced by an extract from HepG2 cells. The B region appears to be the most active of the three, as by itself it stimulates strong cell-specific transcription, whereas addition of the other two regions has little effect. When the B region is at its normal distance from the basal promoter, deletion of D severely reduces transcription, but when B is placed near the promoter, D is unimportant. This suggests that the D region may function primarily to promote interactions that bring B close to the promoter.	NINCDS,MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)								ALLORE RJ, 1990, J BIOL CHEM, V265, P15537; AMEMIYA K, 1989, J BIOL CHEM, V264, P7025; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BESNARD F, 1989, INT J DEV NEUROSCI, V7, P401, DOI 10.1016/0736-5748(89)90061-0; BESNARD F, 1987, NEUROSCI LETT, V73, P287, DOI 10.1016/0304-3940(87)90260-6; BRENNER M, 1990, MOL BRAIN RES, V7, P277, DOI 10.1016/0169-328X(90)90078-R; CHIU FC, 1985, J NEUROIMMUNOL, V8, P283, DOI 10.1016/S0165-5728(85)80067-9; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Eng LF, 1980, PROTEINS NERVOUS SYS, P85; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; NAKATANI Y, 1990, P NATL ACAD SCI USA, V87, P4289, DOI 10.1073/pnas.87.11.4289; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORENBERG M, 1988, BIOCH PATHOLOGY ASTR; PFREUNDSCHUH M, 1978, P NATL ACAD SCI USA, V75, P5122, DOI 10.1073/pnas.75.10.5122; RAJU TR, 1980, BRAIN RES, V200, P225, DOI 10.1016/0006-8993(80)91114-2; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHMID CW, 1982, SCIENCE, V216, P1065, DOI 10.1126/science.6281889; SENSENBRENNER M, 1980, DIFFERENTIATION, V17, P51, DOI 10.1111/j.1432-0436.1980.tb01081.x; SHAFITZAGARDO B, 1988, GLIA, V1, P346, DOI 10.1002/glia.440010507; TAMURA T, 1988, BIOCHEM BIOPH RES CO, V157, P419, DOI 10.1016/S0006-291X(88)80265-1	35	136	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18877	18883						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918004				2022-12-25	WOS:A1991GJ47200073
J	ELY, JA; AMBROZ, C; BAUKAL, AJ; CHRISTENSEN, SB; BALLA, T; CATT, KJ				ELY, JA; AMBROZ, C; BAUKAL, AJ; CHRISTENSEN, SB; BALLA, T; CATT, KJ			RELATIONSHIP BETWEEN AGONIST-SENSITIVE AND THAPSIGARGIN-SENSITIVE CALCIUM POOLS IN ADRENAL GLOMERULOSA CELLS - THAPSIGARGIN-INDUCED CA2+ MOBILIZATION AND ENTRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; PLASMA-MEMBRANE; TUMOR PROMOTER; ACINAR-CELLS; FREE CA-2+; RELEASE; CA-2+-ATPASE; PHOSPHATES	The relationships between agonist-sensitive calcium pools and those discharged by the Ca2+-ATPase inhibitor thapsigargin were studied in intact bovine adrenal glomerulosa cells and a subcellular adrenocortical membrane fraction. In Fura-2-loaded glomerulosa cells, angiotensin II (AII) stimulated a rapid increase in cytoplasmic Ca2+ concentration ([Ca2+]i) followed by a smaller plateau phase that was dependent on extracellular Ca2+. In such cells thapsigargin caused a sustained and dose-dependent increase in [Ca2+]i which was diminished in Ca2+-deficient medium. The contribution of an influx component to the thapsigargin-induced [Ca2+]i response was demonstrated by measurement of Ca-45 influx rate in glomerulosa cells. Thapsigargin-induced Ca2+ entry was significantly less than that evoked by AII, and its kinetics were similar to those of the concomitant increase in [Ca2+]i. The rate of emptying of the agonist-responsive Ca2+ pool after thapsigargin treatment, as indicated by the progressive decrease in the size of the AII-induced Ca2+ transient, showed a rapid initial (t1/2 = 1.7 min) component that accounted for about 80% of the response and a slowly decreasing phase with t1/2 = 112 min. The latter thapsigargin-resistant component was abolished by the removal of extracellular Ca2+. Pretreatment with AII dose-dependently attenuated but did not abolish the subsequent Ca2+ response to thapsigargin and also increased the rate of the Ca2+ rise induced by thapsigargin. In bovine adrenocortical microsomes, thapsigargin inhibited the ATP-dependent filling of Ca2+ pools and caused a dose-dependent rise in extravesicular Ca2+ levels when added to previously loaded microsomes. The thapsigargin-releasable Ca2+ pool in adrenal microsomes was larger than the inositol 1,4,5-trisphosphate (Ins(1,4,5)P3)-sensitive Ca2+ pool but only slightly greater than the GTP-releasable pool. Ins(1,4,5)P3-induced Ca2+ release was reduced markedly when ATP-dependent Ca2+ loading of the microsomes was prevented by prior addition of thapsigargin. However, the subsequent Ca2+ response to Ins(1,4,5)P3 was consistently better preserved after the addition of thapsigargin to microsomes preloaded with Ca2+. This difference suggests that although Ca2+ uptake by the Ins(1,4,5)P3-responsive pool is also sensitive to thapsigargin, once filled, this pool shows a slower passive leakage than other thapsigargin-sensitive pools. These findings indicate that thapsigargin increases [Ca2+]i by inhibiting Ca2+ uptake into multiple intracellular Ca2+ pools and by also promoting entry of extracellular Ca2+. The AII-responsive and thapsigargin-sensitive Ca2+ pools are largely coincident in adrenal cells, but there is a component of agonist-induced Ca2+ influx which is not mimicked by thapsigargin, and not all of the thapsigargin-sensitive Ca2+ pool is responsive to Ins(1,4,5)P3.	NICHHD, ENDOCRINOL & REPROD RES BRANCH, BLDG 10, RM B1L400, BETHESDA, MD 20892 USA; ROYAL DANISH SCH PHARM, DEPT CHEM BC, DK-2100 COPENHAGEN, DENMARK	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Royal Danish School of Pharmacy			Christensen, Søren Brøgger/H-4526-2019	Christensen, Søren Brøgger/0000-0002-5773-6874; Balla, Tamas/0000-0002-9077-3335	NICHD NIH HHS [HD07383-03] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALLA T, 1988, J BIOL CHEM, V263, P4083; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CHEEK TR, 1989, CELL CALCIUM, V10, P213, DOI 10.1016/0143-4160(89)90004-3; DAWSON AP, 1989, CELL CALCIUM, V10, P343, DOI 10.1016/0143-4160(89)90060-2; ELLIOTT ME, 1985, ENDOCRINOLOGY, V116, P1051, DOI 10.1210/endo-116-3-1051; ELY JA, 1990, BIOCHEM J, V268, P333, DOI 10.1042/bj2680333; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLEMETTE G, 1988, J BIOL CHEM, V263, P4541; HAKAII H, 1986, J CANCER RES CLIN, V111, P177; HANSEN CA, 1990, ADV SEC MESS PHOSPH, V24, P128; IRVINE RF, 1988, PHILOS T ROY SOC B, V320, P281, DOI 10.1098/rstb.1988.0077; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; KOJIMA I, 1987, J BIOL CHEM, V262, P4557; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LAW GJ, 1990, BIOCHEM J, V267, P359, DOI 10.1042/bj2670359; MULLANEY JM, 1987, J BIOL CHEM, V262, P13865; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RASMUSSEN U, 1978, ACTA PHARM SUEC, V15, P133; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSSIER MF, 1989, J BIOL CHEM, V264, P14078; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; THASTRUP O, 1990, AGENTS ACTIONS, V29, P8, DOI 10.1007/BF01964706; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	31	97	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18635	18641						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917986				2022-12-25	WOS:A1991GJ47200038
J	NYITRAY, L; GOODWIN, EB; SZENTGYORGYI, AG				NYITRAY, L; GOODWIN, EB; SZENTGYORGYI, AG			COMPLETE PRIMARY STRUCTURE OF A SCALLOP STRIATED-MUSCLE MYOSIN HEAVY-CHAIN - SEQUENCE COMPARISON WITH OTHER HEAVY-CHAINS REVEALS REGIONS THAT MIGHT BE CRITICAL FOR REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ESSENTIAL LIGHT-CHAIN; ATPASE ACTIVITY; ROD PHOSPHORYLATION; SECONDARY-STRUCTURE; SKELETAL MYOSIN; DNA-SEQUENCE; ACTIN; BINDING; DOMAINS	We have determined the primary structure of the myosin heavy chain (MHC) of the striated adductor muscle of the scallop Aequipecten irradians by cloning and sequencing its cDNA. It is the first heavy chain sequence obtained in a directly Ca2+-regulated myosin. The 1938-amino acid sequence has an overall structure similar to other MHCs. The subfragment-1 region of the scallop MHC has a 59-62% sequence identity with sarcomeric and a 52-53% identity with nonsarcomeric (smooth and metazoan nonmuscle) MHCs. The heavy chain component of the regulatory domain (Kwon, H., Goodwin, E. B., Nyitray, L., Berliner, E., O'Neall-Hennessey, E., Melandri, F. D., and Szent-Gyorgyi, A. G. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4771-4775) starts at either Leu-755 or Val-760. Ca2+-sensitive Trp residues (Wells, C., Warriner, K. E., and Bagshaw, C. R. (1985) Biochem. J. 231, 31-38) are located near the C-terminal end of this segment (residues 818-827). More detailed sequence comparison with other MHCs reveals that the 50-kDa domain and the N-terminal two-thirds of the 20-kDa domain differ substantially between sarcomeric and nonsarcomeric myosins. In contrast, in the light chain binding region of the regulatory domain (residues 784-844) the scallop sequence shows greater homology with regulated myosins (smooth muscle, nonmuscle, and invertebrate striated muscles) than with unregulated ones (vertebrate skeletal and heart muscles). The N-terminal 25-kDa domain also contains several residues which are preserved only in regulated myosins. These results indicate that certain heavy chain sites might be critical for regulation. The rod has features typical of sarcomeric myosins. It is 52-60% and 30-33% homologous with sarcomeric and nonsarcomeric MHCs, respectively. A Ser-rich tailpiece (residues 1918-1938) is apparently nonhelical.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University			Nyitray, László/AAE-5910-2020	Nyitray, László/0000-0003-4717-5994	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR004671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR015963, R37AR015963] Funding Source: NIH RePORTER; NCRR NIH HHS [RR04671] Funding Source: Medline; NIAMS NIH HHS [AR15963] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANKRETT RJ, 1991, J MOL BIOL, V217, P323, DOI 10.1016/0022-2836(91)90546-I; BURKE M, 1985, BIOCHEMISTRY-US, V24, P846, DOI 10.1021/bi00325a006; CASTELLANI L, 1988, J MUSCLE RES CELL M, V9, P533, DOI 10.1007/BF01738758; CASTELLANI L, 1987, P NATL ACAD SCI USA, V84, P4058, DOI 10.1073/pnas.84.12.4058; CASTELLANI L, 1987, SCIENCE, V235, P334, DOI 10.1126/science.3026049; CHALOVICH JM, 1984, J BIOL CHEM, V259, P2617; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; CHAUSSEPIED P, 1986, BIOCHEMISTRY-US, V25, P1134, DOI 10.1021/bi00353a028; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COLLINS JH, 1986, BIOCHEMISTRY-US, V25, P7651, DOI 10.1021/bi00371a056; CRAIG R, 1983, NATURE, V302, P436, DOI 10.1038/302436a0; CREMO CR, 1989, J BIOL CHEM, V264, P6608; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEORGE EL, 1989, MOL CELL BIOL, V9, P2957, DOI 10.1128/MCB.9.7.2957; GOODWIN EB, 1990, J MOL BIOL, V216, P85, DOI 10.1016/S0022-2836(05)80062-2; GOODWIN EB, 1987, J BIOL CHEM, V262, P11051; GRAMMER JC, 1991, BIOPHYS J S, V59, P226; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; IKEBE M, 1982, J BIOCHEM, V92, P1973, DOI 10.1093/oxfordjournals.jbchem.a134128; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KETCHUM AS, 1990, P NATL ACAD SCI USA, V87, P6316, DOI 10.1073/pnas.87.16.6316; KRESCHMIZRACHI I, 1990, GENE AMST, V89, P289; KWON H, 1990, P NATL ACAD SCI USA, V87, P4771, DOI 10.1073/pnas.87.12.4771; LABBE JP, 1988, BIOCHEMISTRY-US, V27, P5914, DOI 10.1021/bi00416a014; LEHMAN W, 1975, J GEN PHYSIOL, V66, P1, DOI 10.1085/jgp.66.1.1; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MCNALLY EM, 1991, J CELL BIOL, V113, P585, DOI 10.1083/jcb.113.3.585; MCNALLY EM, 1989, J MOL BIOL, V210, P665, DOI 10.1016/0022-2836(89)90141-1; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; MORNET D, 1985, J MOL BIOL, V183, P479, DOI 10.1016/0022-2836(85)90015-4; NYITRAY L, 1990, NUCLEIC ACIDS RES, V18, P7158, DOI 10.1093/nar/18.23.7158; OFFER G, 1990, J MOL BIOL, V216, P213, DOI 10.1016/S0022-2836(05)80309-2; OKAMOTO Y, 1985, P NATL ACAD SCI USA, V82, P1575, DOI 10.1073/pnas.82.6.1575; RIMM DL, 1989, J CELL BIOL, V108, P1783, DOI 10.1083/jcb.108.5.1783; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLEY JM, 1981, BIOCHIMIE, V63, P255, DOI 10.1016/S0300-9084(81)80115-0; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SELLERS JR, 1980, J MOL BIOL, V144, P223, DOI 10.1016/0022-2836(80)90088-1; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; STAFFORD WF, 1979, BIOCHEMISTRY-US, V18, P5273, DOI 10.1021/bi00591a002; STEDMAN HH, 1990, J BIOL CHEM, V265, P3568; STREHLER EE, 1986, J MOL BIOL, V190, P291, DOI 10.1016/0022-2836(86)90003-3; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; SZENTKIRALYI EM, 1987, J MUSCLE RES CELL M, V8, P349, DOI 10.1007/BF01568891; SZENTKIRALYI EM, 1984, J MUSCLE RES CELL M, V5, P147, DOI 10.1007/BF00712153; TITUS MA, 1986, BIOPHYS J, V49, P187; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; VIBERT P, 1985, J CELL BIOL, V101, P830, DOI 10.1083/jcb.101.3.830; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WALLIMANN T, 1981, BIOCHEMISTRY-US, V20, P1176, DOI 10.1021/bi00508a020; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cb.03.110187.002115; WELLS C, 1985, BIOCHEM J, V231, P31, DOI 10.1042/bj2310031; WERBER MM, 1972, BIOCHEMISTRY-US, V11, P2872, DOI 10.1021/bi00765a021; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	60	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18469	18476						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1917970				2022-12-25	WOS:A1991GJ47200013
J	STIFANI, S; BARBER, DL; AEBERSOLD, R; STEYRER, E; SHEN, XY; NIMPF, J; SCHNEIDER, WJ				STIFANI, S; BARBER, DL; AEBERSOLD, R; STEYRER, E; SHEN, XY; NIMPF, J; SCHNEIDER, WJ			THE LAYING HEN EXPRESSES 2 DIFFERENT LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN OOCYTE RECEPTOR; HEYMANN NEPHRITIS; APOLIPOPROTEIN-E; GROWTH-FACTOR; LDL-RECEPTOR; ALPHA-2-MACROGLOBULIN RECEPTOR; GEL-ELECTROPHORESIS; ALPHA-MACROGLOBULIN; BINDING PROTEINS; HIGH-AFFINITY	We have identified, by a combination of ligand, Ca-45(2+), and immunoblotting, two large membrane proteins akin to the mammalian so-called low density lipoprotein (LDL) receptor-related protein (LRP) in chicken tissues. LRP has thus far been demonstrated only in mammalian species where it is thought to act as a receptor for proteinase-alpha-2-macroglobulin complexes and/or chylomicron remnants, lipoproteins not produced in birds. One of the chicken LRPs was demonstrated in liver, and has the same apparent M(r) and hallmark biochemical properties as rat liver LRP. The other chicken LRP is smaller (approximately 380 kDa) and is expressed in ovarian follicles, but is undetectable in liver. Immunological analysis demonstrated a lack of cross-reactivity between the two LRPs, as well as between them and the previously identified chicken oocyte-specific 95-kDa receptor for the yolk precursors, very low density lipoprotein, and vitellogenin (Stifani, S., Barber, D. L., Nimpf, J., and Schneider, W. J. (1989) Proc. Natl. Acad, Sci. U. S. A. 87, 1955-1959). As shown by ligand blotting, both chicken LRPs have the ability to interact with vitellogenin, a property they share not only with rat LRP, but also with mammalian LDL receptors. To obtain independent confirmation of the ligand blotting results, the smaller (follicular) LRP was purified and high-affinity binding of vitellogenin to it was demonstrated by a solid-phase filtration binding assay. Amino acid sequences of tryptic fragments of the smaller LRP were obtained, and its homology with human LRP demonstrated through unambiguous alignment of three fragments. Both chicken LRPs, the chicken oocyte 95-kDa receptor, as well as rat LRP, could be shown by ligand blotting to interact specifically with chicken serum alpha-2-macroglobulin. In addition, human apolipoprotein E, a ligand implicated in receptor-mediated metabolism of chylomicron remnants, also binds to the smaller chicken LRP, further emphasizing the similarities between LDL receptors and related proteins from a variety of species. In analogy to the known dichotomy of chicken LDL receptors, which is characterized by the production of the 95-kDa oocyte-specific receptor on one hand and a 130-kDa LDL receptor that is exclusively expressed in somatic cells (Hayashi, K., Nimpf, J., and Schneider, W. J. (1989) J. Biol. Chem. 264, 3131-3139), it appears that the smaller and larger chicken LRPs also may be restricted to the oocyte and somatic cells, respectively.	UNIV ALBERTA, LIPID & LIPOPROT RES GRP, 327 HERITAGE MED RES CTR, EDMONTON T6G 2S2, ALBERTA, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON T6G 2S2, ALBERTA, CANADA; UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA	University of Alberta; University of Alberta; University of British Columbia; University of British Columbia				Barber, Dwayne/0000-0001-5528-8150; Nimpf, Johannes/0000-0002-9273-3492; Stifani, Stefano/0000-0002-2376-7701				AEBERSOLD R, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P71; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; FEINMAN RD, 1983, ANN NY ACAD SCI, V421, P178, DOI 10.1111/j.1749-6632.1983.tb18108.x; FELDMAN SR, 1984, ARCH BIOCHEM BIOPHYS, V235, P267, DOI 10.1016/0003-9861(84)90275-3; GEORGE R, 1987, J BIOL CHEM, V262, P16838; Griffin H. D., 1984, PHYSL BIOCH DOMESTIC, V5, P345; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HAYASHI K, 1989, J LIPID RES, V30, P1421; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HO KJ, 1974, ARCH PATHOL, V98, P161; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; KERJASCHKI D, 1987, J EXP MED, V166, P109, DOI 10.1084/jem.166.1.109; KERJASCHKI D, 1982, P NATL ACAD SCI-BIOL, V79, P5557, DOI 10.1073/pnas.79.18.5557; KITAMOTO T, 1982, J BIOCHEM, V92, P1679, DOI 10.1093/oxfordjournals.jbchem.a134097; KOVANEN PT, 1979, J BIOL CHEM, V254, P1367; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MILLER HT, 1966, BIOCHEMISTRY-US, V5, P952, DOI 10.1021/bi00867a022; NIMPF J, 1989, J BIOL CHEM, V264, P1393; NORBERG B, 1985, COMP BIOCHEM PHYS B, V81, P869, DOI 10.1016/0305-0491(85)90081-1; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; SCHNEIDER WJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P303, DOI 10.1016/0304-4157(89)90023-3; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1990, J BIOL CHEM, V265, P882; STIFANI S, 1990, BIOCHIM BIOPHYS ACTA, V1045, P271, DOI 10.1016/0005-2760(90)90130-P; STIFANI S, 1988, BIOCHEM J, V250, P467, DOI 10.1042/bj2500467; STIFANI S, 1990, P NATL ACAD SCI USA, V87, P1955, DOI 10.1073/pnas.87.5.1955; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WHITE HB, 1988, ANNU REV NUTR, V8, P279, DOI 10.1146/annurev.nu.08.070188.001431; WHITE HB, 1987, J EXP ZOOL, P53; WINDLER EET, 1980, J BIOL CHEM, V255, P464	50	66	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19079	19087						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1918027				2022-12-25	WOS:A1991GJ47200103
J	ENSIGN, SA; LUDDEN, PW				ENSIGN, SA; LUDDEN, PW			CHARACTERIZATION OF THE CO OXIDATION/H-2 EVOLUTION SYSTEM OF RHODOSPIRILLUM-RUBRUM - ROLE OF A 22-KDA IRON-SULFUR PROTEIN IN MEDIATING ELECTRON-TRANSFER BETWEEN CARBON-MONOXIDE DEHYDROGENASE AND HYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWN METHANOSARCINA-THERMOPHILA; METHYLENE-BLUE OXIDOREDUCTASE; PSEUDOMONAS-CARBOXYDOVORANS; RHODOPSEUDOMONAS-GELATINOSA; NICKEL; PURIFICATION; NITROGENASE; IDENTIFICATION; REQUIREMENT; FERREDOXIN	The response of the membrane-associated carbon monoxide dehydrogenase (CODH) from Rhodospirillum rubrum to solubilization by detergents and organic solvents, the properties of solubilized CODH, and the mechanism for coupling CO oxidation to hydrogen evolution via a CO-induced hydrogenase activity have been investigated. The release of CODH by a variety of ionic and nonionic detergents occurs in a redox-dependent fashion: CODH is solubilized in the presence of low-potential reductants (dithionite, CO, and H-2) but is resistant to solubilization from membranes prepared in the absence of reductant or membranes prepared in the presence of reductant and subsequently dye-oxidized. This redox-dependent response to detergent solubilization has been exploited to release CODH from the membranes in a purified state. CODH can also be solubilized from deoxycholate-washed membranes in a redox-independent manner with 20% ethanol. CODH solubilized by deoxycholate or ethanol, when purified to homogeneity by the protocol previously described for heat-solubilized CODH (Bonam, D., and Ludden, P. W. (1987) J. Biol. Chem. 262, 2980-2987), is associated with a previously unobserved 22-kDa protein. The 22-kDa protein can be dissociated from CODH with acetonitrile and can be reconstituted with CODH, after removal of acetonitrile, in a stoichiometric (1:1) fashion. The isolated 22-kDa protein contained 4.0 iron atoms, a reducible Fe-S center, and was O2- and heat-labile. The 22-kDa protein did not alter the catalytic properties of CODH as assayed in vitro with methyl viologen as the electron acceptor for CO oxidation, but was required for reconstituting CO oxidation to hydrogen evolution via the CO-induced membrane-bound hydrogenase. Other electron carrier proteins (ferredoxins and flavodoxin) were ineffective at coupling CO oxidation and hydrogen evolution. We conclude that the 22-kDa protein is a reversibly dissociable subunit of CODH that mediates electron transfer to hydrogenase.	UNIV WISCONSIN,COLL AGR & LIFE SCI,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [5T32GM07215-14] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONAM D, 1987, J BIOL CHEM, V262, P2980; BONAM D, 1984, J BACTERIOL, V159, P693, DOI 10.1128/JB.159.2.693-699.1984; BONAM D, 1989, J BACTERIOL, V171, P3102, DOI 10.1128/jb.171.6.3102-3107.1989; Cleland W W, 1979, Methods Enzymol, V63, P103; DANIELS L, 1977, J BACTERIOL, V132, P118, DOI 10.1128/JB.132.1.118-126.1977; DASHEKVICZ MP, 1979, INT J SYST BACTERIOL, V29, P145, DOI 10.1099/00207713-29-2-145; DIEKERT GB, 1978, J BACTERIOL, V136, P597, DOI 10.1128/JB.136.2.597-606.1978; ENSIGN SA, 1990, BIOCHEMISTRY-US, V29, P2162, DOI 10.1021/bi00460a029; ENSIGN SA, 1989, BIOCHEMISTRY-US, V28, P4973, DOI 10.1021/bi00438a011; ENSIGN SA, 1989, BIOCHEMISTRY-US, V28, P4968, DOI 10.1021/bi00438a010; ESCHENBRUCH M, 1982, ANAL BIOCHEM, V125, P96, DOI 10.1016/0003-2697(82)90387-6; JANSEN K, 1984, ARCH MICROBIOL, V138, P257, DOI 10.1007/BF00402132; KANEMOTO RH, 1984, J BACTERIOL, V158, P713, DOI 10.1128/JB.158.2.713-720.1984; KRZYCKI JA, 1984, J BACTERIOL, V158, P231, DOI 10.1128/JB.158.1.231-237.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYER O, 1980, J BACTERIOL, V141, P74, DOI 10.1128/JB.141.1.74-80.1980; MEYER O, 1982, J BIOL CHEM, V257, P1333; MEYER O, 1988, BIOTECHNOLOGY FOCUS, V1, P3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORMEROD JG, 1961, ARCH BIOCHEM BIOPHYS, V94, P449, DOI 10.1016/0003-9861(61)90073-X; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Ragsdale S.W., 1988, BIOINORGANIC CHEM NI, P311; SAARI LL, 1984, J BIOL CHEM, V259, P5502; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STECK G, 1980, ANAL BIOCHEM, V118, P197; STEPHENS PJ, 1989, J BIOL CHEM, V264, P16347; TERLESKY KC, 1988, J BIOL CHEM, V263, P4080; TERLESKY KC, 1986, J BACTERIOL, V168, P1053, DOI 10.1128/jb.168.3.1053-1058.1986; TERLESKY KC, 1988, J BIOL CHEM, V263, P4075; UFFEN RL, 1976, P NATL ACAD SCI USA, V73, P3298, DOI 10.1073/pnas.73.9.3298; UFFEN RL, 1981, ENZYME MICROB TECH, V3, P197, DOI 10.1016/0141-0229(81)90086-7; UFFEN RL, 1983, J BACTERIOL, V155, P956, DOI 10.1128/JB.155.3.956-965.1983; WOOD HG, 1986, BIOCHEM INT, V12, P421; YAGI T, 1958, BIOCHIM BIOPHYS ACTA, V30, P194, DOI 10.1016/0006-3002(58)90263-4; Yoch D. C., 1979, A treatise on dinitrogen fixation. Inorganic and physical chemistry and biochemistry, P605; YOCH DC, 1975, J BACTERIOL, V121, P743, DOI 10.1128/JB.121.2.743-745.1975	36	81	100	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18395	18403						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917963				2022-12-25	WOS:A1991GG55300102
J	IHARA, F; KAGEYAMA, Y; HIRATA, M; NIHIRA, T; YAMADA, Y				IHARA, F; KAGEYAMA, Y; HIRATA, M; NIHIRA, T; YAMADA, Y			PURIFICATION, CHARACTERIZATION, AND MOLECULAR-CLONING OF LACTONIZING LIPASE FROM PSEUDOMONAS SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; PANCREATIC LIPASE; ESCHERICHIA-COLI; GENE; EXPRESSION; FRAGI; CDNA	An extracellular lipase catalyzing the synthesis of macrocyclic lactones in anhydrous organic solvents was purified to homogeneity from Pseudomonas nov. sp. 109, and characterized. The lipase showed a pI of 5.3 on isoelectric focusing and a M(r) of 29,000 +/- 1,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. With respect to substrate specificity, optimum chain length for acyl moiety varied depending on the type of reaction catalyzed: C18 in monomer lactone formation, C11 or shorter in dimer lactone formation, and C8 in ester hydrolysis. The amino-terminal 19 amino acid residues of the purified lipase were determined as Ser-Thr-Tyr-Thr-Gln-Thr-Lys-Tyr-Pro-Ile-Val-Leu-Ala-His-Gly-Met-Leu-Gly-Phe, and the gene encoding the lipase was identified by hybridization to a synthetic 20-nucleotide probe, cloned, and sequenced. Nucleotide sequence analysis predicted a 311-amino acid open reading frame, a putative ribosome-binding site, and a 26-amino acid sequence at the amino terminus of the sequence that is not found in the mature protein. This 26-amino acid sequence has many of the characteristics common to known signal peptides. The lipase gene encoded a sequence of Val-Asn-Leu-Ile-Gly-His-Ser-His-Gly-Gly which is very well conserved among lipases, and showed 38-40% overall homology to the amino acid sequences of lipases from Pseudomonas fragie and Pseudomonas cepacia, but showed little homology to those of other lipases, suggesting that some structural features are required for catalyzing macrocyclic lactone synthesis in organic solvents and are restricted to lipases of the Pseudomonas origin.	OSAKA UNIV,FAC ENGN,DEPT BIOTECHNOL,2-1 YAMADA OKA,SUITA,OSAKA 565,JAPAN	Osaka University								AOYAMA S, 1988, FEBS LETT, V242, P36, DOI 10.1016/0014-5793(88)80980-3; ARGOS P, 1987, J MOL BIOL, V193, P385, DOI 10.1016/0022-2836(87)90226-9; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; COLEMAN K, 1983, J BACTERIOL, V153, P909, DOI 10.1128/JB.153.2.909-915.1983; COREY EJ, 1974, J AM CHEM SOC, V96, P5614, DOI 10.1021/ja00824a073; DECARO J, 1981, BIOCHIM BIOPHYS ACTA, V671, P129, DOI 10.1016/0005-2795(81)90126-4; DOCHERTY AJP, 1985, NUCLEIC ACIDS RES, V13, P1891, DOI 10.1093/nar/13.6.1891; ENTRESSANGLES B, 1968, BIOCHIM BIOPHYS ACTA, V159, P285, DOI 10.1016/0005-2744(68)90077-6; GABRIEL O, 1971, METHOD ENZYMOL, V22, P578; GOTZ F, 1985, NUCLEIC ACIDS RES, V13, P5895, DOI 10.1093/nar/13.16.5895; INANAGA J, 1979, B CHEM SOC JPN, V52, P1989, DOI 10.1246/bcsj.52.1989; JORGENSEN S, 1991, J BACTERIOL, V173, P559, DOI 10.1128/jb.173.2.559-567.1991; KAWAGUCHI Y, 1989, NATURE, V341, P164, DOI 10.1038/341164a0; Keller-Schierlein W., 1973, FORTSCHR CHEM ORG NA, V30, P313; KUGIMIYA W, 1986, BIOCHEM BIOPH RES CO, V141, P185, DOI 10.1016/S0006-291X(86)80352-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CY, 1986, J BACTERIOL, V166, P385, DOI 10.1128/jb.166.2.385-391.1986; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKITA A, 1987, TETRAHEDRON LETT, V28, P805, DOI 10.1016/S0040-4039(01)80995-3; Mandel M, 1970, J MOL BIOL, V53, P154; Maniatis T., 1982, MOL CLONING; MICKEL FS, 1989, J BIOL CHEM, V264, P12895; MUKAIYAMA T, 1977, CHEM LETT, P441, DOI 10.1246/cl.1977.441; PERRONYANISCH C, 1985, GENE, V33, P103; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMADA Y, 1989, J BIOCHEM-TOKYO, V106, P383, DOI 10.1093/oxfordjournals.jbchem.a122862; SIDIDO M, 1974, BIOPHYSICS, V14, P135; SIMADA Y, 1990, J BIOCHEM-TOKYO, V1073, P7037; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	31	78	81	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18135	18140						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917947				2022-12-25	WOS:A1991GG55300065
